



# Policy Assessment for the Reconsideration of the Ozone National Ambient Air Quality Standards

External Review Draft



EPA-452/D-22-002  
April 2022

Policy Assessment for the Reconsideration of the  
Ozone National Ambient Air Quality Standards  
External Review Draft

U.S. Environmental Protection Agency  
Office of Air Quality Planning and Standards  
Health and Environmental Impacts Division  
Research Triangle Park, NC

## **DISCLAIMER**

This document has been prepared by staff in the U.S. Environmental Protection Agency's Office of Air Quality Planning and Standards. Any findings and conclusions are those of the authors and do not necessarily reflect the views of the Agency. This document does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Questions or comments related to this document should be addressed to Dr. Mary Hutson (email: [hutson.mary@epa.gov](mailto:hutson.mary@epa.gov)) or Ms. Leigh Meyer (email: [meyer.leigh@epa.gov](mailto:meyer.leigh@epa.gov)), U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards, C504-06, Research Triangle Park, North Carolina 27711.



## TABLE OF CONTENTS

|          |   |            |
|----------|---|------------|
| <b>1</b> | <b>INTRODUCTION.....</b>  | <b>1-1</b> |
| 1.1      | Purpose .....   | 1-2        |
| 1.2      | Legislative Requirements .....  | 1-3        |
| 1.3      | History of the O <sub>3</sub> NAAQS, Reviews and Decisions.....                                   | 1-6        |
| 1.4      | Review Completed in 2020 .....  | 1-12       |
| 1.5      | Reconsideration of the 2020 O <sub>3</sub> NAAQS Decision.....                                    | 1-13       |
|          | References .....  | 1-16       |
| <b>2</b> | <b>AIR QUALITY.....</b>   | <b>2-1</b> |
| 2.1      | O <sub>3</sub> and Photochemical Oxidants in the Atmosphere.....                                  | 2-1        |
| 2.2      | Sources and Emissions of O <sub>3</sub> Precursors .....  | 2-4        |
| 2.3      | Ambient Air Monitoring and Data Handling Conventions .....  | 2-10       |
| 2.3.1    | Ambient Air Monitoring Requirements and Monitoring Networks.....                                  | 2-10       |
| 2.3.2    | Data Handling Conventions and Computations for Determining Whether the<br>Standards are Met ..... | 2-14       |
| 2.4      | O <sub>3</sub> in Ambient Air.....  | 2-15       |
| 2.4.1    | Concentrations Across the U.S.....  | 2-15       |
| 2.4.2    | Trends in U.S. O <sub>3</sub> Concentrations.....   | 2-16       |
| 2.4.3    | Diurnal Patterns .....  | 2-20       |
| 2.4.4    | Seasonal Patterns .....   | 2-23       |
| 2.4.5    | Variation in Recent Daily Maximum 1-hour Concentrations .....                                     | 2-25       |
| 2.5      | Background O <sub>3</sub> .....   | 2-28       |
| 2.5.1    | Summary of U.S. Background O <sub>3</sub> Sources .....   | 2-29       |
| 2.5.1.1  | Stratosphere.....   | 2-31       |
| 2.5.1.2  | Biogenic VOC .....  | 2-32       |
| 2.5.1.3  | Wildland Fires .....  | 2-33       |
| 2.5.1.4  | Lightning Nitrogen Oxides.....  | 2-33       |
| 2.5.1.5  | Natural and Agricultural Soil NO <sub>x</sub> .....   | 2-34       |
| 2.5.1.6  | Post-Industrial Methane .....   | 2-35       |
| 2.5.1.7  | International Anthropogenic Emissions .....   | 2-36       |
| 2.5.2    | Approach for Quantifying U.S. Background Ozone .....  | 2-37       |
| 2.5.2.1  | Methodology: USB Attribution .....  | 2-38       |

|   |            |
|---|------------|
| 2.5.2.2 Methodology: Strengths, Limitations and Uncertainties.....                                      | 2-40       |
| 2.5.3 Estimates of USB and Contributions to USB in 2016.....  | 2-42       |
| 2.5.3.1 Spatial Characterization of O <sub>3</sub> Contributions .....                                  | 2-43       |
| 2.5.3.2 Seasonal and Geographic Variations in Ozone Contributions .....                                 | 2-45       |
| 2.5.3.3 Ozone Source Contributions as a function of Total Ozone<br>Concentration.....                   | 2-52       |
| 2.5.3.4 Predicted USB Seasonal Mean and USB on Peak O <sub>3</sub> Days .....                           | 2-58       |
| 2.5.4 Summary of USB .....  | 2-64       |
| References .....  | 2-68       |
| <b>3 RECONSIDERATION OF THE PRIMARY STANDARD .....</b>  | <b>3-1</b> |
| 3.1 Background on the Current Standard .....  | 3-2        |
| 3.2 General Approach and Key Issues .....   | 3-17       |
| 3.3 Health Effects Evidence .....   | 3-20       |
| 3.3.1 Nature of Effects.....  | 3-21       |
| 3.3.1.1 Respiratory Effects .....   | 3-22       |
| 3.3.1.2 Other Effects .....   | 3-27       |
| 3.3.2 Public Health Implications and At-risk Populations .....  | 3-29       |
| 3.3.3 Exposure Concentrations Associated with Effects .....   | 3-37       |
| 3.3.4 Uncertainties in the Health Effects Evidence .....  | 3-47       |
| 3.4 Exposure and Risk Information .....   | 3-50       |
| 3.4.1 Conceptual Model and Assessment Approach .....  | 3-51       |
| 3.4.2 Population Exposure and Risk Estimates for Air Quality Just Meeting the<br>Current Standard ..... | 3-62       |
| 3.4.3 Population Exposure and Risk Estimates for Additional Air Quality<br>Scenarios .....              | 3-68       |
| 3.4.4 Key Uncertainties .....   | 3-71       |
| 3.4.5 Public Health Implications .....  | 3-77       |
| 3.5 Key Considerations Regarding the Current Primary Standard.....                                      | 3-81       |
| 3.5.1 Evidence-based Considerations.....  | 3-82       |
| 3.5.2 Exposure/risk-based Considerations .....  | 3-85       |
| 3.5.3 Preliminary Conclusions on the Primary Standard .....   | 3-89       |
| 3.6 Key Uncertainties and Areas for Future Research .....   | 3-102      |
| References .....  | 3-105      |

|   |            |
|---|------------|
| <b>4 RECONSIDERATION OF THE SECONDARY STANDARD .....</b>  | <b>4-1</b> |
| 4.1 Background on the Current Standard .....  | 4-1        |
| 4.2 General Approach and Key Issues.....  | 4-15       |
| 4.3 Welfare Effects Evidence .....  | 4-18       |
| 4.3.1 Nature of Effects.....  | 4-19       |
| 4.3.2 Public Welfare Implications .....   | 4-26       |
| 4.3.3 Exposures Associated with Effects .....   | 4-33       |
| 4.3.3.1 Growth-related Effects.....   | 4-33       |
| 4.3.3.2 Visible Foliar Injury .....   | 4-41       |
| 4.3.3.3 Other Effects .....   | 4-48       |
| 4.3.4 Key Uncertainties .....   | 4-50       |
| 4.4 Exposure and Air Quality Information .....  | 4-58       |
| 4.4.1 Influence of Form and Averaging Time of Current Standard on W126 Index and Peak Concentration Metrics ..... | 4-62       |
| 4.4.2 Environmental Exposures in Terms of W126 Index .....  | 4-71       |
| 4.4.3 Limitations and Uncertainties.....  | 4-75       |
| 4.5 Key Considerations Regarding the Current Secondary Standard.....  | 4-77       |
| 4.5.1 Evidence and Exposure/Risk-based Considerations .....   | 4-77       |
| 4.5.1.1 Welfare Effects Evidence .....  | 4-77       |
| 4.5.1.2 General Approach for Considering Public Welfare Protection.....   | 4-85       |
| 4.5.1.3 Public Welfare Implications of Air Quality under the Current Standard .....                               | 4-100      |
| 4.5.2 Preliminary Conclusions .....   | 4-107      |
| 4.6 Key Uncertainties and Areas for Future Research .....   | 4-121      |
| References .....  | 4-123      |

## **APPENDICES**

- APPENDIX 2A. ADDITIONAL DETAILS ON DATA ANALYSIS PRESENTED IN PA SECTION 2.4
- APPENDIX 2B. ADDITIONAL DETAILS ON BACKGROUND OZONE MODELING AND ANALYSIS
- APPENDIX 3A. DETAILS ON CONTROLLED HUMAN EXPOSURE STUDIES
- APPENDIX 3B. AIR QUALITY INFORMATION FOR LOCATIONS OF EPIDEMIOLOGIC STUDIES OF RESPIRATORY EFFECTS
- APPENDIX 3C. AIR QUALITY DATA USED IN POPULATION EXPOSURE AND RISK ANALYSES
- APPENDIX 3D. EXPOSURE AND RISK ANALYSIS FOR THE OZONE NAAQS REVIEW
- APPENDIX 4A. EXPOSURE-RESPONSE FUNCTIONS FOR 11 TREE SPECIES AND TEN CROPS
- APPENDIX 4B. U.S. DISTRIBUTION OF 11 TREE SPECIES
- APPENDIX 4C. VISIBLE FOLIAR INJURY SCORES AT U.S. FOREST SERVICE BIOSITES (2006-2010)
- APPENDIX 4D. ANALYSIS OF THE W126 O<sub>3</sub> EXPOSURE INDEX AT U.S. AMBIENT AIR MONITORING SITES
- APPENDIX 4E. OZONE WELFARE EFFECTS AND RELATED ECOSYSTEM SERVICES AND PUBLIC WELFARE ASPECTS
- APPENDIX 4F. ADDITIONAL ANALYSIS OF OZONE METRICS RELATED TO CONSIDERATION OF THE SECONDARY STANDARD

## TABLE OF TABLES

|            |  |      |
|------------|--|------|
| Table 2-1. | Simulation names and descriptions for hemispheric-scale and regional-scale simulations.....  | 2-39 |
| Table 2-2. | Expressions used to calculate contributions from specific sources.....   | 2-40 |
| Table 2-3. | Predicted USB for U.S. and U.S. regions based on averages for all U.S. grid cells.....   | 2-62 |
| Table 2-4. | Predicted USB for high elevation locations (>1500 m). ....   | 2-63 |
| Table 2-5. | Predicted USB for locations within 100 km of Mexico or Canada Border.....  | 2-63 |
| Table 2-6. | Predicted USB for low-elevation ( $\leq 1500$ m) that are 100 km or farther from the border. ....  | 2-64 |
| Table 3-1. | National prevalence of asthma, 2017. ....  | 3-36 |
| Table 3-2. | Summary of 6.6-hour controlled human exposure study-findings, healthy adults. . ....   | 3-43 |
| Table 3-3. | Percent and number of simulated children and children with asthma estimated to experience at least one or more days per year with a daily maximum 7-hour average exposure at or above indicated concentration while breathing at an elevated rate in areas just meeting the current standard. .... | 3-65 |
| Table 3-4. | Percent of simulated children and children with asthma estimated to experience at least one or more days per year with a lung function decrement at or above 10, 15 or 20% while breathing at an elevated rate in areas just meeting the current standard. ....                                    | 3-68 |
| Table 3-5. | Percent and number of simulated children and children with asthma estimated to experience one or more days per year with a daily maximum 7-hour average exposure at or above indicated concentration while breathing at an elevated rate – additional air quality scenarios. ....                  | 3-70 |
| Table 3-6. | Percent of risk estimated for air quality just meeting the current standard in three study areas using the E-R function approach on days where the daily maximum 7-hour average concentration is below specified values. ....  | 3-76 |
| Table 3-7. | Percent of risk estimated for air quality just meeting the current standard in three study areas using the MSS model approach on days where the daily maximum 7-hour average concentration is below specified values. ....   | 3-76 |
| Table 3-8. | Comparison of current assessment and 2014 HREA (all study areas) for percent of children estimated to experience at least one, or two, days with an exposure at or above benchmarks while at moderate or greater exertion.....   | 3-89 |
| Table 4-1. | Percent of monitoring sites during the 2018-2020 period with 4 <sup>th</sup> max or W126 metrics at or below various thresholds that have N100 or D100 values above various thresholds.....  | 4-69 |
| Table 4-2. | Average percent of monitoring sites per year during 2016-2020 with 4 <sup>th</sup> max or  |      |

|            |  |      |
|------------|--|------|
|            | W126 metrics at or below various thresholds that have N100 or D100 values above various thresholds .....   | 4-70 |
| Table 4-3. | Distribution of 3-year average seasonal W126 index for sites in Class I areas and across U.S. that meet the current standards and for those that do not..... | 4-75 |

## TABLE OF FIGURES

|              |   |      |
|--------------|---|------|
| Figure 2-1.  | U.S. O <sub>3</sub> precursor emissions by sector: A) NO <sub>x</sub> ; B) CO; C) VOCs; D) CH <sub>4</sub> . ....   | 2-6  |
| Figure 2-2.  | U.S. anthropogenic O <sub>3</sub> precursor emission trends for: A) NO <sub>x</sub> ; B) CO; C) VOCs; and D) CH <sub>4</sub> . ....   | 2-7  |
| Figure 2-3.  | U.S. county-level CO emissions density estimates (tons/year/mi <sup>2</sup> ) for 2017. ....  | 2-9  |
| Figure 2-4.  | U.S. county-level NO <sub>x</sub> emissions density estimates (tons/year/mi <sup>2</sup> ) for 2017. ...  | 2-9  |
| Figure 2-5.  | U.S. county-level VOC emissions density estimates (tons/year/mi <sup>2</sup> ) for 2017..   | 2-10 |
| Figure 2-6.  | Current O <sub>3</sub> monitoring seasons in the U.S. ....  | 2-12 |
| Figure 2-7.  | Map of U.S. ambient air O <sub>3</sub> monitoring sites reporting data to the EPA during the 2018-2020 period.....  | 2-14 |
| Figure 2-8.  | O <sub>3</sub> design values in ppb for the 2018-2020 period. ....  | 2-16 |
| Figure 2-9.  | Trends in O <sub>3</sub> design values based on data from 2000-2002 through 2018-2020.....  | 2-17 |
| Figure 2-10. | National trend in annual 4 <sup>th</sup> highest MDA8 values, 1980 to 2020. ....  | 2-18 |
| Figure 2-11. | National trend in annual 4 <sup>th</sup> highest MDA8 concentrations and O <sub>3</sub> design values in ppb, 2000 to 2020. ....  | 2-18 |
| Figure 2-12. | Regional trends in median annual 4 <sup>th</sup> highest MDA8 concentrations, 2000 to 2020. ....  | 2-19 |
| Figure 2-13. | Diurnal patterns in hourly O <sub>3</sub> concentrations at selected monitoring sites: A) an urban site in Los Angeles; B) a downwind suburban site in Los Angeles; C) a low elevation rural site in New Hampshire; and D) a high elevation rural site in New Hampshire. . .... | 2-22 |
| Figure 2-14. | Seasonal patterns in MDA8 O <sub>3</sub> concentrations at selected monitoring sites (2015-2017): A) an urban site in Baltimore, MD; B) an urban site in Baton Rouge, LA; C) a rural site in Colorado; and D) a site in Utah experiencing high wintertime O <sub>3</sub> . .... | 2-24 |
| Figure 2-15. | Boxplots showing the distribution of MDA1 concentrations (2018-2020), binned according to each site's 2018-2020 design value. ....  | 2-26 |
| Figure 2-16. | Number of days in 2018-2020 at each monitoring site with a MDA1 concentration greater than or equal to 120 ppb compared to its 8-hour design value in ppb. . ....   | 2-26 |

|              |  |      |
|--------------|--|------|
| Figure 2-17. | National trend in the annual 2 <sup>nd</sup> highest MDA1 O <sub>3</sub> concentration, 2000 to 2020. ....   | 2-27 |
| Figure 2-18. | Conceptual models for O <sub>3</sub> sources: (a) in the U.S., and (b) at a single location. ....  | 2-30 |
| Figure 2-19. | Predicted MDA8 total O <sub>3</sub> concentration (top left), Natural (top right), International (bottom left), and USA (bottom right) contributions in spring (March, April, May). ....   | 2-44 |
| Figure 2-20. | Predicted MDA8 total O <sub>3</sub> concentration (top left), Natural (top right), International (bottom left), and USA (bottom right) contributions in summer (June, July, Aug). ....   | 2-45 |
| Figure 2-21. | Predicted contribution of International sources as a function of distance from Mexico/Canada (left) and at “interior” locations (excluding border areas) by elevation (right). ....  | 2-47 |
| Figure 2-22. | Grid cell assignments to East, West, High Elevation, Near Border, and Near and High (i.e., both High Elevation and Near Border). ....  | 2-48 |
| Figure 2-23. | Annual time series of regional average predicted MDA8 total O <sub>3</sub> concentration and contributions of each source (see legend) for the West (top), and the East (bottom). ....   | 2-49 |
| Figure 2-24. | Annual time series of regional urban area-weighted average predicted MDA8 total O <sub>3</sub> concentration and contributions of each source (see legend) for the High-elevation West (top), near-border West (middle), and Low/Interior West (bottom). ....  | 2-51 |
| Figure 2-25. | Predicted contribution of Natural as a function of predicted total (Base) MDA8 O <sub>3</sub> concentration in the West and East. ....   | 2-53 |
| Figure 2-26. | Predicted contribution of International as a function of predicted total (Base) MDA8 O <sub>3</sub> concentration in the West and East. ....   | 2-54 |
| Figure 2-27. | Predicted contribution of USA as a function of predicted total (Base) MDA8 O <sub>3</sub> concentration in the West and East. Sloped lines show percent contribution as a quick reference.. ....   | 2-54 |
| Figure 2-28. | Annual time series of regional average predicted MDA8 O <sub>3</sub> and contributions of each source to predicted MDA8 total O <sub>3</sub> (see legend) in the West (top) and East (bottom) including only those grid-cell days with MDA8 greater than 70 ppb. ....  | 2-56 |
| Figure 2-29. | Annual time series of regional average predicted MDA8 O <sub>3</sub> and contributions of each source to predicted MDA8 O <sub>3</sub> (see legend) in the high-elevation West (top), in the near-border West (middle), and in the Low/Interior West weighted toward urban areas (bottom) including only those grid-cell days with MDA8 O <sub>3</sub> greater than 70 ppb. .... | 2-57 |
| Figure 2-30. | Map of predicted USB contributions by O <sub>3</sub> season for spring average (top left), summer average (top right), top 10 predicted total O <sub>3</sub> days (center left),   |      |

|              |   |      |
|--------------|---|------|
|              | 4 <sup>th</sup> highest total O <sub>3</sub> simulated day (center right), and all days with total O <sub>3</sub> greater than 70 ppb (bottom left), along with a map of the number of days with total O <sub>3</sub> above 70 ppb (bottom right).....  | 2-60 |
| Figure 3-1.  | Overview of general approach for the primary O <sub>3</sub> standard. ....  | 3-19 |
| Figure 3-2.  | Group mean O <sub>3</sub> -induced reduction in FEV1 from controlled human exposure studies of healthy adults exposed for 6.6 hours with quasi-continuous exercise.....   | 3-39 |
| Figure 3-3.  | Conceptual model for exposure-based risk assessment. ....   | 3-52 |
| Figure 3-4.  | Analysis approach for exposure-based risk analyses. ....  | 3-53 |
| Figure 4-1.  | Overview of general approach for the secondary O <sub>3</sub> standard.....   | 4-17 |
| Figure 4-2.  | Potential effects of O <sub>3</sub> on the public welfare.....  | 4-32 |
| Figure 4-3.  | Established RBL functions for seedlings of 11 tree species. ....  | 4-39 |
| Figure 4-4.  | Established RYL functions for 10 crops. ....  | 4-40 |
| Figure 4-5.  | Distribution of nonzero BI scores at USFS biosites (normal soil moisture) grouped by assigned W126 index estimates.....   | 4-47 |
| Figure 4-6.  | W126 index at monitoring sites with valid design values (2018-2020 average) .....   | 4-60 |
| Figure 4-7.  | N100 values at monitoring sites with valid design values (2018-2020 average) .....  | 4-61 |
| Figure 4-8.  | D100 values at monitoring sites with valid design values (2018-2020 average) .....  | 4-61 |
| Figure 4-9.  | Relationship between the W126 index and design values for the current standard (2018-2020). The W126 is analyzed in terms of averages across the 3-year design value period (left) and annual values (right).....   | 4-63 |
| Figure 4-10. | Relationship between trends in the W126 index and trends in design values across a 21-year period (2000-2020) at U.S. monitoring sites. W126 is analyzed in terms of averages across 3-year design value periods (left) and annual values (right).....  | 4-65 |
| Figure 4-11. | Distributions of MDA1 concentrations for the three design value periods in 2000-2004 (red) and 2016-2020 (blue), binned by the design value at each monitoring site. Boxes represent the 25 <sup>th</sup> , 50 <sup>th</sup> , and 75 <sup>th</sup> percentiles; whiskers represent the 1 <sup>st</sup> and 99 <sup>th</sup> percentiles; and circles are outlier values.....         | 4-67 |
| Figure 4-12. | Distributions of N100 (top panels) and D100 (bottom panels) values at monitoring sites differing by design values (left panels) and W126 index values (right panels) based on the 2018-2020 monitoring data. The boxes represent the 25 <sup>th</sup> , 50 <sup>th</sup> , and 75 <sup>th</sup> percentiles and the whiskers extend to the 1 <sup>st</sup> and 99 <sup>th</sup> ..... | 4-68 |
| Figure 4-13. | Analytical approach for characterizing vegetation exposure with W126 index.....   | 4-72 |



# 1 INTRODUCTION

This document, *Policy Assessment for the Reconsideration of the Ozone National Ambient Air Quality Standards, External Review Draft* (hereafter referred to as the draft PA), presents the draft policy assessment for the U.S. Environmental Protection Agency's (EPA's) reconsideration of the decision reached in the review of the ozone (O<sub>3</sub>) national ambient air quality standards (NAAQS) completed in 2020.<sup>1, 2</sup> This draft PA considers the key policy-relevant issues, drawing on those identified in the *Integrated Review Plan for the Ozone National Ambient Air Quality Standards* (IRP; [U.S. EPA, 2019]) in light of the available evidence assessed in the *Integrated Science Assessment for Ozone and Related Photochemical Oxidants* (ISA [U.S. EPA, 2020a]) and quantitative air quality, exposure and risk analyses based on that evidence, including any analyses updated for this reconsideration. Thus, this document will reassess the policy implications of the scientific evidence described in the 2020 ISA and related air quality, exposure and risk analyses. Accordingly, this document draws heavily on information presented in the 2020 PA (U.S. EPA, 2020b), with some updates to include more recent air quality information.

This document is organized into four chapters. Chapter 1 presents introductory information on the purpose of the PA in the context of NAAQS reviews, legislative requirements for NAAQS reviews, an overview of the history of the O<sub>3</sub> NAAQS, including background information on prior reviews, and a summary of the process for this reconsideration. Chapter 2 provides an overview of how photochemical oxidants, including O<sub>3</sub>, are formed in the atmosphere, along with updated information on sources and emissions of important precursor chemicals, as well as updated ambient air monitoring data. Chapter 2 also summarizes key aspects of the ambient air monitoring requirements, and O<sub>3</sub> air quality, including model-based estimates of O<sub>3</sub> resulting from natural sources and anthropogenic sources outside the U.S. Chapters 3 focuses on policy-relevant aspects of the health effects evidence (as presented in the 2020 ISA) and exposure/risk information, identifying and summarizing key considerations related to review of the primary (health-based) standard. Similarly, Chapter 4 focuses on policy-

---

<sup>1</sup> The scope for this reconsideration, as for the 2020 decision on the O<sub>3</sub> NAAQS, focuses on the presence in ambient air of photochemical oxidants, a group of gaseous compounds of which ozone (the indicator for the current standards) is the most prevalent in the atmosphere and the one for which there is a very large, well-established evidence base of its health and welfare effects. The ozone standards that were established in 2015 (80 FR 65292, October 26, 2015) and retained in 2020 (85 FR 87256, December 31, 2020), are referred to in this document as the "current" or "existing" standards.

<sup>2</sup> On October 29, 2021, the Agency announced its decision to reconsider the 2020 O<sub>3</sub> NAAQS final action. This announcement is available at <https://www.epa.gov/ground-level-ozone-pollution/epa-reconsider-previous-administrations-decision-retain-2015-ozone>.

relevant aspects of the welfare effects evidence (as presented in the 2020 ISA) and air quality, exposure and risk information, identifying and summarizing key considerations related to review of the secondary (welfare -based) standard.

## **1.1 PURPOSE**

Generally in each NAAQS review, the PA, when final, presents an evaluation, for consideration by the EPA Administrator, of the policy implications of the available scientific information, assessed in the ISA, any quantitative air quality, exposure or risk analyses based on the ISA findings, and related limitations and uncertainties. Ultimately, a final decision on the NAAQS will reflect the judgments of the Administrator. The role of the PA is to help “bridge the gap” between the Agency’s scientific assessment and quantitative technical analyses, and the judgments required of the Administrator in determining whether it is appropriate to retain or revise the NAAQS.

In evaluating the question of adequacy of the current standards and whether it may be appropriate to consider alternative standards, the PA focuses on information that is most pertinent to evaluating the standards and their basic elements: indicator, averaging time, form, and level.<sup>3</sup> These elements, which together serve to define each standard, must be considered collectively in evaluating the public health and public welfare protection the standards afford.

The development of the PA is also intended to facilitate advice to the Agency and recommendations to the Administrator from an independent scientific review committee, the Clean Air Scientific Advisory Committee (CASAC), as provided for in the Clean Air Act (CAA). The EPA generally makes available to the CASAC and the public one or more drafts of the PA for CASAC review and public comment. As discussed below in section 1.2, the CASAC is to advise on subjects including the Agency’s assessment of the relevant scientific information and on the adequacy of the current standards, and to make recommendations as to any revisions of the standards that may be appropriate. In its review of the draft PA, the CASAC also conveys its advice on the standards.

In this draft PA for the reconsideration of the December 2020 O<sub>3</sub> NAAQS decision, we<sup>4</sup> take into account the scientific evidence, as characterized in the 2020 ISA and the additional

---

<sup>3</sup> The indicator defines the chemical species or mixture to be measured in the ambient air for the purpose of determining whether an area attains the standard. The averaging time defines the period over which air quality measurements are to be averaged or otherwise analyzed. The form of a standard defines the air quality statistic that is to be compared to the level of the standard in determining whether an area attains the standard. For example, the form of the annual NAAQS for fine particulate matter is the average of annual mean concentrations for three consecutive years, while the form of the 8-hour NAAQS for carbon monoxide is the second-highest 8-hour average in a year. The level of the standard defines the air quality concentration used for that purpose.

<sup>4</sup> The terms “staff,” “we” and “our” throughout this document refer to the staff in the EPA’s Office of Air Quality Planning and Standards (OAQPS).

1 policy-relevant quantitative air quality, exposure and risk analyses described herein. Advice and  
2 comments from the CASAC and the public on this draft PA will inform the final evaluation and  
3 conclusions in the final PA.

4 The final PA is designed to assist the Administrator in considering the available scientific  
5 and risk information and formulating judgments regarding the standards. Accordingly, the final  
6 PA will inform the Administrator’s decision in this reconsideration. Beyond informing the  
7 Administrator and facilitating the advice and recommendations of the CASAC, the final PA is  
8 also intended to be a useful reference to all interested parties. In these roles, it is intended to  
9 serve as a source of policy-relevant information that supports the Agency’s reconsideration of  
10 the 2020 O<sub>3</sub> NAAQS decision, and it is written to be understandable to a broad audience.

## 11 **1.2 LEGISLATIVE REQUIREMENTS**

12 Two sections of the CAA govern the establishment and revision of the NAAQS. Section  
13 108 (42 U.S.C. 7408) directs the Administrator to identify and list certain air pollutants and then  
14 to issue air quality criteria for those pollutants. The Administrator is to list those pollutants  
15 “emissions of which, in his judgment, cause or contribute to air pollution which may reasonably  
16 be anticipated to endanger public health or welfare”; “the presence of which in the ambient air  
17 results from numerous or diverse mobile or stationary sources”; and for which he “plans to issue  
18 air quality criteria....” (42 U.S.C. § 7408(a)(1)). Air quality criteria are intended to “accurately  
19 reflect the latest scientific knowledge useful in indicating the kind and extent of all identifiable  
20 effects on public health or welfare which may be expected from the presence of [a] pollutant in  
21 the ambient air....” (42 U.S.C. § 7408(a)(2)).

22 Section 109 [42 U.S.C. 7409] directs the Administrator to propose and promulgate  
23 “primary” and “secondary” NAAQS for pollutants for which air quality criteria are issued [42  
24 U.S.C. § 7409(a)]. Section 109(b)(1) defines primary standards as ones “the attainment and  
25 maintenance of which in the judgment of the Administrator, based on such criteria and allowing  
26 an adequate margin of safety, are requisite to protect the public health.”<sup>5</sup> Under section  
27 109(b)(2), a secondary standard must “specify a level of air quality the attainment and  
28 maintenance of which, in the judgment of the Administrator, based on such criteria, is requisite  
29 to protect the public welfare from any known or anticipated adverse effects associated with the  
30 presence of [the] pollutant in the ambient air.”<sup>6</sup>

---

<sup>5</sup> The legislative history of section 109 indicates that a primary standard is to be set at “the maximum permissible ambient air level . . . which will protect the health of any [sensitive] group of the population,” and that for this purpose “reference should be made to a representative sample of persons comprising the sensitive group rather than to a single person in such a group.” S. Rep. No. 91-1196, 91st Cong., 2d Sess. 10 (1970).

<sup>6</sup> Under CAA section 302(h) (42 U.S.C. § 7602(h)), effects on welfare include, but are not limited to, “effects on soils, water, crops, vegetation, manmade materials, animals, wildlife, weather, visibility, and climate, damage to

1 In setting primary and secondary standards that are “requisite” to protect public health  
2 and welfare, respectively, as provided in section 109(b), the EPA’s task is to establish standards  
3 that are neither more nor less stringent than necessary. In so doing, the EPA may not consider the  
4 costs of implementing the standards. See generally, *Whitman v. American Trucking Ass’n*, 531  
5 U.S. 457, 465-472, 475-76 (2001). Likewise, “[a]ttainability and technological feasibility are not  
6 relevant considerations in the promulgation of national ambient air quality standards” (*American  
7 Petroleum Institute v. Costle*, 665 F.2d 1176, 1185 [D.C. Cir. 1981], *cert. denied*, 455 U.S. 1034  
8 [1982]; *accord Murray Energy Corp. v. EPA*, 936 F.3d 597, 623-24 [D.C. Cir. 2019]). At the  
9 same time, courts have clarified the EPA may consider “relative proximity to peak background  
10 ... concentrations” as a factor in deciding how to revise the NAAQS in the context of  
11 considering standard levels within the range of reasonable values supported by the air quality  
12 criteria and judgments of the Administrator (*American Trucking Ass’n v. EPA*, 283 F.3d 355,  
13 379 [D.C. Cir. 2002], hereafter referred to as “*ATA III*”).

14 The requirement that primary standards provide an adequate margin of safety was  
15 intended to address uncertainties associated with inconclusive scientific and technical  
16 information available at the time of standard setting. It was also intended to provide a reasonable  
17 degree of protection against hazards that research has not yet identified. See *Lead Industries  
18 Ass’n v. EPA*, 647 F.2d 1130, 1154 (D.C. Cir 1980), *cert. denied*, 449 U.S. 1042 (1980);  
19 *American Petroleum Institute v. Costle*, 665 F.2d at 1186; *Coalition of Battery Recyclers Ass’n v.  
20 EPA*, 604 F.3d 613, 617-18 (D.C. Cir. 2010); *Mississippi v. EPA*, 744 F.3d 1334, 1353 (D.C. Cir.  
21 2013). Both kinds of uncertainties are components of the risk associated with pollution at levels  
22 below those at which human health effects can be said to occur with reasonable scientific  
23 certainty. Thus, in selecting primary standards that include an adequate margin of safety, the  
24 Administrator is seeking not only to prevent pollution levels that have been demonstrated to be  
25 harmful but also to prevent lower pollutant levels that may pose an unacceptable risk of harm,  
26 even if the risk is not precisely identified as to nature or degree. The CAA does not require the  
27 Administrator to establish a primary NAAQS at a zero-risk level or at background concentration  
28 levels (see *Lead Industries v. EPA*, 647 F.2d at 1156 n.51, *Mississippi v. EPA*, 744 F.3d at 1351),  
29 but rather at a level that reduces risk sufficiently so as to protect public health with an adequate  
30 margin of safety.

31 In addressing the requirement for an adequate margin of safety, the EPA considers such  
32 factors as the nature and severity of the health effects involved, the size of the sensitive  
33 population(s), and the kind and degree of uncertainties. The selection of any particular approach

---

and deterioration of property, and hazards to transportation, as well as effects on economic values and on personal comfort and well-being.”

1 to providing an adequate margin of safety is a policy choice left specifically to the  
2 Administrator’s judgment. See *Lead Industries Ass’n v. EPA*, 647 F.2d at 1161-62; *Mississippi v.*  
3 *EPA*, 744 F.3d at 1353.

4 Section 109(d)(1) of the Act requires periodic review and, if appropriate, revision of  
5 existing air quality criteria to reflect advances in scientific knowledge on the effects of the  
6 pollutant on public health and welfare. Under the same provision, the EPA is also to periodically  
7 review and, if appropriate, revise the NAAQS, based on the revised air quality criteria.<sup>7</sup>

8 Section 109(d)(2) addresses the appointment and advisory functions of an independent  
9 scientific review committee. Section 109(d)(2)(A) requires the Administrator to appoint this  
10 committee, which is to be composed of “seven members including at least one member of the  
11 National Academy of Sciences, one physician, and one person representing State air pollution  
12 control agencies.” Section 109(d)(2)(B) provides that the independent scientific review  
13 committee “shall complete a review of the criteria...and the national primary and secondary  
14 ambient air quality standards...and shall recommend to the Administrator any new...standards  
15 and revisions of existing criteria and standards as may be appropriate....” Since the early 1980s,  
16 this independent review function has been performed by the CASAC of the EPA’s Science  
17 Advisory Board. A number of other advisory functions are also identified for the committee by  
18 section 109(d)(2)(C), which reads:

19 Such committee shall also (i) advise the Administrator of areas in which  
20 additional knowledge is required to appraise the adequacy and basis of existing,  
21 new, or revised national ambient air quality standards, (ii) describe the research  
22 efforts necessary to provide the required information, (iii) advise the  
23 Administrator on the relative contribution to air pollution concentrations of  
24 natural as well as anthropogenic activity, and (iv) advise the Administrator of any  
25 adverse public health, welfare, social, economic, or energy effects which may  
26 result from various strategies for attainment and maintenance of such national  
27 ambient air quality standards.

28 As previously noted, the Supreme Court has held that section 109(b) “unambiguously bars cost  
29 considerations from the NAAQS-setting process” (*Whitman v. American Trucking Ass’ns*, 531  
30 U.S. 457, 471 [2001]). Accordingly, while some of the issues listed in section 109(d)(2)(C) as  
31 those on which Congress has directed the CASAC to advise the Administrator are ones that are  
32 relevant to the standard setting process, others are not. Issues that are not relevant to standard  
33 setting may be relevant to implementation of the NAAQS once they are established.<sup>8</sup>

---

<sup>7</sup> This section of the Act requires the Administrator to complete these reviews and make any revisions that may be appropriate “at five-year intervals.”

<sup>8</sup> Because some of these issues are not relevant to standard setting, some aspects of CASAC advice may not be relevant to EPA’s process of setting primary and secondary standards that are requisite to protect public health and welfare. Indeed, were the EPA to consider costs of implementation when reviewing and revising the

### 1.3 HISTORY OF THE O<sub>3</sub> NAAQS, REVIEWS AND DECISIONS

Primary and secondary NAAQS were first established for photochemical oxidants in 1971 (36 FR 8186, April 30, 1971) based on the air quality criteria developed in 1970 (U.S. DHEW, 1970; 35 FR 4768, March 19, 1970). The EPA set both primary and secondary standards at 0.08 parts per million (ppm), as a 1-hour average of total photochemical oxidants, not to be exceeded more than one hour per year based on the scientific information in the 1970 air quality criteria document (AQCD). Since that time, the EPA has reviewed the air quality criteria and standards a number of times, with the most recent review being completed in 2020.

The EPA initiated the first periodic review of the NAAQS for photochemical oxidants in 1977. Based on the 1978 AQCD (U.S. EPA, 1978), the EPA published proposed revisions to the original NAAQS in 1978 (43 FR 26962, June 22, 1978) and final revisions in 1979 (44 FR 8202, February 8, 1979). At that time, the EPA changed the indicator from photochemical oxidants to O<sub>3</sub>, revised the level of the primary and secondary standards from 0.08 to 0.12 ppm and revised the form of both standards from a deterministic (i.e., not to be exceeded more than one hour per year) to a statistical form. With these changes, attainment of the standards was defined to occur when the average number of days per calendar year (across a 3-year period) with maximum hourly average O<sub>3</sub> concentration greater than 0.12 ppm equaled one or less (44 FR 8202, February 8, 1979; 43 FR 26962, June 22, 1978).

Following the EPA's decision in the 1979 review, several petitioners sought judicial review. Among those, the city of Houston challenged the Administrator's decision arguing that the standard was arbitrary and capricious because natural O<sub>3</sub> concentrations and other physical phenomena in the Houston area made the standard unattainable in that area. The U.S. Court of Appeals for the District of Columbia Circuit (D.C. Circuit) rejected this argument, holding (as noted in section 1.1 above) that attainability and technological feasibility are not relevant considerations in the promulgation of the NAAQS (*American Petroleum Institute v. Costle*, 665 F.2d at 1185). The court also noted that the EPA need not tailor the NAAQS to fit each region or locale, pointing out that Congress was aware of the difficulty in meeting standards in some locations and had addressed this difficulty through various compliance related provisions in the CAA (*id.* at 1184-86).

---

standards “it would be grounds for vacating the NAAQS” (*Whitman v. American Trucking Ass'ns*, 531 U.S. 457, 471 n.4 [2001]). At the same time, the CAA directs CASAC to provide advice on “any adverse public health, welfare, social, economic, or energy effects which may result from various strategies for attainment and maintenance” of the NAAQS to the Administrator under section 109(d)(2)(C)(iv). In *Whitman*, the Court clarified that most of that advice would be relevant to implementation but not standard setting, as it “enable[s] the Administrator to assist the States in carrying out their statutory role as primary *implementers* of the NAAQS” (*id.* at 470 [emphasis in original]). However, the Court also noted that CASAC's “advice concerning certain aspects of ‘adverse public health ... effects’ from various attainment strategies is unquestionably pertinent” to the NAAQS rulemaking record and relevant to the standard setting process (*id.* at 470 n.2).

1 The next periodic reviews of the criteria and standards for O<sub>3</sub> and other photochemical  
2 oxidants began in 1982 and 1983, respectively (47 FR 11561, March 17, 1982; 48 FR 38009,  
3 August 22, 1983). The EPA subsequently published the 1986 AQCD (U.S. EPA, 1986) and the  
4 1989 Staff Paper (U.S. EPA, 1989). Following publication of the 1986 AQCD, a number of  
5 scientific abstracts and articles were published that appeared to be of sufficient importance  
6 concerning potential health and welfare effects of O<sub>3</sub> to warrant preparation of a supplement to  
7 the 1986 AQCD (U.S. EPA, 1992). In August of 1992, the EPA proposed to retain the existing  
8 primary and secondary standards based on the health and welfare effects information contained  
9 in the 1986 AQCD and its 1992 Supplement (57 FR 35542, August 10, 1992). In March 1993,  
10 the EPA announced its decision to conclude this review by affirming its proposed decision to  
11 retain the standards, without revision (58 FR 13008, March 9, 1993).

12 In the 1992 notice of its proposed decision in that review, the EPA announced its  
13 intention to proceed as rapidly as possible with the next review of the air quality criteria and  
14 standards for O<sub>3</sub> and other photochemical oxidants in light of emerging evidence of health effects  
15 related to 6- to 8-hour O<sub>3</sub> exposures (57 FR 35542, August 10, 1992). The EPA subsequently  
16 published the AQCD and Staff Paper for that next review (U.S. EPA, 1996). In December 1996,  
17 the EPA proposed revisions to both the primary and secondary standards (61 FR 65716,  
18 December 13, 1996). With regard to the primary standard, the EPA proposed to replace the then-  
19 existing 1-hour primary standard with an 8-hour standard set at a level of 0.08 ppm (equivalent  
20 to 0.084 ppm based on the proposed data handling convention) as a 3-year average of the annual  
21 third-highest daily maximum 8-hour concentration. The EPA proposed to revise the secondary  
22 standard either by setting it identical to the proposed new primary standard or by setting it as a  
23 new seasonal standard using a cumulative form. The EPA completed this review in 1997 by  
24 setting the primary standard at a level of 0.08 ppm, based on the annual fourth-highest daily  
25 maximum 8-hour average concentration, averaged over three years, and setting the secondary  
26 standard identical to the revised primary standard (62 FR 38856, July 18, 1997).

27 On May 14, 1999, in response to challenges by industry and others to the EPA's 1997  
28 decision, the D.C. Circuit remanded the O<sub>3</sub> NAAQS to the EPA, finding that section 109 of the  
29 CAA, as interpreted by the EPA, effected an unconstitutional delegation of legislative authority  
30 (*American Trucking Ass'n v. EPA*, 175 F.3d 1027, 1034-1040 [D.C. Cir. 1999]). In addition, the  
31 court directed that, in responding to the remand, the EPA should consider the potential beneficial  
32 health effects of O<sub>3</sub> pollution in shielding the public from the effects of solar ultraviolet (UV)  
33 radiation, as well as adverse health effects (*id.* at 1051-53). In 1999, the EPA sought panel  
34 rehearing and for rehearing *en banc* on several issues related to that decision. The court granted  
35 the request for panel rehearing in part and denied it in part but declined to review its ruling with  
36 regard to the potential beneficial effects of O<sub>3</sub> pollution (*American Trucking Ass'n v. EPA*, 195

1 F.3d 4, 10 [D.C. Cir., 1999]). On January 27, 2000, the EPA petitioned the U.S. Supreme Court  
2 for *certiorari* on the constitutional issue (and two other issues) but did not request review of the  
3 ruling regarding the potential beneficial health effects of O<sub>3</sub>. On February 27, 2001, the U.S.  
4 Supreme Court unanimously reversed the judgment of the D.C. Circuit on the constitutional  
5 issue (*Whitman v. American Trucking Ass 'ns*, 531 U.S. 457, 472-74 [2001], [holding that section  
6 109 of the CAA does not delegate legislative power to the EPA in contravention of the  
7 Constitution]). The Court remanded the case to the D.C. Circuit to consider challenges to the O<sub>3</sub>  
8 NAAQS that had not been addressed by that court's earlier decisions. On March 26, 2002, the  
9 D.C. Circuit issued its final decision on the remand, finding the 1997 O<sub>3</sub> NAAQS to be "neither  
10 arbitrary nor capricious," and so denying the remaining petitions for review. See *ATA III*, 283  
11 F.3d at 379.

12 Specifically, in *ATA III*, the D.C. Circuit upheld the EPA's decision on the 1997 O<sub>3</sub>  
13 standard as the product of reasoned decision making. With regard to the primary standard, the  
14 court made clear that the most important support for the EPA's decision to revise the standard  
15 was the health evidence of insufficient protection afforded by the then-existing standard ("the  
16 record [is] replete with references to studies demonstrating the inadequacies of the old one-hour  
17 standard"), as well as extensive information supporting the change to an 8-hour averaging time  
18 (*id.* at 378). The court further upheld the EPA's decision not to select a more stringent level for  
19 the primary standard noting "the absence of *any* [emphasis in original] human clinical studies at  
20 ozone concentrations below 0.08 [ppm]" which supported the EPA's conclusion that "the most  
21 serious health effects of ozone are 'less certain' at low concentrations, providing an eminently  
22 rational reason to set the primary standard at a somewhat higher level, at least until additional  
23 studies become available" (*id.* at 379, internal citations omitted). The court also pointed to the  
24 significant weight that the EPA properly placed on the advice it received from the CASAC (*id.* at  
25 379). In addition, the court noted that "although relative proximity to peak background ozone  
26 concentrations did not, in itself, necessitate a level of 0.08 [ppm], EPA could consider that factor  
27 when choosing among the three alternative levels" (*id.* at 379).

28 Coincident with the continued litigation of the other issues, the EPA responded to the  
29 court's 1999 remand to consider the potential beneficial health effects of O<sub>3</sub> pollution in  
30 shielding the public from effects of UV radiation (66 FR 57268, Nov. 14, 2001; 68 FR 614,  
31 January 6, 2003). The EPA provisionally determined that the information linking changes in  
32 patterns of ground-level O<sub>3</sub> concentrations to changes in relevant patterns of exposures to UV  
33 radiation of concern (UV-B) to public health was too uncertain, at that time, to warrant any  
34 relaxation in 1997 O<sub>3</sub> NAAQS. The EPA also expressed the view that any plausible changes in  
35 UV-B radiation exposures from changes in patterns of ground-level O<sub>3</sub> concentrations would  
36 likely be very small from a public health perspective. In view of these findings, the EPA



1 proposed to leave the 1997 primary standard unchanged (66 FR 57268, Nov. 14, 2001). After  
2 considering public comment on the proposed decision, the EPA published its final response to  
3 this remand in 2003, re-affirming the 8-hour primary standard set in 1997 (68 FR 614, January 6,  
4 2003).

5 The EPA initiated the fourth periodic review of the air quality criteria and standards for  
6 O<sub>3</sub> and other photochemical oxidants with a call for information in September 2000 (65 FR  
7 57810, September 26, 2000). In 2007, the EPA proposed to revise the level of the primary  
8 standard within a range of 0.075 to 0.070 ppm (72 FR 37818, July 11, 2007). The EPA proposed  
9 to revise the secondary standard either by setting it identical to the proposed new primary  
10 standard or by setting it as a new seasonal standard using a cumulative form. Documents  
11 supporting these proposed decisions included the 2006 AQCD (U.S. EPA, 2006) and 2007 Staff  
12 Paper (U.S. EPA, 2007) and related technical support documents. The EPA completed the  
13 review in March 2008 by revising the levels of both the primary and secondary standards from  
14 0.08 ppm to 0.075 ppm while retaining the other elements of the prior standards (73 FR 16436,  
15 March 27, 2008).

16 In May 2008, state, public health, environmental, and industry petitioners filed suit  
17 challenging the EPA's final decision on the 2008 O<sub>3</sub> standards. On September 16, 2009, the EPA  
18 announced its intention to reconsider the 2008 O<sub>3</sub> standards,<sup>9</sup> and initiated a rulemaking to do so.  
19 At the EPA's request, the court held the consolidated cases in abeyance pending the EPA's  
20 reconsideration of the 2008 decision.

21 In January 2010, the EPA issued a notice of proposed rulemaking to reconsider the 2008  
22 final decision (75 FR 2938, January 19, 2010). In that notice, the EPA proposed that further  
23 revisions of the primary and secondary standards were necessary to provide a requisite level of  
24 protection to public health and welfare. The EPA proposed to revise the level of the primary  
25 standard from 0.075 ppm to a level within the range of 0.060 to 0.070 ppm, and to revise the  
26 secondary standard to one with a cumulative, seasonal form. At the EPA's request, the CASAC  
27 reviewed the proposed rule at a public teleconference on January 25, 2010 and provided  
28 additional advice in early 2011 (Samet, 2010, Samet, 2011). Later that year, in view of the need  
29 for further consideration and the fact that the Agency's next periodic review of the O<sub>3</sub> NAAQS  
30 required under CAA section 109 had already begun (as announced on September 29, 2008),<sup>10</sup> the  
31 EPA decided to consolidate the reconsideration with its statutorily required periodic review.<sup>11</sup>

---

<sup>9</sup> The press release of this announcement is available at:

[https://archive.epa.gov/epapages/newsroom\\_archive/newsreleases/85f90b7711acb0c88525763300617d0d.html](https://archive.epa.gov/epapages/newsroom_archive/newsreleases/85f90b7711acb0c88525763300617d0d.html).

<sup>10</sup> The *Call for Information* initiating the new review was announced in the Federal Register (73 FR 56581, September 29, 2008).

<sup>11</sup> This rulemaking, completed in 2015, concluded the reconsideration process.

1 In light of the EPA's decision to consolidate the reconsideration with the ongoing  
2 periodic review, the D.C. Circuit proceeded with the litigation on the 2008 O<sub>3</sub> NAAQS decision.  
3 On July 23, 2013, the court upheld the EPA's 2008 primary standard, but remanded the 2008  
4 secondary standard to the EPA (*Mississippi v. EPA*, 744 F.3d 1334 [D.C. Cir. 2013]). With  
5 respect to the primary standard, the court first rejected arguments that the EPA should not have  
6 lowered the level of the existing primary standard, holding that the EPA reasonably determined  
7 that the existing primary standard was not requisite to protect public health with an adequate  
8 margin of safety, and consequently required revision. The court went on to reject arguments that  
9 the EPA should have adopted a more stringent primary standard. With respect to the secondary  
10 standard, the court held that the EPA's explanation for the setting of the secondary standard  
11 identical to the revised 8-hour primary standard was inadequate under the CAA because the EPA  
12 had not adequately explained how that standard provided the required public welfare protection.

13 At the time of the court's decision, the EPA had already completed significant portions of  
14 its next statutorily required periodic review of the O<sub>3</sub> NAAQS. This review had been formally  
15 initiated in 2008 with a call for information in the *Federal Register* (73 FR 56581, September 29,  
16 2008). In late 2014, based on the ISA, Risk and Exposure Assessments (REAs) for health and  
17 welfare, and PA<sup>12</sup> developed for this review, the EPA proposed to revise the 2008 primary and  
18 secondary standards by reducing the level of both standards to within the range of 0.070 to 0.065  
19 ppm (79 FR 75234, December 17, 2014).

20 The EPA's final decision in this review was published in October 2015, establishing the  
21 now-current standards (80 FR 65292, October 26, 2015). In this decision, based on consideration  
22 of the health effects evidence on respiratory effects of O<sub>3</sub> in at-risk populations, the EPA revised  
23 the primary standard from a level of 0.075 ppm to a level of 0.070 ppm, while retaining all the  
24 other elements of the standard (80 FR 65292, October 26, 2015). The EPA's decision on the  
25 level for the standard was based on the weight of the scientific evidence and quantitative  
26 exposure/risk information. The level of the secondary standard was also revised from 0.075 ppm  
27 to 0.070 ppm based on the scientific evidence of O<sub>3</sub> effects on welfare, particularly the evidence  
28 of O<sub>3</sub> impacts on vegetation, and quantitative analyses available in the review.<sup>13</sup> The other  
29 elements of the standard were retained. This decision on the secondary standard also  
30 incorporated the EPA's response to the D.C. Circuit's remand of the 2008 secondary standard in  
31 *Mississippi v. EPA*, 744 F.3d 1344 (D.C. Cir. 2013). The 2015 revisions to the NAAQS were

---

<sup>12</sup> The final versions of these documents, released in August 2014, were developed with consideration of the comments and recommendations from the CASAC, as well as comments from the public on the draft documents (Frey, 2014a, Frey, 2014b, Frey, 2014c, U.S. EPA, 2014a, U.S. EPA, 2014b, U.S. EPA, 2014c).

<sup>13</sup> These standards, set in 2015, are specified at 40 CFR 50.19.

1 accompanied by revisions to the data handling procedures, and the ambient air monitoring  
2 requirements<sup>14</sup> (80 FR 65292, October 26, 2015).<sup>15</sup>

3 After publication of the final rule, a number of industry groups, environmental and health  
4 organizations, and certain states filed petitions for judicial review in the D.C. Circuit. The  
5 industry and state petitioners argued that the revised standards were too stringent, while the  
6 environmental and health petitioners argued that the revised standards were not stringent enough  
7 to protect public health and welfare as the Act requires. On August 23, 2019, the court issued an  
8 opinion that denied all the petitions for review with respect to the 2015 primary standard while  
9 also concluding that the EPA had not provided a sufficient rationale for aspects of its decision on  
10 the 2015 secondary standard and remanding that standard to the EPA (*Murray Energy Corp. v.*  
11 *EPA*, 936 F.3d 597 [D.C. Cir. 2019]).

12 In the August 2019 decision, the court additionally addressed arguments regarding  
13 considerations of background O<sub>3</sub> concentrations, and socioeconomic and energy impacts. With  
14 regard to the former, the court rejected the argument that the EPA was required to take  
15 background O<sub>3</sub> concentrations into account when setting the NAAQS, holding that the text of  
16 CAA section 109(b) precluded this interpretation because it would mean that if background O<sub>3</sub>  
17 levels in any part of the country exceeded the level of O<sub>3</sub> that is requisite to protect public health,  
18 the EPA would be obliged to set the standard at the higher nonprotective level (*id.* at 622-23).  
19 Thus, the court concluded that the EPA did not act unlawfully or arbitrarily or capriciously in  
20 setting the 2015 NAAQS without regard for background O<sub>3</sub> (*id.* at 624). Additionally, the court  
21 denied arguments that the EPA was required to consider adverse economic, social, and energy  
22 impacts in determining whether a revision of the NAAQS was “appropriate” under section  
23 109(d)(1) of the CAA (*id.* at 621-22). The court reasoned that consideration of such impacts was  
24 precluded by *Whitman*’s holding that the CAA “unambiguously bars cost considerations from the  
25 NAAQS-setting process” (531 U.S. at 471, summarized in section 1.2 above). Further, the court  
26 explained that section 109(d)(2)(C)’s requirement that CASAC advise the EPA “of any adverse  
27 public health, welfare, social, economic, or energy effects which may result from various  
28 strategies for attainment and maintenance” of revised NAAQS had no bearing on whether costs  
29 are to be considered in setting the NAAQS (*Murray Energy Corp. v. EPA*, 936 F.3d at 622).

---

<sup>14</sup> The current federal regulatory measurement methods for O<sub>3</sub> are specified in 40 CFR 50, Appendix D and 40 CFR part 53. Consideration of ambient air measurements with regard to judging attainment of the standards set in 2015 is specified in 40 CFR 50, Appendix U. The O<sub>3</sub> monitoring network requirements are specified in 40 CFR 58.

<sup>15</sup> This decision additionally announced revisions to the exceptional events scheduling provisions, as well as changes to the air quality index and the regulations for the prevention of significant deterioration permitting program.

1 Rather, as described in *Whitman* and discussed further in section 1.2 above, most of that advice  
2 would be relevant to implementation but not standard setting (*id.*).

### 3 **1.4 REVIEW COMPLETED IN 2020**

4 The EPA announced its initiation of the next periodic review of the air quality criteria for  
5 photochemical oxidants and the O<sub>3</sub> NAAQS in June 2018, issuing a call for information in the  
6 *Federal Register* (83 FR 29785, June 26, 2018). Two types of information were called for:  
7 information regarding significant new O<sub>3</sub> research to be considered for the ISA for the review,  
8 and policy-relevant issues for consideration in this NAAQS review. Based in part on the  
9 information received in response to the call for information, the EPA developed a draft IRP  
10 which was made available for consultation with the CASAC and for public comment (83 FR  
11 55163, November 2, 2018; 83 FR 55528, November 6, 2018). Comments from the CASAC  
12 (Cox, 2018) and the public were considered in preparing the final IRP (U.S. EPA, 2019).

13 Under the plan outlined in the IRP and consistent with revisions to the process identified  
14 by the Administrator in his 2018 memo directing initiation of the review and completion within  
15 the statutorily required timeframe, the O<sub>3</sub> NAAQS review completed in 2020 progressed on an  
16 accelerated schedule (Pruitt, 2018).<sup>16</sup> The EPA incorporated a number of changes in various  
17 aspects of the review process, as summarized in the IRP, to support completion within the  
18 required period (Pruitt, 2018). For example, rather than produce separate documents for the PA  
19 and associated quantitative analyses, the human exposure and health risk analyses (that inform  
20 the decision on the primary standard) and the air quality and exposure analyses (that inform the  
21 decision on the secondary standard) were included in full as appendices in the PA, along with a  
22 number of other technical appendices.

23 Drafts of the ISA and PA (including the associated quantitative and exposure analyses)  
24 were reviewed by the CASAC and made available for public comment (84 FR 50836, September  
25 26, 2019; 84 FR 58711, November 1, 2019).<sup>17</sup> In a divergence from recent past practice, an O<sub>3</sub>  
26 panel was not assembled to assist the CASAC in its review. Rather, the CASAC was assisted in  
27 its review by a pool of consultants with expertise in a number of fields (84 FR 38625, August 7,  
28 2019).<sup>18</sup> The approach employed by the CASAC in utilizing outside technical expertise

---

<sup>16</sup> The Administrator's May 2018 direction to initiate this review of the O<sub>3</sub> NAAQS included further direction to the EPA staff to expedite the review, implementing an accelerated schedule aimed at completion of the review within the statutorily required period (Pruitt, 2018).

<sup>17</sup> The draft ISA and draft PA were released for public comment and CASAC review on September 26, 2019 and October 31, 2019, respectively. The charges for the CASAC review summarized the overarching context for the document review (including reference to Pruitt [2018], and the CASAC's role under section 109(d)(2)(C) of the Act), as well as specific charge questions for review of each of the documents.

<sup>18</sup> Rather than join with some or all of the CASAC members in a pollutant specific review panel as had been common in previous NAAQS reviews, the consultants comprised a pool of expertise that CASAC members drew

1 represented an additional modification of the process from past reviews. The CASAC discussed  
2 its draft letters describing its advice and comments on the documents in a public teleconference  
3 in early February 2020 (85 FR 4656; January 27, 2020). The letters to the Administrator  
4 conveying the CASAC advice and comments on the draft PA and draft ISA were released later  
5 that month (Cox, 2020a, Cox, 2020b). Comments from the CASAC and the public on the draft  
6 ISA were considered by the EPA and led to a number of revisions in developing the final  
7 document (ISA, Appendix 10, section 10.4.5). The ISA was completed and made available to the  
8 public in April 2020 (85 FR 21849, April 20, 2020). The comments from CASAC and the public  
9 were also considered in completing the PA and the advice regarding the standards was described  
10 and considered in the final 2020 PA (85 FR 31182, May 22, 2020), and in the EPA's decision-  
11 making. On August 14, 2020, the EPA proposed to retain both the primary and secondary O<sub>3</sub>  
12 standards, without revision (85 FR 49830, August 14, 2020). In December 2020, the EPA issued  
13 its final decision to retain the existing standards without revision (85 FR 87256, December 31,  
14 2020).<sup>19</sup>

15 Following publication of the 2020 final action, three petitions were filed for review of the  
16 EPA's final decision in the D.C. Circuit and the court consolidated the cases. The EPA also  
17 received two petitions for reconsideration of the 2020 action. On October 29, 2021, the Agency  
18 filed a motion with the court explaining that it had decided to reconsider the 2020 O<sub>3</sub> NAAQS  
19 final decision<sup>20</sup> and requested that the consolidated cases be held in abeyance until December 15,  
20 2023. On December 21, 2021, the court ordered that the consolidated cases continue to be held in  
21 abeyance pending further order of the court and directed the parties to file motions to govern by  
22 December 15, 2023.

## 23 **1.5 RECONSIDERATION OF THE 2020 O<sub>3</sub> NAAQS DECISION**

24 On October 29, 2021, the EPA announced that it will reconsider the 2020 decision to  
25 retain the 2015 O<sub>3</sub> standards. The EPA's plans are to reconsider the decision based on the  
26 existing scientific record and in a manner that adheres to rigorous standards of scientific integrity  
27 and provides ample opportunities for public input and engagement.<sup>21</sup> Consistent with the

---

on through the use of specific questions, posed in writing prior to the public meeting, regarding aspects of the documents being reviewed, as a means of obtaining subject matter expertise for its document review.

<sup>19</sup> The decision on the secondary standard also considered and addressed the 2019 remand of the secondary standard by the D.C. Circuit such that that decision incorporated the EPA's response to that remand.

<sup>20</sup> The Agency's October 29, 2021 announcement is available at <https://www.epa.gov/ground-level-ozone-pollution/epa-reconsider-previous-administrations-decision-retain-2015-ozone>.

<sup>21</sup> Information about the decision to reconsider the December 2020 O<sub>3</sub> NAAQS decision is available on this webpage: <https://www.epa.gov/ground-level-ozone-pollution/epa-reconsider-previous-administrations-decision-retain-2015-ozone>

1 commitment to rigorous standards of scientific integrity, the EPA will receive advice and  
2 comments from a reestablished CASAC<sup>22</sup> assisted by an expert O<sub>3</sub> Panel.<sup>23</sup> This reflects EPA’s  
3 renewed commitment to a rigorous NAAQS review process, with a focus on protecting scientific  
4 integrity.

5 Presentations and considerations to be included in the PA for reconsideration will be  
6 based on the conclusions, studies and related information included in the air quality criteria for  
7 the 2020 review. This includes the studies assessed in the 2020 ISA and PA and the integration  
8 of the scientific evidence presented in them. The EPA has additionally provisionally considered  
9 two sets of scientific studies on the health and welfare effects of O<sub>3</sub> that were not included in the  
10 ISA (“‘new’ studies”) and that did not go through the comprehensive review process utilized in  
11 review of the air quality criteria. With regard to the first set of studies, the EPA provisionally  
12 considered a set of “new” scientific studies on the health and welfare effects of O<sub>3</sub> that were  
13 raised and discussed in public comments on the July 2020 proposed decision (Luben et al.,  
14 2020). In considering and responding to the comments, the EPA provisionally considered the  
15 studies in the context of the findings of the ISA, as described in the December 2020 decision (85  
16 FR 87262, December 31, 2020). The EPA concluded that, taken in context, the “new”  
17 information and findings did not materially change any of the broad scientific conclusions  
18 regarding the health and welfare effects of O<sub>3</sub> in ambient air made in the air quality criteria, and  
19 accordingly, reopening the air quality criteria review was not warranted (Luben et al., 2020).<sup>24</sup>  
20 More recently, in the context of this reconsideration of the 2020 decision on the primary  
21 standard, given the primary role of controlled human exposure studies in the most recent  
22 decisions on the primary standard, the EPA has conducted a literature search for any “new”  
23 controlled human exposure studies that may have been published since the literature cutoff date  
24 for the 2020 ISA, and provisionally evaluated this small set of such newly identified studies  
25 (Duffney et al., 2022). Based on this provisional evaluation, the EPA has concluded that, taken in  
26 context, the “new” information and findings do not materially change any of the broad scientific

---

<sup>22</sup> Consistent with his decision to reestablish the membership of the CASAC to “ensure the agency received the best possible scientific insight to support our work to protect human health and the environment,” after consideration of a candidate list based on public request for nominations (86 FR 17146-17147, April 1, 2021) the Administrator announced selection of the seven members to serve on the chartered CASAC on June 17, 2021 (<https://www.epa.gov/newsreleases/epa-announces-selections-charter-members-clean-air-scientific-advisory-committee>). The current CASAC membership is listed here: [https://casac.epa.gov/ords/sab/f?p=105:29:1723269351020:::RP.29:P29\\_COMMITTEEON:CASAC](https://casac.epa.gov/ords/sab/f?p=105:29:1723269351020:::RP.29:P29_COMMITTEEON:CASAC).

<sup>23</sup> The members of the O<sub>3</sub> CASAC panel are identified here: [https://casac.epa.gov/ords/sab/f?p=113:14:11923922295141:::14:P14\\_COMMITTEEON:2022%20CASAC%20Ozone%20Review%20Panel](https://casac.epa.gov/ords/sab/f?p=113:14:11923922295141:::14:P14_COMMITTEEON:2022%20CASAC%20Ozone%20Review%20Panel).

<sup>24</sup> As noted at that time, “new” studies may sometimes be of such significance that it is appropriate to delay a decision in a NAAQS review and to supplement the pertinent air quality criteria so the studies can be taken into account (58 FR at 13013– 13014, March 9, 1993).

1 conclusions regarding the health and welfare effects of O<sub>3</sub> in ambient air made in the air quality  
2 criteria; thus, reopening the air quality criteria review is not warranted (Duffney et al., 2022).

3 This PA is being developed for consideration by the EPA Administrator in reaching his  
4 decision on the reconsideration of the December 2020 decision to retain the existing O<sub>3</sub> NAAQS.  
5 In assessing the policy implications of the available scientific information, this PA for the  
6 reconsideration, as for the 2020 PA, is intended to help “bridge the gap” between the Agency’s  
7 scientific assessment, presented in the 2020 ISA, and quantitative technical analyses, and the  
8 judgments required of the Administrator in determining whether it is appropriate to retain or  
9 revise the O<sub>3</sub> NAAQS. Accordingly, the PA for reconsideration will again address policy-  
10 relevant questions based on those identified in the 2018 IRP. With regard to considerations  
11 related to the primary standard, the PA for the reconsideration will focus on the evidence  
12 described in the 2020 ISA,<sup>25</sup> and the exposure/risk analyses presented in the 2020 PA, which  
13 will be included in full in this PA. With regard to considerations related to the secondary  
14 standard, the PA for reconsideration will focus on the evidence documented in the 2020 ISA,  
15 along with quantitative analyses presented in the 2020 PA and in subsequent technical memos,  
16 which have been updated to reflect recent air quality data.

17 This draft PA for the reconsideration is being provided to the CASAC for review and  
18 comment and made available for public comment. The CASAC advice and public comment on  
19 this draft PA will inform completion of the final PA and development of the Administrator’s  
20 proposed decision. The EPA is targeting the end of 2023 to complete decision-making in this  
21 reconsideration.  
22

---

<sup>25</sup> The ISA builds on evidence and conclusions from previous assessments, focusing on synthesizing and integrating the newly available evidence (ISA, section IS.1.1). Past assessments are generally cited when providing further, still relevant, details that informed the current assessment but are not repeated in the latest assessment.

## 1 REFERENCES

- 2 Cox, LA. (2018). Letter from Dr. Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
3 Committee, to Acting Administrator Andrew R. Wheeler, Re: Consultation on the EPA's  
4 *Integrated Review Plan for the Review of the Ozone*. December 10, 2018. EPA-CASAC-  
5 19-001. Available at:  
6 [https://yosemite.epa.gov/sab/sabproduct.nsf/LookupWebReportsLastMonthCASAC/A286](https://yosemite.epa.gov/sab/sabproduct.nsf/LookupWebReportsLastMonthCASAC/A286A0F0151DC8238525835F007D348A/$File/EPA-CASAC-19-001.pdf)  
7 [A0F0151DC8238525835F007D348A/\\$File/EPA-CASAC-19-001.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/LookupWebReportsLastMonthCASAC/A286A0F0151DC8238525835F007D348A/$File/EPA-CASAC-19-001.pdf).
- 8 Cox, LA. (2020a). Letter from Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
9 Committee, to Administrator Andrew R. Wheeler. Re: CASAC Review of the EPA's  
10 *Integrated Science Assessment for Ozone and Related Photochemical Oxidants (External*  
11 *Review Draft – September 2019)*. February 19, 2020. EPA-CASAC-20-002. Availbale at:  
12 [https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/F22](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/F228E5D4D848BBED85258515006354D0/$File/EPA-CASAC-20-002.pdf)  
13 [8E5D4D848BBED85258515006354D0/\\$File/EPA-CASAC-20-002.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/F228E5D4D848BBED85258515006354D0/$File/EPA-CASAC-20-002.pdf).
- 14 Cox, LA. (2020b). Letter from Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
15 Committee, to Administrator Andrew R. Wheeler. Re: CASAC Review of the EPA's  
16 *Policy Assessment for the Review of the Ozone National Ambient Air Quality Standards*  
17 *(External Review Draft – October 2019)*. February 19, 2020. EPA-CASAC-20-003.  
18 Available at:  
19 [https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf)  
20 [D217BC07103485258515006359BA/\\$File/EPA-CASAC-20-003.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf).
- 21 Duffney, PF, Brown, JS, and Stone, SL (2022). Memorandum to the Review of the Ozone  
22 National Ambient Air Quality Standards (NAAQS) Docket (EPA–HQ–ORD–2018–  
23 0279). Re: Provisional Evaluation of Newly Identified Controlled Human Exposure  
24 Studies in the context of the 2020 Integrated Science Assessment for Ozone and Related  
25 Photochemical Oxidants. April 15, 2020.
- 26 Frey, HC. (2014a). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory  
27 Committee, to Administrator Gina McCarthy. Re: CASAC Review of the EPA's Welfare  
28 Risk and Exposure Assessment for Ozone (Second External Review Draft). June 18,  
29 2014. EPA-CASAC-14-003. Available at:  
30 <http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P100JMSY.PDF>.
- 31 Frey, HC. (2014b). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory  
32 Committee to Honorable Gina McCarthy, Administrator, US EPA. Re: CASAC Review  
33 of the EPA's Second Draft Policy Assessment for the Review of the Ozone National  
34 Ambient Air Quality Standards. June 26, 2014. EPA-CASAC-14-004. Available at:  
35 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100JR6F.txt>.
- 36 Frey, HC. (2014c). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory  
37 Committee, to Administrator Gina McCarthy. Re: Health Risk and Exposure Assessment  
38 for Ozone (Second External Review Draft - February 2014). EPA-CASAC-14-005.  
39 Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100JR8I.txt>.



- 1 Luben, T, Lassiter, M and Herrick, J (2020). Memorandum to Ozone NAAQS Review Docket  
2 (EPA–HQ–ORD–2018–0279). RE: List of Studies Identified by Public Commenters That  
3 Have Been Provisionally Considered in the Context of the Conclusions of the 2020  
4 Integrated Science Assessment for Ozone and Related Photochemical Oxidants.  
5 December 2020. Docket Document ID: EPA-HQ-OAR-2018-0279-0560.
- 6 Pruitt, E. (2018). Memorandum from E. Scott Pruitt, Administrator, U.S. EPA to Assistant  
7 Administrators. Back-to-Basics Process for Reviewing National Ambient Air Quality  
8 Standards. May 9, 2018. Office of the Administrator U.S. EPA HQ, Washington DC.  
9 Available at: [https://www.epa.gov/criteria-air-pollutants/back-basics-process-reviewing-](https://www.epa.gov/criteria-air-pollutants/back-basics-process-reviewing-national-ambient-air-quality-standards)  
10 [national-ambient-air-quality-standards](https://www.epa.gov/criteria-air-pollutants/back-basics-process-reviewing-national-ambient-air-quality-standards).
- 11 Samet, JM. (2010). Letter from Jonathan Samet, Chair, Clean Air Scientific Advisory  
12 Committee, to Administrator Lisa Jackson. Re: CASAC Review of EPA’s Proposed  
13 Ozone National Ambient Air Quality Standard (Federal Register, Vol. 75, Nov. 11,  
14 January 19, 2010). February 19, 2010. EPA-CASAC-10-007. Available at:  
15 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P10072T1.txt>.
- 16 Samet, JM. (2011). Letter from Jonathan Samet, Chair, Clean Air Scientific Advisory  
17 Committee, to Administrator Lisa Jackson. Re: CASAC Response to Charge Questions  
18 on the Reconsideration of the 2008 Ozone National Ambient Air Quality Standards. .  
19 March 30, 2011. EPA-CASAC-11-004. Available at:  
20 [https://yosemite.epa.gov/sab/sabproduct.nsf/368203f97a15308a852574ba005bbd01/F08](https://yosemite.epa.gov/sab/sabproduct.nsf/368203f97a15308a852574ba005bbd01/F08BEB48C1139E2A8525785E006909AC/$File/EPA-CASAC-11-004-unsigned+.pdf)  
21 [BEB48C1139E2A8525785E006909AC/\\$File/EPA-CASAC-11-004-unsigned+.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/368203f97a15308a852574ba005bbd01/F08BEB48C1139E2A8525785E006909AC/$File/EPA-CASAC-11-004-unsigned+.pdf).
- 22 U.S. DHEW (1970). Air Quality Criteria for Photochemical Oxidants. National Air Pollution  
23 Control Administration Washington, DC. U.S. DHEW. publication no. AP-63. NTIS,  
24 Springfield, VA; PB-190262/BA.
- 25 U.S. EPA (1978). Air Quality Criteria for Ozone and Other Photochemical Oxidants  
26 Environmental Criteria and Assessment Office. Research Triangle Park, NC. EPA-600/8-  
27 78-004. April 1978. Available at:  
28 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=200089CW.txt>.
- 29 U.S. EPA (1986). Air Quality Criteria for Ozone and Other Photochemical Oxidants (Volume I -  
30 V). Environmental Criteria and Assessment Office. Research Triangle Park, NC. U.S.  
31 EPA. EPA-600/8-84-020aF, EPA-600/8-84-020bF, EPA-600/8-84-020cF, EPA-600/8-  
32 84-020dF, EPA-600/8-84-020eF. August 1986. Available at:  
33 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001D3J.txt>  
34 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001DAV.txt>  
35 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001DNN.txt>  
36 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001E0F.txt>  
37 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001E9R.txt>.
- 38 U.S. EPA (1989). Review of the National Ambient Air Quality Standards for Ozone: Policy  
39 Assessment of Scientific and Technical Information. OAQPS Staff Paper. Office of Air  
40 Quality Planning and Standards. Research Triangle Park, NC U.S. EPA.

- 1 U.S. EPA (1992). Summary of Selected New Information on Effects of Ozone on Health and  
2 Vegetation: Supplement to 1986 Air Quality Criteria for Ozone and Other Photochemical  
3 Oxidants. Office of Research and Development. Washington, DC. U.S. EPA. EPA/600/8-  
4 88/105F.
- 5 U.S. EPA (1996). Air Quality Criteria for Ozone and Related Photochemical Oxidants. Volume I  
6 - III. Office of Research and Development Research Triangle Park, NC. U.S. EPA. EPA-  
7 600/P-93-004aF, EPA-600/P-93-004bF, EPA-600/P-93-004cF. July 1996. Available at:  
8 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=300026GN.txt>  
9 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=300026SH.txt>  
10 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=10004RHL.txt>.
- 11 U.S. EPA (2006). Air Quality Criteria for Ozone and Related Photochemical Oxidants (Volume I  
12 - III). Office of Research and Development U.S. EPA. EPA-600/R-05-004aF, EPA-  
13 600/R-05-004bF, EPA-600/R-05-004cF February 2006. Available at:  
14 <https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=149923>.
- 15 U.S. EPA (2013). Integrated Science Assessment of Ozone and Related Photochemical Oxidants  
16 (Final Report). Office of Research and Development, National Center for Environmental  
17 Assessment. Research Triangle Park, NC. U.S. EPA. EPA-600/R-10-076F. February  
18 2013. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KETF.txt>.
- 19 U.S. EPA (2014a). Policy Assessment for the Review of National Ambient Air Quality  
20 Standards for Ozone (Final Report). Office of Air Quality Planning and Standards, Health  
21 and Environmental Impacts Division. Research Triangle Park, NC. U.S. EPA. EPA-  
22 452/R-14-006 August 2014. Available at:  
23 <https://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P100KCZ5.txt>.
- 24 U.S. EPA (2014b). Welfare Risk and Exposure Assessment for Ozone (Final). . Office of Air  
25 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/P-14-  
26 005a August 2014. Available at:  
27 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KB9D.txt>.
- 28 U.S. EPA (2014c). Health Risk and Exposure Assessment for Ozone. (Final Report). Office of  
29 Air Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-  
30 14-004a. August 2014. Available at:  
31 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KBUF.txt>.
- 32 U.S. EPA (2019). Integrated Review Plan for the Ozone National Ambient Air Quality  
33 Standards. Office of Air Quality Planning and Standards. Research Triangle Park, NC.  
34 U.S. EPA. EPA-452/R-19-002. Available at:  
35 [https://www.epa.gov/sites/production/files/2019-08/documents/o3-irp-aug27-](https://www.epa.gov/sites/production/files/2019-08/documents/o3-irp-aug27-2019_final.pdf)  
36 [2019\\_final.pdf](https://www.epa.gov/sites/production/files/2019-08/documents/o3-irp-aug27-2019_final.pdf).
- 37 U.S. EPA (2020a). Integrated Science Assessment for Ozone and Related Photochemical  
38 Oxidants. U.S. Environmental Protection Agency. Washington, DC. Office of Research  
39 and Development. EPA/600/R-20/012. Available at: [https://www.epa.gov/isa/integrated-](https://www.epa.gov/isa/integrated-science-assessment-isa-ozone-and-related-photochemical-oxidants)  
40 [science-assessment-isa-ozone-and-related-photochemical-oxidants](https://www.epa.gov/isa/integrated-science-assessment-isa-ozone-and-related-photochemical-oxidants).

1 U.S. EPA (2020b). Policy Assessment for the Review of the Ozone National Ambient Air  
2 Quality Standards. U.S. Environmental Protection Agency, Office of Air Quality  
3 Planning and Standards, Health and Environmental Impacts Division. Research Triangle  
4 Park, NC. U.S. EPA. EPA-452/R-20-001. 2020 Available at: [https://www.epa.gov/  
5 naaqs/ozone-o3-standards-policyassessments-current-review](https://www.epa.gov/naaqs/ozone-o3-standards-policyassessments-current-review).

6

## 2 AIR QUALITY

This chapter begins with an overview of O<sub>3</sub> and other photochemical oxidants in the atmosphere (section 2.1). Subsequent sections summarize the sources and emissions of O<sub>3</sub> precursors (section 2.2), ambient air monitoring and data handling conventions for determining whether the standards are met (section 2.3), O<sub>3</sub> concentrations measured in the U.S. ambient air (section 2.4), and available evidence and information related to background O<sub>3</sub> in the U.S. (section 2.5). These focus primarily on tropospheric O<sub>3</sub> and surface-level concentrations occurring in ambient air<sup>1</sup>.

### 2.1 O<sub>3</sub> AND PHOTOCHEMICAL OXIDANTS IN THE ATMOSPHERE

O<sub>3</sub> is one of many photochemical oxidants formed in the troposphere<sup>2</sup> by photochemical reactions of precursor gases in the presence of sunlight (ISA, Appendix 1, section 1.1)<sup>3</sup> and is generally not directly emitted from specific sources. Tropospheric O<sub>3</sub> and other oxidants, such as peroxyacetyl nitrate (PAN) and hydrogen peroxide, form in polluted areas through atmospheric reactions involving two main classes of precursor pollutants: volatile organic compounds (VOCs) and nitrogen oxides (NO<sub>x</sub> = NO and NO<sub>2</sub>). The photolysis of the primary pollutant nitrogen dioxide (NO<sub>2</sub>) results in products of NO and a singlet oxygen radical that can subsequently either form ozone or react with NO to reform the parent NO<sub>2</sub> compound. The reaction of the oxygen radical with NO to form NO<sub>2</sub> is disrupted by the presence of VOCs<sup>4</sup> which leads to net ozone formation in the troposphere. Thus, NO<sub>x</sub>, VOCs, CH<sub>4</sub> and CO are considered to be the primary precursors of tropospheric O<sub>3</sub> (ISA, Appendix 1, section 1.3.1)

The formation of O<sub>3</sub>, other oxidants and oxidation products from these precursors is a complex, nonlinear function of many factors including (1) the intensity and spectral distribution of sunlight; (2) atmospheric mixing; (3) concentrations of precursors in the ambient air and the rates of chemical reactions of these precursors; and (4) processing on cloud and aerosol particles (ISA, Appendix 1, section 1.4; 2013 ISA, section 3.2). As a result, O<sub>3</sub> changes in a nonlinear fashion with the concentrations of its precursors rather than varying proportionally to emissions

---

<sup>1</sup> Ambient air means that portion of the atmosphere, external to buildings, to which the general public has access (see 40 CFR 50.1(e)).

<sup>2</sup> Ozone also occurs in the stratosphere, where it serves the beneficial role of absorbing the sun's harmful ultraviolet radiation and preventing the majority of this radiation from reaching the Earth's surface.

<sup>3</sup> The only other appreciable source of O<sub>3</sub> to the troposphere is transport from the stratosphere, as described in section 2.5.1.1 below.

<sup>4</sup> This reaction can also be disrupted by the radical that results from methane (CH<sub>4</sub>) oxidation or a reaction between carbon monoxide (CO) and the hydroxyl radical (OH) in the atmosphere.

1 of its precursors (2013 ISA, section 3.2.4). In addition to the chemistry described above, NO can  
2 also react with ozone directly such that emissions of NO<sub>x</sub> lead to both the formation and  
3 destruction of O<sub>3</sub>, with the net formation or destruction depending on the local quantities of  
4 NO<sub>x</sub>, VOCs, radicals, and sunlight. O<sub>3</sub> chemistry is often described in terms of which precursors  
5 most directly impact formation rates. A NO<sub>x</sub>-limited regime indicates that O<sub>3</sub> concentrations will  
6 decrease in response to decreases in ambient NO<sub>x</sub> concentrations and vice-versa. These  
7 conditions tend to occur when NO<sub>x</sub> concentrations are generally low compared to VOC  
8 concentrations and during warm, sunny conditions when NO<sub>x</sub> photochemistry is relatively fast.  
9 NO<sub>x</sub>-limited conditions are more common during daylight hours, in the summertime, in  
10 suburban and rural areas, and in portions of the country with high biogenic VOC emissions like  
11 the Southeast. In contrast, NO<sub>x</sub>-saturated conditions (also referred to as VOC-limited or radical-  
12 limited) indicate that O<sub>3</sub> will increase as a result of NO<sub>x</sub> reductions but will decrease as a result  
13 of VOC reductions (2013 ISA, section 3.2; 2006 AQCD, chapter 2). NO<sub>x</sub>-saturated conditions  
14 occur at times when and at locations with lower levels of available sunlight, resulting in slower  
15 photochemical formation of O<sub>3</sub>, and when NO<sub>x</sub> concentrations are in excess compared to VOC  
16 concentrations. NO<sub>x</sub>-saturated conditions are more common during nighttime hours, in the  
17 wintertime, and in densely populated urban areas or industrial plumes. These varied relationships  
18 between precursor emissions and O<sub>3</sub> chemistry result in localized areas in which O<sub>3</sub>  
19 concentrations are suppressed compared to surrounding areas, but which contain NO<sub>2</sub> that  
20 contributes to subsequent O<sub>3</sub> formation further downwind (2013 ISA, section 3.2.4).  
21 Consequently, O<sub>3</sub> response to reductions in NO<sub>x</sub> emissions is complex and may include  
22 decreases in O<sub>3</sub> concentrations at some times and locations and increases in O<sub>3</sub> concentrations at  
23 other times and locations. Over the past decade, there have been substantial decreases in NO<sub>x</sub>  
24 emissions in the U.S. (see Figure 2-2) and many locations have transitioned from NO<sub>x</sub>-saturated  
25 to NO<sub>x</sub>-limited (Jin et al., 2017) during times of year that are conducive to O<sub>3</sub> formation  
26 (generally summer). As these NO<sub>x</sub> emissions reductions have occurred, lower O<sub>3</sub> concentrations  
27 have generally increased while the higher O<sub>3</sub> concentrations have generally decreased, resulting  
28 in a compressed O<sub>3</sub> distribution, relative to historical conditions (ISA, Appendix 1, section 1.7).

29 Prior to 1979, the indicator for the NAAQS for photochemical oxidants was total  
30 photochemical oxidants (36 FR 8186, April 30, 1971). Early ambient air monitoring indicated  
31 similarities between O<sub>3</sub> measurements and the photochemical oxidant measurements, as well as  
32 reduced precision and accuracy of the latter (U.S. EPA, 1978). To address these issues, the EPA  
33 established O<sub>3</sub> as the indicator for the NAAQS for photochemical oxidants in 1979 (44 FR 8202,  
34 February 8, 1979), and it is currently the only photochemical oxidant other than nitrogen dioxide  
35 that is routinely monitored in a national ambient air monitoring network.

O<sub>3</sub> is present not only in polluted urban atmospheres, but throughout the troposphere, even in remote areas of the globe. The same basic processes involving sunlight-driven reactions of NO<sub>x</sub>, VOCs, CH<sub>4</sub> and CO contribute to O<sub>3</sub> formation throughout the troposphere. These processes also lead to the formation of other photochemical products, such as PAN, HNO<sub>3</sub>, and H<sub>2</sub>SO<sub>4</sub>, HCHO and other carbonyl compounds, as well as a number of organic particulate compounds (ISA, Appendix 1, section 1.4; 2013 ISA, section 3.2).

As mentioned above, the formation of O<sub>3</sub> from precursor emissions is also affected by meteorological parameters such as the intensity of sunlight and atmospheric mixing (2013 ISA, section 3.2). Major episodes of high O<sub>3</sub> concentrations in the eastern U.S. are often associated with slow-moving high-pressure systems which can persist for several days. High pressure systems during the warmer seasons are associated with the sinking of air, resulting in warm, generally cloudless skies, with light winds. The sinking of air results in the development of stable conditions near the surface which inhibit or reduce the vertical mixing of O<sub>3</sub> precursors, concentrating them near the surface. Photochemical activity involving these precursors is enhanced because of higher temperatures and the availability of sunlight during the warmer seasons. In the eastern U.S., concentrations of O<sub>3</sub> and other photochemical oxidants are determined by meteorological and chemical processes extending typically over areas of several hundred thousand square kilometers. Therefore, O<sub>3</sub> episodes are often regarded as regional in nature, although more localized episodes often occur in some areas, largely the result of local pollution sources during summer, e.g., Houston, TX (2013 ISA, section 2.2.1; Webster et al., 2007). In addition, in some parts of the U.S. (e.g., Los Angeles, CA), mountain barriers limit O<sub>3</sub> dispersion and result in a higher frequency and duration of days with elevated O<sub>3</sub> concentrations (2013 ISA, section 3.2).

More recently, high O<sub>3</sub> concentrations of up to 150 parts per billion (ppb)<sup>5</sup> have been measured during the wintertime in two western U.S. mountain basins (ISA, Appendix 1, section 1.4.1). Wintertime mountain basin O<sub>3</sub> episodes occur on cold winter days with low wind speeds, clear skies, substantial snow cover, extremely shallow boundary layers driven by strong temperature inversions, and substantial precursor emissions activity from the oil and gas sector. The results of recent modeling studies suggest that photolysis of VOCs provides the source of reactive chemical species (radicals) needed to initiate the chemistry driving these wintertime O<sub>3</sub> episodes. This mechanism is somewhat different from the chemistry driving summertime O<sub>3</sub> formation, which is initiated with the photolysis of NO<sub>2</sub> followed by the formation of the OH radicals (ISA, Appendix 1, section 1.4.1).

---

<sup>5</sup> Although the standards are specified in ppm (e.g., as described in Chapter 1), the units, ppb, are commonly used in describing O<sub>3</sub> concentrations throughout this document, with 0.070 ppm being equivalent to 70 ppb.

O<sub>3</sub> concentrations in a region are affected both by local formation and by transport of O<sub>3</sub> and its precursors from upwind areas. O<sub>3</sub> transport occurs on many spatial scales including local transport within urban areas, regional transport over large regions of the U.S., and long-range transport which may also include international transport. In addition, O<sub>3</sub> can be transferred into the troposphere from the stratosphere, which is rich in naturally occurring O<sub>3</sub>, through stratosphere-troposphere exchange (STE). These intrusions usually occur behind cold fronts, bringing stratospheric air with them and typically affect O<sub>3</sub> concentrations in higher elevation areas (e.g., > 1500 m) more than areas at lower elevations, as discussed in section 2.5.3.2 (ISA, Appendix 1, section 1.3.2.1; 2013 ISA, section 3.4.1.1).

## 2.2 SOURCES AND EMISSIONS OF O<sub>3</sub> PRECURSORS

Sources of emissions of O<sub>3</sub> precursor compounds can be divided into anthropogenic and natural source categories, with natural sources further divided into emissions from biological processes of living organisms (e.g., plants, microbes, and animals) and emissions from chemical or physical processes (e.g., biomass burning, lightning, and geogenic sources). Anthropogenic emissions associated with combustion processes, including mobile sources and power plants, account for the majority of U.S. NO<sub>x</sub> and CO emissions (Figure 2-1 and Figure 2-2). Emissions of these chemicals have declined appreciably in the U.S. since 2002 (Figure 2-2). Anthropogenic sources are also important for VOC emissions, though in some locations and times of the year (e.g., southern states during summer) the majority of VOC emissions come from vegetation (2013 ISA, section 3.2.1).<sup>6</sup> In practice, the distinction between natural and anthropogenic sources is often unclear, as human activities directly or indirectly affect emissions from what would have been considered natural sources during the preindustrial era. Thus, precursor emissions from plants, animals, and wildfires could be considered either natural or anthropogenic, depending on whether emissions result from agricultural practices, forest management practices, lightning strikes, or other types of events. There are additional challenges in distinguishing between ozone resulting from natural versus anthropogenic sources because much O<sub>3</sub> results from reactions of anthropogenic precursors with natural precursors (ISA, Appendix 1, section 1.8.1.2).

The National Emissions Inventory (NEI) is a comprehensive and detailed estimate of air emissions of criteria pollutants, precursors to criteria pollutants, and hazardous air pollutants from air emissions sources (U.S. EPA, 2021b). The NEI is released every three years based primarily upon data provided by State, Local, and Tribal air agencies for sources in their

---

<sup>6</sup> It should be noted that the definition of VOCs used in this section does not include CH<sub>4</sub> because it is excluded from the EPA's regulatory definition of VOCs in 40 CFR 51.100(s). More information about this regulatory definition of VOCs is available at <https://www.epa.gov/indoor-air-quality-iaq/technical-overview-volatile-organic-compounds>.


1 jurisdictions and supplemented by data developed by the US EPA. The NEI is built using the  
2 EPA’s Emissions Inventory System (EIS) which collects data from State, Local, and Tribal air  
3 agencies and blends that data with other data sources.<sup>7</sup>

4 Anthropogenic emissions of air pollutants result from a variety of sources such as power  
5 plants, industrial sources, motor vehicles, and agriculture. The emissions from any individual  
6 source typically vary in both time and space. For many of the thousands of sources that make up  
7 the NEI, there is uncertainty in both of these factors. For some sources, such as power plants,  
8 direct emission measurements enable more certain quantification of the magnitude and timing of  
9 emissions than from sources without such direct measurements. However, for many source  
10 categories emission inventories necessarily contain assumptions, interpolation and extrapolation  
11 from a limited set of sample data (U.S. EPA, 2021b).

---


<sup>7</sup> More details are available from: <https://www.epa.gov/enviro/nei-overview>.





**Sources:** The 2017 National Emissions Inventory (U.S. EPA, 2021b) for panels A-C, and the *Inventory of U.S. Greenhouse Gas Emissions and Sinks: 1990-2019* (U.S. EPA, 2021a) for panel D. Categories contributing less than 2% each have been summed and are represented by the "other" category.

**Figure 2-1. U.S. O<sub>3</sub> precursor emissions by sector: A) NO<sub>x</sub>; B) CO; C) VOCs; D) CH<sub>4</sub>.**




Sources: EPA's Air Pollutant Emissions Trends Data webpage (<https://www.epa.gov/air-emissions-inventories/air-pollutant-emissions-trends-data>) for panels A-C, and the *Inventory of U.S. Greenhouse Gas Emissions and Sinks: 1990-2019* (U.S. EPA, 2021a) for panel D.

**Figure 2-2. U.S. anthropogenic O<sub>3</sub> precursor emission trends for: A) NO<sub>x</sub>; B) CO; C) VOCs; and D) CH<sub>4</sub>.**

Figure 2-3, Figure 2-4, and Figure 2-5 show county-level estimates of U.S. emissions densities (in tons/year/mi<sup>2</sup>) for CO, NO<sub>x</sub>, and VOCs, respectively. In general, CO and NO<sub>x</sub> emissions tend to be highest in urban areas which typically have the most anthropogenic sources, however, CO emissions may be higher in some rural areas due to fires, and similarly, NO<sub>x</sub> emissions may be higher in some rural areas due to sources such as electricity generation, oil and gas extraction, and traffic along major highways. While there are some significant anthropogenic sources of VOC emissions in urban areas, in rural areas the vast majority of VOC emissions come from plants and trees (biogenics), particularly in the southeastern U.S. In other areas of the U.S., such as the Great Plains region and parts of the inter-mountain west, areas with higher levels of VOC emissions are largely due to oil and gas extraction (U.S. EPA, 2021b).


It should be noted that O<sub>3</sub> levels in a given area are impacted by both local emissions that form O<sub>3</sub> in the area as well as remote emissions that form O<sub>3</sub> that is then transported into the area. Biogenic VOC emissions that lead to O<sub>3</sub> formation may vary greatly depending on the type and amount of vegetation, which is generally much lower in urban areas than in rural areas. However, biogenic VOC emissions that are upwind of an urban area can have a significant impact on urban O<sub>3</sub> levels. Thus, while the county-level maps shown in Figure 2-3, Figure 2-4, and Figure 2-5 illustrate the variability in precursor emissions in the U.S., it is not sufficient to look only at the patterns in local emissions when considering the impact on O<sub>3</sub> concentrations.





Source: 2017 National Emissions Inventory, January 2021 Updated Release (U.S. EPA, 2021b; data downloaded from <https://www.epa.gov/air-emissions-inventories/2017-national-emissions-inventory-nei-data>)


**Figure 2-3. U.S. county-level CO emissions density estimates (tons/year/mi<sup>2</sup>) for 2017.**



Source: 2017 National Emissions Inventory, January 2021 Updated Release (U.S. EPA, 2021b; data downloaded from <https://www.epa.gov/air-emissions-inventories/2017-national-emissions-inventory-nei-data>)

**Figure 2-4. U.S. county-level NO<sub>x</sub> emissions density estimates (tons/year/mi<sup>2</sup>) for 2017.**





Source: 2017 National Emissions Inventory, January 2021 Updated Release (U.S. EPA, 2021b; data downloaded from <https://www.epa.gov/air-emissions-inventories/2017-national-emissions-inventory-nei-data>)

**Figure 2-5. U.S. county-level VOC emissions density estimates (tons/year/mi<sup>2</sup>) for 2017.**

## 2.3 AMBIENT AIR MONITORING AND DATA HANDLING CONVENTIONS

### 2.3.1 Ambient Air Monitoring Requirements and Monitoring Networks

State and local environmental agencies operate a network of O<sub>3</sub> monitors at state or local air monitoring stations (SLAMS). The requirements for the SLAMS network depend on the population and most recent O<sub>3</sub> design values<sup>8</sup> in an area. The minimum number of O<sub>3</sub> monitors required in a metropolitan statistical area (MSA) ranges from zero for areas with a population less than 350,000 and no recent history of an O<sub>3</sub> design value greater than 85 percent of the level of the standard, to four for areas with a population greater than 10 million and an O<sub>3</sub> design value greater than 85 percent of the standard level.<sup>9</sup> At least one monitoring site for each MSA must be situated to record the maximum concentration for that particular metropolitan area. Siting criteria

<sup>8</sup> A design value is a statistic that summarizes the air quality data for a given area in terms of the indicator, averaging time, and form of the standard. Design values can be compared to the level of the standard and are typically used to designate areas as meeting or not meeting the standard and assess progress towards meeting the NAAQS.

<sup>9</sup> The SLAMS minimum monitoring requirements to meet the O<sub>3</sub> design criteria are specified in 40 CFR Part 58, Appendix D. The minimum O<sub>3</sub> monitoring network requirements for urban areas are listed in Table D-2 of Appendix D to 40 CFR Part 58 (accessible at <https://www.ecfr.gov>).

1 for SLAMS includes horizontal and vertical inlet probe placement; spacing from minor sources,  
2 obstructions, trees, and roadways; inlet probe material; and sample residence times.<sup>10</sup> Adherence  
3 to these criteria ensures uniform collection and comparability of O<sub>3</sub> data. Since the highest O<sub>3</sub>  
4 concentrations tend to be associated with a particular season for various locations, the EPA  
5 requires O<sub>3</sub> monitoring during specific O<sub>3</sub> monitoring seasons (shown in Figure 2-6) which vary  
6 by state from five months (May to September in Oregon and Washington) to all twelve months  
7 (in 11 states), with the most common season being March to October (in 27 states).<sup>11</sup>

8 Most of the state, local, and tribal air monitoring stations that report data to the EPA use  
9 ultraviolet Federal Equivalent Methods (FEMs). The Federal Reference Method (FRM) was  
10 revised in 2015 to include a new chemiluminescence by nitric oxide (NO-CL) method. The  
11 previous ethylene (ET-CL) method, while still included in the CFR as an acceptable method, is  
12 no longer used due to lack of availability and safety concerns with ethylene.<sup>12</sup> The NO-CL  
13 method is beginning to be implemented in the SLAMS network.<sup>13</sup>

14 Ambient air quality data and associated quality assurance (QA) data are reported to the  
15 EPA via the Air Quality System (AQS). Data are reported quarterly and must be submitted to  
16 AQS within 90 days after the end of the quarterly reporting period. Each monitoring agency is  
17 required to certify data that is submitted to AQS from the previous year. The data are certified,  
18 taking into consideration any QA findings, and a data certification letter is sent to the EPA  
19 Regional Administrator. Data must be certified by May 1<sup>st</sup> of the following year. Data collected  
20 by FRM or FEM monitors that meet the QA requirements must be certified.<sup>14</sup> To provide  
21 decision makers with an assessment of data quality, the EPA's QA group derives estimates of  
22 both precision and bias for O<sub>3</sub> and the other gaseous criteria pollutants from quality control (QC)  
23 checks using calibration gas, performed at each site by the monitoring agency. The data quality  
24 goal for precision and bias is 7 percent.<sup>15</sup>

---

<sup>10</sup> The probe and monitoring path siting criteria for ambient air quality monitoring are specified in 40 CFR, Part 58, Appendix E.


<sup>11</sup> The required O<sub>3</sub> monitoring seasons for each state are listed in 40 CFR Part 58, Appendix D, Table D-3.

<sup>12</sup> The current FRM for O<sub>3</sub> (established in 2015) is a chemiluminescence method, which is fully described in 40 CFR Part 50, Appendix D.

<sup>13</sup> The EPA is currently participating in an international effort to implement a globally coordinated change in the parameter (the absorption cross-section value) used in the determination of atmospheric ozone for ozone monitoring, which will require an update of this parameter in the ozone monitoring regulations (40 CFR Part 50, Appendix D, section 4). The global implementation target date for this change is the beginning of the 2024 ozone season.

<sup>14</sup> Quality assurance requirements for monitors used in evaluations of the NAAQS are provided in 40 CFR Part 58, Appendix A.

<sup>15</sup> Annual summary reports of precision and bias can be obtained for each monitoring site at <https://www.epa.gov/outdoor-air-quality-data/single-point-precision-and-bias-report>.



**Figure 2-6. Current O<sub>3</sub> monitoring seasons in the U.S.** Numbers in each state indicate the months of the year the state is required to monitor for O<sub>3</sub> (e.g., 3-10 means O<sub>3</sub> monitoring is required from March through October).

1 In 2020, there were over 1,300 federal, state, local, and tribal ambient air monitors  
2 reporting O<sub>3</sub> concentrations to the EPA. Figure 2-7 shows the locations of such monitoring sites  
3 that reported data to the EPA at any time during the 2018-2020 period. Nearly 80% of this  
4 network are SLAMS monitors operated by state and local governments to meet regulatory  
5 requirements and provide air quality information to public health agencies; these sites are largely  
6 focused on urban and suburban areas.

7 Two important subsets of SLAMS sites separately make up the National Core (NCore)  
8 multi-pollutant monitoring network and the Photochemical Assessment Monitoring Stations  
9 (PAMS) network. Each state is required to have at least one NCore station, and O<sub>3</sub> monitors at  
10 NCore sites are required to operate year-round. At each NCore site located in a MSA with a  
11 population of 1 million or more (based on the most recent census), a PAMS network site is  
12 required.<sup>16</sup> In addition to reporting O<sub>3</sub> concentrations, the NCore and PAMS networks provide  
13 data on O<sub>3</sub> precursor chemicals. The NCore sites feature co-located measurements of chemical  
14 species such as nitrogen oxide and total reactive nitrogen, along with various meteorological  
15 measurements. At a minimum, monitoring sites in the PAMS network are required to measure  
16 certain O<sub>3</sub> precursors, such as NO<sub>x</sub> and a target set of VOCs, during the months of June, July and  
17 August, although some precursor monitoring may be required for longer periods of time to  
18 improve the usefulness of data collected during an area's O<sub>3</sub> season (U.S. EPA, 2018a). The  
19 enhanced monitoring at sites in these two networks informs our understanding of local O<sub>3</sub>  
20 formation.


21 While the SLAMS network has a largely urban and population-based focus, there are  
22 monitoring sites in other networks that can be used to track compliance with the NAAQS in rural  
23 areas. For example, the Clean Air Status and Trends Network (CASTNET) monitors are located  
24 in rural areas. There were 84 CASTNET monitors operating in 2020, with most of the sites in the  
25 eastern U.S. being operated by the EPA, and most of the sites in the western U.S. being operated  
26 by the National Park Service (NPS). Finally, there are also a number of Special Purpose  
27 Monitoring Stations (SPMs), which are not required but are often operated by air agencies for  
28 short periods of time (less than 3 years) to collect data for human health and welfare studies, as  
29 well as other types of monitoring sites, including monitors operated by tribes and industrial  
30 sources. The SPMs are typically not used to assess compliance with the NAAQS.<sup>17</sup>

---

<sup>16</sup> The requirements for PAMS, which were most recently updated in 2015, is fully described in section 5 of Appendix D to 40 CFR Part 58.

<sup>17</sup> However, SPMs that use federal reference or equivalent methods, meet all applicable requirements in 40 CFR Part 58, and operate continuously for more than 24 months may be used to assess compliance with the NAAQS.





1           ● SLAMS (961)           ● NCORE/PAMS (126)   ● CASTNET (84)           ● SPM/OTHER (191)  
2 **Figure 2-7. Map of U.S. ambient air O<sub>3</sub> monitoring sites reporting data to the EPA during**  
3 **the 2018-2020 period.**

### 4 **2.3.2 Data Handling Conventions and Computations for Determining Whether the** 5 **Standards are Met**

6       To assess whether a monitoring site or geographic area (usually a county or urban area)  
7 meets or exceeds a NAAQS, the monitoring data are analyzed consistent with the established  
8 regulatory requirements for the handling of monitoring data for the purposes of deriving a design  
9 value. A design value summarizes ambient air concentrations for an area in terms of the  
10 indicator, averaging time and form for a given standard such that its comparison to the level of  
11 the standard indicates whether the area meets or exceeds the standard. The procedures for  
12 calculating design values for the current O<sub>3</sub> NAAQS (established in 2015) are detailed in  
13 Appendix U to 40 CFR Part 50 and are summarized below.

14       Hourly average O<sub>3</sub> concentrations at the monitoring sites used for assessing whether an  
15 area meets or exceeds the NAAQS are required to be reported in ppm to the third decimal place,  
16 with additional digits truncated, consistent with the typical measurement precision associated  
17 with most O<sub>3</sub> monitoring instruments. Monitored hourly O<sub>3</sub> concentrations flagged by the States  
18 as having been affected by an exceptional event, having been the subject of a demonstration  
19 submitted by the State, and having received concurrence from the appropriate EPA Regional

Office, are excluded from design value calculations consistent with 40 CFR 50.14.<sup>18</sup> The hourly concentrations are used to compute moving 8-hour averages, which are stored in the first hour of each 8-hour period (e.g., the 8-hour average for the 7:00 AM to 3:00 PM period is stored in the 7:00 AM hour), and digits to the right of the third decimal place are truncated. Each 8-hour average is considered valid if 6 or more hourly concentrations are available for the 8-hour period.

Next, the daily maximum 8-hour average (MDA8) concentration for each day is identified as the highest of the 17 consecutive, valid 8-hour average concentrations beginning at 7:00 AM and ending at 11:00 PM (which includes hourly O<sub>3</sub> concentrations from the subsequent day). MDA8 values are considered valid if at least 13 valid 8-hour averages are available for the day, or if the MDA8 value is greater than the level of the NAAQS. Finally, the O<sub>3</sub> design value is calculated as the 3-year average of the annual 4<sup>th</sup> highest MDA8 value<sup>19</sup>. An O<sub>3</sub> design value less than or equal to the level of the NAAQS is considered to be valid if valid MDA8 values are available for at least 90% of the days in the O<sub>3</sub> monitoring season (as defined for each state and shown in Figure 2-6) on average over the 3 years, with a minimum of 75% data completeness in any individual year. Design values greater than the level of the NAAQS are always considered to be valid.

An O<sub>3</sub> monitoring site meets the NAAQS if it has a valid design value less than or equal to the level of the standard, and it exceeds the NAAQS if it has a design value greater than the level of the standard. A geographic area meets the NAAQS if all ambient air monitoring sites in the area have valid design values meeting the standard. Conversely, if one or more monitoring sites has a design value exceeding the standard, then the area exceeds the NAAQS.

## **2.4 O<sub>3</sub> IN AMBIENT AIR**

### **2.4.1 Concentrations Across the U.S.**


Figure 2-8 below shows a map of the O<sub>3</sub> design values at U.S. ambient air monitoring sites based on data from the 2018-2020 period. From the figure it is apparent that many monitoring sites have recent design values exceeding the current NAAQS, and that most of these sites are located in or near urban areas. The highest design values are located in California, Texas, along the shoreline of Lake Michigan, and near large urban areas in the northeastern and western U.S. There are also high design values associated with wintertime O<sub>3</sub> in the Uinta Basin in Utah. The lowest design values are located in the north central region of the U.S., rural parts

---

<sup>18</sup> A variety of resources and guidance documents related to identification and consideration of exceptional events in design value calculations are available at <https://www.epa.gov/air-quality-analysis/final-2016-exceptional-events-rule-supporting-guidance-documents-updated-faqs>.

<sup>19</sup> Design values are reported in ppm to the third decimal place, with additional digits truncated. This truncation step also applies to the initially calculated 8-hour average concentrations (Appendix 2A, section 2A.1).

of New England and the southeastern U.S., and along the Pacific Ocean, including Alaska and Hawaii.



**Figure 2-8. O<sub>3</sub> design values in ppb for the 2018-2020 period.**


#### 2.4.2 Trends in U.S. O<sub>3</sub> Concentrations

Figure 2-9 shows a map of the site-level trends in the O<sub>3</sub> design values at U.S. monitoring sites having complete data<sup>20</sup> from 2000-2002 through 2018-2020. The trends were computed using the Thiel-Sen estimator (Sen, 1968; Thiel, 1950), and tests for significance were computed using the Mann-Kendall test (Kendall, 1948; Mann, 1945). From this figure it is apparent that design values have decreased significantly over most of the eastern U.S. during this period. These decreases are in part due to EPA regulations aimed at reducing NO<sub>x</sub> emissions from EGUs, such as the Clean Air Interstate Rule and the Cross-State Air Pollution Rule, with the goal of achieving broad, regional reductions in summertime NO<sub>x</sub> emissions; as well as mobile emission reductions from federal motor vehicle emissions and fuel standards, and; local controls resulting from implementation of the existing O<sub>3</sub> standards. Other areas of the country have also

<sup>20</sup> The data completeness criteria for Figure 2-8 through Figure 2-14 are listed in Table 2A-1 of Appendix 2A.




1 experienced decreases in design values, most notably in California and near urban areas in the  
2 intermountain west.



3  
4 **Figure 2-9. Trends in O<sub>3</sub> design values based on data from 2000-2002 through 2018-2020.**

5 Figure 2-10 shows the national trend in the annual 4<sup>th</sup> highest MDA8 values based on 188  
6 ambient air monitoring sites with complete data from 1980 to 2020. This figure shows that, on  
7 average, there has been a 33% decrease in U.S. annual 4<sup>th</sup> highest MDA8 levels since 1980.  
8 Since relatively few sites have been monitoring continuously since 1980, Figure 2-11 shows the  
9 national trend in the annual 4<sup>th</sup> highest MDA8 values and the design values based on the 822  
10 monitoring sites with complete data from 2000 to 2020. The U.S. median annual 4<sup>th</sup> highest  
11 MDA8 values decreased by 25% nationally from 2002 (88 ppb) to 2013 (66 ppb), with some  
12 variability among individual years in this period which can partially be attributed to changes in  
13 meteorological conditions. Similarly, the U.S. median design value decreased by 20% from  
14 2000-2002 (84 ppb) to 2013-2015 (67 ppb). The trend in the annual 4<sup>th</sup> highest MDA8  
15 concentrations was relatively flat from 2013 to 2018, with decreases occurring in 2019 and 2020.  
16 The design values have been relatively constant since 2015, though there are slight decreases in  
17 2019 and 2020. In general, the design value metric is more stable and therefore better reflects  
18 long-term changes in O<sub>3</sub> than the annual 4<sup>th</sup> highest MDA8 metric.


# Ozone Air Quality, 1980 - 2020 (Annual 4th Maximum of Daily Max 8-Hour Average) National Trend based on 188 Sites



1980 to 2020 : 33% decrease in National Average


Source: EPA's Air Trends website (<https://www.epa.gov/air-trends/ozone-trends/>).

**Figure 2-10. National trend in annual 4<sup>th</sup> highest MDA8 values, 1980 to 2020. The white center line is the average while the filled area represents the range between the 10<sup>th</sup> and 90<sup>th</sup> percentiles. The dotted line is the level of the standard.**



**Figure 2-11. National trend in annual 4<sup>th</sup> highest MDA8 concentrations and O<sub>3</sub> design values in ppb, 2000 to 2020.**

Figure 2-12 shows regional trends in the median annual 4<sup>th</sup> highest MDA8 values for the 9 National Oceanic and Atmospheric Administration (NOAA) climate regions<sup>21</sup> based on ambient air monitoring sites with complete O<sub>3</sub> monitoring data for 2000-2020. The five eastern U.S. regions (Central, East North Central, Northeast, Southeast, South) have all shown decreases of at least 10 ppb in median annual 4<sup>th</sup> highest MDA8 values since the early 2000's, with the Southeast region in particular showing the largest decrease of over 20 ppb. In contrast, the median annual 4<sup>th</sup> highest MDA8 values have changed by less than 10 ppb in each of the four western U.S. regions (Northwest, Southwest, West, West North Central). The large increase in the Northwest region in 2017 and 2018 correspond to years with historically high wildfire activity.



**Figure 2-12. Regional trends in median annual 4<sup>th</sup> highest MDA8 concentrations, 2000 to 2020.**

<sup>21</sup> These regions are defined per Karl and Koss (1984) as illustrated in Appendix 2B, Figure 2B-1.



Trends presented in this section have focused on annual 4<sup>th</sup> high MDA8 concentrations and design values. Additional information from the published literature has examined trends in MDA8 concentrations across the distribution of high and low O<sub>3</sub> days. Simon et al., 2015) found that, similar to results presented in this section for DVs and annual 4<sup>th</sup> high MDA8 concentrations, the 95<sup>th</sup> percentile of summertime MDA8 concentrations decreased significantly at most sites across the U.S. between 1998 and 2013. In contrast, trends over that time period for the 5<sup>th</sup> percentile, median and mean of MDA8 varied with location and time of year. Similarly, Lefohn et al. (2017) reported that between 1980 and 2014 there was a compression of the distribution of measured hourly O<sub>3</sub> values with extremely high and extremely low concentrations becoming less common. As a result, O<sub>3</sub> metrics impacted by high hourly O<sub>3</sub> concentrations, such as the annual 4<sup>th</sup> highest MDA8 value, decreased at most U.S. sites across this period. Concurrently, metrics that are impacted by averaging longer time periods of hourly O<sub>3</sub> measurements, such as the 6-month (April-September) average of daytime (8am-7pm) O<sub>3</sub> concentrations, were more varied with only about half of the sites exhibiting decreases in this metric and most other sites exhibiting no trend (Lefohn et al., 2017).

### 2.4.3 Diurnal Patterns


Tropospheric O<sub>3</sub> concentrations in most locations exhibit a diurnal pattern due to the photochemical reactions that drive formation and destruction of O<sub>3</sub> molecules. Figure 2-13 shows boxplots of O<sub>3</sub> concentrations in ambient air, by hour of the day for four monitoring sites that represent diurnal patterns commonly observed in the U.S. The boxes represent the 25<sup>th</sup> percentile, median, and 75<sup>th</sup> percentiles and each box has “whiskers” which extend up to 1.5 times the interquartile range (i.e., the 75<sup>th</sup> percentile minus the 25<sup>th</sup> percentile) from the box, and dots which represent outlier values. The top panels show diurnal patterns, based on available data from 2015-2017, at urban (panel A) and downwind suburban (panel B) monitoring sites in the Los Angeles metropolitan area. Both sites generally measure their highest O<sub>3</sub> concentrations during the early afternoon hours, and their lowest concentrations during the early morning hours, as is typical of most urban and suburban areas in the U.S. However, higher levels of NO<sub>x</sub> emissions near the urban site may suppress O<sub>3</sub> formation throughout the day and increase the O<sub>3</sub> titration rate at night, resulting in lower O<sub>3</sub> concentrations than those typically observed at the downwind site.

Ozone concentrations are generally lower in rural areas than in urban and suburban areas, with less pronounced diurnal patterns. However, elevation and transport also play a larger role in influencing concentrations in rural areas than in urban areas. The bottom panels in Figure 2-13 show diurnal patterns at low elevation (panel C) and high elevation (panel D) rural monitoring sites in New Hampshire. The low elevation site experiences O<sub>3</sub> concentrations that are 10-20 ppb lower, on average, than at the high elevation site. Ozone concentrations at the low elevation site

1 exhibit a slight diurnal pattern similar to that seen at the urban and suburban sites (generally  
2 related to photochemical O<sub>3</sub> formation that increases concentrations in the late morning and  
3 afternoon), while O<sub>3</sub> concentrations at the high elevation site do not exhibit any diurnal pattern.  
4 The lack of a diurnal pattern observed at the high elevation site is typical of high elevation rural  
5 sites throughout the U.S., suggesting that observed O<sub>3</sub> concentrations at such sites are primarily  
6 driven by transport from upwind areas rather than being formed from local precursor emissions.  
7 The presence of peak O<sub>3</sub> concentrations that are higher at the high elevation site than at the low  
8 elevation site at all hours of the day indicates that the high elevation site may be influenced by  
9 transport from the free troposphere to a greater extent than the low elevation site.

10





**Figure 2-13. Diurnal patterns in hourly O<sub>3</sub> concentrations at selected monitoring sites: A) an urban site in Los Angeles; B) a downwind suburban site in Los Angeles; C) a low elevation rural site in New Hampshire; and D) a high elevation rural site in New Hampshire.**


#### 2.4.4 Seasonal Patterns

Tropospheric O<sub>3</sub> concentrations also tend to experience seasonal patterns due to seasonal changes in meteorological conditions and the length and intensity of daylight. High O<sub>3</sub> concentrations are most commonly observed on hot, sunny, and stagnant days during the spring and summer. Figure 2-14 shows boxplots of MDA8 O<sub>3</sub> concentrations by month of the year for four monitoring sites that represent different kinds of seasonal patterns commonly observed in the U.S. This figure is based on data from 2015-2017. The boxes represent the 25<sup>th</sup> percentile, median, and 75<sup>th</sup> percentiles and each box has “whiskers” which extend up to 1.5 times the interquartile range (i.e., the 75<sup>th</sup> percentile minus the 25<sup>th</sup> percentile) from the box, and dots which represent outlier values. Panel A shows the seasonal pattern for an urban site in Baltimore, MD, which reflects the typical seasonal pattern observed at many urban and suburban monitoring sites across the U.S. The highest O<sub>3</sub> concentrations are observed during May to September, when the days are the longest and solar radiation is strongest.

Panel B shows the seasonal pattern for an urban site in Baton Rouge, LA. In parts of the southeastern U.S., the highest O<sub>3</sub> concentrations are often observed in April and May due to the onset of warm temperatures combined with abundant emissions of biogenic VOCs at the start of the growing season. This is often followed by lower concentrations during the summer months, which is associated with high humidity levels that tend to suppress O<sub>3</sub> formation in the region (Camalier et al., 2007). Some areas, particularly in the states bordering the Gulf of Mexico, may experience a second peak in O<sub>3</sub> concentrations in September and October.

Panel C shows the seasonal pattern for a high elevation rural site in Colorado. The highest O<sub>3</sub> concentrations in rural areas are typically observed in the spring. This can be due to several factors, including those mentioned previously, and additionally, long-range transport from Asia is most prevalent at this time of year. Stratospheric Tropospheric Exchange events, which most often affect high elevation areas in the western U.S., are also most common during the spring.

Finally, Panel D shows the seasonal pattern for a monitoring site in Utah where high wintertime O<sub>3</sub> concentrations were observed. Over the past decade, high O<sub>3</sub> concentrations have been observed in two mountain basins in the western U.S. during the winter months (December to March). These wintertime O<sub>3</sub> episodes require a unique set of conditions, including a shallow inversion layer, snow cover, calm or light winds, and pervasive local NO<sub>x</sub> and VOC emissions (in these cases, from oil and gas extraction). These conditions are relatively uncommon, and elevated wintertime O<sub>3</sub> levels may not occur in some years.



**Figure 2-14. Seasonal patterns in MDA8 O<sub>3</sub> concentrations at selected monitoring sites (2015-2017): A) an urban site in Baltimore, MD; B) an urban site in Baton Rouge, LA; C) a rural site in Colorado; and D) a site in Utah experiencing high wintertime O<sub>3</sub>.**

## 2.4.5 Variation in Recent Daily Maximum 1-hour Concentrations

To provide a characterization of recent O<sub>3</sub> concentrations in the U.S. for periods shorter than 8 hours, this section presents recent O<sub>3</sub> monitoring data in terms of daily maximum 1-hour average (MDA1) concentrations, and their variation across monitoring sites that vary with regard to design values for the current O<sub>3</sub> standards.

Figure 2-15 shows boxplots of MDA1 values at U.S. monitoring sites based on 2018-2020 data stratified by each site's 8-hour O<sub>3</sub> design value. The boxes representing the 25<sup>th</sup> percentile, median, and 75<sup>th</sup> percentile MDA1 values increase slightly with higher design values. Although the overall range (minimum and maximum) of observed MDA1 values does not appear to change much, there is an increasing presence of higher MDA1 values extending up to around 160 ppb for the rightmost bin which includes only sites that exceed the current standards. The upper percentiles, including the 75<sup>th</sup> and the 99<sup>th</sup> percentiles (represented by top of box and upper whisker, respectively), in particular, are increased for the sites that do not meet the current standards (up to nearly 80 ppb and 120 ppb in the rightmost bin). In contrast, the boxplots show that there are only a small fraction of MDA1 values above 120 ppb for sites that meet the current standards.


Figure 2-16 shows a scatter plot of the number of days at each monitoring site that have a MDA1 value of 120 ppb or greater based on 2018-2020 data compared to the site's 2018-2020 design value. According to the figure, a small proportion of O<sub>3</sub> monitoring sites in the U.S. observe MDA1 values at or above 120 ppb more than once per year, but these sites all exceed the current 8-hour standards. There are no sites that were meeting the current standards based on 2018-2020 data that had MDA1 values above 120 ppb more than three times over the same 3-year period (Appendix 2A, Table 2A-2).

Figure 2-17 shows the national trend in the annual 2<sup>nd</sup> highest MDA1 O<sub>3</sub> concentration, which was the metric used to track progress towards meeting the 1-hour O<sub>3</sub> NAAQS, originally set in 1979 and later replaced by the current 8-hour metric in 1997 (62 FR 38856, July 18, 1997).<sup>22</sup> The monitoring sites represented in Figure 2-17 are the 834 sites with complete data from 2000 to 2020 (as summarized in Appendix 2A, Section 2A.2). The shapes of the trend lines in Figure 2-17 are similar to those shown for the annual 4<sup>th</sup> highest MDA8 values in Figure 2-11. The national median annual 2<sup>nd</sup> highest MDA1 value decreased by 27% from 2002 (105 ppb) to 2013 (77 ppb), which is comparable to the decrease observed in the national median annual 4<sup>th</sup> highest MDA8 value (25%) during the same period.


---

<sup>22</sup> The 1-hour O<sub>3</sub> standards were formally revoked in 2005 (70 FR 44470, August 3, 2005).






**Figure 2-15. Boxplots showing the distribution of MDA1 concentrations (2018-2020), binned according to each site's 2018-2020 design value.**



**Figure 2-16. Number of days in 2018-2020 at each monitoring site with a MDA1 concentration greater than or equal to 120 ppb compared to its 8-hour design value in ppb.**



**Figure 2-17. National trend in the annual 2<sup>nd</sup> highest MDA1 O<sub>3</sub> concentration, 2000 to 2020. The solid blue line represents the median value, dotted blue lines represent the 25<sup>th</sup> and 75<sup>th</sup> percentile values, and the light blue shaded area represents the range from the 10<sup>th</sup> to the 90<sup>th</sup> percentile values.**

## 2.5 BACKGROUND O<sub>3</sub>

There are a number of definitions of background O<sub>3</sub> used in various contexts that differ by the specific emissions sources and/or natural processes the definition includes (e.g., see ISA, Appendix 1, section 1.2.2). In this reconsideration, as in past reviews, the EPA generally characterizes O<sub>3</sub> concentrations that would exist in the absence of U.S. anthropogenic emissions as U.S. background (USB). An alternative phrasing for USB is the O<sub>3</sub> concentrations created collectively from global natural sources and from anthropogenic sources existing outside of the U.S. Such a definition helps distinguish the O<sub>3</sub> that can be controlled by precursor emissions reductions within the U.S. from O<sub>3</sub> originating from global natural and foreign precursor sources that cannot be controlled by U.S. regulations (ISA, section 1.2.2).

Because monitors cannot distinguish the origins of the O<sub>3</sub> they measure,<sup>23</sup> photochemical grid models have been widely used to estimate the contribution of background sources to observed surface O<sub>3</sub> concentrations. This section summarizes results of a state-of-the-science modeling analysis to estimate the magnitude of present-day USB and its various components. Conceptually, these USB estimates represent O<sub>3</sub> concentrations that occur as a result of global natural sources (or processes, see section 2.5.1 for more details) and those anthropogenic sources existing outside the U.S., i.e., the O<sub>3</sub> concentrations that would occur in the absence of any U.S. anthropogenic O<sub>3</sub> precursor emissions. Modeling results summarized in this section include average estimates of MDA8 USB concentrations for several temporal periods including seasons. Average USB estimates are also presented for days on which the total model-predicted MDA8 O<sub>3</sub> concentration was greater than either 60 ppb or 70 ppb, and for the days on which the 4th-highest MDA8 O<sub>3</sub> concentration was predicted to occur. Additionally, this modeling analysis investigated the contributions to USB of some specific groups of sources, such as international anthropogenic sources, and how those contributions vary by season and by location.

The section, which presents the information and analysis that were also presented in the parallel section of the 2020 PA, is organized as follows. Section 2.5.1 provides an overview of the various sources that contribute to USB, including currently available information on the magnitude, seasonal variability, and spatial variability of their contributions to USB. Section 2.5.2 summarizes the methodology for the modeling analyses used to quantify USB and component contributions. More detailed information about the modeling methodology is presented in Appendix 2B. Section 2.5.3 summarizes USB estimates using methodology

---

<sup>23</sup> Ozone concentrations that do not include contributions from U.S. anthropogenic emissions cannot be determined exclusively from O<sub>3</sub> measurements because even relatively remote monitoring sites in U.S. receive transport of U.S. anthropogenic O<sub>3</sub> from other locations.

described in section 2.5.2, including estimates specific to certain subgroups of sources. Section 2.5.4 summarizes key findings of the analyses.

### 2.5.1 Summary of U.S. Background O<sub>3</sub> Sources

Jaffe et al. (2018) reviewed the literature on sources that contribute to USB. While the term “background” may imply a low concentration well-mixed<sup>24</sup> environment, background sources can create well-defined plumes and/or contribute to the well-mixed environment. The USB definition, which is based on sources, includes both the well-mixed environment and more well-defined plumes. Figure 2-18a (adapted from Jaffe et al. (2018)) illustrates sources of USB O<sub>3</sub> (blue) and U.S. anthropogenic sources of O<sub>3</sub> (yellow). Figure 2-18b shows two theoretical examples where background sources contribute to the total ground-level O<sub>3</sub>. The first example (Ex 1) highlights a typical monitoring site with lower USB, and the second example (Ex 2) presents a scenario in which USB is a large contributor. Both examples oversimplify methane, which has both natural and anthropogenic and both domestic and foreign contributions. Source contributions to USB vary in space and time, and the stacked bar plot in this figure oversimplifies the complex relationship between USB and total O<sub>3</sub>. Even so, USB sources can broadly be discussed as global natural sources (see sections 2.5.1.1 to 2.5.1.6) and international anthropogenic sources (see section 2.5.1.7). In the simplest interpretation, the natural sources are background regardless of where they occur, or which definition of background is being used (e.g., USB or natural background<sup>25</sup>). By contrast, ozone formed from anthropogenic emissions is only considered as background when the emissions sources are not from sources within the focus area. However, this paradigm is complicated by the fact that many sources of O<sub>3</sub> precursors are the result of interactions between human and natural systems (for instance forest management practices can impact both biogenic VOC emissions from trees and wildfires). In the context of USB, anthropogenic background is synonymous with O<sub>3</sub> originating from international anthropogenic emission sources. The relative contribution of international and natural background sources can vary dramatically from place to place and are most notably larger at locations near borders (international) or high elevation (natural). At non-border locations and many border locations, the natural background is usually the dominant background source.

---


<sup>24</sup> We use the term “well-mixed” here to refer to conditions when the contributions from various types of sources are mixed due to chemistry or physical processes to the point where it is not possible to discern the contribution to O<sub>3</sub> from each individual source.

<sup>25</sup> Natural background is the O<sub>3</sub> that would exist in the absence of anthropogenic emission sources.





(a)



(b)

(a) U.S. O<sub>3</sub> sources shown with yellow boxes or arrows represent domestic sources. Sources shown with blue boxes or arrows represent USB sources. Note that locations for each process are not specific to any one region. The base map shows satellite-observed tropospheric NO<sub>2</sub> columns for 2014 from the Ozone Monitoring Instrument (OMI) onboard the NASA Aura satellite (Credit: NASA Goddard's Scientific Visualization Studio/T. Schindler). NO<sub>2</sub> column amounts are relative with red colors showing highest values, followed by yellow then blue. We use the OMI NO<sub>2</sub> columns as a proxy to show local O<sub>3</sub> precursor emission sources. (b) The bar chart shows two theoretical examples of USB O<sub>3</sub> contributions combine with domestic sources to produce elevated O<sub>3</sub> at a specific location on any given day. Each source varies daily and there are also nonlinear interactions between USB O<sub>3</sub> sources and anthropogenic sources that can further add to O<sub>3</sub> formation, e.g., wildfires and urban anthropogenic emissions (e.g., Singh et al., 2012). Minor adaptation from DOI: <https://doi.org/10.1525/elementa.309.f1>

**Figure 2-18. Conceptual models for O<sub>3</sub> sources: (a) in the U.S., and (b) at a single location.**

The natural and anthropogenic sources of background O<sub>3</sub> vary by location and by season. Emissions from anthropogenic sources largely occur in the same areas year after year. Natural sources of O<sub>3</sub> and precursors, on the other hand, vary both in magnitude and in location from day to day and year to year. As a result, certain types of natural sources may have large O<sub>3</sub> contributions measured at a monitor at one point in time but not at other times. The combination of varying proximity and magnitude means that natural sources can contribute to background in the form of localized plumes of elevated O<sub>3</sub> that contribute to O<sub>3</sub> at monitoring sites on an episodic basis. In the absence of locally well-defined plumes, global natural and international anthropogenic sources are constantly contributing to the well-mixed background.

1 USB varies by location and by season due to both the nature of sources and the loss  
2 processes. The nature of emission sources leads to seasonal and spatial patterns that will be  
3 described further below. The contribution of these sources is modulated by transport patterns that  
4 interact with deposition and chemical losses. For illustration, two emission sources of identical  
5 magnitudes may have different contributions if one emits near the surface in summer and the  
6 other emits in the free troposphere in spring. Warmer moister air in the summer at the surface  
7 enhances O<sub>3</sub> chemistry losses and deposition of O<sub>3</sub> to the surface increases losses further. In  
8 contrast, cooler, drier temperatures in the spring and free troposphere lengthen O<sub>3</sub> lifetimes and  
9 faster winds in the free troposphere enable longer transport. The seasonality of temperature and  
10 transport patterns gives O<sub>3</sub> USB a distinct seasonal cycle that results from both sinks and  
11 sources.

12 The sections below summarize the state of the science estimates of USB contributions.  
13 Each source type is described with respect to its seasonality as well as its local vs well-mixed  
14 contribution potential. Jaffe et al. (2018) reviewed contributions of various sources to USB O<sub>3</sub>  
15 from modeling studies and the references therein are used to illustrate the range of O<sub>3</sub>  
16 contributions from each source. The literature-based estimate ranges provide context to the  
17 estimates of USB that are reported in section 2.5.3.

#### 18 **2.5.1.1 Stratosphere**

19 The only direct source of O<sub>3</sub> to the troposphere with appreciable contributions to O<sub>3</sub>  
20 concentrations is STE (other sources are indirect via precursors). STE occurs when stratospheric  
21 air, which is relatively rich in O<sub>3</sub>, is transported across the tropopause where it enhances  
22 tropospheric concentrations. Most STE events create enhancements that do not immediately  
23 reach the surface. Instead, STE-enhanced O<sub>3</sub> mixes into the free troposphere where it is  
24 dispersed. In cases when the transported air reaches the surface before enough dispersion occurs,  
25 it creates a localized plume of O<sub>3</sub> referred to as a Stratospheric Ozone Intrusion (SOI). The total  
26 stratospheric contribution includes both the well-mixed contribution from the distant stratosphere  
27 exchanges as well as any localized SOI plume.

28 The total global O<sub>3</sub> flux from the stratosphere to the troposphere is estimated at 510±90  
29 teragrams per year (Tg/y) compared to 4620±600 Tg/y (post-2000 literature in Table 2 in Wu et  
30 al., 2007) produced within the troposphere. The majority of the earth's surface is outside the U.S.  
31 and only STE that take place over the U.S. are likely to create a large magnitude local  
32 enhancement at a U.S. monitor.<sup>26</sup> A SOI that occurs outside the U.S. would likely be dispersed

---

<sup>26</sup> Recently methods have been developed for identifying and estimating SOIs that have clear localized contributions to O<sub>3</sub> concentrations with the potential to contribute to standards' exceedances. These are described in documents available at: <https://www.epa.gov/air-quality-analysis/guidance-preparation-exceptional-events-demonstrations-stratospheric-ozone>.

1 into the well-mixed background and reduced through chemical loss and deposition before it  
2 reaches many monitors.

3 Modeling and observational studies show that SOI can episodically contribute large  
4 amounts of O<sub>3</sub> at a subset of U.S. monitors, but stratospheric mixing more frequently contributes  
5 smaller quantities of O<sub>3</sub>. Modeling studies focused on seasons with frequent SOI find median  
6 total stratospheric contributions to MDA8 are 10-22 ppb in the West and 3-13 ppb in the East  
7 with episodic contributions up to 40 ppb mostly in the West (Table S2, Jaffe et al., 2018).  
8 Because these studies focus on the most active season, these medians are expected to be upper  
9 bounds for the annual average. Further, SOI are most common in the spring when MDA8 O<sub>3</sub>  
10 concentrations above 70 ppb are less common (ISA, section 1.3.2).

### 11 **2.5.1.2 Biogenic VOC**

12 Biogenic VOCs are the quintessential “natural” source of O<sub>3</sub> precursors. At global scales,  
13 biogenic sources are the largest contributor to VOCs – even though local anthropogenic sources  
14 of highly reactive VOCs can be very important in some areas. VOCs are also an important  
15 source of carbon monoxide. Biogenic VOCs are emitted by various types of vegetation and  
16 emissions peak in summer which is also when O<sub>3</sub> production is fast and O<sub>3</sub> lifetimes are short.

17 The large abundance of biogenic VOCs leads to NO<sub>x</sub>-limited O<sub>3</sub> production in most of  
18 the world. That is, concentrations of biogenic VOCs are in excess with respect to concentrations  
19 of NO<sub>x</sub>; therefore, O<sub>3</sub> production is controlled by the availability of NO<sub>x</sub>. The methodologies<sup>27</sup>  
20 typically used by the air quality community estimate contribution based on sensitivity of O<sub>3</sub>  
21 production. As a result, the sensitivity-based contribution estimate of biogenic VOC sources to  
22 O<sub>3</sub> shows relatively small contributions considering the large amount of emissions.

23 Estimates of biogenic VOC contributions in the literature are generally small compared to  
24 NO<sub>x</sub>. For example, Lapina et al. (2014) found that North American Background (NAB)<sup>28</sup> for  
25 W126<sup>29</sup> O<sub>3</sub> was relatively insensitive to VOC (10.8% of NAB sensitivity) compared to NO<sub>x</sub>  
26 (79.8% of NAB sensitivity). This well-known global-scale sensitivity to NO<sub>x</sub> would not exist if  
27 concentrations of biogenic VOCs were a broadly limiting factor. Even though background O<sub>3</sub> is  
28 not particularly sensitive to small changes in the biogenic VOC, natural sources of VOCs are a  
29 critical component of all background O<sub>3</sub> estimates.

---

<sup>27</sup> Source apportionment techniques and derivative-normalization techniques use sensitivity to attribute concentrations to sources. When a concentration is insensitive to VOC sources, the contribution estimate solely from that source of VOC will be zero.

<sup>28</sup> North American Background is analogous to USB; but NAB is generally characterized as the O<sub>3</sub> concentrations that would exist in the absence of North American anthropogenic emissions.

<sup>29</sup> W126 is a daytime weighted average concentration where higher concentrations are given greater weight based on a sigmoidal curve (see Chapter 4).

### 2.5.1.3 Wildland Fires

Fires emit a complex mixture of nitrogen oxides, nitrogen reservoir species (e.g., PANs), and VOCs that are all precursors to O<sub>3</sub>. In the northern hemisphere, the fire season generally starts in spring and extends into fall with the specific timing varying widely by region. Fires also exhibit significant year to year variability, with emissions varying by an order of magnitude between high and low fire years in some places (van der Werf et al., 2017). While smoke from fires affects most of the contiguous U.S. at some point during the year, the fire season in the western U.S. occurs primarily late in the summer. Fires across western states and parts of Canada can contribute both to regional background and episodic surface O<sub>3</sub> enhancements (McClure and Jaffe, 2018).<sup>30</sup>

Ozone production in fire plumes depends on a range of factors including the type of fuel combusted, plume age, and interactions with other air masses (e.g. urban plumes) (Jaffe and Wigder, 2012). While some studies have estimated wildfire O<sub>3</sub> contributions to seasonal mean O<sub>3</sub> of up to several ppb during high fire years in the Western U.S. (Jaffe et al., 2018), O<sub>3</sub> production from individual fires varies substantially (Akagi et al., 2013). Several studies have shown that locations near large fires can even experience suppressed O<sub>3</sub> formation, perhaps due to titration from fresh NO emissions and/or reduced solar radiation resulting from high aerosol concentrations (McClure and Jaffe, 2018; Buysse et al., 2019). Large variability in O<sub>3</sub> precursor emissions from fires combined with complex in-plume dynamics and chemistry make accurately quantifying O<sub>3</sub> production from fires extremely difficult at both regional and local scales.<sup>31</sup>

New data from recent and upcoming field and aircraft campaigns<sup>32</sup> are expected to provide new insights that expand current understanding of contributions from fires to O<sub>3</sub> concentrations in the U.S., both in the context of regional background concentrations and production during individual fire episodes.

### 2.5.1.4 Lightning Nitrogen Oxides

Lightning is an indirect natural O<sub>3</sub> precursor source. Lightning produces NO<sub>x</sub> from molecular nitrogen and oxygen, similar to traditional combustion processes. Because NO<sub>x</sub> is the

---

<sup>30</sup> Fires may occur on wildlands naturally or accidentally, or fires may be planned (prescribed) for various purposes and set intentionally. In the USB modeling work described in section 2.5.2.1 below, emissions associated with prescribed fires are categorized as anthropogenic emissions and are not included in estimating USB.

<sup>31</sup> Recently methods have been developed for identifying and estimating wild or prescribed fire contributions to O<sub>3</sub> concentrations with the potential to contribute to standards' exceedances. These are described in documents available at <https://www.epa.gov/air-quality-analysis/final-2016-exceptional-events-rule-supporting-guidance-documents-updated-faqs>.

<sup>32</sup> Western Wildfire Experiment for Cloud Chemistry, Aerosol Absorption and Nitrogen (WE-CAN, [https://www.eol.ucar.edu/field\\_projects/we-can](https://www.eol.ucar.edu/field_projects/we-can)) in 2018 and Fire Influence on Regional to Global Environments and Air Quality (FIREX-AQ, <https://www.esrl.noaa.gov/csd/projects/firex-aq/>) in 2019.

globally limiting precursor for O<sub>3</sub> production and lightning emits where there are few other sources, O<sub>3</sub> production is quite sensitive to this source. Over the U.S., lightning NO<sub>x</sub> (LNO<sub>x</sub>) emissions peak in summer with convective activity and are characterized as having high interannual variability (Murray, 2016). Allen et al. (2012) showed that the majority of LNO<sub>x</sub> is emitted in the free troposphere (i.e., troposphere above the planetary boundary layer). Thus, LNO<sub>x</sub> is produced in a NO<sub>x</sub>-limited environment where any O<sub>3</sub> formed as a result will be efficiently transported and loss pathways are limited.

The total NO<sub>x</sub> created by lightning is highly uncertain (Murray, 2016). Murray (2016) discusses the uncertainty in NO yield per flash rate and the role of large spatial gradients in the yield. The effect of such uncertainties is evident in the range of global lightning emissions (std/mean=0.4). Murray (2016) also discusses the uncertainty in the vertical distribution of NO production and post-production redistribution.

Jaffe et al. (2018) reviewed contributions from lightning to surface USB O<sub>3</sub> based on modeling studies using various flash rate yields, which shows large single day contributions to modeled MDA8 O<sub>3</sub> (up to 46 ppb, Murray, 2016) and smaller contributions to annual means (1-6 ppb) and seasonal means (6-10 ppb). Lapina et al. (2014) showed that, in their modeling, W126 had a 15% contribution from lightning NO<sub>x</sub> over the U.S.<sup>33</sup> A 15% contribution is consistent with the annual and seasonal mean contributions to MDA8 reported by Zhang et al. (2014) and Murray (2016). Lapina et al. (2014) also noted that 40% of the lightning NO<sub>x</sub> sensitivity comes from lightning strikes outside the U.S. The findings from these studies highlight the primary importance of lightning NO<sub>x</sub> as a contributor to the well-mixed background concentrations (Murray, 2016).

#### **2.5.1.5 Natural and Agricultural Soil NO<sub>x</sub>**

Nitrogen oxides from soils are a naturally occurring source that is enhanced by anthropogenic activity. Truly natural soil NO<sub>x</sub> is created as a byproduct of nitrogen fixation in natural environments. The fixation and byproduct release are affected by flora composition, nitrogen availability, and environmental conditions (e.g., humidity). Human activity affects the amount and location of soil NO<sub>x</sub> emissions by changing land cover and by increasing the availability of nitrogen for fixation through the application of fertilizer to crop lands or additions

---

<sup>33</sup> The numbers shown in this report are derived from reported values in Lapina et al. (2014) which showed sensitivity of W126 to anthropogenic NO<sub>x</sub> sources was 58% (of that, 80% US; 9% CAN; 4% MEX) and natural NO<sub>x</sub> sources was 25%. The remaining 17% was attributed natural isoprene (1.3%), VOCs/CO from fires (Fig 9: ~3%) and international VOC/CO (Fig 9: ~14%). So non-North American anthropogenic NO<sub>x</sub> (58% \* 7% non-NA = 4%) and natural NO<sub>x</sub> (25%) create a total NAB NO<sub>x</sub> sensitivity of 29% and total NAB sensitivity of 35% (29% / 79.8%). Of the total sensitivity (parentheses contain percent of NAB NO<sub>x</sub> sensitivity, see Fig 12), lightning was 15% (52.9%), soil NO<sub>x</sub> was 8% (28.2%), fire NO<sub>x</sub> was 1% (4.3%) and international anthropogenic NO<sub>x</sub> was 4% (14.5%).

1 of nitrogen via deposition of emissions from other sources. The effect of human land cover  
2 alteration is readily apparent in soil NO<sub>x</sub> emission measurements. Steinkamp and Lawrence  
3 (2011), highlight that soils in pristine natural ecosystems emit more NO<sub>x</sub> compared to similar  
4 ecosystems that have been disturbed by human activity. At the same time, human managed crop  
5 lands emit more than natural ecosystems (pristine or disturbed) environments because of the  
6 applied fertilizer.

7       Soil NO<sub>x</sub> clearly has both anthropogenic and natural sources, but these are rarely  
8 separated in the literature. First, Hudman et al., 2012 estimate that the majority (~80%) of soil  
9 NO<sub>x</sub> emissions are currently attributed to land surfaces without considering active fertilization or  
10 deposition of anthropogenic nitrogen. Second, the emissions and attribution are relatively  
11 uncertain. Finally, anthropogenic soil NO<sub>x</sub> is associated with agricultural ammonia application  
12 that is not directly regulated in the United States. As a result, the attribution of soil NO<sub>x</sub> as a  
13 “background” source is imperfect. In this assessment, no distinction is made between natural and  
14 fertilizer-enhanced soil NO<sub>x</sub> and instead we include both within “natural sources.”

15       Hudman et al. (2012) estimated the global soil NO<sub>x</sub> emissions at 10.7 TgN/y. As noted  
16 above, soil NO<sub>x</sub> emissions are linked to nitrogen availability in the soil, which is increased by  
17 anthropogenic activities. Hudman et al. (2012) attributed 1.8 TgN/y to anthropogenic soil  
18 fertilization and 0.5 TgN/y to atmospheric deposition. Like lightning, most soil NO<sub>x</sub> emissions  
19 occur outside of the U.S. Unlike lightning, soil NO<sub>x</sub> has a smaller long-range transport  
20 component because it is emitted at the surface. For example, Lapina et al. (2014) calculated that  
21 W126 had an 8% sensitivity to soil NO<sub>x</sub> (see footnote 26) and noted that a small fraction (only  
22 7%) was from emissions outside the U.S. The more local sensitivity is likely due to the emission  
23 height and spatial distribution of soil NO<sub>x</sub>.

#### 24       **2.5.1.6 Post-Industrial Methane**

25       Like VOCs, CH<sub>4</sub> is a hydrocarbon that can form O<sub>3</sub> in the presence of NO<sub>x</sub> and sunlight.  
26 While some atmospheric methane is emitted naturally from wetlands, wildfires, geogenic  
27 sources, and insects, significant global methane enhancements following the industrial revolution  
28 are clearly associated with increased emissions from anthropogenic fossil fuel combustion  
29 (Pachauri et al., 2015). Other human activities such as livestock cultivation, landfills and land  
30 use modification (e.g., rice paddies) also release methane. More recently, changing climate  
31 conditions have led to increased emissions from natural sources (e.g., permafrost melting) in  
32 some areas (Reay et al., 2018), although the exact magnitude of these effects on global methane  
33 concentrations, and consequently O<sub>3</sub> in the U.S., over longer time scales remains uncertain.

34       Due to its long atmospheric lifetime (~10 years), methane is well-mixed at seasonal and  
35 annual time scales. As a result, isolating contributions to atmospheric methane concentrations

1 from individual geographic areas or specific emission sectors is very difficult (Turner et al.,  
2 2017). However, sensitivity simulations with chemical transport models can be used to assess the  
3 overall influence of global methane concentrations on regional O<sub>3</sub> budgets. For example, Lin et  
4 al. (2017) used the GFDL-AM3 chemistry-climate model to estimate that increasing global  
5 methane concentrations contributed ~20% to background MDA8 O<sub>3</sub> trends during boreal spring  
6 and summer at several western U.S. sites during the period 1988 to 2012. In general, post-  
7 industrial anthropogenic methane is estimated to contribute ~5 ppb to surface O<sub>3</sub> in the U.S., an  
8 estimate that primarily comes from modeling studies (Jaffe et al., 2018 and references therein).

9 A major limitation with existing model-based estimates of the influence of global  
10 methane on current U.S. O<sub>3</sub> concentrations is our limited understanding of historical methane  
11 emissions. The U.S. and the rest of the world's anthropogenic methane emissions have not been  
12 tracked quantitatively in detail until relatively recently. As a result, the pre-industrial methane  
13 concentration is relatively unconstrained. Further, post-industrial methane can be attributed to  
14 direct emissions and emissions from natural sources (e.g., permafrost). Many modeling studies,  
15 including this one, do not explicitly track methane sources and sinks, further complicating  
16 attribution in an air quality context. Therefore, the post-industrial methane contribution is  
17 difficult to quantitatively attribute. The post-industrial enhancement of methane is clearly related  
18 to direct anthropogenic emissions and alteration of natural emissions by human activity, which  
19 includes both foreign and domestic contribution.

#### 20 **2.5.1.7 International Anthropogenic Emissions**

21 International anthropogenic emissions are the only anthropogenic contribution to USB.  
22 For the purposes of discussion, NO<sub>x</sub> and VOCs will be discussed separately from methane  
23 (methane is covered in section 2.5.1.6). NO<sub>x</sub> and VOC emission estimates from outside the U.S.  
24 are derived from international collaborative efforts like the Hemispheric Transport of Air  
25 Pollutants (HTAP) task force of the United Nations Economic Commission for Europe  
26 (Janssens-Maenhout et al. 2015). HTAP harmonized national emission databases from individual  
27 countries with global estimates that cover areas without their own estimates. Collecting and  
28 harmonizing these emission datasets requires coordination and technical expertise, which  
29 recently occurred twice (HTAP Phase I and HTAP Phase II) and a new HTAP emission  
30 inventory is currently underway. Global estimates that incorporate national information are  
31 available (e.g., Community Emissions Data System and Emissions Database for Global  
32 Atmospheric Research), but do not always have as much participation from individual countries.  
33 This is particularly important because individual countries are most aware of regulations and  
34 controls that have been promulgated within their borders.

1 International anthropogenic sources of O<sub>3</sub> include emissions within the borders of other  
2 countries (e.g., onroad sources, power plants, etc.) as well as sources in international waters and  
3 air space. Sources within the borders of other countries can be easily attributed to those countries  
4 using geographical bounds based on emission source location. Some studies (e.g., Lin et al.,  
5 2014), however, have done more complex analyses to spatially attribute emissions globally based  
6 on the consumption of produced goods. For the purposes of this document, international  
7 emissions are attributed based on the emission source location. Using emission source location,  
8 maritime shipping and aircraft sources require more artificial distinctions. Typically, aircraft  
9 takeoff and landing are assigned completely to the country where it occurs. Aircraft cruising  
10 emissions are attributed based on geographic boundaries. This assumes that both inbound and  
11 outbound flights change source type (domestic/international) when they cross a border.

### 12 **2.5.2 Approach for Quantifying U.S. Background Ozone**

13 Updating USB estimates is motivated by interannual variability, trends in international  
14 anthropogenic emissions, and continual improvements in simulating processes affecting USB.  
15 USB sources are expected to vary from year to year because natural emissions vary in response  
16 to meteorology (e.g., temperature) and long-range transport patterns alter the efficiency of  
17 transport from long-range USB sources (Lin et al., 2015). In addition, the scientific  
18 characterization of background emission sources continues to evolve. As a result, we provide an  
19 updated assessment of USB for 2016 using the latest stable version of the Community Multiscale  
20 Air Quality (CMAQ) model applied at hemispheric to regional scales.

21 This assessment uses a firmly source-oriented definition of USB based on modeling. The  
22 source composition of a model estimate can be quantified using tagging techniques or by  
23 sensitivity analysis. By contrast, the source composition of measured O<sub>3</sub> is difficult to isolate. In  
24 most areas at most times, measured O<sub>3</sub> concentrations are the result of contributions from a  
25 variety of anthropogenic and non-anthropogenic sources. Measurements from locations  
26 sometimes suggested to be representative of USB often have contributions from U.S.  
27 anthropogenic sources. As a result, some researchers have filtered measurements to focus on  
28 times when US contributions are minimized (e.g., based on wind direction or other indicators).  
29 The measurement filtering approach is based on conceptual or quantitative models of source  
30 contributions as a function of wind direction or another environmental variable. After correction,  
31 the degree of contamination is minimized but not precisely known. Recently, urban  
32 measurements have been paired with simplistic statistical models to estimate background  
33 (Parrish et al., 2017). However, Jaffe et al. (2018) concluded that statistical adjustment cannot be  
34 directly interpreted as “background” – even though the estimate is useful for bounding simulated  
35 background. Due to the complications of quantifying background based on ambient air



1 measurements, the sources that contribute to background are most clearly defined using an air  
2 quality model. Using separate nomenclature (baseline: monitors; background: models) helps to  
3 clearly delineate between these approaches that each have their strengths and weaknesses.

4 This section quantifies O<sub>3</sub> from sources using a sensitivity approach. The multiscale  
5 system is applied to predict total O<sub>3</sub> and then applied multiple times to predict O<sub>3</sub> without U.S.  
6 anthropogenic emission sources. The difference between total O<sub>3</sub> and O<sub>3</sub> without the U.S.  
7 anthropogenic emissions is used to characterize the USB.

#### 8 **2.5.2.1 Methodology: USB Attribution**

9 This assessment attributes O<sub>3</sub> to USB sources using one of several available techniques.  
10 Jaffe et al. (2018) reviewed the methods for identifying USB contributions. The methodologies  
11 reviewed range in complexity from simply turning off U.S. anthropogenic (or specific sources)  
12 emissions, to normalizing derivatives from instrumented models, to complex tagging techniques  
13 (e.g., CAMx OSAT, APCA, or Grewe, 2013).<sup>34</sup> This analysis follows the zero-out approach for  
14 simplicity of interpretation and consistency with previous EPA analyses. In urban areas, this  
15 approach will estimate higher natural and USB contributions than total O<sub>3</sub> when NO<sub>x</sub> titration is  
16 present. The estimate, therefore, is an estimate of what concentrations could be without U.S.  
17 anthropogenic emissions and not the fraction of observed O<sub>3</sub> that is USB.

18 This analysis is designed to quantify O<sub>3</sub> specifically and separately from global natural,  
19 international anthropogenic, and U.S. anthropogenic sources. The precursors that this analysis  
20 focuses on are NO<sub>x</sub> and VOC because they have a response on timescales relevant to the  
21 NAAQS planning schedules (i.e., not methane). Table 2-1 lists simulations and the sources they  
22 exclude at the various spatial scales modeled (i.e., hemispheric – 108 km resolution, regional –  
23 36 km resolution and regional – 12 km resolution). For international shipping and aviation, the  
24 U.S. domain is either included (ZROW) or excluded (ZUSA). These simulations form the basis  
25 for estimating the contributions of USB and its components. Given the long atmospheric lifetime  
26 and attributability to U.S. sources, methane is not separately identified nor is it perturbed in any  
27 simulations. This has the effect of attributing methane to natural processes, which are a  
28 background source.

---

<sup>34</sup> For a discussion of methods and the effect on estimates, see (Jaffe et al., 2018).

**Table 2-1. Simulation names and descriptions for hemispheric-scale and regional-scale simulations.**

| Simulation  | Description  |
|---|--|
| <i>Performed at Hemispheric<sup>A</sup> and Regional<sup>B</sup> Scales</i>   |  |
| BASE  | All emission sectors are included  |
| ZUSA  | All U.S. anthropogenic emissions are removed including prescribed fires. <sup>C</sup>            |
| ZROW  | All international anthropogenic emissions are removed including prescribed fires where possible. |
| ZANTH   | All anthropogenic emissions are removed including prescribed fires.                              |
| <i>Performed at Hemispheric Scale only</i>  |  |
| ZCHN  | All Chinese anthropogenic emissions are removed.   |
| ZIND  | All India anthropogenic emissions are removed.   |
| ZSHIP   | Zero all near-U.S. commercial marine vessel category 3 and all global shipping.                  |
| ZFIRE   | Zero all fire emissions (agricultural, prescribed, and wild).                                    |
| <sup>A</sup> Hemispheric-scale simulations use 108 km grid cells defined on a polar stereographic projection.                             |  |
| <sup>B</sup> Regional-scale simulations use a nested 36 km and 12km simulation on a lambert conformal projection.                         |  |
| <sup>C</sup> Emissions estimated to be associated with intentionally set fires ("prescribed fires") are grouped with anthropogenic fires. |  |

Table 2-2 describes the calculations that are used to derive contributions. It is important to note that contributions are not strictly additive. Large NO<sub>x</sub> sources can create non-linear conditions that decrease O<sub>3</sub> concentrations due to titration which is most relevant at night and in the winter. In some cases, removing a source only increases the efficiency of other sources. In that case, some anthropogenic contribution exists unless all anthropogenic sources are removed. This residual anthropogenic contribution occurs in the model for both International and U.S. sources. The results presented in this section focus on Base, USB, International, Natural contributions. Some components of International and Natural were separately analyzed. Canada/Mexico are separately quantified at both hemispheric and regional scales. The India, China, Fire, and shipping contributions are analyzed only at the hemispheric scale and are presented in Appendix 2B. The analyses in Appendix 2B support the interpretation in the discussion below.

**Table 2-2. Expressions used to calculate contributions from specific sources.**

| Label    | Name          | Description  | Expression                |
|----------|---------------|--|---------------------------|
| BASE     | Total         | Total Concentration  | BASE                      |
| USB      | USB           | U.S. Background  | ZUSA                      |
| USA      | USA           | U.S. Contribution  | BASE – ZUSA               |
| Intl     | International | Rest of the World Contribution   | BASE – ZROW               |
| Natural  | Natural       | Natural Contribution   | ZANTH                     |
| Res-Anth |               | Anthropogenic contribution that is not attributed directly to either the U.S. or International due to non-linear chemistry | BASE - ZANTH - Intl – USA |
| IND      | India         | India Contribution   | BASE – ZIND               |
| CHN      | China         | China Contribution   | BASE – ZCHN               |
| Ship     | Ship          | Ship Contribution  | BASE – ZSHIP              |
| FIRE     | Fire          | Global fire contributions  | BASE – ZFIRE              |

### 2.5.2.2 Methodology: Strengths, Limitations and Uncertainties

The model was evaluated to assess the accuracy of predictions and infer possible biases in USB estimates. Evaluations included comparison to satellite retrievals, O<sub>3</sub> sondes<sup>35</sup>, CASTNET monitors, and AQS monitors. Results were also qualitatively compared to the Tropospheric Ozone Assessment Report (TOAR) database, which has global O<sub>3</sub> observations that have been well characterized<sup>36</sup> but Phase I, which was completed and available at the time of analysis, only extends through 2014. The evaluation of the hemispheric simulation that provides boundary conditions to the 36 km model simulation relies heavily upon the satellites, O<sub>3</sub> sondes and CASTNET monitors. Since the satellite data can be used to provide concentration estimates in areas without surface monitors, these data are particularly useful for evaluating O<sub>3</sub> column totals in the hemispheric modeling. The sonde data provide a means to evaluate predictions aloft which are important for understanding model performance of long-range transport. The regional evaluation analysis focuses on data measured at CASTNET and AQS monitors.<sup>37</sup> Evaluation using the AQS monitors provides information on how the model performs at urban/suburban O<sub>3</sub>, which may exhibit large space/time gradients in O<sub>3</sub> concentration. CASTNET data are included

<sup>35</sup> O<sub>3</sub> sondes are balloon-borne instruments that ascend through the atmosphere taking O<sub>3</sub> and meteorological measurements. For more information, see <https://www.esrl.noaa.gov/gmd/ozwv/ozsondes/>.

<sup>36</sup> The TOAR database includes O<sub>3</sub> globally where each monitor has been consistently characterized as urban or rural. The global observations have been processed for several metrics (MDA8, W126, etc.) and gridded to 2-degree by 2-degree global fields for easy comparison to large-scale models.

<sup>37</sup> In the discussion here in section 2.5, the data for CASTNET sites are referred to as “CASTNET data” and data for all other sites in AQS are referred to as “AQS data” (even though data for many, if not all, CASTNET monitors are stored in AQS).

1 in the evaluation of both the hemispheric and regional models since monitoring sites in this  
2 network are intended to represent O<sub>3</sub> concentrations across broad areas of the U.S. Model  
3 performance evaluation results are summarized in this chapter and provided in more detail in  
4 Appendix 2-B.

5 The evaluation using sonde data shows that the hemispheric model predictions of O<sub>3</sub> are  
6 generally within 20% of the corresponding measurements throughout much of the free  
7 troposphere. Near the tropopause, there is a low bias in the model that is most pronounced in the  
8 spring. The low bias at the tropopause likely suggests an underestimate of stratospheric  
9 exchange. Mean bias drops to below 20% in the middle troposphere (600-300 hPa). The low-bias  
10 in the free troposphere may stem from underestimation of spring time stratospheric contribution  
11 in some regions.

12 The acceptability of model performance was judged for the 2016 CMAQ O<sub>3</sub> performance  
13 results considering the range of performance found in recent regional O<sub>3</sub> model applications  
14 (NRC, 2002, Phillips et al., 2008, Simon et al., 2012, U.S. EPA, 2009, U.S. EPA, 2018b). The  
15 model performance results, as described in this document, demonstrate the predictions from the  
16 2016 modeling platform closely replicate the corresponding observed concentrations in terms of  
17 the magnitude, temporal fluctuations, and spatial differences for 8-hour daily maximum O<sub>3</sub>. At  
18 CASTNET sites, the model performance is similarly good, but has a distinct seasonal pattern  
19 (see Appendix 2B.3). The normalized mean bias increases from a low-bias in boreal Winter  
20 (West: -16%; East: -14%) to relatively neutral in boreal Fall (West: 0%; East: 7%). These results  
21 are consistent with the free troposphere bias seen in the comparison of model predictions to  
22 sonde data. Despite the conceptual consistency, the low-bias in winter at CASTNET sites is also  
23 influenced by local sources. For example, the Uinta Basin monitors have extremely high winter  
24 observations that are underpredicted by the model. These are most likely due to underestimation  
25 of O<sub>3</sub> formed from precursors emitted by local sources as well as the need for finer resolution  
26 meteorological inputs to capture cold pool meteorology conditions that characterize these  
27 events.<sup>38</sup>

28 Model predictions have historically shown poor performance for capturing the impacts  
29 from O<sub>3</sub> of wildfires and stratospheric intrusions. Wildfire contributions have been overpredicted  
30 by models (Baker et al., 2016, Baker et al., 2018). Model predictions of O<sub>3</sub> from stratospheric  
31 intrusions have ranged from underestimated to overestimated (e.g., Emery et al., 2012). Models  
32 are not expected to perform well in capturing the contributions from wildfires and stratospheric

---

<sup>38</sup> The DIN431 CASTNET monitor, among others, is in the Uinta basin where wintertime O<sub>3</sub> can be caused by snow-cover enhanced photolysis combined with light VOC emissions from the oil and gas production. (see Ahmadov et al., 2015).

intrusions without a focused effort on properly characterizing the physical properties of individual events.

This analysis uses an emission inventory with known issues in the fire inventory. The “2016fe” inventory had double counting of some grassland fires.<sup>39</sup> To minimize the effects of double counting, a filter is applied to the data to remove large episodic natural influences including fires. The filter removes days where natural contributions deviate from the mean for that grid cell by whichever is higher: 20 ppb or twice the standard deviation for that grid cell. Using this approach, 0.1% of grid cell days were removed -- 71% of grid cells have no days removed and fewer than 5% have more than 1% removed. Of the days that were removed, fewer than 21% had MDA8 concentrations above 70 ppb.

This study does not directly quantify USB uncertainty. Jaffe et al. (2018) highlight that uncertainties in USB and USB component estimates come from multi-model comparisons. Dolwick et al., 2015) showed that multi-model estimates converged when applying bias correction, indicating that differences in USB estimates are correlated with model performance. No bias correction has been applied here, so in a limited manner bias in ambient predictions can help set expectations for bias in USB. Based on hemispheric model evaluation, the stratospheric component in spring is likely underestimated leading to a USB low bias in spring. As a single estimate, this study relies upon the literature based  $\pm 10$  ppb for seasonal means and higher for individual days (Jaffe et al., 2018). Further, differences between models that share parameterizations may not fully quantify underlying uncertainty and the year-to-year variability complicates comparing model simulations done for different years.

### **2.5.3 Estimates of USB and Contributions to USB in 2016**

Background O<sub>3</sub> is known to vary seasonally, spatially, and with elevation (as discussed in section 2.5.1, above). Seasonal variations are related to temporal changes in both sources and sinks. Spatial variations are related to differential transport patterns and the proximity to sources of background O<sub>3</sub>. Elevation is important in determining USB because it relates to the proximity to the free troposphere. In addition, the seasonality and spatial relationships of USB and USA contributions are not always aligned. As a result, USB can be highest on days with lower total O<sub>3</sub>. For these reasons, estimates of USB and USB components (i.e., Natural and International) contributions developed from the current modeling are summarized spatially, over time, and as a function of total O<sub>3</sub>.

All analyses of USB and components focus on model predictions over land within the U.S. The U.S. and adjoining areas are represented in the modeling using grid cells. Only grid

---

<sup>39</sup> More information related to this issue is available on the fire working group wiki page <http://views.cira.colostate.edu/wiki/wiki/9175#July-12-2018>.

cells in the U.S. are included in this analysis.<sup>40</sup> Grid cells with water as the dominant land use (e.g., lake or ocean) were simply excluded from analysis to acknowledge the potential bias of total O<sub>3</sub> over water bodies (U.S. EPA, 2018). The USB estimates provided here are all in terms of a metric, MDA8, closely related to the form of the current O<sub>3</sub> standards, and do not directly apply to other metrics.

Section 2.5.3.1 characterizes the spatial variation of model-predicted MDA8 O<sub>3</sub> concentrations and contributions using maps of seasonal averages. Section 2.5.3.2 characterizes the time variation of the predicted MDA8 O<sub>3</sub> and contributions using time series of spatial averages. Section 2.5.3.3 characterizes the relationship between predicted USB components and predicted total O<sub>3</sub>. Section 2.5.3.4 summarizes USB predictions across regions and seasons.


### **2.5.3.1 Spatial Characterization of O<sub>3</sub> Contributions**

Figure 2-19 and Figure 2-20 provide seasonally aggregated maps that show the spatial distribution of total model-predicted MDA8 O<sub>3</sub> and contributions from natural, international, and U.S. anthropogenic sources across the U.S.

Figure 2-19 shows predicted MDA8 values for the 12 km domain averaged for spring months (March, April, and May) for total O<sub>3</sub> and contributions from Natural, International, and USA. Natural is a relatively large contributor to total O<sub>3</sub> in spring with a relatively small range of values (ratio max:min = 2). International contributes less with a larger range (ratio max:min = 3). There are spatial gradients primarily along parts of the Mexico border, and an overarching general West-East gradient. The USA contribution, even in spring, has the largest variation (ratio max:min > 20) with enhancements in some urban areas.

---


<sup>40</sup> Modeling grid cells are assigned to the U.S. based on the grid cell centers. For grid cells whose area covers the U.S. and an adjoining area, the grid cell is only assigned to the U.S. if the fraction of anthropogenic NO<sub>x</sub> emissions contributed by the U.S. is greater than 80%. This is designed to remove grid cells from the analysis when the model cannot differentiate the border.



**Figure 2-19. Predicted MDA8 total O<sub>3</sub> concentration (top left), Natural (top right), International (bottom left), and USA (bottom right) contributions in spring (March, April, May). Each panel displays the simple spatial average and range (min, max) in ppb in the lower left-hand corner of the panel.**

Figure 2-20 shows the same type of information for the summer (June, July, August). The summer total concentrations are higher than spring due to increases in USA and Natural contributions. The international contribution spatial gradients have increased (reflecting shorter O<sub>3</sub> lifetimes), so that the maximum International contribution at the border is higher and the average contribution is lower compared to spring. Similarly, the West-East gradient of Natural, International, and USA contributions is enhanced in the summer. In addition, the USA contributions show distinct gradients in urban areas. Figure 2-20 highlights the increasingly near-border or high-elevation influence of international contribution during the summer when O<sub>3</sub> concentrations are most likely to violate the NAAQS.





**Figure 2-20. Predicted MDA8 total O<sub>3</sub> concentration (top left), Natural (top right), International (bottom left), and USA (bottom right) contributions in summer (June, July, Aug). Each contribution has the spatial average and range (min, max) in ppb in the lower left-hand corner of the panel.**

### 2.5.3.2 Seasonal and Geographic Variations in Ozone Contributions

Seasonal and geographic variations are an important part of background O<sub>3</sub>. The geographic variation helps us to understand where USB contributes appreciably to O<sub>3</sub> concentrations. The seasonal variation is particularly important as it determines whether high USB and MDA8 concentrations above 70 ppb are likely to occur at the same time. This section begins by characterizing the dependencies of predictions for different USB components on season and geography to define regions for further analysis. These dependencies are used to define regions for subsequent time series analysis.

**Seasonal dependence:** Comparing Figure 2-19 and Figure 2-20 highlights the seasonal differences in the predicted contributions from Natural, International, and USA sources. Between spring and summer, the International contribution decreases by 33%; the USA contribution increases by 40%; and the contribution from Natural sources shows a relatively small increase of 5%. The differences in contributions between the spring and summer are due to a complex relationship between O<sub>3</sub> production, O<sub>3</sub> lifetime, and therefore transport efficiency. Cooler drier conditions increase the lifetime of O<sub>3</sub> in winter/spring compared to summer/fall (Liu et al., 1987). As a result, winter and spring have more efficient transport of O<sub>3</sub> compared to summer

1 and fall. Summer and fall, however, have warmer weather that promotes higher local O<sub>3</sub>  
2 production rates. Thus, summer and fall have locally fast O<sub>3</sub> production and relatively inefficient  
3 transport, which combined increase the relative contribution of proximate sources.

4 **Border dependence:** In the summer, model-predicted gradients of International O<sub>3</sub> at the  
5 borders are most obvious. As previously discussed, summer temperatures increase O<sub>3</sub> production  
6 rates and decrease O<sub>3</sub> lifetimes. As a result, areas with locally high O<sub>3</sub> are evident near the border  
7 in southern California and the Big Bend and lower Rio Grande areas of Texas. These local  
8 enhancements generally occur within tens of kilometers from the border due to the short O<sub>3</sub>  
9 lifetime in summer as noted above.


10 **Topography dependence:** High elevation monitors are closer to the free troposphere; in  
11 fact, at certain times of day and locations, the surface can sample free tropospheric air (Jaffe et  
12 al., 2018). Complex topography can also enhance downward transport – for example, free  
13 tropospheric air can “downwash” on the lee-side of high elevation mountains. Sites on the lee-  
14 side can then be affected by this large-scale downwash. High elevation sites or sites influenced  
15 by enhanced vertical transport may show higher contributions from more distant sources.

16 **Combined Seasonal and Geographic Dependence:** The simultaneous effects of  
17 topography, proximity to international borders, and seasonal variations are highlighted by  
18 Hovmoller diagrams (Figure 2-21). The Hovmoller diagram shows the average concentration as  
19 a function of month (y-axis) and distance-to-border or elevation (x-axis). Due to the higher  
20 magnitude of estimates of USB sources in the West than the East (Figure 2-19 and Figure 2-20),  
21 the effects of distance and elevation are shown for the West. For the purposes of this analysis, we  
22 use the 97W longitude line as a convenient way to separate the West from the East. The figures  
23 show average estimated values and should not be used to estimate the international contribution  
24 at any specific location. In addition, there are distinct gradients within the 100 m resolution of  
25 the distance-to-border bins. For instance, the 0-100 km from the border grid cell values represent  
26 a spatial average such that the locations directly adjacent to the border have Mexican  
27 contributions higher than that average and the locations 100 km from the border have Mexican  
28 contributions lower than that average.

29 Figure 2-21 shows that proximity to the border with Canada or Mexico is a good  
30 indicator of the role of international contributions on USB predictions. In the spring, the average  
31 international contribution can be as much as 12.4 ppb within 100 km of the border (62 miles). In  
32 the early spring, large contributions persist further from the border because of the longer O<sub>3</sub>  
33 lifetimes. Near the borders the contributions also have much higher variability, both from day-to-  
34 day and between locations on the border. The contribution from international sources drops  
35 notably in the summer months when O<sub>3</sub> concentrations are highest. The day-to-day variability is  
36 associated with the variations in wind direction, while the location variability is associated with

the proximity to an international population center. International contributions are highest in near-border areas of the U.S. where there are emissions sources on the other side of the border.


To isolate the effect of elevation alone, Figure 2-21 shows the predicted international contributions as a function of elevation after excluding border areas. In the spring, higher international contributions are seen at all elevations. The international contribution at all elevations decreases in summer compared to spring, but to lower contributions at lower elevation and mostly slowly for the very high elevations (> 1500 m). This is consistent with findings from Zhang et al. (2011) who used this elevation as a threshold.



**Figure 2-21. Predicted contribution of International sources as a function of distance from Mexico/Canada (left) and at “interior” locations (excluding border areas) by elevation (right).**

**Timeseries Analysis:** The maps in Figure 2-19 and Figure 2-20 and the Hovmoller plots in Figure 2-21 highlight the impact of season and location on predicted O<sub>3</sub> and contributions. To further characterize the temporal variations in contributions, the contribution data are averaged over West and East regions individually using 97W as a dividing line. The coarse “all-cells” averaging of the data from individual grid cells ignores the major features of the relationship between the sources and receptors on a sub-regional basis. For example, there are more grid cells with high urban density and high anthropogenic NO<sub>x</sub> in the East, so the USA contribution will be higher in the East. Similarly, there are more high elevation areas in the West, so transported O<sub>3</sub> from outside the U.S. will be higher there. Within the West, however, there are also urban areas that have both high predicted contributions from international transport and anthropogenic emissions in the U.S. An analysis using “all-cells” will highlight the general characteristics of the region. To highlight the within region variability in the West, we also include analyses that focus on urban cells at high-elevation, near borders, and elsewhere. Figure 2-22 shows regions (West

and East) with high-elevation and near border areas and urban areas highlighted by contours. As can be seen, all the high-elevation areas and Mexico/U.S. border are assigned to the West, the Canada/U.S. border extends across both East and West, and there are no high-elevation areas in the East.



**Figure 2-22. Grid cell assignments to East (of 97W), West (of 97W), High Elevation (> 1500m), Near Border (within 100 km), and Near and High (i.e., both High Elevation and Near Border). The purple outlines highlight grid cells with 20% or greater urban land use.** Near Border areas are in both the West and East, while High Elevation areas are exclusively in the West. Areas matching colors denoted East and West, are thus the Low Elevation/Interior areas.

Figure 2-23 shows the time series of regional average ( $\bar{C}$ ) MDA8 O<sub>3</sub> and O<sub>3</sub> contributions over the year for the West and East at “all-cells,” calculated using equation 2-1.

$$\bar{C} = \frac{\sum_x C_x}{N_x} \quad \text{Equation 2-1}$$

where,


$N_x$  = number of grid cells ( $x$ ) included

$C_x$  = concentration at each grid cell location ( $x$ )

The temporal pattern in the regional average clearly shows that the seasonality of MDA8 predictions for each total O<sub>3</sub> component varies by region. The natural contribution has a single maximum in late summer in the West, whereas, in the East there is evidence of two peaks— the largest in late Spring and a second peak in early Fall. The somewhat lower MDA8 O<sub>3</sub> in summer



in the East requires further analysis but may be related to the lack of lightning emissions within the regional domain. The seasonality international contribution predictions is more similar between the two regions. The international contributions in both the West and East are greatest in Spring, but the contribution in the West is larger both at its peak and its trough, compared to the East. The total international contribution and the separately analyzed long-distance components (e.g., China, India, international shipping) peak in spring when O<sub>3</sub> lifetimes favor long-range transport (see Appendix 2B, Figure 2B-29). However, the Canada/Mexico component of international contributions peaks in summer because of the relative proximity to the U.S. receptors. The predicted USA contribution increases in the summer for both the West and the East, but the USA contribution in the West is smaller than in the East. As mentioned previously, this “all cells” average is disproportionately rural in the West. The following analysis looks further at the different types of land in the West, including urban areas that are more representative of population centers that behave differently than the “all cells” analysis.



**Figure 2-23. Annual time series of regional average predicted MDA8 total O<sub>3</sub> concentration and contributions of each source (see legend) for the West (top), and the East**

(bottom). Natural is global natural sources, Intl is international anthropogenic sources, USA is U.S. anthropogenic sources, and Res-Anth is the residual anthropogenic (see Table 2-2 for further descriptions).




Figure 2-24 shows the predicted contributions to total O<sub>3</sub> in the West split into three parts: the highest elevation areas, the near border areas, and Low/Interior areas with a weighted average focusing on urban areas. Each of these subsets is illustrated in Figure 2-22, which shows high elevation areas (exclusively in the West), near border areas (along the U.S./Mexico and U.S./Canada borders), and dense urban areas. The Low/Interior areas are neither high elevation nor near border. In each subset of cells, the purple outlines show the areas whose urban land use is highest. The effect on O<sub>3</sub> contributions of the relative amount of urban land use can be illustrated by computing an urban area weighted average contribution ( $\overline{C^U}$ ), calculated using equation 2-2.

$$\overline{C^U} = \sum_x \frac{A_x^U C_x}{\sum_x A_x^U} \quad \text{Equation 2-2}$$

where,

$A_x^U$  is the urban area in the grid cell  $x$

The urban area weighted average gives a larger weight to data in those urban areas that have dense emission sources (e.g., mobile). The urban area weighted average shows higher contribution from USA while Natural and International are lower compared to Figure 2-23. The differences between urban-weighted and non-weighted contributions are smaller in the East (not shown) than in the West (compare Figure 2-23 top and Figure 2-24 bottom). Compared to the West, the East has a larger fraction of land use that is urban (see Figure 2-22), which explains this difference. Thus, the non-weighted regional average contributions in the East includes the effects of urban areas much more so than the West. The seasonality of International is also different between the highest elevation areas, near border areas, and urbanized areas. At low/interior and at high-elevation sites, the simulated International contribution peaks earlier in the year than at border sites. This earlier season peak is consistent with seasonality of O<sub>3</sub> lifetime necessary for long-range transport and a smaller contribution of long-distance sources (India, China, and global shipping, see Appendix 2B, Figure 2B-30). At near-border sites, the seasonal cycle of predicted USB contributions from Canada/Mexico and from long-range transport combine to create a maximum later in the spring or early summer that is dominated by Canada/Mexico contributions (see Appendix 2B, Figure 2B-30, middle panel).



**Figure 2-24. Annual time series of regional urban area-weighted average predicted MDA8 total O<sub>3</sub> concentration and contributions of each source (see legend) for the High-elevation West (top), near-border West (middle), and Low/Interior West (bottom).** Natural is global natural sources, Intl is international anthropogenic sources, USA is U.S. anthropogenic sources, and Res-Anth is the residual anthropogenic (see Table 2-2 for further descriptions).



### 2.5.3.3 Ozone Source Contributions as a function of Total Ozone Concentration


Background contributions are also known to vary as a function of total O<sub>3</sub>. To illustrate the relationship, specialized scatter density plots were created to show the contributions as a function of total O<sub>3</sub>. Unlike the rest of this section, the scatter density plots do not apply the episodic natural filter described in section 2.5.2. Thus, episodic natural contributions including double counted fires are included in these presentations, and the effect of large events may be overestimated.<sup>41</sup> In the scatter density plots (Figure 2-25 through Figure 2-27), each pixel represents a 5 ppb O<sub>3</sub> bin. In a traditional scatter density plot, the pixel color would represent the proportion of all points that fall within that pixel. However, in Figure 2-25 through Figure 2-27 the color represents the fraction of grid-cell-days within each 5 ppb total O<sub>3</sub> bin (i.e., the x-axis) that have a particular model-predicted contribution value (i.e., the y-axis). Brighter colors show where the most frequent model-predicted contribution (y-axis: Natural or International) lies within each 5-ppb bin of total O<sub>3</sub> value (x-axis). As a reference, percent contribution lines are overlaid on the plots to help contextualize the results.

Figure 2-25 shows the simulated daily Natural contribution as a function of total MDA8 concentration in the West and East for the whole year. In both regions the majority of total O<sub>3</sub> concentrations are under 40-50 ppb. At these low concentrations, the natural contribution correlates well with total O<sub>3</sub> and frequently contributes half of the total O<sub>3</sub>. At low concentrations, natural contributions estimated by a zero-out approach can be larger than 100% of the total prediction. This is a result of NO<sub>x</sub>-titration by local anthropogenic emissions, which reduces O<sub>3</sub> concentrations and is a well-known non-linearity of O<sub>3</sub> chemistry. Thus, removing the local NO<sub>x</sub> source increases prediction concentrations. At higher concentrations, Figure 2-25 shows that predicted natural contributions in both regions have a bimodal distribution (or a fork in frequency of contributions). The lower mode represents a plateau of natural contributions with increasing total O<sub>3</sub>, which represents enhancement by anthropogenic sources. The upper mode represents instances where natural contributions are correlated with total predicted O<sub>3</sub>. In the West, the lower mode is less dominant than the East. This suggests, at least in the modeling, that there are more frequent model-predicted contributions from wildfires and/or stratospheric intrusions in the West. Wildfire emissions are known to be overestimated in this emission inventory and their contribution to O<sub>3</sub> concentrations are also often overestimated by CMAQ predictions. As a result, these predictions of very high natural contributions should be interpreted

---


<sup>41</sup> When episodic natural events contribute to elevated O<sub>3</sub> concentrations documented in air quality monitoring data to such an extent that they result in a regulatorily significant exceedance or violation of the NAAQS, they can be addressed via the Exceptional Events Rule (40 CFR 50.14).

1 qualitatively as simply indicating that such contributions can be appreciable, rather than as  
2 providing accurate and precise quantitative predictions.




4 **Figure 2-25. Predicted contribution of Natural as a function of predicted total (Base)**  
5 **MDA8 O<sub>3</sub> concentration in the West and East. Sloped lines show percent**  
6 **contribution as a quick reference. The number of cells in each column is**  
7 **identified using the probability density function above the plot, which is on a**  
8 **log scale that highlights infrequent high concentrations.**

9 Figure 2-26 shows the predicted contribution in the West and East from international  
10 anthropogenic sources. Unlike natural contributions, there is very little correlation between  
11 international anthropogenic and total O<sub>3</sub>. There are rare large model-predicted contributions,  
12 which are more frequent in the West than in the East and rarely contribute more than 50% total  
13 O<sub>3</sub> in either region. There are also negative contributions (up to -15 ppb), which arise from non-  
14 linearities in chemistry. The largest negative contribution predictions are along the Mexico  
15 border. These can either be NO<sub>x</sub>-titration events or cases where chemistry associated with  
16 international NO<sub>x</sub>-sources remove precursors that would otherwise enhance O<sub>3</sub> from U.S.  
17 sources. Negative international contributions tend to occur at relatively low total O<sub>3</sub>  
18 concentrations.




**Figure 2-26. Predicted contribution of International as a function of predicted total (Base) MDA8 O<sub>3</sub> concentration in the West and East. Sloped lines show percent contribution as a quick reference. The number of cells in each column is identified using the probability density function above the plot, which is on a log scale that highlights infrequent high concentrations.**

Figure 2-27 illustrates the relationship between predictions of U.S. anthropogenic sources and total O<sub>3</sub>. Above 50 ppb, the predicted contribution from USA increases with total O<sub>3</sub> in both the West and the East. The relationship is stronger in the East, than the West, where near border contributions, fire contributions, and stratospheric exchange are smaller. Even so, the higher total O<sub>3</sub> in the West has a similar association of larger USA contributions at larger concentrations. This is consistent with previous findings (Henderson et al., 2012; U.S. EPA, 2014).






**Figure 2-27. Predicted contribution of USA as a function of predicted total (Base) MDA8 O<sub>3</sub> concentration in the West and East. Sloped lines show percent contribution as a quick reference. The number of cells in each column is identified using the probability density function above the plot, which is on a log scale that highlights infrequent high concentrations.**

Another way of looking at the contributions is to restrict the time series to grid cells where the concentration is above a threshold. Restricting to grid cells with high concentrations implicitly weights the results toward urban areas where these high concentrations occur most frequently. Figure 2-28 shows the seasonal and regional variation of USB (International Anthropogenic and Natural) and USA (anthropogenic only) sources on high O<sub>3</sub> days (MDA8 >70 ppb). The largest magnitude differences between sources in the East and West come from contributions predicted for Natural and USA sources. Recall that the West contains all the high-elevation areas (>1500 m) and the full length of the U.S./Mexican border. Figure 2-29 includes time series for high elevation, near Mexico border, and low-elevation interior areas separately. Compared to the East, the low/interior sites in the West have 9 ppb larger contribution from Natural and 2 ppb more from International. Compared to low/interior sites in the West, the high-elevation sites have 7 ppb larger contributions from Natural and 4 ppb more from International. For border areas, the International contribution is 13 ppb greater than in Low/Interior sites. As previously noted, there are large gradients of predicted international contributions even within the border areas, such that some locations within the 100 km of the border are predicted to receive larger international contributions while others are predicted to receive substantially smaller international contributions than noted above.



**Figure 2-28. Annual time series of regional average predicted MDA8 O<sub>3</sub> and contributions of each source to predicted MDA8 total O<sub>3</sub> (see legend) in the West (top) and East (bottom) including only those grid-cell days with MDA8 greater than 70 ppb.** Natural is global natural sources, Intl is international anthropogenic sources, USA is U.S. anthropogenic sources, and Res-Anth is the residual anthropogenic (see Table 2-2 for further descriptions).





**Figure 2-29. Annual time series of regional average predicted MDA8 O<sub>3</sub> and contributions of each source to predicted MDA8 O<sub>3</sub> (see legend) in the high-elevation West (top), in the near-border West (middle), and in the Low/Interior West weighted toward urban areas (bottom) including only those grid-cell days with MDA8 O<sub>3</sub> greater than 70 ppb. Natural is global natural sources, Intl is international anthropogenic sources, USA is U.S. anthropogenic sources, and Res-Anth is the residual anthropogenic (see Table 2-2 for further descriptions).**

#### 2.5.3.4 Predicted USB Seasonal Mean and USB on Peak O<sub>3</sub> Days

The analyses above describe the contributions from the components of USB to MDA8 O<sub>3</sub> over seasons and days. Jaffe et al. (2018) concluded that model predictions of seasonal means have more certainty than individual daily or episodic estimates of USB. However, from a policy perspective, it is also useful to understand the USB contributions for various regulatory-relevant metrics. In addition to reporting predicted USB using a seasonal average metric, we also examine predicted USB (1) on days with the highest predicted MDA8 total O<sub>3</sub> concentrations (top 10 days); (2) on days predicted to have the 4<sup>th</sup> highest MDA8 total O<sub>3</sub> concentrations in the year; and (3) on days when predicted MDA8 for total O<sub>3</sub> is above 60 ppb or above 70 ppb.

Figure 2-30 shows USB predicted by a single simulation with U.S. anthropogenic emissions zeroed-out. Similar to what was found for the seasonal average metric, the effect of topography and proximity to borders are readily evident for predicted MDA8 USB on the top 10 days and the 4<sup>th</sup> highest days. The differences in seasonal average contributions between the East and West are also evident with the top 10 days metric and 4<sup>th</sup> highest day metric. The speckled nature of the USB plot for the 4<sup>th</sup> highest day is due to the day or even season on which the 4<sup>th</sup> high is predicted to occur, which varies from grid cell to grid cell. The season in which the 4<sup>th</sup> highest day occurs influences the expected contribution from long-range international transport. The average USB contributions for the top 10 days exhibit a smoother spatial pattern because there is a tendency for high days to be grouped seasonally, even if the 4<sup>th</sup> highest is not. Because the USB contribution varies by season, the predicted USB contribution on the predicted 4<sup>th</sup> highest day is quite sensitive to model bias because bias may change the season on which the 4<sup>th</sup> highest predicted day occurs.

It is also important to highlight that areas with high predicted USB contributions do not always coincide with areas where MDA8 total O<sub>3</sub> concentrations are predicted to be above 70 ppb. On the 10 highest predicted MDA8 O<sub>3</sub> days, predicted USB is relatively constant over large areas (see Figure 2-30 middle left). Within these areas of relatively constant USB, Figure 2-30 shows that the locations having model-predicted MDA8 concentrations above 70 ppb are generally in or near urban areas (Figure 2-30 lower right).


The USB contribution predicted in urban areas on the predicted top 10 days tends to be lower than in surrounding rural areas. This is due to the temporal anti-correlation of local contribution with natural and international contributions. In urban areas, MDA8 total O<sub>3</sub> concentrations above 70 ppb tend to occur in summer and fall when anthropogenic sources result in locally high increments of O<sub>3</sub>. Also during these seasons, long-range transport is limited and USB from intercontinental transport is at its lowest. As a result, the predicted top 10 and 4<sup>th</sup> highest concentration days in urban areas tend to have lower predicted USB contributions than do such days in rural parts of the region even though rural areas have lower MDA8 O<sub>3</sub>. As a



1 result, the areas with predicted top 10 days having MDA8 total O<sub>3</sub> above 70 ppb tend to have  
2 lower percentage USB contributions than the surrounding areas.

3 Predicted USB contributions can be large on top 10 days near populated U.S./Mexico  
4 border areas. In near-border areas with large anthropogenic emissions, international transport can  
5 make a large contribution. For example, across the 4th highest days predicted for every grid cell  
6 in this model simulation, the highest predicted MDA8 USB is 80 ppb (at a location immediately  
7 adjacent to the border). Given the uncertainties associated with such single value predictions,  
8 averaged predictions are important to consider. Compared to the maximum USB on the 4<sup>th</sup> high,  
9 the maximum USB is 10 ppb lower for the average of top 10 days (Figure 2-30, middle left  
10 panel) and 11 ppb lower the average of days with MDA8 above 70 ppb (Figure 2-30, lower left  
11 panel). The very high USB values associated with international anthropogenic emissions are very  
12 near the U.S./Mexico border and, to the extent that associated areas have been designated  
13 nonattainment for the NAAQS, these areas may qualify under Clean Air Act section 179B, titled  
14 “International border areas,” for specified regulatory relief upon submission of a satisfactory  
15 demonstration.

1



**Figure 2-30. Map of predicted USB contributions by O<sub>3</sub> season for spring average (top left), summer average (top right), top 10 predicted total O<sub>3</sub> days (center left), 4<sup>th</sup> highest total O<sub>3</sub> simulated day (center right), and all days with total O<sub>3</sub> greater than 70 ppb (bottom left), along with a map of the number of days with total O<sub>3</sub> above 70 ppb (bottom right, where yellow pixels have 10+ days). Each contribution has the spatial average and range (min, max) in the lower left-hand corner of the panel.**

1       The maps in Figure 2-30 provide a detailed spatial representation of predicted USB but  
2 may imply more precision than can be expected from a modeling system. For example, the  
3 maximum USB on predicted fourth highest day reaches 80 ppb near the Mexico border. The  
4 largest USB at nearby monitoring sites was 71 ppb.<sup>42</sup> The observed 4<sup>th</sup> highs at those monitors  
5 occurred in late February and early March, while the predicted 4<sup>th</sup> highs occurred in summer.  
6 After selecting the 4<sup>th</sup> highs based on the observations and applying bias correction  
7 proportionally to contributions, the new USB at these locations is 51 and 63 ppb. The USB  
8 values for any given grid cell may be biased due to local features of topography, meteorology,  
9 emissions bias, or model construct.

10       To complement the spatially resolved data and reduce bias associated with individual  
11 daily model predictions, we also spatially aggregate the data by NOAA climate region. The  
12 predicted USB values by climate region are provided in Table 2-3 to Table 2-6. Similar to the  
13 figures, the tables separately quantify all grid cells (Table 2-3), high elevation (>1500 m) areas  
14 (Table 2-4), near border areas (Table 2-5), and low-elevation (≤1500 m) interior areas (Table 2-  
15 6). These tables show the spatial averages of USB within each climate region for the annual  
16 average, seasonal averages, averages of days when MDA8 O<sub>3</sub> is greater than 60 or 70 ppb,  
17 averages of each grid cell's top 10-days, and each cell's 4<sup>th</sup> highest day. Note that top 10-day  
18 average and 4<sup>th</sup> high day for each grid cell may be from different times of the year compared to  
19 the neighboring grid cells. As a result, grid cells with highest O<sub>3</sub> driven by transport in the Spring  
20 are being mixed with grid cells with highest O<sub>3</sub> driven by local formation. Applying these  
21 averages to interpret observations must, therefore, be done in the full context of time, space, and  
22 concentration range.

---

<sup>42</sup> Monitor 06-025-1003 measured 4<sup>th</sup> maximum value was 74 ppb on March 1, 2016. Monitor 06-073-1011 measured 4<sup>th</sup> maximum was 75 ppb on February 28, 2016. Predicted USB on predicted 4<sup>th</sup> high at both locations was 71 ppb without bias correction in July and August.

**Table 2-3. Predicted USB for U.S. and U.S. regions based on averages for all U.S. grid cells.**

| Regions <sup>A</sup> | Mean MDA8 for Seasons or Year |                  |                  |                  |                  | Mean MDA8 of Values in Subset |        |       | Annual<br>4 <sup>th</sup> highest<br>MDA8 |
|----------------------|-------------------------------|------------------|------------------|------------------|------------------|-------------------------------|--------|-------|---|
|                      | DJF <sup>B</sup>              | MAM <sup>C</sup> | JJA <sup>D</sup> | SON <sup>E</sup> | ANN <sup>F</sup> | >60ppb                        | >70ppb | Top10 |   |
| U.S.                 | 26                            | 32               | 31               | 29               | 30               | 38                            | 33     | 37    | 37  |
| West                 | 28                            | 35               | 36               | 32               | 33               | 47                            | 43     | 44    | 44  |
| East                 | 24                            | 29               | 24               | 25               | 26               | 28                            | 27     | 28    | 28  |
| NW                   | 27                            | 33               | 33               | 32               | 31               | 43                            | 32     | 41    | 41  |
| W                    | 30                            | 34               | 38               | 34               | 34               | 47                            | 43     | 46    | 47  |
| WNC                  | 24                            | 33               | 36               | 30               | 31               | 48                            | 44     | 43    | 44  |
| SW                   | 31                            | 38               | 39               | 35               | 36               | 51                            | 48     | 49    | 49  |
| S                    | 27                            | 33               | 26               | 27               | 28               | 34                            | 29     | 33    | 33  |
| ENC                  | 21                            | 30               | 28               | 26               | 26               | 31                            | 34     | 32    | 33  |
| C                    | 24                            | 30               | 25               | 26               | 26               | 28                            | 28     | 28    | 28  |
| SE                   | 25                            | 28               | 20               | 24               | 24               | 25                            | 22     | 25    | 25  |
| NE                   | 25                            | 29               | 27               | 27               | 27               | 29                            | 26     | 28    | 27  |

<sup>A</sup> U.S.=continental U.S, West= >97 degrees West longitude, East= <97 degrees West longitude, NW=Northwest, W=West, WNC=WestNorthCentral, SW=Southwest, S=South, ENC=EastNorthCentral, C=Central, SE=Southeast, and NE=Northeast.  
<sup>B</sup> Season defined as December, January and February.  
<sup>C</sup> Season defined as March, April and May.  
<sup>D</sup> Season defined as June, July and August.  
<sup>E</sup> Season defined as September, October and November.  
<sup>F</sup> Annual mean.

1 **Table 2-4. Predicted USB for high elevation locations (>1500 m).**

| Regions <sup>A</sup> | Mean MDA8 for Seasons or Year |                  |                  |                  |                  | Mean MDA8 of values in subset |        |       | Annual<br>4th highest<br>MDA8 |
|----------------------|-------------------------------|------------------|------------------|------------------|------------------|-------------------------------|--------|-------|-------------------------------|
|                      | DJF <sup>B</sup>              | MAM <sup>C</sup> | JJA <sup>D</sup> | SON <sup>E</sup> | ANN <sup>F</sup> | >60ppb                        | >70ppb | Top10 |                               |
| U.S.                 | 31                            | 37               | 40               | 35               | 35               | 52                            | 49     | 49    | 50                            |
| West                 | 31                            | 37               | 40               | 35               | 35               | 52                            | 49     | 49    | 50                            |
| East                 | N/A                           | N/A              | N/A              | N/A              | N/A              | N/A                           | N/A    | N/A   | N/A                           |
| NW                   | 29                            | 35               | 38               | 33               | 34               | 52                            | 42     | 47    | 48                            |
| W                    | 32                            | 36               | 42               | 36               | 36               | 53                            | 47     | 51    | 52                            |
| WNC                  | 28                            | 35               | 39               | 34               | 34               | 52                            | 48     | 48    | 49                            |
| SW                   | 32                            | 38               | 39               | 35               | 36               | 51                            | 50     | 50    | 50                            |
| S                    | 35                            | 43               | 36               | 35               | 37               | 55                            | 59     | 52    | 53                            |
| ENC                  | N/A                           | N/A              | N/A              | N/A              | N/A              | N/A                           | N/A    | N/A   | N/A                           |
| C                    | N/A                           | N/A              | N/A              | N/A              | N/A              | N/A                           | N/A    | N/A   | N/A                           |
| SE                   | N/A                           | N/A              | N/A              | N/A              | N/A              | N/A                           | N/A    | N/A   | N/A                           |
| NE                   | N/A                           | N/A              | N/A              | N/A              | N/A              | N/A                           | N/A    | N/A   | N/A                           |

<sup>A</sup> U.S.=continental U.S, West= >97 degrees West longitude, East= <97 degrees West longitude, NW=Northwest, W=West, WNC=WestNorthCentral, SW=Southwest, S=South, ENC=EastNorthCentral, C=Central, SE=Southeast, and NE=Northeast.  
<sup>B</sup> Season defined as December, January and February.  
<sup>C</sup> Season defined as March, April and May.  
<sup>D</sup> Season defined as June, July and August.  
<sup>E</sup> Season defined as September, October and November.  
<sup>F</sup> Annual mean.

2 **Table 2-5. Predicted USB for locations within 100 km of Mexico or Canada Border.**

| Regions <sup>A</sup> | Mean MDA8 for Seasons or Year |                  |                  |                  |                  | Mean MDA8 of values in subset |        |       | Annual<br>4th highest<br>MDA8 |
|----------------------|-------------------------------|------------------|------------------|------------------|------------------|-------------------------------|--------|-------|-------------------------------|
|                      | DJF <sup>B</sup>              | MAM <sup>C</sup> | JJA <sup>D</sup> | SON <sup>E</sup> | ANN <sup>F</sup> | >60ppb                        | >70ppb | Top10 |                               |
| U.S.                 | 26                            | 34               | 32               | 30               | 30               | 45                            | 43     | 40    | 40                            |
| West                 | 28                            | 36               | 34               | 32               | 32               | 51                            | 56     | 45    | 45                            |
| East                 | 22                            | 29               | 28               | 27               | 27               | 33                            | 34     | 31    | 31                            |
| NW                   | 27                            | 32               | 30               | 31               | 30               | 46                            | N/A    | 38    | 38                            |
| W                    | 30                            | 35               | 41               | 36               | 36               | 46                            | 51     | 51    | 51                            |
| WNC                  | 21                            | 33               | 34               | 29               | 29               | 49                            | N/A    | 42    | 42                            |
| SW                   | 32                            | 40               | 36               | 35               | 36               | 53                            | 55     | 49    | 50                            |
| S                    | 32                            | 41               | 33               | 32               | 34               | 52                            | 63     | 48    | 49                            |
| ENC                  | 20                            | 29               | 28               | 26               | 26               | 32                            | 35     | 32    | 32                            |
| C                    | 24                            | 30               | 29               | 28               | 28               | 31                            | 30     | 31    | 32                            |
| SE                   | N/A                           | N/A              | N/A              | N/A              | N/A              | N/A                           | N/A    | N/A   | N/A                           |
| NE                   | 24                            | 29               | 28               | 27               | 27               | 34                            | 41     | 30    | 30                            |

<sup>A</sup> U.S.=continental U.S, West= >97 degrees West longitude, East= <97 degrees West longitude, NW=Northwest, W=West, WNC=WestNorthCentral, SW=Southwest, S=South, ENC=EastNorthCentral, C=Central, SE=Southeast, and NE=Northeast.  
<sup>B</sup> Season defined as December, January and February.  
<sup>C</sup> Season defined as March, April and May.  
<sup>D</sup> Season defined as June, July and August.  
<sup>E</sup> Season defined as September, October and November.  
<sup>F</sup> Annual mean.

**Table 2-6. Predicted USB for low-elevation ( $\leq 1500$  m) that are 100 km or farther from the border.**

| Regions <sup>A</sup> | Mean MDA8 for Seasons or Year |                  |                  |                  |                  | Mean MDA8 of values in subset |        |       | Annual 4th highest MDA8 |
|----------------------|-------------------------------|------------------|------------------|------------------|------------------|-------------------------------|--------|-------|-------------------------|
|                      | DJF <sup>B</sup>              | MAM <sup>C</sup> | JJA <sup>D</sup> | SON <sup>E</sup> | ANN <sup>F</sup> | >60ppb                        | >70ppb | Top10 |                         |
| U.S.                 | 25                            | 31               | 28               | 28               | 28               | 33                            | 30     | 34    | 34                      |
| West                 | 27                            | 34               | 34               | 31               | 31               | 43                            | 39     | 41    | 41                      |
| East                 | 24                            | 29               | 24               | 25               | 26               | 27                            | 27     | 28    | 28                      |
| NW                   | 27                            | 32               | 31               | 31               | 30               | 37                            | 32     | 38    | 38                      |
| W                    | 29                            | 32               | 35               | 33               | 32               | 42                            | 41     | 42    | 42                      |
| WNC                  | 23                            | 33               | 36               | 29               | 30               | 44                            | 42     | 41    | 42                      |
| SW                   | 29                            | 37               | 38               | 33               | 34               | 49                            | 43     | 47    | 47                      |
| S                    | 26                            | 32               | 26               | 27               | 28               | 32                            | 26     | 32    | 32                      |
| ENC                  | 21                            | 30               | 28               | 26               | 26               | 31                            | 33     | 32    | 33                      |
| C                    | 24                            | 30               | 25               | 26               | 26               | 28                            | 28     | 28    | 28                      |
| SE                   | 25                            | 28               | 20               | 24               | 24               | 25                            | 22     | 25    | 25                      |
| NE                   | 25                            | 29               | 26               | 27               | 27               | 28                            | 25     | 27    | 26                      |

<sup>A</sup> U.S.=continental U.S, West= >97 degrees West longitude, East= <97 degrees West longitude, NW=Northwest, W=West, WNC=WestNorthCentral, SW=Southwest, S=South, ENC=EastNorthCentral, C=Central, SE=Southeast, and NE=Northeast.  
<sup>B</sup> Season defined as December, January and February.  
<sup>C</sup> Season defined as March, April and May.  
<sup>D</sup> Season defined as June, July and August.  
<sup>E</sup> Season defined as September, October and November.  
<sup>F</sup> Annual mean.

### 2.5.4 Summary of USB

Background O<sub>3</sub> results from a variety of sources, each of which has its own temporal pattern and spatial distribution. The location and timing of these sources impacts O<sub>3</sub> production, dispersion and loss and thus different background O<sub>3</sub> sources have unique seasonality and spatial patterns. The analysis presented here provides updated model-based estimates of magnitude, seasonality and spatial patterns of background O<sub>3</sub> contributions. The analysis separately characterizes the estimated magnitude and spatial/temporal patterns of MDA8 O<sub>3</sub> from three sources: natural, international anthropogenic, and USA anthropogenic.

The current analysis indicates that natural and USA O<sub>3</sub> contributions peak during the traditional O<sub>3</sub> season (May through September), while long-range intercontinental transport of international O<sub>3</sub> (i.e. contributions from China, India, etc.) peaks in the spring (February through May). The contributions from Canada/Mexico at near-border locations are associated with relatively short-range transport and the seasonality peaks during May through September, similar to USA anthropogenic O<sub>3</sub>. The influence of Canada/Mexico, however, is indicated by the model predictions to have a stronger spatial gradient in summer, so Canada/Mexico contributions are most evident near the border. Of the three categories of contributions, the USA anthropogenic is best correlated with total O<sub>3</sub> at concentrations above 40-50 ppb in both the West and the East

1 suggesting that US anthropogenic emissions are usually the driving cause of high O<sub>3</sub> events in  
2 the US. This is largely explained by temporal patterns of background O<sub>3</sub> influences in relation to  
3 typical high O<sub>3</sub> events. There can be exceptions to this rule that are generally associated natural  
4 contributions at high-elevation, during fires events, or at near-border sites.

5 This modeling analysis indicates the relationship between predicted international and  
6 USA anthropogenic contributions depend upon the international sources and the location. Long-  
7 range transport and USA anthropogenic contributions tend peak at different times of the year, so  
8 the contribution of international is often at its minimum when local sources are the driving factor  
9 for high total O<sub>3</sub> during the May through September O<sub>3</sub> season. Even in cases where O<sub>3</sub> formed  
10 from international anthropogenic emissions does coincide seasonally with high O<sub>3</sub> periods, the  
11 impact of those sources can have large spatial variation. For example, O<sub>3</sub> formed from  
12 anthropogenic emissions in Canada and Mexico can peak in late spring or early summer when  
13 total O<sub>3</sub> is high. During this time-period, there is a strong spatial variability not shown in the  
14 regional mean. As a result, specific days at specific locations may experience larger or smaller  
15 contributions from cross-border transport on an episodic basis that is not well characterized by  
16 average seasonal contributions. Another example of spatial heterogeneity is exemplified by  
17 wintertime O<sub>3</sub> events associated with emissions from local oil and gas production in the  
18 Intermountain West. Even though these episodes can occur as early in the year as February,  
19 international emissions do not contribute to them substantially. The conditions associated with  
20 these events result in decoupling of the local air masses from the upper atmosphere, essentially  
21 isolating air in the mountain valleys from the atmosphere above and reducing the influence of  
22 long-range transport compared to other winter and early spring days. As a result, these unique  
23 wintertime O<sub>3</sub> episodes have little relative influence from international emissions despite  
24 occurring at a time of year when long-range transport from Asia is efficient. This highlights the  
25 need to perform location specific analysis rather than relying on regional averages.

26 In addition to seasonal patterns, the ISA highlights interannual patterns in background O<sub>3</sub>  
27 as well as long-term trends (ISA, section IS.2.2.1). Natural emissions and international transport  
28 are highly impacted by meteorological patterns which vary from year to year. One key ISA  
29 finding is that decreasing East Asian NO<sub>x</sub> emissions starting around 2010, which would suggest  
30 decreasing contributions from East Asia in the future if those trends continue, and therefore  
31 decreasing spring USB.

32 Assessments of background O<sub>3</sub> in the 2015 review reported regional variation in  
33 background O<sub>3</sub> (2013 ISA; 2014 PA). Consistent with those assessments, modeling presented  
34 here predicts that USB is higher in the West than in the East. In this analysis, we found that on  
35 high O<sub>3</sub> days (greater than 70 ppb) the West-East differences are largely associated with  
36 international contributions in near-border areas and natural contributions at high-elevation



1 locations. The Natural component of USB exhibits the largest magnitude difference between the  
2 West and East. International contributions from intercontinental transport (e.g., Asia) are most  
3 important at high elevations in the West, while international contributions from Canadian and  
4 Mexican sources are most pronounced immediately adjacent to the borders.

5 The modeling performed for this assessment does not differentiate between natural  
6 sources of ozone. For this analysis we did not attempt to separately quantify the contributions  
7 from individual Natural sources (e.g., lightning, soil, fires, stratosphere) or to address exceptional  
8 events beyond basic screening to remove very large fire plumes. Literature-based emissions  
9 estimates and photochemical modeling studies can help to inform the likely contributors to  
10 natural. In the northern hemisphere, the natural NO<sub>x</sub> sources with the largest emissions estimates  
11 are lightning (9.4 megatonN/yr), soils (5.5 megatonN/yr), and wildland fires (~2.2  
12 megatonN/yr). Because NO<sub>x</sub> is the limiting precursor at hemispheric scales, the emissions  
13 estimates suggest that lightning and soils are most likely the largest contributors to Natural O<sub>3</sub>,  
14 except when impacted by specific fire episodes. As noted by Lapina et al. (2014), a large  
15 contribution from lightning may be the result of lightning strikes outside the U.S. while the  
16 contribution from soil NO<sub>x</sub> tends to be largest from emissions within the U.S. The distant  
17 lightning source is likely to have its effect as part of the well-mixed background. The local soil  
18 NO<sub>x</sub> emissions have a clear seasonal cycle and are known to have large local contributions. The  
19 relative effect at any specific site would require further analysis, including identifying the portion  
20 of the effect due to fertilizer.

21 The overall findings of this assessment are consistent with the 2014 PA, with the EPA's  
22 Background Ozone whitepaper (U.S. EPA, 2015) and with the peer reviewed literature (e.g.,  
23 Jaffe et al. 2018). The definition of USB is also consistent with the assessment in the 2014 PA  
24 and includes global natural and international anthropogenic emission sources (NO<sub>x</sub> and VOC).  
25 Specific findings from the current analysis are summarized as:

- 26 • USB has important spatial variation that is related to geography, topography, and  
27 international borders. The spatial variation is influenced by seasonal variation with long-  
28 range international transport contributions peaking in the spring while US anthropogenic  
29 contributions peak in summer.
- 30 • The West has higher predicted USB concentrations than the East, which includes higher  
31 contributions from International and Natural sources. Within the West, high-elevation  
32 and near-border areas stand out as having particularly high USB. The high-elevation  
33 areas have more International and Natural contributions than low-interior areas in the  
34 same region. The near-border areas in the West can have substantially more international  
35 contribution than other parts of the West.
- 36 • The USA contributions that drive predicted MDA8 total O<sub>3</sub> concentrations above 70 ppb  
37 are predicted to typically peak in summer. In this typical case, the predicted USB is  
38 overwhelmingly from Natural sources. The most notable exception to the typical case is

1 reflected by predictions for an area near the Mexico border where the modeling indicates  
2 that a combination of Natural and Canada/Mexico contributions can lead to predicted  
3 MDA8 USB concentrations 60-80 ppb, on specific days, which is consistent with the O<sub>3</sub>  
4 PA prepared for the 2015 review (2014 PA, Section 2.4).<sup>43</sup>

- 5 • Predicted international contributions, in most places, are lowest during the season with the  
6 most frequent occurrence of MDA8 concentrations above 70 ppb. Except for the near-  
7 border areas, the International contribution requires long-distance transport that is most  
8 efficient in Spring.
- 9 • Days for which MDA8 total O<sub>3</sub> concentrations are predicted to be above 70 ppb tend to  
10 have a substantially higher model-predicted USA (anthropogenic) contribution than other  
11 days in both the West and the East.

---

<sup>43</sup> Uncertainties associated with such model predictions for individual days are recognized in section 2.5.3.4 above, along with observations of how they may differ from measurements at monitoring locations in the same area. It is also important to note that the modeling analyses presented here do not provide estimates of design values, which are derived from monitoring data (collected over three years) and used to assess exceedances of the O<sub>3</sub> standards. Additionally, as noted earlier, where such exceedances occur and are shown to be caused by USB, regulations for exceptional events may pertain.

## 1 REFERENCES

- 2 Ahmadov, R, McKeen, S, Trainer, M, Banta, R, Brewer, A, Brown, S, Edwards, PM, de Gouw,  
3 JA, Frost, GJ, Gilman, J, Helmig, D, Johnson, B, Karion, A, Koss, A, Langford, A,  
4 Lerner, B, Olson, J, Oltmans, S, Peischl, J, Petron, G, Pichugina, Y, Roberts, JM,  
5 Ryerson, T, Schnell, R, Senff, C, Sweeney, C, Thompson, C, Veres, PR, Warneke, C,  
6 Wild, R, Williams, EJ, Yuan, B and Zamora, R (2015). Understanding high wintertime  
7 ozone pollution events in an oil- and natural gas-producing region of the western US.  
8 Atmos Chem Phys 15(1): 411-429.
- 9 Akagi, SK, Yokelson, RJ, Burling, IR, Meinardi, S, Simpson, I, Blake, DR, McMeeking, GR,  
10 Sullivan, A, Lee, T, Kreidenweis, S, Urbanski, S, Reardon, J, Griffith, DWT, Johnson, TJ  
11 and Weise, DR (2013). Measurements of reactive trace gases and variable O<sub>3</sub>; formation  
12 rates in some South Carolina biomass burning plumes. Atmos Chem Phys 13(3): 1141-  
13 1165.
- 14 Allen, DJ, Pickering, KE, Pinder, RW, Henderson, BH, Appel, KW and Prados, A (2012).  
15 Impact of lightning-NO on eastern United States photochemistry during the summer of  
16 2006 as determined using the CMAQ model. Atmos Chem Phys 12(4): 1737-1758.
- 17 Baker, KR, Woody, MC, Tonnesen, GS, Hutzell, W, Pye, HOT, Beaver, MR, Pouliot, G and  
18 Pierce, T (2016). Contribution of regional-scale fire events to ozone and PM<sub>2.5</sub> air  
19 quality estimated by photochemical modeling approaches. Atmos Environ 140: 539-554.
- 20 Baker, KR, Woody, MC, Valin, L, Szykman, J, Yates, EL, Iraci, LT, Choi, HD, Soja, AJ,  
21 Koplitz, SN, Zhou, L, Campuzano-Jost, P, Jimenez, JL and Hair, JW (2018).  
22 Photochemical model evaluation of 2013 California wild fire air quality impacts using  
23 surface, aircraft, and satellite data. Sci Total Environ 637-638: 1137-1149.
- 24 Buysse, CE, Kaulfus, A, Nair, U and Jaffe, DA (2019). Relationships between Particulate  
25 Matter, Ozone, and Nitrogen Oxides during Urban Smoke Events in the Western US.  
26 Environ Sci Technol 53(21): 12519-12528.
- 27 Camalier, L, Cox, W and Dolwick, P (2007). The effects of meteorology and their use in  
28 assessing ozone trends. Atmos Environ 41: 7127-7137.
- 29 Dolwick, P, Akhtar, F, Baker, KR, Possiel, N, Simon, H and Tonnesen, G (2015). Comparison of  
30 background ozone estimates over the western United States based on two separate model  
31 methodologies. Atmos Environ 109: 282-296.
- 32 Emery, C, Jung, J, Downey, N, Johnson, J, Jimenez, M, Yarvwood, G and Morris, R (2012).  
33 Regional and global modeling estimates of policy relevant background ozone over the  
34 United States. Atmos Environ 47: 206-217.
- 35 Grewe, V (2013). A generalized tagging method. Geosci Model Dev 6(1): 247-253.

- 1
- 2 Henderson, BH, Possiel, N, Akhtar, F and Simon, H. (2012). Regional and Seasonal Analysis of
- 3 North American Background Ozone Estimates from Two Studies. 08/15/2012. U.S. EPA
- 4 Research Triangle Park, NC.
- 5 Hudman, RC, Moore, NE, Mebust, AK, Martin, RV, Russell, AR, Valin, LC and Cohen, RC
- 6 (2012). Steps towards a mechanistic model of global soil nitric oxide emissions:
- 7 implementation and space based-constraints. Atmos Chem Phys 12(16): 7779-7795.
- 8 Jaffe, DA, Cooper, OR, Fiore, AM, Henderson, BH, Tonneson, GS, Russell, AG, Henze, DK,
- 9 Langford, AO, Lin, M and Moore, T (2018). Scientific assessment of background ozone
- 10 over the U.S.: Implications for air quality management. Elem Sci Anth 6(1): 56.
- 11 Jaffe, DA and Wigder, NL (2012). Ozone production from wildfires: A critical review. Atmos
- 12 Environ 51: 1-10.
- 13 Janssens-Maenhout, G., Crippa, M., Guizzardi, D., Dentener, F., Muntean, M., Pouliot, G.,
- 14 Keating, T., Zhang, Q., Kurokawa, J., Wankmüller, R., Denier van der Gon, H., Kuenen,
- 15 J. J. P., Klimont, Z., Frost, G., Darras, S., Koffi, B., and Li, M. (2015). HTAP\_v2.2: a
- 16 mosaic of regional and global emission grid maps for 2008 and 2010 to study
- 17 hemispheric transport of air pollution. Atmos Chem Phys, 15: 11411-11432.
- 18 Jin, X, Fiore, AM, Murray, LT, Valin, LC, Lamsal, LN, Duncan, B, Folkert Boersma, K, De
- 19 Smedt, I, Abad, GG, Chance, K and Tonnesen, GS (2017). Evaluating a Space-Based
- 20 Indicator of Surface Ozone-NO<sub>x</sub>-VOC Sensitivity Over Midlatitude Source Regions and
- 21 Application to Decadal Trends: Space-Based Indicator of O<sub>3</sub> Sensitivity. Journal of
- 22 Geophysical Research: Atmospheres.
- 23 Lapina, K, Henze, DK, Milford, JB, Huang, M, Lin, M, Fiore, AM, Carmichael, G, Pfister, GG
- 24 and Bowman, K (2014). Assessment of source contributions to seasonal vegetative
- 25 exposure to ozone in the US. JOURNAL OF GEOPHYSICAL RESEARCH-
- 26 ATMOSPHERES 119(1): 324-340.
- 27 Lefohn, AS, Malley, CS, Simon, H, Wells, B, Xu, X, Zhang, L and Wang, T (2017). Responses
- 28 of human health and vegetation exposure metrics to changes in ozone concentration
- 29 distributions in the European Union, United States, and China. Atmos Environ 152: 123-
- 30 145.
- 31 Lin, J-T, Martin, RV, Boersma, KF, Sneep, M, Stammes, P, Spurr, R, Wang, P, Van Roozendael,
- 32 M, Clémer, K and Irie, H (2014). Retrieving tropospheric nitrogen dioxide from the
- 33 Ozone Monitoring Instrument: effects of aerosols, surface reflectance anisotropy, and
- 34 vertical profile of nitrogen dioxide. Atmos Chem Phys 14(3): 1441-1461.
- 35 Lin, M, Fiore, AM, Horowitz, LW, Langford, AO, Oltmans, SJ, Tarasick, D and Rieder, HE
- 36 (2015). Climate variability modulates western US ozone air quality in spring via deep
- 37 stratospheric intrusions. Nature Communications 6(1): 7105.

- 1 Lin, M, Horowitz, LW, Payton, R, Fiore, AM and Tonnesen, G (2017). US surface ozone trends  
2 and extremes from 1980 to 2014: quantifying the roles of rising Asian emissions,  
3 domestic controls, wildfires, and climate. *Atmos Chem Phys* 17(4): 2943-2970.
- 4 Liu, SC, Trainer, M, Fehsenfeld, FC, Parrish, DD, Williams, EJ, Fahey, DW, Hübler, G and  
5 Murphy, PC (1987). Ozone production in the rural troposphere and the implications for  
6 regional and global ozone distributions. *Journal Of Geophysical Research-Atmospheres*  
7 92(D4).
- 8 McClure, CD and Jaffe, DA (2018). Investigation of high ozone events due to wildfire smoke in  
9 an urban area. *Atmos Environ* 194: 146-157.
- 10 Murray, LT (2016). Lightning NO<sub>x</sub> and Impacts on Air Quality. *Curr Pollut Rep* 2(2): 115-133.
- 11 NRC (2002). *National Research Council Committee on Estimating the Health-Risk-Reduction*  
12 *Benefits of Proposed Air Pollution Regulations*. National Academies Press (US).  
13 Washington (DC).
- 14 Pachauri, RK, Mayer, L and Intergovernment Panel on Climate Change (2015). *Climate*  
15 *Change 2014: Synthesis Report. Contribution of Working Groups I, II and III to the Fifth*  
16 *Assessment Report of the Intergovernmental Panel on Climate Change*. IPCC. Geneva,  
17 Switzerland. <https://epic.awi.de/id/eprint/37530/>.
- 18 Parrish, DD, Young, LM, Newman, MH, Aikin, KC and Ryerson, TB (2017). Ozone Design  
19 Values in Southern California's Air Basins: Temporal Evolution and U.S. Background  
20 Contribution: Southern California Ozone Design Values. *Journal of Geophysical*  
21 *Research: Atmospheres* 122(20): 11,166-111,182.
- 22 Phillips, S, Wang, K, Jang, C, Possiel, N, Strum, M and Fox, T (2008). Evaluation of 2002  
23 Multi-pollutant Platform: Air Toxics, Ozone, and Particulate Matter. 7th Annual CMAS  
24 Conference.
- 25 Reay, DS, Smith, P, Christensen, TR, James, RH and Clark, H (2018). Methane and Global  
26 Environmental Change. *Annu Rev Environ Resour* 43(1): 165-192.
- 27 Simon, H, Baker, KR and Phillips, S (2012). Compilation and interpretation of photochemical  
28 model performance statistics published between 2006 and 2012. *Atmos Environ* 61: 124-  
29 139.
- 30 Simon, H, Reff, A, Wells, B, Xing, J and Frank, N (2015). Ozone trends across the United States  
31 over a period of decreasing NO<sub>x</sub> and VOC emissions. *Environ Sci Technol* 49(1): 186-  
32 195.
- 33 Steinkamp, J and Lawrence, MG (2011). Improvement and evaluation of simulated global  
34 biogenic soil NO emissions in an AC-GCM. *Atmos Chem Phys* 11(12): 6063-6082.

- 1 Turner, AJ, Frankenberg, C, Wennberg, PO and Jacob, DJ (2017). Ambiguity in the causes for  
2 decadal trends in atmospheric methane and hydroxyl. *Proc Natl Acad Sci USA* 114(21):  
3 5367-5372.
- 4 U.S. EPA (1978). Air Quality Criteria for Ozone and Other Photochemical Oxidants  
5 Environmental Criteria and Assessment Office. Research Triangle Park, NC. EPA-600/8-  
6 78-004. April 1978. Available at:  
7 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=200089CW.txt>.
- 8 U.S. EPA (2009). Technical Support Document for the Proposal to Designate an Emissions  
9 Control Area for Nitrogen Oxides, Sulfur Oxides, and Particulate Matter. U.S.  
10 Environmental Protection Agency. Research Triangle Park, NC. U.S. EPA. EPA-420-R-  
11 007. Available at: <http://www.epa.gov/otaq/regs/nonroad/marine/ci/420r09007.pdf>.
- 12 U.S. EPA (2014). Policy Assessment for the Review of the Ozone National Ambient Air Quality  
13 Standards,. U.S. Environmental Protection Agency. Research Triangle Park, NC. U.S.  
14 EPA. EPA-452/R-14-006. Available from:  
15 <https://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P100KCZ5.txt>.
- 16 U.S. EPA (2015). Implementation of the 2015 Primary Ozone NAAQS: Issues Associated with  
17 Background Ozone White Paper for Discussion. U.S. Environmental Protection Agency.  
18 Research Triangle Park, NC. U.S. EPA. [https://www.epa.gov/sites/production/files/2016-  
19 03/documents/whitepaper-bgo3-final.pdf](https://www.epa.gov/sites/production/files/2016-03/documents/whitepaper-bgo3-final.pdf).
- 20 U.S. EPA (2018a). Air Quality Modeling Technical Support Document for the Updated 2023  
21 Projected Ozone Design Values. Office of Air Quality Planning and Standards United  
22 States Environmental Protection Agency. RTP, NC. U.S. EPA. 83FR65878.  
23 [https://www.epa.gov/sites/production/files/2018-  
24 06/documents/aq\\_modelingtsd\\_updated\\_2023\\_modeling\\_o3\\_dvs.pdf](https://www.epa.gov/sites/production/files/2018-06/documents/aq_modelingtsd_updated_2023_modeling_o3_dvs.pdf).
- 25 U.S. EPA (2018b). Modeling Guidance for Demonstrating Attainment of Air Quality Goals for  
26 Ozone, PM<sub>2.5</sub>, and Regional Haze. Office of Air Quality Planning and Standards.  
27 Research Triangle Park, NC. U.S. EPA. EPA 454/R-18-009. Available at:  
28 [https://www3.epa.gov/ttn/scram/guidance/guide/O3-PM-RH-Modeling\\_Guidance-  
29 2018.pdf](https://www3.epa.gov/ttn/scram/guidance/guide/O3-PM-RH-Modeling_Guidance-2018.pdf).
- 30 U.S. EPA (2021a). Inventory of U.S. Greenhouse Gas Emissions and Sinks: 1990-2019. Office  
31 of Air Quality Planning and Standards. Research Triangle Park, North Carolina. U.S.  
32 EPA. EPA 430-R-21-005 Available at: [https://www.epa.gov/sites/default/files/2021-  
33 04/documents/us-ghg-inventory-2021-main-text.pdf](https://www.epa.gov/sites/default/files/2021-04/documents/us-ghg-inventory-2021-main-text.pdf).
- 34 U.S. EPA (2021b). 2017 National Emissions Inventory: January 2021 Updated Release,  
35 Technical Support Document. Office of Air Quality Planning and Standards. Research  
36 Triangle Park, North Carolina. U.S. EPA. Available:  
37 [https://www.epa.gov/sites/default/files/2021-02/documents/nei2017\\_tsd\\_full\\_jan2021.pdf](https://www.epa.gov/sites/default/files/2021-02/documents/nei2017_tsd_full_jan2021.pdf).

1 van der Werf, GR, Randerson, JT, Giglio, L, van Leeuwen, TT, Chen, Y, Rogers, BM, Mu, M,  
2 van Marle, MJE, Morton, DC, Collatz, GJ, Yokelson, RJ and Kasibhatla, PS (2017).  
3 Global fire emissions estimates during 1997–2016. *Earth Syst Sci Data* 9(2): 697-720.

4 Wu, S, Mickley, LJ, Jacob, DJ, Logan, JA, Yantosca, RM and Rind, D (2007). Why are there  
5 large differences between models in global budgets of tropospheric ozone? *J Geophys*  
6 *Res* 112(D5).

7 Zhang, L, Jacob, DJ, Downey, NV, Wood, DA, Blewitt, D, Carouge, CC, van Donkelaar, A,  
8 Jones, DBA, Murray, LT and Wang, Y (2011). Improved estimate of the policy-relevant  
9 background ozone in the United States using the GEOS-Chem global model with  $1/2^\circ \times$   
10  $2/3^\circ$  horizontal resolution over North America. *Atmos Environ* 45(37): 6769-6776.

11 Zhang, L, Jacob, DJ, Yue, X, Downey, NV, Wood, DA and Blewitt, D (2014). Sources  
12 contributing to background surface ozone in the US Intermountain West. *Atmos Chem*  
13 *Phys* 14(11): 5295-5309.

14

### 3 RECONSIDERATION OF THE PRIMARY STANDARD

This chapter presents and evaluates the policy implications of the key aspects of the scientific and technical information pertaining to this reconsideration of the 2020 decision on the O<sub>3</sub> primary standard. Specifically, the chapter presents key aspects of the available evidence of the health effects of O<sub>3</sub>, as documented in the 2020 ISA, with support from the prior ISA and AQCDs, and associated public health implications.<sup>1</sup> It also presents key aspects of the quantitative risk and exposure analyses conducted for the 2020 review (and originally presented in the 2020 PA), with the details provided in Appendices 3C and 3D. Together this information provides the basis for our evaluation of the scientific information regarding health effects of O<sub>3</sub> in ambient air and the potential for effects to occur under air quality conditions associated with the existing standard (or any alternatives considered), as well as the associated implications for public health.

Our evaluation in this chapter is framed around key policy-relevant questions derived from the IRP (IRP, section 3.1.1), and also takes into account, as relevant, assessments of the evidence and quantitative exposure/risk analyses in prior reviews. In this way we identify key policy-relevant considerations and summary conclusions regarding the public health protection provided by the current standard for the Administrator's consideration in this reconsideration of the 2020 decision on the primary O<sub>3</sub> standard.

Within this chapter, background information on the current standard is summarized in section 3.1. The general approach for considering the available information, including policy-relevant questions identified to frame our policy evaluation, is summarized in section 3.2. Key aspects of the available health effects evidence and associated public health implications and uncertainties are addressed in section 3.3, and the quantitative exposure and risk information, with associated uncertainties, is addressed in section 3.4. Section 3.5 summarizes the key evidence- and exposure/risk-based considerations identified in our evaluation, and also presents associated preliminary conclusions of this analysis. Key remaining uncertainties and areas for future research are identified in section 3.6.

---

<sup>1</sup> The ISA builds on evidence and conclusions from previous assessments, focusing on synthesizing and integrating the newly available evidence (ISA, section IS.1.1). Past assessments are generally cited when providing further, still relevant, details that informed the current assessment but are not repeated in the latest assessment.



### 3.1 BACKGROUND ON THE CURRENT STANDARD

The current primary O<sub>3</sub> standard of 0.070 ppm,<sup>2</sup> as the annual fourth-highest daily maximum 8-hour average concentration, averaged across three consecutive years, was set in 2015 and retained without revision in 2020 (80 FR 65292, October 26, 2015; 85 FR 87256, December 31, 2020). Establishment of this standard, and its retention in 2020, were based on the extensive body of evidence spanning several decades documenting the causal relationship between O<sub>3</sub> exposure and a broad range of respiratory effects, that had been augmented by evidence available since the 2008 review (80 FR 65292, October 26, 2015; 2013 ISA, p. 1–14). A key consideration driving the 2015 decision was the newly available evidence of adverse respiratory effects from controlled human exposure studies in healthy adults at an exposure concentration lower than had been previously studied (80 FR 65342–47 and 65362–66, October 26, 2015). While the study subjects in the vast majority of the controlled human exposure studies (and in all of these studies conducted at the lowest exposures) are healthy adults, the EPA’s establishment of the standard in 2015, and its retention in 2020, focused particularly on implications of these studies to insure protection of much less well studied at-risk populations,<sup>3</sup> such as people with asthma, and particularly children with asthma (80 FR 65343, October 26, 2015; 85 FR 87305, December 31, 2020).

The 2020 review of the 2015 standard also considered differences in the health effects evidence since 2015 for effects other than respiratory effects. Specifically, the newly available evidence supported updated conclusions regarding metabolic effects, cardiovascular effects, and mortality (ISA, Table ES–1). For example, while the evidence available in the 2015 review was sufficient to conclude that the relationships for short-term O<sub>3</sub> exposure with cardiovascular health effects and mortality were likely to be causal, that conclusion was no longer supported by the more expansive evidence base which the 2020 ISA determines to be suggestive of, but not sufficient to infer, a causal relationship for these health effect categories (ISA, Appendix 4, section 4.1.17; Appendix 6, section 6.1.8). Further, newly available evidence since 2015 supports a new determination that the relationship between short-term O<sub>3</sub> exposure and metabolic effects

---

<sup>2</sup> Although ppm are the units in which the level of the standard is defined, the units, ppb, are more commonly used throughout this PA for greater consistency with their use in the more recent literature. The level of the current primary standard, 0.070 ppm, is equivalent to 70 ppb.

<sup>3</sup> As used here and similarly throughout the document, the term population refers to persons having a quality or characteristic in common, such as, and including, a specific pre-existing illness or a specific age or lifestage. A lifestage refers to a distinguishable time frame in an individual’s life characterized by unique and relatively stable behavioral and/or physiological characteristics that are associated with development and growth. Identifying at-risk populations includes consideration of intrinsic (e.g., genetic or developmental aspects) or acquired (e.g., disease or smoking status) factors that increase the risk of health effects occurring with exposure to O<sub>3</sub> as well as extrinsic, nonbiological factors, such as those related to socioeconomic status, reduced access to health care, or exposure.

1 is likely to be causal (ISA, section IS.4.3.3). The basis for this conclusion is largely experimental  
2 animal studies in which the exposure concentrations are well above those in the controlled  
3 human exposure studies for respiratory effects as well as above those likely to occur in areas of  
4 the U.S. that meet the current standard (85 FR 87270, December 31, 2020). Thus, while new  
5 conclusions were reached in the 2020 review for these non-respiratory effect categories, they did  
6 not lead to a change in focus for the standard, which continued to be protection of at-risk  
7 populations from respiratory effects, as the effects causally related to O<sub>3</sub> at the lowest exposure  
8 levels.

9 With regard to respiratory effects, the health effects evidence base available in the 2015  
10 and 2020 reviews documents a broad range of effects associated with O<sub>3</sub> exposure (2013 ISA, p.  
11 1-14; 2020 ISA, p. ES4-10). Such effects range from small, transient and/or reversible changes in  
12 pulmonary function and pulmonary inflammation (documented in controlled human exposure  
13 studies involving exposures ranging from 1 to 8 hours) to more serious health outcomes such as  
14 emergency department visits and hospital admissions, which have been associated with ambient  
15 air concentrations of O<sub>3</sub> in epidemiologic studies (2013 ISA, section 6.2; 2020 ISA, Appendix 3,  
16 sections 3.1.5.1 and 3.1.5.2).<sup>4</sup>

17 Across the different study types, the controlled human exposure studies, which were  
18 recognized to provide the most certain evidence indicating the occurrence of health effects in  
19 humans following specific O<sub>3</sub> exposures, additionally document the roles of ventilation rate,<sup>5</sup>  
20 exposure duration, and exposure concentration, in eliciting responses to O<sub>3</sub> exposure (80 FR  
21 65343, October 26, 2015; 2014 PA, section 3.4). For example, the exposure concentrations  
22 eliciting a given level of response in subjects at rest are higher than those eliciting a response in  
23 subjects exposed while at elevated ventilation, such as while exercising (2013 ISA, section  
24 6.2.1.1).<sup>6</sup> Accordingly, of particular interest is the extent and magnitude of exposures during

---

<sup>4</sup> In addition to extensive controlled human exposure and epidemiologic studies, the evidence base includes experimental animal studies that provide insight into potential modes of action for these effects, contributing to the coherence and robust nature of the evidence.

<sup>5</sup> Ventilation rate ( $\dot{V}_E$ ) is a specific technical term referring to breathing rate in terms of volume of air taken into the body per unit of time. A person engaged in different activities will exert themselves at different levels and experience different ventilation rates.

<sup>6</sup> In the controlled human exposure studies, the magnitude or severity of the respiratory effects induced by O<sub>3</sub> is influenced by ventilation rate (in addition to exposure duration and exposure concentration), with physical activity increasing ventilation and potential for effects. In studies of generally healthy young adults exposed while at rest for 2 hours, 500 ppb is the lowest concentration eliciting a statistically significant O<sub>3</sub>-induced reduction in group mean lung function measures, while a much lower concentration produces a statistically significant response in lung function when the ventilation rate of the group of study subjects is sufficiently increased with exercise (2013 ISA, section 6.2.1.1). For example, the lowest exposure concentration examined that elicited a statistically significant O<sub>3</sub>-induced reduction in group mean lung function in an exposure of 2 hours or less was 120 ppb in a 1-hour exposure of trained cyclists who maintained a high exertion level throughout the exposure

1 periods of elevated ventilation, such as while exercising, under air quality conditions of interest.  
2 Thus, key considerations in the establishment of the standard in 2015 and in its review in 2020  
3 were the population exposure and risk assessments performed for air quality conditions  
4 associated with just meeting the standard (and with alternative air quality scenarios). These  
5 assessments, which included a focus on the at-risk populations of children and children with  
6 asthma, analyzed the occurrence of exposures to O<sub>3</sub> concentrations of interest by individuals  
7 breathing at elevated rates and characterized the associated risk.

8 The Administrator’s judgment in establishing the standard in 2015 was based primarily  
9 on the extensive evidence of respiratory effects health effects evidence for O<sub>3</sub> with a focus on the  
10 public health implications of the exposure and risk analyses conducted in that review. In the  
11 review concluded in 2020, the Agency considered the health effects evidence base, including that  
12 newly available since the 2015 decision, and the updated exposure/risk analyses. In 2020, the  
13 Administrator reaffirmed judgments of the 2015 decision associated with establishment of the  
14 different elements of the standard and made additional judgments reflecting the information  
15 current to the review, concluding that the existing standard, set in 2015, continued to provide the  
16 requisite public health protection with an adequate margin of safety (85 FR 87300-87306,  
17 December 31, 2020). Key aspects of the health effects evidence and exposure and risk  
18 information available in the 2020 review, as well as the associated judgments reflecting  
19 consideration of associated limitations and uncertainties, are summarized below for each of the  
20 four basic elements of the NAAQS (indicator, averaging time, form, and level), in turn.

21 In 1979, O<sub>3</sub> was established as the indicator for a standard meant to provide protection  
22 against photochemical oxidants in ambient air (44 FR 8202, February 8, 1979). In setting the  
23 current standard in 2015 and reviewing it in 2020, the Administrator considered the available  
24 information presented in the ISA and PA, along with advice from the CASAC and public  
25 comment. Both the 2013 and 2020 ISAs specifically noted that O<sub>3</sub> is the only photochemical  
26 oxidant (other than nitrogen dioxide) that is routinely monitored and for which a comprehensive  
27 database exists (2013 ISA, section 3.6; 80 FR 65347, October 26, 2015; 2020 ISA, p. IS-3; 85  
28 FR 87301, December 31, 2020). The 2020 ISA further noted that “the primary literature  
29 evaluating the health and ecological effects of photochemical oxidants includes ozone almost  
30 exclusively as an indicator of photochemical oxidants” (2020 ISA, p. IS-3). In both reviews, the  
31 CASAC indicated its support for O<sub>3</sub> as the appropriate indicator. Based on these considerations  
32 and public comments, the Administrators in both reviews concluded that O<sub>3</sub> remains the most  
33 appropriate indicator for a standard meant to provide protection against photochemical oxidants

---

period (2013 ISA, section 6.2.1.1; Gong et al., 1986) or after 2-hour exposure (heavy intermittent exercise) of young healthy adults (2013 ISA, section 6.2.1.1; McDonnell et al., 1983).

1 in ambient air, and they retained O<sub>3</sub> as the indicator for the primary standard (80 FR 65347,  
2 October 26, 2015; 85 FR 87306; December 31, 2020).

3 The 8-hour averaging time for the primary O<sub>3</sub> standard was established in 1997 with the  
4 decision to replace the then-existing 1-hour standard with an 8-hour standard (62 FR 38856, July  
5 18, 1997). The decision in that review was based on newly available evidence from numerous  
6 controlled human exposure studies in healthy adults of adverse respiratory effects resulting from  
7 6- to 8-hour exposures, as well as quantitative analyses indicating the control provided by an 8-  
8 hour averaging time of both 8-hour and 1-hour peak exposures and associated health risk (62 FR  
9 38861, July 18, 1997; U.S. EPA, 1996). The 1997 decision was also consistent with advice from  
10 the CASAC (62 FR 38861, July 18, 1997; 61 FR 65727, December 13, 1996). This averaging  
11 time has been retained in each of the three NAAQS reviews since then (73 FR 16436, March 27,  
12 2008; 80 FR 65292, October 26, 2015; 85 FR 87256, December 31, 2020). In the establishment  
13 of the existing standard in 2015 and its review in 2020, the averaging time was retained in light  
14 of both the strong evidence for O<sub>3</sub>-associated respiratory effects following short-term exposures  
15 and the available evidence related to effects following longer-term exposures (80 FR 65347-50,  
16 October 26, 2015). The 2015 decision on a revised standard recognized that an 8-hour averaging  
17 time is similar to the exposure periods evaluated in the more recent controlled human exposure  
18 studies conducted at the lowest concentrations, and that other evidence, including that from  
19 epidemiologic studies did not provide a strong basis of support for alternative averaging times  
20 (80 FR 65348, October 26, 2015). Further, in 2015 the considerations on a revised standard also  
21 included consideration of the extent to which the available evidence and exposure/risk  
22 information suggested that a standard with an 8-hour averaging time can provide protection  
23 against respiratory effects associated with longer-term exposures to ambient air O<sub>3</sub>. Based on the  
24 then-available evidence and information discussed in detail in the 2013 ISA, 2014 Health Risk  
25 and Exposure Assessment (HREA), and 2014 PA, along with CASAC advice and public  
26 comments, the Administrator concluded that a standard with an 8-hour averaging time (and  
27 revised level) could effectively limit health effects attributable to both short- and long-term O<sub>3</sub>  
28 exposures and that it was appropriate to retain the 8-hour averaging time (80 FR 65350, October  
29 26, 2015). The EPA reached similar conclusions in the 2020 review and retained the 8-hour  
30 averaging time (85 FR 87306; December 31, 2020).

31 While giving foremost consideration to the adequacy of public health protection provided  
32 by the combination of all elements of the standard, including the form, in 2015 the Administrator  
33 placed considerable weight on the findings from prior reviews with regard to the use of the *n*th-  
34 high metric, as described below (80 FR 65350-65352, October 26, 2015). Based on these  
35 findings and consideration of CASAC advice, the Administrator judged it appropriate to retain  
36 the fourth-high form, more specifically the annual fourth-highest daily maximum 8-hour O<sub>3</sub>

1 average concentration, averaged over 3 years (80 FR 65352, October 26, 2015). The EPA  
2 reached similar conclusions in the 2020 review and retained the form of the annual fourth-  
3 highest daily maximum 8-hour O<sub>3</sub> average concentration, averaged over 3 years (85 FR 87306;  
4 December 31, 2020).

5 The concentration-based form (e.g., the *n*th-high metric) of the existing standard was  
6 established in the 1997 review when it was recognized that such a form better reflects the  
7 continuum of health effects associated with increasing O<sub>3</sub> concentrations than an expected  
8 exceedance form,<sup>7</sup> which had been the form of the standard prior to 1997. Unlike an expected  
9 exceedance form, a concentration-based form gives proportionally more weight to years when 8-  
10 hour O<sub>3</sub> concentrations are well above the level of the standard than years when 8-hour O<sub>3</sub>  
11 concentrations are just above the level of the standard. With regard to a specific concentration-  
12 based form, the fourth-highest daily maximum was selected in 1997, recognizing that a less  
13 restrictive form (e.g., fifth highest) would allow a larger percentage of sites to experience O<sub>3</sub>  
14 peaks above the level of the standard, and would allow more days on which the level of the  
15 standard may be exceeded when the site attains the standard (62 FR 38868-38873, July 18,  
16 1997), and there was not a basis identified for selection of a more restrictive form (62 FR 38856,  
17 July 18, 1997). In subsequent reviews, the EPA also considered the potential value of a  
18 percentile-based form, recognizing that such a statistic is useful for comparing datasets of  
19 varying length because it samples approximately the same place in the distribution of air quality  
20 values, whether the dataset is several months or several years long (73 FR 16474-75, March 27,  
21 2008). However, the EPA concluded that, because of the differing lengths of the monitoring  
22 season for O<sub>3</sub> across the U.S., a percentile-based statistic would not be effective in ensuring the  
23 same degree of public health protection across the country.<sup>8</sup> The importance of a form that  
24 provides stability to ongoing control programs was also recognized.<sup>9</sup> Advice from the CASAC in  
25 the 2015 review supported this, stating that this concentration-based form that is averaged over  
26 three years “provides health protection while allowing for atypical meteorological conditions that  
27 can lead to abnormally high ambient ozone concentrations which, in turn, provides programmatic

---

<sup>7</sup> The first O<sub>3</sub> standard, set in 1979 as an hourly standard, had an expected exceedance form, such that attainment was defined as when the expected number of days per calendar year, with maximum hourly average concentration greater than 0.12 ppm, was equal to or less than 1 (44 FR 8202, February 8, 1979).

<sup>8</sup> Specifically, a percentile-based form would allow more days with higher air quality values (i.e., higher O<sub>3</sub> concentrations) in locations with longer O<sub>3</sub> seasons relative to locations with shorter O<sub>3</sub> seasons.

<sup>9</sup> In the case of O<sub>3</sub>, for example, it was noted that it was important to have a form that provides stability and insulation from the impacts of extreme meteorological events that are conducive to O<sub>3</sub> occurrence. Such events could have the effect of reducing public health protection, to the extent they result in frequent shifts in and out of attainment due to meteorological conditions because such frequent shifting could disrupt an area’s ongoing implementation plans and associated control programs (73 FR 16475, March 27, 2008).

1 stability” (Frey, 2014, p. 6; 80 FR 65352, October 26, 2015). Advice from the CASAC did not  
2 raise objections with the indicator, averaging time and form of the existing standard (Cox, 2020).

3 In establishing the level of the standard in 2015 and in the decision to retain it in 2020,  
4 the Administrator at each time carefully considered: (1) the assessment of the health effects  
5 evidence and conclusions reached in the ISA; (2) the available quantitative exposure/risk  
6 analyses, including associated limitations and uncertainties, described in detail in the HREA (in  
7 the 2015 review) or appendices of the 2020 PA (in 2020); (3) considerations and staff  
8 conclusions and associated rationales in the PA; (4) advice and comments from the CASAC;  
9 and, (5) public comments (80 FR 65362, October 26, 2015; 85 FR 37300, December 31, 2020).  
10 In weighing the health effects evidence and making judgments regarding the public health  
11 significance of the quantitative estimates of exposures and risks allowed by the existing standard  
12 and potential alternative standards considered, as well as judgments regarding margin of safety,  
13 both of the decisions, in 2015 and 2020, considered the currently available information,  
14 including EPA judgments in prior reviews, advice from the CASAC, statements of the American  
15 Thoracic Society (ATS), an organization of respiratory disease specialists, and public comments.  
16 In so doing, each decision recognized that the determination of what constitutes an adequate  
17 margin of safety is expressly left to the judgment of the EPA Administrator. See *Lead Industries*  
18 *Ass’n v. EPA*, 647 F.2d 1130, 1161-62 (D.C. Cir 1980); *Mississippi v. EPA*, 744 F.3d 1334, 1353  
19 (D.C. Cir. 2013). In NAAQS reviews generally, evaluations of how particular primary standards  
20 address the requirement to provide an adequate margin of safety include consideration of such  
21 factors as the nature and severity of the health effects, the size of the sensitive population(s) at  
22 risk, and the kind and degree of the uncertainties present. Consistent with past practice and long-  
23 standing judicial precedent, in both the 2015 and 2020 decisions, the Administrator took into  
24 account the need for an adequate margin of safety as an integral part of their decision-making.

25 The 2015 decision to set the level of the revised primary O<sub>3</sub> standard at 70 ppb placed the  
26 greatest weight on the results of controlled human exposure studies and on quantitative analyses  
27 based on information from these studies, particularly analyses comparing exposure estimates for  
28 study area populations of children at elevated exertion to exposure benchmark concentrations  
29 (exposures of concern), consistent with CASAC advice and interpretation of the scientific  
30 evidence (80 FR 65362, October 26, 2015; Frey, 2014b).<sup>10</sup> This weighting reflected the  
31 recognition that controlled human exposure studies provide the most certain evidence indicating  
32 the occurrence of health effects in humans following specific O<sub>3</sub> exposures, and, in particular,

---

<sup>10</sup> The Administrator viewed the results of other quantitative analyses in this review – the lung function risk assessment, analyses of O<sub>3</sub> air quality in locations of epidemiologic studies, and epidemiologic-study-based quantitative health risk assessment – as being of less utility for selecting a particular standard level among a range of options (80 FR 65362, October 26, 2015).

1 that the effects reported in the controlled human exposure studies are due solely to O<sub>3</sub> exposures,  
2 and are not complicated by the presence of co-occurring pollutants or pollutant mixtures (as is  
3 the case in epidemiologic studies) (80 FR 65362-65363, October 26, 2015).<sup>11</sup> With regard to this  
4 evidence, the Administrator at that time recognized that: (1) the largest respiratory effects, and  
5 the broadest range of effects, have been studied and reported following exposures to 80 ppb O<sub>3</sub>  
6 or higher (i.e., decreased lung function, increased airway inflammation, increased respiratory  
7 symptoms, airway hyperresponsiveness, and decreased lung host defense<sup>12</sup>); (2) exposures to O<sub>3</sub>  
8 concentrations somewhat above 70 ppb<sup>13</sup> have been shown to both decrease lung function and to  
9 result in respiratory symptoms; and (3) exposures to O<sub>3</sub> concentrations as low as 60 ppb have  
10 been shown to decrease lung function and to increase airway inflammation (80 FR 65363,  
11 October 26, 2015). The Administrator also noted that 70 ppb was well below the O<sub>3</sub> exposure  
12 concentration documented to result in the widest range of respiratory effects (i.e., 80 ppb), and  
13 also below the lowest O<sub>3</sub> exposure concentration shown in 6.6-hour exposures with quasi-  
14 continuous exercise to result in the combination of lung function decrements and respiratory  
15 symptoms (80 FR 65363, October 26, 2015).

16 Consideration of the controlled human exposure study results and quantitative analyses  
17 based on information from those studies focused primarily, both in 2015 and 2020, on the  
18 exposure-based comparison-to-benchmarks analysis. This analysis characterizes the extent to  
19 which individuals in at-risk populations could experience O<sub>3</sub> exposures, while engaging in their  
20 daily activities, with the potential to elicit the effects reported in controlled human exposure  
21 studies for concentrations at or above specific benchmark concentrations. The analysis conducted  
22 for the 2020 review reflected a number of updates and improvements and provided estimates  
23 with reduced uncertainty compared to those from the 2015 review (see section 3.4.1 below for  
24 details). The results for analyses in both reviews are characterized through comparison of  
25 exposure concentration estimates to three benchmark concentrations of O<sub>3</sub>: 60, 70, and 80 ppb.  
26 These are based on the three lowest concentrations targeted in studies of 6- to 6.6-hour exposures  
27 of generally healthy adults engaging in quasi-continuous exercise (at a moderate level of  
28 exertion), and that yielded different occurrences, of statistical significance, and severity of

---

<sup>11</sup> Other quantitative exposure/risk analyses (e.g., the lung function risk assessment, analyses of O<sub>3</sub> air quality in locations of epidemiologic studies, and epidemiologic-study-based quantitative health risk assessment) were viewed as providing information in support of the 2015 decision to revise the then-current standard level of 75 ppb, but of less utility for selecting a particular standard level among a range of options (80 FR 65362, October 26, 2015).

<sup>12</sup> Host defense refers to a decreased ability to repel pathogens and resist infection.

<sup>13</sup> For the 70 ppb target exposure, the time weighted average concentration across the full 6.6-hour exposure was 73 ppb and the mean O<sub>3</sub> concentration during the exercise portion of the study protocol was 72ppb, based on O<sub>3</sub> measurements during the six 50-minute exercise periods (Schelegle et al., 2009).



1 respiratory effects (80 FR 65312, October 26, 2015; 85 FR 87277; December 31, 2020; 2020 PA,  
2 section 3.3.3).<sup>14</sup> A second exposure-based analysis provided population risk estimates of the  
3 occurrence of days with O<sub>3</sub>-attributable lung function reductions of varying magnitudes by using  
4 the exposure-response (E-R) information in the form of E-R functions or other quantitative  
5 descriptions of biological processes.<sup>15</sup> These latter estimates were given less weight in the  
6 Administrator's decisions in both the 2015 and 2020 reviews due to a recognition of relatively  
7 greater uncertainty in interpretation of the results. Analyses in the 2020 PA quantitatively  
8 illustrated this greater uncertainty associated with the lung function risk estimates related to their  
9 greater reliance on estimation of responses at exposure levels below those that have been studied  
10 (80 FR 65464, October 26, 2015; 85 FR 87277, December 31, 2020; 2020 PA, section 3.4.4).

11 In the 2015 decision to revise the standard level to 70 ppb (while retaining the existing  
12 indicator, averaging time and form) and also the 2020 decision to retain that level (and all other  
13 standard elements), without revision, the exposure analysis results for each of the three  
14 benchmarks were considered in the context of the Administrator judgments concerning each  
15 benchmark. Such judgments of the Administrator in setting the standard level of 70 ppb in 2015  
16 are briefly summarized below. These are followed by a description of key aspects of the  
17 considerations and judgments associated with the decision to retain this standard in 2020.

18 In the 2015 considerations of the degree of protection to be provided by a revised  
19 standard, and the extent to which that standard would be expected to limit population exposures  
20 to the broad range of O<sub>3</sub> exposures shown to result in health effects, the Administrator focused  
21 particularly on the exposure analysis estimates of two or more exposures of concern. Placing the  
22 most emphasis on a standard that limits repeated occurrences of exposures at or above the 70 and  
23 80 ppb benchmarks, while at elevated ventilation, the Administrator noted that a standard of the  
24 existing form and averaging time with a revised level of 70 ppb was estimated to eliminate the  
25 occurrence of two or more days with exposures at or above 80 ppb and to virtually eliminate the  
26 occurrence of two or more days with exposures at or above 70 ppb for all children and children  
27 with asthma, even in the worst-case year and location evaluated (80 FR 65363-65364, October  
28 26, 2015).<sup>16</sup> The Administrator's consideration of exposure estimates at or above the 60 ppb  
29 benchmark (focused most particularly on multiple occurrences), an estimated exposure to which

---

<sup>14</sup> The studies given primary focus were those for which O<sub>3</sub> exposures occurred over the course of 6.6 hours during which the subjects engaged in six 50-minute exercise periods separated by 10-minute rest periods, with a 35-minute lunch period occurring after the third hour (e.g., Folinsbee et al., 1988 and Schelegle et al., 2009). Responses after O<sub>3</sub> exposure were compared to those after filtered air exposure.

<sup>15</sup> The E-R information and quantitative models derived from it are based on controlled human exposure studies.

<sup>16</sup> Under conditions just meeting an alternative standard with a level of 70 ppb across the 15 urban study areas, the estimate for two or more days with exposures at or above 70 ppb was 0.4% of children, in the worst year and worst area (80 FR 65313, Table 1, October 26, 2015).

1 the Administrator was less confident would result in adverse effects,<sup>17</sup> was primarily in the  
2 context of considering the extent to which the health protection provided by a revised standard  
3 included a margin of safety against the occurrence of adverse O<sub>3</sub>-induced effects (80 FR 65364,  
4 October 26, 2015). In this context, the Administrator noted that a revised standard with a level of  
5 70 ppb was estimated to protect the vast majority of children in urban study areas (i.e., about  
6 96% to more than 99% of children in individual areas) from experiencing two or more days with  
7 exposures at or above 60 ppb (while at moderate or greater exertion).<sup>18</sup>

8         Given the considerable protection provided against repeated exposures of concern for all  
9 three benchmarks, including the 60 ppb benchmark, the Administrator in 2015 judged that a  
10 standard with a level of 70 ppb would incorporate a margin of safety against the adverse O<sub>3</sub>-  
11 induced effects shown to occur in the controlled human exposure studies following exposures  
12 (while at moderate or greater exertion) to a concentration somewhat higher than 70 ppb (80 FR  
13 65364, October 26, 2015).<sup>19</sup> The Administrator also judged the estimates of one or more  
14 exposures (while at moderate or greater exertion) at or above 60 ppb to also provide support for  
15 her somewhat broader conclusion that “a standard with a level of 70 ppb would incorporate an  
16 adequate margin of safety against the occurrence of O<sub>3</sub> exposures that can result in effects that  
17 are adverse to public health” (80 FR 65364, October 26, 2015).<sup>20</sup>

---

<sup>17</sup> The 2015 decision noted that “the Administrator is notably less confident in the adversity to public health of the respiratory effects that have been observed following exposures to O<sub>3</sub> concentrations as low as 60 ppb,” citing, among other considerations, “uncertainty in the extent to which short-term, transient population-level decrease in FEV<sub>1</sub> would increase the risk of other, more serious respiratory effects in that population” (80 FR 54363, October 26, 2015). Note: FEV<sub>1</sub> (a measure of lung function response) is the forced expiratory volume in one second.

<sup>18</sup> The 2015 decision also noted the Administrator’s consideration of the extent to which she judged that adverse effects could occur following specific O<sub>3</sub> exposures related to each of the three benchmarks. The Administrator recognized the interindividual variability in responsiveness in her interpretation of the exposure analysis results noting noted “that not everyone who experiences an exposure of concern, including for the 70 ppb benchmark, is expected to experience an adverse response,” further judging “that the likelihood of adverse effects increases as the number of occurrences of O<sub>3</sub> exposures of concern increases.” And “[i]n making this judgment, she note[d] that the types of respiratory effects that can occur following exposures of concern, particularly if experienced repeatedly, provide a plausible mode of action by which O<sub>3</sub> may cause other more serious effects. Therefore, her decisions on the primary standard emphasize[d] the public health importance of limiting the occurrence of repeated exposures to O<sub>3</sub> concentrations at or above those shown to cause adverse effects in controlled human exposure studies” (80 FR 65331, October 26, 2015).

<sup>19</sup> In so judging, she noted that the CASAC had recognized the choice of a standard level within the range it recommended based on the scientific evidence (which was inclusive of 70 ppb) to be a policy judgment (80 FR 65355, October 26, 2015; Frey, 2014b).

<sup>20</sup> While the Administrator was less concerned about single exposures, especially for the 60 ppb benchmark, she judged the HREA of one-or-more estimates informative to margin of safety considerations. In this regard, she noted that “a standard with a level of 70 ppb is estimated to (1) virtually eliminate all occurrences of exposures of concern at or above 80 ppb; (2) protect the vast majority of children in urban study areas from experiencing any exposures of concern at or above 70 ppb (i.e., ≥ about 99%, based on mean estimates; Table 1); and (3) to achieve substantial reductions, compared to the [then]-current standard, in the occurrence of one or more exposures of concern at or above 60 ppb (i.e., about a 50% reduction; Table 1)” (80 FR 65364, October 26, 2015).

1       The 2020 review of the 2015 standard also focused on the exposure-based analyses in the  
2 context of results from the controlled human exposure studies of exposures from 60 to 80 ppb,  
3 recognizing this information on exposure concentrations found to elicit respiratory effects in  
4 exercising study subjects to be unchanged from what was available in the 2015 review (2020 PA,  
5 section 3.3.1; 85 FR 87302, December 31, 2020).<sup>21</sup> In considering the significance of responses  
6 documented in these studies and in the full evidence base for the purposes of judging  
7 implications of the available information on public health protection provided by the current  
8 standard, several aspects, limitations and uncertainties of the evidence base were noted. For  
9 example, as also recognized in 2015, the responses reported from exposures ranging from 60 to  
10 80 ppb are transient and reversible in the study subjects who are largely healthy, adult subjects.  
11 Such study data are lacking at these exposure levels for children and people with asthma, and the  
12 evidence indicates that such responses, if repeated or sustained, particularly in people with  
13 asthma, pose risks of effects of greater concern, including asthma exacerbation, as cautioned by  
14 the CASAC (85 FR 87302, December 31, 2020).<sup>22</sup>

15       As in 2015, the Administrator in 2020 also considered statements from the ATS, as well  
16 as judgments made by the EPA in considering similar effects in previous NAAQS reviews (85  
17 FR 87270-72, 87302-87305, December 31, 2020; 80 FR 65343, October 26, 2015). The ATS  
18 statements included one newly available in the 2020 review (Thurston et al., 2017), which is  
19 generally consistent with the prior statement (that was considered in the 2015 review) including  
20 the attention that the prior statement gives to at-risk or vulnerable population groups, while also  
21 broadening the discussion of effects, responses, and biomarkers to reflect the expansion of  
22 scientific research in these areas (ATS, 2000; Thurston et al., 2017). The Administrator  
23 recognized the role of such statements, as described by the ATS, as proposing principles or  
24 considerations for weighing the evidence rather than offering “strict rules or numerical criteria”  
25 (ATS, 2000, Thurston et al., 2017). In keeping with this intent of these statements (to avoid

---

<sup>21</sup> With regard to the epidemiologic studies of respiratory effects, the Administrator recognized that, as a whole, these investigations of associations between O<sub>3</sub> and respiratory effects and health outcomes (e.g., asthma-related hospital admission and emergency department visits) provided strong support for the conclusions of causality but the studies were less informative regarding exposure concentrations associated with O<sub>3</sub> air quality conditions that meet the current standard. He noted that the evidence base in the 2020 review did not include new evidence of respiratory effects associated with appreciably different exposure circumstances than the evidence available in the 2015 review, including particularly any circumstances that would also be expected to be associated with air quality conditions likely to occur under the current standard.

<sup>22</sup> The CASAC noted that “[a]rguably the most important potential adverse effect of acute ozone exposure in a child with asthma is not whether it causes a transient decrement in lung function, but whether it causes an asthma exacerbation” and that O<sub>3</sub> “has respiratory effects beyond its well-described effects on lung function,” including increases in airway inflammation which also have the potential to increase the risk for an asthma exacerbation. The CASAC further cautioned with regard to repeated episodes of airway inflammation, indicating that they have the potential to contribute to irreversible reductions in lung function (Cox, 2020, Consensus Responses to Charge Questions pp. 7–8).

specific criteria), the statements, in discussing what constitutes an adverse health effect, do not comprehensively describe all the biological responses raised, e.g., with regard to magnitude, duration or frequency of small pollutant-related changes in lung function.

The Administrator also recognized the limitations in the available evidence base with regard to our understanding of these aspects of such changes that may be associated with exposure concentrations of interest (e.g., as estimated in the exposure analysis). Notwithstanding these limitations and associated uncertainties, he took note of the emphasis of the earlier ATS statement on consideration of individuals with preexisting compromised function, such as that resulting from asthma (an emphasis which is reiterated and strengthened in the current statement), agreeing that these were important considerations in his judgment on the adequacy of protection provided by the current standard for at-risk populations.

Among such important considerations, it was recognized that the controlled human exposure studies, primarily conducted in healthy adults, on which the depth of our understanding of O<sub>3</sub>-related health effects is based, in combination with the larger evidence base, informs our conceptual understanding of O<sub>3</sub> responses in people with asthma and in children. Aspects of the EPA's understanding continue to be limited, however, including with regard to the risk of particular effects and associated severity for these less studied population groups that may be posed by 7-hour exposures with exercise to concentrations as low as 60 ppb that are estimated in the exposure analyses for the 2020 review (85 FR 87303, December 31, 2020).

Collectively, these aspects of the evidence and associated uncertainties contributed to the recognition that for O<sub>3</sub> in the 2020 review, as for other pollutants and other reviews, the available evidence base in a NAAQS review generally reflects a continuum, consisting of levels at which scientists generally agree that health effects are likely to occur, through lower levels at which the likelihood and magnitude of the response become increasingly uncertain. As is the case in NAAQS reviews in general, the 2020 decision regarding the primary O<sub>3</sub> standard depended on a variety of factors, including science policy judgments and public health policy judgments. These factors included judgments regarding aspects of the evidence and exposure/risk estimates, such as judgments concerning the Administrator's interpretation of the different benchmark concentrations, in light of the available evidence and of associated uncertainties, as well as judgments on the public health significance of the effects that have been observed at the exposures evaluated in the health effects evidence. These judgments are rooted in interpretation of the evidence, which reflects a continuum of health-relevant exposures, with less confidence and greater uncertainty in the existence of adverse health effects as one considers lower O<sub>3</sub> exposures. The factors relevant to judging the adequacy of the standards also included the interpretation of, and decisions as to the relative weight to place on, different aspects of the results of the exposure and risk assessment for the areas studied and the associated uncertainties.

1 Together, factors identified here informed the Administrator’s judgment about the degree of  
2 protection that is requisite to protect public health with an adequate margin of safety, including  
3 the health of sensitive groups, and, accordingly, his conclusion of the requisiteness of the  
4 existing standard to protect public health with an adequate margin of safety (85 FR 87303,  
5 December 31, 2020).

6 In placing greater weight and giving primary attention to the comparison-to-benchmarks  
7 analysis, the Administrator recognized that, as noted in the 2020 PA, the comparison-to-  
8 benchmarks analysis (newly updated in the 2020 review with a number of improvements over  
9 the 2014 analysis, as described in section 3.4.1 below) provides for characterization of risk for  
10 the broad array of respiratory effects documented in the controlled human exposure studies,  
11 facilitating consideration of an array of respiratory effects, including but not limited to lung  
12 function decrements (85 FR 87294, December 31, 2020). The Administrator recognized the three  
13 benchmark concentrations (60, 70 and 80 ppb) to represent exposure conditions (during quasi-  
14 continuous exercise) associated with different levels of respiratory response (both with regard to  
15 the array of effects and severity of individual effects) in the subjects studied and to inform his  
16 judgments on different levels of risk that might be posed to unstudied members of at-risk  
17 populations. The highest benchmark concentration (80 ppb) represented an exposure where  
18 multiple controlled human exposure studies involving 6.6-hour exposures during quasi-  
19 continuous exercise demonstrate a range of O<sub>3</sub>-related respiratory effects including inflammation  
20 and airway responsiveness, as well as respiratory symptoms and lung function decrements in  
21 healthy adult subjects. The second benchmark (70 ppb) represented an exposure level below the  
22 lowest exposures that have reported both statistically significant lung function decrements<sup>23</sup> and  
23 increased respiratory symptoms (reported at 73 ppb, Schelegle et al 2009) or statistically  
24 significant increases in airway resistance and responsiveness (reported at 80 ppb, Horstman et  
25 al., 1990). The lowest benchmark (60 ppb) represents still lower exposure, and a level for which  
26 findings from controlled human exposure studies of largely healthy subjects have included:  
27 statistically significant decrements in lung function (with mean decrements ranging from 1.7% to  
28 3.5% across the four studies with average exposures of 60 to 63 ppb), but not respiratory  
29 symptoms; and, a statistically significant increase in a biomarker of airway inflammatory  
30 response relative to filtered air exposures in one study (Kim et al, 2011).

---

<sup>23</sup> The study group mean lung function decrement for the 73 ppb exposure was 6%, with individual decrements of 15% or greater (moderate or greater) in about 10% of subjects and decrements of 10% or greater in 19% of subjects. Decrement of 20% or greater were reported in 6.5% of subjects (Schelegle et al., 2009; 2020 PA, Table 3–2 and Appendix 3D, Table 3D–20). In studies of 80 ppb exposure, the percent of study subjects with individual FEV<sub>1</sub> decrements of this size ranged up to nearly double this (2020 PA, Appendix 3D, Table 3D–20).

1 In turning to the exposure/risk analysis results, the Administrator considered the  
2 controlled human exposure evidence represented by these benchmarks noting that due to  
3 differences among individuals in responsiveness, not all people experiencing exposures (e.g., to  
4 73 ppb), experience a response, such as a lung function decrement, and among those  
5 experiencing a response, not all will experience an adverse effect (85 FR 87304, December 31,  
6 2020). Accordingly, the Administrator noted that not all people estimated to experience an  
7 exposure of 7-hour duration while at elevated exertion above even the highest benchmark would  
8 be expected to experience an adverse effect, even members of at-risk populations. With these  
9 considerations in mind, he noted that while single occurrences could be adverse for some people,  
10 particularly for the higher benchmark concentration where the evidence base is stronger, the  
11 potential for adverse response and greater severity increased with repeated occurrences (as  
12 cautioned by the CASAC). The Administrator also noted that while the exposure/risk analyses  
13 provide estimates of exposures of the at-risk population to concentrations of potential concern,  
14 they do not provide information on how many of such populations will have an adverse health  
15 outcome. Accordingly, in considering the exposure/risk analysis results, while giving due  
16 consideration to occurrences of one or more days with an exposure at or above a benchmark,  
17 particularly the higher benchmarks, he judged multiple occurrences to be of greater concern than  
18 single occurrences.

19 In this context, the Administrator considered the exposure risk estimates, focusing first on  
20 the results for the highest benchmark concentration (80 ppb), which represents an exposure well  
21 established to elicit an array of responses in sensitive individuals among study groups of largely  
22 healthy adult subjects, exposed while at elevated exertion. Similar to judgments of past  
23 Administrators, the Administrator in 2020 judged these effects in combination and severity to  
24 represent adverse effects for individuals in the population group studied, and to pose a risk of  
25 adverse effects for individuals in at-risk populations, most particularly people with asthma, as  
26 noted above. Accordingly, he judged that the primary standard should provide protection from  
27 such exposures. In considering the exposure/risk estimates, he focused on the results for children,  
28 and children with asthma, given the higher frequency of exposures of potential concern for  
29 children compared to adults, in terms of percent of the population groups. The exposure/risk  
30 estimates indicated more than 99.9% to 100% of children and children with asthma, on average  
31 across the three years, to be protected from one or more occasions of exposure at or above this  
32 level; the estimate is 99.9% of children with asthma and of all children for the highest year and  
33 study area (85 FR 87279, Table 2, December 31, 2020). Further, no children in the simulated  
34 populations (zero percent) were estimated to be exposed more than once (two or more occasions)  
35 in the 3-year simulation to 7-hr concentrations, while at elevated exertion, at or above 80 ppb (85  
36 FR 87279, Table 2, December 31, 2020). These estimates indicated strong protection against

1 exposures of at-risk populations that have been demonstrated to elicit a wide array of respiratory  
2 responses in multiple studies (85 FR 87304, December 31, 2020).

3 The Administrator next considered the results for the second benchmark concentration  
4 (70 ppb), which is just below the lowest exposure concentration (73 ppb) for which a study has  
5 reported a combination of a statistically significant increase in respiratory symptoms and  
6 statistically significant lung function decrements in sensitive individuals in a study group of  
7 largely healthy adult subjects, exposed while at elevated exertion (Schelegle et al., 2009).  
8 Recognizing the lack of evidence for people with asthma from studies at 80 ppb and 73 ppb, as  
9 well as the emphasis in the ATS statement on the vulnerability of people with compromised  
10 respiratory function, such as people with asthma, the Administrator judged it appropriate that the  
11 standard protect against exposure, particularly multiple occurrences of exposure, to somewhat  
12 lower levels. In so doing, he noted that the exposure/risk estimates indicate more than 99% of  
13 children with asthma, and of all children, to be protected from one or more occasions in a year,  
14 on average, of 7-hour exposures to concentrations at or above 70 ppb, while at elevated exertion  
15 (85 FR 87279, Table 2, December 31, 2020). The estimate is 99% of children with asthma for  
16 the highest year and study area (85 FR 87279, Table 2, December 31, 2020). Further, he noted  
17 that 99.9% of these groups were estimated to be protected from two or more such occasions, and  
18 100% from still more occasions. These estimates also indicated strong protection of at-risk  
19 populations against exposures similar to those demonstrated to elicit lung function decrements  
20 and increased respiratory symptoms in healthy subjects, a response described as adverse by the  
21 ATS (85 FR 87304, December 31, 2020).

22 In consideration of the exposure/risk results for the lowest benchmark (60 ppb), the  
23 Administrator noted that the lung function decrements in controlled human exposure studies of  
24 largely healthy adult subjects exposed while at elevated exertion to concentrations of 60 ppb,  
25 although statistically significant, were much reduced from that observed in the next higher  
26 studied concentration (73 ppb), both at the mean and individual level, and were not reported to  
27 be associated with increased respiratory symptoms in healthy subjects.<sup>24</sup> In light of these results  
28 and the transient nature of the responses, the Administrator did not judge these responses to  
29 represent adverse effects for generally healthy individuals. However, he further considered these  
30 findings specifically with regard to protection of at-risk populations, such as people with asthma.  
31 In this regard, he noted that such data are lacking for at-risk groups, such as people with asthma,  
32 and considered the evidence and comments from the CASAC regarding the need to consider  
33 endpoints of particular importance for this population group, such as risk of asthma exacerbation

---

<sup>24</sup> The response for the 60 ppb studies is also somewhat lower than that for the 63 ppb study (Table 1; 2020 PA, Appendix 3D, Table 3D–20).



1 and prolonged inflammation. He took note of comments from the CASAC (and also noted in the  
2 ATS statement) that small lung function decrements in this at-risk group may contribute to a risk  
3 of asthma exacerbation, an outcome described by the CASAC as “arguably the most important  
4 potential adverse effect” of O<sub>3</sub> exposure for a child with asthma. Thus, he judged it important for  
5 the standard to provide protection that reduces such risks. With regard to the inflammatory  
6 response, he noted the evidence indicating the role of repeated occurrences of inflammation in  
7 contributing to severity of response. Thus, he found repeated occurrences of exposure events of  
8 potential concern to pose greater risk than single events, leading him to place greater weight on  
9 exposure/risk estimates for multiple occurrences (85 FR 87304-87305, December 31, 2020).

10 Thus, in this context, and given that the 70 ppb benchmark represents an exposure level  
11 somewhat below the lowest exposure concentration for which both statistically significant lung  
12 function decrements and increased respiratory symptoms have been reported in largely healthy  
13 adult subjects, the Administrator considered the exposure/risk estimates for the third benchmark  
14 of 60 ppb to be informative most particularly to his judgments on an adequate margin of safety.  
15 In so doing, he took note that these estimates indicate more than 96% to more than 99% of  
16 children with asthma to be protected from more than one occasion in a year (two or more), on  
17 average, of 7-hour exposures to concentrations at or above this level (60 ppb), while at elevated  
18 exertion (85 FR 87279, Table 2, December 31, 2020). Additionally, the analysis estimates more  
19 than 90% of all children, on average across the three years, to be protected from one or more  
20 occasions of exposure at or above this level. The Administrator found this to indicate an  
21 appropriate degree of protection from such exposures (85 FR 87305, December 31, 2020).

22 The Administrator additionally considered whether it was appropriate to consider a more  
23 stringent standard that might be expected to result in reduced O<sub>3</sub> exposures. As an initial matter,  
24 he considered the advice from the CASAC. With regard to the CASAC advice, while part of the  
25 Committee concluded the evidence supported retaining the current standard without revision,  
26 another part of the Committee reiterated advice from the prior CASAC, which while including  
27 the current standard level among the range of recommended standard levels, also provided policy  
28 advice to set the standard at a lower level. In considering this advice in the 2020 review, as it was  
29 raised by part of the then-current CASAC, the Administrator noted the slight differences of the  
30 current exposure and risk estimates from the corresponding 2014 estimates for the lowest  
31 benchmark, which were those considered by the CASAC in 2014 (85 FR 87280, Table 3,  
32 December 31, 2020). For example, while the 2014 HREA estimated 3.3 to 10.2% of children, on  
33 average, to experience one or more days with exposures at or above 60 ppb (and as many as  
34 18.9% in a single year), the comparable estimates for the current analyses are lower (3.2 to 8.2%  
35 on average and 10.6% in a single year), particularly with regard to the upper end of the range of  
36 averages and the highest in a single year. While the estimates for two or more days with

1 occurrences at or above 60 ppb, on average across the assessment period, were more similar  
2 between the two assessments, the 2020 estimate for the single highest year was much lower (9.2  
3 versus 4.3%). The Administrator additionally recognized the 2020 PA finding that the factors  
4 contributing to these differences, which includes the use of air quality data reflecting  
5 concentrations much closer to the now-current standard than was the case in the 2015 review,  
6 also contribute to a reduced uncertainty in the current estimates (85 FR 87275-87279, December  
7 31, 2020; 2020 PA, sections 3.4 and 3.5). Thus, he noted that the exposure analysis estimates in  
8 the 2020 review indicate the current standard to provide appreciable protection against multiple  
9 days with a maximum exposure at or above 60 ppb. In the context of his consideration of the  
10 adequacy of protection provided by the standard and of the CAA requirement that the standard  
11 protect public health, including the health of at-risk populations, with an adequate margin of  
12 safety, the Administrator concluded, “in light of all of the considerations raised here, that the  
13 current standard provides appropriate protection, and that a more stringent standard would be  
14 more than requisite to protect public health” (85 FR 87306; December 31, 2020).

15 Therefore, based on his consideration of the evidence and exposure/risk information,  
16 including that related to the lowest exposures studied in controlled human exposure studies, and  
17 the associated uncertainties, the Administrator judged that the current standard provides the  
18 requisite protection of public health, including an adequate margin of safety, and thus should be  
19 retained, without revision. Accordingly, he also concluded that a more stringent standard was not  
20 needed to provide requisite protection and that the current standard provides the requisite  
21 protection of public health under the Act (85 FR 87306, December 31, 2020).

## 22 **3.2 GENERAL APPROACH AND KEY ISSUES**

23 As is the case for primary NAAQS reviews, this reconsideration of the 2020 decision on  
24 the primary O<sub>3</sub> standard is fundamentally based on using the Agency’s assessment of the  
25 scientific evidence and associated quantitative analyses to inform the Administrator’s judgments  
26 regarding a primary standard that is requisite to protect public health with an adequate margin of  
27 safety. This approach builds on the substantial assessments and evaluations performed over the  
28 course of O<sub>3</sub> NAAQS reviews to inform our understanding of the key-policy relevant issues in  
29 this reconsideration of the 2020 decision.

30 The evaluations in the PA of the scientific assessments in the ISA (building on prior such  
31 assessments), augmented by the quantitative risk and exposure analyses,<sup>25</sup> are intended to inform

---

<sup>25</sup> The overarching purpose of the quantitative exposure and risk analyses is to inform the Administrator’s conclusions on the public health protection afforded by the current primary standard. An important focus is the assessment, based on current tools and information, of the potential for exposures and risks beyond those indicated by the information available at the time the standard was established.


the Administrator’s public health policy judgments and conclusions, including his decisions regarding the O<sub>3</sub> standards. The PA considers the potential implications of various aspects of the scientific evidence, the exposure/risk-based information, and the associated uncertainties and limitations. Thus, the approach for this PA is to draw on the evaluation of the scientific and technical information available in the 2020 review to address a series of key policy-relevant questions using both evidence- and exposure/risk-based considerations. Together, consideration of the available evidence and information will inform the answer to the following initial overarching question:

- **Do the available scientific evidence and exposure-/risk-based information support or call into question the adequacy of the public health protection afforded by the current primary O<sub>3</sub> standard?**

In reflecting on this question, we will consider the body of scientific evidence, assessed in the 2020 ISA and used as a basis for developing or interpreting exposure/risk analyses, including whether it supports or calls into question the scientific conclusions reached in the 2020 review regarding health effects related to exposure to ambient air-related O<sub>3</sub>. Information that may be informative to public health judgments regarding significance or adversity of key effects is also be considered. Additionally, the available exposure and risk information will be considered, including with regard to the extent to which it may continue to support judgments made in the 2020 review. Further, in considering this question with regard to the primary O<sub>3</sub> standard, as in all NAAQS reviews, we give particular attention to exposures and health risks to at-risk populations.<sup>26</sup> Evaluation of the available scientific evidence and exposure/risk information with regard to consideration of the current standard and the overarching question above focuses on key policy-relevant issues by addressing a series of questions on specific topics. Figure 3-1 summarizes, in general terms, the approach to considering the available information in the context of policy-relevant questions pertaining to the primary standard.

---

<sup>26</sup> As used here and similarly throughout this document, the term *population* refers to persons having a quality or characteristic in common, such as a specific pre-existing illness or a specific age or lifestage. Identifying at-risk populations involves consideration of *susceptibility* and *vulnerability*. *Susceptibility* refers to innate (e.g., genetic or developmental aspects) or acquired (e.g., disease or smoking status) sensitivity that increases the risk of health effects occurring with exposure to O<sub>3</sub>. *Vulnerability* refers to an increased risk of O<sub>3</sub>-related health effects due to factors such as those related to socioeconomic status, reduced access to health care or exposure.



**Figure 3-1. Overview of general approach for the primary O<sub>3</sub> standard.**

1 The Agency's approach with regard to the O<sub>3</sub> primary standard is consistent with  
2 requirements of the provisions of the CAA related to the review of the NAAQS and with how the  
3 EPA and the courts have historically interpreted these provisions. As discussed in section 1.2  
4 above, these provisions require the Administrator to establish primary standards that, in the  
5 Administrator's judgment, are requisite (i.e., neither more nor less stringent than necessary) to  
6 protect public health with an adequate margin of safety. Consistent with the Agency's approach  
7 across NAAQS reviews, the approach of the PA to informing these judgments is based on a  
8 recognition that the available health effects evidence generally reflects continuums that include  
9 ambient air exposures for which scientists generally agree that health effects are likely to occur  
10 through lower levels at which the likelihood and magnitude of response become increasingly  
11 uncertain. The CAA does not require the Administrator to establish a primary standard at a zero-  
12 risk level or at background concentration levels, but rather at a level that reduces risk sufficiently  
13 so as to protect public health, including the health of sensitive groups,<sup>27</sup> with an adequate margin  
14 of safety.

15 The Agency's decisions on the adequacy of the current primary standard and, as  
16 appropriate, on any potential alternative standards considered in a review are largely public  
17 health policy judgments made by the Administrator. The four basic elements of the NAAQS (i.e.,  
18 indicator, averaging time, form, and level) are considered collectively in evaluating the health  
19 protection afforded by the current standard, and by any alternatives considered. Thus, the  
20 Administrator's final decisions in such reviews draw upon the scientific evidence for health  
21 effects, quantitative analyses of population exposures and/or health risks, as available, and  
22 judgments about how to consider the uncertainties and limitations that are inherent in the  
23 scientific evidence and quantitative analyses.

### 24 **3.3 HEALTH EFFECTS EVIDENCE**

25 The health effects evidence on which this PA for the reconsideration of the 2020 decision  
26 on the O<sub>3</sub> primary standard will focus is the evidence as assessed and described in the 2020 ISA  
27 and prior ISAs or AQCDs. As described in section 1.5 above, the EPA has provisionally  
28 considered more recently available studies that were raised in public comments in the 2020  
29 review or were identified in a literature search that the EPA conducted for this reconsideration of  
30 more recently available controlled human exposure studies (Luben et al., 2020; Duffney et al.

---

<sup>27</sup> More than one population group may be identified as sensitive or at-risk in a NAAQS review. Decisions on NAAQS reflect consideration of the degree to which protection is provided for these sensitive population groups. To the extent that any particular population group is not among the identified sensitive groups, a decision that provides protection for the sensitive groups would be expected to also provide protection for other population groups.

2022). The provisional consideration of these studies concluded that, taken in context, the associated information and findings did not materially change any of the broad scientific conclusions of the ISA regarding the health and welfare effects of O<sub>3</sub> in ambient air or warrant reopening the air quality criteria for this review. Thus, the discussion below focuses on the health effects evidence assessment, with associated conclusions, as described in the 2020 ISA.

### 3.3.1 Nature of Effects

The health effects evidence base for O<sub>3</sub> includes decades of extensive evidence that clearly describes the role of O<sub>3</sub> in eliciting an array of respiratory effects and the more recent evidence suggests the potential for relationships between O<sub>3</sub> exposure and other effects. As was established in prior O<sub>3</sub> NAAQS reviews, the most commonly observed effects, and those for which the evidence is strongest are transient decrements in pulmonary function and respiratory symptoms, such as coughing and pain on deep inspiration, as a result of short-term exposures particularly when breathing at elevated rates (ISA, section IS.4.3.1; 2013 ISA, p. 2-26). These effects are demonstrated in the large, long-standing evidence base of controlled human exposure studies<sup>28</sup> (1978 AQCD, 1986 AQCD, 1996 AQCD, 2006 AQCD, 2013 ISA, ISA). Lung function effects are also positively associated with ambient air O<sub>3</sub> concentrations in epidemiologic panel studies, available in past reviews, that describe these associations for outdoor workers and children attending summer camps in the 1980s and 1990s (2013 ISA, section 6.2.1.2; ISA, Appendix 3, section 3.1.4.1.3). Collectively, the epidemiologic evidence base documents consistent, positive associations of O<sub>3</sub> concentrations in ambient air with lung function effects in epidemiologic panel studies<sup>29</sup> and with more severe health outcomes in other epidemiologic studies, including asthma-related emergency department visits and hospital admissions (2013 ISA, sections 6.2.1.2 and 6.2.7; ISA, Appendix 3, sections 3.1.4.1.3, 3.1.5.1 and 3.1.5.2). Extensive animal toxicological evidence informs a detailed understanding of mechanisms underlying the respiratory effects of short-term exposures, and studies in animal models also provide evidence for effects of longer-term O<sub>3</sub> exposure on the developing lung (ISA, Appendix 3, sections 3.1.11 and 3.2.6).

---

<sup>28</sup> The vast majority of the controlled human exposure studies (and all of the studies conducted at the lowest exposures) involved young healthy adults (typically 18-35 years old) as study subjects (ISA, section 3.1.4; 2013 ISA, section 6.2.1.1). There are also some 1-8 hr controlled human exposure studies in older adults and adults with asthma, and there are still fewer controlled human exposure studies in healthy children (i.e., individuals aged younger than 18 years) or children with asthma (See, for example, Appendix 3A, Table 3A-3).

<sup>29</sup> Panel studies are a type of longitudinal epidemiologic study. The studies referenced here include a number of such past studies investigating O<sub>3</sub> and lung function measures in groups of children attending summer camp and respiratory symptoms in groups of children with asthma (ISA, sections 3.1.4.1.3 and 3.1.5.3; 2013 ISA, sections 6.2.1.2 and 6.2.4.1).

- **Does the available scientific evidence alter prior conclusions regarding the health effects attributable to exposure to O<sub>3</sub>?**

The available scientific evidence, as assessed in the ISA, continues to support the prior conclusion that short-term O<sub>3</sub> exposure causes respiratory effects. Specifically, the full body of evidence continues to support the conclusions of a causal relationship of respiratory effects with short-term O<sub>3</sub> exposures and a likely causal relationship of respiratory effects with longer-term exposures (ISA, sections IS.4.3.1 and IS.4.3.2). The evidence base described in the 2020 ISA which is expanded from the evidence available in the 2015 review (and described in the 2013 ISA), also indicates a likely causal relationship between short-term O<sub>3</sub> exposure and metabolic effects,<sup>30</sup> which were not evaluated as a separate category of effects in the 2015 review when less evidence was available (ISA, section IS.4.3.3). The more recent evidence is primarily from experimental animal research. For other types of health effects, recent evidence has led to different conclusions from those reached previously. Specifically, the evidence base described in the 2020 ISA, particularly in light of the additional controlled human exposure studies, is less consistent than what was previously available and less indicative of O<sub>3</sub>-induced cardiovascular effects.<sup>31</sup> This recent evidence has altered conclusions from the 2015 review with regard to relationships between short-term O<sub>3</sub> exposures and cardiovascular effects and mortality, such that likely causal relationships are no longer concluded.<sup>32</sup> Thus, as discussed in the ISA, conclusions have changed for some effects based on the recent evidence, and conclusions are newly reached for an additional category of health effects. The prior conclusions on respiratory effects, however, continue to be supported.

### **3.3.1.1 Respiratory Effects**

The available evidence, as described in the 2020 ISA, continues to support the conclusion of a causal relationship between short-term O<sub>3</sub> exposure and respiratory effects (ISA, section IS.1.3.1). The strongest evidence for this comes from controlled human exposure studies

---

<sup>30</sup> The term “metabolic effects” is used in the ISA to refer metabolic syndrome (a collection of risk factors including high blood pressure, elevated triglycerides and low high density lipoprotein cholesterol), diabetes, metabolic disease mortality, and indicators of metabolic syndrome that include alterations in glucose and insulin homeostasis, peripheral inflammation, liver function, neuroendocrine signaling, and serum lipids (ISA, section IS.4.3.3).

<sup>31</sup> As described in the ISA, “[t]he number of controlled human exposure studies showing little evidence of ozone induced cardiovascular effects has grown substantially” and “the plausibility for a relationship between short-term ozone exposure to cardiovascular health effects is weaker than it was in the previous review, leading to the revised causality determination” (ISA, p. IS-43).

<sup>32</sup> The evidence for cardiovascular, reproductive and nervous system effects, as well as mortality, is “suggestive of, but not sufficient to infer” a causal relationship with short- or long-term O<sub>3</sub> exposures (ISA, Table IS-1). The evidence is inadequate to infer the presence or absence of a causal relationship between long-term O<sub>3</sub> exposure and cancer (ISA, section IS4.3.6.6).

1 demonstrating O<sub>3</sub>-related respiratory effects in generally healthy adults.<sup>33</sup> The key evidence  
2 comes from the body of controlled human exposure studies that document respiratory effects in  
3 people exposed for short periods (6.6 to 8 hours) during quasi-continuous exercise.<sup>34</sup> The  
4 potential for O<sub>3</sub> exposure to elicit health outcomes more serious than those assessed in the  
5 experimental studies, particularly for children with asthma, continues to be indicated by the  
6 epidemiologic evidence of associations of O<sub>3</sub> concentrations in ambient air with increased  
7 incidence of hospital admissions and emergency department visits for an array of health  
8 outcomes, including asthma exacerbation, COPD exacerbation, respiratory infection, and  
9 combinations of respiratory diseases (ISA, Appendix 3, sections 3.1.5 and 3.1.6). The strongest  
10 such evidence is for asthma-related outcomes and specifically asthma-related outcomes for  
11 children, indicating an increased risk for people with asthma and particularly children with  
12 asthma (ISA, Appendix 3, section 3.1.5.7).

13 Respiratory responses observed in human subjects exposed to O<sub>3</sub> for periods of 8 hours or  
14 less, while intermittently or quasi-continuously exercising, include reduced lung function  
15 decrements (e.g., based on forced expiratory volume in one second [FEV<sub>1</sub>] measurements),<sup>35</sup>  
16 respiratory symptoms, increased airway responsiveness, mild bronchoconstriction (measured as a  
17 change in specific airway resistance [sRaw]), and pulmonary inflammation, with associated  
18 injury and oxidative stress (ISA, Appendix 3, section 3.1.4; 2013 ISA, sections 6.2.1 through  
19 6.2.4). The available mechanistic evidence, discussed in greater detail in the ISA, describes  
20 pathways involving the respiratory and nervous systems by which O<sub>3</sub> results in pain-related  
21 respiratory symptoms and reflex inhibition of maximal inspiration (inhaling a full, deep breath),  
22 commonly quantified by decreases in forced vital capacity (FVC) and total lung capacity. This  
23 reflex inhibition of inspiration combined with mild bronchoconstriction contributes to the

---

<sup>33</sup> The phrases “healthy adults” or “healthy subjects” are used to distinguish from subjects with asthma or other respiratory diseases, because “the study design generally precludes inclusion of subjects with serious health conditions,” such as individuals with severe respiratory diseases (2013 ISA, p. lx).

<sup>34</sup> A quasi-continuous exercise protocol is common to these controlled exposure studies where, in the case of a 6.6-hour study, subjects complete six 50-minute periods of exercise, each followed by 10-minute periods of rest, in addition to a 30-minute lunch exposure period at rest (e.g., ISA, Appendix 3, section 3.1.4.1.1, and p. 3–11; 2013 ISA, section 6.2.1.1).

<sup>35</sup> The measure of lung function response most commonly considered across O<sub>3</sub> NAAQS reviews is changes in FEV<sub>1</sub>. In considering controlled human exposure studies, an O<sub>3</sub>-induced change in FEV<sub>1</sub> is typically the difference between the decrement observed with O<sub>3</sub> exposure ([post-exposure FEV<sub>1</sub> minus pre-exposure FEV<sub>1</sub>] divided by pre-exposure FEV<sub>1</sub>) and what is generally an improvement observed with filtered air (FA) exposure ([postexposure FEV<sub>1</sub> minus pre-exposure FEV<sub>1</sub>] divided by pre-exposure FEV<sub>1</sub>). As explained in the 2013 ISA, “[n]oting that some healthy individuals experience small improvements while others have small decrements in FEV<sub>1</sub> following FA exposure, investigators have used the randomized, crossover design with each subject serving as their own control (exposure to FA) to discern relatively small effects with certainty since alternative explanations for these effects are controlled for by the nature of the experimental design” (2013 ISA, pp. 6-4 to 6-5).



1 observed decrease in forced expiratory volume in one second (FEV<sub>1</sub>), the most common metric  
2 used to assess O<sub>3</sub>-related pulmonary function effects. The evidence also indicates that the  
3 additionally observed inflammatory response is correlated with mild airway obstruction,  
4 generally measured as an increase in sRaw (ISA, Appendix 3, section 3.1.3). As described in  
5 section 3.3.3 below, the prevalence and severity of respiratory effects in controlled human  
6 exposure studies, including symptoms (e.g., pain on deep inspiration, shortness of breath, and  
7 cough) increases, with increasing O<sub>3</sub> concentration, exposure duration, and ventilation rate of  
8 exposed subjects (ISA, Appendix 3, sections 3.1.4.1 and 3.1.4.2).

9         Within the evidence base from controlled human exposure studies, the majority of studies  
10 involve healthy adult subjects (generally 18 to 35 years old), although there are studies involving  
11 subjects with asthma, and a limited number of studies, generally of durations shorter than four  
12 hours, involving adolescents and adults older than 50 years. A summary of salient observations  
13 of O<sub>3</sub> effects on lung function, based on the controlled human exposure study evidence reviewed  
14 in the 1996 and 2006 AQCDs, and recognized in the 2013 ISA, continues to pertain to this  
15 evidence base as it exists today “(1) young healthy adults exposed to ≥80 ppb O<sub>3</sub> develop  
16 significant reversible, transient decrements in pulmonary function and symptoms of breathing  
17 discomfort if minute ventilation ( $\dot{V}_E$ ) or duration of exposure is increased sufficiently [i.e., as  
18 measured by FEV<sub>1</sub> and/or FVC]; (2) relative to young adults, children experience similar  
19 spirometric responses but lower incidence of symptoms from O<sub>3</sub> exposure; (3) relative to young  
20 adults, ozone-induced spirometric responses are decreased in older individuals; (4) there is a  
21 large degree of inter-subject variability in physiologic and symptomatic responses to O<sub>3</sub>, but  
22 responses tend to be reproducible within a given individual over a period of several months; and  
23 (5) subjects exposed repeatedly to O<sub>3</sub> for several days experience an attenuation of spirometric  
24 and symptomatic responses on successive exposures, which is lost after about a week without  
25 exposure” (ISA, Appendix 3, section 3.1.4.1.1, p. 3-11).<sup>36</sup>

26         The evidence is most well established with regard to the effects, reversible with the  
27 cessation of exposure, that are associated with short-term exposures of several hours. For  
28 example, the evidence indicates a rapid recovery from O<sub>3</sub>-induced lung function decrements  
29 (e.g., reduced FEV<sub>1</sub>) and respiratory symptoms (2013 ISA, section 6.2.1.1). However, in some  
30 cases, such as after exposure to higher concentrations such as 300 ppb, the recovery phase may  
31 be slower and involve a longer time period (e.g., at least 24 hours [hrs]). Repeated daily exposure  
32 studies at such higher concentrations also have found FEV<sub>1</sub> response to be enhanced on the  
33 second day of exposure. This enhanced response is absent, however, with repeated exposure at

---

<sup>36</sup> A spirometric response refers to a change in the amount of air breathed out of the body (forced expiratory volumes) and the associated time to do so (e.g., FEV<sub>1</sub>).

1 lower concentrations, perhaps as a result of a more complete recovery or less damage to  
2 pulmonary tissues (2013 ISA, section pp. 6-13 to 6-14; Folinsbee et al., 1994).

3 With regard to airway inflammation and the potential for repeated occurrences to  
4 contribute to further effects, O<sub>3</sub>-induced respiratory tract inflammation “can have several  
5 potential outcomes: (1) inflammation induced by a single exposure (or several exposures over  
6 the course of a summer) can resolve entirely; (2) continued acute inflammation can evolve into a  
7 chronic inflammatory state; (3) continued inflammation can alter the structure and function of  
8 other pulmonary tissue, leading to diseases such as fibrosis; (4) inflammation can alter the  
9 body’s host defense response to inhaled microorganisms, particularly in potentially at-risk  
10 populations such as the very young and old; and (5) inflammation can alter the lung’s response to  
11 other agents such as allergens or toxins” (2013 ISA, p. 6-76; ISA Appendix 3, section 3.1.5.6).  
12 With regard to O<sub>3</sub>-induced increases in airway responsiveness, the controlled human exposure  
13 study evidence for healthy adults generally indicates a resolution within 18 to 24 hours after  
14 exposure, with slightly longer persistence in some individuals (ISA, Appendix 3, section  
15 3.1.4.3.1; 2013 ISA, p. 6–74; Folinsbee and Hazucha, 2000).

16 The extensive evidence base for O<sub>3</sub>-related health effects, compiled over several decades,  
17 continues to indicate respiratory responses to short exposures as the most sensitive effects of O<sub>3</sub>.  
18 This array of respiratory effects, including reduced lung function, respiratory symptoms,  
19 increased airway responsiveness, and inflammation are of increased significance to people with  
20 asthma given aspects of the disease that contribute to a baseline status that includes chronic  
21 airway inflammation and greater airway responsiveness than people without asthma (ISA,  
22 section 3.1.5). For example, O<sub>3</sub> exposure of a magnitude that increases airway responsiveness  
23 may put such people at potential increased risk for prolonged bronchoconstriction in response to  
24 asthma triggers (ISA, Appendix 3, p. 3–7, 3–28; 2013 ISA, section 6.2.9; 2006 AQCD, section  
25 8.4.2). The increased significance of effects in people with asthma and risk of increased exposure  
26 for children (from greater frequency of outdoor exercise as described in Section 3.3.2) is  
27 illustrated by the epidemiological findings of positive associations between O<sub>3</sub> exposure and  
28 asthma-related emergency department visits and hospital admissions for children with asthma.  
29 Thus, the evidence indicates O<sub>3</sub> exposure to increase the risk of asthma exacerbation, and  
30 associated outcomes, in children with asthma.

31 With regard to an increased susceptibility to infectious diseases, the experimental animal  
32 evidence continues to indicate, as described in the 2013 ISA and past AQCDs, a potential role  
33 for O<sub>3</sub> exposures through effects on defense mechanisms of the respiratory tract (2013 ISA,  
34 section 6.2.5). Evidence regarding respiratory infections and associated effects has been  
35 augmented by a number of epidemiologic studies reporting positive associations between short-

term O<sub>3</sub> concentrations and emergency department visits for a variety of respiratory infection endpoints (ISA, Appendix 3, section 3.1.7; 2013 ISA, section 6.2.5).

Although the long-term exposure conditions that may contribute to further respiratory effects are less well understood, the evidence-based conclusion remains that there is likely to be a causal relationship for such exposure conditions with respiratory effects (ISA, section IS.4.3.2). Most notably, experimental studies, including with nonhuman infant primates, have provided evidence relating O<sub>3</sub> exposure to allergic asthma-like effects, and epidemiologic cohort studies have reported associations of O<sub>3</sub> concentrations in ambient air with asthma development in children (ISA, Appendix 3, section 3.2.4.1.3 and 3.2.6). The biological plausibility of such a role for O<sub>3</sub> has been indicated by animal toxicological evidence on biological mechanisms (ISA, Appendix 3, sections 3.2.3 and 3.2.4.1.2). Specifically, the animal evidence, including the nonhuman primate studies of early life O<sub>3</sub> exposure, indicates that such exposures can cause “structural and functional changes that could potentially contribute to airway obstruction and increased airway responsiveness,” which are hallmarks of asthma (ISA, Appendix 3, section 3.2.6, p. 3-113).

Overall, the recent respiratory effects evidence is generally consistent with the evidence base in the 2015 review (ISA, Appendix 3, section 3.1.4). A few recent studies provide insights in previously unexamined areas, both with regard to human study groups and animal models for different effects, while other studies confirm and provide depth to prior findings with updated protocols and techniques (ISA, Appendix 3, sections 3.1.11 and 3.2.6). Thus, our current understanding of the respiratory effects of O<sub>3</sub> is similar to that in the 2015 review.

One aspect of the evidence, augmented in the 2020 review as compared with the 2015 review, concerns pulmonary function in adults older than 50 years of age. Previously available evidence in this age group indicated smaller O<sub>3</sub>-related decrements in middle-aged adults (35 to 60 years) than in adults 35 years of age and younger (2006 AQCD, p. 6-23; 2013 ISA, p. 6-22; ISA, Appendix 3, section 3.1.4.1.1.2). A recent multicenter study of 55- to 70-year old subjects (average of 60 years), conducted for a 3-hour duration involving alternating 15-minute rest and exercise periods and a 120 ppb exposure concentration, reported a statistically significant O<sub>3</sub> FEV<sub>1</sub> response (ISA, Appendix 3, section 3.1.4.1.1.2; Arjomandi et al., 2018). While there is not a precisely comparable study in younger adults, the mean response for the 55- to 70-year olds, 1.2% O<sub>3</sub>-related FEV<sub>1</sub> decrement, is lower than results for somewhat comparable exposures in adults aged 35 or younger, suggesting somewhat reduced responses to O<sub>3</sub> exposure in this older age group (ISA, Appendix 3, section 3.1.4.1.1.2; Arjomandi et al., 2018; Adams, 2000; Adams,

2006a).<sup>37</sup> Such a reduced response in middle-aged and older adults compared to young adults is consistent with conclusions in the past (2013 ISA, section 6.2.1.1; 2006 AQCD, section 6.4).

The strongest evidence of O<sub>3</sub>-related health effects continues to document the respiratory effects of O<sub>3</sub> (ISA, section ES.4.1). There are no new studies, however, of 6.6-hour exposures (with exercise) to O<sub>3</sub> concentrations below those previously studied.<sup>38</sup> Among the newly available studies in the 2020 ISA, are several controlled human exposure studies that investigated lung function effects of higher exposure concentrations (e.g., 100 to 300 ppb) in healthy individuals younger than 35 years old, with findings generally consistent with previous studies (ISA, Appendix 3, section 3.4.1.1.2, p. 3-17). The newly available animal toxicological studies augment the previously available information concerning mechanisms underlying the effects documented in experimental studies. Lastly, newly available epidemiologic studies of hospital admissions and emergency department visits for a variety of respiratory outcomes supplement the previously available evidence with additional findings of consistent associations with O<sub>3</sub> concentrations across a number of study locations (ISA, Appendix 3, sections 3.1.4.1.3, 3.1.5, 3.1.6.1.1, 3.1.7.1 and 3.1.8). These studies include a number that report positive associations for asthma-related outcomes, as well as a few for COPD-related outcomes. Together these epidemiologic studies continue to indicate the potential for O<sub>3</sub> exposures to contribute to such serious health outcomes, particularly for people with asthma.

### 3.3.1.2 Other Effects

As was the case for the evidence available previously, the evidence for health effects other than those on the respiratory system is more uncertain than that for respiratory effects. For some of these other categories of effects, the more recent evidence as described in the 2020 ISA has contributed to changes to conclusions reached in the 2015 review. For example, cardiovascular effects and mortality are no longer concluded to be likely causally related to O<sub>3</sub> exposures based on newly available evidence in combination with the uncertainties that had been recognized for the previously available evidence. Additionally, newly available evidence also led

---

<sup>37</sup> For the same exposure concentration of 120 ppb, Adams (2006a) observed an average 3.2%, statistically significant, O<sub>3</sub>-related FEV<sub>1</sub> decrement in young adults (average age 23 years) at the end of the third hour of an 8-hour protocol that alternated 30 minutes of exercise and rest, with the equivalent ventilation rate (EVR) averaging 20 L/min-m<sup>2</sup> during the exercise periods (versus 15 to 17 L/min-m<sup>2</sup> in Arjomandi et al., 2018). For the same concentration with a lower EVR during exercise (17 L/min-m<sup>2</sup>), although with more exercise, Adams (2000) observed a 4%, statistically significant, O<sub>3</sub>-related FEV<sub>1</sub> decrement in young adults (average age 22 years) after the third hour of a 6.6-hour protocol (alternating 50 minutes exercise and 10 minutes rest).

<sup>38</sup> The 2020 ISA includes a newly available 3-hr study of subjects aged 55 years of age or older that involves a slightly lower target ventilation rate for the exercise periods. The exposure concentrations were 120 ppb and 70 ppb, only the former of which elicited a statistically significant FEV<sub>1</sub> decrement in this age group of subjects (ISA, Appendix 3, section 3.1.4.1.1.2).

1 to conclusions for another category, metabolic effects, for which formal causal determinations  
2 were previously not articulated.

3 The ISA finds the evidence for metabolic effects sufficient to conclude that there is likely  
4 to be a causal relationship with short-term O<sub>3</sub> exposures (ISA, section IS.4.3.3). The evidence of  
5 metabolic effects of O<sub>3</sub> comes primarily from experimental animal study findings that short-term  
6 O<sub>3</sub> exposure can impair glucose tolerance, increase triglyceride levels and elicit fasting  
7 hyperglycemia and increase hepatic gluconeogenesis (ISA, Appendix 5, section 5.1.8, and Table  
8 5-3). The exposure conditions from these studies generally involve much higher O<sub>3</sub>  
9 concentrations than those commonly occurring in areas of the U.S. where the current standard is  
10 met. For example, the animal studies include 4-hour concentrations of 400 to 800 ppb (ISA,  
11 Appendix 5, Tables 5-8 and 5-10). In addition, an epidemiologic study of a Taiwanese cohort  
12 and 2002 air quality that was available in the 2015 review has reported positive associations of  
13 multiday average O<sub>3</sub> concentrations in ambient air with changes in two indicators of glucose and  
14 insulin homeostasis (ISA, Appendix 5, sections 5.1.3.1.1 and 5.1.8).

15 The ISA additionally concludes that the evidence is suggestive of, but not sufficient to  
16 infer, a causal relationship between long-term O<sub>3</sub> exposures and metabolic effects (ISA, section  
17 IS.4.3.6.2). As with metabolic effects and short-term O<sub>3</sub>, the primary evidence is from  
18 experimental animal studies in which the exposure concentrations are appreciably higher than  
19 those commonly occurring in the U.S. For example, the animal studies include exposures over  
20 several weeks to concentrations of 250 ppb and higher (ISA, Appendix 5, section 5.2.3.1.1). The  
21 somewhat limited epidemiologic evidence related to long-term O<sub>3</sub> concentrations and metabolic  
22 effects includes several studies reporting increased odds of being overweight or obese or having  
23 metabolic syndrome and increased hazard ratios for diabetes incidence with increased O<sub>3</sub>  
24 concentrations (ISA, Appendix 5, sections 5.2.3.4.1, 5.2.5 and 5.2.9, Tables 5-12 and 5-15).

25 With regard to cardiovascular effects and total (nonaccidental) mortality and short-term  
26 O<sub>3</sub> exposures, the conclusions in the ISA regarding the potential for a causal relationship have  
27 changed from what they were in the 2015 review after integrating the previously available  
28 evidence with the more recently available evidence. The relationships are now characterized as  
29 suggestive of, but not sufficient to infer, a causal relationship (ISA, Appendix 4, section 4.1.17;  
30 Appendix 6, section 6.1.8). This reflects several aspects of the evidence base: (1) a now-larger  
31 body of controlled human exposure studies providing evidence that is not consistent with a  
32 cardiovascular effect in response to short-term O<sub>3</sub> exposure; (2) a paucity of epidemiologic  
33 evidence indicating more severe cardiovascular morbidity endpoints,<sup>39</sup> that would be expected if

---

<sup>39</sup> These include emergency department visits and hospital admission visits for cardiovascular endpoints including myocardial infarctions, heart failure or stroke (ISA, Appendix 6, section 6.1.8).

1 the impaired vascular and cardiac function (observed in animal toxicological studies) was the  
2 underlying basis for cardiovascular mortality (for which epidemiologic studies have reported  
3 some positive associations with O<sub>3</sub>); and (3) the remaining uncertainties and limitations  
4 recognized in the 2013 ISA (e.g., lack of control for potential confounding by copollutants in  
5 epidemiologic studies) that still remain. Although there exists consistent or generally consistent  
6 evidence for a limited number of O<sub>3</sub>-induced cardiovascular endpoints in animal toxicological  
7 studies and cardiovascular mortality in epidemiologic studies, there is a general lack of  
8 coherence between these results and findings in controlled human exposure and epidemiologic  
9 studies of cardiovascular health outcomes (ISA, section IS.1.3.1). Related to this updated  
10 conclusion for cardiovascular effects, the evidence for short-term O<sub>3</sub> and mortality is also  
11 updated (ISA, Appendix 6, section 6.1.8). While there remain consistent, positive associations  
12 between short-term O<sub>3</sub> and total (nonaccidental), respiratory, and cardiovascular mortality (and  
13 there are some studies reporting associations to remain after controlling for PM<sub>10</sub> and NO<sub>2</sub>), the  
14 full evidence base does not describe a continuum of effects that could lead to cardiovascular  
15 mortality.<sup>40</sup> Therefore, because cardiovascular mortality is the largest contributor to total  
16 mortality, the relatively limited biological plausibility and coherence within and across  
17 disciplines for cardiovascular effects (including mortality) contributes to an accompanying  
18 change in the causality determination for total mortality (ISA, section IS.4.3.5). Thus, the  
19 evidence for cardiovascular effects and total mortality, as evaluated in the ISA, is concluded to  
20 be suggestive of, but not sufficient to infer, a causal relationship with short-term (as well as long-  
21 term) O<sub>3</sub> exposures (ISA, section IS.1.3.1).

22 For other health effect categories, EPA's conclusions, as described in the ISA, are largely  
23 unchanged from those in the 2015 review. For example, the available evidence for reproductive  
24 effects, as well as for effects on the nervous system, continue to be suggestive of, but not  
25 sufficient to infer, a causal relationship (ISA, section IS.4.3.6). Additionally, the evidence is  
26 inadequate to determine if a causal relationship exists between O<sub>3</sub> exposure and cancer (ISA,  
27 section IS.4.3.6.6).

### 28 **3.3.2 Public Health Implications and At-risk Populations**

29 The public health implications of the evidence regarding O<sub>3</sub>-related health effects, as for  
30 other effects, are dependent on the type and severity of the effects, as well as the size of the  
31 population affected. Such factors are discussed here in the context of our consideration of the

---

<sup>40</sup> Due to findings from controlled human exposure studies examining clinical endpoints (e.g., blood pressure) that do not indicate an O<sub>3</sub> effect and from epidemiologic studies examining cardiovascular-related hospital admissions and emergency department visits that do not find positive associations, a continuum of effects that could lead to cardiovascular mortality is not apparent (ISA, Appendices 4 and 6).

1 health effects evidence related to O<sub>3</sub> in ambient air. Additionally, we summarize the available  
2 information related to judgments or interpretative statements developed by public health experts,  
3 including particularly experts in respiratory health. This section also summarizes the current  
4 information on population groups at increased risk of the effects of O<sub>3</sub> in ambient air.

5 With regard to O<sub>3</sub> in ambient air, the potential public health impacts relate most  
6 importantly to the role of O<sub>3</sub> in eliciting respiratory effects, the category of effects that the ISA  
7 concludes to be causally related to O<sub>3</sub> exposure. Controlled human exposure studies have  
8 documented reduced lung function, respiratory symptoms, increased airway responsiveness, and  
9 inflammation, among other effects, in largely healthy adults exposed while at elevated  
10 ventilation, such as while exercising. Such effects, if of sufficient severity and in individuals  
11 with compromised respiratory function, such as individuals with asthma, are plausibly related to  
12 emergency department visits and hospital admissions for asthma which have been associated  
13 with ambient air concentrations of O<sub>3</sub> in epidemiologic studies (as summarized in section 3.3.1  
14 above; 2013 ISA, section 6.2.7; ISA, Appendix 3, sections 3.1.5.1 and 3.1.5.2).

15 The clinical significance of individual responses to O<sub>3</sub> exposure depends on the health  
16 status of the individual, the magnitude of the changes in pulmonary function, the severity of  
17 respiratory symptoms, and the duration of the response among other factors. While a particular  
18 reduction in FEV<sub>1</sub> or increase in inflammation or airway responsiveness may not be of concern  
19 for a healthy group,<sup>41</sup> it may increase the risk of a more severe effect in a group with asthma. As  
20 a more specific example, the same increase in inflammation or airway responsiveness in  
21 individuals with asthma could predispose them to an asthma exacerbation event triggered by an  
22 allergen to which they may be sensitized (e.g., ISA, Appendix 3, section 3.1.5.6.1; 2013 ISA,  
23 sections 6.2.3 and 6.2.6). Duration and frequency of documented effects is also reasonably  
24 expected to influence potential adversity and interference with normal activity. In summary,  
25 consideration of differences in magnitude or severity, and also the relative transience or  
26 persistence of the responses (e.g., FEV<sub>1</sub> changes) and respiratory symptoms, as well as pre-  
27 existing sensitivity to effects on the respiratory system, and other factors, are important to  
28 characterizing implications for public health effects of an air pollutant such as O<sub>3</sub> (ATS, 2000;  
29 Thurston et al., 2017).

30 Decisions made in past reviews of the O<sub>3</sub> primary standard and associated judgments  
31 regarding adversity or health significance of measurable physiological responses to air pollutants

---

<sup>41</sup> For example, for most healthy individuals, moderate effects on pulmonary function, such as transient FEV<sub>1</sub> decrements smaller than 20% or transient respiratory symptoms, such as cough or discomfort on exercise or deep breath, would not be expected to interfere with normal activity, while larger pulmonary function effects (e.g., FEV<sub>1</sub> decrements of 20% or larger lasting longer than 24 hours) and/or more severe respiratory symptoms are more likely to interfere with normal activity for more of such individuals (e.g., 2014 PA, p. 3-53; 2006 AQCD, Table 8-2).

1 have been informed by guidance, criteria or interpretative statements developed within the public  
2 health community, including the ATS, an organization of respiratory disease specialists, as well  
3 as the CASAC. The ATS released its initial statement (titled *Guidelines as to What Constitutes*  
4 *an Adverse Respiratory Health Effect, with Special Reference to Epidemiologic Studies of Air*  
5 *Pollution*) in 1985 and updated it in 2000 (ATS, 1985; ATS, 2000). The ATS described its 2000  
6 statement as being intended to “provide guidance to policy makers and others who interpret the  
7 scientific evidence on the health effects of air pollution for the purposes of risk management”  
8 (ATS, 2000). The statement further asserts that “principles to be used in weighing the evidence  
9 and setting boundaries” and “the placement of dividing lines should be a societal judgment”  
10 (ATS, 2000). The ATS explicitly states that it does “not attempt to provide an exact definition or  
11 fixed list of health impacts that are, or are not, adverse,” providing instead “a number of  
12 generalizable ‘considerations’” and that there “cannot be precise numerical criteria, as broad  
13 clinical knowledge and scientific judgments, which can change over time, must be factors in  
14 determining adversity” (ATS, 2000). A more recent ATS statement, while generally consistent  
15 with the 2000 statement in the attention that statement gives to at-risk or vulnerable population  
16 groups, broadens the discussion of effects, responses and biomarkers to reflect the expansion of  
17 scientific research in these areas (Thurston, et al., 2017). The more recent statement additionally  
18 notes that it does not offer “strict rules or numerical criteria, but rather proposes considerations to  
19 be weighed in setting boundaries between adverse and nonadverse health effects,” providing a  
20 general framework for interpreting evidence that proposes a “set of considerations that can be  
21 applied in forming judgments” for this context (Thurston et al., 2017). Thus, the most recent  
22 statement expands upon (with some specificity) and updates the prior statement by retaining  
23 previously identified considerations, including, for example, its emphasis on consideration of  
24 vulnerable populations, while retaining core consistency with the earlier ATS statement  
25 (Thurston et al., 2017; ATS, 2000).

26 With regard to pulmonary function decrements, the earlier ATS statement concluded that  
27 “small transient changes in forced expiratory volume in 1 s[econd] (FEV<sub>1</sub>) alone were not  
28 necessarily adverse in healthy individuals, but should be considered adverse when accompanied  
29 by symptoms” (ATS, 2000). The more recent ATS statement continues to support this  
30 conclusion and also gives weight to findings of such lung function changes in the absence of  
31 respiratory symptoms in individuals with pre-existing compromised function, such as that  
32 resulting from asthma (Thurston et al., 2017). More specifically, the recent ATS statement  
33 expresses the view that when occurring in individuals with pre-existing compromised function,  
34 such as asthma, the occurrence of “small lung function changes” “should be considered adverse  
35 ... even without accompanying respiratory symptoms” (Thurston et al., 2017). In keeping with  
36 the intent of these statements to avoid specific criteria, neither statement provides more specific



descriptions of such responses, such as with regard to magnitude, duration or frequency of small pollutant-related lung function changes, for consideration of such conclusions. The earlier ATS statement, in addition to emphasizing clinically relevant effects, also emphasized both the need to consider changes in “the risk profile of the exposed population,” and effects on the portion of the population that may have a diminished reserve that puts its members at potentially increased risk if affected by another agent (ATS, 2000). In a similar vein, the more recent statement emphasizes the distinction between population changes and individual changes in lung function measures noting that for an exposed group of study subjects, while the mean change or reduction may be small, some individual study group members will have larger reductions which in some cases may have passed a threshold for clinical importance (Thurston et al., 2017). These concepts, including the consideration of the magnitude of effects occurring in just a subset of study subjects, continue to be recognized as important in the more recent ATS statement (Thurston et al., 2017) and continue to be relevant to the evidence base for O<sub>3</sub>.

- **Does the available evidence alter our prior understanding of populations that are particularly at risk from O<sub>3</sub> exposures? What are important uncertainties in that evidence?**

The newly available information regarding O<sub>3</sub> exposures and health effects among sensitive populations, as thoroughly evaluated in the ISA, has not altered our understanding of human populations at particular risk of health effects from O<sub>3</sub> exposures (ISA, section IS.4.4). For example, the respiratory effects evidence, extending decades into the past and augmented by new studies in this review, supports the conclusion that “individuals with pre-existing asthma are at greater risk of ozone-related health effects based on the substantial and consistent evidence within epidemiologic studies and the coherence with toxicological studies” (ISA, p. IS-57). Numerous epidemiological studies document associations of O<sub>3</sub> with asthma exacerbation. Such studies indicate the associations to be strongest for populations of children which is consistent with their generally greater time outdoors while at elevated exertion. Together, these considerations indicate people with asthma, including particularly children with asthma, to be at relatively greater risk of O<sub>3</sub>-related effects than other members of the general population (ISA, sections IS.4.3.1 and IS.4.4.2, Appendix 3).<sup>42</sup>

With respect to people with asthma, the limited evidence from controlled human exposure studies (which are primarily in adult subjects) indicates similar magnitude of FEV<sub>1</sub> decrements as in people without asthma (ISA, Appendix 3, section 3.1.5.4.1). Across studies of other respiratory effects of O<sub>3</sub> (e.g., increased respiratory symptoms, increased airway

---

<sup>42</sup> Populations or lifestages can be at increased risk of an air pollutant-related health effect due to one or more factors. These factors can be intrinsic, such as physiological factors that may influence the internal dose or toxicity of a pollutant, or extrinsic, such as sociodemographic, or behavioral factors.

responsiveness and increased lung inflammation), the responses observed in study subjects generally do not differ due to the presence of asthma, although the evidence base is more limited with regard to study subjects with asthma (ISA, Appendix 3, section 3.1.5.7). However, the features of asthma (e.g., increased airway responsiveness) contribute to a risk of asthma-related responses, such as asthma exacerbation in response to asthma triggers, which may increase the risk of more severe health outcomes (ISA, section 3.1.5). For example, a particularly strong and consistent component of the epidemiologic evidence is the appreciable number of epidemiologic studies that demonstrate associations between ambient air O<sub>3</sub> concentrations and hospital admissions and emergency department visits for asthma (ISA, section IS.4.4.3.1).<sup>43</sup> We additionally recognize that in these studies, the strongest associations (e.g., highest effect estimates) or associations more likely to be statistically significant are those for childhood age groups, which are, as recognized in section 3.4, the age groups most likely to spend time outdoors during afternoon periods (when O<sub>3</sub> may be highest) and at activity levels corresponding to those that have been associated with respiratory effects in the human exposure studies (ISA, Appendix 3, sections 3.1.4.1 and 3.1.4.2).<sup>44</sup> The epidemiologic studies of hospital admissions and emergency department visits are augmented by a large body of individual-level epidemiologic panel studies that demonstrated associations of short-term ozone concentrations with respiratory symptoms in children with asthma. Additional support comes from epidemiologic studies that observed O<sub>3</sub>-associated increases in indicators of airway inflammation and oxidative stress in children with asthma (ISA, section IS.4.3.1). Together, this evidence continues to indicate the increased risk of population groups with asthma (ISA, Appendix 3, section 3.1.5.7).

Children and outdoor adult workers, are at increased risk largely due to their generally greater time spent outdoors while at elevated exertion rates (including in summer afternoons and

---

<sup>43</sup> In addition to asthma exacerbation, the epidemiologic evidence also includes findings of positive associations of increased O<sub>3</sub> concentrations with hospital admissions or emergency department visits for COPD exacerbation and other respiratory diseases (ISA, Appendix 3, sections 3.1.6.1.3 and 3.1.8).

<sup>44</sup> Evaluations of activity pattern data indicate children to more frequently spend time outdoors during afternoon and early evening hours, while at moderate or greater exertion level, than other age groups (Appendix 3D, section 3D.2.5.3, including Figure 3D-9; 2014 HREA, section 5.4.1.5 and Appendix 5G, section 5G-1.4). For example, for days with some time spent outdoors, children spend, on average, approximately 2¼ hours of afternoon time outdoors, 80% of which is at a moderate or greater exertion level, regardless of their asthma status (Appendix 3D, section 3D.2.5.3). Adults, for days having some time spent outdoors, also spend approximately 2¼ hours of afternoon time outdoors regardless of their asthma status but the percent of afternoon time at moderate or greater exertion levels for adults (about 55%) is lower than that observed for children. Such analyses also note greater participation in outdoor events during the afternoon, compared to other times of day, for children ages 6 through 19 years old during the warm season months (ISA, Appendix 2, section 2.4.1, Table 2-1). Analyses of the limited activity pattern data by health status do not indicate asthma status to have appreciable impact (Appendix 3D, section 3D.2.5.3; 2014 HREA, section 5.4.1.5).

1 early evenings when O<sub>3</sub> levels may be higher).<sup>45</sup> This behavior makes them more likely to be  
2 exposed to O<sub>3</sub> in ambient air under conditions contributing to increased dose, e.g., elevated  
3 ventilation taking greater air volumes into the lungs<sup>46</sup> (ISA, section IS.4.4.2; 2013 ISA, section  
4 5.2.2.7). Thus, in light of the evidence summarized in the prior paragraphs, children and outdoor  
5 workers with asthma may be at increased risk of more severe outcomes, such as asthma  
6 exacerbation. Further, with regard to children, there is experimental evidence from early life  
7 exposures of nonhuman primates that indicates the potential for effects in childhood (through  
8 adolescence) when human respiratory systems are under development (ISA, sections IS.4.4.2 and  
9 IS.4.4.4.1). As noted in the ISA, “these experimental studies indicate that early-life ozone  
10 exposure can cause structural and functional changes that could potentially contribute to airway  
11 obstruction and increased airway responsiveness” (ISA, p. IS-52). Overall, the available  
12 evidence, while not increasing our knowledge about susceptibility or at-risk status of these  
13 population groups, is consistent with that in the 2015 review (ISA, section IS.4.4).

14 Evidence available in the 2020 ISA for older adults, a population identified as at risk in  
15 the 2015 review, adds little to the evidence previously available (ISA, sections IS.4.4.2 and  
16 IS.4.4.4.2; Table IS-10). The ISA notes, however, that “[t]he majority of evidence for older  
17 adults being at increased risk of health effects related to ozone exposure comes from studies of  
18 short-term ozone exposure and mortality evaluated in the 2013 Ozone ISA” (ISA, p. IS-52).  
19 Such studies are part of the larger evidence base that is now concluded to be suggestive, but not  
20 sufficient to infer a causal relationship of O<sub>3</sub> with mortality (ISA, sections IS.4.3.5 and  
21 IS.4.4.4.2, Appendix 4, section 4.1.16.1 and 4.1.17).

22 The ISA also expressly considered the evidence regarding O<sub>3</sub> exposure and health effects  
23 among populations with several other potential risk factors. As in the 2015 review, there is  
24 suggestive evidence of low socioeconomic status (SES) as a factor associated with potentially  
25 increased risk of O<sub>3</sub>-related health effects (2013 ISA, section 8.3.3 and p. 8-37; ISA, section  
26 IS.4.4). The 2013 ISA concluded that “[o]verall, evidence is suggestive of SES as a factor  
27 affecting risk of O<sub>3</sub>-related health outcomes based on collective evidence from epidemiologic  
28 studies of respiratory hospital admissions but inconsistency among epidemiologic studies of

---

<sup>45</sup> More specifically regarding outdoor workers, in 2020 about 4% of civilian workers were required to spend more than two-thirds of their workday outdoors. Among construction, landscaping and groundskeeping workers, about 80-90% were required to spend more than two-thirds of their working day outside. Other employment sectors, including highway maintenance, protection services, extraction and other construction trades like engineers and equipment operators also had a high percentage of employees who spent most of their workday outdoors (Bureau of Labor Statistics, 2020). Such jobs often include physically demanding tasks and involve increased ventilation rates, increasing the potential for exposure to O<sub>3</sub>.

<sup>46</sup> Additionally, compared to adults, children have higher ventilation rates relative to their lung volume which tends to increase the dose normalized to lung surface area (ISA, p. IS-60).

mortality and reproductive outcomes,” additionally stating that “[f]urther studies are needed to confirm this relationship, especially in populations within the U.S.” (2013 ISA, p. 8-28). The evidence in the 2020 ISA adds little to the evidence previously available in this area (ISA, section IS.4.4.2 and Table IS-10). Regarding populations identified by race or ethnicity, including American Indians or Native Americans, the evidence continued to be inadequate to make a determination regarding a potential for increased risk (ISA, section IS.4.4, Table IS-10).

The ISA in the 2015 review additionally identified a role for dietary anti-oxidants such as vitamins C and E in influencing risk of O<sub>3</sub>-related effects, such as inflammation, as well as a role for genetic factors to also confer either an increased or decreased risk (2013 ISA, sections 8.1 and 8.4.1). No recently available evidence was evaluated in the ISA that would inform or change these prior conclusions (ISA, section IS.4.4 and Table IS-10).

- **What does the available information indicate with regard to the size of at-risk populations and their distribution in the U.S.?**

The magnitude and characterization of a public health impact is dependent upon the size and characteristics of the populations affected, as well as the type or severity of the effects. As summarized above, children are an at-risk population and children under the age of 18 account for 22.3% of the total U.S. population, with 6.0% of the total population being children under 5 years of age (U.S. Census Bureau, 2019). Further, as summarized above, a key population most at risk of health effects associated with O<sub>3</sub> in ambient air is people with asthma. The National Center for Health Statistics data for 2019 indicate that approximately 7.8% of the U.S. population has asthma (Table 3-1; CDC, 2019). This is one of the principal populations that the primary O<sub>3</sub> NAAQS is designed to protect (80 FR 65294, October 26, 2015). Table 3-1 below considers the currently available information that helps to characterize key features of this population.<sup>47</sup>

The age group for which asthma prevalence documented by these data is greatest is children aged five to 19, with 9.1% of children aged five to 14 and 7.4% of children aged 15-19 having asthma. In 2012 (the most recent year for which such an evaluation is available), asthma was the leading chronic illness affecting children (Bloom et al., 2013). The prevalence is greater for boys than girls (for those less than 18 years of age). Among populations of different races or ethnicities, black non-Hispanic children have the highest prevalence, at 13.5%. Asthma prevalence is also increased among populations in poverty. For example, 11.8% of people living in households below the poverty level have asthma, compared to 7.2%, on average, of those

---

<sup>47</sup> Additionally, as part of the 2019 National Health Interview Survey, about 41% of people with asthma reported having had an asthma attack or asthma episode within the prior 12 months, with this percentage being slightly greater among children with asthma (44%) compared to adults with asthma (40%). A summary is available in Tables 5-1 and 6-1 of the survey ([https://www.cdc.gov/asthma/most\\_recent\\_national\\_asthma\\_data.htm](https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm)).

living above it. Populations groups with relatively greater asthma prevalence, such as populations in poverty and children, might be expected to have a relatively greater potential for O<sub>3</sub>-related health impacts.<sup>48</sup>

**Table 3-1. National prevalence of asthma, 2019.**

| Characteristic <sup>A</sup> | Number with Current Asthma<br>(in thousands) <sup>B</sup> | Percent with Current<br>Asthma |
|-----------------------------|---|--------------------------------|
| <b>Total</b>                | <b>25,131</b>   | <b>7.8</b>                     |
| Child (Age <18)             | 5,104   | 7.0                            |
| Adult (Age 18+)             | 20,026  | 8.0                            |
| <b>All Age Groups</b>       |   |                                |
| 0-4 years                   | 517   | 2.6                            |
| 5-14 years                  | 3,725   | 9.1                            |
| 15-19 years                 | 1,529   | 7.4                            |
| 20-24 years                 | 2,092   | 9.9                            |
| 25-34 years                 | 3,574   | 8.0                            |
| 35-64 years                 | 9,594   | 7.8                            |
| 65+ years                   | 4,069   | 7.7                            |
| <b>Child Age Group</b>      |   |                                |
| 0-4 years                   | 517   | 2.6                            |
| 5-11 years                  | 2,345   | 8.3                            |
| 12-17 years                 | 2,241   | 8.9                            |
| 12-14 years                 | 1,379   | 10.8                           |
| 15-17 years                 | 861   | 7.0                            |
| <b>Sex</b>                  |   |                                |
| Males                       | 10,487  | 6.6                            |
| Boys (Age <18)              | 3,122   | 8.4                            |
| Men (Age 18+)               | 7,364   | 6.1                            |
| Females                     | 14,643  | 8.9                            |
| Girls (Age <18)             | 1,981   | 5.5                            |
| Women (Age 18+)             | 12,662  | 9.8                            |
| <b>Race/Ethnicity</b>       |   |                                |
| White NH <sup>C</sup>       | 15,094  | 7.7                            |
| Child (Age <18)             | 2,385   | 6.4                            |
| Adult (Age 18+)             | 12,701  | 8.1                            |
| Black NH                    | 4,105   | 10.6                           |
| Child (Age <18)             | 1,289   | 13.5                           |
| Adult (Age 18+)             | 2,814   | 9.7                            |
| AI/AN <sup>E</sup> NH       | 349   | 10.7                           |
| Child (Age <18)             | 67  | 8.2                            |

<sup>48</sup> As summarized in section 3.1 above, the current standard was set to protect at-risk populations, which include people with asthma. Accordingly, populations with asthma living in areas not meeting the standard would be expected to be at increased risk of effects.

| Characteristic <sup>A</sup>  | Number with Current Asthma<br>(in thousands) <sup>B</sup> | Percent with Current<br>Asthma |
|--|---|--------------------------------|
| Adult (Age 18+)  | 281   | 11.6                           |
| Asian NH   | 697   | 3.8                            |
| Child (Age <18)  | 130   | 3.7                            |
| Adult (Age 18+)  | 567   | 3.8                            |
| Multiple <sup>D</sup> NH   | 867   | 12.6                           |
| Child (Age <18)  | 339   | 11.2                           |
| Adult (Age 18+)  | 527   | 13.7                           |
| Hispanic, all  | 3,874   | 6.6                            |
| Child (Age <18)  | 1,387   | 7.5                            |
| Adult (Age 18+)  | 2,486   | 6.1                            |
| Hispanic, Mexican <sup>F</sup>   | 1,933   | 5.3                            |
| Child (Age <18)  | 725   | 6.1                            |
| Adult (Age 18+)  | 1,207   | 5.0                            |
| Hispanic, Other <sup>F</sup>   | 1,929   | 8.5                            |
| Child (Age <18)  | 656   | 10.0                           |
| Adult (Age 18+)  | 1,273   | 7.9                            |
| <b>Federal Poverty Threshold</b>   |   |                                |
| Below 100% of poverty level  | 4,814   | 11.8                           |
| 100% to less than 250% of poverty level  | 7,837   | 8.5                            |
| 250% to less than 450% of poverty level  | 6,345   | 7.3                            |
| 450% of poverty level or higher  | 6,138   | 5.9                            |
| <sup>A</sup> Numbers within selected characteristics may not sum to total due to rounding<br><sup>B</sup> Includes persons who answered "yes" to the questions "Have you EVER been told by a doctor or other health professional that you had asthma" and "Do you still have asthma?"<br><sup>C</sup> NH = non-Hispanic<br><sup>D</sup> Subcategory includes 'Other single and multiple races' for 2019<br><sup>E</sup> AI/AN = American Indian/ Alaska Native<br><sup>F</sup> As a subset of Hispanic<br>Adapted from 2019 National Health Interview Survey, Tables 3-1 and 4-1<br>( <a href="https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm">https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm</a> ). |   |                                |

### 3.3.3 Exposure Concentrations Associated with Effects

The extensive evidence base for O<sub>3</sub> health effects, compiled over several decades and evaluated in the ISA, continues to indicate respiratory responses to short-term exposures as the most sensitive effects. As at the time of the 2015 review, the EPA's conclusions regarding exposure concentrations of O<sub>3</sub> associated with respiratory effects reflect the extensive longstanding evidence base of controlled human exposure studies of short-term O<sub>3</sub> exposures of people with and without asthma.<sup>49</sup> These studies have documented an array of respiratory effects, including reduced lung function, respiratory symptoms, increased airway responsiveness, and


<sup>49</sup> As recognized elsewhere, the studies are largely conducted with adult subjects.

1 inflammation, in study subjects following 1- to 8-hour exposures, primarily while exercising.  
2 The severity of observed responses, the percentage of individuals responding, and strength of  
3 statistical significance at the study group level have been found to increase with increasing  
4 exposure (ISA; 2013 ISA; 2006 AQCD). Factors influencing exposure include activity level or  
5 ventilation rate, exposure concentration, and exposure duration (ISA; 2013 ISA; 2006 AQCD).  
6 For example, evidence from studies with similar duration and exercise aspects (6.6-hour duration  
7 with six 50-minute exercise periods) demonstrates an exposure-response relationship for O<sub>3</sub>-  
8 induced reduction in lung function (Figure 3-2).<sup>50,51</sup> This specific evidence was integral to the  
9 Administrator's judgments and decisions in 2015 and 2020 (80 FR 65292, October 26, 2015; 85

---

<sup>50</sup> For a subset of the studies included in Figure 3-2 (those with face mask rather than chamber exposures), there is no O<sub>3</sub> exposure during some of the 6.6-hr experiment (e.g., during the lunch break). Thus, while the exposure concentration during the exercise periods is the same for the two types of studies, the time-weighted average (TWA) concentration across the full 6.6-hr period differs slightly. For example, in the facemask studies of 120 ppb, the TWA across the full 6.6-hour experiment is 109 ppb (Appendix 3A, Table 3A-2).

<sup>51</sup> The relationship also exists for size of FEV<sub>1</sub> decrement with alternative exposure or dose metrics, including total inhaled O<sub>3</sub> and intake volume averaged concentration.



**Figure 3-2. Group mean O<sub>3</sub>-induced reduction in FEV<sub>1</sub> from controlled human exposure studies of healthy adults exposed for 6.6 hours with quasi-continuous exercise.** FEV<sub>1</sub> values plotted reflect group mean O<sub>3</sub>-induced percent change in FEV<sub>1</sub>, based on subtraction of the group mean filtered air percent change (post-pre exposure) from the group mean O<sub>3</sub> percent change in FEV<sub>1</sub> (adapted from Appendix 3A; ISA, Appendix 3, Figure 3-1). Concentrations are the time-weighted averages of target concentrations across full 6.6-hour period in chamber studies (or the average of target concentrations across the six exposures in face mask studies).

- **Does the available evidence alter prior conclusions regarding the exposure duration and concentrations associated with health effects? Does the available scientific evidence indicate health effects attributable to exposures to O<sub>3</sub> concentrations lower than previously reported?**

The available evidence, as documented in the ISA, including that newly available in the 2020 review, does not alter our conclusions from the 2015 review on exposure duration and



1 concentrations associated with O<sub>3</sub>-related health effects. These conclusions were largely based  
2 on the body of evidence from the controlled human exposure studies. A limited number of newly  
3 available controlled human exposure studies are described in the ISA, although none involve  
4 lower exposure concentrations than those previously studied (e.g., Figure 3-2) or find effects not  
5 previously reported (ISA, Appendix 3, section 3.1.4).<sup>52</sup>

6 The extensive evidence base for O<sub>3</sub> health effects, compiled over several decades,  
7 continues to indicate respiratory responses to short-term exposures as the most sensitive effects  
8 of O<sub>3</sub>. As summarized in section 3.3.1.1 above, an array of respiratory effects is well documented  
9 in controlled human exposure studies of subjects exposed for 1 to 8 hours, primarily while  
10 exercising. The risk of more severe health outcomes associated with such effects is increased in  
11 people with asthma as illustrated by the epidemiological findings of positive associations  
12 between O<sub>3</sub> exposure and asthma-related emergency department visits and hospital admissions.

13 The magnitude of respiratory response (e.g., size of lung function decrements and  
14 magnitude of symptom scores) documented in the controlled human exposure studies is  
15 influenced by ventilation rate, exposure duration, and exposure concentration. When performing  
16 physical activities requiring elevated exertion, ventilation rate is increased, leading to greater  
17 potential for health effects due to an increased internal dose (2013 ISA, section 6.2.1.1, pp. 6-5 to  
18 6-11). Accordingly, the exposure concentrations eliciting a given level of response after a given  
19 exposure duration is lower for subjects exposed while at elevated ventilation, such as while  
20 exercising (2013 ISA, pp. 6-5 to 6-6). For example, in studies of generally healthy young adults  
21 exposed while at rest for 2 hours, 500 ppb is the lowest concentration eliciting a statistically  
22 significant O<sub>3</sub>-induced group mean lung function decrement, while a 1- to 2-hour exposure to  
23 120 ppb produces a statistically significant response in lung function when the ventilation rate of  
24 the group of study subjects is sufficiently increased with exercise (2013 ISA, pp. 6-5 to 6-6).

25 The exposure conditions (e.g., duration and exercise) given primary focus in the past  
26 several reviews are those of the 6.6-hour study design, which involves six 50-minute exercise  
27 periods during which subjects maintain a moderate level of exertion to achieve a ventilation rate  
28 of approximately 20 L/min per m<sup>2</sup> body surface area while exercising. The 6.6 hours of exposure  
29 in these studies has generally occurred in an enclosed chamber and the study design includes  
30 three hours in each of which is a 50-minute exercise period and a 10-minute rest period, followed  
31 by a 35-minute lunch (rest) period, which is followed by three more hours of exercise and rest, as

---

<sup>52</sup> No 6.6-hour studies are newly available (ISA, Appendix 3, section 3.1.4.1.1). The newly available studies are generally for exposures of three hours or less, and in nearly all instances involve exposure (while at elevated exertion) to concentrations above 100 ppb (ISA, Appendix 3, section 3.1.4).

1 before lunch.<sup>53</sup> Most of these studies performed to date involve exposure maintained at a  
2 constant (unchanging) concentration for the full duration, although a subset of studies have  
3 concentrations that vary (generally in a stepwise manner) across the exposure period and are  
4 selected so as to achieve a specific target concentration as the exposure average (Appendix 3A,  
5 Table 3A-2).<sup>54</sup>

6 No studies of the 6.6-hour quasi-continuous exercise design are newly available since the  
7 2015 review. The previously available studies of this design document statistically significant  
8 O<sub>3</sub>-induced reduction in lung function (FEV<sub>1</sub>) and increased pulmonary inflammation in young  
9 healthy adults exposed to O<sub>3</sub> concentrations as low as 60 ppb. Statistically significant group  
10 mean changes in FEV<sub>1</sub>, also often accompanied by statistically significant increases in  
11 respiratory symptoms, become more consistent across such studies of exposures to higher O<sub>3</sub>  
12 concentrations, such as 70 ppb and 80 ppb (Table 3-2; Appendix 3A, Table 3A-1). The lowest  
13 exposures concentration for which these studies document a statistically significant increase in  
14 respiratory symptoms is somewhat above 70 ppb, at 73 ppb<sup>55</sup> (Schelegle et al., 2009; Appendix  
15 3A, Table 3A-1). In the 6.6-hour studies, the group means of O<sub>3</sub>-induced<sup>56</sup> FEV<sub>1</sub> reductions for  
16 target exposure concentrations at or below 70 ppb are approximately 6% or lower (Figure 3-2,  
17 Table 3-2). For example, the group means of O<sub>3</sub>-induced FEV<sub>1</sub> decrements reported in these  
18 studies that are statistically significantly different from the responses in filtered air are 6.1% for  
19 the 70 ppb target (73 ppb time weighted average based on measurements) and 1.7% to 3.5% for  
20 the 60 ppb target (Figure 3-2, Table 3-2).

21 The group mean O<sub>3</sub>-induced FEV<sub>1</sub> decrements generally increase with increasing O<sub>3</sub>  
22 exposures, reflecting increases in both the number of the individuals affected and the magnitude

---

<sup>53</sup> A few studies have involved exposures by facemask rather than in a chamber. To date, there is little research differentiating between exposures conducted with a facemask and in a chamber since the pulmonary responses of interest do not seem to be influenced by the exposure mechanism. However, similar responses have been seen in studies using both exposure methods at higher O<sub>3</sub> concentrations (Adams, 2002; Adams, 2003). In the facemask designs, there is a short period of zero exposure, such that the total period of exposure is closer to 6 hours than 6.6 (Adams, 2000; Adams, 2002; Adams, 2003).

<sup>54</sup> In these studies, the exposure concentration changes for each of the six hours in which there is exercise and the concentration during the 35-minute lunch is the same as in the prior (third) hour with exercise. For example, in the study by Adams (2006b), the protocol for the 6.6-hour period is as follows: 60 minutes at 0.04 ppm, 60 minutes at 0.07 ppm, 95 minutes at 0.09 ppm, 60 minutes at 0.07 ppm, 60 minutes at 0.05 ppm and 60 minutes at 0.04 ppm.

<sup>55</sup> Measurements are reported in this study for each of the six 50-minute exercise periods, for which the mean is 72 ppb (Schelegle et al., 2009). Based on these data, the time-weighted average concentration across the full 6.6-hour duration was 73 ppb (Schelegle et al., 2009). The study design includes a 35-minute lunch period following the third exposure hour during which the exposure concentration remains the same as in the third hour.

<sup>56</sup> Consistent with the ISA and 2013 ISA, the phrase “O<sub>3</sub>-induced” decrement or reduction in lung function or FEV<sub>1</sub> refers to the percent change from pre-exposure measurement of the O<sub>3</sub> exposure minus the percent change from pre-exposure measurement of the filtered air exposure (2013 ISA, p. 6-4).

1 of the FEV<sub>1</sub> reduction (Figure 3-2). For example, following 6.6-hour exposures to a lower  
2 concentration (40 ppb), for which decrements were not statistically significant at the group mean  
3 level, none of 60 subjects across two separate studies experienced an O<sub>3</sub>-induced FEV<sub>1</sub> reduction  
4 as large as 15% or more (Appendix 3D, Table 3D-19). Across the four experiments (with  
5 number of subjects ranging from 30 to 59 subjects) that have reported results for 60 ppb target  
6 exposure,<sup>57</sup> the number of subjects experiencing this magnitude of FEV<sub>1</sub> reduction (at or above  
7 15%) varied (zero of 30, one of 59, two of 31 and two of 30 exposed subjects), while, together,  
8 they represent 3% of all 150 subjects. The percentage of subjects (with reductions of 15% or  
9 more) increased to 10% (three of 31 subjects) for the study at 73 ppb (70 ppb target  
10 concentration) and is higher still (16%) in a variable exposure study at 80 ppb (Appendix 3D,  
11 Tables 3D-19 and 3D-30; Schelegle et al., 2009). In addition to illustrating the E-R relationship,  
12 these findings also illustrate the considerable variability in magnitude of responses observed  
13 among study subjects (Table 3-2, Figure 3-2; ISA, Appendix 3, section 3.1.4.1.1; 2013 ISA, p. 6-  
14 13).

---

<sup>57</sup> For these four experiments, the average concentration across the 6.6-hour period ranged from 60 to 63 ppb (Appendix 3A, Table 3A-2).

**Table 3-2. Summary of 6.6-hour controlled human exposure study-findings, healthy adults.**

| Endpoint                                       | O <sub>3</sub> Target Exposure Concentration <sup>A</sup> | Statistically Significant Effect <sup>B</sup> | O <sub>3</sub> -Induced Group Mean Response <sup>B</sup> | Study  |
|--|---|---|--|--|
| FEV <sub>1</sub> Reduction                     | 120 ppb   | Yes   | -10.3% to -15.9% <sup>C</sup>                            | Horstman et al. 1990; Adams 2002; Folinsbee et al. (1988); Folinsbee et al. (1994); Adams, 2002; Adams 2000; Adams and Ollison 1997 <sup>D</sup>   |
|  | 100 ppb   | Yes   | -8.5% to -13.9% <sup>C</sup>                             | Horstman et al., 1990; McDonnell et al., 1991 <sup>D</sup>   |
|  | 87 ppb  | Yes   | -12.2%   | Schelegle et al., 2009   |
|  | 80 ppb  | Yes   | -7.5%  | Horstman et al., 1990  |
|  |   |   | -7.7%  | McDonnell et al., 1991   |
|  |   |   | -6.5%  | Adams, 2002  |
|  |   |   | -6.2% to -5.5% <sup>C</sup>                              | Adams, 2003  |
|  |   |   | -7.0% to -6.1% <sup>C</sup>                              | Adams, 2006b   |
|  |   |   | -7.8%  | Schelegle et al., 2009   |
|  |   | ND <sup>E</sup>                               | -3.5%  | Kim et al., 2011 <sup>F</sup>  |
|  | 70 ppb  | Yes   | -6.1%  | Schelegle et al., 2009   |
|  | 60 ppb  | Yes <sup>G</sup>                              | -2.9%  | Adams, 2006b; Brown et al., 2008   |
|  |   |   | -2.8%  |  |
|  |   | Yes   | -1.7%  | Kim et al., 2011   |
|  | 40 ppb  | No  | -3.5%  | Schelegle et al., 2009   |
|  |   | No  | -1.2%  | Adams, 2002  |
| Increased Respiratory Symptoms                 | 120 ppb   | Yes   | Increased symptom scores                                 | Horstman et al. 1990; Adams 2002; Folinsbee et al. 1988; Folinsbee et al. 1994; Adams, 2002; Adams 2000; Adams and Ollison 1997; Horstman et al., 1990; McDonnell et al., 1991; Schelegle et al., 2009; Adams, 2003; Adams, 2006b <sup>H</sup> |
|  | 100 ppb   | Yes   |  | Adams, 2006b; Kim et al., 2011; Schelegle et al., 2009; Adams, 2002 <sup>H</sup>   |
|  | 87 ppb  | Yes   |  |  |
|  | 80 ppb  | Yes   |  |  |
|  | 70 ppb  | Yes   |  |  |
|  | 60 ppb  | No  |  |  |
|  | 40 ppb  | No  |  |  |
| Airway Inflammation                            | 80 ppb  | Yes   | Multiple indicators <sup>I</sup>                         | Devlin et al., 1991; Alexis et al., 2010   |
|  | 60 ppb  | Yes   | Increased neutrophils                                    | Kim et al., 2011   |
| Increased Airway Resistance and Responsiveness | 120 ppb   | Yes   | Increased  | Horstman et al., 1990; Folinsbee et al., 1994 (O <sub>3</sub> induced sRaw not reported)   |
|  | 100 ppb   | Yes   |  | Horstman et al., 1990  |
|  | 80 ppb  | Yes   |  | Horstman et al., 1990  |

<sup>A</sup> This refers to the average concentration across the six exercise periods as targeted by authors. This differs from the time-weighted average concentration for the full exposure periods (targeted or actual). For example, as shown in Appendix 3A, Table 3A-2, in chamber studies implementing a varying concentration protocol with targets of 0.03, 0.07, 0.10, 0.15, 0.08 and 0.05 ppm, the exercise period average concentration is 0.08 ppm while the time weighted average for the full exposure period (based on targets) is 0.082 ppm due to the 0.6 hour lunchtime exposure between periods 3 and 4. In some cases this also differs from the exposure period average based on study measurements. For example, based on measurements reported in Schelegle et

al., (2009), the full exposure period average concentration for the 70 ppb target exposure is 73 ppb, and the average concentration during exercise is 72 ppb.

<sup>B</sup> Statistical significance based on the O<sub>3</sub> compared to filtered air response at the study group mean (rounded here to decimal).

<sup>C</sup> Ranges reflect the minimum to maximum FEV<sub>1</sub> decrements across multiple exposure designs and studies. Study-specific values and exposure details provided in the PA, Appendix 3A, Tables 3A-1 and 3A-2, respectively.

<sup>D</sup> Citations for specific FEV<sub>1</sub> findings for exposures above 70 ppb are provided in PA, Appendix 3A, Table 3A-1.

<sup>E</sup> ND (not determined) indicates these data have not been subjected to statistical testing.

<sup>F</sup> The data for 30 subjects exposed to 80 ppb by Kim et al. (2011) are presented in Figure 5 of McDonnell et al. (2012).

<sup>G</sup> Adams (2006) reported FEV<sub>1</sub> data for 60 ppb exposure by both constant and varying concentration designs. Subsequent analysis of the FEV<sub>1</sub> data from the former found the group mean O<sub>3</sub> response to be statistically significant ( $p < 0.002$ ) (Brown et al., 2008; 2013 ISA, section 6.2.1.1). The varying-concentration design data were not analyzed by Brown et al., 2008.

<sup>H</sup> Citations for study-specific respiratory symptoms findings are provided in the PA, Appendix 3A, Table 3A-1.

<sup>I</sup> Increased numbers of bronchoalveolar neutrophils, permeability of respiratory tract epithelial lining, cell damage, production of proinflammatory cytokines and prostaglandins (ISA, Appendix 3, section 3.1.4.4.1; 2013 ISA, section 6.2.3.1).

For shorter exposure periods (e.g., from one to two hours), with heavy intermittent or very heavy continuous exercise, higher exposure concentrations, ranging from 80 ppb to 400 ppb, have been studied (ISA, Appendix 3A, section 3.1, Table 3A-3; 2013 ISA, section 6.2.1.1; 2006 AQCD, Chapter 6). Across these shorter-duration studies (which involved ventilation rates 2-3 times greater than in the prolonged [6.6- or 8-hour] exposure studies),<sup>58</sup> the lowest exposure concentration for which statistically significant respiratory effects were reported is 120 ppb, for a 1-hour exposure combined with continuous very heavy exercise and a 2-hour exposure with intermittent heavy exercise. As recognized above the increased ventilation rate associated with increased exertion increases the amount of O<sub>3</sub> entering the lung, where depending on dose and the individual's susceptibility, it may cause respiratory effects (2013 ISA, section 6.2.1.1). Thus, for exposures involving a lower exertion level, a comparable response would not be expected to occur without a longer duration at this concentration (120 ppb), as is illustrated by the 6.6-hour study results for this concentration (Appendix 3A, Table 3A-1).

With regard to epidemiologic studies reporting positive associations between O<sub>3</sub> exposure concentrations and respiratory health outcomes such as asthma-related emergency department visits and hospitalizations, these studies are generally primarily focused on investigating the existence of a relationship between O<sub>3</sub> occurring in ambient air and specific health outcomes, (*versus* detailing the specific exposure circumstances eliciting such effects). Accordingly, while as a whole, this evidence base of epidemiologic studies provides strong support for the conclusions of causality as summarized in section 3.3.1 above,<sup>59</sup> these studies provide less information on details of the specific O<sub>3</sub> exposure circumstances that may be eliciting health effects associated with such outcomes, and whether these occur under air quality conditions that

<sup>58</sup> A quasi-continuous exercise protocol is common to the prolonged exposure studies where study subjects complete six 50-minute periods of exercise, each followed by 10-minute periods of rest (2013 ISA, section 6.2.1.1).

<sup>59</sup> Combined with the coherent evidence from experimental studies, the epidemiologic studies "can support and strengthen determinations of the causal nature of the relationship between health effects and exposure to ozone at relevant ambient air concentrations" (ISA, p. ES-17).

1 meet the current standard.<sup>60</sup> For example, these studies generally do not measure personal  
2 exposures of the study population or track individuals in the population with a defined exposure  
3 to O<sub>3</sub> alone. Further, the vast majority of these studies were conducted in locations and during  
4 time periods that would not have met the current standard. The extent to which reported  
5 associations with health outcomes in the resident populations in these studies are influenced by  
6 the periods of higher concentrations during times that did not meet the current standard is  
7 unknown. While this does not lessen their importance in the evidence base documenting the  
8 causal relationship between O<sub>3</sub> and respiratory effects, it means they are less informative in  
9 considering O<sub>3</sub> exposure concentrations occurring under air quality conditions allowed by the  
10 current standard. Notwithstanding this, we have considered the epidemiologic studies identified  
11 in the ISA as to what they might indicate regarding O<sub>3</sub> exposure concentrations in this regard.

12 Consistent with the evaluation of the epidemiologic evidence of associations between O<sub>3</sub>  
13 exposure and respiratory health effects in the ISA, we focus on those studies conducted in the  
14 U.S. and Canada as including populations and air quality characteristics that may be most  
15 relevant to circumstances in the U.S. (ISA, Appendix 3, section 3.1.2). Among the epidemiologic  
16 studies finding a statistically significant positive relationship of short- or long-term O<sub>3</sub>  
17 concentrations with respiratory effects, there are no single-city studies conducted in the U.S. in  
18 locations with ambient air O<sub>3</sub> concentrations that would have met the current standard for the  
19 entire duration of the study (see Appendix 3B, Table 3B-1; ISA, Appendix 3, Tables 3-13, 3-14,  
20 3-39, 3-41, 3-42 and Appendix 6, Tables 6-5 and 6-6;). There are (among this large group of  
21 studies) two single city studies conducted in western Canada that include locations for which the  
22 highest-monitor design values<sup>61</sup> fell just below 70 ppb, at 65 and 69 ppb (Appendix 3B, Table  
23 3B-1; Kousha and Rowe, 2014; Villeneuve et al., 2007). These studies did not, however, include  
24 analysis of correlations with other co-occurring pollutants or of the strength of the associations  
25 when accounting for effects of copollutants in copollutant models (ISA, Tables 3-14 and 3-39).  
26 Thus, these studies pose significant limitations with regard to informing conclusions regarding  
27 specific O<sub>3</sub> exposure concentrations and elicitation of such effects. There are also a handful of  
28 multicity studies conducted in the U.S. or Canada in which the O<sub>3</sub> concentrations in a subset of  
29 the study locations and for a portion of the study period appear to have met the current standard  
30 (Appendix 3B). Concentrations in other portions of the study area or study period, however, do  
31 not meet the standard, or data were not available in some cities for the earlier years of the study

---

<sup>60</sup> For example, these studies generally do not measure personal exposures of the study population or track individuals in the population with a defined exposure to O<sub>3</sub> alone.

<sup>61</sup> As described in chapter 2, a design value is the metric used to describe air quality in a given area relative to the level of the standard, taking the averaging time and form into account. For example, a design value of 70 ppb just meets the current primary standard.

1 period when design values for other cities in the study were well above 70 ppb. The extent to  
2 which reported associations with health outcomes in the resident populations in these studies are  
3 influenced by the periods of higher concentrations during times that did not meet the current  
4 standard is unknown. Additionally, with regard to multicity studies, the reported associations  
5 were based on the combined dataset from all cities, complicating interpretations regarding the  
6 contribution of concentrations in the small subset of locations that would have met the current  
7 standard compared to that from the larger number of locations that would have violated the  
8 standard (Appendix 3B, Table 3B-1 and Table 3B-2).<sup>62</sup> Further, given that populations in such  
9 studies may have also experienced longer-term, variable and uncharacterized exposure to O<sub>3</sub> (as  
10 well as to other ambient air pollutants), “disentangling the effects of short-term ozone exposure  
11 from those of long-term ozone exposure (and vice-versa) is an inherent uncertainty in the  
12 evidence base” (ISA, p. IS-87 [section IS.6.1]). While given the depth and breadth of the  
13 evidence base for O<sub>3</sub> respiratory effects, such uncertainties do not change our conclusions  
14 regarding the causal relationship between O<sub>3</sub> and respiratory effects.

15 With regard to the experimental animal evidence (largely rodent studies) and exposure  
16 conditions associated with respiratory effects, the exposure concentrations in the animal studies  
17 are generally much greater than those examined in the controlled human exposure studies  
18 (summarized above) and higher than concentrations commonly occurring in ambient air in areas  
19 of the U.S. where the current standard is met. This is also true for the small number of early life  
20 studies in nonhuman primates (recognized in section 3.3.1.1 above) that reported O<sub>3</sub> to contribute  
21 to allergic asthma-like effects in infant primates.<sup>63</sup> The exposures eliciting the effects in these  
22 studies included multiple 5-day periods with O<sub>3</sub> concentrations of 500 ppb over 8-hours per day,  
23 exposure conditions appreciably greater than occur in areas of the U.S. where the current  
24 standard is met (ISA, Appendix 3, section 3.2.4.1.2).

25 With regard to short-term O<sub>3</sub> and metabolic effects, the category of nonrespiratory effects  
26 for which the ISA concludes there to be a likely causal relationship with O<sub>3</sub>, the evidence base is  
27 comprised primarily of experimental animal studies, as summarized in section 3.3.1.2 above  
28 (ISA, Appendix 5, section 5.1). The exposure conditions from these studies, however, generally  
29 involve much higher O<sub>3</sub> concentrations than those examined in the controlled human exposure  
30 studies for respiratory effects (and much higher than concentrations occurring in ambient air in

---

<sup>62</sup> As recognized in the 2015 review, “multicity studies do not provide a basis for considering the extent to which reported O<sub>3</sub> health effects associations are influenced by individual locations with ambient [air] O<sub>3</sub> concentrations low enough to meet the current O<sub>3</sub> standard versus locations with O<sub>3</sub> concentrations that violate this standard” (80 FR 64344, October 26, 2015).

<sup>63</sup> These studies indicate that sufficient early-life O<sub>3</sub> exposure can cause structural and functional changes that could potentially contribute to airway obstruction and increased airway responsiveness (ISA, Table IS-10, p. 3-92 and p.3-113).

1 areas of the U.S. where the current standard is met). For example, the animal studies include 4-  
2 hour concentrations of 400 to 800 ppb (ISA, Appendix 5, Table 5-8).<sup>64</sup> The two epidemiologic  
3 studies reporting statistically significant positive associations of O<sub>3</sub> with metabolic effects (e.g.,  
4 changes in glucose, insulin, metabolic clearance) are based in Taiwan and South Korea,  
5 respectively.<sup>65</sup> Given the potential for appreciable differences in air quality patterns between  
6 Taiwan and South Korea and the U.S., as well as differences in other factors that might affect  
7 exposure (e.g., activity patterns), those studies are of limited usefulness for informing our  
8 understanding of exposure concentrations and conditions eliciting such effects in the U.S. (ISA,  
9 Appendix 5, section 5.1).

10 Thus, as in the 2015 review, the exposure to which we give greatest attention, particularly  
11 with regard to considering O<sub>3</sub> exposures expected under air quality conditions that meet the  
12 current standard, are those informed by the controlled human exposure studies. The full body of  
13 evidence described in the current ISA continues to indicate respiratory effects as the effects  
14 associated with lowest exposures, with conditions of exposure (e.g., duration, ventilation rate,  
15 and concentration) influencing dose and associated response. Evidence for other categories of  
16 effects does not indicate effects at comparably low exposures.

### 17 **3.3.4 Uncertainties in the Health Effects Evidence**

- 18 • **To what extent have previously identified uncertainties in the health effects evidence**  
19 **been reduced or do important uncertainties remain?**

20 We have not identified any new uncertainties in the evidence since the 2015 review.  
21 However, we continue to recognize important uncertainties that also existed at that time. This  
22 array of important areas of uncertainty relates to the available health evidence, including that  
23 newly available in the 2020 review, and is summarized below.

24 Although the evidence clearly demonstrates that short-term O<sub>3</sub> exposures cause  
25 respiratory effects, as was the case in the last review, we continue to recognize uncertainties that  
26 remain in several aspects of our understanding of these effects. Such uncertainties include those  
27 associated with the severity and prevalence of responses to short (e.g., 6.6- to 8-hour) O<sub>3</sub>  
28 exposures at and below 60 ppb and responses of some population groups not well represented in  
29 the evidence base of controlled human exposure studies (e.g., children and people with asthma).

---

<sup>64</sup> The exposure concentration in the single controlled human exposure study of metabolic effects (e.g., 300 ppb) are also well above those examined in the respiratory effect studies (ISA, Appendix 5, Table 5-7).

<sup>65</sup> Of the five epidemiologic studies discussed in the ISA that investigate associations between short-term O<sub>3</sub> exposure and metabolic effects, three are conducted in Asia or South America and two are conducted in the U.S. The two U.S. studies report either a null or negative association of metabolic markers with O<sub>3</sub> concentration, and while the South American study (focused on hospital admissions associated with diabetes complications) reported positive associations with 24-hr average concentrations for some subgroups, no associations were statistically significant (ISA, Appendix 5, Tables 5-6 and 5-9).



1 There are also uncertainties concerning the potential influence of exposure history and co-  
2 exposure to other pollutants on the relationship between short-term O<sub>3</sub> exposure and respiratory  
3 effects. With regard to the full health effects evidence base, we also recognize as an important  
4 uncertainty the extent to which O<sub>3</sub> exposures are related to health effects other than respiratory  
5 effects. The following discussion touches on each of these types of uncertainty.

6 The majority of the available studies have generally involved healthy young adult  
7 subjects, although there are some studies involving subjects with asthma, and a limited number  
8 of studies, generally of very short durations (i.e., less than four hours), involving adolescents and  
9 adults older than 50. While there is evidence from short (6.6- to 8-hour) controlled exposure  
10 studies of healthy adult subjects to concentrations as low as 40 ppb, the only controlled human  
11 exposure study of such a duration (7.6 hours with quasi-continuous light exercise) conducted in  
12 people with asthma was for an exposure concentration of 160 ppb (Appendix 3A, Table 3A-2).  
13 Given the paucity of studies using subjects that have asthma, particularly those at exposure  
14 concentrations likely to occur under conditions meeting the current standard, uncertainties  
15 remain with regard to characterizing the response in people with asthma while at elevated  
16 ventilation to lower exposure concentrations, e.g., below 80 ppb. The extent to which the  
17 epidemiologic evidence, including that recently available, can inform this area of uncertainty  
18 also may be limited.<sup>66</sup> As discussed in section 3.3.2 above, given the effects of asthma on the  
19 respiratory system, exposures associated with relatively mild respiratory responses in largely  
20 healthy people may pose an increased risk of more severe responses, including asthma  
21 exacerbation, in people with asthma. Such considerations remain areas of uncertainty at this  
22 time. Thus, uncertainty remains with regard to the extent to which the controlled human  
23 exposure study evidence describes the responses of the populations, such as children with  
24 asthma, that may be most at risk of O<sub>3</sub>-related respiratory effects (e.g., through an increased  
25 likelihood of severe responses, or greatest likelihood of response).

26 Other areas of uncertainty concerning the potential influence of O<sub>3</sub> exposure history and  
27 co-exposure to other pollutants on the relationship between short-term O<sub>3</sub> exposures and  
28 respiratory effects also remain in the evidence base. As in the epidemiologic evidence in the  
29 2015 review, there is a limited number of studies that include copollutant analyses for a small set  
30 of pollutants (e.g., PM or NO<sub>2</sub>). Recent studies with such analyses suggest that observed  
31 associations between O<sub>3</sub> concentrations and respiratory effects are independent of co-exposures

---

<sup>66</sup> Associations of health effects with O<sub>3</sub> that are reported in the epidemiologic analyses are based on air quality concentration metrics used as surrogates for the actual pattern of O<sub>3</sub> exposures experienced by study population individuals over the period of a particular study. Therefore, the studies are limited in what they can convey regarding the specific patterns of exposure circumstances (e.g., magnitude of concentrations over specific duration and frequency) that might be eliciting reported health outcomes.

1 to correlated pollutants or aeroallergens (ISA, sections IS.4.3.1 and IS.6.1; Appendix 3, sections  
2 3.1.10.1 and 3.1.10.2). Despite the increased prevalence of copollutant modeling in recent  
3 epidemiologic studies, however, uncertainty still exists with regard to the independent effect of  
4 O<sub>3</sub> given the high correlations observed for some copollutants in some studies and the small  
5 fraction of all atmospheric pollutants included in these analyses (ISA, section IS.4.3.1; Appendix  
6 2, section 2.5). We also note that neither of the two epidemiologic studies of respiratory  
7 outcomes conducting in Canadian areas that would have met the current standard included  
8 copollutant modeling (as recognized in section 3.3.3 above).

9 Further, although there remains uncertainty in the evidence with regard to the potential  
10 role of exposures to O<sub>3</sub> in eliciting health effects other than respiratory effects, the evidence has  
11 been strengthened since the 2015 review with regard to metabolic effects. As noted in section  
12 3.3.1.2 above, the ISA newly identifies metabolic effects as likely to be causally related to short-  
13 term O<sub>3</sub> exposures. The evidence supporting this relationship is limited and not without its own  
14 uncertainties. For example, as noted in section 3.3.1.2 above, the conclusion is based primarily  
15 on animal toxicological studies conducted at much higher O<sub>3</sub> concentrations than those common  
16 in ambient air in the U.S. A limited number of epidemiologic studies of short-term O<sub>3</sub>  
17 concentrations and metabolic effects are available, many of which did not control for  
18 copollutants confounding; just two studies, both in Asia, report significant positive associations  
19 with changes in markers of glucose homeostasis (ISA, Appendix 5; sections 5.1.8 and 5.3).

20 Uncertainty is increased with regard to a relationship between O<sub>3</sub> exposure and  
21 cardiovascular effects and mortality, as discussed in section 3.3.1.2 above, including regarding a  
22 now-larger body of controlled human exposure studies providing evidence that is not consistent  
23 with a cardiovascular effect in response to short-term O<sub>3</sub> exposure; and a paucity of  
24 epidemiologic evidence indicating more severe cardiovascular morbidity endpoints, that would  
25 be expected if the impaired vascular and cardiac function (observed in animal toxicological  
26 studies) was the underlying basis for cardiovascular mortality (for which epidemiologic studies  
27 have reported some positive associations with O<sub>3</sub>). Additionally, uncertainties and limitations  
28 recognized in the 2013 ISA (e.g., lack of control for potential confounding by copollutants in  
29 epidemiologic studies) still remain (ISA, section IS.1.3.1). As discussed in section 3.3.1.2, these  
30 uncertainties also pertain to conclusions regarding short-term O<sub>3</sub> and mortality (ISA, Appendix  
31 6, section 6.1.8). Uncertainties are unchanged with regard to other nonrespiratory categories of  
32 effects (described in section 3.3.1.2 above) for which the evidence is either suggestive of, but not  
33 sufficient to infer, a causal relationship or is inadequate to determine if a causal relationship  
34 exists with O<sub>3</sub> (ISA, section IS.4.3).

35 In summary, while there are some changes with regard to limitations and uncertainties of  
36 the health effects evidence base, some key uncertainties associated with the evidence for

1 respiratory effects that were identified in the 2015 review remain, including those related to the  
2 extent of effects at concentrations below those evaluated in controlled human exposure studies,  
3 and the potential for more severe impacts in individuals with asthma, including particularly  
4 children, and in other at-risk populations.

### 5 **3.4 EXPOSURE AND RISK INFORMATION**

6 Our consideration of the scientific evidence, as in each review of the O<sub>3</sub> NAAQS, is  
7 informed by results from quantitative analyses of estimated population exposure and consequent  
8 risk. Estimates from the exposure-based analyses, particularly the comparison of daily maximum  
9 exposures to benchmark concentrations, were most informative to the Administrator’s decision  
10 in the 2015 review (as summarized in section 3.1 above). This largely reflected the EPA  
11 conclusion that “controlled human exposure studies provide the most certain evidence indicating  
12 the occurrence of health effects in humans following specific O<sub>3</sub> exposures,” and recognition that  
13 “effects reported in controlled human exposure studies are due solely to O<sub>3</sub> exposures, and  
14 interpretation of study results is not complicated by the presence of co-occurring pollutants or  
15 pollutant mixtures (as is the case in epidemiologic studies)” (80 FR 65343, October 26, 2015).<sup>67</sup>  
16 Therefore, the quantitative analyses developed in the 2020 review focused on exposure-based  
17 risk analyses, in reflection of the emphasis given to these types of analyses and the  
18 characterization of their uncertainties in the 2015 review, along with the availability of new or  
19 updated information, models, and tools that address those uncertainties (IRP, Appendix 5A).

20 This reconsideration of the 2020 decision will rely on the exposure-based risk analyses  
21 performed in the 2020 review, which were first presented in the 2020 PA and considered in the  
22 2020 decision. These analyses are also presented here and described in detail in the associated  
23 Appendices 3C and 3D. In section 3.4.1, we summarize the conceptual model for the assessment,  
24 as well as key aspects of the assessment design, including the study areas, populations simulated,

---


<sup>67</sup> In the 2015 review, the Administrator placed relatively less weight on the air quality epidemiologic-based risk estimates, in recognition of an array of uncertainties, including, for example, those related to exposure measurement error (80 FR 65346, October 26, 2015). In so doing, she recognized key uncertainties in utilizing the estimated air concentrations and epidemiologic study relationships (often called epidemiologic-based risk estimates) (80 FR 65316; 79 FR 75277-75279; 2014 HREA, sections 3.2.3.2 and 9.6). These included the heterogeneity in effect estimates between locations, the potential for exposure measurement errors, and uncertainty in the interpretation of the shape of concentration-response functions at lower O<sub>3</sub> concentrations, as well as uncertainties related to the public health importance of increases in relatively low O<sub>3</sub> concentrations following air quality adjustment. Lower confidence was also placed in the results of the epidemiologic-based risk assessment of respiratory mortality risks associated with long-term O<sub>3</sub> exposures in consideration of several factors. Importantly since that time, the causal determinations for short-term O<sub>3</sub> exposure with mortality in the current ISA differ from the 2013 ISA. The current determinations for both short-term and long-term O<sub>3</sub> exposure (as summarized in section 3.1 above) are that the evidence is “suggestive” but not sufficient to infer causal relationships for O<sub>3</sub> with mortality (ISA, Table IS-1).

1 modeling tools, and exposure and risk metrics derived. Sections 3.4.2 and 3.4.3 summarize the  
2 assessment results. Key limitations and uncertainties associated with the assessment estimates  
3 are identified in section 3.4.4. and potential public health implications are discussed in section  
4 3.4.5. An overarching consideration is whether the current exposure and risk information alters  
5 overall conclusions reached in the 2015 review regarding the health risk associated with  
6 exposure to O<sub>3</sub> in ambient air which formed an important foundation in the establishment at that  
7 time of the existing standard.

### 8 **3.4.1 Conceptual Model and Assessment Approach**

9 The long-standing evidence base for O<sub>3</sub>-related health effects is comprised of a large  
10 assemblage of controlled human exposure studies, laboratory animal research studies, and air  
11 quality epidemiologic studies. Together, these health effect studies lead to the strongly supported  
12 conclusion that O<sub>3</sub> exposure causes respiratory effects (as summarized in section 3.3 above).  
13 This conclusion is strongest with regard to short-term O<sub>3</sub> exposures, for which the ISA and  
14 science assessments in prior reviews have determined there to be a causal relationship. The ISA  
15 additionally determines the relationship between long-term exposure and respiratory effects, as  
16 well as between short-term exposures and metabolic effects to be likely causal, recognizing that  
17 associated uncertainties remain in the evidence. Given the relatively greater strength of the  
18 evidence and understanding of the relevant exposure conditions, as well as availability of  
19 appropriate data and modeling tools, the exposure and risk analysis is focused on respiratory  
20 risks associated with short-term O<sub>3</sub> exposures.

21 The controlled human exposure studies document the occurrence of an array of  
22 respiratory effects in humans in a variety of short-term exposure circumstances. These studies, in  
23 combination with the laboratory animal studies, inform our understanding of the mode of action  
24 for O<sub>3</sub>-attributable effects, including those health outcomes associated with ambient air  
25 concentrations in air quality epidemiologic studies (ISA, Appendix 3, section 3.1.3). Figure 3-3  
26 below illustrates the conceptual model for O<sub>3</sub> in ambient air and respiratory effects, with a  
27 particular focus on short-term exposures and including linkages with the risk metrics assessed in  
28 the quantitative analyses described here.




**Figure 3-3. Conceptual model for exposure-based risk assessment.** Solid lines indicate processes explicitly modeled in the assessment. Dashed lines indicate relationships that are not explicitly modeled.

The exposure-based analyses, described in detail in Appendix 3D, were developed based on this conceptual model, in consideration of the information newly available in the 2020 review. In these analyses, we have estimated O<sub>3</sub> exposures and resulting risk for air quality conditions of interest, most particularly air quality conditions that just meet the current primary O<sub>3</sub> standard. These analyses inform our understanding of the protection provided by the current primary standard from effects that the health effects evidence indicates to be elicited in some portion of exercising people exposed for several hours to elevated O<sub>3</sub> concentrations.

The analysis approach employed is summarized in Figure 3-4 below and described in detail in Appendices 3C and 3D. This approach incorporates the use of an array of models and data to develop population exposure and risk estimates for a set of eight urban study areas. Ambient air O<sub>3</sub> concentrations were estimated in each study area using an approach that relies on a combination of ambient air monitoring data, atmospheric photochemical modeling and

statistical methods (described in detail in Appendix 3C). Population exposure and risk modeling is employed to characterize exposures and related lung function risk associated with the ambient air concentration estimates (described in detail in Appendix 3D). While the lung function risk analysis focuses only on the specific O<sub>3</sub> effect of FEV<sub>1</sub> reduction, the comparison-to-benchmark approach, with its use of multiple benchmark concentrations, provides for characterization of the risk of other respiratory effects, the type and severity of which increase with increased exposure concentration.



**Figure 3-4. Analysis approach for exposure-based risk analyses.** Dashed lines and gray box indicate the sole lung function risk approach used prior to 2014 HREA.

The analyses estimate exposure and risk for simulated populations in eight study areas in Atlanta, Boston, Dallas, Detroit, Philadelphia, Phoenix, Sacramento and St. Louis. The eight study areas represent a variety of circumstances with regard to population exposure to short-term

1 concentrations of O<sub>3</sub> in ambient air. The eight study areas range in total population size from  
2 approximately two to eight million and are distributed across the U.S. in seven of the nine  
3 different NOAA climate regions: the Northeast, Southeast, Central, East North Central, South,  
4 Southwest and West (Karl and Koss, 1984). Assessment of this set of study areas and the  
5 associated exposed populations is intended to be informative to the EPA's consideration of  
6 potential exposures and risks that may be associated with the air quality conditions that meet the  
7 current primary standard.

8 This set of eight study areas represents a streamlined set as compared to the 15 study  
9 areas in the 2015 review, with the areas chosen to ensure they reflect the full range of air quality  
10 and exposure variation expected across major urban areas in the U.S. (2014 HREA, section 3.5).  
11 As a specific example, while seven of the eight study areas were also included in the 2014  
12 HREA, the eighth study area was not, and has been included in the more recent assessment to  
13 insure representation of a large city in the southwest. Additionally, the years simulated reflect  
14 more recent emissions and atmospheric conditions subsequent to data used in the 2014 HREA,  
15 and therefore represent O<sub>3</sub> concentrations somewhat nearer the current standard than was the  
16 case for study areas included in the HREA of the 2015 review (Appendix 3C, Table 3C and 2014  
17 HREA, Table 4-1). Thus, the urban study areas (e.g., combined statistical areas that include  
18 urban and suburban populations) the exposure and risk analyses discussed here reflect an array of  
19 air quality, meteorological, and population exposure conditions.

20 Consistent with the health effects evidence (summarized in section 3.3 above), the focus  
21 of the assessment is on short-term exposures of individuals in the population during times when  
22 they are breathing at an elevated rate. Exposure and risk are characterized for four population  
23 groups that include representation of key at-risk populations (children and people with asthma),  
24 as described in section 3.3.2 above. Two of the four groups are populations of school-aged  
25 children, aged 5 to 18 years:<sup>68</sup> all children and children with asthma. Two are populations of  
26 adults: all adults and adults with asthma. Another population identified as at risk for O<sub>3</sub>, outdoor  
27 workers, was not included due to appreciable data limitations, a decision also made for past  
28 exposure assessments.<sup>69</sup>

---

<sup>68</sup> The child population group focuses on ages 5 to 18 in recognition of data limitations and uncertainties, including those related to accurately simulating activities performed, estimating physiological attributes, and also challenges in asthma diagnoses for children younger than 5 years old.

<sup>69</sup> Outdoor workers, due to the requirements of their job spend more time outdoors at elevated exertion. For a number of reasons, including the appreciable data limitations (e.g., related to specific durations of time spent outdoors and activity data), and associated uncertainties summarized in Table 3D-64 of Appendix 3D, this group was not simulated in this assessment. Limited exploratory analyses of a hypothetical outdoor worker population in the 2014 HREA (single study area, single year) for the 75 ppb air quality scenario estimated an appreciably greater portion of this population to experience exposures at or above benchmark concentrations than the full

1 Asthma prevalence estimates for each of the entire populations in the eight study areas  
2 ranges from 7.7 to 11.2%; the rates for children in these study areas range from 9.2 to 12.3%  
3 (Appendix 3D, section 3D.3.1). Spatial variation within each study area related to the population  
4 distribution of age, sex, and family income was also taken into account.<sup>70</sup> For children, this  
5 variation is greatest in the Detroit study area, with census tract level, age-specific asthma  
6 prevalence estimates ranging from 6.4 to 13.2% for girls and from 7.7 to 25.5% for boys  
7 (Appendix 3D, Table 3D-3).

8 Ambient air O<sub>3</sub> concentrations were estimated in each study area for the air quality  
9 conditions of interest by adjusting hourly ambient air concentrations, from monitoring data for  
10 the years 2015-2017, using a photochemical model-based approach and then applying a spatial  
11 interpolation technique to produce air quality surfaces with high spatial and temporal resolution  
12 (Appendix 3C).<sup>71</sup> The photochemical modeling outputs included both modeled O<sub>3</sub> concentrations  
13 and sensitivities of O<sub>3</sub> concentrations to changes in NO<sub>x</sub> emissions for each hour in a single year  
14 at all ambient air monitor locations (Appendix 3C, sections 3C.4 and 3C.5). Linear regression  
15 was used with these single-year model outputs to create relationships between the sensitivities  
16 and O<sub>3</sub> concentrations at each monitoring location for each hour of the day during each of the  
17 four seasons. The relationships between hourly sensitivities and hourly O<sub>3</sub> for each season were  
18 then used with three years of ambient air monitoring data at each location to predict hourly  
19 sensitivities for the complete 3-year record at each monitoring location. From these, we  
20 calculated hourly O<sub>3</sub> concentrations at each monitor location based on iteratively increasing NO<sub>x</sub>  
21 reductions to determine the adjustments necessary for the monitor location with the highest  
22 design value in each study area to just meet the target value, e.g., 70 ppb for the current standard  
23 scenario (Appendix 3C, section 3C.5). Hourly O<sub>3</sub> concentrations for all census tracts comprising  
24 each study area were then derived from the model adjusted hourly concentrations at the ambient  
25 air monitor locations using the Voronoi Neighbor Averaging (VNA) spatial interpolation  
26 technique (Appendix 3C, section 3C.6). The final products were datasets of ambient air O<sub>3</sub>  
27 concentration estimates with high temporal and spatial resolution (hourly concentrations in 500

---

adult or child populations simulated, although there are a number of uncertainties associated with the estimates due to appreciable limitations in the data underlying the analyses (2014 HREA, section 5.4.3.2). It is expected that if an approach similar to that used in the 2014 HREA had been used for this assessment a generally similar pattern might be observed, although with somewhat lower overall percentages based on the comparison of current estimates with estimates from the 2014 HREA (Appendix 3D, section 3D.3.2.4).

<sup>70</sup> As described in Appendix 3D, section 3D.2.2.2, asthma prevalence in each study area is estimated based on combining regional national prevalence information from NHIS with U.S census tract level population data by linking demographic information related to age, sex, and family income. Then, further adjustments were made using state-level prevalence obtained from the U.S. Behavioral Risk Factor Surveillance System. See Appendix 3D, Attachment 1 for details.

<sup>71</sup> A similar approach was used to develop the air quality scenarios for the 2014 HREA.



1 to 1700 census tracts) for each of the eight study areas (Appendix 3C, section 3C.7) representing  
2 each of the three air quality scenarios assessed.<sup>72</sup>

3 The photochemical modeling approach involved use of the Comprehensive Air Quality  
4 Model with Extensions (CAMx), version 6.5, instrumented with the higher order decoupled  
5 direct method (HDDM).<sup>73</sup> The CAMx-HDDM was run with emissions estimates and  
6 meteorology data for calendar year 2016 to estimate the O<sub>3</sub> sensitivities,<sup>74</sup> and the linear  
7 regressions of the modeled O<sub>3</sub> concentrations to their respective sensitivities were applied to  
8 hourly O<sub>3</sub> concentrations reported at ambient air monitors for the 2015-2017 period to determine  
9 the adjustments needed for each air quality scenario (Appendix 3C, sections 3C.4 and 3C.5). We  
10 maximized the spatial representation of the monitoring data by using all available monitors  
11 within each study area (between 12 and 30) in addition to those within 50 km of the study area  
12 boundaries (yielding between 5 and 31 additional monitors per area). Because we selected study  
13 areas having design values close to the level of the current standard, the levels of NO<sub>x</sub> emissions  
14 adjustments needed to meet the air quality scenarios of interest were generally lower than those  
15 used in the 2014 HREA, thus reducing one of the important sources of uncertainty associated  
16 with these air quality estimates.

17 Population exposures were estimated using the EPA's Air Pollutant Exposure model  
18 (APEX) version 5, which probabilistically generates a large sample of hypothetical individuals  
19 from demographic and activity pattern databases and simulates each individual's movements  
20 through time and space to estimate their time-series of O<sub>3</sub> exposures occurring within indoor,  
21 outdoor, and in-vehicle microenvironments (Appendix 3D, section 3D.2).<sup>75</sup> The APEX model  
22 accounts for the most important factors that contribute to human exposure to O<sub>3</sub> from ambient  
23 air, including the temporal and spatial distributions of people and ambient air O<sub>3</sub> concentrations  
24 throughout a study area, the variation of ambient air-related O<sub>3</sub> concentrations within various  
25 microenvironments in which people conduct their daily activities, and the effects of activities

---

<sup>72</sup> For this assessment, high spatial and temporal resolution O<sub>3</sub> concentration datasets were created for conditions representing each area meeting the current standard of 70 ppb and two alternative air quality scenarios characterized by ozone concentrations that would result in design values of 75 and 65 ppb representing a level slightly above and a level slightly below the current standard.

<sup>73</sup> Details on the models, methods and input data used to estimate ambient air concentrations for the eight study areas are provided in Appendix 3C. The "higher order" aspect of the HDDM tool refers to the capability of capturing nonlinear response curves (Appendix 3C, section 3C.5.1).

<sup>74</sup> Sensitivities of O<sub>3</sub> refer to predicted incremental changes in O<sub>3</sub> concentrations in response to incremental changes in precursor emissions (e.g., NO<sub>x</sub> emissions).

<sup>75</sup> The APEX model is a probabilistic model that estimates population exposure using a stochastic, event-based microenvironmental approach. This model has a history of application, evaluation, and progressive model development in estimating human exposure, dose, and risk for reviews of NAAQS for gaseous pollutants, including the 2015 review of the O<sub>3</sub> NAAQS (U.S. EPA, 2008; U.S. EPA, 2009; U.S. EPA, 2010; U.S. EPA, 2014; U.S. EPA, 2018).

1 involving different levels of exertion on breathing rate (or ventilation rate) for the exposed  
2 individuals of different sex, age, and body mass in the study area (Appendix 3D, section 3D.2).  
3 The APEX model generates each simulated person or profile by probabilistically selecting values  
4 for a set of profile variables, including demographic variables, health status and physical  
5 attributes (e.g., residence with air conditioning, height, weight, body surface area) and activity-  
6 specific ventilation rate (Appendix 3D, section 3D.2).

7 By incorporating individual activity patterns<sup>76</sup> and estimating physical exertion for each  
8 exposure event,<sup>77</sup> the model addresses an important determinant of individual's exposure (2013  
9 ISA, section 4.4.1). This aspect of the exposure modeling is critical in estimating exposure,  
10 ventilation rate, O<sub>3</sub> intake (dose), and health risk resulting from ambient air concentrations of  
11 O<sub>3</sub>.<sup>78</sup> Because of variation in O<sub>3</sub> concentrations among the different microenvironments in which  
12 individuals are active, the amount of time spent in each location, as well as the exertion level of  
13 the activity performed, will influence an individual's exposure to O<sub>3</sub> from ambient air and  
14 potential for adverse health effects. Activity patterns vary both among and within individuals,  
15 resulting in corresponding variations in exposure across a population and over time (2013 ISA,  
16 section 4.4.1). For each exposure event, APEX tracks activity performed, ventilation rate,  
17 exposure concentration, and duration for all simulated individuals throughout the assessment  
18 period. This time-series of exposure events serves as the basis for calculating exposure and risk  
19 metrics of interest.

20 The APEX model estimates of population exposures for simulated individuals breathing  
21 at elevated rates<sup>79</sup> are used to characterize health risk based on information from the controlled  
22 human exposure studies on the incidence of lung function decrements in study subjects who are  
23 exposed over multiple hours while intermittently or quasi-continuously exercising (Appendix  
24 3D, section 3D.2.8). In drawing on this evidence base for this purpose, the assessment gives

---

<sup>76</sup> To represent personal time-location-activity patterns of simulated individuals, the APEX model draws from the CHAD developed and maintained by the EPA (McCurdy, 2000; U.S. EPA, 2019). The CHAD is comprised of data from several surveys that collected activity pattern data at city, state, and national levels. Included are personal attributes of survey participants (e.g., age, sex), the locations visited, and activities performed by survey participants throughout a day, and the time-of-day activities occurred and their duration (Appendix 3D, section 3D.2.5.1).

<sup>77</sup> An exposure event occurs when a simulated individual inhabits a microenvironment for a specified time, while engaged at a constant exertion level and experiencing a particular pollutant concentration. If the microenvironmental concentration and/or activity/activity level changes, a new exposure event occurs (McCurdy and Graham, 2003).

<sup>78</sup> Indoor sources are generally minor in comparison to O<sub>3</sub> from ambient air (ISA, Appendix 2, section 2.4.3) and are not accounted for by the exposure modeling in this assessment.

<sup>79</sup> Based on minute-by-minute activity levels, and physiological characteristics of the simulated person, APEX estimates an equivalent ventilation rate (EVR), by normalizing the simulated individuals' activity-specific ventilation rate to their body surface area (Appendix 3D, section 3D.2.2.3.3).

primary focus to the well-documented controlled human exposure studies summarized in Appendix 3A, Table 3A-1 for 6.6-hour average exposure concentrations ranging from 40 ppb to 120 ppb (Figure 3-2; ISA, Appendix 3, Figure 3-3). Health risk is characterized in two ways, producing two types of risk metrics: one involving comparison of population exposures involving elevated exertion to benchmark concentrations (that are specific to elevated exertion exposures), and the second involving estimated population occurrences of ambient air O<sub>3</sub>-related lung function decrements (Figure 3-2). The first risk metric estimates population occurrences of daily maximum 7-hour average exposure concentrations (during periods of elevated breathing rates) at or above concentrations of potential concern (benchmark concentrations). The second metric (lung function risk) uses E-R information for O<sub>3</sub> exposures and FEV<sub>1</sub> decrements to estimate the portion of the simulated at-risk population expected to experience one or more days with an O<sub>3</sub>-related FEV<sub>1</sub> decrement of at least 10%, 15% and 20%. Both of these metrics are used to characterize health risk associated with O<sub>3</sub> exposures among the simulated population during periods of elevated breathing rates. Similar risk metrics were also derived in the HREA for the 2015 review and the associated estimates informed the Administrator's 2015 decision on the current standard (80 FR 65292, October 26, 2015).

The general approach and methodology for the exposure-based assessment is similar to that used in the 2015 review although a number of updates and improvements, related to the air quality, exposure and risk aspects of the assessment, have been implemented (Appendices 3C and 3D). These are summarized here.

- The ambient air monitoring data used is from a more recent period (e.g., 2015-2017) during which O<sub>3</sub> concentrations in the eight study areas are at or near the current standard (Appendix 3C, Table 3C-1). This contrasts with the 2014 HREA use of 2006-2010 air monitoring data, that for many study areas included design values (for unadjusted concentrations) well above (e.g., by more than 10 ppb) the level of the then-existing standard (2014 HREA, section 4.3.1.1, Table 4-1). The use of more recent ambient air monitoring data in the current analysis allows for smaller adjustments to develop the air quality conditions of interest, thus contributing to generally lesser uncertainty in the concentrations estimated in each air quality scenario.
- The most recent CAMx model, with updates to the treatment of atmospheric chemistry and physics within the model, is used to derive spatially and temporally varying relationships between changes to emissions and modeled O<sub>3</sub> concentrations, which are then used in adjusting ambient air concentrations to just meet the air quality scenarios. Model inputs represent recent year emissions, meteorology, and international transport (e.g., 2016). The 2016-based inputs were derived using updated methods for calculating emissions, as well as updated meteorological and hemispheric photochemical models (described in more detail in Appendix 3C).
- A significantly expanded CHAD, with now nearly 180,000 diaries, including over 25,000 for school-aged children is drawn on in the exposure modeling (Appendix 3D, section

3D.2.5.1), as are updated National Health and Nutrition Examination Survey data (2009-2014), which are the basis for the age- and sex-specific body weight distributions used to specify the individuals in the modeled populations (Appendix 3D, section 3D.2.2.3.1).

- Population exposure modeling inputs include the most recent U.S. Census demographics and commuting data (i.e., 2010), meteorological data to reflect the assessment years studied (e.g., 2015-2017), and updated estimates of asthma prevalence for all census tracts in all study areas (e.g., 2013-2017). Regarding asthma prevalence, the more recent information includes increased prevalence reported for adults and for children aged 10-17 years (Akinbami et al., 2016; CDC, 2016).<sup>80</sup>
- The APEX equations used to estimate of ventilation rate ( $\dot{V}_E$ ) and resting metabolic rate have been updated such that the overall statistical model fit and predictability has been improved (U.S. EPA, 2018, Appendix H).
- The approach for deriving population exposure estimates, both for comparison to benchmark concentrations and for use in deriving lung function risk using the E-R function, has been modified to provide for a better match of the simulated population exposure estimates with the 6.6-hour duration of the controlled human exposure studies and with the study subject ventilation rates (Appendix 3D, section 3D.2.8.1). The modifications include deriving estimates for exposures of a duration and ventilation rate more closely corresponding to the duration and average ventilation rate across the 6.6-hour duration in the controlled human exposure studies (Appendix 3D, section 3D.2.8.1).<sup>81</sup>
- In addition to the E-R function, as updated in the 2014 HREA, an updated version of the McDonnell Stewart Smith model (MSS-FEV<sub>1</sub> model, McDonnell et al., 2013) is used to estimate individual-based lung function risk. Although the impact on risk estimates is unclear, the updated MSS model has been described as better accounting for intra-subject variability, yielding an improved model fit (McDonnell et al., 2013; Appendix 3D, section 3D.2.8.2.2).

The comparison-to-benchmarks analysis characterizes the extent to which individuals in at-risk populations could experience O<sub>3</sub> exposures, while engaging in their daily activities, with the potential to elicit the effects reported in controlled human exposure studies for concentrations at or above specific benchmark concentrations. Results are characterized through comparison of exposure concentrations to three benchmark concentrations of O<sub>3</sub>: 60, 70, and 80 ppb. These are based on the three lowest concentrations targeted in studies of 6- to 6.6-hour exposures, with quasi-continuous exercise (at moderate level of exertion), and that yielded different occurrences

---

<sup>80</sup> For more information, see <https://www.cdc.gov/nchs/products/databriefs/db239.htm>.

<sup>81</sup> Estimated exposures for a 7-hour duration are used in the comparison to benchmark concentrations (that are based on the 6.6-hour exposure studies). The use of 7-hour exposure duration provides for a closer match of the duration for the benchmark concentrations to the duration of population exposure concentration estimates than the 8-hour exposure concentrations used in the last review. Additionally, an equivalent ventilation rate (EVR) of at least 17.3 L/min-m<sup>2</sup> is used to more closely correspond to the average across the 6.6 hours of the controlled human exposure studies (Appendix 3D, section 3D.2.8.1).

of statistical significance, and severity of respiratory effects (section 3.3.3 above; Appendix 3A, section 3A.1; Appendix 3D, section 3D.2.8.1). The lowest benchmark, 60 ppb, represents the lowest exposure concentration for which controlled human exposure studies have reported statistically significant respiratory effects (as summarized in section 3.3.3 above). Exposure to approximately 70 ppb<sup>82</sup> averaged over a similar time resulted in a larger group mean lung function decrement, as well as a statistically significant increase in prevalence of respiratory symptoms over what was observed for 60 ppb (Figure 3-3; ISA, Appendix 3, section 3.1.4.1.1; Schelegle et al., 2009). Studies of exposures to approximately 80 ppb have reported larger lung function decrements at the study group mean than following exposures to 60 or 70 ppb, in addition to an increase in airway inflammation, increased respiratory symptoms, increased airway responsiveness, and decreased resistance to other respiratory effects (Figure 3-3 and section 3.3.3, above; ISA, Appendix 3, sections 3.1.4.1-3.1.4.4).

The APEX-generated exposure concentrations for comparison to these benchmark concentrations is the average of concentrations encountered by an individual while at an activity level that elicits the specified elevated ventilation rate.<sup>83</sup> The incidence of such exposures at or above the benchmark concentrations are summarized for each simulated population, study area, and air quality scenario as discussed in sections 3.4.2 and 3.4.3 below (Appendix 3D).

The lung function risk analysis estimates (in two different ways) the extent to which individuals in exposed populations could experience different sizes of O<sub>3</sub>-induced lung function decrements. The two different approaches utilize the evidence from the 6.6-hour controlled human exposure studies in different ways.<sup>84</sup> One, the population-based E-R function, uses quantitative descriptions of the E-R relationships for study group incidence of different

---

<sup>82</sup> The design for the study on which the 70 ppb benchmark concentration is based, Schelegle et al. (2009), involved varying concentrations across the full exposure period. The study reported the average O<sub>3</sub> concentration measured during each of the six exercise periods. The mean concentration across these six values is 72 ppb. The 6.6-hr time weighted average based on the six reported measurements and the study design is 73 ppb (Schelegle et al., 2009). Other 6.6-hr studies generally report an exposure concentration precision at or below 3 ppb (e.g., Adams, 2006b).

<sup>83</sup> The model averages the ventilation rate ( $\dot{V}_E$ ) for the exposed individual (based on the activities performed) over 7-hour periods. This is done based on the APEX estimates of  $\dot{V}_E$  and exposure concentration for every individual's time-series of exposure events. For the exposure duration of interest (e.g., 7 hours), the model derives and outputs the daily maximum average  $\dot{V}_E$  (and hence an equivalent ventilation rate or EVR) and simultaneously occurring exposure concentration for the specified duration for each simulated individual. To reasonably extrapolate the ventilation rate of the controlled human study subjects (i.e., adults having a specified body size and related lung capacity), who were engaging in quasi-continuous exercise during the study period, to individuals having varying body sizes (e.g., children with smaller size and related lung capacity), an equivalent ventilation rate (EVR) was calculated by normalizing the ventilation rate (L/min) by body surface area (m<sup>2</sup>). Seven-hour exposure concentrations associated with 7-hour average EVR at or above the target of  $17.3 \pm 1.2$  L/min-m<sup>2</sup> (i.e., the value corresponding to average EVR across the 6.6-hour study duration in the controlled human exposure studies) are compared to the benchmark concentrations (Appendix 3D, section 3D.2.8.1).

<sup>84</sup> The two approaches also estimate responses associated with unstudied exposure circumstances and population groups in different ways.

1 magnitudes of lung function decrements based on the individual study subject observations. The  
2 second, the individual-based MSS model, uses quantitative estimations of biological processes  
3 identified as important in eliciting the different sizes of decrements at the individual level, with a  
4 factor that also provides a representation of intra- and inter-individual response variability  
5 (Appendix 3D, section 3D.2.8.2.2). The two approaches, described in detail in Appendix 3D,  
6 utilize evidence from the 6.6-hour controlled human exposure studies in different ways, and  
7 accordingly, differ in their strengths, limitations, and uncertainties.

8 The E-R function used for estimating the risk of lung function decrements was developed  
9 from the individual study subject measurements of O<sub>3</sub>-related FEV<sub>1</sub> decrements from the 6.6-  
10 hour controlled human exposure studies targeting mean exposure concentrations from 120 ppb  
11 down to 40 ppb (Appendix 3D, Table 3D-19; Appendix 3A, Figure 3A-1). The FEV<sub>1</sub> responses  
12 reported in these studies have been summarized in terms of percent of study subjects  
13 experiencing O<sub>3</sub>-related decrements equal to at least 10%, 15% or 20%. Across the exposure  
14 range from 40 to 120 ppb, the percentage of exercising study subjects with asthma estimated to  
15 have at least a 10% O<sub>3</sub> related FEV<sub>1</sub> decrement increases from 0 to 7% (a statistically non-  
16 significant response at exposures of 40 ppb) up to approximately 50 to 70% (at exposures of 120  
17 ppb) (Appendix 3D, Section 3D.2.8.2.1, Table 3D-19). The E-R function relies on equations that  
18 describe the fraction of the population experiencing a particular size decrement as a function of  
19 the exposure concentration experienced while at the target ventilation rate.<sup>85</sup> This type of risk  
20 model has been used in risk assessments since the 1997 O<sub>3</sub> NAAQS review. As used here, the  
21 functions (fraction of the population having of a day or more per simulation period with at least  
22 one decrement of one of the specified sizes) are applied to the APEX estimates of 7-hour average  
23 exposure concentrations concomitant with the target ventilation level estimated by APEX, with  
24 the results presented in terms of number of individuals in the simulated populations (and percent  
25 of the population) estimated to experience a day (or more) with a lung function decrement at or  
26 above 10%, 15% and 20%.

27 The MSS model, also used for estimating the risk of lung function decrements, was  
28 developed using the extensive database from controlled human exposure studies that has been  
29 compiled over the past several decades, and biological concepts based on that evidence  
30 (McDonnell et al., 2012; McDonnell et al., 2013). The model mathematically estimates the  
31 magnitude of FEV<sub>1</sub> decrement as a function of inhaled O<sub>3</sub> dose (based on concentration &  
32 ventilation rate) over the time period of interest (Appendix 3D, section 3D.2.8.2.2). The  
33 simulation of decrements is dynamic, based on a balance between predicted development of the

---

<sup>85</sup> This risk model was updated in the 2015 review to include the more recently available study data at that time (Appendix 3D, section 3D.2.8.2.1).

1 decrement in response to inhaled dose and predicted recovery (using a decay factor). Each  
2 occurrence of decrements of interest (e.g., at or above 10%, 15% and 20%) is tallied. This model  
3 was first applied in combination with the APEX model to generate lung function risk estimates  
4 in the 2015 O<sub>3</sub> NAAQS review (80 FR 65314, October 26, 2015).<sup>86</sup>

5 To generate risk estimates for lung function decrements, the model is applied to the  
6 APEX estimates of exposure concentration and ventilation for every exposure event experienced  
7 by a simulated individual. The model then utilizes its mathematical descriptions of dose  
8 accumulation and decay, and relationship of dose to response, to estimate the magnitude of O<sub>3</sub>  
9 response associated with the sequence of exposure events in each individual's day. We report the  
10 MSS model risk results using the same metrics as for the E-R function, i.e., number of  
11 individuals in the simulated populations (and percent of the population) estimated to experience  
12 a day (or more) per simulation period with a lung function decrement at or above 10%, 15% and  
13 20%.

14 The comparison-to-benchmark analysis (involving comparison of 7-hour average  
15 exposure concentrations that coincide with a 7-hour average elevated ventilation rates) provides  
16 perspective on the extent to which the air quality being assessed could be associated with  
17 discrete exposures to O<sub>3</sub> concentrations reported to result in an array of respiratory effects. For  
18 example, estimates of such exposures can indicate the potential for O<sub>3</sub>-related effects in the  
19 exposed population, including effects for which we do not have E-R functions that could be used  
20 in quantitative risk analyses (e.g., airway inflammation). Thus, the comparison-to-benchmark  
21 analysis differs from the two lung function risk analyses with their specific focus on lung  
22 function decrements and provides for a broader risk characterization with consideration of the  
23 array of O<sub>3</sub>-related respiratory effects.

#### 24 **3.4.2 Population Exposure and Risk Estimates for Air Quality Just Meeting the Current** 25 **Standard**

26 In this section, we consider the exposure and risk estimates in the context of the  
27 following questions.

- 28 • **What are the nature and magnitude of O<sub>3</sub> exposures and associated health risks for**  
29 **air quality conditions just meeting the current standard? What portions of the**  
30 **exposed populations are estimated to experience exposures of concern or lung**  
31 **function decrements?**

32 To address these questions, we consider the estimates provided by the exposure and risk  
33 simulations for the eight urban study areas with air quality conditions adjusted to just meet the

---

<sup>86</sup> As noted below, the MSS model used in the current assessment has been updated since the 2015 review based on the most recent study by its developers (McDonnell et al., 2013).

1 current standard (Appendix 3D, sections 3D.3.2 through 3D.3.3). In considering these estimates  
2 here and their associated limitations, uncertainties and implications in greater depth in sections  
3 3.4.5 and 3.5 below, we particularly focus on the extent of protection provided by the standard  
4 from O<sub>3</sub> exposures of potential concern. As described in the prior section, the exposure and risk  
5 analyses present two types of risk estimates for the 3-year simulation in each study area: (1) the  
6 number and percent of simulated people experiencing exposures at or above the particular  
7 benchmark concentrations of interest in a year, while breathing at elevated rates; and (2) the  
8 number and percent of people estimated to experience at least one O<sub>3</sub>-related lung function  
9 decrement (specifically, FEV<sub>1</sub> reductions of a magnitude at or above 10%, 15% or 20%) in a  
10 year and the number and percent of people estimated to experience multiple lung function  
11 decrements.

12 As an initial matter regarding the objectives for the analysis approach, we note that the  
13 analyses and the use of an urban case study approach (summarized in section 3.4.1 above) are  
14 intended to provide assessments of air quality scenarios, including in particular one just meeting  
15 the current standard, for a diverse set of areas and associated exposed populations. These  
16 analyses are not intended to provide a comprehensive national assessment. Nor is the objective to  
17 present an exhaustive analysis of exposure and risk in the areas that currently just meet the  
18 current standard and/or of exposure and risk associated with air quality adjusted to just meet the  
19 current standard in areas that currently do not meet the standard. Rather, the purpose is to assess,  
20 based on current tools and information, the potential for exposures and risks beyond those  
21 indicated by the information available at the time the standard was established. Accordingly, use  
22 of this approach recognizes that capturing an appropriate diversity in study areas and air quality  
23 conditions (that reflect the current standard scenario)<sup>87</sup> is an important aspect of the role of the  
24 exposure and risk analyses in informing the Administrator's conclusions on the public health  
25 protection afforded by the current standard.

26 Of the two types of risk metrics derived in the exposure and risk analyses, we turn first to  
27 the results for the benchmark-based risk metric, which are summarized in terms of the percent of  
28 the simulated populations of all children and children with asthma estimated to experience at

---

<sup>87</sup> A broad variety of spatial and temporal patterns of O<sub>3</sub> concentrations can exist when ambient air concentrations just meet the current standard. These patterns will vary due to many factors including the types, magnitude, and timing of emissions in a study area, as well as local factors, such as meteorology and topography. We focused our current assessment on specific study areas having ambient air concentrations close to conditions that reflect air quality that just meets the current standard. Accordingly, assessment of these study areas is more informative to evaluating the health protection provided by the current standard than would be an assessment that included areas with much higher and much lower concentrations.



1 least one day per year<sup>88</sup> with a 7-hour average exposure concentration at or above the different  
2 benchmark concentrations while breathing at elevated rates under air quality conditions just  
3 meeting the current standard (Table 3-3). The estimates for the adult populations, in terms of  
4 percentages, are generally lower, due to the lesser amount and frequency of time spent outdoors  
5 at elevated exertion (Appendix 3D, section 3D.3.2). Given the recognition of people with asthma  
6 as an at-risk population and the relatively greater amount and frequency of time spent outdoors at  
7 elevated exertion of children, we focus here on the estimates for children, including children with  
8 asthma.

9 Under air quality conditions just meeting the current standard, less than 0.1% of any  
10 study area's children with asthma, on average, were estimated to experience any days per year  
11 with a 7-hour average exposure at or above 80 ppb, while breathing at elevated rates (Table 3-3).  
12 With regard to the 70 ppb benchmark, the study areas' estimates for children with asthma range  
13 up to 0.7 percent (0.6% for all children), on average across the 3-year period, and range up to  
14 1.0% in a single year (Table 3-3). Approximately 3% to nearly 9% of each study area's  
15 simulated children with asthma, on average across the 3-year period, are estimated to experience  
16 one or more days per year with a 7-hour average exposure at or above 60 ppb (Table 3-3). This  
17 range is very similar for the populations of all children (Table 3-3).

18 Regarding multiday occurrences, we see that no children are estimated to experience  
19 more than a single day with a 7-hour average exposure at or above 80 ppb in any year simulated  
20 in any study location (Table 3-3). For the 70 ppb benchmark, the estimate is less than 0.1% of  
21 any area's children (on average across 3-year period), both those with asthma and all children  
22 (Table 3-3, Figure 3-4). The estimates for the 60 ppb benchmark are slightly higher, with up to  
23 3% of children estimated to experience more than a single day with a 7-hour average exposure at  
24 or above 60 ppb, on average (and more than 4% in the highest year across all eight study area  
25 locations) (Table 3-3).

26 These estimates are based on analyses that, while based on conceptually similar  
27 approaches to those used in the 2014 HREA, reflect the updates and revisions to those  
28 approaches that have been implemented since that time. Taking that into consideration, the  
29 estimates for the 3-year period from the current assessment for air quality conditions simulated to  
30 just meet the current standard are of a magnitude roughly similar, although slightly lower at the  
31 upper end of the ranges, to the estimates for these same populations in the 2014 HREA. For

---

<sup>88</sup> The three years of ambient air O<sub>3</sub> concentrations analyzed in the exposure assessment analyses include concentrations during the O<sub>3</sub> seasons for that area. These seasons capture the times during the year when concentrations are elevated (80 FR 65419-65420, October 26, 2015). While the duration of an O<sub>3</sub> season for each year may vary across the study areas, for the purposes of the exposure and risk analyses, the O<sub>3</sub> season in each study area is considered synonymous with a year.

example, for air quality conditions just meeting the standard with a level of 70 ppb, the 2014 HREA estimated 0.1 to 1.2% of children to experience at least one day with exposure at or above 70 ppb, while at elevated ventilation (Appendix 3D, section 3D.3.2.4, Table 3D-38). There are a number of differences between the quantitative modeling and analyses performed in the current assessment and the 2014 HREA that likely contribute to the small differences in estimates between the two assessments (e.g., 2015-2017 vs. 2006-2010 distribution of ambient air concentrations, full statistical distribution of ventilation rates vs. a 5<sup>th</sup> percentile point estimate, 7-hour vs. 8-hour exposure durations).

**Table 3-3. Percent and number of simulated children and children with asthma estimated to experience at least one or more days per year with a 7-hour average exposure at or above indicated concentration while breathing at an elevated rate in areas just meeting the current standard.**

| Exposure Concentration (ppb)  | One or more days                   |                          | Two or more days |                          | Four or more days |                          |
|---|------------------------------------|--------------------------|------------------|--------------------------|-------------------|--------------------------|
|   | Average per year                   | Highest in a single year | Average per year | Highest in a single year | Average per year  | Highest in a single year |
| <i>Children with asthma - percent of simulated population<sup>A</sup></i>   |                                    |                          |                  |                          |                   |                          |
| ≥ 80  | 0 <sup>B</sup> – <0.1 <sup>C</sup> | 0.1                      | 0                | 0                        | 0                 | 0                        |
| ≥ 70  | 0.2 – 0.7                          | 1.0                      | <0.1             | 0.1                      | 0                 | 0                        |
| ≥ 60  | 3.3 – 8.8                          | 11.2                     | 0.6 – 3.2        | 4.9                      | <0.1 – 0.8        | 1.3                      |
| <i>- number of individuals<sup>A</sup></i>  |                                    |                          |                  |                          |                   |                          |
| ≥ 80  | 0 – 67                             | 202                      | 0                | 0                        | 0                 | 0                        |
| ≥ 70  | 93 – 1145                          | 1616                     | 3 – 39           | 118                      | 0                 | 0                        |
| ≥ 60  | 1517 – 8544                        | 11776                    | 282 – 2609       | 3977                     | 23 – 637          | 1033                     |
| <i>All children - percent of simulated population<sup>A</sup></i>   |                                    |                          |                  |                          |                   |                          |
| ≥ 80  | 0 <sup>B</sup> – <0.1              | 0.1                      | 0                | 0                        | 0                 | 0                        |
| ≥ 70  | 0.2 – 0.6                          | 0.9                      | <0.1             | 0.1                      | 0 – <0.1          | <0.1                     |
| ≥ 60  | 3.2 – 8.2                          | 10.6                     | 0.6 – 2.9        | 4.3                      | <0.1 – 0.7        | 1.1                      |
| <i>- number of individuals<sup>A</sup></i>  |                                    |                          |                  |                          |                   |                          |
| ≥ 80  | 0 – 464                            | 1211                     | 0                | 0                        | 0                 | 0                        |
| ≥ 70  | 727 – 8305                         | 11923                    | 16 – 341         | 757                      | 0 – 5             | 14                       |
| ≥ 60  | 14928 – 69794                      | 96261                    | 2601 – 24952     | 36643                    | 158 – 5997        | 9554                     |
| <sup>A</sup> Estimates for each study area were averaged across the 3-year assessment period. Ranges reflect the ranges of averages.<br><sup>B</sup> A value of zero (0) means that there were no individuals estimated to have the selected exposure in any year.<br><sup>C</sup> An entry of <0.1 is used to represent small, non-zero values that do not round upwards to 0.1 (i.e., <0.05). |                                    |                          |                  |                          |                   |                          |

In framing these same exposure estimates from the perspective of estimated protection provided by the current standard, these results indicate that, in the single year with the highest concentrations across the 3-year period, 99% of the population of children with asthma would not be expected to experience such a day with an exposure at or above the 70 ppb benchmark;

99.9% would not be expected to experience such a day with exposure at or above the 80 ppb benchmark. The estimates, on average across the 3-year period, indicate that over 99.9%, 99.3% and 91.2% of the population of children with asthma would not be expected to experience a day with a 7-hour average exposure while at elevated ventilation that is at or above 80 ppb, 70 ppb and 60 ppb, respectively (Table 3-3 above). Further, with regard to multiple days, more than approximately 97% of all children or children with asthma (on average across a 3-year period), are estimated to be protected against multiple days of exposures at or above 60 ppb. These estimates indicate generally similar protection to that described in establishing the current standard in 2015 (as summarized in section 3.1 above), with slightly greater level of protection for occurrences at 70 ppb (see section 3.5.2 below, refer to Table 3-8).

With regard to lung function risk, the estimates for all children and for children with asthma are again roughly similar, with the higher end of the ranges for the eight study areas being just slightly higher in some cases for the children with asthma (Table 3-4). The lung function risk estimates from the MSS model are appreciably higher than those based on the E-R function (full results in Appendix 3D, section 3D.3.3). This difference relates to the fact, noted in section 3.4.1 above, that the two lung function risk approaches are based on different aspects of the controlled human exposure study evidence and differ in how they extrapolate beyond the exposure study conditions and observations. Accordingly, uncertainties associated with the two modeling approaches also differ (as discussed in section 3.4.4 below). The E-R function risk approach conforms more closely to the circumstances of the 6.6-hour controlled human exposure studies, such that the 7-hour duration and moderate or greater exertion level are necessary for nonzero risk. This approach additionally, however, uses a continuous function which predicts responses for exposure concentrations below those studied down to zero. As a result, exposures below those studied in the controlled human exposures will result in a fraction of the population being estimated by the E-R function to experience a lung function decrement (albeit to an increasingly small degree with decreasing exposures). The MSS model, which has been developed based on a conceptualization intended to reflect a broader set of controlled human exposure studies (e.g., including studies of exposures to higher concentrations for shorter durations), does not require a 7-hour exposure period for the model to generate an estimated response, and lung function decrements are estimated for exertion below moderate or greater levels, as well as for exposure concentrations lower than those that have been studied (Appendix 3D, section 3D.3.4.2; 2014 HREA section 6.3.3). These differences in the models, accordingly, result in differences in the extent to which they produce estimates that reflect the particular

1 conditions of the available controlled human exposure studies and the frequency and magnitude  
2 of the measured responses in those studies.<sup>89</sup>

3 For example, the 6.6-hour controlled human exposure studies have reported  
4 approximately 3% of subjects exposed to an average concentration of 60 ppb and 10% of  
5 subjects exposed to 70 ppb to have at least a 15% FEV<sub>1</sub> decrement (Appendix 3D, Table 3D-20  
6 and Figure 3D-11). Table 3-3 above shows that, at a maximum, approximately 11% and 1% of  
7 children with asthma are estimated in a single year to have a day with daily maximum 7-hour  
8 exposure at or above the 60 ppb and 70 ppb benchmarks, respectively, indicating that perhaps  
9 10% (11% minus 1%) might be expected to have a day with an exposure at or above 60 ppb but  
10 less than 70 ppb. If the simulated children had the same sensitivity as the controlled human  
11 exposure study subjects, it might be expected that 0.3% (3% times 10%) of this group could have  
12 a 15% (or larger) FEV<sub>1</sub> decrement resulting from concentrations at or above 60 ppb and less than  
13 70 ppb and 0.1% (10% times 1%) of this group could have a 15% (or larger) decrement resulting  
14 from concentrations at or above 70 ppb. Accordingly, this would yield an estimated lung  
15 function risk for the simulated population of 0.4% for decrements of 15% or larger. This  
16 contrasts with the estimates based on the E-R function, that are at most a 1% risk (Table 3-4),  
17 and the MSS model estimates, that are at most an 8.7% risk (Table 3-4).

---

<sup>89</sup> The two models, their bases in the evidence and associated limitations and uncertainties are discussed in detail in Appendix 3D, sections 3D.2.8.2 and 3D.3.4.

**Table 3-4. Percent of simulated children and children with asthma estimated to experience at least one or more days per year with a lung function decrement at or above 10, 15 or 20% while breathing at an elevated rate in areas just meeting the current standard.**

| Lung Function Decrement <sup>A</sup>   | One or more days                                       |                          | Two or more days |                          | Four or more days       |                          |
|--|--|--------------------------|------------------|--------------------------|-------------------------|--------------------------|
|  | Average per year                                       | Highest in a single year | Average per year | Highest in a single year | Average per year        | Highest in a single year |
| <b>E-R Function</b>  |  |                          |                  |                          |                         |                          |
|  | percent of simulated children with asthma <sup>A</sup> |                          |                  |                          |                         |                          |
| ≥ 20%  | 0.2 – 0.3  | 0.4                      | 0.1 – 0.2        | 0.2                      | <0.1 <sup>B</sup> – 0.1 | 0.1                      |
| ≥ 15%  | 0.5 – 0.9  | 1.0                      | 0.3 – 0.6        | 0.6                      | 0.2 – 0.4               | 0.4                      |
| ≥ 10%  | 2.3 – 3.3  | 3.6                      | 1.5 – 2.4        | 2.6                      | 0.9 – 1.7               | 1.8                      |
|  | percent of all simulated children <sup>A</sup>         |                          |                  |                          |                         |                          |
| ≥ 20%  | 0.2 – 0.3  | 0.4                      | 0.1 – 0.2        | 0.2                      | <0.1 – 0.1              | 0.1                      |
| ≥ 15%  | 0.5 – 0.8  | 0.9                      | 0.3 – 0.5        | 0.6                      | 0.2 – 0.4               | 0.4                      |
| ≥ 10%  | 2.2 – 3.1  | 3.3                      | 1.3 – 2.2        | 2.4                      | 0.8 – 1.6               | 1.7                      |
| <b>MSS Model</b>   |  |                          |                  |                          |                         |                          |
|  | percent of simulated children with asthma <sup>A</sup> |                          |                  |                          |                         |                          |
| ≥ 20%  | 1.8 – 3.5  | 3.9                      | 0.8 – 2.1        | 2.5                      | 0.3 – 1.1               | 1.3                      |
| ≥ 15%  | 4.5 – 8.2  | 8.7                      | 2.2 – 4.9        | 5.3                      | 1.1 – 2.9               | 3.3                      |
| ≥ 10%  | 13.9 – 22  | 23.3                     | 8.0 – 14.9       | 16                       | 4.3 – 9.8               | 10.5                     |
|  | percent of all simulated children <sup>A</sup>         |                          |                  |                          |                         |                          |
| ≥ 20%  | 1.7 – 3.1  | 3.6                      | 0.8 – 1.7        | 2.0                      | 0.3 – 0.9               | 1.1                      |
| ≥ 15%  | 4.1 – 7.1  | 7.8                      | 2.1 – 4.3        | 4.9                      | 1.0 – 2.5               | 2.9                      |
| ≥ 10%  | 13.2 – 20.4  | 21.8                     | 7.4 – 13.6       | 14.8                     | 3.9 – 8.8               | 9.7                      |
| <sup>A</sup> Estimates for each urban case study area were averaged across the 3-year assessment period. Ranges reflect the ranges across urban study area averages. |  |                          |                  |                          |                         |                          |
| <sup>B</sup> An entry of <0.1 is used to represent small, non-zero values that do not round upwards to 0.1 (i.e., <0.05).  |  |                          |                  |                          |                         |                          |

### 3.4.3 Population Exposure and Risk Estimates for Additional Air Quality Scenarios

In addition to estimating population exposure and risk for O<sub>3</sub> concentrations simulated to occur under air quality conditions when the current standard is just met, the exposure and risk analyses also estimated population exposure and risk in the eight study areas for two additional air quality scenarios. In these scenarios, the air quality conditions were adjusted such that the monitor location with the highest concentrations in each area had a design value just equal to either 75 ppb or 65 ppb.

The results for the comparison-to-benchmarks analysis for these additional air quality scenarios are summarized in Table 3-5 below for all three benchmark concentrations. The estimates for these two additional scenarios differ markedly from the results for air quality just meeting the current standard (summarized in Table 3-3 above). For simplicity, the summary of the comparison discussed here focuses on the 70 ppb benchmark concentration, which falls just

1 below the time-weighted exposure concentration for which there was a statistically significant  
2 lung function decrement and also a statistically significant increase in respiratory symptom score  
3 in one of the controlled human exposure studies, as noted in section 3.3.3 (ISA, Appendix 3,  
4 section 3.1.4.1.1; Schelegle et al., 2009). The pattern is similar for the other two benchmarks,  
5 although in general, the differences of the results for the additional scenarios from the results for  
6 the current standard (presented in section 3.4.2) are somewhat greater for the higher benchmark  
7 and slightly smaller for the lower benchmark.

8 Under air quality conditions in the 75 ppb scenario, estimated percentages of children  
9 with asthma expected to experience at least one day per year with exposures at or above the  
10 benchmark concentrations are two or more times higher than the estimates discussed in section  
11 3.4.2 above for air quality conditions just meeting the current standard. For example, the  
12 minimum and maximum percentages, on average per year across the study areas, of children  
13 with asthma estimated to experience one or more days with exposures at or above the 70 ppb  
14 benchmark are five and three times, respectively, greater than the corresponding percentages for  
15 conditions associated with the current standard (Table 3-3 and Table 3-5). The highest estimated  
16 percentage in a single year for the 70 ppb benchmark is more than twice as high for the 75 ppb  
17 scenario compared to conditions associated with the current standard. The corresponding  
18 estimate for two or more days per year is even greater for the 75 ppb scenario versus the current  
19 standard scenario (Table 3-3 and Table 3-5).

20 In contrast, under air quality conditions in the 65 ppb scenario, the estimated percentages  
21 of children with asthma expected to experience at least one day per year with exposures above  
22 the benchmark concentrations are at most one third the estimates discussed in section 3.4.2 above  
23 for air quality conditions just meeting the current standard (Table 3-3 and Table 3-5). The  
24 highest estimated percentage of children expected to experience two or more days a year at or  
25 above the 70 ppb benchmark drops to zero for the 65 ppb scenario compared to <0.1% for air  
26 quality conditions just meeting the current standard (Table 3-3, Table 3-5).

27 As with the estimates for air quality just meeting the current standard, and as expected  
28 given the various exposure and risk analysis updates implemented, the estimates discussed here  
29 for the additional air quality scenarios are also slightly different from the estimates for such  
30 scenarios that were derived in the 2015 review. However, the differences are not of such a  
31 magnitude that the estimates for one air quality scenario in the current analyses are similar to  
32 results for a different scenario in the 2015 review. For example, while the current estimates for  
33 the 75 ppb air quality scenario are somewhat lower for some benchmarks than those for that  
34 scenario in the 2015 review, they are still higher than the estimates from the 2015 review for the  
35 air quality scenario just meeting the current standard.

**Table 3-5. Percent and number of simulated children and children with asthma estimated to experience one or more days per year with a daily maximum 7-hour average exposure at or above indicated concentration while breathing at an elevated rate – additional air quality scenarios.**

| Exposure Concentration (ppb)  | One or more days        |                          | Two or more days      |                          | Four or more days |                          |
|---|-------------------------|--------------------------|-----------------------|--------------------------|-------------------|--------------------------|
|   | Average per year        | Highest in a single year | Average per year      | Highest in a single year | Average per year  | Highest in a single year |
| <i>Air quality scenario for 75 ppb</i>                                    |                         |                          |                       |                          |                   |                          |
| <i>Children with asthma - percent of simulated population<sup>A</sup></i> |                         |                          |                       |                          |                   |                          |
| ≥ 80  | <0.1 <sup>B</sup> – 0.3 | 0.6                      | 0 <sup>C</sup> – <0.1 | <0.1                     | 0                 | 0                        |
| ≥ 70  | 1.1 – 2.1               | 3.9                      | 0.1 – 0.4             | 0.8                      | 0 – <0.1          | 0.1                      |
| ≥ 60  | 7.6 – 17.1              | 19.2                     | 2.0 – 8.9             | 11.0                     | 0.1 – 3.3         | 4.4                      |
| <i>- number of individuals<sup>A</sup></i>                                |                         |                          |                       |                          |                   |                          |
| ≥ 80  | 23 – 410                | 888                      | 0 – 7                 | 20                       | 0                 | 0                        |
| ≥ 70  | 502 – 2480              | 4544                     | 36 – 316              | 637                      | 0 – 33            | 99                       |
| ≥ 60  | 3538 – 14054            | 17673                    | 1188 – 7232           | 8931                     | 204 – 2708        | 3595                     |
| <i>All children - percent of simulated population<sup>A</sup></i>         |                         |                          |                       |                          |                   |                          |
| ≥ 80  | <0.1 <sup>B</sup> – 0.3 | 0.6                      | 0 <sup>C</sup> – <0.1 | <0.1                     | 0                 | 0                        |
| ≥ 70  | 1.1 – 2.0               | 3.4                      | 0.1 – 0.3             | 0.7                      | <0.1              | <0.1                     |
| ≥ 60  | 6.6 – 15.7              | 17.9                     | 1.7 – 8.0             | 9.9                      | 0.1 – 3.0         | 4.1                      |
| <i>- number of individuals<sup>A</sup></i>                                |                         |                          |                       |                          |                   |                          |
| ≥ 80  | 129 – 3127              | 6658                     | 0 – 54                | 121                      | 0                 | 0                        |
| ≥ 70  | 4915 – 19794            | 34981                    | 414 – 2750            | 5775                     | 3 – 141           | 368                      |
| ≥ 60  | 34918 – 133400          | 162894                   | 11087 – 67747         | 83660                    | 1813 – 25773      | 34902                    |
| <i>Air quality scenario for 65 ppb</i>                                    |                         |                          |                       |                          |                   |                          |
| <i>Children with asthma - percent of simulated population<sup>A</sup></i> |                         |                          |                       |                          |                   |                          |
| ≥ 80  | 0 – <0.1                | <0.1                     | 0                     | 0                        | 0                 | 0                        |
| ≥ 70  | 0 – 0.2                 | 0.3                      | 0                     | 0                        | 0                 | 0                        |
| ≥ 60  | 0.5 – 2.5               | 4.3                      | <0.1 – 0.3            | 0.6                      | 0 – <0.1          | 0.1                      |
| <i>- number of individuals<sup>A</sup></i>                                |                         |                          |                       |                          |                   |                          |
| ≥ 80  | 0 – 23                  | 68                       | 0                     | 0                        | 0                 | 0                        |
| ≥ 70  | 0 – 311                 | 455                      | 0                     | 0                        | 0                 | 0                        |
| ≥ 60  | 212 – 3542              | 5165                     | 13 – 386              | 709                      | 0 – 14            | 42                       |
| <i>All children - percent of simulated population<sup>A</sup></i>         |                         |                          |                       |                          |                   |                          |
| ≥ 80  | 0 – <0.1                | <0.1                     | 0                     | 0                        | 0                 | 0                        |
| ≥ 70  | 0 – 0.2                 | 0.2                      | 0 – <0.1              | <0.1                     | 0                 | 0                        |
| ≥ 60  | 0.4 – 2.3               | 3.7                      | <0.1 – 0.3            | 0.5                      | 0 – <0.1          | <0.1                     |
| <i>- number of individuals<sup>A</sup></i>                                |                         |                          |                       |                          |                   |                          |
| ≥ 80  | 0 – 38                  | 114                      | 0                     | 0                        | 0                 | 0                        |
| ≥ 70  | 0 – 2495                | 3140                     | 0 – 13                | 23                       | 0                 | 0                        |
| ≥ 60  | 1832 – 29486            | 39772                    | 83 – 3681             | 7188                     | 0 – 179           | 354                      |

<sup>A</sup> Estimates for each study area were averaged across the 3-year assessment period. Ranges reflect the ranges of averages.  
<sup>B</sup> An entry of <0.1 is used to represent small, non-zero values that do not round upwards to 0.1 (i.e., <0.05).  
<sup>C</sup> A value of zero (0) means that there were no individuals estimated to have the selected exposure in any year.

Lung function risk estimated for children and children with asthma in air quality scenarios with design values just above and below the current standard are presented in detail in Appendix 3D, section 3D.3.3. The patterns of the estimates are, as expected, higher for the 75 ppb air quality scenario and lower for the 65 ppb scenario. For each scenario, the differences in risk estimates between the two models is similar to that which occurs with the risk estimates for air quality just meeting the current standard (as discussed in section 3.4.2 above). These estimates (for both lung function risk approaches) are less different from those for the current standard air quality scenario than are differences noted above for the comparison-to-benchmarks estimates. This is due to the greater influence on the risk results of exposures associated with the low O<sub>3</sub> concentrations that are less affected by air quality adjustments used to develop air concentration surfaces for which the highest-concentration location has a design value just meeting the different targets.

#### **3.4.4 Key Uncertainties**

In this section, we consider the uncertainties associated with the quantitative estimates of exposure and risk, including those recognized by the characterization of uncertainty in Appendix 3D (section 3D.3.4). This characterization is based on an approach intended to identify and compare the relative impact that important sources of uncertainty may have on the exposure and risk estimates. The approach utilized is largely qualitative and is adapted from the World Health Organization (WHO) approach for characterizing uncertainty in exposure assessment (WHO, 2008) augmented by several quantitative sensitivity analyses of key aspects of the assessment approach (described in detail in Appendix 3D, section 3D.3.4). This characterization and associated analyses build upon information generated from a previously conducted quantitative sensitivity analysis of population-based O<sub>3</sub> exposure modeling (Langstaff, 2007), considering the various types of data, algorithms, and models that together yield exposure and risk estimates for the eight study areas. In this way, we considered the limitations and uncertainties underlying these data, algorithms and models and the extent of their influence on the resultant exposure/risk estimates using the general approach applied in past risk and exposure assessments for O<sub>3</sub>, nitrogen oxides, carbon monoxide and SO<sub>x</sub> (U.S. EPA, 2008; U.S. EPA, 2010; U.S. EPA, 2014; U.S. EPA, 2018).

The exposure and risk uncertainty characterization and quantitative sensitivity analyses, presented in Appendix 3D, section 3D.3.4, involve consideration of the various types of inputs and approaches that together result in the exposure and risk estimates for the eight study areas. In this way the limitations and uncertainties underlying these inputs and approaches and the extent of their influence on the resultant exposure/risk estimates are considered. Consistent with the WHO (2008) guidance, the overall impact of the uncertainty is scaled by considering the extent



1 or magnitude of the impact of the uncertainty as implied by the relationship between the source  
2 of the uncertainty and the exposure and risk output. The characterization in Appendix 3D also  
3 evaluated the direction of influence, indicating how the source of uncertainty was judged, or  
4 found, to quantitatively affect the exposure and risk estimates, e.g., likely to over- or under-  
5 estimate (Appendix 3D, section 3D.3.4.1).

6 • **What are the important uncertainties associated with the exposure and risk**  
7 **estimates?**

8 Based on the uncertainty characterization and associated analyses in Appendix 3D and  
9 consideration of associated policy implications, we recognize several areas of uncertainty as  
10 particularly important in our consideration of the exposure and risk estimates, while also  
11 recognizing several areas where new or updated information reduced uncertainties in the  
12 exposure and risk estimates compared to those in the 2015 review. In so doing, we note areas  
13 that pertain to estimates for both types of risk metrics, as well as areas that pertain more to one  
14 type of estimate versus the other. We also note differences in the uncertainties that pertain to  
15 each of the two approaches used for the lung function risk metric.

16 An overarching and important area of uncertainty, remaining from the 2015 review and  
17 important to our consideration of the exposure and risk analysis results, relates to the underlying  
18 health effects evidence base. The quantitative analysis focuses on the evidence providing the  
19 “strongest evidence” of O<sub>3</sub> respiratory effects (ISA, p. IS-1), the controlled human exposure  
20 studies, and on the array of respiratory responses documented in those studies (e.g., lung function  
21 decrements, respiratory symptoms, increased airway responsiveness and inflammation). The  
22 comparison-to-benchmarks analysis is particularly focused on consideration of the potential for  
23 exposures that pose a risk of experiencing this array of effects. We note, however, evidence is  
24 lacking from controlled human exposure studies of 6.6-hour duration at the lower concentrations  
25 (e.g., 60, 70 and 80 ppb) for children and for people of any age with asthma. While the limited  
26 evidence informing our understanding of potential risk to people with asthma is uncertain, it  
27 indicates the potential for this group, given their disease status, to be at risk (e.g., of asthma  
28 exacerbation), as summarized in section 3.3.4 above. Such a conclusion is consistent with the  
29 epidemiological study findings of positive associations of O<sub>3</sub> concentrations with asthma-related  
30 emergency department visits and hospital admissions (and the higher effect estimates from these  
31 studies), as referenced in section 3.3.1 above and presented in detail in the ISA. Thus, we  
32 recognize uncertainty in interpretation of the exposure and risk estimates in the broader context  
33 (e.g., as discussed in section 3.4.5 below).

34 Key uncertainties and limitations in data and tools that affect the quantitative estimates of  
35 exposure and risk, particularly in their interpretation in the context of considering the current  
36 standard, relate to each step in the assessment. These include uncertainty related to estimation of

1 the concentrations in ambient air for the current standard and the additional air quality scenarios;  
2 lung function risk approaches that rely, to varying extents, on extrapolating from controlled  
3 human exposure study conditions to lower exposure concentrations, lower ventilation rates, and  
4 shorter durations; and characterization of risk for particular population groups that may be at  
5 greatest risk, particularly for people with asthma, and particularly children with asthma. Areas in  
6 which uncertainty has been reduced by new or updated information or methods include the use  
7 of updated air quality modeling, with a more recent model version and model inputs, applied to  
8 study areas with design values near the current standard, as well as updates to several inputs to  
9 the exposure model, including changes to the exposure duration to better match those in the  
10 controlled human exposure studies and an alternate approach to characterizing periods of activity  
11 while at moderate or greater exertion for simulated individuals.

12 With regard to the analysis approach overall, two updates since the 2014 HREA reduce  
13 uncertainty in the results. The first relates to identifying when simulated individuals may be at  
14 moderate or greater exertion, with the new approach reducing the potential for overestimation of  
15 the number of people achieving the associated ventilation rate, which was an important  
16 uncertainty in the 2014 HREA. Additionally, the current analysis focus on exposures of 7 hours  
17 duration better represents the 6.6-hour exposures from the controlled human exposure studies  
18 (than the 8-hour exposure durations used for the 2014 HREA and prior assessments).

19 Additional aspects of the analytical design pertaining to both exposure-based risk metrics  
20 include the estimation of ambient air O<sub>3</sub> concentrations for the air quality scenarios, and main  
21 components of the exposure modeling. Uncertainties include the modeling approach used to  
22 adjust ambient air concentrations to meet the air quality scenarios of interest and the method  
23 used to interpolate monitor concentrations to census tracts. While the adjustment to conditions  
24 near, just above, or just below the current standard is an important area of uncertainty, the size of  
25 the adjustment needed to meet a given air quality scenario is minimized with the selection of  
26 study areas for which recent O<sub>3</sub> design values were near the level of the current standard. Also,  
27 more recent data are used as inputs for the air quality modeling, such as more recent O<sub>3</sub>  
28 concentration data (2015-2017), meteorological data (2016) and emissions data (2016), as well  
29 as a recently updated air quality photochemical model which includes state-of-the-science  
30 atmospheric chemistry and physics (Appendix 3C). Further, the number of ambient monitors  
31 sited in each of the eight study areas provides a reasonable representation of spatial and temporal  
32 variability for the air quality conditions simulated in those areas.

33 Among other key aspects, there is uncertainty associated with the simulation of study  
34 area populations (and at-risk populations), including those with particular physical and personal  
35 attributes. As also recognized in the 2014 HREA, exposures could be underestimated for some  
36 population groups that are frequently and routinely outdoors during the summer (e.g., outdoor

workers, children.<sup>90</sup> In addition, longitudinal activity patterns do not exist for these and other potentially important population groups (e.g., those having respiratory conditions other than asthma), limiting the extent to which the exposure model outputs reflect information that may be particular to these groups. Important uncertainties in the approach used to estimate energy expenditure (i.e., metabolic equivalents of work or METs used to estimate ventilation rates), include the use of longer-term average MET distributions to derive short-term estimates, along with extrapolating adult observations to children. Both of these approaches are reasonable based on the availability of relevant data and appropriate evaluations conducted to date, and uncertainties associated with these steps are somewhat reduced in the current analyses (compared to the 2014 HREA) because of the added specificity and use of redeveloped METs distributions (based on newly available information), which is expected to more realistically estimate activity-specific energy expenditure.

With regard to the exposure and risk modeling aspects of the two risk metrics, we recognize that there are some uncertainties that apply to the estimation of lung function risk and not the comparison-to-benchmarks analysis. For example, both lung function risk approaches utilized in the risk analyses incorporate some degree of extrapolation beyond the exposure circumstances evaluated in the controlled human exposure studies in recognition of the potential for lung function decrements to be greater in unstudied population groups than is evident from the available studies. For example, both models generate nonzero predictions for 7-hour concentrations below the 6.6-hour concentrations investigated in the controlled human exposure studies. In considering these risk estimates, we recognize that the uncertainty in the lung function risk estimates increases with decreasing exposure concentration, and is particularly increased for concentrations below those evaluated in controlled exposure studies (section 3.4.4 and Appendix 3D, section 3D.3.4). Further, the two lung function risk approaches differ in how they extrapolate beyond the controlled human exposure study conditions and in the impact on the estimates. The E-R function risk approach generates nonzero predictions from the full range of potential nonzero concentrations for 7-hour average durations in which the average exertion levels meets or exceeds the target. The MSS model, which draws on evidence-based concepts of how human physiological processes respond to O<sub>3</sub>, extrapolates beyond the controlled experimental conditions, with regard to exposure concentration, exposure duration, and also, ventilation rate (both magnitude and duration). The impact of this extrapolation, and the difference between the two models in its extent beyond the studied exposure circumstances, is illustrated by differences in the percent of the risk estimates derived on days for which the

---

<sup>90</sup> As described in section 3.4.1 above, the child populations modeled were school ages (ages 5 to 18), in recognition of limitations and uncertainties in the data for children younger than five years.

1 highest 7-hour average concentration is below the lowest 6.6-hour exposure concentration tested  
2 (Table 3-6 and Table 3-7). For example, while 3 to 6% of the risk to children (based on single-  
3 year estimates for three study areas) of experiencing at least one day with decrements greater  
4 than 20% estimated by the E-R model is associated with exposure concentrations below 40 ppb  
5 (the lowest exposure concentration studied, and at which no decrements of this severity occurred  
6 in any study subjects), 25% to nearly 40% of MSS model estimates of decrements greater than  
7 20% derive from exposures below 40 ppb (Table 3-6 and Table 3-7). Further, using ventilation  
8 rates lower than those used for the E-R function risk approach (which are based on the controlled  
9 human exposure study conditions) also contribute to relatively greater risks estimated by the  
10 MSS model. Limiting the MSS model results to estimates for individuals with at least the same  
11 exertion level achieved by study subjects ( $\geq 17.3 \text{ L/min-m}^2$ ), reduces the risks of experiencing at  
12 least one lung function decrement by an amount between 24 to 42% (Appendix 3D, Table 3D-  
13 69).

14 The difference between the two models for risk contribution from low concentrations is  
15 smaller for risk estimates for two or more days than the estimates for one or more days. This is  
16 largely because the percent contribution to low-concentration risk for two or more decrement  
17 days predicted by the E-R approach is, by design, greater than the corresponding contribution to  
18 low-concentration risk for one or more days.<sup>91</sup> This also occurs because the MSS model  
19 estimates risk from a larger variety of exposure and ventilation conditions (Table 3-6, Table 3-7).  
20 Further, many of the uncertainties previously identified as part of the 2014 HREA unique to the  
21 MSS model remain as important uncertainties in the current assessment. For example, the  
22 extrapolation of the MSS model age parameter down to age 5 (from the age range of 18- to 35-  
23 year old study subjects to which the model was fit) is an important uncertainty given that  
24 children are an at-risk population of particular interest in this assessment. Also, there is  
25 uncertainty in estimating the frequency and magnitude of lung function decrements as a result of  
26 the statistical form and parameters used for the MSS model inter- and intra-individual variability  
27 terms. Each of these, among other newly identified MSS model uncertainties, are evaluated and  
28 discussed in the current uncertainty characterization (Appendix 3D, section 3D.3.4). As a whole,  
29 the differences between the two lung function risk approaches described above and the estimates  
30 generated by these approaches indicate appreciably greater uncertainty associated with the MSS

---

<sup>91</sup> The E-R function approach uses the daily maximum exposure concentration for the simulated population. By design, every individual would more than likely have a lower exposure on the second day than that experienced on the first day, and so on for each progressive day throughout the simulation period. Therefore, if any risk is estimated, the distribution of exposures would be shifted more so to lower concentrations for a greater proportion of the population.

model estimates than the E-R function estimates due to the significantly greater portion of relatively low concentrations contributing to risk.

**Table 3-6. Percent of risk estimated for air quality just meeting the current standard in three study areas using the E-R function approach on days where the daily maximum 7-hour average concentration is below specified values.**

| Size of Lung Function Decrement  | Percent of child population at risk of decrement from specific 7-hour concentrations <sup>A</sup> |          |          |          |                                  |          |          |          |
|--|---|----------|----------|----------|----------------------------------|----------|----------|----------|
|  | Percent of one-or-more-days risk  |          |          |          | Percent of two-or-more-days risk |          |          |          |
|  | < 30 ppb  | < 40 ppb | < 50 ppb | < 60 ppb | < 30 ppb                         | < 40 ppb | < 50 ppb | < 60 ppb |
| ≥ 20%  | 0.7 – 1%  | 3 – 6%   | 12 – 25% | 39 – 70% | 2 – 3%                           | 7 – 12%  | 24 – 44% | 67 – 93% |
| ≥ 15%  | 2 – 3%  | 6 – 11%  | 19 – 34% | 48 – 78% | 4 – 5%                           | 12 – 18% | 34 – 54% | 75 – 95% |
| ≥ 10%  | 4 – 5%  | 11 – 16% | 29 – 45% | 61 – 86% | 7 – 9%                           | 18 – 25% | 45 – 63% | 83 – 97% |
| <sup>A</sup> The ranges presented are based on 1-year simulations in three study areas (Atlanta, Dallas, and St Louis); the values presented here are rounded to whole numbers or at least one significant digit (full results are in Appendix 3D, section 3D.3.4.2, Table 3D-62). |   |          |          |          |                                  |          |          |          |

**Table 3-7. Percent of risk estimated for air quality just meeting the current standard in three study areas using the MSS model approach on days where the daily maximum 7-hour average concentration is below specified values.**

| Size of Lung Function Decrement  | Percent of child population at risk of decrement from specified 7-hour concentrations <sup>A</sup> |          |          |          |                                  |          |          |          |
|--|--|----------|----------|----------|----------------------------------|----------|----------|----------|
|  | Percent of one-or-more-days risk   |          |          |          | Percent of two-or-more-days risk |          |          |          |
|  | < 30 ppb   | < 40 ppb | < 50 ppb | < 60 ppb | < 30 ppb                         | < 40 ppb | < 50 ppb | < 60 ppb |
| ≥ 20%  | 5 – 9%   | 25 – 38% | 63 – 78% | 88 – 96% | 5 – 10%                          | 28 – 42% | 66 – 81% | 90 – 98% |
| ≥ 15%  | 11 – 18%   | 36 – 51% | 72 – 84% | 92 – 98% | 11 – 19%                         | 38 – 54% | 74 – 87% | 93 – 99% |
| ≥ 10%  | 25 – 32%   | 57 – 67% | 84 – 91% | 96 – 99% | 26 – 33%                         | 57 – 68% | 84 – 91% | 96 – 99% |
| <sup>A</sup> The ranges presented are based on 1-year simulations in three study areas (Atlanta, Dallas, and St Louis); the values presented here are rounded to whole numbers or at least one significant digit (full results are in Appendix 3D, section 3D.3.4.2, Table 3D-63). |  |          |          |          |                                  |          |          |          |

An additional area in which uncertainty has been reduced for the exposure estimates is related to the approach to identifying when simulated individuals may be at moderate or greater exertion. The approach used in the current assessment reduces the potential for overestimation of the number of people achieving the associated ventilation rate, an important uncertainty identified in the 2014 HREA. We also note that the exposure duration in the assessment was a 7-hour averaging time, which was selected to better represent the 6.6-hour exposures from the controlled human exposure studies, compared to the 8-hour exposure durations used in the model in the 2014 HREA and prior assessments.

In summary, among the multiple uncertainties and limitations in data and tools that affect the quantitative estimates of exposure and risk and their interpretation in the context of

considering the current standard, we recognize several here as particularly important, noting that some of these uncertainties are similar to those recognized in the 2015 review. These include uncertainty related to estimation of the concentrations in ambient air for the current standard and the additional air quality scenarios; lung function risk approaches that rely, to varying extents, on extrapolating from controlled human exposure study conditions to lower exposure concentrations, lower ventilation rates, and shorter durations; and, characterization of risk for particular population groups that may be at greatest risk, particularly for people with asthma, particularly children. We also recognize several areas in which uncertainty has been reduced by new or updated information or methods, including more refined air quality modeling based on selection of study areas with design values near the current standard and more recent model inputs, as well as updates to several inputs to the exposure model including changes to the exposure duration to better match those in the controlled human exposure studies and an alternate approach to characterizing periods of activity while moderate or greater exertion for simulated individuals.

### 3.4.5 Public Health Implications

In considering public health implications of the quantitative exposure and risk estimates that may inform the Administrator's judgments in this area, this section discusses the information pertaining to the following question.

- **To what extent are the estimates of exposures and risks to at-risk populations associated with air quality conditions just meeting the current standard reasonably judged important from a public health perspective?**

Several factors are important to the consideration of public health implications. These include the magnitude or severity of the effects associated with the estimated exposures, as well as their adversity at the individual and population scale. Other important considerations include the size of the population estimated to experience such effects or to experience exposures associated with such effects. Thus, the discussion here reflects consideration of the health evidence, and exposure and risk estimates, as well as the consideration of potential public health implications in previous NAAQS decisions and ATS policy statements (as also discussed in section 3.3.2).

In considering the severity of responses associated with the exposure and risk estimates, we take note of the health effects evidence for the different benchmark concentrations and judgments made with regard to the severity of these effects in the 2015 review. We recognize the greater prevalence of more severe lung function decrements among study subjects exposed to 80 ppb or higher concentrations (compared to the study findings for lower exposure concentrations), as well as the prevalence of other effects such as respiratory symptoms; thus, such exposures (of

1 80 ppb and greater) are appropriately considered to be associated with adverse respiratory effects  
2 consistent with past and recent ATS position statements and with EPA's judgments in  
3 establishing the current standard in 2015.<sup>92</sup> Further, in the controlled human exposure study of an  
4 average exposure level somewhat above 70 ppb (73 ppb), statistically significant increases in  
5 transient lung function decrements (specifically reduced FEV<sub>1</sub>) and respiratory symptoms have  
6 been reported, leading EPA to also characterize these exposure conditions as being associated  
7 with adverse responses, consistent with ATS statements as summarized in section 3.1 above  
8 (e.g., 80 FR 65343, 65345, October 26, 2015; 85 FR 87304, December 31, 2020). Studies of  
9 controlled human exposures to the lowest benchmark concentration of 60 ppb have found small  
10 but statistically significant O<sub>3</sub>-related decrements in lung function and airway inflammation  
11 (without increased incidence of respiratory symptoms).

12 We additionally take note of the greater significance of estimates for multiple  
13 occurrences of exposures at or above these benchmarks consistent with the evidence. This is  
14 consistent with past O<sub>3</sub> NAAQS reviews in which it was recognized, using the example of effects  
15 such as inflammation, that while isolated occurrences can resolve entirely, repeated occurrences  
16 from repeated exposure could potentially result in more severe effects (2013 ISA, section 6.2.3  
17 and p. 6-76). The ascribing of greater significance to repeated occurrences of exposures of  
18 potential concern is also consistent with public health judgments in NAAQS reviews for other  
19 pollutants, such as SO<sub>x</sub> and carbon monoxide (84 FR 9900, March 18, 2019; 76 FR 54307,  
20 August 31, 2011).

21 The exposure-based analyses include two types of metrics, one involving comparison-to-  
22 benchmark concentrations corresponding to 6.6-hour exposure concentrations to which  
23 exposures while at elevated ventilation have elicited lung function decrements, and the second  
24 involving estimates of lung function risk with regard to such decrements of magnitudes at or  
25 above 10%, 15% or 20%. Based on evidence base described in the 2020 ISA, which is largely  
26 consistent with that available in the 2015 review (as summarized in section 3.3.1 above), the  
27 quantitative exposure and risk analyses results in which we have the greatest confidence are  
28 estimates from the comparison-to-benchmarks analysis, as discussed in section 3.4.4 above.

29 In light of the conclusions that people with asthma and children are at-risk populations  
30 for O<sub>3</sub>-related health effects (summarized in section 3.3.2 above) and the exposure and risk  
31 analysis findings of higher exposures and risks for children (in terms of percent of that  
32 population), we have focused the discussion here on children, and specifically children with

---

<sup>92</sup> The ATS statements indicate that consideration of differences in magnitude or severity, and also the relative transience or persistence of the adverse responses (e.g., FEV<sub>1</sub> changes) and respiratory symptoms, as well as pre-existing sensitivity to effects on the respiratory system, and other factors, is important to characterizing implications for public health effects of an air pollutant such as O<sub>3</sub> (ATS, 2000; Thurston et al., 2017).

1 asthma. We recognize that the exposure and risk estimates indicate that in some areas of the U.S.  
2 where O<sub>3</sub> concentrations just meet the current standard, on average across the 3-year period  
3 simulated, just over 0.5%, and less than 0.1% of the simulated population of children with  
4 asthma might be expected to experience a single day per year with a 7-hour exposure at or above  
5 70 ppb and 80 ppb, respectively, while breathing at an elevated rate. With regard to the lowest  
6 benchmark considered (60 ppb), the corresponding percentage is just over 8%, with higher  
7 percentages in some individual years (Table 3-6). The corresponding estimates for the air quality  
8 scenario with higher O<sub>3</sub> concentrations are notably higher (Table 3-5). For example, for the 75  
9 ppb air quality scenario, 1.1% to 2.1% of children with asthma, on average across the 3-year  
10 design period, are estimated to experience at least one day with exposure concentrations at or  
11 above 70 ppb, while at moderate or greater exertion, with as many as 3.9% in a single year  
12 (Table 3-5). For the 60 ppb benchmark, the single-day occurrence estimates for the 75 ppb  
13 scenario range up to nearly 16%. Estimates for the 65 ppb scenario are appreciably lower.

14 With regard to estimates of lung function decrements, we focus on the E-R model  
15 estimates as having less associated uncertainty, as discussed in section 3.4.4 above. The exposure  
16 and risk analysis estimates 0.2 to 0.3% of children with asthma, on average across the 3-year  
17 design period to experience one or more days with a lung function decrement at or above 20%,  
18 and 0.5 to 0.9 % to experience one or more days with a decrement at or above 15% (Table 3-4  
19 above). In a single year, the highest estimate is 1.0% of this at-risk population expected to  
20 experience one or more days with a decrement at or above 15%. The corresponding estimate for  
21 two or more days is 0.6% (Table 3-4 above). As discussed in section 3.4.3 above, the estimates  
22 for the 75 ppb air quality scenario are notably higher, while the estimates for the 65 ppb scenario  
23 are notably lower (Table 3-5). In reviewing the lung function risk estimates, we note the  
24 uncertainties discussed in section 3.4.4 above, including the appreciable portion of these  
25 estimates that are based on quantifying risk for exposure concentrations below those studied.

26 The size of the at-risk population (people with asthma, particularly children) in the U.S.  
27 is substantial. As summarized in section 3.3.2, nearly 8% of the total U.S. population<sup>93</sup> and 7.0%  
28 of U.S. children have asthma. The asthma prevalence in U.S. child populations (younger than 18  
29 years) of different races or ethnicities ranges from 7.5% for all Hispanic children to 13.5% for  
30 black non-Hispanic children (Table 3-1 above). This is well reflected in the exposure and risk  
31 analysis study areas in which the asthma prevalence ranged from 7.7% to 11.2% of the total  
32 populations and 9.2% to 12.3% of the children. In each study area, the prevalence varies among

---

<sup>93</sup> The number of people in the US with asthma is estimated to be about 25 million. As shown in Table 3-1 the estimated number of people with asthma was 25,131,000 in 2019.



1 census tracts, with the highest tract having a prevalence in boys of 25.5% and a prevalence in  
2 girls of 17.1% (Appendix 3D, Table 3D-3).

3       The exposure and risk analyses inherently recognize that variability in human activity  
4 patterns (where people go and what they do) is key to understanding the magnitude, duration,  
5 pattern, and frequency of population exposures. For O<sub>3</sub> in particular, the amount and frequency  
6 of afternoon time outdoors at moderate or greater exertion is an important factor for  
7 understanding the fraction of the population that might experience O<sub>3</sub> exposures that have  
8 elicited respiratory effects in controlled human exposure studies (2014 HREA, section 5.4.2). In  
9 considering the available information regarding prevalence of behavior (time outdoors and  
10 exertion levels) and daily temporal pattern of O<sub>3</sub> concentrations, we take note of the findings of  
11 evaluations of the data in the CHAD. Based on these evaluations of human activity pattern data,  
12 it appears that children and adults both, on average, spend about 2 hours of afternoon time  
13 outdoors per day, but differ substantially in their participation in these events at elevated exertion  
14 levels (rates of about 80% versus 60%, respectively) (2014 HREA, section 5.4.1.5), indicating  
15 children are more likely to experience exposures that may be of concern. This is one basis for  
16 their identification as an at-risk population for O<sub>3</sub>-related health effects. The human activity  
17 pattern evaluations have also shown there is little to no difference in the amount or frequency of  
18 afternoon time outdoors at moderate or greater exertion for people with asthma compared with  
19 those who do not have asthma (2014 HREA, section 5.4.1.5). Further, recent CHAD analyses  
20 indicate that while 46 – 73% of people do not spend any afternoon time outdoors at moderate or  
21 greater exertion, a fraction of the population (i.e., between 5.5 – 6.8% of children) spend more  
22 than 4 hours per day outdoors at moderate or greater exertion and may have greater potential to  
23 experience exposure events of concern than adults (Appendix 3D, section 3D.2.5.3 and Figure  
24 3D-9). It is this potential that contributes importance to consideration of the exposure and risk  
25 estimates.

26       In considering the public health implications of the exposure and risk estimates across the  
27 eight study areas, we note the purpose for the study areas is to illustrate exposure circumstances  
28 that may occur in areas that just meet the current standard, and not to estimate exposure and risk  
29 associated with conditions occurring in those specific locations today. To the extent that  
30 concentrations in the specific areas simulated may differ from others across the U.S., the  
31 exposure and risk estimates for these areas are informative to consideration of potential  
32 exposures and risks in areas existing across the U.S. that have air quality and population  
33 characteristics similar to the study areas assessed, and that have ambient concentrations of O<sub>3</sub>  
34 that just meet the current standard today or that will be reduced to do so at some period in the  
35 future. We note that numerous areas across the U.S. have air quality for O<sub>3</sub> that is near or above

1 the existing standard.<sup>94</sup> Thus, the air quality and exposure circumstances assessed in the eight  
2 study areas are of particular importance in considering whether the available information calls  
3 into question the adequacy of public health protection afforded by the current standard.

4 The exposure and risk estimates for the eight study areas reflect differences in exposure  
5 circumstances among those areas and illustrate the exposures and risks that might be expected to  
6 occur in other areas with such circumstances under air quality conditions that just meet the  
7 current standard (or the alternate conditions assessed). Thus, the exposure and risk estimates  
8 indicate the magnitude of exposure and risk that might be expected in many areas of the U.S.  
9 with O<sub>3</sub> concentrations at or near the current standard. Although the methodologies and data used  
10 to estimate population exposure and lung function risk in this assessment differ in several ways  
11 from what was used in the 2015 review, the findings and considerations summarized here present  
12 a pattern of exposure and risk that is generally similar to that considered in the last review (as  
13 described in section 3.4.2 above), and indicate a level of protection generally consistent with that  
14 described in the 2015 decision.

15 In summary, the considerations raised here are important to conclusions regarding the  
16 public health significance of the exposure and risk results. We recognize that such conclusions  
17 also depend in part on public health policy judgments that weigh in the Administrator's decision  
18 regarding the protection afforded by the current standard. Such judgments that are common to  
19 NAAQS decisions include those related to public health implications of effects of differing  
20 severity (75 FR 355260 and 35536, June 22, 2010; 76 FR 54308, August 31, 2011; 80 FR 65292,  
21 October 26, 2015). Such judgments also include those concerning the public health significance  
22 of effects at exposures for which evidence is limited or lacking, as discussed in section 3.4.4  
23 above, such as effects at the lower benchmark concentrations considered and lung function risk  
24 estimates associated with exposure concentrations lower than those tested or for population  
25 groups not included in the controlled exposure studies.

### 26 **3.5 KEY CONSIDERATIONS REGARDING THE CURRENT PRIMARY** 27 **STANDARD**

28 In considering what the available evidence and exposure/risk information indicate with  
29 regard to the current primary O<sub>3</sub> standard, the overarching question we consider is:

---

<sup>94</sup> Based on data from 2016-2018, 142 counties have O<sub>3</sub> concentrations that exceed the current standard. Population size in these counties ranges from approximately 20,000 to more than ten million, with a total population of over 112 million living in counties that exceed the current standard. Air quality data are from Table 4. Monitor Status in the Excel file labeled *ozone\_designvalues\_20162018\_final\_06\_28\_19.xlsx* downloaded from <https://www.epa.gov/air-trends/air-quality-design-values>. Population sizes are based on 2017 estimates from the U.S. Census Bureau (<https://www.census.gov/programs-surveys/popest.html>).

- **Does the available scientific evidence- and exposure/risk-based information support or call into question the adequacy of the protection afforded by the current primary O<sub>3</sub> standard?**

To assist us in interpreting the available scientific evidence and the results of recent quantitative exposure/risk analyses to address this question, we have focused on a series of more specific questions, as detailed in sections 3.5.1 and 3.5.2 below. In considering the scientific and technical information, we take into account the information available at the time of the 2015 review and information newly available in the 2020 review, which have been critically analyzed and characterized in the 2013 ISA for the 2015 review and the ISA for the 2020 review, respectively. In this context, a primary consideration is whether the available information alters overall prior conclusions regarding health effects associated with photochemical oxidants, including O<sub>3</sub>, in ambient air.

### **3.5.1 Evidence-based Considerations**

In considering the evidence with regard to the overarching question posed above regarding the adequacy of the current standard, we address a series of more specific questions that focus on policy-relevant aspects of the evidence. These questions begin with consideration of the available evidence on health effects associated with exposure to photochemical oxidants, and particularly O<sub>3</sub>.

- **Is there evidence that indicates the importance of photochemical oxidants other than O<sub>3</sub> with regard to abundance in ambient air, and potential for human exposures and health effects?**

The 2020 ISA did not identify any newly available evidence regarding the importance of photochemical oxidants other than O<sub>3</sub> with regard to abundance in ambient air, and potential for health effects.<sup>95</sup> As summarized in section 2.1 above, O<sub>3</sub> is one of a group of photochemical oxidants formed by atmospheric photochemical reactions of hydrocarbons with nitrogen oxides in the presence of sunlight, with O<sub>3</sub> being the only photochemical oxidant other than nitrogen dioxide that is routinely monitored in ambient air. Data for other photochemical oxidants are generally derived from a few special field studies such that national scale data for these other oxidants are scarce (ISA, Appendix 1, section 1.1; 2013 ISA, sections 3.1 and 3.6). Moreover, few studies of the health impacts of other photochemical oxidants beyond O<sub>3</sub> have been identified by literature searches conducted for other recent O<sub>3</sub> assessments (ISA, Appendix 1, section 1.1). As stated in the ISA, “the primary literature evaluating the health...effects of

---

<sup>95</sup> Close agreement between past O<sub>3</sub> measurements and the photochemical oxidant measurements upon which the early photochemical oxidants NAAQS was based indicated the very minor contribution of other oxidant species in comparison to O<sub>3</sub> (U.S. DHEW, 1970).

photochemical oxidants includes ozone almost exclusively as an indicator of photochemical oxidants” (ISA, section IS.1.1, p. IS-3). Thus, the evidence base for health effects of photochemical oxidants does not indicate an importance of any other photochemical oxidants. For these reasons, discussion of photochemical oxidants in this document focuses on O<sub>3</sub>.

- **Does the available scientific evidence alter prior conclusions regarding the nature of health effects attributable to human exposure to O<sub>3</sub> from ambient air?**

The evidence, as evaluated in the 2020 ISA, is largely consistent with the conclusion in the last ISA (in the 2015 review) regarding the health effects causally related to O<sub>3</sub> exposures, and most specifically regarding respiratory effects, which, as in the past, are concluded to be causally related to short-term exposures to O<sub>3</sub>. Also, as in the 2015 and prior reviews, respiratory effects are concluded to be likely causally related to longer-term O<sub>3</sub> exposures (ISA, section IS.1.3.1, Appendix 3). Further, while a causal determination was not made in the 2015 review regarding metabolic effects, the 2020 ISA finds there to be sufficient evidence to conclude there to likely be a causal relationship of short-term O<sub>3</sub> exposures and metabolic effects and finds the evidence to be suggestive of, but not sufficient to infer, such a relationship between long-term O<sub>3</sub> exposure and metabolic effects (ISA, section IS.1.3.1). This is based on more recently available evidence, largely from experimental animal studies, on these effects (ISA, Appendix 5). Additionally, the EPA’s causal determinations regarding cardiovascular effects and mortality have been updated from what they were in 2013 ISA based on more recently available evidence in combination with uncertainties that had been identified in the previously available evidence (ISA, Appendix 4, section 4.1.17 and Appendix 6, section 6.1.8). The EPA has concluded that the evidence base is suggestive of, but not sufficient to infer, causal relationships between O<sub>3</sub> exposures (short- and long-term) and cardiovascular effects, mortality, reproductive and developmental effects, and nervous system effects (ISA, section IS.1.3.1). As in the 2015 and prior O<sub>3</sub> NAAQS reviews, the strongest evidence, including with regard to characterization of relationships between O<sub>3</sub> exposure and occurrence and magnitude of effects, is for respiratory effects, and particularly for effects such as lung function decrements, respiratory symptoms, airway responsiveness, and respiratory inflammation.

- **Does the available evidence alter our prior understanding of populations that are particularly at risk from O<sub>3</sub> exposures?**

The evidence, as evaluated in the 2020 ISA, does not alter our prior understanding of populations at risk from health effects of O<sub>3</sub> exposures. As in the past, people with asthma, and particularly children, are the at-risk population groups for which the evidence is strongest. In addition to populations with asthma, groups with relatively greater exposures, particularly those who spend more time outdoors during times when ambient air concentrations of O<sub>3</sub> are highest

1 and while engaged in activities that result in elevated ventilation, are recognized as at increased  
2 risk. Such groups include outdoor workers and children. Other groups for which the evidence is  
3 less clear include older adults, individuals with reduced intake of certain nutrients and  
4 individuals with certain genetic variants. Recent evidence does not provide additional  
5 information for these groups beyond the evidence available at the time of the 2015 review (ISA,  
6 section IS.4.4).

- 7 • **Does the available evidence alter past conclusions regarding the exposure duration**  
8 **and concentrations associated with health effects? To what extent does the scientific**  
9 **evidence indicate health effects attributable to exposures to O<sub>3</sub> concentrations lower**  
10 **than previously reported and what are important uncertainties in that evidence?**

11 The available evidence documented in the 2020 ISA regarding O<sub>3</sub> exposures associated  
12 with health effects is largely similar to that available at the time of the 2015 review and does not  
13 indicate effects attributable to exposures of shorter duration or lower concentrations than  
14 previously understood. Respiratory effects continue to be the effects for which the experimental  
15 information regarding exposure concentrations eliciting effects is well established, as  
16 summarized in section 3.3.3 above. Such information allows for characterization of potential  
17 population risk associated with O<sub>3</sub> in ambient air under conditions allowed by the current  
18 standard. The more recently available controlled human exposure studies, as discussed in section  
19 3.3.3 above, are conducted over shorter durations while at much higher concentrations than the  
20 key set of 6.6-hour studies that have been the focus of the last several reviews. The respiratory  
21 effects evidence includes support from a large number of epidemiologic studies. The positive  
22 associations of O<sub>3</sub> with respiratory health outcomes (e.g., asthma-related hospital admissions and  
23 emergency department visits) reported in these studies are coherent with findings from the  
24 controlled human exposure and experimental animal studies. All but a few of these studies,  
25 however, are conducted in areas during periods when the current standard is not met, making  
26 them less useful with regard to indication of health effects of exposures allowed by the current  
27 standard.

28 Within the evidence base for the recently identified category of metabolic effects, the  
29 evidence derives largely from experimental animal studies of exposures appreciably higher than  
30 those for the 6.6-hour human exposure studies along with a small number of epidemiologic  
31 studies. As discussed in section 3.3.3 above, these studies do not prove to be informative to our  
32 consideration of exposure circumstances likely to elicit health effects.

33 Thus, the 6.6-hour controlled human exposure studies of respiratory effects remain the  
34 focus for our consideration of exposure circumstances associated with O<sub>3</sub> health effects. Based  
35 on these studies, the exposure concentrations investigated range from as low as approximately 40  
36 ppb to 120 ppb. This information on concentrations that have been found to elicit effects for 6.6-

hour exposures while exercising is unchanged from what was available in the 2015 review. The lowest concentration for which lung function decrements have been found to be statistically significantly increased over responses to filtered air remains approximately 60 ppb, at which group mean decrements on the order of 2% to 4% have been reported (Table 3-2, Figure 3-2). Respiratory symptoms were not increased with this exposure level.<sup>96</sup> Exposure to concentrations slightly above 70 ppb, with quasi-continuous exercise, has been reported to elicit statistically significant increases in both lung function decrements and respiratory symptom scores, as summarized in section 3.3.3 above. Still greater group mean and individual responses in lung function decrements and respiratory symptom scores, as well as inflammatory response and airway responsiveness, are reported for higher exposure concentrations.

- **To what extent have previously identified uncertainties in the health effects evidence been reduced or do important uncertainties remain?**

Uncertainties identified in the health effects evidence at the time of the 2015 review generally remain. These include uncertainties related to the susceptibility of population groups not studied, the potential for effects to result from exposures to concentrations below those included in controlled human exposure studies, and the potential for increased susceptibility as a result of prior exposures. We additionally recognize uncertainties associated with the epidemiologic studies (e.g., the potential for copollutant confounding and exposure measurement error). In this context, however, we note the appreciably greater strength in the epidemiologic evidence in its support for determination of a causal relationship for respiratory effects than the epidemiologic evidence related to other categories, such as metabolic effects, more recently determined to have a likely causal relationship with short-term O<sub>3</sub> exposures (as summarized in section 3.3.1 above).

### **3.5.2 Exposure/risk-based Considerations**

Our consideration of the scientific evidence is informed by results from a quantitative analysis of estimated population exposure and associated risk, as at the time of the 2015 review. The overarching consideration in this section is whether the current exposure/risk information alters overall conclusions of the 2015 review regarding health risk associated with exposure to O<sub>3</sub> in ambient air. As in our consideration of the evidence in section 3.3.1 above, we have focused the discussion regarding the exposure/risk information around key questions to assist us in considering the exposure/risk analyses of at-risk populations living in a set of urban areas

---

<sup>96</sup>A statistically significant increase in sputum neutrophils (a marker of increased airway inflammation) was observed in one controlled human exposure study following 6.6-hour exposures to 60 ppb (Table 3-2, Figure 3-2; Appendix 3A).

under air quality conditions simulated to just meet the existing primary O<sub>3</sub> standard. These questions are as follows.

- **To what extent are the estimates of exposures and risks to at-risk populations associated with air quality conditions just meeting the current standard reasonably judged important from a public health perspective? What are the important uncertainties associated with any exposure/risk estimates?**

The exposure and risk analyses conducted for the 2020 review, as described in section 3.4, provide exposure and risk estimates associated with air quality that might occur in an area under conditions that just meet the current standard. These estimates illustrate the differences likely to occur across various locations with such air quality as a result of area-specific differences in emissions, meteorological and population characteristics. In understanding these results, we note that the eight study areas provide a variety of circumstances with regard to population exposure to concentrations of O<sub>3</sub> in ambient air. These study areas reflect different combinations of different types of sources of O<sub>3</sub> precursor emissions, and also illustrate different patterns of exposure to O<sub>3</sub> concentrations in a populated area in the U.S. (Appendix 3C, section 3C.2). In this way, the eight areas provide a variety of examples of exposure patterns that can be informative to the EPA's consideration of potential exposures and risks that may be associated with air quality conditions occurring under the current O<sub>3</sub> standard. While the same conceptual air quality scenario is simulated in all eight study areas (i.e., conditions that just meet the existing standard), variability in emissions patterns of O<sub>3</sub> precursors, meteorological conditions, and population characteristics in the study areas contribute to variability in the estimated magnitude of exposure and associated risk across study areas.

In considering the exposure and risk results, we focus first on estimates for the eight study areas from the comparison-to-benchmarks analysis, the results in which we have the greatest confidence, as discussed in section 3.4.4 above. These results for urban areas with air quality that just meets the current standard indicate that up to 0.7% of children with asthma, on average across the 3-year period, and up to 1.0% in a single year might be expected to experience, while at elevated exertion, at least one day with a 7-hour average O<sub>3</sub> exposure concentration at or above 70 ppb (Table 3-3). As noted earlier, this benchmark concentration reflects the finding of statistically significant O<sub>3</sub>-related decrements and increased respiratory symptoms in a controlled human exposure study of individuals at elevated exertion. Less than 0.1% of this population group is estimated to have multiple days with an occurrence of this exposure level (Table 3-3). For the benchmark concentration of 80 ppb (which reflects the potential for more severe effects), a much lower percentage of children with asthma, <0.1% on average across the 3-year period, with 0.1% in the highest single year, might be expected to experience, while at elevated exertion, at least one day with such a concentration (Table 3-3).

1 There are no children with asthma estimated to experience more than a single day per year with a  
2 7-hour average O<sub>3</sub> concentration at or above 80 ppb (Table 3-3). With regard to the lowest  
3 benchmark concentration of 60 ppb, 8.8% of children with asthma, on average across the 3-year  
4 period, might be expected to experience one or more days with a 7-hour average O<sub>3</sub> exposure  
5 concentration at or above 60 ppb (the concentration associated with less severe effects), and just  
6 over 11% in the highest single year (Table 3-3). Regarding multiple day occurrences, the  
7 percentages for more than a single day occurrence are 3%, on average across the three years, and  
8 just below 5% in the highest single year period (Table 3-3).

9 The estimates for the additional air quality scenarios differ as would be expected. For the  
10 75 ppb air quality scenario, the percent of children with asthma that might be expected to  
11 experience at least one day with a 7-hour average O<sub>3</sub> exposure concentration, while at elevated  
12 exertion, at or above 70 ppb, is a factor of three or more higher than for the current standard  
13 (Table 3-3, Table 3-5). The corresponding estimates for multiple days are a factor of four or  
14 more higher than those for air quality just meeting the current standard. By comparison,  
15 corresponding estimates for the 65 ppb scenario are approximately a third those for the current  
16 standard scenario, with a correspondingly smaller incremental difference in absolute number of  
17 children (Table 3-3, Table 3-5). With regard to the 80 ppb benchmark, the difference of the 75  
18 ppb scenario from the current standard is a factor of three (for average across the 3-year period)  
19 to six (for the highest in a single year) (Table 3-3, Table 3-5). In contrast, the estimates for the 80  
20 ppb benchmark (which is associated with the more severe effects) in the 65 ppb air quality  
21 scenario are nearly identical to those for the current standard (Table 3-3, Table 3-5).

22 With regard to the estimates of lung function risk, as an initial matter we note the  
23 uncertainty associated with these estimates, as discussed in section 3.4.4 above. In this context,  
24 we also recognize the lesser uncertainty associated with estimates derived using the E-R function  
25 (in comparison to estimates based on MSS model). Accordingly, it is those estimates which we  
26 consider here for air quality conditions just meeting the current standard. The E-R lung function  
27 risk analysis for the eight study areas indicates that the percent of children with asthma in an  
28 urban area that just meets the current standard that might be expected to experience one or more  
29 days with a lung function decrement of at least 15% or 20% might range up 0.9% or 0.3%,  
30 respectively, on average across the three years, and 1.0% or 0.4%, respectively, in a single-year  
31 period (Table 3-4). The estimates for a day with a decrement of at least 10% might range up to  
32 3.3%, on average across the three years, and just over 3.5% in a single-year period (Table 3-4).  
33 With regard to multiple day occurrences, the percent of children with asthma that might be  
34 expected to experience two or more days with a lung function decrement of at least 10% may be  
35 as high as 2.4%, on average across the three years, and 2.6% in a single year (Table 3-4), with  
36 much smaller percentages for larger decrements. For multiple days with a decrement of at least



1 15% or 20%, the corresponding percentages are much lower, 0.6% or 0.2%, respectively, on  
2 average across the three years, and 0.6% or 0.2%, respectively, in a single year period (Table 3-  
3 4).

4 We also consider the estimates from this assessment in light of the estimates from the  
5 2014 HREA that were a focus of the decision on the standard in 2015. The estimates across all  
6 study areas from this assessment are generally similar to those reported in the 2015 review across  
7 all study areas included in that HREA, particularly for the two or more occurrences and for the  
8 80 ppb benchmark (Table 3-8).<sup>97</sup> In our consideration here, we focus on the full array of study  
9 areas (e.g., rather than limiting to areas common to the two assessments) given the purpose of the  
10 assessments in providing estimates across a range of study areas to inform decision making with  
11 regard to the exposures and risks that may occur across the U.S. in areas that just meet the  
12 current standard. We note only slight differences, particularly for the lower benchmarks, and  
13 most particularly in the estimates for the highest year. For example, for the 70 ppb benchmark,  
14 the lower and higher end of the range of average per year percent of children with at least one  
15 day above the benchmark from the 2014 HREA are both twice the corresponding values from the  
16 current assessment (Table 3-8). Consideration of the percentage of children estimated to  
17 experience a day or more with an exposure at or above 70 ppb across the three air quality  
18 conditions in the two assessments, however, indicates that differences between air quality  
19 scenarios in the current assessment remain appreciably larger than the slight differences in  
20 estimates between the two assessments for a given scenario. The factors likely contributing to the  
21 slight differences between the two assessments, such as for the lowest benchmark, include  
22 greater variation in ambient air concentrations in some of the study areas in the 2014 HREA, as  
23 well as the lesser air quality adjustments required in study areas for the current assessment due to  
24 closer proximity of conditions to meeting the current standard (70 ppb).<sup>98</sup> Other important  
25 differences between the two assessments are the updates made to the ventilation rates used for  
26 identifying when a simulated individual is at moderate or greater exertion and the use of 7 hours  
27 for the exposure duration. Both of these changes were made to provide closer linkages to the  
28 conditions of the controlled human exposure studies which are the basis for the benchmark  
29 concentrations. Thus, we recognize there to be reduced uncertainty associated with the current  
30 estimates. Overall, particularly in light of differences in the assessments, we conclude the current

---

<sup>97</sup> For consistency with the estimates highlighted in the 2015 review, Table 3-8 focuses on the simulated population of all children (*versus* the simulated population for children with asthma that are the focus in section 3.4).

<sup>98</sup> The 2014 HREA air quality scenarios involved adjusting 2006-2010 ambient air concentrations, and some study areas had design values in that time period that were well above the then-existing standard (and more so for the current standard). Study areas included the current exposure analysis had 2015-2017 design values close to the current standard, requiring less of an adjustment for the current standard (70 ppb) air quality scenario.

estimates to be generally similar to those which were the focus in the 2015 decision on establishing the current standard.

**Table 3-8. Comparison of current assessment and 2014 HREA (all study areas) for percent of children estimated to experience at least one, or two, days with an exposure at or above benchmarks while at moderate or greater exertion.**

| Air Quality Scenario (DVC, ppb)   | Estimated average % of simulated children with at least one day per year at or above benchmark (highest in single season) |                        | Estimated average % of simulated children with at least two days per year at or above benchmark (highest in single season) |                        |
|---|---|------------------------|--|------------------------|
|   | Current PA <sup>A</sup>   | 2014 HREA <sup>B</sup> | Current PA <sup>A</sup>  | 2014 HREA <sup>B</sup> |
| <i>Benchmark Exposure Concentration of 80 ppb</i>   |   |                        |  |                        |
| 75  | <0.1 <sup>A</sup> – 0.3 (0.6)   | 0 – 0.3 (1.1)          | 0 – <0.1 (<0.1)  | 0 (0.1)                |
| 70  | 0 – <0.1 (0.1)  | 0 – 0.1 (0.2)          | 0 (0)  | 0 (0)                  |
| 65  | 0 – <0.1 (<0.1)   | 0 (0)                  | 0 (0)  | 0 (0)                  |
| <i>Benchmark Exposure Concentration of 70 ppb</i>   |   |                        |  |                        |
| 75  | 1.1 – 2.0 (3.4)   | 0.6 – 3.3 (8.1)        | 0.1 – 0.3 (0.7)  | 0.1 – 0.6 (2.2)        |
| 70  | 0.2 – 0.6 (0.9)   | 0.1 – 1.2 (3.2)        | <0.1 (0.1)   | 0 – 0.1 (0.4)          |
| 65  | 0 – 0.2 (0.2)   | 0 – 0.2 (0.5)          | 0 – <0.1 (<0.1)  | 0 (0)                  |
| <i>Benchmark Exposure Concentration of 60 ppb</i>   |   |                        |  |                        |
| 75  | 6.6 – 15.7 (17.9)   | 9.5 – 17.0 (25.8)      | 1.7 – 8.0 (9.9)  | 3.1 – 7.6 (14.4)       |
| 70  | 3.2 – 8.2 (10.6)  | 3.3 – 10.2 (18.9)      | 0.6 – 2.9 (4.3)  | 0.5 – 3.5 (9.2)        |
| 65  | 0.4 – 2.3 (3.7)   | 0 – 4.2 (9.5)          | <0.1 – 0.3 (0.5)   | 0 – 0.8 (2.8)          |
| <sup>A</sup> For the current analysis, calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1"<br><sup>B</sup> For the 2014 HREA, calculated percent was rounded to the nearest tenth decimal using conventional rounding. Values that did not round upwards to 0.1 (i.e., <0.05) were given a value of "0".<br><sup>C</sup> The monitor location with the highest concentrations in each area had a design value just equal to the indicated value. |   |                        |  |                        |

### 3.5.3 Preliminary Conclusions on the Primary Standard

This section describes our preliminary conclusions for the Administrator's consideration with regard to the current primary O<sub>3</sub> standard. These preliminary conclusions are based on considerations described in the sections above, and in the discussion below regarding the available scientific evidence (as summarized in the 2020 ISA, and the ISA and AQCDs from prior reviews), and the risk and exposure information developed in the 2020 review and summarized in section 3.4 above. Taking into consideration the discussions above in this chapter, this section addresses the following overarching policy question.

- **Do the available scientific evidence- and exposure/risk-based information support or call into question the adequacy of the protection afforded by the current primary O<sub>3</sub> standard?**

In considering this question, we recognize that, as is the case in NAAQS reviews in general, the extent to which the protection provided by the current primary O<sub>3</sub> standard is judged to be adequate will depend on a variety of factors, including science policy judgments and public health policy judgments. These factors include public health policy judgments concerning the appropriate benchmark concentrations on which to place weight, as well as judgments on the public health significance of the effects that have been observed at the exposures evaluated in the health effects evidence. The factors relevant to judging the adequacy of the standards also include the interpretation of, and decisions as to the weight to place on, different aspects of the results of the quantitative exposure risk analyses and the associated uncertainties. Thus, we recognize that the Administrator's conclusions regarding the adequacy of the current standard will depend in part on public health policy judgments, science policy judgments, including those regarding aspects of the evidence and exposure/risk estimates, and judgments about the degree of protection that is requisite to protect public health with an adequate margin of safety.

Our response to the overarching question above takes into consideration the discussions that address the specific policy-relevant questions in prior sections of this document (see section 3.2) and builds on the approach from previous reviews. We focus first on consideration of the evidence, including that newly available in the 2020 ISA, including the extent to which it alters prior key conclusions supporting the current standard. We then turn to consideration of the quantitative exposure and risk estimates developed for the 2020 review, including associated limitations and uncertainties. We consider what they indicate regarding the level of protection from adverse effects provided by the current standard, as well as the extent to which exposure/risk estimates may indicate differing conclusions regarding air quality conditions associated with the current standard from those based on past assessments. We additionally consider the key aspects of the evidence and exposure/risk estimates emphasized in establishing the current standard, and the associated public health policy judgments and judgments about the uncertainties inherent in the scientific evidence and quantitative analyses that are integral to decisions on the adequacy of the current primary O<sub>3</sub> standard.

As an initial matter, we recognize the continued support in the available evidence for O<sub>3</sub> as the indicator for photochemical oxidants, as recognized in section 3.5.1 above. Of the photochemical oxidants, O<sub>3</sub> is the only one other than nitrogen dioxide (for which there are separate NAAQS) that is routinely monitored in ambient air. Further, as stated in the ISA, "the primary literature evaluating the health and ecological effects of photochemical oxidants includes ozone almost exclusively as an indicator of photochemical oxidants" (ISA, section

1 IS.1.1, p. IS-3). In summary, the evidence base for health effects of photochemical oxidants does  
2 not indicate an importance of any other photochemical oxidants as it includes O<sub>3</sub> almost  
3 exclusively as an indicator of photochemical oxidants, thus continuing to support the  
4 appropriateness of O<sub>3</sub> as the indicator for photochemical oxidants.

5 In considering the extensive evidence base for health effects of O<sub>3</sub>, we give particular  
6 attention to the longstanding evidence of respiratory effects causally related to O<sub>3</sub> exposures.  
7 This array of effects, and the underlying evidence base, was integral to the basis for setting the  
8 current standard in 2015. As summarized in section 3.3.1 above and addressed in detail in the  
9 ISA, the available evidence base does not include new evidence of respiratory effects associated  
10 with appreciably different exposure circumstances, including any that would be expected to  
11 occur under air quality conditions associated with the current standard. Thus, in considering the  
12 information available at this time, we continue to focus on exposure circumstances associated  
13 with the current standard as those of importance in this reconsideration.

14 Further, while the evidence base has been augmented somewhat since the 2015 review,  
15 we note that the newly available evidence does not lead to different conclusions regarding the  
16 respiratory effects of O<sub>3</sub> in ambient air or regarding exposure concentrations associated with  
17 those effects; nor does it identify different populations at risk of O<sub>3</sub>-related effects. For example,  
18 as in the 2015 review, people of all ages with asthma, children, and outdoor workers, are  
19 populations at increased risk of respiratory effects related to O<sub>3</sub> in ambient air. Children with  
20 asthma, which number approximately five million in the U.S., may be particularly at risk (section  
21 3.3.2 and Table 3.1).<sup>99</sup> In these ways, the health effects evidence is consistent with evidence  
22 available in the 2015 review when the current standard was established. This strong evidence  
23 base continues to demonstrate a causal relationship between short-term O<sub>3</sub> exposures and  
24 respiratory effects, including in people with asthma. This conclusion is primarily based on  
25 evidence from controlled human exposure studies that was available at the time the standard was  
26 set that reported lung function decrements and respiratory symptoms in people exposed to O<sub>3</sub> for  
27 6.6 hours during which they engage in five hours of exercise. Support is also provided by the  
28 experimental animal and epidemiologic evidence that is coherent with the controlled exposure  
29 studies. The epidemiologic evidence, including that recently available, includes studies reporting  
30 positive associations for asthma-related hospital admissions and emergency department visits,  
31 which are strongest for children, with short-term O<sub>3</sub> exposures. Based collectively on this  
32 evidence, populations identified as at risk of such effects include people with asthma and  
33 children.

---

<sup>99</sup> The size of the U.S. population with asthma is approximately 25 million.

1 As in the 2015 review, the most certain evidence of health effects in humans elicited by  
2 exposures to specific O<sub>3</sub> exposure concentrations is provided by controlled human exposure  
3 studies. This category of short-term studies includes an extensive evidence base of 1- to 3-hour  
4 studies, conducted with continuous or intermittent exercise and generally involving relatively  
5 higher exposure concentrations (e.g., greater than 120 ppb).<sup>100</sup> Given the lack of ambient air  
6 concentrations of this magnitude in areas meeting the current standard (see section 2.4.1 above  
7 and Appendix 2A), we continue to focus primarily on a second group of somewhat longer-  
8 duration studies of much lower exposure concentrations. These studies employ a 6.6-hour  
9 protocol that includes six 50-minute periods of exercise at moderate or greater exertion. There  
10 are no new such studies with exercise available since the 2015 review. Thus, the newly available  
11 evidence does not extend our understanding of the range of exposure concentrations that elicit  
12 effects in such studies beyond what was understood previously.

13 Similarly, as in the 2015 review, 60 ppb remains the lowest exposure concentration  
14 (target concentration, as average across exercise periods) at which statistically significant lung  
15 function decrements have been reported in the 6.6-hour exposure studies. Two studies have  
16 assessed exposure concentrations at the lower concentration of 40 ppb, with no statistically  
17 significant finding of O<sub>3</sub>-related FEV<sub>1</sub> decrements for the group mean in either study (which is  
18 just above 1% in one study, and well below in the second). At 60 ppb, the group mean O<sub>3</sub>-related  
19 decrement in FEV<sub>1</sub> ranges from approximately 2 to 4%, with associated individual study subject  
20 variability in decrement size. In the single study assessing the next highest exposure  
21 concentration (just above 70 ppb, at 73 ppb),<sup>101</sup> the group mean FEV<sub>1</sub> decrement (6%) was also  
22 statistically significant, as were respiratory symptom scores. At higher exposure concentrations,  
23 the incidence of both respiratory symptom scores and O<sub>3</sub>-related lung function decrements in the  
24 study subjects is increased. Other respiratory effects, such as inflammatory response and airway  
25 resistance are also increased at higher exposures (ISA; 2013 ISA; 2006 AQCD).

26 In considering what may be indicated by the epidemiologic evidence with regard to  
27 exposure concentrations eliciting effects, we recognize that of the numerous epidemiologic  
28 studies of respiratory outcome associations with O<sub>3</sub> in ambient air, none were conducted in U.S.

---

<sup>100</sup> Table 3A-3 in Appendix 3 summarizes controlled human exposures to O<sub>3</sub> for 1 to 2 hours during continuous or intermittent exercise in contrast to similar exposure durations at rest. This table was adapted from Table 7-1 in the 1996 AQCD and Table AX6-1 in the 2006 CD, with additional studies from Table AX6-13 in the 2006 AQCD, as well as more recent studies from the 2013 ISA and the ISA.

<sup>101</sup> As noted in sections 3.1.1 and 3.3.3 above, the 70 ppb target exposure comes from Schelegle et al. (2009). That study reported, based on O<sub>3</sub> measurements during the six 50-minute exercise periods, that the mean O<sub>3</sub> concentration during the exercise portion of the study protocol was 72 ppb. Based on the measurements for the six exercise periods, the time weighted average concentration across the full 6.6-hour exposure was 73 ppb (Schelegle et al., 2009).

1 locations during time periods when the current standard was met. In fact, the vast majority of  
2 these studies were conducted in locations and during time periods that would not have met the  
3 current standard, thus making them less useful for considering the potential for O<sub>3</sub> concentrations  
4 allowed by the current standard to contribute to health effects. While there were a handful of  
5 multi-city studies in which the O<sub>3</sub> concentrations in a subset of the study locations and for a  
6 portion of the study period appear to have met the current standard, data were not available in  
7 some cities for the earlier years of the study period when design values for other cities were well  
8 above 70 ppb (as discussed in section 3.3.3). We recognize that the study analyses and  
9 associations reported were based on the combined dataset across the full time period (and, for  
10 multicity studies, from all cities), and the extent to which risk associated with exposures derived  
11 from the concentrations in the subset of years (and locations) that would have met the current  
12 standard compared to that from the years (and locations) that would have violated the standard  
13 influenced the study findings is not clear. There were no studies conducted in U.S. locations with  
14 ambient air O<sub>3</sub> concentrations that would meet the current standard for the entire duration of the  
15 study (i.e., with design values<sup>102</sup> at or below 70 ppb). Thus, the epidemiologic studies provide  
16 limited insight regarding exposure concentrations associated with health outcomes that might be  
17 expected under air quality conditions that meet the current standard (section 3.3.3 above). Thus,  
18 the studies of 6.6-hour exposures with quasi-continuous exercise, and particularly those for  
19 concentrations ranging from 60 to 80 ppb continue to provide an appropriate focus in this  
20 reconsideration.

21 As in the 2015 review, we recognize some uncertainty, reflecting limitations in the  
22 evidence base, with regard to the exposure levels eliciting effects as well as the severity of the  
23 effects in some population groups not included in the available controlled human exposure  
24 studies, such as children and individuals with asthma. Further, we note uncertainty in the extent  
25 or characterization of effects at exposure levels below those studied. In this context, we  
26 recognize that the controlled human exposure studies, primarily conducted in healthy adults, on  
27 which the depth of our understanding of O<sub>3</sub>-related health effects is based, provide limited, but  
28 nonetheless important information with regard to responses in people with asthma or in children.  
29 We also note that the evidence indicates that responses such as those observed in the controlled  
30 human exposure studies, if repeated or sustained, particularly in people with asthma, can pose  
31 risks of effects of greater concern, including asthma exacerbation. We also take note of  
32 statements from the ATS, and judgments made by the EPA in considering similar effects in past  
33 NAAQS reviews (80 FR 65343, October 26, 2015; 85 FR 87302, December 31, 2020). In so

---

<sup>102</sup> As described in chapter 2, a design value is the metric used to describe air quality in a given area relative to the level of the standard, taking the averaging time and form into account. For example, a design value of 70 ppb just meets the current primary standard.

1 doing, we recognize the role of such statements in proposing principles or considerations for  
2 weighing the evidence rather than offering “strict rules or numerical criteria” (ATS, 2000;  
3 Thurston et al., 2017).

4 The more recent statement is generally consistent with the prior (2000) statement, that  
5 was considered in the 2015 O<sub>3</sub> NAAQS review, including the attention that statement gives to at-  
6 risk or vulnerable population groups, while also broadening the discussion of effects, responses,  
7 and biomarkers to reflect the expansion of scientific research in these areas. One example of this  
8 increased specificity is in the discussion of small changes in lung function (in terms of FEV<sub>1</sub>) in  
9 people with compromised function, such as people with asthma (Thurston et al., 2017). We note  
10 that, in keeping with the intent of these statements to avoid specific criteria, the statements, in  
11 discussing what constitutes an adverse health effect, do not comprehensively describe all the  
12 biological responses raised, e.g., with regard to magnitude, duration or frequency of small  
13 pollutant-related changes in lung function. These concepts, including the consideration of the  
14 magnitude of effects occurring in just a subset of study subjects, continue to be recognized as  
15 important in the more recent ATS statement (Thurston et al., 2017) and continue to be relevant to  
16 the evidence base for O<sub>3</sub>. In this context, we also recognize the limitations in the available  
17 evidence base with regard to our understanding of these aspects (e.g. magnitude, duration and  
18 frequency) of such changes (e.g., in lung function) that may be associated with exposure  
19 concentrations of interest, including with regard to the exposure levels eliciting effects (as well  
20 as the severity or magnitude of the effects) in some population groups not included in the  
21 available controlled human exposure studies, such as children and individuals with asthma.  
22 Notwithstanding these limitations, we recognize that the controlled human exposure studies,  
23 primarily conducted in healthy adults, on which the depth of our understanding of O<sub>3</sub>-related  
24 health effects is based, in combination with the larger evidence base, inform our conceptual  
25 understanding of O<sub>3</sub> responses in people with asthma and in children. Aspects of our  
26 understanding continue to be limited, however, including with regard to the risk of particular  
27 effects and associated severity for these less studied population groups that may be posed by 7-  
28 hour exposures with exercise to concentrations as low as 60 ppb that are estimated in the  
29 exposure analyses. Notwithstanding these limitations and associated uncertainties, we take note  
30 of the emphasis of the ATS statement on consideration of effects in individuals with pre-existing  
31 compromised function, such as that resulting from asthma (an emphasis which is reiterated and  
32 strengthened in the current statement) Such considerations are important to the judgments on the  
33 adequacy of protection provided by the current standard for at-risk populations. Collectively,  
34 these aspects of the evidence and associated uncertainties contribute to a recognition that for O<sub>3</sub>,  
35 as for other pollutants, the available evidence base in a NAAQS review generally reflects a  
36 continuum, consisting of exposure levels at which scientists generally agree that health effects

1 are likely to occur, through lower levels at which the likelihood and magnitude of the response  
2 become increasingly uncertain.

3 As at the time the current standard was set in 2015, the exposure and risk estimates  
4 developed from modeling exposures to O<sub>3</sub> derived from precursors emitted into ambient air are  
5 critically important to consideration of the potential for exposures and risks of concern under air  
6 quality conditions of interest, and consequently are critically important to judgments on the  
7 adequacy of public health protection provided by the current standard. In turning to consideration  
8 of the public health implications of estimated occurrences of exposures (while at increased  
9 exertion) to the three benchmark concentrations (60, 70 and 80 ppb), we note the respiratory  
10 effects reported for this range of concentrations in controlled human exposure studies during  
11 quasi-continuous exercise. In this context, we recognize that the three benchmarks represent  
12 exposure conditions associated with different levels of respiratory responses in the subjects  
13 studied and can inform judgments on different levels of risk that might be posed to unstudied  
14 members of at-risk populations. The highest benchmark concentration (80 ppb) represents an  
15 exposure where multiple controlled human exposure studies, involving 6.6-hour exposures  
16 during quasi-continuous exercise, demonstrate a range of O<sub>3</sub>-related respiratory effects. These  
17 respiratory effects include a statistically significant increase in multiple types of respiratory  
18 inflammation indicators in multiple studies; statistically significantly increased airway resistance  
19 and responsiveness; statistically significant FEV<sub>1</sub> decrements; and statistically significant  
20 increases in respiratory symptoms (Table 3.2). In one variable exposure study for which 80 ppb  
21 was the exposure period average concentration, the study subject group mean FEV<sub>1</sub> decrement  
22 was nearly 8%, with individual decrements of 15% or greater (of moderate or greater size) in  
23 16% of subjects and decrements of 10% or greater in 32% of subjects (Schelegle et al., 2009;  
24 Table 3.2; Appendix 3D, Figure 3D-11 and Table 3D-20); the percentages of individual subjects  
25 with decrements greater than 10 or 15% were lower in other studies for this exposure (Appendix  
26 3D, Figure 3D-11 and Table 3D-20). The second benchmark (70 ppb) represents an exposure  
27 level below the lowest exposures that have reported both statistically significant FEV<sub>1</sub>  
28 decrements<sup>103</sup> and increased respiratory symptoms (reported at 73 ppb, Schelegle et al., 2009) or  
29 statistically significant increases in airway resistance and responsiveness (reported at 80 ppb,  
30 Horstman et al., 1990). The lowest benchmark (60 ppb) represents still lower exposure, and a  
31 level for which findings from controlled human exposure studies of largely healthy subjects have  
32 included: statistically significant decrements in lung function (with group mean decrements

---

<sup>103</sup> The study group mean lung function decrement for the 73 ppb exposure was 6%, with individual decrements of 15% or greater (of moderate or greater size) in about 10% of subjects and decrements of 10% or greater in 19% of subjects. Decrement of 20% or greater were reported in 6.5% of subjects (Schelegle et al., 2009; Table 3-2; Appendix 3D, Figure 3D-11 and Table 3D-20).



1 ranging from 1.7% to 3.5% across the four studies with average exposures of 60 to 63 ppb<sup>104</sup>),  
2 but not respiratory symptoms; and, a statistically significant increase in a biomarker of airway  
3 inflammatory response relative to filtered air exposures in one study (Kim et al, 2011; Table 3.2).

4 In this context, we additionally note that while not all people experiencing such  
5 exposures experience a response (e.g. lung function decrement), as illustrated by the percentages  
6 cited above, and among those individuals that experience a response, not all will experience an  
7 adverse effect, the likelihood of adverse effects increase as the number of occurrences of O<sub>3</sub>  
8 exposures of concern increases (as recognized in the 2015 decision establishing the current  
9 standard).<sup>105</sup> Thus, while single occurrences can be adverse for some people, particularly for the  
10 higher benchmark concentration where the evidence base is stronger, the potential for adverse  
11 response increases with repeated occurrences (particularly for people with asthma). Accordingly,  
12 we recognize that the exposure/risk analyses provide estimates of exposures of the at-risk  
13 population to concentrations of potential concern but are not yet able to provide information on  
14 how many of such populations will have an adverse health outcome. Thus, in considering the  
15 exposure/risk analysis results, while taking note of the extent of occurrences of one or more days  
16 with an exposure at or above a benchmark, particularly the higher benchmarks, we additionally  
17 recognize the potential for multiple occurrences to be of greater concern than single occurrences  
18 (as was judged in establishing the current standard in 2015).

19 In the 2015 decision establishing the current standard, the controlled human exposure  
20 study evidence as a whole provided context for consideration of the 2014 HREA results for the  
21 exposures of concern (i.e., the comparison-to-benchmarks analysis) (80 FR 65363, October 26,  
22 2015).<sup>106</sup> Similarly, in this reconsideration of the 2020 decision to retain the standard, the

---

<sup>104</sup> Among subjects in all four of these studies, individual FEV<sub>1</sub> decrements of at least 15% were reported in 3% of subjects, with 7% of subjects reported to have decrements at or above a lower value of 10% (Appendix 3D, Figure 3D-11 and Table 3D-20).

<sup>105</sup> The 2015 decision establishing the current standard stated for example, “the Administrator acknowledge[d] such interindividual variability in responsiveness in her interpretation of estimated exposures of concern.” In this 2015 decision context, the Administrator noted “that not everyone who experiences an exposure of concern, including for the 70 ppb benchmark, is expected to experience an adverse response,” judging “that the likelihood of adverse effects increases as the number of occurrences of O<sub>3</sub> exposures of concern increases.” In making this judgment, the Administrator noted that “the types of respiratory effects that can occur following exposures of concern, particularly if experienced repeatedly, provide a plausible mode of action by which O<sub>3</sub> may cause other more serious effects.” Therefore, the 2015 decision included her emphasis on “the public health importance of limiting the occurrence of repeated exposures to O<sub>3</sub> concentrations at or above those shown to cause adverse” (80 FR 65331, October 26, 2015).

<sup>106</sup> As summarized in section 3.1 above, the decision in the 2015 review considered the breadth of the O<sub>3</sub> respiratory effects evidence, recognizing the relatively greater significance of effects reported for exposures at and above 80 ppb as well as the greater array of effects elicited. The decision additionally emphasized consideration of the much less severe effects associated with lower exposures, such as 60 ppb, in light of the need for a margin of safety in setting the standard.

evidence base of 6.6-hour controlled human exposure studies, particularly those of exposures from 60 to 80 ppb, which is little changed from the 2015 review, provides context for our consideration of the public health implications of the results from the updated exposure/risk analyses. In our consideration of these analyses, we first note several ways in which they differ from and improve upon those available in the 2015 review. For example, we note the number of improvements to input data and modeling approaches summarized in section 3.4.1 above. As in past reviews, exposure and risk are estimated from air quality scenarios designed to just meet an O<sub>3</sub> standard in all its elements. That is, the air quality scenarios are defined by the highest design value in the study area, which is the location with the highest 3-year average of annual fourth highest daily maximum 8-hour O<sub>3</sub> concentrations (e.g., equal to 70 ppb for the current standard scenario). The risk and exposure analyses include air quality simulations based on more recent ambient air quality data that include O<sub>3</sub> concentrations closer to the current standard than was the case for the analyses in the 2015 review. As a result, much smaller reductions in precursor emissions were needed in the photochemical modeling than was the case with the 2014 HREA. Further, this modeling was updated to reflect the current state of the science. Additionally, the approach for deriving population exposure estimates, both for comparison to benchmark concentrations and for use in deriving lung function risk using the E-R function approach, has been modified to provide for a better match of the simulated population exposure estimates with the 6.6-hour duration of the controlled human exposure studies and with the study subject ventilation rates. Together, these differences, as well as a variety of updates to model inputs, are believed to reduce uncertainty associated with our interpretation of the analysis results.

As we consider the exposure and risk estimates, we also take note of the array of air quality and exposure circumstances represented by the eight study areas. As summarized in section 3.2.2 above, the areas fall into seven of the nine climate regions in the continental U.S. The population sizes of the associated metropolitan areas range in size from approximately 2.4 to 8 million and vary in population demographic characteristics. While there are uncertainties and limitations associated with the exposure and risk estimates, as noted in section 3.4.4 above, the factors recognized here contribute to their usefulness in informing judgments relevant to the Administrator's consideration of the current standard.

While there are more adults in the U.S. with asthma than children with asthma, the exposure and risk analysis results in terms of percent of the simulated at-risk populations, indicate higher frequency of exposures of potential concern and risks for children as compared to adults. This finding relates to children's greater frequency and duration of outdoor activity, as well as their greater activity level while outdoors (section 3.4.3 above). In light of these conclusions and findings, we have focused our consideration of the exposure and risk analyses here on children.

1 As can be seen by variation in exposure estimates across the study areas, the eight study  
2 areas represent an array of exposure circumstances, including those contributing to relatively  
3 higher and relatively lower exposures and associated risk. As recognized in Appendix 3D and in  
4 section 3.4.3 above, the risk and exposure analyses are not intended to provide a comprehensive  
5 national assessment. Rather, the analyses for this array of study areas and air quality patterns are  
6 intended to indicate the magnitude of exposures and risks that may be expected in areas of the  
7 U.S. that just meet the current standard but that may differ in ways affecting population  
8 exposures of interest. In that way, the exposure and risk estimates are intended to be informative  
9 to the EPA's consideration of potential exposures and risks associated with the current standard  
10 and the Administrator's decision on the adequacy of protection provided by the current standard.

11 While we note reduced uncertainty in several aspects of the exposure and risk analysis  
12 approach (as summarized above), we continue to recognize the relatively greater uncertainty  
13 associated with the lung function risk estimates compared to the results of the comparison-to-  
14 benchmarks analysis (and the greater uncertainty with the estimates derived using the MSS  
15 model approach than the E-R approach). Thus, we focus primarily on the estimates of exposures  
16 at or above different benchmark concentrations that represent different levels of significance of  
17 O<sub>3</sub>-related effects, both with regard to the array of effects and severity of individual effects.

18 Based on all of the above, and taking into consideration related information, limitations  
19 and uncertainties, such as those recognized above, we address the extent to which the recently  
20 available information supports or calls into question the adequacy of protection afforded by the  
21 current standard. Focusing on the air quality scenario for the current standard, we note that  
22 across all eight study areas, which provide an array of exposure situations, less than 1% of  
23 children with asthma are estimated to experience, while breathing at an elevated rate, a daily  
24 maximum 7-hour exposure per year at or above 70 ppb, on average across the 3-year period, with  
25 a maximum of 1% for the study area with the highest estimates in the highest single year (as  
26 summarized in section 3.4.2 above). Further, the percentage for at least one day with such an  
27 exposure above 80 ppb is less than 0.1%, as an average across the 3-year period (and 0.1% or  
28 less in each of the three years simulated across the eight study areas). No simulated individuals  
29 were estimated to experience more than a single such day with an exposure at or above the 80  
30 ppb benchmark. Although the exposure and risk analysis approaches have been updated since the  
31 2015 review as summarized in section 3.4.1 above, these estimates are generally similar to the  
32 comparable estimates for these benchmarks from the 2014 HREA considered at the time the  
33 current standard was set,<sup>107</sup> with only slight differences observed, e.g., for the lowest benchmark.

---

<sup>107</sup> For example, in the 2015 decision to set the standard level at 70 ppb, the Administrator took note of several findings for the air quality scenarios for this level, noting that "a revised standard with a level of 70 ppb is

1 We take note, however, of the differences across air quality scenarios for both sets of estimates  
2 which remain appreciably larger than the slight differences between the current and 2014  
3 estimates. Thus, we observe that the current estimates of children and children with asthma that  
4 might be expected to experience a day with an exposure while exercising at or above the three  
5 benchmark concentrations are generally similar to those that were a primary focus of the decision  
6 in establishing the current standard in 2015.

7 We additionally consider the estimates of 7-hour exposures, at elevated ventilation, at or  
8 above 60 ppb. In so doing, we recognize that the role of this consideration in the 2015 decision  
9 was in the context of the judgment of the Administrator at the time regarding an adequate margin  
10 of safety for the new standard. We additionally recognize the greater significance of risk for  
11 multiple occurrences of days at or above this benchmark, given the associated greater potential  
12 for more lasting effects. The exposure analysis estimates indicate fewer than 1% to just over 3%  
13 of children with asthma, on average across the 3-year period, to be expected to experience two or  
14 more days with an exposure at or above 60 ppb, while at elevated ventilation. This finding of  
15 about 97% to more than 99% of children protected from experiencing two or more days with  
16 exposures at or above 60 ppb while at elevated exertion is quite similar to the characterization of  
17 such estimates at the time of the 2015 decision establishing the current standard (as summarized  
18 in section 3.1.2.4 above),<sup>108</sup> and half that indicated by the comparable estimates for air quality  
19 just meeting the slightly higher design value of 75 ppb. In addition to this level of protection at  
20 the lower exposure level (of 60 ppb), the current information also indicates more than 99% of  
21 children with asthma, on average per year, to be protected from a day or more with an exposure  
22 at or above 70 ppb. In light of public health judgments by the EPA in prior NAAQS reviews, and  
23 related considerations, as well as ATS guidance, we recognize a greater concern for 7-hour  
24 exposures generally at or above 70 and 80 ppb (while at elevated exertion) than such exposures  
25 to O<sub>3</sub> concentrations below 70 ppb, and a greater concern for repeated (*versus* single)  
26 occurrences of such exposures at concentrations at or above 60 ppb up to 70 ppb. With this in  
27 mind, we find the current exposure and risk estimates to indicate that the current standard is

---

estimated to eliminate the occurrence of two or more exposures of concern to O<sub>3</sub> concentrations at or above 80 ppb and to virtually eliminate the occurrence of two or more exposures of concern to O<sub>3</sub> concentrations at or above 70 ppb for all children and children with asthma, even in the worst-case year and location evaluated” (80 FR 65363, October 26, 2015). This statement remains true for the results of the current assessment (Table 3-8).

<sup>108</sup> For example, with regard to the 60 ppb benchmark, for which the 2015 decision placed relatively greater weight on multiple (*versus* single) occurrences of exposures at or above it, the Administrator at that time noted the 2014 HREA estimates for the 70 ppb air quality scenario that estimated 0.5-3.5% of children to experience multiple such occurrences on average across the study areas, stating that the now-current standard “is estimated to protect the vast majority of children in urban study areas ... from experiencing two or more exposures of concern at or above 60 ppb” (80 FR 65364, October 26, 2015). The corresponding estimates, on average across the 3-year period in the current assessments, are remarkably similar at 0.6 -2.9% (Table 3-8).

1 likely to provide a high level of protection from O<sub>3</sub>-related health effects to at-risk populations of  
2 all children and children with asthma. We additionally recognize such protection to be generally  
3 similar to what was estimated when the standard was set in 2015.

4 As recognized above, the protection afforded by the current standard stems from its  
5 elements collectively, including the level of 70 ppb, the averaging time of eight hours and the  
6 form of the annual fourth-highest daily maximum concentration averaged across three years. The  
7 current evidence as considered in the ISA, the current air quality information as analyzed in  
8 chapter 2 of this document, and the current risk and exposure information (presented in  
9 Appendix 3D and summarized in section 3.4 above) provide continued support to these elements,  
10 as well as to the current indicator, as discussed earlier in this section.

11 In summarizing the information discussed thus far, we reflect on the key aspects of the  
12 2015 decision that established the current standard. As an initial matter, effects associated with  
13 6.6-hour exposures with quasi-continuous exercise (in controlled human exposure studies) to 73  
14 ppb O<sub>3</sub> (as a time-weighted average) included both lung function decrements and respiratory  
15 symptoms, which the EPA recognized to be adverse; this judgment was based on consideration  
16 of the EPA decisions in prior NAAQS reviews and CASAC advice, as well as ATS guidance (80  
17 FR 65343, October 26, 2015). We note that the newly available information since the 2015  
18 review includes an additional statement from ATS on assessing adverse effects of air pollution  
19 which is generally consistent with the earlier statement (available at the time of the 2015  
20 decision), e.g., continuing to emphasize potentially at-risk groups, including specific  
21 consideration of effects in people with compromised lung function. While recognizing the  
22 differences between the current and past exposure and risk analyses, as well as uncertainties  
23 associated with such analyses, we note a rough consistency of the associated estimates when  
24 considering the array of study areas in both reviews. Overall, the recent quantitative analyses  
25 appear to comport with the conclusions reached in the 2015 review regarding control expected to  
26 be exerted by the current standard on exposures of concern.

27 We additionally recognize that decisions regarding the adequacy of the current standard  
28 depend in part on public health policy judgments, such as those identified above, and judgments  
29 about when a standard is requisite to protect the public health, including the health of at-risk  
30 populations, allowing for an adequate margin of safety. In this context, we take note of the long-  
31 standing health effects evidence that documents the effects of 6.6-hour O<sub>3</sub> exposures on people  
32 exposed while breathing at elevated rates and recognize that these effects have been reported in a  
33 few individuals for the lowest concentration studied in exposure chambers (40 ppb). Thus, in  
34 considering the exposure analysis estimates for 7-hour exposures at and above 60 ppb, we also  
35 take note of the variability in the responses at low concentrations, including, for example, the  
36 variation in average response to a 7-hour 60 ppb exposure with exercise (group mean FEV<sub>1</sub>

1 decrement of 1.7 to 3.5% change), as well as the lack of statistically significant decrements in  
2 lung function from such exposures at concentrations below 60 ppb. Consistent with the EPA's  
3 judgments in previous reviews, we also recognize the greater potential for health risk from  
4 repeated (*versus* isolated single) occurrences. In light of this, we note that the exposure estimates  
5 indicate the current standard may be expected to protect more than 97% of populations of  
6 children with asthma residing in areas just meeting the current standard from experiencing more  
7 than a single day per year with an exposure at or above 60 ppb, on average over a 3-year period.  
8 We additionally note the estimates that indicate protection of more than 99.9% of children with  
9 asthma living in such areas from experiencing any days with a 7-hour exposure while at elevated  
10 exertion of 80 ppb or higher in a 3-year period, on average. In light of ATS guidance, CASAC  
11 advice and EPA judgments and considerations in past NAAQS reviews, these results indicate a  
12 high level of protection of key at-risk populations from O<sub>3</sub>-related health effects that is a  
13 generally similar level of protection to what was articulated when the standard was set in 2015  
14 and retained in 2020. Thus, the evidence and exposure/risk information, including that related to  
15 the lowest exposures studied, lead us to conclude that the combined consideration of the body of  
16 evidence and the quantitative exposure estimates including the associated uncertainties, do not  
17 call into question the adequacy of the protection provided by the current standard. Rather, this  
18 information continues to provide support for the current standard, and thus supports  
19 consideration of retaining the current standard, without revision.

20 In reaching these conclusions, we recognize that the Administrator's decisions in primary  
21 standard reviews, in general, are largely public health judgments, as described above. We further  
22 note that different public health policy judgments (e.g., from those made in both 2020 and 2015)  
23 could lead to different conclusions regarding the extent to which the current standard provides  
24 protection of public health with an adequate margin of safety. Such public health judgments  
25 include those related to the appropriate degree of public health protection that should be afforded  
26 to protect against risk of respiratory effects in at-risk populations, such as asthma exacerbation  
27 and associated health outcomes in people with asthma, as well as with regard to the appropriate  
28 weight to be given to differing aspects of the evidence and exposure/risk information, and how to  
29 consider their associated uncertainties. For example, different judgments might give greater  
30 weight to more uncertain aspects of the evidence or reflect a differing view with regard to margin  
31 of safety. Such judgments are left to the discretion of the Administrator. In this context, we note  
32 that the scientific evidence and quantitative exposure and risk information in the record on which  
33 this reconsideration is based are largely unchanged. Staff conclusions regarding the adequacy of  
34 the current standards thus remain unchanged from those reached in the 2020 PA.

35 In summary, the newly available health effects evidence, critically assessed in the 2020  
36 ISA as part of the full body of evidence, reaffirms conclusions on the respiratory effects

1 recognized for O<sub>3</sub> in prior reviews. Further, we observe the general consistency of the more  
2 recent evidence with the evidence that was available in the 2015 review with regard to key  
3 aspects on which the current standard is based. We additionally note the quantitative exposure  
4 and risk estimates for conditions just meeting the current standard that indicate a generally  
5 similar level of protection for at-risk populations from respiratory effects, as that described in the  
6 2015 review for the now-current standard. We also recognize limitations and uncertainties  
7 associated with the available information, similar to those at the time of the 2015 review.  
8 Collectively, these considerations (including those discussed above) provide the basis for the  
9 preliminary conclusion that the available evidence and exposure/risk information does not call  
10 into question the adequacy of protection provided by the existing standard or the scientific and  
11 public health judgments that informed the 2020 decision to retain the current standard, which  
12 was established in the 2015 review. Accordingly, we conclude it is appropriate in this  
13 reconsideration of the 2020 decision that consideration be given to retaining the current primary  
14 standard of 0.070 ppm O<sub>3</sub>, as the fourth-highest daily maximum 8-hour concentration averaged  
15 across three years, without revision. In light of this conclusion, we have not identified any  
16 potential alternative standards for consideration.

### 17 **3.6 KEY UNCERTAINTIES AND AREAS FOR FUTURE RESEARCH**

18 In this section, we highlight key uncertainties associated with reviewing and establishing  
19 the primary O<sub>3</sub> standard, while additionally recognizing that research in these areas may be  
20 informative to the development of more efficient and effective control strategies. The list in this  
21 section includes key uncertainties and data gaps thus far highlighted in this review of the primary  
22 standard. A critical aspect of our consideration of the evidence and the quantitative risk/exposure  
23 estimates is our understanding of O<sub>3</sub> effects below the lowest concentrations studied in  
24 controlled human exposure studies, for longer exposures and for different population groups,  
25 particularly including people with asthma. Additional information in several areas would reduce  
26 uncertainty in our interpretation of the available information for purposes of risk characterization  
27 and, accordingly, reduce uncertainty in characterization of O<sub>3</sub>-related health effects. In this  
28 section, we highlight areas for future health-related research, model development, and data  
29 collection activities to address these uncertainties and limitations in the current scientific  
30 evidence. These areas are similar to those highlighted in past reviews.

#### 31 Exposure and Risk Assessment Data and Tools:

- 32 • An important aspect of risk assessment and characterization to inform decisions regarding  
33 the primary standard is our understanding of the exposure-response relationship for O<sub>3</sub>-  
34 related health effects in at-risk populations. Additional research is needed to more

comprehensively assess risk of respiratory effects in at-risk individuals exposed to O<sub>3</sub> in the range of 40 to 80 ppb, and lower, for 6.6 hours while engaged in moderate exertion.

- Population- or cohort-based information on human exposure and associated health effects for healthy adults and children and at-risk populations, including people with asthma, to relevant levels and durations of O<sub>3</sub> concentrations in ambient air, including exposure information in various microenvironments and at varying activity levels, is needed to better evaluate current and future O<sub>3</sub> exposure and lung function risk models. Such information across extended periods would facilitate evaluation of exposure models for the O<sub>3</sub> season.
- Collection of time-activity data over longer time periods, and particularly for children (including under the age of five), is needed to reduce uncertainty in the modeled exposure distributions that form an important part of the basis for decisions regarding NAAQS for O<sub>3</sub> and other air pollutants. Research addressing energy expenditure and associated breathing rates in various population groups, particularly healthy children and children with asthma, in various locations, across the spectrum of physical activity, including sleep to vigorous exertion, is needed.

#### Health Effects Evidence Base:

- Epidemiologic studies assessing the influence of “long-term” or “short-term” O<sub>3</sub> exposures is complicated by a lack of knowledge regarding the exposure history of study populations. Further, existing studies generally focus on either long-term or short-term exposure separately, thereby making it difficult to assess whether a single short-term high-level exposure versus a repeated long-term low-level exposure, or a combination of both short-term high-level and repeated long-term low-level exposures, influence health outcomes of the study subjects. Epidemiologic studies that include exposure measurements across a longer-term assessment period and can simultaneously assess the impact of these various elements of exposure (i.e., magnitude, frequency, durations, and pattern) are needed.
- The extent to which the broad mix of photochemical oxidants as well as other copollutants in the ambient air (e.g., PM, NO<sub>2</sub>, SO<sub>2</sub>, etc.) may play a role in modifying or contributing to the observed associations between ambient air O<sub>3</sub> concentrations and reported health outcomes continues to be an important research question. A better understanding of the broader mixture of photochemical oxidants other than O<sub>3</sub> in ambient air, the associated human exposures, and of the extent to which effects of the mixture may differ from those of O<sub>3</sub>, would be informative to future NAAQS reviews. Studies that examine and improve analytical approaches to better understand the role of copollutants, as well as temperature, in contributing to potential confounding or effect modification in epidemiologic models would be helpful.
- Most epidemiologic study designs remain subject to uncertainty due to use of fixed-site ambient air monitors serving as a surrogate for exposure measurements. The accuracy with which measurements made at stationary outdoor monitors actually reflect subjects’ exposure is not yet fully understood. The degree to which discrepancies between



stationary monitor measurements and actual pollutant exposures introduces error into statistical estimates of pollutant effects in epidemiologic studies needs to be investigated.

- For health endpoints reported in epidemiologic studies, such as respiratory hospital admissions, emergency department visits, and premature mortality, a more comprehensive characterization of the exposure circumstances (including ambient air concentrations, as well as duration of exposure and activity levels of individuals) eliciting such effects is needed
- Further research investigating additional uncertainties and factors that modify epidemiologic associations, particularly for different population groups would improve our understanding in these areas.
- The evidence base, expanded by evidence newly available for the 2020 review, indicates a likely causal relationship between short-term O<sub>3</sub> exposure and metabolic effects. Further research characterizing perturbations of glucose and insulin homeostasis by O<sub>3</sub> in controlled human exposure studies at exertion and in animal toxicology studies at concentrations closer to the current standard are needed inform decisions regarding the primary standard. The collection of population-based information on clinical health outcomes such as metabolic syndrome, diabetes, etc., as well as intermediate indicators like insulin resistance is also needed for an array of populations and lifestages. Such studies would provide an improved understanding of relationships between O<sub>3</sub> exposure and metabolic-related health outcomes.

#### Air Quality:

- Advances in photochemical modeling representations of the atmosphere and in high spatial and temporal resolution estimates of ozone precursor emissions will further reduce uncertainties in photochemical modeling used in estimating O<sub>3</sub> concentrations for different air quality scenarios.

A more robust ambient monitoring network is needed to better understand ozone concentration gradients in urban areas. With the recent development of low-cost ozone sensors, this could be achieved in the near future.

## 1 REFERENCES

- 2 Adams, WC (2000). Ozone dose-response effects of varied equivalent minute ventilation rates. J  
3 Expo Anal Environ Epidemiol 10(3): 217-226.
- 4 Adams, WC (2002). Comparison of chamber and face-mask 6.6-hour exposures to ozone on  
5 pulmonary function and symptoms responses. Inhal Toxicol 14(7): 745-764.
- 6 Adams, WC (2003). Comparison of chamber and face mask 6.6-hour exposure to 0.08 ppm  
7 ozone via square-wave and triangular profiles on pulmonary responses. Inhal Toxicol  
8 15(3): 265-281.
- 9 Adams, WC (2006a). Human pulmonary responses with 30-minute time intervals of exercise and  
10 rest when exposed for 8 hours to 0.12 ppm ozone via square-wave and acute triangular  
11 profiles. Inhal Toxicol 18(6): 413-422.
- 12 Adams, WC (2006b). Comparison of chamber 6.6-h exposures to 0.04-0.08 PPM ozone via  
13 square-wave and triangular profiles on pulmonary responses. Inhal Toxicol 18(2): 127-  
14 136.
- 15 Akinbami, LJ, Simon, AE and Schoendorf, KC (2016). Trends in allergy prevalence among  
16 children aged 0-17 years by asthma status, United States, 2001-2013. J Asthma 53(4):  
17 356-362.
- 18 Alexis, NE, Lay, JC, Hazucha, M, Harris, B, Hernandez, ML, Bromberg, PA, Kehrl, H, Diaz-  
19 Sanchez, D, Kim, C, Devlin, RB and Peden, DB (2010). Low-level ozone exposure  
20 induces airways inflammation and modifies cell surface phenotypes in healthy humans.  
21 Inhal Toxicol 22(7): 593-600.
- 22 Arjomandi, M, Balmes, JR, Frampton, MW, Bromberg, P, Rich, DQ, Stark, P, Alexis, NE,  
23 Costantini, M, Hollenbeck-Pringle, D, Dagincourt, N and Hazucha, MJ (2018).  
24 Respiratory Responses to Ozone Exposure. MOSES (The Multicenter Ozone Study in  
25 Older Subjects). Am J Respir Crit Care Med 197(10): 1319-1327.
- 26 ATS (1985). Guidelines as to what constitutes an adverse respiratory health effect, with special  
27 reference to epidemiologic studies of air pollution. Am Rev Respir Dis 131(4): 666-668.
- 28 ATS (2000). What constitutes an adverse health effect of air pollution? Am J Respir Crit Care  
29 Med 161(2): 665-673.
- 30 Brown, JS, Bateson, TF and McDonnell, WF (2008). Effects of exposure to 0.06 ppm ozone on  
31 FEV1 in humans: a secondary analysis of existing data. Environ Health Perspect 116(8):  
32 1023-1026.
- 33 Bureau of Labor Statistics (2020). U.S. Department of Labor, The Economics Daily, Civilian  
34 occupations required to spend the most time outdoors in 2020 on the Internet at  
35 [https://www.bls.gov/opub/ted/2021/civilian-occupations-required-to-spend-the-most-](https://www.bls.gov/opub/ted/2021/civilian-occupations-required-to-spend-the-most-time-outdoors-in-2020.htm)  
36 [time-outdoors-in-2020.htm](https://www.bls.gov/opub/ted/2021/civilian-occupations-required-to-spend-the-most-time-outdoors-in-2020.htm) (visited January 26, 2022).

- 1 CDC (2016). Current Asthma Prevalence by Weight Status Among Adults: United States, 2001–  
2 2014. NCHS Data Brief No. 239, March 2016. Available at:  
3 <https://www.cdc.gov/nchs/products/databriefs/db239.htm>.
- 4 CDC (2019). National Health Interview Survey, 2019. National Center for Health Statistics,  
5 CDC. Washington, DC. Most Recent National Asthma Data. Available at:  
6 [www.cdc.gov/asthma/most\\_recent\\_national\\_asthma\\_data.htm](http://www.cdc.gov/asthma/most_recent_national_asthma_data.htm). Accessed January 26,  
7 2022.
- 8 Cox, LA. (2020). Letter from Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
9 Committee, to Administrator Andrew R. Wheeler. Re: CASAC Review of the EPA’s  
10 *Policy Assessment for the Review of the Ozone National Ambient Air Quality Standards*  
11 *(External Review Draft – October 2019)*. February 19, 2020. EPA-CASAC-20-003.  
12 Available at:  
13 [https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf)  
14 [D217BC07103485258515006359BA/\\$File/EPA-CASAC-20-003.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf).
- 15 Devlin, RB, McDonnell, WF, Mann, R, Becker, S, House, DE, Schreinemachers, D and Koren,  
16 HS (1991). Exposure of humans to ambient levels of ozone for 6.6 hours causes cellular  
17 and biochemical changes in the lung. *Am J Respir Cell Mol Biol* 4(1): 72-81.
- 18 Duffney, PF, Brown, JS, and Stone, SL (2022). Memorandum to the Review of the Ozone  
19 National Ambient Air Quality Standards (NAAQS) Docket (EPA–HQ–ORD–2018–  
20 0279). Re: Provisional Evaluation of Newly Identified Controlled Human Exposure  
21 Studies in the context of the 2020 Integrated Science Assessment for Ozone and Related  
22 Photochemical Oxidants. April 15, 2020.
- 23 Folinsbee, LJ and Hazucha, MJ (2000). Time course of response to ozone exposure in healthy  
24 adult females. *Inhal Toxicol* 12: 151-167.
- 25 Folinsbee, LJ, Horstman, DH, Kehrl, HR, Harder, S, Abdul-Salaam, S and Ives, PJ (1994).  
26 Respiratory responses to repeated prolonged exposure to 0.12 ppm ozone. *Am J Respir*  
27 *Crit Care Med* 149(1): 98-105.
- 28 Folinsbee, LJ, McDonnell, WF and Horstman, DH (1988). Pulmonary function and symptom  
29 responses after 6.6-hour exposure to 0.12 ppm ozone with moderate exercise. *JAPCA*  
30 38(1): 28-35.
- 31 Frey, HC. (2014). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory  
32 Committee to Honorable Gina McCarthy, Administrator, US EPA. Re: CASAC Review  
33 of the EPA’s *Second Draft Policy Assessment for the Review of the Ozone National*  
34 *Ambient Air Quality Standards*. June 26, 2014. EPA-CASAC-14-004. Available at:  
35 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100JR6F.txt>.
- 36 Frey, HC and Samet, JM. (2012). Letter from Dr. H. Christopher Frey, Chair, Clean Air  
37 Scientific Advisory Committee Ambient Air Monitoring & Methods Committee and  
38 Jonathan Samet, Immediate Past Chair, Clean Air Scientific Advisory Committee, to  
39 Administrator Lisa Jackson. Re: CASAC Review of the EPA’s Policy Assessment for the

- Review of the Ozone National Ambient Air Quality Standards (First External Review Draft – August 2012). November 26, 2012. EPA-CASAC-13-003. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100J7PQ.txt>.
- Gong, H, Jr., Bradley, PW, Simmons, MS and Tashkin, DP (1986). Impaired exercise performance and pulmonary function in elite cyclists during low-level ozone exposure in a hot environment. *Am J Respir Crit Care Med* 134(4): 726-733.
- Horstman, DH, Folinsbee, LJ, Ives, PJ, Abdul-Salaam, S and McDonnell, WF (1990). Ozone concentration and pulmonary response relationships for 6.6-hour exposures with five hours of moderate exercise to 0.08, 0.10, and 0.12 ppm. *Am Rev Respir Dis* 142(5): 1158-1163.
- Karl, T and Koss, WJ (1984). Regional and national monthly, seasonal, and annual temperature weighted by area, 1895-1983. 4-3. National Environmental Satellite and Data Information Service (NESDIS). Asheville, NC.
- Kim, CS, Alexis, NE, Rappold, AG, Kehrl, H, Hazucha, MJ, Lay, JC, Schmitt, MT, Case, M, Devlin, RB, Peden, DB and Diaz-Sanchez, D (2011). Lung function and inflammatory responses in healthy young adults exposed to 0.06 ppm ozone for 6.6 hours. *Am J Respir Crit Care Med* 183(9): 1215-1221.
- Kousha, T and Rowe, BH (2014). Ambient ozone and emergency department visits due to lower respiratory condition. *Int J Occup Med Environ Health* 27(1): 50-59.
- Langstaff, J (2007). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-OAR-2005-0172). Analysis of Uncertainty in Ozone Population Exposure Modeling. Docket Document ID: EPA-HQ-OAR-2005-0172-0174.
- Luben, T, Lassiter, M and Herrick, J (2020). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-ORD-2018-0279). RE: List of Studies Identified by Public Commenters That Have Been Provisionally Considered in the Context of the Conclusions of the 2020 Integrated Science Assessment for Ozone and Related Photochemical Oxidants. December 2020. Docket Document ID: EPA-HQ- OAR-2018-0279-0560.
- Mar, TF and Koenig, JQ (2009). Relationship between visits to emergency departments for asthma and ozone exposure in greater Seattle, Washington. *Ann Allergy, Asthma Immunol* 103(6): 474-479.
- McCurdy, T (2000). Conceptual basis for multi-route intake dose modeling using an energy expenditure approach. *J Expo Anal Environ Epidemiol* 10(1): 86-97.
- McCurdy, T and Graham, SE (2003). Using human activity data in exposure models: Analysis of discriminating factors. *J Expo Anal Environ Epidemiol* 13(4): 294-317.
- McDonnell, WF, Horstman, DH, Hazucha, MJ, Seal, E, Jr., Haak, ED, Salaam, SA and House, DE (1983). Pulmonary effects of ozone exposure during exercise: Dose-response characteristics. *J Appl Physiol* (1985) 54(5): 1345-1352.

1 McDonnell, WF, Kehrl, HR, Abdul-Salaam, S, Ives, PJ, Folinsbee, LJ, Devlin, RB, O'Neil, JJ  
2 and Horstman, DH (1991). Respiratory response of humans exposed to low levels of  
3 ozone for 6.6 hours. Arch Environ Health 46(3): 145-150.

4 McDonnell, WF, Stewart, PW and Smith, MV (2013). Ozone exposure-response model for lung  
5 function changes: an alternate variability structure. Inhal Toxicol 25(6): 348-353.

6 McDonnell, WF, Stewart, PW, Smith, MV, Kim, CS and Schelegle, ES (2012). Prediction of  
7 lung function response for populations exposed to a wide range of ozone conditions.  
8 Inhal Toxicol 24(10): 619-633.

9 Schelegle, ES, Morales, CA, Walby, WF, Marion, S and Allen, RP (2009). 6.6-hour inhalation of  
10 ozone concentrations from 60 to 87 parts per billion in healthy humans. Am J Respir Crit  
11 Care Med 180(3): 265-272.

12 Thurston, GD, Kipen, H, Annesi-Maesano, I, Balmes, J, Brook, RD, Cromar, K, De Matteis, S,  
13 Forastiere, F, Forsberg, B, Frampton, MW, Grigg, J, Heederik, D, Kelly, FJ, Kuenzli, N,  
14 Laumbach, R, Peters, A, Rajagopalan, ST, Rich, D, Ritz, B, Samet, JM, Sandstrom, T,  
15 Sigsgaard, T, Sunyer, J and Brunekreef, B (2017). A joint ERS/ATS policy statement:  
16 what constitutes an adverse health effect of air pollution? An analytical framework. Eur  
17 Respir J 49(1).

18 U.S. Census Bureau (2021). Quick Facts: Population estimates in the United States as of July 1,  
19 2021. <https://www.census.gov/quickfacts/fact/table/US/PST045221> Accessed February 2,  
20 2022.

21 U.S. DHEW (Department of Health, Education, and Welfare) (1970). Air Quality Criteria for  
22 Photochemical Oxidants. Washington, D.C.: National Air Pollution Control  
23 Administration; publication no. AP-63. Available from: NTIS, Springfield, VA; PB-  
24 190262/BA

25 U.S. EPA (1996). Review of national ambient air quality standards for ozone: Assessment of  
26 scientific and technical information: OAQPS staff paper . Office of Air Quality Planning  
27 and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-96-007. June 1996.  
28 Available at: <http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=2000DKJT.PDF>.

29 U.S. EPA (2008). Risk and Exposure Assessment to Support the Review of the NO<sub>2</sub> Primary  
30 National Ambient Air Quality Standard. EPA-452/R-08-008a. Office of Air Quality  
31 Planning and Standards. Research Triangle Park, NC. Available at:  
32 [https://www3.epa.gov/ttn/naaqs/standards/nox/s\\_nox\\_cr\\_rea.html](https://www3.epa.gov/ttn/naaqs/standards/nox/s_nox_cr_rea.html).

33 U.S. EPA (2009). Risk and Exposure Assessment to Support the Review of the SO<sub>2</sub> Primary  
34 National Ambient Air Quality Standard. Office of Air Quality Planning and Standards.  
35 Research Triangle Park, NC. US EPA. EPA-452/R-09-007. Available at:  
36 <https://www3.epa.gov/ttn/naaqs/standards/so2/data/200908SO2REAFinalReport.pdf>.

37 U.S. EPA (2010). Quantitative Risk and Exposure Assessment for Carbon Monoxide - Amended.  
38 Office of Air Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA.

- 1 EPA-452/R-10-006. Available at: [https://www.epa.gov/naaqs/carbon-monoxide-co-](https://www.epa.gov/naaqs/carbon-monoxide-co-standards-risk-and-exposure-assessments-current-review)  
2 [standards-risk-and-exposure-assessments-current-review](https://www.epa.gov/naaqs/carbon-monoxide-co-standards-risk-and-exposure-assessments-current-review).
- 3 U.S. EPA (2014). Health Risk and Exposure Assessment for Ozone. (Final Report). Office of Air  
4 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-14-  
5 004a. August 2014. Available at:  
6 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KBUF.txt>.
- 7 U.S. EPA (2018). Risk and Exposure Assessment for the Review of the Primary National  
8 Ambient Air Quality Standard for Sulfur Oxides. Office of Air Quality Planning and  
9 Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-18-003. Available at:  
10 [https://www.epa.gov/sites/production/files/2018-05/documents/primary\\_so2\\_naaqs\\_-](https://www.epa.gov/sites/production/files/2018-05/documents/primary_so2_naaqs_-_final_rea_-_may_2018.pdf)  
11 [\\_final\\_rea\\_-\\_may\\_2018.pdf](https://www.epa.gov/sites/production/files/2018-05/documents/primary_so2_naaqs_-_final_rea_-_may_2018.pdf).
- 12 U.S. EPA (2019). The Consolidated Human Activity Database (CHAD). Documentation and  
13 User's Guide. Research Triangle Park, NC. US EPA. EPA-452/B-19-001. Available at:  
14 [https://www.epa.gov/healthresearch/consolidated-human-activity-database-chad-use-](https://www.epa.gov/healthresearch/consolidated-human-activity-database-chad-use-human-exposure-and-health-studies-and)  
15 [human-exposure-and-health-studies-and](https://www.epa.gov/healthresearch/consolidated-human-activity-database-chad-use-human-exposure-and-health-studies-and).
- 16 U.S. EPA (2020a). Integrated Science Assessment for Ozone and Related Photochemical  
17 Oxidants. U.S. Environmental Protection Agency. Washington, DC. Office of Research  
18 and Development. EPA/600/R-20/012. Available at: [https://www.epa.gov/isa/ integrated-](https://www.epa.gov/isa/integrated-science-assessment-isa-ozoneand-related-photochemical-oxidants)  
19 [science-assessment-isa-ozoneand- related-photochemical-oxidants](https://www.epa.gov/isa/integrated-science-assessment-isa-ozoneand-related-photochemical-oxidants).
- 20 U.S. EPA (2020b). Policy Assessment for the Review of the Ozone National Ambient Air  
21 Quality Standards. U.S. Environmental Protection Agency, Office of Air Quality  
22 Planning and Standards, Heath and Environmental Impacts Division. Research Triangle  
23 Park, NC. U.S. EPA. EPA-452/R-20-001. 2020 Available at: [https://www.epa.gov/](https://www.epa.gov/naaqs/ozone-o3-standards-policyassessments-current-review)  
24 [naaqs/ozone-o3-standards-policyassessments-current-review](https://www.epa.gov/naaqs/ozone-o3-standards-policyassessments-current-review)
- 25 Villeneuve, PJ, Chen, L, Rowe, BH and Coates, F (2007). Outdoor air pollution and emergency  
26 department visits for asthma among children and adults: A case-crossover study in  
27 northern Alberta, Canada. *Environ Health* 6: 40.
- 28 WHO (2008). Uncertainty and Data Quality in Exposure Assessment. The International  
29 Programme on Chemical Safety. Geneva. WHO.  
30 [https://www.who.int/ipcs/publications/methods/harmonization/exposure\\_assessment.pdf](https://www.who.int/ipcs/publications/methods/harmonization/exposure_assessment.pdf).  
31

## 4 RECONSIDERATION OF THE SECONDARY STANDARD

This chapter presents and evaluates the policy implications of the available scientific and technical information pertaining to this reconsideration of the 2020 decision on the O<sub>3</sub> secondary standard. Specifically, the chapter presents key aspects of the available evidence of the welfare effects of O<sub>3</sub>, as documented in the 2020 ISA, with support from the prior ISA and AQCDs, and associated public welfare implications, as well as key aspects of quantitative analyses, including air quality and environmental exposure-related information that has been updated for this reconsideration using more recent air quality monitoring data, and is presented in detail in appendices 4D and 4F associated with this chapter. Together all of this information provides the foundation for our evaluation of the scientific information regarding welfare effects of O<sub>3</sub> in ambient air and the potential for welfare effects to occur under air quality conditions associated with the current standard (or any alternatives considered), as well as the associated public welfare implications. Our evaluation is framed around key policy-relevant questions derived from the questions included in the IRP (IRP, section 3.2.1) and also takes into account, as relevant, prior assessments of the evidence and quantitative exposure/risk analyses. In light of all of these considerations, we will identify key policy-relevant considerations and summary conclusions regarding the public welfare protection provided by the current standard for the Administrator's consideration in this reconsideration.

Within this chapter, background information on the current standard, including considerations in its establishment in the 2015 review, is summarized in section 4.1. The general approach for considering the available information, including policy-relevant questions identified to frame our policy evaluation, is summarized in section 4.2. Key aspects of the available welfare effects evidence and associated public welfare implications and uncertainties are addressed in section 4.3, and the current air quality and exposure information, with associated uncertainties, is addressed in section 4.4. Section 4.5 summarizes the key evidence- and air quality or exposure-based considerations identified in our evaluation, and also presents associated preliminary conclusions of this analysis. Key remaining uncertainties and areas for future research are identified in section 4.6.

### 4.1 BACKGROUND ON THE CURRENT STANDARD

As a result of the O<sub>3</sub> NAAQS review completed in 2015, the level of the secondary standard was revised to 0.070 ppm, in conjunction with retaining the indicator (O<sub>3</sub>), averaging time (8 hours) and form (fourth-highest annual daily maximum 8-hour average concentration,

1 averaged across three years). The establishment of this standard in 2015, and its retention in  
2 2020, is based primarily on consideration of the extensive welfare effects evidence base  
3 compiled from more than fifty years of extensive research on the phytotoxic effects of O<sub>3</sub>,  
4 conducted both in and outside of the U.S., that documents the impacts of O<sub>3</sub> on plants and their  
5 associated ecosystems (U.S. EPA, 1978, 1986, 1996, 2006, 2013). Key considerations in the  
6 2015 decision were the scientific evidence and technical analyses available at that time, as well  
7 as the Administrator's judgments regarding the available welfare effects evidence, the  
8 appropriate degree of public welfare protection for the revised standard, and available air quality  
9 information on seasonal cumulative exposures (in terms of the W126-based exposure index<sup>1</sup>) that  
10 may be allowed by such a standard (80 FR 65292, October 26, 2015).

11 The 2020 decision to retain the standard, without revision, additionally took into account  
12 updates to the evidence base since the 2015 review, and associated conclusions regarding welfare  
13 effects; updated and expanded quantitative analyses of air quality data, including the frequency  
14 of cumulative exposures of potential concern and of elevated hourly concentrations in areas with  
15 air quality meeting the standard; and also the August 2019 decision of the D.C. Circuit  
16 remanding the 2015 secondary standard to the EPA for further justification or reconsideration, as  
17 mentioned earlier in Section 1.3 (*Murray Energy Corp. v. EPA*, 936 F.3d 597 [D.C. Cir. 2019]).  
18 In the August 2019 decision, the court held that EPA had not adequately explained its decision to  
19 focus on a 3-year average for consideration of the cumulative exposure, in terms of W126,  
20 identified as providing requisite public welfare protection, or its decision to not identify a  
21 specific level of air quality related to visible foliar injury. The EPA's decision not to use a  
22 seasonal W126 index as the form and averaging time of the secondary standard was also  
23 challenged, but the court did not reach a decision on that issue, concluding that it lacked a basis  
24 to assess the EPA's rationale because the EPA had not yet fully explained its focus on a 3-year  
25 average W126 in its consideration of the standard. Accordingly, the 2020 decision included  
26 discussion of these areas to address these aspects of the court's decision.

27 Among the updates to the welfare effects evidence considered in the 2020 decision was  
28 the welfare effects evidence for two insect-related categories of effects with new determinations  
29 in the 2020 ISA. Specifically, the 2020 ISA concluded the evidence sufficient to infer likely  
30 causal relationships of O<sub>3</sub> with alterations of plant-insect signaling and insect herbivore growth  
31 and reproduction. Uncertainties in the evidence for the effects, however, precluded a full  
32 understanding of the effects, the air quality conditions that might elicit them, and the potential

---

<sup>1</sup> The W126 index is a cumulative seasonal metric described as the sigmoidally weighted sum of all hourly O<sub>3</sub> concentrations during a specified daily and seasonal time window, with each hourly O<sub>3</sub> concentration given a weight that increases from zero to one with increasing concentration (80 FR 65373-74, October 26, 2015). The units for W126 index values are ppm-hours (ppm-hrs). More detail is provided in section 4.3.3.1.1 below.



1 for impacts in a natural ecosystem. Together this resulted in a lack of clarity in the  
2 characterization of these effects, and a lack of important quantitative information to consider  
3 such effects in the context of reviewing the standard, such as in judging how particular ambient  
4 air concentrations of O<sub>3</sub> relate to the degree of impacts on public welfare related to these effects.

5 With regard to the more well-established vegetation-related effects of O<sub>3</sub> in ambient air,  
6 the extensive evidence base considered in the 2015 and 2020 decisions documents an array of  
7 effects, ranging from the organism scale to larger-scale impacts, such as those on populations,  
8 communities, and ecosystems. These categories of effects which the 2013 and 2020 ISAs  
9 identified as causally or likely causally related to O<sub>3</sub> in ambient air include: reduced vegetation  
10 growth, reproduction, crop yield, productivity and carbon sequestration in terrestrial systems;  
11 alteration of terrestrial community composition, belowground biogeochemical cycles and  
12 ecosystem water cycling; and visible foliar injury (2013 ISA, Appendix 9; 2020 ISA, Appendix  
13 8).<sup>2</sup> Across the different types of studies, the strongest quantitative evidence available in both the  
14 2015 and 2020 reviews for effects from O<sub>3</sub> exposure on vegetation comes from controlled  
15 exposure studies of growth effects in a number of species (2013 ISA, p. 1-15). Of primary  
16 importance in considering the appropriate level of protection for the standard, both in the 2015  
17 decision establishing it and in its 2020 retention, were the studies of O<sub>3</sub> exposures that reduced  
18 growth in tree seedlings from which E-R functions of seasonal relative biomass loss (RBL)<sup>3</sup> have  
19 been established (80 FR 65385-86, 65389-90, October 26, 2015). Consistent with advice from  
20 the CASAC in both reviews, the Administrators considered the effects of O<sub>3</sub> on tree seedling  
21 growth as a surrogate or proxy for the broader array of vegetation-related effects of O<sub>3</sub>, ranging  
22 from effects on sensitive species to broader ecosystem-level effects (80 FR 65369, 65406,  
23 October 26, 2015; 85 FR 87319, 87399, December 31, 2020).

24 In their consideration of O<sub>3</sub> effects on tree seedling growth, the Administrators in both  
25 the 2015 and 2020 decisions ascribed importance to the intended use of the natural resources and  
26 ecosystems potentially affected. For example, the 2015 decision considered the available  
27 evidence and quantitative analyses in the context of an approach for considering and identifying  
28 public welfare objectives for the revised standard (80 FR 65403-65408, October 26, 2015). In  
29 light of the extensive evidence base of O<sub>3</sub> effects on vegetation and associated terrestrial

---

<sup>2</sup> The 2020 ISA also newly determined the evidence sufficient to infer likely causal relationships of O<sub>3</sub> with increased tree mortality, although it does not indicate a potential for O<sub>3</sub> concentrations that occur in locations that meet the current standard to cause this effect (85 FR 87319, December 31, 2020; 2020 PA, section 4.3.1).

<sup>3</sup> These functions were developed to quantify O<sub>3</sub>-related reduced growth in tree seedlings relative to control treatments (without O<sub>3</sub>). In this way, RBL is the percentage by which the O<sub>3</sub> treatment growth in a growing season differs from the control seedlings over the same period, and the functions provide a quantitative estimate of the reduction in a year's growth as a percentage of that expected in the absence of O<sub>3</sub> (2013 ISA, section 9.6.2; 2020 PA, Appendix 4A).

1 ecosystems, the Administrator, in both decisions, focused on protection against adverse public  
2 welfare effects of O<sub>3</sub>-related effects on vegetation, giving particular attention to such effects in  
3 natural ecosystems, such as those in areas with protection designated by Congress, and areas  
4 similarly set aside by states, tribes and public interest groups, with the intention of providing  
5 benefits to the public welfare for current and future generations (80 FR 65405, October 26, 2015;  
6 85 FR 87344, December 31, 2020).

7 Climate-related effects were also considered in both reviews (2013 ISA, Appendix 10,  
8 Section 10.3; 2020 ISA, Appendix 9, Section 9.2 and 9.3). In 2020, as was the case when the  
9 standard was set in 2015, the evidence documents tropospheric O<sub>3</sub> as a greenhouse gas causally  
10 related to radiative forcing, and likely causally related to subsequent effects on variables such as  
11 temperature and precipitation. In 2020, as in 2015, limitations and uncertainties in the evidence  
12 base affected characterization of the extent of any relationships between ground-level O<sub>3</sub>  
13 concentrations in ambient air in the U.S. and climate-related effects and preclude quantitative  
14 characterization of climate responses to changes in ground-level O<sub>3</sub> concentrations in ambient air  
15 at regional or national (vs global) scales. As a result, the EPA recognized the lack of important  
16 quantitative tools with which to consider such effects in its review of the standard. For example,  
17 it was not feasible to relate different patterns of ground-level O<sub>3</sub> concentrations at the regional  
18 (or national) scale in the U.S. with specific risks of alterations in temperature, precipitation, and  
19 other climate-related variables. Thus, the available information did not provide a sufficient basis  
20 for use in considering the adequacy of the secondary standard in either review (80 FR 65370,  
21 October 26, 2015; 85 FR 87337-87339, December 31, 2020).

22 For quantifying effects on tree seedling growth as a surrogate or proxy for a broader array  
23 of vegetation-related effects using the RBL metric, in 2015 and 2020 the evidence base provided  
24 established E-R functions for seedlings of 11 tree species (80 FR 65391-92, October 26, 2015;  
25 2014 PA, Appendix 5C; 85 FR 87307-9, 87313-4, December 31, 2020; 2020 PA, Appendix 4A).  
26 Cumulative O<sub>3</sub> exposure was evaluated in terms of the W126 cumulative seasonal exposure  
27 index, an index supported by the evidence in the 2013 and 2020 ISAs for this purpose and that  
28 was consistent with advice from the CASAC in both reviews (2013 ISA, section 9.5.3, p. 9-99;  
29 80 FR 65375, October 26, 2015; 2020 ISA, section 8.13; 85 FR 87307-8, December 31, 2020).  
30 In judgments regarding effects that are adverse to the public welfare, the decision setting the  
31 standard in 2015, and that retaining it in 2020, both utilized the RBL as a quantitative tool within  
32 a larger framework of considerations pertaining to the public welfare significance of O<sub>3</sub> effects  
33 (80 FR 65389, October 26, 2015; 73 FR 16496, March 27, 2008; 85 FR 87339-41, December 31,  
34 2020).

35 Accordingly, in both the 2015 and 2020 decisions, consideration of the appropriate public  
36 welfare protection objective for the secondary standard gave prominence to the estimates of tree

1 seedling growth impacts (in terms of RBL) for a range of W126 index values, developed from  
2 the E-R functions for 11 tree species (80 FR 65391-92, Table 4, October 26, 2015; 85 FR 87339-  
3 41, December 31, 2020). The Administrators also incorporated into their considerations the  
4 broader evidence base associated with forest tree seedling biomass loss, including other less  
5 quantifiable effects of potentially greater public welfare significance. That is, in drawing on  
6 these RBL estimates, the Administrators noted they were not simply making judgments about a  
7 specific magnitude of growth effect in seedlings that would be acceptable or unacceptable in the  
8 natural environment. Rather, though mindful of associated uncertainties, the RBL estimates were  
9 used as a surrogate or proxy for consideration of the broader array of related vegetation-related  
10 effects of potential public welfare significance, which included effects on individual species and  
11 extending to ecosystem-level effects (80 FR 65406, October 26, 2015; 85 FR 87304, December  
12 31, 2020). This broader array of vegetation-related effects included those for which public  
13 welfare implications are more significant but for which the tools for quantitative estimates were  
14 more uncertain.

15 In the 2015 decision to revise the standard level to 70 ppb, and also the 2020 decision to  
16 retain that standard, without revision, air quality analyses played an important role in the  
17 Administrator's judgments. Such judgments of the Administrator in setting the standard in 2015  
18 are briefly summarized below. These are followed by a summary of additional key aspects of the  
19 considerations and judgments associated with the decision to retain this standard in 2020.

20 In using the RBL estimates as a proxy, the Administrator in 2015 focused her attention on  
21 a revised standard that would generally limit cumulative exposures to those for which the median  
22 RBL estimate for seedlings of the 11 species with established E-R functions would be somewhat  
23 below 6% (80 FR 65406-07, October 26, 2015).<sup>4</sup> She noted that the median RBL estimate was  
24 6% for a cumulative seasonal W126 exposure index of 19 ppm-hrs (80 FR 65391-92, Table 4,  
25 October 26, 2015). Given the information on median RBL at different W126 exposure levels,  
26 using a 3-year cumulative exposure index for assessing vegetation effects,<sup>5</sup> the potential for

---

<sup>4</sup> The Administrator noted the CASAC view regarding 6%, most particularly the CASAC's characterization of this level of effect in the median studied species as "unacceptably high" (Frey, 2014, pp. iii, 13, 14). These comments were provided in the context of CASAC's considering the significance of effects associated with a range of alternatives for the secondary standard (80 FR 65406, October 26, 2015).

<sup>5</sup> Based on a number of considerations, the Administrator recognized greater confidence in judgments related to public welfare impacts based on a 3-year average metric than a single-year metric, and consequently concluded it to be appropriate to use a seasonal W126 index averaged across three years for judging public welfare protection afforded by a revised secondary standard. For example, she recognized uncertainties associated with interpretation of the public welfare significance of effects resulting from a single-year exposure, and that the public welfare significance of effects associated with multiple years of critical exposures are potentially greater than those associated with a single year of such exposure. She additionally concluded that use of a 3-year average metric could address the potential for adverse effects to public welfare that may relate to shorter exposure periods, including a single year (80 FR 65404, October 26, 2015).

1 single-season effects of concern, and CASAC comments on the appropriateness of a lower value  
2 for a 3-year average W126 index, the Administrator concluded it was appropriate to identify a  
3 standard that would restrict cumulative seasonal exposures to 17 ppm-hrs or lower, in terms of a  
4 3-year W126 index, in nearly all instances (80 FR 65407, October 26, 2015). Based on such  
5 information, available at that time, to inform consideration of vegetation effects and their  
6 potential adversity to public welfare, the Administrator additionally judged that the RBL  
7 estimates associated with marginally higher exposures in isolated, rare instances were not  
8 indicative of effects that would be adverse to the public welfare, particularly in light of  
9 variability in the array of environmental factors that can influence O<sub>3</sub> effects in different systems  
10 and uncertainties associated with estimates of effects associated with this magnitude of  
11 cumulative exposure in the natural environment (80 FR 65407, October 26, 2015).

12 Using these objectives, the 2015 decision regarding a standard revised from the then-  
13 existing (2008) standard was based on extensive air quality analyses that included the most  
14 recently available data as well as air monitoring data that extended back more than a decade (80  
15 FR 65408, October 26, 2015; Wells, 2015). These analyses evaluated the cumulative seasonal  
16 exposure levels in locations meeting different alternative levels for a standard of the existing  
17 form and averaging time. These analyses supported the Administrator's judgment that a standard  
18 with a revised level in combination with the existing form and averaging time could achieve the  
19 desired level of public welfare protection, considered in terms of cumulative exposure, quantified  
20 as the W126 index (80 FR 65408, October 26, 2015). Based on the extensive air quality analyses  
21 and consideration of the W126 index value associated with a median RBL of 6%, and the W126  
22 index values at monitoring sites that met different levels for a revised standard of the existing  
23 form and averaging time, the Administrator additionally judged that a standard level of 70 ppb  
24 would provide the requisite protection. The Administrator noted that such a standard would be  
25 expected to limit cumulative exposures, in terms of a 3-year average W126 exposure index, to  
26 values at or below 17 ppm-hrs, in nearly all instances, and accordingly, to eliminate or virtually  
27 eliminate cumulative exposures associated with a median RBL of 6% or greater (80 FR 65409,  
28 October 26, 2015).

29 The 2015 decision also took note of the well-recognized evidence for visible foliar injury  
30 and crop yield effects. However, the RBL information available for seedlings of a set of 11 tree  
31 species was judged to be more useful (particularly in a role as surrogate for the broader array of  
32 vegetation-related effects) in informing judgments regarding the nature and severity of effects  
33 associated with different air quality conditions and associated public welfare significance than  
34 the available information on visible foliar injury and crop yield effects (80 FR 65405-06,  
35 October 26, 2015). With regard to visible foliar injury, while the Administrator recognized the  
36 potential for this effect to affect the public welfare in the context of affecting value ascribed to

1 natural forests, particularly those afforded special government protection, she also recognized  
2 limitations in the available information that might inform consideration of potential public  
3 welfare impacts related to this vegetation effect noting the significant challenges in judging the  
4 specific extent and severity at which such effects should be considered adverse to public welfare  
5 (80 FR 65407, October 26, 2015).<sup>6</sup> Similarly, while O<sub>3</sub>-related growth effects on agricultural and  
6 commodity crops had been extensively studied and robust E-R functions developed for a number  
7 of species, the Administrator found this information less useful in informing judgments  
8 regarding an appropriate level of public welfare protection (80 FR 65405, October 26, 2015).<sup>7</sup>

9 In summary, the 2015 decision focused primarily on the information related to trees and  
10 growth impacts in identifying the public welfare objectives for the revised secondary standard  
11 (80 FR 65409-65410, October 26, 2015). In this context, the Administrator in 2015 judged that  
12 the 70 ppb standard would protect natural forests in Class I and other similarly protected areas  
13 against an array of adverse vegetation effects, most notably including those related to effects on  
14 growth and productivity in sensitive tree species. She additionally judged that the new standard  
15 would be sufficient to protect public welfare from known or anticipated adverse effects. These  
16 judgments by the Administrator at that time appropriately recognized that the CAA does not  
17 require that standards be set at a zero-risk level, but rather at a level that reduces risk sufficiently  
18 so as to protect the public welfare from known or anticipated adverse effects.

19 In 2020, as in 2015, the Administrator considered the available information regarding the  
20 appropriate O<sub>3</sub> exposure metric to employ in assessing adequacy of air quality control in  
21 protecting against RBL. In addition to finding it appropriate to continue to consider the seasonal  
22 W126 index averaged over a 3-year period to estimate median RBL (as was concluded in 2015),  
23 the Administrator in 2020 also judged it appropriate to also consider other metrics including peak  
24 hourly concentrations<sup>8</sup> (85 FR 87344, December 2020). With regard to these conclusions, his

---

<sup>6</sup> These limitations included the lack of established E-R functions that would allow prediction of visible foliar injury severity and incidence under varying air quality and environmental conditions, a lack of consistent quantitative relationships linking visible foliar injury with other O<sub>3</sub>-induced vegetation effects, such as growth or related ecosystem effects, and a lack of established criteria or objectives relating reports of foliar injury with public welfare impacts (80 FR 65407, October 26, 2015).

<sup>7</sup> With respect to commercial production of commodities, the Administrator noted the difficulty in discerning the extent to which O<sub>3</sub>-related effects on commercially managed vegetation are adverse from a public welfare perspective, given that the extensive management of such vegetation (which, as the CASAC noted, may reduce yield variability) may also to some degree mitigate potential O<sub>3</sub>-related effects. Management practices are highly variable and are designed to achieve optimal yields, taking into consideration various environmental conditions. Further, changes in yield of commercial crops and commercial commodities, such as timber, may affect producers and consumers differently, complicating the assessment of overall public welfare effects still further (80 FR 65405, October 26, 2015).

<sup>8</sup> Both the 2020 and 2013 ISAs reference the longstanding recognition of the risk posed to vegetation of peak hourly O<sub>3</sub> concentrations (e.g., “[h]igher concentrations appear to be more important than lower concentrations in

1 considerations included the extent of conceptual similarities of the 3-year average W126 index to  
2 some aspects of the derivation approach for the established E-R functions, the context of RBL as  
3 a proxy (as recognized above), and limitations associated with a reliance solely on W126 index  
4 as a metric to control exposures that might be termed “unusually damaging”<sup>9</sup> (85 FR 877339-40,  
5 December 31, 2020).

6 With regard to the derivation and application of the established E-R functions, the 2020  
7 review recognized several factors to contribute uncertainty and some resulting imprecision or  
8 inexactitude to RBL estimated from single-year seasonal W126 index values (85 FR 49900-01,  
9 August 14, 2020; 2020 PA sections 4.5.1.2 and 4.5.3).<sup>10</sup> Additionally recognized was the  
10 qualitative and conceptual nature of our understanding, in many cases, of relationships of O<sub>3</sub>  
11 effects on plant growth and productivity with larger-scale impacts, such as those on populations,  
12 communities and ecosystems. From these considerations, it was judged that use of a seasonal  
13 RBL averaged over multiple years, such as a 3-year average, is reasonable, and provides a more

---

eliciting a response” [ISA, p. 8-180]; “higher hourly concentrations have greater effects on vegetation than lower concentrations” [2013 ISA, p. 91-4] “studies published since the 2006 O<sub>3</sub> AQCD do not change earlier conclusions, including the importance of peak concentrations, ... in altering plant growth and yield” [2013 ISA, p. 9-117]). While the evidence does not indicate a particular threshold number of hours at or above 100 ppb (or another reference point for elevated concentrations), the evidence of greater impacts from higher concentrations (particularly with increased frequency) and the air quality analyses that document variability in such concentrations for the same W126 index value led the Administrator to judge such a multipronged approach to be needed to ensure appropriate consideration of exposures of concern and the associated protection from them afforded by the secondary standard (85 FR 87340, December 31, 2020).

<sup>9</sup> In its discussion regarding the EPA’s use of a 3-year average W126 index, the 2019 court decision remanding the 2015 standard back to the EPA referenced advice from the CASAC in the 2015 review on protection against “unusually damaging years.” Use of this term occurs in the 2014 CASAC letter on the second draft PA (Frey, 2014). Most prominently, the CASAC defined as damage “injury effects that reach sufficient magnitude as to reduce or impair the intended use or value of the plant to the public, and thus are adverse to public welfare” (Frey, 2014, p. 9). We also note that the context for the CASAC’s use of the phrase “unusually damaging years” in the 2015 review is in considering the form and averaging time for a revised secondary standard in terms of a W126 index (Frey, 2014, p. 13), which as discussed below is relatively less controlling of high-concentration years (whether as a single year index or averaged over three years) than the current secondary standard and its fourth highest daily maximum 8-hour metric (85 FR 87327, December 31, 2020).

<sup>10</sup> The E-R functions were derived mathematically from studies of different exposure durations (varying from shorter than one to multiple growing seasons) by applying adjustments so that they would yield estimates normalized to the same period of time (season). Accordingly, the estimates may represent average impact for a season, and have compatibility with W126 index averaged over multiple growing seasons or years (85 FR 87326, December 31, 2020; 2020 PA, section 4.5.1.2, Appendix 4A, Attachment 1). The available information also indicated that the patterns of hourly concentrations (and frequency of peak concentrations, e.g., at/above 100 ppb) in O<sub>3</sub> treatments on which the E-R functions are based differ from the patterns in ambient air meeting the current standard across the U.S. today (85 FR 87327, December 31, 2020). Additionally noted was the year-to-year variability of factors other than O<sub>3</sub> exposures that affect tree growth in the natural environment (e.g., related to variability in soil moisture, meteorological, plant-related and other factors), that have the potential to affect O<sub>3</sub> E-R relationships (ISA, Appendix 8, section 3.12; 2013 ISA section 9.4.8.3; PA, sections 4.3 and 4.5). All of these considerations contributed to the finding of a consistency of the use of W126 index averaged over multiple years with the approach used in deriving the E-R function, and with other factors that may affect growth in the natural environment (85 FR 87340, December 31, 2020).

1 stable and well-founded RBL estimate for its use as a proxy to represent the array of vegetation-  
2 related effects identified above. More specifically, the Administrator concluded that the use of an  
3 average seasonal W126 index derived from multiple years (with their representation of  
4 variability in environmental factors) provides an appropriate representation of the evidence and  
5 attention to the identified considerations. In so doing, he found that a sole reliance on single year  
6 W126 estimates for reaching judgments with regard to magnitude of O<sub>3</sub> related RBL and  
7 associated judgments of public welfare protection would ascribe a greater specificity and  
8 certainty to such estimates than supported by the evidence. Rather, consistent with the judgment  
9 of the prior Administrator, the Administrator in 2020 found it appropriate, for purposes of  
10 considering public welfare protection from effects for which RBL is used as a proxy, to primarily  
11 consider W126 index in terms of a 3-year average metric (85 FR 87339-87340, December 31,  
12 2020).

13 With regard to the EPA's use of a 3-year average W126 index to assess protection from  
14 RBL, the 2020 decision additionally took into account the 2019 court remand on this issue,  
15 including the remand's reference to protection against "unusually damaging years." (85 FR  
16 87325-87328, December 31, 2020). Accordingly, the EPA considered air quality analyses of  
17 peak hourly concentrations in the context of considering protection against "unusually damaging  
18 years." With regard to this caution, and in the context of controlling exposure circumstances of  
19 concern (e.g., for growth effects, among others), the EPA considered air quality analyses that  
20 investigated the annual occurrence of elevated hourly O<sub>3</sub> concentrations which may contribute to  
21 vegetation exposures of concern (2020 PA, Appendix 2A, section 2A.2; Wells, 2020). These air  
22 quality analyses illustrate limitations of the W126 index (whether in terms of a 3-year average or  
23 a single year) for the purpose of controlling peak concentrations,<sup>11</sup> and also the strengths of the  
24 current standard in this regard. The air quality analyses show that the form and averaging time of  
25 the existing standard, in addition to controlling cumulative exposures in terms of W126 (as found  
26 in the 2015 review), is much more effective than the W126 index in limiting peak concentrations  
27 (e.g., hourly O<sub>3</sub> concentrations at or above 100 ppb)<sup>12</sup> and in limiting number of days with any  
28 such hours (Wells, 2020, e.g., Figures 4, 5, 8, 9 compared to Figures 6, 7, 10 and 11).<sup>13</sup> Thus, the  
29 W126 index, by its very definition, and as illustrated by the air quality data analyses, does not

---

<sup>11</sup> The W126 index cannot, by virtue of its definition, always differentiate between air quality patterns with high peak concentrations and those without such concentrations.

<sup>12</sup> As described in section 4.3.3 below, the occurrence of high concentrations (including those at or above 100 ppb [e.g., Smith, 2012; Smith et al., 2012]), as well as cumulative exposures influence the effects of O<sub>3</sub> on plants.

<sup>13</sup> With regard to the existing standard, historical air quality data extending back to 2000 additionally show the appreciable reductions in peak concentrations that have been achieved in the U.S. as air quality has improved under O<sub>3</sub> standards of the existing form and averaging time (Wells, 2020, Figures 12 and 13).

1 provide specificity with regard to year-to-year variability in elevated hourly O<sub>3</sub> concentrations  
2 with the potential to contribute to the “unusually damaging years” that the CASAC had identified  
3 for increased concern in the 2015 review. As a result, the 2020 decision found that a standard  
4 based on a W126 index (either a 3-year or a single-year index) would not be expected to provide  
5 effective control of the peak concentrations that may contribute to “unusually damaging years”  
6 for vegetation.<sup>14</sup> Based on all of the above, the 2020 decision concluded that control of such  
7 years is a characteristic of the existing standard (the effectiveness of which is demonstrated by  
8 the air quality analyses), and that that use of a seasonal W126 averaged over a 3-year period,  
9 which is the design value period for the current standard, to estimate median RBL using the  
10 established E-R functions, in combination with a broader consideration of air quality patterns,  
11 such as peak hourly concentrations, is appropriate for considering the public welfare protection  
12 provided by the standard (85 FR 87340-87341, December 31, 2020).

13 With regard to O<sub>3</sub> effects on crop yield for which there is long-standing evidence,  
14 qualitative and quantitative, of the reducing effect of O<sub>3</sub> on the yield of many crops and a  
15 potential for public welfare significance, the 2020 decision concluded that the existing standard  
16 provides adequate protection of public welfare related to crop yield loss (85 FR 87342,  
17 December 31, 2020). Key considerations in this conclusion included the established E-R  
18 functions for 10 crops and the estimates of RYL derived from them (2020 ISA, 2020 PA,  
19 Appendix 4A, section 4A.1, Table 4A-4), as well as the existence of a number of complexities  
20 related to the heavy management of many crops to obtain a particular output for commercial  
21 purposes, and related to other factors (85 FR 87341-87342, December 31, 2020). For example,  
22 the Administrator considered the extensive management of agricultural crops that occurs to elicit  
23 optimum yields (e.g., through irrigation and usage of soil amendments, such as fertilizer) to be  
24 relevant in evaluating the extent of RYL estimated from experimental O<sub>3</sub> exposures that should  
25 be judged adverse to the public welfare. With regard to the E-R functions for RYL for 10 crops,  
26 the Administrator considered the air quality data with regard to the W126 index levels and  
27 corresponding estimated RYL for the median species. He also took into consideration the  
28 extensive management of agricultural crops, and the complexities associated with identifying  
29 adverse public welfare effects for market-traded goods (where producers and consumers may be  
30 impacted differently). Further, he noted that the secondary standard is not intended to protect  
31 against all known or anticipated O<sub>3</sub>-related effects, but rather those that are judged to be adverse  
32 to the public welfare. The air quality data indicated that the current standard generally maintains

---

<sup>14</sup> From these analyses, the Administrator concluded that the form and averaging time of the current standard is effective in controlling peak hourly concentrations and that a W126 index based standard would be much less effective in providing the needed protection against years with such elevated and potentially damaging hourly concentrations.



1 air quality at a W126 index below 17 ppm-hrs, with few exceptions, and would accordingly limit  
2 the associated estimates of median RYL below 5.1% (based on experimental O<sub>3</sub> exposures), a  
3 level which the Administrator judged would not constitute an adverse effect on public welfare.  
4 Therefore, he concluded that the current standard provides adequate protection of public welfare  
5 related to crop yield loss and did not need to be revised to provide additional protection against  
6 this effect (85 FR 87342, December 31, 2020).

7 With regard to visible foliar injury, the Administrator considered the question of a level  
8 of air quality that would provide protection against visible foliar injury related effects known or  
9 anticipated to cause adverse effects to the public welfare. Based on the evidence and associated  
10 quantitative analyses in this review, summarized in the 2020 PA, the Administrator's judgment  
11 reflected his recognition of less confidence and greater uncertainty in the existence of adverse  
12 public welfare effects with lower O<sub>3</sub> exposures (85 FR 87342-87344, December 31, 2020).

13 While recognizing there to be a paucity of established approaches for interpreting specific levels  
14 of severity and extent of foliar injury in natural areas with regard to impacts on the public  
15 welfare (e.g., related to recreational services), the Administrator recognized that injury to whole  
16 stands of trees of a severity apparent to the casual observer (e.g., when viewed as a whole from a  
17 distance) would reasonably be expected to affect recreational values and thus pose a risk of  
18 adverse effects to the public welfare. He further noted that the available information did not  
19 provide for specific characterization of the incidence and severity that would not be expected to  
20 be apparent to the casual observer, nor for clear identification of the pattern of O<sub>3</sub> concentrations  
21 that would provide for such a situation. In recognizing that quantitative analyses and evidence  
22 are lacking that might support a more precise identification of a severity of visible foliar injury  
23 and extent of occurrence that might be judged adverse to the public welfare, the Administrator  
24 considered the USFS system for interpreting visible foliar injury impacts in surveys conducted at  
25 biomonitoring sites (biosites) across the U.S. from 1994 through 2011. At these sites, the USFS  
26 followed a national protocol that includes a scoring system with descriptors for biosite index  
27 (BI)<sup>15</sup> scores of differing magnitude for his purposes in this regard. More specifically, he  
28 concluded that findings of BI scores categorized as "moderate to severe" injury by the USFS  
29 scheme would be an indication of visible foliar injury occurrence that, depending on extent and  
30 severity, may raise public welfare concerns. In this framework, the Administrator considered the  
31 2020 PA evaluations of the available information and what that information indicated with  
32 regard to patterns of air quality of concern for such an occurrence, and the extent to which they  
33 are expected to occur in areas that meet the current standard. For example, the incidence of  
34 nonzero BI scores, and particularly of relatively higher scores such as those above 15, classified

---

<sup>15</sup> The BI is a measure of the severity of O<sub>3</sub>-induced visible foliar injury observed at each biosite (Smith, 2012).

1 as indicative of “moderate to severe” injury in the USFS scheme appear to markedly increase  
2 only with W126 index values above 25 ppm-hrs. He further took note of the multiple published  
3 studies analyzing the USFS data across multiple years and multiple U.S. regions with regard to  
4 metrics intended to quantify influential aspects of O<sub>3</sub> air quality, which indicated a potential role  
5 for an additional metric related to the occurrence of days with relatively high hourly  
6 concentrations (e.g., number of days with a 1-hour concentration at or above 100 ppb [2020 PA,  
7 section 4.5.1.2]). In light of this evidence and the 2020 PA analyses of these data, the  
8 Administrator judged that W126 index values at or below 25 ppm-hrs, when in combination with  
9 infrequent occurrences of hourly concentrations at or above 100 ppb, would not be anticipated to  
10 pose risk of visible foliar injury of an extent and severity so as to be adverse to the public welfare  
11 (85 FR 87343, December 31, 2020).

12 With these conclusions in mind, the Administrator considered the available air quality  
13 analyses (85 FR 87316-18, December 31, 2020; 2020 PA, Appendix 4C, section 4C.3; Appendix  
14 4D; Wells, 2020). Together these analyses indicated that a W126 index above 25 ppm-hrs (either  
15 as a 3-year average or in a single year) is not seen to occur at monitoring locations where the  
16 current standard is met (including in or near Class I areas), and that, in fact, values above 17 or  
17 19 ppm-hrs are rare and that days with any hourly concentrations at or above 100 ppb at  
18 monitoring sites that meet the current standard are uncommon. Based on these findings, the  
19 Administrator concluded that the current standard provides control of air quality conditions that  
20 contribute to increased BI scores and to scores of a magnitude indicative of “moderate to severe”  
21 foliar injury. Further, he noted the 2020 PA finding that the information from the USFS biosite  
22 monitoring program, particularly in locations meeting the current standard or with W126 index  
23 estimates likely to occur under the current standard, does not indicate a significant extent and  
24 degree of injury (e.g., based on analyses of BI scores in the PA, Appendix 4C) or specific  
25 impacts on recreational or related services for areas, such as wilderness areas or national parks,  
26 thus giving credence to the associated 2020 PA conclusion that the evidence indicates that areas  
27 that meet the current standard are unlikely to have BI scores reasonably considered to be impacts  
28 of public welfare significance (85 FR 87344, December 31, 2020).

29 Before reaching a final decision on the standard, the Administrator, in returning to his  
30 primary focus on RBL in its role as proxy for the broader array of vegetation-related effects of  
31 O<sub>3</sub>, further considered the available analyses of both the air quality data newly available in the  
32 2020 review and of historical air quality at sites across the U.S., particularly including those sites  
33 in or near Class I areas, for which the findings were consistent with the air quality analyses

1 available in the 2015 review.<sup>16</sup> That is, in virtually all design value periods between 2000 and  
2 2018 and all locations at which the current standard was met across the 19 years and 17 design  
3 value periods (in more than 99.9% of such observations), the 3-year average W126 metric was at  
4 or below 17 ppm-hrs. Further, in all such design value periods and locations the 3-year average  
5 W126 index was at or below 19 ppm-hrs (85 FR 87344, December 31, 2020).

6 The Administrator additionally considered the protection provided by the current  
7 standard from the occurrence of O<sub>3</sub> exposures within a single year with potentially damaging  
8 consequences, including a significantly increased incidence of areas with visible foliar injury that  
9 might be judged moderate to severe. He gave particular focus to BI scores above 15, termed  
10 “moderate to severe injury” by the USFS categorization scheme (85 FR 87344, December 31,  
11 2020; 2020 PA, sections 4.3.3.2, 4.5.1.2 and Appendix 4C). As discussed above, the incidence of  
12 USFS sites with BI scores above 15 markedly increases with W126 index estimates above 25  
13 ppm-hrs, a magnitude of W126 index indicated by the air quality analysis to be scarce at sites  
14 that meet the current standard, with just a single occurrence across all U.S. sites with design  
15 values meeting the current standard in the 19-year historical dataset dating back to 2000 (2020  
16 PA, section 4.4, and Appendix 4D). Further, in light of the evidence indicating that peak short-  
17 term concentrations (e.g., of durations as short as one hour) may also play a role in the  
18 occurrence of visible foliar injury, the Administrator additionally took note of the air quality  
19 analyses of hourly concentrations (2020 PA, Appendix 2A; Wells 2020). These analyses of data  
20 from the past 20 years show a declining trend in 1-hour daily maximum concentrations mirroring  
21 the declining trend in design values, supporting the 2020 PA conclusion that the form and  
22 averaging time of the current standard provides appreciable control of peak 1-hour  
23 concentrations. Furthermore, these analyses for the period from 2000 to 2018 indicate that sites  
24 meeting the current standard had only a few days (up to just seven) with hourly concentrations at  
25 or above 100 ppb (Wells, 2020). In light of these findings from the air quality analyses and  
26 considerations in the 2020 PA, both with regard to 3-year average W126 index values at sites  
27 meeting the current standard and the rarity of such values at or above 19 ppm-hrs, and with  
28 regard to single-year W126 index values at sites meeting the current standard, and the rarity of  
29 such values above 25 ppm-hrs, as well as with regard to the appreciable control of 1-hour daily  
30 maximum concentrations, the Administrator judged that the current standard provides adequate  
31 protection from air quality conditions with the potential to be adverse to the public welfare (85  
32 FR 87344, December 31, 2020).

---

<sup>16</sup> These data are distributed across all nine NOAA climate regions and 50 states, although some geographic areas within specific regions and states may be more densely covered and represented by monitors than others (2020 PA, Appendix 4D).

1 In reaching his conclusion on the current secondary O<sub>3</sub> standard, the Administrator  
2 recognized, as is the case in NAAQS reviews in general, his decision depended on a variety of  
3 factors, including science policy judgments and public welfare policy judgments, as well as the  
4 available information. In the 2020 decision, the Administrator gave primary attention to the  
5 principal effects of O<sub>3</sub> as recognized in the current ISA, the 2013 ISA and past AQCDs, and for  
6 which the evidence is strongest (e.g., growth, reproduction, and related larger-scale effects, as  
7 well as visible foliar injury). With regard to growth and the categories of effects identified above  
8 for which RBL has been identified for use as a proxy, based on all of the identified  
9 considerations, including the discussion of air quality immediately above, the Administrator  
10 judged the current standard to provide adequate protection for air quality conditions with the  
11 potential to be adverse to the public welfare. Further, with regard to visible foliar injury, the  
12 Administrator concluded that the available information on visible foliar injury and with regard to  
13 air quality analyses that may be informative to identification of air quality conditions associated  
14 with appreciably increased incidence and severity of BI scores at USFS biomonitoring sites, and  
15 with particular attention to Class I and other areas afforded special protection, indicated the  
16 current standard to provide adequate protection from visible foliar injury of an extent or severity  
17 that might be anticipated to be adverse to the public welfare.

18 In summary, the 2020 decision was based on consideration of the public welfare  
19 protection afforded by the secondary O<sub>3</sub> standard from identified O<sub>3</sub>-related welfare effects, and  
20 from their potential to present adverse effects to the public welfare, and also on judgments  
21 regarding what the available evidence, quantitative information, and associated uncertainties and  
22 limitations (such as those identified above) indicate with regard to the protection provided from  
23 the array of O<sub>3</sub> welfare effects. As a whole, the decision found that this information did not  
24 indicate the current standard to allow air quality conditions with implications of concern for the  
25 public welfare. Based on all of the identified considerations, as well as consideration of advice  
26 from the CASAC<sup>17</sup> and public comment, and including consideration of the available evidence  
27 and quantitative exposure/risk information, the Administrator concluded the current secondary  
28 standard to be requisite to protect the public welfare from known or anticipated adverse effects  
29 of O<sub>3</sub> and related photochemical oxidants in ambient air, and thus that the standard should be  
30 retained without revision (85 FR 87345, December 31, 2020).

---

<sup>17</sup> Among other things, in the 2020 letter communicating the CASAC's comments on the 2019 draft PA, the CASAC advised EPA that it "finds, in agreement with the EPA, that the available evidence does not reasonably call into question the adequacy of the current secondary ozone standard and concurs that it should be retained" (Cox, 2020, p. 1). It further stated that the approach described in the draft PA to considering the evidence for welfare effects "is laid out very clearly, thoroughly discussed and documented, and provided a solid scientific underpinning for the EPA conclusion leaving the current secondary standard in place" (85 FR 87318-87319, December 31, 2020).

## 4.2 GENERAL APPROACH AND KEY ISSUES


As in the case for secondary standard reviews, this reconsideration of the 2020 decision on the secondary standard is fundamentally based on using the Agency's assessment of the scientific evidence and associated quantitative analyses to inform the Administrator's judgments regarding a secondary standard that is requisite to protect the public welfare from known or anticipated adverse effects. This approach builds on the substantial assessments and evaluations performed over the course of O<sub>3</sub> NAAQS reviews to inform our understanding of the key-policy relevant issues in this reconsideration of the 2020 decision. As noted above, we are also considering the court's 2019 decision on the O<sub>3</sub> secondary standard, particularly with regard to issues raised by the court in its remand of the standard (recognized in section 4.1.2 above) as was also done as part of the 2020 decision on the standard.

The evaluations in the PA, of the scientific assessments in the ISA (building on prior such assessments) augmented by quantitative air quality and exposure analyses, are intended to inform the Administrator's public welfare policy judgments and conclusions, including his decisions regarding the O<sub>3</sub> standards. The PA considers the potential implications of various aspects of the scientific evidence, the air quality, exposure or risk-based information, and the associated uncertainties and limitations. Thus, the approach for this PA involves evaluating the available scientific and technical information to address a series of key policy-relevant questions using both evidence- and exposure/risk-based considerations. Together, consideration of the full set of evidence and information available will inform the answer to the following initial overarching question:

**Do the available scientific evidence and exposure-/risk-based information support or call into question the adequacy of the public welfare protection afforded by the current secondary O<sub>3</sub> standard?**

In reflecting on this question in the remaining sections of this chapter, we consider the body of scientific evidence assessed in the ISA, and considered as a basis for developing or interpreting air quality and exposure analyses, including whether it supports or calls into question the scientific conclusions reached in the 2020 review regarding welfare effects related to exposure to O<sub>3</sub> in ambient air. Information that may be informative to public policy judgments on the significance or adversity of key effects on the public welfare is also considered. Additionally, the available exposure and air quality information is considered, including with regard to the extent to which it may continue to support judgments made in previous reviews. Further, in considering this question with regard to the secondary O<sub>3</sub> standard, we give particular attention to exposures and risks for effects with the greatest potential for public welfare significance. Evaluation of the available scientific evidence and exposure/risk information with regard to consideration of the current standard and the overarching question above focuses on

1 key policy-relevant issues by addressing a series of questions on specific topics. Figure 3-1  
2 summarizes, in general terms, the approach to considering the available information in the  
3 context of policy-relevant questions pertaining to the secondary standard.  
4



1

2 **Figure 4-1. Overview of general approach for the secondary O<sub>3</sub> standard.**

1 The Agency's approach with regard to the O<sub>3</sub> secondary standard is consistent with the  
2 requirements of the provisions of the CAA related to the review of NAAQS and with how the  
3 EPA and the courts have historically interpreted these provisions. As discussed in section 1.2  
4 above, these provisions require the Administrator to establish secondary standards that, in the  
5 Administrator's judgment, are requisite (i.e., neither more nor less stringent than necessary) to  
6 protect the public welfare from known or anticipated adverse effects associated with the presence  
7 of the pollutant in the ambient air. Consistent with the Agency's approach across NAAQS  
8 reviews, the approach of this PA to informing the Administrator's judgments is based on a  
9 recognition that the available evidence generally reflects continuums that include ambient air  
10 exposures for which scientists generally agree that effects are likely to occur through lower  
11 levels at which the likelihood and magnitude of response become increasingly uncertain. The  
12 CAA does not require that standards be set at a zero-risk level, but rather at a level that reduces  
13 risk sufficiently so as to protect the public welfare from known or anticipated adverse effects.

14 The Agency's decisions on the adequacy of the current secondary standard and, as  
15 appropriate, on any potential alternative standards considered in a review, are largely public  
16 welfare policy judgments made by the Administrator. The four basic elements of the NAAQS  
17 (i.e., indicator, averaging time, form, and level) are considered collectively in evaluating the  
18 protection afforded by the current standard, or by any alternatives considered. Thus, the  
19 Administrator's final decisions in such reviews draw upon the scientific information and  
20 analyses about welfare effects, environmental exposures and risks, and associated public welfare  
21 significance, as well as judgments about how to consider the range and magnitude of  
22 uncertainties that are inherent in the scientific evidence and analyses.

### 23 **4.3 WELFARE EFFECTS EVIDENCE**

24 The welfare effects evidence on which this PA for the reconsideration of the 2020  
25 decision on the O<sub>3</sub> secondary standard will focus is the evidence described in the 2020 ISA and  
26 prior ISAs or AQCDs. As described in section 1.5 above, the EPA has provisionally considered  
27 more recently available studies that were raised in public comments in the 2020 review or were  
28 identified in a literature search that the EPA conducted for this reconsideration of more recently  
29 available controlled human exposure studies (Luben et al., 2020; Duffney et al. 2022). The  
30 provisional consideration of these studies concluded that, taken in context, the associated  
31 information and findings did not materially change any of the broad scientific conclusions of the  
32 ISA regarding the health and welfare effects of O<sub>3</sub> in ambient air or warrant reopening the air  
33 quality criteria for this review. Thus, the discussion below focuses on the welfare effects  
34 evidence assessment, with associated conclusions, as described in the 2020 ISA.



### 4.3.1 Nature of Effects

The welfare effects evidence base includes more than fifty years of extensive research on the phytotoxic effects of O<sub>3</sub>, conducted both in and outside of the U.S., that documents the impacts of O<sub>3</sub> on plants and their associated ecosystems (1978 AQCD, 1986 AQCD, 1996 AQCD, 2006 AQCD, 2013 ISA, 2020 ISA). As has been long established, O<sub>3</sub> can interfere with carbon gain (photosynthesis) and allocation of carbon within the plant, making fewer carbohydrates available for plant growth, reproduction, and/or yield (1996 AQCD, pp. 5-28 and 5-29). For seed-bearing plants, reproductive effects can include reduced seed or fruit production or yield. The strongest evidence for effects from O<sub>3</sub> exposure on vegetation was recognized at the time of the 2015 review to be from controlled exposure studies, which “have clearly shown that exposure to O<sub>3</sub> is causally linked to visible foliar injury, decreased photosynthesis, changes in reproduction, and decreased growth” in many species of vegetation (2013 ISA, p. 1-15). Such effects at the plant scale can also be linked to an array of effects at larger spatial scales (and higher levels of biological organization), with the evidence available in the 2015 review indicating that “O<sub>3</sub> exposures can affect ecosystem productivity, crop yield, water cycling, and ecosystem community composition” (2013 ISA, p. 1-15, Chapter 9, section 9.4). Beyond its effects on plants, the evidence in the 2015 review also recognized O<sub>3</sub> in the troposphere as a major greenhouse gas (ranking behind carbon dioxide and methane in importance), with associated radiative forcing and effects on climate, with accompanying “large uncertainties in the magnitude of the radiative forcing estimate ... making the impact of tropospheric O<sub>3</sub> on climate more uncertain than the effect of the longer-lived greenhouse gases (2013 ISA, sections 10.3.4 and 10.5.1 [p. 10-30]).

- **Does the available evidence alter prior conclusions regarding the nature of welfare effects attributable to O<sub>3</sub> in ambient air? Is there new evidence on welfare effects beyond those identified in the 2015 review?**

The available evidence supports, sharpens, and expands somewhat on the conclusions reached in the 2015 review (ISA, Appendices 8 and 9). Consistent with the previously available evidence, the available evidence describes an array of O<sub>3</sub> effects on vegetation and related ecosystem effects, as well as the role of tropospheric O<sub>3</sub> in radiative forcing and subsequent climate-related effects. The ISA concludes there to be causal relationships between O<sub>3</sub> and visible foliar injury, reduced vegetation growth and reduced plant reproduction,<sup>18</sup> as well as reduced yield and quality of agricultural crops, reduced productivity in terrestrial ecosystems,

---

<sup>18</sup> The 2013 ISA did not include a separate causality determination for reduced plant reproduction. Rather, it was included with the conclusion of a causal relationship of O<sub>3</sub> with reduced vegetation growth (ISA, Table IS-12).

1 alteration of terrestrial community composition<sup>19</sup>, and alteration of belowground biogeochemical  
2 cycles (ISA, section IS.5). The ISA also concludes there likely to be a causal relationship  
3 between O<sub>3</sub> and alteration of ecosystem water cycling, reduced carbon sequestration in terrestrial  
4 ecosystems, and with increased tree mortality (ISA, section IS.5). Additionally, newly available  
5 evidence in the 2020 ISA augments more limited previously available evidence related to insect  
6 interactions with vegetation, contributing to the ISA conclusion that the evidence is sufficient to  
7 infer that there are likely to be causal relationships between O<sub>3</sub> exposure and alteration of plant-  
8 insect signaling (ISA, Appendix 8, section 8.7) and of insect herbivore growth and reproduction  
9 (ISA, Appendix 8, section 8.6). Thus, prior conclusions continue to be supported and conclusions  
10 are also reached in the 2020 ISA for a few new areas based on the now expanded evidence.

11 As in the 2015 review, the strongest evidence and the associated findings of causal or  
12 likely causal relationships with O<sub>3</sub> in ambient air, and the quantitative characterizations of  
13 relationships between O<sub>3</sub> exposure and occurrence and magnitude of effects are for vegetation  
14 effects. The scales of these effects range from the individual plant scale to the ecosystem scale,  
15 with potential for impacts on the public welfare (as discussed in section 4.3.2 below). The  
16 following summary addresses the identified vegetation-related effects of O<sub>3</sub> across these scales.

17 Visible foliar injury has long been used as a bioindicator of O<sub>3</sub> exposures, although it is  
18 not always a reliable indicator of other negative effects on vegetation (ISA, sections IS.5.1.2 and  
19 8.2, and Appendix 8, section 8.2; 2013 ISA, section 9.4.2; 2006 AQCD, 1996 AQCD, 1986  
20 AQCD, 1978 AQCD). More specifically, ozone-induced visible foliar injury symptoms on  
21 certain tree and herbaceous species, such as black cherry, yellow-poplar and common milkweed,  
22 have long been considered diagnostic of exposure to elevated O<sub>3</sub> based on the consistent  
23 association established with experimental evidence (ISA, Appendix 8, section 8.2; 2013 ISA, p.  
24 1-10).<sup>20</sup> The available evidence, consistent with that in past reviews, indicates that “visible foliar  
25 injury usually occurs when sensitive plants are exposed to elevated ozone concentrations in a  
26 predisposing environment,” with a major factor for such an environment being the amount of soil  
27 moisture available to the plant (ISA, Appendix 8, p. 8-23; 2013 ISA, section 9.4.2). The  
28 significance of O<sub>3</sub> injury at the leaf and whole plant levels also depends on an array of factors  
29 that include the amount of total leaf area affected, age of plant, size, developmental stage, and  
30 degree of functional redundancy among the existing leaf area (ISA, Appendix 8, section 8.2;

---

<sup>19</sup> The 2013 ISA concluded alteration of terrestrial community composition to be likely causally related to O<sub>3</sub> based on the then available information (ISA, Table IS-12).

<sup>20</sup> As described in the ISA, “[t]ypical types of visible injury to broadleaf plants include stippling, flecking, surface bleaching, bifacial necrosis, pigmentation (e.g., bronzing), and chlorosis or premature senescence and [t]ypical visible injury symptoms for conifers include chlorotic banding, tip burn, flecking, chlorotic mottling, and premature senescence of needles” (ISA, Appendix 8, p. 8-13).

1 2013 ISA, section 9.4.2). Such modifying factors contribute to the difficulty in quantitatively  
2 relating visible foliar injury to other vegetation effects (e.g., individual tree growth, or effects at  
3 population or ecosystem levels), such that visible foliar injury “is not always a reliable indicator  
4 of other negative effects on vegetation” (ISA, Appendix 8, section 8.2; 2013 ISA, p. 9-39).<sup>21</sup>

5 Effects of O<sub>3</sub> on physiology of individual plants at the cellular level, such as through  
6 photosynthesis and carbon allocation, can impact plant growth and reproduction (ISA, section  
7 IS.5.1.2, Appendix 8, sections 8.3 and 8.4; 2013 ISA, p. 9-42). The available studies come from  
8 a variety of different study types that cover an array of different species, effects endpoints, and  
9 exposure methods and durations. In addition to studies on scores of plant species that have found  
10 O<sub>3</sub> to reduce plant growth, the evidence accumulated over the past several decades documents O<sub>3</sub>  
11 alteration of allocation of biomass within the plant and plant reproduction (ISA, Appendix 8,  
12 sections 8.3 and 8.4; 2013 ISA, p. 1-10). The biological mechanisms underlying the effect of O<sub>3</sub>  
13 on plant reproduction include “both direct negative effects on reproductive tissues and indirect  
14 negative effects that result from decreased photosynthesis and other whole plant physiological  
15 changes” (ISA, section IS.5.1.2). A newly available meta-analysis of more than 100 studies  
16 published between 1968 and 2010 summarizes effects of O<sub>3</sub> on multiple measures of  
17 reproduction (ISA, Appendix 8, section 8.4.1).

18 Studies involving experimental field sites have also reported effects on measures of plant  
19 reproduction, such as effects on seeds (reduced weight, germination, and starch levels) that could  
20 lead to a negative impact on species regeneration in subsequent years, and bud size that might  
21 relate to a delay in spring leaf development (ISA, Appendix 8, section 8.4; 2013 ISA, section  
22 9.4.3; Darbah et al., 2007, Darbah et al., 2008). A more recent laboratory study reported 6-hour  
23 daily O<sub>3</sub> exposures of flowering mustard plants to 100 ppb during different developmental stages  
24 to have mixed effects on reproductive metrics. While flowers exposed early *versus* later in  
25 development produced shorter fruits, the number of mature seeds per fruit was not significantly  
26 affected by flower developmental stage of exposure (ISA, Appendix 8, section 8.4.1; Black et al.,  
27 2012). Another study assessed seed viability for a flowering plant in laboratory and field

---

<sup>21</sup> Similar to the 2013 ISA, the 2020 ISA states the following (ISA, pp. 8-23 to 8-24).

Although visible injury is a valuable indicator of the presence of phytotoxic concentrations of ozone in ambient air, it is not always a reliable indicator of other negative effects on vegetation [e.g., growth, reproduction; U.S. EPA (2013)]. The significance of ozone injury at the leaf and whole-plant levels depends on how much of the total leaf area of the plant has been affected, as well as the plant’s age, size, developmental stage, and degree of functional redundancy among the existing leaf area (U.S. EPA, 2013). Previous ozone AQCDs have noted the difficulty in relating visible foliar injury symptoms to other vegetation effects, such as individual plant growth, stand growth, or ecosystem characteristics (U.S. EPA, 2006, 1996). Thus, it is not presently possible to determine, with consistency across species and environments, what degree of injury at the leaf level has significance to the vigor of the whole plant.

1 conditions, finding effects on seed viability of O<sub>3</sub> exposures (90 and 120 ppb) under laboratory  
2 conditions but less clear effects under more field-like conditions (ISA, Appendix 8, section 8.4.1;  
3 Landesmann et al., 2013).

4 With regard to agricultural crops, the current evidence base, as in the 2015 review, is  
5 sufficient to infer a causal relationship between O<sub>3</sub> exposure and reduced yield and quality (ISA,  
6 section IS.5.1.2). The evidence in the current ISA is augmented by new research in a number of  
7 areas, including studies on soybean, wheat, and other non-soy legumes. The new information  
8 assessed in the ISA remains consistent with the conclusions reached in the 2013 ISA (ISA,  
9 section IS.5.1.2).

10 The evidence base for trees includes a number of studies conducted at the Aspen free-air  
11 carbon-dioxide and ozone enrichment (FACE) experiment site in Wisconsin (that operated from  
12 1998 through 2011) and also available in the 2015 review (ISA, IS.5.1 and Appendix 8, section  
13 8.1.2.1; 2013 ISA, section 9.2.4). These studies, which occurred in a field setting (more similar  
14 to natural forest stands than open-top-chamber studies), reported reduced tree growth when  
15 grown in single or three species stands within 30-m diameter rings and exposed over one or more  
16 years to elevated O<sub>3</sub> concentrations (hourly concentrations 1.5 times concentrations in ambient  
17 air at the site) compared to unadjusted ambient air concentrations (2013 ISA, section 9.4.3;  
18 Kubiske et al., 2006, Kubiske et al., 2007).<sup>22</sup>

19 With regard to tree mortality, the 2013 ISA did not include a determination of causality  
20 (ISA, Appendix 8, section 8.4). While the then-available evidence included studies identifying  
21 ozone as a contributor to tree mortality, which contributed to the 2013 conclusion regarding O<sub>3</sub>  
22 and alteration of community composition (2013 ISA, section 9.4.7.4), a separate causality  
23 determination regarding O<sub>3</sub> and tree mortality was not assessed (ISA, Appendix 8, section 8.4;  
24 2013 ISA, Table 9-19). The evidence assessed in the 2013 ISA (and 2006 AQCD) was largely  
25 observational, including studies that reported declines in conifer forests for which elevated O<sub>3</sub>  
26 was identified as contributor but in which a variety of environmental factors may have also  
27 played a role (2013 ISA, section 9.4.7.1; 2006 AQCD, sections AX9.6.2.1, AX9.6.2.2,  
28 AX9.6.2.6, AX9.6.4.1 and AX9.6.4.2). Since the 2015 review, three additional studies are now  
29 available (ISA, Appendix 8, Table 8-9). Two of these are analyses of field observations, one of  
30 which is set in the Spanish Pyrenees.<sup>23</sup> A second study is a large-scale empirical statistical

---

<sup>22</sup> Seasonal (92-day) W126 index values for unadjusted O<sub>3</sub> concentrations over six years of the Aspen FACE experiments ranged from 2 to 3 ppm-hrs, while the elevated exposure concentrations (reflecting addition of O<sub>3</sub> to ambient air concentrations) ranged from somewhat above 20 to somewhat above 35 ppm-hrs (ISA, Appendix 8, Figure 8-17).

<sup>23</sup> The concentration gradient with altitude in the Spanish study, includes - at the highest site - annual average April-to-September O<sub>3</sub> concentrations for the 2004 to 2007 period that range up to 74 ppb (Diaz-de-Quijano et al., 2016), indicating O<sub>3</sub> concentrations likely to exceed the current U.S. secondary standard.

1 analysis of factors potentially contributing to tree mortality in eastern and central U.S. forests  
2 during the 1971-2005 period, which reported O<sub>3</sub> (county-level 11-year [1996-2006] average 8  
3 hour metric)<sup>24</sup> to be ninth among the 13 potential factors assessed<sup>25</sup> and to have a significant  
4 positive correlation with tree mortality (ISA, section IS.5.2, Appendix 8, section 8.4.3; Dietze  
5 and Moorcroft, 2011). A newly available experimental study also reported increased mortality in  
6 two of five aspen genotypes grown in mixed stands under elevated O<sub>3</sub> concentrations (ISA,  
7 section IS.5.1.2; Moran and Kubiske, 2013). Coupled with the plant-level evidence of  
8 phytotoxicity discussed above, as well as consideration of community composition effects, this  
9 evidence was concluded to indicate the potential for elevated O<sub>3</sub> concentrations to contribute to  
10 tree mortality (ISA, section IS.5.1.2 and Appendix 8, sections 8.4.3 and 8.4.4). Based on the  
11 available evidence, the ISA concludes there is likely to be a causal relationship between O<sub>3</sub> and  
12 increased tree mortality (ISA, Table IS-2, Appendix 8, section 8.4.4).

13 A variety of factors in natural environments can either mitigate or exacerbate predicted  
14 O<sub>3</sub>-plant interactions and are recognized sources of uncertainty and variability. Such factors at  
15 the plant level include multiple genetically influenced determinants of O<sub>3</sub> sensitivity, changing  
16 sensitivity to O<sub>3</sub> across vegetative growth stages, co-occurring stressors and/or modifying  
17 environmental factors (ISA, Appendix 8, section 8.12).

18 Ozone-induced effects at the scale of the whole plant have the potential to translate to  
19 effects at the ecosystem scale, such as reduced productivity and carbon storage, and altered  
20 terrestrial community composition, as well as impacts on ecosystem functions, such as  
21 belowground biogeochemical cycles and ecosystem water cycling. For example, under the  
22 relevant exposure conditions, O<sub>3</sub>-related reduced tree growth and reproduction, as well as  
23 increased mortality, could lead to reduced ecosystem productivity. Recent studies from the  
24 Aspen FACE experiment and modeling simulations indicate that O<sub>3</sub>-related negative effects on  
25 ecosystem productivity may be temporary or may be limited in some systems (ISA, Appendix 8,  
26 section 8.8.1). Previously available studies had reported impacts on productivity in some forest  
27 types and locations, such as ponderosa pine in southern California and other forest types in the  
28 mid-Atlantic region (2013 ISA, section 9.4.3.4). Through reductions in sensitive species growth,

---

<sup>24</sup> As indicated in Figures 2-11 and 2-12, annual fourth highest daily maximum 8-hour O<sub>3</sub> concentrations in these regions were above 80 ppb in the early 2000s and the median design values at national trend sites was nearly 85 ppb.

<sup>25</sup> This statistical analysis, which utilized datasets from within the 1971-2005 period, included an examination of the sensitivity of predicted mortality rate to 13 different covariates. On average across the predictions for 10 groups of trees (based on functional type and major representative species), the order of mortality rate sensitivity to the covariates, from highest to lowest, was: sulfate deposition, tree diameter, nitrate deposition, summer temperature, tree age, elevation, winter temperature, precipitation, O<sub>3</sub> concentration, tree basal area, topographic moisture index, slope and topographic radiation index (Dietze and Moorcroft, 2011).

1 and related ecosystem productivity, O<sub>3</sub> could lead to reduced ecosystem carbon storage (ISA,  
2 IS.5.1.4; 2013 ISA, section 9.4.3). With regard to forest community composition, available  
3 studies have reported changes in tree communities composed of species with relatively greater  
4 and relatively lesser sensitivity to O<sub>3</sub>, such as birch and aspen, respectively (ISA, section  
5 IS.5.1.8.1, Appendix 8, section 8.10; 2013 ISA, section 9.4.3; Kubiske et al., 2007). As the ISA  
6 concludes, “[t]he extent to which ozone affects terrestrial productivity will depend on more than  
7 just community composition, but other factors, which both directly influence [net primary  
8 productivity] (i.e., availability of N and water) and modify the effect of ozone on plant growth”  
9 (ISA, Appendix 8, section 8.8.1). Thus, the magnitude of O<sub>3</sub> impact on ecosystem productivity,  
10 as on forest composition, can vary among plant communities based on several factors, including  
11 the type of stand or community in which the sensitive species occurs (e.g., single species *versus*  
12 mixed canopy), the role or position of the species in the stand (e.g., dominant, sub-dominant,  
13 canopy, understory), and the sensitivity of co-occurring species and environmental factors (e.g.,  
14 drought and other factors).

15 The effects of O<sub>3</sub> on plants and plant populations also have implications for other  
16 ecosystem functions. Two such functions, effects with which O<sub>3</sub> is concluded to be likely  
17 causally or causally related, are ecosystem water cycling and belowground biogeochemical  
18 cycles, respectively (ISA, Appendix 8, sections 8.11 and 8.9). With regard to the former, the  
19 effects of O<sub>3</sub> on plants (e.g., *via* stomatal control, as well as leaf and root growth and changes in  
20 wood anatomy associated with water transport) can affect ecosystem water cycling through  
21 impacts on root uptake of soil moisture and groundwater as well as transpiration through leaf  
22 stomata to the atmosphere (ISA, Appendix 8, section 8.11.1). These “impacts may in turn affect  
23 the amount of water moving through the soil, running over land or through groundwater and  
24 flowing through streams” (ISA, Appendix 8, section 8.11, p. 8-161). Evidence newly available  
25 for the 2020 ISA is supportive of previously available evidence in this regard (ISA, Appendix 8,  
26 section 8.11.6). This evidence, including that newly available, indicates the extent to which the  
27 effects of O<sub>3</sub> on plant leaves and roots (e.g., through effects on chemical composition and  
28 biomass) can impact belowground biogeochemical cycles involving root growth, soil food web  
29 structure, soil decomposer activities, soil microbial respiration, soil carbon turnover, soil water  
30 cycling and soil nutrient cycling (ISA, Appendix 8, section 8.9).

31 Additional vegetation- and insect-related effects with implications beyond individual  
32 plants include the effects of O<sub>3</sub> on insect herbivore growth and reproduction and plant-insect  
33 signaling (ISA, Table IS-12, Appendix 8, sections 8.6 and 8.7). With regard to insect herbivore  
34 growth and reproduction, the evidence includes multiple effects in an array of insect species,  
35 although without a consistent pattern of response for most endpoints (ISA, Appendix 8, Table 8-

11). As was also the case with the studies available at the time of the 2015 review,<sup>26</sup> in the newly available studies the individual-level responses are highly context- and species-specific and not all species tested showed a response (ISA, p. IS-64, Table IS-12, section IS.5.1.3 and Appendix 8, section 8.6). Evidence on plant-insect signaling comes from laboratory, greenhouse, open top chambers (OTC) and FACE experiments (ISA, section IS.5.1.3 and Appendix 8, section 8.7). The available evidence indicates a role for elevated O<sub>3</sub> in altering and degrading emissions of chemical signals from plants and reducing detection of volatile plant signaling compounds (VPSCs) by insects, including pollinators. Elevated O<sub>3</sub> concentrations degrade some VPSCs released by plants, potentially affecting ecological processes including pollination and plant defenses against herbivory. Further, the available studies report elevated O<sub>3</sub> conditions to be associated with plant VPSC emissions that may make a plant either more attractive or more repellant to herbivorous insects, and to predators and parasitoids that target phytophagous (plant-eating) insects (ISA, section IS.5.1.3 and Appendix 8, section 8.7).

Ozone welfare effects also extend beyond effects on vegetation and associated biota due to it being a major greenhouse gas and radiative forcing agent.<sup>27</sup> As in the 2015 review, the available evidence, augmented since the 2013 ISA, continues to support a causal relationship between the global abundance of O<sub>3</sub> in the troposphere and radiative forcing, and a likely causal relationship between the global abundance of O<sub>3</sub> in the troposphere and effects on temperature, precipitation, and related climate variables<sup>28</sup> (ISA, section IS.5.2 and Appendix 9; Myhre et al., 2013). As was also true at the time of the 2015 review, tropospheric O<sub>3</sub> has been ranked third in importance for global radiative forcing, after carbon dioxide and methane, with the radiative forcing of O<sub>3</sub> since pre-industrial times estimated to be about 25 to 40% of the total warming effects of anthropogenic carbon dioxide and about 75% of the effects of anthropogenic methane (ISA, Appendix 9, section 9.1.3.3). Uncertainty in the magnitude of radiative forcing estimated to be attributed to tropospheric O<sub>3</sub> is a contributor to the relatively greater uncertainty associated with climate effects of tropospheric O<sub>3</sub> compared to such effects of the well mixed greenhouse gases, such as carbon dioxide and methane (ISA, section IS.6.2.2).

---

<sup>26</sup> During the 2015 review, the 2013 ISA stated with regard to O<sub>3</sub> effects on insects and other wildlife that “there is no consensus on how these organisms respond to elevated O<sub>3</sub> (2013 ISA, section 9.4.9.4, p. 9-98).

<sup>27</sup> Radiative forcing is a metric used to quantify the change in balance between radiation coming into and going out of the atmosphere caused by the presence of a particular substance. The ISA describes it more specifically as “a perturbation in net radiative flux at the tropopause (or top of the atmosphere) caused by a change in radiatively active forcing agent(s) after stratospheric temperatures have readjusted to radiative equilibrium (stratospherically adjusted RF)” (ISA, Appendix 9, section 9.1.3.3).

<sup>28</sup> Effects on temperature, precipitation, and related climate variables were referred to as “climate change” or “effects on climate” in the 2013 ISA (ISA, p. IS-82; 2013 ISA, pp. 1-14, 10-31).

1 Lastly, the evidence regarding tropospheric O<sub>3</sub> and UV-B shielding was evaluated in the  
2 2013 ISA and determined to be inadequate to draw a causal conclusion (2013 ISA, section  
3 10.5.2). The current ISA concludes there to be no new evidence since the 2013 ISA relevant to  
4 the question of UV-B shielding by tropospheric O<sub>3</sub> (ISA, IS.1.2.1 and Appendix 9, section  
5 9.1.3.4).

#### 6 **4.3.2 Public Welfare Implications**

7 The public welfare implications of the evidence regarding O<sub>3</sub> welfare effects are  
8 dependent on the type and severity of the effects, as well as the extent of the effect at a particular  
9 biological or ecological level of organization. We discuss such factors here in light of judgments  
10 and conclusions made in NAAQS reviews regarding effects on the public welfare.

11 As provided in section 109(b)(2) of the CAA, the secondary standard is to “specify a  
12 level of air quality the attainment and maintenance of which in the judgment of the  
13 Administrator ... is requisite to protect the public welfare from any known or anticipated adverse  
14 effects associated with the presence of such air pollutant in the ambient air.” The secondary  
15 standard is not meant to protect against all known or anticipated O<sub>3</sub>-related welfare effects, but  
16 rather those that are judged to be adverse to the public welfare, and a bright-line determination of  
17 adversity is not required in judging what is requisite (78 FR 3212, January 15, 2013; 80 FR  
18 65376, October 26, 2015; see also 73 FR 16496, March 27, 2008). Thus, the level of protection  
19 from known or anticipated adverse effects to public welfare that is requisite for the secondary  
20 standard is a public welfare policy judgment made by the Administrator. The Administrator’s  
21 judgment regarding the available information and adequacy of protection provided by an existing  
22 standard is generally informed by considerations in prior reviews and associated conclusions.

#### 23 • **Is there newly available information relevant to consideration of the public welfare** 24 **implications of O<sub>3</sub>-related welfare effects?**

25 The categories of effects identified in the CAA to be included among welfare effects are  
26 quite diverse,<sup>29</sup> and among these categories, any single category includes many different types of  
27 effects that are of broadly varying specificity and level of resolution. For example, effects on  
28 vegetation is a category identified in CAA section 302(h), and the ISA recognizes numerous  
29 vegetation-related effects of O<sub>3</sub> at the organism, population, community, and ecosystem level, as  
30 summarized in section 4.3.1 above (ISA, Appendix 8). The significance of each type of  
31 vegetation-related effect with regard to potential effects on the public welfare depends on the

---

<sup>29</sup> Section 302(h) of the CAA states that language referring to “effects on welfare” in the CAA “includes, but is not limited to, effects on soils, water, crops, vegetation, manmade materials, animals, wildlife, weather, visibility, and climate, damage to and deterioration of property, and hazards to transportation, as well as effects on economic values and on personal comfort and well-being” (CAA section 302(h)).



1 type and severity of effects, as well as the extent of such effects on the affected environmental  
2 entity, and on the societal use of the affected entity and the entity’s significance to the public  
3 welfare. Such factors have been considered in the context of judgments and conclusions made in  
4 some prior reviews regarding public welfare effects. For example, judgments regarding public  
5 welfare significance in two prior O<sub>3</sub> NAAQS decisions gave particular attention to O<sub>3</sub> effects in  
6 areas with special federal protections (such as Class I areas), and lands set aside by states, tribes  
7 and public interest groups to provide similar benefits to the public welfare (73 FR 16496, March  
8 27, 2008; 80 FR 65292, October 26, 2015).<sup>30</sup> In the 2015 review, the EPA recognized the “clear  
9 public interest in and value of maintaining these areas in a condition that does not impair their  
10 intended use and the fact that many of these lands contain O<sub>3</sub>-sensitive species” (73 FR 16496,  
11 March 27, 2008).

12 Judgments regarding effects on the public welfare can depend on the intended use for, or  
13 service (and value) of, the affected vegetation, ecological receptors, ecosystems and resources  
14 and the significance of that use to the public welfare (73 FR 16496, March 27, 2008; 80 FR  
15 65377, October 26, 2015). Uses or services provided by areas that have been afforded special  
16 protection can flow in part or entirely from the vegetation that grows there. Uses or services  
17 provided by areas that have been afforded special protection can flow in part or entirely from the  
18 vegetation that grows there. Ecosystem services range from those directly related to the natural  
19 functioning of the ecosystem to ecosystem uses for human recreation or profit, such as through  
20 the production of lumber or fuel (Costanza et al., 2017; ISA, section IS.5.1). Services of aesthetic  
21 value and outdoor recreation depend, at least in part, on the perceived scenic beauty of the  
22 environment. Additionally, public surveys have indicated that Americans rank as very important  
23 the existence of resources, the option or availability of the resource and the ability to bequest or  
24 pass it on to future generations (Cordell et al., 2008). The spatial, temporal, and social  
25 dimensions of public welfare impacts are also influenced by the type of service affected. For  
26 example, a national park can provide direct recreational services to the thousands of visitors that  
27 come each year, but also provide an indirect value to the millions who may not visit but receive

---

<sup>30</sup> For example, the fundamental purpose of parks in the National Park System “is to conserve the scenery, natural and historic objects, and wild life in the System units and to provide for the enjoyment of the scenery, natural and historic objects, and wild life in such manner and by such means as will leave them unimpaired for the enjoyment of future generations” (54 U.S.C. 100101). Additionally, the Wilderness Act of 1964 defines designated “wilderness areas” in part as areas “protected and managed so as to preserve [their] natural conditions” and requires that these areas “shall be administered for the use and enjoyment of the American people in such manner as will leave them unimpaired for future use and enjoyment as wilderness, and so as to provide for the protection of these areas, [and] the preservation of their wilderness character ...” (16 U.S.C. 1131 (a) and (c)). Other lands that benefit the public welfare include national forests which are managed for multiple uses including sustained yield management in accordance with land management plans (see 16 U.S.C. 1600(1)-(3); 16 U.S.C. 1601(d)(1)).

1 satisfaction from knowing it exists and is preserved for the future (80 FR 65377, October 26,  
2 2015).

3       The different types of effects on vegetation discussed in section 4.3.1 above differ with  
4 regard to aspects important to judging their public welfare significance. For example, in the case  
5 of crop yield loss, such judgments may consider aspects such as the heavy management of  
6 agriculture in the U.S., while judgments for other categories of effects may generally relate to  
7 considerations regarding natural areas, including specifically those areas that are not managed  
8 for harvest. For example, effects on tree growth and reproduction, and also visible foliar injury,  
9 have the potential to be significant to the public welfare through impacts in Class I and other  
10 areas given special protection in their natural/existing state, although they differ in how they  
11 might be significant.

12       In this context, it may be important to consider that O<sub>3</sub> effects on tree growth and  
13 reproduction could, depending on severity, extent, and other factors, lead to effects on a larger  
14 scale including reduced productivity, altered forest and forest community (plant, insect and  
15 microbe) composition, reduced carbon storage and altered ecosystem water cycling (ISA, section  
16 IS.5.1.8.1; 2013 ISA, Figure 9-1, sections 9.4.1.1 and 9.4.1.2). For example, the composition of  
17 plants and other members of terrestrial communities can be affected through O<sub>3</sub> effects on  
18 growth and reproductive success of sensitive plant species in the community, with the extent of  
19 compositional changes dependent on factors such as competitive interactions (ISA, section  
20 IS.5.1.8.1; 2013 ISA, sections 9.4.3 and 9.4.3.1). Impacts on some of these characteristics (e.g.,  
21 forest or forest community composition) may be considered of greater public welfare  
22 significance when occurring in Class I or other protected areas, due to value for particular  
23 services that the public places on such areas.

24       Agriculture and silviculture provide ecosystem services with clear public welfare  
25 benefits. With regard to agriculture-related effects, however, there are complexities in this  
26 consideration related to areas and plant species that are heavily managed to obtain a particular  
27 output (such as commodity crops or commercial timber production). In light of this, the degree to  
28 which O<sub>3</sub> impacts on vegetation that could occur in such areas and on such species would impair  
29 the intended use at a level that might be judged adverse to the public welfare has been less clear  
30 (80 FR 65379, October 26, 2015; 73 FR 16497, March 27, 2008). While having sufficient crop  
31 yields is of high public welfare value, important commodity crops are typically heavily managed  
32 to produce optimum yields. Moreover, based on the economic theory of supply and demand,  
33 increases in crop yields would be expected to result in lower prices for affected crops and their  
34 associated goods, which would primarily benefit consumers. Analyses in past reviews have  
35 described how these competing impacts on producers and consumers complicate consideration of

1 these effects in terms of potential adversity to the public welfare (2014 WREA, sections 5.3.2  
2 and 5.7).

3 Other ecosystem services valued by people that can be affected by reduced tree growth,  
4 productivity and associated forest effects include aesthetic value, food, fiber, timber, other forest  
5 products, habitat, recreational opportunities, climate and water regulation, erosion control, air  
6 pollution removal, and desired fire regimes, as summarized in Figure 4-2 (ISA, section IS.5.1;  
7 2013 ISA, sections 9.4.1.1 and 9.4.1.2). In considering such services in past reviews, the Agency  
8 the Agency has given particular attention to effects in natural ecosystems, indicating that a  
9 protective standard, based on consideration of effects in natural ecosystems in areas afforded  
10 special protection, would also “provide a level of protection for other vegetation that is used by  
11 the public and potentially affected by O<sub>3</sub> including timber, produce grown for consumption and  
12 horticultural plants used for landscaping” (80 FR 65403, October 26, 2015). For example,  
13 locations potentially vulnerable to O<sub>3</sub>-related impacts might include forested lands, both public  
14 and private, where trees are grown for timber production. Forests in urbanized areas also provide  
15 a number of services that are important to the public in those areas, such as air pollution removal,  
16 cooling, and beautification. There are also many other tree species, such as various ornamental  
17 and agricultural species (e.g., Christmas trees, fruit and nut trees), that provide ecosystem  
18 services that may be judged important to the public welfare.

19 With its effect on the physical appearance of plants, visible foliar injury has the potential  
20 to be significant to the public welfare, depending on its severity and spatial extent, by impacting  
21 aesthetic or scenic values and outdoor recreation in Class I and other similarly protected areas  
22 valued by the public.<sup>31</sup> To assess evidence of injury to plants in forested areas on national and  
23 regional scales, the U.S. Forest Service (USFS) conducted surveys of the occurrence and severity  
24 of visible foliar injury on sensitive (bioindicator) species at biomonitoring sites across most of  
25 the U.S., beginning in 1994 (in the eastern U.S.) and extending through 2011 (Smith, 2012;  
26 Coulston et al., 2003). At these sites (biosites), a national protocol, including verification and  
27 quality assurance procedures and a scoring system, was implemented. The resultant biosite index  
28 (BI) scores may be described with regard to one of several categories ranging from little or no  
29 foliar injury to severe injury. For example, BI scores of zero to five are described as “little or no

---

<sup>31</sup> For example, although analyses specific to visible foliar injury are of limited availability, there have been analyses developing estimates of recreation value damages of severe impacts related to other types of forest effects, such as tree mortality due to bark beetle outbreaks (e.g., Rosenberger et al., 2013). Such analyses estimate reductions in recreational use when the damage is severe (e.g., reductions in the density of live, robust trees). Such damage would reasonably be expected to also reflect damage indicative of injury with which a relationship with other plant effects (e.g., growth and reproduction) would be also expected. Similarly, a couple of studies from the 1970s and 1980s indicated potential for differences in recreational use for areas with stands of pine in which moderate to severe injury was apparent from 30 or 40 feet (1996 AQCD, section 5.8.3).

foliar injury,” scores above five to 15 as “low” or “light to moderate” foliar injury, scores from 15 to 25 as “moderate foliar injury” and scores above 25 as “severe injury” (Campbell et al., 2007; Smith et al., 2007; Smith, 2012).<sup>32</sup> However, available information does not yet address or describe the relationships expected to exist between some level of injury severity (e.g., little, low/light, moderate or severe) and/or spatial extent affected and scenic or aesthetic values. This gap impedes consideration of the public welfare implications of different injury severities, and accordingly judgments on the potential for public welfare significance. That notwithstanding, while minor spotting on a few leaves of a plant may easily be concluded to be of little public welfare significance, some level of severity and widespread occurrence of visible foliar injury, particularly if occurring in specially protected areas, where the public can be expected to place value (e.g., for recreational uses), might reasonably be concluded to impact the public welfare.

The tropospheric O<sub>3</sub>-related effects of radiative forcing and subsequent effects on temperature, precipitation and related climate variables also have important public welfare implications, although their quantitative evaluation in response to O<sub>3</sub> concentrations in the U.S. is complicated by “[c]urrent limitations in climate modeling tools, variation across models, and the need for more comprehensive observational data on these effects” (ISA, section IS.6.2.2). An ecosystem service provided by forested lands is carbon sequestration or storage (ISA, section IS.5.1.4 and Appendix 8, section 8.8.3; 2013 ISA, section 2.6.2.1 and p. 9-37),<sup>33</sup> which has an extremely valuable role in counteracting the impact of greenhouse gases on radiative forcing and related climate effects on the public welfare. Accordingly, the service of carbon storage can be of paramount importance to the public welfare no matter in what location the trees are growing or what their intended current or future use (e.g., 2013 ISA, section 9.4.1.2). The benefit exists as long as the trees are growing, regardless of what additional functions and services it provides.

Categories of effects newly identified as likely causally related to O<sub>3</sub> in ambient air, such as alteration of plant-insect signaling and insect herbivore growth and reproduction, also have potential public welfare implications, e.g., given the role of the plant-insect signaling process in pollination and seed dispersal (ISA, section IS.5.1.3). Uncertainties and limitations in the evidence (e.g., as summarized in sections 4.3.3.3 and 4.3.4 below) preclude an assessment of the extent and magnitude of O<sub>3</sub> effects on these endpoints, which thus also precludes an evaluation of the potential for associated public welfare implications.

---

<sup>32</sup> Authors of studies presenting USFS biomonitoring program data have suggested what might be considered “assumptions of risk” (e.g., for the forest resource) related to scores in these categories, e.g., none, low, moderate and high for BI scores of zero to five, five to 15, 15 to 25 and above 25, respectively (e.g., Smith et al., 2003; Smith et al., 2012). For example, maps of localized moderate to high risk areas may be used to identify areas where more detailed evaluations are warranted (Smith et al., 2012).

<sup>33</sup> While carbon sequestration or storage also occurs for vegetated ecosystems other than forests, it is relatively larger in forests given the relatively greater biomass for trees compared to some other plants.

1           In summary, several considerations are recognized as important to judgments on the  
2 public welfare significance of the array of welfare effects of different O<sub>3</sub> exposure conditions.  
3 These include uncertainties and limitations associated with the consideration of the magnitude of  
4 key vegetation effects that might be concluded to be adverse to ecosystems and associated  
5 services. Additionally, the presence of O<sub>3</sub>-sensitive tree species may contribute to a vulnerability  
6 of numerous locations to public welfare impacts from O<sub>3</sub> related to tree growth, productivity and  
7 carbon storage and their associated ecosystems and services. Other important considerations  
8 include the exposure circumstances that may elicit effects and the potential for the significance  
9 of the effects to vary in specific situations due to differences in sensitivity of the exposed  
10 species, the severity and associated significance of the observed or predicted O<sub>3</sub>-induced effect,  
11 the role that the species plays in the ecosystem, the intended use of the affected species and its  
12 associated ecosystem and services, the presence of other co-occurring predisposing or mitigating  
13 factors, and associated uncertainties and limitations.




Figure 4-2. Potential effects of O<sub>3</sub> on the public welfare.

### 4.3.3 Exposures Associated with Effects

The types of effects identified in section 4.3.1 above vary widely with regard to the extent and level of detail of the available information that describes the O<sub>3</sub> exposure circumstances that may elicit them. The information on exposure metric and E-R relationships for effects related to vegetation growth is long-standing, having been first described in the 1997 review, while such information is much less established for visible foliar injury. The evidence base for other categories of effects is also lacking in information that might support characterization of potential impacts of changes in O<sub>3</sub> concentrations. The discussion in this section is organized in recognition of this variation. We focus first on growth and yield effects, the category of effects for which the information on exposure metric and E-R relationships is most advanced (section 4.3.3.1). Section 4.3.3.2 discusses the information regarding exposure metrics and relationships between exposure and the occurrence and severity of visible foliar injury. The availability of such information for other categories of effects is addressed in section 4.3.3.3.

#### 4.3.3.1 Growth-related Effects

##### 4.3.3.1.1 Exposure Metrics

The longstanding body of vegetation effects evidence includes a wealth of information on aspects of O<sub>3</sub> exposure that influence effects on plant growth and yield, and that has been described in the scientific assessments across the last several decades (1996 AQCD; 2006 AQCD; 2013 ISA; 2020 ISA). A variety of factors have been investigated, including “concentration, time of day, respite time, frequency of peak occurrence, plant phenology, predisposition, etc.” (2013 ISA, section 9.5.2). The importance of the duration of the exposure and the relatively greater importance of higher concentrations over lower concentrations have been consistently well documented (2013 ISA, section 9.5.3). For example, key conclusions of the 1996 AQCD, that have been confirmed in the 2006 AQCD, 2013 ISA and 2020 ISA include that “Ozone effects in plants are cumulative” and “Higher O<sub>3</sub> concentrations appear to be more important than lower concentrations in eliciting a response” (2006 AQCD, p. E-27; 2013 ISA, p. 2-44; 2020 ISA, p. 8-180) These AQCDs and ISAs described several mathematical approaches for a single metric or index that would, to some extent, reflect both conclusions.

The consideration of these different exposure metrics has primarily focused on their ability to summarize ambient air concentrations of O<sub>3</sub> in a way that best correlates with effects on vegetation, particularly growth-related effects. Metrics based on mean concentrations over several hours (e.g., a seasonal average 12-hour concentration), have generally been considered to be less robust as a metric relating exposure to growth effects (2020 ISA, p. 8-181). The approaches that cumulate exposures over some specified period while weighting higher

1 concentrations more than lower had been evaluated for their predictiveness of growth responses  
2 in a set of crop and tree species assessed in experimental O<sub>3</sub> exposure studies for which hourly  
3 O<sub>3</sub> concentrations were available for analysis (2013 ISA, sections 9.5.2 and 9.5.3; ISA,  
4 Appendix 8, section 8.2.2.2).

5 Along with the non-threshold concentration weighted W126 index, two other cumulative  
6 indices that have received greatest attention across the past several O<sub>3</sub> NAAQS reviews have  
7 been the threshold weighted indices, AOT60<sup>34</sup> and SUM06 (ISA, section IS.3.2).<sup>35</sup> Accordingly,  
8 some studies of O<sub>3</sub> vegetation effects have reported exposures in terms of these metrics. Based  
9 on extensive review of the published literature on different types of such E-R metrics, and  
10 comparisons between metrics, and in the context of a single metric, the EPA has generally  
11 focused on cumulative, concentration-weighted indices of exposure that reflect some  
12 consideration of both concern for cumulative effects of O<sub>3</sub> exposure and for the greater  
13 importance of higher concentrations than lower concentrations in vegetation effects (1996  
14 AQCD; 2006 AQCD; 2013 ISA).<sup>36</sup> Quantifying exposure using such indices has been found to  
15 improve the explanatory power of E-R models with regard to O<sub>3</sub> effects in studies of growth and  
16 yield over that of indices based only on mean and peak exposure values (2013 ISA, section  
17 2.6.6.1, p. 2-44).<sup>37</sup>

18 The most well-studied datasets in this in this regard are two datasets established two  
19 decades ago (referenced above and described further in section 4.3.3.1.2 below), one for growth  
20 effects on seedlings of a set of 11 tree species and the second for quality and yield effects for a  
21 set of 10 crops (e.g., Lee and Hogsett, 1996, Hogsett et al., 1997). These datasets, which include  
22 growth and yield response information across a range of multiple seasonal cumulative exposures,  
23 were used to develop quantitative E-R functions for reduced growth (termed relative biomass

---

<sup>34</sup> The AOT60 index is the seasonal sum of the difference between an hourly concentration above 60 ppb, minus 60 ppb (2006 AQCD, p. AX9-161). More recently, some studies have also reported O<sub>3</sub> exposures in terms of AOT40, which is conceptually similar but with 40 substituted for 60 in its derivation (ISA, Appendix 8, section 8.13.1).

<sup>35</sup> The SUM06 index is the seasonal sum of hourly concentrations at or above 0.06 ppm during a specified daily time window (2006 AQCD, p. AX9-161; 2013 ISA, section 9.5.2). This may sometimes be referred to as SUM60, e.g., when concentrations are in terms of ppb. There are also variations on this metric that utilize alternative reference points above which hourly concentrations are summed. For example, SUM08 is the seasonal sum of hourly concentrations at or above 0.08 ppm and SUM0 is the seasonal sum of all hourly concentrations.

<sup>36</sup> The Agency has focused its analyses in the last several reviews on metrics that characterize cumulative exposures over a season or seasons: SUM06 in the 1997 review (61 FR 65716, December 13, 1996; 62 FR 38856, July 18, 1997) and W126 in both the 2008 and 2015 reviews (72 FR 37818, July 11, 2007; 73 FR 16436, March 27, 2008; 80 FR 65373-65374, October 26, 2015). This approach to characterizing O<sub>3</sub> exposure concentrations with regard to potential vegetation effects, particularly growth, has been supported by CASAC in the past reviews (Henderson, 2006; Samet, 2010; Frey, 2014; Cox, 2020).

<sup>37</sup> As described in section 4.3.3.2 below, the W126 index and other similar cumulative exposure indices do not completely describe the relationship of O<sub>3</sub> to visible foliar injury in national surveys.



1 loss or RBL) in seedlings of the tree species and E-R functions for RYL for a set of common  
2 crops (ISA, Appendix 8, section 8.13.2; 2013 ISA, section 9.6.2).

3 The EPA's conclusions regarding cumulative exposure levels of O<sub>3</sub> associated with  
4 vegetation-related effects at the time of the 2015 review were based primarily on these  
5 established E-R functions and the W126 index, which is a cumulative, seasonal<sup>38</sup> concentration-  
6 weighted index (80 FR 65404, October 26, 2015; ISA, section IS.3.2, Appendix 8, section 8.13).  
7 This metric is a non-threshold approach described as the sigmoidally weighted sum of all hourly  
8 O<sub>3</sub> concentrations observed during a specified daily and seasonal time window, where each  
9 hourly O<sub>3</sub> concentration is given a weight that increases from zero to one with increasing  
10 concentration (2013 ISA, p. 9-101).

11 Alternative methods for characterizing O<sub>3</sub> exposure to predict various plant responses  
12 have, in recent years, included flux models (models that are based on the amount of O<sub>3</sub> that  
13 enters the leaf). However, as was the case in the 2015 review, there remain a variety of  
14 complications, limitations and uncertainties associated with this approach. For example, “[w]hile  
15 some efforts have been made in the U.S. to calculate ozone flux into leaves and canopies, little  
16 information has been published relating these fluxes to effects on vegetation” (ISA, section  
17 IS.3.2). Further, as flux of O<sub>3</sub> into the plant under different conditions of O<sub>3</sub> in ambient air is  
18 affected by several factors including temperature, vapor pressure deficit, light, soil moisture, and  
19 plant growth stage, use of this approach to quantify the vegetation impact of O<sub>3</sub> would require  
20 information on these various types of factors (ISA, section IS.3.2). In addition to these data  
21 requirements, each species has different amounts of internal detoxification potential that may  
22 protect species to differing degrees. The lack of detailed species- and site-specific data required  
23 for flux modeling in the U.S. and the lack of understanding of detoxification processes continues  
24 to make this technique less viable for use in risk assessments in the U.S. (ISA, section IS.3.2).

25 Among the studies newly available since the 2015 review, no new exposure indices for  
26 assessing effects on vegetation growth or other physiological process parameters have been  
27 identified. In the literature available since the 2013 ISA, the SUM06, AOTx (e.g., AOT60) and  
28 W126 exposure metrics remain the metrics that are most commonly discussed (ISA, Appendix 8,  
29 section 8.13.1). The ISA notes that “[c]umulative indices of exposure that differentially weight  
30 hourly concentrations [which would include the W126 index] have been found to be best suited  
31 to characterize vegetation exposure to ozone with regard to reductions in vegetation growth and  
32 yield” (ISA, section ES.3). Accordingly, in this reconsideration of the 2020 decision, as in the  
33 2015 and 2020 reviews, we use the seasonal W126-based cumulative, concentration-weighted

---

<sup>38</sup> In describing the form as “seasonal,” the EPA is referring generally to an index focused on a time period of a duration that may relate to that of a growing season for O<sub>3</sub>-sensitive vegetation, not to the seasons of the year (spring, summer, fall, winter).

metric in interpreting quantitative exposure analyses, particularly related to growth effects of cumulative O<sub>3</sub> exposures (as summarized in sections 4.3.3.2 and 4.4 below).

The first step in calculating the seasonal W126 index for a specific year is to sum the weighted hourly O<sub>3</sub> concentrations in ambient air during daylight hours (defined as 8:00 a.m. to 8:00 p.m. local standard time) within each calendar month, resulting in monthly index values. The monthly W126 index values are calculated from hourly O<sub>3</sub> concentrations as follows.<sup>39</sup>

$$\text{Monthly W126} = \sum_{d=1}^N \sum_{h=8}^{19} \frac{C_{dh}}{1 + 4403 \cdot \exp(-126 \cdot C_{dh})}$$

where,

$N$  is the number of days in the month

$d$  is the day of the month ( $d = 1, 2, \dots, N$ )

$h$  is the hour of the day ( $h = 0, 1, \dots, 23$ )

$C_{dh}$  is the hourly O<sub>3</sub> concentration observed on day  $d$ , hour  $h$ , in parts per million

The W126 index value for a specific year is the maximum sum of the monthly index values for three consecutive months within a calendar year (i.e., January to March, February to April, ... October to December). Three-year average W126 index values are calculated by taking the average of seasonal W126 index values for three consecutive years (e.g., as described in Appendix 4D, section 4D.2.2).

#### 4.3.3.1.2 Relationships Between Cumulative Concentration-weighted Exposure Levels and Effects

Across the array of O<sub>3</sub>-related welfare effects, consistent and systematically evaluated information on E-R relationships across multiple exposure levels is limited. Most prominent is the information on E-R relationships for growth effects on tree seedlings and crops,<sup>40</sup> which has been available for the past several reviews. The information on which these functions are based comes primarily from the U.S. EPA's National Crop Loss Assessment Network (NCLAN)<sup>41</sup> project for crops and the NHEERL-WED project for tree seedlings, projects implemented primarily to define E-R relationships for major agricultural crops and tree species, thus advancing understanding of responses to O<sub>3</sub> exposures (ISA, Appendix 8, section 8.13.2). These projects and related studies included a series of experiments that used OTCs to investigate tree seedling growth response and crop yield over a growing season under a variety of O<sub>3</sub> exposures

<sup>39</sup> In situations where data are missing, an adjustment is factored into the monthly index (as described in Appendix 4D, section 4D.2.2).

<sup>40</sup> The E-R functions estimate O<sub>3</sub>-related reduction in a year's tree seedling growth or crop yield as a percentage of that expected in the absence of O<sub>3</sub> (Appendix 4A; ISA, Appendix 8, section 8.13.2).

<sup>41</sup> The NCLAN program, which was undertaken in the early to mid-1980s, assessed multiple U.S. crops, locations, and O<sub>3</sub> exposure levels, using consistent methods, to provide the largest, most uniform database on the effects of O<sub>3</sub> on agricultural crop yields (1996 AQCD, 2006 AQCD, 2013 ISA, sections 9.2, 9.4, and 9.6; ISA, Appendix 8, section 8.13.2).

1 and growing conditions (2013 ISA, section 9.6.2; Lee and Hogsett, 1996). These experiments  
2 assessed O<sub>3</sub> effects on tree seedling growth and crop yield for a variety of O<sub>3</sub> treatments and  
3 growing conditions. The higher exposure levels in these datasets generally included numerous  
4 hours at or above 100 ppb (Lefohn et al., 1997; Appendix 4A, Table 4A-6). Importantly, the  
5 information on exposure includes hourly concentrations across the season (or longer) exposure  
6 period which allowed for derivation of various seasonal metrics that were analyzed for  
7 association with reduced growth. In the initial analyses of these data, exposure was characterized  
8 in terms of several metrics, including seasonal SUM06 and W126 indices (Lee and Hogsett,  
9 1996; 1997 Staff Paper, sections IV.D.2 and IV.D.3; 2007 Staff Paper, section 7.6), while use of  
10 these functions in the 2015 review focused on their implementation in terms of seasonal W126  
11 index (2013 ISA, section 9.6; 80 FR 65391-92, October 26, 2015).<sup>42</sup>

12 The 11 species for which robust and well-established E-R functions for RBL were  
13 derived black cherry, Douglas fir, loblolly pine, ponderosa pine, quaking aspen, red alder, red  
14 maple, sugar maple, tulip poplar, Virginia pine, and white pine (Figure 4-3; Appendix 4A; 2020  
15 ISA, Appendix 8, section 8.13.2; 2013 ISA, section 9.6).<sup>43</sup> While these 11 species represent only  
16 a small fraction of the total number of native tree species in the contiguous U.S., this small  
17 subset includes eastern and western species, deciduous and coniferous species, and species that  
18 grow in a variety of ecosystems and represent a range of tolerance to O<sub>3</sub> (Appendix 4B; 2020  
19 ISA, Appendix 8, section 8.13.2; 2013 ISA, section 9.6.2). The established E-R functions for  
20 most of the 11 species were derived using data from multiple studies or experiments, many of  
21 which employed open top chambers, an established experimental approach, involving a wide  
22 range of exposure and/or growing conditions. For example, many of the experimental treatments  
23 for exposures to elevated O<sub>3</sub> on which the established E-R functions for the 11 tree seedling  
24 species are based, involved W126 index levels well above 20 ppm-hrs and had many (tens to

---

<sup>42</sup> This underlying database for the exposure is a key characteristic that sets this set of studies (and their associated E-R analyses) apart from other available studies.

<sup>43</sup> A quantitative analysis of E-R information for an additional species was considered in the 2014 WREA. But the underlying study, rather than being an OTC controlled exposure study, involves exposure to ambient air along an existing gradient of O<sub>3</sub> concentrations in the New York City metropolitan area, such that O<sub>3</sub> and climate conditions were not controlled (2013 ISA, section 9.6.3.3). Based on comments from the CASAC on the WREA cautioning against placing too much emphasis on these data (e.g., saying that the eastern cottonwood response data from a single study “receive too much emphasis,” explaining that these “results are from a gradient study that did not control for ozone and climatic conditions and show extreme sensitivity to ozone compared to other studies” and that “[a]lthough they are important results, they are not as strong as those from other experiments that developed E-R functions based on controlled ozone exposure”) (Frey, 2014, p. 10), the EPA did not include the E-R function for eastern cottonwood among the set of tree seedling E-R functions given focus in the WREA, or relied on in decision-making for the 2015 review (80 FR 65292, October 26, 2015.)

1 more than a hundred) of hours of O<sub>3</sub> concentrations above 100 ppb (Appendix 4A, Table 4A-6;  
2 Lefohn et al 1997).<sup>44 45</sup>

3 From the available data, separate E-R functions were developed for each combination of  
4 species and experiment<sup>46</sup> (2013 ISA, section 9.6.1; Lee and Hogsett, 1996). For the 11 species,  
5 there are 51 separate “experiment-specific” E-R functions (Appendix 4A, section 4A.1.1; ISA,  
6 section 8.1.2.1.2). For six of the 11 species, the species-specific function is based on just one or  
7 two experimental datasets (e.g., red maple), while for other species there were as many as 11  
8 datasets supporting 11 experiment-specific E-R functions (e.g., ponderosa pine). The exposure  
9 durations varied from periods of 82 to 140 days in a single year to periods of 180 to 555 days  
10 occurring across two years (Lee and Hogsett, 1996; Appendix 4A, Table 4A-5). The  
11 experimental datasets for more than half the 11 species include exposures occurring across two  
12 years. To account for potential for a delayed response, some datasets are for growth  
13 measurements taken in the spring of the year after a prior year growing season exposure and  
14 others are for growth measurements taken immediately after the exposure. From the separate  
15 species-experiment-specific E-R functions, species-specific composite E-R functions were  
16 developed (Appendix 4A). In order to be utilized in deriving a single species-specific function  
17 and to produce species-specific E-R functions of consistent duration, the separate species-  
18 experiment-specific E-R functions were derived first based on the exposure duration of the  
19 experiment and then normalized to 3-month (seasonal) periods<sup>47</sup> (see Lee and Hogsett, 1996,  
20 section I.3; Appendix 4A).

21 The 11 species-specific composite median functions are presented in Appendix 4A (see  
22 section 4A.1.1). Biomass growth loss predictions using the function for aspen was evaluated in  
23 the 2013 and 2020 ISAs based on a recent study for aspen (2013 ISA, section 9.6.2; ISA,

---

<sup>44</sup> Among the experiments on which the E-R functions are based, N100 values for exposure levels most common at U.S. sites that meet the current standard (e.g., W126 index less than 25 ppm-hrs for a single season), extend up above 10, to more than 40. Additionally, in a study that has reported the distributions of hourly concentrations, the 90<sup>th</sup> percentile in replicates for one of the elevated O<sub>3</sub> treatments ranged from 142 to 156 ppb, and the maximum ranged from 210 to 260 ppb (Appendix 4A, Table 4A-6; Lefohn et al 1992).


<sup>45</sup> Similarly, the experimental exposures in studies supporting some of the established E-R functions for 10 crop species also include many hours with hourly O<sub>3</sub> concentrations at or above 100 ppb (Lefohn and Foley, 1992).

<sup>46</sup> Use of the term, experiment, refers to each separate seedling response dataset (from each separate harvest), including, for example, a 2<sup>nd</sup> harvest in the spring that received the same growing season exposure as the response documented for seedlings in the 1<sup>st</sup> harvest immediately following the growing season. As an initial step in deriving species-specific E-R functions each of those response datasets were used to derive separate E-R functions (Appendix 4A, Attachment 1).

<sup>47</sup> Underlying the adjustment is a simplifying assumption of uniform W126 distribution across the exposure periods and of a linear relationship between duration of cumulative exposure in terms of the W126 index and plant growth response. Some functions for experiments that extended over two seasons were derived by distributing responses observed at the end of two seasons of varying exposures equally across the two seasons (e.g., essentially applying the average to both seasons).


Appendix 8, section 8.13.2). The species-specific composite E-R functions developed from the experiment-specific functions indicate a wide variation in growth sensitivity of the studied tree species at the seedling stage (Appendix 4A, section 4A.1.1). A stochastic analysis performed for the 2014 WREA provides a sense of the variability and uncertainty associated with the estimated E-R relationships among and within species<sup>48</sup> (Appendix 4A, section 4A.1.1, Figure 4A-13). Further, based on the species-specific E-R functions, the studied tree species appear to vary widely in sensitivity to reduced growth at the seedling stage (Figure 4-3).

With regard to crops, established E-R functions are available for 10 crops: barley, field corn, cotton, kidney bean, lettuce, peanut, potato, grain sorghum, soybean, and winter wheat (Figure 4-4; Appendix 4A; ISA, Appendix 8, section 8.13.2). Since the 2015 review, new evidence is available for seven soybean cultivars that confirms the reliability of the soybean E-R functions developed from NCLAN data and indicates that they extend in applicability to recent cultivars (ISA, Appendix 8, section 8.13.2).



**Figure 4-3. Established RBL functions for seedlings of 11 tree species.**

<sup>48</sup> The multiple functions derived for each species are derived from separate datasets, some of which may have the same exposure during the growing season but which reflect response derived from seedlings harvested in the spring subsequent to the growing season exposure (Lee and Hogsett, 1996). Accordingly, this analysis provides a sense of both uncertainty in experimental design and environmental and seedling response variability.



**Figure 4-4. Established RYL functions for 10 crops.**

Since the initial set of tree seedling studies were completed, several additional studies, focused on aspen, have been published based on the Aspen FACE experiment in a planted forest in Wisconsin; the findings were consistent with many of the OTC studies (ISA, Appendix 8, section 8.13.2). Newly available studies that investigated growth effects of O<sub>3</sub> exposures are also consistent with the existing evidence base, and generally involved particular aspects of the effect rather than expanding the conditions under which plant species, particularly trees, have been assessed (ISA, section IS.5.1.2). These publications include a compilation of previously available studies on plant biomass response to O<sub>3</sub> (in terms of AOT40); the compilation reports linear regressions conducted on the associated varying datasets (ISA, Appendix 8, section 8.13.2). Based on these regressions, this study describes distributions of sensitivity to O<sub>3</sub> effects on biomass across many tree and grassland species, including 17 species native to the U.S. and 65 introduced species (ISA, Appendix 8, section 8.13.2; van Goethem et al., 2013). Additional information is needed to describe O<sub>3</sub> E-R relationships more completely for these species in the U.S.<sup>49</sup> As was noted in the 2013 ISA, “[i]n order to support quantitative modeling of exposure-

<sup>49</sup> The studies compiled in this publication included at least 21 days exposure above 40 ppb O<sub>3</sub> (expressed as AOT40 [seasonal sum of the difference between an hourly concentration above 40 ppb and 40 ppb]) and had a maximum hourly concentration that was no higher than 100 ppb (van Goethem et al., 2013). The publication does not report study-specific exposure durations, details of biomass response measurements or hourly O<sub>3</sub> concentrations, making it less useful for describing E-R relationships that might support estimation of specific impacts associated with air quality conditions meeting the current standard (e.g., 2013 ISA, p. 9-118).

1 response relationships, data should preferably include more than three levels of exposure, and  
2 some control of potential confounding or interacting factors should be present in order to model  
3 the relationship with sufficient accuracy” (2013 ISA, p. 9-118). The 2013 ISA further discussed  
4 the differences across available studies, recognizing that the majority of studies contrast only two  
5 (or sometimes three with the addition of a carbon filtration) O<sub>3</sub> exposure levels. While such  
6 studies can be important for verifying more extensive studies, they “do not provide exposure-  
7 response information that is highly relevant to reviewing air quality standards” (2013 ISA, p. 9-  
8 118).

#### 9 **4.3.3.2 Visible Foliar Injury**

10 The evidence “continues to show a consistent association between visible injury and  
11 ozone exposure,” while also recognizing the role of modifying factors such as soil moisture and  
12 time of day (ISA, section IS.5.1.1). The ISA, in concluding that the newly available information  
13 is consistent with conclusions of the 2013 ISA, also summarizes several recently available  
14 studies that continue to document that O<sub>3</sub> elicits visible foliar injury in many plant species,  
15 including a synthesis of previously published studies that categorizes studied species (and their  
16 associated taxonomic classifications) as to whether or not O<sub>3</sub>-related foliar injury has been  
17 reported. Although this recent publication identifies many species in which visible foliar injury  
18 has been documented to occur in the presence of elevated O<sub>3</sub>,<sup>50</sup> it does not provide quantitative  
19 information regarding specific exposure conditions or analyses of E-R relationships (ISA,  
20 Appendix 8, section 8.3). Additionally, one recent study is identified as reporting visible foliar  
21 injury in a non-native, yet established, and invasive tree species in a location with O<sub>3</sub>  
22 concentrations corresponding to a seasonal W126 index of 11.6 ppm-hrs (ISA, Appendix 8,  
23 sections 8.2 and 8.2.1). The annual fourth highest 8-hour daily maximum concentration for the  
24 study year and location of this study (monitoring site 42-027-9991) is 76 ppb. The design value  
25 for the 3-year design period encompassing the year and location of this study exceeds 70 ppb  
26 (monitoring site 42-027-9991 for 2011-2013 design period), indicating that the air quality  
27 associated with the exposure would not have met the current secondary standard.<sup>51</sup>

28 As in the past, the available evidence, while documenting that elevated O<sub>3</sub> conditions in  
29 ambient air generally result in visible foliar injury in sensitive species (when in a predisposing

---

<sup>50</sup> The publication identifies 245 species across 28 plant genera, many native to the U.S., in which O<sub>3</sub>-related visible foliar injury has been reported (ISA, Appendix 8, section 8.3).

<sup>51</sup> Ozone design values for this period are available at: <https://www.epa.gov/air-trends/air-quality-design-values>. The year 2011 is the first year for which data are available and adequate for use in deriving a design value at this monitoring site.

environment)<sup>52</sup>, it does not include a quantitative description of the relationship of incidence or severity of visible foliar injury in sensitive species in natural areas of the U.S. with specific metrics of O<sub>3</sub> exposure. Several studies of the extensive USFS field-based dataset of visible foliar injury incidence in forests across the U.S.<sup>53</sup> illustrate the limitations of current understanding of this relationship. For example, a study that was available in the 2015 review presents a trend analysis of these data for sites located in 24 states of the northeast and north central U.S. for the 16-year period from 1994 through 2009 that provides some insight into the influence of changes in air quality and soil moisture on visible foliar injury and the difficulty inherent in predicting foliar injury response under different air quality and soil moisture scenarios (Smith, 2012, Smith et al., 2012; ISA, Appendix 8, section 8.2). This study, like prior analyses of such data, shows the dependence of foliar injury incidence and severity on local site conditions for soil moisture availability and O<sub>3</sub> exposure. For example, while the authors characterize the ambient air O<sub>3</sub> concentrations to be the “driving force” behind incidence of injury and its severity, they state that “site moisture conditions are also a very strong influence on the biomonitoring data” (Smith et al., 2003). In general, the USFS data analyses have found foliar injury prevalence and severity to be higher during seasons and sites that have experienced the highest O<sub>3</sub> than during other periods (e.g., Campbell et al., 2007; Smith, 2012).

#### **4.3.3.2.1 Exposure Metrics**

Although studies of the incidence of visible foliar injury in national forests, wildlife refuges, and similar areas have often used cumulative indices (e.g., SUM06) to investigate variations in incidence of foliar injury, studies also suggest an additional role for metrics focused on peak concentrations (ISA; 2013 ISA; 2006 AQCD; Hildebrand et al., 1996; Smith, 2012). Other studies have indicated this uncertainty regarding a most influential metric(s), by recognizing a research need. For example, a study of six years of USFS biosite data for three western states found that the biosites with the highest cumulative O<sub>3</sub> exposure (SUM06 at or above 25 ppm-hrs) had the highest percentage of biosites with injury and the highest mean biosite index, with little discernable difference among the lower exposure categories; this study also identified “better linkage between air levels and visible injury” as an O<sub>3</sub> research need

---

<sup>52</sup> As noted in the 2013 and 2020 ISAs, visible foliar injury usually occurs when sensitive plants are exposed to elevated ozone concentrations in a predisposing environment, with a major modifying factor being the amount of soil moisture available to a plant. Accordingly, dry periods are concluded to decrease the incidence and severity of ozone-induced visible foliar injury, such that the incidence of visible foliar injury is not always higher in years and areas with higher ozone, especially with co-occurring drought (ISA, Appendix 8, p. 8-23; Smith, 2012; Smith et al., 2003).

<sup>53</sup> These data were collected as part of the U.S. Forest Service Forest Health Monitoring/Forest Inventory and Analysis (USFS FHM/FIA) biomonitoring network program (2013 ISA, section 9.4.2.1; Campbell et al., 2007, Smith et al., 2012).



1 (Campbell et al., 2007). More recent studies of the complete 16 years of data in 24 northeast and  
2 north central states have suggested that a cumulative exposure index alone may not completely  
3 describe the O<sub>3</sub>-related risk of this effect (Smith et al., 2012; Smith, 2012). For example, Smith  
4 (2012) observed there to be a declining trend in the 16-year dataset, “especially after 2002 when  
5 peak ozone concentrations declined across the entire region” thus suggesting a role for peak  
6 concentrations.

7         Some studies of visible foliar injury incidence data have investigated the role of peak  
8 concentrations quantified by an O<sub>3</sub> exposure index that is a count of hourly concentrations (e.g.,  
9 in a year or growing season) above a threshold 1-hour concentration of 100 ppb, N100 (e.g.,  
10 Smith, 2012; Smith et al., 2012). For example, analyses of injury patterns over 16 years at USFS  
11 biosites in 24 states in the Northeast and North Central regions, in the context of the SUM06  
12 index and N100 metrics (although not in statistical combination), suggested that there may be a  
13 threshold exposure needed for injury to occur,<sup>54</sup> and that the number of hours of elevated O<sub>3</sub>  
14 concentrations during the growing season (such as what is captured by a metric like N100) may  
15 be more important than cumulative exposure in determining the occurrence of foliar injury  
16 (Smith, 2012).<sup>55</sup> This finding is consistent with statistical analyses of seven years of visible foliar  
17 injury data from a wildlife refuge in the mid-Atlantic (Davis and Orendovici, 2006). The latter  
18 study investigated the fit of multiple models that included various metrics of cumulative O<sub>3</sub> (e.g.,  
19 SUM06, SUM0, SUM08), alone and in combination with some other variables (Davis and  
20 Orendovici, 2006). Among the statistical models investigated, the model with the best fit to the  
21 visible foliar injury incidence data was found to be one that included N100 and W126 indices, as  
22 well as drought index (Davis and Orendovici, 2006).<sup>56</sup>

23         The established significant role of higher or peak O<sub>3</sub> concentrations, as well as pattern of  
24 their occurrence, in plant responses has also been noted in prior ISAs or AQCDs. The evidence  
25 has included studies that use indices to summarize the incidence of injury on bioindicator species  
26 present at specific monitored sites, as well as experimental studies that assess the occurrence of  
27 foliar injury in response to varying O<sub>3</sub> concentrations. In identifying support with regard to foliar

---

<sup>54</sup> Authors of the study observed that “injury is minimized when seasonal ozone concentrations, especially peak (N100) O<sub>3</sub> concentrations, drop below a certain threshold as in 2004 through 2009” (Smith et al., 2012).

<sup>55</sup> Although the ISA and past assessments have not described extensive evaluations of specific peak concentration metrics such as the N100 (that might assist in identifying one best suited for such purposes), in summarizing this study in the last review, the ISA observed that “[o]verall, there was a declining trend in the incidence of foliar injury as peak O<sub>3</sub> concentrations declined” (2013 ISA, p. 9-40).

<sup>56</sup> The models evaluated included several with cumulative exposure indices alone. These included SUM60 (i.e., SUM06 in ppb), SUM0, and SUM80 (SUM08 in ppb), but not W126. They did include a model with W126 that did not also include N100. Across all of these models evaluated, the model with the best fit to the data was found to be the one that included N100 and W126, along with the drought index (Davis and Orendovici, 2006).

1 injury as the response, the 2013 ISA and 2006 AQCD both cite studies that support the  
2 “important role that peak concentrations, as well as the pattern of occurrence, plays in plant  
3 response to O<sub>3</sub>” (2013 ISA, p. 9-105; 2006 AQCD, p. AX9-169). For example, a study of  
4 European white birch saplings reported that peak concentrations and the duration of the exposure  
5 event were important determinants of foliar injury (2013 ISA, section 9.5.3.1; Oksanen and  
6 Holopainen, 2001). This study also evaluated tree growth, which was found to be more related to  
7 cumulative exposure (2013 ISA, p. 9-105).<sup>57</sup> A second study that was cited by both assessments  
8 that focused on aspen, reported that “the variable peak exposures were important in causing  
9 injury, and that the different exposure treatments, although having the same SUM06, resulted in  
10 very different patterns of foliar injury (2013 ISA, p. 9-105; 2006 AQCD, p. AX9-169; Yun and  
11 Laurence, 1999). As noted in the 2006 AQCD, the cumulative exposure indices (e.g., SUM06,  
12 W126) were “originally developed and tested using only growth/yield data, not foliar injury” and  
13 “[t]his distinction is critical in comparing the efficacy of one index to another” (2006 AQCD, p.  
14 AX9-173). It is also recognized that where cumulative indices are highly correlated with the  
15 frequency or occurrence of higher hourly average concentrations, they could be good predictors  
16 of such effects (2006 AQCD, section AX9.4.4.3).

17 Dose modeling or flux models, discussed in section 4.3.3.1.1 above, have also been  
18 considered for quantifying O<sub>3</sub> dose that may be related to plant injury. Among the newly  
19 available evidence is a study examining relationships between short-term flux and leaf injury on  
20 cotton plants that described a sensitivity parameter that might characterize the influence on the  
21 flux-injury relationship of diel and seasonal variability in plant defenses (among other factors)  
22 and suggested additional research might provide for such a sensitivity parameter to “function  
23 well in combination with a sigmoidal weighting of flux, analogous to the W126 weighting of  
24 concentration”, and perhaps an additional parameter (Grantz et al., 2013, p. 1710; ISA, Appendix  
25 8, section 8.13.1). However, the ISA recognizes there is “much unknown” with regard to the  
26 relationship between O<sub>3</sub> uptake and leaf injury, and relationships with detoxification processes  
27 (ISA, Appendix 8, section 8.13.1 and p. 8-184). These uncertainties have made this technique  
28 less viable for assessments in the U.S., precluding use of a flux-based approach at this time (ISA,  
29 Appendix 8, section 8.13.1 and p. 8-184).

30 A study (by Wang et al. [2012], newly described in the 2020 ISA) involved a statistical  
31 modeling analysis on a subset of the years of data that were described in Smith (2012). This  
32 analysis, which involved 5,940 data records from 1997 through 2007 from the 24 northeast and  
33 north central states, tested a number of models for their ability to predict the presence of visible

---

<sup>57</sup> The study authors concluded that “high peak concentrations were important for visible injuries and stomatal conductance, but less important for determining growth responses” (Oksanen and Holopainen, 2001).

foliar injury (a nonzero biosite score), regardless of severity, and generally found that the type of O<sub>3</sub> exposure metric (e.g., SUM06 *versus* N100) made only a small difference, although the models that included both a cumulative index (SUM06) and N100 had a just slightly better fit (Wang et al., 2012). Based on their investigation of 15 different models, using differing combinations of several types of potential predictors, the study authors concluded that they were not able to identify environmental conditions under which they “could reliably expect plants to be damaged” (Wang et al., 2012). This is indicative of the current state of knowledge, in which there remains a lack of established quantitative functions describing E-R relationships that would allow prediction of visible foliar injury severity and incidence under varying air quality and environmental conditions.

#### 4.3.3.2.2 Exposure Levels Associated with Effects

The available information related to O<sub>3</sub> exposures associated with visible foliar injury of varying severity also includes the dataset developed by the EPA in the 2015 review from USFS BI scores, collected during the years 2006 through 2010 at locations in 37 states (Appendix 4C). In developing this dataset, the BI scores were combined with estimates of soil moisture<sup>58</sup> and estimates of seasonal cumulative O<sub>3</sub> exposure in terms of W126 index<sup>59</sup> (Smith and Murphy, 2015; Appendix 4C). This dataset includes more than 5,000 records of which more than 80 percent have a BI score of zero (indicating a lack of visible foliar injury).<sup>60</sup> While the estimated W126 index assigned to records in this dataset (described in Appendix 4C) ranges from zero to somewhat above 50 ppm-hrs, more than a third of all the records (and also of records with BI scores above zero or five)<sup>61</sup> are at sites with W126 index estimates below 7 ppm-hrs and only 8% of the records have W126 index values above 15 ppm-hrs. In an extension of analyses developed

---

<sup>58</sup> Soil moisture categories (dry, wet or normal) were assigned to each biosite record based on the NOAA Palmer Z drought index values obtained from the NCDC website for the April-through-August periods, averaged for the relevant year; details are provided in Appendix 4C, section 4C.2. There are inherent uncertainties in this assignment, including the substantial spatial variation in soil moisture and large size of NOAA climate divisions (hundreds of miles). Uncertainties and limitations in the dataset are summarized in Appendix 4C, section 4C.5).

<sup>59</sup> The W126 index values assigned to the biosite locations are estimates developed for 12 kilometer (km) by 12 km cells in a national-scale spatial grid for each year. The grid cell estimates were derived from applying a spatial interpolation technique to annual W126 values derived from O<sub>3</sub> measurements at ambient air monitoring locations for the years corresponding to the biosite surveys (details in Appendix 4C, sections 4C.2 and 4C.5).

<sup>60</sup> In the scheme used by the USFS to categorize severity of biosite scores the lowest category encompasses BI scores from zero to just below 5; scores of this magnitude are described as “little or no foliar injury” (Smith et al., 2012). The next highest category encompasses scores from five to just below 15 and is described as “light to moderate foliar injury,” BI scores of 15 up to 25 are described as “moderate” and above 25 is described as “severe” (Smith, 2012; Smith et al., 2012)..

<sup>61</sup> One third (33%) of scores above 15 are at sites with W126 below 7 ppm-hrs (Appendix 4C, Table 4C-3).

1 in the 2015 review, the presentation in the Appendix 4C<sup>62</sup> describes the BI scores for the records  
2 in the dataset in relation to the W126 index estimate for each record, using “bins” of increasing  
3 W126 index values. The presentation utilizes the BI score breakpoints in the scheme used by the  
4 USFS to categorize severity. This presentation indicates that, across the W126 bins, there is  
5 variation in both the incidence of particular magnitude BI scores and in the average score per  
6 bin. In general, however, the greatest incidence of records with BI scores above zero, five, or  
7 higher – and the highest average BI score (as noted below) – occurs with the highest W126 bin  
8 (i.e., the bin for W126 index estimates greater than 25 ppm-hrs), as seen in Figure 4-5 for records  
9 in the normal soil moisture category<sup>63</sup> (see also Appendix 4C, Table 4C-6).

10 The average BI score per W126 index bin is also variable, although for records  
11 categorized as normal soil moisture, the average BI score in the highest W126 bin is noticeably  
12 greater than for lower W126 bin scores (Figure 4-5). For example, the average BI score for the  
13 normal soil moisture category is 7.9 among records with W126 index estimates greater than 25  
14 ppm-hrs, compared to 1.6 among records for W126 index estimates between 19 and 25 ppm-hrs.  
15 For records categorized as wet soil moisture, the sample size for the W126 bins above 13 ppm-  
16 hrs is quite small (including only 18 of the 1,189 records in that soil moisture category),  
17 precluding meaningful interpretation.<sup>64</sup>


18 While for BI scores above zero, the data may indicate a suggestion of increased incidence  
19 among records in the W126 bins just below the highest (e.g., for the dry or normal soil moisture  
20 categories), for BI scores above 5, there is little or no difference across the W126 bins except for  
21 the highest bin, which is for W126 above 25 ppm-hrs (Appendix 4C, Table 4C-6). For example,  
22 among records in the normal soil category, the proportion of records with BI above five  
23 fluctuates between 5% and 13% across all but the highest W126 bin (>25 ppm-hrs) for which the  
24 proportion is 41% (Appendix 4C, Table 4C-6). The same pattern is observed for BI scores above  
25 15 at sites with normal and dry soil moisture conditions, albeit with lower incidences. For  
26 example, the incidence of normal soil moisture records with BI score above 15 in the bin for  
27 W126 index values above 25 ppm-hrs was 20% but fluctuates between 1% and 4% in the bin  
28 with W126 index values at or below 25 ppm-hrs (Appendix 4C, Table 4C-6).

---

<sup>62</sup> Beyond the presentation of a statistical analysis developed in the last review (Appendix 4C, section 4C.4.1), the PA presentations are primarily descriptive (as compared to statistical) in recognition of the limitations and uncertainties of the dataset (Appendix 4C, section 4C.5).

<sup>63</sup> The number of records per W126 bin in Figure 4-5 ranges from a low of 15 in the “>19-25” bin to 158 in the “<7” bin (Appendix 4C, Table 4C-4).

<sup>64</sup> In the full database for the wet soil moisture category, there are only 18 records at sites with a W126 index value above 13 ppm-hrs, with 9 or fewer (less than 1%) in each of them (Appendix 4C, Table 4C-3). Across the W126 bins in which at least 1% of the wet soil moisture records are represented, differences of incidence or average score of lower bins from the highest bin is less than a factor of two (Appendix 4C, section 4C.4.2).



Key: The boxes denote the 25th, 50th and 75th percentiles, the x's the arithmetic mean, and the whiskers denote the value equal to the 75<sup>th</sup> percentile plus 1.5 times the interquartile range (75<sup>th</sup> minus 25<sup>th</sup> percentile). Circles show scores higher than that.

**Figure 4-5. Distribution of nonzero BI scores at USFS biosites (normal soil moisture) grouped by assigned W126 index estimates.**

Overall, the dataset described in Appendix 4C generally indicates the risk of injury, and particularly injury considered at least light, moderate or greater injury, to be higher at the highest W126 index values, with appreciable variability in the data for the lower bins. This appears to be consistent with the conclusions of the detailed quantitative analysis studies, summarized above, that the pattern is stronger at higher O<sub>3</sub> concentrations. A number of factors may contribute to the observed variability in BI scores and lack of a clear pattern with W126 index bin; among others, these may include uncertainties in assignment of W126 estimates and soil moisture categories to biosite locations, variability in biological response among the sensitive species monitored, and the potential role of other aspects of O<sub>3</sub> air quality not captured by the W126 index. Thus, the dataset has limitations affecting associated conclusions, and uncertainty remains regarding the tools for and the appropriate metric (or metrics) for quantifying influence of O<sub>3</sub> exposures, as well as perhaps for quantifying soil moisture conditions, with regard to their influence on extent and/or severity of injury in sensitive species in natural areas, as quantified via BI scores (Davis and Orendovici, 2006; Smith et al., 2012; Wang et al., 2012). Accordingly, the limitations recognized in the past remain in our ability to quantitatively estimate incidence and severity of visible foliar injury likely to occur in areas across the U.S. under different air quality conditions over a year, or over a multi-year period (Appendix 4C, section 4C.5).

#### 4.3.3.3 Other Effects

With regard to radiative forcing and subsequent climate effects associated with the global tropospheric abundance of O<sub>3</sub>, the available evidence does not provide more detailed quantitative information regarding O<sub>3</sub> concentrations at the national scale than was available in the 2015 review (ISA, Appendix 9). Rather, it is noted that “the heterogeneous distribution of ozone in the troposphere complicates the direct attribution of spatial patterns of temperature change to ozone induced [radiative forcing]” and there are “ozone climate feedbacks that further alter the relationship between ozone [radiative forcing] and temperature (and other climate variables) in complex ways” (ISA, Appendix 9, section 9.3.1, p. 9-19). Further, “precisely quantifying the change in surface temperature (and other climate variables) due to tropospheric ozone changes requires complex climate simulations that include all relevant feedbacks and interactions” (ISA, section 9.3.3, p. 9-22). Yet, there are limitations in current climate modeling capabilities for O<sub>3</sub>; an important one is representation of important urban- or regional-scale physical and chemical processes, such as O<sub>3</sub> enhancement in high-temperature urban situations or O<sub>3</sub> chemistry in city centers where NO<sub>x</sub> is abundant. Such limitations impede our ability to quantify the impact of incremental changes in ground-level O<sub>3</sub> concentrations in the U.S. on radiative forcing and subsequent climate effects.

With regard to tree mortality, the evidence available in the last several reviews included field studies of pollution gradients that concluded O<sub>3</sub> damage to be an important contributor to tree mortality although “several confounding factors such as drought, insect outbreak and forest management” were identified as potential contributors (2013 ISA, p. 9-81, section 9.4.7.1). Among the newly available studies, there is only limited experimental evidence that isolates the effect of O<sub>3</sub> on tree mortality<sup>65</sup> and might be informative regarding O<sub>3</sub> concentrations of interest in the review, and evidence is lacking regarding exposure conditions closer to those occurring under the current standard and any contribution to tree mortality.

With regard to alteration of herbivore growth and reproduction, although “there are multiple studies demonstrating ozone effects on fecundity and growth in insects that feed on ozone-exposed vegetation”, “no consistent directionality of response is observed across studies and uncertainties remain in regard to different plant consumption methods across species and the exposure conditions associated with particular severities of effects” (ISA, pp. ES-18, IS-64, IS91 and Appendix 8, section 8.6.3). Such limitations and uncertainties in the evidence base for this category of effects preclude broader characterization, as well as quantitative analysis related to

---

<sup>65</sup> Of the three new studies on tree mortality described in the ISA is another field study of a pollution gradient that, like such studies in prior reviews, recognizes O<sub>3</sub> exposures as one of several contributing environmental and anthropogenic stressors (ISA, p. 8-55).

1 air quality conditions meeting the O<sub>3</sub> standard. As characterized in the ISA, uncertainties remain  
2 in the evidence; these relate to the different plant consumption methods across species and the  
3 exposure conditions associated with particular responses, as well as variation in study designs  
4 and endpoints used to assess O<sub>3</sub> response (ISA, IS.6.2.1 and Appendix 8, section 8.6). Thus,  
5 while the evidence describes changes in nutrient content and leaf chemistry following O<sub>3</sub>  
6 exposure (ISA, p. IS-73), the effect of these changes on herbivores consuming the leaves is not  
7 well characterized or clear.

8 The evidence for a second newly identified category of effects, alteration of plant-insect  
9 signaling, draws on new research yielding clear evidence of O<sub>3</sub> modification of VPSCs and  
10 behavioral responses of insects to these modified chemical signals (ISA, section IS.6.2.1). While  
11 the evidence documents effects on plant production of signaling chemicals and on the  
12 atmospheric persistence of signaling chemicals, as well as on the behaviors of signal-responsive  
13 insects, it is limited with regard to characterization of mechanisms and the consequences of any  
14 modification of VPSCs by O<sub>3</sub> (ISA, section IS.6.2.1). Further, the evidence includes a relatively  
15 small number of plant species and plant-insect associations<sup>66</sup> and is limited to short, controlled  
16 exposures, posing limitations for our purposes of considering the potential for associated impacts  
17 to be elicited by air quality conditions that meet the current standard (ISA, section IS.6.2.1 and  
18 Appendix 8, section 8.7).

19 For categories of vegetation-related effects that were recognized in past reviews, other  
20 than growth and visible foliar injury (e.g., reduced plant reproduction, reduced productivity in  
21 terrestrial ecosystems, alteration of terrestrial community composition and alteration of below-  
22 ground biogeochemical cycles), the newly available evidence includes a variety of studies that  
23 quantify exposures of varying duration in various countries using a variety of metrics (ISA,  
24 Appendix 8, sections 8.4, 8.8 and 8.10). The ISA additionally describes publications that  
25 summarize previously published studies in several ways. For example, a meta-analysis of  
26 reproduction studies categorized the reported O<sub>3</sub> exposures into bins of differing magnitude,  
27 grouping differing concentration metrics and exposure durations together, and performed  
28 statistical analyses to reach conclusions regarding the presence of an O<sub>3</sub>-related effect (ISA,  
29 Appendix 8, section 8.4.1). While such studies continue to support conclusions of the ecological  
30 hazards of O<sub>3</sub>, they do not improve capabilities for characterizing the likelihood of such effects  
31 under patterns of environmental O<sub>3</sub> concentrations occurring with air quality conditions that meet  
32 the current standard (e.g., factors such as variation in exposure assessments and limitations in  
33 response information preclude detailed analysis for such conditions).

---

<sup>66</sup> The available studies vary with regard to the experimental exposure circumstances in which the different types of effects have been reported; most of the studies have been carried out in laboratory conditions rather than in natural environments (ISA, section IS.6.2.1).

As at the time of the 2015 review, growth impacts, most specifically as evaluated by RBL for tree seedlings and RYL for crops, remain the type of vegetation-related effects for which we have the best understanding of exposure conditions likely to elicit them. Accordingly, as was the case in the 2015 review, the quantitative analyses of exposures occurring under air quality that meets the current standard (summarized in section 4.4 below) is focused primarily on the W126 index, given its established relationship with growth effects.

#### 4.3.4 Key Uncertainties

The type of uncertainties for each category of effects generally tends to vary in relation to the maturity of the associated evidence base from those associated with overarching characterizations of the effects to those associated with quantification of the cause-and-effect relationships. For example, given the longstanding nature of the evidence for many of the vegetation effects identified in the ISA as causally or likely causally related to O<sub>3</sub> in ambient air, the key uncertainties and limitations in our understanding of these effects relate largely to the implications or specific aspects of the evidence, as well as to current understanding of the quantitative relationships between O<sub>3</sub> concentrations in the environment and the occurrence and severity (or relative magnitude) of such effects or understanding of key influences on these relationships. For more newly identified categories of effects, the evidence may be less extensive, thus precluding consideration of such details.

- **What are important uncertainties in the evidence? To what extent have important uncertainties in the evidence identified in the past been reduced and/or have new uncertainties been recognized?**

Among the categories of effects identified in past reviews, key uncertainties remain in the evidence. The category of O<sub>3</sub> welfare effects for which current understanding of quantitative relationships is strongest is reduced plant growth. As a result, this category was the focus of decision-making on the standard in the 2015 review, with RBL in tree seedlings playing the role of surrogate (or proxy) for the broader array of vegetation-related effects that range from the individual plant level to ecosystem services. Limitations in the evidence base and associated uncertainties recognized then remain and include a number of uncertainties that affect characterization of the magnitude of cumulative exposure conditions that might be expected to elicit growth reductions in U.S. forests. These limitations and uncertainties relate both to aspects related to the extent and precision of the E-R evidence for the O<sub>3</sub> concentration patterns and associated cumulative seasonal exposures common in areas of the U.S. that meet the current standard, and with regard broader interpretation of RBL estimates with regard to longer term and population and ecosystem scale impacts.



Uncertainties in RBL estimates for today's O<sub>3</sub> air quality stem from limitations and imprecision in our tools, and aspects of the underlying data. While the tree seedling E-R relationships for the 11 species are long-established, there is large variation among the species regarding the number of experimental datasets supporting each, and among the species and experiments in the duration of the controlled exposures assessed. For example, the E-R function for aspen (representing a mixture of wild type and four specific clones) is based on functions for 13 experimental datasets (for six different exposure studies), while the E-R functions for the red maple and Virginia pine were each derived from a single experimental study (of 55 days for red maple and 159 days for Virginia pine) (Appendix 4A, section 4A.2, Table 4A-6; 1996 AQCD, Table 5-28; Lee and Hogsett, 1996).

Across these varied datasets, the controlled exposure periods vary in duration both within and across years (e.g., from exposure periods of 82 to 140 days in a single year to periods of 180 to 555 days distributed across two years) and in whether measurements were made immediately following exposure period or in the subsequent spring. The final set of E-R functions were derived first for the exposure duration of the experiment and, then adjusted or normalized to 3-month periods based on assumptions regarding relationships between duration, cumulative exposure in terms of W126 index and plant growth response (Lee and Hogsett, 1996, section I.3; Appendix 4A, Attachment 1). For example, while the functions are defined as describing a seasonal response, some were derived by distributing responses observed at the end of two seasons of varying exposures equally across the two seasons (essentially applying the average to both seasons). Uncertainty associated with this variation in durations and assumptions inherent in the adjustment step is contributed to RBL estimates derived through application of the resultant functions.

Further, there is uncertainty associated with estimates of effects across multiple years related to the limited availability of studies of seasonal growth effects on trees across multiple years (particularly more than two) that have also reported detailed O<sub>3</sub> concentration data throughout the exposure. This contributes uncertainty, and accordingly a lack of precision, to an understanding of the quantitative impacts of seasonal O<sub>3</sub> exposure, including its year-to-year variability, on tree growth and annual biomass accumulation. This uncertainty limits our understanding of the extent to which tree biomass would be expected to appreciably differ at the end of multi-year exposures for which the overall average exposure is the same, yet for which the individual year exposures vary in different ways (e.g., as analyzed in Appendix 4D).<sup>67</sup>

---

<sup>67</sup> Variation in annual W126 index values is described in Appendix 4D, indicating for the period, 2016-2018, that the amount by which annual W126 index values at a site differ from the 3-year average varies, but generally falls below 10 ppm-hrs across all sites and generally below 5 ppm-hrs at sites with design values at or below 70 ppb (Appendix 4D, Figure 4D-7).

One available study of multi-year growth effects for aspen, was summarized and assessed in the 2020 and 2013 ISAs with regard the extent to which it confirmed O<sub>3</sub>-related biomass impacts estimated using the established E-R functions for aspen (King et al., 2005; 2013 ISA, section 9.6.3.2; ISA, Appendix 8, section 8.13.2). The 2013 ISA applied the E-R functions to O<sub>3</sub> exposure (quantified as cumulative average seasonal W126 index) at each of six consecutive years and compared the estimated aboveground biomass to estimates based on data reported for each year by the study (2013 ISA, section 9.6.3.2). The conclusions reached were that the experimental observations are “very close” to estimates based on the established E-R function for aspen, and that “the function based on one year of growth was shown to be applicable to subsequent years” (2013 ISA, p. 9-135; ISA, Appendix 8, p. 8-186). A similar assessment in the 2020 ISA that applied the E-R functions to O<sub>3</sub> exposure, quantified individually after a 92-day season in each of six consecutive years similarly also concluded that predictions based on the E-R functions generally agreed with the observations, given generally similar pattern and magnitude of cumulative response (with some variation). In addition to indicating general support for the E-R functions based on the cumulative W126 index, these assessments also indicated uncertainty associated with the relative influences of individual seasonal exposures and longer-term exposures, as represented by a cumulative average, given that either multiyear average or single year W126 estimates provided general agreement with experimental observations (Appendix 4A, section 4A.3.1; 2013 ISA, Figure 9-20; 2020 ISA, Appendix 8, Figure 8-17).

Another area of important uncertainties relates to the extent to which the E-R functions for reduced growth in tree seedlings are also descriptive of such relationships during later lifestages, for which there is a paucity of established E-R relationships. Although such information is limited with regard to mature trees, the analyses in the 2013 and 2020 ISAs (summarized above) indicated that reported growth response of young aspen over six years was similar to the reported growth response of seedlings (ISA, Appendix 8, section 8.13.2; 2013 ISA, section 9.6.3.2). Evidence is lacking, however, on the shape of such relationships for older, mature trees, or the extent to which these relationships in seedlings might also reflect responses in older, mature trees

Additionally, there are uncertainties with regard to the extent to which various factors in natural environments can either mitigate or exacerbate predicted O<sub>3</sub>-plant interactions and contribute variability in vegetation-related effects, including reduced growth. Such factors include multiple genetically influenced determinants of O<sub>3</sub> sensitivity, changing sensitivity to O<sub>3</sub> across vegetative growth stages, co-occurring stressors and/or modifying environmental factors. Such factors contribute uncertainties to interpretations of potential impacts in a season as well as over multi-year periods. With regard to the latter, there is variability in ambient air O<sub>3</sub>

1 concentrations from year to year, as well as year-to-year variability in environmental factors,  
2 including rainfall and other meteorological factors that affect plant growth and reproduction,  
3 such as through changes in soil moisture. These variabilities contribute uncertainties to estimates  
4 of the occurrence and magnitude of O<sub>3</sub>-related effects in any year, and to such estimates over  
5 multi-year periods, as well as related effects in associated communities and ecosystems. All the  
6 factors identified here contribute uncertainty and an associated imprecision or inexactitude to  
7 estimates for trees in natural areas derived from the E-R functions and W126 index values in a  
8 single year/season.

9       The uncertainties identified here are important for our interpretation of potential impacts  
10 under air quality conditions that meet the current standard, which as described in section 4.4.2  
11 below are generally associated with cumulative seasonal exposures lower than 20 or 25 ppm-hrs,  
12 in terms of W126 index, and with quite low N100 values in a year. Such conditions are not  
13 extensively represented in the datasets on which the tree seedling E-R functions are based. While  
14 the functions have been concluded to provide a good fit to the underlying experimental datasets,  
15 the datasets vary with regard to their representation of relatively lower O<sub>3</sub> treatment levels,<sup>68</sup> in  
16 terms of W126 index (e.g., below 20 ppm-hrs). Additionally, the experimental datasets include  
17 patterns of hourly concentrations that differ markedly from those common in areas meeting the  
18 current standard (e.g., with greater prevalence of peak hourly concentrations). With regard to  
19 W126 index level, the W126 index levels across the experiments range as high as 109.5 ppm-hrs  
20 across a 121-day exposure (which, assuming a constant daily cumulative exposure would  
21 correspond to 83 ppm-hrs across a 92-day season). Three of the eleven species include just one  
22 of their treatment levels below a W126 index value of 20 ppm-hrs, with the other levels ranging  
23 from 25.6 ppm-hrs (over 112 days) to 109.5 ppm-hrs (over 121 days), corresponding to 21 to 83  
24 ppm-hrs for a 92-day season, based on assuming uniform cumulative exposure distribution  
25 across the period (Appendix 4A, Table 4A-5).<sup>69</sup> With regard to peak concentrations, for the  
26 experimental treatments with W126 index levels of a magnitude common at U.S. sites that meet  
27 the current standard (e.g., less than 20 ppm-hrs for a single season), the values for N100 extend  
28 up above 10, to more than 40 in one instance (Appendix 4A, Table 4A-6, black cherry and  
29 aspen). Across the full set of treatments, values for N100 extend into the hundreds up to 515 in a  
30 single treatment over 121 days. As discussed in section 4.4.1 below, such occurrences of  
31 concentrations at or above 100 ppb are not common for U.S. sites that meet the current standard,

---

<sup>68</sup> As noted in Appendix 4A, section 4A.2, the baseline, untreated, ambient air was treated with O<sub>3</sub> to develop exposure levels for comparison to charcoal-filtered air and the baseline ambient air.

<sup>69</sup> For three of the five species in Table 4A-5 in Appendix 4A for which only one treatment exposure is for a W126 index below 20 ppm-hrs, there are three other treatments that range from a W126 index of 25 ppm-hrs up to one of 109.5 ppm-hrs (Appendix 4A, Table 4A-6).

1 at which N100 is virtually always less than 10 (and generally less than 5 [see Figure 4-7  
2 below]).<sup>70</sup> Collectively, all of the factors identified above contribute uncertainty and an  
3 associated imprecision or inexactitude to estimates based on the E-R functions for W126 index  
4 levels at sites in the U.S. with air quality meeting the current standard.

5 We also note, as recognized in the 2015 review, uncertainties in the extent to which the  
6 11 tree species for which there are established E-R functions encompass the range of O<sub>3</sub> sensitive  
7 species in the U.S., and also the extent to which they represent U.S. vegetation as a whole. These  
8 11 species include both deciduous and coniferous trees with a wide range of sensitivities and  
9 species native to every NOAA climate region across the U.S. and in most cases are resident  
10 across multiple states and regions. While recognizing this uncertainty, the available information  
11 does not lead us to assume any difference in the range of sensitivity indicated by the species with  
12 E-R functions.<sup>71</sup>

13 There are also uncertainties associated with our consideration of the magnitude of tree  
14 growth effects, quantified as RBL, that might cause or contribute to adverse effects for trees,  
15 forests, forested ecosystems, or the public welfare, these are related to various uncertainties or  
16 limitations in the evidence base, including those associated with relating magnitude of tree  
17 seedling growth reduction to larger-scale forest ecosystem impacts. Additionally, several factors  
18 can also influence the degree to which O<sub>3</sub>-induced growth effects in a sensitive species affect  
19 forest and forest community composition and other ecosystem service flows (e.g., productivity,  
20 belowground biogeochemical cycles, and terrestrial ecosystem water cycling) from forested  
21 ecosystems. These include (1) the type of stand or community in which the sensitive species is  
22 found (i.e., single species versus mixed canopy); (2) the role or position the species has in the  
23 stand (i.e., dominant, sub-dominant, canopy, understory); (3) the O<sub>3</sub> sensitivity of the other co-  
24 occurring species (O<sub>3</sub> sensitive or tolerant); and (4) environmental factors, such as soil moisture  
25 and others. The lack of such established relationships with O<sub>3</sub> complicates consideration of the  
26 extent to which different estimates of impacts on tree seedling growth would indicate  
27 significance to the public welfare. Further, efforts to estimate O<sub>3</sub> effects on carbon sequestration  
28 are handicapped by the large uncertainties involved in attempting to quantify the additional

---

<sup>70</sup> Among published studies of the datasets for the eleven E-R functions, the findings for at least one study (black cherry) reported statistical significance only for biomass effects observed for the highest O<sub>3</sub> exposure, which had a seasonal W126 index of 23 ppm-hrs and 77 hours with an O<sub>3</sub> concentration at or above 100 ppb (e.g., Appendix 4A, Table 4A-6, black cherry).

<sup>71</sup> The CASAC in the 2015 review recognized this uncertainty, expressing the view that it should be anticipated that there are highly sensitive vegetation species for which we do not have E-R functions and others that are insensitive (Frey, 2014, p. 15), and concluding it to be more appropriate to assume that the sensitivity of species without E-R functions might be similar to the range of sensitivity for those species with E-R functions (Frey, 2014, p. 11).

1 carbon uptake by plants as a result of avoided O<sub>3</sub>-related growth reductions. Such analyses  
2 require complex modeling of biological and ecological processes with their associated sources of  
3 uncertainty.

4 With regard to crop yield effects, as at the time of the 2015 review, we recognize the  
5 potential for greater uncertainty in estimating the impacts of O<sub>3</sub> exposure on agricultural crop  
6 production than that associated with O<sub>3</sub> impacts on vegetation in natural forests. This relates to  
7 uncertainty in the extent to which agricultural management methods influence potential for O<sub>3</sub>-  
8 related effects and accordingly, the applicability of the established E-R functions for RYL in  
9 current agricultural areas. Additionally, as changes in yield of commercial crops and commercial  
10 commodities may affect producers and consumers differently, consideration of these effects in  
11 terms of potential adversity to the public welfare impacts is limited.

12 With regard to visible foliar injury, for which longstanding evidence documents a causal  
13 role for O<sub>3</sub>, important uncertainties and limitations fall into two categories. The first category  
14 relates to our understanding of the key aspects of O<sub>3</sub> concentrations - and other key variables  
15 (e.g., soil moisture) - that have a direct bearing on the severity and incidence of vegetation  
16 injury, while the second concerns the impacts on aesthetic and recreational values of various  
17 severities and incidences of injury. With regard to the former, there is a lack of detailed  
18 understanding of specific patterns of O<sub>3</sub> concentrations over a growing season and the key  
19 aspects of those patterns (e.g., incidence of concentrations of particular magnitude) that  
20 contribute to an increased incidence and severity of injury occurrence in the U.S. For example,  
21 “the incidence of visible foliar injury is not always higher in years and areas with higher ozone,  
22 especially with co-occurring drought” (ISA, Appendix 8, p. 8-24). Accordingly, there are no  
23 established, quantitative E-R functions that document visible foliar injury severity and incidence  
24 under varying air quality and environmental conditions (e.g., soil moisture). As discussed in  
25 section 4.3.3.2 above, the available studies that have investigated the role of different variables,  
26 including different metrics for characterizing O<sub>3</sub> concentrations over a growing season, do not  
27 provide a basis for a single metric that would characterize the potential for different patterns of  
28 O<sub>3</sub> concentrations to contribute to different incidences and severity of foliar injury in U.S.  
29 forests. Further, while several studies of the USFS biosite dataset indicate a role for two metrics -  
30 one reflecting cumulative, concentration-weighted exposures and a second that reflects peak  
31 concentrations, statistical analyses of a number of models containing various metrics and  
32 combinations of metrics have not been able to identify environmental conditions under which  
33 visible foliar injury could be reliably expected (Smith, 2012; Wang et al., 2012). The second  
34 category of uncertainties and limitations concerns the information that would support associated  
35 judgments on the public welfare significance of different patterns of and severity of foliar injury,  
36 such as the extent to which such effects in areas valued by the public for different uses may be

1 considered adverse to public welfare. In considering this issue, we note that some level of  
2 severity of injury to a tree stand would be obvious to the casual observer (e.g., when viewing a  
3 stand covering a hillside from a distance), and some level of severity of injury (e.g., leaf and  
4 crown damage that appreciably affects overall plant physiology) would also be expected to affect  
5 plant growth and reproduction. The extent to which recreational values are affected by lesser  
6 levels of injury severity and incidence is not clear from the available information. Thus,  
7 limitations and uncertainties in the available information, such as those described above,  
8 complicate our ability to comprehensively estimate the potential for visible foliar injury, its  
9 severity or extent of occurrence for specific air quality conditions, and associated public welfare  
10 implications, thus affecting a precise identification of air quality conditions that might be  
11 expected to provide a specific level of protection for this effect.

12 During the 2015 review, the 2013 ISA did not assess the evidence of O<sub>3</sub> exposure and  
13 tree mortality with regard to its support for inference of a causal relationship. Evidence available  
14 in the last several reviews included field studies of pollution gradients that concluded O<sub>3</sub> damage  
15 to be an important contributor to tree mortality although several confounding factors such as  
16 drought, insect outbreak and forest management were identified as potential contributors (2013  
17 ISA, section 9.4.7.1). Since the 2015 review, three additional studies have been identified, as  
18 summarized in section 4.3.1 above, contributing to the ISA conclusion of sufficient evidence to  
19 infer a likely causal relationship for O<sub>3</sub> with tree mortality (ISA, Appendix 8, section 8.4). As  
20 noted in the ISA, there is only limited evidence from experimental studies that isolate the effect  
21 of O<sub>3</sub> on tree mortality, with the recently available Aspen FACE study of aspen survival  
22 involving cumulative seasonal exposures above 30 ppm-hrs during the first half of the 11-year  
23 study period (ISA, Appendix 8, Tables 8-8 and 8-9). Evidence is lacking regarding exposure  
24 conditions closer to those occurring under the current standard and any contribution to tree  
25 mortality.

26 In the case of the two newly identified categories of effects, the key uncertainties relate to  
27 comprehensive characterization of the effects. For example, with regard to alteration of herbivore  
28 growth and reproduction, although “there are multiple studies demonstrating ozone effects on  
29 fecundity and growth in insects that feed on ozone-exposed vegetation”, “no consistent  
30 directionality of response is observed across studies and uncertainties remain in regard to  
31 different plant consumption methods across species and the exposure conditions associated with  
32 particular severities of effects” (ISA, pp. ES-18, IS-64, IS91 and Appendix 8, section 8.6.3).  
33 Such limitations and uncertainties in the evidence base for this category of effects preclude  
34 broader characterization, as well as quantitative analysis related to air quality conditions meeting  
35 the O<sub>3</sub> standard. As characterized in the ISA, uncertainties remain in the evidence; these relate to  
36 the different plant consumption methods across species and the exposure conditions associated

1 with particular responses, as well as variation in study designs and endpoints used to assess O<sub>3</sub>  
2 response (ISA, IS.6.2.1 and Appendix 8, section 8.6). Thus, while the evidence describes  
3 changes in nutrient content and leaf chemistry following O<sub>3</sub> exposure, the effect of these changes  
4 on herbivores consuming the leaves is not well characterized or clear (ISA, p. IS-73).

5 The evidence for a second newly identified category of effects, alteration of plant-insect  
6 signaling, draws on new research that has provided clear evidence of O<sub>3</sub> modification of VPSCs  
7 and behavioral responses of insects to these modified chemical signals. Most of these studies,  
8 however, have been carried out in laboratory conditions rather than in natural environments, and  
9 involve a relatively small number of plant species and plant-insect associations. While the  
10 evidence documents effects on plant production of signaling chemicals and on the atmospheric  
11 persistence of signaling chemicals, as well as on the behaviors of signal-responsive insects, it is  
12 limited with regard to characterization of mechanisms and the consequences of any modification  
13 of VPSCs by O<sub>3</sub> (ISA, section IS.6.2.1). Further, the available studies vary with regard to the  
14 experimental exposure circumstances in which the different types of effects have been reported  
15 (most of the studies have been carried out in laboratory conditions rather than in natural  
16 environments), and many of the studies involve quite short controlled exposures (hours to days)  
17 to elevated concentrations, posing limitations for our purposes of considering the potential for  
18 impacts associated with the studied effects to be elicited by air quality conditions that meet the  
19 current standard (ISA, section IS.6.2.1 and Appendix 8, section 8.7).

20 With regard to radiative forcing and climate effects, “uncertainty in the magnitude of  
21 radiative forcing estimated to be attributed to tropospheric ozone is a contributor to the relatively  
22 greater uncertainty associated with climate effects of tropospheric ozone compared to such  
23 effects of the well mixed greenhouse gases (e.g., carbon dioxide and methane)” (ISA, section  
24 IS.6.2.2). With regard to O<sub>3</sub> effects on temperature, “the heterogeneous distribution of ozone in  
25 the troposphere complicates the direct attribution of spatial patterns of temperature change to  
26 ozone induced RF” and the existence of O<sub>3</sub> climate feedbacks “further alter the relationship  
27 between ozone RF and temperature (and other climate variables) in complex ways” (ISA,  
28 Appendix 9, section 9.3.1). Thus, various uncertainties “render the precise magnitude of the  
29 overall effect of tropospheric ozone on climate more uncertain than that of the well-mixed  
30 GHGs” (ISA, Appendix 9, section 9.3.3). Further, “[c]urrent limitations in climate modeling  
31 tools, variation across models, and the need for more comprehensive observational data on these  
32 effects represent sources of uncertainty in quantifying the precise magnitude of climate responses  
33 to ozone changes, particularly at regional scales” (ISA, Appendix 9, section 9.3.3).

## 4.4 EXPOSURE AND AIR QUALITY INFORMATION

In general, decision-making in the 2015 review placed greatest weight on estimates of cumulative exposures to vegetation based on ambient air monitoring data and consideration of those estimates in light of E-R functions for O<sub>3</sub>-related reduction in tree seedling growth (summarized in section 4.3.3 above). These analyses supported the consideration of the potential for O<sub>3</sub> effects on tree growth and productivity, as well as its associated impacts on a range of ecosystem services, including forest ecosystem productivity and community composition (80 FR 65292, October 26, 2015). These analyses were recognized as involving relatively reduced uncertainty (compared to the national or regional-scale modeling performed in the 2015 review) for the purposes of informing a characterization of cumulative O<sub>3</sub> exposure (in terms of the W126 index) associated with air quality just meeting the existing standard (IRP, section 5.2.2). The lesser uncertainty of these air quality monitoring-based analyses contributed to their being more informative in the 2015 review and to their being updated in the 2020 PA. A second set of air quality analyses was also considered in the 2020 decision; these analyses investigated the occurrence of peak concentrations at sites for which the O<sub>3</sub> concentrations meet different design values or contribute to different cumulative exposure levels in terms of the W126 index (Wells, 2020). Both sets of analyses have been updated for this reconsideration of the 2020 decision using the more recently available air quality data now available (Appendices 4D and 4F).

The first set of analyses are air quality and exposure analyses. They are an update of the analyses considered in the 2015 decision establishing the current standard, and in the 2020 decision to retain that standard. This set of analyses, in 2015 and 2020, as well as the current updated analyses presented here, evaluate W126-based cumulative exposure estimates at all U.S. monitoring locations, nationwide, and at the subset of sites in or near Class I areas, during 3-year periods that met the then-current standard and potential alternatives (80 FR 65485-86, Table 3, October 26, 2015; Wells, 2015; 2020 PA, section 4.4). For the 2015 and 2020 decisions, W126 index values<sup>72</sup> occurring in locations with air quality meeting the then-current standard (or potential alternatives) were considered in the context of the magnitude of W126 exposure index associated with an estimate of 6% RBL in tree seedlings for the median tree species among the 11 species for which there are established E-R relationships (80 FR 65391-92, Table 4, October 26, 2015; 2020 PA, section 4.4). That magnitude of W126 index is 19 ppm-hrs (80 FR 65391-65392). This set of analyses also includes an evaluation of relationships between W126 index

---

<sup>72</sup> Based on judgments in the last review, the W126 metric analyzed and considered in the 2015 decision was the 3-year average of consecutive year seasonal W126 index values (derived as described in section 4.3.3.1 above).



1 values and design values<sup>73</sup> based on the form and averaging time of the then-current secondary  
2 standard (Wells, 2015; 2020 PA, section 4.4).

3 The second set of analyses (initially performed for consideration in the 2020 decision and  
4 updated here) focus on the occurrence of peak concentrations, investigating the occurrence of  
5 peak concentrations at sites for which the O<sub>3</sub> concentrations meet different design values or  
6 contribute to different cumulative exposure levels in terms of the W126 index. The metrics used  
7 for these analyses are the number of hours in a year for which the O<sub>3</sub> concentration was at or  
8 above 100 ppb (N100), and the number of days in a year in which there was at least one hour  
9 with an O<sub>3</sub> concentration at or above 100 ppb (D100). The value of 100 ppb is used here as it has  
10 been in some studies focused on O<sub>3</sub> effects on vegetation (and discussed in section 4.3.3 2  
11 above), simply as an indicator of elevated or peak hourly O<sub>3</sub> concentrations (e.g., Lefohn et al.,  
12 1997, Smith, 2012; Davis and Orendovici, 2006; Kohut, 2007). Other values that have also been  
13 considered in this way in other studies are 95 ppb and 110 ppb (2013 ISA, section 9.5.3.1). These  
14 analyses provided additional information for the 2020 review beyond that provided by the first  
15 set of analyses that focused only on W126 index.

16 Both sets of analyses described here have been performed with the expanded set of air  
17 monitoring data now available,<sup>74</sup> which includes 1,578 monitoring sites with sufficient data for  
18 derivation of design values (Appendix 4D, section 4D.2.2; Appendix 4F). Both sets of analyses  
19 include a component based on data for the most recent periods, and a second component  
20 considering data across the full historical period back to 2000, which is now expanded from that  
21 previously available.<sup>75</sup> The most recent data analyzed are those for the design value period from  
22 2018 to 2020. The first set of analyses include a focus on all sites in the U.S., as well as on the  
23 subset of sites in or near Class I areas is described in detail in Appendix 4D. The second set of  
24 analyses, which investigate the occurrence of peak concentrations at sites varying by design  
25 value and W126 index, are described in detail in Appendix 4F.

26 For all monitoring sites with valid design values for the recent period of 2018 through  
27 2020, Figure 4-6 presents the 3-year average seasonal W126 index and also denotes whether  
28 each site meets the current standard. Similarly, Figure 4-7 and Figure 4-8 present N100 and  
29 D100 values, respectively, for these sites. Consideration of all three figures indicates that the


---

<sup>73</sup> As described in earlier chapters, a design value is a statistic that describes the air quality status of a given area relative to the level of the standard, taking the averaging time and form into account. For example, a design value of 75 would have indicated O<sub>3</sub> concentrations that just met the prior standard in a specific 3-yr period.


<sup>74</sup> In addition to being expanded with regard to data for more recent time periods than previously available, the current dataset also includes a small amount of newly available older data for some monitoring sites that are now available in the AQS.

<sup>75</sup> In the 2015 review, the dataset analyzed included data from 2000 through 2013 (Wells, 2015).


monitoring sites with design values above the level of the current standard have the higher W126 index values and also the higher values of N100 and D100 (compared to monitoring sites not meeting the current standard, denoted with triangles). It can also be seen that there are some sites that have relatively lower W126 index values, e.g., in the Northwest, Northeast and Midwest, while recording N100 or D100 values of more than 5 (including some N100 values above 1010 and 5 respectively). The sections below summarize more completely the findings of all the air quality analyses involving these three metrics.



**Figure 4-6. W126 index at monitoring sites with valid design values (2018-2020 average).**



**Figure 4-7. N100 values at monitoring sites with valid design values (2018-2020 average).**




**Figure 4-8. D100 values at monitoring sites with valid design values (2018-2020 average).**



#### **4.4.1 Influence of Form and Averaging Time of Current Standard on W126 Index and Peak Concentration Metrics**

In revising the standard in 2015 to the now-current standard, the Administrator concluded that, with revision of the standard level, the existing form and averaging time provided the control needed to achieve the cumulative seasonal exposure circumstances identified for the secondary standard (80 FR 65408, October 26, 2015). The focus on cumulative seasonal exposure primarily reflected the evidence on E-R relationships for plant growth. The 2015 conclusion was based on the air quality data analyzed at that time (80 FR 65408, October 26, 2015). Analyses of the now expanded set of air monitoring data, which includes 1,578 monitoring sites with sufficient data for derivation of design values (Appendix 4D, section 4D.2.2), document similar findings as from the analysis of data from 2000-2013 described in the 2015 review, and the 2020 analysis of 2000-2018 data. The current (updated) analyses, which now span 21 years and 19 3-year periods, are described in detail in Appendix 4D.

These analyses document the positive nonlinear relationship that is observed between cumulative seasonal exposure, quantified using the W126 index, and design values, based on the form and averaging time of the current standard. This is shown for both the average W126 index across the 3-year design value period (Figure 4-9, left) and for annual index values within the period (Figure 4-9, right). For both annual and 3-year average index values, it is clear that cumulative seasonal exposures, assessed in terms of W126 index, are lower at monitoring sites with lower design values. This is seen both for design values above the level of the current standard (70 ppb), where the slope is steeper (due to the sigmoidal weighting of higher concentrations by the W126 index function), as well as for lower design values that meet the current standard (Figure 4-9; Appendix 4D). These presentations also indicate some regional differences. For example, as shown in Figure 4-6 and Figure 4-9 for the 2018-2020 period, sites meeting the current standard in the regions outside of the West and Southwest regions, all 3-year average W126 index values (and virtually all annual values) are at or below 13 ppm-hrs. Ozone concentrations, and W126 index values, are generally higher in the West and Southwest regions (Figure 4-6). However, the positive relationship between the W126 index and the design value is evident in all regions (Figure 4-9).




**Figure 4-9. Relationship between the W126 index and design values for the current standard (2018-2020). The W126 index is analyzed in terms of averages across the 3-year design value period (left) and annual values (right).**

1 An additional analysis, which was also performed in the 2015 review with the then-  
2 available data, assesses the relationship between long-term changes in design value and long-  
3 term changes in the W126 index (presented in detail in Appendix 4D, section 4D.3.2.3). Ozone  
4 monitoring data have well documented reductions in O<sub>3</sub> design values in response to national  
5 programs to control O<sub>3</sub> precursors (see section 2.4.2 above). The current analysis explores the  
6 extent to which the W126 index has responded to these declines by focusing on the relationship  
7 between changes (at each monitoring site) in the 3-year design value (termed “4<sup>th</sup> max” in  
8 Appendix 4D, Figure 4-10 and Figure 4-10) across the 19 design value periods from 2000-2002  
9 to 2018-2020 and changes in the W126 index over the same period.<sup>76</sup> This analysis, performed  
10 using either the 3-year average W126 index or annual values, shows there to be a positive, linear  
11 relationship between the changes in the W126 index and the changes in the design value at  
12 monitoring sites across the U.S. (Figure 4-10). This means that a change in the design value at a  
13 monitoring site was generally accompanied by a similar change in the W126 index (e.g., a  
14 reduction in design value accompanied by a reduction in W126 index). Nationally, the W126  
15 index (in terms of 3-year average) decreased by approximately 0.59 ppm-hrs per ppb decrease in  
16 design value over the full period from 2000 to 2020. This relationship varies across the NOAA  
17 climate regions, with the greatest change in the W126 index per unit change in design value  
18 observed in the Southwest and West regions. Thus, the regions which had the highest W126  
19 index values at sites meeting the current standard (Figure 4-10) also showed the greatest  
20 improvement in the W126 index per unit decrease in their design values over the past 21 years  
21 (Appendix 4D, Table 4D-12 and Figure 4D-12). This indicates that going forward as design  
22 values are reduced in areas that are presently not meeting the current standard, the W126 index  
23 in those areas would also be expected to decline (Appendix 4D, section 4D.3.2.3 and 4D.4).

24 Thus, the air quality analyses indicate control by the form and averaging time of the  
25 current standard of W126 index exposures, both in terms of 3-year average and single-year  
26 values. The overall trend showing reductions in the W126 index concurrent with reductions in  
27 the design value metric for the current standard is positive whether the W126 index is expressed  
28 in terms of the average across the 3-year design value period or the annual value (Appendix 4D,  
29 section 4D.3.2.3). This similarity is consistent with the relationship between the W126 index and  
30 the design value metric for the current standard summarized above, which shows a strong  
31 positive relationship between those metrics (Figure 4-9, Appendix 4D, section 4D.3.1.2).

---


<sup>76</sup> At each site, the trend in values of a metric (W126 or 4<sup>th</sup> max), in terms of a per-year change in metric value, is calculated using the Theil-Sen estimator, a type of linear regression method that chooses the median slope among all lines through pairs of sample points. For example, if applying this method to a dataset with metric values for four consecutive years (e.g., W126<sub>1</sub>, W126<sub>2</sub>, W126<sub>3</sub>, W126<sub>4</sub>), the trend would be the median of the different per-year changes observed in the six possible pairs of values ([W126<sub>4</sub>- W126<sub>3</sub>]/1, [W126<sub>3</sub>- W126<sub>2</sub>]/1, [W126<sub>2</sub>- W126<sub>1</sub>]/1, [W126<sub>4</sub>- W126<sub>2</sub>]/2, [W126<sub>3</sub>- W126<sub>1</sub>]/2, [W126<sub>4</sub>- W126<sub>1</sub>]/3).



**Figure 4-10. Relationship between trends in the W126 index and trends in design values across a 21-year period (2000-2020) at U.S. monitoring sites. W126 is analyzed in terms of averages across 3-year design value periods (left) and annual values (right).**


1 In considering the control of the current form and averaging time on vegetation exposures  
2 of potential concern, we additionally take note of the evidence discussed in section 4.3.3.2 above  
3 regarding the potential for days with particularly high O<sub>3</sub> concentrations to play a contributing  
4 role in vegetation effects. While the occurrence and severity of visible foliar injury indicates  
5 some relationship with cumulative concentration-weighted indices such as SUM06 and W126,  
6 the evidence also indicates a contributing role for occurrences of peak concentrations. We note  
7 that the current standard's form and averaging time, by their very definition, limit such  
8 occurrences. For example, the peak 8-hour average concentrations are lower at sites with lower  
9 design values, as illustrated by the declining trends in annual fourth highest MDA8  
10 concentrations that accompany the declining trend in design values described in chapter 2 (e.g.,  
11 Figure 2-11). Additionally, peak hourly concentrations are also lower with lower design values.  
12 As shown in Figure 4-11, the 99<sup>th</sup> through 25<sup>th</sup> percentile daily maximum 1-hour concentrations  
13 (MDA1) are lower with lower design values. This is true both for the most recent three design  
14 value periods and the three periods in 2000 through 2004. Additionally Figure 4-11 shows that  
15 for sites with design values below the level of the standard (i.e., at or below 70 ppb) the 99<sup>th</sup>  
16 percentile of daily maximum 1-hour ozone concentrations is less than 80 ppb. Further analyses  
17 summarized in Appendix 2A document many fewer hourly concentrations at or above 100 ppb at  
18 sites that meet the current standard compared to sites that do not. For example, the average  
19 number of hours at or above 100 ppb per site in a 3-year period was well below one for sites  
20 meeting the current standard compared to approximately 10 occurrences per site for sites not  
21 meeting the current standard (Appendix 2A, Table 2A-2). This pattern also holds for hourly  
22 concentrations at or above 120 or 160 ppb and is true for the recent air quality as well as past air  
23 quality (Appendix 2A, Tables 2A-2 through 2A-4).





**Figure 4-11. Distributions of MDA1 concentrations for the three design value periods in 2000-2004 (red) and 2016-2020 (blue), binned by the design value at each monitoring site. Boxes represent the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles; whiskers represent the 1<sup>st</sup> and 99<sup>th</sup> percentiles; and circles are outlier values.**

An additional investigation into the extent of control the current standard exerts on peak concentrations is described in the set of analyses presented in Appendix 4F. This investigation tallied the number of hours at or above 100 ppb (N100), and the number of days with an hour at or above 100 ppb (D100), at sites meeting different criteria with regard to seasonal W126 index, in a single year and as an average across three years, and also at sites with varying design values. The strong control of these peak concentration metrics exerted by the current standard is illustrated in Figure 4-12 by the low values common at sites meeting the current standard (design value of 70 ppb or lower). The parallel presentation for varying values of W126 index suggests that this metric has generally less potential for control of such peaks (Figure 4-12). For example, the distributions for N100 and D100 observed for monitoring sites meeting the current standard are more compressed and have lower maximum values than any of the W126 bins, with the lowest bins (for W126 index values at or below 7 ppm-hrs) being most similar (Figure 4-12).



**Figure 4-12. Distributions of N100 (top panels) and D100 (bottom panels) values at monitoring sites differing by design values (left panels) and W126 index values (right panels) based on 2018-2020 monitoring data. The boxes represent the 25th, 50th and 75th percentiles and the whiskers extend to the 1st and 99<sup>th</sup>.**

In considering the prevalence of peak concentrations occurring at monitoring sites, it can be seen that O<sub>3</sub> concentrations at or above 100 ppb occur at lower prevalence at sites that meet the current standard than at sites that meet a range of W126 index values. As shown in Table 4-1, during the highest year for the different N100 or D100 thresholds, the percentage of sites exceeding those thresholds is greater for the sites restricted to meet the different annual W126 levels, with the exception of 7 ppm-hrs, than it is for sites meeting the current standard (design values [3-year 4<sup>th</sup> Max] at or below 70 ppb) for which the percentages are similar to those for the sites meeting a W126 of 7 ppm-hrs. This observation can also be made for the average percentages across the 3-year period. Further, in looking at the three most recent 3-year periods (extending from 2016 through 2020), a similar finding holds (Table 4-2).

**Table 4-1. Percent of monitoring sites during the 2018 to 2020 period with 4<sup>th</sup> max or W126 metrics at or below various thresholds that have N100 or D100 values above various thresholds.**

|   | Total<br>Number of<br>Sites | Number of sites where:   |          |           | Number of sites where: |          |          |
|---|-----------------------------|--|----------|-----------|------------------------|----------|----------|
|   |                             | N100 > 0   | N100 > 5 | N100 > 10 | D100 > 0               | D100 > 2 | D100 > 5 |
|   |                             | Average percent of sites exceeding N100 or D100 threshold per year*            |          |           |                        |          |          |
| 3-year 4 <sup>th</sup> Max ≤ 70   | 877                         | 6%   | 0.4%     | <0.1%     | 6%                     | 0.3%     | 0%       |
| Annual W126 ≤ 25  | 1134-1144                   | 11%  | 1.7%     | 0.5%      | 11%                    | 1.7%     | 0.3%     |
| Annual W126 ≤ 19  | 1091-1129                   | 10%  | 1.3%     | 0.3%      | 10%                    | 1.3%     | 0.2%     |
| Annual W126 ≤ 17  | 1067-1117                   | 9.3%   | 1.3%     | 0.2%      | 9.3%                   | 1.3%     | 0.2%     |
| Annual W126 ≤ 15  | 1031-1091                   | 9%   | 1.2%     | 0.2%      | 9%                     | 1.2%     | 0.1%     |
| Annual W126 ≤ 7   | 626-860                     | 5.3%   | 0.4%     | 0%        | 5.3%                   | 0.4%     | 0%       |
| Annual 4 <sup>th</sup> Max ≤ 70   | 802-1000                    | 3.7%   | 0%       | 0%        | 3.7%                   | 0%       | 0%       |
|   |                             | Percent of sites exceeding N100 or D100 threshold in maximum year of the three |          |           |                        |          |          |
| 3-year 4 <sup>th</sup> Max ≤ 70   | See above                   | 9%   | 0.6%     | 0.1%      | 9%                     | 0.5%     | 0%       |
| Annual W126 ≤ 25  |                             | 15%  | 2%       | 0.6%      | 15%                    | 2%       | 0.4%     |
| Annual W126 ≤ 19  |                             | 13%  | 2%       | 0.4%      | 13%                    | 28%      | 0.3%     |
| Annual W126 ≤ 17  |                             | 13%  | 2%       | 0.3%      | 13%                    | 2%       | 0.3%     |
| Annual W126 ≤ 15  |                             | 13%  | 2%       | 0.3%      | 13%                    | 2%       | 0.3%     |
| Annual W126 ≤ 7   |                             | 8%   | 1%       | 0%        | 8%                     | 1%       | 0%       |
| Annual 4 <sup>th</sup> Max ≤ 70   |                             | 4%   | 0%       | 0%        | 4%                     | 0%       | 0%       |
| * For the annual metrics, the entries for each N100 or D100 column may be for different years in the 3-year period. Thus the “Total Number of Sites” column presents the range in number of sites that meet the annual 4 <sup>th</sup> Max or W126 thresholds in each of the three years (as presented in Table 4F-2, Appendix 4F). |                             |  |          |           |                        |          |          |

**Table 4-2. Average percent of monitoring sites per year during 2016-2020 with 4<sup>th</sup> max or W126 metrics at or below various thresholds that have N100 or D100 values above various thresholds.**

|                                     | Total<br>Number<br>of Sites | Percent of sites where:  |          |           | Percent of sites where: |          |          |
|-------------------------------------|-----------------------------|--|----------|-----------|-------------------------|----------|----------|
|                                     |                             | N100 > 0   | N100 > 5 | N100 > 10 | D100 > 0                | D100 > 2 | D100 > 5 |
|                                     |                             | Average percent of sites exceeding N100 or D100 threshold per year (2016 – 2020) |          |           |                         |          |          |
| 3-year 4 <sup>th</sup> Max ≤ 70     |                             | 5.1%   | 0.3%     | 0.01%     | 5.1%                    | 0.2%     | 0%       |
| Annual W126 ≤ 25                    |                             | 11.0%  | 1.7%     | 0.5%      | 11.0%                   | 1.8%     | 0.4%     |
| Annual W126 ≤ 19                    |                             | 10.0%  | 1.4%     | 0.3%      | 10.0%                   | 1.4%     | 0.2%     |
| Annual W126 ≤ 17                    |                             | 9.5%   | 1.2%     | 0.2%      | 9.5%                    | 1.2%     | 0.1%     |
| Annual W126 ≤ 15                    |                             | 9.1%   | 1.2%     | 0.2%      | 9.1%                    | 1.1%     | 0.1%     |
| Annual W126 ≤ 7                     |                             | 5.1%   | 0.4%     | 0%        | 5.1%                    | 0.3%     | 0%       |
| Annual 4 <sup>th</sup> Max ≤ 70     |                             | 3.3%   | 0.02%    | 0%        | 3.3%                    | 0.3%     | 0%       |
| Drawn from Appendix 4F, Table 4F-3. |                             |  |          |           |                         |          |          |

These air quality analyses illustrate limitations of the W126 index for purposes of controlling peak concentrations, and also the strengths of the current standard in this regard. As discussed more fully in section 4.5.1.1 below, the W126 index cannot, by virtue of its definition, always differentiate between air quality patterns with high peak concentrations and those without such concentrations. This is demonstrated in the air quality analyses referenced above which indicate that the form and averaging time of the existing standard is much more effective than the W126 index in limiting peak concentrations (e.g., hourly O<sub>3</sub> concentrations at or above 100 ppb) and in limiting number of days with any such hours (e.g., Appendix 4F, Figures 4F-4, 4F-5, 4F-8, 4F-9 compared to Figures 4F-6, 4F-7, 4F-10 and 4F-11). A similar finding is evidenced in the historical data extending back to 2000. These data show the appreciable reductions in peak concentrations that have been achieved in the U.S. as air quality has improved under O<sub>3</sub> standards of the existing form and averaging time (Appendix 4F, Figures 4F-12 and 4F-13). From the analyses, it can be seen that the form and averaging time of the current standard is effective in controlling peak hourly concentrations and that a W126 index-based standard would be much less effective in providing the needed protection against years with such elevated and potentially damaging hourly concentrations.

In summary, monitoring sites with lower O<sub>3</sub> concentrations as measured by the design value metric (based on the current form and averaging time of the secondary standard) have lower cumulative seasonal exposures, as quantified by the W126 index, and also lower short-term peak concentrations, thus indicating a level of control exerted by the current standard on these other metrics. As the form and averaging time of the secondary standard have not changed

1 since 1997, the decreasing trends in W126 index and in hourly and 8-hour daily maximum  
2 concentrations over time also support the finding that a change in level (i.e., from 80 ppb in 1997  
3 to 75 ppb in 2008 to 70 ppb in 2015) for a standard of the current form and averaging time  
4 contributes to reductions in the level on cumulative seasonal exposures in terms of W126 index  
5 (and on the magnitude of short-term peak concentrations). That is, that reductions in design  
6 value, presumably associated with implementation of the revised standards, have been  
7 accompanied by reductions in cumulative seasonal exposures in terms of W126 index, as well as  
8 reductions in short-term peak concentrations. Further, the analyses focused on N100 and D100  
9 metrics provide additional evidence of the control of the current standard on peak concentrations,  
10 and also indicate a likely lesser effectiveness of the W126 index metric in providing such  
11 control. Altogether, the analyses summarized here demonstrate the form and averaging time of  
12 the current standards to be effective in controlling cumulative, concentration-weighted exposures  
13 as well as peak hourly concentrations (e.g., concentrations at/above 100 ppb), two metrics that  
14 have been found to be important to O<sub>3</sub> effects on vegetation (as discussed in section 4.3 above).


#### 15 **4.4.2 Environmental Exposures in Terms of W126 Index**

16 Given the evidence indicating the W126 index to be strongly related to growth effects  
17 and its use in the E-R functions for tree seedling RBL, exposure in the analyses described here is  
18 quantified using the W126 metric (Figure 4-13). These analyses are intended to inform  
19 conclusions regarding the magnitude of cumulative, concentration-weighted exposures, in terms  
20 of W126 index, likely to occur in areas that meet the current standard. In light of the importance  
21 placed on Class I areas in past secondary standard reviews and the greater public welfare  
22 significance of O<sub>3</sub> related impacts in such areas, as discussed in section 4.3.2 above, a separate  
23 evaluation is conducted on cumulative O<sub>3</sub> exposure at monitoring sites in or near Class I areas<sup>77</sup>,  
24 in addition to that at all monitoring sites nationwide. The potential for impacts of interest is  
25 assessed through considering the magnitude of estimated exposure in light of current information  
26 and, in comparison to levels given particular focus in the 2015 decision on the current standard  
27 (80 FR 65292; October 26, 2015).<sup>78</sup>

---

<sup>77</sup> Included are monitors sited within Class I areas or the closest monitoring site within 15 km of the area boundary.

<sup>78</sup> The W126 index values were rounded to the nearest unit ppm-hr for these comparisons to a specific whole-number W126 level (Appendix 4D, section 4D.2).



**Figure 4-13. Analytical approach for characterizing vegetation exposure with W126 index.**

The updated analyses discussed here and described in greater detail in Appendix 4D include assessment of all monitoring sites nationally and also a focused evaluation in Class I areas for which such monitoring data are available. The analyses include air quality monitoring data for the most recent 3-year period (2018 to 2020) for which data were available when the analyses were performed, and also all 3-year periods going back as far as the 2000-2002 period. Design values (3-year average annual fourth-highest 8-hour daily maximum concentration, also termed “4<sup>th</sup> max metric” in this analysis) and W126 index values (in terms of the 3-year average) were calculated at each site where sufficient data were available.<sup>79</sup> Across the nineteen 3-year periods from 2000-2002 to 2018-2020, the number of monitoring sites with sufficient data for calculation of valid design values and W126 index values ranged from a low of 992 in 2000-2002 to a high of 1,118 in 2015-2017. As specific monitoring sites differed somewhat across the 21 years, there were 1,578 sites with sufficient data for calculation of valid design values and W126 index values for at least one 3-year period between 2000 and 2020, and 510 sites had such data for all nineteen 3-year periods. The sections below discuss key aspects of these analyses and what they indicate with regard to protection from vegetation-related effects of potential public welfare significance.

The analyses of cumulative seasonal exposures included a focus on the W126 index in terms of the average seasonal index across the 3-year design value period, with additional analyses also characterizing the annual W126 index. Among the analyses performed is an evaluation of the variability of annual W126 index values across the 3-year period (Appendix

<sup>79</sup> Data adequacy requirements and methods for these calculations are described in Appendix 4D, section 4D.2.

4D, section 4D.3.1.2). This evaluation was performed for all monitoring sites in the most recent 3-year period, 2018 to 2020. This analysis indicates the extent to which single-year values within the 3-year period deviate from the average for the period. Across the 877 sites (Appendix 4D, Table 4D-1) meeting the current standard (design value at or below 70 ppb), 99% of single-year W126 values in this subset differ from the 3-year average by no more than 5 ppm-hrs, and 78% by no more than 2 ppm-hrs (Appendix 4D, Figure 4D-7).

The following discussion is framed by a key policy-relevant question based on those identified in the IRP. The question considers all areas nationally, with particular focus on air quality data for Class I areas.

- **What are the nature and magnitude of vegetation exposures associated with conditions meeting the current standard at sites across the U.S., particularly in specially protected areas, such as Class I areas, and what do they indicate regarding the potential for O<sub>3</sub>-related vegetation impacts?**

To address this question, we considered both recent air quality (2018-2020) and air quality since 2000. These air quality analyses of cumulative seasonal exposures associated with conditions meeting the current standard nationally provide conclusions generally similar to those based on the data available at the time of the 2015 review when the current standard was set, when the most recent data available for analysis were 2011 to 2013 (Wells, 2015). Cumulative exposures vary across the U.S, with the highest W126 index values for sites that met the current standard being located exclusively in the Southwest and West climate regions (Figure 4-6). In all other NOAA climate regions, average W126 index values (for the 3-year period, 2018-2020) at sites meeting the current standard are generally at or below 13 ppm-hrs (Figure 4-6). In the Southwest and West, W126 index values at all sites meeting the current standard are at or below 17 ppm-hrs in the most recent 3-year period (Figure 4-6) and virtually all sites meeting the current standard are at or below 17 ppm-hr across all of the nineteen 3-year periods in the full dataset evaluated<sup>80</sup> (Table 4-3). Additionally, the historical dataset includes no occurrences of a 3-year average W126 index above 19 ppm-hrs at sites meeting the current standard, and just a small number of occurrences (limited to eight [less than 0.08% of values], all but one from a period prior to 2011) of a W126 index above 17 ppm-hrs, with the highest just equaling 19 ppm-hrs (Table 4-3; Appendix 4D, section 4D.3.2.1).

---

<sup>80</sup> On over 99.9 percent of occasions across all sites with valid design values at or below 70 ppb during the 2000 to 2020 period, the W126 metric (seasonal W126, averaged over three years) was at or below 17 ppm-hrs (Table 4-1). All but one of the eight occasions when it was above 17 ppm-hrs (the highest was 19 ppm-hrs) occurred in the Southwest region during a period before 2011. The eighth occasion occurred at a site in the West region when the 3-year average W126 index value was 18 ppm-hrs. On more than 97 percent of occasions in the full dataset with valid design values at or below 70 ppb, the 3-year average W126 index was at or below 13 ppm-hrs (Appendix 4D, section 4D.3.2).

1           Given the recognition of more significant public welfare implications of effects in  
2   protected areas, such as Class I areas (as discussed in section 4.3.2 above), we give particular  
3   attention to Class I areas (Appendix 4D, section 4D.3.2.4). In so doing, we consider the updated  
4   air quality analysis presented in Appendix 4D for 65 Class I areas. The findings for these sites,  
5   which are distributed across all nine NOAA climate regions in the contiguous U.S., as well as  
6   Alaska and Hawaii, mirror all U.S. sites. Among the Class I area sites meeting the current  
7   standard (i.e., having a design value at or below 70 ppb) in the most recent period of 2018 to  
8   2020, there are none with a W126 index (averaged over design value period) above 17 ppm-hrs  
9   (Table 4-3). The historical dataset includes just seven occurrences (all dating from the 2000-2010  
10   period) of a Class I area site meeting the current standard and having a 3-year average W126  
11   index above 17 ppm-hrs, and no such occurrences above 19 ppm-hrs (Table 4-1). Additionally,  
12   across the full 21-year dataset for 56 Class I areas with monitors meeting the current standard  
13   during at least one or as many as nineteen 3-year periods since 2000, there are no more than 15  
14   occurrences of a single-year W126 index above 19 ppm-hrs, the majority occurring during the  
15   earlier years of the period (Appendix 4D, section 4D.3.2.4, Tables 4D-14 and 4D-16). For  
16   example, the highest values were equal to 23 ppm-hrs, all occurring before 2012 (Appendix 4D,  
17   4D-16).

18           Across the complete dataset (2000-2020), the W126 index, averaged over a 3-year  
19   period, at sites with design values above 70 ppb (i.e., that would not meet the current standard)  
20   ranges up to approximately 60 ppm-hrs (Appendix 4D, Table 4D-17). Focusing on the most  
21   recent period, among all sites across the U.S. that do not meet the current standard in the 2018 to  
22   2020 period, more than a quarter have average W126 index values above 19 ppm-hrs and more  
23   than a third exceed 17 ppm-hrs (Table 4-3).<sup>81</sup> A similar situation exists for Class I area sites  
24   (Table 4-3). Thus, as at the time of the 2015 decision, the available quantitative information  
25   continues to indicate appreciable control of seasonal W126 index-based cumulative exposure at  
26   all sites with air quality meeting the current standard.

---

<sup>81</sup> As described above and in detail in Appendix 4D, W126 index values were rounded to the nearest unit ppm-hr for comparisons to a specific whole-number W126 level.



**Table 4-3. Distribution of 3-yr average seasonal W126 index for sites in Class I areas and across U.S. that meet the current standard and for those that do not.**

| 3-year periods   | Number of Occurrences or Site-DVs <sup>A</sup> |                |     |     |   |                |       |        |
|--|--|----------------|-----|-----|---|----------------|-------|--------|
|  | In Class I Areas                               |                |     |     | Across All Monitoring Sites (urban and rural) |                |       |        |
|  | Total  | W126 (ppm-hrs) |     |     | Total   | W126 (ppm-hrs) |       |        |
|  |  | >19            | >17 | ≤17 |   | >19            | >17   | ≤17    |
| <b>At sites that meet the current standard (design value at or below 70 ppb)</b> |  |                |     |     |   |                |       |        |
| 2018-2020  | 47   | 0              | 0   | 47  | 877   | 0              | 0     | 877    |
| All from 2000 to 2020  | 589  | 0              | 7   | 582 | 10,039  | 0              | 8     | 10,031 |
| <b>At sites that exceed the current standard (design value above 70 ppb)</b>     |  |                |     |     |   |                |       |        |
| 2018-2020  | 10   | 7              | 8   | 2   | 213   | 58             | 77    | 136    |
| All from 2000 to 2020  | 391  | 174            | 219 | 172 | 11,142  | 2,424          | 3,317 | 7,825  |

<sup>A</sup> The counts presented here are drawn from Appendix D, Tables 4D-2, 4D-4, 4D-5, 4D-6, 4D-9, 4D-10, and 4D-14 through 17.

In summary, as discussed in section 4.3.3 above, the evidence available leads us to similar conclusions regarding exposure levels associated with effects as in the 2015 review. Based largely on this evidence in combination with the use of RBL as a surrogate or proxy for all vegetation-related effects, the value of 17 ppm-hrs, as an average W126 index (over three years) was generally identified as a target level for protection in the 2015 decision (80 FR 65393; October 26, 2015). The available information continues to indicate that average cumulative seasonal exposure levels at virtually all sites and 3-year periods with air quality meeting the current standard fall at or below this level of 17 ppm-hrs. Additionally, at sites meeting the current standard, single-year W126 index values are less than or equal to 19 ppm-hrs well over 99% of the time (Appendix 4D, section 4D.3.2.1). In Class I area sites that meet the current standard for the most recent 3-year period, the average W126 index is below 17 ppm-hrs (Appendix 4D, Table 4D-16). Further, across the full 21-year dataset, with the exception of seven values that occurred prior to 2011, Class I area W126 index values (averages for each 3-year period) were no higher than 17 ppm-hrs during periods that met the current standard. This contrasts with the occurrence of much higher seasonal W126 index values in sites when the current standard was not met. For example, out of the 10 Class I area sites with design values above 70 ppb during the most recent period, seven had a W126 index (based on 3-year average) above 19 ppm-hrs (ranging up to 47 ppm-hrs) and eight sites had a W126 index above 17 ppm-hrs (Table 4-3; Appendix 4D, Table 4D-17). This same pattern is exhibited at all sites in the full dataset, as shown in Table 4-3, including both urban and rural sites.

#### 4.4.3 Limitations and Uncertainties

- **What are the important uncertainties associated with any exposure estimates and associated characterization of potential for public welfare effects?**

The analyses described above in sections 4.1 and 4.2 are based primarily on the hourly air monitoring dataset that is available at O<sub>3</sub> monitoring sites nationwide. While there are inherent limitations in any air monitoring network, the monitors for O<sub>3</sub> are distributed across the U.S., covering all NOAA regions and all states (e.g., Figure 4-6).

That distribution notwithstanding, there is uncertainty about whether areas that are not monitored would show the same patterns of exposure as areas with monitors. There are limitations in the distributions of the monitors, such that some geographical areas are more densely covered than others. For example, only about 40% of all Federal Class I Areas have or have had O<sub>3</sub> monitors within 15 km with valid design values, thus allowing inclusion in the Class I area analysis. Even so, the dataset includes sites in 27 states distributed across all nine NOAA climatic regions across the contiguous U.S, as well as Hawaii and Alaska. Some NOAA regions have far fewer numbers of Class I areas with monitors than others. For instance, the Central, Northeast, East North Central, and South regions all have three or fewer Class I areas in the dataset. However, these areas also have appreciably fewer Class I areas in general when compared to the Southwest, Southeast, West, and West North Central regions, which are more well represented in the dataset. The West and Southwest regions are identified as having the largest number of Class I areas, and they have approximately a third of those areas represented with monitors, which include locations where W126 index values are generally higher, thus playing a prominent role in the analysis. We also recognize a limitation that accompanies any analysis, i.e., that it is based on information available at this time. Thus, it may or may not reflect conditions far out into the future as air quality and patterns of O<sub>3</sub> concentrations in ambient air continue to change in response to changing circumstances, such as changes in precursor emissions to meet the current standard across the U.S. That said, we note that for the air quality analyses (e.g., involving W126 index) that were also conducted in the 2015 review, the findings are largely consistent.

In considering the estimates of exposure represented by the W126 index, we note a limitation in this index in its ability to distinguish among air quality conditions with differing prevalence of peak concentrations (e.g., hourly concentrations at or above 100 ppb). As indicated in the analyses in Appendix 4F, summarized above in section 4.1.1, two different locations or years may have appreciably different patterns of hourly concentrations but the same W126 index value. To the extent that these concentrations influence vegetation responses, this may contribute an uncertainty to applications of the tree seedling E-R functions (as recognized by Lefohn et al., 1997).

Further, we note the discussion in section 4.4.1 above of how changes in O<sub>3</sub> patterns in the past have affected the relationship between W126 index and the averaging time and form of the current standard, as represented by design values (section 4.4.1, and Appendix 4D, section 4D.3.2.3). This analysis finds a positive, linear relationship between trends in design values and trends in the W126 index (both in terms of single-year W126 index and averages over 3-year design value period), as was also the case for similar analyses conducted for the data available at the time of the 2015 review (Wells, 2015). While this relationship varies across NOAA regions, the regions showing the greatest potential for exceeding W126 index values of interest (e.g., with 3-year average values above 17 and/or 19 ppm-hrs) also showed the greatest improvement in the W126 index per unit decrease in design value over the historical period assessed (Appendix 4D, section 4D.3.2.3). Thus, the available data and this analysis appear to indicate that as design values are reduced to meet the current standard in areas that presently do not, W126 values in those areas would also be expected to decline (Appendix 4D, section 4D.4).

## **4.5 KEY CONSIDERATIONS REGARDING THE CURRENT SECONDARY STANDARD**

In considering what the available evidence and exposure/risk information indicate with regard to the current secondary O<sub>3</sub> standard, the overarching question we address is:

- **Does the available scientific evidence and air quality and exposure analyses support or call into question the adequacy of the protection afforded by the current secondary O<sub>3</sub> standard?**

To assist us in interpreting the available scientific evidence and the results of recent quantitative analyses to address this question, we have focused on a series of more specific questions. In considering the scientific and technical information, we consider both the information available at the time of the 2015 review and information newly available since then which has been critically analyzed and characterized in the current ISA, the 2013 ISA and prior AQCDs. In this context, an important consideration is whether the newly available information alters the EPA's overall conclusions from the 2015 review regarding welfare effects associated with photochemical oxidants, including O<sub>3</sub>, in ambient air. We also consider the available quantitative information regarding environmental exposures, characterized by the pertinent metric, likely to occur in areas of the U.S. where the standard is met. Additionally, we consider the significance of these exposures with regard to the potential for O<sub>3</sub>-related vegetation effects, their potential severity, and any associated public welfare implications.

#### 4.5.1 Evidence and Exposure/Risk-based Considerations

In considering first the available evidence with regard to the overarching question posed above regarding the protection provided by the current standard from welfare effects, we address a series of more specific questions that focus on policy-relevant aspects of the evidence. These questions relate to three main areas of consideration: (1) the available evidence on welfare effects associated with exposure to photochemical oxidants, and particularly O<sub>3</sub> (section 4.5.1.1); (2) the risk management framework or approach for reaching conclusions on the adequacy of protection provided by the secondary standard (section 4.5.1.2); and (3) findings from the air quality and exposure analyses pertaining to public welfare protection under the current standard (section 4.5.1.3).

##### 4.5.1.1 Welfare Effects Evidence

- **Is there newly available evidence that indicates the importance of photochemical oxidants other than O<sub>3</sub> with regard to abundance in ambient air, and potential for welfare effects?**

No newly available evidence has been identified regarding the importance of photochemical oxidants other than O<sub>3</sub> with regard to abundance in ambient air, and potential for welfare effects.<sup>82</sup> As summarized in section 2.1 above, O<sub>3</sub> is one of a group of photochemical oxidants formed by atmospheric photochemical reactions of hydrocarbons with nitrogen oxides in the presence of sunlight, with O<sub>3</sub> being the only photochemical oxidant other than nitrogen dioxide that is routinely monitored in ambient air (ISA, Appendix 1, section 1.1).<sup>83</sup> Data for other photochemical oxidants are generally derived from a few special field studies, such that national scale data for these other oxidants are scarce (ISA, Appendix 1, section 1.1; 2013 ISA, sections 3.1 and 3.6). Moreover, few studies of the welfare effects of other photochemical oxidants beyond O<sub>3</sub> have been identified by literature searches conducted for the 2013 ISA and prior AQCDs (ISA; Appendix 1, section 1.1). As stated in the current ISA, “the primary literature evaluating the health and ecological effects of photochemical oxidants includes ozone almost exclusively as an indicator of photochemical oxidants” (ISA, section IS.1.1). Thus, as was the case for previous reviews, the evidence base for welfare effects of photochemical oxidants does not indicate an importance of any other photochemical oxidants. For these reasons, discussion of photochemical oxidants in this document focuses on O<sub>3</sub>.

---

<sup>82</sup> Close agreement between past ozone measurements and the photochemical oxidant measurements upon which the early NAAQS (for photochemical oxidants including O<sub>3</sub>) was based indicated the very minor contribution of other oxidant species in comparison to O<sub>3</sub> (U.S. DHEW, 1970).

<sup>83</sup> Consideration of welfare effects associated with nitrogen oxides in ambient air is addressed in the review of the secondary NAAQS for ecological effects of oxides of nitrogen, oxides of sulfur and particulate matter (U.S. EPA, 2018).

1       • **Does the available evidence alter prior conclusions regarding the nature of welfare**  
2       **effects attributable to O<sub>3</sub> in ambient air?**

3       The current evidence documented in the 2020 ISA, including that newly available,  
4       supports, sharpens, and expands somewhat on the conclusions reached in the 2015 review (ISA,  
5       sections IS.1.3.2 and IS.5 and Appendices 8 and 9). A wealth of scientific evidence, spanning  
6       more than six decades, demonstrates effects on vegetation and ecosystems of O<sub>3</sub> in ambient air  
7       (ISA, section IS.6.2.1; 2013 ISA, 2006 AQCD, 1997 AQCD, 1986 AQCD; U.S. DHEW, 1970).  
8       Accordingly, consistent with the evidence in the 2015 review, the available evidence describes  
9       an array of O<sub>3</sub> effects on vegetation and related ecosystem effects. The evidence also describes  
10      climate effects of tropospheric O<sub>3</sub>, through a role in radiative forcing and subsequent effects on  
11      temperature, precipitation, and related climate variables. Evidence newly available in the 2020  
12      ISA strengthens previous conclusions, provides further mechanistic insights and augments  
13      current understanding of varying effects of O<sub>3</sub> among species, communities, and ecosystems  
14      (ISA, section IS.6.2.1). The current evidence, including a wealth of longstanding evidence,  
15      supports conclusions reached in the 2015 review of causal relationships between O<sub>3</sub> and visible  
16      foliar injury, reduced yield and quality of agricultural crops, reduced vegetation growth and plant  
17      reproduction,<sup>84</sup> reduced productivity in terrestrial ecosystems, and alteration of belowground  
18      biogeochemical cycles. The current evidence, including that previously available, also supports  
19      conclusions reached in the 2015 review of likely causal relationships between O<sub>3</sub> and reduced  
20      carbon sequestration in terrestrial systems, and alteration of terrestrial ecosystem water cycling  
21      (ISA, section IS.I.3.2). Additionally, as in the 2015 review, the current ISA determines there to  
22      be a causal relationship between tropospheric O<sub>3</sub> and radiative forcing and a likely causal  
23      relationship between tropospheric O<sub>3</sub> and temperature, precipitation, and related climate  
24      variables (ISA, section IS.1.3.3). Further, the current evidence has led to an updated conclusion  
25      on the relationship of O<sub>3</sub> with alteration of terrestrial community composition to causal (ISA,  
26      sections IS.I.3.2). Lastly, the current ISA concludes the current evidence sufficient to infer likely  
27      causal relationships of O<sub>3</sub> with three additional categories of effects (ISA, sections IS.I.3.2).  
28      While previous recognition of O<sub>3</sub> as a contributor to tree mortality in a number of field studies  
29      was a factor in the 2013 conclusion regarding composition, it has been separately assessed in the  
30      current ISA, with the conclusion that the evidence is sufficient to infer a likely causal  
31      relationship with O<sub>3</sub>. Additionally, evidence newly available since the last ISA on two additional  
32      plant-related effects augments more limited previously available evidence related to insect  
33      interactions with vegetation, contributing to additional conclusions that the body of evidence is

---

<sup>84</sup> As noted in section 4.3.1 above, the 2020 ISA includes a causality determination specific to reduced plant reproduction, while this category of effects was considered in combination with reduced plant growth in the 2015 review (ISA, Table IS.13).

1 sufficient to infer likely causal relationships between O<sub>3</sub> and alterations of plant-insect signaling  
2 and insect herbivore growth and reproduction (ISA, Appendix 8, sections 8.6 and 8.7).<sup>85</sup>

3 As in the 2015 review, the strongest evidence and the associated findings of causal or  
4 likely causal relationships with O<sub>3</sub> in ambient air, and quantitative characterizations of  
5 relationships between O<sub>3</sub> exposure and occurrence and magnitude of effects, are for vegetation-  
6 related effects, and particularly those identified in the 2015 review. The evidence base for the  
7 newly identified category of increased tree mortality includes previously available evidence  
8 largely comprised of field observations from locations and periods of O<sub>3</sub> concentrations higher  
9 than are common today and three more recently available publications assessing O<sub>3</sub> exposures  
10 not expected under conditions meeting the current standard. Among the three more recent  
11 publications, one assessed survival of aspen clones across an 11-year period under O<sub>3</sub> exposures  
12 that included single-year seasonal W126 index values ranging above 30 ppm-hrs during the first  
13 four years, and the other two were analyses based on field observations during periods when O<sub>3</sub>  
14 concentrations were such that they would not be expected to meet the current standard, as  
15 summarized in section 4.3.1 above (ISA, Appendix 8, section 8.4.3).

16 The information available regarding the newly identified categories of plant-insect  
17 signaling and insect herbivore growth and reproduction does not provide for a clear  
18 understanding of the specific environmental effects that may occur in the natural environment  
19 under specific exposure conditions (as discussed in sections 4.3.1, 4.3.3.2 and 4.3.4 above). For  
20 example, while the evidence base for effects on herbivore growth and reproduction is expanded  
21 since the 2013 ISA, “there is no clear trend in the directionality of response for most metrics,”  
22 such that some show an increased effect and some show reductions (ISA, p. IS-64; section  
23 IS.5.1.3 and section 8.6). More specifically “no consistent directionality of response is observed  
24 across the literature, and uncertainties remain in regard to different plant consumption methods  
25 across species and the exposure conditions associated with particular severities of effects” (ISA,  
26 p. IS-91). Additionally, while the available evidence documents effects of O<sub>3</sub> on some plant  
27 VPSCs (e.g., changing the floral scent composition and reducing dispersion), and indicates  
28 reduced pollinator attraction, decreased plant host detection and altered plant-host preference in  
29 some insect species in the presence of elevated O<sub>3</sub> concentrations, characterization of such  
30 effects is still “an emerging area of research with information available on a relatively small  
31 number of insect species and plant-insect associations,” and with gaps remaining in the  
32 consequences of modification of signaling compounds by O<sub>3</sub> in natural environments (ISA, p.

---

<sup>85</sup> As in the 2015 review, the 2020 ISA again concludes that the evidence is inadequate to determine if a causal relationship exists between changes in tropospheric ozone concentrations and UV-B effects (ISA, Appendix 9, section 9.1.3.4; 2013 ISA, section 10.5.2).

IS-91 and section IS.6.2.1). Accordingly, we focus on other vegetation effects described above, rather than these two newly identified categories.

With regard to tropospheric O<sub>3</sub> and effects on climate, we recognize the strength of the ISA conclusion that tropospheric O<sub>3</sub> is a greenhouse gas at the global scale, with associated effects on climate (ISA, section 9.1.3.3). Accordingly, as indicated by the ISA causal determinations, O<sub>3</sub> abundance in the troposphere contributes to radiative forcing and likely also to subsequent climate effects. There is appreciable uncertainty, however, associated with understanding quantitative relationships involving regional O<sub>3</sub> concentrations near the earth's surface and climate effects of tropospheric O<sub>3</sub> on a global scale. As recognized in the ISA (and summarized in sections 4.3.3.3 and 4.3.4 above), there are limitations in our modeling tools and associated uncertainties in interpretations related to capabilities for quantitatively estimating effects of regional-scale lower tropospheric O<sub>3</sub> concentrations on climate. Thus, while additional characterizations of tropospheric O<sub>3</sub> and climate have been completed since the 2015 review, uncertainties and limitations in the evidence that were also recognized in the 2015 review remain. As summarized in sections 4.3.3.3 and 4.3.4 above, these affect our ability to make a quantitative characterization of the potential magnitude of climate response to changes in O<sub>3</sub> concentrations in ambient air, particularly at regional (vs global) scales, and thus our ability to assess the impact of changes in ambient air O<sub>3</sub> concentrations in regions of the U.S. on global radiative forcing or temperature, precipitation, and related climate variables. Consequently, the evidence in this area is not informative to our consideration of the adequacy of public welfare protection of the current standard.

- **To what extent does the available evidence provide E-R information (e.g., quantitative E-R relationships) for O<sub>3</sub>-related effects that can inform judgments on the likelihood of occurrence of such effects in areas with air quality that meets the current standard? Does the available evidence provide new or altered such information since the 2015 review?**

In considering what the available information indicates with regard to exposures associated with welfare effects and particularly in the context of what is indicated for exposures associated with air quality conditions that meet the current standard, we focus particularly on the availability of quantitatively characterized E-R relationships for key effects. While the ISA describes additional studies of welfare effects associated with O<sub>3</sub> exposures since the 2015 review, the established E-R functions for tree seedling growth and crop yield that have been available in the last several reviews continue to be the most robust descriptions of E-R relationships for welfare effects. These well-established E-R functions for seedling growth reduction in 11 tree species and yield loss in 10 crop species are based on response information across multiple levels of cumulative seasonal exposure (estimated from extensive records of

1 hourly O<sub>3</sub> concentrations across the exposure periods). Studies of some of the same species,  
2 conducted since the E-R function derivation, provide supporting information for these functions  
3 (ISA, Appendix 8, section 8.13.2; 2013 ISA, sections 9.6.3.1 and 9.6.3.2). The E-R functions  
4 provide for estimation of growth-related effects for a range of cumulative seasonal exposures.

5 The newly available evidence does not include new studies that assessed reductions in  
6 tree growth or crop yield responses across multiple O<sub>3</sub> exposures and for which sufficient data  
7 are available for analyses of the shape of the E-R relationship across the range of cumulative  
8 exposure levels (e.g., in terms of W126 index) relevant to conditions associated with the current  
9 standard. For example, among the newly available studies are several that summarize previously  
10 available studies or draw from them, such as for linear regression analyses.<sup>86</sup> However, as  
11 discussed in section 4.3.3.2 above, these do not provide robust E-R functions or cumulative  
12 seasonal exposure levels associated with important vegetation effects that define the associated  
13 exposure circumstances in a consistent manner, limiting their usefulness for our purposes here  
14 with regard to considering the potential for occurrence of welfare effects in air quality conditions  
15 that meet the current standard. Thus, robust E-R functions are not available for growth or yield  
16 effects on any additional tree species or crops.

17 Based on these established E-R functions for tree seedling growth reductions in 11  
18 species, the tree seedling RBL for the median tree species is 5.3% for a W126 index of 17 ppm-  
19 hrs, rising to 5.7% for 18 ppm-hrs, 6.0% for 19 ppm-hrs and 6.4% for 20 ppm-hrs. Below 17  
20 ppm-hrs, the median estimates include 4.9% for 16 ppm-hrs, 4.5% for 15 ppm-hrs, 4.2% for 14  
21 ppm-hrs and 3.8% for 13 ppm-hrs (Appendix 4A, Table 4A-5). These RBL estimates are  
22 unchanged from what was indicated by the evidence in the 2015 review. As summarized in  
23 section 4.1 above, the RBL estimates were used in the 2015 decision as a surrogate or proxy for  
24 the broader array of vegetation-related effects.

25 With regard to visible foliar injury, as in the 2015 review, we lack established E-R  
26 relationships that would quantitatively describe relationships between visible foliar injury  
27 (occurrence and incidence, as well as injury severity) and O<sub>3</sub> exposure, as well as factors  
28 influential in those relationships, such as soil moisture conditions. As discussed in section  
29 4.3.3.2 above, the available evidence continues to include both experimental studies that

---

<sup>86</sup> For example, among the newly available publications cited in the ISA is a publication on tree and grassland species that compiles EC<sub>10</sub> values (estimated concentration at which 10% lower biomass [compared to zero O<sub>3</sub>] is predicted) derived using linear regression of previously published data on plant growth response and O<sub>3</sub> concentration quantified as AOT40. The data were from studies of various experimental designs, that involved various durations ranging up from 21 days, and involving various concentrations no higher than 100 ppb as a daily maximum hourly concentration. More detailed analyses of consistent, comparable E-R information across a relevant range of seasonal exposure levels, accompanied by detailed records of O<sub>3</sub> concentrations, that would support derivation of robust E-R functions for purposes discussed here are not available (ISA, Appendix 8, section 8.10.1.2).



document foliar injury in specific plants in response to O<sub>3</sub> exposures, and quantitative analyses of the relationship between environmental O<sub>3</sub> exposures and occurrence of foliar injury. The analyses involving environmental conditions, while often using cumulative exposure metrics to quantify O<sub>3</sub> exposures (e.g., the W126 and SUM06 indices), have additionally reported there to also be a role for a metric that quantifies the frequency or incidence of “high” O<sub>3</sub> days, such as N100 (2013 ISA, p. 9-10; Smith, 2012; Wang et al., 2012). However, such analyses have not resulted in the establishment of specific air quality metrics and associated quantitative functions for describing the influence of ambient air O<sub>3</sub> on incidence and severity of visible foliar injury.

Multiple studies have involved quantitative analysis of data collected as part of the USFS biosite biomonitoring program (e.g., Smith, 2012). These analyses continue to indicate the limitations in capabilities for predicting the exposure circumstances under which visible foliar injury would be expected to occur, as well as the circumstances contributing to increased injury severity (Smith, 2012; Wang et al., 2012). As noted in section 4.3.3.2 above, expanded summaries of the dataset compiled in the 2015 review from several years of USFS biosite records does not clearly and consistently describe the shape of a relationship between incidence of foliar injury or severity (based on individual site scores) and W126 index estimates (as a sole representative of exposure). Overall, however, the dataset indicates that the proportion of records having different levels of severity score is generally highest in the group of records for sites with the highest W126 index (e.g., greater than 25 ppm-hrs for the normal and dry soil moisture categories). Thus, the available evidence indicates increased occurrence and severity at the highest category of exposures in the dataset (above 25 ppm-hrs in terms of a W126 index), but does not provide for identification of air quality conditions, in terms of O<sub>3</sub> concentrations associated with the relatively lower environmental exposures most common in the USFS dataset that would correspond to a specific magnitude of injury incidence or severity scores across locations.

Thus, based on considering the available information for the array of O<sub>3</sub> welfare effects, we again recognize the E-R relationships available in the 2015 review for purposes of considering O<sub>3</sub> exposure levels associated with growth-related impacts to be the most robust E-R information available. The available evidence for growth-related effects, including that newly available, does not indicate the occurrence of growth-related responses attributable to cumulative O<sub>3</sub> exposures lower than was established at the time of the 2015 review. With regard to visible foliar injury, the available information continues to be limited with regard to estimating occurrence and severity (e.g., as quantified by BI score) across a range of air quality conditions quantified by W126 index, such that a clear shape for a relationship between these variables is not evident with the available data. Thus, the available information provides for only limited and somewhat qualitative conclusions related to potential occurrence and/or severity under different

1 air quality conditions. The quantitative information for other effects is still more limited, as  
2 recognized in sections 4.3.3 and 4.3.4 above. Thus, the newly available evidence does not  
3 appreciably address key limitations or uncertainties needed to expand capabilities for estimating  
4 welfare impacts that might be expected as a result of differing patterns of O<sub>3</sub> concentrations in  
5 the U.S.

- 6 • **Does the evidence continue to support a cumulative, seasonal exposure index, such as**  
7 **the W126 function, as a biologically relevant and appropriate metric for assessment**  
8 **of vegetation-related effects of O<sub>3</sub> in ambient air?**

9 As in the 2015 review, the available evidence continues to support a cumulative, seasonal  
10 exposure index as a biologically relevant and appropriate metric for assessment of the evidence  
11 of exposure/risk information for vegetation, most particularly for growth-related effects. The  
12 most commonly used such metrics are the SUM06, AOT40 (or AOT60) and W126 indices (ISA,  
13 section IS.3.2).<sup>87</sup> The evidence for growth-related effects continues to support important roles for  
14 cumulative exposure and for weighting higher concentrations over lower concentrations. Thus,  
15 among the various such indices considered in the literature, the cumulative, concentration-  
16 weighted metric, defined by the W126 function, continues to be best supported for purposes of  
17 relating O<sub>3</sub> air quality to growth-related effects.

18 We additionally note that while in its approach to emphasizing higher concentrations, the  
19 W126 index assigns greater weights to higher hourly concentrations, it cannot, given its  
20 definition as an index that sums three months of weighted hourly concentrations into one, single  
21 value, always differentiate between air quality patterns with frequent high peak concentrations  
22 and those without such concentrations.<sup>88</sup> While the metric describes the pattern of varying  
23 growth response observed across the broad range of cumulative exposures examined in the tree  
24 seedling E-R studies (see Appendix 4A), given the way it is calculated the W126 index can  
25 conceal peak concentrations that can be of concern. More specifically, one season or location

---

<sup>87</sup> While the evidence includes some studies reporting O<sub>3</sub>-reduced soybean yield and perennial plant biomass loss using AOT40 (as well as W126) as the exposure metric, no newly available analyses are available that compare AOT40 to W126 in terms of the strength of association with such responses. Nor are studies available that provide analyses of E-R relationships for AOT with reduced growth or RBL with such extensiveness as the analyses supporting the established E-R functions for W126 with RBL and RYL.

<sup>88</sup> This is illustrated by the following two hypothetical examples. In the first example, two air quality monitors have a similar pattern of generally lower average hourly concentrations but differ in the occurrence of higher concentrations (e.g., hourly concentrations at or above 100 ppb). The W126 index describing these two monitors would differ. In the second example, one monitor has appreciably more hourly concentrations above 100 ppb compared to a second monitor; but the second monitor has higher average hourly concentrations than the first. In the second example, the two monitors may have the same W126 index, even though the air quality patterns observed at those monitors are quite different, particularly with regard to the higher concentrations, which have been recognized to be important in eliciting responses (as noted above).

could have few, or even no, hourly concentrations above 100 ppb<sup>89</sup> and the second could have many such concentrations; yet (due to greater prevalence of more mid-range concentrations, e.g., contributing to a generally higher average hourly concentration in the second) each of the two seasons or locations could have the identical W126 index (e.g., equal to 25 or 15 or 10 ppm-hrs, or some other value), as discussed in section 4.4.1 above.

Accordingly, in our consideration of the potential for vegetation-related effects to occur under air quality conditions associated with the current standard, we continue to focus on the W126 index as the appropriate metric, while also being aware of the importance of considering the occurrence and frequency of particularly high concentrations. We also recognize that this metric may not well describe the key circumstances of O<sub>3</sub> exposure for occurrences of other effects, particularly, visible foliar injury. As discussed in section 4.3.3.2 above, the evidence indicates an important role for peak concentrations (e.g., N100) in influencing the occurrence and severity of visible foliar injury. Thus, while we continue to recognize the W126 index as an appropriate and biologically relevant focus for assessing air quality conditions with regard to potential effects on vegetation growth and related effects, we also recognize the need for attention to the pattern and magnitude of peak concentrations.

#### **4.5.1.2 General Approach for Considering Public Welfare Protection**

The general approach and risk management framework applied in 2015 for making judgements and reaching conclusions regarding the adequacy of public welfare protection provided by the newly established secondary standard is summarized in section 4.1 above. In light of the available evidence and air quality information, we discuss here key considerations in judging public welfare protection provided by the O<sub>3</sub> secondary standard in the context of a series of questions.

- Does the newly available information continue to support the use of tree seedling RBL as a proxy for the broad array of vegetation-related effects?**

As summarized in section 4.3 above, the available evidence is largely consistent with that available in the 2015 review and does not call into question conceptual relationships between plant growth impacts and the broader array of vegetation effects. Rather, the ISA describes (or relies on) conceptual relationships in considering causality determinations for ecosystem-scale effects such as altered terrestrial community composition and reduced productivity, as well as reduced carbon sequestration, in terrestrial ecosystems (ISA, Appendix 8, sections 8.8 and 8.10).

---

<sup>89</sup> As noted in section 4.4 above, the value of 100 ppb is used here as it has been in some studies focused on O<sub>3</sub> effects on vegetation, simply as an indicator of elevated or peak hourly O<sub>3</sub> concentrations (e.g., Lefohn et al., 1997, Smith, 2012; Davis and Orendovici, 2006; Kohut, 2007). Values of 95 ppb and 110 ppb have also been considered in this way (2013 ISA, section 9.5.3.1).

1 Thus, the evidence continues to support the use of tree seedling RBL as a proxy for a broad array  
2 of vegetation-related effects, most particularly those conceptually related to growth.

3 Beyond these relationships of plant-level effects and ecosystem-level effects,<sup>90</sup> RBL can  
4 be appropriately described as a scientifically valid surrogate of a variety of welfare effects based  
5 on consideration of ecosystem services and the potential for adverse impacts on public welfare,  
6 as well as conceptual relationships between vegetation growth-related effects (including carbon  
7 allocation) and ecosystem-scale effects. Beyond tree seedling growth (on which RBL is  
8 specifically based), two other vegetation effect categories with extensive evidence bases are crop  
9 yield and visible foliar injury, both types of effects, their evidence bases and key considerations  
10 with regard to protection afforded by the current standard (which go beyond a RBL target for  
11 tree seedlings) are separately addressed in section 4.5.1.3 below.

- 12 • **To what extent does the available information alter our understanding of an**  
13 **appropriate magnitude of RBL, in its role as a surrogate or proxy, reasonably**  
14 **expected to be of public welfare significance?**

15 The available information does not differ from that available in the 2015 review with  
16 regard to a magnitude of RBL in the median species appropriately considered a reference for  
17 judgments concerning potential vegetation-related impacts to the public welfare. Based on the  
18 available information, a 6% RBL median estimate from the established species-specific E-R  
19 functions continues to be appropriate for such a reference point. We note this in the context of  
20 RBL's role as a surrogate or proxy of a larger array of vegetation effects for which it was judged  
21 that isolated rare instances of cumulative exposures that correspond to 6% (as the median of the  
22 11 E-R functions) were not indicative of adverse effects to the public welfare (80 FR 65409,  
23 October 26, 2015). The available evidence continues to indicate conceptual relationships  
24 between reduced growth and the broader array of vegetation-related effects (as discussed above).  
25 Quantitative representations of such relationships have been used to study potential impacts of  
26 tree growth effects on such larger-scale effects as community composition and productivity with  
27 the results indicating the array of complexities involved (e.g., ISA, Appendix 8, section 8.8.4).  
28 Given their purpose in exploring complex ecological relationships and their responses to  
29 environmental variables, as well as limitations of the information available for such work, these  
30 analyses commonly utilize somewhat general representations. This work indicates how

---

<sup>90</sup> As summarized in the ISA, O<sub>3</sub> can mediate changes in plant carbon budgets (affecting carbon allocation to leaves, stems, roots and other biomass pools) contributing to growth impacts, and altering ecosystem properties such as productivity, carbon sequestration and biogeochemical cycling. In this way, O<sub>3</sub> mediated changes in carbon allocation can “scale up” to population, community and ecosystem-level effects including changes in soil biogeochemical cycling, increased tree mortality, shifts in community composition, changes in species interactions, declines in ecosystem productivity and carbon sequestration and alteration of ecosystem water cycling (ISA, section 8.1.3).

established the existence of such relationships is, while also identifying complexities inherent in quantitative aspects of such relationships and interpretation of estimated responses. Thus, the currently available evidence, as characterized in the 2020 ISA, is little changed from the 2015 review with regard to informing identification of an RBL reference point reflecting ecosystem-scale effects with public welfare impacts elicited through such linkages.

- **What does the available information indicate with regard to the roles of seasonal cumulative and peak exposures on O<sub>3</sub> vegetation effects, and accordingly regarding the uses of cumulative and peak exposure metrics in assessing air quality conditions that may pose risk of harm to vegetation?**

As summarized in section 4.3.3, longstanding conclusions regarding O<sub>3</sub> effects on vegetation recognize both the cumulative effect of O<sub>3</sub> on plants and the importance of higher concentrations in eliciting responses (1996 and 2006 AQCDs; 2013 and 2020 ISAs). As a result, there has been substantial research into identification of an air quality exposure-related metric that might address both aspects of potentially harmful O<sub>3</sub> conditions. As discussed in section 4.3.3.1.1 above, the metrics explored have included, among others, those that sum the portion of a concentration above a reference point (e.g., AOT06), those that sum only those concentrations above a reference point (e.g., SUM06), and also, the W126 index, a non-threshold approach described as the sigmoidally weighted sum of hourly O<sub>3</sub> concentrations (2013 ISA, p. 9-101). These indices (designed to address both cumulative effects and the importance of higher concentrations) have been analyzed with regard to the extent to which they may describe the growth response of plants (e.g., crops and tree seedlings) in studies assessing multiple exposure levels and have been found to improve the explanatory power of E-R models over those based only on mean (e.g., seasonal mean of 7-hour daily means) or peak exposure values (e.g., seasonal maximum of maximum daily 7-hour and/or 1-hour averages) (2020 ISA, p. IS-79; 2013 ISA, p. 2-44; 2006 AQCD 1996 AQCD).

The explanatory strength of these cumulative, concentration-weighted approaches with regard to plant response to O<sub>3</sub> indicates the influence of the various dimensions of exposure (e.g., concentration, duration, frequency) on plant response. With regard to the role of concentrations, the 2020 and 2013 ISAs and past AQCDs generally recognize higher O<sub>3</sub> concentrations to be associated with relatively greater risk of vegetation damage, in terms growth-related effects (and/or visible foliar injury, which is discussed more specifically in response to a question below) and emphasize the risk posed to vegetation from higher hourly average O<sub>3</sub> concentrations.<sup>91</sup> With regard to duration and cumulative effects, analyses of the controlled

---

<sup>91</sup> For example, as stated in the 2020 and 2013 ISAs, “[h]igher concentrations appear to be more important than lower concentrations in eliciting a response” [ISA, p. 8-180]; “higher hourly concentrations have greater effects

1 exposure datasets also supported conclusions in the 1996 and 2006 AQCDs (retained in more  
2 recent ISAs) that a model focused only on a peak-concentration based metric (found to be an  
3 improvement over earlier use of a long-term average to summarize exposure), without  
4 consideration of duration was less descriptive of response (e.g., 1996 AQCD, Volume II, section  
5 5.5.1.1). Accordingly, metrics that cumulated concentrations, e.g., through summing, as is the  
6 case for those identified above, were developed, with preference to those that emphasized higher  
7 concentrations (1996 and 2006 AQCDs; 2020 ISA, IS 5.1.9).

8       As recognized across several past reviews, the strength of the cumulative, concentration-  
9 weighted approaches, including the continuously weighted W126 index function, is in describing  
10 variation in response documented in controlled exposure studies or crops and tree seedlings for  
11 which extensive hourly O<sub>3</sub> datasets are available. We note that in these exposures studies, the  
12 higher cumulative exposure levels (e.g., W126 index levels) were generally accompanied by an  
13 appreciable prevalence of high concentrations (e.g., Appendix 4A, Table 4A-6; Lefohn et al  
14 1997; Lefohn and Foley, 1992). While these were part of the patterns of O<sub>3</sub> concentrations to  
15 which the plants were exposed, another exposure circumstance may have the same W126 index,  
16 yet with a different pattern of peak concentrations that may contribute to differences in risk of  
17 vegetation effects. In an example highlighted in the 2006 AQCD and 2013 ISA, a study by Yun  
18 and Lawrence (1999) used exposure regimes constructed from 10 U.S. cities to demonstrate that  
19 in regimes with similar values of cumulative, concentration-weighted metrics, differences in the  
20 magnitude and occurrence of peak concentrations were influential with regard to injury in tree  
21 seedlings (2006 AQCD, p. AX9-176; 2013 ISA, section 9.5.3.1; Yun and Lawrence, 1999).<sup>92</sup>  
22 Given this, we recognize that the seasonal cumulative metrics may not always differentiate  
23 between air quality patterns that include particularly high peak concentrations and those without  
24 or with relatively fewer such concentrations.

25       For example, while the W126 index preferentially weights higher hourly concentrations,  
26 given its definition as an index that sums three months of weighted hourly concentrations into a  
27 single value, it can estimate the same value for very different incidence of elevated O<sub>3</sub>  
28 concentrations. As described in section 4.5.1.1, at two sites with the same W126 index value, the  
29 air quality patterns may differ such that one site may have appreciably more hourly

---

on vegetation than lower concentrations” [2013 ISA, p. 91-4] “studies published since the 2006 O<sub>3</sub> AQCD do not  
change earlier conclusions, including the importance of peak concentrations, ... in altering plant growth and  
yield” [2013 ISA, p. 9-117]).

<sup>92</sup> The 2013 ISA, in examining trends (1970s through 1990s) in an areas of the San Bernardino Mountains in  
California, noted the reductions in ponderosa pine growth impacts occurring with reductions in SUM06,  
maximum peak concentration and hourly concentrations over 95 ppb. In observing that there had been little  
change in mid-range O<sub>3</sub> concentrations over the same period, the 2013 ISA noted the lesser role indicated for the  
mid-range concentration ranges compared to the higher values (2013 ISA, p. 9-106).

1 concentrations at or above 100 ppb compared to the other site. This is also supported by the  
2 analyses of available air quality data summarized in section 4.4.1 (e.g., Appendix 4F, Figure 4F-  
3 10). Focusing on the data for the most recent five years (2016 through 2020), the distribution of  
4 N100 or D100 values at monitoring sites meeting different W126 index values also shows this  
5 variability, which contrasts with the much lesser variability in N100 and D100 values for sites  
6 meeting the current standard (see Figure 4-12, W126 index bins at/below 19 ppm-hrs compared  
7 to design value bins for 70 ppb or lower). It can be seen that (1) there is little difference in D100  
8 at sites with W126 index ranging from 8 to 19 ppm-hrs (single-year or 3-year average index);  
9 and (2) the form and averaging time of the existing standard is much more effective than the  
10 W126 index in limiting the number of hours with O<sub>3</sub> concentrations at or above 100 ppb (N100)  
11 and in limiting the number of days with any such hours.<sup>93</sup>

12         Given the considerations raised here, we recognize that focusing solely on W126 index  
13 for considering the public welfare protection provided by the current standard would not be  
14 considering all the relevant scientific information. Further, we note that such a sole focus, given  
15 the damaging potential for repeated elevated hourly concentrations (e.g., at or above 100 ppb), as  
16 discussed in sections 4.3.3 and 4.5.1.1 above (ISA, p. 8-180; 2013 ISA, section 9.5.3.1)<sup>94</sup>, may  
17 not give adequate attention to ensuring protection against “unusually damaging years.” As a  
18 result, we find that focusing solely on the W126 index may not ensure protection is provided  
19 from potentially damaging air quality, such as that associated with exposure patterns marked by  
20 repeated occurrences of elevated concentrations. Thus, we conclude it is important to consider  
21 both cumulative, concentration-weighted and peak exposure metrics in assessing air quality with  
22 regard to the potential for specific exposure conditions that might be harmful to vegetation.”<sup>95</sup>

---

<sup>93</sup> As one example contained in Table 4-1 above, across all sites that met the current standard during the recent period (2018-2020), few sites had more than 5 hours at or above 100 ppb in a year (0.6% in the highest year, Appendix 4F, Table 4F-2). Among the sites with any such hours, all had fewer than five days in any one year with any such concentrations (Table 4-1, Appendix 4F, Figure 4F-5). In comparison, across all sites with an annual W126 index below 15 ppm-hrs, 2% of them had more than 5 hours with a concentration at or above 100 ppb, and this included sites with as many as eight days with such a concentration (Table 4-1, Appendix 4F, Figure 4F-11). We note that we are not intending to ascribe specific significance to five days with an hour at or above 100 ppb or ten such hours, *per se*. Rather, these are used simply as reference points to facilitate comparison and to illustrate the point that such high concentrations, which based on toxicological principles, pose greater risk to biota than lower concentrations, are not necessarily limited at sites meeting particular W126 index values.

<sup>94</sup> The section of the 2013 ISA titled “Role of Concentration,” summarizes the experimental evidence base on which the significant role of peak O<sub>3</sub> concentrations was established (2013 ISA, section 9.5.3.1).

<sup>95</sup> With regard to air quality occurring under the current standard, we note analyses presented in section 4.4 above that show the current standard to provide control of both cumulative exposures and of peak concentrations indicating the potential to address both aspects of potentially harmful O<sub>3</sub> conditions noted here.

- **What does the available information indicate regarding the use of W126 index in a single year or averaged over three years in considering cumulative seasonal exposure protection objectives for the secondary standard?**

In setting the current standard in 2015, as described in section 4.1 above, the decision focused on control of seasonal cumulative exposures in terms of a 3-year average W126 index based on consideration of several factors.<sup>96</sup> We again consider here the extent to which the available evidence supports the 3-year average W126 index as a reasonable metric for assessing the level of protection provided by the current standard from cumulative seasonal exposures related to RBL, or whether an alternate approach is more appropriate for use with the E-R functions.

We first consider the evidence and information underlying the E-R functions and the extent to which they can be said to better describe or predict growth reductions specific to single season exposures, as compared to growth reductions generally reflecting an average seasonal exposure. With regard to the established tree seedling E-R functions themselves, we note there are aspects of the datasets and methodology on which the E-R functions are based which provide support for a multiyear (e.g. 3-year) average approach. As summarized in section 4.3.4 above, the E-R functions were derived from studies of durations that varied from shorter than 92 days to as many as 140 days in a single year, and up to 555 days distributed across multiple years or growing seasons, with the results normalized to the duration of a single 92-day seasonal period (Appendix 4A, pp. 4A-31 to 4A- 32). Inherent in this approach is an assumption that the growth impacts relate generally to the cumulative O<sub>3</sub> exposure across the full time period (which may include multiple growing seasons), i.e., with little additional influence related to any seasonal or year to year differences in the exposures. Consequently, given this step in their derivation approach, the E-R functions cannot provide precise estimates of response from a single year's seasonal exposure (e.g., *vs* averages over a period longer than 92 days or one that spans multiple growing seasons). Thus, the use of a multiyear (e.g. 3-year) average in assessing RBL using the established tree seedling E-R functions is reasonably described as compatible with the normalization step taken to derive functions for a seasonal 90-day period from the underlying data with its varying exposure durations.

---

<sup>96</sup> These factors include consideration of the strengths and limitations of the evidence and of the information on which to base judgments regarding adversity of effects on the public welfare (80 FR 65390, October 26, 2015). Also recognized was year-to-year variability, not just in O<sub>3</sub> concentrations, but also in environmental factors, including rainfall and other meteorological factors, that influence the occurrence and magnitude of O<sub>3</sub>-related effects in any year (e.g., through changes in soil moisture), contributing uncertainties to projections of the potential for harm to public welfare based on a single year, particularly at the exposure levels of interest (80 FR 65404, October 26, 2015).



1 We also take note of aspects of the evidence that reflect variability in organism response  
2 under different experimental conditions and the extent to which this variability is represented in  
3 the available data, which might indicate an appropriateness of assessing environmental  
4 conditions using a mean across seasons in recognition of the existence of such year-to-year  
5 variability in conditions and responses. For example, among the species for which there are more  
6 than two or three experimental datasets comprising the support for the species' E-R function (14  
7 experimental datasets for aspen [seven for which the E-R function for wild aspen has been  
8 derived and seven supporting a function for aspen clones] and 11 for ponderosa pine) illustrate  
9 appreciable variability in response across experiments (Appendix 4A, Figure 4A-10).  
10 Contributions to this variability may come from several factors, including variability in seasonal  
11 response related to variability in non-O<sub>3</sub> related environmental influences on growth, such as  
12 rainfall, temperature and other meteorological variables, as well as biological variability across  
13 individual seedlings. An additional variability could also be due to influential aspects of the O<sub>3</sub>  
14 air quality on plant growth that are not completely captured by the W126 index, e.g., different  
15 patterns of hourly concentrations that yield the same W126 index (see section 4.4.1 and below).  
16 Such variability in the data underlying these E-R functions may further support a multiyear (e.g.  
17 3-year) average approach.

18 An additional aspect of considering the evidence and information, is how well the data  
19 underlying the E-R functions represent and reflect conditions that are currently being  
20 experienced in the U.S., and most importantly, conditions that reflect current air quality patterns  
21 when meeting the current standard. On a related note, it is also important to understand the extent  
22 to which E-R predictions are extrapolated beyond the tested exposure conditions. As noted in  
23 section 4.3.4 above, the O<sub>3</sub> concentrations and cumulative exposures for the experimental  
24 datasets from which the tree seedling E-R functions were derived include conditions that do not  
25 occur in ambient air at sites the meet the current standard (section 4.4; Appendix 4A, Table 4A-  
26 6; section 4.4). A similar issue was discussed in a previously available publication that observed  
27 appreciable differences between the prevalence of hourly concentrations at or above 100 ppb in  
28 exposures on which the E-R functions are based and those common in ambient air at that time, a  
29 difference which is in many ways only increased with today's air quality (Lefohn et al., 1997).<sup>97</sup>

---

<sup>97</sup> For example, many of the experimental exposure of elevated O<sub>3</sub> on which the established E-R functions for the 11 tree seedling species are based, had hundreds of hours of O<sub>3</sub> concentrations above 100 ppb, far more than are common in (unadjusted) ambient air, including in areas that meet the current standard (Lefohn et al., 1997, Appendix 2A, section 2A.2, Appendix 4 F). To illustrate, in the most recent 2018-2020 design value period, the mean number of observations per site at or above 100 ppb was well below one. In contrast, across most of the O<sub>3</sub> treatments in the experiments comprising the E-R function database, well below half had an N100 value less than 20 hours through the exposure period (Appendix 4A, Table 4A-6). Similarly, the experimental exposures in studies supporting some of the established E-R functions for 10 crop species also include many hours with O<sub>3</sub> concentrations at or above 100 ppb (Lefohn and Foley, 1992)

1 This issue is also discussed in section 4.3.4 above, where it is noted that in the E-R tree seedling  
2 datasets, the O<sub>3</sub> treatments for W126 index levels observed in areas that meet the current  
3 standard had N100 counts ranging up above 40. And for many of the treatments, N100 values  
4 range up to several hundred (Appendix 4A, Table 4A-6). We find it reasonable to interpret this  
5 information, and its contribution to uncertainty in the application of the underlying E-R  
6 functions, as arguing for a less precise interpretation, such as an average across multiple seasons.

7 In further considering the evidence and information and its support for use of a single or  
8 multiple year W126 index, the concept of cumulative multiyear exposures and associated  
9 impacts should be considered. In particular, we ask the question of whether applying the E-R  
10 functions to a W126 index averaged over multiple years would over- or under-estimate  
11 cumulative exposure response, whereas use of a single seasonal exposure metric would not. The  
12 evidence relevant to this question, e.g., that allows for specific evaluation of the predictability of  
13 growth impacts from single-year versus multiple-year average exposure estimates, is limited.  
14 Multi-year studies reporting results for each year of the study are the most informative to the  
15 question of plant annual and cumulative responses to individual years (high and low) over  
16 multiple-year periods. However, as summarized in section 4.3.4 above, the evidence is quite  
17 limited with regard to studies of O<sub>3</sub> effects that report seasonal observations across multi-year  
18 periods and that also include detailed hourly O<sub>3</sub> concentration records (to allow for derivation of  
19 cumulative exposure index values). One such study, which tracked exposures across six years, is  
20 available for aspen (King et al., 2005; 2013 ISA, section 9.6.3.2; ISA, Appendix 8, section  
21 8.13.2). This study is presented in the 2013 and 2020 ISAs in an evaluation of predicted growth  
22 impacts compared to observations from the multiple years of the study.

23 For this evaluation, the ISAs considered the 6-year experimental dataset of O<sub>3</sub> exposures  
24 and aspen growth effects with regard to correspondence of E-R function predictions with study  
25 observations (2020 ISA, Appendix 8, section 8.13.2 and Figure 8-17; 2013 ISA, section 9.6.3.2,  
26 Table 9-15, Figure 9-20). The analysis in the 2013 ISA compared observed reductions in growth  
27 for each of the six years to those predicted by applying the established E-R function for Aspen to  
28 cumulative multi-year average W126 index values (2013 ISA, section 9.6.3.2).<sup>98 99</sup> The  
29 evaluation in the 2020 ISA applied the E-R functions to the single-year W126 index for each  
30 year rather than the cumulative multi-year W126 (2020 ISA, Appendix 8, Figure 8-17), with this

---

<sup>98</sup> Although not emphasized or explained in detail in the 2013 ISA, the W126 index estimates used to generate the predicted growth response were cumulative averages. For example, the growth impact estimate for year 1 used the W126 index for year 1; the estimate for year 2 used the average of W126 index in year 1 and W126 index in year 2; the estimate for year 3 used the average of W126 index in years 1, 2 and 3; and so on.

<sup>99</sup> One finding of this evaluation was that “the function based on one year of growth was shown to be applicable to subsequent years” (2013 ISA, p. 9-135).

1 approach indicating a somewhat less tight fit to the experimental observations (2020 ISA,  
2 Appendix 8, p. 8-192),<sup>100</sup> Both ISAs reach similar conclusions regarding general support for the  
3 E-R functions across a multiyear study of trees in naturalistic settings (ISA, Appendix 8, section  
4 8.13.3 and p. 8-192; 2013 ISA, p. 9-135).<sup>101</sup> We additionally note that an illustrative  
5 mathematical exercise that explored estimates of above ground biomass of an aspen stand when a  
6 multi-year O<sub>3</sub> exposure was quantified in terms of a single year varying W126 index or as a  
7 repeated yearly exposure equal to the associated 3-year average. These analyses suggest that the  
8 two approaches may yield generally similar total biomass estimates after multiple years'  
9 exposure (Appendix 4A, section 4A.3).

10 Thus, while the E-R functions are based on strong evidence of cumulative seasonal O<sub>3</sub>  
11 exposure reducing tree growth, and while they provide for quantitative characterization of the  
12 extent of such effects across cumulative seasonal O<sub>3</sub> exposure levels of appreciable magnitude,  
13 there is uncertainty associated with the resulting RBL predictions that might be described as an  
14 imprecision or inexactitude. Further, as summarized above, the evidence does not indicate  
15 single-year seasonal exposure in combination with the established E-R functions to be a better  
16 predictor of RBL than a seasonal exposure based on a multi-year average. Accordingly, it is  
17 reasonable to conclude that the evidence provides support for use of a 3-year average in  
18 assessing the level of protection provided by the current standard from cumulative seasonal  
19 exposures related to RBL of concern based on the established E-R functions.<sup>102</sup> The 3-year  
20 average metric also appears to be reasonable for use in the context of the use of RBL as a proxy  
21 to represent an array of vegetation-related effects. Accordingly, upon consideration of all of the  
22 factors raised above, we find the use of a multiyear average, and more specifically a 3-year  
23 average, W126 index in assessing protection for RBL based on the established tree seedling E-R  
24 functions to be reasonable. We also note, as discussed in response to the prior question, the  
25 importance of also considering an additional aspect of O<sub>3</sub> air quality, specifically the occurrence

---

<sup>100</sup> Based on information drawn from Figure 8-17 in the 2020 ISA, the correlation metric ( $r^2$ ) for the percent difference (estimated vs observed biomass) and year of growth can be estimated to be approximately 0.7, while using values reported in Table 9-15 of the 2013 ISA (which are plotted in Figure 9-20), the  $r^2$  for predicted O<sub>3</sub> impact *versus* observed impact is 0.99 and for the percent difference *versus* year is approximately 0.85.

<sup>101</sup> For the 2013 ISA, the conclusions reached were that the agreement between the set of predictions and the Aspen FACE observations were “very close” (2013 ISA, p. 9-135). The results indicate that when considering O<sub>3</sub> impacts across multiple years, a multi-year average index yields predictions close to observed measurements (2013 ISA, section 9.6.3.2 and Figure 9-20; Appendix 4A, section 4.A.3). For the 2020 ISA, the conclusion reached was that results from the aspen study were “exceptionally close” to predictions from the E-R model (ISA, p. 8-192).

<sup>102</sup> Three years (versus two or four years) was selected based on its compatibility with the multiyear duration often used in forms for NAAQS to account for year-to-year variability in air quality.

1 of elevated hourly concentrations that influence vegetation exposures of potential concern, in  
2 reaching conclusions about the adequacy of the current standard.

3 • **What does the available information indicate for considering potential public welfare**  
4 **protection from O<sub>3</sub>-related visible foliar injury?**

5 In establishing the current secondary standard in 2015 and its underlying public welfare  
6 protection objectives, as summarized in section 4.1, above, the Administrator focused primarily  
7 on RBL in tree seedlings as a proxy or surrogate for the full array of vegetation related effects of  
8 O<sub>3</sub> in ambient air, from sensitive species to broader ecosystem-level effects. At that time, the  
9 Administrator also concluded the information regarding visible foliar injury to also provide  
10 support for strengthening the standard at that time, taking note of the available analyses of USFS  
11 biosite data (80 FR 65407-65408, October 26, 2015). She also concluded, however, that, due to  
12 associated uncertainties and complexities, the evidence was not conducive to use for identifying  
13 a quantitative public welfare protection objective focused specifically on visible foliar injury. In  
14 reaching this conclusion, she recognized significant challenges in judging the specific extent and  
15 severity at which such effects should be considered adverse to public welfare, in light of the  
16 variability in the occurrence of visible foliar injury and the lack of clear quantitative relationships  
17 for prediction of visible foliar injury severity and incidence or extent under varying air quality  
18 and environmental conditions, as well as the lack of established criteria or objectives that might  
19 inform consideration of potential public welfare impacts related to this vegetation effect (80 FR  
20 65407, October 26, 2015).

21 As an initial matter, we note that, as recognized in the 2015 review, some level of visible  
22 foliar injury can impact public welfare and thus might reasonably be judged adverse to public  
23 welfare.<sup>103</sup> As summarized in section 4.3.2 above, depending on its spatial extent and severity,  
24 there are many locations in which visible foliar injury can adversely affect the public welfare.  
25 For example, significant, readily perceivable (or obvious) and widespread injury in national  
26 parks and wilderness areas can adversely impact the perceived scenic beauty of these areas,  
27 impacting the aesthetic experience for both outdoor enthusiasts and the occasional park visitor.<sup>104</sup>

---

<sup>103</sup> As stated in the *Federal Register* notice for the 2015 decision: “[d]epending on the extent and severity, O<sub>3</sub>-induced visible foliar injury might be expected to have the potential to impact the public welfare in scenic and/or recreational areas during the growing season, particularly in areas with special protection, such as Class I areas. (80 FR 65379, October 26, 2015); “[t]he Administrator also recognizes the potential for this effect to affect the public welfare in the context of affecting values pertaining to natural forests, particularly those afforded special government protection (80 FR 65407, October 26, 2015). The CASAC in the 2015 review also stated that visible foliar injury “can impact public welfare” (Frey, 2014, p. 10).

<sup>104</sup> In the discussion of the need for revision of the 1997 secondary standard, the 2008 decision noted that “[i]n considering what constitutes a vegetation effect that is adverse from a public welfare perspective, ... the Administrator has taken note of a number of actions taken by Congress to establish public lands that are set aside

1 Thus, as aesthetic value and outdoor recreation depend, at least in part, on the perceived scenic  
2 beauty of the environment, judgments related to the extent of public welfare impacts of visible  
3 foliar injury depend on the severity and extent of the injury, as well as the location where the  
4 effects occur and the associated intended use. Beyond the limitations associated with the  
5 evidence for descriptive quantitative relationships for O<sub>3</sub> concentrations and visible foliar injury  
6 (as summarized in sections 4.3.3.2 and 4.3.4 above), there is little information clearly relating  
7 differing severity and prevalence of injury to conditions in natural areas that would reasonably be  
8 concluded to impact public use and enjoyment in a way that might suggest adversity to the public  
9 welfare. The available information does not yet address or describe the relationships expected to  
10 exist between some level of severity and/or extent of location affected and scenic or aesthetic  
11 values (e.g., reflective of visitor enjoyment and likelihood of frequenting such areas). However,  
12 while minor spotting on a few leaves of a plant may easily be concluded to be of little public  
13 welfare significance, it might reasonably be expected that in cases of widespread and relatively  
14 more severe injury during the growing season (particularly when sustained across multiple years  
15 and accompanied by obvious impacts on the plant canopy), O<sub>3</sub>-induced visible foliar injury could  
16 adversely impact the public welfare in scenic and/or recreational areas, particularly in parks and  
17 other areas with special protection, such as Class I areas.

18 In the face of the paucity of established approaches that might be informative to the  
19 Administrator in judging severity and extent of visible foliar injury in a natural area that may be  
20 appropriate to consider of public welfare significance, we take note of the USFS scheme,  
21 summarized in section 4.3.2 above, for categorizing areas based on BI scores (e.g., Smith, 2012).  
22 In this scheme, BI scores may be described with regard to one of several categories ranging from  
23 little or no foliar injury to severe injury (e.g., Smith et al., 2003; Campbell et al., 2007; Smith et  
24 al., 2007; Smith, 2012). However, the available information does not yet address or describe the  
25 relationships expected to exist between some level of severity of foliar injury (e.g., little or  
26 severe) and/or a spatial extent affected and scenic or aesthetic values. This gap impedes  
27 consideration of the public welfare implications of different injury severities, and accordingly,  
28 judgments on the potential for public welfare significance.

29 With regard to the USFS BI program, we further note that authors of studies presenting  
30 USFS biomonitoring program data have suggested what might be “assumptions of risk” (e.g., for  
31 the forest resource) related to scores in these categories, e.g., as described in section 4.3.2 above.

---

for specific uses that are intended to provide benefits to the public welfare, including lands that are to be protected so as to conserve the scenic value and the natural vegetation and wildlife within such areas, and to leave them unimpaired for the enjoyment of future generations” (73 FR 16496, March 27, 2008). This passage of the *Federal Register* notice announcing the 2008 decision clarified that “[s]uch public lands that are protected areas of national interest include national parks and forests, wildlife refuges, and wilderness areas” (73 FR 16496, March 27, 2008).

1 One suggestion has been that maps of localized moderate to high-risk areas may be used to  
2 identify areas (for scores of 15 or higher) where more detailed evaluations are warranted (Smith  
3 et al., 2012). While these are not explicitly related to consideration of the public values described  
4 above (e.g., with regard to public aesthetic or recreational value), the description of the BI score  
5 categories as well as these corresponding judgments related to risk for the forest resource may  
6 both be informative for the Administrator’s purposes. For example, it might be reasonable to  
7 conclude that a small discoloring on a single leaf of a plant that might yield a quite low, nonzero  
8 BI score in the USFS system is not adverse to the public welfare. On the other hand, BI scores  
9 corresponding to a high risk to the resource may reasonably be concluded to indicate the need for  
10 attention and, perhaps a public welfare adversity potential. Thus, while the available evidence  
11 does not include characterization of USFS biosite scores with regard to public perception and  
12 potential impacts on public enjoyment, we find that they may be useful for the Administrator’s  
13 purposes in considering the potential public welfare significance of different severities and  
14 extents of visible foliar injury, as scored by BI. That notwithstanding, limitations remain in our  
15 tools for characterizing the air quality conditions at sites that elicit scores of a particular severity  
16 level, thus continuing to challenge our ability to precisely identify conditions that might provide  
17 particular levels of public welfare protection for this effect.

18 In considering the available information regarding a relationship between W126 index  
19 and the severity of visible foliar injury, we consider the presentation of USFS biosite data in  
20 Appendix 4C, summarized in section 4.3.3.2.2 above. While recognizing limitations in the  
21 dataset<sup>105</sup> and considering the records for the normal or dry soil moisture categories, for which  
22 there is somewhat better representation of W126 index levels above 13 ppm-hrs,<sup>106</sup> we note the  
23 lack of a clear trend in the percentage of USFS records recording visible foliar injury (of any  
24 severity level) W126 index estimates below 17 ppm-hrs. Focusing on the magnitude of BI score,  
25 we note that among records in the normal soil category, BI scores are noticeably increased in the  
26 highest W126 index bin (above 25 ppm-hrs) compared to the others. The percentages of records  
27 in the greater than 25 ppm-hrs bin that have BI scores above 15 (“moderate” and “severe” injury)  
28 and above 5 (“light,” “moderate” and “severe” injury) are more than three times greater than  
29 percentages for these score levels in any of the lower W126 bins. Additionally, the average BI of  
30 7.9 in the greater-than-25-ppm-hrs bin is more than three times the average BI for the next

---

<sup>105</sup> For example, the majority of these data are records with W126 index estimates at or below 9 ppm-hrs, and fewer than 10% of the records have W126 estimates above 15 ppm-hrs. Additionally, the BI scores are quite variable across the full dataset, with even the bin for the lowest W126 index estimates (below 7 ppm-hrs) including BI scores well above 15 (Appendix 4C, section 4C.4.2).

<sup>106</sup> In the case of records in the wet soil moisture category, nearly 90% of the records are for W126 estimates at or below 9 ppm-hrs, limiting interpretations for higher W126 bins (Appendix 4C, Table 4C.4 and section 4C.6).

1 highest W126 index bin. The average BI in the next two lower W126 bins (which vary inversely  
2 with W126 index) are just slightly higher than average BIs for the rest of the bins, and the  
3 average BI for all bins at or below 25 ppm-hrs are well below 5. Among records in the dry soil  
4 moisture category, the two highest W126 bins (which together include the W126 index estimates  
5 above 19 ppm-hrs) exhibit percentages of records with BI above 15 or above 5 that are  
6 appreciably greater than that for the lower W126 bins. With regard to average scores across all  
7 dry soil moisture records, average BI for all W126 index bins is below 5, although the three  
8 highest W126 index bins (above 17 ppm-hrs) are markedly greater than the lower bins (e.g.,  
9 average BIs greater than *versus* less than 1).

10 Thus, the strongest conclusions that can be reached from the USFS dataset described in  
11 Appendix 4C are that the incidence of sites with more severe injury (e.g., BI score above 15 or 5)  
12 is also lower at sites with W126 index values below 25 ppm-hrs than at sites with higher W126  
13 index values and that clear trends in such incidence related to increasing W126 index levels are  
14 not evident across the bins for lower W126 index estimates (all of which are below 5%). As  
15 discussed in section 4.3.3.2 above, variability in the data across sites, and uncertainty, with  
16 regard to the role of peak O<sub>3</sub> concentrations as an influence on occurrence of visible foliar injury  
17 separate from cumulative W126 index, lead to the conclusion that the available information does  
18 not support precise conclusions as to the severity and extent of such injury associated with the  
19 lower values of W126 index most common at USFS sites during the time of the dataset (2006-  
20 2010). Notwithstanding this, records categorized as normal soil moisture indicate there to be an  
21 appreciable difference in severity of injury between records with W126 index estimates above 25  
22 ppm-hrs and those with estimates at or below 25 ppm-hrs (e.g., Appendix 4C, Figures 4C-5 and  
23 4C-6 and Table 4C-5). The records categorized as dry soil moisture do not indicate such a clear  
24 pattern. The records categorized as wet soil moisture are too limited (and variable) for W126  
25 index estimates above 13 ppm-hrs to support a conclusion (Appendix 4C). Thus, we conclude,  
26 based primarily on the BI scores records categorized as having normal soil moisture, that under  
27 conditions that maintain W126 index values below 25 ppm-hrs a reduced severity (average BI  
28 score below 5) and incidence of visible foliar injury, as quantified by biosite index scores, would  
29 be expected. The observation of a lack of clear relationship between levels of a cumulative  
30 seasonal index and BI scores until reaching a higher value is conceptually similar to findings of  
31 the study by Campbell et al. (2007), identified in the 2013 ISA that focused on visible foliar  
32 injury in west coast states. This study observed that both percentage of USFS biosites with injury  
33 and the average BI were higher for sites with average cumulative O<sub>3</sub> concentrations above 25  
34 ppm-hrs in terms of SUM06 as compared to groups of sites with lower average cumulative  
35 exposure levels, with little difference apparent between the two lower exposure groups (80 FR

1 65395, October 26, 2015; Smith and Murphy, 2015; Campbell et al., 2007, Figures 27 and 28  
2 and p. 30).<sup>107</sup>

3 Such findings of variability in scores at lower values of a cumulative seasonal index and  
4 a lack of clear relationship with exposure may relate to patterns of peak concentrations at sites  
5 with similar cumulative seasonal index values. As discussed in section 4.3.3.2 above, several  
6 studies of the USFS data have concluded that inclusion of a metric for quantifying peak  
7 concentrations, in combination with one for cumulative seasonal exposures, may yield a more  
8 predictive description of the relationship between O<sub>3</sub> air quality and the occurrence of visible  
9 foliar injury. Similarly, a county-scale analysis of USFS biosite data in the 2007 Staff Paper  
10 (from earlier years than those analyzed in the 2015 review) indicated a somewhat smaller  
11 incidence of biosites with nonzero BI scores in counties with air quality meeting a fourth-high  
12 metric of 74 ppb as compared to larger groups that also included sites with air quality meeting a  
13 fourth-high metric up to 84 ppb (U.S. EPA 2007, pp. 7-63 to 7-64; 80 FR 65395, October 26,  
14 2015). Given the control of the averaging time and form of the current standard on peak  
15 concentrations (as discussed in section 4.4.1 above), this observation is consistent with a role for  
16 peak concentrations in eliciting visible foliar injury. Although given that lower design values for  
17 the current standard also yield lower W126 index values, the relative influence of peak  
18 concentrations and cumulative seasonal exposures cannot be distinguished. With regard to the  
19 control of the current standard on peak concentrations, however, we note the conceptual  
20 similarity to the finding of the most recent and extensive USFS data analysis that reductions in  
21 peak 1-hour concentrations have influenced the declining trend in visible foliar injury since 2002  
22 (Smith, 2012).

23 In consideration of all of the above, we recognize the appreciable limitations of the  
24 available information touched on above with regard to providing a foundation for judgments on  
25 public welfare protection objectives specific to visible foliar injury. In light of such limitations  
26 and in light of the above discussion, we recognize that while the evidence continues to show a  
27 consistent association between the occurrence of visible injury and ozone, “visible foliar injury is  
28 not always a reliable indicator of other negative effects on vegetation” (ISA, Appendix 8, section  
29 8.2), and we do not have a precise understanding of the appropriate metrics for quantifying O<sub>3</sub> air  
30 quality conditions for the purposes of informing the Administrator’s consideration of this  
31 endpoint. Based on studies and analyses of the USFS biosite data, the conditions associated with  
32 visible foliar injury in locations with sensitive species appear to relate to peak concentration

---

<sup>107</sup> In considering their findings, the authors expressed the view that “[a]lthough the number of sites or species with injury is informative, the average biosite injury index (which takes into account both severity and amount of injury on multiple species at a site) provides a more meaningful measure of injury” for their assessment at a statewide scale (Campbell et al., 2007).



(e.g., hours above a concentration such as 100 ppb) as well as sustained exposure to higher concentrations over the growing season, such that cumulative exposure metrics may not well or completely describe or predict the occurrence and severity of injury. Thus, in making judgments regarding air quality conditions of concern and those providing protection with regard to impacts associated with incidence and severity of visible foliar injury, we find it appropriate to consider both cumulative concentration-weighted seasonal exposures and the occurrence of peak concentrations. In this context, we note the control of these metrics achieved by the form and averaging time of the current standard, as discussed in section 4.4 above. Lastly, we take note of the USFS BI scheme as potentially useful to informing the Administrator's consideration of the potential public welfare significance of differing magnitudes of BI scores.

- **What does the available information indicate for considering potential public welfare protection from O<sub>3</sub>-related climate effects?**

In considering the available information for the effects of the global abundance of O<sub>3</sub> in the troposphere on radiative forcing, and temperature, precipitation and related climate variables, we note as an initial matter that, as summarized in section 4.3.3 above, there are limitations and uncertainties in the associated evidence bases with regard to assessing potential for occurrence of climate-related effects as a result of varying ground-level O<sub>3</sub> concentrations in ambient air of locations in the U.S. Specifically, such limitations and uncertainties affect our ability to characterize the extent of any relationships between O<sub>3</sub> concentrations in ambient air in the U.S. and climate-related effects, thus precluding a quantitative characterization of climate responses to changes in ground-level O<sub>3</sub> concentrations in ambient air at regional (vs global) scales that might inform considerations related to the current standard. While the evidence supports a causal relationship between the global abundance of O<sub>3</sub> in the troposphere and radiative forcing, and a likely causal relationship between the global abundance of O<sub>3</sub> in the troposphere and effects on temperature, precipitation, and related climate variables (ISA, section IS.5.2 and Appendix 9; Myhre et al., 2013), the non-uniform distribution of O<sub>3</sub> (spatially and temporally) makes the development of quantitative relationships between the magnitude of such effects and differing ground-level O<sub>3</sub> concentrations in the U.S. challenging (ISA, Appendix 9). Additionally, "the heterogeneous distribution of ozone in the troposphere complicates the direct attribution of spatial patterns of temperature change to ozone induced [radiative forcing]" and there are "ozone climate feedbacks that further alter the relationship between ozone [radiative forcing] and temperature (and other climate variables) in complex ways" (ISA, Appendix 9, section 9.3.1, p. 9-19). Thus, various uncertainties "render the precise magnitude of the overall effect of tropospheric ozone on climate more uncertain than that of the well-mixed GHGs" and "[c]urrent limitations in climate modeling tools, variation across models, and the need for more comprehensive observational data on these effects represent sources of uncertainty in quantifying

1 the precise magnitude of climate responses to ozone changes, particularly at regional scales”  
2 (ISA, section IS.6.2.2, Appendix 9, section 9.3.3, p. 9-22).

3 As one example, current limitations in modeling tools include “uncertainties associated  
4 with simulating trends in upper tropospheric ozone concentrations” (ISA, section 9.3.1, p. 9-19),  
5 and uncertainties such as “the magnitude of [radiative forcing] estimated to be attributed to  
6 tropospheric ozone” (ISA, section 9.3.3, p. 9-22). Further, “precisely quantifying the change in  
7 surface temperature (and other climate variables) due to tropospheric ozone changes requires  
8 complex climate simulations that include all relevant feedbacks and interactions” (ISA, section  
9 9.3.3, p. 9-22). An important specific limitation in current climate modeling capabilities for O<sub>3</sub> is  
10 representation of important urban- or regional-scale physical and chemical processes, such as O<sub>3</sub>  
11 enhancement in high-temperature urban situations or O<sub>3</sub> chemistry in city centers where NO<sub>x</sub> is  
12 abundant. Because of such limitations in the available information, we lack the ability to quantify  
13 or judge the impact of incremental changes in ground-level O<sub>3</sub> concentrations in the U.S. on  
14 radiative forcing and subsequent climate effects, thus precluding a consideration of potential  
15 public welfare protection provided by the existing O<sub>3</sub> standard from O<sub>3</sub>-related climate effects.<sup>108</sup>

#### 16 **4.5.1.3 Public Welfare Implications of Air Quality under the Current Standard**

17 Our consideration of the available scientific evidence in this reconsideration, as at the  
18 time of the 2015 review, is informed by results from a quantitative analysis of air quality and  
19 associated exposure. An overarching consideration is whether this information calls into question  
20 the adequacy of protection provided by the current standard. As in our consideration of the  
21 evidence above, we have organized the discussion regarding the information related to exposures  
22 and potential risk around a key question to assist us in considering the quantitative analyses of air  
23 quality at U.S. locations nationwide, particularly including those in Class I areas. We first  
24 consider analyses particular to cumulative O<sub>3</sub> exposures, in terms of the W126 index, given the  
25 established E-R relationships with growth-related effects, and specifically RBL as the identified  
26 proxy or surrogate for the full array of such effects.

27 To understand the cumulative O<sub>3</sub> exposures likely occurring under the current standard  
28 nationally, including in Class I areas, we consider the air quality analyses summarized in section  
29 4.4 above. Nationwide in the most recent 3-year period, seasonal W126 index values are at or  
30 below 17 ppm-hrs, as assessed by the 3-year average, when the current standard is met (Table 4-

---

<sup>108</sup> While these complexities inhibit our ability to analyze and quantitatively climate-related effects of O<sub>3</sub>, such as radiative forcing, we note that our consideration of O<sub>3</sub> growth-related impacts on trees inherently encompasses consideration of the potential for O<sub>3</sub> to reduce carbon sequestration in terrestrial ecosystems (e.g., through reduced tree biomass as a result of reduced growth). That is, limiting the extent of O<sub>3</sub>-related effects on growth would be expected to also limit reductions in carbon sequestration, a process that can reduce the tropospheric abundance of CO<sub>2</sub>, the greenhouse gas ranked highest in importance (section 4.3.3.3 above; ISA, section 9.1.1).

3). With very few exceptions, this is also true across the full historical period. Further, such exposures are generally well below 17 ppm-hrs across most of the U.S. Additionally, the overall pattern for single-year seasonal W126 index values at monitors meeting the current standard in the most recent period is generally similar, with few sites (about a dozen of the 877 sites nationwide) having a single-year W126 index above 19 ppm-hrs (and under two dozen above 17 ppm-hrs).<sup>109</sup> The frequency of such higher single-year W126 index values at Class I area monitors is also low during periods when the current standard is met. During the most recent three years, the average seasonal W126 index is at or below 17 ppm-hrs at all Class I area monitors meeting the current standard, just two single-year W126 index values above 17 ppm-hrs and none above 19 ppm-hrs (Appendix 4D, Table 4D-16).<sup>110</sup>

Combining this information regarding likely W126-based exposure levels with the established E-R functions for 11 tree seedling species indicates that based on monitoring data for locations meeting the current standard during the most recent design period, the median species RBL for tree seedlings, based on the 3-year average W126, would be at or below 5.3%, with very few exceptions; the highest estimates are associated with W126 index values occurring in areas that are not near or within Class I areas. Looking at the data over a longer time period (2000-2018) confirms this general pattern for the bulk of the data, with some infrequent higher occurrences, such that virtually all RBL estimates would be below 6%.<sup>111</sup> Further, given the variability and uncertainty associated with the data underlying the E-R functions (as discussed in section 4.5.1.2 above), the few higher single-year occurrences are reasonably considered to be of less significance than 3-year average values.

With regard to visible foliar injury, as discussed earlier, the evidence is somewhat limited and unclear with regard to the metric and quantitative approach that well describes a relationship between incidence or severity of injury in U.S. forests across a broad range of air quality conditions. However, we note several key findings of the evidence and quantitative analyses. First, the increased incidence of BI scores associated with injury considered greater than “a little” by the USFS scheme appears most consistently with higher W126 estimates, with greatest

---

<sup>109</sup> These highest W126 index values occur in the Southwest and West regions in which there are nearly 150 monitor locations meeting the current standard (Figure 4-6; Appendix 4D, Table 4D-1).

<sup>110</sup> Across the full 21-year dataset for Class I area monitors meeting the current standard (57 monitors with at least one such period), there are 15 design value periods with single-year W126 index values above 19 ppm-hrs, all of which are prior to the 2013-2015 period (Appendix 4D, section 4D.3.2.4).

<sup>111</sup> Although potential for effects on crop yield was not given particular emphasis in the 2015 review (for reasons similar to those summarized earlier), we additionally note that combining the exposure levels summarized for areas across the U.S. where the current standard is met with the E-R functions established for 10 crop species indicates a median RYL across crops to be at or below 5.1%, on average, with very few exceptions. Further, estimates based on W126 index at the great majority of the areas are below 5%.

1 incidence for the highest exposure level (W126 index above 25 ppm-hrs), a magnitude not seen  
2 to occur in Class I area monitoring sites, or in virtually any sites nationwide, that meet the  
3 current standard (Appendix 4C, section 4C.3). Further, we note a decline in frequency of peak  
4 hourly concentrations, including those at/above 100 ppb, at U.S. monitoring sites over the past  
5 15 years. The analyses of hourly concentrations summarized in section 4.4.1 above, also  
6 demonstrate substantial control of peak 1-hour concentrations by the current standard. Thus, we  
7 lack an established metric or combination of metrics that well describes the relationship between  
8 occurrence and severity of visible foliar injury across a broad range of O<sub>3</sub> concentration patterns  
9 from those more common in the past to those in areas recently meeting today's standard, the  
10 current information indicates air quality conditions of concern for this endpoint to generally  
11 include cumulative seasonal exposures, in terms of seasonal single-year W126 index, at/above 25  
12 ppm-hrs, in addition to appreciable occurrence of peak hourly concentrations at/above 100 ppb.  
13 Based on this information, the available air quality information indicates that the exposure  
14 conditions occurring at sites with air quality meeting the current standard are not those that might  
15 reasonably be concluded to elicit the occurrence of significant foliar injury (with regard to  
16 severity and extent).

- 17 • **Are such exposures (in terms of W126 index) that occur in areas that meet the**  
18 **current standard indicative of welfare effects reasonably judged important from a**  
19 **public welfare perspective? What are important associated uncertainties?**

20 Given the findings summarized in section 4.4 above regarding W126 index values in  
21 areas where the current standard is met, we reflect on the potential public welfare significance of  
22 vegetation-related effects that may be associated with such exposures. This consideration is  
23 important to judgments regarding the secondary standard, which is not meant to protect against  
24 all known or anticipated O<sub>3</sub>-related welfare effects, but rather those that are judged to be adverse  
25 to the public welfare (as noted in section 4.3.2 above). Accordingly, for the purposes of  
26 informing that judgment, we consider here the exposures indicated to occur under conditions that  
27 meet the current standard, the associated potential for effects and the potential public welfare  
28 implications.

29 As an initial matter, we recognize the increased significance to the public welfare of  
30 effects in areas that have been accorded special protection, such as Class I areas. In this context,  
31 we note some general similarities of the exposure estimates in Class I areas for periods when the  
32 current standard was met to such estimates at monitoring sites in other areas, as documented in  
33 the larger air quality data analysis. Across both datasets, and extending back 21 years, the  
34 cumulative exposure estimates, averaged over the design value period, for these air quality  
35 conditions were virtually all at or below 17 ppm-hrs, with most of the W126 index values below  
36 13 ppm-hrs (Appendix 4D, Table 4D-10), corresponding to median RBL estimates of 3.8% or

1 less (based on the established tree seedling E-R relationships detailed in Appendix 4A). We  
2 additionally note that single-year W126 index values in Class I areas over the 21-year dataset  
3 evaluated were generally at or below 19 ppm-hrs, particularly in the more recent years  
4 (Appendix 4D, section 4D.3.2.4). Regarding the potential for effects associated with commonly  
5 occurring exposures, we consider first the categories of effects for which the quantitative  
6 information related to exposure and associated effects is most well developed. In this  
7 reconsideration, as in the 2015 review, these are effects on plant growth. Based on the median of  
8 RBL estimates derived from the established E-R functions for 11 tree species seedlings, W126  
9 index values at or below 17 ppm-hrs correspond to median species tree seedling RBL estimates  
10 at or below 5.3% (Appendix 4A, Table 4A-5). Judgments in the 2015 review (in the context of  
11 the framework considered in section 4.5.1.2 above) concluded isolated rare occurrences of  
12 exposures for which median RBL estimates might be at or just above 6% to not be indicative of  
13 conditions adverse to the public welfare, particularly considering the variability in the array of  
14 environmental factors that can influence O<sub>3</sub> effects in different systems, and the uncertainties  
15 associated with estimates of effects in the natural environment.

16 In the 2015 review, the Administrator focused on cumulative exposure estimates derived  
17 as the average W126 index over the 3-year design value period, concluding variations of single-  
18 year W126 index from the average to be of little significance. This focus generally reflected the  
19 judgment that estimates based on the average adequately, and appropriately, reflected the  
20 precision of the current understanding of O<sub>3</sub>-related growth reductions, given the various  
21 limitations and uncertainties in such predictions. Additional analyses have been explored since  
22 the 2015 to further examine this issue, as summarized in section 4.5.1.2 above. The current air  
23 quality data indicate single-year W126 index values generally to vary by less than 5 ppm-hrs  
24 from the 3-year average when the 3-year average is below 20 ppm-hrs (which is the case for  
25 locations meeting the current standard). With such variation, year-to-year differences in tree  
26 growth responding to each year's seasonal exposure from estimated response based on the 3-year  
27 average of those seasonal exposures would, given the offsetting impacts of seasonal exposures  
28 above and below the average, reasonably be expected to generally be small over tree lifetimes.  
29 Additionally, we have also further considered the experimental data underlying the E-R  
30 functions for estimating RBL, particularly those pertaining to cumulative exposures on the order  
31 of 17 ppm-hrs and informing estimates of multiyear impacts. We note limitations in the evidence  
32 base in these regards, as discussed further in section 4.5.1.2 above, that contribute to imprecision  
33 or inexactitude to estimates of growth impacts associated with multi-year exposures in this range.  
34 Further, the information available since 2015 does not appreciably address these limitations and  
35 uncertainties to improve the certainty or precision in RBL estimates for such exposures.

1 With regard to visible foliar injury, as discussed in sections 4.3.3.2 and 4.5.1.2 above, a  
2 quantitative description of the relationship between O<sub>3</sub> concentrations and visible foliar injury  
3 extent or incidence, as well as severity, that would support estimation of injury under varying air  
4 quality and environmental conditions (e.g., moisture), most particularly for locations that meet  
5 the current standard is not yet established. In light of the potential role of peak O<sub>3</sub> concentrations  
6 (e.g., hourly concentrations at or above 100 ppb) as an influence on visible foliar injury  
7 occurrence and severity (that may not be fully captured by a focus on cumulative seasonal O<sub>3</sub>  
8 indices), we take note of analyses of peak concentrations summarized in section 4.4.1. These  
9 indicate that the magnitude of daily maximum 1-hour concentrations has declined appreciably  
10 since 2000. For example, the median annual 2<sup>nd</sup> highest MDA1 concentration across U.S. trend  
11 monitoring sites declined by 27% from 2002 to 2013 (Figure 2-17 above), and the 99<sup>th</sup> percentile  
12 MDA1 for all sites meeting the current standard in 2020 is below 80 ppb (Figure 4-11)). The  
13 analysis in Appendix 2A of three recent design value periods (covering 2016 through 2020) and  
14 three periods more than ten years prior (covering 2000 through 2004) show that the mean  
15 number of observations per site at or above 100 ppb was well below one (0.22) for sites meeting  
16 the current standards compared to well above one (10.04) for sites not meeting the current  
17 standard. Further, the number of days with an hour at or above 100 ppb is below five at sites  
18 meeting the current standard, and 99% are well below five (Figure 4-11, Appendix 2A, section  
19 2A.2). These data and analyses indicate that the current standard provides appreciable control of  
20 peak 1-hour concentrations, and thus, to the extent that such peak concentrations play a role in  
21 the occurrence and severity of visible foliar injury, the current standard also provides appreciable  
22 control.

23 In considering protection for visible foliar injury impacts provided by the standard, we  
24 note, as discussed in section 4.3.2 above, that the public welfare implications associated with  
25 visible foliar injury (when considered as an effect separate from effects on plant physiology)  
26 relate largely to effects on scenic and aesthetic values. The available information does not yet  
27 address or describe the relationships expected to exist for some level of visible foliar injury  
28 severity (below that at which broader physiological effects on plant growth and survival might  
29 also be expected) and/or extent of location or site injury (e.g., BI) scores with values held by the  
30 public and associated impacts on public uses of the locations.<sup>112</sup> As discussed in section 4.3.2  
31 above, this gap limits our ability to identify air quality conditions that might be expected to  
32 provide a specific level of protection from public welfare effects of this endpoint (e.g., separate  
33 from effects that might relate to plant growth and reproduction under conditions where foliar

---

<sup>112</sup> Information with some broadly conceptual similarity to this has been used for judging public welfare implications of visibility effects of PM in setting the PM secondary standard (78 FR 3086, January 15, 2012).

injury may also be severe).<sup>113</sup> Thus, key considerations of this endpoint in past reviews have related to qualitative consideration of potential impacts related to the plant's aesthetic value in protected forested areas and the somewhat general, nonspecific judgment that a more restrictive standard is likely to provide increased protection. Nevertheless, while minor spotting on a few leaves of a plant may easily be concluded to be of little public welfare significance, it is reasonable to conclude that cases of widespread and relatively severe injury during the growing season (particularly when sustained across multiple years and accompanied by obvious impacts on the plant canopy) would likely impact the public welfare in scenic and/or recreational areas, particularly in areas with special protection, such as Class I areas. In this context, we note the potential usefulness of the USFS scheme for the purposes of informing the Administrator's judgments with regard to public welfare significance of such effects.

In light of the discussions here and in sections 4.3.3.2 and 4.5.1.2 (with consideration of presentations in Appendix 4C and air quality analyses in Appendices 2A, 4D and 4F) we find that the available information does not indicate that a situation of widespread and relatively severe visible foliar injury is likely associated with air quality that meets the current standard. More specifically, the air quality data for areas meeting the standard do not indicate conditions associated with BI scores reasonably considered of concern in the context described above (concerning potential for public welfare significance). For example, we note that the air quality analyses indicate that virtually all seasonal W126 index values at locations meeting the current standard are below 25 ppm-hr. Further, the average number of observations of 1-hour concentrations at or above 100 ppb per site and design value period are well below one during periods when the current standard is met. Thus, while the current evidence is limited for the purposes of identifying public welfare protection objectives related to visible foliar injury in terms of specific air quality metrics, the current information indicates that the occurrence of injury categorized as more severe than "little" by the USFS categorization (i.e., a BI score above 5 or above 15) would be expected to be infrequent in areas that meet the current standard. Based on the USFS dataset presentations as well as the air quality analyses of W126 index values and frequency of 1-hour observations at or above 100 ppb, the prevalence of injury scores categorized as severe, which, depending on spatial extent, might contribute to impacts of public welfare significance do not appear likely to occur under air quality conditions that meet the current standard.

With regard to other vegetation-related effects, including those at the ecosystem scale, such as alteration in community composition or reduced productivity in terrestrial ecosystems, as

---

<sup>113</sup> Further, no criteria have been established regarding a level or prevalence of visible foliar injury considered to be adverse to the affected vegetation as the current evidence does not provide for determination of a degree of leaf injury that would have significance to the vigor of the whole plant (ISA, Appendix 8, p. 8-24).

1 recognized in section 4.5.1.1, the available evidence is not clear with regard to the risk of such  
2 impacts (and their magnitude or severity) associated with the environmental O<sub>3</sub> exposures  
3 estimated to occur under air quality conditions meeting the current standard (e.g., W126 index  
4 generally at or below 17 ppm-hrs). In considering effects on crop yield, the air quality analyses at  
5 monitoring locations that meet the current standard indicate estimates of RYL for such  
6 conditions to be at and below 5.1%, based on the median estimate derived from the established  
7 E-R functions for 10 crops (Appendix 4A, Table 4A-5). We additionally recognize there to be  
8 complexities involved in interpreting the significance of such small estimates in light of the  
9 factors identified in section 4.3.2 above. These include the extensive management of crops in  
10 agricultural areas that may to some degree mitigate potential O<sub>3</sub>-related effects, as well as the use  
11 of variable management practices to achieve optimal yields, while taking into consideration  
12 various environmental conditions. We also recognize that changes in yield of commercial crops  
13 and commercial commodities may affect producers and consumers differently, further  
14 complicating consideration of these effects in terms of potential adversity to the public welfare  
15 impacts. In light of these factors complicating conclusions regarding crop yield impacts, in  
16 combination with the relatively low RYL estimates associated with W126 index values occurring  
17 in areas meeting the current standard, as well as the relative scarcity of peak hourly  
18 concentrations at or above 100 ppb, a situation which differs from the extensive occurrences  
19 associated with the exposure treatments on which the established E-R functions for the 10 crop  
20 species are based (e.g., Lefohn and Foley, 1992), the current information does not indicate  
21 exposures occurring in areas meeting the current standard to be of public welfare significance  
22 with regard to crop yield.

#### 23 **4.5.2 Preliminary Conclusions**

24 This section describes preliminary conclusions for the Administrator's consideration with  
25 regard to the current secondary O<sub>3</sub> standard. These preliminary conclusions are based on  
26 consideration of the assessment and integrative synthesis of the evidence (as summarized in the  
27 ISA, and the 2013 ISA and AQCDs from prior reviews), and the information on quantitative  
28 exposure and air quality analyses summarized above. Taking into consideration the discussions  
29 above in this chapter, this section addresses the following overarching policy question.

- 30 • **Do the scientific evidence and air quality and exposure analyses support or call into**  
31 **question the adequacy of the protection afforded by the current secondary O<sub>3</sub>**  
32 **standard?**

33 In considering this question, we first recognize what the CAA specifies with regard to  
34 protection to be provided by the secondary standard. Under section 109(b)(2) of the CAA, a  
35 secondary standard must “specify a level of air quality the attainment and maintenance of which,



1 in the judgment of the Administrator, based on such criteria, is requisite to protect the public  
2 welfare from any known or anticipated adverse effects associated with the presence of [the]  
3 pollutant in the ambient air.” Accordingly, as noted in section 4.3.2 above, the secondary  
4 standard is meant to protect against O<sub>3</sub>-related welfare effects that are judged to be adverse to the  
5 public welfare (78 FR 8312, January 15, 2013; see also 73 FR 16496, March 27, 2008). Thus,  
6 our consideration of the available information regarding welfare effects of O<sub>3</sub> is in this context,  
7 while recognizing that the level of protection from known or anticipated adverse effects to public  
8 welfare that is requisite for the secondary standard is a public welfare policy judgment made by  
9 the Administrator.

10 As is the case in NAAQS reviews in general, the extent to which the protection provided  
11 by the current secondary O<sub>3</sub> standard is judged to be adequate will depend on a variety of factors,  
12 including science policy judgments and public welfare policy judgments. These factors include  
13 public welfare policy judgments concerning the appropriate benchmarks on which to place  
14 weight, as well as judgments on the public welfare significance of the effects that have been  
15 observed at the exposures evaluated in the welfare effects evidence. The factors relevant to  
16 judging the adequacy of the standard also include the interpretation of, and decisions as to the  
17 weight to place on, different aspects of the quantitative analyses of air quality and cumulative O<sub>3</sub>  
18 exposure and any associated uncertainties. Thus, we recognize that the Administrator’s  
19 conclusions regarding the adequacy of the current standard will depend in part on public welfare  
20 policy judgments, science policy judgments regarding aspects of the evidence and exposure/risk  
21 estimates, as well as judgments about the level of public welfare protection that is requisite under  
22 the Clean Air Act.

23 As an initial matter, we recognize the continued support in the current evidence for O<sub>3</sub> as  
24 the indicator for photochemical oxidants (as summarized in section 4.5.1.1 above). We note that  
25 no newly available evidence has been identified since the 2015 decision regarding the  
26 importance of photochemical oxidants other than O<sub>3</sub> with regard to abundance in ambient air,  
27 and potential for welfare effects, and that, as stated in the current ISA, “the primary literature  
28 evaluating the health and ecological effects of photochemical oxidants includes ozone almost  
29 exclusively as an indicator of photochemical oxidants” (ISA, section IS.1.1). Thus, we recognize  
30 that, as was the case for the 2015 and prior reviews, the evidence base for welfare effects of  
31 photochemical oxidants does not indicate an importance of any other photochemical oxidants.  
32 Thus, we conclude that the evidence continues to support O<sub>3</sub> as the indicator for the secondary  
33 NAAQS for photochemical oxidants.

34 Our response to the overarching question above takes into consideration the discussions  
35 that address the specific policy-relevant questions in prior sections of this document and the  
36 approach described in section 4.2. We consider the evidence and the extent to which it alters key

1 conclusions supporting the current standard. We also consider the quantitative analyses,  
2 including associated limitations and uncertainties, and what they may indicate regarding level of  
3 protection provided by the current standard from adverse effects. We additionally consider the  
4 key aspects of the evidence and air quality/exposure information emphasized in establishing the  
5 now-current standard, and the associated public welfare policy judgments and judgments about  
6 inherent uncertainties that are integral to decisions on the adequacy of the current secondary O<sub>3</sub>  
7 standard. Together these considerations contribute to our preliminary conclusion as to whether  
8 the available scientific evidence and air quality and exposure analyses support or call into  
9 question the adequacy of the protection afforded by the current secondary O<sub>3</sub> standard.

10 In considering the available evidence, we recognize the longstanding evidence base of the  
11 vegetation-related effects of O<sub>3</sub>, augmented in some aspects since the 2015 review. Consistent  
12 with the evidence in the 2015 review, the existing evidence describes an array of effects on  
13 vegetation and related ecosystem effects causally or likely causally related to O<sub>3</sub> in ambient air,  
14 as well as the causal relationship of tropospheric O<sub>3</sub> with radiative forcing and subsequent likely  
15 causally related effects on temperature, precipitation, and related climate variables. As was the  
16 case in the 2015 review, a category of effects for which the evidence supports quantitative  
17 description of relationships between air quality conditions and response is plant growth or yield.  
18 The evidence base continues to indicate growth-related effects as sensitive welfare effects, with  
19 the potential for ecosystem-scale ramifications. For this category of effects, there are established  
20 E-R functions that relate cumulative seasonal exposure of varying magnitudes to various  
21 incremental reductions in expected tree seedling growth (in terms of RBL) and in expected crop  
22 yield (in terms of RYL). Many decades of research also recognize visible foliar injury as an  
23 effect of O<sub>3</sub>, although uncertainties continue to hamper efforts to quantitatively characterize the  
24 relationship of its occurrence and relative severity with O<sub>3</sub> exposures. The evidence for these  
25 categories of vegetation-related O<sub>3</sub> effects is discussed further below. But before focusing further  
26 on these key vegetation-related effects, we address two endpoints newly identified in the 2020  
27 ISA, as well as tropospheric O<sub>3</sub> effects related to climate.

28 With regard to categories of effects newly identified in the 2020 ISA as likely causally  
29 related to O<sub>3</sub> in ambient air, such as alteration of plant-insect signaling and insect herbivore  
30 growth and reproduction, we recognize that uncertainties limit our consideration of the  
31 protection that might be provided by the current standard against these effects. Depending on a  
32 number of factors, such effects may have a potential for adverse effects to the public welfare,  
33 e.g., given the role of plant-insect signaling in such important ecological processes as pollination  
34 and seed dispersal, as well as natural plant defenses against predation and parasitism (as  
35 discussed in section 4.3.2 above Uncertainties in the evidence, however, preclude a sufficient  
36 understanding to support a focus on such effects in considering protection provided by the

1 current standard. Areas of uncertainty and limitations in the evidence include key aspects of such  
2 effects, the air quality conditions that might elicit them (and the magnitude or severity), the  
3 potential for impacts in a natural ecosystem and, consequently, the potential for such impacts  
4 under air quality conditions associated with meeting the current standard, as discussed in section  
5 4.5.1.1 above. Thus, we do not find the evidence to provide sufficient information to support  
6 judgments related to how particular patterns of O<sub>3</sub> concentrations in ambient air may relate to the  
7 occurrence of such effects in natural systems or, accordingly, to any related impacts to the public  
8 welfare.

9 We next recognize the strong evidence documenting tropospheric O<sub>3</sub> as a greenhouse gas  
10 causally related to radiative forcing, and likely causally related to subsequent effects on variables  
11 such as temperature and precipitation. In so doing, however, we take note of the limitations and  
12 uncertainties in the evidence base that affect our ability to characterize the extent of any  
13 relationships between O<sub>3</sub> concentrations in ambient air in the U.S. and climate-related effects,  
14 thus precluding a quantitative characterization of climate responses to changes in O<sub>3</sub>  
15 concentrations in ambient air at regional (vs global) scales (as summarized in sections 4.3.3.3  
16 and 4.3.4 above).<sup>114</sup> As a result, we recognize the lack of important quantitative tools with which  
17 to consider such effects in the context of protection provided by the current secondary O<sub>3</sub>  
18 standard, such that it is not feasible to relate different patterns of O<sub>3</sub> concentrations at the  
19 regional (or national) scale in the U.S. with specific risks of alterations in temperature,  
20 precipitation and other climate-related variables. We find these significant limitations and  
21 uncertainties together to contribute to an insufficiency in the available information for the  
22 purposes of supporting the Administrator's judgments particular to a secondary O<sub>3</sub> NAAQS and  
23 protection of the public welfare from adverse effects linked to O<sub>3</sub> influence on radiative forcing,  
24 and related climate effects.<sup>115</sup> Thus, as is the case for the two newly identified categories of  
25 insect-related effects discussed above, we conclude that the available evidence does not support a  
26 focus on radiative forcing and related climate effects in considering the extent to which the  
27 available evidence supports or calls into question the adequacy of protection afforded by the  
28 current secondary standard.

29 Turning next to consideration of visible foliar injury, the available information has been  
30 examined and analyzed as to what it indicates and supports with regard to adequacy of protection

---

<sup>114</sup> With regard to radiative forcing and effects on temperature, precipitation, and related climate variables, while additional characterizations have been completed since the 2015 review, uncertainties and limitations in the evidence that were also recognized at that time remain.

<sup>115</sup> Notwithstanding consideration of these effects, we note that a focus on the protection offered by the standard against vegetation-related effects is expected to also have positive implications for climate change protection through the protection of terrestrial ecosystem carbon storage.

1 provided by the current standard (e.g., as discussed in section 4.5.1 above). Visible foliar injury  
2 is an effect for which an association with O<sub>3</sub> in ambient air is well documented. The public  
3 welfare significance of visible foliar injury of vegetation in areas not closely managed for  
4 harvest, particularly specially protected natural areas, has generally been considered in the  
5 context of potential effects on aesthetic and recreational values, such as the aesthetic value of  
6 scenic vistas in protected natural areas such as national parks and wilderness areas (e.g., 73 FR  
7 16496, March 27, 2008). Accordingly, depending on its severity and spatial extent, as well as the  
8 location(s) and the associated intended use, its effects on the physical appearance of the plant  
9 have the potential to be significant to the public welfare. For example, while limited occurrences  
10 (e.g., of severity or prevalence) may easily be concluded to be of little public welfare  
11 significance, cases of widespread and relatively severe injury during the growing season  
12 (particularly when sustained across multiple years and accompanied by obvious impacts on the  
13 plant canopy) might reasonably be expected to have the potential to adversely impact the public  
14 welfare in scenic and/or recreational areas, particularly in areas with special protection, such as  
15 Class I areas.

16 In considering existing approaches for categorizing the severity of injury in natural areas,  
17 we take note of the system developed by the USFS for its monitoring program<sup>116</sup> to categorize BI  
18 scores of visible foliar injury at biosites (sites with O<sub>3</sub>-sensitive vegetation assessed for visible  
19 foliar injury) in natural vegetated areas by severity levels (described in section 4.3.2 above). We  
20 recognize, however, that quantitative analyses and evidence are lacking that might support a  
21 precise conclusion - and associated judgment - as to a magnitude of BI score coupled with an  
22 extent of occurrence that might be specifically identified as adverse to the public welfare. That  
23 notwithstanding, we additionally note that the scale of the USFS biosite monitoring program's  
24 objectives, which focus on natural settings in the U.S. and forests as opposed to individual  
25 plants, may be informative to the Administrator with regard to his judgments concerning the  
26 public welfare protection afforded by the current standard for such effects.

27 In considering the availability of established approaches that might be employed for  
28 considering degrees of public welfare impacts related to the occurrence of visible foliar injury of  
29 differing severity and extent (e.g., as summarized in sections 4.3.3.2 and 4.5.1.1 above), we note  
30 the paucity of established approaches for interpreting specific levels of severity and extent of  
31 foliar injury in protected forests with regard to impacts on public welfare effects (e.g., related to

---

<sup>116</sup> During the period from 1994 (beginning in eastern U.S.) through 2011, the USFS conducted surveys of the occurrence and severity of visible foliar injury on sensitive species at sites across most of the U.S. following a national protocol (Smith, 2012).

1 recreational services).<sup>117</sup> In this context, we recognize a potential usefulness of the USFS system,  
2 including its descriptors for BI scores of differing magnitudes intended for that Agency’s  
3 consideration in identifying areas of potential impact to forest resources. As described in section  
4 4.3.2 above, very low BI scores (at or below 5) are described by the USFS scheme as “little or no  
5 foliar injury” (Smith et al., 2007; Smith et al., 2012),<sup>118</sup> and BI scores above 15 are categorized  
6 as moderate to severe (and scores above 25 as severe). The lower categories of BI scores are  
7 described by the USFS descriptions as indicative of injury of generally lesser risk to the natural  
8 area, which we would suggest may also indicate lesser risk to public enjoyment. Accordingly, to  
9 the extent that the USFS ranking system is of value to the Administrator’s judgments in this  
10 context, it may be reasonable to conclude that occurrence of BI scores categorized as “moderate  
11 to severe” injury by the USFS scheme would be an indication of visible foliar injury occurrence  
12 that, depending on extent and severity, may be indicative of conditions of public welfare  
13 significance. Thus, this framework may be informative to the Administrator’s consideration of  
14 the evidence and analyses summarized in the sections above and what they indicate with regard  
15 to patterns of air quality of concern for such an occurrence, and the extent to which they are  
16 expected to occur in areas that meet the current standard.

17 We additionally consider the USFS biosite monitoring program studies of the occurrence,  
18 extent, and severity of visible foliar injury in indicator species in defined plots or biosites in  
19 natural areas across the U.S. Some of these studies, particularly those examining such data across  
20 multiple years and multiple regions of the U.S., have reported that variation in cumulative O<sub>3</sub>  
21 exposure, in terms of metrics such as SUM06 or W126 index, does not completely explain the  
22 patterns of occurrence and severity of injury observed. Although the availability of detailed  
23 analyses that have explored multiple exposure metrics and other influential variables is limited,  
24 multiple studies have indicated a potential role for an additional metric, one related to the  
25 occurrence of days with relatively high concentrations (e.g., number of days with a 1-hour  
26 concentration at or above 100 ppb), as summarized in section 4.5.1.2 above. Also noteworthy are  
27 the publications related to the USFS biosite monitoring program that provide extensive evidence  
28 of trends across the past nearly 20 years that indicate reductions in severity of visible foliar  
29 injury that parallel reductions in peak concentrations that have been suggested to be influential in  
30 the severity of visible foliar injury. For example, observations of such reductions in the incidence  
31 of the higher BI scores over the 16-year period of the program (1994 through 2010), especially

---

<sup>117</sup> This contrasts with another welfare effect, visibility, for which there is evidence relating to levels of visibility found to be acceptable by the public that was considered in judging the public welfare protection provided by the particulate matter secondary standard (78 FR 3226-3228, January 15, 2013).

<sup>118</sup> Studies that consider such data for purposes of identifying areas of potential impact to the forest resource suggest this category corresponds to “none” with regard to “assumption of risk” (Smith et al., 2007; Smith et al., 2012).

1 after 2002, have led to researcher conclusions of a “declining risk of probable impact” on the  
2 monitored forests over this period (e.g., Smith, 2012). These reductions parallel the O<sub>3</sub>  
3 concentration trend information nationwide that show clear reductions in cumulative seasonal  
4 exposures, as well as in peak O<sub>3</sub> concentrations, both in terms of 8-hour and hourly  
5 concentrations (e.g., Figures 2-11 and 2-17, and as summarized in section 4.4.1 above). . That is,  
6 the extensive air quality evidence of trends across the past nearly 20 years indicate reductions in  
7 peak concentrations that some studies have suggested to be influential in the severity of visible  
8 foliar injury, as discussed in section 4.5.1 above.

9 In considering the available information that might inform the Administrator’s judgments  
10 regarding visible foliar injury, we note a paucity of established approaches to inform the  
11 Administrator’s judgment of a magnitude, severity or extent of visible foliar injury related effects  
12 appropriately concluded to be known or anticipated to cause adverse effects to the public  
13 welfare. However, some general conclusions or observations may be supported. For example,  
14 based on the available evidence and associated quantitative analyses, we have less confidence  
15 and greater uncertainty in the existence of adverse public welfare effects with lower O<sub>3</sub>  
16 exposures. More specifically, as discussed in the prior sections, the available information  
17 suggests that O<sub>3</sub> air quality associated with W126 index values below 25 ppm-hrs (in a single  
18 year), particularly when in combination with infrequent occurrences of hourly concentrations at  
19 or above 100 ppb, is not likely to pose a risk of visible foliar injury in natural areas of an extent  
20 and severity that might reasonably be considered to be of public welfare significance.

21 Support for this conclusion is seen in the air quality analyses that inform our  
22 understanding of the occurrence and magnitude of cumulative seasonal exposures, in terms of  
23 W126 index, and peak concentrations, in terms of the N100 and D100 metrics, in areas that meet  
24 the current standard. These analyses indicate that virtually all W126 index values in a single year  
25 are below 25 ppm-hrs at all monitoring locations (including in or near Class I areas) where the  
26 current standard is met, and that, in fact, such values above 19 ppm-hrs are rare, as summarized  
27 in section 4.4.2 above (Appendix 4D, sections 4D.3.1.24 and 4D.3.2.4). Thus, the analyses of air  
28 quality since 2000 for areas that meet the current standard do not indicate the occurrence of  
29 cumulative seasonal exposure, in terms of W126 index, of a magnitude that might be expected,  
30 based on the available information (e.g., based on analyses of BI scores considered in sections  
31 4.5.1.2 and 4.5.1.3 above), to contribute to a significant extent and degree of injury or specific  
32 impacts on recreational or related services for areas, such as wilderness areas or national parks.  
33 Further, we take note of the uncommonness of days with any hours at or above 100 ppb at  
34 monitoring sites that meet the current standard, as well as the minimal number of hours on any  
35 such days (as summarized in section 4.4.1). Based on these considerations, it would appear that  
36 the current standard provides control of air quality conditions that contribute to increased BI

1 scores and to scores of a magnitude indicative of “moderate to severe” foliar injury. Thus, we  
2 conclude that the evidence indicates that areas that meet the current standard are unlikely to have  
3 BI scores reasonably considered to pose a risk of impacts of public welfare significance.  
4 Accordingly, based on all of the considerations raised here, and in the sections above, we find it  
5 reasonable to conclude that the available evidence and quantitative exposure information for  
6 visible foliar injury do not call into question the adequacy of protection provided by the current  
7 standard.

8 We turn now to consideration of the other vegetation-related effects, the evidence for  
9 which as a whole is extensive, spans several decades, and supports the Agency’s conclusions of  
10 causal or likely to be causal relationship for O<sub>3</sub> in ambient air with an array of effect categories  
11 (as noted above). As an initial matter, we note the new ISA determination that the current  
12 evidence is sufficient to infer likely causal relationships of O<sub>3</sub> with increased tree mortality,  
13 while also noting that the evidence does not indicate a potential for O<sub>3</sub> concentrations that occur  
14 in locations that meet the current standard to cause increased tree mortality, as summarized in  
15 section 4.3.1 above.

16 As we turn our focus now to the more sensitive effect of vegetation growth and  
17 conceptually related effects with a focus on RBL (described in section 4.5.1.2 above), we  
18 recognize that public welfare policy judgments play an important role in decisions regarding a  
19 secondary standard, just as public health policy judgments have important roles in primary  
20 standard decisions. One type of public welfare policy judgment focuses on how to consider the  
21 nature and magnitude of the array of uncertainties that are inherent in the scientific evidence and  
22 analyses. These judgments are traditionally made with a recognition that current understanding  
23 of the relationships between the presence of a pollutant in ambient air and associated welfare  
24 effects is based on a broad body of information encompassing not only more established aspects  
25 of the evidence but also aspects in which there may be substantial uncertainty. This may be true  
26 even of the most robust aspect of the evidence base. In the case of the available evidence base, as  
27 an example, we recognize increased uncertainty, and associated imprecision, at lower cumulative  
28 exposures in application of the established and well-founded E-R functions, and in the current  
29 understanding of aspects of relationships of such estimated effects with larger-scale impacts,  
30 such as those on populations, communities, and ecosystems, as summarized in sections 4.5.1.3  
31 and 4.3.4 above. Further, we recognize uncertainties in the details and quantitative aspects of  
32 relationships between plant-level effects such as growth and reproduction, and ecosystem  
33 impacts, the occurrence of which are influenced by many other ecosystem characteristics and  
34 processes. These examples illustrate the role of public welfare policy judgments, both with  
35 regard to the Administrator’s consideration of the extent of protection that is requisite and

1 concerning the weighing of uncertainties and limitations of the underlying evidence base and  
2 associated quantitative analyses.

3 As summarized in section 4.1 above, the decisions that established the current standard in  
4 2015, and retained it in 2020, involved a series of judgments contributing to the standard's  
5 foundation with regard to growth-related effects. The first of these judgments relates to  
6 consideration of the O<sub>3</sub> effect of reduced growth (quantified using the metric, RBL) as a proxy  
7 for an array of other vegetation-related effects to the public welfare. The category of effects for  
8 which the evidence is most certain with regard to quantitative functions describing relationships  
9 between O<sub>3</sub> in ambient air and response continues to be reduced plant growth or yield. The  
10 evidence base includes established E-R functions for seedlings of 11 tree species that relate  
11 cumulative seasonal exposure of varying magnitudes to various incremental reductions in  
12 expected tree seedling growth (in terms of RBL) and in expected crop yield. These functions are  
13 well established and have been recognized across multiple O<sub>3</sub> NAAQS reviews. Uncertainties  
14 related to use of the RBL estimates include the limited information regarding the extent to which  
15 they reflect growth impacts in mature trees, and the fact that the 11 species represent a very small  
16 portion of the tree species across the U.S.

17 While recognizing these and other uncertainties, RBL estimates based on the median of  
18 the 11 species were used in the 2015 and 2020 decisions as a surrogate for comparable  
19 information on other species and lifestages, as well as a proxy or surrogate for other vegetation-  
20 related effects, including larger-scale effects. Use of this approach continues to appear to be a  
21 reasonable judgment in this reconsideration of the 2020 decision. More specifically, the currently  
22 available information continues to support (and does not call into question) the consideration of  
23 RBL as a useful and evidence-based approach for consideration of the extent of protection from  
24 the broad array of vegetation-related effects associated with O<sub>3</sub> in ambient air. As discussed in  
25 section 4.5.1.2 above, these categories of effects include reduced vegetation growth,  
26 reproduction, productivity, and carbon sequestration in terrestrial systems, and also alteration of  
27 terrestrial community composition, belowground biogeochemical cycles, and ecosystem water  
28 cycling. The current evidence base and available information (qualitative and quantitative), as in  
29 the 2015 review, continue to support consideration of the potential for O<sub>3</sub>-related vegetation  
30 impacts in terms of the RBL estimates from established E-R functions as a quantitative tool  
31 within a larger framework of considerations pertaining to the public welfare significance of O<sub>3</sub>  
32 effects. Such consideration would include effects that are associated with effects on vegetation,  
33 and particularly those that conceptually relate to growth, and that are causally or likely causally  
34 related to O<sub>3</sub> in ambient air, yet for which there are greater uncertainties affecting estimates of  
35 impacts on public welfare. This approach to weighing the available information in reaching  
36 judgments regarding the secondary standard additionally takes into account uncertainties



1 regarding the magnitude of growth impact that might be expected in mature trees, and of related,  
2 broader, ecosystem-level effects for which the available tools for quantitative estimates are more  
3 uncertain and those for which the policy foundation for consideration of public welfare impacts  
4 is less well established. (80 FR 65389, October 26, 2015). The currently available evidence,  
5 while somewhat expanded since the 2015 review, does not indicate an alternative metric for such  
6 a use; nor is an alternative approach evident.

7 In considering tree growth effects, we take note of the other public welfare policy  
8 judgments inherent in the Administrators' decisions in establishing the current standard in 2015,  
9 and in retaining it in 2020. In addition to adoption of the median tree seedling RBL estimate for  
10 the studied species as a surrogate for the broad array of vegetation related effects that extend to  
11 the ecosystem scale, the decisions in 2015 and 2020 both incorporated the judgment that  
12 cumulative seasonal exposures (in terms of the average W126 index across the 3-year design  
13 period for the standard) associated with a median RBL somewhat below 6% is an appropriate  
14 focus for considering target levels of protection for the secondary standard.

15 Decisions on the adequacy of secondary NAAQS require judgments on the extent to  
16 which particular welfare effects (e.g., with regard to type, magnitude/severity, or extent) are  
17 important from a public welfare perspective. In the case of O<sub>3</sub>, such a judgment includes  
18 consideration of the public welfare significance of small magnitude estimates of RBL and  
19 associated unquantified potential for larger-scale related effects. In establishing the current  
20 standard in 2015 with a focus on RBL as a proxy or surrogate for the broad array of vegetation  
21 effects, the Administrator took note of the 2014 CASAC characterization of 6% RBL (in  
22 seedlings of median tree species). As described in section 4.1 above, the rationale provided by  
23 the CASAC with this characterization was primarily conceptual and qualitative, rather than  
24 quantitative. The conceptual characterization recognized linkages between effects at the plant  
25 scale and broader ecosystem impacts, with the CASAC recommending that the Administrator  
26 consider RBL as a surrogate or proxy for the broader impacts that could be elicited by O<sub>3</sub>. In the  
27 2015 decision, the Administrator took note of this CASAC advice regarding use of RBL as a  
28 proxy and set the standard with an underlying objective of limiting cumulative exposures (in  
29 terms of W126 index, averaged over three years) "in nearly all instances to those for which the  
30 median RBL estimate would be somewhat lower than 6%" (80 FR 65407, October 26, 2015).<sup>119</sup>  
31 The information available in this reconsideration of the 2020 decision does not appear to call into  
32 question such judgments, indicating them to continue to appear reasonable.

---

<sup>119</sup> The 2015 decision additionally noted that "the Administrator does not judge RBL estimates associated with marginal higher exposures [at or above 19 ppm-hrs] in isolated, rare instances to be indicative of adverse effects to the public welfare" (80 FR 65407, October 26, 2015).

1 In considering what the available information indicates regarding the level of protection  
2 for growth-related effects provided by the current standard, we recognize the importance of  
3 considering the extent of both cumulative seasonal O<sub>3</sub> exposures and of elevated hourly  
4 concentrations, as discussed in section 4.5.1.2 above. These aspects of O<sub>3</sub> air quality can  
5 contribute to damaging conditions for vegetation. Thus, in considering the extent of protection  
6 provided by the current standard, in addition to considering seasonal W126 index to estimate  
7 median RBL using the established E-R functions, we also consider metrics that convey  
8 information regarding peak hourly concentrations. While we recognize that the evidence does  
9 not indicate a particular threshold number of hours at or above 100 ppb (or another reference  
10 point for elevated concentrations), we take particular note of the evidence of greater impacts  
11 from higher concentrations (particularly with increased frequency) and of the air quality analyses  
12 that document variability in such concentrations for the same W126 index value. In light of these  
13 factors, a multipronged approach is reasonably concluded to be appropriate for considering  
14 exposures of concern and the protection from them that may be afforded by the secondary  
15 standard.

16 The air quality analyses summarized in section 4.4 above describe the air quality  
17 conditions that occur under the current standard and also the conditions in areas where the  
18 standard is not met. We consider what is indicated regarding protection overall and protection  
19 against “unusually damaging years” (an issue raised in the court remand of the 2015 decision on  
20 the secondary standard). With regard to this issue, we take note of the air quality analyses  
21 summarized in section 4.4.1, as also considered in section 4.5.1.2 above, that investigate the  
22 annual occurrence of elevated hourly O<sub>3</sub> concentrations which may contribute to vegetation  
23 exposures of concern (Appendix 2A, section 2A.2; Appendix 4F).<sup>120</sup> These air quality analyses  
24 illustrate limitations of the W126 index for purposes of controlling peak concentrations, and also  
25 the strengths of the current standard in this regard, showing that the form and averaging time of  
26 the existing standard is much more effective than the W126 index in limiting peak concentrations  
27 (e.g., hourly O<sub>3</sub> concentrations at or above 100 ppb) and in limiting number of days with any  
28 such hours. As noted in prior sections, the W126 index, by virtue of its definition, does not  
29 provide specificity with regard to year-to-year variability in elevated hourly O<sub>3</sub> concentrations  
30 with the potential to contribute to the increased risk of vegetation effects, and the air quality  
31 analyses illustrate this limitation. These analyses additionally document the control exerted by

---

<sup>120</sup> The ISA references the longstanding recognition of the risk posed to vegetation of peak hourly O<sub>3</sub> concentrations (e.g., “[h]igher concentrations appear to be more important than lower concentrations in eliciting a response” [ISA, p. 8-180]; “higher hourly concentrations have greater effects on vegetation than lower concentrations” [2013 ISA, p. 91-4] “studies published since the 2006 O<sub>3</sub> AQCD do not change earlier conclusions, including the importance of peak concentrations, ... in altering plant growth and yield” [2013 ISA, p. 9-117]).

1 the current standard, through all of its elements, on both cumulative seasonal O<sub>3</sub> exposures and  
2 peak hourly concentrations.

3 In considering cumulative seasonal O<sub>3</sub> exposures occurring in areas that meet the current  
4 standard with regard to growth-related effects represented by RBL (as discussed more fully  
5 earlier, including in section 4.5.1.2), we focus, as was done in the 2015 decision, on a seasonal  
6 W126 index, averaged across three years. In do so based on consideration of the extent of  
7 conceptual similarities of the 3-year average W126 index with some aspects of the derivation  
8 approach for the established E-R functions, the context of RBL as a proxy (as recognized above)  
9 and other factors. With regard to the established E-R functions used to describe the relationship  
10 of RBL with O<sub>3</sub> in terms of a seasonal W126 index, we recognize that the functions were derived  
11 mathematically from studies of different exposure durations (varying from shorter than one to  
12 multiple growing seasons) by applying adjustments so that they would yield estimates  
13 normalized to the same period of time (season), such that the estimates may conceptually  
14 represent average impact for a season. We note the compatibility of W126 index averaged over  
15 multiple growing seasons or years with these adjustments. We also note that the exposure levels  
16 represented in the data underlying the E-R functions are somewhat limited with regard to the  
17 relatively lower cumulative exposure levels most commonly associated with the current standard  
18 (e.g., at or below 17 ppm-hrs), with generally greater representation for higher exposures (e.g.,  
19 ranging up to W126 index levels above 100 ppm-hrs), indicating additional uncertainty for  
20 applications of the E-R functions to the lower cumulative exposure levels. We additionally note  
21 the differing patterns of hourly concentrations of the elevated exposure levels (particularly with  
22 regard to peak hourly concentrations, such as those at/above 100 ppb) in the datasets from which  
23 the E-R functions from the patterns in ambient air meeting the current standard across the U.S.  
24 today, as summarized in section 4.5.1.2 above. With these considerations regarding the E-R  
25 functions and their underlying datasets in mind, we also take note of year-to-year variability of  
26 factors other than O<sub>3</sub> exposures that affect tree growth in the natural environment (e.g., related to  
27 variability in soil moisture, meteorological, plant-related and other factors), that have the  
28 potential to affect O<sub>3</sub> E-R relationships, as noted in sections 4.3 and 4.5 above (ISA, Appendix 8,  
29 section 3.12; 2013 ISA section 9.4.8.3). Thus, the use of the W126 index averaged over multiple  
30 years has a compatibility with the approach used in deriving the E-R functions, and reflects  
31 consideration of other aspects of the E-R function datasets and other factors that may affect  
32 growth in the natural environment.

33 We additionally recognize the qualitative and conceptual nature of our understanding, in  
34 many cases, of relationships of O<sub>3</sub> effects on plant growth and productivity with larger-scale  
35 impacts, such as those on populations, communities and ecosystems. Based on these  
36 considerations, use of a seasonal RBL averaged over multiple years, such as a 3-year average,

1 appears to be a reasonable approach, and provides a stable and well-founded RBL estimate for its  
2 purposes as a proxy to represent the array of vegetation-related effects identified above. In light  
3 of these considerations, we conclude there is support in the available information for use of an  
4 average seasonal W126 index derived from multiple years (with their representation of  
5 variability in environmental factors), and that the use of such averaging may provide an  
6 appropriate representation of the evidence and attention to considerations summarized above.  
7 Thus, we conclude that application of the multipronged approach referenced above would assess  
8 anticipated exposures and protection afforded by the current secondary standard using a seasonal  
9 W126 averaged over a 3-year period, which is the design value period for the current standard, to  
10 estimate median RBL via the established E-R functions, in combination with a broader  
11 consideration of air quality patterns, such as peak hourly concentrations.

12 In considering the quantitative analyses available in this review with regard to the control  
13 of air quality conditions that might pose risks to the public welfare by the current standard, we  
14 note the findings from the analysis of recent air quality at sites across the U.S., including in or  
15 near 65 Class I areas, and also analyses of historical air quality. Findings from the analysis of the  
16 air quality data from the most recent period and from the larger analysis of historical air quality  
17 data extending back to 2000 are consistent with the air quality analysis findings that were part of  
18 the basis for the current standard. That is, in virtually all design value periods and all locations at  
19 which the current standard was met (more than 99.9% of the observations), the 3-year average  
20 W126 metric was at or below 17 ppm-hrs, the target identified by the Administrator in  
21 establishing the current standard and, in all such design value periods and locations, the W126  
22 metric was at or below 19 ppm-hrs, as was also the case for the earlier and smaller dataset (80  
23 FR 65404-65410, October 26, 2015). Additionally, across the full 21-year dataset for 56 Class I  
24 areas with monitors meeting the current standard during at least one or as many as nineteen 3-  
25 year periods since 2000, there are no more than 15 occurrences of a single-year W126 index  
26 above 19 ppm-hrs, the majority occurring during the earlier years of the period (Appendix 4D,  
27 section 4D.3.2.4, Tables 4D-14 and 4D-16). For example, the highest values were equal to 23  
28 ppm-hrs, all occurring before 2012. Additionally, as emphasized in earlier sections, the current  
29 standard better controls for peak concentrations (at or above 100 ppm-hrs), which may pose risks  
30 of vegetation effects, than would be expected by either a single-year or three-year average  
31 W126.<sup>121</sup> Based on the evidence and air quality analyses described in sections 4.3 and 4.4 above,  
32 as well as considerations summarized in section 4.5.1 above, the occurrences of 3-year average  
33 W126 index values allowed by the current standard in Class I areas, including such infrequent

---

<sup>121</sup> The historical dataset also shows the appreciable reductions in peak concentrations (via either the N100 or D100 metric) that have been achieved in the U.S. as air quality has improved under O<sub>3</sub> standards of the existing form and averaging time (Appendix 4F, Figures 4F-13 and 4F-14).

1 single-year deviations of the magnitude recognized here, above the average, can reasonably be  
2 concluded not to raise concerns of adverse effects on the public welfare.

3 With regard to O<sub>3</sub> effects on crop yield, we take note of the long-standing evidence,  
4 qualitative and quantitative, of the reducing effect of O<sub>3</sub> on the yield of many crops, as  
5 summarized in the ISA and characterized in detail in past reviews (e.g., 2013 ISA, 2006 AQCD,  
6 1997 AQCD, 2014 WREA). We also note the established E-R functions for 10 crops and the  
7 estimates of RYL derived from them (Appendix 4A, section 4A.1, Table 4A-4), and the potential  
8 public welfare significance of reductions in crop yield, as summarized in section 4.3.2 above. We  
9 additionally recognize, however, that not every effect on crop yield will be judged adverse to  
10 public welfare. In the case of crops in particular there are a number of complexities related to the  
11 heavy management of many crops to obtain a particular output for commercial purposes, and  
12 related to other factors, that are relevant to consider in evaluating potential O<sub>3</sub>-related public  
13 welfare impacts, as summarized in sections 4.3.2 and 4.5.1.3). For example, the extensive  
14 management of agricultural crops that occurs to elicit optimum yields (e.g., through irrigation  
15 and usage of soil amendments, such as fertilizer) is relevant to judgments concerning evaluation  
16 of the extent of RYL estimated from experimental O<sub>3</sub> exposures reasonably considered to be  
17 adverse to the public welfare. Such considerations include opportunities in crop management for  
18 market objectives, as well as complications in judging relative adversity that relate to market  
19 responses and their effects on producers and consumers in evaluating the potential impact on  
20 public welfare of estimated crop yield losses.

21 In light of such complexities, uncertainties, and limitations, we have considered how  
22 RYL estimates relate to RBL estimates identified above for evaluating protection provided by  
23 the current standard. In this context, we note that W126 index values (3-year average) were at or  
24 below 17 ppm-hrs in virtually all monitoring sites with air quality meeting the current standard.  
25 Based on the established E-R functions, the median RYL estimate corresponding to 17 ppm-hrs  
26 is 5.1%. In considering single-year index values, as discussed in section 4.4.2 above, the vast  
27 majority are similarly low (with more than 99% less than or equal to 17 ppm-hrs), and the higher  
28 values predominantly occur in urban areas. We additionally take note of the role of elevated  
29 hourly concentrations in effects on vegetation growth and yield. In this context we also note the  
30 extensive management of agricultural crops, and the complexities associated with identifying  
31 adverse public welfare effects for market-traded goods (where producers and consumers may be  
32 impacted differently). We also recognize that the current standard generally maintains air quality  
33 at a W126 index below 17 ppm-hrs, with few exceptions, and accordingly would limit the  
34 estimated RYL (based on experimental O<sub>3</sub> exposures) to this degree. In light of all of these  
35 factors, we do not find the available information to call into question the adequacy of protection  
36 afforded by the current standard for crop yield-related effects.

1           Thus, the available information leads us to conclude that the combined consideration of  
2 the body of evidence and the quantitative air quality and exposure analyses, including associated  
3 uncertainties, does not call into question the adequacy of the protection provided by the current  
4 secondary standard. Rather, this information provides support for the current standard, and thus  
5 supports consideration of retaining the current standard, without revision. In reaching these  
6 conclusions, we recognize that the Administrator's decisions in secondary standard reviews, in  
7 general, are largely public welfare judgments, as described above. We further note that different  
8 public welfare policy judgments (e.g., from those in both 2020 and 2015) could lead to different  
9 conclusions regarding the extent to which the current standard provides the requisite protection  
10 of the public welfare. Such public welfare judgments include those related to the appropriate  
11 level of protection that should be afforded to protect against vegetation-related effects of public  
12 welfare significance, as well as with regard to the appropriate weight to be given to differing  
13 aspects of the evidence and air quality information, and how to consider their associated  
14 uncertainties and limitations. For example, different judgments might give greater weight to  
15 more uncertain aspects of the evidence or reflect a differing view with regard to public welfare  
16 significance. Such judgments are left to the discretion of the Administrator. We note, however,  
17 that the scientific evidence and quantitative air quality, exposure and risk information in the  
18 record on which this reconsideration is based are largely unchanged. Staff conclusions regarding  
19 the adequacy of the current standards thus remain unchanged from those reached in the 2020 PA.

20           In summary, the evidence characterized in the 2020 ISA is consistent with that available  
21 in the 2015 review for the principal effects for which the evidence is strongest (e.g., plant  
22 growth, reproduction, and related larger-scale effects, as well as visible foliar injury) and for key  
23 aspects of the current standard. The evidence regarding RBL and air quality in areas meeting the  
24 current standard does not appear to call into question the adequacy of public welfare protection  
25 afforded by the standard. With regard to visible foliar injury, the currently available evidence for  
26 forested locations across the U.S., such as studies of USFS biosites, does not indicate an  
27 incidence of significant visible foliar injury that might reasonably be concluded to be adverse to  
28 the public welfare under air quality conditions meeting the current standard. For the insect-  
29 related effects that the ISA newly concludes likely to be causally related to O<sub>3</sub>, the new  
30 information does not support an understanding of the potential for the occurrence of such effects  
31 in areas that meet the current standard to an extent that they might reasonably be judged  
32 significant to public welfare. Thus, we do not find the current information for these newly  
33 identified categories to call into question the adequacy of the current standard. Similarly, key  
34 uncertainties recognized in the 2015 review remain in the evidence for O<sub>3</sub> contribution to  
35 radiative forcing or effects on temperature, precipitation and related climate variables, including  
36 specifically uncertainties that limit quantitative evaluations that might inform consideration of

these effects (as discussed above). Based on all of the above considerations, we conclude that the currently available evidence and quantitative exposure/risk information does not call into question the protection afforded by the current secondary standard, such that it is appropriate to consider retaining the current standard without revision. In light of this conclusion, we have not identified any potential alternative standards for consideration.

## **4.6 KEY UNCERTAINTIES AND AREAS FOR FUTURE RESEARCH**

In this section, we highlight key uncertainties associated with reviewing and establishing the secondary O<sub>3</sub> standard and additionally recognize that research in these areas may additionally be informative to the development of more efficient and effective control strategies. The list in this section includes key uncertainties and data gaps thus far highlighted in this review of the secondary standard. Additional information in several areas would reduce uncertainty in our interpretation of the available information and, accordingly, reduce uncertainty in our characterization of O<sub>3</sub>-related welfare effects. For example, the items listed below generally include uncertainties associated with the extrapolation to plant species and environments outside of specific experimental or field study conditions and the assessment of ecosystem-scale impacts, such as structure and function. Additional E-R studies in different species or for responses other than reduced growth over multiple exposure conditions over growing seasons, that include details on exposure circumstances (e.g., hourly concentrations throughout the exposure), and exposure history, etc. would improve on and potentially expand characterizations of the potential for and magnitude of the identified vegetation effects under different seasonal exposures. Accordingly, in this section, we highlight areas for future welfare effects research, model development, and data collection activities to address these uncertainties and limitations in the current scientific evidence. These areas are similar to those highlighted in past reviews.

- While national visible foliar injury surveys have provided an extensive dataset on the incidence of such effects at sites across the country that experienced differing cumulative seasonal O<sub>3</sub> exposures and soil moisture conditions, there remain uncertainties in the current understanding of the relationship between seasonal O<sub>3</sub> exposures (and other influential factors, such as relative soil moisture) and the incidence and relative severity of visible foliar injury. Further research investigating the role of peak concentrations, in addition to cumulative seasonal exposures (particularly for W126 index values below 25 ppm ) is also needed to improve consideration of the occurrence and variability of higher hourly O<sub>3</sub> concentrations associated with vegetation effects. Research to better characterize the relationship between O<sub>3</sub>, soil moisture and foliar injury and specifically a quantifiable relationship between these (and any other influential) factors. Additionally, research would assist in interpreting connections between O<sub>3</sub>-related foliar injury and other physiological effects and ecosystem services. For example, research is needed on the extent and severity of visible foliar injury that might impact ecosystem services (e.g., tourism), and the extent of impact it might have.

- Additional controlled exposure studies of effects, such as biomass impacts, that include multiple exposure levels within the lower range of exposures associated with ambient air quality conditions common today, extend over multiple years, and include the collection of detailed O<sub>3</sub> concentration data over the exposure would reduce uncertainty in estimates of effects across multiple-year periods and at the O<sub>3</sub> exposures common today. Also needed is evaluation of such datasets with regard to the role of peak concentrations in combination with that of cumulative seasonal exposures (e.g., as quantified by metrics such as the W126 and SUM06 indices).
- Evidence newly available since the 2015 review includes studies on insect-plant interactions that have established some statistically significant effects, but the evidence is still limited with regard to discerning a pattern of responses in growth, reproduction, or mortality, and a directionality of responses for most effects. More research is needed to investigate the degree of response and directionalities of these relationships, and to investigate potential effects on pollination. The evidence is also limited with regard to the species represented (i.e., currently confined to three insect orders).
- Some evidence provides for linkages of effects on tree seedlings with larger trees and similarities in results between exposure techniques. Uncertainties remain in this area as well as uncertainties in extrapolating from O<sub>3</sub> effects on young trees (e.g., seedlings through a few years of age) to mature trees and from trees grown in the open versus those within the forest canopy.
- Uncertainties that remain in extrapolating individual plant response spatially or to higher levels of biological organization, including ecosystems, could be informed by research that explores and better quantifies the nature of the relationship between O<sub>3</sub>, plant response and multiple biotic and abiotic stressors, including those associated with the affected ecosystem services (e.g., hydrology, productivity, carbon sequestration).
- Other uncertainties are associated with estimates of the effects of O<sub>3</sub> on the ecosystem processes of water, carbon, and nutrient cycling, particularly at the stand and community levels. These below- and above-ground processes include interactions of roots with the soil or microorganisms, effects of O<sub>3</sub> on structural or functional components of soil food webs and potential impacts on plant species diversity, changes in the water use of sensitive trees, and if the sensitive tree species is dominant, potential changes to the hydrologic cycle at the watershed and landscape level. Research on competitive interactions under different O<sub>3</sub> exposures and any associated impacts on biodiversity or genetic diversity would improve current understanding.
- Uncertainties related to characterizing the potential public welfare significance of O<sub>3</sub>-induced effects and impacts to associated ecosystem services could also be informed by research. Research relating effects such as those on plant reproduction and propagation to effects on production of non-timber forest products, and research to characterize public preferences including valuation related to non-use and recreation for foliar injury, could also help inform consideration of the public welfare significance of these effects.



## 1 REFERENCES

- 2 Black, VJ, Stewart, CA, Roberts, JA and Black, CR (2012). Timing of exposure to ozone affects  
3 reproductive sensitivity and compensatory ability in *Brassica campestris*. *Environ Exp*  
4 *Bot* 75: 225-234.
- 5 Campbell, SJ, Wanek, R and Coulston, JW (2007). Ozone injury in west coast forests: 6 years of  
6 monitoring - Introduction. U.S. Department of Agriculture. Portland, OR.
- 7 Cordell, H, Betz, FM, Mou, S and Green, G (2008). How do Americans View Wilderness. A  
8 WILDERNESS Research Report in the Internet Research Information Series. Natinoal  
9 Survey on Recreation and the Environment. This research is a collaborative effort  
10 between the U.S. Department of Agriculture Forest Service's Southern Research Station  
11 and its Forestry Sciences Laboratory in Athens, Georgia; the University of Georgia in  
12 Athens; and the University in Tennessee in Knoxville, Tennessee. .
- 13 Costanza, R, De Groot, R, Braat, L, Kubiszewski, I, Fioramonti, L, Sutton, P, Farber, S and  
14 Grasso, M (2017). Twenty years of ecosystem services: How far have we come and how  
15 far do we still need to go? *Ecosyst Serv* 28: 1-16.
- 16 Cox, LA. (2020). Letter from Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
17 Committee, to Administrator Andrew R. Wheeler. Re: CASAC Review of the EPA's  
18 *Policy Assessment for the Review of the Ozone National Ambient Air Quality Standards*  
19 *(External Review Draft – October 2019)*. February 19, 2020. EPA-CASAC-20-003.  
20 Available at:  
21 [https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf)  
22 [D217BC07103485258515006359BA/\\$File/EPA-CASAC-20-003.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf).
- 23 Darbah, JNT, Kubiske, ME, Neilson, N, Oksanen, E, Vaapavuori, E and Karnosky, DF (2007).  
24 Impacts of elevated atmospheric CO<sub>2</sub> and O<sub>3</sub> on paper birch (*Betula papyrifera*):  
25 Reproductive fitness. *ScientificWorldJournal* 7: 240-246.
- 26 Darbah, JNT, Kubiske, ME, Nelson, N, Oksanen, E, Vapaavuori, E and Kamosky, DF (2008).  
27 Effects of decadal exposure to interacting elevated CO<sub>2</sub> and/or O<sub>3</sub> on paper birch  
28 (*Betula papyrifera*) reproduction. *Environ Pollut* 155(3): 446-452.
- 29 Davis, DD and Orendovici, T (2006). Incidence of ozone symptoms on vegetation within a  
30 National Wildlife Refuge in New Jersey, USA. *Environ Pollut* 143(3): 555-564.
- 31 Diaz-de-Quijano, M, Kefauver, S, Ogaya, R, Vollenweider, P, Ribas, À and Peñuelas, J (2016).  
32 Visible ozone-like injury, defoliation, and mortality in two *Pinus uncinata* stands in the  
33 Catalan Pyrenees (NE Spain). *Eur J Forest Res* 135(4): 687-696.
- 34 Dietze, MC and Moorcroft, PR (2011). Supplemental information 1: Tree mortality in the eastern  
35 and central United States: Patterns and drivers. *Global Change Biol* 17.
- 36 Duffney, PF, Brown, JS, and Stone, SL (2022). Memorandum to the Review of the Ozone  
37 National Ambient Air Quality Standards (NAAQS) Docket (EPA-HQ-ORD-2018-

- 0279). Re: Provisional Evaluation of Newly Identified Controlled Human Exposure Studies in the context of the 2020 Integrated Science Assessment for Ozone and Related Photochemical Oxidants. April 15, 2020.
- Frey, HC. (2014). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory Committee to Honorable Gina McCarthy, Administrator, US EPA. Re: CASAC Review of the EPA's Second Draft Policy Assessment for the Review of the Ozone National Ambient Air Quality Standards. June 26, 2014. EPA-CASAC-14-004. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100JR6F.txt>.
- Haefele, M, Kramer, RA and Holmes, TP (1991). Estimating the Total Value of a Forest Quality in High-Elevation Spruce-Fir Forests. The Economic Value of Wilderness: Proceedings of the Conference, Southeastern For Exper. Station. Asheville, NC, USDA Forest Service.
- Heck, WW and Cowling, EB (1997). The need for a long term cumulative secondary ozone standard - An ecological perspective. Environ Manager January: 23-33.
- Henderson, R. (2006). Letter from Dr. Rogene Henderson, Chair, Clean Air Scientific Advisory Committee to Honorable Stephen L. Johnson, Administrator, US EPA. Re: CASAC Peer Review of the Agency's 2nd Draft Ozone Staff Paper October 24, 2006. EPA-CASAC-07-001. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P1000WO7.txt>.
- Hildebrand, E, Skelly, JM and Fredericksen, TS (1996). Foliar response of ozone-sensitive hardwood tree species from 1991 to 1993 in the Shenandoah National Park, Virginia. Can J For Res 26(4): 658-669.
- Hogsett, WE, Weber, JE, Tingey, D, Herstrom, A, Lee, EH and Laurence, JA (1997). Environmental auditing: An approach for characterizing tropospheric ozone risk to forests. J Environ Manage 21(1): 105-120.
- King, JS, Kubiske, ME, Pregitzer, KS, Hendrey, GR, McDonald, EP, Giardina, CP, Quinn, VS and Karnosky, DF (2005). Tropospheric O<sub>3</sub> compromises net primary production in young stands of trembling aspen, paper birch and sugar maple in response to elevated atmospheric CO<sub>2</sub>. New Phytol 168(3): 623-635.
- Kohut, R (2007). Handbook for Assessment of Foliar Ozone Injury on Vegetation in the National Parks: Revised Second Edition. Kohut, R.
- Kubiske, ME, Quinn, VS, Heilman, WE, McDonald, EP, Marquardt, PE, Teclaw, RM, Friend, AL and Karnoskey, DF (2006). Interannual climatic variation mediates elevated CO<sub>2</sub> and O<sub>3</sub> effects on forest growth. Global Change Biol 12(6): 1054-1068.
- Kubiske, ME, Quinn, VS, Marquardt, PE and Karnosky, DF (2007). Effects of elevated atmospheric CO<sub>2</sub> and/or O<sub>3</sub> on intra- and interspecific competitive ability of aspen. Plant Biol 9(2): 342-355.

- Landesmann, JB, Gundel, PE, Martínez-Ghersa, MA and Ghersa, CM (2013). Ozone exposure of a weed community produces adaptive changes in seed populations of *Spergula arvensis*. PLoS ONE 8(9): e75820.
- Lee, EH and Hogsett, WE (1996). Methodology for calculating inputs for ozone secondary standard benefits analysis part II. Office of Air Quality Planning and Standards. Research Triangle Park, NC.
- Lefohn, A, Shadwick, D, Somerville, M, Chappelka, A, Lockaby, B and Meldahl, R (1992). The characterization and comparison of ozone exposure indices used in assessing the response of loblolly pine to ozone. Atmospheric Environment, Part A: General Topics 26(2): 287-298.
- Lefohn, AS, Jackson, W, Shadwick, DS and Knudsen, HP (1997). Effect of surface ozone exposures on vegetation grown in the southern Appalachian Mountains: Identification of possible areas of concern. Atmos Environ 31(11): 1695-1708.
- Luben, T, Lassiter, M and Herrick, J (2020). Memorandum to Ozone NAAQS Review Docket (EPA–HQ–ORD–2018–0279). RE: List of Studies Identified by Public Commenters That Have Been Provisionally Considered in the Context of the Conclusions of the 2020 Integrated Science Assessment for Ozone and Related Photochemical Oxidants. December 2020. Docket Document ID: EPA-HQ-OAR-2018-0279-0560.
- Moran, EV and Kubiske, ME (2013). Can elevated CO<sub>2</sub> and ozone shift the genetic composition of aspen (*Populus tremuloides*) stands? New Phytol 198(2): 466-475.
- Myhre, G, Shindell, D, Bréon, FM, Collins, W, Fuglestad, J, Huang, J, Koch, D, Lamarque, JF, Lee, D, Mendoza, B, Nakajima, T, Robock, A, Stephens, G, Takemura, T and Zhang, H, Eds. (2013). Anthropogenic and natural radiative forcing. Cambridge University Press Cambridge, UK.
- Oksanen, E and Holopainen, T (2001). Responses of two birch (*Betula pendula* Roth) clones to different ozone profiles with similar AOT40 exposure. Atmos Environ 35(31): 5245-5254.
- Rosenberger, RS, Bell, LA, Champ, PA and White, EM (2013). Estimating the economic value of recreation losses in Rocky Mountain National Park due to a mountain pine beetle outbreak. Western Economics Forum 12(1): 31-39.
- Samet, JM. (2010). Letter from Jonathan Samet, Chair, Clean Air Scientific Advisory Committee, to Administrator Lisa Jackson. Re: CASAC Review of EPA's Proposed Ozone National Ambient Air Quality Standard (Federal Register, Vol. 75, Nov. 11, January 19, 2010). . February 19, 2010. EPA-CASAC-10-007. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P10072T1.txt>.
- Smith, G (2012). Ambient ozone injury to forest plants in Northeast and North Central USA: 16 years of biomonitoring. Environ Monit Assess(184): 4049-4065.

- 1 Smith, G, Coulston, J, Jepsen, E and Prichard, T (2003). A national ozone biomonitoring  
2 program: Results from field surveys of ozone sensitive plants in northeastern forests  
3 (1994-2000). *Environ Monit Assess* 87(3): 271-291.
- 4 Smith, GC, Morin, RS and McCaskill, GL (2012). Ozone injury to forests across the Northeast  
5 and North Central United States, 1994-2010. General Technical Report NRS-103. United  
6 States Department of Agriculture, US Forest Service, Northern Research Station.
- 7 Smith, GC, Smith, WD and Coulston, JW (2007). Ozone bioindicator sampling and estimation.  
8 General Technical Report NRS-20. United States Department of Agriculture, US Forest  
9 Service, Northern Research Station.
- 10 Smith, JT and Murphy, D. (2015). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-  
11 OAR-2008-0699). Additional Observations from WREA Datasets for Visible Foliar  
12 Injury. September 24, 2015. Docket Document ID EPA-HQ-OAR-2008-0699-4250.  
13 Available at: <https://www.regulations.gov/document/EPA-HQ-OAR-2008-0699-4250>.
- 14 U.S. DHEW (1970). Air Quality Criteria for Photochemical Oxidants. National Air Pollution  
15 Control Administration, . Washington, DC. U.S. DHEW. publication no. AP-63. NTIS,  
16 Springfield, VA; PB-190262/BA.
- 17 U.S. EPA (1996). Air Quality Criteria for Ozone and Related Photochemical Oxidants. Volume I  
18 - III. Office of Research and Development Research Triangle Park, NC. U.S. EPA. EPA-  
19 600/P-93-004aF, EPA-600/P-93-004bF, EPA-600/P-93-004cF. July 1996. Available at:  
20 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=300026GN.txt>  
21 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=300026SH.txt>  
22 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=10004RHL.txt>.
- 23 U.S. EPA (2007). Review of the National Ambient Air Quality Standards for Ozone: Policy  
24 Assessment of Scientific and Technical Information: OAQPS Staff Paper. Office of Air  
25 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-07-  
26 003. January 2007. Available at:  
27 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P10083VX.txt>.
- 28 U.S. EPA (2018) Review of the Secondary Standards for Ecological Effects of Oxides of  
29 Nitrogen, Oxides of Sulfur, and Particulate Matter: Risk and Exposure Assessment  
30 Planning Document. Office of Air Quality Planning and Standards, Health and  
31 Environmental Impacts Division. Research Triangle Park, N.C. EPA-452/D-18-001.  
32 Available at: [https://www.epa.gov/naaqs/nitrogen-dioxide-no2-and-sulfur-dioxide-so2-](https://www.epa.gov/naaqs/nitrogen-dioxide-no2-and-sulfur-dioxide-so2-secondary-standards-planning-documents-current)  
33 [secondary-standards-planning-documents-current](https://www.epa.gov/naaqs/nitrogen-dioxide-no2-and-sulfur-dioxide-so2-secondary-standards-planning-documents-current).
- 34 U.S. Forest Service, NPS, and U.S. Fish and Wildlife Service (2010). Federal land managers' air  
35 quality related values work group (FLAG): phase I report—revised (2010). National Park  
36 Service, Denver, CO.
- 37 USFS (2013). Forest Inventory and Analysis: Fiscal Year 2012 Business Report. United States  
38 Department of Agriculture. [http://www.fia.fs.fed.us/library/bus-org-](http://www.fia.fs.fed.us/library/bus-org-documents/docs/FIA_Annual_Report_2013.pdf)  
39 [documents/docs/FIA\\_Annual\\_Report\\_2013.pdf](http://www.fia.fs.fed.us/library/bus-org-documents/docs/FIA_Annual_Report_2013.pdf).

- 1 USFS (2017). Forest Inventory and Analysis: Fiscal Year 2016 Business Report. United State  
2 Department of Agriculture.  
3 [https://www.fs.fed.us/sites/default/files/fs\\_media/fs\\_document/publication-15817-usda-](https://www.fs.fed.us/sites/default/files/fs_media/fs_document/publication-15817-usda-forest-service-fia-annual-report-508.pdf)  
4 [forest-service-fia-annual-report-508.pdf](https://www.fs.fed.us/sites/default/files/fs_media/fs_document/publication-15817-usda-forest-service-fia-annual-report-508.pdf).
- 5 van Goethem, TM, Azevedo, LB, van Zelm, R, Hayes, F, Ashmore, MR and Huijbregts, MA  
6 (2013). Plant species sensitivity distributions for ozone exposure. *Environ Pollut* 178: 1-  
7 6.
- 8 Wang, P, Baines, A, Lavine, M and Smith, G (2012). Modelling ozone injury to U.S. forests.  
9 *Environ Ecol Stat* 19(4): 461-472.
- 10 Wells, B. (2015). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-OAR-2008-0699).  
11 Expanded Comparison of Ozone Metrics Considered in the Current NAAQS Review.  
12 September 28, 2015. Docket Document Identifier EPA-HQ-OAR-2008-0699-0163.  
13 Available at: [https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-](https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-4325&contentType=pdf)  
14 [2008-0699-4325&contentType=pdf](https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-4325&contentType=pdf).
- 15 Wells, B (2020). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-OAR-2018-0279).  
16 Additional Analyses of Ozone Metrics Related to Consideration of the Ozone Secondary  
17 Standard. December 2020. Docket Document Identifier EPA-HQ-OAR-2018-0279-0557.
- 18 Yun, S-C and Laurence, JA (1999). The response of clones of *Populus tremuloides* differing in  
19 sensitivity to ozone in the field. *New Phytol* 141(3): 411-421.
- 20

## APPENDIX 2A

### ADDITIONAL DETAILS ON DATA ANALYSIS PRESENTED IN SECTION 2.4

#### TABLE OF CONTENTS

|  |      |
|--|------|
| 2A.1 Analyses of 8-Hour Concentrations ..... | 2A-2 |
| 2A.2 Analyses of 1-Hour Concentrations ..... | 2A-3 |

#### TABLE OF FIGURES

|   |      |
|---|------|
| Figure 2A-1. Boxplots comparing the distribution of MDA1 concentrations for 2000-2004 (red) to the distribution of MDA1 concentrations for 2016-2020 (blue), binned by the 8-hour design value at each monitoring site. The boxes represent the 25 <sup>th</sup> , 50 <sup>th</sup> and 75 <sup>th</sup> percentiles and the whiskers represent the 1 <sup>st</sup> and 99 <sup>th</sup> percentiles. Outlier values are represented by circles. .... | 2A-5 |
| Figure 2A-2. Map showing the average number of days with MDA1 $\geq$ 100 ppb, 2000-2004. ....   | 2A-7 |
| Figure 2A-3. Map showing the average number of days with MDA1 $\geq$ 100 ppb, 2016-2020. ....   | 2A-7 |
| Figure 2A-4. Number of days in 2018-2020 at each monitoring site with a MDA1 concentration greater than or equal to 100 ppb and an 8-hour design value less than 98 ppb. Sites with higher design values had more days, up to a maximum of 164 (at a site in southern CA). ....   | 2A-8 |

#### TABLE OF TABLES

|   |      |
|---|------|
| Table 2A-1. Summary of criteria describing the sites for which 8-hour metrics are presented in section 2.4 of main document. .... | 2A-3 |
| Table 2A-2. Summary statistics for MDA1 concentrations at sites with differing design values for 2018-2020. ....                  | 2A-4 |
| Table 2A-3. Summary statistics for MDA1 concentrations at differing design values for 2000-2004. ....                             | 2A-6 |
| Table 2A-4. Summary statistics for MDA1 concentrations at differing design values for 2016-2020. ....                             | 2A-6 |

## 2A.1 ANALYSES OF 8-HOUR CONCENTRATIONS

The analyses presented in section 2.4 of the main document are based on hourly O<sub>3</sub> concentration data from the EPA's Air Quality System (AQS) database (retrieved on August 12, 2021) for the years 2000 to 2020 for the sites meeting data completeness criteria as summarized in Table 2A-1 below. The daily maximum 8-hour (hr) average (MDA8) values, annual fourth highest MDA8 values, and design values (DVs) for the current standards were calculated according to Appendix U to 40 CFR Part 50. Those steps are generally as follows.

- 8-hr average concentrations are derived as the average of concentrations during eight consecutive hours for the:
  - o 8-hr periods which have at least six hourly concentrations;<sup>1</sup> and
  - o 8-hr periods which have fewer than six hourly concentrations and the sum of concentrations divided by eight, after truncation of the digits after the third decimal place, is greater than 0.070 parts per million (ppm)<sup>2</sup>
- The digits for the resultant 8-hr average concentration are truncated after the third decimal place.
- **MDA8 concentrations** are derived as the highest of the consecutive 8-hr averages beginning with the 8-hr period from 7am to 3pm and ending with the period from 11pm to 7am the following day for those days with:
  - o 8-hr concentrations for at least 13 of the 17 8-hr periods that begin with the 7am-to-3pm period and end with the 11pm-to-7am (next day) period, or
  - o 8-hr concentrations for fewer than 13 of the 17 8-hr periods if the maximum 8-hr concentration, after truncation of the digits after the third decimal place, is greater than 0.070 ppm.
- **Design Values** in ppm are derived as average of the annual 4<sup>th</sup> highest MDA8 concentrations in three consecutive years, with digits after the third decimal place truncated.
  - o Design values greater than 0.070 ppm are always considered valid.
  - o Design values less than or equal to 0.070 ppm must have MDA8 values for at least 90% of the days in the ozone monitoring season<sup>3</sup>, on average over the 3-year period, with a minimum of 75% of those days in any individual year.

---

<sup>1</sup> When there are at least six hours with a concentration reported, the 8-hr average is the average calculated using the number of hours with concentrations in the denominator.

<sup>2</sup> When there are fewer than six hours with a concentration reported, the 8-hr average is the average calculated using eight in the denominator and substituting zero for the missing hourly concentrations.

<sup>3</sup> Ozone monitoring seasons are defined for each State in Table D-2 of Appendix D to 40 CFR Part 58.

**Table 2A-1. Summary of criteria describing the sites for which 8-hour metrics are presented in section 2.4 of main document.**

| Presentation of 8-hour metrics in section 2.4 | Time Period | Data included  |
|---|-------------|--|
| Figure 2-8, DVs                               | 2018-2020   | Design values are presented for all sites with valid design values, which are sites having at least 75% data completeness in each of the three years and at least 90% completeness on average across the three years (per Appendix U)  |
| Figure 2-9, DVs                               | 2000-2020   |  |
| Figure 2-10, Trends                           | 1980-2020   | Annual fourth highest MDA8 values are based on all sites with at least 75% annual data completeness for at least 31 of the 41 years, with no more than two consecutive years having less than 75% complete data (n = 188 sites)  |
| Figure 2-11, Trends                           | 2000-2020   | Annual fourth highest MDA8 values are based on all sites with at least 75% annual data completeness for at least 16 of the 21 years, with no more than two consecutive years having less than 75% complete data (n = 822 sites)<br>Design values are presented for sites with valid DVs for at least 15 of the 19 3-year periods, with no more than two consecutive periods having invalid DVs (n = 658 sites) |
| Figure 2-12, Trends                           | 2000-2020   |  |
| Figure 2-13, Diurnal Patterns                 | 2015-2017   | All hourly concentrations are presented for 2015-2017 for these four monitoring sites  |
| Figure 2-14, Seasonal Pattern                 | 2015-2017   | All valid MDA8 values are presented for 2015-2017 for these four monitoring sites  |

## 2A.2 ANALYSES OF 1-HOUR CONCENTRATIONS

Figure 2-15 of Chapter 2 presents hourly concentrations available in AQS (at the time of the data query on August 12, 2021) from any site with such data during the 2018-2020 period. The daily maximum 1-hr (MDA1) values presented in section 2.4.5 and (summary statistics shown in Table 2A-2 below) were calculated according to Appendix H to 40 CFR Part 50 for all sites with valid 2018-2020 design values for the current 8-hour standards. Generally, MDA1 values are derived (as the maximum 1-hr concentration during a day) for days for which at least 18 hourly concentrations are available in AQS or for which at least one hourly concentration greater than 0.12 ppm has been reported in AQS. For this most recent design value period, the mean number of observations per site at or above 100 parts per billion (ppb) was well below one (0.22) for sites meeting the current standards compared to well above one (10.53) for sites not meeting the current standards.




**Table 2A-2. Summary statistics for MDA1 concentrations at sites with differing design values for 2018-2020.**

| Statistic  | Design Value (ppb) |           |           |            |
|--|--------------------|-----------|-----------|------------|
|  | 31-60              | 61-70     | 71-84     | 85-114     |
| Number of observations (obs)   | 261,302            | 554,712   | 164,988   | 27,958     |
| Number of sites  | 287                | 590       | 170       | 26         |
| 25 <sup>th</sup> percentile concentration (ppb)  | 34                 | 36        | 40        | 44         |
| Median concentration (ppb)   | 40                 | 44        | 48        | 57         |
| Mean concentration (ppb)   | 40.7               | 44.5      | 49.7      | 61.2       |
| 75 <sup>th</sup> percentile concentration (ppb)  | 48                 | 52        | 59        | 75         |
| 95 <sup>th</sup> percentile concentration (ppb)  | 58                 | 65        | 76        | 101        |
| 99 <sup>th</sup> percentile concentration (ppb)  | 67                 | 76        | 90        | 121        |
| # of obs (# of sites) $\geq$ 240 ppb   | 0 (0)              | 0 (0)     | 0 (0)     | 0 (0)      |
| # of obs (# of sites) $\geq$ 200 ppb   | 0 (0)              | 0 (0)     | 0 (0)     | 0 (0)      |
| # of obs (# of sites) $\geq$ 160 ppb   | 0 (0)              | 0 (0)     | 4 (4)     | 14 (6)     |
| # of obs (# of sites) $\geq$ 120 ppb   | 2 (2)              | 22 (17)   | 46 (29)   | 328 (21)   |
| # of obs (# of sites) $\geq$ 100 ppb   | 15 (12)            | 180 (112) | 526 (127) | 1,538 (26) |
| Mean # of obs $\geq$ 100 ppb per site <sup>A</sup>   | 0.05               | 0.31      | 3.09      | 59.15      |
| <sup>A</sup> This is the number of obs at or above 100 ppb divided by the number of sites in this bin (column). For the two lowest bins combined (i.e., all sites with a design value $\leq$ 70 ppb), the mean is 0.22 obs $\geq$ 100 ppb per site, and for the two highest bins combined (i.e., all sites with a design value $>$ 70 ppb), the mean is 10.53 obs $\geq$ 100 ppb per site. |                    |           |           |            |

The figures and tables presented below contain additional analyses based on the MDA1 concentrations for years 2000-2004 and 2016-2020. Figure 2A-1 compares the distribution of MDA1 concentrations for each 8-hour design value bin between the earlier (2000-2004; red boxes) and latter (2016-2020; blue boxes) periods. The comparison shows a slight upward shift in the mid-range concentrations for the highest ( $\geq$  85 ppb) and lowest ( $\leq$  60 ppb) DV bins, while the two middle bins show little change. The range between the 1<sup>st</sup> and 99<sup>th</sup> percentiles as represented by the whiskers shrinks slightly between the earlier and latter periods in all four bins. Finally, the very highest concentrations (shown as dots above the top whisker) are reduced in the two highest DV bins. This is also reflected in Table 2A-3 and Table 2A-4, which show summary statistics similar to Table 2A-2 for the 2000-2004 and 2016-2020 periods, respectively. These tables show, as might be expected, that sites with higher design values have a larger number of days with MDA1 values at or above 100 ppb than sites with lower design values. This statistic is over 35 times higher for sites not meeting the current standard compared to sites meeting the current standard in 2000-2004, and over 45 times higher in 2016-2020. Across the three design value periods in 2016 to 2020, sites not meeting the current standards have on average over 9 observations at or above 100 ppb per 3-year period, while the average for sites meeting the current standards is about 0.2.

Figure 2A-2 and Figure 2A-3 show maps of the average number of days where the MDA1 concentrations were greater than or equal to 100 ppb (also known as the D100 metric, see

Appendix 4F) for the 2000-2004 and 2016-2020 periods, respectively. These maps show that nearly all sites in the U.S. have seen a large reduction in the number of days with high MDA1 concentrations since the beginning of the century. This is also reflected in the final rows of Table 2A-3 and Table 2A-4, which indicate a decrease of 83% in the total number MDA1 values greater than or equal to 100 ppb between 2000-2004 and 2016-2020.




**Figure 2A-1. Boxplots comparing the distribution of MDA1 concentrations for 2000-2004 (red) to the distribution of MDA1 concentrations for 2016-2020 (blue), binned by the 8-hour design value at each monitoring site. The boxes represent the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles and the whiskers represent the 1<sup>st</sup> and 99<sup>th</sup> percentiles. Outlier values are represented by circles.**

**Table 2A-3. Summary statistics for MDA1 concentrations at differing design values for 2000-2004.**


| Statistic  | Design Value (ppb) |          |               |                |
|--|--------------------|----------|---------------|----------------|
|  | 35-60              | 61-70    | 71-84         | 85-131         |
| Number of observations (obs)   | 117,848            | 288,396  | 1,312,716     | 912,178        |
| Number of design values (DVs) <sup>A</sup>   | 130                | 313      | 1,518         | 1,151          |
| 25 <sup>th</sup> percentile concentration (ppb)  | 29                 | 35       | 37            | 39             |
| Median concentration (ppb)   | 36                 | 44       | 48            | 52             |
| Mean concentration (ppb)   | 36.5               | 44.3     | 49.3          | 54.8           |
| 75 <sup>th</sup> percentile concentration (ppb)  | 44                 | 53       | 60            | 68             |
| 95 <sup>th</sup> percentile concentration (ppb)  | 56                 | 68       | 79            | 95             |
| 99 <sup>th</sup> percentile concentration (ppb)  | 68                 | 79       | 94            | 116            |
| # of obs (# of DVs <sup>A</sup> ) ≥ 240 ppb  | 0 (0)              | 0 (0)    | 0 (0)         | 0 (0)          |
| # of obs (# of DVs <sup>A</sup> ) ≥ 200 ppb  | 0 (0)              | 0 (0)    | 0 (0)         | 4 (4)          |
| # of obs (# of DVs <sup>A</sup> ) ≥ 160 ppb  | 0 (0)              | 0 (0)    | 15 (12)       | 252 (100)      |
| # of obs (# of DVs <sup>A</sup> ) ≥ 120 ppb  | 0 (0)              | 8 (6)    | 623 (339)     | 7,203 (940)    |
| # of obs (# of DVs <sup>A</sup> ) ≥ 100 ppb  | 26 (16)            | 161 (87) | 7,078 (1,277) | 32,133 (1,151) |
| Mean # of obs ≥ 100 ppb per DV <sup>B</sup>  | 0.20               | 0.51     | 4.66          | 27.92          |
| <sup>A</sup> Since this table covers three design value periods, individual sites may be counted up to three times.  |                    |          |               |                |
| <sup>B</sup> This is the number of obs at or above 100 ppb divided by the number of site-DVs in this bin (column). For the two lowest bins combined (i.e., sites with a design value ≤ 70 ppb), the mean is 0.40 obs ≥ 100 ppb per site, and for the two highest bins combined (i.e., sites with a design value > 70 ppb), the mean is 14.69 obs ≥ 100 ppb per site. |                    |          |               |                |

**Table 2A-4. Summary statistics for MDA1 concentrations at differing design values for 2016-2020.**

| Statistic   | Design Value (ppb) |           |             |            |
|---|--------------------|-----------|-------------|------------|
|   | 29-60              | 61-70     | 71-84       | 85-114     |
| Number of observations (obs)  | 582,220            | 1,824,438 | 558,927     | 99,742     |
| Number of design values (DVs) <sup>A</sup>  | 637                | 1,969     | 579         | 93         |
| 25 <sup>th</sup> percentile concentration (ppb)   | 33                 | 37        | 39          | 45         |
| Median concentration (ppb)  | 40                 | 44        | 48          | 57         |
| Mean concentration (ppb)  | 40.6               | 44.8      | 49.2        | 60.6       |
| 75 <sup>th</sup> percentile concentration (ppb)   | 48                 | 53        | 59          | 74         |
| 95 <sup>th</sup> percentile concentration (ppb)   | 58                 | 65        | 76          | 99         |
| 99 <sup>th</sup> percentile concentration (ppb)   | 66                 | 75        | 89          | 118        |
| # of obs (# of DVs <sup>A</sup> ) ≥ 240 ppb   | 0 (0)              | 0 (0)     | 0 (0)       | 0 (0)      |
| # of obs (# of DVs <sup>A</sup> ) ≥ 200 ppb   | 0 (0)              | 0 (0)     | 0 (0)       | 0 (0)      |
| # of obs (# of DVs <sup>A</sup> ) ≥ 160 ppb   | 0 (0)              | 1 (1)     | 4 (4)       | 15 (7)     |
| # of obs (# of DVs <sup>A</sup> ) ≥ 120 ppb   | 8 (6)              | 51 (42)   | 101 (77)    | 904 (69)   |
| # of obs (# of DVs <sup>A</sup> ) ≥ 100 ppb   | 41 (32)            | 486 (335) | 1,591 (423) | 4,761 (93) |
| Mean # of obs ≥ 100 ppb per DV <sup>B</sup>   | 0.06               | 0.25      | 2.75        | 51.19      |
| <sup>A</sup> Since this table covers three design value periods, individual sites may be counted up to three times.   |                    |           |             |            |
| <sup>B</sup> This is the number of obs at or above 100 ppb divided by the number of site-DVs in this bin (column). For the two lowest bins combined (i.e., sites with a design value ≤ 70 ppb), the mean is 0.20 obs ≥ 100 ppb per site, and for the two highest bins combined (i.e., sites with a design value > 70 ppb), the mean is 9.45 obs ≥ 100 ppb per site. |                    |           |             |            |




**Figure 2A-2. Map showing the average number of days with MDA1  $\geq$  100 ppb, 2000-2004.**



**Figure 2A-3. Map showing the average number of days with MDA1  $\geq$  100 ppb, 2016-2020.**



Figure 2A-4 below shows the number of days in 2018-2020 with an MDA1 concentration at or above 100 ppb and 8-hour design values (similar to Figure 2-16), for all sites with a 2018-2020 design value less than 102 ppb. All sites meeting the current standard had seven or fewer (i.e., two or fewer per year) MDA1 values at or above 100 ppb, and all but eight sites meeting the current standard had three or fewer (i.e., one or fewer per year) MDA1 values at or above 100 ppb.



**Figure 2A-4. Number of days in 2018-2020 at each monitoring site with a MDA1 concentration greater than or equal to 100 ppb and an 8-hour design value less than 102 ppb. Sites with higher design values had more days, up to a maximum of 173 (at a site in southern CA with a design value of 114 ppb).**

## APPENDIX 2B

### ADDITIONAL DETAILS ON BACKGROUND OZONE MODELING AND ANALYSIS

#### TABLE OF CONTENTS

|  |       |
|--|-------|
| 2B.1 Photochemical Modeling Methodology .....  | 2B-2  |
| 2B.1.1 Modeling Platform Overview.....         | 2B-4  |
| 2B.1.2 Emissions Overview.....                 | 2B-5  |
| 2B1.2.1 Natural Emission Inventory .....       | 2B-3  |
| 2B1.2.2 Anthropogenic Emission Inventory ..... | 2B-4  |
| 2B.2 Evaluation.....                           | 2B-8  |
| 2B.3 International Contributions.....          | 2B-40 |
| References .....                               | 2B-44 |

#### TABLE OF FIGURES

|  |       |
|--|-------|
| Figure 2B-1. NOAA U.S. climate regions. ....   | 2B-9  |
| Figure 2B-2. (a) Normalized Mean Bias (%) and (b) Mean Bias (ppb) of maximum daily<br>average 8-hr ozone (MDA8) by NOAA climate region (y-axis) and by season<br>(x-axis) at AQS monitoring sites.. ....                   | 2B-17 |
| Figure 2B-3. NMB (a) and MB (b) of MDA8 O <sub>3</sub> greater than or equal to 60 ppb from the<br>12km resolution CONUS simulation by NOAA climate region (y-axis) and<br>by season (x-axis) at AQS monitoring sites..... | 2B-17 |
| Figure 2B-4. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km<br>resolution CONUS simulation for the Northeast region by season.. ....   | 2B-18 |
| Figure 2B-5. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km<br>resolution CONUS simulation for the Central region by season.. ....   | 2B-19 |
| Figure 2B-6. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km<br>resolution CONUS simulation for the EastNorthCentral region by season....   | 2B-20 |
| Figure 2B-7. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km<br>resolution CONUS simulation for the Southeast region by season. ....  | 2B-21 |
| Figure 2B-8. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km<br>resolution CONUS simulation for the South region by season. ....  | 2B-22 |
| Figure 2B-9. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km<br>resolution CONUS simulation for the Southwest region by season. ....  | 2B-23 |

|    |  |       |
|----|--|-------|
| 1  | Figure 2B-10. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km |       |
| 2  | resolution CONUS simulation for the WestNorthCentral region by season. .                           | 2B-24 |
| 3  | Figure 2B-11. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km |       |
| 4  | resolution CONUS simulation for the Northwest region by season. ....                               | 2B-25 |
| 5  | Figure 2B-12. Density scatter plots of observed versus predicted MDA8 O <sub>3</sub> from the 12km |       |
| 6  | resolution CONUS simulation for the West region by season. ....                                    | 2B-26 |
| 7  | Figure 2B-13. Mean Bias (ppb) from the 12km resolution CONUS simulation of MDA8 O <sub>3</sub>     |       |
| 8  | greater than or equal to 60 ppb over the period May through September 2016                         |       |
| 9  | at AQS and CASTNET monitoring sites in the continental U.S. modeling                               |       |
| 10 | domain.....  | 2B-27 |
| 11 | Figure 2B-14. Mean Error (ppb) from the 12km resolution CONUS simulation of MDA8 O <sub>3</sub>    |       |
| 12 | greater than or equal to 60 ppb over the period May through September 2016 at                      |       |
| 13 | AQS and CASTNET monitoring sites in the continental U.S. modeling domain.                          |       |
| 14 | .....  | 2B-27 |
| 15 | Figure 2B-15. NMB (%) from the 12km resolution CONUS simulation of MDA8 O <sub>3</sub> greater     |       |
| 16 | than or equal to 60 ppb over the period May through September 2016 at AQS                          |       |
| 17 | and CASTNET monitoring sites in the continental U.S. modeling domain. ..                           | 2B-28 |
| 18 | Figure 2B-16. NME (%) from the 12km resolution CONUS simulation of MDA8 O <sub>3</sub> greater     |       |
| 19 | than or equal to 60 ppb over the period May through September 2016 at AQS                          |       |
| 20 | and CASTNET monitoring sites in the continental U.S. modeling domain. ..                           | 2B-28 |
| 21 | Figure 2B-17. WOUDC sonde locations and sampling frequency used in evaluation of                   |       |
| 22 | hemispheric model simulation. ....   | 2B-29 |
| 23 | Figure 2B-18. WOUDC sonde releases averaged by release location over 2016; observations            |       |
| 24 | (left), predictions from the hemispheric CMAQ simulation (middle), ratio                           |       |
| 25 | (right). Observations are ordered with increasing latitude (South to North). .                     | 2B-30 |
| 26 | Figure 2B-19. WOUDC sonde releases averaged by day with a 20-point moving average;                 |       |
| 27 | observations (left), predictions from the hemispheric CMAQ simulation                              |       |
| 28 | (middle), ratio (right). ....  | 2B-31 |
| 29 | Figure 2B-20. WOUDC sonde releases averaged by release location over March, April, May             |       |
| 30 | in 2016; observations (left), predictions from the hemispheric CMAQ simulation                     |       |
| 31 | (middle), ratio (right). ....  | 2B-32 |
| 32 | Figure 2B-21. WOUDC sonde releases averaged by release location over June, July, August in         |       |
| 33 | 2016; observations (left), predictions from the hemispheric CMAQ simulation                        |       |
| 34 | (middle), ratio (right). ....  | 2B-33 |
| 35 | Figure 2B-22. OMI O <sub>3</sub> (OMPROFOZ v003, left) compared to simulated (hemispheric CMAQ     |       |
| 36 | simulation, center), and ratios (right) of vertical column densities for January                   |       |
| 37 | (top) and April (bottom).....  | 2B-34 |
| 38 | Figure 2B-23. OMI O <sub>3</sub> (OMPROFOZ v003, left) compared to simulated (hemispheric CMAQ     |       |
| 39 | simulation, center), and ratios (right) of vertical column densities for July (top),               |       |
| 40 | and October (bottom). ....   | 2B-35 |

|    |  |       |
|----|--|-------|
| 1  | Figure 2B-24. OMI Nitrogen Dioxide (OMNO2D_HR v003, left) compared to simulated                        |       |
| 2  | (hemispheric CMAQ simulation, center), and ratios (right) of vertical column                           |       |
| 3  | densities for January (top) and April (bottom). ....   | 2B-36 |
| 4  | Figure 2B-25. OMI Nitrogen Dioxide (OMNO2D_HR v003, left) compared to simulated                        |       |
| 5  | (hemispheric CMAQ simulation, center), and ratios (right) of vertical column                           |       |
| 6  | densities for July (top) and and October (bottom). ....  | 2B-37 |
| 7  | Figure 2B-26. OMI Formaldehyde (OMHCHO v003, left) compared to simulated (hemispheric                  |       |
| 8  | CMAQ simulation, center), and ratios (right) of vertical column densities for                          |       |
| 9  | January (top) and April (bottom). ....   | 2B-38 |
| 10 | Figure 2B-27. OMI Formaldehyde (OMHCHO v003, left) compared to simulated (hemispheric                  |       |
| 11 | CMAQ simulation, center), and ratios (right) of vertical column densities for                          |       |
| 12 | July (top), and October (bottom). ....   | 2B-39 |
| 13 | Figure 2B-28. Total predicted MDA8 O <sub>3</sub> and contributions (see legend) over time in the West |       |
| 14 | (top), and all East (bottom) averaged over all grid cells and days in the U.S. ....                    | 2B-41 |
| 15 | Figure 2B-29. International contribution (black line) to predicted MDA8 O <sub>3</sub> and components  |       |
| 16 | (see legend) over time in the West (top), and all East (bottom) averaged over                          |       |
| 17 | all grid cells and days in the U.S. ....   | 2B-42 |
| 18 | Figure 2B-30. International contribution (black line) to predicted MDA8 O <sub>3</sub> and components  |       |
| 19 | (see legend) over time averaged over all grid cells in the West at high elevation                      |       |
| 20 | (top), near-border sites (middle), and Low/Interior sites (bottom). ....                               | 2B-43 |

21

## 22 **TABLE OF TABLES**

|    |   |       |
|----|---|-------|
| 23 | Table 2B-1. Summary of 12km resolution CONUS CMAQ 2016 model performance            |       |
| 24 | statistics for MDA8 O <sub>3</sub> by NOAA climate region, by season and monitoring |       |
| 25 | Network. ....   | 2B-15 |

26

27

28

29



1 This appendix for the background ozone (O<sub>3</sub>) modeling and analysis, which presents the  
2 analysis that was also presented in Appendix 2B of the 2020 PA (and is virtually identical to that  
3 appendix), includes a description of the methodology for photochemical modeling, an evaluation  
4 of the modeling, and a more detailed analysis of the predicted contributions from international  
5 anthropogenic emissions. The methodology section includes a description of the modeling  
6 platform and emissions. The evaluation section includes comparisons against surface, sondes and  
7 satellite measurements. The international component analysis separately estimates O<sub>3</sub> impacts  
8 from China, India, Canada/Mexico, and global shipping at the hemispheric scale.

## 9 **2B.1 PHOTOCHEMICAL MODELING METHODOLOGY**

### 10 **2B.1.1 Modeling Platform Overview**

11 A multiscale modeling system is applied at both hemispheric and regional scales with  
12 consistent methodologies for emissions inputs, meteorological inputs, model chemistry, and  
13 photochemical models. Consistency across spatial scales reduces the number of assumptions that  
14 have to be made in integrating predictions from the global and the regional modeling. However,  
15 methodological consistency does not address sources of uncertainty associated with individual  
16 inputs used by the modeling system.

17 The modeling system uses one emission model, one meteorological model, and one  
18 chemical transport model. The meteorological model is the Weather Research and Forecasting  
19 model (WRF v3.8). The emissions model is the Sparse Matrix Operating Kernel for Emissions  
20 (SMOKE v4.5). The chemical transport model is the Community Multiscale Air Quality model  
21 (CMAQ) version 5.2.1 with the Carbon Bond mechanism (CB6r3) and the non-volatile aerosol  
22 option (AE6). Each of these models is applied at hemispheric and regional scales. The regional  
23 meteorology components of the modeling system are described in more detail in section 3C.4.1.4  
24 of Appendix 3C, while emissions inputs are summarized here.

25 The models identified above are configured differently for the hemispheric and regional  
26 scales as appropriate for the intended purpose. The hemispheric scale model uses a polar  
27 stereographic projection at 108 kilometer (km) resolution to completely and continuously cover  
28 the Northern Hemisphere. At the regional scale, the model employs a Lambert conic conformal  
29 projection at 36 km resolution to cover North America and at 12 km resolution to cover the  
30 lower 48 contiguous states. The hemispheric scale allows for long-range free tropospheric  
31 transport with 44 layers between the surface and 50 hPa (~20 km asl). The 36 km and 12 km  
32 regional modeling has 35 vertical layers between the surface and 50 hPa. The hemispheric  
33 modeling system was initiated on May 1, 2015 and run continuously through December 31,  
34 2016. The regional model was initialized using the hemispheric result on December 21, 2015 and  
35 run continuously through December 31, 2016.

## 2B.1.2 Emissions Overview

The emissions inventories are summarized here and more information is available in the Emissions Technical Support Documents (U.S. EPA, 2019a, U.S. EPA, 2019b) and in Appendix 3C. The emissions model inputs are discussed separately for natural and anthropogenic emissions. The stratospheric fluxes (section 2.5.1.1 of main document) are not discussed here because, although they are a source of ozone, they are not emissions. The regional inventories over North America are based on the Inventory Collaborative 2016 emissions modeling platform (<http://views.cira.colostate.edu/wiki/wiki/9169>), which was developed through the summer of 2019. Three versions of the 2016 inventory developed: “alpha” (also known as the 2016v7.1 platform) – which consisted of data closely related to the 2014 National Emissions Inventory (NEI) version 2 and 2016-specific data for some sectors; “beta” (also known as the 2016v7.2 platform) – which incorporated data from state and local agencies and adjustments to better represent the year 2016; and “version 1” (also known as the 2016v7.3 platform) – which has the completed representation of 2016 and some elements from the 2017 NEI. For any regional inventories, this analysis used the 2016 “alpha release” (specifically the modeling case abbreviated 2016fe) that is publicly available from <https://www.epa.gov/air-emissions-modeling/2016-alpha-platform>. Any changes in the 2016 “beta” or “version 1” platforms are not included in this modeling and therefore are not captured in the subsequent analysis.

### 2B.1.2.1 Natural Emission Inventory

The natural emission inventory databases cover all the sources discussed in section 2.5.1 except the International Anthropogenics. The databases that are available depend upon the scale. At the global scale, lightning NO<sub>x</sub> emissions are based on monthly climatological data; biogenic VOC emissions have hourly and day-specific (MEGAN v2.1, Guenther et al., 2012) temporal scales; soil NO<sub>x</sub> also has hourly and day-specific temporal scales (Berkeley Dalhousie Soil NO<sub>x</sub> Parameterization, as implemented by Hudman et al., 2012); and fire emissions are based on day-specific data (FINN v1.5, Wiedinmyer et al., 2011). Over our regional domain, regional inventories supersede the biogenic VOCs, soil NO<sub>x</sub>, and fire emissions using estimates consistent with the 2016 collaborative emissions modeling platform (<https://www.epa.gov/air-emissions-modeling/2016-alpha-platform>). The regional biogenic VOCs and soil NO<sub>x</sub> are derived from the Biogenic Emission Inventory System (BEIS v3.61). Of the natural inventories, only fires are expected to change significantly in future versions of the 2016 emissions platform. The biogenic VOC and NO<sub>x</sub> changes will be minor due to small changes to the land use data input to BEIS3.

Emissions of NO<sub>x</sub> are of particular importance to this study and the natural inventory is summarized here. The total natural NO<sub>x</sub> emissions<sup>4</sup> in this platform is 56 megatons NO<sub>x</sub> (reported as equivalent NO<sub>2</sub> mass) which is approximately 15.5 TgN. The contributors in order of magnitude are lightning (55%), soil (33%), and wildfires (12%). Lightning is treated as a climatological monthly mean contribution, while soils and wildfires are day-specific. It is important to note that outside North America, prescribed fires are not identified distinctly from wildfires. Therefore, all wildland fires outside North America are treated as natural. Though not directly comparable, the lightning and soil magnitudes are consistent with the ranges reported by (Lamarque et al., 2012). Consistent with previous regional modeling platforms, the lightning emissions are not included in the emissions inputs to the regional modeling platform. At the regional scale, the representation of lightning as a monthly mean rate would add lightning on days where it may not have occurred. At the hemispheric scale, omitting lightning would remove an important contribution to the well-mixed background O<sub>3</sub>.

#### **2B.1.2.2 Anthropogenic Emission Inventory**

Anthropogenic emissions inputs include both domestic and international sources. The domestic inventory includes a high-level of detail that is consistent with previous EPA emissions platforms such as those used to model the year 2011 (<https://www.epa.gov/air-emissions-modeling/2011-version-6-air-emissions-modeling-platforms>). For the hemispheric emissions modeling platform, there are over thirty anthropogenic sector of emission files. The traditional regional platform covers North America including the U.S. sectors, Canadian sectors, and Mexican sectors. In addition to the typical regional platform sectors, there are nine sectors based on the Hemispheric Transport of Air Pollution Version 2 (EDGAR-HTAPv2) inventory and 15 sectors that represent emissions in China which together comprise the anthropogenic emissions outside of North America. The international emission inventories are synthesized from the EDGAR-HTAP v2 harmonized emission inventory and country specific databases where updates were likely to be influential. Previous assessments like HTAP (2010, Phase 1) and HTAP (Phase 2) have shown that the anthropogenic portion of USB is most sensitive to emissions in Mexico, Canada, and China. For Mexico and Canada, the hemispheric platform relies on the same country-specific databases as the regional platform. For China, as mentioned above, the hemispheric platform uses a new country specific database. The sources are detailed further below.

The EDGAR-HTAP v2 inventories were projected to represent the year 2014. Projection factors were calculated from the Community Emissions Data System (CEDS) inventory at a

---

<sup>4</sup> We refer to wildfires and soil NO<sub>x</sub> as natural for the purposes of this section even though both may be impacted to various degrees by human activity.

country-sector level. This allowed our inventory to evolve without the risks associated with transitioning to a new inventory system. Especially because EDGAR-HTAP v2 is superseded for critical counties, this was the optimal approach. Details of scaling factor development are described in Section 2.1.5 of the 2016v7.1 Hemispheric Modeling Platform Technical Support Document (U.S. EPA, 2019a).

Emissions estimates over Mexico are a combination of emissions supplied by the Mexican government and emissions developed by the EPA. For the 2016 platform, emissions for point, nonpoint, and nonroad sources were developed based on projections of Secretariat of Environment and Natural Resources (SEMARNAT)-supplied data for the year 2008. For the onroad mobile sources, the EPA developed year-specific inventories for 2014 and 2017 by applying the MOVES-Mexico model and interpolating to the year 2016. More details are available in the 2016v7.1 emissions platform TSD (U.S. EPA, 2019b).

Emissions for Canada were supplied by Canadian agencies and reprocessed by the EPA for the domains and model years used in this analysis. Environment and Climate Change Canada (ECCC) supplied data for four broad inventory sectors (point, on-road mobile, fugitive dust, and area and non-road mobile sources, the latter including commercial marine vessels). The ECCC emissions were interpolated to 2016 based on inventories from the years 2013 and 2025.

The China emission inventory was developed at Tsinghua University (THU) and documented in Zhao et al., 2018 (see supplement). This inventory was extensively compared to the EDGAR-HTAP v2 and EDGAR v4.3 inventories before use. The largest differences for NO<sub>x</sub> in 2016 occurred in individual emissions sectors rather than inventory totals. The SO<sub>2</sub> emissions were more different than NO<sub>x</sub> emissions between the two inventories because the THU inventory applies controls to the metal industry that have been adopted by China. The difference between emissions, primarily NO<sub>x</sub> emissions, causes small decrease in the spring time surface O<sub>3</sub> over the U.S. compared to using EDGAR-HTAP v2. Comparisons of this update are summarized by Henderson et al.(2019).


Emissions for the United States representing the year 2016 were developed using the 2014 National Emissions Inventory version 2 (2014NEIv2) as the starting point, although emissions for some data categories were updated to better represent the year 2016. The point source emission inventories for the platform are partially updated to represent 2016. Because 2016 is not a year for which a full NEI is compiled, states are only required to submit emissions for their larger point sources. For units without 2016-specific emissions, the emissions were carried forward from the 2014 NEIv2. For electric generating units, 2016-specific Continuous Emissions Monitoring System (CEMS) data are used where the data can be matched to units in the NEI. Point and nonpoint oil and gas emissions were projected from 2014 to 2016 using factors based on historic production levels.

Other sectors are briefly summarized here and the reader is directed to the TSD for more details (U.S. EPA, 2019a). Agricultural and wildland (including prescribed) fire emissions were developed for the year 2016 using methods similar to those used to develop the 2014 NEI, except that the input data relied on nationally-available data sets and did not benefit from state-submitted data as are used for NEI year emissions. The assignment of wildland fires to wild or prescribed is a complex process that is documented in the regional platform emissions TSD (U.S. EPA, 2019b). Most area source sectors for this platform use unadjusted 2014 NEIv2 emissions estimates except for commercial marine vehicles (CMV), fertilizer emissions, oil and gas emissions, and onroad and nonroad mobile source emissions. For CMV, SO<sub>2</sub> emissions were updated to reflect new rules for the North American Emission Control Area (regulation 13.6.1 and appendix VII of MARPOL Annex VI) on sulfur emissions that took effect in the year 2015. For fertilizer ammonia emissions, a 2016-specific emissions inventory is used in this platform, while animal ammonia emissions were the same as those in 2014 NEIv2. Onroad and nonroad emissions were developed based on MOVES2014a outputs for the year 2016, and the activity data used to compute the onroad emissions were projected from 2014 to 2016 based on distinct state-specific factors for urban and rural roads. Emissions from 2014 NEIv2 were used directly for residential wood combustion, fugitive dust, and other nonpoint sources, although meteorological-based adjustments for dust sources and temporal allocation for residential wood and agricultural ammonia sources were based on 2016 meteorology. Additional details on the development of the U.S., Canada, and Mexico emissions are provided in the 2016v7.1 (U. S. EPA, 2019b).

## **2B.2 EVALUATION**

An operational model performance evaluation for O<sub>3</sub> was conducted for the 2016fe simulation (as referred to in Section 2.5.2.2) using monitoring data, ozone sonde data, and satellite data in order to estimate the ability of the CMAQv5.2.1 modeling system to replicate the 2016 base year O<sub>3</sub> concentrations for the 12 km continental U.S. domain and the 108 km Northern Hemispheric domain. The purpose of this evaluation is to examine the ability of the 2016 air quality modeling platform to represent the magnitude and spatial and temporal variability of measured (i.e., observed) O<sub>3</sub> concentrations within the modeling domain. The model evaluation for O<sub>3</sub> focuses on comparisons of model-predicted 8-hour daily maximum concentrations (MDA8) to the corresponding concentrations from monitoring data (for 2016) collected at monitoring sites in the AQS. The evaluation divided these data into two datasets, one limited to only CASTNET sites (described in section 2.3.1), and the second comprised of all other sites. We refer to this second dataset as “AQS.”

Included in the evaluation are statistical measures of model performance based upon model-predicted versus observed MDA8 O<sub>3</sub> concentrations that were paired in space and time. Statistics were generated for each of the nine National Oceanic and Atmospheric Administration (NOAA) climate regions of the 12-km U.S. modeling domain (Figure 2B-1). The regions include the Northeast, Central, EastNorthCentral, Southeast, South, Southwest, WestNorthCentral, Northwest and West as were originally identified in Karl and Koss (1984). Note that most monitoring sites in the West region are located in California, therefore statistics for the West will be mostly representative of California O<sub>3</sub> model performance.



Source: <http://www.ncdc.noaa.gov/monitoring-references/maps/us-climate-regions.php#references>

**Figure 2B-1. NOAA U.S. climate regions.**

For MDA8 O<sub>3</sub>, model performance statistics were calculated for each climate region by season and for the May through September O<sub>3</sub> season of 2016. Seasons were defined as: winter (December-January-February), spring (March-April-May), summer (June-July-August), and fall (September-October-November). Observational data were excluded from the analysis and model evaluations for sites that did not meet a 75% completeness criterion.<sup>5</sup> In addition to the performance statistics, several graphical presentations of model performance were prepared for MDA8 O<sub>3</sub> concentrations. These graphical presentations include:

<sup>5</sup> Each monitoring site had to have 75% of MDA8 values within any seasonal subset to be included in that subset. Thus individual monitors may be included in one evaluation of season, but not another.

- (1) density scatter plots of observations obtained from the AQS system excluding CASTNET (hereafter AQS) and predicted MDA8 O<sub>3</sub> concentrations for May through September;
- (2) regional maps that show the mean bias and error as well as normalized mean bias and error calculated for MDA8 ≥ 60 ppb for May through September at individual AQS and CASTNET monitoring sites;
- (3) tile plots that show normalized mean bias (%) and mean bias (ppb) of MDA8 and MDA8 ≥ 60 ppb by NOAA climate region (y-axis) and by season (x-axis) at AQS monitoring sites;
- (4) O<sub>3</sub> sonde evaluations comparing vertically resolved ozone model predictions to ozone sondes measurements from the World Ozone and Ultraviolet Data Centre (*woudc.org*).
- (5) satellite evaluation comparing simulated tropospheric vertical column densities of O<sub>3</sub>, nitrogen dioxide, and formaldehyde to OMI retrievals.

The Atmospheric Model Evaluation Tool (AMET) was used to calculate the model performance statistics used in this evaluation (Gilliam et al., 2005). For this evaluation of the O<sub>3</sub> predictions in the 2016fe CMAQ modeling platform, we have selected the mean bias, mean error, normalized mean bias, and normalized mean error to characterize model performance, statistics which are consistent with the recommendations in Simon et al. (2012) and the photochemical modeling guidance (U.S. EPA, 2018).

Mean bias (MB) is used as average of the difference (predicted – observed) divided by the total number of replicates (*n*). Mean bias is defined as:

$$MB = \frac{1}{n} \sum_1^n (P - O) , \text{ where } P = \text{predicted and } O = \text{observed concentrations for every site and day included in the evaluation.}$$

Mean error (ME) calculates the absolute value of the difference (predicted - observed) divided by the total number of replicates (*n*). Mean error is defined as:

$$ME = \frac{1}{n} \sum_1^n |P - O|$$

Normalized mean bias (NMB) is used as a normalization to facilitate a range of concentration magnitudes. This statistic averages the difference (predicted - observed) over the sum of observed values. NMB is a useful model performance indicator because it avoids overinflating the observed range of values, especially at low concentrations. Normalized mean bias is defined as:

$$\text{NMB} = \frac{\sum_{i=1}^n (P - O)}{\sum_{i=1}^n (O)} * 100, \text{ where } P = \text{predicted concentrations and } O = \text{observed}$$

Normalized mean error (NME) is also similar to NMB, where the performance statistic is used as a normalization of the mean error. NME calculates the absolute value of the difference (model - observed) over the sum of observed values. Normalized mean error is defined as

$$\text{NME} = \frac{\sum_{i=1}^n |P - O|}{\sum_{i=1}^n (O)} * 100$$

As described in more detail below, the model performance statistics indicate that the MDA8 O<sub>3</sub> concentrations predicted by the 2016 CMAQ modeling platform closely reflect the corresponding monitoring data-based MDA8 O<sub>3</sub> concentrations in space and time in each region of the U.S. modeling domain. The acceptability of model performance was judged for the 2016 CMAQ O<sub>3</sub> performance results considering the range of performance found in recent regional O<sub>3</sub> model applications (NRC, 2002; Phillips et al., 2008; Simon et al., 2012; U.S. EPA, 2009; U.S. EPA, 2018). These other modeling studies represent a wide range of modeling analyses that cover various models, model configurations, domains, years and/or episodes, chemical mechanisms, and aerosol modules. Overall, the 2016 CMAQ O<sub>3</sub> model performance results are within the range found in other recent peer-reviewed and regulatory applications. The model performance results, as described in this document, demonstrate the predictions from the 2016 modeling platform closely replicate the corresponding observed concentrations in terms of the magnitude, temporal fluctuations, and spatial differences for 8-hour daily maximum O<sub>3</sub>.

The model performance bias and error statistics for MDA8 O<sub>3</sub> predictions in each of the nine NOAA climate regions and each season are provided in Table 2B-1. As noted above, seasons were defined as: winter (December-January-February), spring (March-April-May), summer (June-July-August), and fall (September-October-November). As indicated by the statistics in Table 2-7, mean bias and error for 8-hour daily maximum O<sub>3</sub> are relatively low in each subregion, not only in the summer when concentrations are highest, but also during other times of the year. Generally, MB for MDA8 O<sub>3</sub> ≥ 60 ppb is less than ± 10 ppb. Generally, MDA8 O<sub>3</sub> at the AQS sites in the summer and fall is over predicted except in the Southwest, with the greatest over-prediction in the EastNorthCentral and WestNorthCentral. Likewise, MDA8 O<sub>3</sub> at the CASTNET sites in the summer and fall is typically over predicted except in the West, Southwest and WestNorthCentral where the bias shows an under-prediction. In the winter and spring,



MDA8 O<sub>3</sub> is under predicted at AQS and CASTNET sites in all the climate regions (with NMBs less than approximately  $\pm 25$  percent in each subregion).

Figure 2B-2 and Figure 2B-3 are tile plots that summarize to provide an overview of model performance by region and by season. Figure 2B-2 shows NMB (%) and MB (ppb) of MDA8 by NOAA climate region (y-axis) and by season (x-axis) at AQS monitoring sites. Likewise, Figure 2B-3 shows the NMB (%) and MB (ppb) of MDA8  $\geq 60$  ppb by NOAA climate region (y-axis) and by season (x-axis) at AQS monitoring sites. Figure 2B-2 shows that for the majority of the nine climate regions throughout each year the NMB is within  $\pm 10$  percent. There is greater over-prediction ( $< 20\%$ ) during the fall in the South, EastNorthCentral (*aka* Upper Midwest), and Central (*aka* Ohio Valley) regions and during the summer in the South, Southeast and Central (*aka* Ohio Valley) regions. However, there is greater under-prediction (up to 30 percent) during the winter in the Northwest, Southwest, WestNorthCentral (*aka* NRockiesPlains), EastNorthCentral (*aka* Upper Midwest), Central (*aka* Ohio Valley), and Northeast regions as well during the spring in the Northwest.

The density scatterplots in Figure 2B-4 to Figure 2B-12 provide a qualitative comparison of model-predicted and observed MDA8 O<sub>3</sub> concentrations for each climate region by season. In these plots the intensity of the colors indicates the density of individual observed/predicted paired values. The greatest number of individual paired values is denoted by locations in the plot denoted in warmer colors. The plots indicate that the predictions correspond closely to the observations in that a large number of observed/predicted paired values lie along or close to the 1:1 line shown on each plot. The model is more likely to over-predict the observed values at low and mid-range concentrations generally  $< 60$  ppb in each of the regions. There are some relatively infrequent very large over predictions at high concentrations. Preliminary review of these biases finds that some are related to fire impacts.

Spatial plots of the MB, ME, NMB and NME for individual monitors are shown in Figure 2B-13 through Figure 2B-16, respectively. The statistics shown in these two figures were calculated over the May through September period, using data pairs on days with observed 8-hr O<sub>3</sub> of greater than or equal to 60 ppb. Model bias at individual sites during the O<sub>3</sub> season is similar to that seen on a sub-regional basis for the summer. Figure 2B-13 shows the mean bias for 8-hr daily maximum O<sub>3</sub> greater than 60 ppb is under predicted overall, but generally within  $\pm 10$  ppb across the AQS and CASTNET sites. The greatest exceptions are most evident at certain near-coastal sites where, on average, the model over predicts MDA8 observed O<sub>3</sub>  $\geq 60$  ppb. Likewise, the information in Figure 2B-15 indicates that the normalized mean bias for days with observed 8-hr daily maximum O<sub>3</sub> greater than 60 ppb is within  $\pm 10\%$  at the vast majority of monitoring sites across the U.S. domain. Model error, as seen from Figure 2B-14 and Figure 2B-16, is generally 2 to 10 ppb and 20 percent or less at most of the sites across the U.S. modeling

1 domain. Somewhat greater error is evident at sites in several areas most notably in the West,  
2 WestNorthCentral, Northeast, EastNorthCentral, Southeast, and along portions of the Gulf Coast  
3 and Great Lakes coastlines.

4 Sonde evaluations are shown for the 108 km Northern Hemisphere domain in Figure 2B-  
5 18 through Figure 2B-21. The sondes used in this analysis and their release frequencies are  
6 shown in Figure 2B-17. Figure 2B-18 shows that the annual mean prediction is generally within  
7 20% of the measured sonde data, except for near the tropopause. Figure 2B-19 shows that the  
8 performance of all sites is generally not as good in the spring (March, April, May) than in the  
9 summer (June, July, August). The seasonal performance of each monitor is shown in Figure 2B-  
10 20 for spring and Figure 2B-21 for summer. By comparison, Figure 2B-20 shows that low biases  
11 extend deeper into the troposphere in spring than in summer. The structure of the bias seems to  
12 suggest a stratospheric causal mechanism because the bias is near the tropopause.

13 Satellite evaluations in this analysis include tropospheric vertical columns of O<sub>3</sub>, nitrogen  
14 dioxide (an ozone precursor as described in chapter 2), and formaldehyde (a VOC reaction  
15 product which is an indicator of VOCs and total reactivity of the atmosphere). At this time, only  
16 formaldehyde comparison includes the application of the scattering weights and air mass factor  
17 to the model, which are often used to create an averaging kernel. Similar processing for O<sub>3</sub> and  
18 NO<sub>2</sub> was not available at the time this appendix was completed. Satellite evaluations focus  
19 exclusively on the 108 km results over the Northern Hemisphere.

20 Simulated O<sub>3</sub> tropospheric vertical column densities are compared to the O<sub>3</sub> product  
21 described and evaluated by Huang et al. (2017). Figure 2B-22 and Figure 2B-23 compares the  
22 model to the retrieved column data without application of the averaging kernel. Omitting the  
23 averaging kernel introduces some error into the comparison (Huang et al., 2017; see Figure 9 for  
24 details). Even so, the comparison shows reasonable performance within the mid-latitudes. There  
25 is a notable low bias in January mid-latitudes and near the north pole in April. In addition, high  
26 biases are consistently seen near the corners of the domain in January and April. This cause of  
27 this high-bias pattern will require further analysis. Within the mid latitudes, the model is  
28 performing well with notable low biases in January and scattered high biases in Asia in July.  
29 Given the limitations of the comparison, the performance is quite good.


30 Simulated nitrogen dioxide (NO<sub>2</sub>) vertical columns are compared is the OMNO2d  
31 (Krotkov et al., 2017, as processed by Lok Lamsal called OMNO2D\_HR). Similar to O<sub>3</sub>, the  
32 averaging kernel is not being applied for NO<sub>2</sub>. Figure 2B-24 and Figure 2B-25 show larger  
33 relative biases for NO<sub>2</sub> than O<sub>3</sub>, particularly in low NO<sub>2</sub> regions like over the oceans. Best  
34 performance was over land during July. Model comparisons to NO<sub>2</sub> have commonly shown  
35 biases and research in the broader community continues to resolve this issue.

1            Formaldehyde retrieval comparisons are shown in Figure 2B-26 and Figure 2B-27 using  
2 the OMHCHO files, but using the recommended product described by González Abad et al.  
3 (2015). The formaldehyde retrievals show a seasonal cycle in the evaluation with a low bias for  
4 the northern-most retrievals in January and October. During April there are high biases that seem  
5 to migrate northward by July. Though we note this bias feature, the main result is reasonable  
6 spatial consistency between the satellite product and the model results. Future work should  
7 explore this evaluation further.  
8  
9


**Table 2B-1. Summary of 12km resolution CONUS CMAQ 2016 model performance statistics for MDA8 O<sub>3</sub> by NOAA climate region, by season and monitoring Network.**

| Climate region   | Monitor Network | Season | No. of Obs | MB (ppb) | ME (ppb) | NMB (%) | NME (%) |
|------------------|-----------------|--------|------------|----------|----------|---------|---------|
| Northeast        | AQS             | Winter | 11,462     | -5.9     | 6.9      | -18.1   | 21.2    |
|                  |                 | Spring | 15,701     | -4.3     | 6.7      | -9.8    | 15.2    |
|                  |                 | Summer | 16,686     | 4.6      | 7.7      | 10.0    | 17.0    |
|                  |                 | Fall   | 13,780     | 3.3      | 5.8      | 9.5     | 16.9    |
|                  | CASTNET         | Winter | 1,195      | -6.7     | 7.3      | -19.6   | 21.3    |
|                  |                 | Spring | 1,246      | -5.0     | 6.9      | -11.0   | 15.2    |
|                  |                 | Summer | 1,224      | 2.9      | 6.5      | 6.7     | 15.1    |
|                  |                 | Fall   | 1,215      | 3.4      | 5.6      | 9.9     | 16.5    |
| Central          | AQS             | Winter | 4,178      | -3.8     | 5.7      | -12.5   | 18.8    |
|                  |                 | Spring | 15,498     | -1.1     | 5.5      | -2.5    | 12.1    |
|                  |                 | Summer | 20,501     | 5.5      | 8.1      | 12.1    | 17.9    |
|                  |                 | Fall   | 14,041     | 4.9      | 6.1      | 12.6    | 15.7    |
|                  | CASTNET         | Winter | 1,574      | -3.1     | 5.4      | -9.6    | 16.3    |
|                  |                 | Spring | 1,600      | -2.2     | 5.5      | -4.8    | 12.0    |
|                  |                 | Summer | 1,551      | 3.9      | 7.1      | 9.0     | 16.2    |
|                  |                 | Fall   | 1,528      | 2.7      | 5.1      | 6.9     | 12.8    |
| EastNorthCentral | AQS             | Winter | 1,719      | -8.5     | 9.2      | -27.3   | 29.5    |
|                  |                 | Spring | 6,892      | -3.8     | 6.8      | -8.4    | 15.2    |
|                  |                 | Summer | 9,742      | 3.2      | 6.9      | 7.7     | 16.3    |
|                  |                 | Fall   | 6,050      | 5.6      | 3.4      | 17.6    | 20.2    |
|                  | CASTNET         | Winter | 435        | -9.6     | 10.1     | -28.6   | 30.1    |
|                  |                 | Spring | 434        | -6.5     | 7.8      | -14.4   | 17.4    |
|                  |                 | Summer | 412        | 0.2      | 5.5      | 0.5     | 13.4    |
|                  |                 | Fall   | 426        | 2.9      | 5.1      | 9.2     | 16.0    |
| Southeast        | AQS             | Winter | 7,196      | -1.4     | 5.0      | -3.9    | 14.0    |
|                  |                 | Spring | 14,569     | -1.5     | 5.3      | -3.2    | 11.3    |
|                  |                 | Summer | 15,855     | 5.1      | 7.1      | 12.9    | 17.9    |
|                  |                 | Fall   | 12,589     | 3.4      | 5.4      | 8.4     | 13.3    |
|                  | CASTNET         | Winter | 887        | -3.5     | 5.3      | -9.3    | 14.3    |
|                  |                 | Spring | 947        | -3.6     | 5.6      | -7.5    | 11.7    |
|                  |                 | Summer | 926        | 3.9      | 6.2      | 9.9     | 16.0    |
|                  |                 | Fall   | 928        | 1.7      | 5.0      | 4.0     | 11.9    |
| South            | AQS             | Winter | 11,342     | -1.0     | 5.0      | -3.1    | 15.0    |
|                  |                 | Spring | 13,093     | 1.3      | 6.1      | 2.8     | 13.9    |
|                  |                 | Summer | 12,819     | 6.0      | 7.8      | 15.7    | 20.4    |
|                  |                 | Fall   | 12,443     | 4.8      | 6.3      | 12.1    | 16.0    |


| Climate region   | Monitor Network | Season | No. of Obs | MB (ppb) | ME (ppb) | NMB (%) | NME (%) |
|------------------|-----------------|--------|------------|----------|----------|---------|---------|
|                  | CASTNET         | Winter | 516        | -1.7     | 5.0      | -4.8    | 13.7    |
|                  |                 | Spring | 532        | -1.2     | 5.6      | -2.6    | 12.3    |
|                  |                 | Summer | 508        | 2.6      | 6.1      | 6.7     | 15.8    |
|                  |                 | Fall   | 520        | 3.5      | 5.0      | 9.0     | 12.9    |
| Southwest        | AQS             | Winter | 9,695      | -4.2     | 6.2      | -11.0   | 16.1    |
|                  |                 | Spring | 10,608     | -4.8     | 6.5      | -9.4    | 12.7    |
|                  |                 | Summer | 10,549     | -1.2     | 6.0      | -2.3    | 11.2    |
|                  |                 | Fall   | 10,298     | 2.5      | 4.9      | 6.0     | 12.0    |
|                  | CASTNET         | Winter | 757        | -8.1     | 8.5      | -18.0   | 18.9    |
|                  |                 | Spring | 810        | -6.9     | 7.6      | -13.1   | 14.5    |
|                  |                 | Summer | 812        | -2.8     | 5.5      | -5.3    | 10.3    |
|                  |                 | Fall   | 791        | -0.1     | 3.6      | -0.3    | 8.3     |
| WestNorthCentral | AQS             | Winter | 4,740      | -9.3     | 9.6      | -24.9   | 25.9    |
|                  |                 | Spring | 5,066      | -3.1     | 5.9      | -7.2    | 13.5    |
|                  |                 | Summer | 5,134      | 0.7      | 4.9      | 1.4     | 10.6    |
|                  |                 | Fall   | 4,940      | 3.3      | 5.2      | 9.8     | 15.3    |
|                  | CASTNET         | Winter | 568        | -9.1     | 9.8      | -23.1   | 25.0    |
|                  |                 | Spring | 607        | -5.8     | 7.3      | -12.4   | 15.6    |
|                  |                 | Summer | 600        | -1.8     | 4.6      | -3.7    | 9.4     |
|                  |                 | Fall   | 505        | 1.7      | 4.8      | 4.4     | 12.8    |
| Northwest        | AQS             | Winter | 677        | -5.7     | 7.5      | -17.5   | 23.1    |
|                  |                 | Spring | 1,288      | -4.3     | 7.3      | -10.5   | 18.2    |
|                  |                 | Summer | 2,444      | 1.2      | 6.6      | 3.3     | 17.5    |
|                  |                 | Fall   | 1,236      | 2.8      | 5.9      | 9.0     | 18.7    |
|                  | CASTNET         | Winter | --         | --       | --       | --      | --      |
|                  |                 | Spring | --         | --       | --       | --      | --      |
|                  |                 | Summer | --         | --       | --       | --      | --      |
|                  |                 | Fall   | --         | --       | --       | --      | --      |
| West             | AQS             | Winter | 14,550     | -2.1     | 5.3      | -6.1    | 15.3    |
|                  |                 | Spring | 17,190     | -4.0     | 6.1      | -8.8    | 13.3    |
|                  |                 | Summer | 18,046     | 0.6      | 8.1      | 1.2     | 15.2    |
|                  |                 | Fall   | 16,163     | 0.4      | 5.5      | 0.9     | 12.8    |
|                  | CASTNET         | Winter | 506        | -3.4     | 5.6      | -8.7    | 14.1    |
|                  |                 | Spring | 519        | -5.7     | 6.6      | -11.8   | 13.7    |
|                  |                 | Summer | 526        | -5.3     | 8.1      | -8.7    | 13.3    |
|                  |                 | Fall   | 530        | -2.2     | 4.7      | -4.6    | 10.0    |



**Figure 2B-2. (a) Normalized Mean Bias (%) and (b) Mean Bias (ppb) of maximum daily average 8-hr ozone (MDA8) by NOAA climate region (y-axis) and by season (x-axis) at AQS monitoring sites.** In the text, alternative names are used: Ohio Valley is Central, Upper Midwest is EastNorthCentral, and NRockiesPlains is NorthWestCentral.




**Figure 2B-3. NMB (a) and MB (b) of MDA8 O<sub>3</sub> greater than or equal to 60 ppb from the 12km resolution CONUS simulation by NOAA climate region (y-axis) and by season (x-axis) at AQS monitoring sites.** Dark grey cells indicate missing values (i.e., no monitored days with MDA8  $\geq$  60 ppb in that region). In the text, alternative names are used: Ohio Valley is Central, Upper Midwest is EastNorthCentral, and NRockiesPlains is NorthWestCentral.




**Figure 2B-4. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the Northeast region by season.** Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.






5 **Figure 2B-5. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km**  
6 **resolution CONUS simulation for the Central region by season. Each plot has**  
7 **a separate scale that is shared for the x and y axes. The dashed line represents the**  
8 **best fit linear regression line.**







**Figure 2B-6. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the EastNorthCentral region by season.** Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.



**Figure 2B-7. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the Southeast region by season. Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.**




**Figure 2B-8. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the South region by season. Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.**




**Figure 2B-9. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the Southwest region by season.** Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.






**Figure 2B-10. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the WestNorthCentral region by season.** Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.




**Figure 2B-11. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the Northwest region by season. Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.**




**Figure 2B-12. Density scatter plots of observed versus predicted MDA8 O<sub>3</sub> from the 12km resolution CONUS simulation for the West region by season.** Each plot has a separate scale that is shared for the x and y axes. The dashed line represents the best fit linear regression line.






**Figure 2B-13. Mean Bias (ppb) from the 12km resolution CONUS simulation of MDA8 O<sub>3</sub> greater than or equal to 60 ppb over the period May through September 2016 at AQS and CASTNET monitoring sites in the continental U.S. modeling domain.**




**Figure 2B-14. Mean Error (ppb) from the 12km resolution CONUS simulation of MDA8 O<sub>3</sub> greater than or equal to 60 ppb over the period May through September 2016 at AQS and CASTNET monitoring sites in the continental U.S. modeling domain.**






**Figure 2B-15. NMB (%) from the 12km resolution CONUS simulation of MDA8 O<sub>3</sub> greater than or equal to 60 ppb over the period May through September 2016 at AQS and CASTNET monitoring sites in the continental U.S. modeling domain.**



**Figure 2B-16. NME (%) from the 12km resolution CONUS simulation of MDA8 O<sub>3</sub> greater than or equal to 60 ppb over the period May through September 2016 at AQS and CASTNET monitoring sites in the continental U.S. modeling domain.**



1 **Figure 2B-17. Woudc sonde locations and sampling frequency used in evaluation of**  
2 **hemispheric model simulation.**







Figure 2B-18. Woudc sonde releases averaged by release location over 2016; observations (left), predictions from the hemispheric CMAQ simulation (middle), ratio (right). Observations are ordered with increasing latitude (South to North).

1



2

3 **Figure 2B-19. Woudc sonde releases averaged by day with a 20-point moving average; observations (left), predictions from**  
 4 **the hemispheric CMAQ simulation (middle), ratio (right).**




Figure 2B-20. Woudc sonde releases averaged by release location over March, April, May in 2016; observations (left), predictions from the hemispheric CMAQ simulation (middle), ratio (right).








Figure 2B-21. Woudc sonde releases averaged by release location over June, July, August in 2016; observations (left), predictions from the hemispheric CMAQ simulation (middle), ratio (right).




**Figure 2B-22. OMI O<sub>3</sub> (OMPROFOZ v003, left) compared to simulated (hemispheric CMAQ simulation, center), and ratios (right) of vertical column densities for January (top) and April (bottom).**






**Figure 2B-23. OMI O<sub>3</sub> (OMPROFOZ v003, left) compared to simulated (hemispheric CMAQ simulation, center), and ratios (right) of vertical column densities for July (top), and October (bottom).**






**Figure 2B-24. OMI Nitrogen Dioxide (OMNO2D\_HR v003, left) compared to simulated (hemispheric CMAQ simulation, center), and ratios (right) of vertical column densities for January (top) and April (bottom).**






**Figure 2B-25. OMI Nitrogen Dioxide (OMNO2D\_HR v003, left) compared to simulated (hemispheric CMAQ simulation, center), and ratios (right) of vertical column densities for July (top) and and October (bottom).**





**Figure 2B-26. OMI Formaldehyde (OMHCHO v003, left) compared to simulated (hemispheric CMAQ simulation, center), and ratios (right) of vertical column densities for January (top) and April (bottom).**





**Figure 2B-27. OMI Formaldehyde (OMHCHO v003, left) compared to simulated (hemispheric CMAQ simulation, center), and ratios (right) of vertical column densities for July (top), and October (bottom).**

## 2B.3 INTERNATIONAL CONTRIBUTIONS


This section characterizes the components of predicted international anthropogenic contributions to local O<sub>3</sub> concentrations and the sensitivities to model resolution. The main characterization of predicted O<sub>3</sub> contributions focused on results, based on simulations at a 12 km grid cell resolution, that separated Natural, International, and USA contributions to O<sub>3</sub>. In this appendix, the International component is further characterized into some of its component parts. The component parts are only analyzed at the 108 km hemispheric resolution. First, the 108 km results are compared to the 12 km results to ensure general consistency to build confidence that, for large scale transport contributions, the 108 km characterization is relevant to the 12 km results.

Figure 2B-28 shows the 108 km modeling averaged to the West (<97W) and East (>97W), which can be compared to the 12 km results in the main body. The results from the two modeling resolution are very consistent with very high correlation coefficients ( $r$ ) for total O<sub>3</sub> ( $r_{\text{West}}=0.987$ ;  $r_{\text{East}}=0.989$ ), USA ( $r_{\text{West}}=0.987$ ;  $r_{\text{East}}=0.993$ ), International ( $r_{\text{West}}=0.981$ ;  $r_{\text{East}}=0.990$ ), and Natural ( $r_{\text{West}}=0.959$ ;  $r_{\text{East}}=0.814$ ). Within International, the Canada/Mexico component was separately estimated at both resolutions and agrees well for all grid cells ( $r_{\text{West}}=0.966$ ;  $r_{\text{East}}=0.935$ ), for high-elevation ( $r_{\text{West}}=0.961$ ,  $r_{\text{East}}=\text{N/A}$ ), and near-border ( $r_{\text{West}}=0.961$ ,  $r_{\text{East}}=0.947$ ). Since the coarser resolution model cannot resolve urban locations, the urban area weighted results have lower  $r$  (~0.8). While any particular grid cell may deviate due to local conditions, the averages across these large regions are quite consistent. The analysis is restricted to large scale averages when drawing conclusions from the 108 km analysis for the 12 km results.

Figure 2B-29 shows the predicted International contribution and some of its component parts: Canada/Mexico, China, India, and global shipping. This analysis did not attempt to quantify all International components separately, so the stacked bars generally account for only a portion of the total. However, the global shipping component of international is an overestimate as this sector includes some U.S. emissions. Global shipping includes O<sub>3</sub> produced within the U.S. Federal waters, which are also included in the USA contribution. As a result, the sum of components overstates shipping contributions to the total International contribution, but generally does not fully account for all components of the International contribution. The partial accounting is most obvious in the Winter and Spring when large-scale transport is most important. This suggests that during the summer, the selected components (China, India, Ships, Canada, Mexico) are a larger fraction of total International contribution. In both the East and the West, the International contribution peaks in Spring. The same seasonal signal can be seen for each International component except for Canada/Mexico. As a result, areas where

Canada/Mexico are more important will have a later peak of International than those influenced by the long-range components (e.g., India, China). The 108 km results cannot resolve the border well and will likely not fully capture the “near-border” effect.


Figure 2B-30 demonstrates the effect of International contribution on seasonality. Figure 2B-30 shows the West broken out into high-elevation, near-border, and Low/Interior sites. The near-border areas have a larger Canada/Mexico component. The combination of long-range sources and Canada/Mexico create a peak International contribution at near-border sites that is one to two months later than at high-elevation or Low/Interior sites. Note that “near-border” sites are not well resolved by the 108 km simulations.



Average across all grid cells derived as  $\bar{C} = \frac{1}{N_x} \sum_x C_x$




**Figure 2B-28. Total predicted MDA8 O<sub>3</sub> and contributions (see legend) over time in the West (top), and all East (bottom) averaged over all grid cells and days in the U.S.**





Average across all grid cells derived as  $\bar{C} = \frac{1}{N_x} \sum_x C_x$

**Figure 2B-29. International contribution (black line) to predicted MDA8 O<sub>3</sub> and components (see legend) over time in the West (top), and all East (bottom) averaged over all grid cells and days in the U.S.**



Average across all grid cells derived as  $\bar{C} = \frac{1}{N_x} \sum_x C_x$

**Figure 2B-30. International contribution (black line) to predicted MDA8 O<sub>3</sub> and components (see legend) over time averaged over all grid cells in the West at high elevation (top), near-border sites (middle), and Low/Interior sites (bottom).**



## REFERENCES

- Gilliam, RC, Appel, KW and Phillips, S (2005). The Atmospheric Model Evaluation Tool (AMET): Meteorology Module. 4th Annual CMAS Models-3 Users Conference.
- González Abad, G, Liu, X, Chance, K, Wang, H, Kurosu, TP and Suleiman, R (2015). Updated Smithsonian Astrophysical Observatory Ozone Monitoring Instrument (SAO OMI) formaldehyde retrieval. *Atmospheric Measurement Techniques* 8(1): 19-32.
- Guenther, AB, Jiang, X, Heald, CL, Sakulyanontvittaya, T, Duhl, T, Emmons, LK and Wang, X (2012). The Model of Emissions of Gases and Aerosols from Nature version 2.1 (MEGAN2.1): an extended and updated framework for modeling biogenic emissions. *Geosci Model Dev* 5(6): 1471-1492.
- Henderson, BH, Dolwick, PD, Jang, CJ, Eyth, A, Vukovich, J, Mathur, R, Hogrefe, C, Pouliot, G, Possiel, N, Timin, B and Appel, W (2019). Meteorological and Emission Sensitivity of Hemispheric Ozone and PM<sub>2.5</sub>. 9th International GEOS-Chem Conference Boston, MA.
- Huang, G, Liu, X, Chance, K, Yang, K, Bhartia, PK, Cai, Z, Allaart, M, Ancellet, G, Calpini, B, Coetzee, GJR, Cuevas-Agulló, E, Cupeiro, M, De Backer, H, Dubey, MK, Fuelberg, HE, Fujiwara, M, Godin-Beekmann, S, Hall, TJ, Johnson, B, Joseph, E, Kivi, R, Kois, B, Komala, N, König-Langlo, G, Laneve, G, Leblanc, T, Marchand, M, Minschwaner, KR, Morris, G, Newchurch, MJ, Ogino, S-Y, Ohkawara, N, Piters, AJM, Posny, F, Querel, R, Scheele, R, Schmidlin, FJ, Schnell, RC, Schrems, O, Selkirk, H, Shiotani, M, Skrivánková, P, Stübi, R, Taha, G, Tarasick, DW, Thompson, AM, Thouret, V, Tully, MB, Van Malderen, R, Vömel, H, von der Gathen, P, Witte, JC and Yela, M (2017). Validation of 10-year SAO OMI Ozone Profile (PROFOZ) product using ozonesonde observations. *Atmospheric Measurement Techniques* 10(7): 2455-2475.
- Hudman, RC, Moore, NE, Mebust, AK, Martin, RV, Russell, AR, Valin, LC and Cohen, RC (2012). Steps towards a mechanistic model of global soil nitric oxide emissions: implementation and space based-constraints. *Atmos Chem Phys* 12(16): 7779-7795.
- Karl, T and Koss, WJ (1984). Regional and national monthly, seasonal, and annual temperature weighted by area, 1895-1983. 4-3. National Environmental Satellite and Data Information Service (NESDIS). Asheville, NC.
- Krotkov, NA, Lamsal, LN, Celarier, EA, Swartz, WH, Marchenko, SV, Bucsela, EJ, Chan, KL and Wenig, M (2017). The version 3 OMI NO<sub>2</sub> standard product. *Atmospheric Measurement Techniques Discussions*: 1-42.
- Lamarque, J-F, Emmons, LK, Hess, PG, Kinnison, DE, Tilmes, S, Vitt, F, Heald, CL, Holland, EA, Lauritzen, PH, Neu, J, Orlando, JJ, Rasch, PJ and Tyndall, GK (2012). CAM-chem: description and evaluation of interactive atmospheric chemistry in the Community Earth System Model. *Geosci Model Dev* 5(2): 369-411.

- 1 NRC (2002). *National Research Council Committee on Estimating the Health-Risk-Reduction*  
2 *Benefits of Proposed Air Pollution Regulations*. National Academies Press (US).  
3 Washington (DC).
- 4 Phillips, S, Wang, K, Jang, C, Possiel, N, Strum, M and Fox, T (2008). Evaluation of 2002  
5 Multi-pollutant Platform: Air Toxics, Ozone, and Particulate Matter. 7th Annual CMAS  
6 Conference.
- 7 Simon, H, Baker, KR and Phillips, S (2012). Compilation and interpretation of photochemical  
8 model performance statistics published between 2006 and 2012. *Atmos Environ* 61: 124-  
9 139.
- 10 U.S. EPA (2009). Technical Support Document for the Proposal to Designate an Emissions  
11 Control Area for Nitrogen Oxides, Sulfur Oxides, and Particulate Matter. U.S.  
12 Environmental Protection Agency. Research Triangle Park, NC. U.S. EPA. EPA-420-R-  
13 007. Available at: <http://www.epa.gov/otaq/regs/nonroad/marine/ci/420r09007.pdf>.
- 14 U.S. EPA (2018). Modeling Guidance for Demonstrating Attainment of Air Quality Goals for  
15 Ozone, PM<sub>2.5</sub>, and Regional Haze. U.S. Environmental Protection Agency. Research  
16 Triangle Park, NC. EPA 454/R-18-009. Available at:  
17 [https://www3.epa.gov/ttn/scram/guidance/guide/O3-PM-RH-Modeling\\_Guidance-](https://www3.epa.gov/ttn/scram/guidance/guide/O3-PM-RH-Modeling_Guidance-2018.pdf)  
18 [2018.pdf](https://www3.epa.gov/ttn/scram/guidance/guide/O3-PM-RH-Modeling_Guidance-2018.pdf).
- 19 U.S. EPA (2019a). Technical Support Document: Preparation of Emissions Inventories for the  
20 Version 7.1 2016 Hemispheric Emissions Modeling Platform. Office of Air Quality  
21 Planning and Standards, U.S. Environmental Protection Agency. Research Triangle Park,  
22 NC. Available at: [https://www.epa.gov/sites/production/files/2019-](https://www.epa.gov/sites/production/files/2019-12/documents/2016fe_hemispheric_tsd.pdf)  
23 [12/documents/2016fe\\_hemispheric\\_tsd.pdf](https://www.epa.gov/sites/production/files/2019-12/documents/2016fe_hemispheric_tsd.pdf).
- 24 U.S. EPA (2019b). Technical Support Document: Preparation of Emissions Inventories for the  
25 Version 7.1 2016 North American Emissions Modeling Platform. Office of Air Quality  
26 Planning and Standards, U.S. Environmental Protection Agency. Research Triangle Park,  
27 NC. Available at: [https://www.epa.gov/sites/production/files/2019-](https://www.epa.gov/sites/production/files/2019-08/documents/2016v7.1_northamerican_emismod_tsd.pdf)  
28 [08/documents/2016v7.1\\_northamerican\\_emismod\\_tsd.pdf](https://www.epa.gov/sites/production/files/2019-08/documents/2016v7.1_northamerican_emismod_tsd.pdf).
- 29 Wiedinmyer, C, Akagi, SK, Yokelson, RJ, Emmons, LK, Al-Saadi, JA, Orlando, JJ and Soja, AJ  
30 (2011). The Fire INventory from NCAR (FINN): a high resolution global model to  
31 estimate the emissions from open burning. *Geosci Model Dev* 4(3): 625-641.
- 32 Zhao, B, Zheng, H, Wang, S, Smith, KR, Lu, X, Aunan, K, Gu, Y, Wang, Y, Ding, D, Xing, J,  
33 Fu, X, Yang, X, Liou, K-N and Hao, J (2018). Change in household fuels dominates the  
34 decrease in PM<sub>2.5</sub> exposure and premature mortality in China in 2005–2015. *Proc Natl*  
35 *Acad Sci USA* 115(49): 12401-12406.  
36

**APPENDIX 3A**

**DETAILS ON CONTROLLED HUMAN EXPOSURE  
STUDIES**

### 3A.1. OVERVIEW

This appendix gives further study-specific details of the range of respiratory effects (with a particular focus on pulmonary function) in controlled human O<sub>3</sub> exposures during exercise. In these studies, the magnitude or severity of the respiratory effects induced by O<sub>3</sub> was influenced by ventilation rate, exposure duration, and exposure concentration. Because ventilation rates increase with increased physical activity level, the exposure concentrations eliciting a significant response in exercising subjects are lower than in subjects exposed while at rest (ISA, Appendix 3, section 3.1.4.2.1).

Table 3A-1 presents the O<sub>3</sub> induced change in forced expiratory volume in one second (FEV<sub>1</sub>) in 6.6 to 8-hour controlled human exposure studies (involving quasi-continuous or intermittent exercise). The FEV<sub>1</sub> values presented are derived by subtracting the percent changes in mean FEV<sub>1</sub> in response to filtered air exposure with exercise from the corresponding percent changes in FEV<sub>1</sub> in response to O<sub>3</sub> exposure with exercise. The controlled human exposure studies presented involve exposures, with intermittent exercise, of duration 6 to 8 hours and target exposure concentrations ranging from 0.04 to 0.16 ppm O<sub>3</sub>. Study design variables are also described in Table 3A-1 and include mode of exposure (chamber or facemask), whether the exposure concentration is constant or varying, exposure duration, exercise duration, and minute ventilation rate normalized by body surface area during exercise (equivalent ventilation rate,<sup>1</sup> or EVR). Table 3A-2 provides further details of individual study design protocols and subject characteristics for the studies summarized in Table 3A-1.

Table 3A-3 summarizes studies of controlled human exposure to O<sub>3</sub> for shorter durations (1 to 3 hours) during continuous or intermittent exercise in contrast to similar exposure durations at rest. The table presents reported effects related to pulmonary function, airway responsiveness, respiratory symptoms, inflammation and/or host defense. Key study design variables are also described and include exposure concentrations (ranging from 0.07 to 0.40 ppm O<sub>3</sub> for studies during exercise and 0.10 to 1.00 ppm for studies of subjects at rest), ventilation characteristics during exercise and subject characteristics (sex and health status). This table was adapted from Tables 7-1, 7-2 and 7-10 in the 1996 AQCD (U.S. EPA, 1996) and Table AX6-1 in the 2006 AQCD (U.S. EPA, 2006), with additional studies from Tables AX6-8 through AX6-13 in the 2006 AQCD, as well as more recent studies from the 2013 ISA (U.S. EPA, 2013) and 2020 ISA (U.S. EPA, 2020).

---

<sup>1</sup> The EVR is derived by dividing the minute ventilation rate ( $\dot{V}_E$  in L/min) by body surface area in m<sup>2</sup>. Values reflect the study mean EVR across the six exercise periods except for R11, as described below.

1 **Table 3A-1. Cross-study comparison of mean O<sub>3</sub>-induced FEV<sub>1</sub> decrements in 6.6 to 8-**  
2 **hour controlled human exposure studies (that include periods of exercise).**

| Exposure Design <sup>C</sup>  |                        | Ref <sup>D</sup>    | EVR <sup>E</sup><br>(L/min<br>-m <sup>2</sup> ) | ΔFEV <sub>1</sub> <sup>A, B</sup> (%)   |        |        |         |       |                      |         |       |
|---|------------------------|---------------------|---|---|--------|--------|---------|-------|----------------------|---------|-------|
|   |                        |                     |   | Average Target Ozone Concentration During Exercise Periods (ppm) <sup>F</sup> |        |        |         |       |                      |         |       |
|   |                        |                     |   | 0.04  | 0.06   | 0.07   | 0.08    | 0.087 | 0.10                 | 0.12    | 0.16  |
| <b>6.6 Hour Chamber:</b> Six 50-min exercise periods, each followed by 10 min rest; 35 min rest-lunch after 3rd hour.   | [constant]             | R1                  | 20  |   | -2.85* |        | -6.06*  |       |                      |         |       |
|   |                        | R2                  | 20  |   | -1.71* |        | -3.46*  |       |                      |         |       |
|   |                        | R3                  | 20  |   |        |        | -7.45*  |       | -8.45*               | -13.14* |       |
|   |                        | R4                  | 20  |   |        |        | -6.17*  |       |                      |         |       |
|   |                        | R5                  | 19  |   |        |        |         |       |                      | -15.65* |       |
|   |                        | R6                  | 22  |   |        |        |         |       |                      | -14.92* |       |
|   |                        | R7                  | 20  |   |        |        | -7.71*  |       | -13.88* <sup>G</sup> |         |       |
|   |                        | R8                  | 20  |   |        |        |         |       |                      | -12.79* |       |
|   | [varying]              | R1                  | 20  | -0.17   | -2.78  |        | -6.99*  |       |                      |         |       |
| R4  |                        | 20                  |   |   |        | -5.77* |         |       |                      |         |       |
| R9  |                        | 20                  |   | -3.52   | -6.14* | -7.82* | -12.23* |       |                      |         |       |
| <b>6.6 Hour with 6-hour facemask exposure:</b> Six 60-min periods each consisting of 50 min of exercise and 10 min of rest, each followed by 3 min testing period without exposure; 24 min lunch without exposure after 3rd hour. | [constant]             | R4                  | 20  |   |        |        | -6.14*  |       |                      |         |       |
|   |                        | R5                  | 20  | -1.24   |        |        | -6.35*  |       |                      | -15.41* |       |
|   |                        | R10                 | 17  |   |        |        |         |       |                      | -11.28* |       |
|   |                        | R10                 | 20  |   |        |        |         |       |                      | -13.69* |       |
|   |                        | R10                 | 23  |   |        |        |         |       |                      | -15.88* |       |
|   |                        | R11                 | 18 <sup>#</sup>                                 |   |        |        |         |       |                      | -11.00* |       |
|   | R11                    | 20 <sup>15-23</sup> |   |   |        |        |         |       | -13.68*              |         |       |
|   | [varying]              | R4                  | 20  |   |        |        | -5.45*  |       |                      |         |       |
|   |                        | R11                 | 10 <sup>9-12</sup>                              |   |        |        | 0.80    |       |                      |         |       |
|   |                        | R11                 | 12 <sup>7-11</sup>                              |   |        |        |         |       |                      | -3.50   |       |
|   |                        | R11                 | 18 <sup>#, X</sup>                              |   |        |        |         |       |                      | -13.96* |       |
| R11   |                        | 18 <sup>#, Y</sup>  |   |   |        |        |         |       | -10.31*              |         |       |
| <b>7.6 Hour Chamber:</b> additional hour onto 6.6 hr protocol above.  | [constant]             | R12                 | 15  |   |        |        |         |       |                      |         | -9.8* |
|   |                        | R12 <sup>As</sup>   | 14  |   |        |        |         |       |                      |         |       |
| <b>8-Hour Chamber:</b> Eight 30-min exercise periods, each followed by 30 min rest  | [constant]             | R13                 | 20  |   |        |        |         |       |                      | -8.13*  |       |
|   |                        | R14                 | 20  |   |        |        |         |       |                      | -4.07*  |       |
|   | [varying] <sup>T</sup> | R13                 | 20  |   |        |        |         |       |                      | -6.73*  |       |
|   |                        | R14                 | 20  |   |        |        |         |       |                      | -5.62*  |       |

<sup>A</sup> Values reflect O<sub>3</sub>-induced percent change in FEV<sub>1</sub> at the group mean level, based on subtraction of the filtered air percent change (post-pre exposure) from the O<sub>3</sub> % change in FEV<sub>1</sub>. For studies R1, R2, R4, R5 and R9,  $\Delta$ FEV<sub>1</sub> values were calculated from individual subject data provided by author.  $\Delta$ FEV<sub>1</sub> values for R3, R6, R12 were calculated from individual subject data in publication; R7, R8, R10, R11, R13 and R14  $\Delta$ FEV<sub>1</sub> values were derived from group mean response provided in publication. Statistically significant findings are indicated by asterisk (\*). A lack of statistical testing is indicated by (^). Unless indicated otherwise, all studies were in healthy adults.

<sup>B</sup> In addition to  $\Delta$ FEV<sub>1</sub>, some studies reported respiratory symptoms scores (e.g. cough and pain on deep inspiration). The exposures with statistically significant increase in respiratory symptoms scores are indicated by orange shading (■). Blue shading (■) indicates symptom scores that were not statistically significant from filtered air.

<sup>C</sup> Exposure designs with nonvarying exposure concentrations are indicated by [constant], while studies involving different O<sub>3</sub> concentrations for different periods of exposures are indicated by [varying]. [varying]<sup>T</sup> denotes triangular wave exposure concentrations (0.07 ppm->0.16 ppm->0.10 ppm). Further details on concentrations are provided in Table 3A-2.

<sup>D</sup> R1=Adams (2006b) and Brown et al. (2008); R2=Kim et al. (2011) and McDonnell et al., 2012; R3=Horstman et al. (1990); R4=Adams (2003); R5=Adams (2002); R6=Folinsbee et al. (1988); R7=McDonnell et al. (1991); R8=Folinsbee et al. (1994); R9=Schelegle et al. (2009). R10=Adams (2000); R11=Adams and Ollison (1997); R12=Horstman et al. (1995). R12<sup>As</sup> refers to subjects with asthma; R13=Adams (2006a); R14=Hazucha et al. (1992).

<sup>E</sup> The average mean EVR during exercise periods (calculated from study-reported information, see also Table 3A-2).

# indicates value derived as average of reported mean hourly EVR (which included 50 minutes exercise and 10 minutes rest) (although study protocol indicated EVR of 20 L/min-m<sup>2</sup>).

<sup>15-23</sup> indicates hourly ventilation rate varied from 15-23 L/min-m<sup>2</sup>; value presented is the average mean EVR across the entire experimental period (including both exercise and rest periods).

<sup>9-12</sup> indicates hourly ventilation rate varied from 9-12 L/min-m<sup>2</sup>; value presented is average mean EVR across the entire experimental period (including both exercise and rest periods).

<sup>7-11</sup> indicates hourly ventilation rate varied from 7-11 L/min-m<sup>2</sup>; value presented is the average mean EVR across the entire experimental period (including both exercise and rest periods).

<sup>x</sup> and <sup>y</sup> refer to two different varying concentration protocols (Details on concentrations are provided in Table 3A-2.)

<sup>F</sup> Author's target for average O<sub>3</sub> concentrations across the six exercise periods. This differs from the time-weighted average concentration (based on target or measurements) for full exposure period. For example, as shown in Table 3A-2 in chamber studies implementing a varying concentration protocol with targets of 0.03, 0.07, 0.10, 0.15, 0.08 and 0.05 ppm, the exercise period average concentration is 0.08 ppm while the TWA for the full exposure period (based on targets) is 0.82 ppm due to the 0.6 hour lunchtime exposure to 0.10 ppm between periods 3 and 4.

<sup>G</sup> Results at 0.08 ppm for a subset of the study subjects that were exposed to 0.10 ppm.

1  
2

1 **Table 3A-2. Study-specific details of O<sub>3</sub> exposure protocols for 6.6 to- 8-hour controlled**  
2 **human exposure studies (that include periods of exercise).**

| Ref <sup>A</sup>  | EVR <sup>B</sup><br>during<br>exercise<br>(L/min-m <sup>2</sup> )                     | Target Exposure Concentration <sup>C</sup> (ppm)   |   | Number of<br>Subjects <sup>E</sup> | Avg.<br>Age<br>(Range) | Reference                            |
|---|---|--|---|------------------------------------|------------------------|--------------------------------------|
|   |   | Constant,<br>(6.6-hr TWA) <sup>D</sup>   | Varying (hourly concentrations),<br>(6.6-hr TWA) <sup>D</sup>   |                                    |                        |                                      |
| 6.6-Hour Chamber Study: <b>50m+10m, 50m+10m, 50m+10m, 35m, 50m+10m, 50m+10m, 50m+10m</b><br><b>Face Mask Exposure (FM): 50m+10m, 3m, 50m+10m, 3m, 50m+10m, 24m, 50m+10m, 3m, 50m+10m, 3m, 50m+10m</b><br><i>red=O<sub>3</sub> exposure, black = no exposure (i.e., no facemask) bold =exercise periods, non-bold=rest periods</i> |   |  |   |                                    |                        |                                      |
| R1  | 20  | 0.06<br>0.08   | 0.04 (0.03, 0.04, 0.05, 0.05, 0.04, 0.03), (0.041)<br>0.06 (0.04, 0.07, 0.09, 0.07, 0.05, 0.04), (0.063)<br>0.08 (0.03, 0.07, 0.10, 0.15, 0.08, 0.05), (0.082)  | 30 (15M,15F)                       | 23<br>(21-29)          | Adams (2006b)<br>Brown et al. (2008) |
| R2  | 20  | 0.06<br>0.08   |   | 59 (27M,32F)<br>30 (15M,15F)       | 25<br>(19-35)          | Kim et al. (2011) <sup>F</sup>       |
| R3  | 20  | 0.08<br>0.10<br>0.12   |   | 22 (M)                             | 25<br>(18-35)          | Horstman et al.<br>(1990)            |
| R4  | 20  | 0.08<br>0.08 <sup>FM</sup> , (0.073)   | 0.08 (0.03, 0.07, 0.10, 0.15, 0.08, 0.05), (0.082)<br>0.08 <sup>FM</sup> (0.03, 0.07, 0.10, 0.15, 0.08, 0.05), (0.073)  | 30<br>(15M,15F)                    | 22                     | Adams (2003)                         |
| R5  | 19-20   | 0.04 <sup>FM</sup> , (0.036)<br>0.08 <sup>FM</sup> , (0.073)<br>0.12 <sup>FM</sup> , (0.109)<br>0.12 |   | 30<br>(15M,15F)                    | 22                     | Adams (2002)                         |
| R6  | 22  | 0.12   |   | 10 (M)                             | 25<br>(18-33)          | Folinsbee et al.<br>(1988)           |
| R7  | 20  | 0.08<br>0.08+0.10  |   | 38 (M)<br>10 (M)                   | 25<br>(18-30)          | McDonnell et al.<br>(1991)           |
| R8  | 18, 20  | 0.12   |   | 17 (M)                             | 25                     | Folinsbee et al.<br>(1994)           |
| R9  | 20  |  | 0.06 (0.04, 0.07, 0.07, 0.09, 0.05, 0.04), (0.061) <sup>G</sup><br>0.07 (0.05, 0.07, 0.08, 0.09, 0.08, 0.05), (0.071) <sup>G</sup><br>0.08 (0.03, 0.07, 0.10, 0.15, 0.08, 0.05), (0.082) <sup>G</sup><br>0.087 (0.04, 0.08, 0.09, 0.12, 0.10, 0.09), (0.087) <sup>G</sup> | 31 (15M,16F)                       | 21<br>(18-25)          | Schelegle et al.<br>(2009)           |
| R10   | 17, 20, 23  | 0.12 <sup>FM</sup> , (0.109)   |   | 30(15M, 15F)                       | 22                     | Adams (2000)                         |
| R11   | 10 <sup>9-12</sup> ,<br>11 <sup>7-11</sup> ,<br>18 <sup>#</sup> , 20 <sup>15-23</sup> | 0.08 <sup>FM</sup> , (0.073)<br>0.12 <sup>FM</sup> , (0.109)   | 0.12 <sup>FM</sup> (0.07, 0.16, 0.10), (0.109)<br>0.12 <sup>FM</sup> (0.115, 0.115, 0.130, 0.130, 0.115, 0.115),<br>(0.109)   | 12<br>(6M, 6F)                     | 22                     | Adams and Ollison<br>(1997)          |
| 7.6-hour Chamber: Additional hour on 6.6 hr chamber protocol above.   |   |  |   |                                    |                        |                                      |
| R12   | 15-17   | 0.16   |   | 13 (NR)<br>17As(7M,10F)            | 25<br>(18-35)          | Horstman et al.<br>(1995)            |
| 8-hour Chamber: Eight 30-min exercise periods, each followed by 30 min rest   |   |  |   |                                    |                        |                                      |
| R13   | 20  | 0.12   | 0.12 triangular* (0→0.24→0)   | 30 (15M,15F)                       | 23<br>(21-29)          | Adams (2006a)                        |
| R14   | 20  | 0.12   | 0.12 triangular* (0→0.24→0)   | 23 (M)                             | 26<br>(20-35)          | Hazucha et al.<br>(1992)             |
| <sup>A</sup> R1-R14 matches study codes in Table 3A-1.  |   |  |   |                                    |                        |                                      |
| <sup>B</sup> EVR values are the study means during exercise periods except for R11, for which the EVRs are described below.   |   |  |   |                                    |                        |                                      |
| 9-12 indicates the study protocol varied the hourly ventilation rate from 9-12 L/min-m <sup>2</sup> and value reflects the average mean EVR across the 6-hr experimental period which includes 50-min of exercise and 10 min of rest.   |   |  |   |                                    |                        |                                      |
| 7-11 indicates the study protocol varied the hourly ventilation rate from 7-11 L/min-m <sup>2</sup> and the value reflects the average mean EVR across the 6-hr experimental period which includes 50-min of exercise and 10 min of rest.   |   |  |   |                                    |                        |                                      |

# The study protocol describes the target exercise EVR as 20 L/min-m<sup>2</sup> but the actual mean EVR during exercise was not reported and could not be calculated from study data presented. The value was derived from the average of the mean hourly EVR which consisted of 50-min of exercise and 10-min of rest resulting in an EVR somewhat lower than the target of 20 L/min-m<sup>2</sup>.

<sup>15-23</sup> indicates the study varied the hourly ventilation rate from 15-23 L/min-m<sup>2</sup>; and the value reflects the average mean EVR across the 6-hr experimental period which includes 50-min of exercise and 10 min of rest.

<sup>c</sup> Unless marked by "F" (for face mask exposure), exposures were conducted in exposure chamber.

<sup>d</sup> TWA (time weighted average) was calculated taking into account all exposure concentrations during experiment, including lunch and rest periods. The TWA concentrations for facemask exercise protocols (whether the exposure concentration was constant or varying) are lower than the target exposure concentrations because the subjects were not exposed to O<sub>3</sub> during the 3 minute rest and 24 minute lunch periods. Conversely, the TWA concentrations for varying exposure chamber protocols were higher than the targeted average exposure because of the sequence of concentrations, and their relative magnitude during the 35 minute lunch period.

<sup>e</sup> All subjects were healthy adults unless marked by "As" for subjects with asthma. M=male, F=female, NR=sex not reported.

<sup>f</sup> The 0.08 ppm data for the Kim study were reported in McDonnell et al., 2012.

\* Triangular = steadily increasing concentration from 0 ppm to 0.24 ppm at hour 4, then back to 0 ppm.

<sup>g</sup> While Schelegle et al. (2009) reported measured O<sub>3</sub> concentrations, the TWA target concentrations listed in the table for the four protocols are 0.061, 0.071, 0.082 and 0.087. Based on the O<sub>3</sub> concentration measurements taken during the 6 exercise periods, the average O<sub>3</sub> concentrations for the four protocols are 0.063 ppm, 0.072 ppm, 0.081 ppm and 0.088 ppm, while the 6.6-hour TWA concentrations are 0.063 ppm, 0.073 ppm, 0.083 ppm and 0.088 ppm

1  
2



**Table 3A-3. Summary of controlled human exposures to O<sub>3</sub> for 1 to 3 hours during exercise or at rest.**

| O <sub>3</sub> <sup>A</sup><br>(ppm)             | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>                           | Subject<br>Characteristics <sup>B</sup> |                                      | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA   |
|--|--|---|--------------------------------------|---|---|
|  |  | Pop <sup>C</sup>                        | n <sup>D</sup>                       |   |   |
| Adult Subjects During Moderate to Heavy Exercise |  |   |                                      |   |   |
| 0.07   | 3 hr IE (6 ×15 min, EVR=15-17 L/min-m <sup>2</sup> )   | H <sup>NS</sup>                         | 35M and 52F (55-70 yrs)              | PF: No significant change in FEV <sub>1</sub><br>SY: No significant change<br>IF: No significant change   | Arjomandi et al., 2018<br>Frampton et al., 2017;<br>2020 ISA U.S. EPA, 2020 |
| 0.08   | 1 hr CE (mean $\dot{V}_E$ =57 L/min)   | H <sup>At</sup>                         | 42M and 8F (mean 26 yrs)             | PF: No significant change in FEV <sub>1</sub><br>SY: No significant change  | Avol et al., 1984 <sup>F</sup>  |
| 0.08   | 2 hr IE (4×15 min, $\dot{V}_E$ =68 L/min)  | H                                       | 24M (18-33 yrs)                      | PF: No significant change in FEV <sub>1</sub><br>SY: No significant change  | Linn et al., 1986;<br>1996 AQCD, Table 7-1                                  |
| 0.10   | 0.5 hr (8 km time trial at 70% HR at 20°C and 31°C)  | H <sup>At</sup>                         | 9M (mean 24 yrs)                     | IF: NL 15 min postexposure showed no differences in inflammatory response between heat only or O <sub>3</sub> only compared to control; significantly increased in nasal Club cells and glutathione after high-temperature O <sub>3</sub> relative to lower temperature FA control.                                   | Gomes et al., 2011<br>2020 ISA, p. 3-30, Table 3-9                          |
| 0.10   | 1 hr IE (2 × 15 min, $\dot{V}_E$ =27 L/min)  | As <sup>M</sup>                         | 12M and 9F (19-40 yrs)               | PF/AR: No significant differences in FEV <sub>1</sub> or FVC compared to FA and no exacerbation of exercise-induced asthma in a postexposure exercise challenge<br>SY: No significant change  | Weymer et al., 1994;<br>1996 AQCD, Table 7-2                                |
| 0.10   | 2 hr Mild IE   | H                                       | 12M and 10F; (mean 30 yrs)           | PF: No significant change in FEV <sub>1</sub><br>IF: Markers of exposure in exhaled breath condensate including markers of inflammation (8-isoprostane, TBARS and LTB <sub>4</sub> ), and markers of oxidative stress (ROS-DNA interaction: 8-OHdG), increased in a sub-set of NQO1 wildtypes and GSTM1 null subjects | Corradi et al., 2002;<br>2006 AQCD, Table AX6-12                            |
| 0.10   | 2 hr IE (4×15 min, $\dot{V}_E$ =68 L/min)  | H                                       | 24M (18-33 yrs)                      | PF: No significant change in FEV <sub>1</sub><br>SY: No significant change  | Linn et al., 1986;<br>1996 AQCD, Table 7-1                                  |
| 0.10   | 2 hr IE (4×15 min at either $\dot{V}_E$ =30 L/min, $\dot{V}_E$ =50 L/min or $\dot{V}_E$ =70 L/min) | H                                       | 30M (three groups of 10) (19-28 yrs) | PF: No significant change in any of the three 10-male groups separately exposed via three ventilation rates   | Folinsbee et al., 1978; <sup>G</sup><br>1996 AQCD, p. 7-10                  |
| 0.10   | 2 hr IE (4×14 min, $\dot{V}_E$ =70 L/min)  | H <sup>NS</sup>                         | 20M (mean 25 yrs)                    | PF: No significant change<br>AR: No significant change in sRAW<br>SY: No significant change   | Kulle et al., 1985;<br>1996 AQCD, Table 7-1                                 |
| 0.10   | 3 hr IE (6×15 min, EVR=25 L/min-m <sup>2</sup> )   | H <sup>NS</sup>                         | 15M and 9F (18-40 yrs)               | PF: No significant change<br>SY: No significant change  | Frampton et al., 2015;<br>2020 ISA, p. 3-15, Table 3-4                      |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>   | Subject<br>Characteristics <sup>B</sup> |   | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)   | Reference<br>AQCD/ISA   |
|--------------------------------------|--|---|---|--|---|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>  |  |   |
| 0.12                                 | 45 min IE ( $\dot{V}_E$ =40-46 L/min)<br>(two sequential 10 min exposures to 0.1 and 0.25 ppm SO <sub>2</sub> ); +/- 4 wk pre-treatment with antioxidant | As <sup>SO2</sup>                       | 5M and 12F<br>(19- 38 yrs)                                  | <b>PF:</b> ↓ FEV <sub>1</sub> * with no significant differences due to O <sub>3</sub> between placebo and antioxidant supplement<br><b>AR:</b> No significant differences due to O <sub>3</sub> in placebo vs. antioxidant pretreatment in bronchial hyperresponsiveness to 0.1 ppm SO <sub>2</sub> .                              | Trenga et al., 2001;<br>2006 AQCD, p. 6-67 and Table AX6-7                      |
| 0.12                                 | 1 hr CE (30 min warm up $\dot{V}_E$ =54 L/min, 30 min competitive $\dot{V}_E$ =120 L/min; overall mean $\dot{V}_E$ =87 L/min)                            | H <sup>Ath</sup>                        | 10M<br>(19-29 yrs)  | <b>PF:</b> No significant change in pulmonary function compared to FA<br><b>SY:</b> No significant symptoms  | Schelegle and Adams, 1986;<br>1996 AQCD, p. 7-11, Table 7-1                     |
| 0.12                                 | 1 hr CE (mean $\dot{V}_E$ =89 L/min)   | H <sup>Ath</sup>                        | 15M and 2F<br>(19-30 yrs)                                   | <b>PF:</b> ↓ FEV <sub>1</sub> <sup>J</sup><br><b>AR:</b> > 20% increase in histamine responsiveness in one subject<br><b>SY:</b> Mild respiratory symptoms   | Gong et al., 1986;<br>1996 AQCD, Tables 7-1 and 7-10; 2013 ISA, p. 6-6          |
| 0.12                                 | 1.5 hr IE (3×15 min, $\dot{V}_E$ =20 L/min)  | As <sup>A</sup><br>H <sup>NAs</sup>     | 5M and 5F<br>4M and 4F<br>(18-41 yrs)                       | NL immediately and 24 hr after exposure<br><b>PF:</b> No change in lung or nasal function.<br><b>IF:</b> No change in PMN number   | McBride et al., 1994;<br>2006 AQCD, Table AX6-12                                |
| 0.12                                 | 3 hr IE (6×15 min, EVR=15-17 L/min/m <sup>2</sup> )  | H <sup>NS</sup>                         | 35M and 52F<br>(55-70 yrs)                                  | <b>PF:</b> Small statistically significant attenuation of exercise-related increases FEV <sub>1</sub> and FVC<br><b>SY:</b> No significant change<br><b>IF:</b> Significant increase in PMN independent of GSTM1 phenotype and significant increase in plasma CC16 (marker of airway epithelial injury) 4 hr and 22hr postexposure | Arjomandi et al., 2018<br>Frampton et al., 2017;<br>2020 ISA, p.3-30, Table 3-4 |
| 0.12                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | H <sup>NS</sup>                         | 9M and 3F<br>(mean 28 yrs)                                  | <b>PF:</b> No changes in FEV <sub>1</sub> or FVC<br><b>IF:</b> Increased percentage of vessels expressing P-selectin in bronchial biopsies 1.5 hr postexposure; no change in BAL markers, PMNs or expression of VCAM-1, E-selectin or ICAM-1 in vessel biopsies  | Krishna et al., 1997;<br>2006 AQCD, Table AX6-12                                |
| 0.12                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =68 L/min)  | H                                       | 24M<br>(18-33 yrs)  | <b>PF:</b> No significant change in FEV <sub>1</sub><br><b>SY:</b> No significant change in respiratory symptoms   | Linn et al., 1986;<br>1996 AQCD, Table 7-1                                      |
| 0.12                                 | 2.5 hr IE (4×15 min, $\dot{V}_E$ =68 L/min)  | H                                       | 22M<br>(18-30 yrs)  | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * and ↓ FEF <sub>25-75</sub> *<br><b>AR:</b> No significant change in sRaw<br><b>SY:</b> Increased respiratory symptoms  | McDonnell et al., 1983;<br>1996 AQCD, p. 7-15, Table 7-1                        |
| 0.12                                 | 2.5 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )   | H                                       | 30M and 31F<br>(18-35 yrs)                                  | <b>PF:</b> ↓ FEV <sub>1</sub> * compared with FA<br><b>AR:</b> No significant change in sRaw<br><b>SY:</b> No significant change   | Seal et al., 1993;<br>1996 AQCD, p. 7-15, Table 7-1                             |
| 0.125                                | 3 hr IE (6×15 min, $\dot{V}_E$ =26 L/min)  | H<br>As <sup>M</sup>                    | 10M and 11F<br>(mean 28 yrs)<br>5M and 10F<br>(mean 30 yrs) | <b>PF:</b> No significant change in pulmonary function.<br><b>IF:</b> Small but significant neutrophil increases in As <sup>M</sup> subjects   | Holz et al., 1999;<br>2006 AQCD, p. AX6-35 and Table AX6-3                      |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>   | Subject<br>Characteristics <sup>B</sup> |  | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)   | Reference<br>AQCD/ISA  |
|--------------------------------------|--|---|--|--|--|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>   |  |  |
| 0.125                                | 3 hr IE (4×15 min, $\dot{V}_E=30$ L/min);<br>3 hr IE (4×15 min, $\dot{V}_E=30$ L/min) × 4<br>days; *challenged with allergen 20 hr<br>following the last exposure and<br>sputum collected 6-7 hr later | As <sup>A</sup><br><br>AI               | 6M and 5F (20-<br>53 yrs)<br><br>16M and 6F<br>(19-48 yrs) | <b>PF:</b> Incidence and magnitude of early-phase FEV <sub>1</sub> decrements to<br>allergen were significantly greater in AI subjects exposed for 4 days.<br><b>IF:</b> Significant increase in sputum eosinophils in As <sup>A</sup> and AI subjects<br>exposed for 4 days: increased sputum lymphocytes, mast cell<br>tryptase, histamine, and LDH only in As <sup>A</sup> subjects exposed for 4 days. | Holz et al., 2002;<br>2006 AQCD, Tables AX6-3<br>and AX6-11    |
| 0.14                                 | 2 hr IE (4×15 min, $\dot{V}_E=68$ L/min)   | H                                       | 24M<br>(18-33 yrs)   | <b>PF:</b> No significant change in FEV <sub>1</sub><br><b>SY:</b> No significant change in respiratory symptoms   | Linn et al., 1986;<br>1996 AQCD, Table 7-1                     |
| 0.15                                 | 2 hr IE (4×14 min, $\dot{V}_E=70$ L/min)   | H <sup>NS</sup>                         | 20M<br>(mean 25 yrs)                                       | <b>PF:</b> ↓ FEV <sub>1</sub> *<br><b>AR:</b> 6 subjects with >15% decrease in sGaw<br><b>SY:</b> No significant change in respiratory symptoms  | Kulle et al., 1985;<br>1996 AQCD, Table 7-1                    |
| 0.16                                 | 1 hr CE (mean $\dot{V}_E=57$ L/min)  | H <sup>At</sup>                         | 42M and 8F<br>(mean 26 yrs)                                | <b>PF:</b> Small ↓ FEV <sub>1</sub> *<br><b>SY:</b> ↑ in mild respiratory symptoms*  | Avol et al., 1984;<br>1996 AQCD, Table 7-1                     |
| 0.16                                 | 2 hr IE (4×15 min, $\dot{V}_E=68$ L/min)   | H                                       | 24M<br>(18-33 yrs)   | <b>PF:</b> Small ↓ FEV <sub>1</sub> *<br><b>SY:</b> No significant change in respiratory symptoms  | Linn et al., 1986; 1996<br>AQCD, p. 7-11 and Table 7-1         |
| 0.18                                 | 1 hr CE (30 min warm up $\dot{V}_E=54$<br>L/min, 30 min competitive $\dot{V}_E=120$<br>L/min; overall mean $\dot{V}_E=87$ L/min)   | H <sup>At</sup>                         | 10M<br>(19-29 yrs)   | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> * compared to FA; ↓ exercise time for<br>subjects unable to complete simulation<br><b>SY:</b> ↑ respiratory symptoms*   | Schelegle and Adams, 1986;<br>1996 AQCD, p. 7-11, Table<br>7-1 |
| 0.18                                 | 2 hr IE (4×15 min, EVR=35 L/min-m <sup>2</sup> )   | AI                                      | 26M with<br>(18-30 yrs)                                    | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> *<br><b>AR:</b> ↑ sRaw* and increased reactivity to histamine*<br><b>SY:</b> ↑ respiratory symptoms*   | McDonnell et al., 1987;<br>1996 AQCD, Table 7-2                |
| 0.18                                 | 2.5 hr IE (4×15 min, EVR=25 L/min-<br>m <sup>2</sup> )   | H                                       | 32M and 32F<br>(18-35 yrs)                                 | <b>PF:</b> ↓ FEV <sub>1</sub> * compared with FA<br><b>AR:</b> ↑ sRaw* compared with FA<br><b>SY:</b> ↑ respiratory symptoms* compared with FA   | Seal et al., 1993;<br>1996 AQCD, p. 7-15, Table<br>7-1         |
| 0.18                                 | 2.5 hr IE (4×15 min, $\dot{V}_E=65$ L/min)   | H                                       | 20M<br>(18-30 yrs)   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * and ↓ FEF <sub>25-75</sub> *<br><b>AR:</b> No significant change in sRaw<br><b>SY:</b> ↑ respiratory symptoms*   | McDonnell et al., 1983;<br>1996 AQCD, p. 7-15, Table<br>7-1    |
| 0.20                                 | 30 to 80 min CE ( $\dot{V}_E=33$ or 66 L/min)  | H                                       | 8M<br>(22-46 yrs)  | <b>PF:</b> O <sub>3</sub> effective dose significantly related to pulmonary function<br>decrements (threshold for significant responses > 0.2 ppm) and<br>exercise ventilatory pattern changes; O <sub>3</sub> concentration accounted for<br>the majority of the pulmonary function variance  | Adams et al., 1981;<br>1996 AQCD, Table 7-1                    |
| 0.20                                 | 1 hr CE ( $\dot{V}_E=80$ L/min); 1 hr<br>competitive simulation (30 min at<br>$\dot{V}_E=52$ L/min, 30 min at $\dot{V}_E=100$<br>L/min; overall mean $\dot{V}_E=77.5$ L/min)                           | H <sup>At</sup>                         | 10M<br>(19-31 yrs)   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * and ↓ FEF <sub>25-75</sub> * compared to FA with both<br>protocols; ↓ V <sub>T</sub> * and ↑ f <sub>R</sub> * with CE<br><b>SY:</b> ↑ respiratory symptoms*  | Adams and Schelegle, 1983;<br>1996 AQCD, Table 7-1             |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>                    | Subject<br>Characteristics <sup>B</sup> |                              | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA   |
|--------------------------------------|---|---|------------------------------|---|---|
|                                      |   | Pop <sup>C</sup>                        | n <sup>D</sup>               |   |   |
| 0.20                                 | 1 hr CE ( $\dot{V}_E=89$ L/min)   | H <sup>Ath</sup>                        | 15M and 2F<br>(19-30 yrs)    | <b>PF:</b> $\downarrow V_{E\max}^*$ , $\downarrow VO_{2\max}^*$ , $\downarrow V_{T\max}^*$ , $\downarrow$ work load*, $\downarrow$ ride time*, $\downarrow$ FVC*,<br>and $\downarrow$ FEV <sub>1</sub> * compared with FA<br><b>AR:</b> > 20% increase in histamine responsiveness in nine subjects<br><b>SY:</b> $\uparrow$ respiratory symptoms*  | Gong et al., 1986;<br>1996 AQCD, Tables 7-1<br>and 7-10         |
| 0.20                                 | 1hr CE (mean $\dot{V}_E=60$ L/min);<br>2 exposures $\times$ 24 hr apart                     | H <sup>NS</sup>                         | 15M<br>(mean 25 yrs)         | <b>PF:</b> Consecutive days of exposure produced similar $\downarrow$ FVC* and $\downarrow$<br>FEV <sub>1</sub> * on each day compared to FA<br><b>SY:</b> Consecutive days of exposure produced similar $\uparrow$ respiratory<br>symptoms*  | Brookes et al., 1989;<br>2006 AQCD, Table AX6-9                 |
| 0.20                                 | 2 hr IE (4 $\times$ 15 min, 2 $\times$ resting $\dot{V}_E$ )                                | H <sup>NS</sup>                         | 12M and 7F (21-<br>32 yrs)   | <b>AR:</b> No change in sRaw to a 10-breath histamine (1.6%) aerosol<br>challenge after O <sub>3</sub> exposure.  | Dimeo et al., 1981;<br>2006 AQCD, Table AX6-11                  |
| 0.20                                 | 2 hr IE (4 $\times$ 15 min, $\dot{V}_E=20$ L/min)   | As <sup>A</sup>                         | 4M and 5F<br>(21-42 yrs)     | <b>PF:</b> $\downarrow$ FEV <sub>1</sub> * but not FVC<br><b>AR:</b> No change in sRaw<br><b>IF:</b> 6 hr postexposure $\uparrow$ PMNs* with no change in permeability<br>markers; 24 hr postexposure PMNs decreased while albumin, total<br>protein, myeloperoxidase and eosinophil cationic protein increased.  | Newson et al., 2000;<br>2006 AQCD, Tables AX6-3,<br>AX6-13      |
| 0.20                                 | 2 hr IE (4 $\times$ 15 min, $\dot{V}_E=30$ L/min)   | H <sup>NS</sup>                         | 10M and 2F<br>(mean 28 yrs)  | <b>IF:</b> Significant increase in PMNs and epithelial cells, IL-8, Gro- $\alpha$ , and<br>total protein in BAL fluid; % PMNs correlated positively with<br>chemokine levels; significant decrease in the CD4+/CD8+ ratio and<br>% of activated CD4+ and CD8+ T cells in BAL fluid.   | Krishna et al., 1998<br>2006 AQCD, Table AX6-13                 |
| 0.20                                 | 2 hr IE (4 $\times$ 15 min, EVR=20 L/min-m <sup>2</sup> )                                   | H <sup>NS</sup>                         | 8M and 5F<br>(20-31 yrs)     | <b>PF:</b> $\downarrow$ FVC*, $\downarrow$ FEV <sub>1</sub> *, and $\downarrow$ FEF <sub>25-75</sub> *<br><b>IF:</b> Spirometry responses did not predict inflammatory responses;<br>increased adhesion molecule expression, submucosal mast cell<br>numbers and alterations in lining fluid redox status; increase in human<br>leukocyte antigen+ alveolar macrophages in BAL 1.5 hr postexposure. | Blomberg et al., 1999;<br>2006 AQCD, Tables AX6-1<br>and AX6-12 |
| 0.20                                 | 2 hr IE (4 $\times$ 15 min, EVR=20 L/min-m <sup>2</sup> )                                   | H                                       | 10M and 12F<br>(mean 24 yrs) | <b>PF:</b> $\downarrow$ FEV <sub>1</sub> * immediately postexposure but not significantly different<br>from baseline 2 hr later.<br><b>IF:</b> Elevated CC16 levels remained high 6 hr postexposure but<br>returned to baseline by 18 hr postexposure. No correlation between<br>CC16 and FEV <sub>1</sub> decrement.   | Blomberg et al., 2003;<br>2006 AQCD, Table AX6-1                |
| 0.20                                 | 2 hr IE (4 $\times$ 15 min, EVR=20 L/min-m <sup>2</sup> )<br>chronic inhaled corticosteroid | As                                      | 8M and 5F<br>(mean 33 yrs)   | <b>PF:</b> $\downarrow$ FEV <sub>1</sub> * and $\downarrow$ FVC*<br><b>AR:</b> Significant increase sRaw<br><b>IF:</b> Significant increase in BAL neutrophils, but not eosinophils 18 hr<br>postexposure; significant increase in mast cells in bronchial biopsy   | Stenfors et al., 2010;<br>2013 ISA, p. 6-21                     |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>   | Subject<br>Characteristics <sup>B</sup> |  | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA  |
|--------------------------------------|--|---|--|---|--|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>   |   |  |
| 0.20                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | H <sup>NAs</sup><br>As <sup>M</sup>     | 6M and 9F<br>(19-32 yrs);<br>9M and 6F<br>(21-48 yrs)                              | <b>PF:</b> ↓FEV <sub>1</sub> * (8%, H <sup>NAs</sup> ; 3% As <sup>M</sup> ) and ↓FVC* in both groups with no significant difference between H <sup>NAs</sup> and As <sup>M</sup><br><b>IF:</b> Significant increase in PMN in both groups with no significant difference between As <sup>M</sup> and H <sup>NAs</sup> 6 hr postexposure; no relationship between antioxidant levels and spirometric or cellular responses   | Mudway et al., 2001;<br>Stenfors et al., 2002;<br>2006 AQCD, Table AX6-1 |
| 0.20                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | H                                       | 8M and 5F<br>(19-31 yrs)<br>6M and 9F<br>(19-32 yrs)<br>16M and 15F<br>(19-32 yrs) | <b>IF:</b> Postexposure bronchoscopy was performed at 1.5 hr, 6 hr, and 18 hr; significant correlations between lung PMNs and blood PMNs postexposure; significant increase in PMN at 6 hr in bronchial wash and BAL-fluid as well as in bronchial epithelium and submucosa biopsies; 18 hr, PMN increase persisted in both bronchial wash and BAL while PMN in biopsies tended slightly lower; significant decrease in blood PMNs in subjects 1.5 hr postexposure compared to FA that rebounded above FA levels at 6 hr and at 18 hr postexposure, there was no difference in PMN levels when compared to FA | Bosson et al., 2013;<br>2020 ISA, p. 3-29, p. 4-28                       |
| 0.20                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | H <sup>NAs</sup><br>As <sup>M</sup>     | 6M and 6F<br>(19-31 yrs)<br>9M and 6F (21-48 yrs)                                  | <b>IF:</b> Significantly higher baseline expression of IL-4 and IL-5 in bronchial mucosal biopsies from As <sup>M</sup> vs. H <sup>NAs</sup> subjects 6 hr postexposure. Epithelial expression of IL-5, GM-CSF, ENA-78, and IL-8 increased significantly in As <sup>M</sup> vs. H <sup>NAs</sup> subjects.  | Bosson et al., 2003;<br>2006 AQCD, Table AX6-12                          |
| 0.20                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | H <sup>NS</sup>                         | 8M and 5F<br>(20-31 yrs)   | <b>IF:</b> No neutrophils in NL 1.5 hr postexposure. 30% depletion of uric acid in NL during hr 2 of exposure with increase in plasma uric acid levels. No depletion of ascorbic acid, reduced glutathione, or extracellular superoxide dismutase.  | Mudway et al., 1999;<br>2006 AQCD, Table AX6-12                          |
| 0.20                                 | 2 hr IE (4×14 min, $\dot{V}_E$ =70 L/min)  | H <sup>NS</sup>                         | 20M<br>(mean 25 yrs)   | <b>PF:</b> ↓FVC*, ↓FEV <sub>1</sub> *, ↓FEF <sub>25-75</sub> *, ↓IC* and ↓TLC*<br><b>AR:</b> ↓sGaw<br><b>SY:</b> ↑respiratory symptoms*   | Kulle et al., 1985;<br>1996 AQCD, Table 7-1                              |
| 0.20                                 | 3 hr IE (6×15 min, EVR=25 L/min-m <sup>2</sup> )   | H <sup>NS</sup>                         | 15M and 9F<br>(18-40 yrs)  | <b>PF:</b> ↓FEV <sub>1</sub> * and ↓FVC*<br><b>SY:</b> ↑respiratory symptoms*   | Frampton et al., 2015;<br>2020 ISA, p. 3-15, Table 3-4                   |
| 0.21                                 | 1 hr CE (75% VO <sub>2max</sub> )  | H <sup>Ath</sup>                        | 6M and 1F<br>(18-27 yrs)   | <b>PF:</b> ↓FVC*, ↓FEV <sub>1</sub> *, ↓FEF <sub>25-75</sub> *, and ↓MVV* compared to FA<br><b>SY:</b> ↑respiratory symptoms*   | Folinsbee et al., 1984; 1996<br>AQCD, Table 7-1                          |
| 0.21                                 | 1 hr CE ( $\dot{V}_E$ =80 L/min) followed by maximal sprint (peak $\dot{V}_E$ >140 L/min)<br>Pre-treatment with albuterol or placebo | H <sup>Ath</sup>                        | 14M and 1F<br>(16-34 yrs)  | <b>PF:</b> ↓FVC*, ↓FEV <sub>1</sub> *, ↓FEF <sub>25-75</sub> *, and ↓V <sub>Emax</sub> in both treatment groups. No difference in the effects of albuterol on exercise performance vs. placebo.<br><b>AR:</b> No significant differences in the effects of albuterol on airway reactivity to histamine challenge vs placebo.  | Gong et al., 1988;<br>1996 AQCD, Table 7-1                               |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>   | Subject<br>Characteristics <sup>B</sup> |                                       | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)   | Reference<br>AQCD/ISA                                       |
|--------------------------------------|--|---|---------------------------------------|--|---|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>                        |  |   |
| 0.22                                 | 2.25 hr IE (4×15 min, 6-8×resting $\dot{V}_E$ )  | H                                       | 83M and 55F<br>(mean 22 yrs)          | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> *<br><b>AR:</b> Increased airway responsiveness 1 day postexposure<br><b>IF:</b> Increased epithelial permeability 1 day postexposure; airway responsiveness and epithelial permeability 1 day postexposure did not correlate with FEV <sub>1</sub> responses immediately following the O <sub>3</sub> exposure               | Que et al., 2011;<br>2013 ISA, p. 6-74                      |
| 0.24                                 | 1 hr CE (mean $\dot{V}_E$ =57 L/min)   | H <sup>Ath</sup>                        | 42M and 8F<br>(mean 26 yrs)           | <b>PF:</b> ↓ FEV <sub>1</sub> *<br><b>SY:</b> ↑ respiratory symptoms*  | Avol et al., 1984;<br>1996 AQCD, Table 7-1                  |
| 0.24                                 | 1 hr competitive simulation at mean $\dot{V}_E$ =87 L/min; (30 min at $\dot{V}_E$ =54 L/min, 30 min at $\dot{V}_E$ =120 L/min) | H <sup>Ath</sup>                        | 10M<br>(19-29 yrs)                    | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * and ↓ FEF <sub>25-75</sub> * compared to FA; ↓ exercise time* for subjects unable to complete simulation<br><b>SY:</b> ↑ respiratory symptoms*   | Schelegle and Adams, 1986;<br>1996 AQCD, p. 7-11, Table 7-1 |
| 0.24                                 | 1.5 hr IE (3×15 min, $\dot{V}_E$ =20 L/min)  | As <sup>A</sup><br>H <sup>NAs</sup>     | 5M and 5F<br>4M and 4F<br>(18-41 yrs) | NL immediately and 24 hr after exposure<br><b>PF:</b> No change in pulmonary or nasal function.<br><b>IF:</b> Significant increase in PMNs (at both time points) and in epithelial cells (immediately after exposure) only in As <sup>A</sup> subjects   | McBride et al., 1994;<br>2006 AQCD, Table AX6-12            |
| 0.24                                 | 2.5 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )   | H                                       | 31M and 33F<br>(18-35 yrs)            | <b>PF:</b> ↓ FEV <sub>1</sub> * compared with FA<br><b>AR:</b> ↑ sRaw* compared with FA<br><b>SY:</b> ↑ respiratory symptoms* compared with FA   | Seal et al., 1993; 1996<br>AQCD, p. 7-15, Table 7-1         |
| 0.24                                 | 2.5 hr IE (4×15 min, $\dot{V}_E$ =65 L/min)  | H                                       | 21M<br>(18-30 yrs)                    | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> * and ↓ V <sub>T</sub> * and ↑ f*<br><b>AR:</b> ↑ sRaw*<br><b>SY:</b> ↑ respiratory symptoms*  | McDonnell et al., 1983;<br>1996 AQCD, Table 7-1             |
| 0.25                                 | 1 hr IE (2×15 min, $\dot{V}_E$ =27 L/min)  | As <sup>M</sup>                         | 12M and 9F<br>(19-40 yrs)             | <b>PF/AR:</b> No significant differences in FEV <sub>1</sub> or FVC compared to FA and no exacerbation of exercise-induced asthma in a postexposure exercise challenge   | Weymer et al., 1994; 2006<br>AQCD, Table AX6-11             |
| 0.25                                 | 1 hr CE (EVR=30 L/min-m <sup>2</sup> )   | H <sup>NS</sup>                         | 5M and 2F<br>(22-30 yrs)              | <b>PF:</b> ↓ FEV <sub>1</sub> *<br><b>IF:</b> ↑ substance P* and ↑ 8-epi-PGF <sub>2α</sub> * in segmental washing but not BAL fluid  | Hazbun et al., 1993;<br>1996 AQCD, Table 7-1                |
| 0.25                                 | 1 hr CE ( $\dot{V}_E$ =30L/min);<br>Facemask exposure  | H <sup>NS</sup>                         | 32M and 28F<br>(mean 23 yrs)          | <b>PF:</b> ↓ FEV <sub>1</sub> *; sex differences in FEV <sub>1</sub> decrements not significant; Uptake of O <sub>3</sub> greater in M vs. F, but uptake not correlated with significant differences in spirometric responses between M and F.   | Ultman et al., 2004;<br>2006 AQCD, Table AX6-1              |
| 0.25                                 | 1 hr CE (mean $\dot{V}_E$ =63 L/min)   | H                                       | 19M and 7F<br>(mean 21 yrs)           | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> * and ↓ MVV* compared to FA  | Folinsbee et al., 1986; 1996<br>AQCD, Table 7-1             |
| 0.25                                 | 2 hr IE (2×30 min at $\dot{V}_E$ =39 L/min)<br>4 consecutive days  | H <sup>NS</sup>                         | 5M and 3F<br>25-31 yrs                | <b>PF:</b> Maximal mean ↓ FEV <sub>1</sub> * and ↓ FVC* on day 2, negligible by day 4.<br><b>AR/IF:</b> Significant small airway function depression accompanied by significant PMN in BAL fluid one day following the end of O <sub>3</sub> exposure; PMN number in BAL fluid on day 5 were significantly higher following O <sub>3</sub> , compared to air exposures | Frank et al., 2001;<br>AQCD 2006 Tables AX6-9,<br>AX6-12    |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>  | Subject<br>Characteristics <sup>B</sup>  |  | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA                                       |
|--------------------------------------|---|--|--|---|---|
|                                      |   | Pop <sup>C</sup>                         | n <sup>D</sup>   |   |   |
| 0.25                                 | 2 hr IE (4×14 min, $\dot{V}_E$ =70 L/min)   | H <sup>NS</sup>                          | 20M<br>(mean 25 yrs)   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> *, ↓ IC* and ↓ TLC*<br><b>AR:</b> ↓ SGaw*<br><b>SY:</b> ↑ respiratory symptoms*   | Kulle et al., 1985;<br>1996 AQCD, Table 7-1                 |
| 0.25                                 | 3 hr IE (6×15 min, EVR=14 L/min-m <sup>2</sup> )  | H  | 15M and 3F<br>(mean 44yrs)   | <b>IF:</b> significant increase in 3 hr postexposure sputum PMN compared to pre-exposure sputum; Bimosiamose pretreatment reduced PMN after O <sub>3</sub> exposure to approximately the pre-exposure baseline  | Kirsten et al., 2011;<br>2020 ISA, p. 3-30 and Table 3-9    |
| 0.25                                 | 3 hr IE (6×15 min, $\dot{V}_E$ =30 L/min)   | As <sup>A</sup><br>Al<br>H <sup>NS</sup> | 13M and 11F<br>(mean 26 yrs)<br>6M and 6F<br>(mean 25 yrs)<br>5M and 5F<br>(mean 23 yrs) | <b>PF:</b> O <sub>3</sub> -induced FEV <sub>1</sub> * decrements of 12.5, 14.1, and 10.2% in As <sup>M</sup> , Al and H <sup>NS</sup> , respectively (group differences not significant)<br><b>AR:</b> Methacholine responsiveness increased in As <sup>A</sup> subjects; allergen responsiveness increased significantly after O <sub>3</sub> exposure in both As <sup>A</sup> and Al subjects; no change in H <sup>NS</sup> subjects; allergen or methacholine response not correlated with each other or lung function | Jorres et al., 1996;<br>2006 AQCD, Table AX6-11             |
| 0.25                                 | 3 hr IE (6×15 min, $\dot{V}_E$ =30 L/min)<br>*challenged with allergen 20 hr following the last exposure and sputum collected 6-7 hr later                  | As <sup>M</sup><br>Al                    | 6M and 5F<br>(20-53 yrs);<br>16M and 6F<br>(19-48 yrs)                                   | <b>PF/AR:</b> Significantly greater mean early-phase allergen FEV <sub>1</sub> response and number of ≥20% reductions in FEV <sub>1</sub> in Al subjects<br><b>IF:</b> Significant increase in sputum eosinophils (As <sup>M</sup> and Al) and lymphocytes, mast cell tryptase, histamine, and LDH (As <sup>M</sup> only).  | Holz et al., 2002;<br>2006 AQCD, Tables AX6-3 and AX6-11    |
| 0.25                                 | 3 hr IE (6×15 min, EVR=20 L/min-m <sup>2</sup> )<br>four O <sub>3</sub> exposures: screening, placebo, and two treatments (inhaled or oral corticosteroids) | H <sup>NS</sup>                          | 14M and 4F<br>(mean 31.4 yrs)  | <b>PF:</b> Postexposure spirometry not significantly different from baseline.<br><b>IF:</b> Screening and placebo O <sub>3</sub> exposures caused > 9-fold increase in sputum neutrophils relative to baseline levels; relative to placebo, inhaled or oral corticosteroids significantly reduced neutrophil levels   | Holz et al., 2005<br>2006 AQCD, p. AX6-123 and Table AX6-13 |
| 0.25                                 | 3 hr IE (6×15 min, EVR=20 L/min-m <sup>2</sup> )  | H  | 12M and 12F<br>(20-48 yrs)   | <b>IF/HD:</b> Sputum neutrophils, sputum CD14+ cells, as well as concentrations of IL1B, IL6, IL8, MMP9, and TNFα in sputum supernatant significantly increased 3 hr postexposure   | Holz et al., 2015;<br>2020 ISA, p.3-29 and Table 3-9        |
| 0.25                                 | 3 hr IE (6×15 min, EVR=20 L/min-m <sup>2</sup> )  | H  | 11M and 3F<br>(mean 33 yrs)  | <b>IF:</b> Increase in blood neutrophils, neutrophil activation and total leukocytes at 5 and 7 hr postexposure, but not 24 hr.   | Billir et al., 2011;<br>2020 ISA, p. 4-28 and Table 3-4     |
| 0.25                                 | 3 hr IE (6×15 min, EVR=20 L/min-m <sup>2</sup> )  | H  | 11M and 3F<br>(22-47 yrs)  | <b>PF:</b> ↓ FVC*, and ↓ FEV <sub>1</sub> *<br><b>IF:</b> PMN increased in the blood 5 hr after the start of a 3-hr exposure and returned to baseline 21 hr postexposure  | Tank et al., 2011;<br>2020 ISA, p.3-29 and Table 3-4        |
| 0.25                                 | 3 hr IE (6×15 min, $\dot{V}_E$ =26 L/min) and repeated 1 week later   | H <sup>NS</sup><br>As <sup>M</sup>       | 10M and 11F<br>(mean 28 yrs)<br>5M and 10F<br>(mean 30 yrs)                              | <b>PF/SY:</b> Significant ↓ FVC* and ↓ FEV <sub>1</sub> that tended to be greater in the As <sup>M</sup> ; no significant group differences in symptoms or spirometry.<br><b>IF:</b> Significant ↑ neutrophils that did not differ between groups.  | Holz et al., 1999; 2006<br>AQCD, p. AX6-35 and Table AX6-3  |



| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>  | Subject<br>Characteristics <sup>B</sup> |  | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA                               |
|--------------------------------------|---|---|--|---|---|
|                                      |   | Pop <sup>C</sup>                        | n <sup>D</sup>   |   |   |
| 0.27                                 | 2 hr IE (3×20 min, EVR=25 L/min-m <sup>2</sup> )  | As <sup>A</sup>                         | 12 - sex not<br>indicated<br>(18-37 yrs)                     | <b>PF/SY:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * and ↓ VC* and significant increase in<br>symptom scores 24 hr following allergen challenge compared to FA<br><b>IF:</b> Percentage of eosinophils, but not neutrophils, in induced sputum<br>was higher 6 hr after O <sub>3</sub> vs. FA exposure  | Vagaggini et al., 2002;<br>AQCD 2006 Table AX6-12   |
| 0.27                                 | 2 hr CE (EVR=25 L/min-m <sup>2</sup> )<br>FA and to O <sub>3</sub> exposures before and<br>after 4 wk of treatment with<br>budesonide | As <sup>M</sup>                         | 7M and 7F<br>(20-50 yrs)                                     | <b>PF/SY:</b> Significant ↓ FEV <sub>1</sub> and symptom scores; no change in FEV <sub>1</sub><br>decrements or symptom scores with budesonide<br><b>IF:</b> Significant O <sub>3</sub> -induced increase in sputum PMN and IL-8 was<br>significantly reduced by budesonide 6 hr postexposure.  | Vagaggini et al., 2001;<br>AQCD 2006 Table AX6-13   |
| 0.27                                 | 2 hr IE (3×20 min, EVR=25 L/min-m <sup>2</sup> )<br>repeated 4 days after prednisone or<br>placebo                                    | As <sup>A</sup>                         | 8M and 1F<br>(mean 25 yrs)                                   | <b>PF:</b> Corticosteroid pretreatment did not prevent ↓ FEV <sub>1</sub> * vs placebo.<br><b>IF:</b> Significant inflammatory response (PMN influx) was prevented by<br>corticosteroid pretreatment in induced sputum 6 hr postexposure.   | Vagaggini et al., 2007;<br>2013 ISA, p. 6-78        |
| 0.30                                 | 30 to 80 min CE (V <sub>E</sub> =33 or 66 L/min)  | H                                       | 8M<br>(22-46 yrs)  | <b>PF:</b> Significant pulmonary function decrements and exercise<br>ventilatory pattern changes; multiple regression analysis showed O <sub>3</sub><br>effective dose is a better predictor of response than concentration, V <sub>E</sub> ,<br>or duration of exposure, and O <sub>3</sub> concentration accounted for the<br>majority of the pulmonary function variance   | Adams et al., 1981;<br>1996 AQCD, Table 7-1         |
| 0.30                                 | 1 hr CE (EVR=15 L/min-m <sup>2</sup> )  | H <sup>NS</sup><br>S                    | 17M and 13F<br>(mean 25 yrs)<br>19M and 11F<br>(mean 24 yrs) | <b>PF:</b> ↓ FEV <sub>1</sub> * was similar in both groups; based on exhaled CO <sub>2</sub> , only<br>smokers showed a reduction in dead space (-6.1 ± 1.2%) and an<br>increase in the alveolar slope  | Bates et al., 2014;<br>2020 ISA, p. 3-18, Table 3-4 |
| 0.30                                 | 1 hr CE (V <sub>E</sub> =60 L/min)  | H                                       | 5M   | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> * 1 hr postexposure<br><b>AR:</b> ↑ sRaw* 1 hr postexposure<br><b>IF:</b> ↑ PMNs* at 1 hr, 6 hr, and 24 hr postexposure compared with FA<br>in first aliquot "bronchial" sample (peaked at 6 hr); ↑ PMNs* at 6 and<br>24 hr in pooled aliquots.  | Schelegle et al., 1991;<br>1996 AQCD, Table 7-1     |
| 0.30                                 | 1 hr CE (V <sub>E</sub> =60 L/min) or<br>2hr IE (V <sub>E</sub> =45-47 L/min)   | H                                       | 12M<br>(mean 24 yrs)   | <b>PF:</b> ↓ FEV <sub>1</sub> * was equivalent for both protocols<br><b>SY:</b> Significant symptom scores only in CE protocol  | McKittrick and Adams, 1995;<br>1996 AQCD, Table 7-1 |
| 0.30                                 | 2 hr CE (EVR=25 L/min-m <sup>2</sup> )  | As                                      | 13M and 10F<br>(mean 33 yrs);                                | <b>PF:</b> 4% group mean FEV <sub>1</sub> decrement; no baseline difference between<br>responders (8 subjects with >10% FEV <sub>1</sub> decrements) and<br>nonresponders<br><b>IF:</b> Significant correlation between changes in FEV <sub>1</sub> and changes in<br>sputum neutrophils 6 hr postexposure compared to FA in responders;<br>significant increase in eosinophils in nonresponders only; NQO1<br>wildtype and GSTM1 null genotypes (6 subjects) not associated with<br>the changes in lung function or inflammatory responses | Vagaggini et al., 2010;<br>2013 ISA, p. 6-79-80     |



| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>                           | Subject<br>Characteristics <sup>B</sup> |   | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)   | Reference<br>AQCD/ISA  |
|--------------------------------------|--|---|---|--|--|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>                          |  |  |
| 0.30                                 | 2 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )<br>at 22°C and 32.5°C                             | H <sup>NS</sup>                         | 14M and 2F<br>(20-36 yrs)               | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> * compared to FA; no significant effect of temperature or O <sub>3</sub> -temperature interaction<br><b>IF:</b> Significant decrease in PAI-1 and plasminogen levels 24 hr postexposure at 22°C, but a significant increase in these coagulation markers 24 hr postexposure at 32.5°C                                   | Kahle et al., 2015;<br>2020 ISA, p. 4-26, Table 3-4                                  |
| 0.30                                 | 2 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )   | H                                       | 14M and 5F<br>(18-35 yrs)               | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> *<br><b>IF:</b> Significant relationship between FEV <sub>1</sub> and plasma ferritin (larger FEV <sub>1</sub> decrements in subjects with lower baseline plasma ferritin)  | Ghio et al., 2014;<br>2020 ISA, p. 3-15, Table 3-4                                   |
| 0.30                                 | 2 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )   | H                                       | 20M and 3F<br>(19-33 yrs)               | <b>IF:</b> Significant increases in CRP, IL-1, and IL-8, but not TNF-α; significant decrease in PAI-1 immediately and 24 hr postexposure; metabolomics analysis of BALF samples concluded that 1 hr responses reflected oxidative stress and at 24 hr responses reflected tissue repair  | Devlin et al., 2012;<br>Cheng et al., 2018;<br>2020 ISA, p. 4-26, 4-28,<br>Table 3-9 |
| 0.30                                 | 2 hr IE (4×15 min at either $\dot{V}_E$ =30 L/min, $\dot{V}_E$ =50 L/min or $\dot{V}_E$ =70 L/min) | H                                       | 30M (three groups of 10)<br>(19-26 yrs) | <b>PF:</b> ↓ FEV <sub>1</sub> * and ↓ FVC* at all ventilation rates; ↓ MVV* only at highest $\dot{V}_E$ . Note: additional exposure at 0.50 ppb resulted in ↓ FEV <sub>1</sub> *, ↓ FVC*, ↓ MVV*, ↓ IC*, and ↓ TLC* at all ventilation rates.  | Folinsbee et al., 1978 <sup>G</sup><br>1996 AQCD p. 7-10                             |
| 0.30                                 | 2.5 hr IE (4×15 min, $\dot{V}_E$ =65 L/min)  | H                                       | 20M<br>(18-30 yrs)                      | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> * and ↓ V <sub>T</sub> *; and ↑ f <sub>R</sub> *<br><b>AR:</b> ↑ sRaw*<br><b>SY:</b> ↑ respiratory symptoms*   | McDonnell et al., 1983;<br>1996 AQCD, p. 7-15, Table 7-1                             |
| 0.30                                 | 2.5 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )   | H                                       | 30M and 30F<br>(18-35 yrs)              | <b>PF:</b> ↓ FEV <sub>1</sub> * compared with FA<br><b>AR:</b> ↑ sRaw* compared with FA<br><b>SY:</b> ↑ respiratory symptoms* compared with FA   | Seal et al., 1993; 1996<br>AQCD, p. 7-15, Table 7-1                                  |
| 0.30                                 | 2 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )<br>2 consecutive days                             | H                                       | 11M and 4F<br>(23-36 yrs)               | <b>PF:</b> 2 consecutive days of O <sub>3</sub> exposure resulted in greater ↓ FEV <sub>1</sub> * than the decrement immediately after the first day of O <sub>3</sub> exposure  | Madden et al., 2014;<br>2020 ISA, p. 3-15, Table 3-4                                 |
| 0.30                                 | 2 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )<br>for 2 days                                     | H                                       | 11M and 4F<br>(23-36 yrs)               | <b>PF/IF:</b> ↓ FEV <sub>1</sub> * positively correlated with significant decrease in the inflammatory cytokine IFN-γ in the blood   | Stiegel et al., 2017;<br>2020 ISA, p. 3-15, Table 3-4                                |
| 0.30                                 | 2 hr IE (2×20 min, EVR=25 L/min-m <sup>2</sup> )   | As                                      | 86M and 34F<br>(mean 33 yrs)            | <b>PF/AR:</b> Magnitude of O <sub>3</sub> -induced FEV <sub>1</sub> response increased with decreasing baseline FEV <sub>1</sub> and lack of inhaled corticosteroid treatment; FEV <sub>1</sub> response was unrelated to methacholine responsiveness  | Bartoli et al., 2013;<br>2020 ISA, p. 3-17, p. 3-47,<br>Table 3-16                   |
| 0.32                                 | 1 hr CE (mean $\dot{V}_E$ =57 L/min)   | H <sup>At</sup>                         | 42M and 8F<br>(mean 26 yrs)             | <b>PF:</b> ↓ FEV <sub>1</sub> *<br><b>SY:</b> ↑ respiratory symptoms*  | Avol et al., 1984;<br>1996 AQCD, Table 7-1   |
| 0.33                                 | 2 hr IE (4×15 min, bicycle at 600 kpm/min)   | H <sup>NS</sup>                         | 9M<br>(mean 27 yrs)                     | <b>PF:</b> ↓ FVC*; post FA, normal gradient in ventilation which increased from apex to the base of the lung; post-O <sub>3</sub> , ventilation shifted away from the lower-lung into middle and upper-lung regions; post-O <sub>3</sub> increase in ventilation to mid-lung region correlated with decrease in midmaximal expiratory flow (r = 0.76, p < 0.05). | Foster et al., 1993;<br>2006 AQCD, Table AX6-1                                       |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>   | Subject<br>Characteristics <sup>B</sup> |  | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA   |
|--------------------------------------|--|---|--|---|---|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>   |   |   |
| 0.35                                 | 50 min CE ( $\dot{V}_E=60$ L/min)<br>repeat exposures over 4 days  | H <sup>NS</sup>                         | 8M<br>(19-26 yrs)<br>(some known<br>O <sub>3</sub> -sensitive) | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> * and ↓ V <sub>T</sub> * compared to FA on days 1-4; largest ↓ FEV <sub>1</sub> * on day 2; ↓ exercise performance time* on day 1 significantly less after the 4th day; ↑ f <sub>R</sub> *, and ↓ VO <sub>2max</sub> * on day 1, recovered by day 4.                          | Foxcroft and Adams, 1986;<br>2006 AQCD, Tables AX6-9,<br>AX6-10 |
| 0.35                                 | 1 hr CE ( $\dot{V}_E=80$ L/min) or 1 hr<br>competitive simulation (30 min at<br>$\dot{V}_E=52$ L/min, 30 at min $\dot{V}_E=100$<br>L/min; overall mean $\dot{V}_E=77.5$ L/min) | H <sup>At</sup>                         | 10M<br>(19-31 yrs)   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * and ↓ FEF <sub>25-75</sub> * compared to FA with both<br>protocols; ↓ V <sub>T</sub> * and ↑ f <sub>R</sub> * with CE; reduced exercise time in 3 subjects<br>who were unable to complete CE and competitive protocols<br><b>SY:</b> ↑ respiratory symptoms*  | Adams and Schelegle, 1983;<br>1996 AQCD, Table 7-1              |
| 0.35                                 | 1 hr CE (mean $\dot{V}_E=60$ L/min)<br>Pretreatment: no drug, placebo, or<br>indomethacin  | H                                       | 14M<br>(18-34 yrs)   | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> *; indomethacin significantly attenuated<br>decreases in FVC and FEV <sub>1</sub> compared to no drug and placebo;<br><b>AR:</b> ↑ sRaw* not affected by indomethacin  | Schelegle et al., 1987;<br>1996 AQCD, Table 7-1                 |
| 0.35/<br>0.20                        | 1 hr CE (mean $\dot{V}_E=60$ L/min);<br>2 exposures 24 hr apart  | H <sup>NS</sup>                         | 15M<br>(mean 25 yrs)   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * responses on each day compared to FA with an<br>increased response to 0.20 ppm on the second day<br><b>SY:</b> Consecutive exposures produced similar ↑ respiratory symptoms*   | Brookes et al., 1989;<br>2006 AQCD, Table AX6-9                 |
| 0.35                                 | 1 hr CE (mean $\dot{V}_E=60$ L/min);<br>2 exposures 24 hr apart  | H <sup>NS</sup>                         | 15M<br>(mean 25 yrs)   | <b>PF:</b> Significant ↓ FVC*, ↓ FEV <sub>1</sub> * responses on each day compared to<br>FA with an increased response to 0.35 ppm on the second day<br><b>SY:</b> Significant symptom responses were worse after second day of<br>exposure to 0.35 ppm   | Brookes et al., 1989;<br>2006 AQCD, Table AX6-9                 |
| 0.35                                 | 1 hr CE ( $\dot{V}_E=60$ L/min);<br>two exposures for each subject<br>separated by 24, 48, 72, or 120 hr   | H <sup>NS</sup>                         | 40M, 4 groups of<br>10<br>(19-35 yrs)                          | <b>PF/AR:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> * and ↑ sRaw* for all exposures.<br>Enhanced FEV <sub>1</sub> * response after 24 hr repeat exposure and a trend<br>toward an enhanced response at 48 hr. No differences between<br>responses to exposures separated by 72 or 120 hr. Similar trends<br>observed for sRaw. | Schonfeld et al., 1989;<br>2006 AQCD, Table AX6-9               |
| 0.35                                 | 70 min IE ( $\dot{V}_E=40$ L/min)  | H <sup>NS</sup>                         | 18F<br>(19-28 yrs)   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> * and ↓ MVV* immediately<br>postexposure.<br><b>AR:</b> ↑ sRaw* at 1 hr and 18 hr postexposure.   | Folinsbee and Hazucha,<br>1989; 2006 AQCD, Table<br>AX6-11      |
| 0.35                                 | 1.25 hr IE (2 × 30 min, $\dot{V}_E=40$ L/min)  | H                                       | 19F<br>(mean 22 yrs)   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> * and ↓ FEF <sub>25-75</sub> * 1 hr postexposure; Persistence<br>of small effects on both inspired and expired spirometry past 18 hr.<br><b>AR:</b> ↑ sRaw* 1 hr and 18 hr postexposure but not 42 hr postexposure.   | Folinsbee and Hazucha,<br>2000;<br>2006 AQCD, Table AX6-6       |
| 0.35                                 | 2.2 hr IE (2 × 30 min, $\dot{V}_E=50$ L/min;<br>final 10 min rest)   | H <sup>NS</sup>                         | 15M<br>(mean 25 yrs)   | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> *; pronounced slow phase in multi-breath<br>nitrogen washouts post O <sub>3</sub> exposure; washout delays not related to<br>changes in ventilatory pattern or lung volume at FRC.   | Foster et al., 1997;<br>2006 AQCD, Table AX6-1                  |
| 0.37                                 | 2 hr IE (4×15 min, $\dot{V}_E=2.5 \times$ rest)  | H                                       | 20M and 8F<br>(19-29 yrs)                                      | <b>PF:</b> ↓ FEF <sub>25</sub> * and ↓ FEF <sub>50</sub> * compared to FA<br>Note: additional exposure at 0.50 and 0.75 ppb resulted in ↓ FVC*, ↓<br>FEV <sub>1</sub> *, ↓ FEF <sub>25</sub> * and ↓ FEF <sub>50</sub> * compared to FA   | Silverman et al., 1976;<br>1996 AQCD, Table 7-1                 |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>     | Subject<br>Characteristics <sup>B</sup>                  |   | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA  |
|--------------------------------------|--|--|---|---|--|
|                                      |  | Pop <sup>C</sup>   | n <sup>D</sup>  |   |  |
| 0.40                                 | 1 hr IE (2×15 min, $\dot{V}_E$ =27 L/min)                                    | As <sup>M</sup>  | 6M and 6F<br>(19-40 yrs)  | <b>PF:</b> ↓ FEV <sub>1</sub> * but no exacerbation of exercise-induced asthma in a postexposure exercise challenge<br><b>SY:</b> Significant increase in respiratory symptoms regardless of exercise induced asthma status (7 subjects)  | Weymer et al., 1994;<br>2006 AQCD, Table AX6-11  |
| 0.40                                 | 1 hr CE (EVR=20 L/min-m <sup>2</sup> )                                       | H  | 22M<br>(18-35 yrs)  | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEV <sub>1</sub> /FVC*, and ↓ FEF <sub>25-75</sub> ; half-width of an expired aerosol bolus was significantly increased, suggesting an O <sub>3</sub> -induced change in small airway function.  | Keefe et al., 1991;<br>1996 AQCD, Table 7-1  |
| 0.40                                 | 1 hr CE (EVR=20 L/min-m <sup>2</sup> )                                       | H  | 20M<br>(18-35 yrs)  | <b>PF:</b> 25% ↓ V <sub>T</sub> and 9% ↓ O <sub>3</sub> uptake efficiency in the lower respiratory tract  | Gerrity et al., 1994;<br>1996 AQCD, Table 7-1  |
| 0.40                                 | 1 hr CE (EVR=30 L/min-m <sup>2</sup> )                                       | H <sup>NS</sup>  | 4 subjects (sex and age not indicated)  | <b>IF:</b> Apoptotic cells in BAL fluid 6 hr postexposure<br><b>HD:</b> Alveolar macrophages from BAL fluid showed the presence of 4-HNE, protein adduct, 72-kD heat shock protein and ferritin.  | Hamilton et al., 1998;<br>2006 AQCD, Table AX6-12  |
| 0.40                                 | 2 hr IE (4×15 min, cycle ergometry: 100W for M and 83W for F)                | H <sup>NS</sup>  | 7M and 3F<br>(23-41 yrs)  | <b>AR:</b> Increase in airway responsiveness to methacholine challenge<br><b>IF:</b> Increase in percentage of PMN and PGF <sub>2α</sub> ; increased TBX <sub>2</sub> , and PGE <sub>2</sub> concentrations in BAL fluid 3 hr postexposure vs FA  | Seltzer et al., 1986;<br>1996 AQCD, Tables 7-1, 7-11   |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =30 L/min)<br>3 day indomethacin pretreatment | H <sup>NAs</sup><br>As <sup>M</sup>                      | 5M and 4F<br>6M and 7F<br>(18-28 yrs)   | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> * in both groups; significant reductions in mid-flows in both groups but were greater in As <sup>M</sup> vs. H <sup>NAs</sup> subjects; indomethacin pretreatment attenuated ↓ FVC* and ↓ FEV <sub>1</sub> * responses to O <sub>3</sub> in H <sup>NAs</sup> but not As <sup>M</sup> subjects.   | Alexis et al., 2000;<br>2006 AQCD, Table AX6-1, AX6-13   |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =30-40 L/min)                                 | HG <sup>STM</sup><br>+<br>HG <sup>STM</sup><br>-         | 6M and 13F<br>9M and 7F<br>(mean 24 yrs)  | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> * from baseline across groups; no difference in lung function response between groups<br><b>IF:</b> ↑ PMN* and increased expression of HLA-DR on airway macrophages and dendritic cells in GSTM1- subjects 24 hr postexposure; decreased macrophages in GSTM1-sufficient subjects 4-24 hr postexposure. Note: no FA control  | Alexis et al., 2009;<br>2013 ISA, p. 6-80, p. 6-125  |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =30-40 L/min)                                 | H <sup>NS</sup>  | 4M and 5F<br>(21-30 yrs)  | <b>IF/HD:</b> Significant increase in sputum neutrophils; activation of monocytes and upregulation of cell surface molecules associated with antigen presentation (HLA-DR and CD86)   | Lay et al., 2007;<br>2013 ISA, p. 5-44   |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =30-40 L/min)                                 | H <sup>NAs</sup><br>Al <sup>NAs</sup><br>As <sup>A</sup> | 14M and 20F<br>(mean 24 yrs)<br>7M and 7F<br>(mean 25 yrs)<br>7M and 10F<br>(mean 24 yrs) | <b>IF/HD:</b> Enhanced inflammatory response in As <sup>A</sup> with greater numbers of neutrophils, higher levels of cytokines (IL-6, IL-8, IL-18, and TNF-α) and greater macrophage cell-surface expression of TLR4 and IgE receptors in induced sputum compared with H <sup>NAs</sup> ; increase hyaluronan in Al <sup>NAs</sup> and As <sup>A</sup> compared with H <sup>NAs</sup><br>Note: no FA control | Hernandez et al., 2010;<br>Hernandez et al., 2012;<br>2013 ISA, p. 6-130, p. 8-13;<br>2020 ISA, p. 3-29 p. 3-52,<br>Table 3-20 |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =40 L/min);<br>Mouthpiece exposure            | H  | 5M and 5F<br>(mean 30 yrs)  | <b>IF:</b> Significant increase in PMNs and decrease in macrophages in sputum 4 hr postexposure; IL-6, IL-8, and myeloperoxidase increased; possible relationship of IL-8 and PMN levels.   | Fahy et al., 1995;<br>2006 AQCD, Table AX6-12  |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>   | Subject<br>Characteristics <sup>B</sup> |   | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)   | Reference<br>AQCD/ISA   |
|--------------------------------------|--|---|---|--|---|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>  |  |   |
| 0.40                                 | 2 hr IE (4×15 min, EVR=18 L/min-m <sup>2</sup> )<br>Postexposure, H <sup>WR</sup> treated with<br>naxloxone or saline and H <sup>SR</sup> treated<br>with sufentanil or saline | H <sup>WR</sup><br>H <sup>SR</sup>      | 7M and 13F<br>21M and 21F<br>(20-59 yrs)                              | <b>PF/SY:</b> ↓ spirometric lung function* across groups, young adults (<35 yrs) significantly more responsive than older individuals (>35 yrs). Sufentanil, a narcotic analgesic, largely abolished symptom responses and improved FEV <sub>1</sub> in strong responders. Naloxone, an opioid antagonist, did not affect O <sub>3</sub> effects in weak responders. | Passannante et al., 1998;<br>2006 AQCD, Table AX6-13                                    |
| 0.40                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | H <sup>NAs</sup><br><br>As <sup>A</sup> | 5M and 1F<br>(mean 29 yrs)<br>6M<br>(mean 24 yrs)                     | <b>PF:</b> Similar ↓ FEV <sub>1</sub> * in both groups<br><b>AR:</b> Maximal FEV <sub>1</sub> response to methacholine increased similarly in both groups 12 hr postexposure<br><b>IF:</b> Significant increase in PMN in both groups  | Hiltermann et al., 1995;<br>2006 AQCD, Table AX6-3                                      |
| 0.40                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | As <sup>M</sup>                         | 1M and 5F<br>(18-27 yrs)  | <b>PF:</b> ↓ FEV <sub>1</sub> *<br><b>AR:</b> Increased airway responsiveness to methacholine 16 hr postexposure; no effect of proteinase inhibitor (rALP)   | Hiltermann et al., 1998;<br>2006 AQCD, Table AX6-12                                     |
| 0.40                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | As                                      | 10M and 6F<br>(19-35 yrs)   | <b>IF:</b> Levels of eosinophil cationic protein, IL-8 and percentage eosinophils highly correlated in sputum and BAL 16 hr postexposure.  | Hiltermann et al., 1999;<br>2006 AQCD, Table AX6-12                                     |
| 0.40                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )<br>Apocynin or placebo  | As <sup>M</sup>                         | 1M and 6F<br>(19-26 yrs)  | <b>AR/IF:</b> Increased bronchial responsiveness to methacholine 16 hr postexposure; inhaled apocynin (an inhibitor of NADPH oxidase present in inflammatory cells) treatment significantly reduced O <sub>3</sub> -induced airway responsiveness  | Peters et al., 2001;<br>2006 AQCD, Table AX6-11,  |
| 0.40                                 | 2 hr IE (4×15 min, EVR=20 L/min-m <sup>2</sup> )   | H <sup>NS</sup><br><br>H <sup>NS</sup>  | Placebo: 15M<br>and 1F<br>Antioxidant: 13M<br>and 2F<br>(mean 27 yrs) | <b>AR:</b> ↓ FVC*, and ↓ FEV <sub>1</sub> * in both groups<br><b>IF:</b> no difference in PMNs and IL-6 levels in BAL fluid 1 hr postexposure between treatment groups.  | Samet et al., 2001; Steck-<br>Scott et al., 2004;<br>2006 AQCD, Tables AX6-1,<br>AX6-13 |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =25 L/min)  | H <sup>Wt</sup><br>Ob                   | 19F<br>19F<br>(18-35 yrs)   | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> * in both groups; ↓ FVC* was greater in obese women than in normal-weight women.<br><b>AR/IF:</b> Increase in airway responsiveness or increase in PMN after O <sub>3</sub> exposure did not differ between normal-weight and obese women.<br><b>SY:</b> Symptoms in response to exposure did not differ between groups     | Bennett et al., 2016;<br>2020 ISA, p. 3-57, p. 3-59,<br>Tables 3-4, 3-8, 3-9, 3-31      |
| 0.40                                 | 2 hr IE (4×20 min of mild-moderate<br>exercise)<br>2 wk pretreatment with budesonide or<br>placebo   | H <sup>NAs</sup>                        | 6M and 9F<br>(mean 31 yrs)  | <b>PF:</b> ↓ FVC* and ↓ FEV <sub>1</sub> * immediately postexposure; FVC and FEV <sub>1</sub> decrements recovered 4 hr postexposure;<br><b>AR:</b> Small increased bronchial reactivity to methacholine<br><b>IF:</b> Increased PMNs and myeloperoxidase in 4 hr postexposure sputum; no protection from inhaled corticosteroid, budesonide.                        | Nightingale et al., 2000;<br>2006 AQCD, Table AX6-13                                    |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>                                       | Subject<br>Characteristics <sup>B</sup>                 |  | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA   |
|--------------------------------------|--|---|--|---|---|
|                                      |  | Pop <sup>C</sup>  | n <sup>D</sup>                                     |   |   |
| 0.40                                 | 2 hr IE (4×20 min, 50W cycle<br>ergometry, 10 min rest)<br><br>2 wk pretreatment with budesonide or<br>placebo | H <sup>NS</sup>   | 4M and 5F<br>(mean 30 yrs)                         | <b>PF:</b> Placebo-control: Immediately postexposure significant ↓ FVC and FEV <sub>1</sub> relative to pre-exposure values; 3 hr postexposure FVC and FEV <sub>1</sub> recovered to preexposure values.<br><b>IF:</b> Significant increases in 8-isoprostane at 4 hr postexposure; Budesonide for 2 wk prior to exposure did not affect responses.   | Montuschi et al., 2002;<br>2006 AQCD, Table AX6-1                         |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =50-75 L/min)   | H <sup>NAs</sup><br>A <sup>NAs</sup><br>As <sup>A</sup> | 5M and 8F<br>4M and 1F<br>3M and 8F<br>(21-35 yrs) | <b>PF/IF:</b> FEV <sub>1</sub> responses to O <sub>3</sub> not differentiated by asthma; precent predicted FEV <sub>1</sub> both before and after O <sub>3</sub> exposure did not differ between inflammatory responders (>10% increase in PMN) and nonresponders   | Fry et al., 2012;<br>2020 ISA, p. 3-29, p. 3-36,<br>Table 3-17            |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =50-75 L/min)<br>Pretreatment: saline or atropine                               | H <sup>NS</sup>   | 8M<br>(18-27yrs)                                   | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ V <sub>T</sub> *, and ↓ TLC*; and ↑ f <sub>R</sub> *. Atropine pretreatment attenuated FEV <sub>1</sub> and FEF <sub>25-75</sub> response.<br><b>AR:</b> ↑ sRaw*; Atropine pretreatment abolished increase in sRaw   | Beckett et al., 1985;<br>1996 AQCD, Table 7-1                             |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =53-55 L/min)   | H <sup>NAs</sup><br>As <sup>M</sup>                     | 4M and 5F<br>4M and 5F<br>(18-34 yrs)              | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, and ↓ FEF <sub>25-75</sub> in both groups with a significantly greater percent ↓ in As compared to H <sup>NAs</sup> subjects<br><b>AR:</b> ↑ sRaw* in As; airway responsiveness (methacholine challenge) was not statistically different between H <sup>NAs</sup> and As <sup>M</sup> subjects   | Kreit et al., 1989;<br>2006 AQCD, Table AX6-11                            |
| 0.40                                 | 2 hr IE (4×15 min, EVR=30 L/min-m <sup>2</sup> )<br>4 day pretreatment with indomethacin<br>or placebo         | H <sup>NS</sup>   | 13M<br>(18-31 yrs)                                 | <b>PF:</b> Indomethacin pretreatment resulted in a significantly smaller FVC and FEV <sub>1</sub> decrements than with O <sub>3</sub> alone<br><b>AR:</b> airway hyperresponsiveness was not significantly affected by indomethacin pretreatment.   | Ying et al., 1990;<br>1996 AQCD, Table 7-1                                |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =66 L/min)  | H <sup>NS</sup>   | 8M<br>(18-35 yrs)                                  | <b>IF:</b> BAL fluid at 1 hr postexposure vs. 18 hr postexposure. At 1 hr, PMN's, total protein, LDH, α1-antitrypsin, fibronectin, PGE <sub>2</sub> , thromboxane B <sub>2</sub> , C3a, tissue factor, and clotting factor VII were increased; IL-6 and PGE <sub>2</sub> were higher after 1 hr than 18 hr; fibronectin and tissue plasminogen activator higher after 18 hr. No time differences for PMN and protein. | Devlin et al., 1996;<br>2006 AQCD, Table AX6-12                           |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =70 L/min);   | H   | 11M<br>(18-35 yrs)                                 | <b>IF/HD:</b> Macrophages 18 hr postexposure had changes in the rate of synthesis of 123 different proteins as assayed by computerized densitometry of two-dimensional gel protein profiles   | Devlin and Koren, 1990;<br>2006 AQCD, Table AX6-12                        |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =70 L/min);   | H   | 11M<br>(18-35 yrs)                                 | <b>IF/HD:</b> BAL fluid 18 hr postexposure contained increased levels of the coagulation factors, tissue factor, and factor VII; macrophages in the BAL fluid had elevated tissue factor mRNA   | McGee et al., 1990;<br>2006 AQCD, Table AX6-12                            |
| 0.40                                 | 2 hr IE (4×15 min, $\dot{V}_E$ =70 L/min);   | H   | 11M<br>(18-35 yrs)                                 | <b>IF:</b> NL done immediately before, immediately after, and 22 hr after exposure; increased PMNs at both postexposure times; increased levels of tryptase (marker of mast cell degranulation) immediately postexposure; increased levels of albumin 22 hr postexposure.   | Graham and Koren, 1990;<br>Koren et al., 1990;<br>2006 AQCD, Table AX6-12 |

| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>                                      | Subject<br>Characteristics <sup>B</sup> |                            | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)  | Reference<br>AQCD/ISA  |
|--------------------------------------|---|---|----------------------------|---|--|
|                                      |   | Pop <sup>C</sup>                        | n <sup>D</sup>             |   |  |
| 0.40                                 | 2 hr IE (4×15 min, EVR=35 L/min-m <sup>2</sup> )  | H                                       | 11M<br>(18-35 yrs)         | <b>PF/IF:</b> Significant increase in PMNs, total protein, albumin, IgG, PGE <sub>2</sub> , plasminogen activator, neutrophil elastase complement C3a, and fibronectin; no correlation between pulmonary function and inflammatory endpoints in BAL fluid 18 hr postexposure<br><b>HD:</b> decrease in percentage of macrophages compared to FA   | Koren et al., 1989a;<br>Koren et al., 1989b;<br>1996 AQCD, Table 7-1;<br>2006 AQCD, Table AX6-12 |
| 0.40                                 | 2 hr IE (4×15 min, EVR=35 L/min-m <sup>2</sup> )  | H                                       | 10M<br>(18-35 yrs)         | <b>PF/IF:</b> Increased PMN, protein, PGE <sub>2</sub> , LDH, TXB <sub>2</sub> , IL-6 $\alpha$ -1 anti-trypsin, and tissue factor in BAL fluid 1 hr postexposure compared to 18 hr; fibronectin and urokinase-type plasminogen activator higher 18 hr postexposure than 1 hr<br><b>HD:</b> Decreased phagocytosis of yeast by alveolar macrophages.   | Koren et al., 1991;<br>1996 AQCD, Table 7-1;<br>2006 AQCD, Table AX6-12                          |
| 0.40                                 | 2 hr IE (4×15 min, EVR=35 L/min-m <sup>2</sup> )  | H                                       | 8M<br>(20-30 yrs)          | <b>PF:</b> ↓ FVC*<br><b>AR:</b> ↑ sRaw*<br><b>IF:</b> Significantly increased clearance of <sup>99m</sup> Tc-DTPA from the lung indicating epithelial damage, and changes in permeability.  | Kehrl et al., 1987;<br>2006 AQCD, Table AX6-13   |
| 0.40                                 | 2.5 hr IE (4×15 min, EVR=25 L/min-m <sup>2</sup> )  | H                                       | 30M and 30F<br>(18-35 yrs) | <b>PF:</b> ↓ FEV <sub>1</sub> * compared with FA<br><b>AR:</b> ↑ sRaw* compared with FA<br><b>SY:</b> ↑ Respiratory symptoms* compared with FA  | Seal et al., 1993; 1996<br>AQCD, p. 7-15, Table 7-1  |
| 0.40                                 | 2.5 hr IE (4×15 min at $\dot{V}_E$ =64 L/min)   | H                                       | 29M<br>(18-30 yrs)         | <b>PF:</b> ↓ FVC*, ↓ FEV <sub>1</sub> *, ↓ FEF <sub>25-75</sub> *, ↓ V <sub>T</sub> * and ↑ f*<br><b>AR:</b> ↑ sRaw*<br><b>SY:</b> ↑ Respiratory symptoms*  | McDonnell et al., 1983;<br>1996 AQCD, p. 7-15, Table 7-1   |
| 0.40                                 | 2 Hr IE (4×15 min, 2 × resting $\dot{V}_E$ )<br>2 Hr IE (4×15 min, 2 × resting $\dot{V}_E$ ) × 3 days         | H <sup>NS</sup>                         | 12M and 7F<br>(21-32 yrs)  | <b>AR:</b> Significant increase in histamine airway responsiveness with progressive adaptation of the effect; after day 3 histamine responsiveness was not different from sham exposures  | Dimeo et al., 1981;<br>2006 AQCD, Table AX6-11   |
| 0.40                                 | IE (2×15 min, $\dot{V}_E$ =40 L/min-m <sup>2</sup> )<br>2 h/day for 5 days,<br>2 h either 10 or 20 days later | H <sup>NS</sup>                         | 16M<br>(18-35 yrs)         | <b>PF:</b> ↓ FEV <sub>1</sub> * at each time point; FEV <sub>1</sub> decrement was greatest on day 2 and was significantly attenuated by days 4 and 5.<br><b>IF:</b> BAL immediately after day 5 of exposure and again after exposure 10 or 20 days later. Most markers of inflammation (PMNs, IL-6, PGE <sub>2</sub> , fibronectin) showed complete attenuation; markers of damage (LDH, IL-8, protein, 1-antitrypsin, elastase) did not. Reversal of attenuation was not complete for some markers, even after 20 days. | Devlin et al., 1997;<br>2006 AQCD, Tables AX6-9,<br>and AX 6-12                                  |
| 0.40                                 | 3 hr/day (2 hr resting followed by 1 hr CE at 4-5 resting $\dot{V}_E$ ) for 5 days,                           | H <sup>NS</sup>                         | 13M and 11F<br>(19-46 yrs) | <b>AR:</b> Enhanced airway response to methacholine after the first 3 days which normalized by day 5  | Kulle et al., 1982;<br>1996 AQCD, Table 7-10   |

| O <sub>3</sub> <sup>A</sup><br>(ppm)     | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup>              | Subject<br>Characteristics <sup>B</sup> |                              | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)   | Reference<br>AQCD/ISA                                     |
|--|---|---|------------------------------|--|---|
|  |   | Pop <sup>C</sup>                        | n <sup>D</sup>               |  |   |
| 0.40                                     | 3 hr/day for 5 days: IE (6×15 min<br>mild-moderate exercise, $\dot{V}_E=32$<br>L/min) | As <sup>M</sup>                         | 8M and 2F<br>(mean 31 yrs)   | <b>PF/SY:</b> Significant ↓ FEV <sub>1</sub> and increase in symptom response on O <sub>3</sub><br>exposure days 1 and 2 that diminished with continued exposure;<br>tolerance partially lost 4 and 7 days postexposure<br><b>AR:</b> bronchial reactivity to methacholine peaked after O <sub>3</sub> exposure on<br>day 1, but remained elevated with continued exposure | Gong et al., 1997;<br>2006 AQCD, Table AX6-11             |
| <b>Children During Moderate Exercise</b> |   |   |                              |  |   |
| 0.12                                     | 2.5 hr IE (4×15 min, EVR=35 L/min-<br>m <sup>2</sup> )                                | H                                       | 23 M<br>(8-11 yrs)           | <b>PF:</b> ↓ FEV <sub>1</sub> * compared with clean air which persisted for 16-20 hr<br><b>SY:</b> No significant increase in severity of respiratory symptoms   | McDonnell et al. (1985);<br>2006 AQCD                     |
| <b>Adult Subjects at Rest</b>            |   |   |                              |  |   |
| 0.10                                     | 2 hr  | H                                       | 10M<br>(18-28 yrs)           | <b>PF:</b> No significant change in pulmonary function   | Folinsbee et al., 1978;<br>1996 AQCD, p. 7-10             |
| 0.10                                     | 2 hr  | H <sup>NS</sup>                         | 13M and 1F<br>(mean 24 yrs)  | <b>AR:</b> No increased airway responsiveness to methacholine<br>immediately after exposure.   | Konig et al., 1980;<br>1996 AQCD, Table 7-10              |
| 0.12                                     | 1 hr<br>Air-antigen/O <sub>3</sub> -antigen   | As <sup>A</sup>                         | 4M and 3F<br>(21-64 yrs)     | <b>PF:</b> No change in baseline pulmonary function.<br><b>AR:</b> Increased allergen-specific airway responsiveness to inhaled<br>ragweed or grass after O <sub>3</sub> exposure compared to FA   | Molfino et al., 1991;<br>1996 AQCD, Tables 7-2, 7-<br>10  |
| 0.12                                     | 1 hr  | As <sup>A</sup>                         | 10M and 5F<br>(19-34 yrs)    | <b>PF:</b> No significant change in pulmonary function to O <sub>3</sub> alone.<br><b>AR:</b> No significant change in sRaw to O <sub>3</sub> alone; no significant effect<br>on airway responsiveness to grass allergen   | Ball et al., 1996<br>2006 AQCD, Table AX6-11              |
| 0.12                                     | 1 hr<br>(Air-Antigen)   | As <sup>A</sup>                         | 9M and 6F (18-<br>49 yrs)    | <b>AR:</b> No effect of O <sub>3</sub> on airway responsiveness to grass or ragweed<br>allergen.   | Hanania et al., 1998;<br>2006 AQCD, Table AX6-11          |
| 0.12                                     | 1 hr O <sub>3</sub> at rest followed by 6 min<br>maximal exercise                     | As <sup>A</sup>                         | 7M and 8F (19-<br>45 yrs)    | <b>PF:</b> No significant change in FEV <sub>1</sub><br><b>AR:</b> O <sub>3</sub> pre-exposure did not affect the magnitude or time course of<br>exercise-induced bronchoconstriction.   | Fernandes et al., 1994<br>1996 AQCD, Table 7-2            |
| 0.20                                     | 2 hr  | H <sup>NS</sup>                         | 15 subjects                  | <b>IF/HD:</b> Increased numbers of CD3+, CD4+, and CD8+ T lymphocyte<br>subsets, in addition to neutrophils, in BAL fluid 6 hr postexposure.   | Blomberg et al., 1997;<br>2006 AQCD, Table AX6-12         |
| 0.25                                     | 2 hr  | H                                       | 8M and 5F<br>(21-22 yrs)     | <b>PF:</b> No significant change in FVC compared with FA   | Horvath et al., 1979;<br>1996 AQCD, Table 7-1             |
| 0.30                                     | 2 hr  | H                                       | 10M<br>(18-28 yrs)           | <b>PF:</b> No significant change in pulmonary function   | Folinsbee et al., 1978 <sup>G</sup><br>1996 AQCD, p. 7-10 |
| 0.30                                     | 2 hr  | H                                       | 9-11 subjects<br>(18-35 yrs) | <b>IF:</b> Significantly elevated levels of pro-inflammatory oxysterols in BAL<br>fluid compared to FA   | Speen et al., 2016<br>2020 ISA, Table 3-9                 |
| 0.32                                     | 2 hr  | H <sup>NS</sup>                         | 13M and 1F<br>(mean 24 yrs)  | <b>AR:</b> Increased airway responsiveness to methacholine immediately<br>after exposure.  | Konig et al., 1980;<br>1996 AQCD, Table 7-10              |



| O <sub>3</sub> <sup>A</sup><br>(ppm) | Exposure and Ventilation<br>Characteristics During Exercise <sup>W</sup> | Subject<br>Characteristics <sup>B</sup> |                             | Reported Effects on Pulmonary Function (PF), Airway<br>Resistance and/or Responsiveness (AR), Respiratory<br>Symptoms (SY), Inflammation (IF) <sup>E</sup> and Host Defense (HD)   | Reference<br>AQCD/ISA   |
|--------------------------------------|--|---|-----------------------------|--|---|
|                                      |  | Pop <sup>C</sup>                        | n <sup>D</sup>              |  |   |
| 0.37                                 | 2 hr   | H                                       | 20M and 8F<br>(19-29 yrs)   | <b>PF:</b> No significant change in FEV <sub>1</sub> , FEF <sub>25</sub> , and FEF <sub>50</sub> compared with FA  | Silverman et al., 1976;<br>1996 AQCD, Table 7-1                       |
| 0.40                                 | 2 hr   | As <sup>A</sup>                         | 12 subjects<br>(18-35 yrs)  | <b>IF:</b> Release of early-onset mast cell-derived mediators into NL in response to allergen not enhanced after O <sub>3</sub> exposure. No increase in neutrophil and eosinophil inflammatory mediators after O <sub>3</sub> exposure or enhancement after allergen challenge. O <sub>3</sub> increased eosinophil influx following allergen exposure. | Michelson et al., 1999<br>2006 AQCD, Table AX6-12                     |
| 0.40                                 | 2 hr   | As <sup>M</sup>                         | 10 subjects<br>(18-35 yrs)  | <b>IF:</b> Increased response to allergen; significant increase in PMN and eosinophils after O <sub>3</sub> plus allergen challenge; O <sub>3</sub> alone increased nasal inflammation (PMN).  | Peden et al., 1995;<br>2006 AQCD, Table AX6-12                        |
| 0.40                                 | 2hr × 2 days during and out of grass pollen season                       | AI                                      | 5M and 5F<br>(mean 28 yrs)  | <b>IF:</b> Significant increase in nasal mucus total protein, albumin, PMNs, and eosinophils following O <sub>3</sub> exposures during pollen season, but an allergen exaggerated the inflammatory response cannot be concluded because statistical tests were not performed across the seasons  | Dokic and Trajkovska-Dokic,<br>2013; 2020 ISA, p. 3-51,<br>Table 3-21 |
| 0.50                                 | 2 hr   | H                                       | 10M<br>(18-28 yrs)          | <b>PF:</b> ↓ FEV <sub>1</sub> <sup>*</sup> , ↓ FVC <sup>*</sup> but no change in MVV   | Folinsbee et al., 1978; <sup>G</sup><br>1996 AQCD, Table 7-1          |
| 0.50                                 | 2 hr   | H                                       | 8M and 5F<br>(21-22 yrs)    | <b>PF:</b> ↓ FVC <sup>*</sup> compared with FA   | Horvath et al., 1979;<br>1996 AQCD, Table 7-1                         |
| 0.50                                 | 2 hr   | H                                       | 20M and 8F<br>(19-29 yrs)   | <b>PF:</b> No significant change in FEV <sub>1</sub> , FEF <sub>25</sub> , and FEF <sub>50</sub> compared with FA  | Silverman et al., 1976;<br>1996 AQCD, Table 7-1                       |
| 0.60                                 | 2 hr   | H <sup>NS</sup>                         | 5M and 3F<br>(22-30 yrs)    | <b>AR:</b> 300% increase in histamine-induced ΔRaw 5 min after O <sub>3</sub> exposure; 84 and 50% increases 24 hr and 1 week after exposure (p > 0.05), respectively. Two subjects had an increased response to histamine 1 week after exposure.  | Golden et al., 1978;<br>1996 AQCD, Table 7-10;                        |
| 0.75                                 | 2 hr   | H                                       | 8M and 5F<br>(21-22 yrs)    | <b>PF:</b> ↓ FVC <sup>*</sup> compared with FA   | Horvath et al., 1979;<br>1996 AQCD, Table 7-1                         |
| 0.75                                 | 2hr  | H                                       | 20M and 8F<br>(19-29 yrs)   | <b>PF:</b> ↓ FEV <sub>1</sub> <sup>*</sup> , ↓ FEF <sub>25</sub> <sup>*</sup> , and ↓ FEF <sub>50</sub> <sup>*</sup> compared with FA  | Silverman et al., 1976;<br>1996 AQCD, Table 7-1                       |
| 1.00                                 | 2 hr   | H <sup>NS</sup>                         | 13M and 1F<br>(mean 24 yrs) | <b>AR:</b> Increased airway responsiveness to methacholine immediately after exposure.   | Konig et al., 1980<br>1996 AQCD, Table 7-10                           |

Note: Newly added studies since the 2015 review are in blue font.

<sup>A</sup> Reported target mean O<sub>3</sub> concentrations

<sup>W</sup> Focused on O<sub>3</sub> exposures below 0.4 ppm during exercise and below 1.00 ppm at rest

<sup>B</sup> Subject Characteristics are subdivided into subject population (Pop) and number (n) subjects.

<sup>C</sup> Subject population included: healthy subjects (H), athletes included competitive endurance cyclists and runners (H<sup>A</sup>), nonsmokers (H<sup>NS</sup>), nonasthmatics (H<sup>NAs</sup>), nonasthmatics with allergies (AI<sup>NAs</sup>), asthmatics (As), mild asthmatics (As<sup>M</sup>), SO<sub>2</sub>-sensitive asthmatics (As<sup>SO2</sup>), asthmatics with allergies (As<sup>A</sup>), subjects with allergies (AI), smokers (S), healthy



subjects with the GSTM1 genotype (H<sup>GSTM+</sup>) or null for the GSTM1 genotype (H<sup>GSTM-</sup>), healthy subjects that have a weak O<sub>3</sub> response (H<sup>WR</sup>) or have a strong O<sub>3</sub> response (H<sup>SR</sup>), healthy weight subjects (H<sup>W</sup>) and obese subjects (Ob).

<sup>D</sup> Number is further characterized by sex, male (M) and female (F), and age range or mean age of the subjects.

<sup>E</sup> For the purposes of this table the "IF" category includes reported effects on inflammation (the most commonly tested endpoint) as well as injury and oxidative stress responses because injury, inflammation, and oxidative stress responses are difficult to disentangle. Inflammation generally occurs as a consequence of injury and oxidative stress, but it can also lead to further oxidative stress and injury due to secondary production of reactive oxygen species (ROS) by inflammatory cells (2020 ISA section 3.1.3).

\* Indicates statistical significance

<sup>F</sup> Avol et al., 1984 reported O<sub>3</sub>-induced effects for 0.08, 0.16, 0.24 and 0.32 ppm but only effects from 0.16, 0.24 and 0.32 ppm was referenced in 1996 AQCD, Table 7-1.

<sup>G</sup> Folinsbee et al., 1978 reported data for subjects exposed to O<sub>3</sub> during exercise at 0.1 ppm and 0.3 ppm at 3 different ventilation rates and at rest at 0.1 ppm, 0.3 ppm and 0.5 ppm. Only the 0.5 ppm O<sub>3</sub> exposure to subjects at rest was referenced in 1996 AQCD, Table 7-1 (although the number of subjects was incorrectly identified for this exposure).

<sup>J</sup> Subtracted from FA, the group mean decrement in FEV<sub>1</sub> was 9.7% (2006 AQCD and 2013 ISA).

**Abbreviations:** BAL, bronchoalveolar lavage; C3a, complement protein fragment; CC16, protein secreted by Clara cells in the non-ciliated respiratory epithelium; CD86, surface costimulatory marker for T-cell activation; CE, continuous exercise; CRP, C-reactive protein; ENA-78, epithelial cell-derived neutrophil-activating peptide; FA, filtered air; FEF<sub>25</sub>, (formerly designated as V<sub>25%VC</sub>) instantaneous forced expiratory flow after 25% of forced vital capacity; FEF<sub>25-75</sub>, forced expiratory flow over the middle half of forced vital capacity; FEF<sub>50</sub>, (formerly designated as V<sub>50%VC</sub>) instantaneous forced expiratory flow after 50% of forced vital capacity; FEV<sub>1</sub>, forced expiratory volume in one second; f<sub>R</sub>, respiratory frequency (also abbreviated as f); FRC, functional reserve capacity; FVC, forced vital capacity; GM-CSF, granulocyte-macrophage colony-stimulating factor; GSTM1, glutathione S-transferase M1 polymorphism; HLA-DR, human leukocyte antigens; 4-HNE, 4-hydroxynonenal; IC, inspiratory capacity; IE, intermittent exercise; IgE, immunoglobulin E; IgG, immunoglobulin G antibody; IL-6, IFN-γ, interferon-gamma; IL-1, interleukin 1 pro-inflammatory cytokine interleukin 6 pro-inflammatory cytokine; IL-8, interleukin 8 pro-inflammatory cytokine; IL-18, interleukin 18 pro-inflammatory cytokine; ISA, Integrated Science Assessment; LDH, lactate dehydrogenase; LTB<sub>4</sub>, leukotriene; MMP9, metalloproteinase 9; MVV, maximal voluntary ventilation; NQO1, NAD(P)H:quinone oxidoreductase; NL, nasal lavage; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; PAI-1, plasminogen activator fibrinogen inhibitor-1; PGE<sub>2</sub>, prostaglandin E<sub>2</sub> a mediator of inflammation; PGE<sub>2</sub>, bronchodilatory prostaglandin; PGF<sub>2α</sub>, prostaglandin 2 alpha; PMN, polymorphonuclear neutrophils; ROS, reactive oxygen species; sGaw, specific airway conductance; sRaw, specific airway resistance; substance P, neuropeptide that act as a neurotransmitter and neuromodulator; TBARS, Thiobarbituric acid reactive substance, <sup>99m</sup>Tc-DTPA, radiolabelled diethylene triamine pentaacetic acid; TBX2, thromboxane B2; TLC, total lung capacity; TLR4, Toll-like receptor protein 4; TNF-α, tumor necrosis factor alpha; tPA, tissue plasminogen activator; VC, vital capacity; V<sub>E</sub>max, maximal expiratory volume; VO<sub>2</sub>max, maximum rate of oxygen consumption during exercise; V<sub>T</sub>, tidal volume; V<sub>T</sub>max, peak tidal volume during exercise; W, watts; 8-epi-PGF<sub>2α</sub>, prostaglandin 2 alpha; <sup>99m</sup>Tc-DTPA, technetium 99m-labelled diethylenetriamine penta-acetic acid used aerosol ventilation studies

## 1 REFERENCES

- 2 Adams, WC (2000). Ozone dose-response effects of varied equivalent minute ventilation rates. J  
3 Expo Anal Environ Epidemiol 10(3): 217-226.
- 4 Adams, WC (2002). Comparison of chamber and face-mask 6.6-hour exposures to ozone on  
5 pulmonary function and symptoms responses. Inhal Toxicol 14(7): 745-764.
- 6 Adams, WC (2003). Comparison of chamber and face mask 6.6-hour exposure to 0.08 ppm  
7 ozone via square-wave and triangular profiles on pulmonary responses. Inhal Toxicol  
8 15(3): 265-281.
- 9 Adams, WC (2006a). Human pulmonary responses with 30-minute time intervals of exercise and  
10 rest when exposed for 8 hours to 0.12 ppm ozone via square-wave and acute triangular  
11 profiles. Inhal Toxicol 18(6): 413-422.
- 12 Adams, WC (2006b). Comparison of chamber 6.6-h exposures to 0.04-0.08 PPM ozone via  
13 square-wave and triangular profiles on pulmonary responses. Inhal Toxicol 18(2): 127-  
14 136.
- 15 Adams, WC and Ollison, WM (1997). Effects of prolonged simulated ambient ozone dosing  
16 patterns on human pulmonary function and symptomatology Air & Waste Management  
17 Association Pittsburgh, PA.
- 18 Adams, WC, Savin, WM and Christo, AE (1981). Detection of ozone toxicity during continuous  
19 exercise via the effective dose concept. J Appl Physiol (1985) 51(2): 415-422.
- 20 Adams, WC and Schelegle, ES (1983). Ozone and high ventilation effects on pulmonary  
21 function and endurance performance. J Appl Physiol (1985) 55(3): 805-812.
- 22 Alexis, N, Urch, B, Tarlo, S, Corey, P, Pengelly, D, O'Byrne, P and Silverman, F (2000).  
23 Cyclooxygenase metabolites play a different role in ozone-induced pulmonary function  
24 decline in asthmatics compared to normals. Inhal Toxicol 12(12): 1205-1224.
- 25 Alexis, NE, Zhou, H, Lay, JC, Harris, B, Hernandez, ML, Lu, TS, Bromberg, PA, Diaz-Sanchez,  
26 D, Devlin, RB, Kleeberger, SR and Peden, DB (2009). The glutathione-S-transferase Mu  
27 1 null genotype modulates ozone-induced airway inflammation in human subjects. J  
28 Allergy Clin Immunol 124(6): 1222-1228.
- 29 Arjomandi, M, Balmes, JR, Frampton, MW, Bromberg, P, Rich, DQ, Stark, P, Alexis, NE,  
30 Costantini, M, Hollenbeck-Pringle, D, Dagincourt, N and Hazucha, MJ (2018).  
31 Respiratory responses to ozone exposure: the multicenter ozone study in older subjects  
32 (moses). Am J Respir Crit Care Med 197: 1319–1327.
- 33 Avol, EL, Linn, WS, Venet, TG, Shamoo, DA and Hackney, JD (1984). Comparative respiratory  
34 effects of ozone and ambient oxidant pollution exposure during heavy exercise. J Air  
35 Waste Manage Assoc 34(8): 804-809.

1 Ball, BA, Folinsbee, LJ, Peden, DB and Kehrl, HR (1996). Allergen bronchoprovocation of  
2 patients with mild allergic asthma after ozone exposure. *J Allergy Clin Immunol* 98(3):  
3 563-572.

4 Bartoli, ML, Vagaggini, B, Malagrino, L, Bacci, E, Cianchetti, S, Dente, FL, Novelli, F, Costa, F  
5 and Paggiaro, P (2013). Baseline airway inflammation may be a determinant of the  
6 response to ozone exposure in asthmatic patients. *Inhal Toxicol* 25(3): 127-133.

7 Bates, ML, Brenza, TM, Ben-Jebria, A, Bascom, R, Eldridge, MW and Ultman, JS (2014).  
8 Pulmonary function responses to ozone in smokers with a limited smoking history.  
9 *Toxicol Appl Pharmacol* 278(1): 85-90.

10 Beckett, WS, McDonnell, WF, Horstman, DH and House, DE (1985). Role of the  
11 parasympathetic nervous system in acute lung response to ozone. *J Appl Physiol* (1985)  
12 59(6): 1879-1885.

13 Bennett, WD, Ivins, S, Alexis, NE, Wu, J, Bromberg, PA, Brar, SS, Travlos, G and London, SJ  
14 (2016). Effect of obesity on acute ozone-induced changes in airway function, reactivity,  
15 and inflammation in adult females. *PLoS ONE* 11(8): e0160030.

16 Biller, H, Holz, O, Windt, H, Koch, W, Müller, M, Jörres, RA, Krug, N and Hohlfeld, JM  
17 (2011). Breath profiles by electronic nose correlate with systemic markers but not ozone  
18 response. *Respir Med* 105(9): 1352-1363.

19 Blomberg, A, Helleday, R, Pourazar, J, Stenfors, N, Kelly, FJ, Frew, AJ, Holgate, ST and  
20 Sandstrom, T (1997). Early airway and peripheral blood cell responses to 020 ppm ozone  
21 in healthy human subjects. *Eur Respir J* 10: 274S.

22 Blomberg, A, Mudway, I, Svensson, M, Hagenbjork-Gustafsson, A, Thomasson, L, Helleday, R,  
23 Dumont, X, Forsberg, B, Nordberg, G and Bernard, A (2003). Clara cell protein as a  
24 biomarker for ozone-induced lung injury in humans. *Eur Respir J* 22(6): 883-888.

25 Blomberg, A, Mudway, IS, Nordenhall, C, Hedenstrom, H, Kelly, FJ, Frew, AJ, Holgate, ST and  
26 Sandstrom, T (1999). Ozone-induced lung function decrements do not correlate with  
27 early airway inflammatory or antioxidant responses. *Eur Respir J* 13(6): 1418-1428.

28 Bosson, J, Stenfors, N, Bucht, A, Helleday, R, Pourazar, J, Holgate, ST, Kelly, FJ, Sandstrom, T,  
29 Wilson, S, Frew, AJ and Blomberg, A (2003). Ozone-induced bronchial epithelial  
30 cytokine expression differs between healthy and asthmatic subjects. *Clin Exp Allergy*  
31 33(6): 777-782.

32 Bosson, JA, Blomberg, A, Stenfors, N, Helleday, R, Kelly, FJ, Behndig, AF and Mudway, I  
33 (2013). Peripheral blood neutrophilia as a biomarker of ozone-induced pulmonary  
34 inflammation. *PLoS ONE* 8(12): e81816.

35 Brookes, KA, Adams, WC and Schelegle, ES (1989). 035 ppm O<sub>3</sub> exposure induces  
36 hyperresponsiveness on 24-h reexposure to 020 ppm O<sub>3</sub>. *J Appl Physiol* (1985) 66(6):  
37 2756-2762.

- 1 Brown, JS, Bateson, TF and McDonnell, WF (2008). Effects of exposure to 0.06 ppm ozone on  
2 FEV1 in humans: a secondary analysis of existing data. *Environ Health Perspect* 116(8):  
3 1023-1026.
- 4 Cheng, W, Duncan, KE, Ghio, AJ, Ward-Caviness, C, Karoly, ED, Diaz-Sanchez, D, Conolly,  
5 RB and Devlin, RB (2018). Changes in metabolites present in lung lining fluid following  
6 exposure of humans to ozone. *Toxicol Sci* 163(2): 430–439.
- 7 Corradi, M, Alinovi, R, Goldoni, M, Vettori, M, Folesani, G, Mozzoni, P, Cavazzini, S,  
8 Bergamaschi, E, Rossi, L and Mutti, A (2002). Biomarkers of oxidative stress after  
9 controlled human exposure to ozone. *Toxicol Lett* 134(1-3): 219-225.
- 10 Devlin, RB, Duncan, KE, Jardim, M, Schmitt, MT, Rappold, AG and Diaz-Sanchez, D (2012).  
11 Controlled exposure of healthy young volunteers to ozone causes cardiovascular effects.  
12 *Circulation* 126(1): 104-111.
- 13 Devlin, RB, Folinsbee, LJ, Biscardi, F, Hatch, G, Becker, S, Madden, MC, Robbins, M and  
14 Koren, HS (1997). Inflammation and cell damage induced by repeated exposure of  
15 humans to ozone. *Inhal Toxicol* 9(3): 211-235.
- 16 Devlin, RB and Koren, HS (1990). The use of quantitative two-dimensional gel electrophoresis  
17 to analyze changes in alveolar macrophage proteins in humans exposed to ozone. *Am J*  
18 *Respir Cell Mol Biol* 2(3): 281-288.
- 19 Devlin, RB, McDonnell, WF, Becker, S, Madden, MC, McGee, MP, Perez, R, Hatch, G, House,  
20 DE and Koren, HS (1996). Time-dependent changes of inflammatory mediators in the  
21 lungs of humans exposed to 0.4 ppm ozone for 2 hr: A comparison of mediators found in  
22 bronchoalveolar lavage fluid 1 and 18 hr after exposure. *Toxicol Appl Pharmacol* 138(1):  
23 176-185.
- 24 Dimeo, MJ, Glenn, MG, Holtzman, MJ, Sheller, JR, Nadel, JA and Boushey, HA (1981).  
25 Threshold concentration of ozone causing an increase in bronchial reactivity in humans  
26 and adaptation with repeated exposures. *Am Rev Respir Dis* 124(3): 245-248.
- 27 Dokic, D and Trajkovska-Dokic, E (2013). Ozone exaggerates nasal allergic inflammation.  
28 Makedonska Akademija na Naukite i Umetnostite. Oddelenie za Bioloski i Medicinski  
29 Nauki. *Prilozi* 34(1): 131-141.
- 30 Fahy, JV, Wong, HH, Liu, JT and Boushey, HA (1995). Analysis of induced sputum after air and  
31 ozone exposures in healthy subjects. *Environ Res* 70(2): 77-83.
- 32 Fernandes, ALG, Molfino, NA, McClean, PA, Silverman, F, Tarlo, S, Raizenne, M, Slutsky, AS  
33 and Zamel, N (1994). The effect of pre-exposure to 012 ppm of ozone on exercise-  
34 induced asthma. *Chest* 106(4): 1077-1082.
- 35 Folinsbee, LJ, Bedi, JF and Horvath, SM (1984). Pulmonary function changes after 1 h  
36 continuous heavy exercise in 0.21 ppm ozone. *J Appl Physiol* (1985) 57(4): 984-988.

- 1 Folinsbee, LJ, Drinkwater, BL, Bedi, JF and Horvath, SM, Eds. (1978). The influence of  
2 exercise on the pulmonary function changes due to exposure to low concentrations of  
3 ozone. Academic Press New York, NY.
- 4 Folinsbee, LJ and Hazucha, MJ (1989). *Atmospheric ozone research and its policy implications:*  
5 *Persistence of ozone-induced changes in lung function and airway responsiveness.*  
6 Elsevier. Amsterdam, The Netherlands.
- 7 Folinsbee, LJ and Hazucha, MJ (2000). Time course of response to ozone exposure in healthy  
8 adult females. *Inhal Toxicol* 12(3): 151-167.
- 9 Folinsbee, LJ, Horstman, DH, Kehrl, HR, Harder, S, Abdul-Salaam, S and Ives, PJ (1994).  
10 Respiratory responses to repeated prolonged exposure to 0.12 ppm ozone. *Am J Respir*  
11 *Crit Care Med* 149(1): 98-105.
- 12 Folinsbee, LJ, Horstman, DH, Vorona, RD, Prince, JM and Berry, M (1986). *Determinants of*  
13 *endurance performance during ozone inhalation.* Vancouver, Canada.
- 14 Folinsbee, LJ, McDonnell, WF and Horstman, DH (1988). Pulmonary function and symptom  
15 responses after 6.6-hour exposure to 0.12 ppm ozone with moderate exercise. *JAPCA*  
16 38(1): 28-35.
- 17 Foster, WM, Silver, JA and Groth, ML (1993). Exposure to ozone alters regional function and  
18 particle dosimetry in the human lung. *J Appl Physiol* (1985) 75(5): 1938-1945.
- 19 Foster, WM, Weinmann, GG, Menkes, E and Macri, K (1997). Acute exposure of humans to  
20 ozone impairs small airway function. *Ann Occup Hyg* 1(inhaled particles VIII): 659-666.
- 21 Foxcroft, WJ and Adams, WC (1986). Effects of ozone exposure on four consecutive days on  
22 work performance and VO<sub>2</sub>max. *J Appl Physiol* (1985) 61(3): 960-966.
- 23 Frampton, MW, Balmes, JR, Bromberg, PA, Stark, P, Arjomandi, M, Hazucha, MJ, Rich, DQ,  
24 Hollenbeck-Pringle, D, Dagincourt, N, Alexis, N, Ganz, P, Zareba, W and Costantini,  
25 MG (2017). Multicenter Ozone Study in oldEr Subjects (MOSES: Part 1. Effects of  
26 exposure to low concentrations of ozone on respiratory and cardiovascular outcomes.  
27 Research Report 192, Pt 1. Health Effects Institute. Boston, MA.
- 28 Frampton, MW, Pietropaoli, A, Dentler, M, Chalupa, D, Little, EL, Stewart, J, Frasier, L, Oakes,  
29 D, Wiltshire, J, Vora, R and Utell, MJ (2015). Cardiovascular effects of ozone in healthy  
30 subjects with and without deletion of glutathione-S-transferase M1. *Inhal Toxicol* 27(2):  
31 113-119.
- 32 Frank, R, Liu, MC, Spannhake, EW, Mlynarek, S, Macri, K and Weinmann, GG (2001).  
33 Repetitive ozone exposure of young adults: Evidence of persistent small airway  
34 dysfunction. *Am J Respir Crit Care Med* 164(7): 1253-1260.

- 1 Fry, RC, Rager, JE, Zhou, H, Zou, B, Brickey, JW, Ting, J, Lay, JC, Peden, DB and Alexis, NE  
2 (2012). Individuals with increased inflammatory response to ozone demonstrate muted  
3 signaling of immune cell trafficking pathways. *Respir Res* 13: 89.
- 4 Gerrity, TR, McDonnell, WF and House, DE (1994). The relationship between delivered ozone  
5 dose and functional responses in humans. *Toxicol Appl Pharmacol* 124(2): 275-283.
- 6 Ghio, AJ, Soukup, JM, Dailey, LA, Richards, JH, Duncan, KE and Lehmann, J (2014). Iron  
7 decreases biological effects of ozone exposure. *Inhal Toxicol* 26(7): 391-399.
- 8 Golden, JA, Nadel, JA and Boushey, HA (1978). Bronchial hyperirritability in healthy subjects  
9 after exposure to ozone. *Am Rev Respir Dis* 118(2): 287-294.
- 10 Gomes, EC, Stone, V and Florida-James, G (2011). Impact of heat and pollution on oxidative  
11 stress and CC16 secretion after 8 km run. *Eur J Appl Physiol* 111(9): 2089-2097.
- 12 Gong, H, Jr., Bedi, JF and Horvath, SM (1988). Inhaled albuterol does not protect against ozone  
13 toxicity in nonasthmatic athletes. *Arch Environ Occup Health* 43(1): 46-53.
- 14 Gong, H, Jr., Bradley, PW, Simmons, MS and Tashkin, DP (1986). Impaired exercise  
15 performance and pulmonary function in elite cyclists during low-level ozone exposure in  
16 a hot environment. *Am J Respir Crit Care Med* 134(4): 726-733.
- 17 Gong, H, Jr., McManus, MS and Linn, WS (1997). Attenuated response to repeated daily ozone  
18 exposures in asthmatic subjects. *Arch Environ Occup Health* 52(1): 34-41.
- 19 Graham, DE and Koren, HS (1990). Biomarkers of inflammation in ozone-exposed humans:  
20 Comparison of the nasal and bronchoalveolar lavage. *Am J Respir Crit Care Med* 142(1):  
21 152-156.
- 22 Hamilton, RF, Li, L, Eschenbacher, WL, Szweda, L and Holian, A (1998). Potential involvement  
23 of 4-hydroxynonenal in the response of human lung cells to ozone. *Am J Physiol* 274(1  
24 Pt 1): L8-L16.
- 25 Hanania, NA, Tarlo, SM, Silverman, F, Urch, B, Senathirajah, N, Zamel, N and Corey, P (1998).  
26 Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic  
27 asthmatic patients. *Chest* 114(3): 752-756.
- 28 Hazbun, ME, Hamilton, R, Holian, A and Eschenbacher, WL (1993). Ozone-induced increases  
29 in substance P and 8-epi-prostaglandin F2 alpha in the airways of human subjects. *Am J*  
30 *Respir Cell Mol Biol* 9(5): 568-572.
- 31 Hazucha, MJ, Folinsbee, LJ and Seal, E, Jr. (1992). Effects of steady-state and variable ozone  
32 concentration profiles on pulmonary function. *Am Rev Respir Dis* 146(6): 1487-1493.
- 33 Hernandez, M, Brickey, WJ, Alexis, NE, Fry, RC, Rager, JE, Zhou, B, Ting, JP, Zhou, H and  
34 Peden, DB (2012). Airway cells from atopic asthmatic patients exposed to ozone display

- an enhanced innate immune gene profile. *J Allergy Clin Immunol* 129(1): 259-261.e251-252.
- Hernandez, ML, Lay, JC, Harris, B, Esther, CR, Brickey, WJ, Bromberg, PA, Diaz-Sanchez, D, Devlin, RB, Kleeberger, SR, Alexis, NE and Peden, DB (2010). Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone. *J Allergy Clin Immunol* 126(3): 537-544.
- Hiltermann, JTN, Lapperre, TS, Van Bree, L, Steerenberg, PA, Brahim, JJ, Sont, JK, Sterk, PJ, Hiemstra, PS and Stolck, J (1999). Ozone-induced inflammation assessed in sputum and bronchial lavage fluid from asthmatics: A new noninvasive tool in epidemiologic studies on air pollution and asthma. *Free Radical Biol Med* 27(11-12): 1448-1454.
- Hiltermann, TJN, Peters, EA, Alberts, B, Kwikkers, K, Borggreven, PA, Hiemstra, PS, Dijkman, JH, van Bree, LA and Stolck, J (1998). Ozone-induced airway hyperresponsiveness in patients with asthma: Role of neutrophil-derived serine proteinases. *Free Radical Biol Med* 24(6): 952-958.
- Hiltermann, TJN, Stolck, J, Hiemstra, PS, Fokkens, PHB, Rombout, PJA, Sont, JK, Sterk, PJ and Dijkman, JH (1995). Effect of ozone exposure on maximal airway narrowing in non-asthmatic and asthmatic subjects. *Clinical Science* 89(6): 619-624.
- Holz, O, Biller, H, Mueller, M, Kane, K, Rosano, M, Hanrahan, J, Hava, DL and Hohlfeld, JM (2015). Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. *BMC Pharmacol Toxicol* 16: 21.
- Holz, O, Jorres, RA, Timm, P, Mucke, M, Richter, K, Koschyk, S and Magnussen, H (1999). Ozone-induced airway inflammatory changes differ between individuals and are reproducible. *Am J Respir Crit Care Med* 159(3): 776-784.
- Holz, O, Mucke, M, Paasch, K, Bohme, S, Timm, P, Richter, K, Magnussen, H and Jorres, RA (2002). Repeated ozone exposures enhance bronchial allergen responses in subjects with rhinitis or asthma. *Clin Exp Allergy* 32(5): 681-689.
- Holz, O, Tal-Singer, R, Kannies, F, Simpson, KJ, Gibson, A, Vessey, RSJ, Janicki, S, Magnussen, H, Jorres, RA and Richter, K (2005). Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. *J Clin Pharmacol* 45(5): 498-503.
- Horstman, DH, Ball, BA, Brown, J, Gerrity, T and Folinsbee, LJ (1995). Comparison of pulmonary responses of asthmatic and nonasthmatic subjects performing light exercise while exposed to a low level of ozone. *Toxicol Ind Health* 11(4): 369-385.
- Horstman, DH, Folinsbee, LJ, Ives, PJ, Abdul-Salaam, S and McDonnell, WF (1990). Ozone concentration and pulmonary response relationships for 6.6-hour exposures with five hours of moderate exercise to 0.08, 0.10, and 0.12 ppm. *Am Rev Respir Dis* 142(5): 1158-1163.

- 1 Horvath, SM, Gliner, JA and Matsen-Twisdale, JA (1979). Pulmonary function and maximum  
2 exercise responses following acute ozone exposure. *Aviat Space Environ Med* 50(9):  
3 901-905.
- 4 Jorres, R, Nowak, D, Magnussen, H, Speckin, P and Koschyk, S (1996). The effect of ozone  
5 exposure on allergen responsiveness in subjects with asthma or rhinitis. *Am J Respir Crit*  
6 *Care Med* 153(1): 56-64.
- 7 Kahle, JJ, Neas, LM, Devlin, RB, Case, MW, Schmitt, MT, Madden, MC and Diaz-Sanchez, D  
8 (2015). Interaction effects of temperature and ozone on lung function and markers of  
9 systemic inflammation, coagulation, and fibrinolysis: a crossover study of healthy young  
10 volunteers. *Environ Health Perspect* 123(4): 310-316.
- 11 Keefe, MJ, Bennett, WD, Dewitt, P, Seal, E, Strong, AA and Gerrity, TR (1991). The effect of  
12 ozone exposure on the dispersion of inhaled aerosol boluses in healthy human subjects.  
13 *Am J Respir Crit Care Med* 144(1): 23-30.
- 14 Kehrl, HR, Vincent, LM, Kowalsky, RJ, Horstman, DH, O'Neil, JJ, McCartney, WH and  
15 Bromberg, PA (1987). Ozone exposure increases respiratory epithelial permeability in  
16 humans. *Am Rev Respir Dis* 135(5): 1124-1128.
- 17 Kim, CS, Alexis, NE, Rappold, AG, Kehrl, H, Hazucha, MJ, Lay, JC, Schmitt, MT, Case, M,  
18 Devlin, RB, Peden, DB and Diaz-Sanchez, D (2011). Lung function and inflammatory  
19 responses in healthy young adults exposed to 0.06 ppm ozone for 6.6 hours. *Am J Respir*  
20 *Crit Care Med* 183(9): 1215-1221.
- 21 Kirsten, A, Watz, H, Kretschmar, G, Pedersen, F, Bock, D, Meyer-Sabellek, W and Magnussen,  
22 H (2011). Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway  
23 inflammation in healthy subjects - A double blind, randomized, placebo-controlled,  
24 cross-over clinical trial. *Pulm Pharmacol Ther* 24(5): 555-558.
- 25 Konig, G, Rommelt, H, Kienle, H, Dirnagl, K, Polke, H and Fruhmman, G (1980). Anderung der  
26 bronchomotorischen Reagibilitat des Menschen durch Einwirkung von Ozon [Changes in  
27 the bronchial reactivity of humans caused by the influence of ozone]. *Arbeitsmed*  
28 *Sozialmed Umweltmed* 151: 261-263.
- 29 Koren, G, Sharav, T, Pastuszak, A, Garrettson, LK, Hill, K, Samson, I, Rorem, M, King, A and  
30 Dolgin, JE (1991). A multicenter, prospective study of fetal outcome following accidental  
31 carbon monoxide poisoning in pregnancy. *Reprod Toxicol* 5(5): 397-403.
- 32 Koren, HS, Devlin, RB, Graham, DE, Mann, R and McDonnell, WF (1989a). *Atmospheric ozone*  
33 *research and its policy implications: The inflammatory response in human lung exposed*  
34 *to ambient levels of ozone*. Amsterdam, The Netherlands.
- 35 Koren, HS, Devlin, RB, Graham, DE, Mann, R, McGee, MP, Horstman, DH, Kozumbo, WJ,  
36 Becker, S, House, DE, McDonnell, WF and Bromberg, PA (1989b). Ozone-induced  
37 inflammation in the lower airways of human subjects. *Am J Respir Crit Care Med*  
38 139(2): 407-415.



- 1 Koren, HS, Hatch, GE and Graham, DE (1990). Nasal lavage as a tool in assessing acute  
2 inflammation in response to inhaled pollutants. *Toxicology* 60(1-2): 15-25.
- 3 Kreit, JW, Gross, KB, Moore, TB, Lorenzen, TJ, D'Arcy, J and Eschenbacher, WL (1989).  
4 Ozone-induced changes in pulmonary function and bronchial responsiveness in  
5 asthmatics. *J Appl Physiol* (1985) 66(1): 217-222.
- 6 Krishna, MT, Blomberg, A, Biscione, GL, Kelly, F, Sandstrom, T, Frew, A and Holgate, S  
7 (1997). Short-term ozone exposure upregulates P-selectin in normal human airways. *Am*  
8 *J Respir Crit Care Med* 155(5): 1798-1803.
- 9 Krishna, MT, Madden, J, Teran, LM, Biscione, GL, Lau, LCK, Withers, NJ, Sandstrom, T,  
10 Mudway, I, Kelly, FJ, Walls, A, Frew, AJ and Holgate, ST (1998). Effects of 02 ppm  
11 ozone on biomarkers of inflammation in bronchoalveolar lavage fluid and bronchial  
12 mucosa of healthy subjects. *Eur Respir J* 11(6): 1294-1300.
- 13 Kulle, TJ, Sauder, LR, Hebel, JR and Chatham, MD (1985). Ozone response relationships in  
14 healthy nonsmokers. *Am Rev Respir Dis* 132(1): 36-41.
- 15 Kulle, TJ, Sauder, LR, Kerr, HD, Farrell, BP, Bermel, MS and Smith, DM (1982). Duration of  
16 pulmonary function adaptation to ozone in humans. *Am Ind Hyg Assoc J* 43(11): 832-  
17 837.
- 18 Lay, JC, Alexis, NE, Kleeberger, SR, Roubey, RA, Harris, BD, Bromberg, PA, Hazucha, MJ,  
19 Devlin, RB and Peden, DB (2007). Ozone enhances markers of innate immunity and  
20 antigen presentation on airway monocytes in healthy individuals. *J Allergy Clin Immunol*  
21 120(3): 719-722.
- 22 Linn, WS, Avol, EL, Shamoo, DA, Spier, CE, Valencia, LM, Venet, TG, Fischer, DA and  
23 Hackney, JD (1986). A dose-response study of healthy, heavily exercising men exposed  
24 to ozone at concentrations near the ambient air quality standard. *Toxicol Ind Health* 2(1):  
25 99-112.
- 26 Madden, MC, Stevens, T, Case, M, Schmitt, M, Diaz-Sanchez, D, Bassett, M, Montilla, TS,  
27 Berntsen, J and Devlin, RB (2014). Diesel exhaust modulates ozone-induced lung  
28 function decrements in healthy human volunteers. *Part Fibre Toxicol* 11(1): 37.
- 29 McBride, DE, Koenig, JQ, Luchtel, DL, Williams, PV and Henderson, WR, Jr. (1994).  
30 Inflammatory effects of ozone in the upper airways of subjects with asthma. *Am J Respir*  
31 *Crit Care Med* 149(5): 1192-1197.
- 32 McDonnell, WF, 3rd, Chapman, RS, Leigh, MW, Strope, GL and Collier, AM (1985).  
33 Respiratory responses of vigorously exercising children to 0.12 ppm ozone exposure. *The*  
34 *American review of respiratory disease* 132(4): 875-879.
- 35 McDonnell, WF, Horstman, DH, Abdul-Salaam, S, Raggio, LJ and Green, JA (1987). The  
36 respiratory responses of subjects with allergic rhinitis to ozone exposure and their  
37 relationship to nonspecific airway reactivity. *Toxicol Ind Health* 3(4): 507-517.

- 1 McDonnell, WF, Horstman, DH, Hazucha, MJ, Seal, E, Jr., Haak, ED, Salaam, SA and House,  
2 DE (1983). Pulmonary effects of ozone exposure during exercise: Dose-response  
3 characteristics. J Appl Physiol (1985) 54(5): 1345-1352.
- 4 McDonnell, WF, Kehrl, HR, Abdul-Salaam, S, Ives, PJ, Folinsbee, LJ, Devlin, RB, O'Neil, JJ  
5 and Horstman, DH (1991). Respiratory response of humans exposed to low levels of  
6 ozone for 6.6 hours. Arch Environ Health 46(3): 145-150.
- 7 McDonnell, WF, Stewart, PW, Smith, MV, Kim, CS and Schelegle, ES (2012). Prediction of  
8 lung function response for populations exposed to a wide range of ozone conditions.  
9 Inhal Toxicol 24(10): 619-633.
- 10 McGee, MP, Devlin, R, Saluta, G and Koren, H (1990). Tissue factor and factor VII messenger  
11 RNAs in human alveolar macrophages: effects of breathing ozone. Blood 75(1): 122-127.
- 12 McKittrick, T and Adams, WC (1995). Pulmonary function response to equivalent doses of  
13 ozone consequent to intermittent and continuous exercise. Arch Environ Occup Health  
14 50(2): 153-158.
- 15 Michelson, PH, Dailey, L, Devlin, RB and Peden, DB (1999). Ozone effects on the immediate-  
16 phase response to allergen in the nasal airways of allergic asthmatic subjects. Otolaryngol  
17 Head Neck Surg 120(2): 225-232.
- 18 Molfino, NA, Wright, SC, Katz, I, Tarlo, S, Silverman, F, McClean, PA, Szalai, JP, Raizenne,  
19 M, Slutsky, AS and Zamel, N (1991). Effect of low concentrations of ozone on inhaled  
20 allergen responses in asthmatic subjects. The Lancet 338(8761): 199-203.
- 21 Montuschi, P, Nightingale, JA, Kharitonov, SA and Barnes, PJ (2002). Ozone-induced increase  
22 in exhaled 8-isoprostane in healthy subjects is resistant to inhaled budesonide. Free  
23 Radical Biol Med 33(10): 1403-1408.
- 24 Mudway, IS, Krishna, MT, Frew, AJ, Macleod, D, Sandstrom, T, Holgate, ST and Kelly, FJ  
25 (1999). Compromised concentrations of ascorbate in fluid lining the respiratory tract in  
26 human subjects after exposure to ozone. Occup Environ Med 56(7): 473-481.
- 27 Mudway, IS, Stenfors, N, Blomberg, A, Helleday, R, Dunster, C, Marklund, SL, Frew, AJ,  
28 Sandstrom, T and Kelly, FJ (2001). Differences in basal airway antioxidant  
29 concentrations are not predictive of individual responsiveness to ozone: A comparison of  
30 healthy and mild asthmatic subjects. Free Radical Biol Med 31(8): 962-974.
- 31 Newson, EJ, Krishna, MT, Lau, LCK, Howarth, PH, Holgate, ST and Frew, AJ (2000). Effects  
32 of short-term exposure to 0.2 ppm ozone on biomarkers of inflammation in sputum,  
33 exhaled nitric oxide, and lung function in subjects with mild atopic asthma. J Occup  
34 Environ Med 42(3): 270-277.
- 35 Nightingale, JA, Rogers, DF, Chung, KF and Barnes, PJ (2000). No effect of inhaled budesonide  
36 on the response to inhaled ozone in normal subjects. Am J Respir Crit Care Med 161(2 Pt  
37 1): 479-486.

- 1 Passannante, AN, Hazucha, MJ, Bromberg, PA, Seal, E, Folinsbee, L and Koch, G (1998).  
2 Nociceptive mechanisms modulate ozone-induced human lung function decrements. J  
3 Appl Physiol (1985) 85(5): 1863-1870.
- 4 Peden, DB, Setzer, RW, Jr. and Devlin, RB (1995). Ozone exposure has both a priming effect on  
5 allergen-induced responses and an intrinsic inflammatory action in the nasal airways of  
6 perennially allergic asthmatics. Am J Respir Crit Care Med 151(5): 1336-1345.
- 7 Peters, EA, Hiltermann, JT and Stolk, J (2001). Effect of apocynin on ozone-induced airway  
8 hyperresponsiveness to methacholine in asthmatics. Free Radical Biol Med 31(11): 1442-  
9 1447.
- 10 Que, LG, Stiles, JV, Sundy, JS and Foster, WM (2011). Pulmonary function, bronchial  
11 reactivity, and epithelial permeability are response phenotypes to ozone and develop  
12 differentially in healthy humans. J Appl Physiol (1985) 111(3): 679-687.
- 13 Samet, JM, Hatch, GE, Horstman, D, Steck-Scott, S, Arab, L, Bromberg, PA, Levine, M,  
14 McDonnell, WF and Devlin, RB (2001). Effect of antioxidant supplementation on ozone-  
15 induced lung injury in human subjects. Am J Respir Crit Care Med 164(5): 819-825.
- 16 Schelegle, ES and Adams, WC (1986). Reduced exercise time in competitive simulations  
17 consequent to low level ozone exposure. Med Sci Sports Exerc 18(4): 408-414.
- 18 Schelegle, ES, Adams, WC and Siefkin, AD (1987). Indomethacin pretreatment reduces ozone-  
19 induced pulmonary function decrements in human subjects. Am Rev Respir Dis 136(6):  
20 1350-1354.
- 21 Schelegle, ES, Morales, CA, Walby, WF, Marion, S and Allen, RP (2009). 6.6-hour inhalation of  
22 ozone concentrations from 60 to 87 parts per billion in healthy humans. Am J Respir Crit  
23 Care Med 180(3): 265-272.
- 24 Schelegle, ES, Siefkin, AD and McDonald, RJ (1991). Time course of ozone-induced  
25 neutrophilia in normal humans. Am J Respir Crit Care Med 143(6): 1353-1358.
- 26 Schonfeld, BR, Adams, WC and Schelegle, ES (1989). Duration of enhanced responsiveness  
27 upon re-exposure to ozone. Arch Environ Occup Health 44(4): 229-236.
- 28 Seal, E, Jr., McDonnell, WF, House, DE, Salaam, SA, Dewitt, PJ, Butler, SO, Green, J and  
29 Raggio, L (1993). The pulmonary response of white and black adults to six  
30 concentrations of ozone. Am J Respir Crit Care Med 147(4): 804-810.
- 31 Seltzer, J, Bigby, BG, Stulbarg, M, Holtzman, MJ, Nadel, JA, Ueki, IF, Leikauf, GD, Goetzel, EJ  
32 and Boushey, HA (1986). O<sub>3</sub>-induced change in bronchial reactivity to methacholine and  
33 airway inflammation in humans. J Appl Physiol (1985) 60(4): 1321-1326.
- 34 Silverman, F, Folinsbee, LJ, Barnard, J and Shephard, RJ (1976). Pulmonary function changes in  
35 ozone - interaction of concentration and ventilation. J Appl Physiol (1985) 41(6): 859-  
36 864.

1 Speen, AM, Kim, HH, Bauer, RN, Meyer, M, Gowdy, KM, Fessler, MB, Duncan, KE, Liu, W,  
2 Porter, NA and Jaspers, I (2016). Ozone-derived oxysterols affect liver X receptor (LXR)  
3 signaling: a potential role for lipid-protein adducts. *J Biol Chem* 291(48): 25192-25206.

4 Steck-Scott, S, Arab, L, Craft, NE and Samet, JM (2004). Plasma and lung macrophage  
5 responsiveness to carotenoid supplementation and ozone exposure in humans. *Eur J Clin*  
6 *Nutr* 58(12): 1571-1579.

7 Stenfors, N, Bosson, J, Helleday, R, Behndig, AF, Pourazar, J, Tornqvist, H, Kelly, FJ, Frew, AJ,  
8 Sandstrom, T, Mudway, IS and Blomberg, A (2010). Ozone exposure enhances mast-cell  
9 inflammation in asthmatic airways despite inhaled corticosteroid therapy. *Inhal Toxicol*  
10 22(2): 133-139.

11 Stenfors, N, Pourazar, J, Blomberg, A, Krishna, MT, Mudway, I, Helleday, R, Kelly, FJ, Frew,  
12 AJ and Sandstrom, T (2002). Effect of ozone on bronchial mucosal inflammation in  
13 asthmatic and healthy subjects. *Respir Med* 96(5): 352-358.

14 Stiegel, MA, Pleil, JD, Sobus, JR, Stevens, T and Madden, MC (2017). Linking physiological  
15 parameters to perturbations in the human exposome: Environmental exposures modify  
16 blood pressure and lung function via inflammatory cytokine pathway. *J Toxicol Environ*  
17 *Health, A: Curr Iss* 80(9): 485-501.

18 Tank, J, Biller, H, Heusser, K, Holz, O, Diedrich, A, Framke, T, Koch, A, Grosshennig, A,  
19 Koch, W, Krug, N, Jordan, J and Hohlfeld, JM (2011). Effect of acute ozone induced  
20 airway inflammation on human sympathetic nerve traffic: a randomized, placebo  
21 controlled, crossover study. *PLoS ONE* 6(4): e18737.

22 Trenga, CA, Koenig, JQ and Williams, PV (2001). Dietary antioxidants and ozone-induced  
23 bronchial hyperresponsiveness in adults with asthma. *Arch Environ Occup Health* 56(3):  
24 242-249.

25 U.S. EPA (1996). Air Quality Criteria for Ozone and Related Photochemical Oxidants. Volumes  
26 I to III. . U.S. EPA. Research Triangle Park, NC. EPA/600/P-93/004aF, EPA/600/P-  
27 93/004bF, and EPA/600/P-93/004cF.

28 U.S. EPA (2006). Air Quality Criteria for Ozone and Related Photochemical Oxidants (Volumes  
29 I-III). EPA-600/R-05-004aF, EPA-600/R-05-004bF and EPA-600/R-05-004cF. U.S.  
30 Environmental Protection Agency. Washington, DC. Available at:  
31 [http://www.epa.gov/ttn/naaqs/standards/ozone/s\\_o3\\_cr\\_cd.html](http://www.epa.gov/ttn/naaqs/standards/ozone/s_o3_cr_cd.html).

32 U.S. EPA (2013). Integrated Science Assessment of Ozone and Related Photochemical Oxidants  
33 (Final Report). Office of Research and Development, National Center for Environmental  
34 Assessment. Research Triangle Park, NC. U.S. EPA. EPA-600/R-10-076F. February  
35 2013. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KETF.txt>.

36 U.S. EPA (2020). Integrated Science Assessment for Ozone and Related Photochemical  
37 Oxidants. U.S. Environmental Protection Agency. Washington, DC. Office of Research

- and Development. EPA/600/R-20/012. Available at: <https://www.epa.gov/isa/integrated-science-assessment-isa-ozone-and-related-photochemical-oxidants>.
- Ultman, JS, Ben-Jebria, A and Arnold, SF (2004). Uptake distribution of ozone in human lungs: Intersubject variability in physiologic response. HEI Research Report 125. Health Effects Institute. Boston, MA. <http://pubs.healtheffects.org/view.php?id=70>.
- Vagaggini, B, Bartoli, MLE, Cianchetti, S, Costa, F, Bacci, E, Dente, FL, Di Franco, A, Malagrino, L and Paggiaro, P (2010). Increase in markers of airway inflammation after ozone exposure can be observed also in stable treated asthmatics with minimal functional response to ozone. *Respir Res* 11: 5.
- Vagaggini, B, Cianchetti, S, Bartoli, M, Ricci, M, Bacci, E, Dente, FL, Di Franco, A and Paggiaro, P (2007). Prednisone blunts airway neutrophilic inflammatory response due to ozone exposure in asthmatic subjects. *Respiration* 74(1): 61-58.
- Vagaggini, B, Taccola, M, Clanchetti, S, Carnevali, S, Bartoli, ML, Bacci, E, Dente, FL, Di Franco, A, Giannini, D and Paggiaro, PL (2002). Ozone exposure increases eosinophilic airway response induced by previous allergen challenge. *Am J Respir Crit Care Med* 166(8): 1073-1077.
- Vagaggini, B, Taccola, M, Conti, I, Carnevali, S, Cianchetti, S, Bartoli, ML, Bacci, E, Dente, FL, Di Franco, A, Giannini, D and Paggiaro, PL (2001). Budesonide reduces neutrophilic but not functional airway response to ozone in mild asthmatics. *Am J Respir Crit Care Med* 164(12): 2172-2176.
- Weymer, AR, Gong, H, Jr., Lyness, A and Linn, WS (1994). Pre-exposure to ozone does not enhance or produce exercise-induced asthma. *Am J Respir Crit Care Med* 149(6): 1413-1419.
- Ying, RL, Gross, KB, Terzo, TS and Eschenbacher, WL (1990). Indomethacin does not inhibit the ozone-induced increase in bronchial responsiveness in human subjects. *Am Rev Respir Dis* 142(4): 817-821.

## **APPENDIX 3B**

### **AIR QUALITY INFORMATION FOR LOCATIONS OF EPIDEMIOLOGIC STUDIES OF RESPIRATORY EFFECTS**

1 This appendix provides summary information about the O<sub>3</sub> concentrations in locations  
2 and time periods of epidemiologic studies of associations between O<sub>3</sub> in ambient air and  
3 respiratory health outcomes. Included here are studies conducted in the U.S. and Canada that  
4 found associations between O<sub>3</sub> exposure and respiratory health effects such as emergency  
5 department visits and hospital admissions, including studies that are newly available since the  
6 2020 review, as well as those that were available at the time of the 2015 review, and that are  
7 identified in the ISA. Information for studies identified in the ISA<sup>1</sup> as short-term are summarized  
8 in Table 3B-1 and a subset of studies identified as long-term are summarized in Table 3B-2.

9 Air quality information for U.S.-based studies was obtained from the EPA's Air Quality  
10 System (AQS) database.<sup>2</sup> For Canada-based studies, air quality information was obtained from  
11 the National Air Pollutant Surveillance (NAPS) program.<sup>3</sup> In Table 3B-1 and Table 3B-2, design  
12 values (DVs)<sup>4</sup> are presented as a range across all locations and time periods in the study.<sup>5</sup>  
13 Detailed information about designs values for individual study locations and time periods are  
14 available in the Attachment.<sup>6</sup>

---

<sup>1</sup> Single- and multi-city studies are included. Given the purpose of describing the air quality conditions in the cities studied, meta-analysis studies are not included; rather, the relevant underlying studies would be.

<sup>2</sup> Available at: <https://www.epa.gov/aqs>.

<sup>3</sup> Available at: <https://www.canada.ca/en/environment-climate-change/services/air-pollution/monitoring-networks-data/national-air-pollution-program.html>.

<sup>4</sup> The design value for the current standard is the 3-year average of the annual 4<sup>th</sup> highest daily maximum 8-hour average O<sub>3</sub> concentration.

<sup>5</sup> For those locations with more than one monitor, the design values presented in Table 3B-1, Table 3B-2, and in the attachment for that location are for the highest monitor in that area.

<sup>6</sup> In the attachment tables, blank cells indicate one of two situations: (1) monitoring data are unavailable for the specific time period or the entire period for the city, or (2) the available data do not meet the data requirements for the calculations.

1 **Table 3B-1. Epidemiologic studies of associations between short-term ozone concentrations and respiratory effects.**

| Study Information   |                          |                         |                              |  |  |   |  |   | Ambient Air Quality   |
|---------------------|--------------------------|-------------------------|------------------------------|--|--|---|--|---|---|
| Study Area          | Health Study Time Period | Air Quality Time Period | Study Reference <sup>A</sup> | Health Outcome                               | O <sub>3</sub> Concentration Metric Associated with Health Outcome | Assignment of Monitors to Study Subjects  | Study-reported O <sub>3</sub> Concentrations, in terms of study metric (ppb) |   | Design Values for Current NAAQS, across cities and study years (ppb) <sup>B</sup> |
|                     |                          |                         |                              |  |  |   | Mean/median  | Range   |   |
| U.S. Studies        |                          |                         |                              |  |  |   |  |   |   |
| Single City Studies |                          |                         |                              |  |  |   |  |   |   |
| Indianapolis, IN    | 2007-2011                | 2007-2011               | Byers et al., 2015           | ED Visits for Asthma                         | 8-hr daily maximums, moving average of lag 0-2                     | Distance and population-weighted daily average O <sub>3</sub> concentration of 11 monitor values for the Indianapolis MSA (9 counties)  | 8-hr (WS): 48.5  | NA  | 73-77   |
| Atlanta, GA         | 1993-2004                | 1993-2004               | Darrow et al., 2011          | ED Visits for Aggregate Respiratory Diseases | 1-hr and 8-hr daily maximums, previous day lag (lag 1)             | Daily O <sub>3</sub> concentration of single centrally located monitor in the Atlanta MSA   | 1-hr (WS): 62.0<br>8-hr (WS): 53.0   | 1-h Max: 180.0<br>8-hr Max: 148.0   | 91-121  |
| Atlanta, GA         | 1993-2010                | 1993-2010               | Darrow et al., 2014          | ED Visits for Respiratory Infection          | 8-hr daily maximum, 3-day moving average of lag 0-2                | Population-weighted daily average O <sub>3</sub> concentration of 5 monitor values for the Atlanta MSA (20 counties)  | 8-hr (YR): 45.9  | 3.0-127.1   | 80-121  |
| New Jersey          | 2004-2007                | 2004-2007               | Gleason et al., 2014         | ED Visits for Asthma                         | 8-hr daily maximum, same day lag (lag 0)                           | Daily O <sub>3</sub> concentration obtained from Bayesian spatio-temporal model assigned to study participants based on corresponding grid cells for geocoded residential addresses | NA   | NA  | 92-93   |
| New York, NY        | 1999-2009                | 1999-2009               | Goodman et al., 2017a        | HA for Asthma                                | 8-hr daily maximum, average of lag 0-1                             | Daily average O <sub>3</sub> concentrations of all monitors within 20-mile of the geographic center of NY city  | 8-hr (YR): 30.7  | 2.0-105.4   | 84-115  |
| New York, NY        | 1999-2002                | 1999-2002               | Ito et al., 2007             | ED Visits for Asthma                         | 8-hr daily maximum, average of lag 0-1                             | Average of 16 monitors within 20 miles of the geographic city center of NY city   | 8-hr (YR): 30.4<br>8-hr (WS): 42.7   | 5 <sup>th</sup> and 95 <sup>th</sup> percentiles: YR: 6.0-68.0<br>WS: 18.0-77.0 | 109-115   |
| Atlanta, GA         | 1998-2007                | 1998-2007               | Klemm et al., 2011           | Respiratory Mortality                        | 8-hr daily maximum, average of lag 0-1                             | Daily average O <sub>3</sub> concentration of all monitors in four counties in Atlanta  | 8-hr (YR): 35.5  | 0.0-109.1   | 90-121  |



| Study Information |                          |                         |                              |  |  |  |  |  | Ambient Air Quality   |
|-------------------|--------------------------|-------------------------|------------------------------|--|--|--|--|--|---|
| Study Area        | Health Study Time Period | Air Quality Time Period | Study Reference <sup>A</sup> | Health Outcome                               | O <sub>3</sub> Concentration Metric Associated with Health Outcome | Assignment of Monitors to Study Subjects   | Study-reported O <sub>3</sub> Concentrations, in terms of study metric (ppb) |  | Design Values for Current NAAQS, across cities and study years (ppb) <sup>B</sup> |
|                   |                          |                         |                              |  |  |  | Mean/median  | Range  |   |
| Atlanta, GA       | 2002-2008                | 2002-2008               | O'Lenick et al., 2017        | ED Visits for Asthma                         | 8-hr daily maximum, 3-day moving average of lag 0-2                | Daily O <sub>3</sub> concentration obtained from spatio-temporal model assigned to study participants based on corresponding ZCTA for residential ZIP code | NA   | NA   | 90-95   |
| Little Rock, AR   | 2002-2012                | 2002-2012               | Rodopoulou et al., 2015      | ED Visits for Respiratory Infection          | 8-hr daily maximum, lag 2  | Daily O <sub>3</sub> concentration from one monitor in Little Rock, AR   | 8-hr (YR): 40.0  | NA   | 70-83   |
| Atlanta, GA       | 1999-2002                | 1999-2002               | Sarnat et al., 2013          | ED Visits for Asthma                         | 24-hr daily average  | Spatially resolved daily O <sub>3</sub> concentration at ZIP code centroid assigned to participants based on residential ZIP code                          | 8-hr (YR): 41.9  | 3.5-132.7  | 99-107  |
| St. Louis, MO     | 2001-2003                | 2001-2004               | Sarnat et al., 2015          | ED Visits for Asthma                         | 8-hr daily maximum, distributed lags (lags 0-2)                    | Daily O <sub>3</sub> concentration from one monitor in St. Louis, MO.  | 8-hr (YR): 36.2  | NA   | 92  |
| New York, NY      | 2005-2011                | 2005-2012               | Sheffield et al., 2015       | ED Visits for Asthma                         | 24-hr daily average  | Daily average O <sub>3</sub> concentration of seven monitors in NYC.   | NA   | NA   | 82-94   |
| New York, NY      | 2005-2011                | 2005-2011               | Shmool et al., 2016          | ED Visits for Asthma                         | 24-hr daily average, case-day                                      | Near-residence exposure was determined by combining data from temporally- and spatially-refined estimates  | Temporal estimates (WS): 30.4<br>Spatiotemporal estimates: 29.0              | Temporal estimates: 5.0-60.0<br>Spatiotemporal estimates: 4.6-60.3 | 82-94   |
| New York, NY      | 1999-2006                | 1999-2006               | Silverman and Ito, 2010      | HA for Asthma                                | 8-hr daily maximum, average of lag 0-1                             | Average of 13 monitors within 20 miles of the geographic city center of NY city  | 8-hr (WS): 41.0  | 10 <sup>th</sup> and 90 <sup>th</sup> percentiles: 18.0-77.0       | 93-115  |
| Atlanta, GA       | 2002-2010                | 2002-2010               | Strickland et al., 2014      | ED Visits for Asthma                         | 8-hr daily maximum, 3-day moving average lag 0-2                   | Distance and population-weighted daily average of five monitor values for the Atlanta MSA (20 counties)  | 8-hr (YR): 42.2  | NA   | 80-95   |
| Atlanta, GA       | 1993-2004                | 1993-2004               | Tolbert et al., 2007         | ED Visits for Aggregate Respiratory Diseases | 8-hr daily maximum, average of lag 0-1                             | Average of monitors in Atlanta city  | 8-hr (EC): 53.0  | 2.9-147.5  | 91-121  |

| Study Information   |                          |                         |                              |   |  |  |  |   | Ambient Air Quality   |
|---------------------|--------------------------|-------------------------|------------------------------|---|--|--|--|---|---|
| Study Area          | Health Study Time Period | Air Quality Time Period | Study Reference <sup>A</sup> | Health Outcome  | O <sub>3</sub> Concentration Metric Associated with Health Outcome | Assignment of Monitors to Study Subjects   | Study-reported O <sub>3</sub> Concentrations, in terms of study metric (ppb) |   | Design Values for Current NAAQS, across cities and study years (ppb) <sup>B</sup> |
|                     |                          |                         |                              |   |  |  | Mean/median  | Range                                       |   |
| St. Louis, MO       | 2001-2007                | 2001-2007               | Winqvist et al., 2012        | HA for Asthma<br>ED Visits for Asthma<br>ED Visits for Respiratory Infection<br>HA for Aggregate Respiratory Diseases<br>ED Visits Aggregate Respiratory Diseases | 8-hr daily maximum, distributed lags (lags 0-4)                    | Daily O <sub>3</sub> concentration from one monitor in St. Louis, MO.  | NA   | NA  | 86-92   |
| Atlanta, GA         | 1998-2004                | 1998-2004               | Winqvist et al., 2014        | ED Visits for Asthma  | 8-hr daily maximum, 3-day moving average of lag 0-2                | Population-weighted daily average of five monitor values for the Atlanta MSA (20 counties)   | 8-hr (WS): 53.9  | NA  | 91-121  |
| Multi-city Studies  |                          |                         |                              |   |  |  |  |   |   |
| 3 U.S. cities       | 1993-2009                | 1993-2009               | Alhanti et al., 2016         | ED Visits for Asthma  | 8-hr maximum, 3-day moving average of lag 0-2                      | Population-weighted daily average of monitor values for each city  | 8-hr (YR) for 3 cities<br>mean range: 37.3-43.7                              | NA  | 86-121  |
| 5 U.S. cities       | 2002-2008                | 2002-2008               | Barry et al., 2018           | ED Visits for Asthma<br>ED Visits for Respiratory Infection<br>ED Visits Aggregate Respiratory Diseases   | 8-hr maximum, 3-day moving average of lag 0-2                      | Daily O <sub>3</sub> concentration obtained model simulations and monitor measurements were spatially averaged for each metropolitan area using population weighting   | 8-hr (YR) for 5 cities<br>mean range: 37.5-42.2                              | Min Range: 3.9-9.4<br>Max Range: 80.2-106.3 | 83-95   |
| 3 metro areas in TX | 2003-2011                | 2003-2011               | Goodman et al., 2017b        | HA for Asthma   | 8-hr maximum, same day lag (lag 0)                                 | City-specific daily O <sub>3</sub> concentrations were calculated using all monitors within each city: Dallas (8 monitors), Houston (44 monitors), Austin (6 monitors), then were averaged to obtain area-specific daily maximum 8-hr concentrations | 8-hr (YR): 41.8  | 2.0-107.0                                   | 74-103  |
| Nationwide (U.S.)   | 1987-1996                | 1987-1996               | Katsouyanni et al., 2009     | Respiratory Mortality   | 1-hr maximum, 2-day average of lag 0-1                             | Daily average of O <sub>3</sub> concentrations from all monitors in each city  | NA   | NA  | 18-192  |

| Study Information |                          |                         |                              |   |  |   |  |  | Ambient Air Quality   |
|-------------------|--------------------------|-------------------------|------------------------------|---|--|---|--|--|---|
| Study Area        | Health Study Time Period | Air Quality Time Period | Study Reference <sup>A</sup> | Health Outcome  | O <sub>3</sub> Concentration Metric Associated with Health Outcome | Assignment of Monitors to Study Subjects  | Study-reported O <sub>3</sub> Concentrations, in terms of study metric (ppb) |  | Design Values for Current NAAQS, across cities and study years (ppb) <sup>B</sup> |
|                   |                          |                         |                              |   |  |   | Mean/median  | Range  |   |
| California        | 2005-2008                | 2005-2009               | Malig et al., 2016           | ED Visits for Asthma<br>ED Visits for Respiratory Infection<br>ED Visits Aggregate Respiratory Diseases | 1-hr maximum, 2-day average of lag 0-1                             | Daily O <sub>3</sub> concentration from nearest monitor within 20 km of population-weighted ZIP code centroid assigned to participants based on residential ZIP code  | 8-hr for 16 climatic zones<br>mean range: (YR): 33.0-55.0 (WS): 31.0-75.0    | NA   | 119-122   |
| 3 U.S. cities     | 2002-2008                | 2002-2008               | O'Lenick et al., 2017        | ED Visits Aggregate Respiratory Diseases  | 8-hr daily maximum, 3-day moving average of lag 0-2                | Daily O <sub>3</sub> concentration obtained from spatio-temporal model assigned to study participants based on corresponding ZCTA for residential ZIP code  | 8-hr (YR) for 3 cities<br>mean ranges from 40.0-42.2                         | Min Range: 0.15-2.21<br>Max Range: 115-125   | 85-96   |
| North Carolina    | 2006-2008                | 2006-2008               | Sacks et al., 2014           | ED Visits for Asthma  | 8-hr daily maximum, 3-day moving average of lag 0-2                | O <sub>3</sub> estimates from CMAQ model with Bayesian space-time approach assigned to census tract centroids and aggregated to county-level using area-weighted average of census tract centroids  | 8-hr (YR): 43.6<br>8-hr (WS): 50.1   | Max:108.1                                    | 94  |
| Georgia           | 2002-2008                | 2002-2008               | Xiao et al., 2016            | ED Visits for Asthma<br>ED Visits for Respiratory Infection   | 8-hr daily maximum, 3-day moving average of lag 0-2                | Daily O <sub>3</sub> concentration obtained from spatio-temporal model assigned to study participants based on residential ZIP code   | 8-hr (YR): 42.1  | 5.4-106.1                                    | 91-95   |
| 48 U.S. cities    | 1989-2000                | 1989-2000               | Zanobetti and Schwartz, 2008 | Respiratory Mortality   | 8-hr daily average, same day lag (lag 0)                           | Daily average of O <sub>3</sub> concentrations from all monitors in each city   | 8-hr (WS) for 40 U.S. cities<br>mean range: 15.1-62.8                        | Min Range: 0.9-23.6<br>Max Range: 34.3-146.2 | 45-179  |
| 6 cities in TX    | 2001-2013                | 2001-2013               | Zu et al., 2017              | HA for Asthma   | 8-hr daily maximum, lag 0-3  | City specific daily O <sub>3</sub> concentrations were calculated using all monitors within each city: Dallas (15 monitors), Houston (44 monitors), Austin (6 monitors), El Paso (6 monitors), Fort Worth (9 monitors); then were averaged to obtain area-specific daily maximum 8-hr concentrations. | 8-hr (YR): 32.2  | 1.0-82.8                                     | 71-103  |

| Study Information  |                          |                         |                              |   |  |  |  |  | Ambient Air Quality   |
|--|--------------------------|-------------------------|------------------------------|---|--|--|--|--|---|
| Study Area   | Health Study Time Period | Air Quality Time Period | Study Reference <sup>A</sup> | Health Outcome  | O <sub>3</sub> Concentration Metric Associated with Health Outcome | Assignment of Monitors to Study Subjects   | Study-reported O <sub>3</sub> Concentrations, in terms of study metric (ppb) |  | Design Values for Current NAAQS, across cities and study years (ppb) <sup>B</sup> |
|  |                          |                         |                              |   |  |  | Mean/median  | Range                                      |   |
| Canadian Studies   |                          |                         |                              |   |  |  |  |  |   |
| Single City Studies  |                          |                         |                              |   |  |  |  |  |   |
| Edmonton, Canada   | 1992-2002                | 1992-2002               | Kousha and Rowe, 2014        | ED Visits for Respiratory Infection                         | 8-hr daily maximum, same day lag (lag 0).                          | Daily average of O <sub>3</sub> concentrations from three monitors in Edmonton, Canada   | 8-hr (YR): 18.6  | NA   | 56-65   |
| Windsor, Canada  | 2004-2010                | 2004-2010               | Kousha and Castner, 2016     | ED Visits for Respiratory Infection                         | 8-hr daily maximum, same day lag (lag 0).                          | Daily average of O <sub>3</sub> concentrations from monitors in Windsor, Canada  | 8-hr (YR): 25.3  | NA   | 73-87   |
| Alberta, Canada  | 1992-2002                | 1992-2002               | Villeneuve et al., 2007      | ED Visits for Asthma  | 8-hr daily maximum, lag 1.   | Daily average of three monitors in census metropolitan of Edmonton, Alberta  | 8-hr (WS): 38.0 (Median)   | NA   | 60-69   |
| Multi-city Studies   |                          |                         |                              |   |  |  |  |  |   |
| 7 Canadian cities  | 1992-2003                | 1992-2003               | Stieb et al., 2009           | ED visits for Asthma  | 24-hr average, lag 1   | Daily average of O <sub>3</sub> concentrations from monitors in each city  | 24-hr (YR): Mean range: 10.3-22.1  | NA   | 51-85   |
| 9 Canadian cities  | 2004-2011                | 2004-2011               | Szyszkowicz et al., 2018     | ED Visits for Asthma<br>ED Visits for Respiratory Infection | 24-hr daily average, lag 1.  | Daily average of O <sub>3</sub> concentrations from all monitors within 35 km of participants residential 3-digit postal codes     | 24-hr (YR) for 9 urban areas/districts mean range: 22.5-29.2                 | Min Range: 1.0-3.0<br>Max Range: 60.7-80.0 | 57-79   |
| 10 Canadian cities   | 1981-1999                | 1981-1999               | Vanos et al., 2014           | Respiratory Mortality                                       | 24-hr daily average, lag 1.  | Daily average O <sub>3</sub> concentrations from all monitors either downtown or at city airports located within 27 km of downtown | 24-hr (YR): 19.3   | NA   | 51-94   |
| ED – emergency department; HA – hospital admission; WS – warm season; YR – year round; ZCTA – ZIP code tabulation area   |                          |                         |                              |   |  |  |  |  |   |
| <sup>A</sup> Studies investigating associations between short-term O <sub>3</sub> exposure and respiratory mortality are summarized in the following tables and figures of Appendix 3 of the ISA (U.S. EPA, 2020): HA for asthma: Table 3-13, Figure 3-4; ED visits for asthma: Table 3-14, Figure 3-5; ED visits for respiratory infection: Table 3-39, Figure 3-6; Respiratory-related HA and ED: Figure 3-7; HA for aggregate respiratory diseases: Table 3-41; ED visits for aggregate respiratory diseases: Table 3-42. |                          |                         |                              |   |  |  |  |  |   |
| <sup>B</sup> For those studies available at the time of the last review, design values were drawn from (Wells, 2012) and are presented in units of ppm. For those studies available since the time of the last review, design values were calculated based on data available from the EPA's Air Quality System (AQS) for U.S. studies and the National Air Pollutant Surveillance (NAPS) program for Canadian studies.   |                          |                         |                              |   |  |  |  |  |   |

1 **Table 3B-2. Subset of epidemiologic studies of associations between long-term ozone and respiratory effects.**

| Study Information            |                                 |                         |                              |                       |   |   |  |             | Ambient Air Quality Data  |
|------------------------------|---------------------------------|-------------------------|------------------------------|-----------------------|---|---|--|-------------|---|
| Study Area                   | Health Study Time Period        | Air Quality Time Period | Study Reference <sup>A</sup> | Health Outcome        | O <sub>3</sub> Concentration Metric Associated with Health Outcome  | Assignment of Monitors to Study Subjects  | Study-reported O <sub>3</sub> Concentrations, in terms of study metric (ppb) |             | Design Values for Current NAAQS, across cities and study years (ppb) <sup>B</sup> |
|                              |                                 |                         |                              |                       |   |   | Mean/median  | Range       |   |
| U.S. Studies, multi-city     |                                 |                         |                              |                       |   |   |  |             |   |
| Nationwide                   | 1982-2000                       | 1977-2000               | Jerrett et al., 2009         | Respiratory Mortality | Long-term warm-season average O <sub>3</sub> value including year 1977-2000   | Study participants assigned long-term O <sub>3</sub> concentrations for MSA of residence <sup>C</sup>   | Mean range for MSAs: 33.33-104.0   | NA          | 59-248  |
| California                   | 1982-2000                       | 1988-2002               | Jerrett et al., 2013         | Respiratory Mortality | Monthly average O <sub>3</sub> value calculated using IDW from year 1988-2002   | Study participants were assigned O <sub>3</sub> concentration based on their residential address corresponding to the study site <sup>D</sup> | 50.35  | 17.11-89.33 | 128-186   |
| California (9 areas)         | 1993-2001, 1996-2004, 2006-2014 | 1993--2014              | Garcia et al., 2019          | Asthma diagnosis      | Areawide annual mean O <sub>3</sub> concentration (10am-6pm)  | Community-specific annual mean concentrations for each year of each of the three cohorts.   | -  | 26-76       | 65-165 [for 1993-2014]  |
| Canadian Studies, multi-city |                                 |                         |                              |                       |   |   |  |             |   |
| Nationwide                   | 1991-2011                       | 2002-2009               | Weichenenthal et al., 2017   | Respiratory Mortality | Monthly average O <sub>3</sub> value calculated using pollutant-specific interpolation techniques to generate 21 km <sup>2</sup> grid cell concentrations | Study participants were assigned O <sub>3</sub> concentration from interpolation surface based on their residential postal code <sup>E</sup>  | 38.29  | <1-60.46    | 35-98   |
| Quebec                       | 1999-2010                       | 1999-2010               | Tétreault et al., 2016       | Asthma incidence      | Average summer (June-Aug) concentration [8hr midday concentration per ISA]  | Study participants were assigned concentration estimated for postal code centroid using interpolation based approach.                         | Mean: 32.07<br>Median: 32.19   | 12.18-43.12 | 49-79   |

<sup>A</sup> Studies investigating associations between long-term O<sub>3</sub> exposure and respiratory mortality are summarized in the ISA, Appendix 6, Table 6-8 and Figure 6-9 (U.S. EPA, 2020).

<sup>B</sup> For those studies available at the time of the last review, design values were drawn from (Wells, 2012). For those studies available since the time of the last review, design values were calculated based on data available from the EPA's Air Quality System (AQS) for U.S. studies and the National Air Pollutant Surveillance (NAPS) program for Canadian studies.

<sup>C</sup> Data for monitors were obtained for 1977-2000. Daily maximum 1-hour O<sub>3</sub> concentrations were used to calculate quarterly averages for each monitor. Averages for quarters 2 and 3 were then averaged to create a warm-season average O<sub>3</sub> concentration for each monitor. The warm-season O<sub>3</sub> concentrations for the time period 1977-2000 were computed for each year to form a single annual time series of O<sub>3</sub> measurements for 96 metropolitan areas.

<sup>D</sup> Inverse distance weighted monthly average O<sub>3</sub> concentrations for all sites within a 50 km radius of operating monitors were calculated for the years 1988-2002.

<sup>E</sup> A surface for average daily 8-hour maximum O<sub>3</sub> concentrations was generated for the months of May-October for years 2002-2009 using an air pollution-specific interpolation technique to generate a 21 km<sup>2</sup> grid value. The interpolation method incorporates modeled O<sub>3</sub> from the Canadian Hemispheric Regional Ozone and NO<sub>x</sub> (CHRONOS) air quality forecast model with observations from Canada and the U.S.

2

## ATTACHMENT

### DESIGN VALUES FOR LOCATIONS AND TIME PERIODS ANALYZED IN EPIDEMIOLOGIC STUDIES

NOTE: Design values generally provided in parts per billion (ppb) rather than parts per million (ppm) in tables below for simplicity of presentation.

**Alhanti et al., 2016** (3019562) - ED Visits for Asthma

Three U.S. cities. O<sub>3</sub>: Atlanta (1993–2009), Dallas (2006–2009), St. Louis (2001–2007)

| City        | Census Area Name                  | dv.1993<br>1995 | dv.1994<br>.1996 | dv.1995<br>.1997 | dv.1996<br>.1998 | dv.1997<br>.1999 | dv.1998<br>.2000 | dv.1999<br>.2001 | dv.2000<br>.2002 | dv.2001<br>.2003 | dv.2002<br>.2004 | dv.2003<br>.2005 | dv.2004<br>.2006 | dv.2005<br>.2007 | dv.2006<br>.2008 | dv.2007<br>.2009 |
|-------------|-----------------------------------|-----------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Atlanta, GA | Atlanta-Sandy Springs-Roswell, GA | 109             | 105              | 110              | 113              | 118              | 121              | 107              | 99               | 91               | 93               | 90               | 91               | 95               | 95               | 87               |

| City       | Census Area Name         | dv.2006.2008 | dv.2007.2009 |
|------------|--------------------------|--------------|--------------|
| Dallas, TX | Dallas-Fort Worth, TX-OK | 91           | 86           |

| City      | Census Area Name                        | dv.2001.<br>2003 | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 |
|-----------|---|------------------|------------------|------------------|------------------|------------------|
| St. Louis | St. Louis-St. Charles-Farmington, MO-IL | 92               | 89               | 86               | 86               | 89               |

**Barry et al., 2018** (4829120) - ED Visits for Asthma, ED Visits for Aggregate Respiratory Diseases, ED Visit - Respiratory Infection

Five U.S. Cities: 20-co Atlanta (2002-2008), 7-co Birmingham (2002-2008), 12-co Dallas-Ft Worth (2006-2008), 3-co Pittsburgh (2002-2008), 16-co St Louis (2002-2007)

| City        | Census Area Name                  | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 |
|-------------|-----------------------------------|------------------|------------------|------------------|------------------|------------------|
| Atlanta, GA | Atlanta-Sandy Springs-Roswell, GA | 93               | 90               | 91               | 95               | 95               |

| City           | Census Area Name                | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 |
|----------------|---------------------------------|------------------|------------------|------------------|------------------|------------------|
| Birmingham, AL | Birmingham-Hoover-Talladega, AL | 85               | 84               | 85               | 89               | 87               |

| City            | Census Area Name         | dv.2006.2008 |
|-----------------|--------------------------|--------------|
| Dallas-Ft Worth | Dallas-Fort Worth, TX-OK | 91           |

| City           | Census Area Name                        | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 |
|----------------|---|--------------|--------------|--------------|--------------|--------------|
| Pittsburgh, PA | Pittsburgh-New Castle-Weirton, PA-OH-WV | 90           | 84           | 83           | 87           | 86           |

| City      | Census Area Name                        | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 |
|-----------|---|--------------|--------------|--------------|--------------|
| St. Louis | St. Louis-St. Charles-Farmington, MO-IL | 89           | 86           | 86           | 89           |

**Byers et al., 2015** (3019032) - ED Visits for Asthma

Indianapolis MSA (Marion and 8 surrounding counties), IN, U.S. O<sub>3</sub>: 2007-2011

| City             | Census Area Name               | dv.2007.2009 | dv.2008.2010 | dv.2009.2011 |
|------------------|--------------------------------|--------------|--------------|--------------|
| Indianapolis, IN | Indianapolis-Carmel-Muncie, IN | 77           | 73           | 74           |

**Cakmak et al., 2017** (4167344) - Long-Term Ozone and Respiratory Mortality

Nationwide, Canada. O<sub>3</sub>: 2002-2009

Air quality data are not described for this study as it relied on O<sub>3</sub> concentrations for the years 2002–2009 as surrogates for study population annual O<sub>3</sub> concentrations during the 1984 to 2011 period (Cakmak, 2017).

**Crouse et al., 2015** (3019335) - Long-Term Ozone and Respiratory Mortality

Nationwide, Canada. O<sub>3</sub>: 2002-2009

Air quality data are not described for this study as it relied on O<sub>3</sub> concentrations for the years 2002–2009 as surrogates for study population annual O<sub>3</sub> concentrations during the 1984 to 2006 period (Crouse, 2015).

1 **Darrow et al., 2011** (202800) - ED Visits for Aggregate Respiratory Diseases

2 20-county Atlanta area, GA, U.S. O<sub>3</sub>: 1993-2004

| City   | Census Area Name                   | dv1993_<br>1995 | dv1994_<br>1996 | dv1995_<br>1997 | dv1996_<br>_1998 | dv1997_<br>1999 | dv1998_<br>2000 | dv1999_<br>2001 | dv2000_<br>2002 | dv2001_<br>2003 | dv2002_<br>2004 |
|--|------------------------------------|-----------------|-----------------|-----------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Atlanta, GA  | Atlanta-Sandy Springs-Marietta, GA | 0.109           | 0.105           | 0.110           | 0.113            | 0.118           | 0.121           | 0.107           | 0.099           | 0.091           | 0.093           |
| Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb. |                                    |                 |                 |                 |                  |                 |                 |                 |                 |                 |                 |

3  
4 **Darrow et al., 2014** (2526768) - ED Visit - Respiratory Infection

5 20-county Atlanta area, GA, U.S. O<sub>3</sub>: 1993-2010

| City        | Census Area Name                  | dv.1993.<br>1995 | dv.1994.<br>1996 | dv.1995.<br>1997 | dv.1996.<br>1998 | dv.1997.<br>1999 | dv.1998.<br>2000 | dv.1999.<br>2001 | dv.2000.<br>2002 |
|-------------|-----------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Atlanta, GA | Atlanta-Sandy Springs-Roswell, GA | 109              | 105              | 110              | 113              | 118              | 121              | 107              | 99               |
|             |                                   | dv.2001.<br>2003 | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 | dv.2007.<br>2009 | dv.2008.<br>2010 |
|             |                                   | 91               | 93               | 90               | 91               | 95               | 95               | 87               | 80               |

6  
7 **Eckel et al., 2016** (3426159) - Long-Term Ozone and Respiratory Mortality

8 California, U.S. O<sub>3</sub>: 1988-2011

| State      | dv.1988.<br>1990 | dv.1989.<br>1991 | dv.1990.<br>1992 | dv.1991.<br>1993 | dv.1992.<br>1994 | dv.1993.<br>1995 | dv.1994.<br>1996 | dv.1995.<br>1997 | dv.1996.<br>1998 | dv.1997.<br>1999 | dv.1998.<br>2000 |
|------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| California | 186              | 182              | 180              | 177              | 171              | 165              | 161              | 148              | 154              | 147              | 146              |
|            | dv.1999.<br>2001 | dv.2000.<br>2002 | dv.2001.<br>2003 | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 | dv.2007.<br>2009 | dv.2008.<br>2010 | dv.2009.<br>2011 |
|            | 129              | 128              | 131              | 127              | 127              | 121              | 122              | 119              | 118              | 112              | 107              |

9  
10



1 **Garcia et al., 2019** (5119704) - Asthma Incidence  
 2 Nine communities in Southern California, U.S. O<sub>3</sub>: 1993-2014

| City  | Census Area Name                            | dv.1993<br>.1995 | dv.1994<br>.1996 | dv.1995<br>.1997 | dv.1996<br>.1998 | dv.1997<br>.1999 | dv.1998<br>.2000 | dv.1999.<br>2001 | dv.2000<br>.2002 | dv.2001<br>.2003 | dv.2002<br>.2004 |
|---|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Long Beach, San Dimas                                     | Los Angeles-Long Beach-Anaheim, CA (CBSA)   | 156              | 145              | 135              | 133              | 118              | 115              | 105              | 113              | 126              | 125              |
| Lake Elsinore, Lake Gregory, Mira Loma, Riverside, Upland | Riverside-San Bernardino-Ontario, CA (CBSA) | 165              | 161              | 148              | 154              | 147              | 146              | 129              | 128              | 131              | 127              |
| Alpine  | San Diego-Carlsbad, CA (CBSA)               | 108              | 104              | 99               | 102              | 99               | 100              | 94               | 95               | 93               | 89               |
| Santa Maria   | Santa Maria-Santa Barbara, CA (CBSA)        | 90               | 94               | 89               | 87               | 82               | 81               | 80               | 82               | 84               | 82               |

3

| City  | Census Area Name                            | dv.2003<br>.2005 | dv.2004<br>.2006 | dv.2005<br>.2007 | dv.2006<br>.2008 | dv.2007<br>.2009 | dv.2008<br>.2010 | dv.2009.<br>2011 | dv.2010<br>.2012 | dv.2011<br>.2013 | dv.2012<br>.2014 |
|---|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Long Beach, San Dimas                                     | Los Angeles-Long Beach-Anaheim, CA (CBSA)   | 120              | 112              | 110              | 107              | 108              | 103              | 97               | 96               | 99               | 97               |
| Lake Elsinore, Lake Gregory, Mira Loma, Riverside, Upland | Riverside-San Bernardino-Ontario, CA (CBSA) | 127              | 121              | 122              | 119              | 118              | 112              | 107              | 106              | 107              | 102              |
| Alpine  | San Diego-Carlsbad, CA (CBSA)               | 86               | 88               | 89               | 92               | 89               | 88               | 82               | 91               | 80               | 79               |
| Santa Maria   | Santa Maria-Santa Barbara, CA (CBSA)        | 78               | 75               | 75               | 73               | 77               | 76               | 73               | 68               | 65               | 68               |

4

5

1 **Gleason et al., 2014** (2369662) - ED Visits for Asthma  
 2 New Jersey (statewide), U.S. O<sub>3</sub>: April-September, 2004-2007

| State      | dv.2004.2006 | dv.2005.2007 |
|------------|--------------|--------------|
| New Jersey | 93           | 92           |

3  
 4 **Goodman et al., 2017a** (3859548) - Hospital Admissions for Asthma,  
 5 New York City (20-mi radius from center), NY, U.S. O<sub>3</sub>: 1999-2009

| City         | Census Area Name             | dv.1999.<br>.2001 | dv.2000.<br>.2002 | dv.2001.<br>.2003 | dv.2002.<br>.2004 | dv.2003.<br>.2005 | dv.2004.<br>.2006 | dv.2005.<br>.2007 | dv.2006.<br>.2008 | dv.2007.<br>.2009 |
|--------------|------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| New York, NY | New York-Newark, NY-NJ-CT-PA | 109               | 115               | 109               | 102               | 94                | 93                | 94                | 89                | 84                |

6  
 7 **Goodman et al., 2017b** (4169406) - Hospital Admissions for Asthma  
 8 Houston, Dallas, and Austin, TX metro areas, U.S. O<sub>3</sub>: 2003-2011

| City    | Census Area Name                  | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 | dv.2007.<br>2009 | dv.2008.<br>2010 | dv.2009.<br>2011 |
|---------|-----------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Houston | Houston-The Woodlands, TX         | 103              | 103              | 96               | 91               | 84               | 84               | 89               |
| Dallas  | Dallas-Fort Worth, TX-OK          | 95               | 96               | 95               | 91               | 86               | 86               | 90               |
| Austin  | Austin-Round Rock, TX (CBSA ONLY) | 82               | 82               | 80               | 77               | 75               | 74               | 75               |

9  
 10 **Ito et al., 2007** (156594) - Emergency Department Visits for Asthma  
 11 New York City, NY. O<sub>3</sub>: 1999-2002

| City   | Census Area Name                                   | dv.1999.2001 | dv.2000.2002 |
|--|--|--------------|--------------|
| New York, NY   | New York-Northern New Jersey-Long Island, NY-NJ-PA | 0.109        | 0.115        |
| Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb. |  |              |              |

- 1 **Jerrett et al., 2009** (194160) - Long-Term Ozone and Respiratory Mortality
- 2 Nationwide, U.S. O<sub>3</sub>: 1977-2000

| City                 | Census Area Name                            | dv1977_<br>1979 | dv1978_<br>1980 | dv1979_<br>1981 | dv1980_<br>1982 | dv1981_<br>1983 | dv1982_<br>1984 | dv1983_<br>1985 |
|----------------------|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Charleston, SC       | Charleston-North Charleston-Summerville, SC |                 | 0.088           | 0.08            | 0.074           | 0.072           | 0.076           | 0.077           |
| Charleston, WV       | Charleston, WV                              | 0.077           | 0.077           | 0.075           | 0.078           | 0.082           | 0.086           | 0.087           |
| Charlotte, NC        | Charlotte-Gastonia-Concord, NC-SC           |                 |                 |                 | 0.1             | 0.099           | 0.097           | 0.098           |
| Chattanooga, TN      | Chattanooga, TN-GA                          |                 | 0.09            | 0.094           | 0.097           | 0.097           | 0.093           | 0.091           |
| Chicago, IL          | Chicago-Naperville-Joliet, IL-IN-WI         | 0.112           | 0.112           | 0.1             | 0.096           | 0.103           | 0.103           | 0.106           |
| Cincinnati, OH       | Cincinnati-Middletown, OH-KY-IN             | 0.119           | 0.109           | 0.104           | 0.101           | 0.1             | 0.1             | 0.097           |
| Cleveland, OH        | Cleveland-Elyria-Mentor, OH                 | 0.108           | 0.101           | 0.094           | 0.092           | 0.096           | 0.098           | 0.1             |
| Colorado Springs, CO | Colorado Springs, CO                        |                 |                 |                 | 0.06            | 0.06            | 0.063           | 0.062           |
| Columbia, SC         | Columbia, SC                                | 0.078           | 0.109           | 0.091           | 0.087           | 0.088           | 0.084           | 0.082           |
| Columbus, OH         | Columbus, OH                                | 0.098           | 0.103           | 0.091           | 0.093           | 0.092           | 0.094           | 0.093           |
| Corpus Christi, TX   | Corpus Christi, TX                          |                 |                 |                 |                 | 0.079           | 0.086           | 0.084           |
| Dallas/Ft Worth, TX  | Dallas-Fort Worth-Arlington, TX             |                 | 0.109           | 0.111           | 0.108           | 0.108           | 0.11            | 0.118           |
| Dayton, OH           | Dayton, OH                                  | 0.122           | 0.108           | 0.102           | 0.103           | 0.104           | 0.1             | 0.092           |
| Denver, CO           | Denver-Aurora-Broomfield, CO                | 0.091           | 0.089           | 0.088           | 0.084           | 0.089           | 0.087           | 0.082           |
| Detroit, MI          | Detroit-Warren-Livonia, MI                  | 0.101           | 0.097           | 0.092           | 0.097           | 0.103           | 0.098           | 0.094           |
| El Paso, TX          | El Paso, TX                                 |                 |                 |                 |                 | 0.079           | 0.084           | 0.089           |
| Evansville, IN       | Evansville, IN-KY                           |                 |                 |                 |                 | 0.096           | 0.094           | 0.092           |
| Flint, MI            | Flint, MI                                   | 0.082           | 0.086           | 0.082           | 0.085           | 0.088           | 0.087           | 0.08            |
| Fresno, CA           | Fresno, CA                                  | 0.101           | 0.103           | 0.123           | 0.123           | 0.116           | 0.114           | 0.11            |
| Ft. Lauderdale, FL   | Broward County, FL                          |                 |                 | 0.074           | 0.075           | 0.071           | 0.069           | 0.069           |
| City                 | Census Area Name                            | dv1977_<br>1979 | dv1978_<br>1980 | dv1979_<br>1981 | dv1980_<br>1982 | dv1981_<br>1983 | dv1982_<br>1984 | dv1983_<br>1985 |
| Gary, IN             | Lake County, IN                             | 0.105           | 0.098           | 0.087           | 0.09            | 0.095           | 0.097           | 0.095           |
| Greely, CO           | Greeley, CO                                 |                 |                 |                 |                 | 0.059           | 0.071           | 0.069           |
| Greensboro, NC       | Greensboro-High Point, NC                   |                 |                 | 0.086           | 0.09            | 0.087           | 0.089           | 0.087           |
| Greenville, SC       | Greenville-Mauldin-Easley, SC               |                 |                 | 0.094           | 0.094           | 0.093           | 0.089           | 0.088           |
| Harrisburg, PA       | Harrisburg-Carlisle, PA                     |                 | 0.095           | 0.087           | 0.096           | 0.098           | 0.1             | 0.098           |
| Houston, TX          | Houston-Sugar Land-Baytown, TX              | 0.099           | 0.14            | 0.132           | 0.124           | 0.139           | 0.128           | 0.124           |

|                   |  |                    |                    |                    |                    |                    |                    |                    |
|-------------------|--|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Huntington, WV    | Huntington-Ashland, WV-KY-OH                       |                    |                    | 0.088              | 0.09               | 0.095              | 0.097              | 0.097              |
| Indianapolis, IN  | Indianapolis-Carmel, IN                            | 0.076              | 0.09               | 0.087              | 0.103              | 0.101              | 0.101              | 0.096              |
| Jackson, MS       | Jackson, MS  | 0.098              | 0.09               | 0.084              | 0.081              | 0.079              | 0.076              | 0.078              |
| Jacksonville, FL  | Jacksonville, FL                                   | 0.086              | 0.086              | 0.087              | 0.085              | 0.08               | 0.076              | 0.075              |
| Jersey City, NJ   | Hudson County, NJ                                  |                    |                    |                    |                    |                    |                    | 0.111              |
| Johnstown, PA     | Johnstown, PA                                      | 0.1                | 0.107              | 0.1                | 0.097              | 0.087              | 0.087              | 0.087              |
| Kansas City, MO   | Kansas City, MO-KS                                 | 0.074              | 0.081              | 0.097              | 0.089              | 0.089              | 0.094              | 0.096              |
| Kenosha, WI       | Kenosha County, WI                                 |                    |                    |                    | 0.095              | 0.103              | 0.097              | 0.1                |
| Knoxville, TN     | Knoxville, TN                                      |                    |                    |                    |                    | 0.09               | 0.088              | 0.083              |
| Lancaster, PA     | Lancaster, PA                                      | 0.088              | 0.096              | 0.092              | 0.096              | 0.101              | 0.1                | 0.098              |
| Lansing, MI       | Lansing-East Lansing, MI                           |                    |                    | 0.086              | 0.073              | 0.08               | 0.08               | 0.076              |
| Las Vegas, NV     | Las Vegas-Paradise, NV                             |                    |                    | 0.074              | 0.085              | 0.085              | 0.08               | 0.079              |
| Lexington, KY     | Lexington-Fayette, KY                              |                    | 0.091              | 0.087              | 0.085              | 0.086              | 0.091              | 0.092              |
| Little Rock, AR   | Little Rock-North Little Rock-Conway, AR           | 0.098              | 0.107              | 0.1                | 0.085              | 0.082              | 0.083              | 0.087              |
| Los Angeles, CA   | Los Angeles-Long Beach-Santa Ana, CA               | 0.174              | 0.248              | 0.229              | 0.21               | 0.204              | 0.225              | 0.226              |
| Madison, WI       | Madison, WI  | 0.096              | 0.102              | 0.095              | 0.088              | 0.078              | 0.076              | 0.078              |
| Memphis, TN       | Memphis, TN-MS-AR                                  | 0.102              | 0.103              | 0.085              | 0.096              | 0.097              | 0.092              | 0.092              |
| Milwaukee, WI     | Milwaukee-Waukesha-West Allis, WI                  | 0.114              | 0.11               | 0.11               | 0.106              | 0.111              | 0.104              | 0.105              |
| Minneapolis, MN   | Minneapolis-St. Paul-Bloomington, MN-WI            |                    |                    | 0.08               | 0.079              | 0.076              | 0.073              | 0.073              |
| Nashville, TN     | Nashville-Murfreesboro-Franklin, TN                | 0.092              | 0.085              | 0.077              | 0.083              | 0.083              | 0.09               | 0.095              |
| Nassau, NY        | Nassau County, NY                                  |                    |                    |                    |                    |                    |                    |                    |
| New Haven, CT     | New Haven-Milford, CT                              | 0.135              | 0.127              | 0.118              | 0.121              | 0.13               | 0.136              | 0.128              |
| New Orleans, LA   | New Orleans-Metairie-Kenner, LA                    |                    | 0.087              | 0.087              | 0.085              | 0.083              | 0.099              | 0.089              |
| <b>City</b>       | <b>Census Area Name</b>                            | <b>dv1977_1979</b> | <b>dv1978_1980</b> | <b>dv1979_1981</b> | <b>dv1980_1982</b> | <b>dv1981_1983</b> | <b>dv1982_1984</b> | <b>dv1983_1985</b> |
| New York City, NY | New York-Northern New Jersey-Long Island, NY-NJ-PA | 0.124              | 0.118              | 0.116              | 0.12               | 0.121              | 0.12               | 0.128              |
| Newark, NJ        | Essex County, NJ                                   |                    |                    |                    |                    |                    |                    |                    |
| Norfolk, VA       | Virginia Beach-Norfolk-Newport News, VA-NC         | 0.1                | 0.101              | 0.091              | 0.091              | 0.096              | 0.095              | 0.093              |
| Oklahoma City, OK | Oklahoma City, OK                                  | 0.089              | 0.093              | 0.084              | 0.084              | 0.087              | 0.085              | 0.089              |
| Orlando, FL       | Orlando-Kissimmee, FL                              | 0.078              | 0.08               | 0.077              | 0.078              | 0.078              | 0.078              | 0.074              |

|                   |   |                    |                    |                    |                    |                    |                    |                    |
|-------------------|---|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Philadelphia, PA  | Philadelphia-Camden-Wilmington, PA-NJ-DE-MD | 0.126              | 0.136              | 0.127              | 0.125              | 0.114              | 0.122              | 0.119              |
| Phoenix, AZ       | Phoenix-Mesa-Scottsdale, AZ                 | 0.076              | 0.078              | 0.081              | 0.085              | 0.09               | 0.093              | 0.096              |
| Pittsburgh, PA    | Pittsburgh, PA                              | 0.111              | 0.123              | 0.109              | 0.104              | 0.106              | 0.099              | 0.099              |
| Portland, ME      | Portland-South Portland-Biddeford, ME       |                    |                    |                    |                    | 0.107              | 0.11               | 0.116              |
| Portland, OR      | Portland-Vancouver-Beaverton, OR-WA         | 0.084              | 0.088              | 0.082              | 0.082              | 0.081              | 0.074              | 0.076              |
| Portsmouth, NH    | Rockingham County, NH                       |                    |                    |                    | 0.097              | 0.094              | 0.082              | 0.077              |
| Providence, RI    | Providence-New Bedford-Fall River, RI-MA    | 0.121              | 0.124              | 0.124              | 0.121              | 0.115              | 0.121              | 0.121              |
| Racine, WI        | Racine, WI                                  | 0.093              | 0.112              | 0.108              | 0.109              | 0.113              | 0.112              | 0.111              |
| Raleigh, NC       | Raleigh-Cary, NC                            |                    |                    | 0.088              | 0.091              | 0.089              | 0.085              | 0.087              |
| Reading, PA       | Reading, PA                                 | 0.098              | 0.105              | 0.109              | 0.114              | 0.106              | 0.102              | 0.1                |
| Richmond, VA      | Richmond, VA                                |                    |                    |                    | 0.084              | 0.098              | 0.098              | 0.099              |
| Riverside, CA     | Riverside-San Bernardino-Ontario, CA        | 0.239              | 0.245              | 0.235              | 0.217              | 0.21               | 0.209              | 0.211              |
| Roanoke, VA       | Roanoke, VA                                 |                    |                    |                    |                    | 0.083              | 0.086              | 0.084              |
| Rochester, NY     | Rochester, NY                               | 0.093              | 0.091              | 0.084              | 0.086              | 0.09               | 0.091              | 0.09               |
| Sacramento, CA    | Sacramento-Arden Arcade-Roseville, CA       |                    |                    | 0.102              | 0.112              | 0.114              | 0.115              | 0.118              |
| Salinas, CA       | Salinas, CA                                 |                    | 0.066              | 0.061              | 0.061              | 0.057              | 0.065              | 0.074              |
| San Antonio, TX   | San Antonio, TX                             |                    | 0.086              | 0.089              | 0.092              | 0.09               | 0.087              | 0.086              |
| San Diego, CA     | San Diego-Carlsbad-San Marcos, CA           | 0.115              | 0.118              | 0.141              | 0.137              | 0.13               | 0.126              | 0.132              |
| San Francisco, CA | San Francisco-Oakland-Fremont, CA           | 0.085              | 0.092              | 0.086              | 0.091              | 0.089              | 0.091              | 0.096              |
| San Jose, CA      | San Jose-Sunnyvale-Santa Clara, CA          | 0.093              | 0.101              | 0.102              | 0.094              | 0.095              | 0.1                | 0.103              |
| Seattle, WA       | Seattle-Tacoma-Bellevue, WA                 | 0.088              | 0.081              | 0.084              | 0.085              | 0.08               | 0.069              | 0.069              |
| Shreveport, LA    | Shreveport-Bossier City, LA                 |                    |                    |                    | 0.08               | 0.081              | 0.077              | 0.079              |
| South Bend, IN    | South Bend-Mishawaka, IN-MI                 |                    | 0.093              | 0.093              | 0.102              | 0.095              | 0.09               | 0.088              |
| <b>City</b>       | <b>Census Area Name</b>                     | <b>dv1977_1979</b> | <b>dv1978_1980</b> | <b>dv1979_1981</b> | <b>dv1980_1982</b> | <b>dv1981_1983</b> | <b>dv1982_1984</b> | <b>dv1983_1985</b> |
| Springfield, MA   | Springfield, MA                             |                    |                    |                    |                    |                    | 0.1                | 0.112              |
| St Louis, MO      | St. Louis, MO-IL                            | 0.122              | 0.117              | 0.109              | 0.101              | 0.107              | 0.111              | 0.113              |
| Steubenville, OH  | Weirton-Steubenville, WV-OH                 | 0.098              | 0.099              | 0.088              | 0.083              | 0.073              | 0.071              | 0.064              |
| Syracuse, NY      | Syracuse, NY                                |                    |                    |                    |                    |                    |                    |                    |
| Tacoma, WA        | Seattle-Tacoma-Bellevue, WA                 | 0.088              | 0.081              | 0.084              | 0.085              | 0.08               | 0.069              | 0.069              |
| Tampa, FL         | Tampa-St. Petersburg-Clearwater, FL         | 0.09               | 0.088              | 0.087              | 0.087              | 0.089              | 0.09               | 0.087              |

|                |  |       |       |       |       |       |       |       |
|----------------|--|-------|-------|-------|-------|-------|-------|-------|
| Toledo, OH     | Toledo, OH                                   | 0.108 | 0.104 | 0.102 | 0.1   | 0.101 | 0.09  | 0.087 |
| Trenton, NJ    | Trenton-Ewing, NJ                            |       |       |       |       | 0.116 | 0.117 | 0.12  |
| Tucson, AZ     | Tucson, AZ                                   | 0.07  | 0.074 | 0.074 | 0.082 | 0.081 | 0.082 | 0.079 |
| Vallejo, CA    | Vallejo-Fairfield, CA                        | 0.068 | 0.069 | 0.063 | 0.074 | 0.072 | 0.074 | 0.075 |
| Ventura, CA    | Ventura County, CA                           | 0.13  | 0.13  | 0.109 | 0.104 | 0.098 | 0.112 | 0.113 |
| Washington, DC | Washington-Arlington-Alexandria, DC-VA-MD-WV | 0.112 | 0.101 | 0.101 | 0.113 | 0.113 | 0.112 | 0.11  |
| Wichita, KS    | Wichita, KS                                  |       |       |       | 0.074 | 0.078 | 0.079 | 0.081 |
| Wilmington, DE | New Castle County, DE                        |       | 0.083 | 0.088 | 0.093 | 0.106 | 0.112 | 0.116 |
| Worcester, MA  | Worcester, MA                                |       |       | 0.102 |       | 0.092 | 0.096 | 0.099 |
| York, PA       | York-Hanover, PA                             | 0.105 | 0.107 | 0.098 | 0.096 | 0.097 | 0.098 | 0.099 |
| Youngstown, OH | Youngstown-Warren-Boardman, OH-PA            |       |       |       |       | 0.097 | 0.093 | 0.089 |

Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb.

1  
2 **Jerrett et al., 2009 (194160) - Long-Term Ozone and Respiratory Mortality (Continued)**

| City                 | Census Area Name                            | dv1984<br>_1986 | dv1985<br>_1987 | dv1986<br>_1988 | dv1987<br>_1989 | dv1988<br>_1990 | dv1989<br>_1991 | dv1990<br>_1992 |
|----------------------|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Charleston, SC       | Charleston-North Charleston-Summerville, SC | 0.081           | 0.085           | 0.09            | 0.087           | 0.083           | 0.076           | 0.074           |
| Charleston, WV       | Charleston, WV                              | 0.084           | 0.087           | 0.099           | 0.094           | 0.089           | 0.081           | 0.074           |
| Charlotte, NC        | Charlotte-Gastonia-Concord, NC-SC           | 0.094           | 0.102           | 0.112           | 0.104           | 0.101           | 0.092           | 0.091           |
| Chattanooga, TN      | Chattanooga, TN-GA                          | 0.089           | 0.089           | 0.094           | 0.092           | 0.09            | 0.086           | 0.083           |
| Chicago, IL          | Chicago-Naperville-Joliet, IL-IN-WI         | 0.098           | 0.101           | 0.112           | 0.114           | 0.114           | 0.104           | 0.099           |
| Cincinnati, OH       | Cincinnati-Middletown, OH-KY-IN             | 0.093           | 0.098           | 0.109           | 0.106           | 0.107           | 0.102           | 0.095           |
| Cleveland, OH        | Cleveland-Elyria-Mentor, OH                 | 0.094           | 0.092           | 0.104           | 0.105           | 0.104           | 0.093           | 0.09            |
| Colorado Springs, CO | Colorado Springs, CO                        | 0.062           | 0.06            | 0.061           | 0.063           | 0.065           | 0.066           | 0.063           |
| Columbia, SC         | Columbia, SC                                | 0.081           | 0.084           | 0.069           | 0.091           | 0.091           | 0.081           | 0.084           |
| Columbus, OH         | Columbus, OH                                | 0.089           | 0.089           | 0.093           | 0.097           | 0.095           | 0.089           | 0.092           |
| Corpus Christi, TX   | Corpus Christi, TX                          | 0.078           | 0.083           | 0.086           | 0.089           | 0.085           | 0.079           | 0.077           |
| Dallas/Ft Worth, TX  | Dallas-Fort Worth-Arlington, TX             | 0.113           | 0.108           | 0.101           | 0.1             | 0.105           | 0.105           | 0.099           |
| Dayton, OH           | Dayton, OH                                  | 0.088           | 0.09            | 0.095           | 0.096           | 0.092           | 0.086           | 0.082           |
| Denver, CO           | Denver-Aurora-Broomfield, CO                | 0.079           | 0.081           | 0.088           | 0.087           | 0.086           | 0.08            | 0.074           |
| Detroit, MI          | Detroit-Warren-Livonia, MI                  | 0.089           | 0.093           | 0.1             | 0.099           | 0.099           | 0.096           | 0.091           |
| El Paso, TX          | El Paso, TX                                 | 0.096           | 0.096           | 0.092           | 0.088           | 0.083           | 0.08            | 0.079           |

| City               | Census Area Name                         | dv1984<br>_1986 | dv1985<br>_1987 | dv1986<br>_1988 | dv1987<br>_1989 | dv1988<br>_1990 | dv1989<br>_1991 | dv1990<br>_1992 |
|--------------------|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Evansville, IN     | Evansville, IN-KY                        | 0.09            | 0.094           | 0.099           | 0.1             | 0.099           | 0.091           | 0.088           |
| Flint, MI          | Flint, MI                                | 0.077           | 0.079           | 0.09            | 0.091           | 0.09            | 0.085           | 0.081           |
| Fresno, CA         | Fresno, CA                               | 0.117           | 0.118           | 0.121           | 0.115           | 0.11            | 0.108           | 0.108           |
| Ft. Lauderdale, FL | Broward County, FL                       | 0.073           | 0.073           | 0.077           | 0.076           | 0.079           | 0.075           | 0.073           |
| Gary, IN           | Lake County, IN                          | 0.088           | 0.087           | 0.093           | 0.096           | 0.092           | 0.087           | 0.083           |
| Greely, CO         | Greeley, CO                              | 0.067           | 0.068           | 0.07            | 0.072           | 0.074           | 0.075           | 0.072           |
| Greensboro, NC     | Greensboro-High Point, NC                | 0.089           | 0.089           | 0.1             | 0.097           | 0.1             | 0.088           | 0.085           |
| Greenville, SC     | Greenville-Mauldin-Easley, SC            | 0.085           | 0.089           | 0.091           | 0.09            | 0.085           | 0.075           | 0.075           |
| Harrisburg, PA     | Harrisburg-Carlisle, PA                  | 0.091           | 0.096           | 0.103           | 0.103           | 0.098           | 0.094           | 0.091           |
| Houston, TX        | Houston-Sugar Land-Baytown, TX           | 0.127           | 0.127           | 0.118           | 0.117           | 0.119           | 0.119           | 0.116           |
| Huntington, WV     | Huntington-Ashland, WV-KY-OH             | 0.09            | 0.093           | 0.099           | 0.103           | 0.103           | 0.092           | 0.096           |
| Indianapolis, IN   | Indianapolis-Carmel, IN                  | 0.09            | 0.091           | 0.096           | 0.098           | 0.095           | 0.091           | 0.089           |
| Jackson, MS        | Jackson, MS                              | 0.077           | 0.076           | 0.077           | 0.075           | 0.079           | 0.076           | 0.076           |
| Jacksonville, FL   | Jacksonville, FL                         | 0.075           | 0.081           | 0.084           | 0.086           | 0.084           | 0.081           | 0.079           |
| Jersey City, NJ    | Hudson County, NJ                        | 0.104           | 0.109           | 0.117           | 0.118           | 0.115           | 0.107           | 0.104           |
| Johnstown, PA      | Johnstown, PA                            | 0.085           | 0.087           | 0.097           | 0.097           | 0.093           | 0.086           | 0.083           |
| Kansas City, MO    | Kansas City, MO-KS                       | 0.089           | 0.084           | 0.088           | 0.088           | 0.086           | 0.082           | 0.083           |
| Kenosha, WI        | Kenosha County, WI                       | 0.089           | 0.098           | 0.111           | 0.114           | 0.114           | 0.104           | 0.099           |
| Knoxville, TN      | Knoxville, TN                            | 0.094           | 0.087           | 0.097           | 0.093           | 0.094           | 0.086           | 0.089           |
| Lancaster, PA      | Lancaster, PA                            | 0.09            | 0.091           | 0.097           | 0.097           | 0.093           | 0.09            | 0.09            |
| Lansing, MI        | Lansing-East Lansing, MI                 | 0.073           | 0.077           | 0.09            | 0.089           | 0.087           | 0.081           | 0.082           |
| Las Vegas, NV      | Las Vegas-Paradise, NV                   | 0.08            | 0.083           | 0.082           | 0.081           | 0.078           | 0.078           | 0.076           |
| Lexington, KY      | Lexington-Fayette, KY                    | 0.092           | 0.094           | 0.099           | 0.099           | 0.096           | 0.085           | 0.078           |
| Little Rock, AR    | Little Rock-North Little Rock-Conway, AR | 0.087           | 0.089           | 0.09            | 0.085           | 0.082           | 0.079           | 0.08            |
| Los Angeles, CA    | Los Angeles-Long Beach-Santa Ana, CA     | 0.222           | 0.217           | 0.205           | 0.192           | 0.186           | 0.179           | 0.177           |
| Madison, WI        | Madison, WI                              | 0.075           | 0.079           | 0.09            | 0.091           | 0.079           | 0.081           | 0.079           |
| Memphis, TN        | Memphis, TN-MS-AR                        | 0.093           | 0.096           | 0.1             | 0.095           | 0.095           | 0.089           | 0.091           |
| Milwaukee, WI      | Milwaukee-Waukesha-West Allis, WI        | 0.095           | 0.105           | 0.113           | 0.117           | 0.105           | 0.101           | 0.095           |
| Minneapolis, MN    | Minneapolis-St. Paul-Bloomington, MN-WI  | 0.071           | 0.073           | 0.077           | 0.08            | 0.079           | 0.075           | 0.071           |
| Nashville, TN      | Nashville-Murfreesboro-Franklin, TN      | 0.097           | 0.098           | 0.106           | 0.104           | 0.104           | 0.096           | 0.096           |

| City              | Census Area Name                              | dv1984<br>_1986 | dv1985<br>_1987 | dv1986<br>_1988 | dv1987<br>_1989 | dv1988<br>_1990 | dv1989<br>_1991 | dv1990<br>_1992 |
|-------------------|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Nassau, NY        | Nassau County, NY                             |                 |                 |                 |                 |                 |                 |                 |
| New Haven, CT     | New Haven-Milford, CT                         | 0.115           | 0.108           | 0.112           | 0.113           | 0.116           | 0.116           | 0.113           |
| New Orleans, LA   | New Orleans-Metairie-Kenner, LA               | 0.089           | 0.088           | 0.094           | 0.09            | 0.085           | 0.077           | 0.08            |
| New York City, NY | New York-Northern New Jersey-Long Island, NY- | 0.119           | 0.122           | 0.129           | 0.129           | 0.128           | 0.122           | 0.116           |
| Newark, NJ        | Essex County, NJ                              |                 | 0.086           | 0.092           | 0.105           | 0.098           | 0.088           | 0.086           |
| Norfolk, VA       | Virginia Beach-Norfolk-Newport News, VA-NC    | 0.087           | 0.089           | 0.095           | 0.093           | 0.091           | 0.084           | 0.086           |
| Oklahoma City, OK | Oklahoma City, OK                             | 0.087           | 0.084           | 0.085           | 0.087           | 0.087           | 0.086           | 0.084           |
| Orlando, FL       | Orlando-Kissimmee, FL                         | 0.075           | 0.078           | 0.082           | 0.082           | 0.082           | 0.08            | 0.079           |
| Philadelphia, PA  | Philadelphia-Camden-Wilmington, PA-NJ-DE-MD   | 0.119           | 0.123           | 0.132           | 0.123           | 0.12            | 0.113           | 0.107           |
| Phoenix, AZ       | Phoenix-Mesa-Scottsdale, AZ                   | 0.09            | 0.086           | 0.081           | 0.077           | 0.082           | 0.083           | 0.091           |
| Pittsburgh, PA    | Pittsburgh, PA                                | 0.09            | 0.093           | 0.104           | 0.107           | 0.098           | 0.092           | 0.088           |
| Portland, ME      | Portland-South Portland-Biddeford, ME         | 0.112           | 0.112           | 0.112           | 0.117           | 0.115           | 0.109           | 0.105           |
| Portland, OR      | Portland-Vancouver-Beaverton, OR-WA           | 0.085           | 0.086           | 0.085           | 0.077           | 0.085           | 0.082           | 0.091           |
| Portsmouth, NH    | Rockingham County, NH                         | 0.078           | 0.087           | 0.094           | 0.104           | 0.1             | 0.098           | 0.092           |
| Providence, RI    | Providence-New Bedford-Fall River, RI-MA      | 0.114           | 0.107           | 0.113           | 0.108           | 0.108           | 0.107           | 0.105           |
| Racine, WI        | Racine, WI                                    | 0.102           | 0.107           | 0.12            | 0.124           | 0.11            | 0.098           | 0.088           |
| Raleigh, NC       | Raleigh-Cary, NC                              | 0.087           | 0.092           | 0.104           | 0.099           | 0.093           | 0.089           | 0.086           |
| Reading, PA       | Reading, PA                                   | 0.092           | 0.096           | 0.104           | 0.105           | 0.102           | 0.096           | 0.094           |
| Richmond, VA      | Richmond, VA                                  | 0.095           | 0.097           | 0.104           | 0.103           | 0.097           | 0.087           | 0.087           |
| Riverside, CA     | Riverside-San Bernardino-Ontario, CA          | 0.21            | 0.2             | 0.188           | 0.188           | 0.185           | 0.182           | 0.18            |
| Roanoke, VA       | Roanoke, VA                                   | 0.083           | 0.087           | 0.095           | 0.092           | 0.085           | 0.076           | 0.074           |
| Rochester, NY     | Rochester, NY                                 | 0.09            | 0.091           | 0.099           | 0.099           | 0.095           | 0.092           | 0.09            |
| Sacramento, CA    | Sacramento-Arden Arcade-Roseville, CA         | 0.118           | 0.114           | 0.114           | 0.114           | 0.107           | 0.105           | 0.105           |
| Salinas, CA       | Salinas, CA                                   | 0.071           | 0.071           | 0.068           | 0.072           | 0.07            | 0.07            | 0.071           |
| San Antonio, TX   | San Antonio, TX                               | 0.085           | 0.083           | 0.084           | 0.085           | 0.085           | 0.082           | 0.079           |
| San Diego, CA     | San Diego-Carlsbad-San Marcos, CA             | 0.125           | 0.124           | 0.121           | 0.125           | 0.129           | 0.125           | 0.118           |
| San Francisco, CA | San Francisco-Oakland-Fremont, CA             | 0.093           | 0.089           | 0.087           | 0.089           | 0.087           | 0.084           | 0.082           |
| San Jose, CA      | San Jose-Sunnyvale-Santa Clara, CA            | 0.097           | 0.092           | 0.092           | 0.097           | 0.088           | 0.082           | 0.083           |
| Seattle, WA       | Seattle-Tacoma-Bellevue, WA                   | 0.075           | 0.077           | 0.074           | 0.076           | 0.079           | 0.078           | 0.086           |
| Shreveport, LA    | Shreveport-Bossier City, LA                   | 0.082           | 0.085           | 0.086           | 0.087           | 0.088           | 0.084           | 0.086           |



| City  | Census Area Name                             | dv1984_1986 | dv1985_1987 | dv1986_1988 | dv1987_1989 | dv1988_1990 | dv1989_1991 | dv1990_1992 |
|---|--|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| South Bend, IN  | South Bend-Mishawaka, IN-MI                  | 0.081       | 0.088       | 0.092       | 0.093       | 0.087       | 0.08        | 0.083       |
| Springfield, MA   | Springfield, MA                              | 0.102       | 0.096       | 0.106       | 0.109       | 0.115       | 0.107       | 0.105       |
| St Louis, MO  | St. Louis, MO-IL                             | 0.103       | 0.102       | 0.114       | 0.111       | 0.102       | 0.098       | 0.098       |
| Steubenville, OH  | Weirton-Steubenville, WV-OH                  | 0.062       | 0.069       | 0.086       | 0.09        | 0.088       | 0.085       | 0.083       |
| Syracuse, NY  | Syracuse, NY                                 |             | 0.083       | 0.096       | 0.092       | 0.088       | 0.083       | 0.083       |
| Tacoma, WA  | Seattle-Tacoma-Bellevue, WA                  | 0.075       | 0.077       | 0.074       | 0.076       | 0.079       | 0.078       | 0.086       |
| Tampa, FL   | Tampa-St. Petersburg-Clearwater, FL          | 0.088       | 0.091       | 0.09        | 0.086       | 0.085       | 0.079       | 0.081       |
| Toledo, OH  | Toledo, OH                                   | 0.079       | 0.083       | 0.097       | 0.102       | 0.099       | 0.086       | 0.082       |
| Trenton, NJ   | Trenton-Ewing, NJ                            | 0.11        | 0.114       | 0.124       | 0.123       | 0.117       | 0.111       | 0.112       |
| Tucson, AZ  | Tucson, AZ                                   | 0.076       | 0.074       | 0.069       | 0.071       | 0.075       | 0.074       | 0.075       |
| Vallejo, CA   | Vallejo-Fairfield, CA                        | 0.073       | 0.077       | 0.079       | 0.082       | 0.075       | 0.074       | 0.074       |
| Ventura, CA   | Ventura County, CA                           | 0.116       | 0.114       | 0.131       | 0.132       | 0.13        | 0.126       | 0.117       |
| Washington, DC  | Washington-Arlington-Alexandria, DC-VA-MD-WV | 0.104       | 0.11        | 0.116       | 0.115       | 0.107       | 0.1         | 0.1         |
| Wichita, KS   | Wichita, KS                                  | 0.077       | 0.076       | 0.08        | 0.08        | 0.081       | 0.075       | 0.074       |
| Wilmington, DE  | New Castle County, DE                        | 0.102       | 0.106       | 0.114       | 0.114       | 0.115       | 0.107       | 0.101       |
| Worcester, MA   | Worcester, MA                                | 0.091       | 0.086       | 0.088       | 0.091       | 0.091       | 0.089       | 0.091       |
| York, PA  | York-Hanover, PA                             | 0.093       | 0.094       | 0.1         | 0.099       | 0.099       | 0.094       | 0.093       |
| Youngstown, OH  | Youngstown-Warren-Boardman, OH-PA            | 0.085       | 0.089       | 0.101       | 0.103       | 0.099       | 0.09        | 0.091       |
| Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb |  |             |             |             |             |             |             |             |

1  
2 **Jerrett et al., 2009 (194160) - Long-Term Ozone and Respiratory Mortality (Continued)**

| City            | Census Area Name                            | dv1991_1993 | dv1992_1994 | dv1993_1995 | dv1994_1996 | dv1995_1997 | dv1996_1998 | dv1997_1999 | dv1998_2000 |
|-----------------|---|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Charleston, SC  | Charleston-North Charleston-Summerville, SC | 0.074       | 0.075       | 0.074       | 0.072       | 0.076       | 0.077       | 0.079       | 0.082       |
| Charleston, WV  | Charleston, WV                              | 0.069       | 0.064       | 0.076       | 0.081       | 0.081       | 0.081       | 0.09        | 0.093       |
| Charlotte, NC   | Charlotte-Gastonia-Concord, NC-SC           | 0.091       | 0.092       | 0.094       | 0.094       | 0.097       | 0.103       | 0.104       | 0.104       |
| Chattanooga, TN | Chattanooga, TN-GA                          | 0.082       | 0.086       | 0.091       | 0.091       | 0.09        | 0.093       | 0.094       | 0.097       |
| Chicago, IL     | Chicago-Naperville-Joliet, IL-IN-WI         | 0.1         | 0.093       | 0.099       | 0.097       | 0.096       | 0.091       | 0.095       | 0.093       |
| Cincinnati, OH  | Cincinnati-Middletown, OH-KY-IN             | 0.091       | 0.091       | 0.098       | 0.099       | 0.095       | 0.092       | 0.095       | 0.094       |

|                      |                                 |                         |                         |                         |                         |                         |                         |                         |                         |
|----------------------|---------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Cleveland, OH        | Cleveland-Elyria-Mentor, OH     | 0.092                   | 0.093                   | 0.098                   | 0.1                     | 0.099                   | 0.098                   | 0.099                   | 0.095                   |
| Colorado Springs, CO | Colorado Springs, CO            | 0.062                   | 0.061                   | 0.061                   | 0.059                   | 0.056                   | 0.059                   | 0.062                   | 0.065                   |
| Columbia, SC         | Columbia, SC                    | 0.085                   | 0.087                   | 0.086                   | 0.081                   | 0.08                    | 0.087                   | 0.092                   | 0.096                   |
| Columbus, OH         | Columbus, OH                    | 0.09                    | 0.086                   | 0.09                    | 0.092                   | 0.092                   | 0.093                   | 0.097                   | 0.095                   |
| Corpus Christi, TX   | Corpus Christi, TX              | 0.078                   | 0.079                   | 0.082                   | 0.083                   | 0.083                   | 0.08                    | 0.081                   | 0.083                   |
| Dallas/Ft Worth, TX  | Dallas-Fort Worth-Arlington, TX | 0.095                   | 0.096                   | 0.106                   | 0.104                   | 0.104                   | 0.098                   | 0.101                   | 0.102                   |
| Dayton, OH           | Dayton, OH                      | 0.084                   | 0.086                   | 0.092                   | 0.093                   | 0.091                   | 0.093                   | 0.093                   | 0.09                    |
| Denver, CO           | Denver-Aurora-Broomfield, CO    | 0.071                   | 0.074                   | 0.081                   | 0.081                   | 0.079                   | 0.084                   | 0.083                   | 0.086                   |
| Detroit, MI          | Detroit-Warren-Livonia, MI      | 0.089                   | 0.088                   | 0.093                   | 0.094                   | 0.092                   | 0.093                   | 0.095                   | 0.089                   |
| El Paso, TX          | El Paso, TX                     | 0.078                   | 0.081                   | 0.084                   | 0.089                   | 0.08                    | 0.082                   | 0.078                   | 0.08                    |
| Evansville, IN       | Evansville, IN-KY               | 0.087                   | 0.089                   | 0.094                   | 0.095                   | 0.093                   | 0.093                   | 0.094                   | 0.091                   |
| Flint, MI            | Flint, MI                       | 0.077                   | 0.071                   | 0.075                   | 0.082                   | 0.084                   | 0.086                   | 0.089                   | 0.086                   |
| Fresno, CA           | Fresno, CA                      | 0.111                   | 0.107                   | 0.108                   | 0.107                   | 0.111                   | 0.115                   | 0.113                   | 0.111                   |
| Ft. Lauderdale, FL   | Broward County, FL              | 0.076                   | 0.079                   | 0.074                   | 0.069                   | 0.069                   | 0.072                   | 0.075                   | 0.075                   |
| Gary, IN             | Lake County, IN                 | 0.08                    | 0.077                   | 0.084                   | 0.091                   | 0.095                   | 0.09                    | 0.091                   | 0.088                   |
| Greely, CO           | Greeley, CO                     | 0.068                   | 0.066                   | 0.068                   | 0.071                   | 0.07                    | 0.071                   | 0.071                   | 0.071                   |
| Greensboro, NC       | Greensboro-High Point, NC       | 0.083                   | 0.084                   | 0.088                   | 0.086                   | 0.085                   | 0.089                   | 0.092                   | 0.094                   |
| Greenville, SC       | Greenville-Mauldin-Easley, SC   | 0.082                   | 0.081                   | 0.082                   | 0.081                   | 0.083                   | 0.087                   | 0.09                    | 0.09                    |
| Harrisburg, PA       | Harrisburg-Carlisle, PA         | 0.091                   | 0.089                   | 0.092                   | 0.087                   | 0.088                   | 0.088                   | 0.094                   | 0.093                   |
| Houston, TX          | Houston-Sugar Land-Baytown, TX  | 0.104                   | 0.11                    | 0.114                   | 0.116                   | 0.117                   | 0.116                   | 0.118                   | 0.112                   |
| Huntington, WV       | Huntington-Ashland, WV-KY-OH    | 0.092                   | 0.09                    | 0.096                   | 0.091                   | 0.088                   | 0.092                   | 0.095                   | 0.094                   |
| Indianapolis, IN     | Indianapolis-Carmel, IN         | 0.087                   | 0.09                    | 0.094                   | 0.098                   | 0.097                   | 0.098                   | 0.097                   | 0.095                   |
| <b>City</b>          | <b>Census Area Name</b>         | <b>dv1991_<br/>1993</b> | <b>dv1992_<br/>1994</b> | <b>dv1993_<br/>1995</b> | <b>dv1994_<br/>1996</b> | <b>dv1995_<br/>1997</b> | <b>dv1996_<br/>1998</b> | <b>dv1997_<br/>1999</b> | <b>dv1998_<br/>2000</b> |
| Jackson, MS          | Jackson, MS                     | 0.074                   | 0.075                   | 0.076                   | 0.077                   | 0.077                   | 0.08                    | 0.081                   | 0.083                   |
| Jacksonville, FL     | Jacksonville, FL                | 0.079                   | 0.081                   | 0.08                    | 0.078                   | 0.081                   | 0.088                   | 0.088                   | 0.085                   |
| Jersey City, NJ      | Hudson County, NJ               | 0.103                   | 0.096                   | 0.1                     | 0.095                   | 0.098                   | 0.093                   | 0.1                     | 0.092                   |
| Johnstown, PA        | Johnstown, PA                   | 0.084                   | 0.08                    | 0.085                   | 0.085                   | 0.088                   | 0.091                   | 0.093                   | 0.091                   |
| Kansas City, MO      | Kansas City, MO-KS              | 0.082                   | 0.082                   | 0.09                    | 0.092                   | 0.094                   | 0.093                   | 0.091                   | 0.089                   |
| Kenosha, WI          | Kenosha County, WI              | 0.1                     | 0.093                   | 0.099                   | 0.097                   | 0.096                   | 0.09                    | 0.095                   | 0.093                   |

|                   |  |                    |                    |                    |                    |                    |                    |                    |                    |
|-------------------|--|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Knoxville, TN     | Knoxville, TN                                      | 0.088              | 0.089              | 0.093              | 0.093              | 0.095              | 0.1                | 0.104              | 0.104              |
| Lancaster, PA     | Lancaster, PA                                      | 0.093              | 0.091              | 0.096              | 0.093              | 0.096              | 0.096              | 0.101              | 0.097              |
| Lansing, MI       | Lansing-East Lansing, MI                           | 0.081              | 0.079              | 0.082              | 0.084              | 0.083              | 0.08               | 0.082              | 0.082              |
| Las Vegas, NV     | Las Vegas-Paradise, NV                             | 0.075              | 0.079              | 0.079              | 0.08               | 0.079              | 0.08               | 0.077              | 0.085              |
| Lexington, KY     | Lexington-Fayette, KY                              | 0.077              | 0.079              | 0.087              | 0.087              | 0.085              | 0.085              | 0.087              | 0.085              |
| Little Rock, AR   | Little Rock-North Little Rock-Conway, AR           | 0.078              | 0.077              | 0.08               | 0.08               | 0.081              | 0.08               | 0.082              | 0.087              |
| Los Angeles, CA   | Los Angeles-Long Beach-Santa Ana, CA               | 0.177              | 0.168              | 0.156              | 0.145              | 0.135              | 0.133              | 0.118              | 0.115              |
| Madison, WI       | Madison, WI  | 0.073              | 0.072              | 0.072              | 0.08               | 0.081              | 0.078              | 0.08               | 0.078              |
| Memphis, TN       | Memphis, TN-MS-AR                                  | 0.09               | 0.09               | 0.091              | 0.094              | 0.095              | 0.093              | 0.095              | 0.097              |
| Milwaukee, WI     | Milwaukee-Waukesha-West Allis, WI                  | 0.09               | 0.084              | 0.092              | 0.097              | 0.098              | 0.093              | 0.097              | 0.092              |
| Minneapolis, MN   | Minneapolis-St. Paul-Bloomington, MN-WI            | 0.07               | 0.07               | 0.072              | 0.074              | 0.072              | 0.07               | 0.074              | 0.074              |
| Nashville, TN     | Nashville-Murfreesboro-Franklin, TN                | 0.095              | 0.096              | 0.099              | 0.099              | 0.099              | 0.101              | 0.102              | 0.1                |
| Nassau, NY        | Nassau County, NY                                  |                    |                    |                    |                    |                    |                    |                    |                    |
| New Haven, CT     | New Haven-Milford, CT                              | 0.108              | 0.097              | 0.105              | 0.101              | 0.107              | 0.1                | 0.103              | 0.096              |
| New Orleans, LA   | New Orleans-Metairie-Kenner, LA                    | 0.081              | 0.086              | 0.084              | 0.085              | 0.083              | 0.084              | 0.086              | 0.091              |
| New York City, NY | New York-Northern New Jersey-Long Island, NY-NJ-PA | 0.108              | 0.1                | 0.106              | 0.104              | 0.108              | 0.104              | 0.107              | 0.107              |
| Newark, NJ        | Essex County, NJ                                   | 0.084              | 0.081              | 0.088              | 0.088              | 0.092              | 0.088              | 0.093              | 0                  |
| Norfolk, VA       | Virginia Beach-Norfolk-Newport News, VA-NC         | 0.09               | 0.088              | 0.087              | 0.083              | 0.087              | 0.09               | 0.094              | 0.089              |
| Oklahoma City, OK | Oklahoma City, OK                                  | 0.081              | 0.081              | 0.084              | 0.085              | 0.083              | 0.085              | 0.086              | 0.084              |
| Orlando, FL       | Orlando-Kissimmee, FL                              | 0.078              | 0.082              | 0.079              | 0.079              | 0.078              | 0.084              | 0.085              | 0.085              |
| Philadelphia, PA  | Philadelphia-Camden-Wilmington, PA-NJ-DE-MD        | 0.106              | 0.099              | 0.104              | 0.101              | 0.11               | 0.107              | 0.11               | 0.106              |
| Phoenix, AZ       | Phoenix-Mesa-Scottsdale, AZ                        | 0.088              | 0.086              | 0.089              | 0.09               | 0.092              | 0.091              | 0.088              | 0.088              |
| <b>City</b>       | <b>Census Area Name</b>                            | <b>dv1991_1993</b> | <b>dv1992_1994</b> | <b>dv1993_1995</b> | <b>dv1994_1996</b> | <b>dv1995_1997</b> | <b>dv1996_1998</b> | <b>dv1997_1999</b> | <b>dv1998_2000</b> |
| Pittsburgh, PA    | Pittsburgh, PA                                     | 0.095              | 0.096              | 0.105              | 0.103              | 0.105              | 0.099              | 0.101              | 0.096              |
| Portland, ME      | Portland-South Portland-Biddeford, ME              | 0.102              | 0.095              | 0.096              | 0.092              | 0.096              | 0.092              | 0.092              | 0.084              |
| Portland, OR      | Portland-Vancouver-Beaverton, OR-WA                | 0.076              | 0.078              | 0.071              | 0.083              | 0.078              | 0.08               | 0.071              | 0.072              |
| Portsmouth, NH    | Rockingham County, NH                              | 0.096              | 0.093              | 0.096              | 0.094              | 0.095              | 0.091              | 0.09               | 0.08               |
| Providence, RI    | Providence-New Bedford-Fall River, RI-MA           | 0.099              | 0.092              | 0.097              | 0.094              | 0.097              | 0.09               | 0.092              | 0.088              |

|                   |  |                    |                    |                    |                    |                    |                    |                    |                    |
|-------------------|--|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Racine, WI        | Racine, WI                                   | 0.086              | 0.082              | 0.088              | 0.089              | 0.092              | 0.088              | 0.091              | 0.085              |
| Raleigh, NC       | Raleigh-Cary, NC                             | 0.087              | 0.086              | 0.087              | 0.087              | 0.089              | 0.096              | 0.103              | 0.101              |
| Reading, PA       | Reading, PA                                  | 0.094              | 0.086              | 0.088              | 0.089              | 0.092              | 0.091              | 0.096              | 0.092              |
| Richmond, VA      | Richmond, VA                                 | 0.091              | 0.092              | 0.093              | 0.087              | 0.09               | 0.092              | 0.099              | 0.091              |
| Riverside, CA     | Riverside-San Bernardino-Ontario, CA         | 0.177              | 0.171              | 0.165              | 0.161              | 0.148              | 0.154              | 0.147              | 0.146              |
| Roanoke, VA       | Roanoke, VA                                  | 0.077              | 0.08               | 0.082              | 0.078              | 0.078              | 0.085              | 0.09               | 0.089              |
| Rochester, NY     | Rochester, NY                                | 0.088              | 0.08               | 0.085              | 0.081              | 0.083              | 0.08               | 0.086              | 0.081              |
| Sacramento, CA    | Sacramento-Arden Arcade-Roseville, CA        | 0.11               | 0.104              | 0.106              | 0.106              | 0.099              | 0.103              | 0.103              | 0.107              |
| Salinas, CA       | Salinas, CA                                  | 0.069              | 0.07               | 0.069              | 0.067              | 0.065              | 0.066              | 0.062              | 0.064              |
| San Antonio, TX   | San Antonio, TX                              | 0.079              | 0.082              | 0.087              | 0.087              | 0.087              | 0.085              | 0.088              | 0.086              |
| San Diego, CA     | San Diego-Carlsbad-San Marcos, CA            | 0.112              | 0.109              | 0.108              | 0.104              | 0.099              | 0.102              | 0.099              | 0.1                |
| San Francisco, CA | San Francisco-Oakland-Fremont, CA            | 0.081              | 0.082              | 0.087              | 0.093              | 0.09               | 0.089              | 0.086              | 0.087              |
| San Jose, CA      | San Jose-Sunnyvale-Santa Clara, CA           | 0.08               | 0.08               | 0.083              | 0.088              | 0.085              | 0.086              | 0.082              | 0.082              |
| Seattle, WA       | Seattle-Tacoma-Bellevue, WA                  | 0.077              | 0.074              | 0.071              | 0.076              | 0.078              | 0.081              | 0.074              | 0.075              |
| Shreveport, LA    | Shreveport-Bossier City, LA                  | 0.085              | 0.086              | 0.083              | 0.08               | 0.082              | 0.084              | 0.089              | 0.092              |
| South Bend, IN    | South Bend-Mishawaka, IN-MI                  | 0.089              | 0.087              | 0.089              | 0.094              | 0.094              | 0.092              | 0.092              | 0.088              |
| Springfield, MA   | Springfield, MA                              | 0.1                | 0.095              | 0.094              | 0.092              | 0.097              | 0.096              | 0.099              | 0.089              |
| St Louis, MO      | St. Louis, MO-IL                             | 0.091              | 0.091              | 0.098              | 0.104              | 0.1                | 0.095              | 0.095              | 0.094              |
| Steubenville, OH  | Weirton-Steubenville, WV-OH                  | 0.085              | 0.08               | 0.087              | 0.086              | 0.085              | 0.084              | 0.087              | 0.083              |
| Syracuse, NY      | Syracuse, NY                                 | 0.087              | 0.081              | 0.082              | 0.079              | 0.079              | 0.077              | 0.082              | 0.08               |
| Tacoma, WA        | Seattle-Tacoma-Bellevue, WA                  | 0.077              | 0.074              | 0.071              | 0.076              | 0.078              | 0.081              | 0.074              | 0.075              |
| Tampa, FL         | Tampa-St. Petersburg-Clearwater, FL          | 0.08               | 0.08               | 0.08               | 0.081              | 0.082              | 0.088              | 0.09               | 0.088              |
| Toledo, OH        | Toledo, OH                                   | 0.085              | 0.086              | 0.09               | 0.091              | 0.089              | 0.089              | 0.086              | 0.084              |
| Trenton, NJ       | Trenton-Ewing, NJ                            | 0.111              | 0.105              | 0.104              | 0.1                | 0.101              | 0.097              | 0.104              | 0.102              |
| <b>City</b>       | <b>Census Area Name</b>                      | <b>dv1991_1993</b> | <b>dv1992_1994</b> | <b>dv1993_1995</b> | <b>dv1994_1996</b> | <b>dv1995_1997</b> | <b>dv1996_1998</b> | <b>dv1997_1999</b> | <b>dv1998_2000</b> |
| Tucson, AZ        | Tucson, AZ                                   | 0.077              | 0.078              | 0.081              | 0.079              | 0.079              | 0.077              | 0.075              | 0.073              |
| Vallejo, CA       | Vallejo-Fairfield, CA                        | 0.074              | 0.073              | 0.077              | 0.079              | 0.078              | 0.082              | 0.085              | 0.085              |
| Ventura, CA       | Ventura County, CA                           | 0.115              | 0.112              | 0.117              | 0.119              | 0.115              | 0.112              | 0.106              | 0.105              |
| Washington, DC    | Washington-Arlington-Alexandria, DC-VA-MD-WV | 0.101              | 0.096              | 0.098              | 0.094              | 0.1                | 0.101              | 0.106              | 0.101              |

|  |                                   |       |       |       |       |       |       |       |       |
|--|-----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| Wichita, KS  | Wichita, KS                       | 0.068 | 0.065 | 0.07  | 0.072 | 0.074 | 0.078 | 0.08  | 0.08  |
| Wilmington, DE   | New Castle County, DE             | 0.098 | 0.099 | 0.103 | 0.098 | 0.099 | 0.095 | 0.1   | 0.097 |
| Worcester, MA  | Worcester, MA                     |       | 0.095 | 0.095 | 0.089 | 0.087 | 0.087 | 0.094 | 0.088 |
| York, PA   | York-Hanover, PA                  | 0.091 | 0.085 | 0.086 | 0.083 | 0.087 | 0.09  | 0.094 | 0.093 |
| Youngstown, OH   | Youngstown-Warren-Boardman, OH-PA | 0.091 | 0.089 | 0.091 | 0.092 | 0.093 | 0.096 | 0.096 | 0.092 |
| Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb. |                                   |       |       |       |       |       |       |       |       |

## 1 **Jerrett et al., 2013** (2094363) - Long-Term Ozone and Respiratory Mortality

2 California, U.S. O<sub>3</sub>: 1988-2002

| State      | dv.1988<br>.1990 | dv.1989<br>.1991 | dv.1990<br>.1992 | dv.1991<br>.1993 | dv.1992<br>.1994 | dv.1993<br>.1995 | dv.1994<br>.1996 | dv.1995<br>.1997 | dv.1996<br>.1998 | dv.1997<br>.1999 | dv.1998<br>.2000 | dv.1999<br>.2001 | dv.2000<br>.2002 |
|------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| California | 186              | 182              | 180              | 177              | 171              | 165              | 161              | 148              | 154              | 147              | 146              | 129              | 128              |

## 3 **Katsouyanni et al., 2009** (199899) - Short-Term Ozone and Respiratory Mortality

4 Nationwide, U.S. O<sub>3</sub>: 1987-1996

| City              | Census Area Name                      | dv1987_<br>1989 | dv1988_<br>1990 | dv1989_<br>1991 | dv1990_<br>1992 | dv1991_<br>1993 | dv1992_<br>1994 | dv1993_<br>1995 | dv1994_<br>1996 |
|-------------------|---------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Honolulu, HI      | Honolulu, HI                          | 0.020           | 0.018           |                 |                 |                 |                 |                 |                 |
| Lincoln, NE       | Lincoln, NE                           | 0.058           | 0.061           | 0.058           | 0.061           | 0.058           | 0.059           | 0.057           | 0.058           |
| Colorado Springs, | Colorado Springs, CO                  | 0.063           |                 | 0.066           | 0.063           | 0.062           | 0.061           | 0.061           | 0.056           |
| Des Moines, IA    | Des Moines-West Des Moines, IA        |                 |                 |                 |                 |                 |                 |                 | 0.062           |
| Spokane, WA       | Spokane, WA                           |                 |                 |                 |                 |                 |                 | 0.064           | 0.066           |
| Omaha, NE         | Omaha-Council Bluffs, NE-IA           | 0.077           | 0.078           | 0.072           | 0.071           | 0.065           | 0.062           | 0.062           | 0.067           |
| Albuquerque, NM   | Albuquerque, NM                       | 0.073           | 0.073           | 0.071           | 0.071           | 0.069           | 0.070           | 0.071           | 0.074           |
| Wichita, KS       | Wichita, KS                           | 0.080           | 0.081           | 0.075           | 0.073           | 0.067           | 0.065           | 0.065           | 0.072           |
| Mobile, AL        | Mobile, AL                            | 0.078           | 0.080           | 0.062           | 0.064           | 0.070           | 0.074           | 0.075           | 0.077           |
| Minneapolis, MN   | Minneapolis-St. Paul-Bloomington, MN- | 0.080           | 0.079           | 0.068           | 0.070           | 0.069           | 0.070           | 0.072           | 0.074           |
| Tucson, AZ        | Tucson, AZ                            | 0.068           | 0.074           | 0.069           | 0.072           | 0.077           | 0.078           | 0.081           | 0.079           |
| Jackson, MS       | Jackson, MS                           | 0.075           | 0.079           | 0.076           | 0.076           | 0.074           | 0.075           | 0.076           | 0.077           |
| Seattle, WA       | Seattle-Tacoma-Bellevue, WA           | 0.076           | 0.079           | 0.078           | 0.086           | 0.077           | 0.074           | 0.071           | 0.076           |

| City               | Census Area Name                         | dv1987_<br>1989 | dv1988_<br>1990 | dv1989_<br>1991 | dv1990_<br>1992 | dv1991_<br>1993 | dv1992_<br>1994 | dv1993_<br>1995 | dv1994_<br>1996 |
|--------------------|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Tacoma, WA         | Seattle-Tacoma-Bellevue, WA              | 0.076           | 0.079           | 0.078           | 0.086           | 0.077           | 0.074           | 0.071           | 0.076           |
| Miami, FL          | Miami-Fort Lauderdale-Pompano Beach,     | 0.083           | 0.079           | 0.075           | 0.073           | 0.076           | 0.080           | 0.080           | 0.074           |
| Las Vegas, NV      | Las Vegas-Paradise, NV                   | 0.081           | 0.078           | 0.078           | 0.076           | 0.075           | 0.079           | 0.079           | 0.080           |
| Madison, WI        | Madison, WI                              | 0.091           | 0.079           | 0.081           | 0.079           | 0.073           | 0.072           | 0.072           | 0.080           |
| Portland, OR       | Portland-Vancouver-Beaverton, OR-WA      | 0.077           | 0.085           | 0.082           | 0.091           | 0.076           | 0.078           | 0.058           | 0.083           |
| Denver, CO         | Denver-Aurora-Broomfield, CO             | 0.087           | 0.086           | 0.080           | 0.074           | 0.071           | 0.074           | 0.081           | 0.081           |
| Little Rock, AR    | Little Rock-North Little Rock-Conway, AR | 0.085           | 0.082           | 0.079           | 0.080           | 0.078           | 0.077           | 0.080           | 0.080           |
| Orlando, FL        | Orlando-Kissimmee, FL                    | 0.082           | 0.082           | 0.080           | 0.079           | 0.078           | 0.082           | 0.079           | 0.079           |
| Salt Lake City, UT | Salt Lake City, UT                       | 0.085           | 0.082           | 0.078           | 0.075           | 0.076           | 0.079           | 0.082           | 0.089           |
| Jacksonville, FL   | Jacksonville, FL                         | 0.086           | 0.084           | 0.081           | 0.079           | 0.079           | 0.081           | 0.080           | 0.078           |
| Corpus Christi, TX | Corpus Christi, TX                       | 0.089           | 0.085           | 0.079           | 0.077           | 0.078           | 0.079           | 0.082           | 0.083           |
| St. Petersburg, FL | Tampa-St. Petersburg-Clearwater, FL      | 0.086           | 0.085           | 0.079           | 0.081           | 0.080           | 0.080           | 0.080           | 0.081           |
| Tampa, FL          | Tampa-St. Petersburg-Clearwater, FL      | 0.086           | 0.085           | 0.079           | 0.081           | 0.080           | 0.080           | 0.080           | 0.081           |
| Huntsville, AL     | Huntsville, AL                           | 0.087           | 0.083           | 0.077           | 0.082           | 0.085           | 0.083           | 0.080           | 0.078           |
| El Paso, TX        | El Paso, TX                              | 0.088           | 0.083           | 0.080           | 0.079           | 0.078           | 0.081           | 0.084           | 0.089           |
| San Antonio, TX    | San Antonio, TX                          | 0.085           | 0.085           | 0.082           | 0.079           | 0.079           | 0.082           | 0.087           | 0.087           |
| New Orleans, LA    | New Orleans-Metairie-Kenner, LA          | 0.090           | 0.085           | 0.077           | 0.080           | 0.081           | 0.086           | 0.084           | 0.085           |
| Austin, TX         | Austin-Round Rock, TX                    | 0.084           | 0.086           | 0.084           | 0.084           | 0.081           | 0.082           | 0.084           | 0.084           |
| Oklahoma City, OK  | Oklahoma City, OK                        | 0.087           | 0.087           | 0.086           | 0.084           | 0.081           | 0.081           | 0.084           | 0.085           |
| Syracuse, NY       | Syracuse, NY                             | 0.092           | 0.088           | 0.083           | 0.083           | 0.087           | 0.081           | 0.082           | 0.079           |
| Shreveport, LA     | Shreveport-Bossier City, LA              | 0.087           | 0.088           | 0.084           | 0.086           | 0.085           | 0.086           | 0.083           | 0.080           |
| San Jose, CA       | San Jose-Sunnyvale-Santa Clara, CA       | 0.097           | 0.088           | 0.082           | 0.083           | 0.080           | 0.080           | 0.083           | 0.088           |
| Kansas City, MO    | Kansas City, MO-KS                       | 0.088           | 0.086           | 0.082           | 0.083           | 0.082           | 0.082           | 0.090           | 0.092           |
| Oakland, CA        | San Francisco-Oakland-Fremont, CA        | 0.089           | 0.087           | 0.084           | 0.082           | 0.081           | 0.082           | 0.087           | 0.093           |
| San Francisco, CA  | San Francisco-Oakland-Fremont, CA        | 0.089           | 0.087           | 0.084           | 0.082           | 0.081           | 0.082           | 0.087           | 0.093           |
| Phoenix, AZ        | Phoenix-Mesa-Scottsdale, AZ              | 0.077           | 0.082           | 0.083           | 0.091           | 0.088           | 0.086           | 0.089           | 0.090           |
| Lexington, KY      | Lexington-Fayette, KY                    | 0.099           | 0.096           | 0.085           | 0.078           | 0.077           | 0.079           | 0.087           | 0.087           |
| Tulsa, OK          | Tulsa, OK                                | 0.089           | 0.090           | 0.087           | 0.087           | 0.082           | 0.083           | 0.088           | 0.091           |
| Stockton, CA       | Stockton, CA                             | 0.093           | 0.090           | 0.087           | 0.088           | 0.088           | 0.087           | 0.086           | 0.085           |
| Rochester, NY      | Rochester, NY                            | 0.099           | 0.095           | 0.092           | 0.090           | 0.088           | 0.080           | 0.085           | 0.081           |

| City                | Census Area Name                       | dv1987_<br>1989 | dv1988_<br>1990 | dv1989_<br>1991 | dv1990_<br>1992 | dv1991_<br>1993 | dv1992_<br>1994 | dv1993_<br>1995 | dv1994_<br>1996 |
|---------------------|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Dayton, OH          | Dayton, OH                             | 0.096           | 0.092           | 0.086           | 0.082           | 0.084           | 0.086           | 0.092           | 0.093           |
| Greensboro, NC      | Greensboro-High Point, NC              | 0.097           | 0.100           | 0.088           | 0.085           | 0.083           | 0.084           | 0.088           | 0.086           |
| Ft. Wayne, IN       | Fort Wayne, IN                         | 0.094           | 0.092           | 0.087           | 0.085           | 0.085           | 0.088           | 0.089           | 0.093           |
| Buffalo, NY         | Buffalo-Niagara Falls, NY              | 0.100           | 0.095           | 0.089           | 0.088           | 0.086           | 0.083           | 0.087           | 0.086           |
| Raleigh, NC         | Raleigh-Cary, NC                       | 0.099           | 0.093           | 0.089           | 0.086           | 0.087           | 0.086           | 0.087           | 0.087           |
| Newark, NJ          | Essex County, NJ                       | 0.105           | 0.098           | 0.088           | 0.086           | 0.084           | 0.081           | 0.088           | 0.088           |
| Toledo, OH          | Toledo, OH                             | 0.102           | 0.099           | 0.086           | 0.082           | 0.085           | 0.086           | 0.090           | 0.091           |
| Knoxville, TN       | Knoxville, TN                          | 0.093           | 0.094           | 0.086           | 0.089           | 0.088           | 0.089           | 0.093           | 0.093           |
| Columbus, OH        | Columbus, OH                           | 0.097           | 0.095           | 0.089           | 0.092           | 0.090           | 0.086           | 0.090           | 0.092           |
| Birmingham, AL      | Birmingham-Hoover, AL                  | 0.094           | 0.093           | 0.084           | 0.088           | 0.089           | 0.092           | 0.096           | 0.096           |
| Worcester, MA       | Worcester, MA                          | 0.091           | 0.091           | 0.089           | 0.091           |                 | 0.095           | 0.095           | 0.089           |
| Memphis, TN         | Memphis, TN-MS-AR                      | 0.095           | 0.095           | 0.089           | 0.091           | 0.090           | 0.090           | 0.091           | 0.094           |
| Grand Rapids, MI    | Grand Rapids-Wyoming, MI               | 0.105           | 0.103           | 0.096           | 0.090           | 0.085           | 0.081           | 0.086           | 0.089           |
| Indianapolis, IN    | Indianapolis-Carmel, IN                | 0.098           | 0.095           | 0.091           | 0.089           | 0.087           | 0.090           | 0.094           | 0.098           |
| Madera, CA          | Madera-Chowchilla, CA                  |                 |                 |                 | 0.091           | 0.096           | 0.091           | 0.093           | 0.093           |
| Detroit, MI         | Detroit-Warren-Livonia, MI             | 0.099           | 0.099           | 0.096           | 0.091           | 0.089           | 0.088           | 0.093           | 0.094           |
| Baton Rouge, LA     | Baton Rouge, LA                        | 0.098           | 0.101           | 0.099           | 0.096           | 0.090           | 0.087           | 0.091           | 0.094           |
| Modesto, CA         | Modesto, CA                            | 0.102           | 0.099           | 0.095           | 0.092           | 0.086           | 0.093           | 0.095           | 0.096           |
| Charlotte, NC       | Charlotte-Gastonia-Concord, NC-SC      | 0.104           | 0.101           | 0.092           | 0.091           | 0.091           | 0.092           | 0.094           | 0.094           |
| Louisville, KY      | Louisville/Jefferson County, KY-IN     | 0.098           | 0.099           | 0.096           | 0.092           | 0.094           | 0.094           | 0.100           | 0.094           |
| Akron, OH           | Akron, OH                              | 0.112           | 0.109           | 0.099           | 0.093           | 0.094           | 0.088           | 0.090           | 0.089           |
| Boston, MA          | Boston-Cambridge-Quincy, MA-NH         | 0.105           | 0.101           | 0.098           | 0.092           | 0.096           | 0.093           | 0.096           | 0.094           |
| Cleveland, OH       | Cleveland-Elyria-Mentor, OH            | 0.105           | 0.104           | 0.093           | 0.090           | 0.092           | 0.093           | 0.098           | 0.100           |
| Milwaukee, WI       | Milwaukee-Waukesha-West Allis, WI      | 0.117           | 0.105           | 0.101           | 0.095           | 0.090           | 0.084           | 0.092           | 0.097           |
| Pittsburgh, PA      | Pittsburgh, PA                         | 0.107           | 0.098           | 0.092           | 0.088           | 0.095           | 0.096           | 0.105           | 0.103           |
| Cincinnati, OH      | Cincinnati-Middletown, OH-KY-IN        | 0.106           | 0.107           | 0.102           | 0.095           | 0.091           | 0.091           | 0.098           | 0.099           |
| Nashville, TN       | Nashville-Murfreesboro-Franklin, TN    | 0.104           | 0.104           | 0.096           | 0.096           | 0.095           | 0.096           | 0.099           | 0.099           |
| St Louis, MO        | St. Louis, MO-IL                       | 0.111           | 0.102           | 0.098           | 0.098           | 0.091           | 0.091           | 0.098           | 0.104           |
| Dallas/Ft Worth, TX | Dallas-Fort Worth-Arlington, TX        | 0.100           | 0.105           | 0.105           | 0.099           | 0.095           | 0.096           | 0.106           | 0.104           |
| Providence, RI      | Providence-New Bedford-Fall River, RI- | 0.108           | 0.108           | 0.107           | 0.105           | 0.099           | 0.092           | 0.097           | 0.094           |

| City   | Census Area Name                             | dv1987_<br>1989 | dv1988_<br>1990 | dv1989_<br>1991 | dv1990_<br>1992 | dv1991_<br>1993 | dv1992_<br>1994 | dv1993_<br>1995 | dv1994_<br>1996 |
|--|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Washington, DC   | Washington-Arlington-Alexandria, DC-VA-MD-WV | 0.115           | 0.107           | 0.100           | 0.100           | 0.101           | 0.096           | 0.098           | 0.094           |
| Chicago, IL  | Chicago-Naperville-Joliet, IL-IN-WI          | 0.114           | 0.114           | 0.104           | 0.099           | 0.100           | 0.093           | 0.099           | 0.097           |
| Jersey City, NJ  | Hudson County, NJ                            | 0.118           | 0.115           | 0.107           | 0.104           | 0.103           | 0.096           | 0.100           | 0.095           |
| Atlanta, GA  | Atlanta-Sandy Springs-Marietta, GA           | 0.113           | 0.107           | 0.104           | 0.105           | 0.101           | 0.101           | 0.109           | 0.105           |
| Sacramento, CA   | Sacramento-Arden Arcade-Roseville, CA        | 0.114           | 0.107           | 0.105           | 0.105           | 0.110           | 0.104           | 0.106           | 0.106           |
| Baltimore, MD  | Baltimore-Towson, MD                         | 0.125           | 0.115           | 0.104           | 0.106           | 0.107           | 0.103           | 0.107           | 0.105           |
| Philadelphia, PA   | Philadelphia-Camden-Wilmington, PA-NJ-DE-MD  | 0.123           | 0.120           | 0.113           | 0.107           | 0.106           | 0.099           | 0.104           | 0.101           |
| Fresno, CA   | Fresno, CA                                   | 0.115           | 0.110           | 0.108           | 0.108           | 0.111           | 0.107           | 0.108           | 0.107           |
| New York City, NY  | New York-Northern New Jersey-Long            | 0.129           | 0.128           | 0.122           | 0.116           | 0.108           | 0.100           | 0.106           | 0.104           |
| Houston, TX  | Houston-Sugar Land-Baytown, TX               | 0.117           | 0.119           | 0.119           | 0.116           | 0.104           | 0.110           | 0.114           | 0.116           |
| Bakersfield, CA  | Bakersfield, CA                              | 0.116           | 0.112           | 0.118           | 0.115           | 0.112           | 0.111           | 0.119           | 0.119           |
| San Diego, CA  | San Diego-Carlsbad-San Marcos, CA            | 0.125           | 0.129           | 0.125           | 0.118           | 0.112           | 0.109           | 0.108           | 0.104           |
| Anaheim, CA  | Orange County, CA                            | 0.141           | 0.138           | 0.127           | 0.120           | 0.114           | 0.117           | 0.107           | 0.100           |
| Los Angeles, CA  | Los Angeles-Long Beach-Santa Ana, CA         | 0.192           | 0.186           | 0.179           | 0.177           | 0.177           | 0.168           | 0.156           | 0.145           |
| Riverside, CA  | Riverside-San Bernardino-Ontario, CA         | 0.188           | 0.185           | 0.182           | 0.180           | 0.177           | 0.171           | 0.165           | 0.161           |
| San Bernardino, CA   | San Bernardino County, CA                    | 0.188           | 0.185           | 0.182           | 0.180           | 0.177           | 0.171           | 0.165           | 0.161           |
| Anchorage, AK  | Anchorage, AK                                |                 |                 |                 |                 |                 |                 |                 |                 |
| Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb. |  |                 |                 |                 |                 |                 |                 |                 |                 |

**Klemm et al., 2011 (1011160) - Short-Term Ozone and Respiratory Mortality**

Atlanta (Fulton, DeKalb, Gwinnet & Cobb counties), GA, U.S. O<sub>3</sub>: 8/1998 - 12/2007

| City        | Census Area Name                  | dv.1998.<br>2000 | dv.1999.<br>2001 | dv.2000.<br>2002 | dv.2001.<br>2003 | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.2<br>006 | dv.2005.<br>2007 |
|-------------|-----------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Atlanta, GA | Atlanta-Sandy Springs-Roswell, GA | 121              | 107              | 99               | 91               | 93               | 90               | 91               | 95               |



1 **Kousha and Rowe, 2014** (2443421) - ED Visit - Respiratory Infection

2 Edmonton, Canada. O<sub>3</sub>: 1992-2002

| City     | dv.1992.<br>1994 | dv.1993.<br>1995 | dv.1994.<br>1996 | dv.1995.<br>1997 | dv.1996.<br>1998 | dv.1997.<br>1999 | dv.1998.<br>2000 | dv.1999.<br>2001 | dv.2000.<br>2002 |
|----------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Edmonton | 60               | 61               | 58               | 56               | 62               | 64               | 64               | 64               | 65               |

3  
4 **Kousha and Castner, 2016** (3160295) - ED Visit - Respiratory Infection

5 Windsor, Canada. O<sub>3</sub>: 2004-2010

| City    | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 | dv.2007.2009 | dv.2008.2010 |
|---------|--------------|--------------|--------------|--------------|--------------|
| Windsor | 80           | 87           | 84           | 80           | 73           |

6  
7 **Malig et al., 2016** (3285875) - ED Visits for Asthma, ED Visits Aggregate Respiratory Diseases, ED Visit for Respiratory Infection

8 California (statewide), U.S. O<sub>3</sub>: 2005-2008

| State      | dv.2005.2007 | dv.2006.2008 |
|------------|--------------|--------------|
| California | 122          | 119          |

9  
10 **Nishimura et al., 2013** (1632336)

11 Four U.S. cities (Chicago, Houston, New York, San Francisco) and Puerto Rico.

12 This is a case control study with study participants, aged 8-21 years, identified during 2006-2011. Associations examined for annual  
13 average O<sub>3</sub> concentration (1-h max; 8-h max, per ISA), averaged across first three years of life. Median birth year was 1996.

14  
15 **O'Lenick et al., 2017** (3421578) - ED Visits for Asthma

16 20-county Atlanta metro area, GA, U.S. O<sub>3</sub>: 2002-2008

| City        | Census Area Name                                 | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 |
|-------------|--|--------------|--------------|--------------|--------------|--------------|
| Atlanta, GA | Atlanta--Athens-Clarke County--Sandy Springs, GA | 93           | 90           | 91           | 95           | 95           |

17 **O'Lenick et al., 2017** (3859553) - ED Visits Aggregate Respiratory Diseases

18 20-co Atlanta, GA; 12-co Dallas, TX, and 16-co St. Louis, MO, U.S. O<sub>3</sub>: 2002-2008

| City        | Census Area Name                                 | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 |
|-------------|--|------------------|------------------|------------------|------------------|------------------|
| Atlanta, GA | Atlanta--Athens-Clarke County--Sandy Springs, GA | 93               | 90               | 91               | 95               | 95               |

| City       | Census Area Name         | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 |
|------------|--------------------------|--------------|--------------|--------------|--------------|--------------|
| Dallas, TX | Dallas-Fort Worth, TX-OK | 98           | 95           | 96           | 95           | 91           |

| City          | Census Area Name                        | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 |
|---------------|---|--------------|--------------|--------------|--------------|--------------|
| St. Louis, MO | St. Louis-St. Charles-Farmington, MO-IL | 89           | 86           | 86           | 89           | 85           |

**Rodopoulou et al., 2015** (2965674) - ED Visit for Respiratory Infection

Little Rock, AK, U.S. O<sub>3</sub>: 2002-2012

| City            | Census Area Name                     | dv.2002<br>.2004 | dv.2003<br>.2005 | dv.2004<br>.2006 | dv.2005<br>.2007 | dv.2006<br>.2008 | dv.2007<br>.2009 | dv.2008<br>.2010 | dv.2009<br>.2011 | dv.2010<br>.2012 |
|-----------------|--------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Little Rock, AK | Little Rock-North<br>Little Rock, AR | 78               | 77               | 80               | 83               | 80               | 73               | 70               | 74               | 77               |

**Sacks et al., 2014** (2228782) - ED Visits for Asthma

North Carolina (Statewide), U.S. O<sub>3</sub>: 2006-2008

| State          | dv.2006.2008 |
|----------------|--------------|
| North Carolina | 94           |

**Sarnat et al., 2013** (1640373) - ED Visits for Asthma

Metro Atlanta area (186 zip codes), GA, U.S. O<sub>3</sub>: 1999-2002

| City        | Census Area Name                  | dv.1999.2001 | dv.2000.2002 |
|-------------|-----------------------------------|--------------|--------------|
| Atlanta, GA | Atlanta-Sandy Springs-Roswell, GA | 107          | 99           |

**Sarnat et al., 2015** (2772940) - ED Visits for Asthma

St. Louis metro area, MO (8 MO counties, 8 IL counties), U.S. O<sub>3</sub>: 2001-2003

| City      | Census Area Name                        | dv.2001.2003 | dv.2002.2004 |
|-----------|---|--------------|--------------|
| St. Louis | St. Louis-St. Charles-Farmington, MO-IL | 92           | 92           |

**Sheffield et al., 2015** (3025138) - ED Visits for Asthma

New York City (all boroughs), NY, U.S. O<sub>3</sub>: May-Sept. 2005-2011

| City         | Census Area Name             | dv.2005.2007 | dv.2006.2008 | dv.2007.2009 | dv.2008.2010 | dv.2009.2011 | dv.2010.2012 |
|--------------|------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| New York, NY | New York-Newark, NY-NJ-CT-PA | 94           | 89           | 84           | 82           | 84           | 85           |

**Shmool et al., 2016** (3288326) - ED Visits for Asthma

New York City, NY, U.S. O<sub>3</sub>: June-Aug 2005-2011

| City         | Census Area Name             | dv.2005.2007 | dv.2006.2008 | dv.2007.2009 | dv.2008.2010 | dv.2009.2011 |
|--------------|------------------------------|--------------|--------------|--------------|--------------|--------------|
| New York, NY | New York-Newark, NY-NJ-CT-PA | 94           | 89           | 84           | 82           | 84           |

**Silverman and Ito, 2010** (386252) HA for Asthma

New York, NY. O<sub>3</sub>: 1999-2006

| City              | Census Area Name                                   | dv.1999.2001 | dv.2000.2002 | dv.2001.2003 | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 |
|-------------------|--|--------------|--------------|--------------|--------------|--------------|--------------|
| New York City, NY | New York-Northern New Jersey-Long Island, NY-NJ-PA | 0.109        | 0.115        | 0.109        | 0.102        | 0.094        | 0.093        |

Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb.

**Stieb et al., 2009** (195858) - ED Visits for Asthma

7 Canadian cities

| O <sub>3</sub> : 1992-2003City | dv1992_1994 | dv1993_1995 | dv1994_1996 | dv1995_1997 | dv1996_1998 | dv1997_1999 | dv1998_2000 | dv1999_2001 | dv2000_2002 | dv2001_2003 |
|--------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Montreal                       |             |             |             |             |             | 77          | 73          | 73          | 72          |             |
| Ottawa                         | 64          | 64          | 63          | 66          | 65          | 69          | 63          |             |             |             |
| Edmonton                       | 60          | 61          | 58          | 56          | 62          | 64          | 64          | 64          | 65          |             |

|            |    |    |    |  |  |  |  |    |    |    |
|------------|----|----|----|--|--|--|--|----|----|----|
| Saint John | 51 | 54 | 58 |  |  |  |  |    |    |    |
| Halifax    |    |    |    |  |  |  |  |    | 54 |    |
| Toronto    |    |    |    |  |  |  |  | 79 | 81 | 85 |
| Vancouver  |    |    |    |  |  |  |  | 52 | 54 | 57 |

**Strickland et al., 2014** (2519636) - ED Visits for Asthma

20-county Atlanta area, GA, U.S. O<sub>3</sub>: 2002-2010

| City        | Census Area Name                  | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 | dv.2007.<br>2009 | dv.2008.<br>2010 |
|-------------|-----------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Atlanta, GA | Atlanta-Sandy Springs-Roswell, GA | 93               | 90               | 91               | 95               | 95               | 87               | 80               |

**Szyszkowicz et al., 2018** (4245266) - ED Visits for Asthma, [ED Visit - Respiratory Infection]

Multicity (9), Canada. O<sub>3</sub>: 2004-2011

| City        | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 | dv.2007.2009 | dv.2008.2010 | dv.2009.2011 |
|-------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Algoma      | 67           | 70           | 68           | 65           | 62           | 59           |
| Oakville    | 73           | 78           | 75           | 73           | 70           | 69           |
| Burlington  | 70           | 74           | 73           | 70           | 68           | 66           |
| Hamilton    | 73           | 75           | 73           | 72           | 70           | 69           |
| London      | 69           | 72           | 71           | 68           | 65           | 64           |
| Parkhill    |              |              |              |              |              |              |
| Longwoods   |              |              |              |              |              |              |
| Ottawa      | 64           | 69           | 66           | 64           | 62           | 57           |
| Brampton    | 74           | 78           | 75           | 73           | 68           | 67           |
| Mississauga | -            | 79           | -            | -            | 65           | 64           |
| Toronto     | 74           | 79           | 76           | 74           | 73           | 70           |
| Essex       | -            | 79           | 74           |              |              |              |
| New Market  | 77           | 79           | 75           | 75           | 70           | 69           |
| Stouffville |              |              |              |              |              |              |

Note: Some of the locations named as city in the study appear as Municipality in NAPS dataset from Canada and included few other cities within its boundary. In such instances, DV data (if available) were pulled for all the cities included within those municipalities, e.g., Halton included (Oakville, Burlington), Middlesex included (London, Parkhill, Longwoods), Peel included (Toronto, Brampton, Mississauga), York included (New Market, Stouffville).

1 **Tolbert et al., 2007** (90316) - ED Visits for Aggregate Respiratory Diseases

2 Atlanta, GA. O<sub>3</sub>: 1993-2004

| City        | Census Area Name                   | dv1993_<br>1995 | dv1994_<br>1996 | dv1995_<br>1997 | dv1996_<br>_1998 | dv1997_<br>1999 | dv1998_<br>2000 | dv1999_<br>2001 | dv2000_<br>2002 | dv2001_<br>2003 | dv2002_<br>2004 |
|-------------|------------------------------------|-----------------|-----------------|-----------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Atlanta, GA | Atlanta-Sandy Springs-Marietta, GA | 0.109           | 0.105           | 0.110           | 0.113            | 0.118           | 0.121           | 0.107           | 0.099           | 0.091           | 0.093           |

Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb.

3

4 **Tétreault et al., 2016** (3073711) – Asthma Incidence

5 Quebec Province, Canada. O<sub>3</sub>: 1996-2011

| City                           | dv.1996.<br>1998 | dv.1997.<br>1999 | dv.1998.<br>2000 | dv.1999.<br>2001 | dv.2000.<br>2002 | dv.2001.<br>2003 | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 | dv.2007.<br>2009 | dv.2008.<br>2010 | dv.2009.<br>2011 |
|--------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Montreal                       | 69               | 77               | 72               | 72               | 72               | 79               | 72               | 70               | 66               | 70               | 67               | 65               | 61               | 58               |
| Quebec                         | 61               | 65               | 59               | 60               | 63               | 70               | 64               | 59               | 56               | 63               | 60               | 58               | 55               | 54               |
| Laval                          | 72               | 75               | 67               | 68               | 68               | 75               | 68               | 67               | 62               | 65               | 62               | 61               | 59               | 60               |
| Brossard                       | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Longueuil                      | 70               | 76               | 70               | 70               | 68               | 74               | 71               | 68               | 64               | 65               | 62               | 61               | 60               | 60               |
| Terrebonne                     | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Gatineau                       | -                | 75               | 72               | 73               | 69               | 71               | 67               | 66               | 66               | -                | -                | -                | 59               | 55               |
| Levis                          | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | 59               | 57               | 52               | 50               |
| Sherbrooke                     | -                | -                | -                | -                | -                | -                | -                | -                | 63               | 63               | 60               | 59               | 57               | 56               |
| Saguenay                       | -                | -                | -                | -                | -                | -                | -                | 54               | 54               | 57               | 56               | 54               | 52               | 51               |
| Rouyn-Noranda                  | -                | -                | -                | -                | -                | -                | -                | -                | 59               | 63               | 59               | 58               | 55               | 54               |
| Trois-Rivieres                 | -                | -                | -                | 68               | 65               | 70               | 64               | 64               | 59               | 64               | 59               | 58               | 55               | -                |
| St. Zephirin-de-Courval (MUNI) | 72               | 75               | 67               | 71               | 73               | 79               | 73               | 70               | 66               | 69               | 65               | 62               | 60               | 60               |
| Forestville                    | 55               | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Charette (MUNI)                | 70               | 71               | 62               | 65               | 64               | 68               | 63               | 61               | 58               | 62               | 61               | 61               | 58               | 55               |
| Saint-Remi                     | 67               | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Saint-Simon (MUNI)             | 66               | 71               | 65               | 65               | 64               | 70               | 66               | 62               | 58               | 59               | 58               | 56               | 55               | 55               |
| Saint-Faustin-Lac-Carre (MUNI) | 67               | 71               | 66               | 69               | 65               | 68               | 66               | 69               | 67               | 68               | 67               | 65               | 61               | 56               |
| La Pêche (MUNI)                | -                | 71               | 72               | 74               | 72               | 73               | 68               | 66               | 64               | 67               | 66               | 63               | -                | 54               |
| Varennes                       | 74               | 75               | 68               | 69               | 69               | 75               | 68               | 67               | 63               | 65               | 60               | 58               | 55               | 56               |
| Temiscaming (MUNI)             | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | 63               | 60               | 58               | 57               |
| Auclair (MUNI)                 | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | 60               | 57               | 55               | 53               |
| Causapscal                     | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Riviere-Eternite (MUNI)        | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |

| City                            | dv.1996.<br>1998 | dv.1997.<br>1999 | dv.1998.<br>2000 | dv.1999.<br>2001 | dv.2000.<br>2002 | dv.2001.<br>2003 | dv.2002.<br>2004 | dv.2003.<br>2005 | dv.2004.<br>2006 | dv.2005.<br>2007 | dv.2006.<br>2008 | dv.2007.<br>2009 | dv.2008.<br>2010 | dv.2009.<br>2011 |
|---------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| La Dore (MUNI)                  | 54               | 58               | 58               | 62               | 58               | 62               | 56               | 57               | 55               | 61               | 58               | 57               | 53               | 52               |
| Deschambault (MUNI)             | 68               | 70               | 64               | 67               | 68               | 72               | 65               | 61               | 57               | 61               | 58               | 57               | 56               | 55               |
| Saint-François                  | 65               | 69               | 65               | 64               | 65               | 69               | 64               | 62               | 59               | 64               | 60               | 58               | 57               | 55               |
| Notre-Dame-du-Rosaire (MUNI)    | 65               | 66               | 60               | 62               | 64               | 67               | 62               | 60               | 59               | 60               | 59               | 57               | 55               | 53               |
| St-Hilaire-de-Dorset (MUNI)     | 67               | 70               | 66               | 67               | 69               | 73               | 71               | 67               | 65               | 65               | 65               | 63               | 59               | 57               |
| Tingwick (MUNI)                 | 69               | 73               | 66               | 66               | 66               | 72               | 70               | 67               | 62               | 63               | -                | 60               | 61               | 57               |
| Lac-Edouard (MUNI)              | -                | -                | 62               | 65               | 60               | 62               | 58               | 57               | 55               | 59               | 58               | 58               | 54               | 51               |
| Montmorency (COUNTY)            | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Sutton                          | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | 70               | 68               | 65               | 61               |
| Chapais                         | -                | -                | -                | -                | -                | -                | -                | -                | -                | 59               | 56               | 56               | 56               | 55               |
| Ste-Francoise (MUNI)            | 72               | 76               | 78               | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                |
| Saint-Anicet (MUNI)             | 74               | 79               | 76               | 75               | 74               | 79               | 75               | 73               | 69               | 70               | 68               | -                | 67               | 63               |
| L'Assomption (COUNTY)           | -                | 76               | 70               | 70               | 67               | 71               | 60               | 60               | 58               | 67               | 64               | -                | 64               | 59               |
| La Patrie (MUNI)                | -                | 68               | 66               | 67               | 71               | 73               | 72               | 68               | 65               | 63               | 63               | 62               | 59               | 55               |
| Ferme Neuve (MUNI)              | 58               | 60               | 58               | 59               | 56               | 59               | 54               | -                | -                | -                | 59               | 57               | 53               | 50               |
| Senneterre                      | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | 59               | 57               | 55               | 54               |
| Lemieux (MUNI)                  | -                | -                | -                | -                | -                | 64               | 66               | 63               | 65               | 65               | 64               | -                | 63               | 59               |
| Saint-Jean-sur-Richelieu        | -                | -                | -                | -                | 68               | 73               | 67               | 65               | 61               | 64               | 62               | 59               | 57               | 56               |
| Frelighsburg (MUNI)             | -                | -                | -                | -                | -                | -                | -                | -                | -                | 68               | 68               | 66               | 63               | 59               |
| Mingan (First Nations Reserche) | -                | -                | -                | -                | -                | -                | -                | -                | -                | -                | 52               | 51               | 49               | 47               |

1  
2  
3  
4  
5  
6  
7

**Turner et al., 2016 (3060878) - Long-Term Ozone and Respiratory Mortality**

Nationwide, U.S. O<sub>3</sub>: 2002-2004

Air quality data are not described for this study as it relied on estimated O<sub>3</sub> concentrations for the years 2002–2004 as surrogates for study population O<sub>3</sub> concentrations during the 1982 to 2004 period (Turner et al., 2016).

1 **Vanos et al., 2014** (2231512) - Short-Term Ozone and Respiratory Mortality  
 2 10 Canadian cities, Canada. O<sub>3</sub>: 1981 - 1999. The table below does not include design values prior to 1988 as data are not readily  
 3 available for years prior to 1986.

| City       | dv.1986.<br>1988 | dv.1987.<br>1989 | dv.1988.<br>1990 | dv.1989.<br>1991 | dv.1990.<br>1992 | dv.1991.<br>1993 | dv.1992.<br>1994 | dv.1993.<br>1995 | dv.1994.<br>1996 | dv.1995.<br>1997 | dv.1996.<br>1998 | dv.1997.<br>1999 |
|------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Saint John |                  | 65               | 67               | 68               | 66               | 61               | 51               | 54               | 58               | 60               | 55               | 55               |
| Toronto    | 90               | 89               | 85               | 81               | 78               | 75               | 70               | 72               | 73               | 77               | 80               | 84               |
| Montreal   | 66               | 74               | 77               | 72               | 73               | 73               | 69               | 65               | 63               | 71               | 68               | 77               |
| Ottawa     | 67               | 68               | 73               | 71               | 71               | 69               | 64               | 64               | 63               | 66               | 65               | 69               |
| Windsor    | 94               | 94               | 91               | 82               | 79               | 79               | 78               | 85               | 90               | 86               | 86               | 86               |
| Quebec     |                  |                  |                  |                  |                  | 60               | 62.5             | 59               | 57.5             |                  |                  |                  |
| Calgary    | 64               | 63               | 60               | 60               | 60               | 59               | 60               | 59               | 60               | 57               | 59               | 58               |
| Edmonton   | 62               | 60               | 57               | 60               | 62               | 62               | 60               | 61               | 58               | 56               | 62               | 64               |
| Winnipeg   | 62               | 64               | 63               | 58               | 53               | 53               | 54               | 54               | 54               | 56               | 56               | 62               |
| Vancouver  | 73               | 70               | 74               | 61               | 60               | 55               | 55               | 65               | 63               | 59               | 61               | 58               |

4  
 5 **Villeneuve et al., 2007** (195859) - ED Visits for Asthma  
 6 Census Metropolitan of Edmonton, Alberta, Canada. 1992-2002

| City                                  | dv.1992.<br>1994 | dv.1993.<br>1995 | dv.1994.<br>1996 | dv.1995.<br>1997 | dv.1996.<br>1998 | dv.1997.<br>1999 | dv.1998.<br>2000 | dv.1999.<br>2001 | dv.2000.<br>2002 |
|---------------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Census<br>Metropolitan<br>of Edmonton | 60               | 67               | 69               | 63               | 61               | 64               | 64               | 63               | 64               |

7  
 8 **Weichenthal et al., 2017** (4165121) - Long-Term Ozone and Respiratory Mortality  
 9 Nationwide, Canada. O<sub>3</sub>: 2002-2009

| City                  | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 | dv.2007.2009 |
|-----------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| All cities (DV range) | 45-98        | 43-93        | 42-85        | 36-89        | 35-86        | 37-83        |

10

**Winqvist et al., 2012** (1668375) - Hospital Admissions for Asthma, ED Visits for Asthma, Hospital Admissions for Aggregate Respiratory, ED Visits for Aggregate Respiratory Diseases, ED Visits for Respiratory Infection St. Louis, MO (8 MO and 8 IL counties, 269 zip codes), U.S. O<sub>3</sub>: 2001-2007

| City      | Census Area Name                        | dv.2001.2003 | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 |
|-----------|---|--------------|--------------|--------------|--------------|--------------|
| St. Louis | St. Louis-St. Charles-Farmington, MO-IL | 92           | 89           | 86           | 86           | 89           |

**Winqvist et al., 2014** (2347402) - ED Visits for Asthma

Atlanta metro area, GA, U.S. O<sub>3</sub>: 1998-2004

| City        | Census Area Name                  | dv.1998.2000 | dv.1999.2001 | dv.2000.2002 | dv.2001.2003 | dv.2002.2004 |
|-------------|-----------------------------------|--------------|--------------|--------------|--------------|--------------|
| Atlanta, GA | Atlanta-Sandy Springs-Roswell, GA | 121          | 107          | 99           | 91           | 93           |

**Xiao et al., 2016** (3455927) - ED Visits for Asthma, ED Visit - Respiratory Infection

Georgia (statewide), U.S. O<sub>3</sub>: 2002-2008

| State   | dv.2002.2004 | dv.2003.2005 | dv.2004.2006 | dv.2005.2007 | dv.2006.2008 |
|---------|--------------|--------------|--------------|--------------|--------------|
| Georgia | 93           | 93           | 91           | 95           | 95           |

**Zanobetti and Schwartz, 2008** (101596) - Short-Term Ozone and Respiratory Mortality

48 U.S. cities

| City                 | Census Area Name     | dv1989_1991 | dv1990_1992 | dv1991_1993 | dv1992_1994 | dv1993_1995 | dv1994_1996 | dv1995_1997 | dv1996_1998 | dv1997_1999 | dv1998_2000 |
|----------------------|----------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Honolulu, HI         | Honolulu, HI         |             |             |             |             |             |             |             | 0.045       | 0.048       | 0.047       |
| Colorado Springs, CO | Colorado Springs, CO | 0.066       | 0.063       | 0.062       | 0.061       | 0.061       | 0.056       |             |             | 0.062       | 0.065       |
| Spokane, WA          | Spokane, WA          |             |             |             |             | 0.064       | 0.066       | 0.066       | 0.068       | 0.067       | 0.067       |
| Albuquerque, NM      | Albuquerque, NM      | 0.071       | 0.071       | 0.069       | 0.070       | 0.071       | 0.074       | 0.069       | 0.073       | 0.071       | 0.075       |
| Ft. Lauderdale, FL   | Broward County, FL   | 0.075       | 0.073       | 0.076       | 0.079       | 0.074       | 0.069       | 0.069       | 0.072       | 0.075       | 0.075       |
| Boulder, CO          | Boulder, CO          | 0.076       | 0.073       | 0.073       | 0.071       | 0.072       | 0.071       | 0.071       | 0.078       | 0.078       | 0.078       |
| Provo/Orem, UT       | Provo-Orem, UT       |             |             |             | 0.069       | 0.068       | 0.071       | 0.076       | 0.082       | 0.082       | 0.086       |



| City               | Census Area Name                        | dv1989<br>_1991 | dv1990<br>_1992 | dv1991<br>_1993 | dv1992<br>_1994 | dv1993<br>_1995 | dv1994<br>_1996 | dv1995<br>_1997 | dv1996<br>_1998 | dv1997<br>_1999 | dv1998<br>_2000 |
|--------------------|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Miami, FL          | Miami-Fort Lauderdale-Pompano Beach, FL | 0.075           | 0.073           | 0.076           | 0.080           | 0.080           | 0.074           | 0.075           | 0.077           | 0.078           | 0.079           |
| Seattle, WA        | Seattle-Tacoma-Bellevue, WA             | 0.078           | 0.086           | 0.077           | 0.074           | 0.071           | 0.076           | 0.078           | 0.081           | 0.074           | 0.075           |
| Denver, CO         | Denver-Aurora-Broomfield, CO            | 0.080           | 0.074           | 0.071           | 0.074           | 0.081           | 0.081           | 0.079           | 0.084           | 0.083           | 0.086           |
| Orlando, FL        | Orlando-Kissimmee, FL                   | 0.080           | 0.079           | 0.078           | 0.082           | 0.079           | 0.079           | 0.078           | 0.084           | 0.085           | 0.085           |
| Salt Lake City, UT | Salt Lake City, UT                      | 0.078           | 0.075           | 0.076           | 0.079           | 0.082           | 0.089           | 0.085           | 0.088           | 0.082           | 0.088           |
| Tampa, FL          | Tampa-St. Petersburg-Clearwater, FL     | 0.079           | 0.081           | 0.080           | 0.080           | 0.080           | 0.081           | 0.082           | 0.088           | 0.090           | 0.088           |
| New Orleans, LA    | New Orleans-Metairie-Kenner, LA         | 0.077           | 0.080           | 0.081           | 0.086           | 0.084           | 0.085           | 0.083           | 0.084           | 0.086           | 0.091           |
| Oklahoma City,     | Oklahoma City, OK                       | 0.086           | 0.084           | 0.081           | 0.081           | 0.084           | 0.085           | 0.083           | 0.085           | 0.086           | 0.084           |
| Terra Haute, IN    | Terre Haute, IN                         | 0.087           | 0.081           | 0.077           | 0.079           | 0.084           | 0.092           | 0.088           | 0.088           | 0.083           | 0.080           |
| Austin, TX         | Austin-Round Rock, TX                   | 0.084           | 0.084           | 0.081           | 0.082           | 0.084           | 0.084           | 0.081           | 0.081           | 0.089           | 0.089           |
| San Francisco, CA  | San Francisco-Oakland-Fremont, CA       | 0.084           | 0.082           | 0.081           | 0.082           | 0.087           | 0.093           | 0.090           | 0.089           | 0.086           | 0.087           |
| Greensboro, NC     | Greensboro-High Point, NC               | 0.088           | 0.085           | 0.083           | 0.084           | 0.088           | 0.086           | 0.085           | 0.089           | 0.092           | 0.094           |
| Tulsa, OK          | Tulsa, OK                               | 0.087           | 0.087           | 0.082           | 0.083           | 0.088           | 0.091           | 0.089           | 0.087           | 0.088           | 0.093           |
| Kansas City, KS    | Kansas City, MO-KS                      | 0.082           | 0.083           | 0.082           | 0.082           | 0.090           | 0.092           | 0.094           | 0.093           | 0.091           | 0.089           |
| Phoenix, AZ        | Phoenix-Mesa-Scottsdale, AZ             | 0.083           | 0.091           | 0.088           | 0.086           | 0.089           | 0.090           | 0.092           | 0.091           | 0.088           | 0.088           |
| Canton, OH         | Canton-Massillon, OH                    | 0.091           | 0.089           | 0.089           | 0.088           | 0.091           | 0.089           | 0.088           | 0.089           | 0.091           | 0.091           |
| Columbus, OH       | Columbus, OH                            | 0.089           | 0.092           | 0.090           | 0.086           | 0.090           | 0.092           | 0.092           | 0.093           | 0.097           | 0.095           |
| Detroit, MI        | Detroit-Warren-Livonia, MI              | 0.096           | 0.091           | 0.089           | 0.088           | 0.093           | 0.094           | 0.092           | 0.093           | 0.095           | 0.089           |
| Youngstown, OH     | Youngstown-Warren-Boardman, OH-PA       | 0.090           | 0.091           | 0.091           | 0.089           | 0.091           | 0.092           | 0.093           | 0.096           | 0.096           | 0.092           |
| Birmingham, AL     | Birmingham-Hoover, AL                   | 0.084           | 0.088           | 0.089           | 0.092           | 0.096           | 0.096           | 0.095           | 0.095           | 0.097           | 0.102           |
| Boston, MA         | Boston-Cambridge-Quincy, MA-NH          | 0.098           | 0.092           | 0.096           | 0.093           | 0.096           | 0.094           | 0.095           | 0.091           | 0.093           | 0.086           |
| Milwaukee, WI      | Milwaukee-Waukesha-West Allis, WI       | 0.101           | 0.095           | 0.090           | 0.084           | 0.092           | 0.097           | 0.098           | 0.093           | 0.097           | 0.092           |
| Cincinnati, OH     | Cincinnati-Middletown, OH-KY-IN         | 0.102           | 0.095           | 0.091           | 0.091           | 0.098           | 0.099           | 0.095           | 0.092           | 0.095           | 0.094           |
| Cleveland, OH      | Cleveland-Elyria-Mentor, OH             | 0.093           | 0.090           | 0.092           | 0.093           | 0.098           | 0.100           | 0.099           | 0.098           | 0.099           | 0.095           |
| Charlotte, NC      | Charlotte-Gastonia-Concord, NC-SC       | 0.092           | 0.091           | 0.091           | 0.092           | 0.094           | 0.094           | 0.097           | 0.103           | 0.104           | 0.104           |

| City   | Census Area Name                                   | dv1989<br>_1991 | dv1990<br>_1992 | dv1991<br>_1993 | dv1992<br>_1994 | dv1993<br>_1995 | dv1994<br>_1996 | dv1995<br>_1997 | dv1996<br>_1998 | dv1997<br>_1999 | dv1998<br>_2000 |
|--|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| St Louis, MO   | St. Louis, MO-IL                                   | 0.098           | 0.098           | 0.091           | 0.091           | 0.098           | 0.104           | 0.100           | 0.095           | 0.095           | 0.094           |
| Chicago, IL  | Chicago-Naperville-Joliet, IL-IN-WI                | 0.104           | 0.099           | 0.100           | 0.093           | 0.099           | 0.097           | 0.096           | 0.091           | 0.095           | 0.093           |
| Pittsburgh, PA   | Pittsburgh, PA                                     | 0.092           | 0.088           | 0.095           | 0.096           | 0.105           | 0.103           | 0.105           | 0.099           | 0.101           | 0.096           |
| Nashville, TN  | Nashville-Murfreesboro-Franklin, TN                | 0.096           | 0.096           | 0.095           | 0.096           | 0.099           | 0.099           | 0.099           | 0.101           | 0.102           | 0.100           |
| Jersey City, NJ  | Hudson County, NJ                                  | 0.107           | 0.104           | 0.103           | 0.096           | 0.100           | 0.095           | 0.098           | 0.093           | 0.100           | 0.092           |
| Washington, DC   | Washington-Arlington-Alexandria, DC-VA-MD-WV       | 0.100           | 0.100           | 0.101           | 0.096           | 0.098           | 0.094           | 0.100           | 0.101           | 0.106           | 0.101           |
| Dallas/Ft Worth,   | Dallas-Fort Worth-Arlington, TX                    | 0.105           | 0.099           | 0.095           | 0.096           | 0.106           | 0.104           | 0.104           | 0.098           | 0.101           | 0.102           |
| New Haven, CT  | New Haven-Milford, CT                              | 0.116           | 0.113           | 0.108           | 0.097           | 0.105           | 0.101           | 0.107           | 0.100           | 0.103           | 0.096           |
| Sacramento, CA   | Sacramento-Arden Arcade-Roseville, CA              | 0.105           | 0.105           | 0.110           | 0.104           | 0.106           | 0.106           | 0.099           | 0.103           | 0.103           | 0.107           |
| Baltimore, MD  | Baltimore-Towson, MD                               | 0.104           | 0.106           | 0.107           | 0.103           | 0.107           | 0.105           | 0.107           | 0.104           | 0.109           | 0.107           |
| Philadelphia, PA   | Philadelphia-Camden-Wilmington, PA-NJ-DE-MD        | 0.113           | 0.107           | 0.106           | 0.099           | 0.104           | 0.101           | 0.110           | 0.107           | 0.110           | 0.106           |
| San Diego, CA  | San Diego-Carlsbad-San Marcos, CA                  | 0.125           | 0.118           | 0.112           | 0.109           | 0.108           | 0.104           | 0.099           | 0.102           | 0.099           | 0.100           |
| New York City, NY  | New York-Northern New Jersey-Long Island, NY-NJ-PA | 0.122           | 0.116           | 0.108           | 0.100           | 0.106           | 0.104           | 0.108           | 0.104           | 0.107           | 0.107           |
| Atlanta, GA  | Atlanta-Sandy Springs-Marietta, GA                 | 0.104           | 0.105           | 0.101           | 0.101           | 0.109           | 0.105           | 0.110           | 0.113           | 0.118           | 0.121           |
| Houston, TX  | Houston-Sugar Land-Baytown, TX                     | 0.119           | 0.116           | 0.104           | 0.110           | 0.114           | 0.116           | 0.117           | 0.116           | 0.118           | 0.112           |
| Los Angeles, CA  | Los Angeles-Long Beach-Santa Ana, CA               | 0.179           | 0.177           | 0.177           | 0.168           | 0.156           | 0.145           | 0.135           | 0.133           | 0.118           | 0.115           |
| Note: Design values for this study were available in the last review (see Wells, 2012) and are presented in units of ppm, rather than ppb. |  |                 |                 |                 |                 |                 |                 |                 |                 |                 |                 |

1  
2

- 1 **Zu et al., 2017** (3859551) - Hospital Admissions for Asthma
- 2 6 Texas City Metro areas (Austin, Dallas, El Paso, Ft Worth, Houston, San Antonio), U.S. (*pooled, not individually assessed*)
- 3 O<sub>3</sub>: 2001-2013

| City                  | Census Area Name                          | dv.2001<br>.2003 | dv.2002<br>.2004 | dv.2003<br>.2005 | dv.2004<br>.2006 | dv.2005<br>.2007 | dv.2006<br>.2008 | dv.2007<br>.2009 | dv.2008<br>.2010 | dv.2009<br>.2011 | dv.2010<br>.2012 | dv.2011<br>.2013 |
|-----------------------|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Dallas and Fort Worth | Dallas-Fort Worth, TX-OK                  | 100              | 98               | 95               | 96               | 95               | 91               | 86               | 86               | 90               | 87               | 87               |
| El Paso               | El Paso-Las Cruces, TX-NM                 | 79               | 78               | 76               | 78               | 79               | 78               | 75               | 71               | 71               | 72               | 75               |
| Houston               | Houston-The Woodlands, TX                 | 102              | 101              | 103              | 103              | 96               | 91               | 84               | 84               | 89               | 88               | 87               |
| Austin                | Austin-Round Rock, TX (CBSA only)         | 84               | 85               | 82               | 82               | 80               | 77               | 75               | 74               | 75               | 74               | 73               |
| San Antonio           | San Antonio-New Braunfels, TX (CBSA only) | 89               | 91               | 86               | 87               | 82               | 78               | 74               | 75               | 75               | 80               | 81               |

4

## REFERENCES

- Alhanti, BA, Chang, HH, Winquist, A, Mulholland, JA, Darrow, LA and Sarnat, SE (2016). Ambient air pollution and emergency department visits for asthma: a multi-city assessment of effect modification by age. *J Expo Sci Environ Epidemiol* 26(2): 180-188.
- Barry, V, Klein, M, Winquist, A, Chang, HH, Mulholland, JA, Talbott, EO, Rager, JR, Tolbert, PE and Sarnat, SE (2018). Characterization of the concentration-response curve for ambient ozone and acute respiratory morbidity in 5 US cities. *J Expo Sci Environ Epidemiol* 29(2): 267-277.
- Byers, N, Ritchey, M, Vaidyanathan, A, Brandt, AJ and Yip, F (2015). Short-term effects of ambient air pollutants on asthma-related emergency department visits in Indianapolis, Indiana, 2007-2011. *J Asthma* 53(3): 1-8.
- Cakmak, S, Hebbern, C, Pinault, L, Lavigne, E, Vanos, J, Crouse, DL and Tjepkema, M (2017). Associations between long-term PM<sub>2.5</sub> and ozone exposure and mortality in the Canadian Census Health and Environment Cohort (CANCHEC), by spatial synoptic classification zone. *Environ Int* 111: 200-211.
- Crouse, DL, Peters, PA, Hystad, P, Brook, JR, van Donkelaar, A, Martin, RV, Villeneuve, PJ, Jerrett, M, Goldberg, MS, Pope, CA, 3rd, Brauer, M, Brook, RD, Robichaud, A, Menard, R and Burnett, RT (2015). Ambient PM<sub>2.5</sub>, O<sub>3</sub>, and NO<sub>2</sub> Exposures and Associations with Mortality over 16 Years of Follow-Up in the Canadian Census Health and Environment Cohort (CanCHEC). *Environ Health Perspect* 123(11): 1180-1186.
- Darrow, LA, Klein, M, Flanders, WD, Mulholland, JA, Tolbert, PE and Strickland, MJ (2014). Air pollution and acute respiratory infections among children 0-4 years of age: an 18-year time-series study. *Am J Epidemiol* 180(10): 968-977.
- Darrow, LA, Klein, M, Sarnat, JA, Mulholland, JA, Strickland, MJ, Sarnat, SE, Russell, AG and Tolbert, PE (2011). The use of alternative pollutant metrics in time-series studies of ambient air pollution and respiratory emergency department visits. *J Expo Sci Environ Epidemiol* 21(1): 10-19.
- Eckel, SP, Cockburn, M, Shu, YH, Deng, H, Lurmann, FW, Liu, L and Gilliland, FD (2016). Air pollution affects lung cancer survival. *Thorax* 71(10): 891-898.
- Garcia, E, Berhane, KT, Islam, T, McConnell, R, Urman, R, Chen, Z and Gilliland, FD (2019). Association of changes in air quality with incident asthma in children in California, 1993-2014. *J Am Med Assoc* 321(19): 1906-1915.
- Gleason, JA, Bielory, L and Fagliano, JA (2014). Associations between ozone, PM<sub>2.5</sub>, and four pollen types on emergency department pediatric asthma events during the warm season in New Jersey: a case-crossover study. *Environ Res* 132: 421-429.

- 1 Goodman, JE, Loftus, CT, Liu, X and Zu, K (2017a). Impact of respiratory infections, outdoor  
2 pollen, and socioeconomic status on associations between air pollutants and pediatric  
3 asthma hospital admissions. PLoS One 12(7): e0180522.
- 4 Goodman, JE, Zu, K, Loftus, CT, Tao, G, Liu, X and Lange, S (2017b). Ambient ozone and  
5 asthma hospital admissions in Texas: a time-series analysis. Asthma Res Pract 3: 6.
- 6 Ito, A, Sillman, S and Penner, JE (2007). Effects of additional nonmethane volatile organic  
7 compounds, organic nitrates, and direct emissions of oxygenated organic  
8 species on global tropospheric chemistry. J Geophys Res 112: 21 PP.
- 9 Jerrett, M, Burnett, RT, Beckerman, BS, Turner, MC, Krewski, D, Thurston, G, Martin, RV, van  
10 Donkelaar, A, Hughes, E, Shi, Y, Gapstur, SM, Thun, MJ and Pope, CA, 3rd (2013).  
11 Spatial analysis of air pollution and mortality in California. Am J Respir Crit Care Med  
12 188(5): 593-599.
- 13 Jerrett, M, Burnett, RT, Pope, CA, 3rd, Ito, K, Thurston, G, Krewski, D, Shi, Y, Calle, E and  
14 Thun, M (2009). Long-term ozone exposure and mortality. N Engl J Med 360(11): 1085-  
15 1095.
- 16 Katsouyanni, K, Samet, JM, Anderson, HR, Atkinson, R, Le Tertre, A, Medina, S, Samoli, E,  
17 Touloumi, G, Burnett, RT, Krewski, D, Ramsay, T, Dominici, F, Peng, RD, Schwartz, J  
18 and Zanobetti, A (2009). Air pollution and health: a European and North American  
19 approach (APHENA). Res Rep Health Eff Inst(142): 5-90.
- 20 Klemm, RJ, Thomas, EL and Wyzga, RE (2011). The impact of frequency and duration of air  
21 quality monitoring: Atlanta, GA, data modeling of air pollution and mortality. J Air  
22 Waste Manag Assoc 61(11): 1281-1291.
- 23 Kousha, T and Castner, J (2016). The air quality health index and emergency department visits  
24 for otitis media. J Nurs Scholarsh 48(2): 163-171.
- 25 Kousha, T and Rowe, BH (2014). Ambient ozone and emergency department visits due to lower  
26 respiratory condition. Int J Occup Med Environ Health 27(1): 50-59.
- 27 Malig, BJ, Pearson, DL, Chang, YB, Broadwin, R, Basu, R, Green, RS and Ostro, B (2016). A  
28 Time-Stratified Case-Crossover Study of Ambient Ozone Exposure and Emergency  
29 Department Visits for Specific Respiratory Diagnoses in California (2005-2008). Environ  
30 Health Perspect 124(6): 745-753.
- 31 Nishimura, KK, Galanter, JM, Roth, LA, Oh, SS, Thakur, N, Nguyen, EA, Thyne, S, Farber, HJ,  
32 Serebrisky, D, Kumar, R, Brigino-Buenaventura, E, Davis, A, Lenoir, MA, Meade, K,  
33 Rodriguez-Cintron, W, Avila, PC, Borrell, LN, Bibbins-Domingo, K, Rodriguez-Santana,  
34 JR, Sen, S, Lurmann, F, Balmes, JR and Burchard, EG (2013). Early-life air pollution and  
35 asthma risk in minority children: the GALA II and SAGE II studies. Am J Respir Crit  
36 Care Med 188(3): 309-318.

- 1 O'Lenick, CR, Winquist, A, Mulholland, JA, Friberg, MD, Chang, HH, Kramer, MR, Darrow,  
2 LA and Sarnat, SE (2017). Assessment of neighbourhood-level socioeconomic status as a  
3 modifier of air pollution-asthma associations among children in Atlanta. *J Epidemiol*  
4 *Community Health* 71(2): 129-136.
- 5 Rodopoulou, S, Samoli, E, Chalbot, MG and Kavouras, IG (2015). Air pollution and  
6 cardiovascular and respiratory emergency visits in Central Arkansas: A time-series  
7 analysis. *Sci Total Environ* 536: 872-879.
- 8 Sacks, JD, Rappold, AG, Davis, JA, Jr., Richardson, DB, Waller, AE and Luben, TJ (2014).  
9 Influence of urbanicity and county characteristics on the association between ozone and  
10 asthma emergency department visits in North Carolina. *Environ Health Perspect* 122(5):  
11 506-512.
- 12 Sarnat, JA, Sarnat, SE, Flanders, WD, Chang, HH, Mulholland, J, Baxter, L, Isakov, V and  
13 Ozkaynak, H (2013). Spatiotemporally resolved air exchange rate as a modifier of acute  
14 air pollution-related morbidity in Atlanta. *J Expo Sci Environ Epidemiol* 23(6): 606-615.
- 15 Sarnat, SE, Winquist, A, Schauer, JJ, Turner, JR and Sarnat, JA (2015). Fine particulate matter  
16 components and emergency department visits for cardiovascular and respiratory diseases  
17 in the St. Louis, Missouri-Illinois, metropolitan area. *Environ Health Perspect* 123(5):  
18 437-444.
- 19 Sheffield, PE, Zhou, J, Shmool, JL and Clougherty, JE (2015). Ambient ozone exposure and  
20 children's acute asthma in New York City: a case-crossover analysis. *Environ Health* 14:  
21 25.
- 22 Shmool, JL, Kinnee, E, Sheffield, PE and Clougherty, JE (2016). Spatio-temporal ozone  
23 variation in a case-crossover analysis of childhood asthma hospital visits in New York  
24 City. *Environ Res* 147: 108-114.
- 25 Silverman, RA and Ito, K (2010). Age-related association of fine particles and ozone with severe  
26 acute asthma in New York City. *J Allergy Clin Immunol* 125(2): 367-373.
- 27 Stieb, DM, Szyszkowicz, M, Rowe, BH and Leech, JA (2009). Air pollution and emergency  
28 department visits for cardiac and respiratory conditions: A multi-city time-series analysis.  
29 *Environ Health* 8(25): 25.
- 30 Strickland, MJ, Klein, M, Flanders, WD, Chang, HH, Mulholland, JA, Tolbert, PE and Darrow,  
31 LA (2014). Modification of the effect of ambient air pollution on pediatric asthma  
32 emergency visits: susceptible subpopulations. *Epidemiology* 25(6): 843-850.
- 33 Szyszkowicz, M, Kousha, T, Castner, J and Dales, R (2018). Air pollution and emergency  
34 department visits for respiratory diseases: A multi-city case crossover study. *Environ Res*  
35 163: 263-269.

- 1 Tétreault, LF, Doucet, M, Gamache, P, Fournier, M, Brand, A, Kosatsky, T and Smargiassi, A  
2 (2016). Childhood exposure to ambient air pollutants and the onset of asthma: an  
3 administrative cohort study in Québec. *Environ Health Perspect* 124(8): 1276-1282.
- 4 Tolbert, PE, Klein, M, Peel, JL, Sarnat, SE and Sarnat, JA (2007). Multipollutant modeling  
5 issues in a study of ambient air quality and emergency department visits in Atlanta. *J*  
6 *Expo Sci Environ Epidemiol* 17(Suppl 2): S29-S35.
- 7 Turner, MC, Jerrett, M, Pope, CA, 3rd, Krewski, D, Gapstur, SM, Diver, WR, Beckerman, BS,  
8 Marshall, JD, Su, J, Crouse, DL and Burnett, RT (2016). Long-Term Ozone Exposure  
9 and Mortality in a Large Prospective Study. *Am J Respir Crit Care Med* 193(10): 1134-  
10 1142.
- 11 U.S. EPA (2020). Integrated Science Assessment for Ozone and Related Photochemical  
12 Oxidants. U.S. Environmental Protection Agency. Washington, DC. Office of Research  
13 and Development. EPA/600/R-20/012. Available at: [https://www.epa.gov/isa/integrated-](https://www.epa.gov/isa/integrated-science-assessment-isa-ozone-and-related-photochemical-oxidants)  
14 [science-assessment-isa-ozone-and-related-photochemical-oxidants](https://www.epa.gov/isa/integrated-science-assessment-isa-ozone-and-related-photochemical-oxidants).
- 15 Vanos, JK, Hebborn, C and Cakmak, S (2014). Risk assessment for cardiovascular and  
16 respiratory mortality due to air pollution and synoptic meteorology in 10 Canadian cities.  
17 *Environ Pollut* 185: 322-332.
- 18 Villeneuve, PJ, Chen, L, Rowe, BH and Coates, F (2007). Outdoor air pollution and emergency  
19 department visits for asthma among children and adults: A case-crossover study in  
20 northern Alberta, Canada. *Environ Health* 6: 40.
- 21 Weichenthal, S, Pinault, LL and Burnett, RT (2017). Impact of Oxidant Gases on the  
22 Relationship between Outdoor Fine Particulate Air Pollution and Nonaccidental,  
23 Cardiovascular, and Respiratory Mortality. *Sci Rep* 7(1): 16401.
- 24 Wells, BW, K.; Jenkins, S. (2012). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-  
25 OAR-2008-0699). Analysis of Recent U.S. Ozone Air Quality Data to Support the 03  
26 NAAQS Review and Quadratic Rollback Simulations to Support the First Draft of the  
27 Risk and Exposure Assessment. August 15, 2012. . Docket ID No. EPA-HQ-OAR-2008-  
28 0699. Office of Air Quality Planning and Standards Research Triangle Park, NC.  
29 Available at: [https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-](https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-4253&contentType=pdf)  
30 [2008-0699-4253&contentType=pdf](https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-4253&contentType=pdf).
- 31 Winkvist, A, Kirrane, E, Klein, M, Strickland, M, Darrow, LA, Sarnat, SE, Gass, K, Mulholland,  
32 J, Russell, A and Tolbert, P (2014). Joint effects of ambient air pollutants on pediatric  
33 asthma emergency department visits in Atlanta, 1998-2004. *Epidemiology* 25(5): 666-  
34 673.
- 35 Winkvist, A, Klein, M, Tolbert, P, Flanders, WD, Hess, J and Sarnat, SE (2012). Comparison of  
36 emergency department and hospital admissions data for air pollution time-series studies.  
37 *Environ Health* 11: 70.

- 1 Xiao, Q, Liu, Y, Mulholland, JA, Russell, AG, Darrow, LA, Tolbert, PE and Strickland, MJ  
2 (2016). Pediatric emergency department visits and ambient Air pollution in the U.S. State  
3 of Georgia: a case-crossover study. *Environ Health* 15(1): 115.
- 4 Zanobetti, A and Schwartz, J (2008). Mortality displacement in the association of ozone with  
5 mortality: an analysis of 48 cities in the United States. *Am J Respir Crit Care Med*  
6 177(2): 184-189.
- 7 Zu, K, Liu, X, Shi, L, Tao, G, Loftus, CT, Lange, S and Goodman, JE (2017). Concentration-  
8 response of short-term ozone exposure and hospital admissions for asthma in Texas.  
9 *Environ Int* 104: 139-145.



## APPENDIX 3C

### AIR QUALITY DATA USED IN POPULATION EXPOSURE AND RISK ANALYSES

|   |        |
|---|--------|
| Table of Figures .....  | 3C-2   |
| Table of Tables .....   | 3C-10  |
| 3C.1 Overview .....   | 3C-2   |
| 3C.2 Urban Study Areas .....  | 3C-3   |
| 3C.3 Ambient Air Ozone Monitoring Data .....  | 3C-5   |
| 3C.4 Air Quality Modeling Data .....  | 3C-14  |
| 3C.4.1 Comprehensive Air Quality Model with Extensions (CAMx) .....                     | 3C-14  |
| 3C.4.2 Evaluation of Modeled Ozone Concentrations .....                                 | 3C-20  |
| 3C.5 Air Quality Adjustment to Meet Current and Alternative Air Quality Scenarios ..... | 3C-52  |
| 3C.5.1 Overview of the Higher Order Direct Decoupled Method (HDDM) ....                 | 3C-52  |
| 3C.5.2 Using CAMx/HDDM to Adjust Monitored Ozone Concentrations .....                   | 3C-55  |
| 3C.6 Interpolation of Adjusted Air Quality using Voronoi Neighbor Averaging .....       | 3C-82  |
| 3C.7 Results for Urban Study Areas .....  | 3C-84  |
| 3C.7.1 Design Values .....  | 3C-84  |
| 3C.7.2 Distribution of Hourly O <sub>3</sub> Concentrations .....                       | 3C-91  |
| 3C.7.3 Air Quality Inputs for the Exposure and Risk Analyses .....                      | 3C-108 |
| References .....  | 3C-143 |

## TABLE OF FIGURES

|               |  |       |
|---------------|--|-------|
| Figure 3C-1.  | Flowchart showing inputs, processes and outputs of the approach to generate ambient air concentration estimates for use in the exposure modeling. ....   | 3C-2  |
| Figure 3C-2.  | Map of the eight urban study areas analyzed. ....  | 3C-4  |
| Figure 3C-3.  | Map of the Atlanta study area. ....  | 3C-6  |
| Figure 3C-4.  | Map of the Boston study area. ....   | 3C-7  |
| Figure 3C-5.  | Map of the Dallas study area. ....   | 3C-8  |
| Figure 3C-6.  | Map of the Detroit study area. ....  | 3C-9  |
| Figure 3C-7.  | Map of the Philadelphia study area. ....   | 3C-10 |
| Figure 3C-8.  | Map of the Phoenix study area.....   | 3C-11 |
| Figure 3C-9.  | Map of the Sacramento study area.....  | 3C-12 |
| Figure 3C-10. | Map of the St. Louis study area. ....  | 3C-13 |
| Figure 3C-11. | Map of the CAMx modeling domain.....   | 3C-15 |
| Figure 3C-12. | Normalized mean bias for MDA8 O <sub>3</sub> in the Northeastern U.S., winter 2016. ....   | 3C-22 |
| Figure 3C-13. | Normalized mean bias for MDA8 O <sub>3</sub> in the Northeastern U.S., spring 2016. ....   | 3C-23 |
| Figure 3C-14. | Normalized mean bias for MDA8 O <sub>3</sub> in the Northeastern U.S., summer 2016. ....   | 3C-23 |
| Figure 3C-15. | Normalized mean bias for MDA8 O <sub>3</sub> in the Northeastern U.S., fall 2016. ....   | 3C-24 |
| Figure 3C-16. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at Boston monitoring sites in 2016. ....  | 3C-25 |
| Figure 3C-17. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at Boston monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016. .... | 3C-26 |
| Figure 3C-18. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at Philadelphia monitoring sites in 2016. ....  | 3C-27 |
| Figure 3C-19. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at Philadelphia monitoring sites for January (top left),   |       |

|               |   |       |
|---------------|---|-------|
|               | April (top right), July (bottom left), and October (bottom right) 2016. ....  | 3C-28 |
| Figure 3C-20. | Normalized mean bias for MDA8 O <sub>3</sub> in the Southeastern U.S., winter 2016. ....  | 3C-29 |
| Figure 3C-21. | Normalized mean bias for MDA8 O <sub>3</sub> in the Southeastern U.S., spring 2016. ....  | 3C-30 |
| Figure 3C-22. | Normalized mean bias for MDA8 O <sub>3</sub> in the Southeastern U.S., summer 2016. ....  | 3C-30 |
| Figure 3C-23. | Normalized mean bias for MDA8 O <sub>3</sub> in the Southeastern U.S., fall 2016. ....  | 3C-31 |
| Figure 3C-24. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at Atlanta monitoring sites in 2016. ....  | 3C-32 |
| Figure 3C-25. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at Atlanta monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016. .... | 3C-33 |
| Figure 3C-26. | Normalized mean bias for MDA8 O <sub>3</sub> in the Midwest U.S., winter 2016. ....   | 3C-34 |
| Figure 3C-27. | Normalized mean bias for MDA8 O <sub>3</sub> in the Midwest U.S., spring 2016. ....   | 3C-35 |
| Figure 3C-28. | Normalized mean bias for MDA8 O <sub>3</sub> in the Midwest U.S., summer 2016. ....   | 3C-35 |
| Figure 3C-29. | Normalized mean bias for MDA8 O <sub>3</sub> in the Midwest U.S., fall 2016. ....   | 3C-36 |
| Figure 3C-30. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at Detroit monitoring sites in 2016. ....  | 3C-37 |
| Figure 3C-31. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at Detroit monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016. .... | 3C-38 |
| Figure 3C-32. | Normalized mean bias for MDA8 O <sub>3</sub> in the Central U.S., winter 2016. ....   | 3C-39 |
| Figure 3C-33. | Normalized mean bias for MDA8 O <sub>3</sub> in the Central U.S., spring 2016. ....   | 3C-40 |

|               |  |       |
|---------------|--|-------|
| Figure 3C-34. | Normalized mean bias for MDA8 O <sub>3</sub> in the Central U.S., summer 2016.....   | 3C-40 |
| Figure 3C-35. | Normalized mean bias for MDA8 O <sub>3</sub> in the Central U.S., fall 2016. ....  | 3C-41 |
| Figure 3C-36. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at St. Louis monitoring sites in 2016. ....   | 3C-42 |
| Figure 3C-37. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at St. Louis monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016. ....  | 3C-43 |
| Figure 3C-38. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at Dallas monitoring sites in 2016. ....  | 3C-44 |
| Figure 3C-39. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at Dallas monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016. ....     | 3C-45 |
| Figure 3C-40. | Normalized mean bias for MDA8 O <sub>3</sub> in the Western U.S., winter 2016.....   | 3C-47 |
| Figure 3C-41. | Normalized mean bias for MDA8 O <sub>3</sub> in the Western U.S., spring 2016.....   | 3C-47 |
| Figure 3C-42. | Normalized mean bias for MDA8 O <sub>3</sub> in the Western U.S., summer 2016. ....  | 3C-48 |
| Figure 3C-43. | Normalized mean bias for MDA8 O <sub>3</sub> in the Western U.S., fall 2016.....   | 3C-48 |
| Figure 3C-44. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at Sacramento monitoring sites in 2016. ....  | 3C-49 |
| Figure 3C-45. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at Sacramento monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016. .... | 3C-50 |
| Figure 3C-46. | Time series of monitored (black) and modeled (red) MDA8 O <sub>3</sub> at Phoenix monitoring sites in 2016. ....   | 3C-51 |

|               |   |       |
|---------------|---|-------|
| Figure 3C-47. | Time series of monitored (black) and modeled (red) hourly O <sub>3</sub> concentrations at Phoenix monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016. .... | 3C-52 |
| Figure 3C-48. | Flow diagram demonstrating HDDM model-based O <sub>3</sub> adjustment approach. ....  | 3C-57 |
| Figure 3C-49. | Conceptual picture of 3-step application of HDDM sensitivities. ....  | 3C-60 |
| Figure 3C-50. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in Atlanta. ....  | 3C-64 |
| Figure 3C-51. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in Boston. ....   | 3C-65 |
| Figure 3C-52. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in Dallas. ....   | 3C-66 |
| Figure 3C-53. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in Detroit. ....  | 3C-67 |
| Figure 3C-54. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in Philadelphia. ....   | 3C-68 |
| Figure 3C-55. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in Phoenix. ....  | 3C-69 |
| Figure 3C-56. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in Sacramento. ....   | 3C-70 |
| Figure 3C-57. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 50% NO <sub>x</sub> cut conditions in St. Louis. ....  | 3C-71 |
| Figure 3C-58. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in Atlanta. ....  | 3C-72 |
| Figure 3C-59. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in Boston. ....   | 3C-73 |
| Figure 3C-60. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in Dallas. ....   | 3C-74 |
| Figure 3C-61. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in Detroit. ....  | 3C-75 |
| Figure 3C-62. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in Philadelphia. ....   | 3C-76 |

|               |   |        |
|---------------|---|--------|
| Figure 3C-63. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in Phoenix. ....    | 3C-77  |
| Figure 3C-64. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in Sacramento. .... | 3C-78  |
| Figure 3C-65. | Comparison of brute force and 3-step HDDM O <sub>3</sub> estimates for 90% NO <sub>x</sub> cut conditions in St. Louis. ....  | 3C-79  |
| Figure 3C-66. | Numerical example of the Voronoi Neighbor Averaging (VNA) technique. ....   | 3C-83  |
| Figure 3C-67. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Atlanta. ....                             | 3C-93  |
| Figure 3C-68. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Boston. ....                              | 3C-94  |
| Figure 3C-69. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Dallas. ....                              | 3C-95  |
| Figure 3C-70. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Detroit. ....                             | 3C-96  |
| Figure 3C-71. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Philadelphia. ....                        | 3C-97  |
| Figure 3C-72. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Phoenix. ....                             | 3C-98  |
| Figure 3C-73. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Sacramento. ....                          | 3C-99  |
| Figure 3C-74. | Diurnal distribution of hourly O <sub>3</sub> concentrations at monitoring sites in St. Louis. ....                           | 3C-100 |
| Figure 3C-75. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Atlanta. ....                             | 3C-101 |
| Figure 3C-76. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Boston. ....                              | 3C-102 |
| Figure 3C-77. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Dallas. ....                              | 3C-103 |
| Figure 3C-78. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Detroit. ....                             | 3C-104 |

|               |   |        |
|---------------|---|--------|
| Figure 3C-79. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Philadelphia. ....  | 3C-105 |
| Figure 3C-80. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Phoenix. ....   | 3C-106 |
| Figure 3C-81. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in Sacramento. ....  | 3C-107 |
| Figure 3C-82. | Monthly distribution of hourly O <sub>3</sub> concentrations at monitoring sites in St. Louis. ....   | 3C-108 |
| Figure 3C-83. | Changes in MDA8 O <sub>3</sub> based on HDDM adjustments in Atlanta. ....   | 3C-111 |
| Figure 3C-84. | Changes in MDA8 O <sub>3</sub> based on HDDM adjustments in Boston. ....  | 3C-112 |
| Figure 3C-85. | Changes in MDA8 O <sub>3</sub> based on HDDM adjustments in Dallas. ....  | 3C-113 |
| Figure 3C-86. | Changes in MDA8 O <sub>3</sub> based on HDDM adjustments in Detroit. ....   | 3C-114 |
| Figure 3C-87. | Changes in MDA8 O <sub>3</sub> based on HDDM adjustments in Philadelphia. ....  | 3C-115 |
| Figure 3C-89. | Changes in MDA8 O <sub>3</sub> based on HDDM adjustments in Sacramento. ....  | 3C-117 |
| Figure 3C-90. | Changes in MDA8 O <sub>3</sub> based on HDDM adjustments in St. Louis. ....   | 3C-118 |
| Figure 3C-91. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Atlanta. ....            | 3C-119 |
| Figure 3C-92. | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Atlanta. .... | 3C-120 |
| Figure 3C-93. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Boston. ....             | 3C-121 |
| Figure 3C-94. | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Boston. ....  | 3C-122 |
| Figure 3C-95. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Dallas. ....             | 3C-123 |
| Figure 3C-96. | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Dallas. ....  | 3C-124 |

|                |   |        |
|----------------|---|--------|
| Figure 3C-97.  | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Detroit. ....                    | 3C-125 |
| Figure 3C-98.  | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Detroit.....          | 3C-126 |
| Figure 3C-99.  | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Philadelphia.....                | 3C-127 |
| Figure 3C-100. | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Philadelphia. ....    | 3C-128 |
| Figure 3C-101. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Phoenix. ....                    | 3C-129 |
| Figure 3C-102. | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Phoenix.....          | 3C-130 |
| Figure 3C-103. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Sacramento.....                  | 3C-131 |
| Figure 3C-104. | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in Sacramento. ....      | 3C-132 |
| Figure 3C-105. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in St. Louis. ....                  | 3C-133 |
| Figure 3C-106. | Changes in annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> based on HDDM adjustments in St. Louis. ....       | 3C-134 |
| Figure 3C-107. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in Atlanta.....       | 3C-135 |
| Figure 3C-108. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in Boston. ....       | 3C-136 |
| Figure 3C-109. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in Dallas. ....       | 3C-137 |
| Figure 3C-110. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in Detroit. ....      | 3C-138 |
| Figure 3C-111. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in Philadelphia. .... | 3C-139 |
| Figure 3C-112. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in Phoenix. ....      | 3C-140 |



|                |   |        |
|----------------|---|--------|
| Figure 3C-113. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in Sacramento. .... | 3C-141 |
| Figure 3C-114. | Annual 4 <sup>th</sup> highest MDA8 O <sub>3</sub> and May-September mean MDA8 O <sub>3</sub> by population based on HDDM adjustments in St. Louis. ....  | 3C-142 |

10

11

## TABLE OF TABLES

|              |  |       |
|--------------|--|-------|
| Table 3C-1.  | Summary information for the eight urban study areas. ....  | 3C-4  |
| Table 3C-2.  | Geographic elements of domain used in the CAMx/HDDM modeling. ....   | 3C-15 |
| Table 3C-3.  | Vertical layer structure for 2016 WRF and CAMx simulations. ....   | 3C-17 |
| Table 3C-4.  | Summary of U.S. emissions totals by sector for the 12km CONUS domain<br>(in thousand tons). . ....                   | 3C-19 |
| Table 3C-5.  | CAMx model performance at monitoring sites in the Northeastern U.S. ....   | 3C-32 |
| Table 3C-6.  | CAMx model performance at monitoring sites in the Boston area. ....  | 3C-24 |
| Table 3C-7.  | CAMx model performance at monitoring sites in the Philadelphia area. ....  | 3C-26 |
| Table 3C-8.  | CAMx model performance at monitoring sites in the Southeastern U.S. ....   | 3C-39 |
| Table 3C-9.  | CAMx model performance at monitoring sites in the Atlanta area. ....   | 3C-31 |
| Table 3C-10. | CAMx model performance at monitoring sites in the Midwest U.S. ....  | 3C-34 |
| Table 3C-11. | CAMx model performance at monitoring sites in the Detroit area. ....   | 3C-36 |
| Table 3C-12. | CAMx model performance at monitoring sites in the Central U.S. ....  | 3C-39 |
| Table 3C-13. | CAMx model performance at monitoring sites in the Saint Louis area. ....   | 3C-41 |
| Table 3C-14. | CAMx model performance at monitoring sites in the Dallas area. ....  | 3C-43 |
| Table 3C-15. | CAMx model performance at monitoring sites in the Western U.S. ....  | 3C-46 |
| Table 3C-16. | CAMx model performance at monitoring sites in the Sacramento area. ....  | 3C-49 |
| Table 3C-17. | CAMx model performance at monitoring sites in the Phoenix area ....  | 3C-50 |
| Table 3C-18. | X and Y cutpoints used in Equations (3C-4) through (3C-7).....   | 3C-63 |
| Table 3C-19. | Percent emissions changes used for each urban area to just meet each of the<br>air quality scenarios evaluated. .... | 3C-82 |
| Table 3C-20. | 2015-2017 design values for monitors in the Atlanta area.....  | 3C-85 |


|              |   |       |
|--------------|---|-------|
| Table 3C-21. | 2015-2017 design values for monitors in the Boston area. ....       | 3C-86 |
| Table 3C-22. | 2015-2017 design values for monitors in the Dallas area. ....       | 3C-87 |
| Table 3C-23. | 2015-2017 design values for monitors in the Detroit area. ....      | 3C-87 |
| Table 3C-24. | 2015-2017 design values for monitors in the Philadelphia area. .... | 3C-88 |
| Table 3C-25. | 2015-2017 design values for monitors in the Phoenix area. ....      | 3C-89 |
| Table 3C-26. | 2015-2017 design values for monitors in the Sacramento area.....    | 3C-90 |
| Table 3C-27. | 2015-2017 design values for monitors in the St. Louis area. ....    | 3C-91 |

14

15

### 3C.1 OVERVIEW

This appendix describes the development of the ozone (O<sub>3</sub>) air quality estimates used in the population exposure and risk modeling described in Appendix 3D. Figure 3C-1 below shows a flowchart of the various data sources, processes and outputs involved in generating these ambient O<sub>3</sub> concentration surfaces. This approach was used for eight urban study areas, which are described further in section 3C.2.



**Figure 3C-1. Flowchart showing inputs, processes and outputs of the approach to generate ambient air concentration estimates for use in the exposure and risk modeling.**

Generation of the O<sub>3</sub> concentration surfaces for the exposure and risk modeling relied on a combination of recent monitoring data and a model-based adjustment. Ambient hourly O<sub>3</sub> monitoring data for years 2015 through 2017 in each of the eight urban study areas was adjusted using a model-based adjustment approach to create three different air quality scenarios. These scenarios included conditions that just meet the current O<sub>3</sub> standard (design value of 70 ppb), as well as conditions that just meet two alternative air quality scenarios having design values of 75 ppb and 65 ppb. Section 3C.3 provides additional information on the monitoring data. Section 3C.4 describes the air quality modeling that was used to perform the adjustments, as well as results from the model evaluation that was performed to assess the accuracy of the modeled concentrations. Section 3C.5 describes the model-based adjustment approach and its application to the ambient air quality data to create the three air quality scenarios.

1 The final step in preparing the air quality input data for the exposure and risk modeling is  
2 to interpolate the adjusted air quality data from the ambient air monitoring site locations to each  
3 census tract in the eight urban study areas using Voronoi Neighbor Averaging (VNA), which is  
4 described in section 3C.6. Finally, section 3C.7 provides various results from the model-based  
5 adjustment procedure and the final air quality dataset used as inputs to the Air Pollutants  
6 Exposure Model (APEX). The APEX model and its application to air quality in the eight urban  
7 study areas is described in Appendix 3D.

8 This appendix was developed in support of the risk and exposure analyses for the 2020  
9 review. As outlined in section 1.5, the draft 2019 PA for the 2020 review, with a draft version of  
10 this appendix, was made available for public comment and was reviewed and discussed by  
11 CASAC in a public meeting (84 FR 50836, September 26, 2019; 84 FR 58711, November 1,  
12 2019). In consideration of comments from the CASAC (Cox, 2020) and the public a number of  
13 additional analyses and presentations were added to this appendix in the final 2020 PA (U.S.  
14 EPA, 2020). These additions and clarifications included the following:

- 15 • Cites section in Appendix 3D for description of study area selection (section 3C.2);
- 16 • Summarizes differences in emissions between 2014 NEI and 2016 Platform used for  
17 modeling in this assessment (section 3C.4.1.5);
- 18 • Adds clarifications regarding the model evaluation tables and figures presented in section  
19 3C.4.2 (Figure 3C-12 to Figure 3C-47; Table 3C-5 to Table 3C-17);
- 20 • Provides rationale for choosing nitrogen oxides (NO<sub>x</sub>) reductions only instead of the  
21 combined NO<sub>x</sub> and volatile organic compounds (VOC) reductions which were used in  
22 the previous review (section 3C.5.2.2.3); and
- 23 • Adds a reference to a cross-validation analysis conducted in the last review, which  
24 supports the use of the VNA technique for generating the air quality spatial fields (section  
25 3C.6).

## 26 **3C.2 URBAN STUDY AREAS**

27 Eight urban study areas were chosen for analysis based on several criteria, including  
28 geographic distribution, population, current air quality levels, availability of exposure model  
29 inputs, air quality model performance, and ambient air monitoring network coverage. The  
30 selection criteria and any other considerations in study area selection are described in Appendix  
31 3D, section 3D.2.1. The eight urban study areas selected were: Atlanta, GA; Boston, MA; Dallas,  
32 TX; Detroit, MI; Philadelphia, PA; Phoenix, AZ; Sacramento, CA; and St. Louis, MO. Figure  
33 3C-2 shows a map of these eight study areas and Table 3C-1 provides summary information for  
34 each area. The spatial extent of each study area was determined using the Combined Statistical

1 Area (CSA), with the exception of the Phoenix study area, which is not in a CSA. In that case,  
 2 the Core Based Statistical Area (CBSA) was used as the area boundary.<sup>1</sup>



3  
 4 **Figure 3C-2. Map showing the location of the eight urban study areas.**

5  
 6 **Table 3C-1. Summary information for the eight urban study areas.**

| Study Area Name   | CSA Name   | Land Area (km <sup>2</sup> ) | Population (2010) | Number of O <sub>3</sub> Monitors | 2015-2017 DV (ppb) |
|---|--|------------------------------|-------------------|-----------------------------------|--------------------|
| Atlanta   | Atlanta--Athens-Clarke County--Sandy Springs, GA | 30,665                       | 5,910,296         | 12                                | 75                 |
| Boston  | Boston-Worcester-Providence, MA-RI-NH-CT         | 25,117                       | 7,893,376         | 23                                | 73                 |
| Dallas  | Dallas-Fort Worth, TX-OK                         | 42,664                       | 6,851,398         | 21                                | 79                 |
| Detroit   | Detroit-Warren-Ann Arbor, MI                     | 16,884                       | 5,318,744         | 13                                | 73                 |
| Philadelphia  | Philadelphia-Reading-Camden, PA-NJ-DE-MD         | 18,959                       | 7,067,807         | 20                                | 80                 |
| Phoenix   | Phoenix-Mesa-Scottsdale, AZ <sup>A</sup>         | 34,799                       | 4,192,887         | 30                                | 76                 |
| Sacramento  | Sacramento-Roseville, CA                         | 18,871                       | 2,414,783         | 21                                | 86                 |
| St. Louis   | St. Louis-St. Charles-Farmington, MO-IL          | 23,019                       | 2,892,497         | 16                                | 72                 |
| <sup>A</sup> The Phoenix study area is not part of a CSA. The name listed in Table 3C-1 is the CBSA name. |  |                              |                   |                                   |                    |

<sup>1</sup> CSA and CBSA boundaries are based on delineations promulgated by the Office of Management and Budget (OMB) in February of 2013. CBSA and CSA delineation files are available at <https://www.census.gov/geographies/reference-files/time-series/demo/metro-micro/delineation-files.html>.


### 3C.3 AMBIENT AIR OZONE MONITORING DATA

Hourly O<sub>3</sub> concentration data for all U.S. monitoring sites for 2015-2017 was retrieved from the EPA's Air Quality System (AQS) database in July of 2018. Design values<sup>2</sup> for 2015-2017 were calculated for each monitoring site according to the data handling requirements in Appendix U to 40 CFR Part 50. Monitors within the study area boundary for each urban study area were identified. These monitors were used to determine the NO<sub>x</sub> emissions changes necessary to meet the current standard of 70 ppb, and the two alternative air quality scenarios having design values of 75 ppb and 65 ppb, following the model-based adjustment approach described in section 3C.5.

Additionally, monitors within 50 km of the study area boundary were identified as "buffer sites." Once the emissions changes required to meet the various air quality scenarios had been determined using the monitors within the CSA, these emissions changes were applied to both the CSA monitors and the buffer sites, as described in section 3C.5. The purpose of the buffer sites was to provide additional data for the spatial interpolation approach described in section 3C.6, providing improved estimates of air quality near the edges of the urban study area domain. Figure 3C-3 through Figure 3C-10 show maps of the boundaries for each urban study area, along with the locations of the monitoring sites used in the analysis. In each map, the shaded counties comprise the air quality domain of the urban study area used for estimating exposure and risk, the monitoring sites located inside the study area are denoted by black circles, and buffer sites are denoted by black squares.


---

<sup>2</sup> The design value is the 3-year average of the annual 4<sup>th</sup> highest daily maximum 8-hour average O<sub>3</sub> concentration. A monitoring site meets the current standard if its design value is less than or equal to 70 ppb.




**Figure 3C-3. Map of the Atlanta study area.** Counties in the CSA are shaded, monitoring sites in the CSA are denoted by black circles, and buffer sites are denoted by black squares.







1  
2 **Figure 3C-4. Map of the Boston study area.** Counties in the CSA are shaded, monitoring  
3 sites in the CSA are denoted by black circles, and buffer sites are denoted by  
4 black squares.




**Figure 3C-5. Map of the Dallas study area.** Counties in the CSA are shaded, monitoring sites in the CSA are denoted by black circles, and buffer sites are denoted by black squares.




**Figure 3C-6. Map of the Detroit study area.** Counties in the CSA are shaded, monitoring sites in the CSA are denoted by black circles, and buffer sites are denoted by black squares.




**Figure 3C-7. Map of the Philadelphia study area.** Counties in the CSA are shaded, monitoring sites in the CSA are denoted by black circles, and buffer sites are denoted by black squares.



**Figure 3C-8. Map of the Phoenix study area.** Counties in the CBSA are shaded, monitoring sites in the CBSA are denoted by black circles, and buffer sites are denoted by black squares.



**Figure 3C-9. Map of the Sacramento study area.** Counties in the CSA are shaded, monitoring sites in the CSA are denoted by black circles, and buffer sites are denoted by black squares.



**Figure 3C-10. Map of the St. Louis study area.** Counties in the CSA are shaded, monitoring sites in the CSA are denoted by black circles, and buffer sites are denoted by black squares.

It is worth noting that for an area to show compliance with the current O<sub>3</sub> standard, all monitors within the urban area must have design values less than or equal to 70 ppb. According to Appendix U to 40 CFR Part 50, air quality monitors must also meet certain data completeness requirements to show compliance with the standard. However, any design value based on 3 years of monitoring data that exceeds the standard is not in compliance, regardless of data completeness. Therefore, when performing the air quality adjustments to create the three air quality scenarios, all monitors in each urban study area with data reported for each of the 3 years were included, regardless of data completeness.

Finally, per Appendix U to 40 CFR Part 50, data not meeting the ambient air monitoring requirements in 40 CFR Part 58, data reported using methods other than Federal Reference or Equivalent Methods, and data concurred by the appropriate EPA Regional Office as having been affected by an exceptional event were excluded from design value calculations. However, once the emissions changes required to determine compliance with the various air quality scenarios

had been determined, these values were included in the final adjustment and spatial interpolation. In practice, fewer than 10,000 hourly concentrations out of more than 3 million (~0.3%) were excluded from design value calculations in this manner.

## **3C.4 AIR QUALITY MODELING DATA**

### **3C.4.1 Comprehensive Air Quality Model with Extensions (CAMx)**

#### **3C.4.1.1 Model Set-up and Simulation**

The Comprehensive Air Quality Model with Extensions (CAMx) was used as the modeling tool for this assessment. CAMx is a peer-reviewed model that simulates the formation and fate of photochemical oxidants, aerosol concentrations, acid deposition, and air toxics, over multiple scales for given input sets of meteorological conditions and emissions. CAMx is used frequently for a range of scientific and regulatory applications related to the analysis of air quality in the U.S. The Higher Order Direct Decoupled Method (HDDM) was implemented in CAMx to estimate the model sensitivities to emissions changes as described in section 3C.5 of this appendix. The CAMx-HDDM configuration tracks gas-phase species concentrations through all modeled processes. However, HDDM implemented in CAMx does not track the effects of aerosol and cloud processing on calculated O<sub>3</sub> sensitivities. Differences in predicted O<sub>3</sub> concentrations between the CAMx-HDDM configuration described here and a standard CAMx v6.5 simulation with full treatment of aerosol-O<sub>3</sub> interactions did not influence O<sub>3</sub> predictions in the urban study areas examined in this assessment. CAMx v6.5<sup>3</sup> was run using the carbon bond version 6 (CB06r4) gas-phase chemical mechanism (Yarwood et al., 2010; Gery et al., 1989) and the AERO6 aerosol module which includes ISORROPIA for gas-particle partitioning of inorganic species (Nenes et al., 1998) and secondary organic aerosol treatment as described in Carlton et al. (2010).

#### **3C.4.1.2 Model Domain**

For this analysis, all CAMx runs were performed for a domain that covers the 48 contiguous states including portions of southern Canada and Northern Mexico with a 12 x 12 km resolution (Figure 3C-11). The CAMx simulations were performed with 35 vertical layers with a top layer at about 17,600 meters, or 50 millibars (mb). Table 3C-2 and Table 3C-3 provide some basic geographic information regarding the CAMx domain and vertical layer structure, respectively. Results from the lowest layer of the model were used for analyses to support the risk and exposure analyses described in Appendix 3D.

---

<sup>3</sup> For more information, see: [http://www.camx.com/files/camxusersguide\\_v6-50.pdf](http://www.camx.com/files/camxusersguide_v6-50.pdf).





**Figure 3C-11. Map of the CAMx modeling domain.**

**Table 3C-2. Geographic elements of domain used in the CAMx/HDDM modeling.**

| Domain Element  | CAMx Modeling Configuration Grid        |
|-----------------|---|
| Map Projection  | Lambert Conformal Projection            |
| Grid Resolution | 12 km                                   |
| True Latitudes  | 33 deg N and 45 deg N                   |
| Grid Dimensions | 396 x 246 x 35                          |
| Vertical extent | 35 Layers: Surface to 50 millibar level |

### 3C.4.1.3 Model Time Period

The CAMx/HDDM modeling was performed for January 1 - December 31 of 2016. The simulations included a 10-day spin-up period<sup>4</sup> from December 22-31, 2015. The spin-up days were not considered in the analysis for the HDDM results.

### 3C.4.1.4 Model Inputs: Meteorology

CAMx model simulations require inputs of meteorological fields, emissions, and initial and boundary conditions. The gridded meteorological data for the entire year of 2016 at the 12 km continental U.S. scale domain were derived from version 3.8 of the Weather Research and Forecasting Model (WRF), Advanced Research WRF (ARW) core (Skamarock et al., 2008). The WRF Model is a mesoscale numerical weather prediction system developed for both operational forecasting and atmospheric research applications.<sup>5</sup> The 2016 WRF simulation included the physics options of the Pleim-Xiu land surface model (LSM), Asymmetric Convective Model version 2 planetary boundary layer (PBL) scheme, Morrison double moment microphysics, Kain-Fritsch cumulus parameterization scheme and the RRTMG long-wave radiation (LWR) scheme (Gilliam and Pleim, 2009). Additionally, lightning data assimilation was utilized to suppress (force) deep convection where lightning was absent (present) in observational data. This method is described by Heath et al. (2016) and was employed to help improve precipitation estimates generated by the WRF model.

The WRF and CAMx simulations used the same map projection, a Lambert conformal projection centered at (-97, 40) with true latitudes at 33 and 45 degrees north. The WRF and CAMx simulations utilized 35 vertical layers with a surface layer of approximately 19 meters. Table 3C-3 shows the vertical layer structure used in WRF to generate the CAMx meteorological inputs.

The WRF meteorological outputs were processed to create model-ready inputs for CAMx using the wrfcamx version 4.3 meteorological pre-processor (Ramboll Environ, 2014). The specific meteorological inputs to CAMx include: horizontal wind components (i.e., speed and direction), temperature, moisture, vertical diffusion rates, and rainfall rates for each grid cell in each vertical layer.

---

<sup>4</sup> It is standard practice to allow chemical transport models to run for several days to weeks prior to the time period of interest in order to minimize the influence of initial conditions.

<sup>5</sup> See: <http://wrf-model.org>

1     **Table 3C-3. Vertical layer structure for 2016 WRF and CAMx simulations.**

| Layer Top Height (m) | Pressure (mb) | Model Layer |
|----------------------|---------------|-------------|
| 17,556               | 50            | 35          |
| 14,780               | 97.5          | 34          |
| 12,822               | 145           | 33          |
| 11,282               | 192.5         | 32          |
| 10,002               | 240           | 31          |
| 8,901                | 287.5         | 30          |
| 7,932                | 335           | 29          |
| 7,064                | 382.5         | 28          |
| 6,275                | 430           | 27          |
| 5,553                | 477.5         | 26          |
| 4,885                | 525           | 25          |
| 4,264                | 572.5         | 24          |
| 3,683                | 620           | 23          |
| 3,136                | 667.5         | 22          |
| 2,619                | 715           | 21          |
| 2,226                | 753           | 20          |
| 1,941                | 781.5         | 19          |
| 1,665                | 810           | 18          |
| 1,485                | 829           | 17          |
| 1,308                | 848           | 16          |
| 1,134                | 867           | 15          |
| 964                  | 886           | 14          |
| 797                  | 905           | 13          |
| 714                  | 914.5         | 12          |
| 632                  | 924           | 11          |
| 551                  | 933.5         | 10          |
| 470                  | 943           | 9           |
| 390                  | 952.5         | 8           |
| 311                  | 962           | 7           |
| 232                  | 971.5         | 6           |
| 154                  | 981           | 5           |
| 115                  | 985.75        | 4           |
| 77                   | 990.5         | 3           |
| 38                   | 995.25        | 2           |
| 19                   | 997.63        | 1           |

2

3             A detailed meteorological model performance evaluation was conducted for the 2016

4 WRF simulations (U.S. EPA, 2017). The analysis included statistical evaluation of temperature,

5 wind speed, and water vapor mixing ratios against observational data from airports, as well as

6 evaluations of monthly precipitation compared to the Parameter-elevation Relationships on

7 Independent Slopes Model (PRISM) and shortwave radiation compared to data from the Surface

1 Radiation Budget Measurement Network (SURFRAD) and the Solar Radiation Network  
2 (SOLRAD).

### 3 **3C.4.1.5 Model Inputs: Emissions**

4 The emissions data used are based on the alpha version of the Inventory Collaborative  
5 2016 emissions modeling platform.<sup>6</sup> The modeling case used is abbreviated “2016fe” and is  
6 publicly available.<sup>7</sup>

7 Emissions were processed to photochemical model inputs with the SMOKE modeling  
8 system version 4.5 (Houyoux et al., 2000). For this analysis, emissions from wildfires and  
9 prescribed burns were based on year 2016 nationally available fire datasets. Electric generating  
10 unit (EGU) emissions are temporally allocated to hourly values based on patterns derived from  
11 year 2016 Continuous Emissions Monitoring System (CEMS) data. In addition, U.S. emissions  
12 are included from other point sources, area sources, agricultural sources (ammonia only),  
13 anthropogenic fugitive dust sources, nonroad mobile sources, onroad mobile sources, and  
14 biogenic sources. Emissions for onroad mobile sources were created using the EPA’s MOVES  
15 2014a model,<sup>8</sup> except that California emissions were adjusted to match the county total  
16 emissions obtained directly from the California Air Resources Board. Biogenic emissions were  
17 estimated using the Biogenic Emissions Inventory System version 3.61 (BEISv3.61) (Pouliot and  
18 Bash, 2015). Other North American emissions from areas outside the U.S. are based on a 2013  
19 Canadian inventory scaled to 2015, and projections of the 2008 Mexican inventory to the year  
20 2016 along with the scaling of MOVES-Mexico emissions to year 2016 (ERG, 2017). The  
21 construction of the emissions is described in more detail in the technical support document  
22 Preparation of Emissions Inventories for the Version 7.1 2016 Regional Emissions Modeling  
23 Platform (U.S. EPA, 2019). Emissions totals within the United States are summarized in Table  
24 3C-4 for CO, NH<sub>3</sub>, NO<sub>x</sub>, PM<sub>10</sub>, PM<sub>2.5</sub>, SO<sub>2</sub>, and VOC. Anthropogenic NO<sub>x</sub> emissions in the  
25 2016 platform are about 19% lower than those reported in the 2014 NEI due to both improved  
26 inventory development methods and updates to specific components (e.g., cleaner vehicles  
27 entering the onroad mobile fleet or EGUs transitioning from coal to natural gas).

---

<sup>6</sup> <http://views.cira.colostate.edu/wiki/wiki/9169>

<sup>7</sup> <https://www.epa.gov/air-emissions-modeling/2016-alpha-platform>

<sup>8</sup> <https://www.epa.gov/moves>

**Table 3C-4. Summary of U.S. emissions totals by sector for the 12km CONUS domain (in thousand tons). “NA” indicates not applicable.**

| Sector Abbrev.      | Sector Description                                     | CO     | NH <sub>3</sub> | NO <sub>x</sub> | PM <sub>10</sub> | PM <sub>2.5</sub> | SO <sub>2</sub> | VOC    |
|---------------------|--|--------|-----------------|-----------------|------------------|-------------------|-----------------|--------|
| afdust_adj          | Anthropogenic fugitive dust                            | NA     | NA              | NA              | 6,217            | 874               | NA              | NA     |
| ag                  | Agricultural sources                                   | NA     | 2,777           | NA              | NA               | NA                | NA              | NA     |
| ptagfire            | Agricultural fires                                     | 593    | 80              | 18              | 96               | 68                | 6               | 36     |
| cmv_c1c2            | Category 1 and 2 Commercial Marine Vessels             | 47     | NA              | 260             | 6                | 6                 | NA              | 5      |
| cmv_c3              | Ocean-going (Category 3) Commercial Marine Vessels     | 11     | NA              | 108             | 4                | 4                 | 4               | 5      |
| nonpt               | Nonpoint (area) sources not in other sectors           | 2,681  | 121             | 758             | 609              | 496               | 162             | 3,673  |
| np_oilgas           | Nonpoint oil and gas sources                           | 642    | NA              | 676             | 18               | 17                | 39              | 2,986  |
| nonroad             | Nonroad (off-road) equipment                           | 12,189 | 2               | 1,207           | 122              | 115               | 2               | 1,465  |
| onroad              | Onroad mobile sources                                  | 20,446 | 101             | 4,046           | 273              | 130               | 27              | 1,962  |
| ptfire              | Wild and Prescribed Fires                              | 23,642 | 388             | 333             | 2,415            | 2,046             | 181             | 5,581  |
| ptegu               | Point sources: electric generation units               | 672    | 25              | 1,289           | 171              | 141               | 1,545           | 33     |
| ptnonipm            | Point sources other than electric generating units     | 1,848  | 61              | 1,073           | 407              | 264               | 673             | 809    |
| pt_oilgas           | Oil and gas-related Point Sources                      | 178    | 4               | 360             | 12               | 11                | 42              | 133    |
| rail                | Locomotive emissions                                   | 118    | NA              | 673             | 21               | 19                | 1               | 35     |
| rwc                 | Residential Wood Combustion emissions                  | 2,099  | 15              | 30              | 314              | 314               | 8               | 338    |
| Total anthro        | Total US anthropogenic emissions (including wildfires) | 65,167 | 3,576           | 10,832          | 10,685           | 4,507             | 2,689           | 17,241 |
| beis                | U.S. biogenic emissions                                | 7,297  | NA              | 979             | NA               | NA                | NA              | 42,861 |
| Total with biogenic | Total US emissions including biogenic emissions        | 72,463 | 3,576           | 11,812          | 10,685           | 4,507             | 2,689           | 60,102 |

### 3C.4.1.6 Model Inputs: Boundary and Initial Conditions

Initial and lateral boundary concentrations for the 12 km US2 domain are provided by the hemispheric version of the Community Multi-scale Air Quality model (H-CMAQ) v5.2.1. H-CMAQ was run for 2016 with a horizontal grid resolution of 108 km and 44 vertical layers up to 50 hPa. The H-CMAQ predictions were used to provide one-way dynamic boundary conditions at one-hour intervals. An operational evaluation against sonde and satellite observations showed

that the 2016 H-CMAQ simulation reasonably captured general patterns of O<sub>3</sub> transport within the northern Hemisphere that are relevant for the 12US2 domain (Henderson et al., 2018).

### 3C.4.2 Evaluation of Modeled Ozone Concentrations

In this section we present the results of an evaluation of the CAMx configuration used to produce the air quality results described in Chapter 3. Specifically, we summarize the ability of the CAMx model to reproduce the corresponding 2016 measured O<sub>3</sub> concentrations. This operational evaluation shows that in general for most regions and seasons, the CAMx model predictions for 2016 generally reproduce patterns of observed O<sub>3</sub>. The notable exception to this is a persistent underestimate in winter across almost all regions, particularly at higher latitude sites.

In the following sections we present general model performance statistics and plots for five regions of the U.S. We compare model predictions of maximum daily 8-hr average (MDA8) O<sub>3</sub> concentrations to measurements reported in EPA's AQS. We note that these comparisons are based on MDA8 values calculated across all available modeled CAMx values and all observed (AQS) concentrations, and that these comparisons include buffer sites. Model performance could be different for comparisons without buffer sites, or using the modeled CAMx MDA8 values only when the corresponding observed MDA8 values are available.

The model statistics presented here include mean bias, mean error, normalized mean bias, and normalized mean error as calculated below, where  $n$  represents the total number of observations:

|                       |  |
|-----------------------|--|
| Mean Bias:            | $(\sum \text{modeled} - \text{observed})/n$                        |
| Mean Error:           | $(\sum  \text{modeled} - \text{observed} )/n$                      |
| Normalized Mean Bias: | $(\sum \text{modeled} - \text{observed})/(\sum \text{observed})$   |
| Normalized Mean Error | $(\sum  \text{modeled} - \text{observed} )/(\sum \text{observed})$ |

Our analysis focuses on regional model evaluation statistics from five US regions as well as evaluations of the eight urban study areas included in the exposure and risk analysis – Atlanta, Boston, Dallas, Detroit, Philadelphia, Phoenix, Sacramento, and St. Louis.<sup>9,10</sup> Statistics for CAMx model performance in these regions and urban study areas are shown by season in Table 3C-5 through Table 3C-17 for observed days with MDA8 O<sub>3</sub> values  $\geq 60$  ppb, observed days

---

<sup>9</sup> The five regions are defined as follows: Northeast (Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont), Southeast (Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia), Midwest (Illinois, Indiana, Michigan, Ohio, Wisconsin), Central (Arkansas, Iowa, Kansas, Louisiana, Minnesota, Missouri, Nebraska, Oklahoma, Texas), and West (Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Utah, Wyoming).

<sup>10</sup> Monitoring sites for each urban study area were selected based on core-based statistical area (CBSA) groupings.

with MDA8 O<sub>3</sub> < 60 ppb, and for all observed days. For each of the five regions listed above, spatial plots are provided for each season showing Normalized Mean Bias (NMB) for MDA8 O<sub>3</sub> at individual sites. Summary NMB ranges are included at the bottom of each map showing the min and max values for the season/region across all sites, as well as the 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentile values. Time series plots are provided for MDA8 O<sub>3</sub> in each urban study area for the period from January-December 2016. Hourly time series plots are also provided for one month in each season (January, April, July, October).<sup>11</sup>

#### **3C.4.2.1 Operational Evaluation in the Northeastern U.S.**

Table 3C-5 shows that in the Northeast Region, model mean bias was generally less than 7 ppb and normalized mean bias was less than 15% in most cases. Errors were largest in the winter, with underestimates also extending to the spring. Spatial maps of normalized mean bias are shown in Figure 3C-12 through Figure 3C-15. During the O<sub>3</sub> season performance was best on high O<sub>3</sub> days, particularly in the summer and fall. Two of the eight urban study areas evaluated were in the Northeast: Boston and Philadelphia.

Model performance at the Boston study area monitoring sites (Table 3C-6) was similar to that of the Northeast Region. The time series plots show that the model reasonably reproduces the measured day-to-day variability in MDA8 O<sub>3</sub> concentrations (Figure 3C-16). The underestimate in winter-spring observed in the Northeast region statistics is particularly pronounced in Boston, likely due to its relatively northerly location where seasonal daylight and temperature changes are more exaggerated. Variability of hourly daytime and nighttime O<sub>3</sub> concentrations is generally well modeled in all seasons, again noting the persistent underestimate in January/April. Model characterization of hourly variability is particularly good in July, although peak daytime O<sub>3</sub> is slightly overestimated. Nighttime O<sub>3</sub> is also consistently overestimated in July/October (Figure 3C-17).<sup>12</sup>

Bulk model performance statistics for Philadelphia (Table 3C-7) are again similar to those for the Northeast as a whole, with more moderate performance compared to Boston during both winter (not as poor) and summer/fall (not as good). The spring underestimate present in the Boston comparisons is much smaller for Philadelphia (Figure 3C-18, Figure 3C-19), again suggesting that the winter-spring underestimate is more pronounced at more northerly sites. Philadelphia also exhibits the nighttime overestimates in the July/October hourly comparisons seen in Boston, with slightly higher overestimates of peak July daytime concentrations.


---

<sup>11</sup> Note that the MDA8 and hourly time series show average concentrations across all monitors within each urban study area. The number of monitors included in this average sometimes changes by season since different monitors within each study area take measurements over different periods of the year.

<sup>12</sup> Note that the Y-axis scale for the various time series are not consistent.

**Table 3C-5. CAMx model performance at monitoring sites in the Northeastern U.S.**  
**Statistics shown are mean bias (MB), normalized mean bias (NMB), mean error (ME), and normalized mean error (NME).**


| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 7056       | -6.4     | -21.0   | 7.3      | 23.8    |
|        | Days ≥ 60        | 1          | -26.7    | -42.4   | 26.7     | 42.4    |
|        | All Days         | 7057       | -6.4     | -21.0   | 7.3      | 23.8    |
| Spring | Days < 60        | 7493       | -6.2     | -14.7   | 7.8      | 18.6    |
|        | Days ≥ 60        | 511        | -5.1     | -7.6    | 7.3      | 10.8    |
|        | All Days         | 8004       | -6.1     | -14.0   | 7.7      | 17.8    |
| Summer | Days < 60        | 7385       | 5.0      | 11.8    | 7.7      | 18.1    |
|        | Days ≥ 60        | 870        | 0.8      | 1.2     | 6.7      | 10.2    |
|        | All Days         | 8255       | 4.5      | 10.1    | 7.6      | 16.9    |
| Fall   | Days < 60        | 7612       | 1.3      | 3.9     | 5.6      | 17.6    |
|        | Days ≥ 60        | 135        | -0.9     | -1.4    | 5.4      | 8.1     |
|        | All Days         | 7747       | 1.2      | 3.7     | 5.6      | 17.3    |



Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -55, -26, -22, -16, 14 ]


**Figure 3C-12. Normalized mean bias for MDA8 O<sub>3</sub> in the Northeastern U.S., winter 2016.**






Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -43, -20, -14, -7.1, 23 ]

**Figure 3C-13. Normalized mean bias for MDA8 O<sub>3</sub> in the Northeastern U.S., spring 2016.**



Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -21, 7.8, 17, 28, 85 ]

**Figure 3C-14. Normalized mean bias for MDA8 O<sub>3</sub> in the Northeastern U.S., summer 2016.**




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -37, 4.8, 15, 28, 93 ]


**Figure 3C-15. Normalized mean bias for MDA8 O<sub>3</sub> in the Northeastern U.S., fall 2016.**

**Table 3C-6. CAMx model performance at monitoring sites in the Boston study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 1346       | -8.4     | -25.6   | 8.9      | 27.2    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 1346       | -8.4     | -25.6   | 8.9      | 27.2    |
| Spring | Days < 60        | 82         | -9.1     | -21.3   | 9.9      | 23.3    |
|        | Days ≥ 60        | 1476       | -8.6     | -12.6   | 10.4     | 15.2    |
|        | All Days         | 1558       | -9.0     | -20.6   | 9.9      | 22.6    |
| Summer | Days < 60        | 1484       | 3.6      | 9.0     | 6.2      | 15.7    |
|        | Days ≥ 60        | 146        | 1.2      | 1.8     | 5.9      | 8.9     |
|        | All Days         | 1630       | 3.3      | 8.0     | 6.2      | 14.8    |
| Fall   | Days < 60        | 1482       | -0.6     | -1.8    | 5.4      | 17.4    |
|        | Days ≥ 60        | 8          | 0.3      | 0.43    | 5.4      | 8.4     |
|        | All Days         | 1490       | -0.6     | -1.8    | 5.4      | 17.3    |




**Figure 3C-16. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at Boston monitoring sites in 2016.**



**Figure 3C-17. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at Boston monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**


**Table 3C-7. CAMx model performance at monitoring sites in the Philadelphia study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 2151       | -5.0     | -17.9   | 6.1      | 21.7    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 2151       | -5.0     | -17.9   | 6.1      | 21.7    |
| Spring | Days < 60        | 2328       | -4.5     | -10.9   | 6.6      | 16.0    |
|        | Days ≥ 60        | 150        | -3.0     | -4.4    | 5.1      | 7.5     |
|        | All Days         | 2478       | -4.4     | -10.3   | 6.5      | 15.2    |
| Summer | Days < 60        | 2229       | 6.7      | 14.7    | 9.1      | 20.2    |
|        | Days ≥ 60        | 352        | 1.0      | 1.5     | 6.8      | 10.3    |
|        | All Days         | 2581       | 5.9      | 12.3    | 8.8      | 18.3    |
| Fall   | Days < 60        | 2333       | 1.9      | 5.9     | 5.7      | 17.7    |
|        | Days ≥ 60        | 71         | -1.0     | -1.4    | 5.2      | 7.7     |
|        | All Days         | 2404       | 1.8      | 5.5     | 5.7      | 17.1    |



**Figure 3C-18. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at Philadelphia monitoring sites in 2016.**





**Figure 3C-19. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at Philadelphia monitoring sites for January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**


### 3C.4.2.2 Operational Evaluation in the Southeastern U.S.

In the Southeast region, mean bias for MDA8 O<sub>3</sub> was generally less than ~5 ppb at most sites in all seasons, as indicated in Table 3C-8. The exception is winter, where there were only four days with measured MDA8 > 60 ppb and all were largely underpredicted. Spatial maps of normalized mean bias are shown in Figure 3C-20 through Figure 3C-23. Performance was best in the spring (slightly underestimated) and on high O<sub>3</sub> days in the summer/fall. Atlanta was the only one of the eight urban study areas located in the Southeast region.

Mean bias and normalized mean bias at Atlanta sites for the spring, summer, and fall months were typical of performance throughout the Southeast region, with much better performance in winter. The MDA8 O<sub>3</sub> time series (Figure 3C-24) shows that the model reasonably represents the variability occurring on high and low O<sub>3</sub> concentration days. The hourly time series plots (Figure 3C-25) also show reasonable model performance during daytime hours but some persistent overestimates of both nighttime and peak daytime O<sub>3</sub> occur, especially in July.


**Table 3C-8. CAMx model performance at monitoring sites in the Southeastern U.S.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 3775       | -3.2     | -9.2    | 5.3      | 15.4    |
|        | Days ≥ 60        | 4          | -27.2    | -40.6   | 27.2     | 40.6    |
|        | All Days         | 3779       | -3.2     | -9.2    | 5.3      | 15.4    |
| Spring | Days < 60        | 7193       | -0.6     | -1.4    | 5.2      | 11.7    |
|        | Days ≥ 60        | 468        | -2.6     | -4.0    | 5.0      | 7.8     |
|        | All Days         | 7661       | -0.7     | -1.6    | 5.2      | 11.3    |
| Summer | Days < 60        | 7825       | 5.2      | 13.9    | 7.6      | 20.2    |
|        | Days ≥ 60        | 396        | 0.4      | 0.6     | 6.2      | 9.5     |
|        | All Days         | 8221       | 5.0      | 12.8    | 7.5      | 19.3    |
| Fall   | Days < 60        | 6456       | 3.4      | 8.7     | 6.0      | 15.5    |
|        | Days ≥ 60        | 139        | 0.6      | 0.9     | 4.8      | 7.6     |
|        | All Days         | 6595       | 3.3      | 8.4     | 6.0      | 15.2    |




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -32, -9.6, -1.8, 7.6, 51 ]

**Figure 3C-20. Normalized mean bias for MDA8 O<sub>3</sub> in the Southeastern U.S., winter 2016.**



Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -18, -1.4, 5.1, 13, 44 ]


**Figure 3C-21. Normalized mean bias for MDA8 O<sub>3</sub> in the Southeastern U.S., spring 2016.**



Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -22, 16, 27, 39, 130 ]

**Figure 3C-22. Normalized mean bias for MDA8 O<sub>3</sub> in the Southeastern U.S., summer 2016.**






Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -12, 12, 29, 44, 120 ]


**Figure 3C-23. Normalized mean bias for MDA8 O<sub>3</sub> in the Southeastern U.S., fall 2016.**

**Table 3C-9. CAMx model performance at monitoring sites in the Atlanta study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 91         | -0.9     | -3.3    | 3.4      | 12.4    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 91         | -0.9     | -3.3    | 3.4      | 12.4    |
| Spring | Days < 60        | 747        | 1.4      | 3.1     | 4.7      | 10.6    |
|        | Days ≥ 60        | 54         | -1.4     | -2.1    | 4.9      | 7.3     |
|        | All Days         | 801        | 1.2      | 2.6     | 4.7      | 10.3    |
| Summer | Days < 60        | 717        | 5.4      | 13.4    | 6.9      | 17.1    |
|        | Days ≥ 60        | 93         | -1.1     | -1.6    | 6.0      | 8.9     |
|        | All Days         | 810        | 4.7      | 10.7    | 6.8      | 15.6    |
| Fall   | Days < 60        | 520        | 5.6      | 12.8    | 6.5      | 15.1    |
|        | Days ≥ 60        | 26         | 3.8      | 6.0     | 5.2      | 8.2     |
|        | All Days         | 546        | 5.5      | 12.4    | 6.5      | 14.6    |



**Figure 3C-24. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at Atlanta monitoring sites in 2016.**



**Figure 3C-25. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at Atlanta monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**


### 3C.4.2.3 Operational Evaluation in the Midwest U.S.

Mean bias for MDA8 O<sub>3</sub> in the Midwest region was around 6 ppb or less at most sites for all seasons (Table 3C-10), except for high O<sub>3</sub> days in spring. Normalized mean bias for MDA8 O<sub>3</sub> was less than 15%, except in the winter when it was somewhat higher (~20%). Normalized mean error was lowest on high O<sub>3</sub> days in spring, summer, and fall, even though bias performance was not notably better during these times. No distinct spatial patterns are apparent from the maps of normalized mean bias (Figure 3C-26 through Figure 3C-29). Detroit was the only one of the eight urban study areas located in the Midwest.

Detroit performance statistics for MDA8 O<sub>3</sub> were similar to those from the rest of the Midwest. However, under-estimates on high O<sub>3</sub> days were more pronounced in Detroit than in the rest of the region. The time series shows that the model accurately estimates both day and nighttime hourly O<sub>3</sub> in Detroit in April and July and generally captures the variations in MDA8 O<sub>3</sub> throughout the year, although the persistent under-estimate in winter-spring is evident (Figure 3C-30, Figure 3C-31).


**Table 3C-10. CAMx model performance at monitoring sites in the Midwest U.S.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 1775       | -5.8     | -20.2   | 6.4      | 22.4    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 1775       | -5.8     | -20.2   | 6.4      | 22.4    |
| Spring | Days < 60        | 3635       | -5.9     | -14.1   | 7.6      | 18.1    |
|        | Days ≥ 60        | 370        | -8.3     | -12.5   | 9.2      | 14.0    |
|        | All Days         | 4005       | -6.1     | -13.9   | 7.8      | 17.6    |
| Summer | Days < 60        | 4680       | 3.3      | 7.8     | 7.4      | 17.8    |
|        | Days ≥ 60        | 556        | -4.9     | -7.3    | 8.6      | 12.8    |
|        | All Days         | 5236       | 2.4      | 5.4     | 7.6      | 17.0    |
| Fall   | Days < 60        | 3439       | 2.2      | 6.7     | 5.1      | 15.3    |
|        | Days ≥ 60        | 51         | 3.3      | 5.1     | 5.6      | 8.6     |
|        | All Days         | 3490       | 2.3      | 6.7     | 5.1      | 15.1    |




**Figure 3C-26. Normalized mean bias for MDA8 O<sub>3</sub> in the Midwest U.S., winter 2016.**






Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -38, -18, -11, -4, 27 ]

**Figure 3C-27. Normalized mean bias for MDA8 O<sub>3</sub> in the Midwest U.S., spring 2016.**



Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -20, 4.4, 11, 22, 87 ]

**Figure 3C-28. Normalized mean bias for MDA8 O<sub>3</sub> in the Midwest U.S., summer 2016.**




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -14, 10, 20, 31, 130 ]


**Figure 3C-29. Normalized mean bias for MDA8 O<sub>3</sub> in the Midwest U.S., fall 2016.**

**Table 3C-11. CAMx model performance at monitoring sites in the Detroit study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 29         | -4.1     | -19.5   | 5.9      | 26.3    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 29         | -4.1     | -19.5   | 5.9      | 26.3    |
| Spring | Days < 60        | 337        | -6.5     | -15.8   | 8.3      | 20.0    |
|        | Days ≥ 60        | 28         | -9.4     | -13.5   | 10.0     | 14.4    |
|        | All Days         | 365        | -6.7     | -15.5   | 8.4      | 19.3    |
| Summer | Days < 60        | 485        | 2.0      | 4.7     | 6.8      | 16.1    |
|        | Days ≥ 60        | 59         | -5.3     | -8.1    | 7.9      | 12.1    |
|        | All Days         | 544        | 1.2      | 2.7     | 6.9      | 15.5    |
| Fall   | Days < 60        | 245        | 3.1      | 9.7     | 5.6      | 17.2    |
|        | Days ≥ 60        | 3          | -4.1     | -6.7    | 4.1      | 6.7     |
|        | All Days         | 248        | 3.0      | 9.3     | 5.5      | 17.0    |



**Figure 3C-30. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at Detroit monitoring sites in 2016.**



**Figure 3C-31. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at Detroit monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**

#### 3C.4.2.4 Operational Evaluation in the Central U.S.

Mean bias for MDA8 O<sub>3</sub> concentrations in the Central U.S. is within 4 ppb, except for high days in winter (-6 ppb) and spring (-7 ppb) (Table 3C-12). Normalized mean error is within 15%, except for days < 60 ppb in winter and summer (~18%). Spatial maps of normalized mean bias are shown in Figure 3C-32 through Figure 3C-35. Overall performance is best on lower O<sub>3</sub> days in spring and high O<sub>3</sub> days in summer and fall. St. Louis and Dallas were the only two of the eight study areas which are located in the Central U.S. region.


St. Louis mean bias for MDA8 was within 5 ppb for all days and seasons. A north-south gradient in NMB is apparent during both the winter and spring seasons in the maps shown in Figure 3C-32 and Figure 3C-33, with larger underestimates visible at higher latitude/more northerly monitors. Overall performance for St. Louis was best on high O<sub>3</sub> days in summer. The MDA8 time series shows reasonable agreement between CAMx and the monitor data for most of the year (Figure 3C-36), with underestimates in January and overestimates in July also apparent in the hourly time series (Figure 3C-37).



Performance statistics for MDA8 O<sub>3</sub> in Dallas were better than those for the broader region, with mean bias less than 5 ppb and normalized mean error just at or below 15% for all days and seasons. The MDA8 and hourly time series also show excellent model performance, with slightly underestimated peak day time O<sub>3</sub> in January (Figure 3C-38, Figure 3C-39). Overestimates of night-time O<sub>3</sub> in April and October, although these overpredictions are less pronounced in Dallas compared to many of the other urban study areas examined in the assessment.


**Table 3C-12. CAMx model performance at monitoring sites in the Central U.S.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 4550       | -4.0     | -12.2   | 5.8      | 18.0    |
|        | Days ≥ 60        | 7          | -5.7     | -9.2    | 9.1      | 14.5    |
|        | All Days         | 4557       | -4.0     | -12.2   | 5.8      | 18.0    |
| Spring | Days < 60        | 7086       | -1.7     | -3.9    | 6.2      | 14.4    |
|        | Days ≥ 60        | 324        | -7.0     | -10.9   | 7.8      | 12.2    |
|        | All Days         | 7410       | -1.9     | -4.3    | 6.2      | 14.3    |
| Summer | Days < 60        | 8234       | 3.8      | 9.6     | 7.0      | 17.9    |
|        | Days ≥ 60        | 346        | -2.7     | -4.2    | 7.0      | 10.8    |
|        | All Days         | 8580       | 3.5      | 8.7     | 7.0      | 17.4    |
| Fall   | Days < 60        | 7109       | 2.6      | 7.4     | 5.1      | 14.6    |
|        | Days ≥ 60        | 124        | -1.8     | -2.8    | 5.3      | 8.2     |
|        | All Days         | 7233       | 2.5      | 7.1     | 5.1      | 14.4    |




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
[ -44, -13, -7.4, 1.6, 36 ]

**Figure 3C-32. Normalized mean bias for MDA8 O<sub>3</sub> in the Central U.S., winter 2016.**




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -28, -7.6, -0.93, 6.6, 41 ]

1  
 2 **Figure 3C-33. Normalized mean bias for MDA8 O<sub>3</sub> in the Central U.S., spring 2016.**



Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -21, 6.9, 16, 24, 72 ]

3  
 4 **Figure 3C-34. Normalized mean bias for MDA8 O<sub>3</sub> in the Central U.S., summer 2016.**




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
[ -9.1, 9.8, 19, 28, 75 ]

**Figure 3C-35. Normalized mean bias for MDA8 O<sub>3</sub> in the Central U.S., fall 2016.**


**Table 3C-13. CAMx model performance at monitoring sites in the Saint Louis study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 181        | -5.9     | -20.9   | 6.5      | 23.1    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 181        | -5.9     | -20.9   | 6.5      | 23.1    |
| Spring | Days < 60        | 756        | -3.5     | -7.8    | 6.1      | 13.7    |
|        | Days ≥ 60        | 63         | -7.2     | -11.2   | 7.3      | 11.3    |
|        | All Days         | 819        | -3.7     | -8.1    | 6.2      | 13.4    |
| Summer | Days < 60        | 1061       | 5.8      | 13.7    | 8.4      | 19.6    |
|        | Days ≥ 60        | 121        | -1.1     | -1.6    | 8.1      | 12.1    |
|        | All Days         | 1182       | 5.1      | 11.4    | 8.4      | 18.5    |
| Fall   | Days < 60        | 773        | 3.9      | 11.1    | 5.7      | 16.1    |
|        | Days ≥ 60        | 35         | 3.5      | 5.1     | 5.0      | 7.3     |
|        | All Days         | 808        | 3.9      | 10.6    | 5.7      | 15.4    |



**Figure 3C-36. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at St. Louis monitoring sites in 2016.**







**Figure 3C-37. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at St. Louis monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**

**Table 3C-14. CAMx model performance at monitoring sites in the Dallas study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 625        | -3.2     | -9.9    | 4.8      | 14.9    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 625        | -3.2     | -9.9    | 4.8      | 14.9    |
| Spring | Days < 60        | 697        | 0.8      | 1.8     | 5.8      | 13.5    |
|        | Days ≥ 60        | 21         | -4.9     | -7.7    | 5.4      | 8.6     |
|        | All Days         | 718        | 0.6      | 1.4     | 5.7      | 13.3    |
| Summer | Days < 60        | 700        | 2.1      | 5.4     | 5.9      | 15.4    |
|        | Days ≥ 60        | 25         | -2.8     | -4.0    | 6.5      | 9.4     |
|        | All Days         | 725        | 1.9      | 4.8     | 5.9      | 15.1    |
| Fall   | Days < 60        | 697        | 1.4      | 3.7     | 4.5      | 11.9    |
|        | Days ≥ 60        | 23         | -3.6     | -5.5    | 4.7      | 7.1     |
|        | All Days         | 720        | 1.3      | 3.2     | 4.5      | 11.6    |



**Figure 3C-38. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at Dallas monitoring sites in 2016.**



**Figure 3C-39. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at Dallas monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**

### 3C.4.2.5 Operational Evaluation in the Western U.S.

Model statistics for MDA8 O<sub>3</sub> in the Western U.S. are best on low O<sub>3</sub> days in summer and fall (Table 3C-15). High wintertime observations were substantially underestimated by the model with an average MB of -26 but likely for different reasons. The high days in Riverside California are probably due to traditionally understood O<sub>3</sub> formation that occurs on warm sunny days. The high O<sub>3</sub> concentrations in Wyoming are an example of wintertime O<sub>3</sub> formation that occurs during cold pool meteorology events which have substantial snow cover and extreme temperature inversions and are still an active area of research. Some spatial patterns in normalized mean bias are apparent in the winter and in the summer (Figure 3C-40 through Figure 3C-43), with overestimates on the West Coast and underestimates in the Intermountain West. Two urban study areas are located in the Western U.S. and are evaluated in this section: Sacramento and Phoenix.

The model performance for MDA8 O<sub>3</sub> values in the Sacramento study area was best on lower O<sub>3</sub> days in summer and fall (Figure 3C-44). In Sacramento there were no days during the


winter with measured MDA8 O<sub>3</sub> > 60 ppb. Normalized mean error is at or below 15% for all seasons except winter. Hourly time series show good agreement in Sacramento, except for winter when the model does not capture very much of the day to day variability in O<sub>3</sub> concentrations (Figure 3C-45).

While normalized mean error was at or less than 15% in Phoenix on all days in all seasons, the MDA8 time series shows frequent underestimates in winter-spring as well as overestimates in summer-fall (Figure 3C-46). The hourly time series also show that though the model captures some of the overnight O<sub>3</sub> patterns in Phoenix, night time O<sub>3</sub> is significantly overestimated, particularly in January and October (Figure 3C-47).

**Table 3C-15. CAMx model performance at monitoring sites in the Western U.S.**


|        |           | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|-----------|------------|----------|---------|----------|---------|
| Winter | Days < 60 | 15888      | -2.8     | -8.2    | 6.0      | 18.1    |
|        | Days ≥ 60 | 113        | -25.8    | -35.7   | 25.8     | 35.7    |
|        | All Days  | 16001      | -2.9     | -8.7    | 6.2      | 18.4    |
| Spring | Days < 60 | 15789      | -4.6     | -10.3   | 6.5      | 14.6    |
|        | Days ≥ 60 | 1471       | -9.5     | -14.7   | 10.0     | 15.4    |
|        | All Days  | 17260      | -5.0     | -10.8   | 6.8      | 14.7    |
| Summer | Days < 60 | 13254      | 1.2      | 2.6     | 6.7      | 14.9    |
|        | Days ≥ 60 | 4461       | -6.6     | -9.5    | 9.5      | 13.7    |
|        | All Days  | 17715      | -0.8     | -1.6    | 7.4      | 14.5    |
| Fall   | Days < 60 | 15975      | 0.7      | 1.9     | 5.4      | 14.5    |
|        | Days ≥ 60 | 795        | -9.2     | -13.6   | 10.7     | 15.8    |
|        | All Days  | 16770      | 0.2      | 0.6     | 5.6      | 14.6    |






Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
[ -47, -12, 8.3, 27, 110 ]

**Figure 3C-40. Normalized mean bias for MDA8 O<sub>3</sub> in the Western U.S., winter 2016.**




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
[ -60, -12, -5.7, 3.1, 82 ]

**Figure 3C-41. Normalized mean bias for MDA8 O<sub>3</sub> in the Western U.S., spring 2016.**



Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -55, -5.2, 3.2, 16, 90 ]

**Figure 3C-42. Normalized mean bias for MDA8 O<sub>3</sub> in the Western U.S., summer 2016.**




Bias Summary: [ min, 25th %, 50th %, 75th %, max ]  
 [ -57, 1.5, 16, 30, 120 ]

**Figure 3C-43. Normalized mean bias for MDA8 O<sub>3</sub> in the Western U.S., fall 2016.**


**Table 3C-16. CAMx model performance at monitoring sites in the Sacramento study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 2359       | -0.9     | -3.2    | 5.5      | 18.9    |
|        | Days ≥ 60        | 0          | NA       | NA      | NA       | NA      |
|        | All Days         | 2359       | -0.9     | -3.2    | 5.5      | 18.9    |
| Spring | Days < 60        | 2474       | -3.2     | -7.9    | 5.6      | 13.6    |
|        | Days ≥ 60        | 116        | -8.1     | -12.6   | 9.4      | 14.6    |
|        | All Days         | 2590       | -3.5     | -8.2    | 5.8      | 13.7    |
| Summer | Days < 60        | 2157       | 0.6      | 1.3     | 5.8      | 13.7    |
|        | Days ≥ 60        | 628        | -7.3     | -10.8   | 8.8      | 13.0    |
|        | All Days         | 2785       | -1.2     | -2.5    | 6.5      | 13.5    |
| Fall   | Days < 60        | 2503       | 0.5      | 1.3     | 5.5      | 15.2    |
|        | Days ≥ 60        | 160        | -7.7     | -11.2   | 10.0     | 14.7    |
|        | All Days         | 2663       | 0.0      | 0.0     | 5.7      | 15.1    |

**AQS MDA8 Comparison for Sacramento Monitors in 2016**



**Figure 3C-44. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at Sacramento monitoring sites in 2016.**




**Figure 3C-45. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at Sacramento monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**


**Table 3C-17. CAMx model performance at monitoring sites in the Phoenix study area.**

| Season | MDA8 level (ppb) | No. of obs | MB (ppb) | NMB (%) | ME (ppb) | NME (%) |
|--------|------------------|------------|----------|---------|----------|---------|
| Winter | Days < 60        | 1292       | -3.5     | -9.8    | 5.3      | 15.0    |
|        | Days ≥ 60        | 3          | -5.9     | -9.7    | 5.9      | 9.7     |
|        | All Days         | 1295       | -3.5     | -9.8    | 5.3      | 14.9    |
| Spring | Days < 60        | 265        | -5.6     | -10.9   | 6.8      | 13.3    |
|        | Days ≥ 60        | 1082       | -8.5     | -13.3   | 9.6      | 14.9    |
|        | All Days         | 1347       | -6.2     | -11.5   | 7.4      | 13.7    |
| Summer | Days < 60        | 974        | -2.1     | -4.2    | 6.5      | 13.0    |
|        | Days ≥ 60        | 346        | -4.7     | -7.3    | 8.5      | 13.0    |
|        | All Days         | 1320       | -2.8     | -5.2    | 7.1      | 13.0    |
| Fall   | Days < 60        | 1278       | 2.6      | 6.7     | 6.1      | 15.4    |
|        | Days ≥ 60        | 5          | -3.8     | -6.2    | 5.4      | 8.7     |
|        | All Days         | 1283       | 2.6      | 6.6     | 6.1      | 15.4    |





**Figure 3C-46. Time series of monitored (black) and modeled (red) MDA8 O<sub>3</sub> at Phoenix monitoring sites in 2016.**



**Figure 3C-47. Time series of monitored (black) and modeled (red) hourly O<sub>3</sub> concentrations at Phoenix monitoring sites in January (top left), April (top right), July (bottom left), and October (bottom right) 2016.**

## **3C.5 AIR QUALITY ADJUSTMENT TO MEET CURRENT AND ALTERNATIVE AIR QUALITY SCENARIOS**

### **3C.5.1 Overview of the Higher Order Direct Decoupled Method (HDDM)**

In this section we present a model-based O<sub>3</sub> adjustment methodology that allows for adjustments to observed hourly O<sub>3</sub> concentrations to reflect the expected impacts of changes in NO<sub>x</sub> emissions. This methodology uses the CAMx model, described above in section 3C.4, instrumented with the Higher order Decoupled Direct Method (HDDM) - a tool that generates modeled sensitivities of O<sub>3</sub> to emissions changes. The outputs of the HDDM are used to estimate the distribution of O<sub>3</sub> concentrations associated with just meeting three air quality scenarios (O<sub>3</sub> monitor design values of 75 ppb, 70 ppb, and 65 ppb) within multiple urban study areas. The HDDM sensitivities are applied to ambient air measurements of O<sub>3</sub> to estimate how O<sub>3</sub> concentrations would respond to changes in U.S. anthropogenic emissions. This approach, based on Simon et al. (2013), was applied previously for the 2015 O<sub>3</sub> NAAQS review.

The CAMx photochemical modeling incorporates emissions from non-anthropogenic sources and anthropogenic emissions from sources in the U.S and in the portions of Canada and Mexico within the regional modeling domain. Pollution from sources in other locations within and outside of North America is included as transport into the boundary of the modeling domain.

### 3C.5.1.1 Capabilities

Chemical transport models, such as CAMx, simulates physical and chemical processes in the atmosphere to predict 3-dimensional (3-D) gridded pollutant concentrations. These models account for the impacts of emissions, transport, chemistry, and deposition on spatially and temporally varying pollutant concentrations. Required model inputs include time-varying emissions and meteorology fields, time varying concentrations of pollutants at the boundaries of the model domain (i.e. boundary conditions), and a characterization of the 3-D field of chemical concentrations to initialize the model (i.e. initial conditions).

Beyond modeling the ambient air concentrations of O<sub>3</sub>, chemical transport models can be used to estimate the response of ambient air O<sub>3</sub> concentrations to changes in emissions. One technique to simulate the response of O<sub>3</sub> to emissions changes, the brute force method, requires the modeler to explicitly model this response by directly altering the emissions inputs in the model simulation. This technique provides an estimate of the O<sub>3</sub> concentration at the altered emission level, but often does not provide accurate information regarding the response of O<sub>3</sub> to other levels of emissions since the chemistry for O<sub>3</sub> formation is nonlinear. Therefore, when using only the brute force method, a new model simulation would need to be performed for every emissions scenario under consideration.

Other analytical techniques have been developed to estimate the O<sub>3</sub> response to emission perturbations without performing multiple simulations. One such method is termed the Decoupled Direct Method (DDM) (Dunker, 1984). DDM, solves for sensitivity coefficients which are defined as the partial derivative of the atmospheric diffusion equations that underly the model calculations, Equations (3C-1) and (3C-2).

$$s_{ij}(t) = \frac{\partial C_i(t)}{\partial p_j}$$

Equation (3C-1)

$$s_{ij}(t) = \tilde{P}_j \frac{\partial C_i(t)}{\partial p_j} = \tilde{P}_j \frac{\partial C_i(t)}{\partial (\epsilon_j \tilde{P}_j)} = \frac{\partial C_i(t)}{\partial \epsilon_j}$$

Equation (3C-2)

Here,  $S_{ij}(t)$ , the sensitivity, gives the change in model concentration,  $C_i$ , (for instance  $O_3$  concentration) with an incremental change in any input parameter,  $p_j$  (in this case emissions). Equation (3C-2) allows us to normalize the sensitivity coefficient,  $S_{ij}(t)$ , so that it shows response in relative terms for the input rather than in absolute units. Therefore,  $\tilde{P}_j(x,t)$  is the normalized input and  $\epsilon_j$  is a scaling variable (Yang et al., 1997). In general terms, the sensitivity coefficient tells us how a model output ( $O_3$  concentration) will change if a model input (emissions of  $NO_x$  or VOC) is perturbed. This first order sensitivity coefficient,  $S_{ij}(t)$  is quite suitable for small perturbations, but gives a linear response which is unlikely to represent the results of large perturbations in very nonlinear chemical environments. Second (and third) order derivatives can be calculated to give higher order sensitivity coefficients (Hakami et al., 2003). Higher order sensitivity coefficients give the curvature and inflection points for the response curve and can capture the nonlinearities in the response of  $O_3$  to emissions changes. Using Higher order DDM (HDDM) allows for the sensitivities to be more appropriately applied over larger emissions perturbations. Hakami et al. (2003) report that for an application in California, HDDM gave reasonable approximations of  $O_3$  changes compared to that generated using brute force emissions reductions of up to 50% using the first three terms of the Taylor series expansion, Equation (3C-3).

$$C(+\Delta\epsilon) = C(0) + \Delta\epsilon S(0) + \frac{\Delta\epsilon^2}{2} S^2(0) + \dots + \frac{\Delta\epsilon^n}{n!} S^n(0) + R_{n+1}$$

Equation (3C-3)

Here  $\Delta\epsilon$  represents the relative change in emissions (for instance  $\Delta\epsilon = -0.2$  would be equivalent to reducing emissions by 20%),  $S^n(0)$  is the  $n^{\text{th}}$  order sensitivity coefficient,  $C(0)$  is the concentration under baseline conditions (no perturbation in emissions) and  $R_{n+1}$  is a remainder term.

A variant of DDM called DDM-3D has been implemented into several chemical transport models, including CAMx, for both  $O_3$  and particulate matter (PM) predictions (Cohan et al., 2005, Hakami et al., 2003, Napelenok et al., 2011, Dunker, 1984, Yang et al., 1997, Koo et al., 2007, Zhang et al., 2012). These implementations allow the modeler to define the parameters for which first and higher order sensitivities will be calculated. For instance, the sensitivity can be calculated for emissions from a specific source type, for emissions in a specific geographic region, and for emissions of a single  $O_3$  precursor or for multiple  $O_3$  precursors. In addition, sensitivities can be calculated to boundary conditions, initial conditions, and various other model inputs. Sensitivities to different sets of parameters can be calculated in a single model simulation



1 but computation time increases as the number of sensitivities increases. Outputs from an HDDM  
2 simulation consist of time varying 3-D fields of first and second order sensitivities.

### 3 **3C.5.1.2 Limitations**

4 For the purposes of the O<sub>3</sub> NAAQS analysis, an HDDM-based approach is well-suited  
5 given its ability to 1) capture the non-linearity of O<sub>3</sub> response to emissions changes, 2)  
6 characterize different O<sub>3</sub> responses at different locations (downtown urban versus downwind  
7 suburban) and at different times of day, allowing us to incorporate temporal and spatial  
8 variations in response into the O<sub>3</sub> adjustment methodology, and 3) explicitly account for physical  
9 and chemical processes influencing predicted sensitivities such as background O<sub>3</sub> sources.  
10 However, in addition to the many potential benefits of using HDDM to understand and  
11 characterize O<sub>3</sub> response to emissions changes, there are several limitations.

12 First, HDDM encompasses all of the uncertainties of the base photochemical model  
13 formulation and inputs. So, uncertainties in how the physical and chemical processes are treated  
14 in the model and in the model inputs propagate to the HDDM results. Also, HDDM can capture  
15 response to larger emissions perturbations than DDM but it is still most accurate for small  
16 perturbations. The larger the relative change in emissions, the less likely that the HDDM  
17 sensitivities will properly capture the change in O<sub>3</sub> that would be predicted by using brute force  
18 emission reductions. Several studies have reported reasonable performance of HDDM for O<sub>3</sub> up  
19 to 50% emissions perturbations (Hakami et al., 2004, Hakami et al., 2003, Cohan et al., 2005),  
20 but the magnitude of perturbation over which HDDM will give accurate estimates will depend on  
21 the specific modeling episode, size of the model domain, emissions and meteorological inputs,  
22 and the size of the emissions source to which the sensitivity is being calculated. In this work, we  
23 applied sensitivities derived from model simulations done under varying NO<sub>x</sub> levels (see section  
24 3C.5.2.2) and found that using this technique we were able to replicate O<sub>3</sub> concentrations  
25 estimated using brute force emission reductions with HDDM sensitivities for up to 90% NO<sub>x</sub>  
26 emissions reductions with a mean bias of less than 3 ppb and a mean error of less than 4 ppb.

## 27 **3C.5.2 Using CAMx/HDDM to Adjust Monitored Ozone Concentrations**

### 28 **3C.5.2.1 Conceptual Framework**

29 This section outlines the methodology in which we apply CAMx/HDDM to estimate  
30 hourly O<sub>3</sub> concentrations that might result from just meeting three air quality scenarios (75 ppb,  
31 70 ppb, and 65 ppb). These methods closely follow those documented in Simon et al. (2013) and  
32 the risk and exposure assessment performed in the 2015 O<sub>3</sub> NAAQS review (U.S. EPA, 2014).  
33 As part of the methodology, photochemical modeling results are not used in an absolute sense,


but instead are applied to modulate ambient air measurements, thus tying estimated O<sub>3</sub> distributions to measured values. The basic steps are outlined below and in Figure 3C-48.

**Step 1:** Run CAMx simulation with HDDM to determine hourly O<sub>3</sub> sensitivities to NO<sub>x</sub> emissions changes for the grid cells containing monitoring sites in an urban study area.

**Step 2:** For each monitoring site, season, and hour of the day use linear regression to relate first order sensitivities of NO<sub>x</sub> ( $S_{NOx}$ ) to modeled O<sub>3</sub> and second order sensitivities of NO<sub>x</sub> ( $S^2_{NOx}$ ) to the first order sensitivities.

**Step 3:** For each measured hourly O<sub>3</sub> value, calculate the first and second order sensitivities based on monitoring site-, season-, and hour-specific functions calculated in Step 2.

**Step 4:** Adjust measured hourly 2015-2017 O<sub>3</sub> concentrations for incrementally increasing levels of emissions reductions using assigned sensitivities, then recalculate 2015-2017 design values until all monitors in the urban study area just meet the levels of the air quality scenario.



**Figure 3C-48. Flow diagram demonstrating HDDM model-based O<sub>3</sub> adjustment approach.**

### 3C.5.2.2 Application to Measured O<sub>3</sub> Concentrations in Urban Study Areas

The model-based adjustment approach described above was applied to the eight urban study areas (Atlanta, Boston, Dallas, Detroit, Philadelphia, Phoenix, Sacramento, and St. Louis) for an air quality scenario adjusted to just meet the current standard of 70 ppb and two alternative air quality scenarios having design values of 75 ppb and 65 ppb. The analysis used CAMx photochemical modeling for January-December of 2016 and ambient air data for the years 2015-2017. When running CAMx with HDDM, additional information is required to designate model inputs for calculating sensitivities. In this analysis, HDDM was set up to calculate the sensitivity of O<sub>3</sub> concentrations to U.S. anthropogenic NO<sub>x</sub> emissions.<sup>13</sup>

U.S. anthropogenic emissions were defined as all emissions in the following sectors: commercial marine, rail, residential wood combustion, agricultural fires, onroad mobile, offroad mobile, EGU point sources, oil and natural gas point, non-EGU point, non-point oil and gas, and non-point area. These anthropogenic sectors account for 10.5 million of the total CONUS-wide 11.8 million tons per year of NO<sub>x</sub> emissions in 2016 (the remaining 1.3 million tons are from biogenics and wildland fires, which included prescribed burns). Sensitivities were not calculated for biogenic, wildland fire, Canadian, or Mexican emissions. In addition, sensitivities were not calculated for any emissions originating from outside the domain (i.e., entering through the use of boundary concentrations).

#### 3C.5.2.2.1 Multi-step Application of HDDM Sensitivities

As discussed in section 3C.5.1.2 of this appendix, HDDM has been reported to reasonably replicate brute force emissions reductions up to a 50% change in emissions. For this analysis, it was desirable to have confidence that the HDDM sensitivities could replicate the entire range of emissions reductions. Evaluations of the HDDM estimated O<sub>3</sub> concentrations compared to that estimated from brute force emissions reduction model runs confirm that the HDDM estimates of O<sub>3</sub> response to NO<sub>x</sub> reductions are fairly comparable for a 50% change. However, O<sub>3</sub> concentrations estimated from the HDDM sensitivities and the brute force method begin to diverge in comparisons under larger emissions changes (90%). Consequently, two additional CAMx/HDDM runs were performed under different levels of NO<sub>x</sub> emissions reductions in order to characterize O<sub>3</sub> sensitivities to NO<sub>x</sub> reductions over a larger range of emissions perturbations. One CAMx/HDDM simulation was performed with U.S. anthropogenic

---

<sup>13</sup> Sensitivities were only assessed using U.S. emissions in the contiguous 48 states. We did not assess responses to VOC emission reductions in this analysis as a means to reduce computational costs because none of the urban study areas considered here required VOC emission reductions to achieve the lower design values in the air quality scenarios simulated in the 2014 HREA.

NO<sub>x</sub> emissions reduced by 50%. A second additional simulation was performed with a 90% NO<sub>x</sub> reduction. Emissions of other species were not modified from the base case in these two additional simulations. These additional HDDM simulations provide O<sub>3</sub> sensitivities to NO<sub>x</sub> under chemical regimes with lower NO<sub>x</sub> emissions. The sensitivities are used in a multistep adjustment approach, as described in the following sections.

Figure 3C-49 provides a conceptual picture of the multistep adjustment procedure using first-order sensitivities. Sensitivities from the base run are used to adjust O<sub>3</sub> concentrations for NO<sub>x</sub> emissions reductions up to X%. Additional emission reductions beyond X% use sensitivities from the 50% NO<sub>x</sub> cut run until reductions exceed (X+Y)%. Finally, sensitivities from the 90% NO<sub>x</sub> emissions reduction run are applied for any emission reductions beyond (X+Y)%. In order to more closely approximate the non-linear O<sub>3</sub> response to any level of emissions reductions, 2<sup>nd</sup> order terms are added to the multistep approximation method in Equations (3C-4) through (3C-7). P represents the percentage NO<sub>x</sub> cut for which the ΔO<sub>3</sub> values are being calculated, S and S<sup>2</sup> are the first and second order O<sub>3</sub> sensitivities to U.S. NO<sub>x</sub> emissions, and X and Y are described above.

$$\Delta O_3 = -a \times S_{NOx_{base}} + \frac{a^2}{2} \times S_{NOx_{base}}^2 - b \times S_{NOx_{50\%cut}} + \frac{b^2}{2} \times S_{NOx_{50\%cut}}^2 - c \times S_{NOx_{90\%cut}} + \frac{c^2}{2} \times S_{NOx_{90\%cut}}^2$$

Equation (3C-4)

$$a = \begin{cases} \frac{P}{100} & \text{for } P \leq X \\ \frac{X}{100} & \text{for } P > X \end{cases}$$


Equation (3C-5)

$$b = \begin{cases} 0 & \text{for } P \leq X \\ \frac{2 \times (P - X)}{100} & \text{for } X < P \leq (X + Y) \\ \frac{2 \times Y}{100} & \text{for } P > (X + Y) \end{cases}$$

Equation (3C-6)

$$c = \begin{cases} 0 & \text{for } P \leq (X + Y) \\ \frac{10 \times (P - (X + Y))}{100} & \text{for } 100 \geq P > (X + Y) \end{cases}$$

Equation (3C-7)



**Figure 3C-49. Conceptual picture of 3-step application of HDDM sensitivities.**

The ideal value for equation transition points, X and Y, are determined by minimizing the least square mean error between the adjusted concentrations using the multistep approach and modeled concentrations from brute force NO<sub>x</sub> emissions reduction runs. We first determined the value of X which gave the lowest error compared to brute forces estimates at 50% NO<sub>x</sub> emissions reductions. Then holding X constant, we determined the value of Y which gave the lowest error compared to brute force method O<sub>3</sub> concentration estimates using 90% NO<sub>x</sub> emissions reductions. This process was performed independently for each of the eight urban study areas in this analysis.

Error in HDDM estimates of hourly O<sub>3</sub> is defined here as the difference between HDDM estimated O<sub>3</sub> and O<sub>3</sub> estimated using the brute force method. Based on equations (3C-4) through (3C-7), this can be calculated from Equations (3C-8) and (3C-9) for 50% NO<sub>x</sub> emissions reductions:

$$\varepsilon = \Delta Ozone_{HDDM,50} - \Delta Ozone_{BF,50}$$

Equation (3C-8)

$$\varepsilon = \frac{-X}{100} \times S_{NOx_{base}} + \frac{X^2}{2 \times 100^2} \times S_{NOx_{base}}^2 - \frac{2(50-X)}{100} \times S_{NOx_{50}\%cut} + \frac{(2 \times (50-X))^2}{2 \times 100^2} \times S_{NOx_{50}\%cut}^2 - \Delta Ozone_{BF,50}$$

Equation (3C-9)

Equation (3C-10) can be rearranged to appear in the form:  $AX^2 + BX + C$ :

$$\varepsilon = \left( \frac{S_{NOx_{base}}^2}{2 \times 100^2} + \frac{4 \times S_{NOx_{50}\%cut}^2}{2 \times 100^2} \right) X^2 + \left( \frac{-S_{NOx_{base}}}{100} + \frac{2 \times S_{NOx_{50}\%cut}}{100} - \frac{400 \times S_{NOx_{50}\%cut}^2}{2 \times 100^2} \right) X + \left( -S_{NOx_{50}\%cut} + \frac{S_{NOx_{50}\%cut}^2}{2} - \Delta Ozone_{BF,50} \right)$$

Equation (3C-10)

$$A = \left( \frac{S_{NOx_{base}}^2}{2 \times 100^2} + \frac{4 \times S_{NOx_{50}\%cut}^2}{2 \times 100^2} \right)$$

Equation (3C-11)

$$B = \left( \frac{-S_{NOx_{base}}}{100} + \frac{2 \times S_{NOx_{50}\%cut}}{100} - \frac{400 \times S_{NOx_{50}\%cut}^2}{2 \times 100^2} \right)$$

Equation (3C-12)

$$C = \left( -S_{NOx_{50}\%cut} + \frac{S_{NOx_{50}\%cut}^2}{2} - \Delta Ozone_{BF,50} \right)$$

Equation (3C-13)

Next, the error is squared, summed over all points (error can be calculated for each hourly O<sub>3</sub> value at each monitoring location), and the derivative is set to 0 to determine X which gives the least squares error (Equations (3C-14), (3C-15), and (3C-16)).

$$\varepsilon^2 = A^2 X^4 + 2ABX^3 + (2AC + B^2)X^2 + 2BCX + C^2$$

Equation (3C-14)

$$\sum \varepsilon^2 = (\sum A^2)X^4 + (\sum 2AB)X^3 + (\sum 2AC + B^2)X^2 + (\sum 2BC)X + \sum C^2$$

Equation (3C-15)

$$(\sum \varepsilon^2)' = (4 \sum A^2)X^3 + (3 \sum 2AB)X^2 + (2 \sum 2AC + B^2)X + (\sum 2BC) = 0$$

Equation (3C-16)

The value of X that gives the least squares error will occur at one of the three roots of the trinomial in Equation (3C-16) or at 0 or 50. All real roots, 0, and 50 were input into equation (3C-15) and X was set to the value which resulted in the lowest error in each city. An analogous procedure was followed to determine Y using the 90% NO<sub>x</sub> emissions reduction brute force simulation and Equations (3C-17) through (3C-23).

$$\begin{aligned} \varepsilon = & \frac{-X}{100} \times S_{NOx_{base}} + \frac{X^2}{2 \times 100^2} \times S_{NOx_{base}}^2 - \frac{2Y}{100} \times S_{NOx_{90\%cut}} \\ & + \frac{2^2 Y^2}{2 \times 100^2} \times S_{NOx_{90\%cut}}^2 - \frac{10(90 - (X + Y))}{100} \times S_{NOx_{90\%cut}} \\ & + \frac{(10^2(90 - (X + Y)))^2}{2 \times 100^2} \times S_{NOx_{90\%cut}}^2 - \Delta Ozone_{BF,90} \end{aligned}$$

Equation (3C-17)

$$\varepsilon^2 = A^2 Y^4 + 2ABY^3 + (2AC + B^2)Y^2 + 2BCY + C^2$$

Equation (3C-18)

$$A = \left( \frac{4 \times S_{NOx_{90\%cut}}^2}{2 \times 100^2} + \frac{100 \times S_{NOx_{90\%cut}}^2}{2 \times 100^2} \right)$$

Equation (3C-19)

$$B = \left( \frac{-2 \times S_{NOx_{90\%cut}}}{100} + \frac{10 \times S_{NOx_{90\%cut}}}{100} - \frac{200 \times (90 - X) S_{NOx_{90\%cut}}^2}{2 \times 100^2} \right)$$

Equation (3C-20)

$$C = \left( \frac{-X}{100} S_{NOx_{base}} + \frac{X^2}{2 \times 100^2} S_{NOx_{base}}^2 - \frac{10 \times (90 - X)}{100} S_{NOx_{90\%cut}} + \frac{100 \times (90 - X)^2}{2 \times 100^2} S_{NOx_{90\%cut}}^2 - \Delta Ozone_{BF,90} \right)$$

Equation (3C-21)

$$\sum \varepsilon^2 = (\sum A^2)Y^4 + (\sum 2AB)Y^3 + (\sum 2AC + B^2)Y^2 + (\sum 2BC)Y + \sum C^2$$

Equation (3C-22)




$$(\sum \epsilon^2)' = (4 \sum A^2)Y^2 + (3 \sum 2AB)Y^2 + (2 \sum 2AC + B^2)Y + (\sum 2BC) = 0$$

Equation (3C-23)


The X and Y cutpoints which have the least square error in each urban study area are shown in Table 3C-18. This 3-step adjustment methodology was shown to be a robust method for minimizing error in the HDDM applications for larger percentage changes in emissions by Simon et al. (2013). Figure 3C-50 through Figure 3C-65 are density scatter plots that compare hourly O<sub>3</sub> estimates from brute force with hourly O<sub>3</sub> estimates from the 3-step HDDM adjustments at all monitor locations in each of the eight urban study areas evaluated in this study. The colors in these plots depict the percentage of points falling at any one location. Mean error for the 50% and 90% 3-step HDDM adjustment NO<sub>x</sub> emissions reductions cases compared to O<sub>3</sub> concentrations estimated using the brute force method are less than 0.5 ppb and 2 ppb respectively in all eight urban study areas.

**Table 3C-18. X and Y cut-points used in Equations (3C-4) through (3C-7).**


| Urban Study Area | X  | Y  |
|------------------|----|----|
| Atlanta          | 37 | 48 |
| Boston           | 38 | 45 |
| Dallas           | 37 | 47 |
| Detroit          | 37 | 45 |
| Philadelphia     | 37 | 45 |
| Phoenix          | 37 | 45 |
| Sacramento       | 38 | 48 |
| St. Louis        | 37 | 47 |




**Figure 3C-50. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in Atlanta.**




**Figure 3C-51. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in Boston.**




**Figure 3C-52. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in Dallas.**




**Figure 3C-53. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in Detroit.**



**Figure 3C-54. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in Philadelphia.**




**Figure 3C-55. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in Phoenix.**




**Figure 3C-56. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in Sacramento.**







**Figure 3C-57. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 50% NO<sub>x</sub> cut conditions in St. Louis.**




**Figure 3C-58. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in Atlanta.**




**Figure 3C-59. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in Boston.**




**Figure 3C-60. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in Dallas.**



**Figure 3C-61. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in Detroit.**




**Figure 3C-62. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in Philadelphia.**




**Figure 3C-63. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in Phoenix.**





**Figure 3C-64. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in Sacramento.**





**Figure 3C-65. Comparison of brute force and 3-step HDDM O<sub>3</sub> estimates for 90% NO<sub>x</sub> cut conditions in St. Louis.**

#### **3C.5.2.2.2 Relationships between HDDM Sensitivities and Modeled O<sub>3</sub> Concentrations**

First and second order hourly O<sub>3</sub> sensitivities to NO<sub>x</sub> emissions reductions were extracted from the HDDM simulation for model grid cells that contained the O<sub>3</sub> monitors in the eight urban study areas. Extracted data included modeled sensitivities at monitor locations for all modeled hours in 2016. These sensitivities cannot be applied directly to observed values for two reasons: 1) high modeled O<sub>3</sub> days/hours do not always occur concurrently with high observed O<sub>3</sub> days/hours and 2) the modeling time period includes only 2016 but the time period we are

analyzing in this assessment includes three full years of ambient air data, 2015-2017. As to the first point, photochemical models are generally used in a relative sense for purposes of projecting design values. In this manner, model predictions are “anchored” to ambient air measurements. In general, the average response on high modeled days is used for this purpose. This allows for more confidence in calculated results when “less than ideal model performance [occurs] on individual days” (U.S. EPA, 2007). Similarly, for this analysis we believe it is appropriate to account for the fact the model does not always perfectly agree with measurements and that sensitivities from a low O<sub>3</sub> modeled day would not be appropriate to apply to a high O<sub>3</sub> measured day (and vice-versa) even if they occur on the same calendar day. For this reason, a method was developed to generalize the modeled site-, season-, and hour-specific sensitivities so that they could be applied to ambient air data during 2015-2017.<sup>14</sup>

Simon et al. (2013) describe how first order sensitivities are generally well correlated with hourly modeled O<sub>3</sub> concentrations and second order sensitivities are well correlated to first order sensitivities. Based on their analysis, we create a separate linear regression for S<sub>NO<sub>x</sub></sub> as a function of hourly O<sub>3</sub> (i.e.  $S_{NO_x} = m \times O_3 + b$ ) for every site, season<sup>15</sup>, and hour-of-the day examined in this analysis. For instance, for summer 8-am hours at Detroit monitor site ID 260990009, S<sub>NO<sub>x</sub></sub> and O<sub>3</sub> values from all 8-am hours in June-August 2016 are used to fit this relationship. Similarly, S<sup>2</sup><sub>NO<sub>x</sub></sub> was calculated as a function of S<sub>NO<sub>x</sub></sub>.

Comparisons between brute force and HDDM O<sub>3</sub> estimates shown in Figure 3C-50 through Figure 3C-65 demonstrate that for the vast majority of data points, HDDM replicates brute force with minimal errors. These figures show a small number of instances, particularly for Philadelphia, in which HDDM predicts very high hourly O<sub>3</sub> (> 100 ppb) while the brute force emissions simulations for the 90% reduction show much lower O<sub>3</sub> (< 40 ppb). In these isolated cases, base modeled O<sub>3</sub> is low due to NO<sub>x</sub> titration and increases occur with reductions of NO<sub>x</sub>. The HDDM sensitivities for these few points appear to be too high to be applied over large (>50%) emissions changes because of strongly nonlinear chemistry. However these extreme cases are not relevant for this analysis, since the largest emissions reduction required for Philadelphia was 53% to meet the air quality scenario for 65 ppb (Table 3C-19). The two urban study areas requiring emission cuts larger than ~50%, Phoenix and Sacramento, both show much better agreement between the 90% brute force and HDDM predictions (Figure 3C-63 and Figure 3C-64 respectively).

---

<sup>14</sup> The 12 months modeled covered a variety of conditions such that we can use the results from this modeled time period in conjunction with the ambient data from the longer 3-year period for estimating responses and applying adjustments

<sup>15</sup> Seasons are defined as follows: Winter = December, January, February; Spring = March, April, May; Summer = June, July, August; Fall = September, October, November.

For the 50% and 90% emissions reduction CAMx/HDDM simulation, regressions were performed for first order NO<sub>x</sub> sensitivities with modeled O<sub>3</sub> from the base HDDM simulation. The regression technique was performed for the first and second order NO<sub>x</sub> sensitivities from the base run and the 50% emissions reduction and 90% emissions reduction simulations. The sensitivities from the emissions reduction runs were fitted to hourly O<sub>3</sub> concentrations in the base simulation. Simon et al. (2013) found that correlation coefficients using for sensitivities from NO<sub>x</sub> reduction simulations to base case O<sub>3</sub> concentrations were similar to those with O<sub>3</sub> concentrations from the NO<sub>x</sub> reduction runs.

### **3C.5.2.2.3 Application of Sensitivity Regressions to Ambient Air Data**

To apply the HDDM adjustments to observed data, sensitivities must be determined for each hour from 2015-2017 at each site based on the linear relationship from the modeled data and the observed O<sub>3</sub> concentration. The linear regression model also allows us to quantify the standard error of each predicted sensitivity value at each hour and site.

Observed hourly O<sub>3</sub> from 2015-2017 at each monitor location was adjusted by applying incrementally increasing emissions reductions using equations (3C-4) through (3C-8) and recalculating MDA8 values for incrementally increasing emissions reductions until an emissions level is reached for which all monitors in an urban study area achieved design values at the level of the air quality scenario being evaluated (design values of 75, 70, or 65 ppb). Therefore, all monitors within an urban study area were treated as responding to the same percentage reduction in NO<sub>x</sub> emissions.

The precursor reductions used to estimate spatial and temporal patterns of O<sub>3</sub> concentrations for the three air quality scenarios were NO<sub>x</sub>-only reductions. We focused on NO<sub>x</sub>-only reductions in light of several key findings from analyses for the 2014 HREA that explored the use of both NO<sub>x</sub> and VOC reductions versus NO<sub>x</sub>-only scenarios (2014 HREA, Appendix 4D). There were several key findings from that comparison. First, in most of the urban study areas, the NO<sub>x</sub> /VOC scenario did not affect O<sub>3</sub> response at the monitor having the highest design value in such a way to reduce the total required emissions cuts. Further, evidence in the literature has shown that locations in the U.S. have gotten more NO<sub>x</sub>-limited since 2007 (the year modeled in the 2014 HREA) (Jin et al., 2017, Laughner and Cohen, 2019) and thus VOC reductions would be expected to have less impact on resulting O<sub>3</sub> concentrations in our scenarios for the 2016 modeling used here than they had in the previous analysis. Finally, the two areas (Denver and Chicago) in which VOC emissions had the most impact in the 2014 HREA were not included in the current analysis. For these reasons, NO<sub>x</sub>-only reductions were determined to be

the most appropriate scenarios for this analysis. The final emissions reductions that were applied in each urban study area are given in Table 3C-19 below.<sup>16</sup>

**Table 3C-19. Percent emissions changes used for each urban study area to just meet each of the air quality scenarios evaluated.**

| Urban Study Area | 75 ppb | 70 ppb | 65 ppb |
|------------------|--------|--------|--------|
| Atlanta          | 0%     | 25%    | 44%    |
| Boston           | +7%    | 14%    | 40%    |
| Dallas           | 15%    | 32%    | 45%    |
| Detroit          | +18%   | 21%    | 47%    |
| Philadelphia     | 23%    | 43%    | 53%    |
| Phoenix          | 14%    | 49%    | 68%    |
| Sacramento       | 45%    | 58%    | 72%    |
| Saint Louis      | +11%   | 13%    | 38%    |

The 2014 HREA included a thorough analysis of the standard error associated with the predicted O<sub>3</sub> concentrations produced using the HDDM adjustment approach. This analysis found that while the error in predicted values varied by site and air quality scenario being evaluated, the magnitudes were small (<1.5 ppb in most cases). We did not repeat such an analysis here given the small magnitude of the standard errors found in this previous assessment.


### **3C.6 INTERPOLATION OF ADJUSTED AIR QUALITY USING VORONOI NEIGHBOR AVERAGING**

The APEX exposure model uses spatial fields of ambient air quality concentrations at variable spatial scales (e.g., 500 m regular grid, census tract centroid) as inputs, but requires that there be no missing values. The final air quality data used as inputs to the APEX model were the hourly O<sub>3</sub> concentrations at monitoring sites adjusted using CAMx/HDDM, then interpolated to each census tract centroid in the eight urban study areas using the Voronoi Neighbor Averaging (VNA; Gold et al., 1997; Chen et al., 2004) technique described below. A cross-validation analysis supporting the use of the VNA technique for the creation of hourly O<sub>3</sub> spatial fields was conducted in the 2015 review (U.S. EPA, 2014; Appendix 4A).


<sup>16</sup> Note that these emissions reductions and broad nationwide emission cuts are not intended to represent recommended control scenarios since they would not be the most efficient method for achieving a particular standard in many areas.

The following paragraphs provide a numerical example of VNA used to estimate an O<sub>3</sub> concentration value for census tract “E” in Figure 3C-66 below.

The first step in the VNA technique is to identify the set of nearest monitors for each census tract. The left-hand panel of Figure 3C-66 presents a numerical example with nine census tracts (squares) and seven monitoring sites (stars), with the focus on identifying the set of nearest neighboring sites to census tract “E” in the center of the panel. The Delaunay triangulation algorithm identifies the set of nearest neighboring monitors by drawing a set of polygons called the “Voronoi diagram” around the census tract “E” centroid and each of the monitoring sites. Voronoi diagrams have the special property that each edge of each of the polygons are the same distance from the two closest points, as shown in the right-hand panel of Figure 3C-66.



# = Census Tract “E” Centroid  
\* = Air Quality Monitor



# = Census Tract “E” Centroid  
\* = Air Quality Monitor

**Figure 3C-66. Numerical example of the Voronoi Neighbor Averaging (VNA) technique.**

The VNA technique then chooses the monitoring sites whose polygons share a boundary with the census tract “E” centroid. These monitors are the “Voronoi neighbors”, which are used to estimate the concentration value for census tract “E”. The VNA estimate of the concentration value in census tract “E” is the inverse distance squared weighted average of the four monitored concentrations. The further the monitor is from the center of census tract “E”, the smaller the weight. For example, the weight for the monitor in census tract “D” 10 miles from the census tract “E” centroid is calculated as follows:

$$\frac{1/10^2}{1/10^2 + 1/15^2 + 1/15^2 + 1/20^2} = 0.4675$$

Equation (3C-24)

The weights for the other monitors are calculated in a similar fashion. The final VNA estimate for census tract “E” is calculated as follows:

$$VNA(E) = 0.4675 * 80 + 0.2078 * 90 + 0.2078 * 60 + 0.1169 * 100 = 80.3 \text{ ppb}$$

Equation (3C-25)

The adjusted hourly O<sub>3</sub> concentrations in the eight urban study areas were used to calculate VNA estimates for approximately 9,725 census tracts \* 26,304 hours \* 3 air quality scenarios ≈ 767 million values. The computations were executed using the R statistical computing program (R Core Team, 2018), with the Delaunay triangulation algorithm implemented in the “deldir” package (Turner, 2018).

## 3C.7 RESULTS FOR URBAN STUDY AREAS

### 3C.7.1 Design Values

Table 3C-20 through Table 3C-27 provide the design values for ambient monitoring sites in each of the eight urban study areas for 2015-2017 based on the observed data, and based on the adjusted O<sub>3</sub> concentrations for the three air quality scenarios (i.e., air quality meeting the current standard of 70 ppb, and air quality meeting two alternative levels of 75 ppb and 65 ppb). In each table, the highest design value for each scenario is displayed in bold text. The data in these tables demonstrate that high O<sub>3</sub> values at monitors within some urban study areas respond differently to reductions in NO<sub>x</sub> emissions.

In five of the eight urban study areas, the monitor with the highest observed design value remained the highest when the air quality was adjusted in each of the three air quality scenarios. For example, Atlanta monitor 131210055 had the highest 2015-2017 design value of 75 ppb, as well as design values of 70 ppb and 65 ppb for the 70 ppb and 65 ppb scenarios, respectively. The other study areas where the same monitor had the highest design value in the observations as well as the 75 ppb, 70 ppb, and 65 ppb scenarios were Dallas (481210034), Detroit (261630019), Sacramento (060570005), and St. Louis (291831002).

Boston and Philadelphia saw shifts in the highest monitor as a result of the adjustments. In Boston, monitor 250051004 in Fall River, MA was highest in the observations and following the upward adjustment to meet 75 ppb. Monitor 250051004 and two other monitors (440090007 in Narragansett, RI and 440090007 east of Providence, RI) had design values of 70 ppb for the adjustment to meet the current standard. After the final adjustment for the 65 ppb scenario, the highest design value occurred at the Narragansett monitor. In Philadelphia, monitor 420170012 near Trenton, NJ was highest in the observations. However, following each of the adjustments to

75 ppb, 70 ppb and 65 ppb, the location of the highest monitor shifted slightly west to monitor 421010024 (east of downtown Philadelphia).

The pattern for Phoenix was unique among the eight urban study areas. One monitor (040139997) was consistently high in the observations and for all adjusted levels. However, two other monitors were equally as high in the observations (040132005; 040131003 – also high at 75 ppb) but responded more strongly to the applied NO<sub>x</sub> reductions. While monitors 040132005 and 040131003 are slightly removed from downtown Phoenix (near Pinnacle Peak to the northeast and Mesa to the southeast, respectively), monitor 040139997 is closer the center of the Phoenix metropolitan area. This location is likely near higher concentrations of urban NO<sub>x</sub> sources, making this monitor slightly less responsive to the NO<sub>x</sub> emissions adjustments.

**Table 3C-20. 2015-2017 design values for monitors in the Atlanta study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 130590002   | 64                    | 64        | 59        | 54        |
| 130670003   | 67                    | 67        | 62        | 57        |
| 130770002   | 63                    | 63        | 59        | 54        |
| 130850001   | 65                    | 65        | 61        | 56        |
| 130890002   | 71                    | 71        | 66        | 59        |
| 130970004   | 69                    | 69        | 64        | 58        |
| 131210055   | <b>75<sup>A</sup></b> | <b>75</b> | <b>70</b> | <b>65</b> |
| 131350002   | 71                    | 71        | 66        | 60        |
| 131510002   | 71                    | 71        | 65        | 59        |
| 132230003 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 132319991   | 67                    | 67        | 62        | 56        |
| 132470001   | 69                    | 69        | 64        | 57        |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

1     **Table 3C-21. 2015-2017 design values for monitors in the Boston study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 090159991   | 70                    | 72        | 68        | 61        |
| 250010002 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 250051004   | <b>73<sup>A</sup></b> | <b>75</b> | <b>70</b> | 63        |
| 250051006   | 69                    | 71        | 68        | 62        |
| 250092006   | 66                    | 68        | 65        | 61        |
| 250094005   | 65                    | 67        | 64        | 59        |
| 250095005   | 62                    | 64        | 61        | 56        |
| 250170009   | 64                    | 66        | 62        | 57        |
| 250213003   | 70                    | 72        | 68        | 62        |
| 250230005   | 68                    | 70        | 65        | 60        |
| 250250042   | 61                    | 62        | 61        | 58        |
| 250270015   | 65                    | 67        | 64        | 59        |
| 250270024   | 66                    | 68        | 64        | 59        |
| 330012004   | 59                    | 61        | 57        | 53        |
| 330111011   | 62                    | 64        | 61        | 57        |
| 330115001   | 67                    | 65        | 65        | 60        |
| 330131007   | 63                    | 64        | 61        | 56        |
| 330150014   | 63                    | 65        | 61        | 57        |
| 330150016   | 66                    | 68        | 65        | 59        |
| 330150018   | 65                    | 67        | 64        | 59        |
| 440030002   | 72                    | 74        | <b>70</b> | 63        |
| 440071010   | 70                    | 72        | 68        | 62        |
| 440090007   | 71                    | 73        | <b>70</b> | <b>65</b> |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

2  
3



1 **Table 3C-22. 2015-2017 design values for monitors in the Dallas study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 400130380 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 480850005   | 74                    | 72        | 67        | 63        |
| 481130069   | 74                    | 72        | 68        | 63        |
| 481130075   | 74                    | 72        | 68        | 63        |
| 481130087   | 64                    | 62        | 58        | 54        |
| 481210034   | <b>79<sup>A</sup></b> | <b>75</b> | <b>70</b> | <b>65</b> |
| 481211032   | 74                    | 71        | 66        | 62        |
| 481390016   | 65                    | 63        | 60        | 56        |
| 481391044   | 64                    | 61        | 58        | 55        |
| 482210001   | 67                    | 65        | 61        | 58        |
| 482311006   | 62                    | 60        | 56        | 53        |
| 482510003   | 73                    | 70        | 65        | 60        |
| 482570005   | 61                    | 59        | 56        | 53        |
| 483491051   | 63                    | 61        | 58        | 56        |
| 483670081   | 70                    | 67        | 63        | 59        |
| 483970001   | 66                    | 63        | 60        | 57        |
| 484390075   | 71                    | 69        | 65        | 60        |
| 484391002   | 72                    | 70        | 67        | 62        |
| 484392003   | 73                    | 71        | 67        | 62        |
| 484393009   | 75                    | 73        | 69        | 64        |
| 484393011   | 67                    | 65        | 61        | 57        |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

2

3 **Table 3C-23. 2015-2017 design values for monitors in the Detroit study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 260490021   | 67                    | 70        | 65        | 60        |
| 260492001   | 67                    | 71        | 65        | 59        |
| 260910007   | 66                    | 70        | 64        | 58        |
| 260990009   | 71                    | 73        | 69        | 63        |
| 260991003   | 66                    | 68        | 65        | 61        |
| 261250001   | 70                    | 72        | 68        | 63        |
| 261470005   | 71                    | 74        | 69        | 64        |
| 261610008   | 67                    | 69        | 65        | 60        |
| 261619991   | 69                    | 72        | 66        | 59        |
| 261630001   | 66                    | 69        | 65        | 60        |
| 261630019   | <b>73<sup>A</sup></b> | <b>75</b> | <b>70</b> | <b>65</b> |
| 261630093 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 261630094 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

1  
2 **Table 3C-24. 2015-2017 design values for monitors in the Philadelphia study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 100010002   | 66                    | 62        | 57        | 53        |
| 100031007   | 67                    | 64        | 59        | 55        |
| 100031010   | 74                    | 70        | 65        | 60        |
| 100031013   | 71                    | 67        | 63        | 58        |
| 100032004   | 72                    | 68        | 63        | 58        |
| 240150003   | 74                    | 70        | 64        | 59        |
| 340010006   | 64                    | 60        | 55        | 51        |
| 340070002   | 77                    | 74        | 68        | 63        |
| 340071001   | 68                    | 64        | 60        | 56        |
| 340110007   | 66                    | 62        | 56        | 53        |
| 340150002   | 74                    | 70        | 68        | 60        |
| 420110006   | 66                    | 63        | 57        | 53        |
| 420110011   | 70                    | 67        | 61        | 58        |
| 420170012   | <b>80<sup>A</sup></b> | <b>75</b> | 69        | 64        |
| 420290100   | 73                    | 69        | 63        | 58        |
| 420450002   | 71                    | 69        | 64        | 60        |
| 420910013   | 72                    | 69        | 64        | 59        |
| 421010004 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 421010024   | 78                    | <b>75</b> | <b>70</b> | <b>65</b> |
| 421010048   | 76                    | 72        | 67        | 63        |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

1     **Table 3C-25. 2015-2017 design values for monitors in the Phoenix study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 040130019   | 74                    | 74        | 68        | 62        |
| 040131003   | 76                    | 75        | 69        | 63        |
| 040131004   | 75                    | 74        | 69        | 63        |
| 040131010   | 74                    | 74        | 69        | 62        |
| 040132001   | 68                    | 67        | 64        | 59        |
| 040132005   | <b>76<sup>A</sup></b> | 74        | 67        | 60        |
| 040133002   | 72                    | 72        | 67        | 62        |
| 040133003   | 69                    | 68        | 63        | 59        |
| 040134003   | 70                    | 69        | 65        | 60        |
| 040134004   | 71                    | 70        | 64        | 59        |
| 040134005 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 040134008   | 70                    | 69        | 64        | 58        |
| 040134010   | 68                    | 68        | 63        | 59        |
| 040134011   | 63                    | 62        | 58        | 54        |
| 040135100 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 040137003   | 66                    | 65        | 60        | 56        |
| 040137020   | 72                    | 72        | 67        | 61        |
| 040137021   | 75                    | 74        | 67        | 60        |
| 040137022   | 75                    | 74        | 67        | 60        |
| 040137024   | 72                    | 71        | 66        | 60        |
| 040139508   | 73                    | 72        | 66        | 61        |
| 040139702   | 72                    | 71        | 64        | 57        |
| 040139704   | 70                    | 69        | 63        | 57        |
| 040139706   | 68                    | 68        | 63        | 57        |
| 040139997   | <b>76</b>             | <b>75</b> | <b>70</b> | <b>65</b> |
| 040213001   | 74                    | 73        | 66        | 60        |
| 040213003   | 66                    | 65        | 61        | 57        |
| 040213007   | 68                    | 67        | 62        | 59        |
| 040217001   | 65                    | 64        | 59        | 55        |
| 040218001   | 73                    | 72        | 65        | 60        |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

2  
3

1     **Table 3C-26. 2015-2017 design values for monitors in the Sacramento study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 060170010   | 83                    | 71        | 65        | 59        |
| 060170012 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 060170020   | 80                    | 69        | 63        | 56        |
| 060570005   | <b>86<sup>A</sup></b> | <b>75</b> | <b>70</b> | <b>65</b> |
| 060570007 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 060610003   | 84                    | 72        | 66        | 58        |
| 060610004   | 77                    | 67        | 62        | 56        |
| 060610006   | 79                    | 71        | 65        | 58        |
| 060611004   | 64                    | 61        | 60        | 58        |
| 060612002   | 75                    | 67        | 61        | 54        |
| 060670002   | 78                    | 70        | 65        | 58        |
| 060670006   | 77                    | 71        | 66        | 59        |
| 060670010   | 69                    | 63        | 59        | 54        |
| 060670011   | 68                    | 61        | 56        | 50        |
| 060670012   | 82                    | 72        | 66        | 59        |
| 060670014 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 060675003   | 78                    | 69        | 63        | 57        |
| 061010003   | 64                    | 56        | 52        | 47        |
| 061010004 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 061130004   | 63                    | 55        | 52        | 47        |
| 061131003   | 69                    | 60        | 55        | 50        |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

2  
3

**Table 3C-27. 2015-2017 design values for monitors in the St. Louis study area.**

| Monitor ID  | Observed              | 75 ppb    | 70 ppb    | 65 ppb    |
|---|-----------------------|-----------|-----------|-----------|
| 170830117 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 170831001 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 171170002   | 65                    | 68        | 63        | 57        |
| 171190008   | 69                    | 72        | 67        | 62        |
| 171191009   | 68                    | 71        | 66        | 61        |
| 171193007   | 70                    | 73        | 68        | 62        |
| 171199991   | 67                    | 70        | 65        | 58        |
| 171630010   | 68                    | 71        | 67        | 61        |
| 290990019   | 68                    | 71        | 66        | 59        |
| 291130003 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 291130004 <sup>B</sup>  | N/A                   | N/A       | N/A       | N/A       |
| 291831002   | <b>72<sup>A</sup></b> | <b>75</b> | <b>70</b> | <b>65</b> |
| 291831004   | 70                    | 73        | 67        | 62        |
| 291890005   | 65                    | 67        | 63        | 58        |
| 291890014   | 69                    | 72        | 67        | 62        |
| 295100085   | 66                    | 69        | 65        | 61        |
| <sup>A</sup> Highest DV for each scenario is displayed in bold.                                       |                       |           |           |           |
| <sup>B</sup> Monitor used to develop AQ surfaces but DVs not calculated because data were incomplete. |                       |           |           |           |

### 3C.7.2 Distribution of Hourly O<sub>3</sub> Concentrations

Figure 3C-67 through Figure 3C-74 display diurnal boxplots of hourly O<sub>3</sub> concentrations for 2015-2017 at monitor locations in each urban study area. For each hour of the day, the rectangular box represents the 25<sup>th</sup> and 75<sup>th</sup> percentiles of the distribution, with a solid line representing the median of the distribution through the center. Each box has “whiskers” which extend up to 1.5 times the interquartile range (i.e., the 75<sup>th</sup> percentile minus the 25<sup>th</sup> percentile) from the box, and dots which represent outlier values. Black boxplots represent observed hourly O<sub>3</sub> concentrations, while blue boxplots represent hourly O<sub>3</sub> concentrations adjusted to meet the current standard of 70 ppb. Red boxplots represent hourly O<sub>3</sub> concentrations adjusted for the 75 ppb<sup>17</sup> scenario, and green boxplots represent hourly O<sub>3</sub> concentrations adjusted for the 65 ppb scenario.


The boxplots include the observed O<sub>3</sub> concentrations as well as the concentrations adjusted to just meet the current standard and the two alternative air quality scenarios. Note that these plots include data from all sites in the study area, and thus the plots provide the overall distribution of O<sub>3</sub> at both the urban core sites and the downwind suburban sites. The hourly plots

<sup>17</sup> No adjusted values are shown for the 75 ppb scenario for Atlanta because the observed design value was 75 ppb, and thus no adjustments were made to the hourly O<sub>3</sub> concentrations for that scenario.


1 show similar patterns in most of the urban study areas. O<sub>3</sub> concentrations during daytime hours  
2 decrease from observed values (black) to values adjusted to meet the current standard of 70 ppb  
3 (blue) and decrease further under the alternative scenario of 65 ppb (green). These daytime  
4 decreases are mainly seen on high O<sub>3</sub> days represented by outlier dots extending above the box  
5 and whiskers. Some study areas had observed 2015-2017 design values already meeting the  
6 alternative scenario of 75 ppb, therefore some plots show increases in O<sub>3</sub> concentrations while  
7 other study areas show decreases in O<sub>3</sub> concentrations for the 75 ppb scenario.

8 In some urban study areas O<sub>3</sub> concentrations on the mid-range days, represented by the  
9 25<sup>th</sup> – 75<sup>th</sup> percentile boxes, remained fairly constant (e.g. Boston) while in other urban study  
10 areas O<sub>3</sub> on mid-range days decreased (e.g. Atlanta). Although daytime O<sub>3</sub> decreased,  
11 concentrations during morning rush-hour period generally increase. These increases are  
12 associated with VOC-limited and NO<sub>x</sub> titration conditions near NO<sub>x</sub> sources during rush-hour  
13 periods. Reducing NO<sub>x</sub> under these conditions results in less O<sub>3</sub> titration and thus increases O<sub>3</sub>  
14 concentrations. Nighttime increases in O<sub>3</sub> as a results of NO<sub>x</sub> reductions are often seen to a lesser  
15 extent than morning rush-hour period increases. Collectively these features generally lead to a  
16 flattening of the diurnal O<sub>3</sub> pattern with smaller differences between daytime and nighttime  
17 concentrations as NO<sub>x</sub> emissions are reduced. Urban study areas that required more substantial  
18 NO<sub>x</sub> reductions for the 65 ppb scenario generally had more pronounced patterns of decreases in  
19 daytime O<sub>3</sub> and increases in nighttime O<sub>3</sub> leading to a flatter diurnal O<sub>3</sub> pattern (e.g., Sacramento  
20 in Figure 3C-73).

21 Figure 3C-75 through Figure 3C-82 display the same information as Figure 3C-67  
22 through Figure 3C-74 but for monthly rather than diurnal distributions. Similar to the diurnal  
23 plots, the seasonal distributions become flatter when adjusted to meet the 70 ppb and 65 ppb  
24 scenarios, especially on the highest O<sub>3</sub> days. This is due to more O<sub>3</sub> decreases during summer  
25 months and more O<sub>3</sub> increases in winter months. The O<sub>3</sub> increases in the winter are consistent  
26 with the understanding that solar insolation rates are lower in the winter reducing total  
27 photochemical activity and shifting the net effect of NO<sub>x</sub> emissions on O<sub>3</sub> which can both create  
28 O<sub>3</sub> through photochemical pathways and destroy O<sub>3</sub> through titration. In addition, the decreases  
29 on the highest O<sub>3</sub> days and increases on the lowest O<sub>3</sub> days show a visible compression of the O<sub>3</sub>  
30 distribution in these plots, similar to what was seen in the diurnal plots.




**Figure 3C-67. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Atlanta study area.** Note: Observed concentrations in this area have a design value of 75 ppb.




**Figure 3C-68. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Boston study area.**







**Figure 3C-69. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Dallas study area.**



**Figure 3C-70. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Detroit study area.**



**Figure 3C-71. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Philadelphia study area.**



**Figure 3C-72. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Phoenix study area.**









Figure 3C-73. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Sacramento study area.



**Figure 3C-74. Diurnal distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the St. Louis study area.**




**Figure 3C-75. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Atlanta study area.** Note: Observed concentrations in this area have a design value of 75 ppb.




**Figure 3C-76. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Boston study area.**







**Figure 3C-77. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Dallas study area.**




**Figure 3C-78. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Detroit study area.**



**Figure 3C-79. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Philadelphia study area.**




**Figure 3C-80. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Phoenix study area.**



**Figure 3C-81. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the Sacramento study area.**





**Figure 3C-82. Monthly distribution of hourly O<sub>3</sub> concentrations at monitoring sites in the St. Louis study area.**

### 3C.7.3 Air Quality Inputs for the Exposure and Risk Analyses

The air quality inputs for the exposure and risk analyses discussed in chapter 3 include spatial surfaces of hourly O<sub>3</sub> concentrations estimated for each census tract in the eight urban study areas using the VNA technique described in section 3C.6. In this section, we present three types of figures which summarize the data from the hourly VNA surfaces for observed air

quality, and air quality adjusted to meet the current standard of 70 ppb, and air quality adjusted to meet alternative scenarios of 75 ppb<sup>18</sup> and 65 ppb.

The first set of figures (Figure 3C-83 through Figure 3C-90) shows density scatter plots of the change in MDA8 O<sub>3</sub> concentrations versus the observed concentrations based on the hourly VNA estimates in each study area. In each of these figures, the left-hand panel shows the observed MDA8 values (x-axis) versus the change in those values that occur when air quality is adjusted for the 75 ppb scenario (y-axis). The middle panel shows the MDA8 values for air quality adjusted to meet the 75 ppb scenario (x-axis) versus the additional change in those values that occur when air quality is adjusted to meet the current standard of 70 ppb (y-axis). Finally, the right-hand panels show the corresponding changes from the current standard to the 65 ppb scenario. Within each panel, the x and y values are rounded to the nearest integer and colored to show the relative frequency of each 1 x 1 ppb square within the plot region. Values falling outside of the plot region were set to the nearest value within the plot region, and frequencies above the range in the color bar were set to the highest value within the color bar.

The second set of figures (Figure 3C-91 through Figure 3C-106) provides maps of the adjusted design values (3-year average of the annual 4<sup>th</sup> highest MDA8 values) and May-September average MDA8 values based on the ambient air data and the hourly VNA surfaces, as well as difference maps showing the changes between these surfaces. For the difference maps, the panels on the left show the changes in these values that occur when air quality is adjusted for the 75 ppb scenario, the panels in the middle show the additional changes in these values that occur when air quality is further adjusted to meet the current standard of 70 ppb, and the right-hand panels show the additional changes that occur then air quality is further adjusted for the 65 ppb scenario. Within each panel, squares show values based on observed data at ambient air monitoring sites while circles show values based on VNA estimates at census tract centroids. While each panel shows both monitors in the study area for each selected urban study area as well as some additional monitors located outside of the study area, only the monitors located within the study area were used when determining the emissions reductions necessary to meet the various standards.

The third set of figures (Figure 3C-107 through Figure 3C-114) shows changes in design values (3-year average of the annual 4<sup>th</sup> highest MDA8 values) and May-September average MDA8 values in the eight urban case study areas versus population and population density. The total population and population density information for each census tract were obtained from the U.S. Census Bureau based on the 2010 U.S. Census. Each panel shows a histogram of the total

---

<sup>18</sup> Atlanta was already just meeting the 75 ppb scenario for the 2015-2017 period. Boston, Detroit, and St. Louis were below 75 ppb for 2015-2017; design values for these urban study areas were adjusted upward to just meet 75 ppb.

1 population stratified by the change in design value or seasonal average. The bars are also color-  
2 coded by population density bin. Values falling outside of the plot region set to the nearest  
3 values within the plot region.

4 In general, the density scatter plots show that the HDDM adjustment procedure predicts  
5 increases in MDA8 O<sub>3</sub> at low ambient air concentrations and decreases in MDA8 O<sub>3</sub> at high  
6 concentrations (Figure 3C-83 through Figure 3C-90). The vast majority of the increases in  
7 MDA8 O<sub>3</sub> occur at ambient air concentrations below 50 ppb. The relationship between the  
8 starting concentrations and the changes in these values based on the HDDM adjustments is fairly  
9 linear with strong negative correlation in all eight urban study areas.<sup>19</sup> In some study areas, such  
10 as Philadelphia and Detroit, there is a bimodal pattern near the center of the distribution, which  
11 may be indicative of differing behavior near the urban population center versus the surrounding  
12 suburban areas.


13 The maps reveal consistent spatial patterns of O<sub>3</sub> changes across the urban study areas.  
14 The design values generally decreased when air quality was adjusted to meet the current standard  
15 of 70 ppb<sup>20</sup> and continued to decrease when air quality was further adjusted for the 65 ppb  
16 scenario (Figure 3C-91 through Figure 3C-106). The design values tend to decrease more  
17 quickly in suburban and rural areas than in the urban population centers. The May-September  
18 “seasonal” average MDA8 values also followed this trend to some extent, although the behavior  
19 in the urban population centers varied slightly amongst the urban study areas (Figure 3C-107  
20 through Figure 3C-114). In summary, these figures show that using the CAMx/HDDM  
21 adjustment methodology, peak O<sub>3</sub> concentrations are reduced in urban study areas with large  
22 domain-wide reductions in U.S. anthropogenic NO<sub>x</sub> emissions.

---


<sup>19</sup> Except for the “Observed - 75 ppb” changes for the three urban study areas where the design values were adjusted upwards: Boston, Detroit, and St. Louis.

<sup>20</sup> All design values from the VNA surfaces decreased when going from recent conditions to the 75 ppb adjustment scenario, with the exceptions of study areas that required upward adjustments for the 75 ppb scenario: Boston, Detroit, and St. Louis.







**Figure 3C-83. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the Atlanta study area.**




**Figure 3C-84. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the Boston study area.**




1  
2 **Figure 3C-85. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the Dallas study area.**



**Figure 3C-86. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the Detroit study area.**




**Figure 3C-87. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the Philadelphia study area.**




**Figure 3C-88. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the Phoenix study area.**





1  
2 **Figure 3C-89. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the Sacramento study area.**



**Figure 3C-90. Changes in MDA8 O<sub>3</sub> based on HDDM adjustments in the St. Louis study area.**







Figure 3C-91. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Atlanta study area.





**Figure 3C-92. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Atlanta study area.**







Figure 3C-93. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Boston study area.





**Figure 3C-94. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Boston study area.**





Figure 3C-95. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Dallas study area.





**Figure 3C-96. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Dallas study area.**





Figure 3C-97. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Detroit study area.





**Figure 3C-98. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Detroit study area.**







Figure 3C-99. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Philadelphia study area.





**Figure 3C-100. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Philadelphia study area.**





Figure 3C-101. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Phoenix study area.





**Figure 3C-102. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Phoenix study area.**




Figure 3C-103. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Sacramento study area.






Figure 3C-104. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the Sacramento study area.






Figure 3C-105. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the St. Louis study area.






**Figure 3C-106. Changes in annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> based on HDDM adjustments in the St. Louis study area.**







**Figure 3C-107. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the Atlanta study area.**



**Figure 3C-108. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the Boston study area.**




**Figure 3C-109. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the Dallas study area.**




**Figure 3C-110. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the Detroit study area.**







**Figure 3C-111. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the Philadelphia study area.**



**Figure 3C-112. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the Phoenix study area.**



**Figure 3C-113. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the Sacramento study area.**



**Figure 3C-114. Annual 4<sup>th</sup> highest MDA8 O<sub>3</sub> and May-September mean MDA8 O<sub>3</sub> by population based on HDDM adjustments in the St. Louis study area.**



## REFERENCES

- Carlton, AG, Bhawe, PV, Napelenok, SL, Edney, EO, Sarwar, G, Pinder, RW, Pouliot, GA and Houyoux, M (2010). Model Representation of Secondary Organic Aerosol in CMAQv4.7. *Environ Sci Technol* 44(22): 8553-8560.
- Chen, J, Zhao, R and Li, Z (2004). Voronoi-based k-order neighbour relations for spatial analysis. *J Photogramm Remote Sens* 59(1): 60-72.
- Cohan, DS, Hakami, A, Hu, Y and Russell, AG (2005). Nonlinear Response of Ozone to Emissions: Source Apportionment and Sensitivity Analysis. *Environ Sci Technol* 39(17): 6739-6748.
- Dunker, AM (1984). The decoupled direct method for calculating sensitivity coefficients in chemical kinetics. *J Chem Phys* 81(5): 2385-2393.
- ERG (2017). Technical Report: Development of Mexico Emission Inventories for the 2014 Modeling Platform. Research Triangle Park, NC. Available at: [ftp://newftp.epa.gov/Air/emismod/2014/v2/2014fd/emissions/EPA%205-18%20Report\\_Clean%20Final\\_01042017.pdf](ftp://newftp.epa.gov/Air/emismod/2014/v2/2014fd/emissions/EPA%205-18%20Report_Clean%20Final_01042017.pdf)
- Gery, MW, Whitten, GZ, Killus, JP and Dodge, MC (1989). A photochemical kinetics mechanism for urban and regional scale computer modeling. *J. Geophys. Res* 94(12): 925-912.
- Gilliam, RC and Pleim, JE (2009). Performance Assessment of New Land Surface and Planetary Boundary Layer Physics in the WRF-ARW. *J Appl Meteorol Climatol* 49(4): 760-774.
- Gold, CM, Remmele, PR and Roos, T (1997). Voronoi methods in GIS. *Algorithmic Foundations of Geographic Information Systems*. Springer Berlin Heidelberg. Berlin, Heidelberg 1340: 21-35.
- Hakami, A, Bergin, M and Russell, A (2004). Ozone formation potential of organic compounds in the eastern United States: a comparison of episodes, inventories, and domains. *Environ. Sci. Technol.*
- Hakami, A, Odman, MT and Russell, AG (2003). High-Order, Direct Sensitivity Analysis of Multidimensional Air Quality Models. *Environ Sci Technol* 37(11): 2442-2452.
- Heath, NK, Pleim, JE, Gilliam, RC and Kang, D (2016). A simple lightning assimilation technique for improving retrospective WRF simulations. *J Adv Model Earth Syst* 8(4): 1806-1824.
- Henderson, B, Dolwick, P, Jang, C, Misenis, C, Possiel, N, Timin, B, Eyth, A, Vukovich, J, Mathur, R, Hogrefe, C, Pouliot, G, Appel, W and Brehme, K (2018). Hemispheric CMAQ Application and Evaluation for 2016. 2018 CMAQ Annual Conference Chapel Hill, NC.

- Houyoux, MR, Vukovich, JM, Coats Jr., CJ, Wheeler, NJM and Kasibhatla, PS (2000). Emission inventory development and processing for the Seasonal Model for Regional Air Quality (SMRAQ) project. *Journal of Geophysical Research: Atmospheres* 105(D7): 9079-9090.
- Koo, B, Dunker, AM and Yarwood, G (2007). Implementing the decoupled direct method for sensitivity analysis in a particulate matter air quality model. *Environ Sci Technol* 41(8): 2847-2854.
- Napelenok, SL, Foley, KM, Kang, D, Mathur, R, Pierce, T and Rao, ST (2011). Dynamic evaluation of regional air quality model's response to emission reductions in the presence of uncertain emission inventories. *Atmos Environ* 45(24): 4091-4098.
- Nenes, A, Pandis, SN and Pilinis, C (1998). ISORROPIA: A New Thermodynamic Equilibrium Model for Multiphase Multicomponent Inorganic Aerosols. *Aquat Geochem* 4(1): 123-152.
- Pouliot, G and Bash, J (2015). Updates to Version 3.61 of the Biogenic Emission Inventory System (BEIS). Presented at Air and Waste Management Association conference Raleigh, NC
- R Core Team (2018). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing Vienna, Austria. Available at <https://www.R-project.org>.
- Ramboll Environ (2014). wrfcamx version 4.3 Release Notes. December 17, 2014 Ramboll Environ International Corporation. Novato, CA. Available at: <http://www.camx.com/>.
- Simon, H, Baker, KR, Akhtar, F, Napelenok, SL, Possiel, N, Wells, B and Timin, B (2013). A direct sensitivity approach to predict hourly ozone resulting from compliance with the National Ambient Air Quality Standard. *Environ Sci Technol* 47(5): 2304-2313.
- Skamarock, C, Klemp, J, Dudhia, J, Gill, D, Barker, D, Duda, M, Huang, X-Y, Wang, W and Powers, G (2008). A Description of the Advanced Research WRF Version 3 (No. NCAR/TN-475+STR). Mesoscale and Microscale Meteorology Division, National Center for Atmospheric Research. Boulder, Colorado, . Available at: <https://opensky.ucar.edu/islandora/object/technotes:500>.
- Turner, R (2018). ddeldir: Delaunay Triangulation and Dirichlet (Voronoi) Tessellation. Version 0.1-15. Available at <https://cran.R-project.org/package=deldir/>.
- U.S. EPA (2007). Guidance on the Use of Models and Other Analyses for Demonstrating Attainment of Air Quality Goals for Ozone, PM<sub>2.5</sub>, and Regional Haze. U.S. Environmental Protection Agency. Research Triangle Park, North Carolina. U.S. EPA. EPA -454/B-07-002. <https://nepis.epa.gov/Exe/ZyPDF.cgi/P1009OL1.PDF?Dockey=P1009OL1.PDF>.
- U.S. EPA (2014). Health Risk and Exposure Assessment for Ozone. (Final Report). Office of Air Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-14-

- 004a. August 2014. Available at:  
<https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KBUF.txt>.
- U.S. EPA (2017). Meteorological Model Performance for Annual 2016 Simulation WRF v3.8. Office of Air Quality Planning and Standards. Research Triangle Park, NC. Available at: [https://www3.epa.gov/ttn/scram/guidance/met/MET\\_TSD\\_2016.pdf](https://www3.epa.gov/ttn/scram/guidance/met/MET_TSD_2016.pdf).
- U.S. EPA (2019). Technical Support Document: Preparation of Emissions Inventories for the Version 7.1 2016 North American Emissions Modeling Platform. Office of Air Quality Planning and Standards, U.S. Environmental Protection Agency. Research Triangle Park, NC. Available at: [https://www.epa.gov/sites/production/files/2019-08/documents/2016v7.1\\_northamerican\\_emismod\\_tsd.pdf](https://www.epa.gov/sites/production/files/2019-08/documents/2016v7.1_northamerican_emismod_tsd.pdf).
- U.S. EPA (2020). Policy Assessment for the Review of the Ozone National Ambient Air Quality Standards. U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards, Health and Environmental Impacts Division. Research Triangle Park, NC. U.S. EPA. EPA-452/R-20-001. 2020 Available at: <https://www.epa.gov/naaqs/ozone-o3-standards-policyassessments-current-review>.
- Yang, Y-J, Wilkinson, JG and Russell, AG (1997). Fast, Direct Sensitivity Analysis of Multidimensional Photochemical Models. *Environ Sci Technol* 31(10): 2859-2868.
- Yarwood, G, Whitten, GZ and Jung, J (2010). Development, Evaluation and Testing of Version 6 of the Carbon Bond Chemical Mechanism (CB6). Texas Commission on Environmental Quality, ENVIRON International Corporation Austin, Texas <https://www.tceq.texas.gov/assets/public/implementation/air/am/contracts/reports/pm/5820784005FY1026-20100922-environ-cb6.pdf>.
- Zhang, W, Capps, SL, Hu, Y, Nenes, A, Napelenok, SL and Russell, AG (2012). Development of the high-order decoupled direct method in three dimensions for particulate matter: enabling advanced sensitivity analysis in air quality models. *Geosci Model Dev* 5(2): 355-368.

**APPENDIX 3D**

**EXPOSURE AND RISK ANALYSIS FOR THE OZONE NAAQS REVIEW**

**TABLE OF CONTENTS**

|        |  |        |
|--------|--|--------|
| 3D.1   | INTRODUCTION .....   | 3D-9   |
| 3D.1.1 | Planning and Scientific/Public Review of the Current Analysis .....      | 3D-10  |
| 3D.1.2 | Overview .....   | 3D-11  |
| 3D.1.3 | 2014 Ozone Exposure and Risk Assessment .....                            | 3D-12  |
| 3D.1.4 | Current Analysis .....   | 3D-14  |
| 3D.2   | POPULATION EXPOSURE AND RISK APPROACH.....                               | 3D-15  |
| 3D.2.1 | Urban Study Areas .....  | 3D-16  |
| 3D.2.2 | Simulated Populations .....  | 3D-20  |
| 3D.2.3 | Ambient Air Concentrations .....   | 3D-34  |
| 3D.2.4 | Meteorological Data.....   | 3D-48  |
| 3D.2.5 | Construction of Human Activity Pattern Sequences .....                   | 3D-50  |
| 3D.2.6 | Microenvironmental Concentrations .....                                  | 3D-61  |
| 3D.2.7 | Estimating Exposure .....  | 3D-72  |
| 3D.2.8 | Estimating Risk.....   | 3D-72  |
| 3D.2.9 | Assessing Variability/Co-Variability and Characterizing Uncertainty..... | 3D-87  |
| 3D.3   | POPULATION EXPOSURE AND RISK RESULTS.....                                | 3D-93  |
| 3D.3.1 | Characteristics of the Simulated Population and Study Areas.....         | 3D-94  |
| 3D.3.2 | Exposures at or above Benchmark Concentrations .....                     | 3D-96  |
| 3D.3.3 | Lung Function Risk.....  | 3D-116 |
| 3D.3.4 | Uncertainty Characterization .....                                       | 3D-144 |
| 3D.4   | REFERENCES .....   | 3D-178 |

**ATTACHMENTS**

1. Estimating U.S. Census Tract-level Asthma Prevalence (2013-2017)
2. ICF Technical Memo: Identification of Simulated Individuals at Moderate Exertion
3. ICF Technical Memo: Updates to the Meteorology Data and Activity Locations within CHAD
4. Detailed Exposure and Risk Results

## TABLE OF TABLES

|              |   |       |
|--------------|---|-------|
| Table 3D-1.  | Criteria used to identify and select urban study areas for inclusion in the O <sub>3</sub> exposure and risk analyses.....  | 3D-19 |
| Table 3D-2.  | General description of ambient air quality domains for the eight study areas.....   | 3D-20 |
| Table 3D-3.  | Descriptive statistics for children and adult asthma prevalence, using all census tracts within eight consolidated statistical areas (CSAs) in the APEX asthma prevalence file..... | 3D-24 |
| Table 3D-4.  | Regression parameters used to estimate RMR by sex and age groups. ....  | 3D-29 |
| Table 3D-5.  | List of states, counties, and O <sub>3</sub> seasons that define the air quality and exposure spatial and temporal modeling domain in each study area. ....                         | 3D-37 |
| Table 3D-6.  | List of ambient air monitor IDs, range of O <sub>3</sub> design values, and number of monitors in each study area.....  | 3D-43 |
| Table 3D-7.  | Range of the percent NO <sub>x</sub> emission changes needed to adjust air quality in the eight study areas for the three air quality scenarios.....                                | 3D-45 |
| Table 3D-8.  | Study area meteorological stations, locations, and hours of missing data.....   | 3D-50 |
| Table 3D-9.  | Overview of Studies Included in the APEX Activity Data Files.....   | 3D-52 |
| Table 3D-10. | Comparison of time spent outdoors and exertion level by asthma status for children and adult diaries used by APEX. ....   | 58    |
| Table 3D-11. | Number of diary days in CHAD for children and adults, grouped by temperature and day-type categories.....   | 3D-59 |
| Table 3D-12. | Microenvironments modeled and calculation method used.....  | 3D-65 |
| Table 3D-13. | Air exchange rates (AER, hr <sup>-1</sup> ) for indoor residential microenvironments with A/C by study area and temperature. ....   | 3D-67 |
| Table 3D-14. | Air exchange rates (AER, hr <sup>-1</sup> ) for indoor residential microenvironments without A/C by study area and temperature.....   | 3D-68 |
| Table 3D-15. | Individual air exchange rate data (hr <sup>-1</sup> ) obtained from three studies used to develop an AER distribution used for schools in all study areas.....                      | 3D-69 |
| Table 3D-16. | A/C prevalence from US Census American Housing Survey (AHS) data by study area.....   | 3D-70 |
| Table 3D-17. | Parameter values for distributions of penetration and proximity factors used for estimating in-vehicle ME concentrations.....   | 3D-72 |
| Table 3D-18. | VMT (2015-2017) derived conditional probabilities for interstate, urban, and local roads used to select inside-vehicle proximity factor distributions in each study area.....       | 3D-72 |
| Table 3D-19. | Responses reported in 6.6-hr controlled human exposure studies at a given benchmark concentration. ....   | 3D-76 |

|    |   |        |
|----|---|--------|
| 1  | Table 3D-20. Summary of controlled human exposure study data stratified by concentration      |        |
| 2  | level and lung function decrements, corrected for individual response that                    |        |
| 3  | occurred while exercising in clean air, ages 18-35. ....                                      | 3D-78  |
| 4  | Table 3D-21. Estimated coefficients for the MSS lung function model. ....                     | 3D-86  |
| 5  | Table 3D-22. Age term parameters for application of the MSS model to all ages. ....           | 3D-88  |
| 6  | Table 3D-23. Summary of how variability was incorporated into the exposure and risk analysis. |        |
| 7  | 3D-90   |        |
| 8  | Table 3D-24. Important components of co-variability in exposure modeling. ....                | 3D-93  |
| 9  | Table 3D-25. Summary of study area features and the simulated population. ....                | 3D-97  |
| 10 | Table 3D-26. Percent of people estimated to experience at least one exposure at or above      |        |
| 11 | benchmarks while at moderate or greater exertion, for air quality adjusted to just            |        |
| 12 | meet the current standard. ....   | 3D-101 |
| 13 | Table 3D-27. Number of people estimated to experience at least one exposure at or above       |        |
| 14 | benchmarks while at moderate or greater exertion, for air quality adjusted to just            |        |
| 15 | meet the current standard. ....   | 3D-102 |
| 16 | Table 3D-28. Percent of people estimated to experience at least two exposures at or above     |        |
| 17 | benchmarks while at moderate or greater exertion, for air quality adjusted to just            |        |
| 18 | meet the current standard. ....   | 3D-103 |
| 19 | Table 3D-29. Number of people estimated to experience at least two exposures at or above      |        |
| 20 | benchmarks while at moderate or greater exertion, for air quality adjusted to just            |        |
| 21 | meet the current standard. ....   | 3D-104 |
| 22 | Table 3D-30. Percent of people estimated to experience at least four exposures at or above    |        |
| 23 | benchmarks while at moderate or greater exertion, for air quality adjusted to just            |        |
| 24 | meet the current standard. ....   | 3D-105 |
| 25 | Table 3D-31. Number of people estimated to experience at least four exposures at or above     |        |
| 26 | benchmarks while at moderate or greater exertion, for air quality adjusted to just            |        |
| 27 | meet the current standard. ....   | 3D-106 |
| 28 | Table 3D-32. Percent of people estimated to experience at least one exposure at or above      |        |
| 29 | benchmarks while at moderate or greater exertion, for the 75 ppb air quality                  |        |
| 30 | scenario. ....  | 3D-108 |
| 31 | Table 3D-33. Percent of people estimated to experience at least two exposures at or above     |        |
| 32 | benchmarks while at moderate or greater exertion, for the 75 ppb air quality                  |        |
| 33 | scenario. ....  | 3D-109 |
| 34 | Table 3D-34. Percent of people estimated to experience at least four exposures at or above    |        |
| 35 | benchmarks while at moderate or greater exertion, for the 75 ppb air quality                  |        |
| 36 | scenario. ....  | 3D-110 |
| 37 | Table 3D-35. Percent of people estimated to experience at least one exposure at or above      |        |
| 38 | benchmarks while at moderate or greater exertion, for the 65 ppb air quality                  |        |
| 39 | scenario. ....  | 3D-112 |

|    |   |        |
|----|---|--------|
| 1  | Table 3D-36. Percent of people estimated to experience at least two exposures at or above       |        |
| 2  | benchmarks while at moderate or greater exertion, for the 65 ppb air quality                    |        |
| 3  | scenario. ....  | 3D-113 |
| 4  | Table 3D-37. Percent of people estimated to experience at least four exposures at or above      |        |
| 5  | benchmarks while at moderate or greater exertion, for the 65 ppb air quality                    |        |
| 6  | scenario. ....  | 3D-114 |
| 7  | Table 3D-38. Comparison of current assessment to 2014 HREA for percent of children              |        |
| 8  | estimated to experience at least one exposure at or above benchmarks while at                   |        |
| 9  | moderate or greater exertion. ....  | 3D-116 |
| 10 | Table 3D-39. Comparison of current assessment to 2014 HREA for percent of children              |        |
| 11 | estimated to experience at least two exposure at or above benchmarks while at                   |        |
| 12 | moderate or greater exertion. ....  | 3D-117 |
| 13 | Table 3D-40. Percent of people estimated to experience at least one lung function decrement at  |        |
| 14 | or above the indicated level, for air quality adjusted to just meet the current                 |        |
| 15 | standard, using the population-based (E-R function) risk approach. ....                         | 3D-120 |
| 16 | Table 3D-41. Number of people estimated to experience at least one lung function decrement at   |        |
| 17 | or above the indicated level, for air quality adjusted to just meet the current                 |        |
| 18 | standard, using the population-based (E-R function) risk approach. ....                         | 3D-121 |
| 19 | Table 3D-42. Percent of people estimated to experience at least two lung function decrements at |        |
| 20 | or above the indicated level, for air quality adjusted to just meet the current                 |        |
| 21 | standard, using the population-based (E-R function) risk approach. ....                         | 3D-122 |
| 22 | Table 3D-43. Number of people estimated to experience at least two lung function decrements     |        |
| 23 | at or above the indicated level, for air quality adjusted to just meet the current              |        |
| 24 | standard, using the population-based (E-R function) risk approach. ....                         | 3D-123 |
| 25 | Table 3D-44. Percent of people estimated to experience at least four lung function decrements   |        |
| 26 | at or above the indicated level, for air quality adjusted to just meet the current              |        |
| 27 | standard, using the population-based (E-R function) risk approach. ....                         | 3D-124 |
| 28 | Table 3D-45. Number of people estimated to experience at least four lung function decrements    |        |
| 29 | at or above the indicated level, for air quality adjusted to just meet the current              |        |
| 30 | standard, using the population-based (E-R function) risk approach. ....                         | 3D-125 |
| 31 | Table 3D-46. Percent of people estimated to experience at least one lung function decrement at  |        |
| 32 | or above the indicated level, for the 75 ppb air quality scenario, using the                    |        |
| 33 | population-based (E-R function) risk approach. ....   | 3D-126 |
| 34 | Table 3D-47. Percent of people estimated to experience at least two lung function decrements at |        |
| 35 | or above the indicated level, for the 75 ppb air quality scenario, using the                    |        |
| 36 | population-based (E-R function) risk approach. ....   | 3D-127 |
| 37 | Table 3D-48. Percent of people estimated to experience at least four lung function decrements   |        |
| 38 | at or above the indicated level, for the 75 ppb air quality scenario, using the                 |        |
| 39 | population-based (E-R function) risk approach. ....   | 3D-128 |

|    |   |        |
|----|---|--------|
| 1  | Table 3D-49. Percent of people estimated to experience at least one lung function decrement at  |        |
| 2  | or above the indicated level, for the 65 ppb air quality scenario, using the                    |        |
| 3  | population-based (E-R function) risk approach. ....   | 3D-129 |
| 4  | Table 3D-50. Percent of people estimated to experience at least two lung function decrements at |        |
| 5  | or above the indicated level, for the 65 ppb air quality scenario, using the                    |        |
| 6  | population-based (E-R function) risk approach. ....   | 3D-130 |
| 7  | Table 3D-51. Percent of people estimated to experience at least four lung function decrements   |        |
| 8  | at or above the indicated level, for the 65 ppb air quality scenario, using the                 |        |
| 9  | population-based (E-R function) risk approach. ....   | 3D-131 |
| 10 | Table 3D-52. Percent of people estimated to experience at least one lung function decrement at  |        |
| 11 | or above the indicated level, for air quality adjusted to just meet the current                 |        |
| 12 | standard, using the individual-based (MSS model) risk approach. ....                            | 3D-133 |
| 13 | Table 3D-53. Number of people estimated to experience at least one lung function decrement at   |        |
| 14 | or above the indicated level, for air quality adjusted to just meet the current                 |        |
| 15 | standard, using the individual-based (MSS model) risk approach. ....                            | 3D-134 |
| 16 | Table 3D-54. Percent of people estimated to experience at least two lung function decrements at |        |
| 17 | or above the indicated level, for air quality adjusted to just meet the current                 |        |
| 18 | standard, using the individual-based (MSS model) risk approach. ....                            | 3D-135 |
| 19 | Table 3D-55. Number of people estimated to experience at least two lung function decrements     |        |
| 20 | at or above the indicated level, for air quality adjusted to just meet the current              |        |
| 21 | standard, using the individual-based (MSS model) risk approach. ....                            | 3D-136 |
| 22 | Table 3D-56. Percent of people estimated to experience at least four lung function decrements   |        |
| 23 | at or above the indicated level, for air quality adjusted to just meet the current              |        |
| 24 | standard, using the individual-based (MSS model) risk approach. ....                            | 3D-137 |
| 25 | Table 3D-57. Number of people estimated to experience at least four lung function decrements    |        |
| 26 | at or above the indicated level, for air quality adjusted to just meet the current              |        |
| 27 | standard, using the individual-based (MSS model) risk approach. ....                            | 3D-138 |
| 28 | Table 3D-58. Percent of people estimated to experience at least one lung function decrement at  |        |
| 29 | or above the indicated level, for the 75 ppb air quality scenario, using the                    |        |
| 30 | individual-based (MSS model) risk approach. ....  | 3D-139 |
| 31 | Table 3D-59. Percent of people estimated to experience at least two lung function decrements at |        |
| 32 | or above the indicated level, for the 75 ppb air quality scenario, using the                    |        |
| 33 | individual-based (MSS model) risk approach. ....  | 3D-140 |
| 34 | Table 3D-60. Percent of people estimated to experience at least four lung function decrements   |        |
| 35 | at or above the indicated level, for the 75 ppb air quality scenario, using the                 |        |
| 36 | individual-based (MSS model) risk approach. ....  | 3D-141 |
| 37 | Table 3D-61. Percent of people estimated to experience at least one lung function decrement at  |        |
| 38 | or above the indicated level, for the 65 ppb air quality scenario, using the                    |        |
| 39 | individual-based (MSS model) risk approach. ....  | 3D-142 |



|    |  |        |
|----|--|--------|
| 1  | Table 3D-62. Percent of people estimated to experience at least two lung function decrements at            |        |
| 2  | or above the indicated level, for the 65 ppb air quality scenario, using the                               |        |
| 3  | individual-based (MSS model) risk approach.....  | 3D-143 |
| 4  | Table 3D-63. Percent of people estimated to experience at least four lung function decrements              |        |
| 5  | at or above the indicated level, for the 65 ppb air quality scenario, using the                            |        |
| 6  | individual-based (MSS model) risk approach.....  | 3D-144 |
| 7  | Table 3D-64. Characterization of key uncertainties in exposure and risk analyses using                     |        |
| 8  | APEX.....  | 3D-147 |
| 9  | Table 3D-65. Percent of children estimated to experience at least one lung function decrement              |        |
| 10 | at or above the indicated level, for air quality adjusted to just meet the current                         |        |
| 11 | standard, using the population-based (E-R function) risk approach. ....                                    | 3D-164 |
| 12 | Table 3D-66. Estimated lung function risk contribution resulting from selected 7-hr average O <sub>3</sub> |        |
| 13 | exposures in children, using the E-R function risk approach, 2016. ....                                    | 3D-167 |
| 14 | Table 3D-67. MSS model risk estimates from varying the number of simulated children.                       | 3D-169 |
| 15 | Table 3D-68. Estimated lung function risk contribution resulting from selected 7-hr average O <sub>3</sub> |        |
| 16 | exposures in children, using the MSS model risk approach, 2016. ....                                       | 3D-170 |
| 17 | Table 3D-69. Percent of children experiencing one or more FEV <sub>1</sub> decrements ≥10, 15, 20%,        |        |
| 18 | 2016 air quality adjusted to just meet the current standard, considering influence                         |        |
| 19 | of moderate or greater exertion level in the MSS model and E-R function risk                               |        |
| 20 | approaches.....  | 3D-175 |
| 21 | Table 3D-70. Percent of children experiencing one or more FEV <sub>1</sub> decrements ≥10, 15, 20%,        |        |
| 22 | 2016 air quality adjusted to just meet the current standard, considering the setting                       |        |
| 23 | of variability parameter, $\nu_l$ , in the MSS model. ....   | 3D-179 |
| 24 |  |        |
| 25 |  |        |

## TABLE OF FIGURES

|               |   |       |
|---------------|---|-------|
| Figure 3D-1.  | Locations of the eight study areas selected for the current O <sub>3</sub> exposure and risk analysis.....  | 3D-18 |
| Figure 3D-2.  | County boundaries, census tract population densities, and meteorological stations in the Atlanta (top) and Boston (bottom) study areas. ....  | 3D-38 |
| Figure 3D-3.  | County boundaries, census tract population densities, and meteorological stations in the Dallas (top) and Detroit (bottom) study areas.....   | 3D-39 |
| Figure 3D-4.  | County boundaries, census tract population densities, and meteorological stations in the Philadelphia (top) and Phoenix (bottom) study areas. ....  | 3D-40 |
| Figure 3D-5.  | County boundaries, census tract population densities, and meteorological stations in the Sacramento (top) and St. Louis (bottom) study areas.....   | 3D-41 |
| Figure 3D-6.  | Hourly O <sub>3</sub> distributions by hour-of-day (left panel) and month (right panel) at ambient air monitoring sites in Philadelphia for observed air quality (black), air quality adjusted to meet the current standard (70 ppb, blue) and two other design values (75 ppb, red; and 65 ppb, green). From draft PA, Appendix 3C, Figures 3C-71 and 3C-79, respectively. ....  | 3D-46 |
| Figure 3D-7.  | Histograms of hourly O <sub>3</sub> concentrations (ppb, x-axis) for the air quality scenario just meeting the current O <sub>3</sub> standard in the eight study areas. The x-axis midpoint concentrations range from 0 to 70 ppb, in 2 ppb increments (rightmost, maximum histogram bar for all study areas represents the frequency of all hourly concentrations >70 ppb)..... | 3D-48 |
| Figure 3D-8.  | Calculated design values for census tracts in the Philadelphia study area, derived from a VNA interpolation of CAMx/HDDM adjusted O <sub>3</sub> concentrations. Figure modified from Appendix 3C, Figure 3C-99. ....   | 3D-49 |
| Figure 3D-9.  | Percent of children (5-18 years) and adults (19-90 years) having afternoon time outdoors while at moderate or greater exertion, categorized by daily maximum temperature (°F) and time (hours/day) groups. ....   | 3D-59 |
| Figure 3D-10. | Illustration of the mass balance model used by APEX to estimate concentrations within indoor microenvironments.....   | 3D-63 |
| Figure 3D-11. | Controlled human exposure data for FEV <sub>1</sub> responses in individual study subjects.....   | 3D-79 |
| Figure 3D-12. | Median value of Bayesian fit population-based E-R function data (left panel) and illustrative curves (right panel) for FEV <sub>1</sub> decrements ≥10% (top panel), ≥15 (middle panel), ≥20% (bottom panel). Drawn from the 2014 HREA, Table 6A-1 with processing and model development described by Abt (2013).....   | 3D-82 |
| Figure 3D-13. | Conceptual representation of the two-compartment model used by the MSS model. $C$ is exposure concentration, $V$ is ventilation rate, $t$ is time, $X$ is an intermediate quantity, $a$ is a decay constant. Adapted from Figure 1 in McDonnell et al. (1999). ....   | 3D-84 |
| Figure 3D-14. | Comparison of a probit function curve (blue line) with the Bayesian logistic/linear function curve (red) in estimating the probability of lung function decrements  |       |

|    |  |        |
|----|--|--------|
| 1  | ≥15% (based on data in Table 3D-20). Confidence intervals for the probit model                                       |        |
| 2  | reflect variability in the regression model coefficients.....  | 3D-162 |
| 3  | Figure 3D-15. Estimated lung function risk contribution resulting from selected 7-hr average O <sub>3</sub>          |        |
| 4  | exposures in children, using the E-R function risk approach and air quality  |        |
| 5  | adjusted to just meet the current standard, for one decrement (top panel) and two                                    |        |
| 6  | decrements (bottom panel), 2016.....   | 3D-168 |
| 7  | Figure 3D-16. Lung function risk contribution resulting from selected 7-hr average O <sub>3</sub> exposures          |        |
| 8  | in children, using the MSS model risk approach and air quality adjusted to just                                      |        |
| 9  | meet the current standard, for one decrement (top panel) and two decrements  |        |
| 10 | (bottom panel), 2016.....  | 3D-171 |
| 11 | Figure 3D-17. Example time-series of O <sub>3</sub> exposures, EVR, and FEV <sub>1</sub> reductions estimated using  |        |
| 12 | MSS model for a simulated child in the Atlanta study area, based on a day in a                                       |        |
| 13 | year (2016) of the current standard air quality scenario. ....   | 3D-173 |
| 14 | Figure 3D-18. Time-series of O <sub>3</sub> exposures, EVR, and FEV <sub>1</sub> reductions of 10% (left panel), 15% |        |
| 15 | (middle panel), and 20% (right panel) estimated using MSS model for two  |        |
| 16 | simulated children (interpersonal variability parameter $U = 0.963$ , top panel; $U =$                               |        |
| 17 | $1.78$ , bottom panel) in the Atlanta study area on three days in a year (2016) of the                               |        |
| 18 | current air quality scenario.....  | 3D-178 |
| 19 |  |        |

### 3D.1 INTRODUCTION

This appendix summarizes the quantitative exposure and risk analysis performed for the 2020 O<sub>3</sub> NAAQS review. The analysis builds upon the methodology and lessons learned from the human exposure and risk analyses conducted in the 2015 O<sub>3</sub> review (2014 HREA; U.S. EPA, 2014), analysis plans outlined in the Integrated Review Plan (IRP; U.S. EPA, 2019d), and information provided in the 2020 O<sub>3</sub> Integrated Science Assessment (ISA; U.S. EPA, 2020a), which builds on the 2013 ISA (U.S. EPA, 2013).

Exposures and risks were modeled for people residing in eight U.S. urban study areas,<sup>1</sup> considering three hypothetical air quality scenarios developed from ambient air O<sub>3</sub> monitoring data adjusted based on a photochemical model-based approach for a single 3-year period (2015 to 2017), and based on health effects observed in controlled human exposure studies. The three air quality scenarios were for O<sub>3</sub> concentrations across the study area such that the location with the highest design value<sup>2</sup> just meets: (1) the current standard (i.e., a design value of 70 ppb), (2) a design value of 75 ppb, and (3) a design value of 65 ppb. The exposures and risks were estimated for (1) all school-age children (ages 5-18), (2) school-age children with asthma (ages 5-18), (3) all adults (ages 19-90),<sup>3</sup> and (4) adults with asthma (ages 19-90),<sup>4</sup> each while at moderate or greater exertion level at the time of exposure. The strong emphasis on children and people with asthma reflects the conclusion based on the currently available evidence that these are important at-risk groups, as summarized in section 3.3.2 above of the main document and described in the ISA (ISA, section IS.6.1).

Health risk is characterized in two ways in these analyses, producing two types of risk metrics: one involving comparison of population exposures, while at elevated exertion, to benchmark concentrations, and the second involving estimated population occurrences of ambient air O<sub>3</sub>-related lung function decrements (Figure 3-3 of main document). The first risk

---

<sup>1</sup> For the 2014 HREA, controlled human exposure-based health risk was estimated in 15 urban study areas considering five air quality scenarios and two 3-year periods (2006-2008 and 2008-2010). In addition, an epidemiologic-based health risk approach was applied in 12 urban study areas also considering the same five air quality scenarios and for two single-year periods (2007 and 2009). Further, an epidemiologic-based health risk approach was applied to the continental U.S. considering a single air quality scenario (unadjusted, as is ambient air concentrations).

<sup>2</sup> The design value for these scenarios is the 3-year average of the annual 4<sup>th</sup> highest daily maximum 8-hr average O<sub>3</sub> concentration. For example, a monitoring site meets the current standard if the design value, derived from the data for that site, is less than or equal to 70 ppb.

<sup>3</sup> For the 2014 HREA, older adults (ages 65-95) were simulated as a separate group. In the current assessment, older adults within this age group are included in the simulation of all adults. Additionally, the upper age limit in the current assessment is 90 years given data limitations since recognized in CHAD for older age entries.

<sup>4</sup> For the 2014 HREA, adults with asthma (ages 19-95) were simulated, similar to the group simulated for the current assessment. Additionally, the upper age limit in the current assessment is 90 years given data limitations since recognized in CHAD for older age entries.

metric is based on comparison of estimated daily maximum 7-hour (7-hr) average exposures for individuals breathing at elevated rates to concentrations of potential concern (benchmark concentrations),<sup>5</sup> and the second uses exposure-response (E-R) information for study subjects experiencing FEV<sub>1</sub> decrements (specifically O<sub>3</sub>-related decrement of 10% or more) to estimate the portion of the simulated at-risk population expected to experience one or more days with an O<sub>3</sub>-related FEV<sub>1</sub> decrement of at least 10%, 15% and 20%.

A description of the exposure and risk modeling performed, including a summary of (1) the ways in which scientific and public review of the current analysis occurred, and (2) the 2014 HREA and important updates in modeling tools and approaches that contributed to planning and completion of the analyses presented in this document is provided in sections 3D.1.1 through 3D.1.4. The detailed description of the modeling tools, algorithms, input data and output metrics, along with an assessment of how variability is addressed in the analysis is provided in section 3D.2. Finally, the exposure and risk results, including a characterization of uncertainties, are found in section 3D.3.

### **3D.1.1 Planning and Scientific/Public Review of the Analysis**

As described in section 1.4 of the main document, a consultation with the Clean Air Scientific Advisory Committee (CASAC) was held in November 2018 on the draft IRP to receive their input and comments from the public were also solicited on the draft IRP. Both comments from the CASAC and the public were considered in shaping the analysis plans, which were summarized in the final IRP.

This appendix was developed in support of the risk and exposure analyses for the 2020 review. As outlined in section 1.5 (of the main document) the draft 2019 PA for the 2020 review, with a draft version of this appendix was made available for public comment and was reviewed and discussed by CASAC in a public meeting (84 FR 50836, September 26, 2019; 84 FR 58711, November 1, 2019). In consideration of comments from the CASAC (Cox, 2020) and the public a number of additional analyses and presentations were added to this appendix in the final 2020 PA (U.S. EPA, 2020b). These analyses, investigations and/or clarifications of the available data address a number of areas.

- Analyses of data on outdoor activity by different population groups including those identified as at risk in this review (e.g., children with asthma and older adults) during times of day when O<sub>3</sub> may be elevated (section 3D.2.5.3);

---

<sup>5</sup> The exposure duration and approach for identifying simulated individuals at moderate or greater exertion have been updated from what was used in the 2014 HREA to more closely match the circumstances of the controlled human exposure studies, as described in section 3D.2.2.3.3 and 3D.2.8.1.

- Estimates for the comparison-to-benchmarks analysis additionally summarized in light of the estimates from the last review (section 3D.3.2.4);
- Evaluation of risk characterization uncertainty related to its representation of population groups having health conditions other than asthma, of older adults, and of outdoor workers (section 3D.3.4.1);
- Evaluation of uncertainty in estimates for people with asthma that may be associated with method for identifying individuals with asthma (section 3D.3.4.1);
- Evaluation of uncertainty with the E-R function and risk estimates (section 3D.3.4.1);
- Analyses investigating the sensitivity of the MSS model outputs to the value assigned the individual variability parameter, and to low-level ventilation rates, as well as overall model uncertainty in the MSS model (section 3D.3.4.1).

### 3D.1.2 Overview

Estimates of human exposure to O<sub>3</sub> can provide meaningful answers to policy-relevant questions regarding exposures of concern and resulting risk estimates. This is particularly true when the important elements of O<sub>3</sub> exposure, i.e., the frequency, magnitude, duration, and pattern, are accounted for and when the exposures are estimated using policy-relevant ambient air quality scenarios, i.e., ambient air conditions that either just meet the current O<sub>3</sub> standard or other air quality scenarios. Further, the policy-relevance of these estimated O<sub>3</sub> exposures can be extended when they are linked with adverse health outcome data obtained from controlled human exposure studies to quantitatively estimate health risk. As a result, via the quantitative relationships that exist between ambient air concentrations, exposures, and health effects, one can estimate the impact varying air quality conditions have on public health.

Exposure to O<sub>3</sub> can be directly estimated by monitoring the concentration of O<sub>3</sub> in a person's breathing zone (close to the nose/mouth) using a personal exposure monitor. Studies employing this measurement approach have been reviewed in the current and 2013 O<sub>3</sub> ISAs and in past O<sub>3</sub> Air Quality Criteria Documents (AQCDs; U.S. EPA, 1986, 1996, U.S. EPA, 2006). Personal exposure measurements from these studies can be useful in describing a general range of exposure concentrations (among other reported measurement data) and in identifying factors that may influence varying exposure levels. However, these measurement studies of personal exposure to O<sub>3</sub> are largely limited by the disparity between measurement sample durations and durations of interest, and in appropriately capturing variability in population exposure occurring over large geographic areas, particularly when considering both O<sub>3</sub> concentrations in ambient air (e.g., spatial variability) and population (e.g., age, sex) attributes that greatly influence exposure.

Because of these limitations in personal exposure measurement data, more commonly human exposure is estimated using sophisticated models that better account for physical (e.g., meteorology) or personal (e.g., age) attributes that may strongly influence variability in

1 exposures. These exposure models can combine information on ambient air O<sub>3</sub> concentrations in  
2 various microenvironments, e.g., near roads, in schools, etc., with information on activity  
3 patterns for individuals sampled from the general population or specific subpopulations, e.g.,  
4 children with asthma. When integrating these varied data (among many others such as population  
5 demographics and disease prevalence) and understanding the key factors affecting exposure,  
6 exposure models can be more informative than the limited information given by measurement  
7 data alone.

8 Ozone exposure is highly dependent on the ambient air concentrations in an urban area,  
9 which vary spatially and temporally. An exposure model can reasonably estimate exposures for  
10 any perceivable at-risk population (e.g., people with asthma living in a large urban area) and  
11 considering any number of defined hypothetical air quality conditions (e.g., those in which  
12 concentrations just meet a particular air quality standard) provided underlying data exist to  
13 generate such estimates. Further, exposure models that account for variability in human  
14 physiology can also realistically estimate pollutant intake dose by using activity-specific  
15 ventilation rates. Each of these important features of O<sub>3</sub> exposure cannot realistically be  
16 measured for a study group or population of interest over wide ranging temporal and spatial  
17 scales, particularly when considering time, cost, and other constraints, and serve as the  
18 justification for using a modeling approach to estimate exposure and health risks.

### 19 **3D.1.3 2014 Ozone Exposure and Risk Assessment**

20 The 2014 HREA included two types of risk analyses. The first type of risk analysis,  
21 exposure-based risk, used health effect information obtained from controlled human exposure  
22 studies (summarized in the IRP, section 5.1.1.1). The second type, epidemiologic-based risk,  
23 used concentration-response functions derived from epidemiologic studies (IRP, section 5.1.1.2).  
24 Because we used only the exposure-based risk analysis approach (see section 3D.1.4 below; IRP,  
25 section 5.1.2), it is only these results that are succinctly summarized in this section.<sup>6,7</sup>

---

<sup>6</sup> Details regarding all of the risk analyses performed for the prior review can be found in chapters 5 (exposure-based health benchmark risk), 6 (exposure-based lung function risk), and 7 (epidemiologic-based risk) of the 2014 HREA.

<sup>7</sup> We note that the CASAC comments on the draft PA included several related to development of risk estimates from epidemiological study results (Cox, 2020). Because an epidemiologic-based risk analysis was not performed for this review, the issues raised by those comments are not considered here.

1 For the 2014 HREA, two exposure-based risk analyses<sup>8</sup> were performed in a set of 15  
2 urban study areas<sup>9</sup> and for five different air quality scenarios: unadjusted ambient air O<sub>3</sub>  
3 conditions, air quality adjusted to just meet the then-existing standard (75 ppb, annual 4<sup>th</sup> highest  
4 daily maximum 8-hr average concentration, averaged over a 3-year period), and air quality  
5 adjusted to just meet potential alternative O<sub>3</sub> standards having the same form and averaging  
6 times, with levels of 70, 65 and 60 ppb.<sup>10</sup> The scenarios were based on air quality from two 3-  
7 year periods: 2006-2008 and 2008-2010. The first exposure-based risk analysis involved  
8 comparison of population exposures, while at elevated exertion, to benchmark concentrations.  
9 The exposure-to-benchmark comparison characterizes the extent to which individuals in at-risk  
10 populations could experience exposures of concern (i.e., average exposure concentrations at or  
11 above specific benchmarks while at moderate or greater exertion levels) while engaging in their  
12 daily activities in study areas with air quality adjusted to just meet the then-existing standard and  
13 other O<sub>3</sub> air quality conditions. Results were characterized using three benchmark concentrations  
14 (60, 70, and 80 ppb O<sub>3</sub>), exposures to which in controlled human exposure studies yielded  
15 different occurrences and severity of respiratory effects in the human subjects (2014 HREA,  
16 section 5.2.8). The second exposure-based risk analysis involves estimated population  
17 occurrences of ambient air O<sub>3</sub>-related lung function decrements. The lung function risk analysis  
18 provides estimates of the extent to which populations in such areas could experience decrements  
19 in lung function. Based on the range of health effects considered clinically relevant and the  
20 potential for varied responses in healthy individuals versus people with asthma, the lung function  
21 risk analysis reported estimates for risk of lung function decrement at or above three different  
22 magnitudes, i.e., forced expiratory volume in one second (FEV<sub>1</sub>) reductions of at least 10%,  
23 15%, and 20% (2014 HREA, section 6.2.1).

24 Key observations and insights from the O<sub>3</sub> exposure-to-benchmark comparison and lung  
25 function risks, in addition to important caveats and limitations, were addressed in Section II.B of  
26 the Final Rule notice (80 FR 65312 to 65315, October 26, 2015). The exposure-based analyses in

---

<sup>8</sup> For the primary analysis results in the 2014 HREA, population exposures were used to estimate health benchmark and lung function risks using an individual-based approach. In addition, a population-based E-R function approach was used to estimate lung function risk but done mainly for comparison with the individual-based approach and with prior review assessment results.

<sup>9</sup> The 15 urban study areas assessed were Atlanta, Baltimore, Boston, Chicago, Cleveland, Dallas, Denver, Detroit, Houston, Los Angeles, New York, Philadelphia, Sacramento, St. Louis, and Washington, DC.

<sup>10</sup> These scenarios reflect air quality with design values that equal the level of the now-current standard and two others having levels just above and below the current standard. The air quality data were generated using a combined ambient monitor data and modeling approach similar to that used for the current assessment. These simulations were intended to be illustrative and do not reflect any consideration of specific control programs designed to meet the specified standards. Further, these simulations were not intended to represent predictions of when, whether, or how areas might meet a specified standard.



the 2014 HREA, and most particularly the exposure to benchmarks analysis were important considerations in the 2015 decision on revisions to the primary O<sub>3</sub> standard (80 FR 65362-65365, October 26, 2015).

#### **3D.1.4 Current Analysis**

As described in the IRP (section 5.1.2.2), the quantitative analyses for focus on the comparison to benchmark exposure-based risk analysis approach, based on the controlled human exposure studies. In part, this is because substantial updates to data, information, models, and tools are available, ensuring that the new exposure and risk estimates are both improved and appropriately targeted. Additionally, estimates from the exposure-based analyses, particularly the comparison of daily maximum exposures to benchmark concentrations, were most informative to the Administrator's decision in the 2015 review (IRP, section 3.1.2). This largely reflected the EPA conclusion that "controlled human exposure studies provide the most certain evidence indicating the occurrence of health effects in humans following specific O<sub>3</sub> exposures," and recognition that "effects reported in controlled human exposure studies are due solely to O<sub>3</sub> exposures, and interpretation of study results is not complicated by the presence of co-occurring pollutants or pollutant mixtures (as is the case in epidemiologic studies)" (80 FR 65343, October 26, 2015). In the 2015 review, the Administrator placed relatively less weight on the air quality epidemiologic-based risk estimates, in recognition of an array of uncertainties, including, for example, those related to exposure measurement error (80 FR 65346, October 26, 2015).

##### **3D.1.4.1 Aspects updated since 2014**

A number of aspects of the exposure-based risk analyses were updated since the 2014 HREA. The updates were based on important uncertainties characterized in the 2015 review and having newly available data, information, models, and tools that could provide risk estimates in which we have greater confidence that was the case for the risks estimated in the 2015 review, as summarized in Appendix 5A of the IRP. These updates include:

- Air quality
  - More recent (2015-2017) ambient air monitoring data from US EPA's Air Quality System (AQS) having unadjusted concentrations at or near the current standard (section 3D.2.3.2);
  - Updated photochemical model (CAMx version 6.5)<sup>11</sup> to adjust ambient air concentrations to just meet the air quality scenarios to be assessed (section 3D.2.3.3).
- Exposure and risk model

---

<sup>11</sup> CAMx is the Comprehensive Air Quality Model with Extensions. This model is briefly described in Appendix 3C. Additional information and model download can be found at <http://www.camx.com/>.

- More recent (2010) U.S. Census demographics and commuting data (section 3D.2.2.1);
- More recent (2013-2017) asthma prevalence for census tracts in all study areas (section 3D.2.2.2);
- Updated equations to estimate resting metabolic rate (RMR) (section 3D.2.2.3.2) and associated ventilation rate ( $\dot{V}_E$ ) (section 3D.2.2.3.3);
- Improved matching of controlled human exposure study duration (6.6-hr) and target ventilation rate to that estimated for simulated individuals (7-hr duration, distribution accounting for resting ventilation) and used for benchmark comparisons and population-based E-R lung function risk (section 3D.2.2.3.3 and 3D.2.8.1);
- More recent (2015-2017) meteorological data to reflect the assessment years (section 3D.2.4)
- Increased number of diary-days and added new activity descriptions to activity pattern data base (section 3D.2.5.1);
- Most recent MSS-FEV<sub>1</sub> model (McDonnell et al., 2013) to estimate individual lung function risk (section 3D.2.8.2.2);
- New evaluations of important uncertainties (section 3D.3.4.2): form of E-R function, E-R function risk confidence intervals, low exposure concentration contribution to lung function risk, influence of ventilation rate on lung function risk, influence of variability parameter settings in MSS-FEV<sub>1</sub> model.

## **3D.2 POPULATION EXPOSURE AND RISK APPROACH**

This section describes the data, information, models, and tools used to characterize exposure and health risk associated with O<sub>3</sub> in ambient air for three air quality scenarios. As summarized above in section 3D.1.4, the overall analysis approach is based on linking the health effects information observed in controlled human exposure studies to estimated population-based exposures that reflect our current understanding of concentrations of O<sub>3</sub> in the ambient air.

Population exposures and risks were estimated using the EPA's Air Pollution Exposure Model (APEX), version 5. APEX is a multipollutant, population-based, stochastic, microenvironmental model that can be used to estimate human exposure via inhalation for criteria and toxic air pollutants. APEX is designed to estimate human exposure to these pollutants at the local, urban, and consolidated metropolitan level. In this analysis, we used APEX to estimate exposure and risk in eight study areas, the details of which are provided in the following subsections. Additional information not provided here regarding all of APEX modules, algorithms, and modeling options can be found in the APEX User's Guide (U.S. EPA, 2019a; U.S. EPA, 2019b).

Briefly, APEX calculates the exposure time-series for a user-specified duration and number of individuals. Collectively and by design, these simulated individuals are intended to be

1 a representative random sample of the population in the chosen study area. To this end,  
2 demographic data from the decennial census are used so that appropriate model sampling  
3 probabilities can be derived considering personal attributes such as age and sex and used to  
4 properly weigh the distribution of individuals in any given geographical area. For the exposure  
5 and risk analyses performed here, the core demographic geographical units for estimating  
6 exposure are census tracts. For each simulated person, the following general steps are performed:

- 7 • Select personal attribute variables and choose values to characterize the simulated  
8 individual (e.g., age, sex, body weight, disease status);
- 9 • Construct an activity event sequence (a minute-by-minute time-series) by selecting a  
10 sequence of appropriate daily activity diaries for the simulated individual (using  
11 demographic and other influential variables);
- 12 • Calculate the pollutant concentrations in the microenvironments (MEs) that simulated  
13 individuals visit;
- 14 • Calculate the simulated individual's exposure, and simultaneously, their breathing  
15 rate for each exposure event and summarize for the selected exposure metric.

16 A simulated individual's complete time-series of exposures (i.e., *exposure profile*),  
17 representing intra-individual variability in exposures, is combined with the exposure profiles for  
18 all simulated individuals in each study area and summarized to generate the population  
19 distribution of exposures, representing inter-individual variability in exposures. As described  
20 above regarding air quality and in the sections that follow describing APEX model inputs and  
21 approaches to estimating exposure, the overarching goal of the exposure and risk analysis is to  
22 account for the most significant factors contributing to inhalation exposure and risk, i.e., the  
23 temporal and spatial distribution of people and pollutant concentrations throughout the study area  
24 and among the microenvironments. The population distributions of exposures are then combined  
25 with the health effects information to characterize associated risk via two types of metrics: a  
26 comparison to benchmark concentrations and lung function risk. The details of the model input  
27 data and general approaches used for estimating exposure and risk are described in the sections  
28 that follow.

### 29 **3D.2.1 Urban Study Areas**

30 To identify a list of urban areas for the current analysis, we first considered the list of 15  
31 urban study areas evaluated in the 2014 HREA, which represented a range of geographic areas,  
32 encompassing variability in air quality, climate, and population demographics. We also  
33 considered other candidate study areas (e.g., Phoenix). As was done for the 2014 HREA, we  
34 developed criteria to select urban study areas for the current exposure and risk analysis. Those  
35 criteria are as follows:

- Have at least 10 ambient air monitors having complete year data for the 2015-2017 period;
- Combined statistical area (CSA)/metropolitan statistical area (MSA) ambient air monitor design values are between 60-80 ppb, thus having minimal adjustment needed to just meet the current 8-hr O<sub>3</sub> NAAQS;
- CSA/MSA population between 2 to 10 million;
- Anticipated reasonable air quality model performance<sup>12</sup>; and
- Reasonable geographic distribution across continental U.S.

Based on these selection criteria, we chose the eight study areas listed in Table 3D-1 (and shown in Figure 3D-1) to develop our population exposure estimates. Included also are the nine other study areas considered but not selected for the current exposure and risk analysis. We recognize the Sacramento study area does not meet the design value criterion (i.e., 86 ppb is outside the range of values considered), however we relaxed this criterion to include a study area in the Pacific/West region of the U.S and because exposure and risk was evaluated in the 2014 HREA (as opposed to using Los Angeles which was also evaluated in the 2014 HREA but has a 2015-17 design value of 112 ppb).

We broadly defined the study areas using geographic coordinates to center the overall exposure modeling domain for the APEX modeling (Table 3D-2). A wide city radius (i.e., 30 km) along with standard political/statistical county aggregations (e.g., whether in a CSA/MSA) were then used to identify the specific counties that comprise each study area. As a result, 131 counties containing 9,725 census tracts were used to define the air quality domain in the eight study areas.<sup>13</sup> As done for prior exposure-based assessments, ambient air O<sub>3</sub> concentrations were estimated to census tracts to capture spatial heterogeneity that may exist within each study area (see Appendix 3C) and to link with the population input data sets (section 3D.2.2).

---

<sup>12</sup> While we expect air quality models to effectively capture relationships between ozone and its chemical precursors in most areas, there are known situations (e.g. documented influence of stratospheric ozone intrusions) that may be more challenging for air quality models to represent. We therefore excluded some of these more challenging areas from this analysis (see Table 3D-1).

<sup>13</sup> The identification of specific counties and census tracts are provided in the APEX ambient air concentration input files for each study area. The approach used to estimate O<sub>3</sub> concentrations is summarized in section 3D.2.3 below and is described fully in the Appendix 3C of this PA.



**Figure 3D-1. Locations of the eight study areas selected for the current O<sub>3</sub> exposure and risk analysis.**

**Table 3D-1. Criteria used to identify and select urban study areas for inclusion in the O<sub>3</sub> exposure and risk analyses.**

| Selected for Analysis?  | Study Area                  | Census Division <sup>A</sup> | U.S. Climate Region <sup>B</sup> | CSA/MSA Population <sup>C</sup> (millions) | CSA/MSA Land Area <sup>D</sup> (Km <sup>2</sup> ) | Ambient Air Monitors (n) | Design Values <sup>E</sup> (ppb) |            |
|---|-----------------------------|------------------------------|----------------------------------|--|---|--------------------------|----------------------------------|------------|
|   |                             |                              |                                  |  |   |                          | 2017                             | 2008, 2010 |
| Yes   | Atlanta                     | South Atlantic               | Southeast                        | 6.6  | 26,873  | 11                       | 75                               | 95, 80     |
|   | Boston                      | New England                  | Northeast                        | 8.3  | 22,780  | 22                       | 73                               | 82, 76     |
|   | Dallas                      | West S Central               | South                            | 8.0  | 36,411  | 20                       | 79                               | 91, 86     |
|   | Detroit                     | East N Central               | Upper Midwest                    | 5.4  | 14,972  | 11                       | 73                               | 82, 75     |
|   | Philadelphia                | Mid Atlantic                 | Northeast                        | 7.2  | 15,391  | 19                       | 80                               | 92, 83     |
|   | Phoenix                     | Mountain                     | Southwest                        | 4.9  | 37,725  | 28                       | 76                               | 81, 77     |
|   | Sacramento                  | Pacific                      | West                             | 2.6  | 20,709  | 18                       | 86                               | 99, 99     |
|   | St. Louis                   | West N Central               | Ohio Valley                      | 2.9  | 23,504  | 12                       | 72                               | 82, 77     |
| No  | Baltimore                   | South Atlantic               | Northeast                        | 2.8  | 6,738   | 5                        | 75                               | 91, 89     |
|   | Chicago <sup>F</sup>        | East N Central               | Ohio Valley                      | 9.9  | 21,941  | 21                       | 78                               | 78, 74     |
|   | Cleveland                   | East N Central               | Ohio Valley                      | 3.5  | 9,322   | 15                       | 74                               | 84, 77     |
|   | Denver <sup>F</sup>         | Mountain                     | Southwest                        | 3.6  | 33,824  | 10                       | 79                               | 86, 78     |
|   | Houston                     | West S Central               | South                            | 7.2  | 27,744  | 19                       | 81                               | 91, 84     |
|   | Los Angeles <sup>F</sup>    | Pacific                      | West                             | 18.8                                       | 87,943  | 41                       | 112                              | 119, 112   |
|   | New York <sup>F</sup>       | Mid Atlantic                 | Northeast                        | 23.5                                       | 30,544  | 36                       | 83                               | 89, 82     |
|   | Salt Lake City <sup>F</sup> | Mountain                     | Southwest                        | 2.6  | 46,517  | 10                       | 78                               | 82, 74     |
|   | Washington DC               | South Atlantic               | Southeast                        | 6.2  | 14,341  | 15                       | 71                               | 87, 81     |
| <sup>A</sup> U.S. Census Division data are found at: <a href="https://www.ncdc.noaa.gov/monitoring-references/maps/us-census-divisions.php">https://www.ncdc.noaa.gov/monitoring-references/maps/us-census-divisions.php</a> .<br><sup>B</sup> U.S. Climate Region data are found at: <a href="https://www.ncdc.noaa.gov/monitoring-references/maps/us-climate-regions.php">https://www.ncdc.noaa.gov/monitoring-references/maps/us-climate-regions.php</a> .<br><sup>C</sup> U.S. Census CSA/MSA population data are found at: <a href="https://www.census.gov/data/tables/time-series/demo/popest/2010s-total-metro-and-micro-statistical-areas.html">https://www.census.gov/data/tables/time-series/demo/popest/2010s-total-metro-and-micro-statistical-areas.html</a> .<br><sup>D</sup> U.S. Census land area data taken from "G001 Geographic Identifiers, 2010 SF1 100% data file" available at: <a href="https://factfinder.census.gov/faces/nav/jsf/pages/searchresults.xhtml?refresh=t">https://factfinder.census.gov/faces/nav/jsf/pages/searchresults.xhtml?refresh=t</a> .<br><sup>E</sup> Ozone ambient air monitor design values (see .xlsx sheet 'Table6. Monitor Trends') are found at: <a href="https://www.epa.gov/air-trends/air-quality-design-values">https://www.epa.gov/air-trends/air-quality-design-values</a> .<br><sup>F</sup> Potential air quality modeling/adjustment issues: VOC-limited (Chicago, Denver), stratospheric O <sub>3</sub> issues (Denver), low monitor density (Salt Lake City), monitor issues (New York), and high DVs (Los Angeles). |                             |                              |                                  |  |   |                          |                                  |            |

**Table 3D-2. General description of ambient air quality domains for the eight study areas.**

| CSA/MSA   |     |         | Coordinates            |                       | Counties <sup>A</sup><br>(n) | Tracts<br>(n) |
|---|-----|---------|------------------------|-----------------------|------------------------------|---------------|
|   |     |         | Longitude<br>(degrees) | Latitude<br>(degrees) |                              |               |
| Name  | ID# | Abbrev. |                        |                       |                              |               |
| Atlanta-Athens-Clarke County-Sandy Springs, GA-AL   | 122 | ATL     | -84.3880               | 33.7490               | 39                           | 1,077         |
| Boston-Worcester-Providence, MA-RI-NH-CT  | 148 | BOS     | -71.0589               | 42.3601               | 19                           | 1,753         |
| Dallas-Fort Worth, TX-OK  | 206 | DAL     | -96.7970               | 32.7767               | 21                           | 1,422         |
| Detroit-Warren-Ann Arbor, MI  | 220 | DET     | -83.0458               | 42.3314               | 10                           | 1,583         |
| Philadelphia-Reading-Camden, PA-NJ-DE-MD  | 428 | PHI     | -75.1652               | 39.9526               | 16                           | 1,725         |
| Phoenix-Mesa, AZ  | 429 | PHX     | -112.0740              | 33.4484               | 2                            | 988           |
| Sacramento-Roseville, CA  | 472 | SAC     | -121.4944              | 38.5816               | 7                            | 539           |
| St. Louis-St. Charles-Farmington, MO-IL   | 476 | STL     | -90.2003               | 38.6303               | 17                           | 638           |
| <sup>A</sup> Delineations promulgated by the Office of Management and Budget (OMB) in February of 2013 (see Appendix 3C, section 3C.2). |     |         |                        |                       |                              |               |

### 3D.2.2 Simulated Populations

APEX stochastically generates a user-specified number of simulated people to represent the population in the study area. The number of simulated individuals can vary and is dependent on the size of the population to be represented. For the current analysis, the number of simulated individuals was set at 60,000 for each of the children and adult study groups (which includes people with asthma for both of these study groups) to represent population residing within each study area (i.e., between 2 and 10 million). Each simulated person is represented by a *personal profile*. The personal profile includes specific attributes such as an age, a home tract, a work tract (or is not employed), housing characteristics, physiological parameters, and so on. The profile does not correspond to any particular individual that resides in the study area, but rather represents a simulated person. Accordingly, while a single profile does not, in isolation, provide information about the study population, a distribution of profiles represents a random sample drawn from the study area population. As such, the statistical properties of the distribution of simulated profiles are meant to reflect statistical properties of the population in the study area.

APEX generates population-based exposures using several population databases. Based on the geographic boundaries defining the study areas and the study groups of interest, APEX simulates representative individuals using appropriate geographic, demographic, and health status information provided by existing population-based surveys. For the current exposure and risk analysis, population input data sets are organized by U.S. census tracts.

Several updates were made to the APEX model inputs and algorithms for use in simulating the populations of interest in this exposure and risk analysis and are described in the following sections: population demographic data that are based on the 2010 census (section 3D.2.2.1), asthma prevalence rates based on the 2013-2017 National Health Interview Survey (NHIS) that vary by age, sex and geographic location (section 3D.2.2.2), and data and equations used to approximate personal attributes such as body weight, resting metabolic rate, and breathing rate (section 3D.2.2.3).

### 3D.2.2.1 Demographics

As briefly described in section 3D.2.1 (and more fully in section 3D.2.3 below and in Appendix 3C), ambient air concentrations were modeled to census tracts in each study area to capture spatial heterogeneity in ambient air O<sub>3</sub> concentrations. Population data were generated using the same spatial scale to also account for variability in population demographics. Tract-level population counts were obtained from the 2010 Census of Population and Housing Summary File 1.<sup>14</sup> Summary File 1 contains what the Census program calls “the 100-percent data,” which is the compiled information from the questions asked of all (100% of) people and housing units in the U.S. Three national-based APEX input files<sup>15</sup> are used for the current exposure and risk analysis as follows.

- *Population\_sectors\_US\_2010.txt*: census tract identifiers (IDs), latitudes and longitudes in degrees.
- *Population\_female\_All\_2010.txt*: census tract IDs, tract-level population counts for females, stratified by 23 age groups.<sup>16</sup>
- *Population\_male\_All\_2010.txt*: census tract IDs, tract-level population counts for males, stratified by the same 23 age groups as done for females.

### 3D.2.2.2 Asthma Prevalence

The four population study groups included in this exposure assessment are adults (19 to 90 years old),<sup>17</sup> children (5 to 18 years old),<sup>18</sup> and those within each of the two groups having

---

<sup>14</sup> Technical documentation - 2010 Census Summary File 1—Technical Documentation/prepared by the U.S. Census Bureau, Revised 2012 - available at: <http://www.census.gov/prod/cen2010/doc/sfl.pdf>.

<sup>15</sup> The names of all APEX files are provided here to link the brief description with the appropriate APEX input file.

<sup>16</sup> The age groups in this file are: 0-4, 5-9, 10-14, 15-17, 18-19, 20-20, 21-21, 22-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-61, 62-64, 65-66, 67-69, 70-74, 75-79, 80-84, >84.

<sup>17</sup> The upper limit for adults was set to age 90 due to the limited information available in CHAD for modeling activity patterns and physiological processes for adults >90.

<sup>18</sup> As in other NAAQS reviews, we do not estimate exposures and risk for children younger than 5 years old due to the more limited information contributing relatively greater uncertainty in modeling their activity patterns and physiological processes than children between the ages of 5 to 18.



1 asthma, based on their identification as an at-risk population (section 3.3.2 of the main  
2 document; ISA, section IS.4.4.2). To best approximate the number (and percent) of individuals  
3 comprising the latter two population groups in each study area, we considered several influential  
4 variables that could affect asthma prevalence. It is widely recognized that there are significant  
5 differences in asthma prevalence based on age, sex, U.S. region, and family income level, among  
6 other factors.<sup>19</sup> There is spatial heterogeneity in family income level across census geographic  
7 areas (and also across age groups)<sup>20</sup> and spatial variability in local scale ambient air  
8 concentrations of O<sub>3</sub> (e.g., Appendix 3C, Figures 3C-91 through 3C-106). Thus, we accounted  
9 for these particular attributes of this study group and their spatial distribution across each of the  
10 study areas to better estimate the variability in population-based O<sub>3</sub> exposures and risks for these  
11 at-risk population groups.

12 With regard to asthma prevalence, the data are used to identify if a simulated individual  
13 residing within a modeled census geographic area has asthma. The data are not used for selection  
14 of any other personal attribute nor in the selection of activity pattern data. Thus, our primary  
15 objective with these data was to generate census tract-level prevalence that reflect variability in  
16 asthma prevalence contributed by several known influential attributes (i.e., age, sex, family  
17 income level, geographic location). Two data sets were identified and linked together to estimate  
18 asthma prevalence used for this exposure and risk analysis: asthma prevalence and population  
19 data.

20 First, asthma prevalence data were obtained from the 2013-2017 National Health  
21 Interview Survey (NHIS) and are stratified by NHIS defined regions (Midwest, Northeast, South,  
22 and West), age, and sex.<sup>21</sup> These asthma prevalence data are particularly useful given that age is  
23 expressed as a continuous variable, a feature not found in other asthma prevalence data that are  
24 available (e.g., state or county level data). We explored variables that were available in the NHIS  
25 data set that contributed to variability in asthma prevalence and that could be used to extrapolate  
26 the asthma prevalence to a finer geographic scale than the NHIS-provided four regions. The  
27 linking variable had to be common with variables available in the population demographic data.  
28 Based on this criterion, we selected family income level to poverty thresholds (i.e., whether the  
29 family income was considered at/below or above a factor of 1.5 of the U.S. Census estimate of  
30 poverty level for the given year) and used that as an additional variable to stratify the NHIS  
31 asthma prevalence.

---

<sup>19</sup> For example, see the Center for Disease Control report “National Surveillance of Asthma: United States, 2001–2010”, available at: [https://www.cdc.gov/nchs/data/series/sr\\_03/sr03\\_035.pdf](https://www.cdc.gov/nchs/data/series/sr_03/sr03_035.pdf).

<sup>20</sup> For example, see the U.S. Census report “Income and Poverty in the United States: 2016”, available at: <https://www.census.gov/content/dam/Census/library/publications/2017/demo/P60-259.pdf>.

<sup>21</sup> Information about the NHIS is available at: <http://www.cdc.gov/nchs/nhis.htm>.

1           Then, we obtained population data from the 2017 Census American Community Survey  
2 (ACS) to estimate family income level to poverty thresholds at the census tract level and  
3 stratified by several ages and age groups.<sup>22</sup> By combining the NHIS and U.S. Census population  
4 data sets, we developed census tract level asthma prevalence for children (by age in years) and  
5 adults (by age groups), also stratified by sex (male, female) that were weighted by the individual  
6 census tract population and family income level proportions. Finally, we adjusted the census  
7 tract-level asthma prevalence data based on individual state-level prevalence data from the 2013-  
8 2016 Behavioral Risk Factor Surveillance System (BRFSS).<sup>23</sup> This was done because overall, the  
9 asthma prevalence data reported from BRFSS were consistently higher than that derived from  
10 the NHIS data, particularly when considering adults, and thus resulted in an upward adjustment  
11 to the initially derived NHIS census tract level data set. A detailed description of how the NHIS,  
12 U.S. Census, and BRFSS data were processed and combined to create the data set used for input  
13 to APEX is provided in Attachment 1. The national-based APEX input file is used for the current  
14 exposure and risk analysis as follows:

- 15           • *asthma\_prev\_1317\_tract\_053119\_adjusted.txt*: census tract IDs, tract-level asthma  
16           prevalence (in fractional form) stratified by sex, 18 single year ages (for ages <18),<sup>24</sup>  
17           and 7 age groups (for ages > 17).

18           The asthma prevalence varies for the different ages and sexes of children and adults<sup>25</sup> that  
19 reside in each census tract of each study area. We evaluated the spatial distribution of the asthma  
20 prevalence using the tracts that comprise the air quality domain in each study area. We first  
21 separated the estimates for children from those for adults and calculated the distribution of  
22 asthma prevalence for the tracts, stratified by sex (Table 3D-3). These summary statistics  
23 represent the range of age- and sex-specific probabilities for the census tracts comprising each  
24 study area that are used by APEX to estimate the number of individuals that have asthma.  
25

---

<sup>22</sup> Census tract level data is the finest scale geographical unit having family income information. The family income/poverty ratio threshold used was 1.5, that is the surveyed person's family income was considered either ≤ or > than a factor of 1.5 of the U.S. Census estimate of poverty level for the given year.

<sup>23</sup> Table C2.1 (for each adults and children) was downloaded to obtain the 2013-2016 BRFSS current asthma prevalence by state and sex, available at: <https://www.cdc.gov/asthma/brfss/default.htm>. Table C1 was also downloaded to obtain the asthma prevalence for the two age groups not stratified by sex. Accessed 5/3/19.

<sup>24</sup> The census data only had children for single years up to and including age 17, after that age they are provided in groups. The upper portion of this age range differs from those considered as children in estimating exposures (i.e., in our exposure assessment children are considered upwards to 18 years old). To simulate the number of children with asthma age 18, estimated prevalence from the first adult group were used (i.e., individuals age 18-24).

<sup>25</sup> While prevalence was estimated for all ages of children (in single years 5-17), for adults they were estimated for seven age groups: 18-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, and ≥75 years old (see Attachment 1 for more information).

**Table 3D-3. Descriptive statistics for children and adult asthma prevalence, using all census tracts within eight consolidated statistical areas (CSAs) in the APEX asthma prevalence file.**

| CSA Name - ID#<br>(# tracts)<br>and<br>Population group   |       | Sex    | Asthma Prevalence across all ages (or age groups) and census tracts <sup>A</sup> |                       |         |        |                                |                                |         |
|---|-------|--------|--|-----------------------|---------|--------|--------------------------------|--------------------------------|---------|
|   |       |        | Mean   | Standard<br>Deviation | Minimum | Median | 95 <sup>th</sup><br>percentile | 99 <sup>th</sup><br>percentile | Maximum |
| Atlanta-122<br>(1,077)  | adult | female | 11.1%  | 1.8%                  | 7.7%    | 11.1%  | 14.0%                          | 15.9%                          | 20.9%   |
|   |       | male   | 5.5%   | 0.8%                  | 4.3%    | 5.4%   | 7.1%                           | 7.5%                           | 7.9%    |
|   | child | female | 9.7%   | 1.7%                  | 6.5%    | 9.6%   | 12.9%                          | 13.9%                          | 15.0%   |
|   |       | male   | 14.1%  | 1.7%                  | 10.6%   | 14.0%  | 16.8%                          | 17.6%                          | 18.3%   |
| Boston-148<br>(1,753)   | adult | female | 13.8%  | 1.8%                  | 10.5%   | 13.5%  | 17.3%                          | 20.5%                          | 28.9%   |
|   |       | male   | 7.6%   | 0.9%                  | 5.4%    | 7.5%   | 9.1%                           | 10.0%                          | 12.9%   |
|   | child | female | 9.4%   | 2.0%                  | 5.6%    | 9.5%   | 12.4%                          | 13.5%                          | 17.1%   |
|   |       | male   | 15.4%  | 2.5%                  | 8.7%    | 15.1%  | 19.5%                          | 20.8%                          | 23.4%   |
| Dallas-206<br>(1,422)   | adult | female | 9.3%   | 1.5%                  | 6.5%    | 9.3%   | 11.8%                          | 13.5%                          | 16.5%   |
|   |       | male   | 4.9%   | 0.7%                  | 3.8%    | 4.9%   | 6.4%                           | 6.8%                           | 9.7%    |
|   | child | female | 7.6%   | 1.3%                  | 5.0%    | 7.4%   | 10.0%                          | 10.9%                          | 13.5%   |
|   |       | male   | 11.0%  | 1.4%                  | 8.3%    | 11.0%  | 13.2%                          | 13.8%                          | 18.1%   |
| Detroit-220<br>(1,583)  | adult | female | 13.3%  | 2.5%                  | 7.8%    | 13.4%  | 17.8%                          | 20.6%                          | 25.6%   |
|   |       | male   | 7.9%   | 2.2%                  | 1.0%    | 7.6%   | 12.4%                          | 14.7%                          | 19.0%   |
|   | child | female | 8.6%   | 1.5%                  | 6.4%    | 8.2%   | 11.6%                          | 12.5%                          | 13.2%   |
|   |       | male   | 13.3%  | 3.0%                  | 7.7%    | 12.7%  | 19.9%                          | 23.6%                          | 25.5%   |
| Philadelphia-428<br>(1,725)   | adult | female | 12.1%  | 2.3%                  | 8.2%    | 12.0%  | 16.4%                          | 19.8%                          | 26.5%   |
|   |       | male   | 6.5%   | 0.9%                  | 4.6%    | 6.4%   | 8.1%                           | 9.0%                           | 11.4%   |
|   | child | female | 9.1%   | 1.9%                  | 5.6%    | 9.2%   | 12.0%                          | 13.1%                          | 15.3%   |
|   |       | male   | 13.6%  | 2.4%                  | 8.2%    | 13.3%  | 17.8%                          | 19.2%                          | 21.1%   |
| Phoenix-429<br>(988)  | adult | female | 11.6%  | 1.6%                  | 8.6%    | 11.7%  | 14.4%                          | 16.0%                          | 19.7%   |
|   |       | male   | 7.0%   | 1.5%                  | 5.1%    | 7.1%   | 9.1%                           | 11.7%                          | 16.7%   |
|   | child | female | 7.6%   | 1.5%                  | 4.6%    | 8.0%   | 9.5%                           | 9.6%                           | 9.6%    |
|   |       | male   | 11.5%  | 1.8%                  | 8.5%    | 11.6%  | 14.8%                          | 15.9%                          | 17.1%   |
| Sacramento-472<br>(539)   | adult | female | 10.4%  | 1.4%                  | 7.7%    | 10.5%  | 12.7%                          | 14.0%                          | 16.5%   |
|   |       | male   | 5.7%   | 1.1%                  | 4.2%    | 5.9%   | 7.3%                           | 9.0%                           | 13.6%   |
|   | child | female | 8.5%   | 1.7%                  | 5.2%    | 9.0%   | 10.7%                          | 10.9%                          | 10.9%   |
|   |       | male   | 10.8%  | 1.7%                  | 8.1%    | 10.9%  | 13.7%                          | 14.8%                          | 16.2%   |
| St. Louis-476<br>(638)  | adult | female | 11.8%  | 2.1%                  | 6.8%    | 11.9%  | 15.0%                          | 17.4%                          | 21.5%   |
|   |       | male   | 6.5%   | 1.8%                  | 0.9%    | 6.5%   | 9.9%                           | 11.8%                          | 14.5%   |
|   | child | female | 9.2%   | 2.0%                  | 5.3%    | 9.1%   | 12.9%                          | 14.2%                          | 15.6%   |
|   |       | male   | 11.1%  | 2.4%                  | 6.5%    | 10.7%  | 15.9%                          | 19.3%                          | 21.9%   |
| A Prevalence is based on single year ages (children) or age groups (adults) and sex derived from 2013-2017 CDC NHIS asthma prevalence and considering U.S. census tract level family income/poverty ratio data. Data presented are not population-weighted and represent the distribution of applied probabilities used by APEX for tracts having a non-zero population. Note, upper and lower percentiles could represent prevalence for a single year age/sex residing in a single tract within a study area. |       |        |  |                       |         |        |                                |                                |         |

1 In general and consistent with broadly defined national asthma prevalence (e.g., Table 3-  
2 1 of the main document), male children have higher rates than female children<sup>26</sup> and adult  
3 females have higher rates than adult males.<sup>27</sup> The overall asthma prevalence for children was  
4 similar to that estimated for adults, largely the result of having a greater BRFSS adjustment  
5 applied to adult females compared to that applied to children of either sex.<sup>28</sup> As described above,  
6 and by design (i.e., in using age, sex, and family income variables) there is wide ranging spatial  
7 variability in the estimated asthma prevalence. For instance, the Boston, Detroit, and  
8 Philadelphia study areas have some of the highest asthma prevalence for boys and adult women  
9 considering most of the descriptive statistics, with rates of 25% or higher in one or more census  
10 tracts for a given year of age (Table 3D-3). In contrast, the Dallas study area exhibits some of the  
11 lowest asthma prevalence (and low variability) for any of the four age/sex groups compared to  
12 the other study areas.

13 There are other personal attributes shown to influence asthma prevalence, such as race,  
14 ethnicity, obesity, smoking, health insurance, and activity level (e.g., Zahran and Bailey, 2013).  
15 The set of variables chosen to stratify asthma prevalence for use in this exposure and risk  
16 analysis (i.e., age, sex, and family income level) was based on maximizing the potential range in  
17 asthma prevalence variability, maximizing the number of survey respondents comprising a  
18 representative subset study group, and having the ability to link the set of attributes to variables  
19 within the Census population demographic data sets. Many of the additional influential factors  
20 identified here are not available in the census population data and/or have limited representation  
21 in the asthma prevalence data (e.g., the survey participant does/does not have health insurance, or  
22 they did/did not provide a response to a question regarding their body weight). Race is perhaps  
23 the only attribute common to both the prevalence and population data sets that could be an  
24 important influential factor and was not directly used to calculate asthma prevalence. However,  
25 the use of race in calculating asthma prevalence, either alone or in combination with family  
26 income level, would further stratify the NHIS analytical data set and appreciably reduce the  
27 number of individuals of specific age, sex, race, and family income level, potentially reducing  
28 the confidence in calculated asthma prevalence based on having so few data in a given

---

<sup>26</sup> Population weighted asthma prevalence, when not categorized by the eight study areas, is greater in boys (mean of 11.1%) than that of girls (mean of 7.3%). Nationally, asthma prevalence for boys is 9.5%, for girls is 7.3% (Table 3-1 of the PA).

<sup>27</sup> Population weighted asthma prevalence, when not categorized by the eight study areas, is greater in women (mean of 12.0%) than that of men (mean of 6.5%). Nationally, asthma prevalence for women is 9.8%, for men is 5.4% (Table 3-1 of the PA).

<sup>28</sup> Population weighted asthma prevalence, when not categorized by the eight study areas and sex, is similar for children (mean of 9.2%) and adults (mean of 9.3%). Nationally, asthma prevalence for children is 8.4% and for adults is 7.7% (Table 3-1 of the PA).

1 stratification. Because family income level already strongly influences asthma prevalence across  
2 all races and stratifies the NHIS data into only two subgroups (i.e., above or below the poverty  
3 threshold) in comparison to the larger number of subgroups a race variable might yield, family  
4 income was chosen as the next most important variable beyond age and sex to rely on for  
5 weighting the spatial distribution of asthma prevalence.

### 6 **3D.2.2.3 Personal Attributes**

7 In addition to using the above demographic information to construct the simulated  
8 individuals, each modeled person is assigned anthropometric and physiological attributes by  
9 APEX. All of these variables are treated probabilistically, accounting for interdependencies  
10 where possible, and reflecting variability in the population. It is not the intention of this  
11 document to provide detailed description of all the model inputs in each of the files and the data  
12 used in their derivation, and where additional details exist, appropriate reference materials are  
13 provided. We describe further a few APEX model inputs that have been recently updated and  
14 that are available for use in this exposure and risk analysis. These are new statistical distributions  
15 for estimating body weight, equations for estimating resting metabolic rate, and equations for  
16 estimating activity-specific ventilation rate. Each of these data and algorithms are important,  
17 particularly the ventilation rate (section 3D.2.2.3.3), because the health response observed in the  
18 controlled human exposure studies is concomitant with elevated breathing rate. Brief  
19 descriptions of the data used to develop these generalized (i.e., non-O<sub>3</sub> specific) input files are  
20 provided in the sections below. For additional detail, see U.S. EPA (2018) Appendices G and H,  
21 and the data within the APEX input files.

#### 22 **3D.2.2.3.1 Body Weight and Surface Area**

23 Anthropometric attributes utilized by APEX in various assessments for estimating  
24 exposures or doses can include height, body weight (BW), and body surface area (BSA). Two  
25 key personal attributes determined for each individual in this assessment are BW and BSA, both  
26 of which are used in the calculation of a number of other variables associated with estimating  
27 exposures (e.g., ventilation rate).

28 Regarding the estimation of body weight, a new APEX input file was recently generated  
29 using 2009-2014 National Health and Nutrition Examination Survey (NHANES) data.<sup>29</sup> Briefly,  
30 body weight and height data for surveyed individuals were obtained and stratified by sex and  
31 single years for ages 0 – 79; all ages above 80 were combined as a single age group. Statistical  
32 form of the age- and sex-specific body weight and height distributions were evaluated using a

---

<sup>29</sup> NHANES questionnaire datasets for 2009-2010, 2011-2012, 2013-2014 are available at  
<https://wwwn.cdc.gov/nchs/nhanes/Default.aspx>. Details regarding the data used and the derivation of the APEX  
input file data distributions is found in U.S. EPA (2018), Appendix G.

log-likelihood statistic. Body weight was found to best fit a lognormal distribution; height was found to best fit a normal distribution. Because height and body weight are not independent, the joint distributions of height and logarithm of body weight were fit assuming a bivariate normal distribution. Then, parameters defining the joint distributions<sup>30</sup> were smoothed using a natural cubic spline to have them represent continuous functions of age rather than vary discontinuously. In addition, having the smoothed parameters could be used to extrapolate information obtained from the single age year distributions (ages 0 – 79) to approximate statistical distributions of body weight for ages ≥80. To do so, a linear function was fit to ages 70 and above to extrapolate the parameter values (and hence the statistical distributions of body weight) up to age 100.

These body weight distributions are randomly sampled by APEX to estimate an age and sex-specific body weight for each simulated individual. Comparison of the new distributions to the body weight distributions previously used by APEX and developed from the 1999-2004 NHIS indicate, for both sexes and across all ages, simulated body weight is about two percent greater using the updated distributions. This difference is expected given the consistent trend of increasing body weight that has occurred in the U.S. population over the past few decades.

Age- and sex-specific body surface area, a variable used in conjunction with breathing rate to approximate moderate or greater exertion (section 3D.2.2.3.3) is estimated for each simulated individual (Equation 3D-1) and is based on an equation provided in Burmaster (1998):

$$BSA = e^{-2.2781} \times BW^{0.6821} \quad \text{Equation 3D-1}$$

One standard APEX input file is used for the current O<sub>3</sub> exposure and risk analysis:

- *Physiology051619\_Ufixed.txt*: Provides parameters for estimating body weight (log BW, standard deviation of BW, lower and upper bounds of BW, by single age years 0-100 and by two sexes) and regression coefficients used in estimating BSA for all sexes and ages.

### 3D.2.2.3.2 Energy Expenditure and Oxygen Consumption Rates

Energy expended by different individuals engaged in different activities can have an important role in pollutant-specific exposure and/or dose. For example, energy expenditure is related to ventilation rate, which is an important variable in estimating exposure and risk given that the O<sub>3</sub>-induced lung function response has been documented to occur under conditions of elevated ventilation (section 3.3.1.1 of the main document). In addition, because we are also interested in exposures that occur over relatively short durations (i.e., < 8 hours), estimating activity-specific ventilation rate ( $\dot{V}_E$ ) has always been an important motivation behind the development of the algorithm used by APEX. The fundamental basis for  $\dot{V}_E$  algorithm is founded in energy expenditure which, for our modeling purposes here, can be related to an individual's

---

<sup>30</sup> Five parameters were used for each age and sex: mean log(BW), standard deviation of log(BW), mean height, standard deviation of height, and body weight-height correlation coefficients.

resting metabolic rate (RMR) or the energy expended while an individual is at complete rest, along with the energy expended while an individual performs activities involving greater exertion, termed here as metabolic equivalents of work (METs) (McCurdy, 2000). The approaches used by APEX for estimating RMR and METs are described below, beginning first with the update to the equations used for estimating a simulated individual's RMR.

Since the 2014 HREA,<sup>31</sup> we have reviewed recent RMR literature and other published sources containing individual data and have compiled the associated individual RMR measurements, along with associated influential attributes such as age, sex, and body weight, where available. Data from these individual studies were then combined with RMR data reported in the Oxford-Brookes database (Henry, 2005; IOM, 2005) and screened for duplicate entries. In addition, observations missing values for RMR, BW, age, or sex were deleted, resulting in a dataset containing 16,254 observations (9,377 males and 6,877 females). Using this new RMR dataset and having a goal of updating the previous RMR equations and reducing discontinuities in RMR between age groups, new equations were developed.

Details regarding the data, the derivation, and performance evaluation of the new equation that APEX uses to estimate RMR are provided in U.S. EPA (2018), Appendix H. Briefly, the equations follow the general format of a multiple linear regression (MLR) model, using age and body weight as independent variables to estimate each simulated individual's RMR, along with a residual error term ( $\epsilon$ ).<sup>32</sup> It is known that RMR and BW, as well as RMR and age, are not exactly linearly related; the algorithms developed here use BW (in kg), age (in years), and the natural logarithms of BW and (age+1)<sup>33</sup> as follows in Equation 3D-2, with their parameter estimates provided in Table 3D-4.

$$RMR = \beta_0 + \beta_1 BW + \beta_2 \log(BW) + \beta_3 Age + \beta_3 \log(Age) + \epsilon_i \quad \text{Equation 3D-2}$$

When comparing observed versus predicted values, the new RMR equations have a bias of less than 0.5%, compared to the previously used APEX equations which had a bias of between 1-2%. Further, the discontinuities in RMR seen across particular age group boundaries using the

---

<sup>31</sup> The algorithm used to estimate RMR for the 2014 HREA was based on analyses by Schofield (1985) who used clinical subject data from studies conducted as far back as 60 years prior to that publication. In addition, the Schofield (1985) RMR equations contained abrupt discontinuities at some of the equation boundaries (e.g., between age 59 and 60). As a result, we felt it was important to obtain newly available study data to develop RMR equations that better represent a more recent population and having fewer discontinuities.

<sup>32</sup> The residual error term largely accounts for the estimation of inter-personal variability in RMR for individuals having the same body weight and age. There are other potentially influential sources of variability that are not explicitly accounted for by the equation (e.g., seasonal influences on RMR) and thus remain as an uncertainty.

<sup>33</sup> The "+1" modifier allows APEX to round age upwards instead of downwards to whole years, which is necessary to avoid undefined log(0) values.

previous equations have been reduced when using these updated equations in APEX. One standard APEX input file is used for the O<sub>3</sub> exposure and risk analysis:

- *Physiology051619\_Ufixed.txt*: Regression coefficients used to estimate RMR (kcal day<sup>-1</sup>) for two sexes and six age groups.

**Table 3D-4. Regression parameters used to estimate RMR by sex and age groups.**

| Sex  | Age Group | Subjects (n) | BW    | log(BW) | Age    | log(Age) | Intercept | Standard Deviation |
|--|-----------|--------------|-------|---------|--------|----------|-----------|--------------------|
| male   | 0–5       | 625          | 13.19 | 270.2   | -18.34 | 131.3    | -208.5    | 69.10              |
|  | 6–13      | 1355         | 10.21 | 260.2   | 13.04  | -205.7   | 333.4     | 115.3              |
|  | 14–24     | 4123         | 0.207 | 1078.0  | 115.1  | -2794.0  | 3360.6    | 161.1              |
|  | 25–54     | 2531         | 2.845 | 729.6   | 3.181  | -191.6   | -1067     | 178.2              |
|  | 55–99     | 743          | 9.291 | 264.8   | -5.288 | 181.5    | -705.9    | 163.6              |
| female   | 0–5       | 625          | 11.94 | 261.5   | -22.31 | 120.9    | -183.6    | 64.16              |
|  | 6–13      | 1618         | 5.296 | 409.1   | 40.37  | -524.9   | 392.7     | 99.43              |
|  | 14–29     | 2657         | 0.968 | 676.9   | 40.89  | -1002    | 772.7     | 143.1              |
|  | 30–53     | 1346         | 4.935 | 355.4   | 16.28  | -896.0   | 2225      | 145.3              |
|  | 54–99     | 631          | 2.254 | 445.9   | 5.464  | -489.9   | 944.2     | 124.5              |
| Units: RMR = kilocalories/day; BW = kilograms; Age = years |           |              |       |         |        |          |           |                    |

Following the estimation of an age- and sex-specific RMR for simulated individuals, the next variable used for estimating ventilation rate involved an approximation of the energy expended for activities an individual performs throughout their day. As mentioned above, activity-specific energy expenditure is highly variable and can be estimated using metabolic equivalents of work (METs), or the ratios of the rate of energy consumption for non-rest activities to the resting metabolic rate of energy consumption, as follows in Equation 3D-3:

$$EE = MET \times RMR \quad \text{Equation 3D-3}$$

where,

$EE$  = Energy expenditure (kcal/minute)

$MET$  = Metabolic equivalent of work (unitless)

$RMR$  = Resting metabolic rate (kcal/minute)

Statistical distributions of METs were developed for simulated activities using the physical-activity compendium (Ainsworth et al., 2011; hereafter “the compendium”). The compendium contains a point value for the MET associated with each of several hundred different activities. Activity-specific MET distributions were developed by cross-walking the



activities described in the compendium with the descriptions of activities in the activity pattern data base used by APEX (section 3D.2.5). The shape of the statistical distribution (e.g., normal, lognormal, triangular, point) for each activity was assigned based on the number of corresponding activities in the compendium and goodness-of-fit statistics. When simulating individuals, APEX randomly samples from the activity-specific METs distributions to obtain values for every activity performed. Two standard APEX input files are used for the current O<sub>3</sub> exposure and risk analysis:

- *MET\_distributions\_092915.txt*: MET distribution number, statistical form, distribution parameters, lower and upper bounds, activity description
- *MET\_mapping\_071018.txt*: activity codes, age group (where applicable), occupation group, MET distribution number, and activity description used to link of MET distributions to activities performed

The rate of oxygen consumption ( $\dot{V}O_2$ , Liters min<sup>-1</sup>) for each activity is then calculated from the energy expended (kcal min<sup>-1</sup>) using an energy conversion factor (ECF, Liters O<sub>2</sub> kcal<sup>-1</sup>) as follows in Equation 3D-4:

$$\dot{V}O_2 = EE \times ECF \quad \text{Equation 3D-4}$$

The value of the ECF is randomly selected from a uniform distribution for each person, U[0.20, 0.21] (Johnson, 2002, adapted from Esmail et al., 1995). One standard APEX input file is used for the current O<sub>3</sub> exposure and risk analysis:

- *Physiology051619\_Ufixed.txt*: Parameters of the uniform distribution representing the ECF used for all ages and both sexes.

### 3D.2.2.3.3 Ventilation Rate

Human activities are variable over time, with a wide range of activities possible within only a single hour of the day. The type of activity an individual performs, such as sleeping or jogging (as well as individual-specific factors such as age, weight, RMR) will influence their ventilation rate. APEX estimates minute-by-minute ventilation rates that account for the expected variability in the activities performed by simulated individuals. Ventilation rate is important in this assessment because the lung function responses associated with short-term O<sub>3</sub> exposures coincide with moderate or greater exertion (2013 ISA, Table 6-1). In our exposure modeling approach, APEX generates the complete time-series of activity-specific ventilation rates and the corresponding time-series of estimated O<sub>3</sub> exposures and is directly used for the individual-based lung function risk (section 3D.2.8.2.2). APEX can then aggregate both the ventilation rate and exposure concentration for the duration of interest (e.g., 7-hr average), and they can be used for the benchmark comparison (section 3D.2.8.1) and estimating the population-based lung function risk (section 3D.2.8.2.1). Thus, the model provides O<sub>3</sub> exposure

estimates for the simulated individuals that pertain to specific target levels for both ventilation rate and exposure concentration. The approach to estimating activity-specific energy expenditure and associated ventilation rate involves several algorithms and physiological variables, with details found in the APEX User's Guide (U.S. EPA, 2019a, U.S. EPA, 2019b).

Using the existing measurement  $\dot{V}_E$  dataset from Graham and McCurdy (2009), new  $\dot{V}_E$  algorithms were developed for predicting activity specific  $\dot{V}_E$  in the individuals simulated by APEX (Appendix H of U.S. EPA (2018)). The new  $\dot{V}_E$  algorithms do not directly employ previously used variables to stratify the data (age groups, sex) and explain variability (age, body weight, height) in ventilation rate, effectively simplifying and reducing the number of equations. The new algorithms utilize a new variable, the maximum volume of oxygen consumed ( $\dot{V}O_{2m}$ ) as an input.<sup>34</sup> Body weight, height, and sex – as well as fitness level (which is often represented by  $\dot{V}O_{2m}$ ) - influence oxygen consumption for a particular activity. However, variability for each of these influential variables are already captured in the algorithm used to estimate each simulated individual's RMR, and subsequently, the estimation of their activity-specific  $\dot{V}O_2$ .<sup>35</sup> Thus, the only input variables needed for the new  $\dot{V}_E$  algorithm are  $\dot{V}O_2$  and  $\dot{V}O_{2m}$ ,<sup>36</sup> both of which are estimated by APEX.

Details for the derivation of and performance evaluation of the new equation that APEX uses to estimate ventilation rate are provided in U.S. EPA (2018) Appendix H. Briefly, the  $\dot{V}_E$  dataset contains 6,636 observations, with 4,565 males and 2,071 females. Similar to the earlier ventilation equation by Graham and McCurdy (2009), a mixed-effects regression (MER) model was fit because the MER separates residuals into within-person ( $e_w$ ) and between-person ( $e_b$ ) effects, known as intrapersonal and interpersonal effects, respectively.<sup>37</sup> It was found that the actual values of  $\dot{V}O_2$  and  $\dot{V}O_{2m}$  are less relevant than the fraction of maximum capacity, represented by  $f_1 = \dot{V}O_2/\dot{V}O_{2m}$ . The variable  $f_1$  may operate non-linearly (for example,  $f_1 = 0.9$  is likely *more* than twice as encumbering as  $f_1 = 0.45$ ). A transformation regression approach

---

<sup>34</sup> Use of  $\dot{V}O_{2m}$  as an explanatory variable in separate related research on metabolic equivalents of task (MET) values for persons with unusual maximum capacity for work suggests that their MET distributions are modified in a predictable way by their maximum MET (or, equivalently, by  $\dot{V}O_{2m}$ ), thus providing support for use of this variable in the new  $\dot{V}_E$  algorithms. Details are provided in Appendix H of U.S. EPA (2018).

<sup>35</sup> Oxygen consumption associated with activities performed is based on the activity specific metabolic equivalents for work (METs), an individual's estimated RMR, and an energy to oxygen conversion factor (Equations 3D-3 and 3D-4 above).

<sup>36</sup> Distributions of  $\dot{V}O_{2m}$  used by APEX were derived from 20 published studies reporting individual data and grouped mean (and standard deviation) data obtained from 136 published studies. Details are provided in Isaacs and Smith, 2005 (and found in Appendix B of U.S. EPA (2009)).

<sup>37</sup>  $N(0, e_b)$  is a normal distribution with mean zero and standard deviation  $e_b = 0.09866$  meant to capture interpersonal variability, which is sampled once per person.  $N(0, e_w)$  is an intrapersonal residual with standard deviation of  $e_w = 0.07852$ , which is sampled daily due to natural intrapersonal fluctuations in  $\dot{V}_E$  that occur daily.

(using PROC TRANSREG; SAS, 2017) was used to determine the most appropriate variable transformation, indicating a power of 4 to 5 be used when only the log transformed  $\dot{V}O_2$  was used as the independent variable and described in Equation 3D-5.

$$\dot{V}_E = e^{(3.300 + 0.8128 \times \ln(\dot{V}O_2) + 0.5126 \times (\dot{V}O_2 / \dot{V}O_{2m})^4 + N(0, e_b) + N(0, e_w))} \quad \text{Equation 3D-5}$$

In comparing the statistical fit of the new equation with the equations used by APEX previously to estimate ventilation rate, the resulting coefficient of determination ( $R^2$  values) for the new equation ( $R^2 = 0.94$ ) indicates an improved fit compared to that of the previous equations ( $R^2 = 0.89 - 0.92$ ). Further, because the data were not stratified by age groups (or any other groupings), there are no discontinuities in predictions made across age boundaries as was observed when employing the previous equations. Information used in estimating ventilation rate is found in the following APEX two input files:

- *Physiology051619\_Ufixed.txt*: parameters describing statistical distributions of normalized maximum oxygen consumption rate ( $\dot{V}O_{2m}$ ) for two sexes by single age years (0-100) (see, Isaacs and Smith, 2005).
- *Ventilation\_062117.txt*: minimum and maximum age ranges, regression coefficients, between and within error terms used to estimate individual activity-specific ventilation.

To use this information to estimate health risks for children, the ventilation rates observed for the adult controlled human exposure study subjects need to be converted into rates that best reflect the different physiology of children. Consistent with prior REAs (U.S. EPA, 2009, 2014, 2018; Whitfield et al., 1996), we used an equivalent ventilation rate (EVR, L/min- $m^2$ ), which is essentially an allometrically normalized ventilation rate (Equation 3D-6), to estimate instances when any simulated individual reaches a ventilation rate as relatively as high as that of the study subjects (i.e., termed here as moderate or greater exertion).

$$EVR = \frac{\dot{V}_E}{BSA} \quad \text{Equation 3D-6}$$

Before discussing the value used to determine whether a simulated individual is at moderate or greater exertion, a brief description of the controlled human exposure study protocol is warranted. Most of the controlled human exposure studies evaluating  $O_3$  health effects of interest for our exposure benchmark analysis (e.g., Adams, 2006; Folinsbee et al., 1988) were conducted over a 6.6-hr exposure period, thus, the most relevant exposures and associated breathing rates for the exposure benchmark comparisons would be those occurring on average over a 6.6-hr period (not an 8-hr period as was used in previous REAs). The typical protocol for the 6.6-hr controlled human exposure studies employed a mixture of exercise and rest periods varied across the duration of the study, with an expectation that the study subject achieves, on

1 average, a target EVR of 20 L/min-m<sup>2</sup> (i.e., a ventilation rate of ~35 L/min in females and ~40  
2 L/min in males) while exercising using a treadmill or cycle ergometer (e.g., Schelegle et al.,  
3 2009). Most researchers collected the ventilation data during periods of exertion and therefore  
4 reported the exercise-only conditions (e.g., Horstman et al., 1990; Folinsbee et al., 1988).

5 More specifically, during the 6.6-hr study experiments, 5 hours were used for exercise  
6 (i.e., six 50-minute (min) periods on a treadmill or cycle ergometer), with the remaining 1.6  
7 hours comprised of a series of 10-min rest periods occurring immediately after the exercise along  
8 with a 35-min lunch break before the fourth exercise period. As a result of these rest/lunch  
9 periods, the study subject's actual ventilation rates (and hence EVRs) are expected to be less than  
10 the target/observed exercise levels reported in the controlled human exposure studies. Note, the  
11 simulated individuals used to estimate exposure and risk perform numerous activities throughout  
12 the day, each having varied durations and exertion levels (e.g., jogging, sleeping, eating). As  
13 such, when time-averaging across a simulated exposure period of interest, the period likely  
14 would contain ventilation rates of varying duration and intensity. To better match the ventilation  
15 information obtained from the controlled human exposure studies with that of the simulated  
16 individuals, we accounted for the impact from the rest/lunch time ventilation rate along with that  
17 attained during exercise to estimate an appropriate EVR for the study subjects.

18 Attachment 2 provides details regarding the data and approach used to estimate the EVR,  
19 an APEX model variable used to identify when a simulated individual is at moderate or greater  
20 exertion. Briefly, the controlled human exposure study data set available used to calculate EVR  
21 was comprised of 177 study subjects, each evaluated for 2 or more exposure levels (i.e., totaling  
22 485 experiments), and having multiple measurements for each exercise period, yielding 4,024  
23 individual EVR data points. Of these six studies providing raw data,<sup>38</sup> only Schelegle et al.  
24 (2009) mentioned resting  $\dot{V}_E$  (and hence a resting EVR), with an average value for males and  
25 females estimated as 7.61 and 8.05 L/min-m<sup>2</sup>, respectively and based on regression equations  
26 provided by Aitken et al. (1986). We calculated total (exercise and rest) EVR for each person  
27 across the 6.6-hr study period as a weighted average based on the observed EVR for the 5 hours  
28 of exercise and the estimated EVR for 1.6 hours of rest/lunch. Descriptive statistics were  
29 calculated and indicated the person-level EVR data were normally distributed, having a mean  
30 value of 17.32 (L/min-m<sup>2</sup>) and a standard deviation of 1.25 (L/min-m<sup>2</sup>). To reflect variability  
31 across simulated individuals, an EVR is probabilistically selected from this distribution once per  
32 person and used for the duration of their simulation period. This new approach for assigning a  
33 unique EVR to every simulated individual, one that accounts for rest and exercise periods and

---

<sup>38</sup> The six studies include Folinsbee et al. (1988), Folinsbee et al. (1994), Horstman et al. (1990), Kim et al. (2011), McDonnell et al. (1991), and Schelegle et al. (2009).

1 based on the distribution of ventilation rates achieved by all controlled human exposure study  
2 subjects, more appropriately reflects the EVR variability expected to exist in the simulated  
3 population compared to the approach used in the 2008 and 2015 reviews (e.g., U.S. EPA, 2007a;  
4 U.S. EPA, 2007b; 2014 HREA) that assigned a single lower bound EVR value to all  
5 individuals.<sup>39</sup>

6 For practical and tractable modeling reasons, this individual-level EVR threshold is  
7 applied to APEX simulated individuals using a 7-hr averaging time (representing the 6.6-hr  
8 period rounded to whole numbers) in order to better represent the exposure study design than the  
9 previously used 8-hr average. Then, once a simulated individual is identified as having surpassed  
10 their personal 7-hr average EVR threshold in a given day, the level of their simultaneously  
11 occurring 7-hr average O<sub>3</sub> exposure is recorded by APEX. Retained for each simulated  
12 individual are the daily maximum 7-hr average exposure concentration(s) that occurred while at  
13 moderate or greater exertion over the assessment period.

### 14 **3D.2.3 Ambient Air Concentrations**

15 Ambient air concentrations serve as a fundamental input used by APEX to estimate  
16 exposure. There are two important attributes of ambient air concentrations to consider when  
17 estimating population exposure and risk using APEX: spatial and temporal variability. This is  
18 because there can be significant spatial and temporal heterogeneity in O<sub>3</sub> concentrations across  
19 each of the study areas and there is substantial flexibility by APEX in handling ambient air  
20 concentrations at varying scales, both temporally (e.g., hourly, daily) and spatially (e.g. 500-  
21 meter grid, census tract).

22 For this exposure and risk analysis (as done for the 2015 review), we were interested in  
23 having hourly O<sub>3</sub> concentrations at the census tract level. Having these temporally and spatially  
24 resolved ambient air concentrations in each study area allows for better utilization of APEX  
25 temporal and spatial capabilities in estimating exposure and risk (e.g., the population data  
26 described in section 3D.2.2 are at a census tract level). Because APEX simulates where  
27 individuals are located and what they are doing at specific times of the day, more realistic  
28 exposure estimates are obtained in simulating the contact of individuals with these temporally  
29 and spatially diverse concentrations.

---

<sup>39</sup> The EVR used in prior REAs (e.g., U.S. EPA, 2007b; U.S. EPA, 2007a; 2014 HREA) was based on a single lower bound EVR value of 13 L/min-m<sup>2</sup> selected from a range provided by Whitfield et al. (1996). For the current assessment approach, assigning randomly sampled values from an EVR distribution of  $N\{17.32, 1.25\}$  still allows for some simulated individuals to be considered at elevated exertion when exceeding an EVR of ~13-14 L/min-m<sup>2</sup> (Appendix 3D, Attachment 2, Table 3) but overall, leads to fewer individuals achieving a moderate or greater exertion level when compared to simulations employing a single lower bound EVR value of 13 L/min-m<sup>2</sup>.

Ambient air monitors for O<sub>3</sub> capture the temporal scale of interest (i.e., hourly) and can provide general information regarding O<sub>3</sub> levels across an urban area. However, given their limited spatial representativeness, i.e., tens of monitors extending across areas >10,000 km<sup>2</sup>, the monitors may not fully inform concentration variability that may exist at a finer spatial scale. In addition, of interest are concentrations that represent a specific air quality scenario (e.g., ambient air quality that just meets the current standard). In general, due to varying levels of precursor emissions and meteorological conditions, most monitored 3-year periods do not have O<sub>3</sub> concentrations that just meet a specific air quality scenario of interest. Therefore, due to these two realities, modeling methods are used to achieve the desired temporal and spatial scale along with estimating ambient air O<sub>3</sub> concentrations that represent a specific air quality scenario.

The sections that follow briefly summarize the data and approaches used to estimate the air quality concentrations used by APEX. A detailed description on the air quality data collection, processing, adjustment, and evaluation is provided in Appendix 3C. First, section 3D.2.3.1 below provides information for the overall bounding of the modeling domains. The identification of ambient air monitoring data used as a foundation for representing fine-scale temporal and broad-scale spatial concentration variability is provided in section 3D.2.3.2. The approach used to adjust concentrations to just meet air quality scenarios of interest is described in section 3D.2.3.3. And finally, Section 3D.2.3.4 describes the technique used to interpolate the concentrations from the monitor locations to the desired spatial scale (i.e., census tracts). It is these estimated hourly census tract O<sub>3</sub> concentrations representing air quality scenarios that serve as the basic ambient air concentrations from which each simulated individual's microenvironmental concentrations and exposures are estimated (sections 3D.2.6 and 3D.2.7, respectively). Multiple unique APEX input files are used for the current exposure and risk analyses, one for each year and study area, and in the following two formats:

- *concsCSA[number]S[air quality scenario]Y[year].txt*: Tract IDs, hourly concentrations (ppm), calendar date, by study area and year
- *districtsCSA[number]Y[year].txt*: Tract IDs, latitude, longitude, begin and end date

### **3D.2.3.1 Spatial and Temporal Boundaries of Modeling Domains**

APEX has several options to select air quality data to use for estimating exposure and risk. For this exposure and risk analysis, we used the list of counties that comprise each CSA/MSA and their geographic boundaries to define the broad spatial characteristics of each study area (0). As a result, simulated individuals residing within these counties would be part of the exposure modeling domain and any ambient air concentrations estimated within these counties would be used by APEX. Figure 3D-2 to Figure 3D-5 depict the spatial extent of the exposure and risk modeling domain in each study area, along with a visualization of tract-level

1 population density and location of meteorological stations (see section 3D.2.4). The air radius for  
2 APEX, a variable used to define the modeling domain, was set at 30 km to include all air quality  
3 receptors (i.e., census tracts) within each county to model exposures and risks.

4 For each study area, three years of recent air quality were selected to estimate exposures.  
5 The exposure periods are the O<sub>3</sub> seasons<sup>40</sup> for which routine hourly O<sub>3</sub> monitoring data were  
6 available, and defined by 40 CFR part 58, Appendix D, Table D-3. These periods are designed to  
7 reasonably capture variability in ambient air O<sub>3</sub> concentrations and meteorology and include the  
8 high concentration events occurring in each area. Having this range of air quality data across  
9 multiple years allows us to realistically estimate a range of exposures, rather than using a single  
10 year of air quality. The number of O<sub>3</sub> monitors in operation did not vary from year to year, thus,  
11 the overall spatial representation of each study area by the ambient air monitors (and that using  
12 the statistically interpolated data) remained constant for each year over the simulation period.



---

<sup>40</sup> In this current analysis and for practical purposes, even though there are different durations of monitoring data available across the study areas (i.e., some areas perform a full year of monitoring, others less than a full year), an O<sub>3</sub> season is considered to be synonymous with a year and exposure results are reported on a per year basis.

1 **Table 3D-5. List of states, counties, and O<sub>3</sub> seasons that define the air quality and**  
2 **exposure spatial and temporal modeling domain in each study area.**



| Study Area  | State Abbreviation: County List <sup>A</sup>  | O <sub>3</sub> season <sup>B</sup> |
|---|---|------------------------------------|
| Atlanta   | GA: Barrow, Bartow, Butts, Carroll, Cherokee, Clarke, Clayton, Cobb, Coweta, Dawson, DeKalb, Douglas, Fayette, Forsyth, Fulton, Gordon, Gwinnett, Hall, Haralson, Heard, Henry, Jackson, Jasper, Lamar, Madison, Meriwether, Morgan, Newton, Oconee, Oglethorpe, Paulding, Pickens, Pike, Polk, Rockdale, Spalding, Troup, Upson, Walton. | March to October                   |
| Boston  | CT: Windham. MA: Barnstable, Bristol, Essex, Middlesex, Norfolk, Plymouth, Suffolk, Worcester. NH: Belknap, Hillsborough, Merrimack, Rockingham, Strafford. RI: Bristol, Kent, Newport, Providence, Washington.   | March to September                 |
| Dallas  | TX: Bryan, Collin, Cooke, Dallas, Denton, Ellis, Fannin, Grayson, Henderson, Hood, Hopkins, Hunt, Johnson, Kaufman, Navarro, Palo Pinto, Parker, Rockwall, Somervell, Tarrant, Wise.  | January to December                |
| Detroit   | MI: Genesee, Lapeer, Lenawee, Livingston, Macomb, Monroe, Oakland, St. Clair, Washtenaw, Wayne.   | March to October                   |
| Philadelphia  | DE: Kent, New Castle. MD: Cecil. NJ: Atlantic, Burlington, Camden, Cape May, Cumberland, Gloucester, Salem PA: Berks, Bucks, Chester, Delaware, Montgomery, Philadelphia.   | March to October                   |
| Phoenix   | AZ: Maricopa, Pinal.  | January to December                |
| Sacramento  | CA: El Dorado, Nevada, Placer, Sacramento, Sutter, Yolo, Yuba.  | January to December                |
| St. Louis   | IL: Bond, Calhoun, Clinton, Jersey, Macoupin, Madison, Marion, Monroe, St. Clair, MO: Franklin, Jefferson, Lincoln, St. Charles, St. Francois, St. Louis, Warren, St. Louis City.   | March to October                   |
| <sup>A</sup> Delineations promulgated by the Office of Management and Budget (OMB) in February of 2013 (see Appendix 3C, section 3C.2). |   |                                    |
| <sup>B</sup> These are the regulatorily required monitoring seasons (see section 2.3.1 of the main document).                           |   |                                    |







**Figure 3D-2. County boundaries, census tract population densities, and meteorological stations in the Atlanta (top) and Boston (bottom) study areas.**







**Figure 3D-3. County boundaries, census tract population densities, and meteorological stations in the Dallas (top) and Detroit (bottom) study areas.**



**Figure 3D-4. County boundaries, census tract population densities, and meteorological stations in the Philadelphia (top) and Phoenix (bottom) study areas.**





**Figure 3D-5. County boundaries, census tract population densities, and meteorological stations in the Sacramento (top) and St. Louis (bottom) study areas.**

### 3D.2.3.2 Ambient Air Monitoring Data

We used hourly O<sub>3</sub> concentrations from ambient air monitors in each study area for the 2015-2017 period to develop the air quality surface used for estimating exposure and risk (Table 3D-6; details in Appendix 3C, section 3C.3).<sup>41</sup> Design values for monitors in each study area were used to determine the direction and magnitude of adjustments needed to just meet the current standard and the other two air quality scenarios (section 3D.2.3.3). The two other air quality scenarios are O<sub>3</sub> concentrations for which the highest design value in the area is just above or just below the current standard level: 75 ppb and 65 ppb. Ambient air monitors outside each study area, but within 50 km, were also used to improve spatial interpolation of air quality near the edges of the study areas (section 3D.2.3.4). All available ambient air O<sub>3</sub> monitor data were used to develop the adjusted air quality surfaces, however design values were not calculated for monitors having incomplete data.

---

<sup>41</sup> Briefly, hourly O<sub>3</sub> concentration data for all U.S. monitoring sites for 2015-2017 were retrieved from the EPA's Air Quality System (AQS) database. Monitors within the CSA boundary for each urban study area were identified and used to determine the NO<sub>x</sub> emissions changes necessary to meet the air quality scenarios of interest (section 3D.2.3.3). Monitors within 50 km of the CSA boundary were identified to provide additional data for spatial interpolation (section 3D.2.3.4).

**Table 3D-6. List of ambient air monitor IDs, range of O<sub>3</sub> design values, and number of monitors in each study area.**

| Study Area   | State: Ambient Air Monitor IDs <sup>A</sup>  | O <sub>3</sub> Design Values (ppb) (# of monitors) |
|--|--|--|
| Atlanta  | GA: 130590002, 130670003, 130770002, 130850001, 130890002, 130970004, <b>131210055</b> , 131350002, 131510002, <i>132230003</i> , 132319991, 132470001   | 63 – 75 (12)                                       |
| Boston   | CT: 090159991 MA: <i>250010002</i> , <b>250051004</b> , 250051006, 250092006, 250094005, 250095005, 250170009, 250213003, 250230005, 250250042, 250270015, 250270024 NH: 330012004, 330111011, 330115001, 330131007, 330150014, 330150016, 330150018 RI: 440030002, 440071010, <b>440090007</b>  | 59 – 73 (23)                                       |
| Dallas   | OK: <i>400130380</i> TX: 480850005, 481130069, 481130075, 481130087, <b>481210034</b> , 481211032, 481390016, 481391044, 482210001, 482311006, 482510003, 482570005, 483491051, 483670081, 483970001, 484390075, 484391002, 484392003, 484393009, 484393011  | 61 – 79 (21)                                       |
| Detroit  | MI: 260490021, 260492001, 260910007, 260990009, 260991003, 261250001, 261470005, 261610008, 261619991, 261630001, <b>261630019</b> , <i>261630093</i> , <i>261630094</i>   | 66 – 73 (13)                                       |
| Philadelphia   | DE: 100010002, 100031007, 100031010, 100031013, 100032004 MD: 240150003 NJ: 340010006, 340070002, 340071001, 340110007, 340150002 PA: 420110006, 420110011, <i>421070004</i> , <b>420170012</b> , 420290100, 420450002, 420910013, <b>421010024</b> , 421010048  | 64 – 80 (20)                                       |
| Phoenix  | AZ: 040130019, 040131003, 040131004, 040131010, 040132001, 040132005, 040133002, 040133003, 040134003, 040134004, <i>040134005</i> , 040134008, 040134010, 040134011, <i>040135100</i> , 040137003, 040137020, 040137021, 040137022, 040137024, 040139508, 040139702, 040139704, 040139706, <b>040139997</b> , 040213001, 040213003, 040213007, 040217001, 040218001 | 63 – 76 (30)                                       |
| Sacramento   | CA: 060170010, <i>060170012</i> , 060170020, <b>060570005</b> , <i>060570007</i> , 060610003, 060610004, 060610006, 060611004, 060612002, 060670002, 060670006, 060670010, 060670011, 060670012, <i>060670014</i> , 060675003, 061010003, <i>061010004</i> , 061130004, 061131003  | 63 – 86 (21)                                       |
| St. Louis  | IL: <i>170830117</i> , <i>170831001</i> , 171170002, 171190008, 171191009, 171193007, 171199991, 171630010 MO: 290990019, <i>291130003</i> , <i>291130004</i> , <b>291831002</b> , 291831004, 291890005, 291890014, 295100085  | 65 – 72 (16)                                       |
| <sup>A</sup> <b>Bold font</b> indicates monitor(s) design value used to adjust ambient air concentrations to just meet selected air quality scenarios. From Appendix 3C, Tables 3C-20 to 3C-27. <i>Italic font</i> indicates monitor did not meet completeness criteria to calculate a design value. |  |  |

### 3D.2.3.3 Model Adjusted Concentrations at Monitor Locations to Represent Air Quality Scenarios

Details of the approach used to develop the three air quality scenarios (design values of 70, 65 and 75 ppb) are provided in Appendix 3C, sections 3C.4 and 3C.5. Briefly, the ambient air concentrations described above in section 3D.2.3.2 were adjusted to just meet the current standard (70 ppb, annual 4<sup>th</sup> highest daily maximum 8-hr average concentration, averaged over a

3-year period) and two other air quality scenarios (75 and 65 ppb, annual 4<sup>th</sup> highest daily maximum 8-hr average concentration, averaged over a 3-year period)<sup>42</sup> using a model-based O<sub>3</sub> methodology that adjusts the observed hourly O<sub>3</sub> concentrations to reflect the expected spatially and temporally varying impacts of changes in NO<sub>x</sub> emissions. The methodology is similar to that used for the 2014 HREA and employs a photochemical air quality model combined with a tool that calculates modeled sensitivities of O<sub>3</sub> to precursor emission changes.

For the current analysis, the Comprehensive Air Quality Model with Extensions (CAMx)<sup>43</sup> served as the chemical transport model,<sup>44</sup> with 2016 selected as the base year for determining the adjustments needed for the 2015-2017 ambient air monitoring data. Model inputs include meteorological data,<sup>45</sup> emissions,<sup>46</sup> and initial and boundary conditions.<sup>47</sup> The evaluation of modeled versus observed O<sub>3</sub> concentrations for 2016 indicated CAMx generally reproduced the observed spatial and temporal patterns, with the exception of concentration underestimates occurring in winter across almost all regions (Appendix 3C, section 3C.4.2).

The CAMx model was instrumented with the Higher order Decoupled Direct Method (HDDM) to calculate modeled nonlinear sensitivities of O<sub>3</sub> to emission changes (Appendix 3C, section 3C.5). The photochemical modeling outputs included both modeled O<sub>3</sub> concentrations and sensitivities of O<sub>3</sub> concentrations to changes in NO<sub>x</sub> emissions for each hour in a single year at all ambient air monitor locations (Appendix 3C, sections 3C.4 and 3C.5). Linear regression was used with these single-year 2106 model outputs to create relationships between the sensitivities and O<sub>3</sub> concentrations for each hour of each of the four seasons at each monitoring location. The relationships between hourly sensitivities and hourly O<sub>3</sub> for each season were then used with three years of ambient air monitoring data at each location to predict hourly sensitivities for the complete 3-year record at each monitoring location. From these, we

---

<sup>42</sup> In these scenarios, the air quality conditions were adjusted such that the monitor location with the highest concentrations in each area had a design value just equal to either 75 ppb or 65 ppb.

<sup>43</sup> The Comprehensive Air Quality Model with Extensions and associated documentation is found at [www.camx.com](http://www.camx.com).

<sup>44</sup> The 2014 HREA used the Community Multiscale Air Quality Modeling System (CMAQ) to model air quality.

<sup>45</sup> Horizontal wind components (i.e., speed and direction), temperature, moisture, vertical diffusion rates, and rainfall rates for each 12 Km grid cell in each vertical layer was derived from version 3.8 of the Weather Research and Forecasting Model (WRF; <http://wrf-model.org>). For details, see PA, Appendix 3C, section 3C.4.1.4.

<sup>46</sup> Emissions from electric generating units, other point sources, area sources, agricultural sources (ammonia only), anthropogenic fugitive dust sources, nonroad mobile sources, onroad mobile sources, and biogenic sources are based on the alpha version of the Inventory Collaborative 2016 emissions modeling platform (<http://views.cira.colostate.edu/wiki/wiki/9169>). For details, see PA, Appendix 3C, section 3C.4.1.5.

<sup>47</sup> Initial and lateral boundary concentrations for the 12 km domain are provided by the hemispheric version of the Community Multi-scale Air Quality model (H-CMAQ) v5.2.1. The H-CMAQ model was run for 2016 with a horizontal grid resolution of 108 km and 44 vertical layers up to 50 hPa. For details, see PA, Appendix 3C, section 3C.4.1.6.

calculated hourly O<sub>3</sub> concentrations at each monitor location based on iteratively increasing NO<sub>x</sub> reductions to determine the adjustments necessary for the monitor location with the highest design value in each study area to just meet the target value, e.g., 70 ppb for the current standard scenario (Appendix 3C, section 3C.5). For the 75 ppb air quality scenario, we note that three areas required an increase in NO<sub>x</sub> emissions as their highest O<sub>3</sub> design values were below 75 ppb. For the other five study areas and that same air quality scenario and for all study areas with the other two air quality scenarios (i.e., 65 and 70 ppb), emission reductions were required (Table 3D-7).

**Table 3D-7. Range of the percent NO<sub>x</sub> emission changes needed to adjust air quality in the eight study areas for the three air quality scenarios.**

| Design Value for each Air Quality Scenario | Range of NO <sub>x</sub> Emission Changes Applied Across the Eight Study Areas |
|--|--|
| 75 ppb                                     | +18% to -45%   |
| 70 ppb                                     | -13% to -58%   |
| 65 ppb                                     | -38% to -72%   |
| From Appendix 3C, Table 3C-19.             |  |


#### **3D.2.3.4 Interpolation of Adjusted Monitor Concentrations to the Census Tracts Comprising Each Study Area**

As described above, model-based relationships between O<sub>3</sub> and NO<sub>x</sub> emissions were used to adjust hourly O<sub>3</sub> concentrations at the ambient air monitor locations (section 3D.2.3.2) to represent conditions in which the study area just meets the selected air quality scenario (section 3D.2.3.3). Simulated O<sub>3</sub> concentrations were then needed at a finer spatial scale than that given by the monitor sites to better represent the spatial heterogeneity in O<sub>3</sub> concentrations across locations frequented by the simulated population (and during the times frequented) across the study area. To accomplish this in each of the eight study areas, the adjusted hourly O<sub>3</sub> concentrations at monitoring sites were interpolated to census tract centroids using the Voronoi Neighbor Averaging (VNA; Appendix 3C, section 3C.6). Nearby monitoring concentrations, for each hour, inform the estimation of O<sub>3</sub> for a given census tract using inverse distance weighting. In so doing, both spatial and temporal gaps in the desired air quality surface are filled simultaneously, resulting in a final dataset of ambient air O<sub>3</sub> concentration estimates with high temporal and spatial resolution (hourly concentrations in 500 to 1700 census tracts) for each of the eight study areas and for years 2015 to 2017 (Appendix 3C, section 3C.7).



### 3D.2.3.5 Evaluation of Temporal and Spatial Characteristics of the Simulated Air Quality Surfaces

We applied the above described approaches to simulate air quality surfaces that represent fine-scale temporal (i.e., hourly) and spatial (i.e., census tract) variability in O<sub>3</sub> concentrations for the three air quality scenarios in each study area. Then, characteristics of the simulated air quality surfaces were evaluated for trends and patterns that would be informative for interpreting the simulated exposure and risk results. For example, Figure 3D-6 illustrates the temporal variability across the three years of monitoring data, stratified by hour-of-day (left panel) and month (right panel), in Philadelphia for the ambient air measurements, and for the three simulated air quality scenarios (following the model-based adjustment at each monitor location).



**Figure 3D-6. Hourly O<sub>3</sub> distributions by hour-of-day (left panel) and month (right panel) at ambient air monitoring sites in Philadelphia for observed air quality (black), air quality adjusted to meet the current standard (70 ppb, blue) and two other design values (75 ppb, red; and 65 ppb, green). From Appendix 3C, Figures 3C-71 and 3C-79, respectively.**

The diurnal and seasonal temporal patterns for the three air quality scenarios are similar to the monitor observations, with highest O<sub>3</sub> concentrations during the during late morning/afternoon hours and during spring/summer months. In addition, the upper end of the O<sub>3</sub> concentration distributions decrease from observed values (black) to values adjusted to meet the current standard of 70 ppb (blue) and decrease further when adjusted to meet a design value of 65 ppb (green). These decreases can be seen when evaluating the highest O<sub>3</sub> hours-of-the day and represented by the data points that extend beyond the whiskers of the boxplots. Further, the


1 overall pattern flattens when decreasing the level of the O<sub>3</sub> standard, considering both the diurnal  
2 and monthly distributions. Regarding the diurnal pattern, O<sub>3</sub> increases during early morning  
3 hours are associated with VOC-limited and NO<sub>x</sub> titration conditions near NO<sub>x</sub> sources during  
4 rush-hour periods. Lower O<sub>3</sub> concentrations in the winter months result from lower solar  
5 insolation rates and a reduction in total photochemical activity. See the accompanying Appendix  
6 3C (Section 3C.7.2 and Figures 3C-67 through 3C-82) for details for temporal characteristics of  
7 all eight study areas.

8 We also evaluated the hourly O<sub>3</sub> concentrations by considering the overall shape of the  
9 concentration distribution using the census-tract resolution interpolated data. Even though both  
10 the temporal and spatial attributes may be conflated in such a presentation, a histogram can be  
11 useful in illustrating important features of the distribution (e.g., skewness, kurtosis, upper  
12 percentile tails) that may be influential in estimated exposures and risks. For example, Figure  
13 3D-7 illustrates the overall shape<sup>48</sup> of the hourly concentration distribution in each of the eight  
14 study areas for the air quality scenario just meeting the current standard. The distribution for all  
15 study areas are skewed to the right, generally representing a lognormal form.

16 There are notable differences across the collection of study areas. For example, the  
17 distributions for Boston, Dallas, Philadelphia, and Sacramento are slender (i.e., leptokurtic),  
18 showing much higher peaks around the mean value, relative to the other four study areas,  
19 Atlanta, Detroit, Phoenix, and St. Louis which exhibit relatively flatter (i.e., platykurtic)  
20 distributions, and the latter three of which, show an increased frequency of upper percentile  
21 concentrations. Phoenix, in particular, exhibits the greatest right-most shift in the hourly O<sub>3</sub>  
22 concentration distribution and would reflect other areas of the U.S. having a similar distribution  
23 of ambient air O<sub>3</sub> concentrations. Also, there are only limited instances of hourly O<sub>3</sub>  
24 concentrations >70 ppb in all study areas for the air quality scenario just meeting the current  
25 standard (Figure 3D-7). This is consistent with recent (unadjusted) ambient air monitoring data,  
26 whereas hourly O<sub>3</sub> concentrations are rarely at or above 100 ppb when design values are ≤70 ppb  
27 (i.e., <0.02% frequency; see Appendix 2A, Table 2A-4). This is important to note because these  
28 distinct features of the O<sub>3</sub> concentration distribution, along with the spatial and temporal  
29 intersection of concentrations with population demographics and activity patterns, play an  
30 important role in contributing to variation in the estimated population exposures and risks  
31 presented in section 3D.3 below.


---

<sup>48</sup> Figure 3D-7 is intended to illustrate the differences in the shape of the distributions. All histograms have the exact same range of values for the x-axis, i.e., the midpoint concentrations range from 0 to 70 ppb, in 2 ppb increments (maximum value represents frequency of all hourly concentrations >70 ppb. Because there are varied distribution shapes, the range of values for the y-axis differ across the study areas. The actual value of the y-axis is unimportant in this context because of interest here are the relative differences that exist across the concentration distributions (e.g., frequency of high O<sub>3</sub> concentrations relative to the occurrence of low O<sub>3</sub> concentrations).



**Figure 3D-7. Histograms of hourly O<sub>3</sub> concentrations (ppb, x-axis) for the air quality scenario just meeting the current O<sub>3</sub> standard in the eight study areas.** The x-axis midpoint concentrations range from 0 to 70 ppb, in 2 ppb increments (rightmost, maximum histogram bar for all study areas represents the frequency of all hourly concentrations >70 ppb).

Regarding spatial variability, Figure 3D-8 displays census tract design values for each of the three air quality scenarios in Philadelphia. A decline in the highest ambient air O<sub>3</sub> concentrations is predicted across the study area when considering air quality scenarios at lower design values.



**Figure 3D-8. Calculated design values for census tracts in the Philadelphia study area, derived from a VNA interpolation of CAM<sub>x</sub>/HDDM adjusted O<sub>3</sub> concentrations.** Figure modified from Appendix 3C, Figure 3C-99.

### 3D.2.4 Meteorological Data

Temperature data are used by APEX in selecting human activity data and in estimating air exchange rates (AERs) for indoor residential microenvironments (MEs). When developing profiles, APEX uses temperature data from the closest weather station to each Census tract. Hourly surface temperature measurements were obtained from the National Oceanic and Atmospheric Administration (NOAA) Integrated Surface Hourly (ISH) data files.<sup>49</sup> The weather stations used for each study area are given in Table 3D-8, along with general locations provided in Figure 3D-2 to Figure 3D-5.

In general, the occurrence of missing temperature data was limited to a few hours per year. Missing hourly temperature data were estimated by the following procedure. Where there were consecutive strings of missing values (data gaps) of 9 or fewer hours, missing values were estimated by linear interpolation between the observed values at the ends of the gap. Remaining missing values at a meteorological station were estimated by fitting linear regression models for each hour of the day, with each of the other monitors, and choosing the model which maximizes R<sup>2</sup>, for each hour of the day, subject to the constraints that R<sup>2</sup> be greater than 0.40 and the number of regression data values (days) is at least 100. If there no suitable regression models to fill the missing values, for gaps of 12 or fewer hours, missing values were estimated by linear

<sup>49</sup> See: <ftp://ftp.ncdc.noaa.gov/pub/data/noaa/isd-lite/>

interpolation between the valid values at the ends of the gap. Any remaining missing values were replaced with the value at the closest station for that hour. Because there were limited instances of missing data, there were negligible differences between the statistically filled and the original temperature data with missing values.

**Table 3D-8. Study area meteorological stations, locations, and hours of missing data.**

| Study Area   | Station Name                 | WBAN <sup>A</sup> | Latitude | Longitude | Number of hours with missing temperature |      |      |
|--------------|------------------------------|-------------------|----------|-----------|--|------|------|
|              |                              |                   |          |           | 2015                                     | 2016 | 2017 |
| Atlanta      | HARTSFIELD-JACKSON ATLANTA   | 13874             | 33.630   | -84.442   | 6  | 4    | 5    |
|              | FULTON CO-BROWN FLD ARPT     | 03888             | 33.779   | -84.521   | 34                                       | 84   | 220  |
|              | DEKALB-PEACHTREE AIRPORT     | 53863             | 33.875   | -84.302   | 13                                       | 6    | 47   |
|              | DOBBINS AIR RESERVE BASE     | 13864             | 33.917   | -84.517   | 171                                      | 142  | 58   |
| Boston       | LAURENCE G HANSCOM FLD       | 14702             | 42.470   | -71.289   | 55                                       | 164  | 19   |
|              | BEVERLY MUNICIPAL AIRPORT    | 54733             | 42.584   | -70.918   | 56                                       | 8    | 7    |
|              | GEN E L LOGAN INTERNATIONAL  | 14739             | 42.361   | -71.010   | 5  | 4    | 5    |
|              | NORWOOD MEMORIAL AIRPORT     | 54704             | 42.191   | -71.174   | 17                                       | 38   | 17   |
| Dallas       | DALLAS LOVE FIELD AIRPORT    | 13960             | 32.852   | -96.856   | 5  | 5    | 5    |
|              | DALLAS/FT WORTH INTERNAT     | 03927             | 32.898   | -97.019   | 5  | 5    | 5    |
|              | DALLAS EXECUTIVE AIRPORT     | 03971             | 32.681   | -96.868   | 27                                       | 14   | 36   |
| Detroit      | DETROIT METRO WAYNE COUNTY   | 94847             | 42.231   | -83.331   | 462                                      | 547  | 619  |
|              | GROSSE ILE MUNICIPAL AIRPORT | 54819             | 42.099   | -83.161   | 484                                      | 397  | 44   |
|              | DETROIT CITY AIRPORT         | 14822             | 42.409   | -83.010   | 25                                       | 22   | 69   |
|              | OAKLAND CO. INTNL AIRPORT    | 94817             | 42.665   | -83.418   | 16                                       | 11   | 17   |
| Philadelphia | WINGS FIELD AIRPORT          | 64752             | 40.100   | -75.267   | 150                                      | 241  | 324  |
|              | SOUTH JERSEY REGIONAL ARPT   | 93780             | 39.941   | -74.841   | na                                       | 90   | 69   |
|              | PHILADELPHIA INTERNATIONAL   | 13739             | 39.873   | -75.227   | 5  | 6    | 5    |
|              | NE PHILADELPHIA AIRPORT      | 94732             | 40.079   | -75.013   | 28                                       | 13   | 51   |
| Phoenix      | PHOENIX SKY HARBOR INTL      | 23183             | 33.428   | -112.004  | 13                                       | 8    | 6    |
|              | SCOTTSDALE AIRPORT           | 03192             | 33.623   | -111.911  | 9  | 19   | 10   |
| Sacramento   | SACRAMENTO EXECUTIVE         | 23232             | 38.507   | -121.495  | 10                                       | 21   | 87   |
|              | SACRAMENTO MCCLELLAN AFB     | 23208             | 38.667   | -121.400  | 366                                      | 368  | 89   |
|              | SACRAMENTO INTL AIRPORT      | 93225             | 38.696   | -121.590  | 28                                       | 53   | 41   |
| St. Louis    | SCOTT AIR FORCE BASE/MIDAMER | 13802             | 38.550   | -89.850   | 110                                      | 49   | 45   |
|              | LAMBERT-ST LOUIS INTERNAT    | 13994             | 38.753   | -90.374   | 11                                       | 7    | 7    |
|              | ST LOUIS DOWNTOWN AIRPORT    | 03960             | 38.571   | -90.157   | 12                                       | 49   | 7    |

<sup>A</sup> Weather Bureau Army Navy (WBAN) number of the meteorological stations.  
"na" is no data available

Multiple unique APEX input files are used for the current exposure and risk analyses, one for each year and study area, and in the following two formats:

- *METdataCSA[number]Y[year].txt*: meteorological station IDs, hour of day, hourly temperature (°F) for each meteorological station, by study area and year
- *METlocsCSA[number]Y[year].txt*: meteorological station IDs, latitudes and longitudes, start and stop dates of temperature data

### **3D.2.5 Construction of Human Activity Pattern Sequences**

Exposure models use human activity pattern data to estimate exposure to pollutants. Different human activities, such as outdoor exercise, indoor reading, or driving a motor vehicle can lead to different pollutant exposures, intakes and doses. This may be due to differences in the pollutant concentration in the varied locations where different activities are performed as well as to differences in the energy expended in performing the activities (because energy expended influences inhalation and thus may influence pollutant intake). To model exposures to ambient air pollutants, it is critical to have information on the locations where people spend time and the activities performed in such locations. The following subsections describe the activity pattern data, population commuting data, and the approaches used to simulate where individuals might be and what they might be doing.

After the basic demographic variables are identified by APEX for a simulated individual in the study area, values for the other variables are selected as well as the development of the activity patterns that account for the places the simulated individual visits and the activities they perform. The following subsections describe the population data we used in the assessment to assign key features of the simulated individuals, and approaches used to simulate the basic physiological functions important to the exposure estimates for this exposure and risk analysis.

#### **3D.2.5.1 Consolidated Human Activity Database**

The Consolidated Human Activity Database (CHAD) provides time series data on human activities through a database system of collected human diaries, or daily time location activity logs (U.S. EPA, 2019c). The purpose of CHAD is to provide a basis for conducting multi-route, multi-media exposure assessments (McCurdy, 2000). The data contained within CHAD come from multiple surveys with variable, study-specific structure (e.g., real time minute-by-minute recording of diary events versus a recall method using time-block-averaging). Common to all of the peer-reviewed studies, individuals provided information on their locations visited and activities performed for each surveyed day. Personal attribute data for the surveyed individuals, such as age and sex, are included in CHAD and are used as variables to link to the population data. The latest version of CHAD contains data for nearly 180,000 individual diary days. Most of the CHAD data are from studies conducted since 2000, several of which are newly included or

updated since the 2014 HREA.<sup>50</sup> Table 3D-9 provides the survey study information including the geographic coverage, year, and the number of diaries available for use by APEX.<sup>51</sup>

**Table 3D-9. Overview of Studies Included in the APEX Activity Data Files.**

| Study Name (abbreviation)  | Geographic Coverage  | Study Year                                | Number of Diary Days <sup>A</sup> |         | Age Range |     | Reference  |
|--|----------------------|---|-----------------------------------|---------|-----------|-----|--|
|  |                      |   | Ages 5-18                         | Any Age | min       | max |  |
| American Time Use Survey, Bureau of Labor Statistics (BLS)                 | Entire US            | 2003-11                                   | 7,559                             | 123,932 | 15        | 85  | US Bureau of Labor Statistics (2014)               |
| Baltimore Retirement Home Study (BAL)                                      | Baltimore County, MD | 1997-98                                   | 0                                 | 390     | 72        | 93  | Williams et al. (2000)                             |
| California Activity Pattern Studies (CAA, CAC, CAY)                        | California           | CAA: 1987-88                              | 36                                | 1,570   | 18        | 94  | Wiley et al. (1991a),<br>Wiley et al. (1991b)      |
|  |                      | CAC: 1989-90                              | 680                               | 1,197   | 0         | 11  |  |
|  |                      | CAY: 1987-88                              | 182                               | 182     | 12        | 17  |  |
| Cincinnati Activity Patterns Study (CIN)                                   | Cincinnati, OH       | 1985                                      | 736                               | 2,595   | 0         | 86  | Johnson (1989)                                     |
| Detroit Exposure and Aerosol Research Study (DEA)                          | Detroit, MI          | 2004-2007                                 | 5                                 | 336     | 18        | 74  | Williams et al. (2009)                             |
| Denver, Colorado Personal Exposure Study (DEN)                             | Denver, CO           | 1982-1983                                 | 7                                 | 784     | 18        | 70  | Johnson (1984);<br>Johnson et al. (1986)           |
| EPA Longitudinal Studies (EPA)   | Central NC           | 1999-2000,<br>2002, 2006-08,<br>2012-2013 | 0                                 | 1,780   | 0         | 72  | Isaacs et al. (2013)                               |
| Los Angeles Ozone Exposure Study: Elementary School/High School (LAE, LAH) | Los Angeles, CA      | 1989-1990                                 | 49                                | 49      | 10        | 12  | Roth Associates (1988); Spier et al. (1992)        |
|  |                      |   | 43                                | 43      | 13        | 17  |  |
| National Human Activity Pattern Study (NHAPS): Air/Water (NHA, NHW)        | 48 states            | 1992-1994                                 | 659                               | 4,723   | 0         | 93  | Klepeis et al. (1995);<br>Tsang and Klepeis (1996) |
|  |                      |   | 713                               | 4,663   | 0         | 93  |  |

<sup>50</sup> CHAD updates since the 2014 HREA include expansion of activity codes, revision to the METs distributions, filling missing temperatures, characterizing ambiguous location entries, etc. See U.S. EPA, 2019c and Attachment 3.

<sup>51</sup> Following stated updates to improve the CHAD diary information, some diaries in the CHAD master database remain unusable for exposure and risk modeling. Most commonly this is from having excessive missing or unknown location or activity data (e.g.,  $\geq 3$  hours/day).



| Study Name<br>(abbreviation)   | Geographic<br>Coverage                | Study Year     | Number of Diary Days <sup>A</sup> |                | Age Range |           | Reference  |
|--|---------------------------------------|----------------|-----------------------------------|----------------|-----------|-----------|--|
|  |                                       |                | Ages 5-18                         | Any Age        | min       | max       |  |
| Population Study<br>of Income<br>Dynamics PSID I,<br>II, III (ISR)   | Whole US                              | I: 1997        | 3,302                             | 5,327          | 0         | 13        | University of<br>Michigan, 2016  |
|  |                                       | II: 2002-2003  | 4,816                             | 4,825          | 5         | 19        |  |
|  |                                       | III: 2007-2008 | 2,633                             | 2,690          | 10        | 19        |  |
| National-scale<br>Activity Study<br>(NSA)  | 7 US metro<br>areas                   | 2009           | 0                                 | 6,820          | 35        | 92        | Knowledge Networks<br>(2009)   |
| RTI Ozone<br>Averting Behavior<br>Study (OAB)  | 35 US metro<br>areas                  | 2002-2003      | 1,941                             | 2,872          | 2         | 12        | Mansfield et al.<br>(2009)   |
| RTP Particulate<br>Matter Panel Study<br>(RTP)   | Wake and<br>Orange<br>Counties,<br>NC | 2000-2001      | 0                                 | 874            | 55        | 85        | (Williams et al.,<br>2003a, 2003b),<br>Williams et al., 2001                     |
| Study of Use of<br>Products and<br>Exposure-related<br>Behaviors (SUP)   | California                            | 2006-2010      | 1,293                             | 8,831          | 1         | 88        | Bennett et al. (2012)  |
| Seattle Study<br>(SEA)   | Seattle, WA                           | 1999-2001      | 317                               | 1,645          | 6         | 91        | Liu et al. (2003)  |
| Valdez Air Health<br>Study (VAL)   | Valdez, AK                            | 1990-1991      | 72                                | 387            | 11        | 71        | Goldstein et al.<br>(1992)   |
| Washington, DC<br>Study (WAS)  | Washington,<br>DC                     | 1982-1983      | 11                                | 695            | 18        | 98        | Hartwell et al. (1984);<br>Johnson et al.<br>(1986); Settergren et<br>al. (1984) |
| <b>All Studies, Areas, and Years (TOTAL):</b>  |                                       |                | <b>25,054</b>                     | <b>177,210</b> | <b>0</b>  | <b>98</b> |  |
| <sup>A</sup> The APEX activity data file differs from that of the CHAD master database by removing what are considered as unusable diaries for our exposure and risk analyses (~2,000 diary days). The four criteria used to screen the CHAD master database are as follows: 1) Daily maximum temperature is missing, 2) daily average temperature is missing, 3) the day-of-week is missing, and 4) at least 3 hours of events have activity or location codes of "unknown" and/or "missing". |                                       |                |                                   |                |           |           |  |

Three standard APEX input files are used for the current exposure and risk analyses to create the activity pattern profiles for all simulated individuals.

- *CHADEvents\_060419A.txt*: CHAD ID, clock hour (hhmm), duration of event (minutes), CHAD activity code, and CHAD location code, serving as a daily sequence of locations visited, activities performed, and their duration
- *CHADQuest\_060419A.txt*: CHAD ID, day-of-week, sex, race, employment status, age, maximum daily temperature, average temperature, occupation, missing time (minutes), record count, commute time (see also section 3D.2.5.2)
- *CHADSTATSOutdoor\_060419A.txt*: CHAD ID, total daily time spent outdoors (minutes) (see also section 3D.2.5.4)



### 3D.2.5.2 Commuting and Employment Data

Exposures can vary across a study area based on spatial heterogeneity in ambient air concentrations and how that corresponds with a simulated individual's activity pattern and geographic location. APEX approximates home-to-work commuting flows between census designated areas for each employed individual, and thus accounts for differing ambient air concentrations that may occur in these geographic locations. APEX has a national commuting database originally derived from 2010 Census tract level data collected as part of the U.S. DOT Census Transportation Planning Package. The data used to generate the APEX commuting file are from the "Part 3-The Journey to Work" files. The Census files contain counts of individuals commuting from home to work locations at a number of geographic scales. These data have been processed to calculate fractions (and hence commute probabilities) for each tract-to-tract flow to create the national commuting data distributed with APEX. This database contains commuting data for each of the 50 states and Washington, D.C. This dataset does not differentiate people that work at home from those that commute within their home tract. A companion file to the commuting flow file is the commuting times file, i.e., an estimate of the usual amount of time in minutes it takes for commuters to get from home to work each day and tract-to-tract commuting distances. The commuting times file information is used to select CHAD activity pattern data from individuals having time spent inside vehicles similar to the census commute times and associated distances travelled. Two standard APEX input files are used for the current exposure and risk analysis, as listed here.

- *Commuting\_times\_US\_2010.txt*: census block IDs, count of all employed individuals, count of employed individuals that do not work at home, 7 groups of block-level one-way commuting times (in minutes)
- *Commuting\_flow\_US\_2010.txt*: census tract IDs, tract-to-tract commute cumulative probabilities (in fractional form), commute distance (km)

Another population-based file associated with commuting is the employment file. This APEX input file contains the probability of employment separately for males and females by age group (starting at age 16) and by census tract (the only census unit available for this type of data). The 2010 Census collected basic population counts and other data using the short form but collected more detailed socioeconomic data (including employed persons) from a relatively small subset of people using the 5-year American Community Survey (ACS).<sup>52</sup> The ACS dataset

---

<sup>52</sup> 2010 U.S. Census American FactFinder: <http://factfinder2.census.gov/>. For instance, to obtain the table ID B23001 "Sex by age by employment status for the population 16 years and over", the following steps were performed. First, select the "guided search option", choose "information about people" and select "employment

provides the number of people in the labor force, which were stratified by sex/age/tract, considering both civilian workers and workers in the Armed Forces. The data were stratified by sex and age group and were processed so that each sex-age group combination is given an employment probability fraction (ranging from 0 to 1) within each census tract. Children under 16 years of age were assumed to be unemployed. One national-based APEX input file is used for the current exposure and risk analyses as follows:

- *Employment\_US\_2010.txt*: census tract IDs, employment probabilities (in fractional form), stratified by 13 age groups.<sup>53</sup>

### 3D.2.5.3 Assignment of Activity Pattern Data to Individuals

Once APEX identifies the basic personal attributes of a simulated individual (section 3D.2.2) and daily air temperatures (section 3D.2.4), activity pattern data obtained from CHAD (section 3D.2.5.1) are then selected based on age, sex, temperature category, and day of the week. These attributes are considered first-order attributes in selecting CHAD diaries when modeling human exposures (Graham and McCurdy, 2004). The particular locations people visit, amount of time spent there, and frequency of these visits can also be influenced by local weather conditions. When considering seasonal temperature ranges (i.e., cold/not cold during cool months; hot/not hot during warm months), (Graham and McCurdy, 2004) found daily maximum temperature (DMT) influences time spent outdoors. Participation rate and amount of time outdoors was found lower on cold DMT days compared to the other three temperature categories, while the participation rate on hot days was less than that on not hot days. Because of these findings, we use a similar DMT range (<55, 55-83, ≥84 °F) to select activity pattern data that best match each study area's meteorological data for every day of the simulated individual's exposure profile. This information for the selecting of activity pattern data is found in the following APEX input file, varying by study area and simulation year:

- *Functions\_O3\_CSA[number]\_040219.txt*: probabilities and interval definitions associated with a few input variables. For activity diary selection - day of week intervals (weekend or weekday) by three temperature ranges.

While there may be other important attributes that may influence activity patterns (e.g., obesity, disease status), there are limits to our ability to link to all the possible personal attributes

---

(labor force) status", "sex" and "age". For geography type select "census tract - 140" for each state. Tables containing the employment numbers were downloaded and used to calculate the employment probabilities for each age group.

<sup>53</sup> The age groups in this file are: 16-19, 20-21, 22-24, 25-29, 30-34, 35-44, 45-54, 55-59, 60-61, 62-64, 65-69, 70-74, and >75.

1 that may be of interest in modeling an individual's activities to the CHAD data. This is largely  
2 because CHAD is a compilation of data collected from numerous individual activity pattern  
3 studies conducted over several decades, many of which had a unique survey design. As a result,  
4 there is a varying amount of missing personal attribute data for the surveyed individuals in  
5 CHAD. For instance, there are only a limited number of CHAD diaries with survey-requested  
6 health information (e.g., the health status of respondents). Specifically regarding whether or not a  
7 survey participant had asthma, very few of the available diaries have either a 'yes' or 'no'  
8 response to this health condition. When considering the 177,210 diary days used by APEX, there  
9 are only 4,935 diary days from individuals having asthma (of which 3,133 are children ages 5-  
10 18),<sup>54</sup> representing a small fraction of the CHAD data. On its own, having approximately 5,000  
11 diaries may appear to be a large number of diaries, however, following a grouping of the diaries  
12 by their first-order attributes when developing simulated profiles (e.g., age, sex, day-of-week,  
13 etc., daily temperature), would likely result in fewer than 100 diaries available for simulating a  
14 single day for a particular individual. Accordingly, the selection of diaries to use for APEX-  
15 simulated individuals does not consider health status (i.e., any diary is used, regardless of  
16 whether the individual indicated they did or did not have asthma, or that information was  
17 unknown).

18 This restriction in the number of diaries from individuals having asthma is not considered  
19 to be a significant limitation for estimating exposures for simulated individuals with asthma. In  
20 general, modeling people with asthma similarly to healthy individuals (i.e., using the same time-  
21 location-activity profiles) is supported by the activity analyses reported by van Gent et al. (2007)  
22 and Santuz et al. (1997). Other researchers, for example, Ford et al. (2003), have shown  
23 significantly lower leisure time activity levels in asthmatics when compared with individuals  
24 who have never had asthma. Based on these inconsistent findings, we evaluated this issue in the  
25 2014 HREA and, using the available activity pattern data in the CHAD database, we compared  
26 participation in afternoon outdoor activities at elevated exertion levels among people having  
27 asthma, people not having asthma, and unknown health status (2014 HREA, Appendix G,  
28 section 5G-1.4). The 2014 HREA analysis indicated health status had little to no impact on the  
29 participation in afternoon activities at elevated exertion levels. A similar analysis was repeated  
30 here to include the diary data currently used by APEX, not just those that would be included in  
31 the simulations for the 2014 HREA (i.e. ~50,000 diaries).

32 Of interest in this current risk and exposure analysis are instances when individuals  
33 experience their highest O<sub>3</sub> exposures. As shown in 2014 HREA, the highest exposures occur

---

<sup>54</sup> The American Time Use Survey, a study contributing the largest number of diaries (n=124,517) to CHAD, did not include a question for whether a surveyed individual has asthma.

1 when individuals spend time outdoors, particularly during the afternoon hours (2014 HREA,  
2 Appendix 5G section 5G-2). To prepare the APEX activity dataset for analysis here, afternoon  
3 hours were characterized as the time between 12 PM and 8 PM and only those persons that spent  
4 some time outdoors were retained. As is done by APEX in simulating individuals, level of  
5 exertion was estimated by sampling from the specific METs distributions assigned for each  
6 person's activity performed. Then, we identified activities having a METs value of greater than  
7 three as instances where a person was at moderate or greater exertion levels (U.S. DHHS, 1999).  
8 Afternoon outdoor time was then stratified by exertion level, summed for two study groups of  
9 interest (i.e., children and adults), and presented in percent form within Table 3D-10.

10 Regarding the diaries for children of interest for these exposure and risk analyses (ages 5-  
11 18), about 13% are from an individual having asthma, 48% are from those who do not have  
12 asthma, and the remaining portion of children's diaries have unknown health status. About 1% of  
13 CHAD diaries for adults are from individuals with asthma and about 11% are from those who do  
14 not have asthma. Far fewer children's diaries are from persons whose asthma status is unknown  
15 (40%) compared to adults (88%), and the proportions are smaller still in terms of the total  
16 available person-days. On average, about 42% of all children having known asthma status spent  
17 some afternoon time outdoors, and the percent is actually higher for children with asthma  
18 (48.4%) than for children not having asthma (40.5%). About half of the adults whose asthma  
19 status was known spent afternoon time outdoors with a participation rate generally similar for  
20 adults having asthma and adults not having asthma. Participation in outdoor events for children  
21 having unknown asthma status varied little from that of persons with known asthma status.  
22 Contrary to this, there were fewer adults with unknown asthma status that participated in outdoor  
23 events (29%) when compared to those having known asthma status.

24 The amount of afternoon time spent outdoors by the persons that did so varied little  
25 across the two study groups and two asthma classifications. Children, on average, spend  
26 approximately 2¼ hours of afternoon time outdoors, 80% of which is at a moderate or greater  
27 exertion level, regardless of their asthma status. For children whose asthma status is unknown,  
28 slightly more afternoon time is spent outdoors (about 150 minutes) but the percent of afternoon  
29 time at moderate or greater exertion levels is slightly lower (about 69%). As seen with children,  
30 adults spend approximately 2¼ hours of afternoon time outdoors regardless of their asthma  
31 status. However, the percent of afternoon time at moderate or greater exertion levels for adults  
32 (about 55%) is lower than that observed for children.

33 Based on this updated analysis and additional comparisons of CHAD diary days with  
34 literature reported values of outdoor time participation at varying activity levels (see 2014  
35 HREA), there are strong similarities in outdoor time, outdoor event participation, and activity  
36 levels achieved among the two study groups and with those reported in independent studies of

people with asthma. Thus, we conclude the use of any CHAD diary, regardless of known/unknown asthma status, is reasonable for purposes of simulating people with asthma in this exposure and risk analysis.

**Table 3D-10. Comparison of time spent outdoors and exertion level by asthma status for children and adult diaries used by APEX.**

| Has Asthma?  | CHAD: Children (5 to 18) <sup>A</sup> |                  |                  | CHAD: Adults (>18) <sup>B</sup> |                  |                   |
|--|---------------------------------------|------------------|------------------|---------------------------------|------------------|-------------------|
|  | Yes                                   | No               | Unknown          | Yes                             | No               | Unknown           |
| Total Person Days (n)  | 3,133                                 | 11,948           | 9,973            | 1,279                           | 16,323           | 127,377           |
| Number of Person Days with Time Spent Outdoors (% participation)   | 1,517<br>(48.4%)                      | 4,840<br>(40.5%) | 4,054<br>(40.6%) | 569<br>(44.5%)                  | 7,900<br>(48.4%) | 36,949<br>(29.0%) |
| Overall Percent of Afternoon Hours Spent Outdoors (%)  | 29.0%                                 | 27.3%            | 31.8%            | 28.3%                           | 28.9%            | 27.2%             |
| Overall Percent of Afternoon Time Outdoors at Moderate or Greater Exertion (%)   | 81.6%                                 | 81.1%            | 69.1%            | 55.4%                           | 55.1%            | 62.3%             |
| <sup>A</sup> CHAD studies for where a survey questionnaire response of whether or not child had asthma include CIN, ISR, NHA, NHW, OAB, and SEA (see Table 3D-9 for study names).<br><sup>B</sup> CHAD studies for where survey a questionnaire response of whether or not adult had asthma include CIN, EPA, ISR, NHA, NHW, NSA, and SEA. |                                       |                  |                  |                                 |                  |                   |


We also evaluated how temperature influences the amount of afternoon time spent outdoors while at moderate or greater exertion by children (5-18 years) and adults (19-90 years). This differs from analyses in Graham and McCurdy (2004) in which all outdoor time at any exertion level was evaluated and the number of diary days available in CHAD was much less at that time (~23,000 diary days). Also, in this current analysis, each CHAD/APEX diary day was grouped by both DMT (<55, 55-83, or ≥84 °F) and day-type (weekday or weekend). Total available diary days for each of these groups is provided in Table 3D-11. Then, afternoon time outdoors (12:00 PM to 8:00 PM) was summed and place into one of five hourly groupings (0, 0-½, ½-≤2, 2-≤4, and >4 hours per day) and the percent of diary days in each group was calculated, the results of which are provided in Figure 3D-9 for children and adults.

Overall, the greatest proportion of diary days would be characterized as not having any afternoon time spent outdoors at moderate or greater exertion (46 - 76%), with adults consistently having a greater frequency of not spending afternoon time outdoors than children (Figure 3D-9). Afternoon time outdoors at moderate or greater exertion for both children and adults is less likely to occur on cold days (DMT <55 °F), with progressively increased frequency of outdoor time with increasing temperatures for both day-types. Children are more frequently spending afternoon time outdoors at elevated exertion levels, particularly when considering the largest duration assessed (e.g., for durations of time outdoors ≥2 hours, the percent of child diary days is greater than adults by a factor of 1.3 to 2.7).

**Table 3D-11. Number of diary days in CHAD for children and adults, grouped by temperature and day-type categories.**

| Daily Maximum Temperature (°F) | Children (5-18 years) Diary Days (n) |         | Adult (19-90 years) Diary Days (n) |         |
|--------------------------------|--------------------------------------|---------|------------------------------------|---------|
|                                | Weekday                              | Weekend | Weekday                            | Weekend |
| <55                            | 3,883                                | 3,504   | 19,316                             | 17,136  |
| 55-83                          | 6,823                                | 5,800   | 36,034                             | 32,982  |
| ≥84                            | 3,460                                | 1,584   | 23,865                             | 15,646  |

The number of diary days here can be used along with Figure 3D-9 to estimate the number of diaries available in each time/hour group. The total number of diary days for this analysis is 170,033 and differs from CHAD/APEX (n=177,210) because of the age range selected.



**Figure 3D-9. Percent of children (5-18 years) and adults (19-90 years) having afternoon time outdoors while at moderate or greater exertion, categorized by daily maximum temperature (°F) and time (hours/day) groups.**

#### 3D.2.5.4 Method for Longitudinal Activity Pattern Sequence

In order to estimate population exposure over a full year, a year-long activity sequence needed to be created for each simulated individual based on CHAD, which is largely a cross-sectional activity database of 24-hr records. On average, the typical surveyed subject provided in CHAD has about two days of diary data. For this reason, the construction of a season-long activity sequence for each individual requires some combination of repeating the same data from one subject and using data from multiple subjects. The best approach would reasonably account for the day-to-day and week-to-week repetition of activities common to individuals and recognizing even these diary sequences are not entirely correlated, while maintaining realistic variability among individuals comprising each study group.

APEX provides three methods of assembling composite diaries: a basic method, a diversity and autocorrelation (D&A) method, and a Markov-chain clustering (MCC) approach. We have selected the diversity and autocorrelation (D&A) method for this assessment based on our consideration of the assessment objectives, an evaluation of differences in results produced by the three methods, and consideration of flexibility provided by each approach with regard to specifying key variable values, as discussed below. First a brief description of each method is provided below.

The basic method involves randomly selecting an activity diary for the simulated individual from a user-defined diary pool (e.g., age, sex). While the method is adequate for estimating a mean short-term exposure for a population as a whole, it is less useful for estimating how often individuals in a population may experience peak O<sub>3</sub> exposures over a year.

The D&A method is a complex algorithm for assembling longitudinal diaries that attempts to realistically simulate day-to-day (within-person correlations) and between-person variation in activity patterns (and thus their exposures to the extent they are influenced by spatial and temporal variability in ambient air and microenvironmental O<sub>3</sub> concentrations). This method was designed to capture the tendency of individuals to repeat activities, based on reproducing realistic variation in a key diary variable, which is a user selected function of diary variables. The method targets two statistics: a population diversity statistic ( $D$ ) and a within-person autocorrelation statistic ( $A$ ). The  $D$  statistic reflects the relative importance of within and between-person variance in the key variable. The  $A$  statistic quantifies the lag-one (day-to-day) key variable autocorrelation. Values of  $D$  and  $A$  for the key variable are selected by the model user and set in the APEX parameters file, and the method algorithm constructs longitudinal diaries that preserve these parameters. Further details regarding this methodology can be found in Glen et al. (2008).

The Markov-chain clustering (MCC) approach is similarly complex in attempting to recreate realistic patterns of day-to-day variability. First, cluster analysis is employed to divide

1 the daily activity pattern records into three groups based on time spent in, for example, five  
2 microenvironments: indoor-residence, other indoors, outdoor-near roads, other outdoors, and  
3 inside vehicles. For each simulated individual, a single time-activity record is randomly selected  
4 from each cluster. Then the Markov process determines the probability of a given time-activity  
5 pattern occurring on a given day based on the time-activity pattern of the previous day and  
6 cluster-to-cluster transition probabilities (and are estimated from the available multi-day time-  
7 activity records), thus constructing a long-term sequence for a simulated individual. Details  
8 regarding the MCC method and supporting evaluations are provided in U.S. EPA (U.S. EPA,  
9 2019a, U.S. EPA, 2019b).

10 Che et al. (2014) performed an evaluation of the impact of the three APEX methods on  
11 PM<sub>2.5</sub> exposure estimates. As expected, little difference was observed across the methods with  
12 regard to estimates of the mean exposures of simulated individuals. Differences were observed,  
13 however, in the number of multiday exposures exceeding a selected benchmark concentration.  
14 With regard to the number of simulated individuals experiencing 3 or more days above  
15 benchmark concentrations, the MCC method estimates were approximately 12-14% greater than  
16 either the random or D&A methods. For the number of persons experiencing at least one  
17 exposure of concern, however, the MCC method estimates were approximately 4% lower than  
18 those of the other two methods. For additional context, we note that, using all methods, there is  
19 an order of magnitude difference in the number of persons exposed at least once versus three or  
20 more times, indicating that, overall, the occurrence of simulated multiday exposures are rare  
21 events regardless of method selection.

22 Che et al. (2014) concludes that while the MCC method produces a higher number of  
23 multiday exposures, there remains a question whether the MCC method has greater accuracy  
24 relative to the other two methods. We note this conclusion applies to both the estimations of  
25 single day and multiday exposures, as there is an inverse relationship between the two when  
26 simulating exposures using APEX and a finite set of activity pattern data. Thus, the MCC  
27 method produces a smaller number of single day exposures above benchmarks relative to the  
28 other two methods, estimations also subject to a degree of uncertainty.

29 In the absence of having a robust data set (e.g., multiday/week diary data from a random  
30 population) to better evaluate the accuracy of any of the methods, we considered selection of the  
31 longitudinal approach for this assessment from a practical perspective, guided by a balancing of  
32 the single day and multiday exposures that can be estimated by each method. In so doing, we  
33 selected the D&A approach, recognizing that the D&A method allows for flexibility in the  
34 selection of the key influential variable and its setting values, and also the ability to directly  
35 observe the impact of changes to these values on model outputs.



1       The key variable selected for this exposure and risk analysis is the amount of time an  
2 individual spends each day outdoors, as that is the most important determinants of exposure to  
3 high levels of O<sub>3</sub> (2014 HREA, Appendix 5G, section 5G-2). In their evaluation, Che et al.  
4 (2014) varied the values of *D* and *A* for this variable to determine the impact to estimated  
5 exposures. Compared to their base level simulation (i.e., *D*=0.19 and *A*=0.22), increasing both *D*  
6 and *A* by 100% increased the number of persons having at least three exposures above the  
7 selected benchmark by about 4%, while also reducing the percent of persons experiencing at  
8 least one day above benchmarks by less than 1% (Che et al., 2014). In recognizing uncertainty in  
9 the parameterization of *D* and *A* (i.e., based on Xue et al., 2004) a limited field study of a small  
10 subset of the population, children 7-12) and that the Che et al., 2014 base level simulation *D*&*A*  
11 values produced a lower estimate of repeated exposures compared with the MCC method, we  
12 have used values of 0.5 for *D* and 0.2 for *A* for all ages to potentially increase representation of  
13 multiday exposures without significantly reducing the percent of the population experiencing at  
14 least one day at or above benchmark concentrations.

### 15       **3D.2.6 Microenvironmental Concentrations**

16       In APEX, exposure of simulated individuals occurs in microenvironments (MEs) rather  
17 than assuming people are exposed continuously and consistently to ambient air. To best estimate  
18 personal exposures, it is important to maintain the spatial and temporal sequence of MEs people  
19 inhabit and to appropriately represent the time series of concentrations that occur within them.  
20 Two methods are available in APEX for calculating pollutant concentrations within MEs: a mass  
21 balance model and a transfer factor approach. In both approaches, ME concentrations depend on  
22 the ambient (outdoor) air O<sub>3</sub> concentrations and ambient air temperatures, as well as statistical  
23 distributions to parameterize the variables used by each approach. Further, the statistical  
24 distributions of some of the key variables depend on values of other variables in the model. For  
25 example, the distribution of air exchange rates inside an individual's residence depends on the  
26 type of heating and air conditioning present, which are also probabilistic inputs to the model. The  
27 value of a variable can be set as a constant for the entire simulation (e.g., house volume remains  
28 identical throughout the exposure period), or APEX can sample a new value hourly, daily, or  
29 seasonally from user-specified statistical distributions. APEX also allows the user to specify  
30 diurnal, weekly, or seasonal patterns for certain ME parameters. Details regarding the two  
31 methods can be found in (U.S. EPA, 2019a, U.S. EPA, 2019b) and are briefly described below.

32       The mass balance method, used for the indoor MEs, assumes that an enclosed  
33 microenvironment (e.g., a room within a home) is a single well-mixed volume in which the air  
34 concentration is approximately spatially uniform (Figure 3D-10). The concentration of an air  
35 pollutant in such a microenvironment is estimated using (1) inflow of air into the

microenvironment, (2) outflow of air from the microenvironment, (3) removal of a pollutant from the microenvironment due to deposition, filtration, and chemical degradation, and (4) emissions from sources of a pollutant inside the microenvironment (not used for this exposure and risk analysis). Considering the microenvironment as a well-mixed fixed volume of air, the mass balance equation for a pollutant in the microenvironment can be written in terms of concentration as follows in Equation 3D-7:

$$\frac{dC(t)}{dt} = \dot{C}_{in} - \dot{C}_{out} - \dot{C}_{removal} \quad \text{Equation 3D-7}$$


where,

$C(t)$  = Concentration in the microenvironment at time  $t$

$\dot{C}_{in}$  = Rate of change in  $C(t)$  due to air entering the microenvironment

$\dot{C}_{out}$  = Rate of change in  $C(t)$  due to air leaving the microenvironment

$\dot{C}_{removal}$  = Rate of change in  $C(t)$  due to all internal removal processes



**Figure 3D-10. Illustration of the mass balance model used by APEX to estimate concentrations within indoor microenvironments.**

The factors model (used for the outdoor and inside vehicle MEs) is simpler than the mass balance model. In this method, the value of the ME concentration is not dependent on the ME concentration during the previous time step. Rather, this model uses Equation 3D-8 to calculate the concentration in an ME from the ambient air quality data:

$$C_{mean} = C_{ambient} \times f_{proximity} \times f_{pollutant} \quad \text{Equation 3D-8}$$

where,

$C_{mean}$  = Mean concentration over the time step in a microenvironment (ppm)

$C_{ambient}$  = The concentration in the ambient (outdoor) air (ppm)

$f_{proximity}$  = Proximity factor (unitless)

$f_{pollutant}$  = fraction of ambient air pollutant entering microenvironment (unitless)

Based on findings from the 2014 HREA, we have specified seven MEs to simulate in this assessment, largely based on two factors: the expectation of a particular ME leading to exposures of interest and the availability of factors needed to reasonably model the ME. The 2014 HREA indicated that high ( $\geq 50$  ppb) 8-hr daily maximum  $O_3$  exposures occurred while individuals spent much larger amounts of afternoon time outdoors compared with those experiencing low ( $< 50$  ppb) exposure levels (2014 HREA, Appendix 5G, Figure 5G-5). Given that finding and the objective for the exposure assessment (i.e., understanding how often and where maximum  $O_3$  exposures occur), we recognized the added efficiency of minimizing the number of MEs compared to that done in the 2014 HREA (i.e., 28 microenvironments), particularly reducing the number of lower-exposure indoor MEs that were parameterized and included at that time.

Accordingly, we aggregated the number of MEs to seven and estimate exposures of ambient air origin that occur within a core group of indoor, outdoor, and inside vehicle MEs. Four indoor MEs (indoor-residence, indoor-restaurant, indoor-school, and indoor-other<sup>55</sup>) were modeled based on having specific air exchange rate data available for each (section 3D.2.6.1). All outdoor locations were assumed to have  $O_3$  concentrations equivalent to ambient air, however there were two MEs used to do so, distinguished by whether or not they occurred near roads. The outdoor near road ME was modeled separately due to the expected decrease in concentrations occurring in that ME relative to that of ambient air concentrations. And finally, an inside-vehicle ME was modeled based on the expectation that it would lead to some instances of relatively lower exposures compared with ambient air concentrations. Table 3D-12 lists the seven microenvironments selected for this analysis and the exposure calculation method used for

---

<sup>55</sup> The indoor-other ME is comprised of all non-residential MEs, thus could include office buildings, stores, etc.

each. The variables and their associated parameters used to calculate ME concentrations are summarized in subsequent sections below.

**Table 3D-12. Microenvironments modeled and calculation method used.**

| Microenvironment (ME)  | APEX ME | Calculation  | Variables <sup>A</sup> |
|--|---------|--------------|------------------------|
| Indoor – Residence   | 1       | Mass balance | AER & RM               |
| Indoor – Restaurant  | 2       | Mass balance | AER & RM               |
| Indoor – School  | 3       | Mass balance | AER & RM               |
| Indoor – Other   | 4       | Mass balance | AER & RM               |
| Outdoor – General  | 5       | Factors      | None                   |
| Outdoor – Near road  | 6       | Factors      | PR                     |
| Inside – Vehicle   | 7       | Factors      | PE                     |
| <sup>A</sup> AER = air exchange rate, RM = removal rate, PR = proximity factor, PE = fraction of pollutant entering microenvironment, None = ME concentration is equal to ambient air concentration. |         |              |                        |

The seven microenvironments were mapped to the 115 CHAD locations<sup>56</sup> because using such a large number of MEs would go well beyond the practical scale needed for the exposure and risk analyses. Note that the ambient air concentration used in calculating ME concentration for each exposure event varies temporally and spatially. For example, commuters (i.e., employed individuals who do not work at home) are assigned to either their home tract or work tract concentration, depending on whether the population probabilities and commuting data base produce either a home or work event. Additionally, depending on the particular ME (i.e., other than home or work), the mapping of CHAD locations to the seven MEs also uses an identifier that designates the relative location in the air quality surface from which the ambient air concentration (used to calculate the ME concentration) is selected. For this assessment, such locations would include the Census tract for a simulated individual's home (H), work (W), near work (NW), near home (NH), last (L, either NH or NW), other (O, average of all), or unknown (U, last ME determined) location. Specific designations are provided in the APEX ME mapping file, with selection based on known factors and professional judgement. For example, when an individual is in their home, the ambient air concentration in the home tract is used to calculate their ME concentration. When the individual is at work, the tract the individual commuted to is used to calculate their ME concentration. Travel inside vehicles used the ambient air concentration data from the tract used to calculate the prior ME concentration. Most other MEs (both indoor and outdoor) use ambient air concentration data selected from near home tracts.

<sup>56</sup> The location codes indicate specific MEs that extend beyond simple aggregations of indoor, in-vehicle, and outdoor locations where people spend time. For example, CHAD has a location code for when individuals spent time inside their residence while in the kitchen.

Status attribute variables are also important in estimating ME concentrations, and can include, but are not limited to, housing type, whether the house has air conditioning, and whether the car has air conditioning. Because outdoor MEs are expected to contribute the most to an individuals' highest O<sub>3</sub> exposure (and potential health risk) and the status attribute variables pertain to indoor MEs, the setting of these particular variables will have limited impact to the exposure and risk results generated here. In this assessment, a number of temperature ranges are used in selecting the particular distribution for estimating air exchange rates (AERs). Maximum daily temperature is also used in diary selection to best match the study area meteorological data for the simulated individual (Graham and McCurdy, 2004) and air conditioning use.

Multiple APEX input files (the first and third in the list below), of the same general format, are used for estimating ME concentrations in each study area. A single APEX ME mapping file is used for all study areas. These ME input files contain the parameter settings for all variables described in the subsections that follow.

- *ME\_descriptions\_O3\_7MEs\_CSA[number].txt*: defines ME calculation method, conditional variables used (e.g., temperature categories – see functions file), distribution type, distribution parameters (mean, standard deviation, minimum, maximum) for AERs, decay rates, proximity factors, and PE fractions used to estimate O<sub>3</sub> in 7 MEs.
- *Microenvironment\_mappings\_07\_MEs.txt*: maps 115 CHAD locations to the 7 APEX MEs and assigns the tract-level ambient air concentrations to use for each location. Contains CHAD location code, CHAD description, APEX ME number, and ambient air concentration location identifier
- *Functions\_O3\_CSA[number]\_040219.txt*: variables used for selecting AER - air conditioning (A/C) prevalence (home has A/C, does not have A/C) by five temperature ranges for air exchange rate (<50, 50-67, 68-76, 77-85, or >85 °F). (see section 3D.2.6.1)

### **3D.2.6.1 Indoor Microenvironments**

As described above, all four indoor MEs (indoor-residential, indoor-restaurant, indoor-school, and indoor-other) were modeled using a mass balance model. The three variables used to calculate ME concentrations, air exchange rates (section 3D.2.6.1.1), air conditioning prevalence (section 3D.2.6.1.2), and ozone removal rate (section 3D.2.6.1.3) are described below.

#### **3D.2.6.1.1 Air Exchange Rates**

Distributions of air exchange rates (AERs, hr<sup>-1</sup>) for the indoor residential ME were developed using data from several studies. The analysis of these data and the development of most of the distributions used in the modeling were originally described in detail in the 2007 exposure analysis (U.S. EPA (2007a), Appendix A) and updated in the 2014 HREA (see Appendix 5E). Briefly, AER distributions for the residential microenvironments depend on the type of air conditioning (A/C) and on the outdoor temperature, among other variables for which we do not have sufficient data to estimate. AER distributions were found vary greatly across

cities, A/C types, and temperatures, so that the selected AER distributions for the modeled cities should also depend on these attributes. For example, the mean AER for residences with A/C ranges from 0.38 in Research Triangle Park, NC at temperatures > 25 °C upwards to 1.244 in New York, NY considering the same temperature range (2014 HREA, Appendix 5E). For each combination of A/C type, city, and temperature with a minimum of 11 AER values, exponential, lognormal, normal, and Weibull distributions were fit to the AER values and compared. Generally, the lognormal distribution was the best-fitting of the four distributions, and so, for consistency, the fitted lognormal distributions are used for all the cases.

There were a number of limitations in generating study-area specific AER stratified by temperature and A/C type. For example, AER data and derived distributions were available only for selected cities, and yet the summary statistics and comparisons demonstrate that the AER distributions depend upon the city as well as the temperature range and A/C type. As a result, city-specific AER distributions were used where possible; otherwise staff selected AER data from a similar city. Another important limitation of the analysis was that distributions were not able to be fitted to all of the temperature ranges due to limited number of available measurement data in these ranges. A description of how these limitations were addressed can be found in the 2014 HREA, Appendix 5E. The AER distributions used for the exposure modeling are given in Table 3D-13 (Residences with A/C) and Table 3D-14 (Residences without A/C).

**Table 3D-13. Air exchange rates (AER, hr<sup>-1</sup>) for indoor residential microenvironments with A/C by study area and temperature.**

| Study Area           | Daily Mean Temperature (°C) | Lognormal Distribution GM, GSD, min, max (hr <sup>-1</sup> ) | Original AER Study Data Used |
|----------------------|-----------------------------|--|------------------------------|
| Atlanta              | < 10                        | 0.962, 1.809, 0.1, 10  | Research Triangle Park, NC   |
|                      | 10 - 20                     | 0.562, 1.906, 0.1, 10  |                              |
|                      | 20 - 25                     | 0.397, 1.889, 0.1, 10  |                              |
|                      | > 25                        | 0.380, 1.709, 0.1, 10  |                              |
| Boston, Philadelphia | < 10                        | 0.711, 2.108, 0.1, 10  | New York, NY                 |
|                      | 10 - 25                     | 1.139, 2.677, 0.1, 10  |                              |
|                      | > 25                        | 1.244, 2.177, 0.1, 10  |                              |
| Dallas, Phoenix      | < 20                        | 0.407, 2.113, 0.1, 10  | Houston, TX                  |
|                      | 20 - 25                     | 0.467, 1.938, 0.1, 10  |                              |
|                      | 25 - 30                     | 0.422, 2.258, 0.1, 10  |                              |
|                      | > 30                        | 0.499, 1.717, 0.1, 10  |                              |
| Detroit              | < 10                        | 0.744, 1.982, 0.1, 10  | Detroit, MI or New York, NY  |
|                      | 10 - 20                     | 0.811, 2.653, 0.1, 10  |                              |
|                      | 20 - 25                     | 0.785, 2.817, 0.1, 10  |                              |
|                      | > 25                        | 0.916, 2.671, 0.1, 10  |                              |

| Study Area | Daily Mean Temperature (°C) | Lognormal Distribution GM, GSD, min, max (hr <sup>-1</sup> ) | Original AER Study Data Used |
|------------|-----------------------------|--|------------------------------|
| Sacramento | < 25                        | 0.503, 1.921, 0.1, 10  | Sacramento                   |
|            | >25                         | 0.830, 2.353, 0.1, 10  |                              |
| St. Louis  | < 10                        | 0.921, 1.854, 0.1, 10  | St. Louis                    |
|            | 10 - 20                     | 0.573, 1.990, 0.1, 10  |                              |
|            | 20 - 25                     | 0.530, 2.427, 0.1, 10  |                              |
|            | 25 - 30                     | 0.527, 2.381, 0.1, 10  |                              |
|            | > 30                        | 0.609, 2.369, 0.1, 10  |                              |

**Table 3D-14. Air exchange rates (AER, hr<sup>-1</sup>) for indoor residential microenvironments without A/C by study area and temperature.**

| Study Area           | Daily Mean Temperature (°C) | Lognormal Distribution GM, GSD, min, max (hr <sup>-1</sup> ) | Original AER Study Data Used |
|----------------------|-----------------------------|--|------------------------------|
| Atlanta, St. Louis   | < 10                        | 0.923, 1.843, 0.1, 10  | St. Louis                    |
|                      | 10 - 20                     | 0.951, 2.708, 0.1, 10  |                              |
|                      | > 20                        | 1.575, 2.454, 0.1, 10  |                              |
| Boston, Philadelphia | < 10                        | 1.016, 2.138, 0.1, 10  | New York, NY                 |
|                      | 10 - 20                     | 0.791, 2.042, 0.1, 10  |                              |
|                      | > 20                        | 1.606, 2.119, 0.1, 10  |                              |
| Dallas, Phoenix      | < 10                        | 0.656, 1.679, 0.1, 10  | Houston, TX                  |
|                      | 10 - 20                     | 0.625, 2.916, 0.1, 10  |                              |
|                      | > 20                        | 0.916, 2.451, 0.1, 10  |                              |
| Detroit              | < 10                        | 0.791, 1.802, 0.1, 10  | Detroit, MI or New York, NY  |
|                      | 10 - 20                     | 1.056, 2.595, 0.1, 10  |                              |
|                      | 20 - 25                     | 1.545, 2.431, 0.1, 10  |                              |
|                      | >25                         | 1.860, 2.437, 0.1, 10  |                              |
| Sacramento           | < 10                        | 0.526, 3.192, 0.1, 10  | Sacramento                   |
|                      | 10 - 20                     | 0.665, 2.174, 0.1, 10  |                              |
|                      | 20 - 25                     | 1.054, 1.711, 0.1, 10  |                              |
|                      | > 25                        | 0.827, 2.265, 0.1, 10  |                              |

The AER distribution (hr<sup>-1</sup>) used for indoor restaurants in all study areas is a fitted lognormal distribution, having a geometric mean = 3.712, geometric standard deviation = 1.855 and bounded by the lower and upper values of the sample data set {1.46, 9.07}. This distribution was developed using data from Bennett et al. (2012) who measured AER in restaurants (details on derivation provided in the 2014 HREA, Appendix 5E). The AER distribution (hr<sup>-1</sup>) used for

indoor schools in all study areas is a fitted Weibull distribution,<sup>57</sup> having a threshold ( $\tau$ ) = 0, shape ( $C$ ) = 1.26, and scale ( $\sigma$ ) = 1.75, bounded by a lower and upper range {0, 10}. This distribution was developed from Lagus Applied Technology, 1995, Shendell et al., 2004, and Turk et al., 1989 who measured AER in schools (raw data provided in Table 3D-15).

**Table 3D-15. Individual air exchange rate data ( $\text{hr}^{-1}$ ) obtained from three studies used to develop an AER distribution used for schools in all study areas.**

| Individual Air Exchange Rate Data ( $\text{hr}^{-1}$ ) |      |      |      |                        |     |     |                    |
|--|------|------|------|------------------------|-----|-----|--------------------|
| Lagus Applied Technology (1995)                        |      |      |      | Shendell et al. (2004) |     |     | Turk et al. (1989) |
| 0.56   | 1.34 | 1.92 | 2.71 | 0.1                    | 0.3 | 0.6 | 0.8                |
| 0.74   | 1.46 | 2.26 | 2.76 | 0.1                    | 0.4 | 0.6 | 1.3                |
| 0.76   | 1.48 | 2.26 | 2.81 | 0.1                    | 0.4 | 0.6 | 1.8                |
| 0.8  | 1.58 | 2.27 | 2.82 | 0.1                    | 0.4 | 0.9 | 2                  |
| 0.98   | 1.61 | 2.29 | 2.83 | 0.2                    | 0.4 | 0.9 | 2.2                |
| 1.15   | 1.61 | 2.33 | 2.87 | 0.2                    | 0.4 | 1.2 | 2.2                |
| 1.19   | 1.67 | 2.38 | 2.93 | 0.2                    | 0.4 | 1.3 | 3                  |
| 1.21   | 1.67 | 2.4  | 3.03 | 0.2                    | 0.5 | 1.3 |                    |
| 1.22   | 1.73 | 2.53 | 3.23 | 0.2                    | 0.5 | 1.4 |                    |
| 1.23   | 1.8  | 2.53 | 3.7  | 0.3                    | 0.6 | 1.8 |                    |
| 1.23   | 1.84 | 2.57 | 4.38 | 0.3                    | 0.6 | 2.9 |                    |
| 1.27   | 1.9  | 2.68 | 5.03 | 0.3                    | 0.6 | 5.4 |                    |
| 1.33   | 1.91 | 2.71 | 8.72 |                        |     |     |                    |

The AER distribution ( $\text{hr}^{-1}$ ) used for indoor other in all study areas is a fitted lognormal distribution, having a geometric mean = 0.949, geometric standard deviation = 1.857 and bounded by the lower and upper values of the sample data set {0.30, 4.02}. This distribution was developed using data from Bennett et al. (2012) who measured AER in non-residential buildings (details on derivation provided in the 2014 HREA, Appendix 5E).

### 3D.2.6.1.2 Air Conditioning Prevalence

The selection of an AER distribution for the indoor residence ME is conditioned on the presence or absence of A/C. We assigned this housing attribute to indoor residential microenvironments using A/C prevalence data from the American Housing Survey (AHS).<sup>58</sup> The

<sup>57</sup> Of the three statistical distributions evaluated (lognormal, gamma, Weibull), results of a Cramer-von Mises goodness of fit test indicated the data distribution was not statistically different than a Weibull distribution.

<sup>58</sup> 2015 and 2017.xlsx files were downloaded from <https://www.census.gov/programs-surveys/ahs/data/interactive/ahstablecreator.html> for Atlanta, Boston, Dallas, Detroit, Philadelphia, and Phoenix (accessed on 3/4/2019). The most recent data available for Sacramento and St. Louis was 2011 and available at



A/C prevalence data were assigned to our study areas where the AHS data best matched our exposure simulation years and or study area. In all study areas and for each year, housing units containing either central or 3 or more room AC were summed, followed by the calculation of the A/C prevalence. If multiple years were available, these data were averaged to generate the final A/C prevalence (unitless) for each study area (Table 3D-16). For the other three indoor MEs (indoor-restaurant, indoor-school, and indoor-other) mechanical ventilation was assumed to be present in all buildings (i.e., A/C prevalence = 1.0).

**Table 3D-16. A/C prevalence from US Census American Housing Survey (AHS) data by study area.**

| Study Area   | Total Housing Units (×1,000) | Central AC (×1,000) | Room AC 3 or more (×1,000) | Year | AC Prevalence (unitless) | Mean AC Prevalence (unitless) | No AC Prevalence (unitless) |
|--------------|------------------------------|---------------------|----------------------------|------|--------------------------|-------------------------------|-----------------------------|
| Atlanta      | 1982.8                       | 1875.2              | 27.3                       | 2015 | 0.96                     | 0.96                          | 0.04                        |
|              | 2109                         | 2001                | 22.7                       | 2017 | 0.96                     |                               |                             |
| Boston       | 1838.4                       | 649                 | 311.9                      | 2015 | 0.523                    | 0.531                         | 0.469                       |
|              | 1854                         | 674.6               | 322.1                      | 2017 | 0.538                    |                               |                             |
| Dallas       | 2471.2                       | 2323.1              | 49.9                       | 2015 | 0.96                     | 0.966                         | 0.034                       |
|              | 2565                         | 2444                | 46.7                       | 2017 | 0.971                    |                               |                             |
| Detroit      | 1709                         | 1267.1              | 34                         | 2015 | 0.761                    | 0.761                         | 0.239                       |
|              | 1723                         | 1280                | 31.1                       | 2017 | 0.761                    |                               |                             |
| Philadelphia | 2216.1                       | 1395.4              | 295.9                      | 2015 | 0.763                    | 0.776                         | 0.224                       |
|              | 2308                         | 1516                | 303.1                      | 2017 | 0.788                    |                               |                             |
| Phoenix      | 1644                         | 1591.3              | 7.4                        | 2015 | 0.972                    | 0.968                         | 0.032                       |
|              | 1686                         | 1619                | 6.7                        | 2017 | 0.964                    |                               |                             |
| Sacramento   | 783.7                        | 677.5               | 4.6                        | 2011 | 0.87                     | 0.87                          | 0.13                        |
| St. Louis    | 1115.2                       | 1013.1              | 23.2                       | 2011 | 0.929                    | 0.929                         | 0.071                       |

### 3D.2.6.1.3 Ozone Decay and Deposition Rates

As done for the 2014 HREA, a distribution for combined O<sub>3</sub> decay and deposition rates was obtained from the analysis of measurements from a study by Lee et al. (1999). This study measured decay rates in the living rooms of 43 residences in Southern California. Measurements of decay rates in a second room were made in 24 of these residences. The 67 decay rates range from 0.95 to 8.05 hr<sup>-1</sup>. A lognormal distribution was fit to the measurements from this study,

<https://www.census.gov/programs-surveys/ahs/data/2011/ahs-2011-summary-tables/ahs-metropolitan-summary-tables.html> (accessed on 4/2/2019).

yielding a geometric mean of  $2.51 \text{ hr}^{-1}$  and a geometric standard deviation of  $1.53 \text{ hr}^{-1}$ . These values are constrained to lie between  $0.95$  and  $8.05 \text{ hr}^{-1}$ . This combined  $\text{O}_3$  decay and deposition rate distribution was used for all four indoor microenvironments.

#### **3D.2.6.2 Outdoor Microenvironments**

As mentioned above, the two outdoor MEs (outdoor-general and outdoor-near road) used the factors approach to estimate ME concentrations. The factors approach uses two variables in combination with ambient air  $\text{O}_3$  concentrations: a proximity factor and a factor expressing the fraction of a pollutant entering (PE factor) an ME, and these are discussed below.

Proximity factors are used to adjust ambient air  $\text{O}_3$  concentrations, based on the ME location relative to that of the ambient air concentration. For the outdoor-general ME, there is no adjustment used (proximity = 1.0); it is assumed that wherever an individual is outdoors, the individual experiences the ambient air  $\text{O}_3$  concentrations for the tract they are present in at that time (e.g., at home, at work, or nearby census tract). For the outdoor-near road ME, a proximity factor is used, recognizing that ambient air concentrations measured away from roadways tend to increase with distance. As done for the 2014 HREA, we employed the distribution for local roads (i.e., a normal distribution  $\{0.755, 0.203\}$ , bounded by 0.422 and 1.0) derived from the Cincinnati Ozone Study (American Petroleum Institute, 1997, Appendix B; Johnson et al., 1995), based on the assumption that most of the outdoors-near-road ozone exposures will occur proximal to local roads (see Table 3D-17 and details below in section 3D.2.6.3).

PE factors are used to adjust for the percent of a pollutant entering a ME. PE factors for the outdoor-general and outdoor-near road MEs, because they are effectively aligned with the ambient air  $\text{O}_3$  concentrations, are set equivalent to 1.

#### **3D.2.6.3 Inside-Vehicle Microenvironments**

As done for the 2014 HREA, for the in-vehicle ME, proximity and PE factor distributions were obtained from the Cincinnati Ozone Study (American Petroleum Institute, 1997, Appendix B; Johnson et al., 1995). This field study was conducted in the greater Cincinnati metropolitan area in August and September 1994. Vehicle tests were conducted according to an experimental design specifying the vehicle type, road type, vehicle speed, and ventilation mode. Vehicle types were defined by the three study vehicles: a minivan, a full-size car, and a compact car. Road types were interstate highways (interstate), principal urban arterial roads (urban), and local roads (local). Nominal vehicle speeds (typically met over 1-min intervals within 5 mph) were at 35 mph, 45 mph, or 55 mph. Ozone concentrations were measured inside the vehicle, outside the vehicle, and at six fixed-site monitors in the Cincinnati area. Table 3D-17 lists the parameters of the normal distributions developed for proximity and PE factors (both are unitless) for in-vehicle microenvironments used in this exposure and risk analysis.

A daily conditional variable was used to select the three proximity factor distributions to use in estimating the inside-vehicle ME concentrations. The 2015-2017 Vehicle Miles of Travel (VMT) data available from the U.S. Department of Transportation (DOT) were used to generate these daily conditional variables.<sup>59</sup> For local and interstate road types, the VMT for the same DOT categories were used. For urban roads, the VMT for all other DOT road types were summed (i.e., other freeways/expressways, other principal arterial, minor arterial, and collector). Table 3D-18 summarizes the conditional variables used for each study area to select for the proximity factor distribution used to estimate inside-vehicle ME concentrations.

**Table 3D-17. Parameter values for distributions of penetration and proximity factors used for estimating in-vehicle ME concentrations.**

| ME Factor   | Road Type  | Arithmetic Mean (unitless) | Standard Deviation (unitless) | Lower Bound <sup>A</sup> (unitless) | Upper Bound (unitless) |
|---|------------|----------------------------|-------------------------------|-------------------------------------|------------------------|
| PE  | All        | 0.300                      | 0.232                         | 0.100                               | 1.0                    |
| Proximity   | Local      | 0.755                      | 0.203                         | 0.422                               | 1.0                    |
|   | Urban      | 0.754                      | 0.243                         | 0.355                               | 1.0                    |
|   | Interstate | 0.364                      | 0.165                         | 0.093                               | 1.0                    |
| <sup>A</sup> A 5 <sup>th</sup> percentile value estimated using a normal approximation as Mean – 1.64 × standard deviation. |            |                            |                               |                                     |                        |

**Table 3D-18. VMT (2015-2017) derived conditional probabilities for interstate, urban, and local roads used to select inside-vehicle proximity factor distributions in each study area.**

| Study Area   | Conditional Probabilities for Vehicle Proximity Factors (unitless) |       |       |
|--------------|--|-------|-------|
|              | Interstate   | Urban | Local |
| Atlanta      | 0.339  | 0.392 | 0.269 |
| Boston       | 0.416  | 0.455 | 0.129 |
| Dallas       | 0.496  | 0.453 | 0.051 |
| Detroit      | 0.357  | 0.531 | 0.112 |
| Philadelphia | 0.361  | 0.523 | 0.116 |
| Phoenix      | 0.364  | 0.542 | 0.094 |
| Sacramento   | 0.456  | 0.433 | 0.111 |
| St. Louis    | 0.460  | 0.363 | 0.177 |

<sup>59</sup> Data were downloaded (accessed on 3/13/2019) from U.S. Department of Transportation (DOT) Federal Highway Administration (FHA) Highway Statistics Series Publications. The three individual years (2015-2017) of data were downloaded from dropdown menu available at: <https://www.fhwa.dot.gov/policyinformation/statistics.cfm>.

### 3D.2.7 Estimating Exposure

APEX estimates the complete time series of exposure and breathing rate for every simulated individual. This is because APEX accounts for important factors that influence exposure and include the magnitude, duration, frequency of exposures, and the breathing rate of individuals at the time of exposure. APEX can summarize exposure data using standardized time metrics (e.g., hourly or daily average, daily maximum 7-hr average), as is needed for comparison to benchmark concentrations (section 3D.2.8.1) or can output the minute-by-minute exposure concentrations and simultaneous breathing rate, as is needed for the lung function risk modeling (section 3D.2.8.2.2). As a reminder, calculated exposures are distinct from that of ambient air concentrations by accounting for simulated individual's time-location-activity patterns and O<sub>3</sub> concentration decay/variation occurring within the occupied microenvironments. Further, exposures (and hence health risks) are estimated for four groups of individuals residing in each study area: children (individuals aged 5 to 18 years), children with asthma, adults (individuals older than 18 years), and adults with asthma.

### 3D.2.8 Estimating Risk

We derived two types of metrics to characterize potential population health risk: a comparison of simulated exposures to benchmark concentrations (section 3D.2.8.1) and by using simulated exposures to estimate lung function risk (section 3D.2.8.2). As done in the 2015 review, these two approaches are based on the body of evidence from the controlled human exposure studies reporting lung function decrements (as measured by changes in FEV<sub>1</sub>)<sup>60</sup> along with supporting health evidence from O<sub>3</sub>-related epidemiologic studies. As discussed in Appendix 3 of the ISA, there is a significant body of controlled human exposure studies reporting lung function decrements and respiratory symptoms in adults associated with 1- to 6.6-hr exposures to O<sub>3</sub>, all but a few of which were available in the 2015 review and no new studies that included 6.6-hour exposures were available (ISA, Appendix 3, section 3.1.4.1.1; 2013 ISA, section 6.2.1.1). The exposure studies of greatest interest are those that have exposed subjects during exercise (ISA, Appendix 3; 2013 ISA, section 6.2.1.1). In general, the 1- to 2-hr exposure studies utilize an intermittent exercise protocol in which subjects rotate between periods of exercise and rest, though a limited number of these studies use a continuous exercise regime. A quasi-continuous exercise protocol is common to the 6.6-hr exposure studies where subjects

---

<sup>60</sup> There are other respiratory responses resulting from O<sub>3</sub> exposures that were measured in these studies, including increased lung inflammation, increased respiratory symptoms, increased airway responsiveness, and impaired host defenses. While the available quantitative information is inadequate to reasonably model these other health endpoints, nevertheless the observed responses remain informative in characterizing overall risks.

complete six 50-min periods of exercise followed by 10-min rest periods (along with a 35-min lunch/rest period) (ISA, Appendix 3, section 3.1.4.1.1).

For lung function risk, we estimate risk of an O<sub>3</sub>-related decrement at or above 10%, 15% and 20%. These sizes of decrements have been used in the risk assessments for reviews completed in 2015, 2008 and 1997 (2014 HREA; U.S. EPA, 2007a, U.S. EPA, 2007b; Whitfield et al., 1996). In the 2015 review, the CASAC concurred with the EPA's use in the 2014 HREA of estimated FEV<sub>1</sub> decrements of  $\geq 15\%$  as a scientifically relevant surrogate for adverse health outcomes in active healthy adults, and an FEV<sub>1</sub> decrement of  $\geq 10\%$  as a scientifically relevant surrogate for adverse health outcomes for people with asthma and lung disease (Frey, 2014, p. 3).

### **3D.2.8.1 Comparison to Benchmark Concentrations**

For the comparison of simulated exposures to benchmark concentrations that reflect observations from the 6.6-hr controlled human exposure studies, APEX estimates the daily maximum 7-hr average O<sub>3</sub> exposure<sup>61</sup> for every simulated individual, stratified by exertion level at the time of exposure. This indicator was selected based on controlled human exposure studies where reported adverse health responses were associated with exposure to O<sub>3</sub> and while the study subject was exercising.<sup>62</sup> A 7-hr average exposure concentration is more appropriate than using an 8-hr average (as was done for the prior REAs) because it aligns more closely to the 6.6-hr durations of the controlled human exposure studies on which the benchmark concentrations are based.<sup>63</sup> The 7-hr average exposure concentrations experienced by simulated individuals while at moderate or greater exertion ( $\text{EVR} \geq 17.32 \pm 1.25 \text{ L/min-m}^2$  body surface area; see above section 3D.2.2.3.3) are then compared to the benchmark concentrations.

Benchmark concentrations used in this assessment include O<sub>3</sub> exposure concentrations of 60, 70 and 80 ppb; the same benchmarks used for the 2014 HREA (based on there being no new 6.6-hr controlled human exposure studies that might inform consideration of alternatives). Estimating the occurrence of ambient air-related 7-hr average O<sub>3</sub> exposures at and above these

---

<sup>61</sup> Only the maximum 7-hr average O<sub>3</sub> exposure concentration is retained by APEX for each day simulated, per person.

<sup>62</sup> Health responses observed in the controlled human exposure studies are from 6.6-hr exposures to O<sub>3</sub>, that involved quasi-continuous exercise. Therefore, it is possible that the effects observed at benchmark levels identified using a 6.6-hr exposure could occur at slightly lower concentrations for a comparable 7-hr exposure and occur at still lower concentrations for a comparable 8-hr exposure. From a practical perspective, there would be a greater number of individuals estimated at or above a particular benchmark when averaging exposures across a 6.6-hr period than when compared to simulations using 7-hr or 8-hr averaging (the latter of which was used in the prior assessments and recognized specifically in the 2014 HREA, section 5.2.8, footnote 18).

<sup>63</sup> Note that the 8-hr averaging time for ambient air O<sub>3</sub> concentrations associated with the current standard remains the same as used in prior assessments. The only difference is that for the current exposure and risk analysis, 8-hr ambient air O<sub>3</sub> concentrations are now evaluated with a more appropriate exposure and risk metric (i.e., a 7-hr average exposure benchmark).

benchmark levels is intended to provide perspective on the potential for public health impacts of O<sub>3</sub>-related health effects observed in human clinical and toxicological studies, but for which available data do not support development of E-R functions, precluding their evaluation in quantitative risk assessments (e.g., lung inflammation, increased airway responsiveness, and decreased resistance to infection), as well as lung function decrements which are currently evaluated in quantitative risk assessments. The 80 ppb benchmark concentration represents an exposure where multiple controlled human exposure studies (of the 6.6-hr, with exercise design) demonstrate a range of O<sub>3</sub>-related respiratory effects including lung inflammation and airway responsiveness, as well as respiratory symptoms, in healthy adults. The 70 ppb benchmark concentration reflects a study that found statistically significant decrements in lung function as well as increased respiratory symptoms. The 60 ppb benchmark level represents the lowest exposure level at which statistically significant decrements in lung function, but not respiratory symptoms, have been observed in studies of healthy individuals (see Table 3-2 of the main document).<sup>64</sup> This is summarized in Table 3D-19 below. Further details on the body of evidence supporting the selection of these benchmark levels is described in the ISA, Appendix 3 and summarized in the section 3.3 of the main document and Appendix 3A.

APEX then calculates two general types of exposure estimates for the population of interest: the estimated number of people exposed to a specified O<sub>3</sub> concentration level and, the number of days per year that they are so exposed, while at moderate or greater exertion. The former highlights the number of individuals exposed *one or more* times per year (i.e., at least once) at or above a selected benchmark level. The latter is expressed as *multiday* exposures, that is, the number of times per year each simulated individual experiences a daily maximum exposure at or above a benchmark. These same exposure results are also used in estimating population-based lung function risk (section 3D.2.8.2.1).

---

<sup>64</sup> Prolonged exposure to 40 ppb O<sub>3</sub> results in a small decrease in group mean FEV<sub>1</sub> that is not statistically different from responses following exposure to filtered air (Adams, 2002; Adams, 2006).

**Table 3D-19. Responses reported in 6.6-hr controlled human exposure studies at a given benchmark concentration.**

| Benchmark Concentration (ppb)  | Responses Reported in Controlled Human Exposure Studies <sup>A</sup>  |   |
|--|---|---|
|  | Decrements in Lung Function, and Other Effects  | Respiratory Symptoms  |
| ≥80  | Prolonged exposure to an average O <sub>3</sub> concentration of 80 ppb, 100 ppb, or 120 ppb O <sub>3</sub> results in statistically significant group mean decrements in FEV <sub>1</sub> ranging from 6 <sup>B</sup> to 8%, 8 to 14%, and 10 to 16%, respectively. <sup>C</sup> Statistically significant increases in multiple inflammatory response indicators and in airway responsiveness.  | Statistically significant increases in respiratory symptoms (ISA, section 3.1.4.2.1).   |
| ≥70  | Prolonged exposure to an average O <sub>3</sub> concentration of 70 ppb results in a statistically significant group mean decrement in FEV <sub>1</sub> of about 6%. <sup>D</sup>   |   |
| ≥60  | Prolonged exposure to an average O <sub>3</sub> concentration of 60 ppb results in group mean FEV <sub>1</sub> decrements ranging from 1.7% to 3.5%. <sup>E</sup> Based on data from multiple studies, the weighted average group mean decrement was 2.5%. In some analyses, these group mean decrements in lung function were statistically significant <sup>F</sup> while in other analyses they were not. <sup>G</sup> Statistically significant increases in sputum neutrophils, an indicator of inflammatory response. | None of studies at this exposure concentration have observed a statistically significant increase in symptom scores (ISA, section 3.1.4.2.1). |
| <sup>A</sup> Information is drawn from Table 3A-1 of Appendix 3A for 6.6-hr exposure protocol with exercise EVR of 20 L/min/m <sup>2</sup> (see also ISA, Figure 3-3). These studies have been performed with healthy adult subjects.<br><sup>B</sup> Measurements collected at 80 ppb exposure for 30 subjects as part of the Kim et al. (2011) study that were presented only in Figure 5 of McDonnell et al. (2012) indicate a group mean decrement of 3.5%.<br><sup>C</sup> Folinsbee et al. (1994), Horstman et al. (1990), McDonnell et al. (1991), Adams (2002), Adams (2006), Adams (2000), Adams and Ollison (1997), Schelegle et al. (2009).<br><sup>D</sup> Schelegle et al. (2009).<br><sup>E</sup> Adams (2002), Adams (2006), Schelegle et al. (2009), and Kim et al. (2011).<br><sup>F</sup> Brown et al. (2008), Kim et al. (2011). In an analysis of the Adams (2006) data, Brown et al. (2008) addressed the more fundamental question of whether there were statistically significant differences in responses before and after the 6.6-hr exposure period and found the study group average effect on FEV <sub>1</sub> at 60 ppb to be small, but statistically significant using several common statistical tests, even after removal of potential outliers.<br><sup>G</sup> Adams (2006), Schelegle et al. (2009). |   |   |

### 3D.2.8.2 Lung Function Risk

We used two approaches to estimate health risk. As done for the lung function risk assessments conducted during prior O<sub>3</sub> NAAQS reviews, the first approach used a Bayesian Markov Chain Monte Carlo technique to develop probabilistic population-based Exposure-Response (E-R) functions. These population-based E-R functions were then combined with the APEX estimated population distribution of 7-hr maximum exposures for people at or above moderate exertion ( $EVR \geq 17.32 \pm 1.25$  L/min-m<sup>2</sup> body surface area) to estimate the number of people expected to experience lung function decrements. The second approach is based on the McDonnell-Stewart-Smith (MSS) FEV<sub>1</sub> model (McDonnell et al., 2013). The MSS model uses the time-series of O<sub>3</sub> exposure and corresponding ventilation rates for each APEX simulated

individual to estimate their personal time-series of FEV<sub>1</sub> reductions, selecting the daily maximum reduction for each person. As done for the exposure benchmark analysis, APEX calculates, for the population of interest, the estimated number of simulated individuals expected to experience an FEV<sub>1</sub> response at or above a selected level and the number of days per year that may occur per person. A key difference between these approaches is that the population-based E-R method directly approximates a population distribution of FEV<sub>1</sub> reductions while the MSS model estimates FEV<sub>1</sub> reductions at the individual level (which are then aggregated to a population level). Each of these approaches is discussed in detail below.

#### **3D.2.8.2.1 Population-based E-R function**

For developing the population-based E-R function, we used the exact same E-R function as used for the 2014 HREA given CASAC advice on the approach used for the 2008 O<sub>3</sub> review (Henderson, 2006) and that there were no new controlled human exposure study data to justify the generating of a new E-R function for this current analysis. Briefly, data from several controlled human exposure studies that evaluated 6.6-hr exposures at moderate exertion were combined and used to estimate E-R functions. Considering the above discussion and as done in the 2014 HREA, we separated the controlled human exposure study data into three lung function decrement categories. The mid- to upper-end of the range of moderate levels of functional responses and higher (i.e., FEV<sub>1</sub> decrements  $\geq 15\%$  and  $\geq 20\%$ ) are included to generally represent potentially adverse lung function decrements in active healthy adults, while for people with asthma or lung disease, a focus on moderate functional responses (FEV<sub>1</sub> decrements down to 10%) may be appropriate (Table 3D-20 and Figure 3D-11).<sup>65</sup> The controlled human exposure study data in this table were first corrected on an individual basis for study effects in clean filtered air to remove any systemic bias that might be present in the data attributable to the effects of the experimental procedures and extraneous responses (e.g., exercise, diurnal variability, etc.) (2013 ISA, pp. 6-4 and 6-5). This is done by subtracting the FEV<sub>1</sub> decrement in filtered air from the FEV<sub>1</sub> decrement (at the same time point) during exposure to O<sub>3</sub>. An example of this calculation is given in the 2014 HREA, Appendix 6D.

---


<sup>65</sup>As in past reviews, the EPA has summarized study results with regard to multiple magnitudes of lung function decrement, including 10%, recognizing that 10% has been used in clinical settings to detect a FEV<sub>1</sub> change likely indicative of a response rather than intrasubject variability, e.g., for purposes of identifying subjects with responses to increased ventilation (Dryden, 2010).



**Table 3D-20. Summary of controlled human exposure study data stratified by concentration level and lung function decrements, corrected for individual response that occurred while exercising in clean air, ages 18-35.**

| Study, Grouped by<br>Average O <sub>3</sub> Exposure | Protocol   | Study<br>Subjects<br>(n) | Subjects Responding (n) <sup>A</sup> |                           |                           |
|--|--|--------------------------|--------------------------------------|---------------------------|---------------------------|
|  |  |                          | ΔFEV <sub>1</sub><br>≥10%            | ΔFEV <sub>1</sub><br>≥15% | ΔFEV <sub>1</sub><br>≥20% |
| <b>0.040 ppm O<sub>3</sub></b>                       |  |                          |                                      |                           |                           |
| Adams (2002)   | Square-wave (constant level), face mask                | 30                       | 2                                    | 0                         | 0                         |
| Adams (2006)   | Variable levels (exercise avg = 0.040 ppm)             | 30                       | 0                                    | 0                         | 0                         |
| <b>0.060 ppm O<sub>3</sub></b>                       |  |                          |                                      |                           |                           |
| Adams (2006)   | Square-wave  | 30                       | 2                                    | 0                         | 0                         |
|  | Variable levels (exercise avg = 0.060 ppm)             | 30                       | 2                                    | 2                         | 0                         |
| Kim et al. (2011)                                    | Square-wave  | 59                       | 3                                    | 1                         | 0                         |
| Schelegle et al. (2009)                              | Variable levels (exercise avg =0.060 ppm)              | 31                       | 4                                    | 2                         | 1                         |
| <b>0.070 ppm O<sub>3</sub></b>                       |  |                          |                                      |                           |                           |
| Schelegle et al. (2009)                              | Variable levels (exercise avg= 0.070 ppm)              | 31                       | 6                                    | 3                         | 2                         |
| <b>0.080 ppm O<sub>3</sub></b>                       |  |                          |                                      |                           |                           |
| Adams (2002)   | Square-wave, face mask                                 | 30                       | 6                                    | 5                         | 2                         |
| Adams (2003)   | Square-wave, chamber                                   | 30                       | 6                                    | 2                         | 1                         |
|  | Square-wave, face mask                                 | 30                       | 5                                    | 2                         | 2                         |
|  | Variable levels (exercise avg=0.080 ppm),<br>chamber   | 30                       | 6                                    | 1                         | 1                         |
|  | Variable levels (exercise avg=0.080 ppm),<br>face mask | 30                       | 5                                    | 1                         | 1                         |
| Adams (2006)   | Square-wave  | 30                       | 7                                    | 2                         | 1                         |
|  | Variable levels (exercise avg=0.080 ppm)               | 30                       | 9                                    | 3                         | 1                         |
| F-H-M <sup>1</sup>                                   | Square-wave  | 60                       | 17                                   | 11                        | 8                         |
| Kim et al. (2011)                                    | Square-wave  | 30                       | 4                                    | 1                         | 0                         |
| Schelegle et al. (2009)                              | Variable levels (exercise avg=0.080 ppm)               | 31                       | 10                                   | 5                         | 4                         |
| <b>0.0870 ppm O<sub>3</sub></b>                      |  |                          |                                      |                           |                           |
| Schelegle et al. (2009)                              | Variable levels (exercise avg=0.087 ppm)               | 31                       | 14                                   | 10                        | 7                         |
| <b>0.100 ppm O<sub>3</sub></b>                       |  |                          |                                      |                           |                           |
| F-H-M <sup>1</sup>                                   | Square-wave  | 32                       | 13                                   | 11                        | 6                         |
| <b>0.120 ppm O<sub>3</sub></b>                       |  |                          |                                      |                           |                           |
| Adams, 2002  | Square-wave, chamber                                   | 30                       | 17                                   | 12                        | 10                        |
|  | Square-wave, face mask                                 | 30                       | 21                                   | 13                        | 7                         |
| F-H-M <sup>B</sup>                                   | Square-wave  | 30                       | 18                                   | 15                        | 10                        |

<sup>A</sup> Data from 2014 HREA, Table 6-3 and were originally compiled by Abt (2013). Individual subject responses were corrected using pre- and post-exposure observations.  
<sup>B</sup> F-H-M combines data from Folinsbee et al. (1988), Horstman et al. (1990), and McDonnell et al. (1991).



**Figure 3D-11. Controlled human exposure data for FEV<sub>1</sub> responses in individual study subjects.**

A Bayesian Markov Chain Monte Carlo (BMCMC) approach (Lunn et al., 2012) developed as part of an earlier O<sub>3</sub> exposure and risk analysis (U.S. EPA, 2007a, U.S. EPA, 2007b, section 3.1.2) was modified for the 2014 HREA and used to generate the population-based E-R functions using the updated controlled human exposure study data (Abt, 2013).<sup>66</sup> Briefly, we considered both linear and logistic functional forms in estimating the E-R function and chose a 90 percent logistic/10 percent piecewise-linear split using a BMCMC approach. For each of the three measures of lung function decrement, we first assumed a 90 percent probability that the E-R function has the following 3-parameter logistic form indicated by Equation 3D-9:<sup>67</sup>

$$y(x; \alpha, \beta, \gamma) = \frac{\alpha e^{\gamma} (1 - e^{\beta x})}{(1 + e^{\gamma})(1 + e^{\beta x + \gamma})} \quad \text{Equation 3D-9}$$

<sup>66</sup> In some of the controlled human exposure studies, subjects were exposed to a given O<sub>3</sub> concentration more than once – for example, using a constant (square-wave) exposure pattern in one protocol and a variable (triangular) exposure pattern in another protocol. However, because there were insufficient data to estimate subject-specific response probabilities, we assumed a single response probability (for a given definition of response) for all individuals and treated the repeated exposures for a single subject as independent exposures in the binomial distribution.

<sup>67</sup> The 3-parameter logistic function is a special case of the 4-parameter logistic, in which the function is forced to go through the origin, so that the probability of response to 0.0 ppm is 0.

1 where  $x$  denotes the O<sub>3</sub> concentration (in ppm) to which the individual is exposed,  $y$   
2 denotes the corresponding response (decrement in FEV<sub>1</sub>  $\geq 10\%$ ,  $\geq 15\%$  or  $\geq 20\%$ ), and  $\alpha$ ,  $\beta$ , and  
3  $\gamma$  are the three parameters whose values are estimated.

4 We then assumed a 10 percent probability that the E-R function has the following 2-piece  
5 linear with threshold (hockey stick) form<sup>68</sup> indicated by Equation 3D-10:

$$y(x; \alpha, \beta) = \begin{cases} \alpha + \beta x, & \text{for } \alpha + \beta x > 0 \\ 0, & \text{for } \alpha + \beta x < 0 \end{cases} \quad \text{Equation 3D-10}$$

7 The selection of the 90 percent logistic/10 percent piecewise-linear split was based  
8 largely on the results of sensitivity analyses in the 2007 O<sub>3</sub> risk assessment combined with  
9 CASAC advice on the model form (U.S. EPA, 2007b),<sup>69</sup> and from model fit determined in the  
10 2014 HREA.<sup>70</sup> Therefore, as done for the 2014 HREA, we are using only the 90/10 E-R function  
11 in the current analysis to estimate risk. Further, because there were no newly available controlled  
12 human exposure study data for 6.6-hr duration exposures since the 2014 HREA, we used the  
13 exact same 90/10 E-R function derived at that time, the overall approach of which is briefly  
14 described below.

15 To generate the E-R functions, prior distributions needed to be specified to estimate the  
16 posterior distribution for each of the unknown parameters (Box and Tiao, 1973). For the logistic  
17 functional form, we assumed lognormal priors and used Max likelihood estimates (MLE) of the  
18 means and variances for the 3 parameters. For the linear functional form, we assumed normal  
19 priors using ordinary least square (OLS) estimates for the means and variances for the  
20 parameters.

21 For each of the two functional forms (logistic and linear), we derived the posterior  
22 distributions using the binomial likelihood function and prior distributions for each of the  
23 unknown parameters. Specifically, we used three Markov chains (each chain corresponds to a set

---

<sup>68</sup> The 2-piece linear models estimate no occurrences below about 40 ppb for the 10% lung function decrement and below about 60 ppb for the 15% and 20% lung function decrements based on the limited available data at those exposure levels. Note that as these two-piece linear model forms are combined with a second model form (logistic) for the final model, their contribution to estimated responses is low.

<sup>69</sup> The 1997 risk assessment used a linear form consistent with the advice from the CASAC O<sub>3</sub> panel at the time that a linear model reasonably fit the available data at exposures of 0.08, 0.10, and 0.12 ppm. Following the addition of exposures data at 0.06 and 0.04 ppm in the 2007 assessment, a logistic model was found to provide a good fit to the data. The CASAC O<sub>3</sub> panel for that review noted that there are only limited data at the two lowest exposure levels and, as a result, a linear model could not entirely be ruled out, resulting in the combined model based on both the logistic and linear forms (U.S. EPA, 2007b).

<sup>70</sup> Analyses using the updated data available for the 2014 HREA determined that for each of the three E-R curves, the 90/10 logistic/linear mix has smaller error in fit (weighted RMSE) relative to the other two E-R curves evaluated: one having a 80/20 logistic/linear mix and the other having a 50/50 mix.

of initial parameter values) and for each chain we used 4,000 iterations as the “burn-in” period<sup>71</sup> followed by 96,000 iterations for the estimation. Each iteration corresponds to a set of estimates for the parameters of the (logistic or linear) exposure-response function. We then examined the outputs using the options WinBUGS provides to check convergence and auto-correlation (e.g., trace plot, auto correlation). Finally, we combined 8,100 sets of values from the logistic model runs (the last 2,700 iterations from each chain) with 900 sets of values from the linear model runs (the last 300 iterations from each chain) to obtain a single combined distribution for each predicted value, reflecting the 90 percent/10 percent assumptions stated above (WinBUGS v 1.4.3; Lunn et al., 2012).

We selected the median (50<sup>th</sup> percentile) E-R function from the 9,000 sets of functions to estimate the risk for changes in FEV<sub>1</sub> ≥10%, ≥15%, and ≥20% (Figure 3D-12). The original E-R data to which the curves were fit are also provided in the figure, along with the derived E-R function data used to combine with the daily maximum 7-hr exposures for the simulated population, while at moderate exertion (section 3D.2.8.1). The population at-risk is estimated by multiplying the expected response rate by the number of people exposed in the relevant population (and stratified by 7-hr average exposures, in 0.01 ppm increments), as shown in Equation 3D-11:

$$R_k = \sum_{j=1}^N P_j x(RR_k | e_j) \quad \text{Equation 3D-11}$$

where:


- $e_j$  = (the midpoint of) the  $j^{\text{th}}$  interval of personal exposure to O<sub>3</sub>
- $P_j$  = fraction of the population with O<sub>3</sub> exposures of  $e_j$  ppm
- $RR_k | e_j$  =  $k^{\text{th}}$  response rate at O<sub>3</sub> exposure concentration  $e_j$
- $N$  = number of intervals (categories) of O<sub>3</sub> personal exposure concentration.

The number of 0.01 ppm intervals was maximally set to 16 (Figure 3D-12), however, given the adjusted air quality scenarios, the midpoint values used in the risk calculation typically ranged from 0.05 to 0.095 ppm. Conventional rounding was applied to the sum of the calculated risk value.<sup>72</sup>

<sup>71</sup> Markov chain Monte Carlo (MCMC) simulations require an initial adaptive “burn-in” set of iterations, which are not used as part of the E-R curve output but allow the BMCMC sampling to stabilize.

<sup>72</sup> For calculated risks (i.e., the summed number of people at each daily maximum 7-hr average exposure interval) where the tenths value was less than 0.5, data were rounded down to the next lowest integer. For calculated risks where the tenths value was greater than or equal to 0.5, data were rounded up to the next highest integer.

| O <sub>3</sub><br>(ppm) | FEV <sub>1</sub><br>≥10% | FEV <sub>1</sub><br>≥15% | FEV <sub>1</sub><br>≥20% |
|-------------------------|--------------------------|--------------------------|--------------------------|
| 0                       | 0                        | 0                        | 0                        |
| 0.005                   | 0.0008                   | 0.0001                   | 0                        |
| 0.010                   | 0.0019                   | 0.0002                   | 0                        |
| 0.015                   | 0.0035                   | 0.0004                   | 0.0001                   |
| 0.020                   | 0.0056                   | 0.0007                   | 0.0001                   |
| 0.025                   | 0.0084                   | 0.0011                   | 0.0002                   |
| 0.030                   | 0.0123                   | 0.0018                   | 0.0003                   |
| 0.035                   | 0.0176                   | 0.0029                   | 0.0006                   |
| 0.040                   | 0.0249                   | 0.0045                   | 0.0011                   |
| 0.045                   | 0.0362                   | 0.0070                   | 0.0019                   |
| 0.050                   | 0.0495                   | 0.0109                   | 0.0033                   |
| 0.055                   | 0.0665                   | 0.0167                   | 0.0060                   |
| 0.060                   | 0.0883                   | 0.0260                   | 0.0108                   |
| 0.065                   | 0.1160                   | 0.0404                   | 0.0180                   |
| 0.070                   | 0.1497                   | 0.0595                   | 0.0296                   |
| 0.075                   | 0.1905                   | 0.0860                   | 0.0476                   |
| 0.080                   | 0.2378                   | 0.1212                   | 0.0738                   |
| 0.085                   | 0.2894                   | 0.1642                   | 0.1083                   |
| 0.090                   | 0.3415                   | 0.2115                   | 0.1482                   |
| 0.095                   | 0.3948                   | 0.2614                   | 0.1879                   |
| 0.100                   | 0.4474                   | 0.3116                   | 0.2219                   |
| 0.105                   | 0.4961                   | 0.3560                   | 0.2493                   |
| 0.110                   | 0.5393                   | 0.3922                   | 0.2704                   |
| 0.115                   | 0.5756                   | 0.4199                   | 0.2853                   |
| 0.120                   | 0.6055                   | 0.4408                   | 0.2952                   |
| 0.125                   | 0.6292                   | 0.4567                   | 0.3012                   |
| 0.130                   | 0.6477                   | 0.4695                   | 0.3047                   |
| 0.135                   | 0.6639                   | 0.4789                   | 0.3068                   |
| 0.140                   | 0.6774                   | 0.4867                   | 0.3082                   |
| 0.145                   | 0.6893                   | 0.4912                   | 0.3089                   |
| 0.150                   | 0.6999                   | 0.4941                   | 0.3093                   |
| 0.155                   | 0.7084                   | 0.4959                   | 0.3096                   |
| 0.160                   | 0.7133                   | 0.4968                   | 0.3097                   |



**Figure 3D-12. Median value of Bayesian fit population-based E-R function data (left panel) and illustrative curves (right panel) for FEV<sub>1</sub> decrements ≥10% (top panel), ≥15 (middle panel), ≥20% (bottom panel). Drawn from the 2014 HREA, Table 6A-1 with processing and model development described by Abt (2013).**

From a practical perspective, the population-based E-R function risk approach takes into account that there is a fraction of the population that could experience a lung function decrement at any daily maximum 7-hr average exposure level (i.e., from the minimum to the maximum, including the level of the exposure benchmarks), having a low probability of decrements resulting from low exposures and higher probability at the highest exposures. That said, the approach allows for decrements to occur at exposures below those tested/observed in the controlled human exposure studies, albeit a small population fraction (e.g., see the response frequency for exposures below 60 ppb in Figure 3D-12), recognizing there is potential for variability in the degree of sensitivity between the controlled human exposure study subjects and the simulated population. Note also that because there is a strict limit on attaining a particular ventilation rate for the simulated individuals (i.e., 7-hr average exposures for individuals must simultaneously occur at moderate or greater exertion, section 3D.2.2.3.3), there may be some potential to underestimate lung function responses if they were to occur at the higher end of the exposure distribution (i.e., where exposures are >60 ppb) that coincide with breathing rates just below those specified by the moderate or greater exertion requirement.

#### **3D.2.8.2.2 The McDonnell-Stewart-Smith (MSS) Model**

The McDonnell-Stewart-Smith (MSS) model, a statistical model to estimate FEV<sub>1</sub> responses for individuals associated with short-term exposures to O<sub>3</sub>, was developed using controlled human exposure data<sup>73</sup> from studies using varying exposure durations and varying exertion levels and breathing rates (McDonnell et al., 2007). Following the development of the model by McDonnell et al., 2007), Schelegle et al. (2009) found a delay in response when modeling FEV<sub>1</sub> decrements as a function of accumulated dose and estimated a threshold associated with the delay. McDonnell et al. (2012) refit a 2010 version of the model that included a body mass index (BMI) variable (McDonnell et al., 2010), adding data from eight additional studies<sup>74</sup> and incorporating a threshold parameter into the model, which allows for modeling a delay in response until accumulated dose (i.e., accounting for decreases over time according to first order reaction kinetics) reaches a threshold value. The threshold is not a concentration threshold and does not preclude responses at low concentration exposures.

The MSS model was first used for estimating lung function risk in the 2014 HREA and was based on the revised version of the model available at that time (McDonnell et al., 2012). Another version of the MSS model has become available since the 2015 review, which differs from the prior model in that it assumes that the intra-subject variance term (Var( $\epsilon$ )) increases


---

<sup>73</sup> Data were from 15 controlled human exposure studies that included 531 volunteers (ages 18 to 35), exposed to O<sub>3</sub> on a total of 864 occasions (McDonnell et al., 2007).

<sup>74</sup> Data from these eight additional studies included 201 individuals.

with the response (McDonnell et al., 2013).<sup>75</sup> Therefore, with a fixed ventilation rate,  $\text{Var}(\varepsilon)$  in this most recent version of the MSS model will be larger for higher exposure concentrations and smaller for lower exposure concentrations. The most recent version of the MSS model is the model described here and is the model used in this risk analysis.

The lung function model is conceptually a two-compartment model (Figure 3D-13). The accumulated amount  $O_3$  (exposure concentration  $\times$  ventilation rate, used to represent dose) is modeled in the first compartment and modified by an exponential decay factor to yield an intermediate quantity  $X$ . The response ( $\text{FEV}_1$  reduction) of the individual to  $X$  is modeled in the second compartment as a sigmoid-shaped function of the net accumulated dose. A threshold parameter imposes the constraint that there is no response while the value of  $X$  is below the threshold value.



**Figure 3D-13. Conceptual representation of the two-compartment model used by the MSS model.  $C$  is exposure concentration,  $V$  is ventilation rate,  $t$  is time,  $X$  is an intermediate quantity,  $a$  is a decay constant. Adapted from Figure 1 in McDonnell et al. (1999).**

$X$  is given by the solution of the differential Equation 3D-12:

$$\frac{dX}{dt} = C(t)V(t)^{\beta_6} - \beta_5 X(t) \quad \text{Equation 3D-12}$$

$X(t)$  increases with “normalized dose” ( $C \cdot V^{\beta_6}$ ) over time for an individual and allows for removal of “normalized dose” with a half-life of  $1/\beta_5$  through the 2<sup>nd</sup> term in Equation 3D-12.

<sup>75</sup> The MSS model used for the 2014 HREA (McDonnell et al., 2012) assumed intra-subject variability was constant for all exposures and responses. It had been shown previously that  $\text{FEV}_1$  response varies within individuals experiencing the same exposure and that the range of variation in response increases with higher exposure and response (McDonnell et al., 1983). Evaluations based on a goodness-of-fit test and visual inspection of observed versus predicted values indicate the most recent MSS model that better accounts for intra-subject variation is improved in its estimation capabilities when compared to the previous MSS model (McDonnell et al., 2013).

The response function  $\mathbf{M}$  is described in Equation 3D-13:

$$\mathbf{M}_{ijk} = (\beta_1 + \beta_2 A_{ik} + \beta_8 B_{ik}) \left\{ \frac{1}{1 + \beta_4 e^{-\beta_3 T_{ijk}}} - \frac{1}{1 + \beta_4} \right\} \quad \text{Equation 3D-13}$$

where,

$$T_{ijk} = \max\{0, X_{ijk} - \beta_9\} \quad \text{Equation 3D-14}$$

$\beta_9$  is a threshold parameter which allows  $\mathbf{X}$  to increase up to the threshold before the median response is allowed to exceed zero. By construction, when  $\mathbf{X} = 0$ , then  $\mathbf{M} = 0$ . Because  $\beta_3$  and  $\beta_4$  are positive, when  $\mathbf{X} > 0$  then  $\mathbf{M} > 0$ . Because  $\mathbf{X}$  is never negative, neither is  $\mathbf{M}$ . This model calculates the percent FEV<sub>1</sub> decrement due to O<sub>3</sub> exposure (compartment 2) as:

$$\% \Delta FEV1_{ijk} = e^{U_i} M_{ijk} + \varepsilon_{ijk} \quad \text{Equation 3D-15}$$

$$Var(\varepsilon_{ijk}) = v_1 + v_2 e^{U_i} M_{ijk} \quad \text{Equation 3D-16}$$

Note that a positive value of  $\% \Delta FEV1$  means a decrease in effective lung volume or a decrement in lung function. The above variance structure also allows for negative  $\% \Delta FEV1$  values or an increase in lung volume, i.e., an improvement in lung function. The indices  $i, j, k$  in Equations 3D-12 to 3D-16 refer to the  $i^{th}$  subject at the  $j^{th}$  time for the  $k^{th}$  exposure protocol for that subject, while the variables are defined as:

$t$  = time (minutes)

$t_0$  = time at the start of the event

$t_1$  = time at the end of the event

$C(t)$  = O<sub>3</sub> exposure (ppm) at time  $t$  during the event

$V_E(t)$  = expired minute volume (L min<sup>-1</sup>) at time  $t$

$BSA$  = body surface area (m<sup>2</sup>),

$V(t)$  =  $V_E(t)/BSA$  (L/min-m<sup>2</sup>) at time  $t$

$A_{ik}$  = age (years) of the  $i^{th}$  subject in the  $k^{th}$  exposure protocol minus 23.8, the mean age of the subjects

$B_{ik}$  = the body mass index (BMI, kg/m<sup>2</sup>) of the  $i^{th}$  subject in the  $k^{th}$  exposure protocol minus 23.1, the mean BMI of the subjects

$U_i$  = subject-level zero-mean Gaussian random effect error/variability term (between-individual variability not otherwise captured by the model)

$\varepsilon_{ijk}$  = Gaussian error/variability term, which includes measurement error and within-individual variability not otherwise captured by the model



$\nu_1$  ,  $\nu_2$  = constants used to parameterize the variance of  $\varepsilon_{ijk}$ .  $\nu_1$  captures the intra-individual noise in FEV<sub>1</sub> that is not due to ozone exposure, while  $\nu_2$  captures the remaining intra-individual variability in FEV<sub>1</sub>.

$\beta_1$  to  $\beta_9$  unitless fitted model parameters (constant for all simulated individuals)

In general, this model would be considered a non-linear random-effects model (Davidian and Giltinan, 2003). The best fit values (based on maximum likelihood) of the  $\beta$ s and the variances  $\{\varepsilon_{ijk}\}$  were estimated from fits of the model to the clinical data (see McDonnell et al., 2013) and are provided in Table 3D-21.

**Table 3D-21. Estimated coefficients for the MSS lung function model.**

| Values for MSS Model Coefficients Used in Equations 3D-12 to 3D-17 <sup>A</sup>                                    |           |           |           |           |           |           |           |         |         |                              |
|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|---------|---------|------------------------------|
| $\beta_1$  | $\beta_2$ | $\beta_3$ | $\beta_4$ | $\beta_5$ | $\beta_6$ | $\beta_8$ | $\beta_9$ | $\nu_1$ | $\nu_2$ | $\text{var}(U)$ <sup>B</sup> |
| 9.763  | -0.4315   | 0.01281   | 30.92     | 0.002921  | 0.9525    | 0.4890    | 32.94     | 9.112   | 2.166   | 1.123                        |
| <sup>A</sup> Based on "Model 3" from McDonnell et al. (2013).  |           |           |           |           |           |           |           |         |         |                              |
| <sup>B</sup> The random sampling from the $\text{var}(U)$ distribution was limited to $\pm 2$ standard deviations. |           |           |           |           |           |           |           |         |         |                              |

As described above in estimating exposure, APEX uses activity pattern data to represent a sequence of events that simulate the movement of a modeled person through geographical locations and microenvironments during the simulation period. Each of these events are defined by a geographic location, start time, duration, microenvironment visited, and activity performed. Events in APEX are intervals of constant activity and exposure concentration, where an individual is in one microenvironment and can range in duration from 1 to 60 minutes. In APEX, because the exposure concentration  $C(t)$ , exertion level, and normalized ventilation rate  $V(t)$  are constant over an event, Equation 3D-17 provides an analytic solution for each event:

$$X(t_1) = X(t_0)e^{-\beta_5(t_1-t_0)} + \frac{C(t_1)}{\beta_5}V(t_1)\beta_6(1 - e^{-\beta_5(t_1-t_0)}) \quad \text{Equation 3D-17}$$

Note that  $C(t_1)$  and  $V(t_1)$  denote the (constant) values of  $C(t)$  and  $V(t)$  during the event<sup>76</sup> from time  $t_0$  to time  $t_1$ . In APEX, values of  $U_i$  and  $\varepsilon_{ijk}$  are drawn from Gaussian distributions with mean zero and variances  $\text{var}(U)$  and  $\text{var}(\varepsilon)$ , constrained to be within  $\pm 2$  standard deviations from the means (when sampled values fall outside of this range, they are discarded and resampled).

<sup>76</sup> Events in APEX are intervals of constant activity and concentration, where an individual is in one microenvironment. Events range in duration from one to 60 minutes.  $C(t_1)$  and  $V(t_1)$  denote the (constant) values of  $C(t)$  and  $V(t)$  during the event from time  $t_0$  to time  $t_1$ .

1 The values of  $U_i$  are chosen once for each individual and remain constant for individuals  
2 throughout the simulation. Values for  $\varepsilon_{ijk}$  are sampled daily for each individual.

3 We are using this model to estimate lung function decrements for people ages 5 and  
4 older. However, this model was developed using only data from individuals aged 18 to 35 and  
5 the age adjustment term  $[\beta_1 + \beta_2 (Age_{ik} - 23.8)]$  in the numerator of Equation 3D-13 is not  
6 appropriate for all ages.<sup>77</sup> Clinical studies data for children which could be used to fit the model  
7 for children are not available at this time. In the absence of data, we are extending the model to  
8 ages 5 to 18 by holding the age term constant at the age 18 level. Since the response increases as  
9 age decreases in the range 18 to 35, this trend may extend into ages of children, in which case the  
10 responses of children could be underestimated. However, the slope of the age term in the MSS  
11 model is estimated based on data for ages 18 to 35 and does not capture differences in age trend  
12 within this range; in particular, we do not know at what age the response peaks, which could be  
13 above or below age 18. The evidence from clinical studies indicates that the responsiveness of  
14 children to  $O_3$  is about the same as for young adults (ISA, Appendix 3, section 3.1.4.1.1) This  
15 suggests that the age term for children should not be higher than the age term for young adults  
16 (2014 HREA).<sup>78</sup>

17 Because the responses to  $O_3$  continuously declines from age 18 to 55 and for ages >55 the  
18 response is generally considered minimal,<sup>79</sup> here we assume the MSS model age term for ages 35  
19 to 55 linearly decreases to zero and set it to zero for ages >55.<sup>80</sup> To extend the age term to ages  
20 outside the range of ages the MSS model is based on (ages 18-35), we re-parameterized the age  
21 term in the numerator of Equation 3D-13 by  $[\beta_1 + \beta_2(\alpha_1 \text{ Age} + \alpha_2)]$ , for different ranges of ages  
22 ( $\alpha_1$  and  $\alpha_2$  depend on age), requiring that these terms match at each boundary to form a piecewise  
23 linear continuous function of age. As a result, the values of  $\alpha_1$  and  $\alpha_2$  for four age ranges are  
24 provided in Table 3D-22.

---

<sup>77</sup> Note that the effect of age is also accounted for by using age-specific ventilation rate and body surface area. In addition, APEX lung function risk for different age groups is also influenced by the time spent outdoors and the activities engaged in by those groups, which vary by age.

<sup>78</sup> See 2014 HREA Chapter 6 (sections 6.4.2 and 6.5.3) and Appendices 6D and 6E for details.

<sup>79</sup> There is a recent 3-hr controlled human exposure study ( $EVR = 15\text{--}17 \text{ L/min-m}^2$  during six 15-min exercise periods) performed on healthy adults (ages  $59.9 \pm 4.5$ ) that found 3-hr  $O_3$  exposures of 120 ppb yielded a statistically significant reduction  $FEV_1$  when compared to the filtered air response (Arjomandi et al., 2018). How this relates to the magnitude and duration of exposures and ventilation rates of interest in this exposure and risk analysis remain uncertain at this time.

<sup>80</sup> “In healthy individuals, the fastest rate of decline in  $O_3$  responsiveness appears between the ages of 18 and 35 years ... During the middle age period (35-55 years),  $O_3$  sensitivity continues to decline, but at a much lower rate. Beyond this age (>55 years), acute  $O_3$  exposure elicits minimal spirometric changes.” (2013 ISA, p. 6-22)

**Table 3D-22. Age term parameters for application of the MSS model to all ages.**

| Age Range   | $\beta_1$ | $\beta_2$ | $\alpha_1$ | $\alpha_2$ |
|---|-----------|-----------|------------|------------|
| 5 – 17  | 9.763     | –0.4315   | 0          | –5.8       |
| 18 – 35   | 9.763     | –0.4315   | 1          | –23.8      |
| 36 – 55   | 9.763     | –0.4315   | 0.5714     | –8.8       |
| > 55  | 0         | –0.4315   | 0          | 0          |
| See Table 3D-21 for related MSS model coefficients. |           |           |            |            |

As described above for the population-based E-R function risk approach (section 3D.2.8.2.1), the individual-based MSS model risk approach also allows for decrements to occur at exposures below those tested/observed in the controlled human exposure studies, however, for this approach there is not a strict limit on the ventilation *per se*. Indeed, FEV<sub>1</sub> decrements are more likely to occur with high breathing rates (and concomitant with high exposures), but it is not necessary that an individual's 7-hr average EVR reach their particular threshold (EVR  $\geq 17.32 \pm 1.25$  L/min-m<sup>2</sup>) for an individual to experience an adverse response as is used for both the exposure benchmarks and the E-R function risk approach. The time-series of exposures, breathing rate, and FEV<sub>1</sub> will vary with each diary event, with FEV<sub>1</sub> non-linearly dependent on exposure levels/breathing rate from both the prior and current exposure/breathing events. That said in doing so, the MSS approach could overstate risk when including instances where both the exposures and ventilation rates are less than that tested/observed in the controlled human exposure studies.

### 3D.2.9 Assessing Variability/Co-Variability and Characterizing Uncertainty

An important issue associated with any population exposure and risk assessment is the assessment of variability and characterization of uncertainty. Variability refers to the inherent heterogeneity in a population or variable of interest (e.g., residential air exchange rates). The degree of variability cannot be reduced through further research, only better characterized with additional measurement. Uncertainty refers to the lack of knowledge regarding the values of model input variables (i.e., parameter uncertainty), the physical systems or relationships used (i.e., use of input variables to estimate exposure or risk or model uncertainty), and in specifying the scenario that is consistent with purpose of the assessment (i.e., scenario uncertainty). Uncertainty is, ideally, reduced to the maximum extent possible through improved measurement of key parameters and iterative model refinement.

Section 3D.2.9.1 summarizes how variability and co-variability are addressed in the current exposure and risk analysis and is based on the above described input data and model algorithms used. Section 3D.2.9.2 summarizes the overall approach used for the uncertainty

1 characterization. The outcome of the updated uncertainty characterization, which builds upon the  
2 important uncertainties identified in the IRP (Appendix 5A) and addressed in this current  
3 exposure and risk analyses, is discussed below in section 3D.3.4.

#### 4 **3D.2.9.1 Variability and Co-variability Assessment**

5 The goal in addressing variability in this exposure and risk analysis is to ensure that the  
6 estimates of exposure and risk reflect the variability of O<sub>3</sub> concentrations in ambient air,  
7 population characteristics, associated O<sub>3</sub> exposures, physiological characteristics of simulated  
8 individuals, and potential health risk across the study areas and for the simulated at-risk  
9 populations. The details regarding many of the variability distributions used as model inputs are  
10 described above, while details regarding the variability addressed within its algorithms and  
11 processes are found in the APEX User Guides (U.S. EPA, 2019a, U.S. EPA, 2019b).

12 APEX is designed to account for variability in the model input data, including the  
13 physiological variables that are important inputs to determining exertion levels and associated  
14 ventilation rates. APEX simulates individuals and then calculates O<sub>3</sub> exposure and lung function  
15 risk for each of these simulated individuals. This collection of probabilistically sampled  
16 individuals represents the variability of the target population, and by accounting for several types  
17 of variability, including demographic, physiological, and human behavior, APEX is able to  
18 represent much of the variability in the exposure and risk estimates. For example, variability may  
19 arise from differences in the population residing within census tracts (e.g., age distribution) and  
20 the activities that may affect population exposure to O<sub>3</sub> (e.g., time spent outdoors, performing  
21 moderate or greater exertion level activities outdoors). The range of exposure and associated risk  
22 estimates are intended to reflect such sources of variability, although we note that the range of  
23 values obtained reflects the input parameters, algorithms, and modeling system used, and may  
24 not necessarily reflect the complete range of the true exposure or risk values.

25 We note also that correlations and non-linear relationships between variables input to the  
26 model can result in the model producing inaccurate results if the inherent relationships between  
27 these variables are not preserved. APEX is designed to account for co-variability, or linear and  
28 nonlinear correlation among the model inputs, provided that enough is known about these  
29 relationships to specify them. This is accomplished by providing inputs that enable the  
30 correlation to be modeled explicitly within APEX. For example, there is a non-linear relationship  
31 between the outdoor temperature and air exchange rate in homes. One factor that contributes to  
32 this non-linear relationship is that windows tend to be closed more often when temperatures are  
33 at either low or high extremes than when temperatures are moderate. This relationship is  
34 explicitly modeled in APEX by specifying different probability distributions of air exchange  
35 rates for different ambient air temperatures. Note that where possible, we identified and

incorporated the observed variability in input data sets rather than employing standard default assumptions and/or using point estimates to describe model inputs. In any event, APEX models variability and co-variability in two ways:

- **Stochastically**. The user provides APEX with probability distributions characterizing the variability of many input parameters. These are treated stochastically in the model and the estimated exposure distributions reflect this variability. For example, the rate of O<sub>3</sub> decay in houses can depend on a number of factors which we are not able to explicitly model at this time, due to a lack of data. However, we can specify a distribution of removal rates that reflects observed variations in O<sub>3</sub> decay. APEX randomly samples from this distribution to obtain values that are used in the mass balance model. Further, co-variability can be modeled stochastically through the use of conditional distributions. If two or more parameters are related, conditional distributions that depend on the values of the related parameters are input to APEX. For example, the distribution of air exchange rates (AERs) in a house depends on the outdoor temperature and whether or not air conditioning (A/C) is in use. In this case, a set of AER distributions is provided to APEX for different ranges of temperatures and A/C use, and the selection of the distribution in APEX is driven by the temperature and A/C status at that time.
- **Explicitly**. For some variables used in modeling exposure, APEX models variability and co-variability explicitly and not stochastically. For example, the complete series of hourly ambient air O<sub>3</sub> concentrations and hourly temperatures are used in the exposure and risk calculations. These are input to the model continuously in the time period modeled at different spatial locations, and in this way the variability and co-variability of hourly O<sub>3</sub> concentrations and hourly temperatures are modeled explicitly.

Important sources of the variability and co-variability accounted for by APEX and used for this exposure and risk analysis are provided in Table 3D-23 and Table 3D-24, respectively.

**Table 3D-23. Summary of how variability was incorporated into the exposure and risk analysis.**

| Component                                     | Variability Source  | Summary  |
|---|---|--|
| Ambient Air Concentration Input (Appendix 3C) | CAMx Air Quality Modeling   | Spatial: model results are output at 12 km spatial resolution for the full CONUS domain.<br>Temporal: model results are calculated and archived at hourly resolution for the full 2016 calendar year.  |
|   | CAMx/HDDM estimates of 1-hr ambient air O <sub>3</sub> concentrations | Spatial: simulations of O <sub>3</sub> response to changes in emissions predicted to multiple monitors in eight geographically representative study areas.<br>Temporal: hourly O <sub>3</sub> for each of three years (2015-2017).   |
|   | Ambient air monitor hourly concentrations                             | Spatial: local ambient air monitor sites used to interpolate adjusted O <sub>3</sub> concentrations to census tracts, including monitors outside of the study area.<br>Temporal: pattern of hourly O <sub>3</sub> concentrations at census tracts also informed by local ambient air monitors. |

| Component  | Variability Source                        | Summary   |
|--|---|---|
| Simulated Individuals                              | Population data                           | Individuals are randomly sampled from U.S. census tracts used in each study area, stratified by age (single years) and sex probabilities (U.S. Census Bureau, 2012).  |
|  | Employment                                | Work status is randomly generated from U.S. census tracts, stratified by age and sex employment probabilities (U.S. Census Bureau, 2012).   |
|  | Activity pattern data                     | Data diaries used to represent locations visited and activities performed by simulated individuals are randomly selected from CHAD (nearly 180,000 diaries) using six diary pools stratified by two day-types (weekday, weekend) and three temperature ranges (< 55.0 °F, between 55.0 and 83.9 °F, and ≥84.0 °F). CHAD diaries capture real locations that people visit and the activities they perform, ranging from 1-min to 1-hr in duration (U.S. EPA, 2019c). |
|  | Commuting data                            | Employed individuals are probabilistically assigned ambient air concentrations originating from either their home or work block based on U.S. Census derived tract-level commuter data (U.S. DOT, 2012; U.S. Census Bureau, 2012).  |
|  | Longitudinal profiles                     | A sequence of diaries is linked together for each individual that preserves both the inter- and intra-personal variability in human activities (Glen et al., 2008).   |
|  | Asthma prevalence                         | Asthma prevalence is stratified by sex, single age years for children (5-17), seven adult age groups, (18-24, 25-34, 35-44, 45-54, 55-64, 65-74, and, ≥75), three regions (Midwest, Northeast, and South), and U.S. Census tract level poverty ratios (Attachment 1).   |
| Physiological Factors Relevant to Ventilation Rate | Resting metabolic rate                    | Five age-group and two sex-specific regression equations, use body mass and age as independent variables (U.S. EPA (2018), Appendix H).   |
|  | Metabolic equivalents by activity         | Randomly sampled from distributions developed for specific activities (some age-specific) (U.S. EPA, 2019c)   |
|  | Oxygen uptake per unit of energy expended | Randomly sampled from a uniform distribution to convert energy expenditure to oxygen consumption (U.S. EPA, 2019a, U.S. EPA, 2019b).  |
|  | Body mass                                 | Randomly selected from population-weighted lognormal distributions with age- and sex-specific geometric mean (GM) and geometric standard deviation (GSD) derived from the National Health and Nutrition Examination Survey (NHANES) for the years 2009-2014 (U.S. EPA (2018), Appendix G).  |
|  | Body surface area                         | Sex-specific exponential equations using body mass as an independent variable (Burmaster, 1998).  |
|  | Height                                    | Randomly sampled from population-weighted normal distributions stratified by single age years and two sexes developed from 2009-2014 NHANES data (U.S. EPA (2018), Appendix G).   |
|  | Ventilation rate                          | Event-level activity-specific regression equation using oxygen consumption rate (VO <sub>2</sub> ) and maximum VO <sub>2</sub> as independent variables, and accounting for intra- and inter-personal variability (U.S. EPA (2018), Appendix H).  |
|  | Fatigue and EPOC                          | APEX approximates the onset of fatigue, controlling for unrealistic or excessive exercise events in an individual's activity time-series while also estimating excess post-exercise oxygen consumption (EPOC) that may occur following vigorous exertion activities using several equations and   |

| Component                   | Variability Source                          | Summary   |
|-----------------------------|---|---|
|                             |   | input variable distributions (Isaacs et al., 2007; U.S. EPA, 2019a; U.S. EPA, 2019b).   |
|                             | Equivalent ventilation rate                 | A randomly sampled value is selected for each simulated individual from a normal distribution derived from the controlled human exposure study data. This approach accounts for interpersonal variability in exertion level that occur during exposure events that include exercise and rest periods (Attachment 2).  |
| Microenvironmental Approach | General                                     | Seven total microenvironments are represented, including those expected to be associated with high exposure concentrations (i.e., outdoors and outdoor near-road). There is variability in particular microenvironmental algorithm inputs. This results in differential exposures for each individual (and event) because people spend varying amounts of time within each microenvironment and ambient air concentrations vary within and among study areas.                                   |
|                             | Spatial Variability                         | Ambient air concentrations used in microenvironmental algorithms vary spatially within (i.e., census tracts) and among study areas (U.S. geographic regions).   |
|                             | Temporal Variability                        | All exposure calculations are performed at the event-level when using either factors or mass balance approach (durations can be as short as one minute). For the indoor microenvironments, using a mass balance model accounts for O <sub>3</sub> concentrations occurring during a previous hour (and of ambient air origin) to calculate a current event's indoor O <sub>3</sub> concentrations.  |
|                             | Air exchange rates                          | For residences, several lognormal distributions are sampled for up to five daily mean temperature ranges, study area region (2014 HREA Appendix 5E) and using study-area specific A/C prevalence rates from AHS survey data (U.S. Census Bureau, 2019). For restaurants, a lognormal distribution is sampled based on Bennett et al. (2012). For schools, a Weibull distribution is sampled based on data from Lagus Applied Technology (1995), Shendell et al. (2004), and Turk et al. (1989). |
|                             | Removal rates                               | Values randomly selected from a lognormal distribution for the three indoor microenvironments modeled (Lee et al., 1999).   |
|                             | PE and PROX factors                         | Penetration and proximity factors randomly sampled from probability distributions for inside-vehicle and near-road microenvironments (American Petroleum Institute (1997), Appendix B; Johnson et al., 1995).   |
| Lung Function Risk          | Population-based Exposure Response Function | A continuous E-R function was derived using data from several controlled human exposure studies and a logit-linear modeling approach. The full distribution of population exposures was stratified by fine-scale bins (10 ppb) and linked to the continuous E-R function to estimate lung function risk.  |
|                             | Individual-based MSS model                  | Calculation accounts for variability in age, body mass, and the continuous time-series of exposures and breathing rates. Residual terms (U and ) addresses intra- and inter-variability in responses across the simulated population.   |

1  
2

**Table 3D-24. Important components of co-variability in exposure modeling.**

| Type of Co-variability  | Modeled by APEX? | Treatment in APEX / Comments   |
|---|------------------|--|
| Within-person correlations <sup>A</sup>   | Yes              | Sequence of activities performed, microenvironments visited, and general physiological parameters (body mass, height, ventilation rates).  |
| Between-person correlations   | No               | Perhaps not important, assuming the same likelihood of the population of individuals either avoiding or experiencing an exposure event based on a social (group) activity.                                     |
| Correlations between profile variables and microenvironment parameters  | Yes              | Profiles are assigned microenvironment parameters.   |
| Correlations between demographic variables and activities   | Yes              | Census tract demographic variables, appropriately weighted and stratified by age and sex, are used in activity diary selection.  |
| Correlations between activities and microenvironment parameters   | No               | Perhaps important, but do not have data. For example, frequency of opening windows when cooking or smoking tobacco products.   |
| Correlations among microenvironment parameters in the same microenvironment   | Yes              | Modeled with joint conditional variables.  |
| Correlations between demographic variables and air quality  | Yes              | Modeled with the spatially varying census tract demographic variables (age and sex) and census tract air quality data input to APEX.   |
| Correlations between meteorological variables and activities  | Yes              | Daily varying temperatures are used in activity diary selection.   |
| Correlations between meteorological variables and microenvironment parameters   | Yes              | The distributions of microenvironment parameters can be functions of temperature.  |
| Correlations between drive times in CHAD and commute distances traveled   | Yes              | CHAD diary selection is weighted by commute times for employed persons during weekdays.  |
| Consistency of occupation/school microenvironmental time and time spent commuting/busing for individuals from one working/school day to the next. | No               | Simulated individuals are assigned activity diaries longitudinally without regard to occupation or school schedule (note though, longitudinal variable used to develop annual profile is time spent outdoors). |
| <sup>A</sup> The term correlation is used to represent linear and nonlinear relationships.  |                  |  |

### 3D.2.9.2 Approach for Uncertainty Characterization

While it may be possible to capture a range of exposure or risk values by accounting for variability inherent to influential factors, the true exposure or risk for any given individual within a study area may be unknown, although it can be estimated. To characterize health risks, exposure and risk assessors commonly use an iterative process of gathering data, developing models, estimating exposures and risks, evaluating results for correctness and identifying areas for potential improvement, given the goals of the assessment, scale and complexity of the assessment performed, and limitations of the input data available. However, important



1 uncertainties often remain in any one of the data sets, tools, and approaches used and emphasis is  
2 then placed on characterizing the nature of that uncertainty and its impact on exposure and risk  
3 estimates.

4 The overall approach used for this exposure and risk generally follows that described by  
5 WHO (2008) but varies in that a greater focus has been placed on evaluating the direction and  
6 the magnitude of the uncertainty. This refers to qualitatively rating how the source of  
7 uncertainty, in the presence of alternative information, may affect the estimated exposures and  
8 health risk results. Following the identification of key uncertainties, we subjectively scale the  
9 overall impact of the identified uncertainty by considering the relationship between the source of  
10 uncertainty and the exposure concentrations (e.g., low, medium, or high potential impact). Also  
11 to the extent possible, we include an assessment of the direction of influence, indicating how the  
12 source of uncertainty may be affecting exposure or risk estimates (e.g., the uncertainty could lead  
13 to over-estimates, under-estimates, or both directions). Further, and consistent with the WHO  
14 (2008) guidance, we discuss the uncertainty in the knowledge-base (e.g., the accuracy of the data  
15 used, recognition of data gaps) and, where possible, particular assessment design decisions (e.g.,  
16 selection of particular model forms). The output of the uncertainty characterization is a summary  
17 that describes, for each identified source of uncertainty, the magnitude of the impact and the  
18 direction of influence the uncertainty may have on the exposure and risk results.

19 We further recognize that uncertainties associated with APEX exposure modeling have  
20 been previously characterized in the REAs for nitrogen dioxide (NO<sub>2</sub>), carbon monoxide (CO)  
21 and sulfur dioxide (SO<sub>2</sub>) conducted for recent primary NAAQS reviews, along with other  
22 pollutant-specific issues (U.S. EPA, 2008, 2010, 2014, 2018), all complementary to quantitative  
23 uncertainty characterizations conducted for the 2007 O<sub>3</sub> exposure assessment by Langstaff  
24 (2007). Conclusions drawn from each of these characterizations are also considered here in light  
25 of new information, data, tools, and approaches used in this exposure and risk analysis.

### 26 **3D.3 POPULATION EXPOSURE AND RISK RESULTS**

27 Exposure and risk results are presented here for simulated populations residing in the  
28 eight study areas – Atlanta, Boston, Dallas, Detroit, Philadelphia, Phoenix, Sacramento, and St.  
29 Louis – for a three-year air quality scenario in which air quality conditions just meet the current  
30 primary 8-hr O<sub>3</sub> standard (70 ppb, annual 4<sup>th</sup> highest daily maximum 8-hr average concentration,  
31 averaged across 3-years) and two other air quality scenarios (i.e., design values of 75 and 65  
32 ppb). Hourly concentrations of O<sub>3</sub> in ambient air for the three hypothetical air quality scenarios  
33 are estimated at census tracts in each study area as described in section 3D.2 above. Population  
34 exposure and risk associated with these concentrations is estimated using the APEX model  
35 simulations (section 3D.2) and is briefly described with the following.

APEX uses the hourly air quality surface in each study area, along with U.S. census tract population demographics, to estimate the number of days per year each simulated individual in a particular study area experiences a daily maximum 7-hr average O<sub>3</sub> exposure at or above benchmark levels of 60, 70, and 80 ppb (section 3D.2.8.1). These short-term exposures were evaluated for children (5-18 years old), adults (>18 years old), and those with asthma within each of these two study groups when the exposure corresponded with moderate or greater exertion (i.e., the individual's EVR  $\geq 17.32 \pm 1.25$  L/minute-m<sup>2</sup>).

Then, individuals expected to experience a lung function decrement (i.e., reduction in FEV<sub>1</sub>  $\geq 10\%$ ,  $\geq 15\%$ ,  $\geq 20\%$ ) were estimated using two approaches. The first approach linked the population-based daily maximum 7-hr exposures while at moderate or greater exertion with an exposure-response function derived from controlled human exposure study data (section 3D.2.8.2.1). The second lung function risk approach, considered an individual-based approach here, used the McDonnell-Stewart-Smith (MSS) FEV<sub>1</sub> model (McDonnell et al., 2013) (section 3D.2.8.2.2). The MSS uses the time-series of O<sub>3</sub> exposure and corresponding ventilation rates for each APEX simulated individual to estimate their personal time-series of FEV<sub>1</sub> reductions, selecting the daily maximum reduction for each person. The number of individuals estimated to experience decrements are then aggregated to the population level. Again, of interest for both of these lung function risk approaches is the number of days per year each simulated individual in a particular study area experiences a lung function decrement.

Study area characteristics and the composition of the simulated population are provided in section 3D.3.1. Exposure results are presented in a series of tables that allow for simultaneous comparison of the exposure and risk metrics across the eight study areas and three simulation years. Two types of results are provided for each study area: the percent (and number) of the simulated population exposed at or above selected benchmarks, stratified by the number of occurrences (i.e., days) in a year (section 3D.3.2) and the percent (and number) of the simulated population experiencing a reduction in FEV<sub>1</sub>  $\geq 10\%$ ,  $\geq 15\%$ ,  $\geq 20\%$ , also stratified by the number of days in a year (section 3D.3.3). Tables summarizing all of the exposure and risk results for each study area are provided in Attachment 4.

### **3D.3.1 Characteristics of the Simulated Population and Study Areas**

The eight study areas differ in population, geographic size, and demographic features (Table 3D-25). In each of the eight study areas, APEX simulated O<sub>3</sub> exposures and risks for 60,000 individuals,<sup>81</sup> the demographic features of which were based on the information

---

<sup>81</sup> While precisely 60,000 children and 60,000 adults were simulated as part of each APEX model run, the number of individuals estimated to be exposed are appropriately weighted to reflect the actual population residing within the census tracts that comprise each respective study area.

1 associated with the hundreds to thousands of census tracts within each area (as described in  
2 section 3D.2.1 above).

3 Asthma prevalence in each modeling domain was estimated based on the 2013-2017  
4 NHIS asthma prevalence data and the demographic characteristics for each study area (e.g., age,  
5 sex and family income) using the methodology summarized in section 3D.2.2.2. Accordingly,  
6 the percent of the simulated populations with asthma within the exposure modeling domain  
7 varied by study area (Table 3D-25). The Dallas, Phoenix, and Sacramento study areas had the  
8 lowest percent of children with asthma (9.2 to 9.6%), while Atlanta and Boston had the highest  
9 percent of children with asthma (11.8 to 12.3%). The Dallas study area had the lowest percent of  
10 adults with asthma (7.2%), while Boston and Detroit had the highest percent of adults with  
11 asthma (both 10.9%). The statistics presented here are the aggregate of the study area as a whole,  
12 within which asthma prevalence varied widely as the modeling approach fully accounted for the  
13 variation in asthma prevalence across census tracts with demographic factors such as family  
14 income to poverty ratios, age, and sex (and as described in section 3D.2.2.2).<sup>82</sup> Nationally,  
15 asthma prevalence is 7.9%; for children it is 8.4% and for adults it is 7.7% (Chapter 3, Table 3-  
16 1). The asthma prevalence for children, adults, and the total population estimated for each of the  
17 eight study areas are all greater than that of the national asthma prevalence, except for adults in  
18 Dallas which has a slightly lower asthma prevalence. This suggests that overall, the at-risk  
19 population simulated in the eight study areas could represent at-risk populations in other U.S.  
20 urban areas that have a similarly above average asthma prevalence.

---

<sup>82</sup> Representing the variation in asthma prevalence that occurs at the census tract level provides a level of resolution for identification of at-risk individuals that is directly compatible with the resolution of the spatially varying ambient air concentrations. In this way, the population in census tracts with higher concentrations is represented appropriately with regard to asthma prevalence and exposures of the at-risk individuals with asthma are not under-represented.

1 **Table 3D-25. Summary of study area features and the simulated population.**

| Study Area<br>(Land Area – km <sup>2</sup> ) <sup>A</sup> | Population<br>Group<br>(age range) | Simulated<br>Population | Simulated<br>Population with<br>Asthma | % of Simulated<br>Population with<br>Asthma |
|---|------------------------------------|-------------------------|--|---|
| Atlanta<br>(30,655)                                       | Children (5-18)                    | 1,210,594               | 142,400                                | 11.8  |
|   | Adults (19-90)                     | 4,226,009               | 359,375                                | 8.5   |
|   | All (5-90)                         | 5,436,603               | 501,775                                | 9.2   |
| Boston<br>(25,117)  | Children (5-18)                    | 1,365,267               | 167,617                                | 12.3  |
|   | Adults (19-90)                     | 5,870,125               | 642,224                                | 10.9  |
|   | All (5-90)                         | 7,235,392               | 809,841                                | 11.2  |
| Dallas<br>(42,664)  | Children (5-18)                    | 1,418,728               | 130,421                                | 9.2   |
|   | Adults (19-90)                     | 4,688,180               | 336,898                                | 7.2   |
|   | All (5-90)                         | 6,106,908               | 467,319                                | 7.7   |
| Detroit<br>(16,884)                                       | Children (5-18)                    | 1,040,588               | 116,899                                | 11.2  |
|   | Adults (19-90)                     | 3,932,484               | 427,221                                | 10.9  |
|   | All (5-90)                         | 4,973,072               | 544,119                                | 10.9  |
| Philadelphia<br>(18,959)                                  | Children (5-18)                    | 1,309,547               | 146,982                                | 11.2  |
|   | Adults (19-90)                     | 5,228,541               | 503,305                                | 9.6   |
|   | All (5-90)                         | 6,538,088               | 650,287                                | 9.9   |
| Phoenix<br>(34,799)                                       | Children (5-18)                    | 849,200                 | 81,396                                 | 9.6   |
|   | Adults (19-90)                     | 2,980,062               | 269,845                                | 9.1   |
|   | All (5-90)                         | 3,829,262               | 351,240                                | 9.2   |
| Sacramento<br>(18,871)                                    | Children (5-18)                    | 465,845                 | 45,208                                 | 9.7   |
|   | Adults (19-90)                     | 1,715,065               | 138,253                                | 8.1   |
|   | All (5-90)                         | 2,180,910               | 183,461                                | 8.4   |
| St. Louis<br>(23,019)                                     | Children (5-18)                    | 546,393                 | 56,039                                 | 10.3  |
|   | Adults (19-90)                     | 2,146,037               | 203,039                                | 9.5   |
|   | All (5-90)                         | 2,692,430               | 259,078                                | 9.6   |
| All Study Areas<br>Combined                               | Children (5-18)                    | 8,206,162               | 886,960                                | 10.8  |
|   | Adults (19-90)                     | 30,786,503              | 2,880,160                              | 9.4   |
|   | All (5-90)                         | 38,992,665              | 3,767,120                              | 9.7   |
| <sup>A</sup> From Appendix 3C, Table 3C-1.                |                                    |                         |  |   |

### 2 **3D.3.2 Exposures at or above Benchmark Concentrations**

3 The exposure to benchmark comparisons are presented in a series of tables focusing on  
4 the benchmark levels (i.e., people experiencing daily maximum 7-hr average O<sub>3</sub> exposures ≥60,  
5 70, and 80 ppb while at moderate or greater exertion). The full range of ambient air O<sub>3</sub>  
6 concentrations for a 3-year O<sub>3</sub> season (2015-2017) were used by APEX, providing a range of  
7 estimated exposures. Adjusted air quality surfaces used to represent three air quality scenarios  
8 were developed using 2015-2017 design values modeled sensitivities to changes in precursor  
9 emissions (section 3D.2.3.3), and then interpolated to census tract centroids (section 3D.2.3.4).

Exposures were estimated for four study groups of interest (i.e., school-age children (5-18), school-age children with asthma, adults (19-90), and adults with asthma).

In this exposure and risk analysis, we are primarily interested in O<sub>3</sub> exposures associated with the ambient air quality adjusted to just meet the current standard (70 ppb, annual 4<sup>th</sup> highest daily maximum 8-hr average concentration, averaged over a 3-year period). Provided are the percent and number of people in each study group estimated to experience 7-hr exposures at or above the benchmarks, while at moderate or greater exertion (section 3D.3.2.1). For each exposure metric and study group, the occurrence of single-day (at least one day per year) and multi-day (at least 2, 4, or 6 days per year) exposures are presented. Exposure results for the two other adjusted air quality scenarios (the 75 ppb and 65 ppb scenarios) are presented in sections 3D.3.2.2 and 3D.3.2.3, respectively. These two sections present only the percent of each study group estimated to experience exposures at or above benchmarks while at moderate or greater exertion, for single-day and multiday exposures during a year, and not also the number of simulated individuals in each study group. The complete exposure results associated with all simulated years, air quality scenarios, the four study groups, and eight study areas are found in Attachment 4.

In general, and for all air quality scenarios, the percent of children estimated to experience exposures at or above any of the benchmarks is consistently higher than that estimated for adults. This is expected because children spend a greater amount of time outdoors, and at a greater frequency, while at moderate or greater exertion when compared to adults (2014 HREA, sections 5.4.1 and 5.4.2). Estimated exposures for healthy people are similar to people with asthma when considered on a percent of population basis. This is because similar diary data are used to simulate the activity patterns of each study group, justified by evaluations that indicated similarities in time spent outdoors, participation rate, and exertion level for people with asthma when compared to healthy individuals (section 3D.2.5.3). When considering the estimated exposures in terms of population counts, while children comprise about 20% of the simulated population (Table 3D-25), the number of children experiencing exposures at or above the benchmarks is greater than that of adults. Again, this a direct result of the differences in time spent outdoors performing activities at elevated exertion. And finally, Detroit, Phoenix, and St. Louis have a higher percent of individuals at or above benchmark levels relative to the other study areas, likely influenced by their having an hourly O<sub>3</sub> concentration distribution shape that, overall, is more skewed to the right and/or has heavy tails at the uppermost percentiles (Figure 3D-7).

### 3D.3.2.1 Air Quality Just Meeting the Current Standard

With air quality adjusted to just meet the current standard, 0 to  $\leq 0.1\%$  of people in all study groups were estimated to experience at least one daily maximum 7-hr exposure per year at or above the 80-ppb benchmark (Table 3D-26). The occurrence of 7-hr O<sub>3</sub> exposures at or above 70-ppb are also limited, even considering the worst year air quality in the three-year period, with 1% or fewer children (and children with asthma) in all study areas estimated to experience at least one daily maximum 7-hr exposure per year at or above the 70-ppb benchmark. For the same benchmark, 0.2% or fewer adults (and adults with asthma) were estimated to experience similar exposures when considering the worst air quality year. When considering the 60-ppb benchmark, on average, between about 3 to 9% of children (and children with asthma) experienced at least one daily maximum 7-hr exposure at or above that benchmark, while during the worst air quality year, the range in percent of children exposed extends slightly upwards (about 4 to 11%), indicating limited variability in ambient air concentrations across the three-year period. Again, there were fewer adults (and adults with asthma) exposed considering this same benchmark, on average ranging from 0.2 to 1.5% of this study group and the worst air quality year ranging from 0.2 to 1.8%.

The number of simulated people in each study group estimated to experience at least one 7-hr exposure per year at or above the benchmarks is provided in Table 3D-27. As noted above, there are few simulated people expected to experience a 7-hr exposure at or above the 80-ppb benchmark, at most about 1,200 children and 500 adults when considering the worst year in a single study area. Regarding the 70-ppb benchmark, on average, between about 700 to 8,300 children are estimated to experience at least one 7-hr exposure at or above that benchmark, while the range for adults is about half that of children (400 to about 3,700), the range of which considers the eight study areas. When considering the worst year, fewer than 12,000 children and 7,700 adults are estimated to experience at least one 7-hr exposure at or above the 70-ppb benchmark in each study area. On average, the number of children estimated to experience at least one 7-hr O<sub>3</sub> exposure at or above the 60-ppb benchmark could be as high as nearly 70,000 in a few study areas, while for adults the number is just below 45,000. During the worst air quality year, the estimated number of people experiencing at least one exposure at or above this same benchmark could be as high as about 100,000 for children and 63,000 for adults. As a whole, the patterns for people with asthma are similar though having smaller counts, the value of which is dictated by the asthma prevalence in each area (Table 3D-25). In general, the number of children with asthma at or above a benchmark would be about 10.8% of that estimated for all children, while the number adults with asthma at or above a benchmark is about 9.4% of that estimated for all adults.

1 Multiday exposures are limited when considering air quality adjusted to just meet the  
2 current standard. For example, there are no children estimated to experience at least two days  
3 with 7-hr O<sub>3</sub> exposures at or above the 80-ppb benchmark and ≤0.1% at or above the 70-ppb  
4 benchmark (Table 3D-28 and Table 3D-29). When considering the worst air quality year, <5% of  
5 children (and ≤0.4% of adults) are estimated to experience at least two days with 7-hr O<sub>3</sub>  
6 exposures at or above the 60-ppb benchmark. There are no people estimated to experience at  
7 least four days with 7-hr O<sub>3</sub> exposures at or above the 70-ppb benchmark except in one study  
8 area (Table 3D-30 and Table 3D-31), and ≤0.5% experience at least six days with 7-hr O<sub>3</sub>  
9 exposures at or above the 60-ppb benchmark (Attachment 4).

10

**Table 3D-26. Percent of people estimated to experience at least one exposure at or above benchmarks while at moderate or greater exertion, for air quality adjusted to just meet the current standard.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|--|-----|------|--|------|------|--|------|------|
|                      |              | Avg  | Min | Max  | Avg  | Min  | Max  | Avg  | Min  | Max  |
| Children             | Atlanta      | 3.3  | 1.4 | 5.2  | 0.4  | 0.1  | 0.8  | <0.1   | 0    | 0.1  |
|                      | Boston       | 4.4  | 3.4 | 6.0  | 0.6  | 0.4  | 0.9  | <0.1   | <0.1 | <0.1 |
|                      | Dallas       | 4.9  | 2.4 | 6.8  | 0.4  | 0.2  | 0.7  | <0.1   | 0    | <0.1 |
|                      | Detroit      | 6.7  | 5.0 | 9.2  | 0.5  | 0.1  | 0.9  | <0.1   | 0    | <0.1 |
|                      | Philadelphia | 4.1  | 3.9 | 4.2  | 0.4  | 0.3  | 0.4  | <0.1   | 0    | <0.1 |
|                      | Phoenix      | 8.2  | 6.0 | 10.6 | 0.2  | <0.1 | 0.6  | 0  | 0    | 0    |
|                      | Sacramento   | 3.2  | 2.3 | 3.9  | 0.2  | 0.1  | 0.3  | 0  | 0    | 0    |
|                      | St. Louis    | 6.0  | 4.1 | 8.7  | 0.4  | 0.1  | 0.9  | <0.1   | 0    | <0.1 |
| Children with Asthma | Atlanta      | 3.6  | 1.5 | 5.8  | 0.5  | 0.1  | 0.9  | <0.1   | 0    | 0.1  |
|                      | Boston       | 5.1  | 3.7 | 7.0  | 0.7  | 0.5  | 1.0  | <0.1   | 0    | 0.1  |
|                      | Dallas       | 5.3  | 2.2 | 7.4  | 0.4  | 0.3  | 0.7  | <0.1   | 0    | <0.1 |
|                      | Detroit      | 7.3  | 5.4 | 10.0 | 0.5  | 0.1  | 0.9  | 0  | 0    | 0    |
|                      | Philadelphia | 4.3  | 4.1 | 4.4  | 0.4  | 0.4  | 0.4  | 0  | 0    | 0    |
|                      | Phoenix      | 8.8  | 6.6 | 11.2 | 0.3  | 0    | 0.7  | 0  | 0    | 0    |
|                      | Sacramento   | 3.3  | 2.6 | 4.0  | 0.2  | 0.1  | 0.3  | 0  | 0    | 0    |
|                      | St. Louis    | 6.0  | 3.9 | 9.0  | 0.3  | <0.1 | 0.8  | <0.1   | 0    | <0.1 |
| Adults               | Atlanta      | 0.5  | 0.2 | 0.8  | 0.1  | <0.1 | 0.1  | <0.1   | 0    | <0.1 |
|                      | Boston       | 0.5  | 0.3 | 0.8  | 0.1  | <0.1 | 0.1  | <0.1   | <0.1 | <0.1 |
|                      | Dallas       | 0.8  | 0.3 | 1.2  | <0.1   | <0.1 | 0.1  | <0.1   | 0    | <0.1 |
|                      | Detroit      | 1.0  | 0.8 | 1.6  | 0.1  | <0.1 | 0.2  | 0  | 0    | 0    |
|                      | Philadelphia | 0.5  | 0.5 | 0.5  | <0.1   | <0.1 | <0.1 | <0.1   | 0    | <0.1 |
|                      | Phoenix      | 1.5  | 1.1 | 1.8  | <0.1   | <0.1 | 0.1  | 0  | 0    | 0    |
|                      | Sacramento   | 0.4  | 0.3 | 0.5  | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    |
|                      | St. Louis    | 0.9  | 0.5 | 1.3  | <0.1   | <0.1 | 0.1  | 0  | 0    | 0    |
| Adults with Asthma   | Atlanta      | 0.4  | 0.2 | 0.6  | <0.1   | 0    | <0.1 | 0  | 0    | 0    |
|                      | Boston       | 0.4  | 0.2 | 0.7  | <0.1   | 0    | 0.1  | <0.1   | 0    | <0.1 |
|                      | Dallas       | 0.6  | 0.2 | 0.9  | <0.1   | 0    | 0.1  | 0  | 0    | 0    |
|                      | Detroit      | 0.8  | 0.6 | 1.2  | 0.1  | <0.1 | 0.2  | 0  | 0    | 0    |
|                      | Philadelphia | 0.4  | 0.3 | 0.5  | <0.1   | 0    | 0.1  | 0  | 0    | 0    |
|                      | Phoenix      | 1.3  | 1.0 | 1.5  | <0.1   | 0    | <0.1 | 0  | 0    | 0    |
|                      | Sacramento   | 0.2  | 0.2 | 0.2  | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    |
|                      | St. Louis    | 0.7  | 0.4 | 1.2  | <0.1   | 0    | 0.1  | 0  | 0    | 0    |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".



**Table 3D-27. Number of people estimated to experience at least one exposure at or above benchmarks while at moderate or greater exertion, for air quality adjusted to just meet the current standard.**

| Study Group  | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |       |       | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |      |       | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |     |      |
|--|--------------|--|-------|-------|--|------|-------|--|-----|------|
|  |              | Avg  | Min   | Max   | Avg  | Min  | Max   | Avg  | Min | Max  |
| Children   | Atlanta      | 39909  | 17291 | 63455 | 5199   | 1069 | 9947  | 464  | 0   | 1211 |
|  | Boston       | 59549  | 46465 | 81939 | 8305   | 5438 | 11923 | 372  | 91  | 592  |
|  | Dallas       | 69794  | 34499 | 96261 | 5864   | 3168 | 9718  | 173  | 0   | 284  |
|  | Detroit      | 69627  | 52203 | 95509 | 5093   | 1492 | 9487  | 29   | 0   | 52   |
|  | Philadelphia | 53117  | 51116 | 54674 | 4656   | 4191 | 5151  | 44   | 0   | 87   |
|  | Phoenix      | 69569  | 50754 | 89775 | 1953   | 269  | 4784  | 0  | 0   | 0    |
|  | Sacramento   | 14928  | 10645 | 18378 | 727  | 272  | 1203  | 0  | 0   | 0    |
|  | St. Louis    | 32841  | 22320 | 47609 | 2331   | 446  | 4863  | 12   | 0   | 36   |
| Children with Asthma   | Atlanta      | 5152   | 2078  | 8333  | 666  | 141  | 1271  | 67   | 0   | 202  |
|  | Boston       | 8518   | 6166  | 11605 | 1145   | 796  | 1616  | 61   | 0   | 114  |
|  | Dallas       | 6952   | 2908  | 9813  | 576  | 355  | 946   | 8  | 0   | 24   |
|  | Detroit      | 8544   | 6209  | 11776 | 578  | 121  | 1110  | 0  | 0   | 0    |
|  | Philadelphia | 6264   | 6024  | 6504  | 597  | 524  | 655   | 0  | 0   | 0    |
|  | Phoenix      | 7171   | 5336  | 9143  | 226  | 0    | 552   | 0  | 0   | 0    |
|  | Sacramento   | 1517   | 1157  | 1871  | 93   | 54   | 155   | 0  | 0   | 0    |
|  | St. Louis    | 3364   | 2195  | 4927  | 191  | 18   | 437   | 3  | 0   | 9    |
| Adults   | Atlanta      | 21318  | 9790  | 34160 | 2512   | 282  | 5001  | 117  | 0   | 352  |
|  | Boston       | 30362  | 19274 | 48429 | 3391   | 2152 | 5283  | 294  | 98  | 489  |
|  | Dallas       | 36646  | 14611 | 54461 | 2318   | 1328 | 4141  | 26   | 0   | 78   |
|  | Detroit      | 40920  | 30215 | 62264 | 3692   | 1049 | 7668  | 0  | 0   | 0    |
|  | Philadelphia | 26375  | 25184 | 27973 | 1597   | 1481 | 1830  | 29   | 0   | 87   |
|  | Phoenix      | 44552  | 33178 | 54585 | 745  | 149  | 1788  | 0  | 0   | 0    |
|  | Sacramento   | 7318   | 4688  | 9176  | 400  | 229  | 600   | 0  | 0   | 0    |
|  | St. Louis    | 18981  | 11016 | 28185 | 942  | 72   | 2075  | 0  | 0   | 0    |
| Adults with Asthma   | Atlanta      | 1385   | 775   | 2113  | 70   | 0    | 141   | 0  | 0   | 0    |
|  | Boston       | 2544   | 1370  | 4207  | 294  | 0    | 685   | 65   | 0   | 98   |
|  | Dallas       | 2109   | 781   | 3047  | 104  | 0    | 234   | 0  | 0   | 0    |
|  | Detroit      | 3299   | 2425  | 5047  | 306  | 66   | 655   | 0  | 0   | 0    |
|  | Philadelphia | 2179   | 1569  | 2614  | 87   | 0    | 261   | 0  | 0   | 0    |
|  | Phoenix      | 3377   | 2831  | 3973  | 50   | 0    | 99    | 0  | 0   | 0    |
|  | Sacramento   | 295  | 257   | 343   | 38   | 29   | 57    | 0  | 0   | 0    |
|  | St. Louis    | 1395   | 787   | 2325  | 72   | 0    | 179   | 0  | 0   | 0    |
| <sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals exposed at the level). |              |  |       |       |  |      |       |  |     |      |

**Table 3D-28. Percent of people estimated to experience at least two exposures at or above benchmarks while at moderate or greater exertion, for air quality adjusted to just meet the current standard.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|--|------|------|--|------|------|--|-----|-----|
|                      |              | Avg  | Min  | Max  | Avg  | Min  | Max  | Avg  | Min | Max |
| Children             | Atlanta      | 0.6  | 0.1  | 1.1  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Boston       | 0.8  | 0.5  | 1.4  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0   |
|                      | Dallas       | 1.2  | 0.4  | 2.1  | <0.1   | <0.1 | 0.1  | 0  | 0   | 0   |
|                      | Detroit      | 1.7  | 1.0  | 2.8  | <0.1   | <0.1 | 0.1  | 0  | 0   | 0   |
|                      | Philadelphia | 0.8  | 0.7  | 0.9  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0   |
|                      | Phoenix      | 2.9  | 1.7  | 4.3  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Sacramento   | 0.6  | 0.3  | 0.9  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | St. Louis    | 1.5  | 0.7  | 2.6  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0   |
| Children with Asthma | Atlanta      | 0.7  | 0.1  | 1.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Boston       | 1.0  | 0.6  | 1.6  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Dallas       | 1.2  | 0.3  | 2.2  | <0.1   | 0    | 0.1  | 0  | 0   | 0   |
|                      | Detroit      | 1.9  | 1.1  | 2.9  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Philadelphia | 0.9  | 0.8  | 0.9  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Phoenix      | 3.2  | 1.8  | 4.9  | <0.1   | 0    | 0.1  | 0  | 0   | 0   |
|                      | Sacramento   | 0.6  | 0.4  | 0.9  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | St. Louis    | 1.3  | 0.6  | 2.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
| Adults               | Atlanta      | <0.1   | <0.1 | 0.1  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | <0.1 | 0.1  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Dallas       | 0.1  | <0.1 | 0.1  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Detroit      | 0.1  | 0.1  | 0.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Philadelphia | <0.1   | <0.1 | <0.1 | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Phoenix      | 0.3  | 0.2  | 0.4  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Sacramento   | <0.1   | <0.1 | 0.1  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | St. Louis    | 0.1  | <0.1 | 0.2  | 0  | 0    | 0    | 0  | 0   | 0   |
| Adults with Asthma   | Atlanta      | <0.1   | 0    | 0.1  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | 0    | 0.1  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Dallas       | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Detroit      | 0.1  | <0.1 | 0.1  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Philadelphia | <0.1   | 0    | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 0.3  | 0.1  | 0.4  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Sacramento   | <0.1   | 0    | 0.1  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | St. Louis    | 0.1  | <0.1 | 0.2  | 0  | 0    | 0    | 0  | 0   | 0   |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-29. Number of people estimated to experience at least two exposures at or above benchmarks while at moderate or greater exertion, for air quality adjusted to just meet the current standard.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |       |       | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |     |     | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |     |     |
|----------------------|--------------|--|-------|-------|--|-----|-----|--|-----|-----|
|                      |              | Avg  | Min   | Max   | Avg  | Min | Max | Avg  | Min | Max |
| Children             | Atlanta      | 7365   | 1675  | 13801 | 155  | 0   | 282 | 0  | 0   | 0   |
|                      | Boston       | 11317  | 6690  | 18477 | 341  | 91  | 660 | 0  | 0   | 0   |
|                      | Dallas       | 17135  | 5226  | 29273 | 276  | 24  | 757 | 0  | 0   | 0   |
|                      | Detroit      | 17829  | 10805 | 28894 | 243  | 69  | 520 | 0  | 0   | 0   |
|                      | Philadelphia | 10142  | 9210  | 11764 | 124  | 65  | 175 | 0  | 0   | 0   |
|                      | Phoenix      | 24952  | 14153 | 36643 | 94   | 0   | 269 | 0  | 0   | 0   |
|                      | Sacramento   | 2601   | 1281  | 4278  | 16   | 0   | 31  | 0  | 0   | 0   |
|                      | St. Louis    | 8305   | 4071  | 14325 | 67   | 9   | 155 | 0  | 0   | 0   |
| Children with Asthma | Atlanta      | 1002   | 202   | 1715  | 20   | 0   | 40  | 0  | 0   | 0   |
|                      | Boston       | 1669   | 1047  | 2617  | 30   | 0   | 68  | 0  | 0   | 0   |
|                      | Dallas       | 1600   | 378   | 2861  | 39   | 0   | 118 | 0  | 0   | 0   |
|                      | Detroit      | 2180   | 1301  | 3469  | 11   | 0   | 17  | 0  | 0   | 0   |
|                      | Philadelphia | 1288   | 1113  | 1375  | 15   | 0   | 44  | 0  | 0   | 0   |
|                      | Phoenix      | 2609   | 1444  | 3977  | 24   | 0   | 71  | 0  | 0   | 0   |
|                      | Sacramento   | 282  | 179   | 396   | 5  | 0   | 8   | 0  | 0   | 0   |
|                      | St. Louis    | 713  | 337   | 1211  | 3  | 0   | 9   | 0  | 0   | 0   |
| Adults               | Atlanta      | 1925   | 211   | 3592  | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Boston       | 2446   | 1076  | 4794  | 98   | 0   | 196 | 0  | 0   | 0   |
|                      | Dallas       | 3724   | 1250  | 6798  | 26   | 0   | 78  | 0  | 0   | 0   |
|                      | Detroit      | 5178   | 2884  | 9438  | 44   | 0   | 131 | 0  | 0   | 0   |
|                      | Philadelphia | 1917   | 1656  | 2266  | 29   | 0   | 87  | 0  | 0   | 0   |
|                      | Phoenix      | 8361   | 4718  | 11324 | 33   | 0   | 50  | 0  | 0   | 0   |
|                      | Sacramento   | 572  | 257   | 972   | 10   | 0   | 29  | 0  | 0   | 0   |
|                      | St. Louis    | 2587   | 858   | 4435  | 0  | 0   | 0   | 0  | 0   | 0   |
| Adults with Asthma   | Atlanta      | 94   | 0     | 211   | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Boston       | 261  | 0     | 489   | 33   | 0   | 98  | 0  | 0   | 0   |
|                      | Dallas       | 104  | 78    | 156   | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Detroit      | 328  | 197   | 590   | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Philadelphia | 58   | 0     | 174   | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Phoenix      | 745  | 397   | 1142  | 17   | 0   | 50  | 0  | 0   | 0   |
|                      | Sacramento   | 38   | 0     | 86    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | St. Louis    | 191  | 72    | 358   | 0  | 0   | 0   | 0  | 0   | 0   |

<sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals exposed at the level).

**Table 3D-30. Percent of people estimated to experience at least four exposures at or above benchmarks while at moderate or greater exertion, for air quality adjusted to just meet the current standard.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |      | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|--|------|------|--|-----|------|--|-----|-----|
|                      |              | Avg  | Min  | Max  | Avg  | Min | Max  | Avg  | Min | Max |
| Children             | Atlanta      | <0.1   | <0.1 | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | <0.1 | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Dallas       | 0.1  | <0.1 | 0.3  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | 0.2  | 0.1  | 0.3  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Philadelphia | 0.1  | <0.1 | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 0.7  | 0.3  | 1.1  | <0.1   | 0   | <0.1 | 0  | 0   | 0   |
|                      | Sacramento   | <0.1   | <0.1 | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | 0.2  | <0.1 | 0.3  | 0  | 0   | 0    | 0  | 0   | 0   |
| Children with Asthma | Atlanta      | <0.1   | 0    | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | 0    | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Dallas       | 0.2  | <0.1 | 0.4  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | 0.1  | <0.1 | 0.2  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Philadelphia | <0.1   | <0.1 | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 0.8  | 0.3  | 1.3  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Sacramento   | 0.1  | 0    | 0.2  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | 0.1  | 0    | 0.3  | 0  | 0   | 0    | 0  | 0   | 0   |
| Adults               | Atlanta      | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Dallas       | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Philadelphia | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
| Adults with Asthma   | Atlanta      | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Boston       | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Dallas       | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Philadelphia | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | <0.1   | <0.1 | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-31. Number of people estimated to experience at least four exposures at or above benchmarks while at moderate or greater exertion, for air quality adjusted to just meet the current standard.**

| Study Group  | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |     |     | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(# per Year) |     |     |
|--|--------------|--|------|------|--|-----|-----|--|-----|-----|
|  |              | Avg  | Min  | Max  | Avg  | Min | Max | Avg  | Min | Max |
| Children   | Atlanta      | 538  | 61   | 1190 | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Boston       | 471  | 137  | 865  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Dallas       | 1986   | 260  | 4422 | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Detroit      | 1665   | 746  | 3035 | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Philadelphia | 662  | 349  | 1157 | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Phoenix      | 5997   | 2633 | 9554 | 5  | 0   | 14  | 0  | 0   | 0   |
|  | Sacramento   | 158  | 8    | 411  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | St. Louis    | 862  | 209  | 1803 | 0  | 0   | 0   | 0  | 0   | 0   |
| Children with Asthma   | Atlanta      | 67   | 0    | 101  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Boston       | 76   | 0    | 137  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Dallas       | 213  | 24   | 473  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Detroit      | 162  | 52   | 243  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Philadelphia | 58   | 22   | 109  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Phoenix      | 637  | 212  | 1033 | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Sacramento   | 23   | 0    | 70   | 0  | 0   | 0   | 0  | 0   | 0   |
|  | St. Louis    | 73   | 0    | 155  | 0  | 0   | 0   | 0  | 0   | 0   |
| Adults   | Atlanta      | 47   | 0    | 141  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Boston       | 33   | 0    | 98   | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Dallas       | 104  | 0    | 234  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Detroit      | 109  | 0    | 262  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Philadelphia | 29   | 0    | 87   | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Phoenix      | 646  | 199  | 894  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|  | St. Louis    | 60   | 0    | 143  | 0  | 0   | 0   | 0  | 0   | 0   |
| Adults with Asthma   | Atlanta      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Boston       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Dallas       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Detroit      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Philadelphia | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Phoenix      | 83   | 50   | 149  | 0  | 0   | 0   | 0  | 0   | 0   |
|  | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|  | St. Louis    | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
| <sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals exposed at the level). |              |  |      |      |  |     |     |  |     |     |

### 3D.3.2.2 Additional Air Quality Scenario: 75 ppb

When considering air quality adjusted so that the design value at the highest monitor location in each urban study area is equal to 75 ppb, there will be a greater percent and number of people estimated to experience 7-hr O<sub>3</sub> exposures at or above each of the benchmarks. For example, estimated exposures to O<sub>3</sub> concentrations at or above the 80-ppb benchmark are limited, but not insignificant. When considering the worst air quality year, upwards to 0.6% of children (and similarly for children with asthma) are estimated to experience at least one day with a 7-hr exposure at or above the 80-ppb benchmark, while on average, most study areas had at least 0.1% of children experiencing such an exposure (Table 3D-32). On average, between about 1 to 2% of children (and similarly for children with asthma) would experience at least one day with a 7-hr exposure at or above the 70-ppb benchmark, while for the worst air quality year upwards to 3.4% of children (and 3.9% children with asthma) would experience such an exposure. On average, between about 7 to 17% of children (and similarly for children with asthma) would experience at least one day with a 7-hr exposure at or above the 60-ppb benchmark, while for the worst year upwards to about 18% of children (and about 19% of children with asthma) would experience such an exposure.

Under the 75 ppb air quality scenario, multiday exposures to the 80 ppb benchmark are few, but not entirely eliminated as was shown with the exposure results considering air quality adjusted to just meet the current standard. A small percent (<0.1%) of children are estimated to experience at least two days with 7-hr exposures at or above the 80-ppb (Table 3D-33). On average, between 0.1 to 0.3% of children (and 0.1 to 0.4% of children with asthma) would experience at least two days with 7-hr exposures at or above the 70-ppb benchmark, while for the worst year upwards to 0.7% of children (and 0.8% of children with asthma) would experience such an exposure. When considering the worst air quality year, between about 3 to 10% of children (and 3 to 11% of children with asthma) and 0.2 to 1.2% of adults (and 0.1 to 1.1% of adults with asthma) are estimated to experience at least two days with 7-hr O<sub>3</sub> exposures at or above the 60-ppb benchmark. On average, all study areas (and study groups) have a small percent (<0.1%) estimated to experience at least four days with 7-hr O<sub>3</sub> exposures at or above the 70-ppb benchmark (Table 3D-34), and at most 2% of children (and 2.3% of children with asthma) are estimated experience at least six days with 7-hr O<sub>3</sub> exposures at or above the 60-ppb benchmark for the worst air quality year (Attachment 4).

**Table 3D-32. Percent of people estimated to experience at least one exposure at or above benchmarks while at moderate or greater exertion, for the 75 ppb air quality scenario.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |     | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|--|------|------|--|------|-----|--|------|------|
|                      |              | Avg  | Min  | Max  | Avg  | Min  | Max | Avg  | Min  | Max  |
| Children             | Atlanta      | 7.7  | 4.8  | 10.7 | 1.5  | 0.4  | 2.8 | 0.3  | <0.1 | 0.6  |
|                      | Boston       | 6.6  | 5.0  | 8.8  | 1.3  | 0.9  | 1.9 | 0.1  | 0.1  | 0.1  |
|                      | Dallas       | 8.3  | 4.7  | 11.5 | 1.3  | 0.7  | 2.1 | 0.1  | <0.1 | 0.1  |
|                      | Detroit      | 11.0   | 8.6  | 13.9 | 1.9  | 0.9  | 3.4 | 0.1  | <0.1 | 0.1  |
|                      | Philadelphia | 8.6  | 8.2  | 8.8  | 1.4  | 1.2  | 1.5 | 0.1  | <0.1 | 0.1  |
|                      | Phoenix      | 15.7   | 13.2 | 17.9 | 2.0  | 0.9  | 3.4 | <0.1   | 0    | 0.1  |
|                      | Sacramento   | 7.5  | 6.3  | 8.9  | 1.1  | 0.8  | 1.4 | <0.1   | <0.1 | <0.1 |
|                      | St. Louis    | 10.6   | 8.5  | 13.0 | 1.7  | 0.8  | 3.2 | 0.1  | 0    | 0.1  |
| Children with Asthma | Atlanta      | 8.5  | 5.2  | 11.8 | 1.7  | 0.4  | 3.1 | 0.3  | <0.1 | 0.6  |
|                      | Boston       | 7.6  | 5.7  | 9.8  | 1.4  | 1.0  | 2.2 | 0.1  | 0.1  | 0.2  |
|                      | Dallas       | 8.9  | 4.6  | 11.9 | 1.4  | 0.9  | 2.2 | 0.1  | <0.1 | 0.1  |
|                      | Detroit      | 12.0   | 9.6  | 15.0 | 2.1  | 1.1  | 3.9 | <0.1   | 0    | 0.1  |
|                      | Philadelphia | 9.4  | 9.1  | 9.6  | 1.5  | 1.3  | 1.6 | 0.1  | <0.1 | 0.1  |
|                      | Phoenix      | 17.1   | 14.4 | 19.2 | 2.1  | 1.0  | 3.8 | 0.1  | 0    | 0.2  |
|                      | Sacramento   | 7.8  | 6.9  | 9.3  | 1.1  | 0.9  | 1.5 | 0.1  | <0.1 | 0.1  |
|                      | St. Louis    | 10.6   | 8.4  | 13.2 | 1.6  | 0.6  | 3.2 | 0.1  | 0    | 0.1  |
| Adults               | Atlanta      | 1.3  | 0.8  | 1.8  | 0.2  | 0.1  | 0.4 | <0.1   | 0    | 0.1  |
|                      | Boston       | 0.9  | 0.5  | 1.3  | 0.1  | 0.1  | 0.2 | <0.1   | <0.1 | <0.1 |
|                      | Dallas       | 1.4  | 0.7  | 2.1  | 0.2  | 0.1  | 0.3 | <0.1   | 0    | <0.1 |
|                      | Detroit      | 1.7  | 1.3  | 2.3  | 0.3  | 0.2  | 0.5 | <0.1   | 0    | <0.1 |
|                      | Philadelphia | 1.2  | 1.1  | 1.4  | 0.2  | 0.1  | 0.2 | <0.1   | <0.1 | <0.1 |
|                      | Phoenix      | 3.2  | 2.6  | 3.6  | 0.3  | 0.2  | 0.4 | <0.1   | 0    | <0.1 |
|                      | Sacramento   | 1.1  | 0.9  | 1.3  | 0.1  | 0.1  | 0.2 | <0.1   | 0    | <0.1 |
|                      | St. Louis    | 1.7  | 1.2  | 2.1  | 0.2  | 0.1  | 0.4 | <0.1   | 0    | <0.1 |
| Adults with Asthma   | Atlanta      | 0.9  | 0.6  | 1.1  | 0.2  | 0.1  | 0.3 | <0.1   | 0    | <0.1 |
|                      | Boston       | 0.6  | 0.4  | 1.0  | 0.1  | <0.1 | 0.1 | <0.1   | 0    | <0.1 |
|                      | Dallas       | 1.1  | 0.5  | 1.5  | 0.1  | <0.1 | 0.1 | <0.1   | 0    | <0.1 |
|                      | Detroit      | 1.5  | 1.1  | 1.7  | 0.2  | 0.1  | 0.4 | <0.1   | 0    | <0.1 |
|                      | Philadelphia | 1.0  | 0.7  | 1.2  | 0.1  | 0.1  | 0.1 | 0  | 0    | 0    |
|                      | Phoenix      | 2.7  | 2.3  | 3.0  | 0.2  | 0.1  | 0.4 | 0  | 0    | 0    |
|                      | Sacramento   | 0.9  | 0.7  | 1.2  | 0.1  | 0.1  | 0.1 | <0.1   | 0    | <0.1 |
|                      | St. Louis    | 1.3  | 1.0  | 1.8  | 0.2  | <0.1 | 0.4 | <0.1   | 0    | <0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-33. Percent of people estimated to experience at least two exposures at or above benchmarks while at moderate or greater exertion, for the 75 ppb air quality scenario.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |      |
|----------------------|--------------|--|------|------|--|------|------|--|-----|------|
|                      |              | Avg  | Min  | Max  | Avg  | Min  | Max  | Avg  | Min | Max  |
| Children             | Atlanta      | 2.5  | 1.1  | 4.0  | 0.2  | <0.1 | 0.4  | <0.1   | 0   | <0.1 |
|                      | Boston       | 1.7  | 1.1  | 2.6  | 0.1  | <0.1 | 0.2  | <0.1   | 0   | <0.1 |
|                      | Dallas       | 2.9  | 1.1  | 4.8  | 0.1  | <0.1 | 0.3  | <0.1   | 0   | <0.1 |
|                      | Detroit      | 4.0  | 2.5  | 5.8  | 0.2  | <0.1 | 0.4  | <0.1   | 0   | <0.1 |
|                      | Philadelphia | 2.8  | 2.5  | 3.0  | 0.1  | 0.1  | 0.2  | <0.1   | 0   | <0.1 |
|                      | Phoenix      | 8.0  | 6.0  | 9.9  | 0.3  | 0.1  | 0.7  | <0.1   | 0   | <0.1 |
|                      | Sacramento   | 2.4  | 1.7  | 3.4  | 0.1  | <0.1 | 0.2  | 0  | 0   | 0    |
|                      | St. Louis    | 3.9  | 2.7  | 5.4  | 0.2  | <0.1 | 0.4  | <0.1   | 0   | <0.1 |
| Children with Asthma | Atlanta      | 2.7  | 1.1  | 4.2  | 0.2  | <0.1 | 0.4  | <0.1   | 0   | <0.1 |
|                      | Boston       | 2.0  | 1.3  | 3.0  | 0.1  | <0.1 | 0.2  | 0  | 0   | 0    |
|                      | Dallas       | 2.9  | 1.0  | 4.8  | 0.1  | 0    | 0.3  | 0  | 0   | 0    |
|                      | Detroit      | 4.4  | 2.8  | 6.4  | 0.2  | <0.1 | 0.4  | 0  | 0   | 0    |
|                      | Philadelphia | 3.0  | 2.8  | 3.1  | 0.1  | 0.1  | 0.1  | 0  | 0   | 0    |
|                      | Phoenix      | 8.9  | 6.7  | 11.0 | 0.4  | 0.2  | 0.8  | 0  | 0   | 0    |
|                      | Sacramento   | 2.6  | 1.9  | 3.8  | 0.1  | <0.1 | 0.2  | 0  | 0   | 0    |
|                      | St. Louis    | 3.6  | 2.5  | 4.9  | 0.1  | 0    | 0.3  | 0  | 0   | 0    |
| Adults               | Atlanta      | 0.2  | 0.1  | 0.4  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Boston       | 0.1  | 0.1  | 0.2  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Dallas       | 0.2  | 0.1  | 0.5  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Detroit      | 0.3  | 0.2  | 0.5  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Philadelphia | 0.2  | 0.1  | 0.2  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Phoenix      | 1.0  | 0.7  | 1.2  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Sacramento   | 0.2  | 0.1  | 0.2  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | St. Louis    | 0.3  | 0.2  | 0.5  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
| Adults with Asthma   | Atlanta      | 0.1  | <0.1 | 0.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Boston       | 0.1  | <0.1 | 0.1  | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Dallas       | 0.1  | <0.1 | 0.2  | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Detroit      | 0.3  | 0.2  | 0.5  | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Philadelphia | 0.1  | <0.1 | 0.2  | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Phoenix      | 0.8  | 0.6  | 1.1  | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Sacramento   | 0.1  | 0.1  | 0.2  | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | St. Louis    | 0.3  | 0.1  | 0.4  | <0.1   | 0    | <0.1 | 0  | 0   | 0    |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".



**Table 3D-34. Percent of people estimated to experience at least four exposures at or above benchmarks while at moderate or greater exertion, for the 75 ppb air quality scenario.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|--|------|------|--|------|------|--|-----|-----|
|                      |              | Avg  | Min  | Max  | Avg  | Min  | Max  | Avg  | Min | Max |
| Children             | Atlanta      | 0.4  | 0.1  | 0.9  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Boston       | 0.1  | 0.1  | 0.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Dallas       | 0.6  | 0.1  | 1.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Detroit      | 0.7  | 0.3  | 1.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Philadelphia | 0.4  | 0.3  | 0.6  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Phoenix      | 3.0  | 2.0  | 4.1  | <0.1   | <0.1 | <0.1 | 0  | 0   | 0   |
|                      | Sacramento   | 0.4  | 0.2  | 0.8  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | St. Louis    | 0.8  | 0.4  | 1.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
| Children with Asthma | Atlanta      | 0.5  | 0.1  | 0.9  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Boston       | 0.1  | 0.1  | 0.2  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Dallas       | 0.5  | 0.1  | 1.1  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Detroit      | 0.6  | 0.2  | 1.0  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Philadelphia | 0.4  | 0.3  | 0.6  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 3.3  | 2.2  | 4.4  | <0.1   | 0    | 0.1  | 0  | 0   | 0   |
|                      | Sacramento   | 0.4  | 0.2  | 0.8  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | St. Louis    | 0.6  | 0.3  | 1.1  | 0  | 0    | 0    | 0  | 0   | 0   |
| Adults               | Atlanta      | <0.1   | 0    | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Dallas       | <0.1   | 0    | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Detroit      | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Philadelphia | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 0.1  | 0.1  | 0.2  | <0.1   | 0    | <0.1 | 0  | 0   | 0   |
|                      | Sacramento   | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | St. Louis    | <0.1   | <0.1 | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
| Adults with Asthma   | Atlanta      | 0  | 0    | 0    | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | 0    | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Dallas       | 0  | 0    | 0    | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Detroit      | <0.1   | 0    | <0.1 | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Philadelphia | 0  | 0    | 0    | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 0.1  | 0.1  | 0.1  | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0    | 0    | 0  | 0   | 0   |
|                      | St. Louis    | <0.1   | 0    | 0.1  | 0  | 0    | 0    | 0  | 0   | 0   |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

### 3D.3.2.3 Additional Air Quality Scenario: 65 ppb

With increasing stringency (i.e., lowering) of the design value used to represent the air quality scenario, there is a reduction in the percent and number of simulated individuals experiencing 7-hr exposures at or above the benchmarks. Under the 65 ppb air quality scenario, in 6 of the 8 study areas, there are no people estimated to experience at least one benchmark at or above the 80-ppb benchmark (Table 3D-35). Exposures at or above the 70-ppb benchmark are also limited, with at most 0.2% of children (and 0.3% of children with asthma) estimated experience one such exposure during the worst air quality year. On average, between 0.4 to 2.3% of children (and 0.5 to 2.5% of children with asthma) and between 0.1 to 0.4% of adults (and <0.1 to 0.3% of adults with asthma) are estimated to experience at least one 7-hr O<sub>3</sub> exposure at or above the 60-ppb benchmark, while during the worst air quality year, upwards to 3.7% of children (and 4.3% of children with asthma) would experience such an exposure.

Multiday exposures at or above the 70-ppb benchmark are nearly eliminated under the 65 ppb air quality scenario, with only three study areas having at most, <0.1% of children (and no children with asthma) estimated to experience 7-hr exposures at or above that benchmark for at least two days (Table 3D-36). When considering the worst air quality year, ≤0.5% of children (and 0.6% of children with asthma) and ≤0.1% of adults (and similarly for adults with asthma) are estimated to experience at least two days with 7-hr O<sub>3</sub> exposures at or above the 60-ppb benchmark. There are no people in any of the study areas estimated to experience at least four days with 7-hr O<sub>3</sub> exposures at or above the 70-ppb benchmark (Table 3D-37), and there no simulated individuals estimated to experience at least six days with 7-hr O<sub>3</sub> exposures at or above the 60-ppb benchmark in all but two study areas (Attachment 4).

**Table 3D-35. Percent of people estimated to experience at least one exposure at or above benchmarks while at moderate or greater exertion, for the 65 ppb air quality scenario.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |     | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |      |
|----------------------|--------------|--|------|-----|--|------|------|--|-----|------|
|                      |              | Avg  | Min  | Max | Avg  | Min  | Max  | Avg  | Min | Max  |
| Children             | Atlanta      | 1.0  | 0.3  | 1.7 | 0.1  | <0.1 | 0.1  | <0.1   | 0   | <0.1 |
|                      | Boston       | 1.8  | 1.1  | 2.5 | 0.2  | 0.1  | 0.2  | <0.1   | 0   | <0.1 |
|                      | Dallas       | 2.1  | 0.9  | 2.8 | 0.1  | 0.1  | 0.1  | 0  | 0   | 0    |
|                      | Detroit      | 2.3  | 1.4  | 3.7 | <0.1   | <0.1 | 0.1  | 0  | 0   | 0    |
|                      | Philadelphia | 1.5  | 1.4  | 1.6 | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Phoenix      | 1.8  | 0.9  | 3.0 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Sacramento   | 0.4  | 0.3  | 0.6 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | St. Louis    | 1.6  | 0.7  | 3.1 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
| Children with Asthma | Atlanta      | 1.1  | 0.3  | 1.9 | 0.1  | <0.1 | 0.2  | <0.1   | 0   | <0.1 |
|                      | Boston       | 2.1  | 1.3  | 3.1 | 0.2  | 0.1  | 0.3  | <0.1   | 0   | <0.1 |
|                      | Dallas       | 2.2  | 1.1  | 2.9 | 0.1  | <0.1 | 0.1  | 0  | 0   | 0    |
|                      | Detroit      | 2.5  | 1.5  | 4.3 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Philadelphia | 1.6  | 1.3  | 1.9 | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Phoenix      | 2.1  | 1.0  | 3.4 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Sacramento   | 0.5  | 0.3  | 0.6 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | St. Louis    | 1.5  | 0.6  | 3.0 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
| Adults               | Atlanta      | 0.1  | <0.1 | 0.3 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Boston       | 0.2  | 0.1  | 0.3 | <0.1   | <0.1 | <0.1 | <0.1   | 0   | <0.1 |
|                      | Dallas       | 0.3  | 0.1  | 0.4 | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Detroit      | 0.4  | 0.2  | 0.6 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Philadelphia | 0.2  | 0.2  | 0.2 | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    |
|                      | Phoenix      | 0.3  | 0.2  | 0.4 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Sacramento   | 0.1  | <0.1 | 0.1 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | St. Louis    | 0.2  | 0.1  | 0.4 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
| Adults with Asthma   | Atlanta      | 0.1  | <0.1 | 0.1 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Boston       | 0.1  | <0.1 | 0.2 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Dallas       | 0.2  | <0.1 | 0.3 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Detroit      | 0.3  | 0.2  | 0.5 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |
|                      | Philadelphia | 0.1  | 0.1  | 0.2 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Phoenix      | 0.2  | 0.1  | 0.4 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | Sacramento   | <0.1   | <0.1 | 0.1 | 0  | 0    | 0    | 0  | 0   | 0    |
|                      | St. Louis    | 0.2  | <0.1 | 0.5 | <0.1   | 0    | <0.1 | 0  | 0   | 0    |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-36. Percent of people estimated to experience at least two exposures at or above benchmarks while at moderate or greater exertion, for the 65 ppb air quality scenario.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |      | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|--|------|------|--|-----|------|--|-----|-----|
|                      |              | Avg  | Min  | Max  | Avg  | Min | Max  | Avg  | Min | Max |
| Children             | Atlanta      | 0.1  | <0.1 | 0.2  | <0.1   | 0   | <0.1 | 0  | 0   | 0   |
|                      | Boston       | 0.2  | 0.1  | 0.3  | <0.1   | 0   | <0.1 | 0  | 0   | 0   |
|                      | Dallas       | 0.3  | <0.1 | 0.5  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | 0.3  | 0.1  | 0.5  | <0.1   | 0   | <0.1 | 0  | 0   | 0   |
|                      | Philadelphia | 0.1  | 0.1  | 0.2  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 0.3  | 0.1  | 0.5  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Sacramento   | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | 0.2  | <0.1 | 0.4  | 0  | 0   | 0    | 0  | 0   | 0   |
| Children with Asthma | Atlanta      | 0.1  | 0    | 0.2  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Boston       | 0.2  | 0.1  | 0.3  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Dallas       | 0.3  | <0.1 | 0.5  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | 0.2  | 0.1  | 0.4  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Philadelphia | 0.2  | 0.1  | 0.2  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | 0.3  | 0.1  | 0.6  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Sacramento   | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | 0.1  | <0.1 | 0.3  | 0  | 0   | 0    | 0  | 0   | 0   |
| Adults               | Atlanta      | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Dallas       | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | <0.1   | <0.1 | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Philadelphia | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Sacramento   | <0.1   | <0.1 | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
| Adults with Asthma   | Atlanta      | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Boston       | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Dallas       | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Detroit      | <0.1   | 0    | 0.1  | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Philadelphia | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Phoenix      | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0    | 0  | 0   | 0   |
|                      | St. Louis    | <0.1   | 0    | <0.1 | 0  | 0   | 0    | 0  | 0   | 0   |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-37. Percent of people estimated to experience at least four exposures at or above benchmarks while at moderate or greater exertion, for the 65 ppb air quality scenario.**

| Study Group          | Study Area   | 60 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |      |      | 70 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |     | 80 ppb Benchmark (7-hr) <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|--|------|------|--|-----|-----|--|-----|-----|
|                      |              | Avg  | Min  | Max  | Avg  | Min | Max | Avg  | Min | Max |
| Children             | Atlanta      | <0.1   | 0    | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Boston       | <0.1   | 0    | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Dallas       | <0.1   | <0.1 | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Detroit      | <0.1   | <0.1 | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Philadelphia | <0.1   | 0    | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Phoenix      | <0.1   | <0.1 | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | St. Louis    | <0.1   | 0    | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
| Children with Asthma | Atlanta      | <0.1   | 0    | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Boston       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Dallas       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Detroit      | <0.1   | 0    | <0.1 | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Philadelphia | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Phoenix      | <0.1   | 0    | 0.1  | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | St. Louis    | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
| Adults               | Atlanta      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Boston       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Dallas       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Detroit      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Philadelphia | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Phoenix      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | St. Louis    | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
| Adults with Asthma   | Atlanta      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Boston       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Dallas       | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Detroit      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Philadelphia | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Phoenix      | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | Sacramento   | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |
|                      | St. Louis    | 0  | 0    | 0    | 0  | 0   | 0   | 0  | 0   | 0   |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

#### 3D.3.2.4 Comparison with 2014 HREA Exposure Results

We compared the exposure results for the current exposure and risk analysis with those generated for the 2014 HREA. Table 3D-38 presents the percent of children experiencing at least one exposure at or above the three benchmarks for the two assessments and Table 3D-39 presents the similar comparison for two or more exposures. Results are presented for all study areas, and for the seven study areas common to both assessments. In general, the comparison indicates similarity between the two assessments, particularly for the highest benchmark and when focusing on the summary for all areas in each assessment. Such a focus is appropriate given the purpose of the assessments in providing estimates across a range of study areas to inform decision making with regard to the exposures and risks that may occur across the U.S. in areas that just meet the current standard. For the lower benchmarks and particularly in comparing for the seven areas common to both assessments, the current assessment estimates are slightly lower than the 2014 HREA results, most notably for the highest single year, likely reflecting the greater variation in ambient air concentrations in some study areas in the 2014 HREA. This is supported by recent analyses that show changes to the distribution of ambient air O<sub>3</sub> concentrations over time occur primarily as reductions to the highest and lowest concentrations (Downey et al., 2015; Simon et al., 2012).

In addition to generally lower baseline O<sub>3</sub> concentrations and lower variability in the concentrations in the three air quality scenarios for the current assessment compared to 2014 HREA, there were also two important differences in the exposure modeling approach. The first is the use, in the current assessment, of an EVR distribution ( $17.32 \pm 1.25$  L/minute-m<sup>2</sup>) to indicate when a simulated individual is at moderate or greater exertion (section 3D.2.2.3.3) rather than using a lower value for all simulated individuals (13 L/minute-m<sup>2</sup>; 5<sup>th</sup> percentile). The current approach would be expected to result in far fewer individuals reaching the exertion level concomitant with the exposure level of interest, thus reducing the percent of the population at or above benchmarks. The second difference is the focus on 7-hr average exposures (compared to the benchmarks) in this assessment rather than 8-hr averages. With this change, it would be expected that there would be more simulated individuals at or above a given benchmark concentration. While these two changes to the exposure modeling approach compete in their overall influence on the exposure results, it would be expected that the change to using the EVR distribution would have a greater impact.

As suggested above, the difference between the two assessments in the highest year estimates is likely a function of the baseline ambient air concentrations in the study areas. As a reminder, the 2014 HREA used air quality scenarios developed from adjusting 2006-2010 ambient air concentrations, and some study areas had design values in that time period that were well above the then-existing standard (and more so for the current standard). In the current

exposure analysis, we selected study areas that had 2015-2017 design values close to the current standard, requiring less of an adjustment for the current standard (70 ppb) air quality scenario.

**Table 3D-38. Comparison of current assessment to 2014 HREA for percent of children estimated to experience at least one exposure at or above benchmarks while at moderate or greater exertion.**

| Air Quality Scenario (DV, ppb)  | Average Percent (%) of Simulated Children with at least One Day per Year at or above Specified Benchmark Exposure Concentration (highest in single season) |                        |                             |                            |
|---|--|------------------------|-----------------------------|----------------------------|
|   | All areas <sup>A</sup>   |                        | 7 common areas <sup>A</sup> |                            |
|   | Current PA <sup>B</sup>  | 2014 HREA <sup>C</sup> | Current PA <sup>B</sup>     | 2014 HREA <sup>C</sup>     |
| <i>Benchmark Exposure Concentration of 80 ppb</i>   |  |                        |                             |                            |
| 75  | <0.1 <sup>B</sup> – 0.3 (0.6)  | 0 – 0.3 (1.1)          | <0.1 – 0.3 (0.6)            | 0.1 – 0.3 (1.1)            |
| 70  | 0 – <0.1 (0.1)   | 0 – 0.1 (0.2)          | 0 – <0.1 (0.1)              | 0 <sup>B</sup> – 0.1 (0.2) |
| 65  | 0 – <0.1 (<0.1)  | 0 (0)                  | 0 – <0.1 (<0.1)             | 0 (0)                      |
| <i>Benchmark Exposure Concentration of 70 ppb</i>   |  |                        |                             |                            |
| 75  | 1.1 – 2.0 (3.4)  | 0.6 – 3.3 (8.1)        | 1.1 – 1.9 (3.4)             | 1.6 – 3.3 (8.1)            |
| 70  | 0.2 – 0.6 (0.9)  | 0.1 – 1.2 (3.2)        | 0.2 – 0.6 (0.9)             | 0.4 – 1.2 (3.2)            |
| 65  | 0 – 0.2 (0.2)  | 0 – 0.2 (0.5)          | 0 <sup>B</sup> – 0.2 (0.2)  | 0.1 – 0.2 (0.5)            |
| <i>Benchmark Exposure Concentration of 60 ppb</i>   |  |                        |                             |                            |
| 75  | 6.6 – 15.7 (17.9)  | 9.5 – 17.0 (25.8)      | 6.6 – 11.0 (13.9)           | 10.3 – 16.3 (25.8)         |
| 70  | 3.2 – 8.2 (10.6)   | 3.3 – 10.2 (18.9)      | 3.2 – 6.7 (9.2)             | 5.8 – 10.2 (16.9)          |
| 65  | 0.4 – 2.3 (3.7)  | 0 – 4.2 (9.5)          | 0.4 – 2.3 (3.7)             | 2.4 – 3.9 (7.6)            |
| <sup>A</sup> Footnote 9 contains the names of the 15 study areas evaluated for the 2014 HREA. The seven study areas common to both include the eight evaluated in this assessment with exception of Phoenix.<br><sup>B</sup> For the current analysis, calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1"<br><sup>C</sup> For the 2014 HREA, calculated percent was rounded to the nearest tenth decimal using conventional rounding. Values that did not round upwards to 0.1 (i.e., <0.05) were given a value of "0". |  |                        |                             |                            |

**Table 3D-39. Comparison of current assessment to 2014 HREA for percent of children estimated to experience at least two exposure at or above benchmarks while at moderate or greater exertion.**

| Air Quality Scenario<br>(DV, ppb)   | Average Percent (%) of Simulated Children with at least Two Days per Year at or above Specified Benchmark Exposure Concentration<br>(highest in single season) |                        |                             |                        |
|---|--|------------------------|-----------------------------|------------------------|
|   | All areas <sup>A</sup>   |                        | 7 common areas <sup>A</sup> |                        |
|   | Current PA <sup>B</sup>  | 2014 HREA <sup>C</sup> | Current PA <sup>B</sup>     | 2014 HREA <sup>C</sup> |
| <i>Benchmark Exposure Concentration of 80 ppb</i>   |  |                        |                             |                        |
| 75  | 0 – <0.1 (<0.1)  | 0 (0.1)                | 0 – <0.1 (<0.1)             | 0 (0.1)                |
| 70  | 0 (0)  | 0 (0)                  | 0 (0)                       | 0 (0)                  |
| 65  | 0 (0)  | 0 (0)                  | 0 (0)                       | 0 (0)                  |
| <i>Benchmark Exposure Concentration of 70 ppb</i>   |  |                        |                             |                        |
| 75  | 0.1 – 0.3 (0.7)  | 0.1 – 0.6 (2.2)        | 0.1 – 0.2 (0.4)             | 0.2 – 0.6 (2.2)        |
| 70  | <0.1 (0.1)   | 0 – 0.1 (0.4)          | <0.1 (0.1)                  | 0 – 0.1 (0.4)          |
| 65  | 0 – <0.1 (<0.1)  | 0 (0)                  | 0 – <0.1 (<0.1)             | 0 (0)                  |
| <i>Benchmark Exposure Concentration of 60 ppb</i>   |  |                        |                             |                        |
| 75  | 1.7 – 8.0 (9.9)  | 3.1 – 7.6 (14.4)       | 1.7 – 4.0 (5.8)             | 3.7 – 7.0 (13.8)       |
| 70  | 0.6 – 2.9 (4.3)  | 0.5 – 3.5 (9.2)        | 0.6 – 1.7 (2.8)             | 1.5 – 3.2 (7.1)        |
| 65  | <0.1 – 0.3 (0.5)   | 0 – 0.8 (2.8)          | <0.1 – 0.3 (0.5)            | 0.3 – 0.7 (2.0)        |
| <sup>A</sup> Footnote 9 contains the names of the 15 study areas evaluated for the 2014 HREA. The seven study areas common to both include the eight evaluated in this assessment with exception of Phoenix.<br><sup>B</sup> For the current analysis, calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals exposed at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1"<br><sup>C</sup> For the 2014 HREA, calculated percent was rounded to the nearest tenth decimal using conventional rounding. Values that did not round upwards to 0.1 (i.e., <0.05) were given a value of "0". |  |                        |                             |                        |

### 3D.3.3 Lung Function Risk

As described above, lung function risk was estimated using two approaches. The first, a population-based risk approach (i.e., using E-R functions, section 3D.2.8.2.1), combined the population distribution of daily maximum 7-hr exposures occurring while at moderate or greater exertion with continuous E-R functions derived from the controlled human exposure study data (Table 3D-20 and Figure 3D-12). Note that the E-R function risk approach uses the full distribution of daily maximum 7-hr exposures, from the minimum to the maximum exposures (i.e., not simply including the upper level exposures or benchmarks). It is, however, necessary that the daily maximum exposure did occur at a 7-hr EVR  $\geq 17.32 \pm 1.25$  L/min-m<sup>2</sup>. The results for the population-based (E-R function) risk approach, represented as percent (or counts) of the population estimated to experience lung function decrements (i.e.,  $\geq 10\%$ ,  $\geq 15\%$ , and  $\geq 20\%$



reduction in FEV<sub>1</sub>) is provided in section 3D.3.3.1. A similar format to that provided for the benchmark results above is followed, focusing largely on the air quality scenario for just meeting the current standard and presenting the percent (and counts) of the population estimated to experience lung function decrements while at elevated exertion.

The second risk approach, an individual-based risk approach (i.e., the MSS model, section 3D.2.8.2.2), calculates the decrements in lung function continuously for each simulated person using their unique time-series of O<sub>3</sub> exposures, simultaneously occurring breathing rates, and personal attributes (e.g., age, body mass). Note that when using the MSS model risk approach, the estimated reduction in FEV<sub>1</sub> considers the prior and current exposures/breathing rates and has no hard restriction on either the exposure or exertion level. As such, lung function decrements could also occur at exposures and/or breathing rates below that observed in the controlled human exposure studies. The results for the individual-based (MSS model) risk approach are found in section 3D.3.3.2. The complete results for both of the risk approaches can be found in Attachment 4.

#### **3D.3.3.1 Population-based (E-R Function) Risk Approach**

As was observed with the exposure benchmarks and considering any of the air quality scenarios, a smaller percent (and number) of adults are estimated to experience lung function decrements when compared to children (Table 3D-40 to Table 3D-51). Again, this is driven largely by the difference in time spent outdoors at elevated exertion. Even though there is limited variability across the eight study areas, Detroit, Phoenix, and St. Louis generally exhibited higher risk estimates relative to the other study areas for instances where risk estimates were above 1% (e.g., where FEV<sub>1</sub> reductions  $\geq 10\%$ ). This is expected given the observation made above regarding the results for the exposure to benchmark comparison and its relationship with the overall distribution of O<sub>3</sub> concentrations in ambient air (Figure 3D-7).

In general, when comparing E-R function risk estimates to the benchmark results, the attenuation of the percent estimated to experience lung function decrements is at a lesser rate than that observed for the percent of the population at or above the benchmark levels, with increasing stringency of the design values, and when considering the number of times per year either might occur. For example, while as much as 0.9% of children (and 1.0% of children with asthma) are estimated to experience at least one FEV<sub>1</sub> reduction  $\geq 15\%$  while at elevated exertion with air quality just meeting the current standard (Table 3D-40), on average between 0.2 to 0.4% of children (and similarly for children with asthma) in all 8 study areas are estimated to experience at least four such decrements (Table 3D-44) when considering the same air quality scenario. For comparison, while as much as 0.9% of children (and 1.0% of children with asthma) are estimated to experience at least one exposure at or above the 70 ppb benchmark while at

1 elevated exertion for air quality just meeting the current standard (Table 3D-26), there are no  
2 children (and similarly for children with asthma) estimated to experience at least four such  
3 exposures in all but one study area (Table 3D-30) when considering the same air quality  
4 scenario. This relative decreased rate of change observed for the E-R function risk results is  
5 likely a function of the broader range (and low level) of exposures used in the calculation  
6 compared to that represented by the exposure benchmarks.

7         The risks of lung function decrements in the 75 ppb air quality scenario, which allows  
8 higher O<sub>3</sub> concentrations, are of course greater (Table 3D-46 through Table 3D-48) than those  
9 for air quality adjusted to just meet the current standard (Table 3D-40 through Table 3D-45),  
10 differing by at most a few tenths of a percentage point for both the 15% and 20% reduction in  
11 FEV<sub>1</sub>. A similar pattern is exhibited when comparing the lung function results for the current  
12 standard to those for the 65 ppb air quality scenario (Table 3D-49 through Table 3D-51). A few  
13 tenths of a percentage point lower risks are estimated for the lower design value scenario  
14 compared to those estimated for the current standard.

**Table 3D-40. Percent of people estimated to experience at least one lung function decrement at or above the indicated level, for air quality adjusted to just meet the current standard, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|-----|-----|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min | Max | Avg   | Min  | Max  |
| Children             | Atlanta      | 2.2   | 1.9 | 2.5 | 0.5   | 0.4 | 0.6 | 0.2   | 0.1  | 0.2  |
|                      | Boston       | 2.2   | 2.0 | 2.3 | 0.5   | 0.5 | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | Dallas       | 2.4   | 2.1 | 2.6 | 0.6   | 0.5 | 0.7 | 0.2   | 0.2  | 0.3  |
|                      | Detroit      | 2.5   | 2.3 | 2.8 | 0.7   | 0.6 | 0.8 | 0.3   | 0.2  | 0.3  |
|                      | Philadelphia | 2.3   | 2.2 | 2.4 | 0.6   | 0.5 | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | Phoenix      | 3.1   | 2.9 | 3.3 | 0.8   | 0.7 | 0.9 | 0.3   | 0.3  | 0.4  |
|                      | Sacramento   | 2.2   | 2.2 | 2.3 | 0.5   | 0.5 | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | St. Louis    | 2.5   | 2.3 | 2.8 | 0.7   | 0.6 | 0.8 | 0.2   | 0.2  | 0.3  |
| Children with Asthma | Atlanta      | 2.3   | 2.0 | 2.6 | 0.6   | 0.5 | 0.7 | 0.2   | 0.1  | 0.3  |
|                      | Boston       | 2.4   | 2.2 | 2.6 | 0.6   | 0.6 | 0.7 | 0.2   | 0.2  | 0.3  |
|                      | Dallas       | 2.6   | 2.3 | 2.8 | 0.7   | 0.5 | 0.8 | 0.2   | 0.2  | 0.3  |
|                      | Detroit      | 2.7   | 2.6 | 3.0 | 0.7   | 0.6 | 0.8 | 0.3   | 0.2  | 0.3  |
|                      | Philadelphia | 2.4   | 2.4 | 2.5 | 0.6   | 0.6 | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | Phoenix      | 3.3   | 3.1 | 3.6 | 0.9   | 0.8 | 1.0 | 0.3   | 0.3  | 0.4  |
|                      | Sacramento   | 2.3   | 2.3 | 2.4 | 0.5   | 0.5 | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | St. Louis    | 2.6   | 2.3 | 2.8 | 0.7   | 0.6 | 0.8 | 0.2   | 0.2  | 0.3  |
| Adults               | Atlanta      | 0.6   | 0.6 | 0.7 | 0.1   | 0.1 | 0.2 | <0.1  | <0.1 | 0.1  |
|                      | Boston       | 0.6   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.7   | 0.6 | 0.7 | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Detroit      | 0.6   | 0.6 | 0.7 | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Philadelphia | 0.6   | 0.6 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.9   | 0.9 | 1.0 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.6   | 0.6 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.7   | 0.6 | 0.7 | 0.1   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
| Adults with Asthma   | Atlanta      | 0.5   | 0.4 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.4   | 0.4 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.6   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.5   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.5   | 0.5 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.7   | 0.7 | 0.8 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.5   | 0.4 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.6   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | 0.1  |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-41. Number of people estimated to experience at least one lung function decrement at or above the indicated level, for air quality adjusted to just meet the current standard, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |      |      |
|----------------------|--------------|---|-------|-------|---|------|------|---|------|------|
|                      |              | Avg   | Min   | Max   | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 26149   | 22779 | 29781 | 6369  | 5064 | 7768 | 2273  | 1634 | 2966 |
|                      | Boston       | 29437   | 27715 | 31856 | 7433  | 6804 | 8442 | 2746  | 2457 | 3254 |
|                      | Dallas       | 34128   | 30101 | 37100 | 8615  | 7070 | 9837 | 3153  | 2412 | 3760 |
|                      | Detroit      | 26489   | 24402 | 28928 | 6978  | 6122 | 8030 | 2642  | 2220 | 3174 |
|                      | Philadelphia | 30134   | 28919 | 31014 | 7406  | 7050 | 7661 | 2655  | 2510 | 2750 |
|                      | Phoenix      | 26169   | 24400 | 28193 | 6930  | 6199 | 7770 | 2614  | 2250 | 3029 |
|                      | Sacramento   | 10458   | 10047 | 10800 | 2484  | 2321 | 2632 | 859   | 784  | 932  |
|                      | St. Louis    | 13912   | 12540 | 15144 | 3594  | 3069 | 4143 | 1345  | 1093 | 1630 |
| Children with Asthma | Atlanta      | 3322  | 2885  | 3793  | 814   | 646  | 989  | 289   | 202  | 383  |
|                      | Boston       | 4027  | 3686  | 4323  | 1024  | 910  | 1160 | 387   | 341  | 455  |
|                      | Dallas       | 3389  | 2956  | 3712  | 859   | 686  | 993  | 315   | 236  | 378  |
|                      | Detroit      | 3208  | 2931  | 3503  | 844   | 728  | 971  | 318   | 260  | 382  |
|                      | Philadelphia | 3594  | 3448  | 3732  | 880   | 829  | 917  | 320   | 306  | 327  |
|                      | Phoenix      | 2684  | 2463  | 2901  | 713   | 623  | 807  | 269   | 226  | 311  |
|                      | Sacramento   | 1043  | 1009  | 1095  | 246   | 233  | 264  | 85  | 78   | 93   |
|                      | St. Louis    | 1439  | 1302  | 1530  | 370   | 319  | 419  | 137   | 109  | 164  |
| Adults               | Atlanta      | 26671   | 24018 | 29934 | 5658  | 4789 | 6691 | 1808  | 1409 | 2254 |
|                      | Boston       | 33036   | 30818 | 35514 | 7011  | 6261 | 7925 | 2218  | 1859 | 2642 |
|                      | Dallas       | 32817   | 29848 | 35083 | 7215  | 6095 | 8126 | 2370  | 1875 | 2813 |
|                      | Detroit      | 25452   | 23857 | 27527 | 5921  | 5309 | 6816 | 2054  | 1770 | 2491 |
|                      | Philadelphia | 32243   | 30936 | 33288 | 6826  | 6449 | 7146 | 2150  | 2004 | 2266 |
|                      | Phoenix      | 28046   | 26622 | 29304 | 6639  | 6109 | 7102 | 2284  | 2036 | 2483 |
|                      | Sacramento   | 10719   | 10490 | 10891 | 2239  | 2144 | 2315 | 677   | 629  | 715  |
|                      | St. Louis    | 14271   | 12662 | 15165 | 3207  | 2683 | 3577 | 1073  | 858  | 1252 |
| Adults with Asthma   | Atlanta      | 1714  | 1550  | 1902  | 352   | 282  | 423  | 117   | 70   | 141  |
|                      | Boston       | 2870  | 2544  | 3131  | 587   | 489  | 685  | 196   | 196  | 196  |
|                      | Dallas       | 1953  | 1797  | 2110  | 443   | 391  | 469  | 130   | 78   | 156  |
|                      | Detroit      | 2338  | 2163  | 2491  | 524   | 459  | 590  | 175   | 131  | 197  |
|                      | Philadelphia | 2585  | 2527  | 2701  | 552   | 523  | 610  | 174   | 174  | 174  |
|                      | Phoenix      | 2020  | 1937  | 2086  | 480   | 447  | 497  | 166   | 149  | 199  |
|                      | Sacramento   | 629   | 600   | 657   | 133   | 114  | 143  | 29  | 29   | 29   |
|                      | St. Louis    | 1132  | 1037  | 1180  | 250   | 215  | 286  | 84  | 72   | 107  |

<sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals experiencing decrements at the level).

**Table 3D-42. Percent of people estimated to experience at least two lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|------|------|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 1.4   | 1.3 | 1.6 | 0.3   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Boston       | 1.3   | 1.3 | 1.4 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Dallas       | 1.6   | 1.5 | 1.7 | 0.4   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.6   | 1.5 | 1.8 | 0.4   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.5   | 1.4 | 1.6 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 2.2   | 2.1 | 2.4 | 0.5   | 0.5  | 0.6  | 0.2   | 0.2  | 0.2  |
|                      | Sacramento   | 1.5   | 1.5 | 1.6 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.7   | 1.5 | 1.8 | 0.4   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
| Children with Asthma | Atlanta      | 1.6   | 1.4 | 1.7 | 0.3   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Boston       | 1.5   | 1.4 | 1.6 | 0.3   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Dallas       | 1.7   | 1.6 | 1.9 | 0.4   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.8   | 1.6 | 1.9 | 0.4   | 0.4  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.6   | 1.6 | 1.7 | 0.4   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 2.4   | 2.2 | 2.6 | 0.6   | 0.5  | 0.6  | 0.2   | 0.2  | 0.2  |
|                      | Sacramento   | 1.6   | 1.6 | 1.6 | 0.3   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.7   | 1.5 | 1.8 | 0.4   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
| Adults               | Atlanta      | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.6   | 0.6 | 0.6 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.3   | 0.3 | 0.3 | 0.1   | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.3   | 0.2 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.3   | 0.3 | 0.4 | 0.1   | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.5   | 0.4 | 0.5 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.3   | 0.3 | 0.3 | <0.1  | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-43. Number of people estimated to experience at least two lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |      |      |
|----------------------|--------------|---|-------|-------|---|------|------|---|------|------|
|                      |              | Avg   | Min   | Max   | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 17291   | 15395 | 19450 | 3632  | 3047 | 4277 | 1110  | 868  | 1372 |
|                      | Boston       | 18378   | 17430 | 19432 | 3891  | 3572 | 4278 | 1206  | 1069 | 1388 |
|                      | Dallas       | 22897   | 20572 | 24757 | 5036  | 4256 | 5722 | 1624  | 1277 | 1939 |
|                      | Detroit      | 17100   | 15973 | 18384 | 3896  | 3503 | 4370 | 1295  | 1127 | 1509 |
|                      | Philadelphia | 19992   | 18901 | 20909 | 4263  | 3972 | 4518 | 1324  | 1222 | 1419 |
|                      | Phoenix      | 18937   | 17748 | 20310 | 4529  | 4076 | 5039 | 1566  | 1359 | 1797 |
|                      | Sacramento   | 7200  | 6972  | 7415  | 1511  | 1436 | 1592 | 461   | 427  | 497  |
|                      | St. Louis    | 9222  | 8351  | 9790  | 2076  | 1803 | 2295 | 680   | 565  | 783  |
| Children with Asthma | Atlanta      | 2219  | 1977  | 2462  | 464   | 383  | 545  | 148   | 121  | 182  |
|                      | Boston       | 2526  | 2321  | 2662  | 539   | 478  | 592  | 159   | 137  | 182  |
|                      | Dallas       | 2278  | 2034  | 2483  | 496   | 402  | 567  | 158   | 118  | 189  |
|                      | Detroit      | 2064  | 1890  | 2220  | 468   | 416  | 520  | 156   | 139  | 173  |
|                      | Philadelphia | 2416  | 2292  | 2532  | 517   | 480  | 546  | 160   | 153  | 175  |
|                      | Phoenix      | 1948  | 1797  | 2109  | 467   | 410  | 524  | 161   | 142  | 184  |
|                      | Sacramento   | 717   | 699   | 753   | 153   | 148  | 163  | 49  | 47   | 54   |
|                      | St. Louis    | 941   | 856   | 1002  | 210   | 182  | 228  | 67  | 55   | 73   |
| Adults               | Atlanta      | 15542   | 14157 | 17468 | 2841  | 2465 | 3310 | 751   | 634  | 916  |
|                      | Boston       | 18654   | 17904 | 19274 | 3326  | 3131 | 3522 | 848   | 783  | 881  |
|                      | Dallas       | 19091   | 17893 | 19925 | 3542  | 3204 | 3829 | 990   | 859  | 1094 |
|                      | Detroit      | 14135   | 13567 | 14747 | 2731  | 2556 | 2949 | 765   | 721  | 852  |
|                      | Philadelphia | 18939   | 18126 | 19607 | 3457  | 3224 | 3660 | 930   | 871  | 959  |
|                      | Phoenix      | 17781   | 16986 | 18625 | 3708  | 3427 | 3973 | 1142  | 1043 | 1242 |
|                      | Sacramento   | 6536  | 6489  | 6574  | 1182  | 1172 | 1201 | 305   | 286  | 314  |
|                      | St. Louis    | 8203  | 7261  | 8870  | 1586  | 1323 | 1753 | 453   | 358  | 501  |
| Adults with Asthma   | Atlanta      | 1010  | 916   | 1127  | 188   | 141  | 211  | 70  | 70   | 70   |
|                      | Boston       | 1631  | 1468  | 1761  | 261   | 196  | 294  | 98  | 98   | 98   |
|                      | Dallas       | 1120  | 1094  | 1172  | 208   | 156  | 234  | 78  | 78   | 78   |
|                      | Detroit      | 1311  | 1245  | 1376  | 262   | 262  | 262  | 66  | 66   | 66   |
|                      | Philadelphia | 1452  | 1394  | 1569  | 261   | 261  | 261  | 87  | 87   | 87   |
|                      | Phoenix      | 1275  | 1192  | 1341  | 265   | 248  | 298  | 83  | 50   | 99   |
|                      | Sacramento   | 391   | 372   | 400   | 67  | 57   | 86   | 29  | 29   | 29   |
|                      | St. Louis    | 656   | 608   | 715   | 131   | 107  | 143  | 36  | 36   | 36   |

<sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals experiencing decrements at the level).

**Table 3D-44. Percent of people estimated to experience at least four lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|------|------|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 1.0   | 0.9 | 1.1 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | 0.1  |
|                      | Boston       | 0.8   | 0.8 | 0.9 | 0.2   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 1.1   | 1.0 | 1.1 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.0   | 1.0 | 1.1 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.0   | 0.9 | 1.1 | 0.2   | 0.2  | 0.2  | 0.1   | <0.1 | 0.1  |
|                      | Phoenix      | 1.6   | 1.5 | 1.7 | 0.4   | 0.3  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 1.1   | 1.0 | 1.1 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.1   | 1.0 | 1.2 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
| Children with Asthma | Atlanta      | 1.0   | 1.0 | 1.2 | 0.2   | 0.2  | 0.2  | 0.1   | <0.1 | 0.1  |
|                      | Boston       | 0.9   | 0.9 | 1.0 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | 0.1  |
|                      | Dallas       | 1.2   | 1.1 | 1.2 | 0.2   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.1   | 1.0 | 1.2 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.1   | 1.0 | 1.1 | 0.2   | 0.2  | 0.2  | 0.1   | <0.1 | 0.1  |
|                      | Phoenix      | 1.7   | 1.6 | 1.8 | 0.4   | 0.4  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 1.1   | 1.1 | 1.1 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.1   | 1.0 | 1.2 | 0.2   | 0.2  | 0.2  | 0.1   | <0.1 | 0.1  |
| Adults               | Atlanta      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Boston       | 0.1   | 0.1 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Dallas       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Detroit      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Philadelphia | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Phoenix      | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | St. Louis    | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-45. Number of people estimated to experience at least four lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |     |      |
|----------------------|--------------|---|-------|-------|---|------|------|---|-----|------|
|                      |              | Avg   | Min   | Max   | Avg   | Min  | Max  | Avg   | Min | Max  |
| Children             | Atlanta      | 11501   | 10371 | 12953 | 2179  | 1876 | 2542 | 592   | 484 | 726  |
|                      | Boston       | 11476   | 11127 | 11673 | 2131  | 2025 | 2207 | 561   | 523 | 592  |
|                      | Dallas       | 15259   | 14022 | 16197 | 3011  | 2648 | 3334 | 851   | 709 | 993  |
|                      | Detroit      | 10816   | 10180 | 11429 | 2174  | 1994 | 2359 | 636   | 572 | 711  |
|                      | Philadelphia | 13227   | 12310 | 13969 | 2539  | 2314 | 2728 | 698   | 611 | 764  |
|                      | Phoenix      | 13597   | 12823 | 14564 | 2972  | 2703 | 3284 | 948   | 835 | 1076 |
|                      | Sacramento   | 4935  | 4814  | 5023  | 944   | 908  | 978  | 256   | 241 | 272  |
|                      | St. Louis    | 6041  | 5446  | 6411  | 1214  | 1056 | 1302 | 352   | 291 | 382  |
| Children with Asthma | Atlanta      | 1486  | 1352  | 1654  | 282   | 242  | 323  | 81  | 61  | 101  |
|                      | Boston       | 1585  | 1502  | 1661  | 296   | 273  | 319  | 83  | 68  | 91   |
|                      | Dallas       | 1529  | 1395  | 1632  | 299   | 260  | 331  | 87  | 71  | 95   |
|                      | Detroit      | 1306  | 1197  | 1387  | 260   | 243  | 277  | 75  | 69  | 87   |
|                      | Philadelphia | 1593  | 1484  | 1702  | 306   | 284  | 327  | 80  | 65  | 87   |
|                      | Phoenix      | 1406  | 1316  | 1500  | 311   | 283  | 340  | 99  | 85  | 113  |
|                      | Sacramento   | 489   | 474   | 512   | 96  | 93   | 101  | 26  | 23  | 31   |
|                      | St. Louis    | 619   | 565   | 674   | 124   | 109  | 137  | 33  | 27  | 36   |
| Adults               | Atlanta      | 8969  | 8382  | 10072 | 1455  | 1338 | 1690 | 329   | 282 | 423  |
|                      | Boston       | 10534   | 10175 | 10762 | 1630  | 1565 | 1663 | 359   | 294 | 391  |
|                      | Dallas       | 10965   | 10548 | 11252 | 1823  | 1719 | 1875 | 417   | 391 | 469  |
|                      | Detroit      | 7865  | 7537  | 8127  | 1311  | 1245 | 1376 | 328   | 328 | 328  |
|                      | Philadelphia | 10922   | 10457 | 11241 | 1772  | 1656 | 1830 | 407   | 349 | 436  |
|                      | Phoenix      | 11093   | 10629 | 11672 | 2069  | 1937 | 2235 | 563   | 497 | 646  |
|                      | Sacramento   | 3992  | 3916  | 4059  | 648   | 629  | 657  | 143   | 143 | 143  |
|                      | St. Louis    | 4626  | 4113  | 5043  | 775   | 680  | 858  | 179   | 143 | 215  |
| Adults with Asthma   | Atlanta      | 587   | 563   | 634   | 70  | 70   | 70   | 0   | 0   | 0    |
|                      | Boston       | 913   | 783   | 978   | 131   | 98   | 196  | 0   | 0   | 0    |
|                      | Dallas       | 651   | 625   | 703   | 78  | 78   | 78   | 0   | 0   | 0    |
|                      | Detroit      | 721   | 655   | 786   | 131   | 131  | 131  | 0   | 0   | 0    |
|                      | Philadelphia | 813   | 784   | 871   | 116   | 87   | 174  | 0   | 0   | 0    |
|                      | Phoenix      | 778   | 745   | 844   | 149   | 149  | 149  | 50  | 50  | 50   |
|                      | Sacramento   | 229   | 229   | 229   | 29  | 29   | 29   | 0   | 0   | 0    |
|                      | St. Louis    | 358   | 322   | 393   | 60  | 36   | 72   | 0   | 0   | 0    |

<sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals experiencing decrements at the level).



**Table 3D-46. Percent of people estimated to experience at least one lung function decrement at or above the indicated level, for the 75 ppb air quality scenario, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|-----|-----|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min | Max | Avg   | Min  | Max  |
| Children             | Atlanta      | 2.8   | 2.4 | 3.2 | 0.8   | 0.6 | 1.0 | 0.3   | 0.2  | 0.4  |
|                      | Boston       | 2.4   | 2.3 | 2.7 | 0.7   | 0.6 | 0.8 | 0.3   | 0.2  | 0.3  |
|                      | Dallas       | 2.8   | 2.4 | 3.1 | 0.8   | 0.6 | 0.9 | 0.3   | 0.2  | 0.4  |
|                      | Detroit      | 3.0   | 2.7 | 3.4 | 0.9   | 0.8 | 1.0 | 0.4   | 0.3  | 0.5  |
|                      | Philadelphia | 2.9   | 2.7 | 3.0 | 0.8   | 0.8 | 0.8 | 0.3   | 0.3  | 0.3  |
|                      | Phoenix      | 3.8   | 3.5 | 4.1 | 1.1   | 1.0 | 1.3 | 0.5   | 0.4  | 0.6  |
|                      | Sacramento   | 2.8   | 2.7 | 2.9 | 0.8   | 0.7 | 0.8 | 0.3   | 0.3  | 0.3  |
|                      | St. Louis    | 3.1   | 2.7 | 3.3 | 0.9   | 0.8 | 1.0 | 0.4   | 0.3  | 0.4  |
| Children with Asthma | Atlanta      | 3.0   | 2.6 | 3.5 | 0.9   | 0.7 | 1.1 | 0.4   | 0.2  | 0.5  |
|                      | Boston       | 2.7   | 2.5 | 3.0 | 0.8   | 0.6 | 0.9 | 0.3   | 0.2  | 0.4  |
|                      | Dallas       | 3.0   | 2.6 | 3.3 | 0.8   | 0.7 | 1.0 | 0.3   | 0.3  | 0.4  |
|                      | Detroit      | 3.3   | 3.0 | 3.6 | 1.0   | 0.8 | 1.1 | 0.4   | 0.3  | 0.5  |
|                      | Philadelphia | 3.1   | 2.9 | 3.1 | 0.9   | 0.8 | 0.9 | 0.3   | 0.3  | 0.4  |
|                      | Phoenix      | 4.1   | 3.7 | 4.4 | 1.2   | 1.1 | 1.4 | 0.5   | 0.4  | 0.6  |
|                      | Sacramento   | 2.9   | 2.8 | 2.9 | 0.8   | 0.7 | 0.8 | 0.3   | 0.3  | 0.3  |
|                      | St. Louis    | 3.1   | 2.7 | 3.4 | 0.9   | 0.7 | 1.0 | 0.4   | 0.3  | 0.4  |
| Adults               | Atlanta      | 0.8   | 0.7 | 0.9 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Boston       | 0.6   | 0.6 | 0.7 | 0.1   | 0.1 | 0.2 | <0.1  | <0.1 | 0.1  |
|                      | Dallas       | 0.8   | 0.7 | 0.9 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 0.7   | 0.7 | 0.8 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 0.7   | 0.7 | 0.8 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 1.1   | 1.0 | 1.2 | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.7   | 0.7 | 0.8 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 0.8   | 0.7 | 0.8 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
| Adults with Asthma   | Atlanta      | 0.6   | 0.5 | 0.7 | 0.1   | 0.1 | 0.2 | <0.1  | <0.1 | 0.1  |
|                      | Boston       | 0.5   | 0.4 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.6   | 0.6 | 0.7 | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Detroit      | 0.6   | 0.6 | 0.7 | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Philadelphia | 0.6   | 0.6 | 0.6 | 0.1   | 0.1 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 0.9   | 0.8 | 0.9 | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.6   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.6   | 0.6 | 0.7 | 0.2   | 0.1 | 0.2 | 0.1   | 0.1  | 0.1  |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-47. Percent of people estimated to experience at least two lung function decrements at or above the indicated level, for the 75 ppb air quality scenario, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|------|-----|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min  | Max | Avg   | Min  | Max  |
| Children             | Atlanta      | 1.8   | 1.6 | 2.0 | 0.4   | 0.3  | 0.5 | 0.1   | 0.1  | 0.2  |
|                      | Boston       | 1.5   | 1.4 | 1.6 | 0.3   | 0.3  | 0.4 | 0.1   | 0.1  | 0.1  |
|                      | Dallas       | 1.9   | 1.6 | 2.1 | 0.4   | 0.4  | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Detroit      | 1.9   | 1.7 | 2.1 | 0.5   | 0.4  | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Philadelphia | 1.9   | 1.8 | 1.9 | 0.4   | 0.4  | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Phoenix      | 2.7   | 2.5 | 2.9 | 0.7   | 0.6  | 0.8 | 0.3   | 0.2  | 0.3  |
|                      | Sacramento   | 1.9   | 1.8 | 1.9 | 0.4   | 0.4  | 0.5 | 0.1   | 0.1  | 0.2  |
|                      | St. Louis    | 2.0   | 1.8 | 2.1 | 0.5   | 0.4  | 0.5 | 0.2   | 0.1  | 0.2  |
| Children with Asthma | Atlanta      | 1.9   | 1.7 | 2.2 | 0.5   | 0.4  | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Boston       | 1.7   | 1.5 | 1.8 | 0.4   | 0.3  | 0.4 | 0.1   | 0.1  | 0.2  |
|                      | Dallas       | 2.0   | 1.8 | 2.2 | 0.5   | 0.4  | 0.6 | 0.2   | 0.1  | 0.2  |
|                      | Detroit      | 2.0   | 1.9 | 2.2 | 0.5   | 0.5  | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | Philadelphia | 2.0   | 1.9 | 2.1 | 0.5   | 0.4  | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Phoenix      | 2.9   | 2.7 | 3.1 | 0.8   | 0.7  | 0.9 | 0.3   | 0.3  | 0.3  |
|                      | Sacramento   | 1.9   | 1.9 | 2.0 | 0.5   | 0.4  | 0.5 | 0.1   | 0.1  | 0.2  |
|                      | St. Louis    | 2.0   | 1.8 | 2.1 | 0.5   | 0.4  | 0.5 | 0.2   | 0.1  | 0.2  |
| Adults               | Atlanta      | 0.4   | 0.4 | 0.5 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.4   | 0.4 | 0.5 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.7   | 0.6 | 0.7 | 0.2   | 0.1  | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Sacramento   | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.4   | 0.4 | 0.5 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.3   | 0.2 | 0.3 | 0.1   | <0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.5   | 0.5 | 0.6 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | 0.1  |
|                      | Sacramento   | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-48. Percent of people estimated to experience at least four lung function decrements at or above the indicated level, for the 75 ppb air quality scenario, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|------|------|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 1.2   | 1.0 | 1.3 | 0.2   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Boston       | 0.9   | 0.9 | 0.9 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | 0.1  |
|                      | Dallas       | 1.2   | 1.1 | 1.3 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.2   | 1.1 | 1.3 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.2   | 1.1 | 1.3 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 1.9   | 1.8 | 2.0 | 0.5   | 0.4  | 0.5  | 0.2   | 0.1  | 0.2  |
|                      | Sacramento   | 1.3   | 1.2 | 1.3 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.3   | 1.1 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
| Children with Asthma | Atlanta      | 1.3   | 1.2 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Boston       | 1.0   | 1.0 | 1.1 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | Dallas       | 1.3   | 1.2 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.2   | 1.2 | 1.3 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.3   | 1.2 | 1.4 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 2.0   | 1.9 | 2.2 | 0.5   | 0.4  | 0.6  | 0.2   | 0.2  | 0.2  |
|                      | Sacramento   | 1.3   | 1.3 | 1.3 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.3   | 1.1 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
| Adults               | Atlanta      | 0.2   | 0.2 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.3   | 0.2 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.3   | 0.3 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.2   | 0.2 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Boston       | 0.1   | 0.1 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Dallas       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Detroit      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | 0    | <0.1 |
|                      | Philadelphia | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Phoenix      | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | St. Louis    | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | 0    | <0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-49. Percent of people estimated to experience at least one lung function decrement at or above the indicated level, for the 65 ppb air quality scenario, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|-----|-----|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min | Max | Avg   | Min  | Max  |
| Children             | Atlanta      | 1.7   | 1.5 | 1.9 | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  |
|                      | Boston       | 1.8   | 1.7 | 1.9 | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.2  |
|                      | Dallas       | 2.0   | 1.8 | 2.1 | 0.5   | 0.4 | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Detroit      | 2.0   | 1.9 | 2.2 | 0.5   | 0.4 | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Philadelphia | 1.9   | 1.8 | 2.0 | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 2.4   | 2.3 | 2.6 | 0.6   | 0.5 | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | Sacramento   | 1.7   | 1.7 | 1.7 | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 2.0   | 1.8 | 2.1 | 0.4   | 0.4 | 0.5 | 0.1   | 0.1  | 0.2  |
| Children with Asthma | Atlanta      | 1.8   | 1.6 | 2.0 | 0.4   | 0.3 | 0.5 | 0.1   | 0.1  | 0.2  |
|                      | Boston       | 2.0   | 1.9 | 2.1 | 0.4   | 0.4 | 0.5 | 0.1   | 0.1  | 0.2  |
|                      | Dallas       | 2.2   | 2.0 | 2.3 | 0.5   | 0.4 | 0.5 | 0.2   | 0.1  | 0.2  |
|                      | Detroit      | 2.2   | 2.1 | 2.4 | 0.5   | 0.5 | 0.6 | 0.2   | 0.2  | 0.2  |
|                      | Philadelphia | 2.0   | 2.0 | 2.1 | 0.5   | 0.4 | 0.5 | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 2.6   | 2.4 | 2.8 | 0.6   | 0.5 | 0.7 | 0.2   | 0.2  | 0.2  |
|                      | Sacramento   | 1.7   | 1.7 | 1.8 | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 2.0   | 1.8 | 2.2 | 0.5   | 0.4 | 0.5 | 0.1   | 0.1  | 0.2  |
| Adults               | Atlanta      | 0.5   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.5   | 0.5 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.6   | 0.6 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.5   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.5   | 0.5 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.8   | 0.7 | 0.8 | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | 0.1  |
|                      | Sacramento   | 0.5   | 0.5 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.6   | 0.5 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.4   | 0.4 | 0.4 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.4   | 0.4 | 0.4 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.5   | 0.5 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.5   | 0.5 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.4   | 0.4 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.6   | 0.6 | 0.6 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.4   | 0.4 | 0.4 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.5   | 0.4 | 0.5 | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-50. Percent of people estimated to experience at least two lung function decrements at or above the indicated level, for the 65 ppb air quality scenario, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|------|------|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 1.1   | 1.0 | 1.3 | 0.2   | 0.2  | 0.2  | 0.1   | <0.1 | 0.1  |
|                      | Boston       | 1.1   | 1.1 | 1.2 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | Dallas       | 1.4   | 1.3 | 1.5 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.4   | 1.3 | 1.4 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.3   | 1.2 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 1.8   | 1.7 | 1.9 | 0.4   | 0.4  | 0.4  | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 1.2   | 1.2 | 1.2 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.4   | 1.2 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
| Children with Asthma | Atlanta      | 1.2   | 1.1 | 1.4 | 0.2   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Boston       | 1.3   | 1.2 | 1.3 | 0.2   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Dallas       | 1.5   | 1.4 | 1.6 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Detroit      | 1.5   | 1.4 | 1.5 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Philadelphia | 1.4   | 1.3 | 1.5 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Phoenix      | 1.9   | 1.8 | 2.1 | 0.4   | 0.4  | 0.5  | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 1.2   | 1.2 | 1.3 | 0.2   | 0.2  | 0.2  | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 1.4   | 1.2 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
| Adults               | Atlanta      | 0.3   | 0.3 | 0.3 | 0.1   | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.3   | 0.3 | 0.3 | <0.1  | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.5   | 0.5 | 0.5 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.2   | 0.2 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | 0    | <0.1 |
|                      | Boston       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.3   | 0.3 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.3   | 0.3 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.3   | 0.2 | 0.3 | <0.1  | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | St. Louis    | 0.3   | 0.2 | 0.3 | <0.1  | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-51. Percent of people estimated to experience at least four lung function decrements at or above the indicated level, for the 65 ppb air quality scenario, using the population-based (E-R function) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|------|------|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 0.8   | 0.7 | 0.9 | 0.1   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.7   | 0.7 | 0.7 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.9   | 0.9 | 1.0 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | 0.1  |
|                      | Detroit      | 0.9   | 0.8 | 0.9 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.9   | 0.8 | 0.9 | 0.2   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 1.3   | 1.2 | 1.4 | 0.3   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.8   | 0.8 | 0.9 | 0.1   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.9   | 0.8 | 1.0 | 0.2   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
| Children with Asthma | Atlanta      | 0.8   | 0.8 | 0.9 | 0.1   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.8   | 0.8 | 0.8 | 0.1   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 1.0   | 0.9 | 1.1 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | 0.1  |
|                      | Detroit      | 0.9   | 0.9 | 1.0 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.9   | 0.9 | 1.0 | 0.2   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 1.4   | 1.3 | 1.5 | 0.3   | 0.3  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.9   | 0.9 | 0.9 | 0.2   | 0.2  | 0.2  | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.9   | 0.8 | 1.0 | 0.2   | 0.1  | 0.2  | <0.1  | <0.1 | <0.1 |
| Adults               | Atlanta      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Boston       | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Dallas       | 0.2   | 0.2 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Detroit      | 0.2   | 0.1 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Philadelphia | 0.1   | 0.1 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | Phoenix      | 0.2   | 0.2 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | <0.1 | <0.1 |
|                      | Sacramento   | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |
|                      | St. Louis    | 0.2   | 0.1 | 0.2 | <0.1  | <0.1 | <0.1 | 0   | 0    | 0    |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

### 3D.3.3.2 Individual-based (MSS Model) Risk Approach

Lung function decrements estimated using the individual-based (MSS model) risk approach are about a factor of four or greater than those estimated using the population-based (E-R function) risk approach (Table 3D-52 through Table 3D-63). The estimated risk of at least one lung function decrement at or above 15% could be as high as 7.8% of children (and 8.7% of children with asthma) considering the worst year air quality and air quality just meeting the current standard, with the average across the 3-year period ranging from about 4.1% to 7.1% of children (and 4.5 to 8.2% of children with asthma) across the eight study areas (Table 3D-52). Recall that when using the E-R approach for the same air quality scenario, only about 1% of children were estimated to experience a decrement at or above 15% in the worst single year, worst area, and between 0.5 to 0.9% on average across the three years. This difference in estimated risks is generally similar to the comparison of the two approaches provided in the 2014 HREA (2014 HREA, Table 6-8) and is directly a result of the differences that exist between the approaches. While both of these risk approaches allow for exposures at and below that observed in the controlled human exposure studies, the MSS model does not have a strict restriction regarding the magnitude of the ventilation rate or its duration. The impact of these important model inputs (i.e., exposure, ventilation rate, and their duration) on the E-R and MSS risk results is discussed further in section 3D.3.4.

**Table 3D-52. Percent of people estimated to experience at least one lung function decrement at or above the indicated level, for air quality adjusted to just meet the current standard, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|---|------|------|---|-----|-----|---|-----|-----|
|                      |              | Avg   | Min  | Max  | Avg   | Min | Max | Avg   | Min | Max |
| Children             | Atlanta      | 13.2  | 11.7 | 15.1 | 4.1   | 3.4 | 5.0 | 1.7   | 1.3 | 2.1 |
|                      | Boston       | 13.2  | 12.4 | 14.1 | 4.4   | 4.0 | 5.0 | 1.9   | 1.6 | 2.3 |
|                      | Dallas       | 14.6  | 13.1 | 15.7 | 4.9   | 4.0 | 5.4 | 2.1   | 1.6 | 2.5 |
|                      | Detroit      | 15.6  | 14.4 | 16.9 | 5.4   | 4.8 | 6.1 | 2.4   | 2   | 2.7 |
|                      | Philadelphia | 14.5  | 13.6 | 15.0 | 4.6   | 4.3 | 4.8 | 1.9   | 1.8 | 1.9 |
|                      | Phoenix      | 20.4  | 19.4 | 21.8 | 7.1   | 6.4 | 7.8 | 3.1   | 2.7 | 3.6 |
|                      | Sacramento   | 14.3  | 13.8 | 14.7 | 4.4   | 4.3 | 4.7 | 1.8   | 1.7 | 2   |
|                      | St. Louis    | 15.4  | 14.0 | 16.3 | 5.2   | 4.5 | 5.9 | 2.2   | 1.9 | 2.7 |
| Children with Asthma | Atlanta      | 14.4  | 12.5 | 16.6 | 4.5   | 3.4 | 5.9 | 1.9   | 1.5 | 2.6 |
|                      | Boston       | 13.9  | 12.9 | 14.7 | 4.8   | 4.4 | 5.4 | 2   | 1.7 | 2.4 |
|                      | Dallas       | 15.7  | 13.6 | 16.9 | 5.4   | 4.5 | 5.9 | 2.5   | 1.8 | 2.8 |
|                      | Detroit      | 16.8  | 15.3 | 18.4 | 6.2   | 5.7 | 6.9 | 2.7   | 2.3 | 3.3 |
|                      | Philadelphia | 15.2  | 15.0 | 15.5 | 4.8   | 4.6 | 5.3 | 1.9   | 1.8 | 2.1 |
|                      | Phoenix      | 22.0  | 20.4 | 23.3 | 8.2   | 7.6 | 8.7 | 3.5   | 3   | 3.9 |
|                      | Sacramento   | 14.7  | 14.2 | 15.0 | 4.5   | 4.3 | 4.8 | 1.8   | 1.6 | 2.1 |
|                      | St. Louis    | 15.8  | 14.5 | 16.5 | 5.4   | 4.7 | 5.8 | 2.4   | 2   | 2.8 |
| Adults               | Atlanta      | 2.5   | 2.3  | 2.8  | 0.7   | 0.6 | 0.8 | 0.3   | 0.2 | 0.4 |
|                      | Boston       | 2.3   | 2.1  | 2.5  | 0.6   | 0.6 | 0.7 | 0.3   | 0.2 | 0.3 |
|                      | Dallas       | 2.9   | 2.6  | 3.1  | 0.8   | 0.7 | 1.0 | 0.3   | 0.3 | 0.4 |
|                      | Detroit      | 2.6   | 2.5  | 2.8  | 0.8   | 0.7 | 0.9 | 0.3   | 0.3 | 0.4 |
|                      | Philadelphia | 2.5   | 2.4  | 2.6  | 0.7   | 0.7 | 0.7 | 0.3   | 0.3 | 0.3 |
|                      | Phoenix      | 4.4   | 4.1  | 4.8  | 1.4   | 1.3 | 1.5 | 0.6   | 0.6 | 0.6 |
|                      | Sacramento   | 2.6   | 2.6  | 2.6  | 0.7   | 0.6 | 0.7 | 0.3   | 0.3 | 0.3 |
|                      | St. Louis    | 2.7   | 2.3  | 2.9  | 0.8   | 0.7 | 0.9 | 0.3   | 0.3 | 0.4 |
| Adults with Asthma   | Atlanta      | 2.3   | 2.2  | 2.4  | 0.6   | 0.6 | 0.7 | 0.2   | 0.1 | 0.3 |
|                      | Boston       | 2.0   | 1.8  | 2.4  | 0.5   | 0.4 | 0.6 | 0.2   | 0.1 | 0.3 |
|                      | Dallas       | 2.5   | 2.1  | 2.9  | 0.7   | 0.5 | 1.0 | 0.3   | 0.1 | 0.5 |
|                      | Detroit      | 2.5   | 2.2  | 2.6  | 0.7   | 0.6 | 0.8 | 0.4   | 0.2 | 0.5 |
|                      | Philadelphia | 2.2   | 2.1  | 2.4  | 0.6   | 0.4 | 0.7 | 0.2   | 0.1 | 0.3 |
|                      | Phoenix      | 3.5   | 3.1  | 3.8  | 1.1   | 1.0 | 1.2 | 0.5   | 0.4 | 0.6 |
|                      | Sacramento   | 2.0   | 2.0  | 2.1  | 0.6   | 0.5 | 0.6 | 0.2   | 0.2 | 0.3 |
|                      | St. Louis    | 2.6   | 2.2  | 2.9  | 0.7   | 0.6 | 0.8 | 0.3   | 0.2 | 0.4 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".



**Table 3D-53. Number of people estimated to experience at least one lung function decrement at or above the indicated level, for air quality adjusted to just meet the current standard, using the individual-based (MSS model) risk approach.**

| Study Group  | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |        |        | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       |
|--|--------------|---|--------|--------|---|-------|-------|---|-------|-------|
|  |              | Avg   | Min    | Max    | Avg   | Min   | Max   | Avg   | Min   | Max   |
| Children   | Atlanta      | 159429  | 141680 | 182558 | 49769   | 40676 | 60328 | 20378   | 15233 | 25685 |
|  | Boston       | 179806  | 168747 | 192821 | 60125   | 55225 | 68218 | 26251   | 22368 | 31924 |
|  | Dallas       | 207221  | 185830 | 222622 | 68911   | 57317 | 76942 | 29588   | 22747 | 34853 |
|  | Detroit      | 162690  | 149480 | 176362 | 56695   | 50434 | 63632 | 24708   | 21037 | 28547 |
|  | Philadelphia | 189412  | 178688 | 196192 | 60159   | 56856 | 62400 | 24692   | 23615 | 25449 |
|  | Phoenix      | 173383  | 164589 | 185182 | 60104   | 54688 | 65827 | 26306   | 22773 | 30302 |
|  | Sacramento   | 66574   | 64364  | 68293  | 20665   | 20024 | 21871 | 8473  | 7904  | 9286  |
|  | St. Louis    | 84339   | 76632  | 89017  | 28337   | 24351 | 32356 | 12185   | 10309 | 14507 |
| Children with Asthma   | Atlanta      | 20513   | 17776  | 23929  | 6356  | 4802  | 8434  | 2670  | 2078  | 3733  |
|  | Boston       | 23353   | 21366  | 24529  | 8002  | 7259  | 9056  | 3390  | 2844  | 3959  |
|  | Dallas       | 20485   | 17781  | 22298  | 7093  | 5911  | 7779  | 3208  | 2388  | 3689  |
|  | Detroit      | 19702   | 17603  | 21662  | 7226  | 6521  | 8151  | 3197  | 2653  | 3902  |
|  | Philadelphia | 22393   | 21869  | 23135  | 7115  | 6701  | 7923  | 2859  | 2575  | 3099  |
|  | Phoenix      | 17885   | 16460  | 18994  | 6690  | 6114  | 7119  | 2854  | 2434  | 3199  |
|  | Sacramento   | 6625  | 6328   | 6972   | 2058  | 1941  | 2244  | 807   | 699   | 978   |
|  | St. Louis    | 8852  | 8278   | 9234   | 3008  | 2650  | 3206  | 1327  | 1157  | 1512  |
| Adults   | Atlanta      | 105509  | 97903  | 117483 | 29535   | 25779 | 35639 | 11692   | 8804  | 15284 |
|  | Boston       | 135567  | 121022 | 149395 | 37732   | 32286 | 41874 | 16110   | 12229 | 18295 |
|  | Dallas       | 133978  | 119705 | 144083 | 39563   | 33442 | 44694 | 15680   | 13127 | 19222 |
|  | Detroit      | 104123  | 97067  | 110175 | 30411   | 26872 | 33426 | 11994   | 10159 | 13764 |
|  | Philadelphia | 131672  | 124004 | 135506 | 36048   | 35118 | 37123 | 14175   | 14030 | 14466 |
|  | Phoenix      | 131520  | 121636 | 143440 | 41440   | 40132 | 43658 | 17367   | 16887 | 18327 |
|  | Sacramento   | 43953   | 43734  | 44306  | 11643   | 10948 | 12291 | 4840  | 4802  | 4888  |
|  | St. Louis    | 57287   | 48965  | 62593  | 17168   | 13985 | 19207 | 6974  | 5508  | 8226  |
| Adults with Asthma   | Atlanta      | 8123  | 7677   | 8875   | 2278  | 2043  | 2395  | 751   | 493   | 1127  |
|  | Boston       | 12980   | 11447  | 15067  | 3229  | 2348  | 3816  | 1337  | 881   | 1663  |
|  | Dallas       | 8413  | 6876   | 9611   | 2344  | 1563  | 3360  | 912   | 391   | 1641  |
|  | Detroit      | 10508   | 9241   | 11273  | 3059  | 2359  | 3474  | 1529  | 852   | 1966  |
|  | Philadelphia | 11241   | 10631  | 12026  | 2905  | 1917  | 3399  | 1220  | 436   | 1656  |
|  | Phoenix      | 9520  | 8543   | 10232  | 2980  | 2632  | 3328  | 1358  | 1093  | 1738  |
|  | Sacramento   | 2811  | 2716   | 2887   | 762   | 715   | 800   | 305   | 229   | 343   |
|  | St. Louis    | 5258  | 4435   | 5687   | 1503  | 1288  | 1610  | 548   | 322   | 715   |
| <sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals experiencing decrements at the level). |              |   |        |        |   |       |       |   |       |       |

**Table 3D-54. Percent of people estimated to experience at least two lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |     |
|----------------------|--------------|---|------|------|---|-----|-----|---|------|-----|
|                      |              | Avg   | Min  | Max  | Avg   | Min | Max | Avg   | Min  | Max |
| Children             | Atlanta      | 7.7   | 6.7  | 9.1  | 2.1   | 1.7 | 2.6 | 0.8   | 0.6  | 1.0 |
|                      | Boston       | 7.4   | 6.9  | 7.9  | 2.1   | 1.9 | 2.4 | 0.8   | 0.7  | 0.9 |
|                      | Dallas       | 8.8   | 7.8  | 9.5  | 2.6   | 2.0 | 3.0 | 1.0   | 0.7  | 1.2 |
|                      | Detroit      | 9.4   | 8.5  | 10.3 | 2.9   | 2.5 | 3.3 | 1.1   | 0.9  | 1.3 |
|                      | Philadelphia | 8.7   | 8.0  | 9.1  | 2.4   | 2.3 | 2.5 | 0.9   | 0.8  | 0.9 |
|                      | Phoenix      | 13.6  | 12.8 | 14.8 | 4.3   | 3.8 | 4.9 | 1.7   | 1.5  | 2   |
|                      | Sacramento   | 8.7   | 8.3  | 8.9  | 2.4   | 2.3 | 2.5 | 0.8   | 0.8  | 0.9 |
|                      | St. Louis    | 9.3   | 8.2  | 10.0 | 2.8   | 2.3 | 3.1 | 1.1   | 0.9  | 1.2 |
| Children with Asthma | Atlanta      | 8.3   | 6.9  | 10.2 | 2.2   | 1.7 | 3.3 | 0.8   | 0.6  | 1.2 |
|                      | Boston       | 8.0   | 7.7  | 8.6  | 2.3   | 2.1 | 2.5 | 0.9   | 0.9  | 0.9 |
|                      | Dallas       | 9.6   | 8.1  | 10.5 | 3.1   | 2.4 | 3.5 | 1.1   | 0.8  | 1.4 |
|                      | Detroit      | 10.3  | 9.3  | 11.5 | 3.3   | 2.9 | 3.9 | 1.3   | 1.1  | 1.5 |
|                      | Philadelphia | 9.3   | 8.6  | 9.7  | 2.5   | 2.3 | 2.6 | 0.9   | 0.7  | 1   |
|                      | Phoenix      | 14.9  | 13.7 | 16.0 | 4.9   | 4.4 | 5.3 | 2.1   | 1.8  | 2.5 |
|                      | Sacramento   | 8.9   | 8.4  | 9.3  | 2.5   | 2.2 | 2.8 | 0.8   | 0.5  | 1.2 |
|                      | St. Louis    | 9.4   | 8.5  | 9.9  | 2.9   | 2.5 | 3.1 | 1.1   | 0.9  | 1.4 |
| Adults               | Atlanta      | 1.2   | 1.0  | 1.4  | 0.3   | 0.2 | 0.4 | 0.1   | 0.1  | 0.1 |
|                      | Boston       | 1.0   | 0.9  | 1.1  | 0.3   | 0.2 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | Dallas       | 1.4   | 1.2  | 1.5  | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1 |
|                      | Detroit      | 1.2   | 1.1  | 1.3  | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1 |
|                      | Philadelphia | 1.2   | 1.2  | 1.2  | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | Phoenix      | 2.4   | 2.3  | 2.6  | 0.7   | 0.7 | 0.7 | 0.3   | 0.2  | 0.3 |
|                      | Sacramento   | 1.2   | 1.2  | 1.2  | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | St. Louis    | 1.3   | 1.0  | 1.4  | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1 |
| Adults with Asthma   | Atlanta      | 1.1   | 0.9  | 1.2  | 0.2   | 0.2 | 0.3 | 0.1   | <0.1 | 0.2 |
|                      | Boston       | 0.8   | 0.7  | 0.9  | 0.2   | 0.2 | 0.3 | 0.1   | <0.1 | 0.1 |
|                      | Dallas       | 1.1   | 0.9  | 1.4  | 0.3   | 0.1 | 0.4 | 0.1   | <0.1 | 0.3 |
|                      | Detroit      | 1.1   | 1.0  | 1.2  | 0.3   | 0.2 | 0.4 | 0.1   | 0.1  | 0.2 |
|                      | Philadelphia | 1.0   | 0.9  | 1.2  | 0.2   | 0.1 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | Phoenix      | 2.0   | 1.8  | 2.1  | 0.6   | 0.5 | 0.7 | 0.2   | 0.2  | 0.2 |
|                      | Sacramento   | 1.0   | 0.9  | 1.0  | 0.2   | 0.2 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | St. Louis    | 1.1   | 0.9  | 1.3  | 0.3   | 0.2 | 0.4 | 0.1   | <0.1 | 0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-55. Number of people estimated to experience at least two lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |        |        | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       |
|----------------------|--------------|---|--------|--------|---|-------|-------|---|-------|-------|
|                      |              | Avg   | Min    | Max    | Avg   | Min   | Max   | Avg   | Min   | Max   |
| Children             | Atlanta      | 92853   | 80585  | 110689 | 25537   | 20338 | 32040 | 9308  | 7042  | 11904 |
|                      | Boston       | 100764  | 94590  | 107742 | 29058   | 25849 | 32471 | 10816   | 9079  | 12697 |
|                      | Dallas       | 124935  | 109975 | 134637 | 36832   | 28658 | 42869 | 13738   | 10475 | 16410 |
|                      | Detroit      | 97682   | 87982  | 107267 | 29946   | 26015 | 33819 | 11643   | 9729  | 13302 |
|                      | Philadelphia | 113291  | 104546 | 118929 | 31574   | 29508 | 32913 | 11226   | 10324 | 11677 |
|                      | Phoenix      | 115472  | 108372 | 125399 | 36615   | 32468 | 41342 | 14766   | 12596 | 17210 |
|                      | Sacramento   | 40342   | 38712  | 41406  | 10991   | 10559 | 11848 | 3822  | 3540  | 4371  |
|                      | St. Louis    | 50799   | 44731  | 54612  | 15129   | 12704 | 17175 | 5795  | 4826  | 6775  |
| Children with Asthma | Atlanta      | 11850   | 9725   | 14608  | 3208  | 2361  | 4681  | 1123  | 807   | 1715  |
|                      | Boston       | 13433   | 12788  | 14267  | 3846  | 3390  | 4210  | 1517  | 1434  | 1570  |
|                      | Dallas       | 12532   | 10570  | 13785  | 4051  | 3121  | 4587  | 1490  | 1017  | 1773  |
|                      | Detroit      | 12036   | 10649  | 13510  | 3850  | 3295  | 4544  | 1515  | 1214  | 1821  |
|                      | Philadelphia | 13612   | 12572  | 14449  | 3660  | 3318  | 3841  | 1317  | 1091  | 1484  |
|                      | Phoenix      | 12091   | 11025  | 13049  | 4015  | 3552  | 4331  | 1703  | 1429  | 1996  |
|                      | Sacramento   | 4040  | 3773   | 4294   | 1121  | 994   | 1320  | 368   | 233   | 536   |
|                      | St. Louis    | 5270  | 4863   | 5509   | 1627  | 1421  | 1739  | 619   | 501   | 747   |
| Adults               | Atlanta      | 48670   | 43528  | 58037  | 12091   | 10354 | 15495 | 4226  | 3029  | 6198  |
|                      | Boston       | 59908   | 55473  | 63495  | 15426   | 12621 | 17513 | 5479  | 4305  | 6164  |
|                      | Dallas       | 63629   | 57118  | 68916  | 16096   | 13908 | 18675 | 5912  | 5391  | 6720  |
|                      | Detroit      | 48523   | 44634  | 52368  | 13130   | 11142 | 14681 | 4566  | 3867  | 5571  |
|                      | Philadelphia | 61406   | 60128  | 62830  | 14146   | 13856 | 14640 | 5025  | 4706  | 5316  |
|                      | Phoenix      | 72697   | 68690  | 78624  | 21043   | 20513 | 21655 | 7665  | 7152  | 8642  |
|                      | Sacramento   | 21086   | 21038  | 21152  | 5203  | 5088  | 5260  | 1906  | 1887  | 1944  |
|                      | St. Louis    | 27183   | 21174  | 30545  | 6927  | 5437  | 7762  | 2528  | 1896  | 3040  |
| Adults with Asthma   | Atlanta      | 3804  | 3381   | 4367   | 845   | 634   | 986   | 305   | 141   | 563   |
|                      | Boston       | 5316  | 4598   | 5870   | 1370  | 978   | 1859  | 424   | 196   | 587   |
|                      | Dallas       | 3620  | 2891   | 4532   | 938   | 469   | 1485  | 416   | 156   | 859   |
|                      | Detroit      | 4719  | 4064   | 5047   | 1442  | 983   | 1704  | 546   | 328   | 852   |
|                      | Philadelphia | 5170  | 4357   | 6013   | 1220  | 610   | 1569  | 378   | 261   | 436   |
|                      | Phoenix      | 5281  | 4818   | 5612   | 1639  | 1341  | 1788  | 596   | 497   | 646   |
|                      | Sacramento   | 1324  | 1258   | 1429   | 324   | 257   | 400   | 153   | 143   | 172   |
|                      | St. Louis    | 2313  | 1860   | 2611   | 632   | 501   | 787   | 179   | 72    | 286   |

<sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals experiencing decrements at the level).

**Table 3D-56. Percent of people estimated to experience at least four lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|------|---|------|-----|---|------|------|
|                      |              | Avg   | Min | Max  | Avg   | Min  | Max | Avg   | Min  | Max  |
| Children             | Atlanta      | 4.3   | 3.6 | 5.2  | 1.0   | 0.8  | 1.3 | 0.3   | 0.2  | 0.4  |
|                      | Boston       | 3.9   | 3.7 | 4.0  | 1.0   | 0.9  | 1.1 | 0.3   | 0.2  | 0.3  |
|                      | Dallas       | 5.1   | 4.4 | 5.4  | 1.3   | 1.0  | 1.5 | 0.4   | 0.3  | 0.5  |
|                      | Detroit      | 5.2   | 4.7 | 5.7  | 1.4   | 1.2  | 1.5 | 0.5   | 0.4  | 0.5  |
|                      | Philadelphia | 4.8   | 4.3 | 5.1  | 1.2   | 1.0  | 1.3 | 0.4   | 0.3  | 0.4  |
|                      | Phoenix      | 8.8   | 8.2 | 9.7  | 2.5   | 2.2  | 2.9 | 0.9   | 0.8  | 1.1  |
|                      | Sacramento   | 5.0   | 4.8 | 5.2  | 1.2   | 1.1  | 1.3 | 0.4   | 0.3  | 0.4  |
|                      | St. Louis    | 5.3   | 4.5 | 5.8  | 1.4   | 1.2  | 1.6 | 0.5   | 0.4  | 0.5  |
| Children with Asthma | Atlanta      | 4.7   | 4.0 | 6.0  | 1.2   | 0.9  | 1.7 | 0.3   | 0.2  | 0.6  |
|                      | Boston       | 4.3   | 4.1 | 4.4  | 1.1   | 0.9  | 1.3 | 0.3   | 0.3  | 0.4  |
|                      | Dallas       | 5.7   | 4.9 | 6.2  | 1.4   | 1.1  | 1.7 | 0.5   | 0.3  | 0.6  |
|                      | Detroit      | 5.8   | 5.4 | 6.3  | 1.6   | 1.4  | 1.8 | 0.5   | 0.4  | 0.7  |
|                      | Philadelphia | 5.1   | 4.9 | 5.6  | 1.3   | 1.2  | 1.5 | 0.4   | 0.3  | 0.5  |
|                      | Phoenix      | 9.8   | 9.2 | 10.5 | 2.9   | 2.6  | 3.3 | 1.1   | 0.9  | 1.3  |
|                      | Sacramento   | 5.1   | 4.9 | 5.3  | 1.2   | 1.1  | 1.5 | 0.5   | 0.3  | 0.7  |
|                      | St. Louis    | 5.4   | 4.8 | 5.7  | 1.5   | 1.3  | 1.8 | 0.5   | 0.4  | 0.6  |
| Adults               | Atlanta      | 0.5   | 0.4 | 0.6  | 0.1   | 0.1  | 0.2 | <0.1  | <0.1 | 0.1  |
|                      | Boston       | 0.4   | 0.4 | 0.5  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.6   | 0.5 | 0.7  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | 0.1  |
|                      | Detroit      | 0.5   | 0.5 | 0.6  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.5   | 0.5 | 0.5  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 1.3   | 1.2 | 1.4  | 0.3   | 0.3  | 0.4 | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.6   | 0.6 | 0.6  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.5   | 0.4 | 0.6  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | 0.1  |
| Adults with Asthma   | Atlanta      | 0.5   | 0.4 | 0.6  | 0.1   | <0.1 | 0.2 | <0.1  | 0    | 0.1  |
|                      | Boston       | 0.3   | 0.2 | 0.4  | 0.1   | <0.1 | 0.1 | <0.1  | 0    | <0.1 |
|                      | Dallas       | 0.5   | 0.3 | 0.8  | 0.2   | 0.1  | 0.3 | <0.1  | <0.1 | 0.1  |
|                      | Detroit      | 0.5   | 0.3 | 0.6  | 0.1   | <0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Philadelphia | 0.5   | 0.3 | 0.6  | 0.1   | <0.1 | 0.1 | <0.1  | 0    | 0.1  |
|                      | Phoenix      | 1.0   | 0.8 | 1.0  | 0.3   | 0.2  | 0.3 | 0.1   | <0.1 | 0.1  |
|                      | Sacramento   | 0.5   | 0.4 | 0.5  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | 0.1  |
|                      | St. Louis    | 0.5   | 0.4 | 0.5  | 0.1   | 0.1  | 0.1 | <0.1  | <0.1 | 0.1  |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-57. Number of people estimated to experience at least four lung function decrements at or above the indicated level, for air quality adjusted to just meet the current standard, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |       |       | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(# per Year) |      |      |
|----------------------|--------------|---|-------|-------|---|-------|-------|---|------|------|
|                      |              | Avg   | Min   | Max   | Avg   | Min   | Max   | Avg   | Min  | Max  |
| Children             | Atlanta      | 51699   | 44106 | 63455 | 12355   | 9967  | 15536 | 3780  | 2764 | 5206 |
|                      | Boston       | 53018   | 51152 | 54929 | 13205   | 11832 | 14358 | 3921  | 3390 | 4323 |
|                      | Dallas       | 71709   | 62140 | 77108 | 18302   | 14282 | 21352 | 6101  | 4540 | 7094 |
|                      | Detroit      | 54058   | 48613 | 59001 | 14453   | 12574 | 16025 | 4839  | 3885 | 5584 |
|                      | Philadelphia | 62298   | 56943 | 66547 | 15358   | 13576 | 16544 | 4780  | 4038 | 5282 |
|                      | Phoenix      | 74522   | 69479 | 81962 | 21334   | 18895 | 24698 | 7954  | 6893 | 9469 |
|                      | Sacramento   | 23088   | 22182 | 24045 | 5531  | 5311  | 5955  | 1703  | 1522 | 1988 |
|                      | St. Louis    | 28838   | 24579 | 31582 | 7625  | 6356  | 8587  | 2504  | 2158 | 2732 |
| Children with Asthma | Atlanta      | 6699  | 5710  | 8636  | 1688  | 1291  | 2421  | 450   | 242  | 847  |
|                      | Boston       | 7190  | 6849  | 7372  | 1821  | 1525  | 2230  | 508   | 432  | 592  |
|                      | Dallas       | 7456  | 6432  | 8158  | 1852  | 1442  | 2128  | 702   | 426  | 851  |
|                      | Detroit      | 6810  | 6226  | 7423  | 1902  | 1596  | 2151  | 613   | 468  | 780  |
|                      | Philadelphia | 7515  | 7093  | 8272  | 1906  | 1746  | 2183  | 597   | 458  | 786  |
|                      | Phoenix      | 7973  | 7445  | 8534  | 2359  | 2081  | 2703  | 887   | 750  | 1033 |
|                      | Sacramento   | 2290  | 2174  | 2453  | 561   | 481   | 683   | 207   | 140  | 303  |
|                      | St. Louis    | 2996  | 2741  | 3151  | 859   | 747   | 965   | 289   | 228  | 319  |
| Adults               | Atlanta      | 21999   | 18947 | 26553 | 4625  | 3029  | 7325  | 1432  | 634  | 2395 |
|                      | Boston       | 25307   | 22111 | 28079 | 5609  | 4403  | 6457  | 1859  | 1174 | 2544 |
|                      | Dallas       | 28181   | 23519 | 31801 | 5730  | 4923  | 6563  | 1823  | 1485 | 2422 |
|                      | Detroit      | 20689   | 17893 | 22743 | 4828  | 3801  | 5571  | 1486  | 1114 | 1704 |
|                      | Philadelphia | 27218   | 26840 | 27450 | 5810  | 5403  | 6100  | 1743  | 1394 | 1917 |
|                      | Phoenix      | 38294   | 36555 | 41423 | 9553  | 8791  | 10828 | 3311  | 2732 | 4172 |
|                      | Sacramento   | 9862  | 9547  | 10119 | 2201  | 1972  | 2344  | 610   | 486  | 715  |
|                      | St. Louis    | 11708   | 9156  | 13520 | 2647  | 2182  | 3076  | 954   | 680  | 1109 |
| Adults with Asthma   | Atlanta      | 1714  | 1409  | 2113  | 376   | 141   | 704   | 164   | 0    | 423  |
|                      | Boston       | 2218  | 1468  | 2739  | 391   | 294   | 489   | 131   | 0    | 196  |
|                      | Dallas       | 1693  | 938   | 2657  | 521   | 313   | 938   | 156   | 78   | 234  |
|                      | Detroit      | 2141  | 1376  | 2687  | 546   | 197   | 852   | 240   | 131  | 328  |
|                      | Philadelphia | 2382  | 1656  | 2789  | 436   | 174   | 610   | 116   | 0    | 349  |
|                      | Phoenix      | 2599  | 2285  | 2781  | 679   | 497   | 844   | 232   | 50   | 397  |
|                      | Sacramento   | 648   | 515   | 772   | 152   | 114   | 200   | 48  | 29   | 86   |
|                      | St. Louis    | 978   | 751   | 1109  | 191   | 107   | 250   | 72  | 36   | 143  |

<sup>A</sup> These values represent the population of individuals exposed in each study area. Values equal to zero are indicated by "0" (there are no individuals experiencing decrements at the level).

**Table 3D-58. Percent of people estimated to experience at least one lung function decrement at or above the indicated level, for the 75 ppb air quality scenario, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|---|------|------|---|-----|------|---|-----|-----|
|                      |              | Avg   | Min  | Max  | Avg   | Min | Max  | Avg   | Min | Max |
| Children             | Atlanta      | 16.4  | 14.5 | 18.7 | 5.8   | 4.7 | 7.1  | 2.6   | 2.0 | 3.3 |
|                      | Boston       | 14.7  | 13.6 | 15.9 | 5.2   | 4.7 | 5.9  | 2.4   | 2.0 | 2.9 |
|                      | Dallas       | 16.7  | 14.9 | 18.2 | 6.0   | 5.0 | 6.8  | 2.7   | 2.1 | 3.2 |
|                      | Detroit      | 17.8  | 16.2 | 19.5 | 6.7   | 5.9 | 7.7  | 3.1   | 2.6 | 3.7 |
|                      | Philadelphia | 17.5  | 16.6 | 18.1 | 6.2   | 5.9 | 6.4  | 2.8   | 2.7 | 2.9 |
|                      | Phoenix      | 23.6  | 22.4 | 25.1 | 9.0   | 8.1 | 9.9  | 4.2   | 3.7 | 4.8 |
|                      | Sacramento   | 17.2  | 16.6 | 17.7 | 6.0   | 5.7 | 6.3  | 2.7   | 2.5 | 2.9 |
|                      | St. Louis    | 17.8  | 16.2 | 18.8 | 6.6   | 5.7 | 7.5  | 3.0   | 2.5 | 3.6 |
| Children with Asthma | Atlanta      | 17.6  | 15.3 | 20.2 | 6.3   | 4.8 | 8.2  | 2.8   | 2.2 | 3.8 |
|                      | Boston       | 15.6  | 14.2 | 16.8 | 5.6   | 4.9 | 6.4  | 2.6   | 2.1 | 3.2 |
|                      | Dallas       | 17.9  | 15.6 | 19.7 | 6.7   | 5.6 | 7.5  | 3.1   | 2.4 | 3.6 |
|                      | Detroit      | 19.1  | 17.5 | 20.9 | 7.6   | 6.7 | 8.8  | 3.5   | 2.9 | 4.3 |
|                      | Philadelphia | 18.4  | 18.0 | 18.7 | 6.7   | 6.5 | 6.9  | 2.9   | 2.8 | 3.1 |
|                      | Phoenix      | 25.1  | 23.5 | 26.4 | 10.2  | 9.3 | 11.0 | 4.9   | 4.2 | 5.3 |
|                      | Sacramento   | 17.5  | 16.7 | 18.2 | 6.2   | 6.0 | 6.4  | 2.6   | 2.4 | 2.8 |
|                      | St. Louis    | 18.1  | 16.5 | 19.0 | 6.8   | 6.0 | 7.3  | 3.1   | 2.6 | 3.6 |
| Adults               | Atlanta      | 3.2   | 2.9  | 3.6  | 1.0   | 0.8 | 1.2  | 0.4   | 0.3 | 0.5 |
|                      | Boston       | 2.6   | 2.3  | 2.9  | 0.7   | 0.6 | 0.8  | 0.3   | 0.3 | 0.4 |
|                      | Dallas       | 3.3   | 2.9  | 3.6  | 1.0   | 0.9 | 1.2  | 0.4   | 0.4 | 0.5 |
|                      | Detroit      | 3.1   | 2.8  | 3.3  | 1.0   | 0.8 | 1.1  | 0.4   | 0.3 | 0.5 |
|                      | Philadelphia | 3.1   | 2.9  | 3.3  | 0.9   | 0.9 | 1.0  | 0.4   | 0.4 | 0.4 |
|                      | Phoenix      | 5.2   | 4.8  | 5.7  | 1.7   | 1.7 | 1.9  | 0.8   | 0.7 | 0.8 |
|                      | Sacramento   | 3.2   | 3.1  | 3.2  | 0.9   | 0.9 | 1.0  | 0.4   | 0.4 | 0.4 |
|                      | St. Louis    | 3.1   | 2.7  | 3.4  | 1.0   | 0.8 | 1.1  | 0.4   | 0.3 | 0.5 |
| Adults with Asthma   | Atlanta      | 2.9   | 2.7  | 3.3  | 0.9   | 0.8 | 1.0  | 0.4   | 0.3 | 0.4 |
|                      | Boston       | 2.2   | 1.9  | 2.5  | 0.6   | 0.4 | 0.7  | 0.2   | 0.1 | 0.3 |
|                      | Dallas       | 3.0   | 2.5  | 3.2  | 0.9   | 0.7 | 1.2  | 0.4   | 0.2 | 0.6 |
|                      | Detroit      | 2.9   | 2.5  | 3.1  | 0.9   | 0.7 | 1.0  | 0.4   | 0.3 | 0.5 |
|                      | Philadelphia | 2.8   | 2.7  | 3.1  | 0.9   | 0.8 | 0.9  | 0.3   | 0.1 | 0.4 |
|                      | Phoenix      | 4.1   | 3.7  | 4.4  | 1.4   | 1.3 | 1.5  | 0.7   | 0.6 | 0.7 |
|                      | Sacramento   | 2.5   | 2.5  | 2.6  | 0.8   | 0.7 | 0.9  | 0.3   | 0.2 | 0.3 |
|                      | St. Louis    | 3.0   | 2.5  | 3.3  | 1.0   | 0.8 | 1.0  | 0.4   | 0.2 | 0.5 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-59. Percent of people estimated to experience at least two lung function decrements at or above the indicated level, for the 75 ppb air quality scenario, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |     |
|----------------------|--------------|---|------|------|---|-----|-----|---|------|-----|
|                      |              | Avg   | Min  | Max  | Avg   | Min | Max | Avg   | Min  | Max |
| Children             | Atlanta      | 10.0  | 8.7  | 11.8 | 3.1   | 2.5 | 3.9 | 1.3   | 1.0  | 1.6 |
|                      | Boston       | 8.4   | 7.8  | 9.0  | 2.6   | 2.3 | 2.9 | 1.0   | 0.8  | 1.2 |
|                      | Dallas       | 10.3  | 9.0  | 11.4 | 3.3   | 2.6 | 4.0 | 1.3   | 1.0  | 1.7 |
|                      | Detroit      | 10.9  | 9.6  | 12.2 | 3.7   | 3.1 | 4.2 | 1.5   | 1.2  | 1.8 |
|                      | Philadelphia | 10.8  | 9.9  | 11.3 | 3.4   | 3.2 | 3.5 | 1.4   | 1.2  | 1.4 |
|                      | Phoenix      | 16.1  | 15.2 | 17.5 | 5.6   | 5.0 | 6.3 | 2.5   | 2.1  | 2.9 |
|                      | Sacramento   | 10.8  | 10.4 | 11.2 | 3.4   | 3.2 | 3.6 | 1.3   | 1.2  | 1.5 |
|                      | St. Louis    | 11.1  | 9.7  | 11.9 | 3.6   | 3.0 | 4.1 | 1.5   | 1.3  | 1.8 |
| Children with Asthma | Atlanta      | 10.8  | 9.2  | 13.1 | 3.4   | 2.6 | 4.6 | 1.3   | 1.0  | 1.9 |
|                      | Boston       | 9.0   | 8.4  | 9.9  | 2.8   | 2.5 | 3.1 | 1.1   | 1.0  | 1.2 |
|                      | Dallas       | 11.1  | 9.4  | 12.3 | 3.7   | 3.0 | 4.3 | 1.5   | 1.1  | 1.8 |
|                      | Detroit      | 11.8  | 10.5 | 13.2 | 4.1   | 3.5 | 4.7 | 1.8   | 1.3  | 2.3 |
|                      | Philadelphia | 11.5  | 10.9 | 11.9 | 3.5   | 3.3 | 3.6 | 1.4   | 1.3  | 1.5 |
|                      | Phoenix      | 17.4  | 16.1 | 18.8 | 6.4   | 5.9 | 6.8 | 2.9   | 2.4  | 3.4 |
|                      | Sacramento   | 11.1  | 10.4 | 11.7 | 3.5   | 3.4 | 3.8 | 1.3   | 1.1  | 1.6 |
|                      | St. Louis    | 11.2  | 9.9  | 11.9 | 3.8   | 3.4 | 4.2 | 1.7   | 1.4  | 2.0 |
| Adults               | Atlanta      | 1.5   | 1.4  | 1.8  | 0.4   | 0.3 | 0.5 | 0.2   | 0.1  | 0.2 |
|                      | Boston       | 1.1   | 1.0  | 1.2  | 0.3   | 0.3 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | Dallas       | 1.6   | 1.4  | 1.7  | 0.4   | 0.4 | 0.5 | 0.2   | 0.1  | 0.2 |
|                      | Detroit      | 1.4   | 1.3  | 1.6  | 0.4   | 0.3 | 0.5 | 0.2   | 0.1  | 0.2 |
|                      | Philadelphia | 1.5   | 1.4  | 1.5  | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.2 |
|                      | Phoenix      | 2.9   | 2.7  | 3.1  | 0.9   | 0.9 | 1.0 | 0.4   | 0.3  | 0.4 |
|                      | Sacramento   | 1.6   | 1.6  | 1.6  | 0.4   | 0.4 | 0.4 | 0.2   | 0.2  | 0.2 |
|                      | St. Louis    | 1.5   | 1.2  | 1.7  | 0.4   | 0.3 | 0.5 | 0.2   | 0.1  | 0.2 |
| Adults with Asthma   | Atlanta      | 1.3   | 1.2  | 1.5  | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.2 |
|                      | Boston       | 0.9   | 0.8  | 1.1  | 0.2   | 0.2 | 0.3 | 0.1   | <0.1 | 0.1 |
|                      | Dallas       | 1.3   | 1.1  | 1.6  | 0.3   | 0.2 | 0.5 | 0.2   | 0.1  | 0.3 |
|                      | Detroit      | 1.3   | 1.1  | 1.4  | 0.4   | 0.3 | 0.5 | 0.2   | 0.1  | 0.3 |
|                      | Philadelphia | 1.3   | 1.1  | 1.4  | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.2 |
|                      | Phoenix      | 2.3   | 2.1  | 2.5  | 0.7   | 0.6 | 0.8 | 0.3   | 0.2  | 0.4 |
|                      | Sacramento   | 1.2   | 1.1  | 1.3  | 0.3   | 0.3 | 0.4 | 0.1   | 0.1  | 0.2 |
|                      | St. Louis    | 1.4   | 1.1  | 1.6  | 0.4   | 0.3 | 0.5 | 0.1   | 0.1  | 0.2 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-60. Percent of people estimated to experience at least four lung function decrements at or above the indicated level, for the 75 ppb air quality scenario, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|------|------|---|-----|-----|---|------|------|
|                      |              | Avg   | Min  | Max  | Avg   | Min | Max | Avg   | Min  | Max  |
| Children             | Atlanta      | 5.8   | 4.9  | 7.1  | 1.6   | 1.3 | 2.1 | 0.6   | 0.4  | 0.7  |
|                      | Boston       | 4.5   | 4.2  | 4.7  | 1.2   | 1.1 | 1.3 | 0.4   | 0.3  | 0.4  |
|                      | Dallas       | 6.0   | 5.1  | 6.6  | 1.7   | 1.3 | 2   | 0.6   | 0.4  | 0.7  |
|                      | Detroit      | 6.2   | 5.4  | 6.9  | 1.8   | 1.6 | 2.1 | 0.7   | 0.5  | 0.8  |
|                      | Philadelphia | 6.2   | 5.6  | 6.7  | 1.7   | 1.5 | 1.9 | 0.6   | 0.5  | 0.7  |
|                      | Phoenix      | 10.6  | 9.8  | 11.7 | 3.4   | 3.1 | 3.9 | 1.4   | 1.2  | 1.7  |
|                      | Sacramento   | 6.4   | 6.1  | 6.7  | 1.8   | 1.7 | 1.9 | 0.6   | 0.6  | 0.7  |
|                      | St. Louis    | 6.5   | 5.6  | 7.0  | 1.9   | 1.6 | 2.1 | 0.7   | 0.6  | 0.8  |
| Children with Asthma | Atlanta      | 6.4   | 5.3  | 8.0  | 1.8   | 1.4 | 2.6 | 0.6   | 0.4  | 1.0  |
|                      | Boston       | 5.0   | 4.7  | 5.2  | 1.3   | 1.2 | 1.6 | 0.4   | 0.3  | 0.5  |
|                      | Dallas       | 6.6   | 5.5  | 7.3  | 2.1   | 1.6 | 2.4 | 0.7   | 0.5  | 0.9  |
|                      | Detroit      | 6.9   | 6.2  | 7.7  | 2.1   | 1.7 | 2.5 | 0.8   | 0.5  | 0.9  |
|                      | Philadelphia | 6.7   | 6.4  | 7.3  | 1.8   | 1.7 | 2.0 | 0.7   | 0.6  | 0.7  |
|                      | Phoenix      | 11.6  | 10.7 | 12.6 | 4.0   | 3.6 | 4.5 | 1.6   | 1.4  | 2.0  |
|                      | Sacramento   | 6.6   | 6.3  | 7.0  | 1.8   | 1.5 | 2.1 | 0.6   | 0.5  | 0.9  |
|                      | St. Louis    | 6.4   | 5.8  | 6.8  | 2.1   | 1.8 | 2.4 | 0.7   | 0.6  | 0.9  |
| Adults               | Atlanta      | 0.7   | 0.6  | 0.9  | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Boston       | 0.5   | 0.4  | 0.5  | 0.1   | 0.1 | 0.1 | <0.1  | <0.1 | 0.1  |
|                      | Dallas       | 0.7   | 0.6  | 0.8  | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Detroit      | 0.6   | 0.5  | 0.7  | 0.1   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Philadelphia | 0.7   | 0.7  | 0.7  | 0.2   | 0.1 | 0.2 | <0.1  | <0.1 | 0.1  |
|                      | Phoenix      | 1.6   | 1.5  | 1.7  | 0.4   | 0.4 | 0.4 | 0.2   | 0.1  | 0.2  |
|                      | Sacramento   | 0.7   | 0.7  | 0.7  | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 0.7   | 0.5  | 0.8  | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
| Adults with Asthma   | Atlanta      | 0.7   | 0.6  | 0.8  | 0.1   | 0.1 | 0.3 | 0.1   | <0.1 | 0.1  |
|                      | Boston       | 0.4   | 0.2  | 0.4  | 0.1   | 0.1 | 0.1 | <0.1  | 0    | <0.1 |
|                      | Dallas       | 0.6   | 0.3  | 0.9  | 0.2   | 0.1 | 0.4 | 0.1   | <0.1 | 0.1  |
|                      | Detroit      | 0.5   | 0.4  | 0.7  | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1  |
|                      | Philadelphia | 0.6   | 0.5  | 0.7  | 0.1   | 0.1 | 0.2 | <0.1  | <0.1 | 0.1  |
|                      | Phoenix      | 1.2   | 1.1  | 1.2  | 0.4   | 0.3 | 0.4 | 0.1   | <0.1 | 0.2  |
|                      | Sacramento   | 0.6   | 0.5  | 0.7  | 0.2   | 0.1 | 0.3 | 0.1   | 0.1  | 0.1  |
|                      | St. Louis    | 0.6   | 0.4  | 0.7  | 0.1   | 0.1 | 0.1 | 0.1   | <0.1 | 0.1  |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".



**Table 3D-61. Percent of people estimated to experience at least one lung function decrement at or above the indicated level, for the 65 ppb air quality scenario, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     |
|----------------------|--------------|---|------|------|---|-----|-----|---|-----|-----|
|                      |              | Avg   | Min  | Max  | Avg   | Min | Max | Avg   | Min | Max |
| Children             | Atlanta      | 10.3  | 9.2  | 11.7 | 2.8   | 2.3 | 3.4 | 1.0   | 0.8 | 1.3 |
|                      | Boston       | 10.8  | 10.4 | 11.4 | 3.3   | 3.1 | 3.8 | 1.3   | 1.2 | 1.6 |
|                      | Dallas       | 12.4  | 11.2 | 13.0 | 3.8   | 3.1 | 4.1 | 1.5   | 1.2 | 1.6 |
|                      | Detroit      | 12.9  | 12.0 | 13.9 | 4.0   | 3.6 | 4.5 | 1.6   | 1.4 | 1.8 |
|                      | Philadelphia | 12.1  | 11.5 | 12.6 | 3.4   | 3.3 | 3.6 | 1.3   | 1.2 | 1.3 |
|                      | Phoenix      | 16.9  | 16.0 | 18.1 | 5.2   | 4.7 | 5.7 | 2.1   | 1.8 | 2.4 |
|                      | Sacramento   | 10.8  | 10.5 | 11.1 | 2.8   | 2.8 | 3.0 | 1.0   | 0.9 | 1.1 |
|                      | St. Louis    | 12.3  | 11.2 | 13.2 | 3.6   | 3.1 | 4.2 | 1.4   | 1.2 | 1.7 |
| Children with Asthma | Atlanta      | 11.2  | 9.6  | 13.2 | 3.1   | 2.5 | 4.0 | 1.1   | 0.8 | 1.6 |
|                      | Boston       | 11.6  | 11.2 | 12.0 | 3.6   | 3.3 | 4.2 | 1.4   | 1.3 | 1.5 |
|                      | Dallas       | 13.5  | 11.8 | 14.3 | 4.3   | 3.6 | 4.6 | 1.8   | 1.3 | 2.1 |
|                      | Detroit      | 14.0  | 12.9 | 15.3 | 4.6   | 4.3 | 5.2 | 1.8   | 1.5 | 2.2 |
|                      | Philadelphia | 12.8  | 12.6 | 13.0 | 3.5   | 3.3 | 3.7 | 1.4   | 1.3 | 1.6 |
|                      | Phoenix      | 18.5  | 17.1 | 19.7 | 6.0   | 5.4 | 6.4 | 2.4   | 2.1 | 2.9 |
|                      | Sacramento   | 11.2  | 11.0 | 11.3 | 2.9   | 2.8 | 3.0 | 1.0   | 0.7 | 1.3 |
|                      | St. Louis    | 12.7  | 11.8 | 13.2 | 3.8   | 3.2 | 4.3 | 1.5   | 1.3 | 1.8 |
| Adults               | Atlanta      | 1.9   | 1.8  | 2.1  | 0.5   | 0.4 | 0.6 | 0.2   | 0.1 | 0.2 |
|                      | Boston       | 1.9   | 1.8  | 2.1  | 0.5   | 0.4 | 0.5 | 0.2   | 0.2 | 0.2 |
|                      | Dallas       | 2.4   | 2.2  | 2.5  | 0.6   | 0.6 | 0.7 | 0.2   | 0.2 | 0.3 |
|                      | Detroit      | 2.1   | 2.0  | 2.3  | 0.6   | 0.5 | 0.6 | 0.2   | 0.2 | 0.2 |
|                      | Philadelphia | 2.1   | 2.0  | 2.1  | 0.5   | 0.5 | 0.5 | 0.2   | 0.2 | 0.2 |
|                      | Phoenix      | 3.6   | 3.3  | 3.9  | 1.0   | 1.0 | 1.0 | 0.4   | 0.4 | 0.4 |
|                      | Sacramento   | 1.9   | 1.9  | 1.9  | 0.4   | 0.4 | 0.5 | 0.2   | 0.2 | 0.2 |
|                      | St. Louis    | 2.1   | 1.8  | 2.3  | 0.5   | 0.4 | 0.6 | 0.2   | 0.2 | 0.2 |
| Adults with Asthma   | Atlanta      | 1.7   | 1.5  | 1.8  | 0.5   | 0.4 | 0.5 | 0.1   | 0.1 | 0.2 |
|                      | Boston       | 1.6   | 1.5  | 1.9  | 0.4   | 0.3 | 0.5 | 0.2   | 0.1 | 0.2 |
|                      | Dallas       | 2.0   | 1.7  | 2.5  | 0.6   | 0.4 | 0.8 | 0.3   | 0.1 | 0.5 |
|                      | Detroit      | 2.0   | 1.8  | 2.1  | 0.5   | 0.4 | 0.6 | 0.3   | 0.2 | 0.3 |
|                      | Philadelphia | 1.9   | 1.7  | 2.0  | 0.4   | 0.3 | 0.5 | 0.2   | 0.1 | 0.2 |
|                      | Phoenix      | 2.9   | 2.5  | 3.1  | 0.8   | 0.8 | 0.9 | 0.3   | 0.2 | 0.3 |
|                      | Sacramento   | 1.6   | 1.5  | 1.7  | 0.4   | 0.3 | 0.4 | 0.1   | 0.1 | 0.2 |
|                      | St. Louis    | 2.0   | 1.8  | 2.2  | 0.5   | 0.4 | 0.6 | 0.2   | 0.1 | 0.3 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-62. Percent of people estimated to experience at least two lung function decrements at or above the indicated level, for the 65 ppb air quality scenario, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |     |
|----------------------|--------------|---|------|------|---|-----|-----|---|------|-----|
|                      |              | Avg   | Min  | Max  | Avg   | Min | Max | Avg   | Min  | Max |
| Children             | Atlanta      | 5.7   | 5.0  | 6.8  | 1.4   | 1.1 | 1.6 | 0.4   | 0.3  | 0.5 |
|                      | Boston       | 5.9   | 5.7  | 6.1  | 1.5   | 1.4 | 1.7 | 0.5   | 0.4  | 0.6 |
|                      | Dallas       | 7.3   | 6.5  | 7.7  | 1.9   | 1.5 | 2.2 | 0.7   | 0.5  | 0.7 |
|                      | Detroit      | 7.4   | 6.8  | 8.0  | 2.0   | 1.8 | 2.2 | 0.7   | 0.6  | 0.8 |
|                      | Philadelphia | 7.0   | 6.5  | 7.3  | 1.7   | 1.6 | 1.8 | 0.6   | 0.5  | 0.6 |
|                      | Phoenix      | 11  | 10.2 | 12.0 | 3.1   | 2.8 | 3.5 | 1.1   | 1.0  | 1.3 |
|                      | Sacramento   | 6.2   | 6.0  | 6.5  | 1.4   | 1.3 | 1.5 | 0.4   | 0.4  | 0.5 |
|                      | St. Louis    | 7.1   | 6.2  | 7.7  | 1.8   | 1.6 | 2.1 | 0.6   | 0.5  | 0.7 |
| Children with Asthma | Atlanta      | 6.2   | 5.3  | 7.5  | 1.4   | 1.1 | 2.0 | 0.4   | 0.3  | 0.7 |
|                      | Boston       | 6.3   | 6.0  | 6.8  | 1.6   | 1.4 | 1.8 | 0.6   | 0.6  | 0.6 |
|                      | Dallas       | 8.1   | 6.9  | 9.0  | 2.3   | 1.9 | 2.6 | 0.8   | 0.5  | 1.0 |
|                      | Detroit      | 8.3   | 7.6  | 9.0  | 2.3   | 2.0 | 2.8 | 0.9   | 0.7  | 1.0 |
|                      | Philadelphia | 7.6   | 7.1  | 8.1  | 1.8   | 1.7 | 1.9 | 0.6   | 0.6  | 0.7 |
|                      | Phoenix      | 12.1  | 11.2 | 12.9 | 3.7   | 3.4 | 4.0 | 1.3   | 1.1  | 1.5 |
|                      | Sacramento   | 6.4   | 6.1  | 6.6  | 1.4   | 1.2 | 1.6 | 0.4   | 0.3  | 0.6 |
|                      | St. Louis    | 7.3   | 6.7  | 7.6  | 2.0   | 1.7 | 2.2 | 0.7   | 0.6  | 0.7 |
| Adults               | Atlanta      | 0.8   | 0.8  | 1.0  | 0.2   | 0.1 | 0.3 | 0.1   | <0.1 | 0.1 |
|                      | Boston       | 0.8   | 0.8  | 0.9  | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1 |
|                      | Dallas       | 1.1   | 1.0  | 1.2  | 0.3   | 0.2 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | Detroit      | 1.0   | 0.9  | 1.0  | 0.2   | 0.2 | 0.3 | 0.1   | 0.1  | 0.1 |
|                      | Philadelphia | 0.9   | 0.9  | 1.0  | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1 |
|                      | Phoenix      | 1.9   | 1.9  | 2.1  | 0.5   | 0.4 | 0.5 | 0.2   | 0.1  | 0.2 |
|                      | Sacramento   | 0.9   | 0.9  | 0.9  | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1 |
|                      | St. Louis    | 1.0   | 0.8  | 1.1  | 0.2   | 0.2 | 0.2 | 0.1   | 0.1  | 0.1 |
| Adults with Asthma   | Atlanta      | 0.7   | 0.6  | 0.9  | 0.2   | 0.1 | 0.3 | 0.1   | <0.1 | 0.1 |
|                      | Boston       | 0.7   | 0.6  | 0.8  | 0.2   | 0.1 | 0.2 | 0.1   | <0.1 | 0.1 |
|                      | Dallas       | 0.8   | 0.7  | 1.1  | 0.2   | 0.1 | 0.4 | 0.1   | 0    | 0.1 |
|                      | Detroit      | 0.9   | 0.7  | 1.0  | 0.3   | 0.2 | 0.3 | 0.1   | 0.1  | 0.2 |
|                      | Philadelphia | 0.8   | 0.6  | 0.9  | 0.2   | 0.1 | 0.3 | <0.1  | <0.1 | 0.1 |
|                      | Phoenix      | 1.5   | 1.5  | 1.6  | 0.4   | 0.3 | 0.5 | 0.1   | 0.1  | 0.2 |
|                      | Sacramento   | 0.7   | 0.6  | 0.8  | 0.2   | 0.1 | 0.2 | <0.1  | <0.1 | 0.1 |
|                      | St. Louis    | 0.9   | 0.7  | 1.0  | 0.2   | 0.1 | 0.3 | <0.1  | <0.1 | 0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

**Table 3D-63. Percent of people estimated to experience at least four lung function decrements at or above the indicated level, for the 65 ppb air quality scenario, using the individual-based (MSS model) risk approach.**

| Study Group          | Study Area   | ≥10% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |     |     | ≥15% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      | ≥20% reduction in FEV <sub>1</sub> <sup>A</sup><br>(% per Year) |      |      |
|----------------------|--------------|---|-----|-----|---|------|------|---|------|------|
|                      |              | Avg   | Min | Max | Avg   | Min  | Max  | Avg   | Min  | Max  |
| Children             | Atlanta      | 3.0   | 2.6 | 3.7 | 0.6   | 0.5  | 0.8  | 0.2   | 0.1  | 0.2  |
|                      | Boston       | 3.0   | 2.9 | 3.0 | 0.6   | 0.6  | 0.7  | 0.2   | 0.2  | 0.2  |
|                      | Dallas       | 4.0   | 3.6 | 4.3 | 0.9   | 0.7  | 1.0  | 0.3   | 0.2  | 0.3  |
|                      | Detroit      | 4.0   | 3.6 | 4.3 | 0.9   | 0.8  | 1.0  | 0.3   | 0.2  | 0.3  |
|                      | Philadelphia | 3.7   | 3.5 | 4.0 | 0.8   | 0.7  | 0.9  | 0.2   | 0.2  | 0.2  |
|                      | Phoenix      | 6.8   | 6.4 | 7.5 | 1.7   | 1.5  | 2.0  | 0.5   | 0.5  | 0.6  |
|                      | Sacramento   | 3.4   | 3.3 | 3.5 | 0.6   | 0.6  | 0.7  | 0.2   | 0.1  | 0.2  |
|                      | St. Louis    | 3.9   | 3.3 | 4.2 | 0.9   | 0.7  | 1.0  | 0.2   | 0.2  | 0.3  |
| Children with Asthma | Atlanta      | 3.2   | 2.7 | 4.3 | 0.7   | 0.4  | 1.1  | 0.2   | 0.1  | 0.2  |
|                      | Boston       | 3.4   | 3.3 | 3.5 | 0.8   | 0.6  | 0.9  | 0.2   | 0.2  | 0.2  |
|                      | Dallas       | 4.6   | 4.0 | 4.9 | 1.1   | 0.8  | 1.3  | 0.3   | 0.2  | 0.4  |
|                      | Detroit      | 4.5   | 4.2 | 4.7 | 1.1   | 0.9  | 1.1  | 0.3   | 0.2  | 0.3  |
|                      | Philadelphia | 3.9   | 3.6 | 4.1 | 0.9   | 0.8  | 1.0  | 0.2   | 0.2  | 0.3  |
|                      | Phoenix      | 7.6   | 7.2 | 8.2 | 2.1   | 1.9  | 2.3  | 0.7   | 0.5  | 0.9  |
|                      | Sacramento   | 3.6   | 3.3 | 3.7 | 0.7   | 0.6  | 0.9  | 0.2   | 0.1  | 0.3  |
|                      | St. Louis    | 4.2   | 3.8 | 4.4 | 1.0   | 0.8  | 1.1  | 0.3   | 0.2  | 0.3  |
| Adults               | Atlanta      | 0.4   | 0.3 | 0.4 | 0.1   | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Boston       | 0.3   | 0.3 | 0.4 | 0.1   | <0.1 | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Dallas       | 0.5   | 0.4 | 0.5 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Detroit      | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Philadelphia | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | Phoenix      | 1.0   | 1.0 | 1.0 | 0.2   | 0.2  | 0.3  | 0.1   | 0.1  | 0.1  |
|                      | Sacramento   | 0.4   | 0.4 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
|                      | St. Louis    | 0.4   | 0.3 | 0.4 | 0.1   | 0.1  | 0.1  | <0.1  | <0.1 | <0.1 |
| Adults with Asthma   | Atlanta      | 0.3   | 0.2 | 0.4 | 0.1   | <0.1 | 0.2  | <0.1  | 0    | 0.1  |
|                      | Boston       | 0.3   | 0.2 | 0.3 | <0.1  | <0.1 | <0.1 | <0.1  | 0    | <0.1 |
|                      | Dallas       | 0.4   | 0.2 | 0.6 | 0.1   | <0.1 | 0.3  | <0.1  | 0    | <0.1 |
|                      | Detroit      | 0.4   | 0.3 | 0.5 | 0.1   | <0.1 | 0.2  | <0.1  | <0.1 | 0.1  |
|                      | Philadelphia | 0.4   | 0.3 | 0.4 | <0.1  | 0    | 0.1  | <0.1  | 0    | <0.1 |
|                      | Phoenix      | 0.7   | 0.6 | 0.8 | 0.2   | 0.1  | 0.3  | 0.1   | 0    | 0.1  |
|                      | Sacramento   | 0.3   | 0.3 | 0.4 | 0.1   | <0.1 | 0.1  | <0.1  | 0    | <0.1 |
|                      | St. Louis    | 0.3   | 0.3 | 0.4 | 0.1   | <0.1 | 0.1  | <0.1  | 0    | <0.1 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

### 3D.3.4 Uncertainty Characterization

While it may be possible to estimate a range of O<sub>3</sub> exposures or risks by accounting for variability inherent to influential factors, the true exposure or risk for any given individual residing within a study area is unknown. To characterize health risks, risk assessors commonly use an iterative process of gathering data, developing models, and estimating exposures and risks, which is based upon 1) the goals of the assessment, 2) evaluating results for correctness and identifying areas for potential improvement, 3) scale and complexity of the assessment performed, and 4) availability and limitations of the input data and information. Uncertainty can still remain following each iteration and emphasis is then placed on characterizing the nature and magnitude of that uncertainty and its impact on exposure and risk estimates. A summary of the overall characterization of uncertainty for the current O<sub>3</sub> exposure and risk analysis is provided in section 3D.3.4.1. The summary is followed by APEX sensitivity analyses in section 3D.3.4.2 that provide additional support to the uncertainty characterization regarding the influence a number of factors (e.g., contribution of low exposures) have on estimating lung function risk resulting from O<sub>3</sub> exposure.

#### 3D.3.4.1 Summary of the Uncertainty Characterization

The REAs for previous reviews of the O<sub>3</sub>, NO<sub>2</sub>, SO<sub>2</sub>, and CO NAAQS characterized uncertainty in exposure and risk modeling (Langstaff, 2007; U.S. EPA, 2008, 2009, 2010, 2014, 2018). The mainly qualitative approach used in this and other REAs, also informed by quantitative sensitivity analyses, is described by WHO (2008). Briefly, we identified key aspects of the assessment approach that may contribute to uncertainty in the exposure and risk estimates and provided the rationale for their inclusion. Then, we characterized the *magnitude* and *direction* of the influence on the assessment for each of these identified sources of uncertainty.

Consistent with the WHO (2008) guidance, we scaled the overall impact of the uncertainty by considering the degree of uncertainty as implied by the relationship between the source of uncertainty and the exposure and risk estimates. A qualitative characterization of *low*, *moderate*, and *high* was assigned to the magnitude of influence and knowledge base uncertainty descriptors, using quantitative observations relating to understanding the uncertainty, where possible. Where the magnitude of uncertainty was rated *low*, it was judged that large changes within the source of uncertainty would have only a small effect on the assessment results (e.g., an impact of few percentage points upwards to a factor of two). A designation of *medium* implies that a change within the source of uncertainty would likely have a moderate (or proportional) effect on the results (e.g., a factor of two or more). A characterization of *high* implies that a change in the source would have a large effect on results (e.g., an order of magnitude). We also included the direction of influence, whether the source of uncertainty was judged to potentially

1 over-estimate (“*over*”), under-estimate (“*under*”), or have an *unknown* impact to exposure/risk  
2 estimates. A summary of the key findings of the prior uncertainty characterizations that are most  
3 relevant to the current O<sub>3</sub> exposure and risk analysis are also provided in Table 3D-64.

1 **Table 3D-64. Characterization of key uncertainties in exposure and risk analyses using APEX.**

| Sources of Uncertainty               |  | Uncertainty Characterization                          |              |                               |  | Newly Characterized/<br>New Information?     |
|--------------------------------------|--|---|--------------|-------------------------------|--|--|
|                                      |  | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base<br>Uncertainty | Comments   |  |
| Category                             | Element  | Direction   | Magnitude    |                               |  |  |
| General Aspects of Assessment Design | Representation of population groups with asthma                                | Unknown   | Low - Medium | Medium                        | Consistent with the ISA identification of people with asthma (and children with asthma in particular) as an important at-risk population for O <sub>3</sub> in ambient air, risk estimates are developed for people with asthma and are reported separately for children and adults. Exposure and risk were not estimated for more targeted population groups with asthma based on additional personal attributes associated with increased asthma prevalence (e.g., obesity or African American or Hispanic ethnicity) generally due to limitations in the data needed to simulate these population groups. Such data limitations affect our ability to characterize O <sub>3</sub> exposure and associated health risks for different population subgroups of children and adults with asthma, some of which may have higher exposure/risk and others lower.   | Yes. Newly identified element of uncertainty |
|                                      | Representation of population groups having health conditions other than asthma | Unknown   | Unknown      | Medium                        | Individuals having health conditions other than asthma have not been explicitly represented in this exposure and risk assessment as the evidence has not indicated any other population groups with a health condition that places them at increased risk (ISA, Table IS-11). Additionally, exposure/risk modeling for other such groups is hampered by data limitations in accurately defining the size of a particular population group, assigning appropriate activity pattern data, and estimating how responses observed in the controlled human exposure study data would quantitatively relate to simulated individuals. For example, the likelihood of individuals having a health condition such as chronic obstructive pulmonary disorder exercising for sufficient duration at a ventilation rate needed (e.g., EVR ≥17.32 ± 1.25 L/min-m <sup>2</sup> ) to receive a dose that would elicit a response is unknown. | Yes. Newly identified element of uncertainty |
|                                      | Representation of older adults   | Neither   | Low          | Low                           | In the current exposure and risk analysis, older adults (ages 65-95) were simulated as part of the all adult groups (ages 18-90) and not as a separate population subgroup. In the 2014 HREA, exposures and risks were estimated separately for older adults (2014 HREA, section 5.6). In those 2014 HREA results, the percent of older adults experiencing exposures at or above any benchmark tended to be lower than the comparable percentage for all adults or all adults with asthma, by a few percentage points or less. A similar pattern would be expected if this group were to have been included in the current analysis.  | Yes. Newly identified element of uncertainty |

| Sources of Uncertainty             |   | Uncertainty Characterization                          |              |                            |  | Newly Characterized/<br>New Information?     |
|------------------------------------|---|---|--------------|----------------------------|--|--|
|                                    |   | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base Uncertainty | Comments   |  |
| Category                           | Element                                   | Direction   | Magnitude    |                            |  |  |
|                                    | Representation of outdoor workers         | Under   | Low - Medium | Medium                     | In the current exposure and risk analysis, outdoor workers were not evaluated as a separate population subgroup. In the 2014 HREA, limited analyses were conducted for this subgroup because of appreciable data limitations and associated uncertainty. The exposures and risk estimates for this subgroup for the single study area and air quality scenario assessed indicated a greater percentage of outdoor workers experience single and multi-day exposures than that estimated for the full adult population, differing by about a factor of 5 or more depending on the benchmark level and number of days per year (2014 HREA, section 5.4.3.2). These limited results suggest that results for the full adult population would likely underestimate exposures and risks for outdoor workers. Important uncertainties exist in generating the simulated activity patterns for this group, including the limited number of CHAD diary days available for outdoor workers, assignment of diaries to proper occupation categories, approximating number of days/week and hours/day outdoors, etc. | Yes. Newly identified element of uncertainty |
| Ambient Air Monitor Concentrations | Ambient Air O <sub>3</sub> Measurements   | Both  | Low          | Low                        | Ozone measurements are assumed to be accurate to within ½ of the instrument's Method Detection Limit (MDL), which is 2.5 ppb for most instruments. The EPA requires that routine quality assurance checks are performed on all instruments. There is a known tendency for smoke produced from wildfires to cause interference in O <sub>3</sub> instruments. Measurements collected by O <sub>3</sub> analyzers were reported to be biased high by 5.1–6.6 ppb per 100 µg/m <sup>3</sup> of PM <sub>2.5</sub> from wildfire smoke (U.S. EPA, 2007b). However, smoke concentrations high enough to cause significant interferences are infrequent and the overall impact is expected to be minimal.   | No   |
|                                    | Air Quality System (AQS) Database Quality | Both  | Low          | Low                        | All ambient air pollutant measurements available from AQS are certified by both the monitoring agency and the corresponding EPA regional office. Monitor malfunctions sometimes occur causing periods of missing data or poor data quality. Monitoring data affected by malfunctions are usually flagged by the monitoring agency and removed from AQS. In addition, the AQS database managers run several routines to identify suspicious data for potential removal.   | Yes. Recent year data used (2015 - 2017)     |
|                                    | Temporal Representation                   | Both  | Low          | Low                        | The temporal scale (hourly) is appropriate for analysis performed. Required O <sub>3</sub> monitoring seasons are used to define the duration of the exposure and risk analyses in each study area. Monitor data are screened for temporal completeness and considered appropriate when calculating design values (and used for adjustments needed to meet air quality scenarios). While some monitoring data used in developing the air quality surface were not screened for temporal completeness, the inclusion of monitor data somewhat less than complete is considered a holistic approach that improves the filling of both temporal and spatial gaps that exist, where present.   | No   |

| Sources of Uncertainty   |  | Uncertainty Characterization                          |              |                               |   | Newly Characterized/<br>New Information?                      |
|--|--|---|--------------|-------------------------------|---|---|
|  |  | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base<br>Uncertainty | Comments  |   |
| Category   | Element  | Direction   | Magnitude    |                               |   |   |
|  | Spatial Representation                                 | Both  | Low - Medium | Low - Medium                  | Overall, the eight study areas have reasonably dense ambient monitoring networks but vary in size and geographic location. They are however considered adequate to capture spatial gradients in O <sub>3</sub> concentrations that occur in urban areas.  | No  |
| Adjusted O <sub>3</sub> Concentrations for Air Quality Scenarios | Modeled atmospheric state (CAMx)                       | Both  | Medium       | Medium                        | In the rollback adjustment framework applied in this assessment, the CAMx air quality model is used to calculate the chemical state of the atmosphere so that the Higher Decoupled Direct Method (HDDM) tool can archive O <sub>3</sub> responsiveness to precursors at all times and locations within the model domain. Model predictions from CAMx, like all deterministic photochemical models, have both parametric and structural uncertainty associated with them. CAMx is regularly updated to include state-of-the-science parameterizations and processes relevant for atmospheric chemistry and physics. CAMx model performance is also routinely evaluated against available observational datasets (See Appendix 3C). | Yes. Recent year meteorology and emissions inputs used (2016) |
|  | Ozone response sensitivities (HDDM)                    | Both  | Medium       | Medium                        | The HDDM approach allows for the approximation of O <sub>3</sub> response to alternate emissions scenarios without re-running the model simulation multiple times using different emissions inputs. This approximation becomes less accurate for larger emissions perturbations especially under nonlinear chemistry conditions. However, even at 90% NO <sub>x</sub> cut conditions, mean error in predicted O <sub>3</sub> using HDDM sensitivities was within 2 ppb across all urban study areas compared to the brute force simulation (See Appendix 3C).   | Yes. Recent year sensitivities used (from 2016 simulation)    |
|  | Voronoi Neighbor Averaging (VNA) spatial interpolation | Both  | Low - Medium | Low - Medium                  | The VNA estimates are weighted based on distance from neighboring monitoring sites, thus the amount of uncertainty tends to increase with distance from the monitoring sites. Areas having a relatively less dense monitoring network (e.g., Atlanta, St. Louis) may have greater uncertainty in the air quality surface than areas with a denser network (e.g., Boston, Philadelphia).   | No  |
| APEX: General Input Databases                                    | Population Demographics and Commuting                  | Both  | Low          | Low                           | The U.S. Census data are comprehensive and subject to quality control. Differences in 2010 population data versus modeled years (2015-2017) are likely small when estimating percent of population exposed. While population counts in most areas have likely increased (and thus total number exposed and at risk is likely underestimated), it is likely that there have not been substantive changes to the demographic distributions and commuting patterns in each study area, thus having minimal impact to the percent of the population exposed or experiencing lung function decrements.   | Yes. Most recent year data used (2010)                        |



| Sources of Uncertainty |                          | Uncertainty Characterization                          |              |                               |   | Newly Characterized/<br>New Information?                                     |
|------------------------|--------------------------|---|--------------|-------------------------------|---|--|
|                        |                          | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base<br>Uncertainty | Comments  |  |
| Category               | Element                  | Direction   | Magnitude    |                               |   |  |
|                        | Activity Patterns (CHAD) | Both  | Low - Medium | Low - Medium                  | The CHAD data are comprehensive and subject to quality control. The current version of CHAD contains an increased number of diaries used to estimate exposure from 2014 HREA. Previously, we evaluated trends and patterns in historical activity pattern data – no major issues noted with use of historical data to represent current patterns (2014 HREA, Appendix G, Figures 5G-1 and 5G-2). Compared outdoor event participation and outdoor time of the larger American Time Use Survey (ATUS) data with all other survey data. Participation rate in outdoor events by ATUS is lower, likely due to ATUS survey methods (i.e., a lack of distinction of time spent inside or outside of residence). This finding would primarily apply to adults (ATUS subjects are ages 16 and older). Comparison of activity data (outdoor events and exertion level) for people with asthma generally similar to individuals without asthma (section 3D.2.5.3, Table 3D-10) (see also 2014 HREA, Appendix G, Tables 5G2 to 5G-5). There is little indication of differences in time spent outdoors comparing activity patterns across U.S. regions, though sample size may be a limiting factor in drawing significant conclusions (2014 HREA, section 5.4.1.6). Remaining uncertainty exists for other influential factors that cannot be accounted for (e.g., SES, region/local participation in outdoor events and associated amount of time). | Yes. New data added to CHAD (ATUS 2003-2013) (U.S. EPA, 2019c, Attachment 3) |
|                        | Meteorological Data      | Both  | Low          | Low                           | The NOAA ISH data are comprehensive and subject to quality control, having very few missing values. Limited use in selecting CHAD diaries for simulated individuals and AERs that may vary with temperature. However, while using three years of varying meteorological conditions, the 2015-2017 MET data set may not reflect the full suite of conditions that could exist in future hypothetical air quality scenarios or across periods greater than 3-years.   | Yes. Recent year data used (2015-2017) (section 3D.2.4)                      |

| Sources of Uncertainty |   | Uncertainty Characterization                          |           |                            | Newly Characterized/<br>New Information?   |
|------------------------|---|---|-----------|----------------------------|--|
|                        |   | Influence of Uncertainty on Exposure   Risk Estimates |           | Knowledge-base Uncertainty |  |
| Category               | Element   | Direction   | Magnitude |                            | Comments   |
|                        | Asthma Prevalence: Selection of "Still" Rather than "Ever" Questionnaire Response | Under   | Low       | Low                        | <p>One of the two datasets used to estimate asthma prevalence is 2013-2017 NHIS data. The NHIS dataset includes several categories describing whether a surveyed individual has asthma based on a series of questions (Attachment 1). The first question inquires whether a doctor has "Ever" told the individual they have asthma. This is followed by a question as to whether they "Still" have asthma. In all instances, those responding "Yes" to the "Still" question is a subset of those responding "Yes" to the "Ever" question. For estimating asthma prevalence for the simulated populations, we focused on the dataset for those answering they "Still" have asthma, consistent with the characterization of asthma prevalence in the ISA (ISA, Table IS-11), and concluding that this approach would provide us with the most appropriate estimate of the population of individuals that have asthma and accordingly (based on the at-risk status of this population group) would likely be at increased risk of response to O<sub>3</sub> exposures. To the extent that some individuals answering "No" to the "Still" question are at increased risk, our approach would underestimate the at-risk group. The answers to subsequent questions in the NHIS dataset (regarding whether the respondent had an asthma attack or asthma-related ER visit during past year) indicate that the extent to which focusing on "Still" have asthma may underestimate this population group is likely small. This conclusion is based on the findings that nearly 95% of those answering "No" to the "Still" have question also did not have an asthma attack or asthma-related ER visit in the past year, while nearly half of those answering "Yes" did have such an experience, as well as the fact that nearly 95% of the survey respondents that indicated they had had an asthma attack or asthma-related ER visit over the past year are captured by the "Still" have asthma category (Attachment 1). Thus, while it is likely that using the response for the "Still" question underestimates asthma prevalence for those not having a physician determined diagnosis, the magnitude of underestimation is likely quite small.</p> |

| Sources of Uncertainty                  |   | Uncertainty Characterization                          |           |                               |   | Newly Characterized/<br>New Information?                                      |
|---|---|---|-----------|-------------------------------|---|---|
|   |   | Influence of Uncertainty on Exposure   Risk Estimates |           | Knowledge-base<br>Uncertainty | Comments  |   |
| Category                                | Element   | Direction   | Magnitude |                               |   |   |
|   | Asthma Prevalence: Weighted by Family Income      | Both  | Low       | Low - Medium                  | Data used are from peer-reviewed quality-controlled sources. Use of these data accounts for variability in important influential variables (poverty status, as well as age, sex, and region). Regional prevalence from NHIS were adjusted to reflect state-level prevalence from BRFSS, improving local representation. It is possible however that variability in microscale prevalence is not entirely represented when considering other potentially influential variables such as race and obesity, two attributes that can influence asthma prevalence and can vary spatially (U.S. EPA, 2018, section 4.1.2). Family income level was used to represent spatial variability in asthma prevalence and may, in some instances, capture spatial variability in race and obesity (Ogden et al., 2010), and thus to some extent, reasonably represent the potential influence race and obesity have on asthma prevalence. However, instances where these influential variables are not fully represented in simulating the at-risk population, and where populations identified by such variables are associated with increased asthma prevalence that may spatially intersect with the highest ambient air concentrations, could lead to uncertainty in estimated exposures and health risk. Further characterization could be appropriate by comparing with local prevalence rates stratified by a similar collection of influential variables, where such data exist. | Yes. Recent year data used (2013-2017) (Attachment 1)                         |
| APEX: Microenvironmental Concentrations | Outdoor Near-road and Vehicle PE and PROX Factors | Both  | Low       | Low - Medium                  | Uncertainty in mean PROX value used is approximately 15 percentage points (Figure 10 and Table 7 of Langstaff (2007)). Factor may be of greater importance in certain study areas or under varying conditions, though even with this mean difference, in-vehicle penetration/decay decreases exposures and hence the importance of in-vehicle microenvironments. Further, considering that the exposures of interest need to be concomitant with elevated exertion, the accurate estimation of exposures occurring inside vehicles is considered relatively unimportant. This uncertainty could be important for exposure events that occur outdoors near roads (i.e., PE factor = 1) and when simulated individuals might be at elevated exertion for long durations. That said, the frequency of these specific events is likely low, but nevertheless unquantified at this time.   | No  |
|   | Indoor: Air Exchange Rates                        | Both  | Low       | Medium                        | Uncertainty due to random sampling variation via bootstrap distribution analysis indicated the AER geometric mean (GM) and standard deviation (GSD) uncertainty for a given study area tends to range from ±1.0 GM and ± 0.5 GSD hr <sup>-1</sup> (Langstaff, 2007). Some of the eight study areas used AER from a geographically similar city. Non-representativeness remains an important issue as city-to-city variability can be wide ranging (GM/GSD pairs can vary by factors of 2-3) and data available for city-specific evaluation are limited (Langstaff, 2007). The restaurant and school AER distributions are derived from small samples and may not be representative of all possible types of restaurants and schools, in general. That said, indoor microenvironments are considered less likely to contribute to an individual's daily maximum 7-hr average O <sub>3</sub> exposure while at elevated exertion levels and likely does not contribute substantially to uncertainty in the exposure and risk estimates.  | Yes. New distribution used for restaurant and school ME (section 3D.2.6.1.1). |

| Sources of Uncertainty            |  | Uncertainty Characterization                          |              |                               |  | Newly Characterized/<br>New Information?                             |
|-----------------------------------|--|---|--------------|-------------------------------|--|--|
|                                   |  | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base<br>Uncertainty | Comments   |  |
| Category                          | Element  | Direction   | Magnitude    |                               |  |  |
|                                   | Indoor-Residence: A/C Prevalence                   | Both  | Low          | Low                           | Data were obtained from a reliable source, are comprehensive, and subject to quality control (U.S. Census Bureau, 2019). For six of the of the eight study areas, A/C prevalence was available for 2015 and 2017, while for the remaining two study areas (Sacramento and St. Louis), the most recent year data available was 2011. There is uncertainty associated with the use of an A/C prevalence derived from a different year than the years simulated in the two study areas due to changes in housing stock that may occur over time. That said, indoor microenvironments are considered less likely to contribute to an individual's daily maximum 7-hr average O <sub>3</sub> exposure while at elevated exertion levels and likely do not contribute substantially to uncertainty in the exposure and risk estimates. | No   |
|                                   | Indoor: Removal Rate                               | Both  | Low          | Medium                        | Greatest uncertainty in the input distribution regarded representativeness, though estimated as unbiased but correct to within 10% (Langstaff, 2007).  | No   |
| APEX: Simulated Activity Profiles | Longitudinal Profiles                              | Under   | Low - Medium | Medium                        | The magnitude of potential influence for this uncertainty would be mostly directed toward estimates of multiday exposures. Simulations indicate the number of single day and multiday exposures of interest can vary based on the longitudinal approach selected (Che et al., 2014). As discussed in section 3D.2.5.4, the D&A method provides a reasonable balance of this exposure feature. Note however, long-term diary profiles (i.e., monthly, annual) do not exist for a population, thus limiting the evaluation. Further, the general population-based modeling approach used for main body results does not assign rigid schedules, for example explicitly representing a 5-day work week for employed people.   | No   |
|                                   | Commuting  | Both  | Low          | Medium                        | Method used in this assessment (and used previously in the 2014 HREA) is designed to link Census commute distances with CHAD vehicle drive times. This is considered an improvement over the former approach that did not match commute distance and activity time. While vehicle time is accounted for through diary selection, it is not rigidly scheduled. However, accurate estimation of exposures occurring while inside vehicles is considered relatively unimportant because it is unlikely to occur while at elevated exertion.   | No   |
|                                   | Activity Patterns for Simulated At-Risk Population | Both  | Low          | Low - Medium                  | Analyses of activity patterns of people with asthma are similar to that of individuals not having asthma regarding participation rate in outdoor activities and exertion level (section 3D.2.5.3; see also 2014 HREA, Appendix G, Tables 5G-2 to 5G-5 ).   | No   |
| APEX: Physiological Processes     | Body Weight (NHANES)                               | Unknown   | Low          | Low                           | Comprehensive and subject to quality control, appropriate years selected for simulated population, though possible small regional variation is possibly not well-represented by national data (U.S. EPA, 2018, Appendix G.)  | Yes. Recent year data used (2009-2014) (U.S. EPA (2018), Appendix G) |
|                                   | NVO <sub>2max</sub>                                | Unknown   | Low          | Low                           | Upper bound control for unrealistic activity levels rarely used by model, thus likely not very influential.  | No   |

| Sources of Uncertainty |                              | Uncertainty Characterization                          |              |                               |   | Newly Characterized/<br>New Information?  |
|------------------------|------------------------------|---|--------------|-------------------------------|---|---|
|                        |                              | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base<br>Uncertainty | Comments  |   |
| Category               | Element                      | Direction   | Magnitude    |                               |   |   |
|                        | Resting Metabolic Rate (RMR) | Unknown   | Low          | Low                           | New, improved algorithm used for the current O <sub>3</sub> exposure and risk analysis (U.S. EPA 2018, Appendix H). Comprehensive literature review resulted in construction of large data base used to derive new RMR equations. Equations consider variables most influential to RMR (i.e., age, body weight, and sex). There are other factors that could affect intra-personal variability in RMR such as time-of-day (Haugen et al., 2003) or seasonal/temperature influences (van Ooijen et al., 2004;Leonard et al., 2014). Variability from these and other potentially influential factors may be indirectly accounted for by the residual error term used in the RMR Equation 3D-2 depending on the extent to which these influential factors varied across the clinical study data that were used to create the RMR analytical data set. However, because there is inadequate information regarding the presence of multiple RMR measurements for individual study subjects, we could not estimate intra-individual variability nor could we use these influential factors, other than age and sex, as explanatory variables in the RMR equation. Therefore, any influences on spatial variability in RMR, both within and among the eight study areas, would largely be driven by the spatial distribution of age and sex.  | Yes. Recent data and new equations (U.S. EPA (2018), Appendix H).               |
|                        | METS Distributions           | Over  | Low - Medium | Medium                        | In a prior characterization of uncertainty in METs, APEX estimated daily mean METs range from about 0.1 to 0.2 units (between about 5-10%) higher than independent literature reported values (Table 15 of Langstaff, 2007). Some of the diary activities in CHAD encompassed broad categories (e.g., ‘play sports’, ‘travel, general’) and as such METs distributions were developed using multiple activities, some of which that could vary greatly in magnitude. Since the 2014 HREA, the list of CHAD activities (and corresponding METs values) were expanded from 142 to 320, by evaluating available diary comment details and disaggregating the originally assigned broad activities to more specific activities (see Attachment 3 and U.S. EPA, 2019c. New distributions were developed using METs estimates provided by Ainsworth et al. (2011). It is expected that the added specificity and redevelopment of METs distributions would more realistically estimate activity-specific energy expenditure. Two important uncertainties remain: the application of literature provided longer-term average METs values to short-term events and the extrapolation of METs data provided for adults to children. However, shorter-term values are of greater importance in this assessment, thus METs could be better characterized where short-term METS data are available. | Yes. New activity codes and MET distributions(U.S. EPA, 2019a, U.S. EPA, 2019b) |

| Sources of Uncertainty |  | Uncertainty Characterization                          |           |                            |  | Newly Characterized/<br>New Information?  |
|------------------------|--|---|-----------|----------------------------|--|---|
|                        |  | Influence of Uncertainty on Exposure   Risk Estimates |           | Knowledge-base Uncertainty | Comments   |   |
| Category               | Element  | Direction   | Magnitude |                            |  |   |
|                        | Ventilation Rates  | Unknown   | Low       | Low - Medium               | Predictions made using the prior algorithm showed excellent agreement with independent measurement data, particularly when considering simulated study group (Graham and McCurdy, 2009; 2014 HREA Figure 5-23 and Figure 5-24). New algorithm derived using the same data observed to have improved predictability (U.S. EPA, 2018, Appendix H). However, a shorter-term comparison (a single hour rather than daily) of predicted versus measured ventilation rates, while more informative, cannot be performed due to lack of ventilation rate data at this duration and considering influential factors (e.g., age, particular activity performed).  | Yes. New equation (U.S. EPA, 2018, Appendix H).   |
| Exposure-based risk    | EVR Characterization of Moderate or Greater Exertion       | Both  | Low       | Low - Medium               | The 2014 HREA recognized that the simulated number of people achieving this level of exertion could be moderately overestimated, affecting the results for comparison to benchmarks and the population-based E-R approach used to estimate lung function risk. A new approach to identifying when individuals may be at moderate or greater exertion was developed to better address inter-personal variability observed in the controlled human exposure study subjects (Attachment 2). Uncertainty remains in the extrapolation of the observations made from adults and proportionally applied to children.   | Yes. New distribution-based approach (Attachment 2).  |
|                        | Benchmark Concentration Levels for Population Study Groups | Under   | Low       | Medium                     | There is only very limited evidence from controlled human exposure studies of population groups potentially at greater risk. Compared to the healthy young adults included in the controlled human exposure studies, members of some populations (e.g., children with asthma) are considered more likely to experience adverse effects following exposures to lower O <sub>3</sub> concentrations (80 FR 65322, 65346, October 26, 2015; Frey, 2014, p. 7). Although not directly characterized in the 2014 HREA, the benchmark levels derived from the controlled human exposure studies may not be entirely representative of effects likely to be exhibited by the simulated population and could underestimate the size of the population at risk and/or the magnitude of adverse effects.   | No  |
|                        | Exposure Duration  | Under   | Low       | Low                        | The exposure duration for the studies from which the benchmark concentrations are drawn is 6.6-hr (six 50-min exercise periods separated by 10-min rest periods, and with a 35-min lunch after 3 <sup>rd</sup> hour). For practical reasons, daily maximum exposures were time averaged over 7 hours (rather than 8 hours previously used) to better relate to the concentrations used for the controlled human exposure study subjects. The whole number 7, was used (rather than 6.6) due to logistical and timeline constraints on implementation of a 6.6-hr duration in the exposure model. Use of 7 hours, while more accurately reflecting the exposure duration in the controlled human exposure studies, would likely underestimate risk relative to directly using 6.6 hours, albeit to a limited extent. Use of 7 hours reduces the magnitude of risk underestimation compared to use of 8 hours (as was done in the prior REAs). | Yes. A 7-hr duration for averaging exposure concentrations was used to better represent 6.6-hr exposures (section 3D.2.8.1) |

| Sources of Uncertainty        |   | Uncertainty Characterization                          |              |                               |  | Newly Characterized/<br>New Information?   |
|-------------------------------|---|---|--------------|-------------------------------|--|--|
|                               |   | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base<br>Uncertainty | Comments   |  |
| Category                      | Element   | Direction   | Magnitude    |                               |  |  |
| Lung Function Risk Estimation | Contribution to Risk of Exposures at or Below 40 ppb                            | Over  | Low - Medium | Low - Medium                  | While there is limited support for O <sub>3</sub> being causally linked to lung function responses at the lowest tested exposure level (i.e., 40 ppb exposures), there are no observations at lower exposures. Data available at 40 ppb are limited to two studies, in one of which O <sub>3</sub> was administered by facemask and had the only positive response. Because the lung function risk analysis assumes there is an exposure response relationship at exposures below 40 ppb, the influence of this source of uncertainty could possibly contribute to the overestimation of risk when including risk resulting from low exposures. The magnitude of influence appears to be greater for the MSS model estimates when compared to the E-R function estimates.  | Yes. New evaluation of the contribution of risk from low exposures. (section 3D.3.4.3) |
|                               | Extrapolation of E-R Data from Healthy Subjects to Simulated People with Asthma | Under   | Low          | Low - Medium                  | Subjects with asthma in controlled human exposure studies appear to be at least as sensitive to acute effects of O <sub>3</sub> in terms of FEV <sub>1</sub> and inflammatory responses as healthy non-asthmatic subjects (2013 ISA, section 8.2.2). Note however, study subjects with asthma are typically characterized as having a “mild” condition, thus, there is uncertainty in how others expressing a more severe condition would respond to similar O <sub>3</sub> exposures. In addition, many epidemiologic studies report greater risk of health effects among individuals with asthma. Considering each of these elements, a direct extrapolation could understate the at-risk population.  | No   |
|                               | Extrapolation of E-R Data from Adults 18-35) to Children and to Older Adults    | Both  | Low - Medium | Low                           | Because the vast majority of controlled human exposure studies investigating lung function responses were conducted with adult subjects, the lung function risk estimates for children, ages 5-18, is based on E-R data from adult subjects to estimate responses in children aged 5-18. However, the few available studies of O <sub>3</sub> -related lung function decrement in children indicate that children's FEV <sub>1</sub> responses are similar to those observed in adults 18-35 years old (e.g. McDonnell et al., 1985). Regarding older adults, the evidence indicates a decline in responsiveness with increasing age 18 to 35, followed by a rate of decrease that dampens for ages 36 to 55, and ultimately leads to limited responsiveness in adults >55 years old (2013 ISA, p. 6-22). A newly available study, Arjomandi et al., 2018, found a statistically significant reduction in FEV <sub>1</sub> (group mean of 1.7%) for older adults (mean age 59.9) following 3-hr exposures of 120 ppb O <sub>3</sub> with exercise (EVR of 15-17 L/min-m <sup>2</sup> ), although statistical significance was not found for 3-hr exposures of 70 ppb. Given the 7-hr focus of the current assessment as well as the fact that the air quality scenario for the current standard includes no hours with an ambient air concentration at or above 120 ppb (Appendix 3C, Figures 3C-67 to 3C-74), the setting of the age term at zero for older adults appears to remain appropriate for the simulated exposure conditions. | No   |

| Sources of Uncertainty |  | Uncertainty Characterization                          |              |                               |   | Newly Characterized/<br>New Information? |
|------------------------|--|---|--------------|-------------------------------|---|--|
|                        |  | Influence of Uncertainty on Exposure   Risk Estimates |              | Knowledge-base<br>Uncertainty | Comments  |  |
| Category               | Element  | Direction   | Magnitude    |                               |   |  |
|                        | Assumed No Interaction of other Co-pollutants on O <sub>3</sub> -related Lung Function Responses | Under   | Low          | Medium                        | There are a few studies regarding the potential for an increased response to O <sub>3</sub> when exposure is in the presence of other common pollutants such as particulate matter (potentially including particulate sulfur compounds), nitrogen dioxide, and sulfur dioxide, although the studies are limited (e.g., with regard to relevance to ambient air exposure concentrations) and/or provide inconsistent results.  | No                                       |
|                        | Statistical model for E-R Function   | Both  | Low          | Low                           | The selection of statistical model to best reflect the E-R relationship can influence risk estimates, particularly for instances when large proportions of the simulated population are exposed to low-level concentrations. The 90/10 logit/linear model (section 3D-2.8.2.1) yielding an E-R function similar in shape to an E-R function developed using a probit link (a commonly used fitting method), would tend to estimate lower risk than a function based on a logistic fit (which would have a relatively higher response at low level exposures). Overall, the relatively low contribution of low-level exposures to risk when using the E-R function approach indicates the selection of the 90/10 logit/linear fit to have a limited impact on uncertainty in risk estimates.   | Yes. Section 3D.3.4.2.1                  |
|                        | Statistical Uncertainty in E-R Function  | Both  | Low - Medium | Low                           | A BMCMC approach was used to iteratively generate 9,000 unique E-R functions section 3D.2.8.2.1). We used the median (50 <sup>th</sup> percentile) function for generating population-based (E-R function) lung function risk in the main body results. A 95% confidence interval for risk estimates was generated using the 2.5 <sup>th</sup> and 97.5 <sup>th</sup> percentile E-R functions. Overall, the range of risk estimates using the confidence intervals was small, on the order of a few percentage points, but increased in relative magnitude when considering the larger lung function decrements.   | Yes. section 3D.3.4.2.2                  |
|                        | Contribution of Low-level Ventilation Rate in MSS model Estimated Risk                           | Over  | Low - Medium | Low - Medium                  | We evaluated the role of ventilation rate in estimating risk with the MSS model approach (section 3D.2.8.2.2) by comparing risk generated using either of two model conditions: risk for when simulated individuals experienced decrements at any ventilation rate, or risk for when ventilation rate was at moderate or greater exertion (the latter reflects the E-R function risk approach). The MSS model risk estimates were about 20-40% lower when selecting for simulated individuals at moderate or greater exertion compared with MSS model risk estimates using individuals at any ventilation rate (Table 3D-69). Even when including only individuals at higher exertion rates, the MSS model risk estimates are still a factor of three or more higher than risks estimated using the E-R function risk approach. Given that the controlled human exposure studies indicate an importance of elevated ventilation in combination with the studied exposure concentrations, the MSS model likely overestimates risk. | Yes. section 3D.3.4.2.4                  |



| Sources of Uncertainty |  | Uncertainty Characterization                          |           |                            | Newly Characterized/<br>New Information?  |
|------------------------|--|---|-----------|----------------------------|---|
|                        |  | Influence of Uncertainty on Exposure   Risk Estimates |           | Knowledge-base Uncertainty |   |
| Category               | Element                                    | Direction   | Magnitude |                            | Comments  |
|                        | Variability Parameter Setting in MSS Model | Over  | Medium    | Low - Medium               | <p>The value of the MSS model variable <math>U</math> (Equations 3D-15 and 3D-16) is randomly assigned from a distribution to simulated individuals and is meant to address inter-individual variability not accounted for by the other MSS model variables. The influence of <math>U</math> was qualitatively evaluated by examining example time series for two children simulated with different values for <math>U</math> and for which similar-sized lung function decrements are predicted. While both children had similar exposure profiles in terms of duration exposed to elevated concentrations, the ventilation duration at peak concentrations differed. The difference observed (Figure 3D-18) suggests that random assignment of high <math>U</math> values leads to simulated individuals being predicted to experience lung function decrements at relatively lower time-averaged breathing rates as those with a lower <math>U</math> value. Given the difference of these exposure conditions from those in which such decrements are observed in controlled human exposure studies, it is likely that the risk is overestimated, and the amount of overestimation may be similar to that described for ventilation rate in the preceding entry. A second variable <math>v_1</math>, a constant, is used by the MSS model to address intra-individual variability (Equation 3D-16). Because the <math>v_1</math> is described as representing the non-ozone related contribution to response variability in the study observations (McDonnell et al., 2013), a non-zero setting may contribute to over estimates in risk. We found estimated risks using <math>v_1</math> set to zero to be about 20-35% lower than when using the default parameter setting (the setting used for the main results in section 3D.3.3.2).</p> |

| Sources of Uncertainty |  | Uncertainty Characterization                          |           |                            |   | Newly Characterized/<br>New Information? |
|------------------------|--|---|-----------|----------------------------|---|--|
|                        |  | Influence of Uncertainty on Exposure   Risk Estimates |           | Knowledge-base Uncertainty | Comments  |  |
| Category               | Element  | Direction   | Magnitude |                            |   |  |
|                        | Statistical and Model Uncertainty in MSS model | Both  | Low       | Low                        | Glasgow and Smith (2017) evaluated statistical uncertainty in the MSS model employed by APEX. Multiple sets of lung function risk results were generated using random draws of the MSS model coefficients (considering their standard errors) and performing APEX simulations for children ages 5-17 and for 2010 air quality just meeting a design value of 75 ppb in Atlanta. Calculated bounds on the risk estimates could extend to as low as 0% and >35% of children experiencing at least one decrement ≥10% (Glasgow and Smith (2017), Figure 1). While the bounds were wide ranging (and affecting mostly the lowest decrement size), the reported median risk estimate (18.1%) is similar to that estimated in the 2014 HREA. Note, these central tendency risk values are based on using the best estimates of the MSS model coefficients and are derived from the existing controlled human exposure study data. It is possible that with new controlled human study observations, these model coefficients (and associated standard errors) could possibly change, resulting in a shift of central tendency risk estimates in either direction (greater or lower frequency of lung function decrements) while also changing the outer bounds (increasing or decreasing the confidence intervals). Even so, the outer bounds of any risk estimates, based on the current MSS model or a newly derived MSS model, are generated by using a distribution of coefficient values, the bounds of which have a lesser probability of occurrence compared to those generated using the central tendency values. Further, Glasgow and Smith (2017) also evaluated MSS model uncertainty using two different parameterizations (one including BMI as an explanatory variable, the other not). Comparison of median risk values for the two parameterizations ranged from fractions to a few percentage points, with the largest difference reported for the lowest decrement and overall, lower values were reported for the MSS model that includes a BMI variable. We note the risk results generated in our assessment are based on the MSS model that includes a BMI variable. While uncertainty in the MSS model risk estimates could be further characterized (e.g., including the type of analyses reported by Glasgow and Smith, 2017), that would not be expected to change the overall conclusion that there is relatively greater uncertainty associated with the MSS model estimates than with the E-R model estimates. | Yes (Glasgow and Smith (2017))           |

#### 3D.3.4.2 Targeted Evaluations of Lung Function Risk Models

The intent of the following targeted evaluations is to provide insight into a few of the important uncertainties identified in section 3D.3.4.1 concerning the lung function risk estimates. Analyses were designed to inform how the uncertainties may influence the exposure and risks reported in section 3D.3. Results or estimates generated in these targeted evaluations do not replace (nor supplement) the results in section 3D.3, nor do they address all aspects of the exposure and risk assessment. Further, because the main body results indicated children were estimated to experience lung function decrements more frequently than adults, we focused these targeted evaluations on simulations with children.

Briefly, we performed five targeted evaluations with each discussed in the following sections. The first section discusses the statistical model used to represent the E-R function (section 3D.3.4.2.1). The next section discusses the development and interpretation of confidence intervals for the lung function risk estimates generated using the population-based E-R function (section 3D.3.4.2.2). This is followed by a section describing an evaluation of the contribution of low-level exposures to risk estimated using the population-based E-R function and the individual MSS model lung function risk approaches (section 3D.3.4.2.3). Section 3D.3.4.2.4 evaluates the role moderate or greater ventilation has in estimating risk using the MSS model. And finally, a discussion and evaluation of variability parameters used in the MSS model is presented in section 3D.3.4.2.5.

##### 3D.3.4.2.1 Statistical Model Used for the E-R Function

There are several approaches available to fit data to a continuous E-R function, for example, regression models (linear, logistic) and use of curve smoothing techniques (moving averages, polynomial splines). Logistic regression is commonly used for concentration-, exposure-, and dose-response relationships when study observations contain a binary dependent variable (e.g., either yes/no response). A logistic regression can be fit using a varied linking approach, such as logit or probit, the selection of which can depend on assumptions made regarding the distribution of responses (logistic or inverse normal, respectively)<sup>83</sup> among other factors (e.g., model fit statistics).

The statistical model selected for the E-R function and used to estimate the frequency of lung function decrements in this exposure and risk analysis is the same as that used in the 2014 and 2007 REAs and was based on combining logistic (with a logit link) and two-piece linear

---

<sup>83</sup> For example, regarding the development of an E-R function describing lung function decrements associated with exposure to SO<sub>2</sub> for the risk assessment performed in the 2012 review of the SO<sub>2</sub> NAAQS (U.S. EPA, 2009), the CASAC for that review (Samet, 2009) suggested that the distribution of individual response thresholds supported use of a probit function rather than a logistic function (pp. 14 and 60-63).

forms in a 90/10 percent proportion, respectively, using a Bayesian Markov Chain Monte Carlo (BMCMC) modeling approach (section 3D.2.8.2.1). The selection of this model was based on advice received from the CASAC review in the 2008 O<sub>3</sub> NAAQS review (Henderson, 2006) and evaluation of the curve fit statistics for this function (U.S. EPA, 2007a; 2014 HREA).


Of practical importance for this assessment is how the response curve is extrapolated from the lowest observed exposure to zero exposure/response. For general context, in comparing a probit to a logit link in a logistic regression, the probit link would yield a relatively lower response at the lowest level exposures. The two-piece linear model used in part for developing the current E-R function resembles a hockey stick, with the paddle representing a zero response for the lowest exposures, and the handle representing the increased response that coincides with increasing exposures, beginning at the junction between the paddle and the stick.<sup>84</sup> Based on this statistical form, when combining the logit linked logistic model with a hockey stick type model (as done for this assessment), it was assumed the 90/10 percent proportion logit/linear E-R form would have a response curve shape for low-level exposures similar to that using a probit link. To better evaluate these E-R functions, we fit the controlled human exposure study data (Figure 3D-12) using a probit link and compared that with the 90/10 logit/linear curve.

As an example, Figure 3D-14 illustrates the E-R functions fit from these two approaches, using the  $\geq 15\%$  lung function decrement observations. Plotted for the probit approach is the curve derived from the best estimate of the model coefficients, along with 95% confidence intervals derived from the model coefficient variability. For the 90/10 logit/linear approach, the median (50<sup>th</sup> percentile) function is plotted, along with 95% confidence intervals derived from the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile E-R functions obtained from the 9,000 BMCMC model iterations. As expected, the probit curve is very similar to the 90/10 logit/linear curve, albeit with the former having a response just below the latter for the lower exposures. The opposite occurs for exposures above 55 ppb; for those higher exposures, a relatively greater response is indicated using the 90/10 logit/linear E-R function. Based on there being little difference between the two curves and only slight off-setting of the response at different exposure levels, it is likely that applying a probit fit for the E-R function to the population distribution of daily maximum 7-hr exposures would result in little to no difference from the risk estimates derived with the 90/10 logit/linear E-R function.<sup>85</sup>

---

<sup>84</sup> The combined two-piece linear/logistic E-R function is used, as described in section 3D.2.8.2.1 above, because of the limited controlled human exposure study data, and associated uncertainty regarding the response, at low level exposures (i.e., <60 ppb). Note, the two-piece linear model has a lower percent contribution (10%) compared to that of the non-threshold logistic model (90%) in deriving the combined E-R function.

<sup>85</sup> Evaluation of the E-R functions fit for the 10% decrement indicated that the 90/10 logit/linear curve had a somewhat higher response than the probit curve at the low-level exposures (and lower response at exposures >55



**Figure 3D-14. Comparison of a probit function curve (blue line) with the Bayesian logistic/linear function curve (red) in estimating the probability of lung function decrements  $\geq 15\%$  (based on data in Table 3D-20). Confidence intervals for the probit model reflect variability in the regression model coefficients.**

#### **3D.3.4.2.2 Confidence Intervals for the Population-based E-R Function and Effect on Lung Function Risk Estimates**

To estimate lung function risk using the population-based E-R function approach, the results of which are presented in the main body of this document (section 3D.3.3.1), we selected the median (50<sup>th</sup> percentile) E-R function originally developed as part of the 2014 HREA. This E-R function was derived from Bayesian Markov Chain Monte Carlo (BMCMC) approach that iteratively combined logistic and linear E-R functions fit to the controlled human exposure study data in Table 3D-20 (section 3D.2.8.2.1). The selection of the median E-R function to estimate risk in the current assessment generally assumes the simulated at-risk population is comprised of

---

ppb). For the 20% decrement, the probit curve was similar to the 90/10 logit/linear curve at low-level exposures, but slightly higher for exposures between 50 and 70 ppb. Given the smallness of the difference and limited contribution of the lower exposures to the risk estimates (Table 3D-66), these finding does not imply significant uncertainty or support generation of new simulations and risk estimates using the probit E-R function.

1 individuals that have a similar response frequency as that of the general collection of controlled  
2 human exposure study test subjects.

3 Because there were two or more studies reporting observed responses at most of the  
4 exposure levels and the BMCMC approach generates numerous E-R functions, statistical  
5 uncertainty in the E-R function can be used to approximate lower and upper bounds to the lung  
6 function risk estimates. To evaluate such bounds here, a 95% confidence interval for lung  
7 function risk was estimated by combining the population distribution of daily maximum 7-hr  
8 exposures (occurring while at moderate or greater exertion) for simulated children in each study  
9 area with the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile population-based E-R functions (2014 HREA, Appendix  
10 6A, Table 6A-1). Lung function risk estimates based on these lower and upper percentile  
11 functions and those based on the median function (for air quality just meeting the existing  
12 standard) are presented, in terms of the minimum and maximum year results, in Table 3D-65 for  
13 each of the three lung function decrements (i.e., FEV<sub>1</sub> decrements  $\geq 10$ , 15, and 20%). The  
14 estimates for the median E-R function are drawn from Table 3D-40. The estimates for the best  
15 and worst air quality years yield the minimum and maximum estimates for each of the three  
16 functions providing a range for estimates based on each of the particular E-R functions.

17 The range of values for the estimated risk generated by each of the E-R functions as a  
18 result of using different air quality years (i.e., the distance in estimated risk between the  
19 minimum and maximum values) is small, on the order of a few tenths of a percentage point, with  
20 the smallest range of values associated with the largest lung function decrement (Table 3D-65).  
21 In general, the range of the overall 95% confidence interval (i.e., the distance in estimated risk  
22 between the 2.5<sup>th</sup> and 97.5<sup>th</sup> values) is also small when considering percentage points. For  
23 example, the lower bound percent of children estimated to experience at least one lung function  
24 decrement  $\geq 10\%$  for the Atlanta study area is about 1.5% and the upper bound value is about  
25 4.0% (median E-R function value  $\sim 2.4\%$ ). With increasing magnitude of the decrement, the  
26 range of percentage points becomes smaller (e.g., a  $\geq 20\%$  decrement has a range of about 0.6  
27 percentage points for Atlanta). In terms of relative magnitude, one might consider this range  
28 large (i.e., a factor of 6 or more), but because there are so few children estimated to experience  
29 these large lung function decrements, this interpretation of the confidence interval would be  
30 inappropriate. Further, it would be unreasonable to simply assume that use of the lower and  
31 upper bounds of the E-R functions would appropriately estimate lower and upper bounds of risk  
32 without additional context regarding the controlled human exposure study data, the interpretation  
33 of the bounds on the E-R function, and how these might relate to statistical uncertainty in the risk  
34 estimates.

**Table 3D-65. Percent of children estimated to experience at least one lung function decrement at or above the indicated level, for air quality adjusted to just meet the current standard, using the population-based (E-R function) risk approach.**

| FEV <sub>1</sub><br>Decrement | Study Area   | Percent of Children Estimated to Experience at Least One<br>Decrement per Year using Specified E-R Functions <sup>A</sup> |                  |   |     |                                     |     |
|-------------------------------|--------------|---|------------------|---|-----|-------------------------------------|-----|
|                               |              | Lower Bound (2.5%)<br>E-R Function  |                  | Median (50%)<br>E-R Function <sup>B</sup> |     | Upper Bound (97.5%)<br>E-R Function |     |
|                               |              | min <sup>C</sup>  | max <sup>C</sup> | min                                       | max | min                                 | max |
| ≥10%                          | Atlanta      | 1.0   | 1.5              | 1.9                                       | 2.5 | 3.1                                 | 4.0 |
|                               | Boston       | 1.2   | 1.4              | 2.0                                       | 2.3 | 3.3                                 | 3.8 |
|                               | Dallas       | 1.2   | 1.6              | 2.1                                       | 2.6 | 3.5                                 | 4.3 |
|                               | Detroit      | 1.4   | 1.8              | 2.3                                       | 2.8 | 3.9                                 | 4.5 |
|                               | Philadelphia | 1.3   | 1.4              | 2.2                                       | 2.4 | 3.6                                 | 3.9 |
|                               | Phoenix      | 1.8   | 2.2              | 2.9                                       | 3.3 | 4.8                                 | 5.4 |
|                               | Sacramento   | 1.2   | 1.4              | 2.2                                       | 2.3 | 3.6                                 | 3.8 |
|                               | St. Louis    | 1.4   | 1.8              | 2.3                                       | 2.8 | 3.8                                 | 4.5 |
| ≥15%                          | Atlanta      | >0.1  | 0.2              | 0.4                                       | 0.6 | 0.7                                 | 1.1 |
|                               | Boston       | 0.1   | 0.2              | 0.5                                       | 0.6 | 0.8                                 | 1.0 |
|                               | Dallas       | 0.1   | 0.2              | 0.5                                       | 0.7 | 0.8                                 | 1.1 |
|                               | Detroit      | 0.1   | 0.3              | 0.6                                       | 0.8 | 1.0                                 | 1.2 |
|                               | Philadelphia | 0.1   | 0.1              | 0.5                                       | 0.6 | 0.9                                 | 1.0 |
|                               | Phoenix      | 0.2   | 0.3              | 0.7                                       | 0.9 | 1.2                                 | 1.5 |
|                               | Sacramento   | 0.1   | 0.1              | 0.5                                       | 0.6 | 0.9                                 | 1.0 |
|                               | St. Louis    | 0.1   | 0.3              | 0.6                                       | 0.8 | 0.9                                 | 1.2 |
| ≥20%                          | Atlanta      | >0.1  | 0.1              | 0.1                                       | 0.2 | 0.4                                 | 0.7 |
|                               | Boston       | >0.1  | 0.1              | 0.2                                       | 0.2 | 0.5                                 | 0.7 |
|                               | Dallas       | >0.1  | 0.1              | 0.2                                       | 0.3 | 0.5                                 | 0.8 |
|                               | Detroit      | 0.1   | 0.1              | 0.2                                       | 0.3 | 0.7                                 | 0.9 |
|                               | Philadelphia | >0.1  | >0.1             | 0.2                                       | 0.2 | 0.6                                 | 0.6 |
|                               | Phoenix      | 0.1   | 0.1              | 0.3                                       | 0.4 | 0.8                                 | 1.1 |
|                               | Sacramento   | >0.1  | >0.1             | 0.2                                       | 0.2 | 0.5                                 | 0.6 |
|                               | St. Louis    | >0.1  | 0.1              | 0.2                                       | 0.3 | 0.6                                 | 0.9 |

<sup>A</sup> Calculated percent is rounded to the nearest tenth decimal using conventional rounding. Values equal to zero are designated by "0" (there are no individuals experiencing decrements at that level). Small, non-zero values that do not round upwards to 0.1 (i.e., <0.05) are given a value of "<0.1".

<sup>B</sup> The median function is used to generate E-R function risk estimates reported in the main body results. Note, these are identical to the results reported in Table 3D-40.

<sup>C</sup> The minimum (min) are results for the best air quality year and the maximum (max) are results for the worst air quality year of the three years simulated.

As a reminder, while the controlled human exposure study subjects are volunteers (and assumed to be selected at random), it is important to note there are important fundamental biases in their collective composition: none of the individuals have known preexisting health conditions

1 (e.g., cardiovascular disease, asthma) and all of the subjects are required to be physically fit  
2 enough to meet a study's exercise target levels. Clearly, not every member of the simulated  
3 population has these attributes, but the risk approach does select for when simulated individuals  
4 are at moderate or greater exertion while exposed, as was done for the controlled human  
5 exposure study subjects. Therefore, representation of potentially sensitive individuals (i.e., those  
6 with pre-existing health conditions) in the study data and thus, in the derived E-R functions, is  
7 absent.

8 In addition, use of this type of statistical approach to estimate lower and upper bounds of  
9 lung function risk does not suggest that the range of functions could be equally applied to the  
10 simulated population as a whole (e.g., that the entire population could have a risk as low as  $X$  or  
11 as high as  $Y$ , based on the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile functions selected, respectively) nor does the  
12 range of E-R functions likely represent individuals that are least sensitive, or more importantly  
13 (given the NAAQS review context for these analyses), those most sensitive to O<sub>3</sub> exposure. The  
14 variability in the observed response in study subjects at given O<sub>3</sub> exposures can be due to many  
15 factors (e.g., uncertainties in exposure conditions, response/concentration measurements, study  
16 subject sensitivity for healthy individuals, number of subjects per study, etc.). When used in such  
17 an analysis here, one might suggest the lower and upper bounds account for some of these  
18 uncertainties, however, they would be bounded by their collective representativeness and actual  
19 weighting of these uncertainties present in the study observations. In its application, it would be  
20 assumed that the distribution of the features of the study subjects are similarly reflected in the  
21 simulated population, which as described above, is not entirely the case.

22 Further, the range of functions used to represent lower and upper bounds is derived from  
23 a distribution of functions. If there were a perfect matching of the study subject attributes with  
24 those of the simulated population, the risks estimated using either end of the 95% interval for the  
25 E-R function would certainly have a much smaller likelihood and better apply to a smaller  
26 proportion of the population, than those estimated from using the median E-R function. That  
27 said, even in the absence of perfectly matching the attributes of the controlled human exposure  
28 study subjects with those of the simulated population, the median E-R function may be most  
29 appropriate to estimate lung function risk for the simulated population as a whole. Still, the  
30 median E-R function may be underestimating the number/percent of individuals experiencing  
31 decrements to the extent that the general population includes individuals that would experience  
32 greater decrements than experienced by individuals represented in the controlled human  
33 exposure studies. Further, as recognized in Chapter 3 of the main document, similarly sized  
34 decrements in individuals with compromised respiratory function or in individuals with asthma  
35 may be more likely to elicit other, perhaps more significant, health outcomes.



### 3D.3.4.2.3 Contribution of Low-Level Exposures to Lung Function Risk Estimates



The two approaches used to estimate lung function risk were evaluated to better understand how the distribution of exposures influences the estimated risk. For the first approach that used the population-based E-R function to estimate risk, we evaluated the risk contribution resulting from each of the daily maximum 7-hr exposure levels that occur while at elevated risk. Because the continuous function used is extrapolated from the lowest observed exposure (40 ppb) in the controlled human exposure studies to zero, of particular interest here were the contributions from low exposures to the estimated risk where there are no controlled human study data available (i.e., O<sub>3</sub> exposures <40 ppb, 6.6-hrs). Further, because there were only two studies that included exposures of 40 ppb (one that elicited decrements between 10 and 15% in two study subjects, with no statistical significance at the group mean level, the other eliciting no decrement of at least 10% in any subjects), we also evaluated the contribution to estimated risk resulting from exposures  $\geq 50$  ppb and  $\geq 60$  ppb.

The APEX exposure output for the E-R function approach that were the basis for the main results reported in section 3D.3.3 are in a format useful for calculating the risk contribution from each 7-hr average exposure bin (0 to 160 ppb, in 10 ppb increments), thus no new APEX simulations were needed for this evaluation. However, given the objectives for this evaluation, time limitations on it, and that new simulations were required to evaluate the MSS model approach (see below), we focused on three of the eight study areas for this evaluation. These areas were selected at random (i.e., Atlanta, Dallas, and St. Louis), and simulations were performed for a single year (2016). The results for this evaluation are provided in Table 3D-66 for the three study areas, three air quality scenarios using 2016 data, and focusing on the risk contribution to lung function decrements occurring at least one and two days per year. Figure 3D-15 illustrates the same results, but for air quality just meeting the current standard.

There is variability in the risk contribution across the three study areas, variability which increases with increasing magnitude of the lung function decrement and increasing O<sub>3</sub> exposures across the three air quality scenarios. The risk estimated from 7-hr average exposures below 40 ppb is generally low and is lower for higher magnitudes of the lung function decrement and higher air quality scenario design value. That said, the majority of risk (84 to 98%) is attributed to 7-hr average exposures  $\geq 40$  ppb for any of the air quality scenarios. The risk contribution attributed to 7-hr average exposures  $\geq 60$  ppb varies greatly across the study areas, the magnitude of the decrements, and the air quality scenarios. For example, on average about 37% of the risk is contributed by 7-hr average exposures  $\geq 60$  ppb. But in Dallas, the contribution from these exposures is much less (on average about 22%), while in St. Louis, the contribution is much more (on average about 50%).

1 **Table 3D-66. Estimated lung function risk contribution resulting from selected 7-hr**  
2 **average O<sub>3</sub> exposures in children, using the E-R function risk approach, 2016.**

| Air Quality Scenario      | 7-hr Exposure | Study Area | Risk Contribution from Indicated 7-hr Exposure, E-R Function Approach |       |       |   |       |       |
|---------------------------|---------------|------------|---|-------|-------|---|-------|-------|
|                           |               |            | One Decrement/FEV <sub>1</sub> Reduction                              |       |       | Two Decrements/FEV <sub>1</sub> Reduction |       |       |
|                           |               |            | ≥10%  | ≥15%  | ≥20%  | ≥10%                                      | ≥15%  | ≥20%  |
| 65 ppb                    | <30 ppb       | Atlanta    | 6.2%  | 3.5%  | 1.8%  | 10.3%                                     | 6.7%  | 3.8%  |
|                           |               | Dallas     | 6.7%  | 3.9%  | 2.1%  | 10.8%                                     | 7.1%  | 4.2%  |
|                           |               | St. Louis  | 5.4%  | 2.9%  | 1.4%  | 9.1%                                      | 5.6%  | 3.0%  |
|                           | <40 ppb       | Atlanta    | 19.8%   | 13.4% | 8.1%  | 30.4%                                     | 23.3% | 16.2% |
|                           |               | Dallas     | 20.9%   | 14.7% | 9.2%  | 31.3%                                     | 24.3% | 17.2% |
|                           |               | St. Louis  | 16.5%   | 10.6% | 6.1%  | 25.6%                                     | 18.5% | 12.0% |
|                           | <50 ppb       | Atlanta    | 54.3%   | 43.1% | 32.2% | 75.4%                                     | 67.7% | 58.2% |
|                           |               | Dallas     | 58.1%   | 48.1% | 37.6% | 76.6%                                     | 69.5% | 60.6% |
|                           |               | St. Louis  | 43.4%   | 32.7% | 23.3% | 62.6%                                     | 53.1% | 42.7% |
|                           | <60 ppb       | Atlanta    | 88.7%   | 81.9% | 74.4% | 98.5%                                     | 97.4% | 95.9% |
|                           |               | Dallas     | 94.2%   | 90.2% | 85.6% | 99.8%                                     | 99.6% | 99.4% |
|                           |               | St. Louis  | 83.3%   | 75.2% | 67.7% | 96.7%                                     | 94.5% | 91.8% |
| Current Standard (70 ppb) | <30 ppb       | Atlanta    | 4.2%  | 2.0%  | 0.9%  | 7.3%                                      | 4.2%  | 2.1%  |
|                           |               | Dallas     | 5.3%  | 2.8%  | 1.4%  | 8.8%                                      | 5.4%  | 2.9%  |
|                           |               | St. Louis  | 3.7%  | 1.7%  | 0.7%  | 6.6%                                      | 3.6%  | 1.7%  |
|                           | <40 ppb       | Atlanta    | 12.9%   | 7.5%  | 3.9%  | 21.0%                                     | 14.4% | 8.8%  |
|                           |               | Dallas     | 16.3%   | 10.5% | 6.0%  | 25.1%                                     | 18.2% | 11.9% |
|                           |               | St. Louis  | 11.1%   | 6.1%  | 3.1%  | 18.0%                                     | 11.5% | 6.6%  |
|                           | <50 ppb       | Atlanta    | 35.9%   | 24.5% | 15.7% | 53.9%                                     | 43.3% | 32.9% |
|                           |               | Dallas     | 45.3%   | 34.4% | 24.5% | 63.4%                                     | 54.0% | 43.7% |
|                           |               | St. Louis  | 29.0%   | 18.7% | 11.6% | 44.9%                                     | 33.7% | 23.8% |
|                           | <60 ppb       | Atlanta    | 72.3%   | 59.7% | 48.7% | 91.7%                                     | 86.6% | 81.2% |
|                           |               | Dallas     | 85.8%   | 77.9% | 69.8% | 97.0%                                     | 95.0% | 92.6% |
|                           |               | St. Louis  | 61.1%   | 48.3% | 38.5% | 82.9%                                     | 74.5% | 66.5% |
| 75 ppb                    | <30 ppb       | Atlanta    | 2.9%  | 1.2%  | 0.4%  | 5.2%                                      | 2.6%  | 1.2%  |
|                           |               | Dallas     | 4.3%  | 2.1%  | 0.9%  | 7.4%                                      | 4.3%  | 2.2%  |
|                           |               | St. Louis  | 2.8%  | 1.2%  | 0.4%  | 5.2%                                      | 2.6%  | 1.1%  |
|                           | <40 ppb       | Atlanta    | 8.6%  | 4.3%  | 1.9%  | 14.7%                                     | 8.8%  | 4.7%  |
|                           |               | Dallas     | 13.1%   | 7.7%  | 4.0%  | 21.0%                                     | 14.4% | 8.8%  |
|                           |               | St. Louis  | 8.4%  | 4.1%  | 1.9%  | 14.1%                                     | 8.1%  | 4.2%  |
|                           | <50 ppb       | Atlanta    | 23.6%   | 13.7% | 7.6%  | 37.6%                                     | 26.5% | 17.6% |
|                           |               | Dallas     | 35.6%   | 24.6% | 16.0% | 52.9%                                     | 42.4% | 32.2% |
|                           |               | St. Louis  | 21.6%   | 12.5% | 7.0%  | 34.6%                                     | 23.5% | 15.1% |
|                           | <60 ppb       | Atlanta    | 52.8%   | 37.7% | 27.0% | 75.8%                                     | 64.9% | 55.2% |
|                           |               | Dallas     | 75.1%   | 63.3% | 52.7% | 92.0%                                     | 87.2% | 82.1% |
|                           |               | St. Louis  | 47.4%   | 33.6% | 24.4% | 69.3%                                     | 57.2% | 47.3% |



**Figure 3D-15. Estimated lung function risk contribution resulting from selected 7-hr average O<sub>3</sub> exposures in children, using the E-R function risk approach and air quality adjusted to just meet the current standard, for one decrement (top panel) and two decrements (bottom panel), 2016.**

As was done with the E-R function results, we evaluated the influence exposure level has on risks estimated using the MSS model. New APEX simulations were performed to estimate the continuous hourly time-series of O<sub>3</sub> exposures and FEV<sub>1</sub> decrements. All simulation conditions remained the same as done for the main body risk results except that for this evaluation, a single year of air quality (2016) was used and fewer children were simulated to maintain a tractable analysis (10,000 rather than the 60,000 done for the main body results). Note, there is little difference in risks estimated when varying the total number of simulated children (Table 3D-67). Because the risk estimated using the MSS model is calculated from a cumulative time-series of O<sub>3</sub> exposures (and EVR, along with contributions from other variables used by the MSS model), we calculated the 7-hr average O<sub>3</sub> exposure occurring just prior to the FEV<sub>1</sub> decrements to allow for reasonable comparison with the above E-R function risk contribution results.



Table 3D-68 and Figure 3D-16 present the risk contribution resulting from selected 7-hr average O<sub>3</sub> exposures that occur prior to a lung function decrement of interest, estimated using the MSS model. While the general pattern in the risk contributions across the air quality scenarios, study areas, and decrements are similar to that described above using the E-R function approach, there are noteworthy differences between the two risk approaches. First, there is less variability in the risk contribution values across the study areas and decrements when using the MSS model risk approach. For example, the overall coefficient of variation (COV; standard deviation/mean) ranges from 1 to 31% (mean 11%) across study areas when evaluating the MSS model risk contributions, while the COV ranges from 6 to 49% (mean 26%) for the same evaluation using the E-R function. Second, the MSS model consistently calculates a greater percent of lung function decrements that result from low O<sub>3</sub> exposures (Table 3D-68) relative to that estimated when using the E-R function (Table 3D-66). While the majority of risk (84 to 98%, mean 91%) using the E-R function risk approach was attributed to 7-hr average exposures  $\geq 40$  ppb, when using the MSS model, between 33 to 75% (mean 54%) of risk is attributed to 7-hr average exposures  $\geq 40$  ppb when considering the three air quality scenarios and all three decrements. Based on this evaluation, the MSS model more frequently predicts responses to occur at lower O<sub>3</sub> exposures than does the E-R function approach.

**Table 3D-67. MSS model risk estimates from varying the number of simulated children.**

| Study Area<br>(2016 AQ)   | APEX Simulation, 70 ppb AQ Scenario<br>(number of simulated children) | % of Children Experiencing at least One Decrement |                              |                              |
|---------------------------|---|---|------------------------------|------------------------------|
|                           |   | FEV <sub>1</sub> $\geq 10\%$                      | FEV <sub>1</sub> $\geq 15\%$ | FEV <sub>1</sub> $\geq 20\%$ |
| Atlanta<br>(worst year)   | Sensitivity (n = 10,000)  | 14.6%   | 5.1%                         | 2.1%                         |
|                           | Main Results, Table 3D-52 (n = 60,000)                                | 15.1%   | 5.0%                         | 2.1%                         |
| Dallas<br>(best year)     | Sensitivity (n = 10,000)  | 13.3%   | 4.1%                         | 1.7%                         |
|                           | Main Results, Table 3D-52 (n = 60,000)                                | 13.1%   | 4.0%                         | 1.6%                         |
| St. Louis<br>(worst year) | Sensitivity (n = 10,000)  | 16.3%   | 5.8%                         | 2.5%                         |
|                           | Main Results, Table 3D-52 (n = 60,000)                                | 16.3%   | 5.9%                         | 2.7%                         |

1 **Table 3D-68. Estimated lung function risk contribution resulting from selected 7-hr**  
2 **average O<sub>3</sub> exposures in children, using the MSS model risk approach, 2016.**

| Air Quality Scenario      | 7-hr Exposure | Study Area | Risk Contribution from Indicated 7-hr Exposure, MSS Model Approach |       |       |   |       |       |
|---------------------------|---------------|------------|--|-------|-------|---|-------|-------|
|                           |               |            | One Decrement/FEV <sub>1</sub> Reduction                           |       |       | Two Decrements/FEV <sub>1</sub> Reduction |       |       |
|                           |               |            | ≥10%   | ≥15%  | ≥20%  | ≥10%                                      | ≥15%  | ≥20%  |
| 65 ppb                    | < 30 ppb      | Atlanta    | 33.5%  | 16.2% | 10.1% | 33.9%                                     | 17.4% | 10.4% |
|                           |               | Dallas     | 36.0%  | 19.6% | 8.8%  | 36.9%                                     | 20.6% | 9.1%  |
|                           |               | St. Louis  | 29.6%  | 13.8% | 9.0%  | 30.3%                                     | 15.1% | 9.4%  |
|                           | <40 ppb       | Atlanta    | 70.9%  | 52.9% | 41.6% | 71.6%                                     | 55.4% | 44.0% |
|                           |               | Dallas     | 71.7%  | 57.2% | 38.9% | 72.6%                                     | 60.6% | 42.1% |
|                           |               | St. Louis  | 64.9%  | 46.4% | 35.1% | 65.5%                                     | 49.3% | 40.3% |
|                           | <50 ppb       | Atlanta    | 93.0%  | 86.8% | 81.3% | 93.6%                                     | 88.9% | 84.9% |
|                           |               | Dallas     | 93.7%  | 89.2% | 81.6% | 94.0%                                     | 90.9% | 86.0% |
|                           |               | St. Louis  | 89.7%  | 82.3% | 70.9% | 90.1%                                     | 84.5% | 76.5% |
|                           | <60 ppb       | Atlanta    | 99.1%  | 97.9% | 96.6% | 99.3%                                     | 98.0% | 96.5% |
|                           |               | Dallas     | 99.5%  | 98.7% | 97.9% | 99.6%                                     | 99.1% | 99.4% |
|                           |               | St. Louis  | 98.4%  | 97.2% | 95.9% | 98.5%                                     | 97.7% | 96.6% |
| Current Standard (70 ppb) | < 30 ppb      | Atlanta    | 28.6%  | 13.8% | 7.3%  | 29.3%                                     | 14.4% | 8.9%  |
|                           |               | Dallas     | 32.4%  | 18.4% | 8.8%  | 33.0%                                     | 19.4% | 9.5%  |
|                           |               | St. Louis  | 24.8%  | 10.5% | 5.2%  | 25.5%                                     | 11.1% | 5.0%  |
|                           | <40 ppb       | Atlanta    | 62.7%  | 44.2% | 33.4% | 63.3%                                     | 45.8% | 36.2% |
|                           |               | Dallas     | 66.7%  | 51.0% | 37.5% | 67.6%                                     | 54.0% | 41.5% |
|                           |               | St. Louis  | 56.6%  | 36.1% | 25.3% | 57.4%                                     | 37.9% | 27.7% |
|                           | <50 ppb       | Atlanta    | 87.7%  | 79.7% | 70.9% | 88.3%                                     | 81.4% | 75.1% |
|                           |               | Dallas     | 90.6%  | 84.0% | 77.5% | 91.1%                                     | 86.7% | 81.1% |
|                           |               | St. Louis  | 83.5%  | 72.0% | 62.9% | 84.4%                                     | 73.5% | 65.8% |
|                           | <60 ppb       | Atlanta    | 97.5%  | 95.2% | 92.5% | 97.8%                                     | 96.2% | 94.6% |
|                           |               | Dallas     | 98.8%  | 98.0% | 96.0% | 99.0%                                     | 98.6% | 97.8% |
|                           |               | St. Louis  | 95.9%  | 91.9% | 87.8% | 96.2%                                     | 92.8% | 89.7% |
| 75 ppb                    | < 30 ppb      | Atlanta    | 25.1%  | 11.7% | 6.5%  | 25.6%                                     | 12.2% | 7.2%  |
|                           |               | Dallas     | 29.7%  | 16.7% | 9.0%  | 30.3%                                     | 17.7% | 10.2% |
|                           |               | St. Louis  | 21.9%  | 9.4%  | 4.9%  | 22.4%                                     | 10.0% | 5.0%  |
|                           | <40 ppb       | Atlanta    | 55.9%  | 38.1% | 28.2% | 56.6%                                     | 39.1% | 30.0% |
|                           |               | Dallas     | 62.1%  | 46.3% | 33.0% | 63.2%                                     | 48.9% | 38.0% |
|                           |               | St. Louis  | 51.9%  | 32.2% | 22.0% | 52.6%                                     | 33.7% | 23.1% |
|                           | <50 ppb       | Atlanta    | 81.4%  | 70.5% | 62.9% | 82.2%                                     | 72.2% | 66.1% |
|                           |               | Dallas     | 87.0%  | 78.8% | 71.2% | 87.9%                                     | 81.5% | 75.8% |
|                           |               | St. Louis  | 78.3%  | 63.7% | 53.2% | 79.1%                                     | 66.1% | 56.3% |
|                           | <60 ppb       | Atlanta    | 94.6%  | 90.6% | 87.2% | 95.0%                                     | 92.1% | 90.4% |
|                           |               | Dallas     | 97.7%  | 95.5% | 93.0% | 98.0%                                     | 96.7% | 94.7% |
|                           |               | St. Louis  | 93.1%  | 87.1% | 83.0% | 93.6%                                     | 88.9% | 85.6% |



**Figure 3D-16. Lung function risk contribution resulting from selected 7-hr average O<sub>3</sub> exposures in children, using the MSS model risk approach and air quality adjusted to just meet the current standard, for one decrement (top panel) and two decrements (bottom panel), 2016.**


#### 3D.3.4.2.4 Influence of Ventilation Rate in Lung Function Risk Estimates

A second important variable used to estimate lung function risk in both the E-R function and MSS model is the ventilation rate. Recall that the E-R function approach uses a threshold value for EVR to designate whether an individual is at moderate or greater exertion ( $\text{EVR} \geq 17.32 \pm 1.25 \text{ L/min-m}^2$ ). Technically, while any 7-hr average  $\text{O}_3$  exposure can potentially lead to a lung function decrement using the E-R function approach, a lung function decrement is only calculated when individuals are at or above their designated EVR value and when it occurs simultaneously with their daily maximum 7-hr average  $\text{O}_3$  exposure. This is not the case with the MSS model lung function risk approach; both  $\text{O}_3$  exposure and ventilation rate are considered cumulatively over time (among other influential MSS model variables) and neither of which have a designated level or duration to attain.

Because of this notable difference in the MSS model approach, we first visually evaluated the relationship between the time-series of  $\text{O}_3$  exposure and ventilation rate (as represented by EVR), along with the simultaneous occurrence of lung function decrements calculated by the MSS model. Of particular interest to this evaluation was whether the pattern of these variables was correlated, and more importantly, how increases in both exposure and ventilation rates eventually corresponded to increases in the magnitude of the  $\text{FEV}_1$  decrement. As was done above to evaluate the risk contribution from selected  $\text{O}_3$  exposure levels, we used the same APEX simulation of 10,000 children (and 2016 air quality) which output the hourly time series of  $\text{O}_3$  exposure, EVR, and MSS model calculated  $\text{FEV}_1$  decrements for each simulated individual. The initial goal was to observe how the MSS model functions and see if there were general patterns in the  $\text{O}_3$  exposure, EVR, and  $\text{FEV}_1$  reductions.

Figure 3D-17 illustrates an example of the estimated hourly time-series of  $\text{O}_3$  exposure, EVR, and  $\text{FEV}_1$  decrement for a child considering 2016 air quality adjusted to just meet the current standard in the Atlanta study area. As shown here (and among all other visualizations of children we reviewed that had a lung function decrement of interest), the  $\text{O}_3$  exposure and EVR are well correlated with subsequent occurrence of a lung function decrement. With increasing  $\text{O}_3$  exposures and breathing rates, there is an increase in the magnitude of the  $\text{FEV}_1$  reduction and, following a continuous episode of high exposure along with elevated breathing rate, a lung function decrement of interest is attained (Figure 3D-17).





**Figure 3D-17. Example time-series of O<sub>3</sub> exposures, EVR, and FEV<sub>1</sub> reductions estimated using MSS model for a simulated child in the Atlanta study area, based on a day in a year (2016) of the current standard air quality scenario.**

When considering the influence of EVR in isolation, we can discern how, in many instances, the MSS model risk estimates are greater than those estimated using the E-R function approach when both use a generally similar O<sub>3</sub> exposure profile (i.e., any level, though using different averaging times). Recall, that the E-R function risk is only estimated for those attaining moderate or greater exertion levels  $EVR \geq 17.32 \pm 1.25 \text{ L/min-m}^2$ . While there is likely a minimum EVR in the MSS model, considering both the level and duration, that would lead to lung function decrements, that minimum is not explicitly defined as it is in the E-R function risk approach.

Note, the E-R method is a fairly direct translation of the controlled human exposure study data to exposure-dependent response probabilities, particularly considering the strict adherence to exertion level needed for a response. As described above (section 3D.3.4.2.2), there is low statistical uncertainty associated with the risk estimates. We already know that relatively lower ventilation rates substantially influence MSS model risk estimates based on analyses described in the 2014 HREA (Chapter 6, Tables 6-9 and 6-10). In that assessment, when restricting the MSS



1 results to when an 8-hr EVR of at least 13 L/min-m<sup>2</sup> was not achieved by simulated individuals  
2 (at that time, the threshold for moderate exertion threshold), about 40 to 50% fewer simulated  
3 individuals were estimated to experience a lung function decrement, a result better aligned with  
4 the E-R function risk results.

5 As a second evaluation of the influence of EVR, a similar evaluation of the degree to  
6 which low-level EVRs influence MSS risk estimates was performed here. We limited the  
7 evaluation to a single year (2016) of air quality adjusted to just meet the current standard in the  
8 three study areas and using the same simulation of 10,000 children described above for  
9 generating the hourly data for the MSS model lung function risks. We identified the days when  
10 children were exercising at moderate or greater exertion, i.e., 7-hr average EVR  $\geq 17.3$  L/min-m<sup>2</sup>  
11 and calculated the percent of children experiencing one or more lung function decrements of  
12 interest (i.e.,  $\geq 10\%$ ,  $\geq 15\%$ , and  $\geq 20\%$ ). Results for each the main body MSS model approach and  
13 the MSS model restricted to children at moderate or greater exertion are presented, along with  
14 results using the E-R function risk approach (Table 3D-69).

15 The pattern of risk estimates was consistent across the three study areas. Using the  
16 Atlanta study area results as an example, the E-R function risk approach predicts the percent of  
17 children experiencing one or more FEV<sub>1</sub> decrements  $\geq 10\%$  to be 2.5%, while the main body  
18 MSS model risk approach predicts 14.6% of children experience the same decrement (Table 3D-  
19 69). When using the MSS model and restricting the risk results to children at moderate or greater  
20 exertion, 8.5% of children experiencing one or more FEV<sub>1</sub> decrements  $\geq 10\%$ . Even with this  
21 adjustment for moderate or greater exertion, this indicates an uncertainty in the MSS model  
22 estimates such that the MSS model is potentially overpredicting risks for children by about a  
23 factor of three or more, particularly when considering the larger lung function decrements.

24 Note that the MSS model used an age-term that extends information developed for 18-  
25 year olds to estimate lung function risks in the simulated children (ages 5 to 18). The age term at  
26 age 18 is at a maximum value and progressively decreases in value (and hence risk) through age  
27 35 adults (the age range of study subjects in the controlled human exposure studies). Therefore,  
28 use of this extrapolation might also contribute to some of the noted differences in the two risk  
29 approaches because this approach uses the maximum possible observed value. However, the  
30 2013 ISA indicates children's responses to O<sub>3</sub> exposure are similar to those for young adults  
31 (2013 ISA, section 8.3.1.1), which lends credence to use of the age-term extrapolation in the  
32 MSS model and, overall, supports the application of E-R risk approach for children.

**Table 3D-69. Percent of children experiencing one or more FEV<sub>1</sub> decrements ≥10, 15, 20%, 2016 air quality adjusted to just meet the current standard, considering influence of moderate or greater exertion level in the MSS model and E-R function risk approaches.**

| Study Area (2016 AQ)   | Lung Function Risk Approach | Exertion Level (L/min-m <sup>2</sup> ) | % of Children Experiencing at least One Decrement |                       |                       |
|------------------------|-----------------------------|--|---|-----------------------|-----------------------|
|                        |                             |  | FEV <sub>1</sub> ≥10%                             | FEV <sub>1</sub> ≥15% | FEV <sub>1</sub> ≥20% |
| Atlanta (worst year)   | E-R function <sup>A</sup>   | ≥17.32 ± 1.25                          | 2.5%  | 0.6%                  | 0.2%                  |
|                        | MSS model <sup>B</sup>      | Any                                    | 14.6%   | 5.1%                  | 2.1%                  |
|                        | MSS model <sup>C</sup>      | ≥17.3                                  | 8.5%  | 3.5%                  | 1.6%                  |
| Dallas (best year)     | E-R function                | ≥17.32 ± 1.25                          | 2.1%  | 0.5%                  | 0.2%                  |
|                        | MSS model                   | Any                                    | 13.3%   | 4.1%                  | 1.7%                  |
|                        | MSS model                   | ≥17.3                                  | 7.9%  | 2.9%                  | 1.3%                  |
| St. Louis (worst year) | E-R function                | ≥17.32 ± 1.25                          | 2.8%  | 0.8%                  | 0.3%                  |
|                        | MSS model                   | Any                                    | 16.3%   | 5.8%                  | 2.5%                  |
|                        | MSS model                   | ≥17.3                                  | 9.7%  | 3.9%                  | 1.9%                  |

<sup>A</sup> The median (50<sup>th</sup> percentile) E-R function used to generate the main body results (Table 3D-40).

<sup>B</sup> Sensitivity results for 10,000 children simulation (Table 3D-67).

<sup>C</sup> Screened sensitivity results for only those children achieving moderate or greater exertion level.

### 3D.3.4.2.5 Influence of MSS Model Variability Parameter Settings

In this evaluation, we considered how the values for two MSS model variables,  $U$  and  $\nu_1$ , influenced the calculated lung function decrements. These variables are used to account for inter- and intra-individual variability, respectively, in the estimated lung function decrements. Both of these variables are in the 2012 MSS model (McDonnell et al., 2012; and used in the 2014 HREA to estimate lung function risk) and the 2013 MSS model (McDonnell et al. (2013); and used for the current assessment). However, because the 2013 MSS model adjusted the structure of the intra-individual variability to now include two explanatory variables,  $\nu_1$  and  $\nu_2$ , the interpretation of  $\nu_1$  has changed (McDonnell et al. (2013)).<sup>86</sup> Each of these variables is discussed in greater detail below.

The first variable is  $U$ , a random variable meant to address inter-individual variability not accounted for by the other MSS model variables. The impact of the values assigned to  $U$  is apparent simply from its roles in the MSS model calculations, as an exponent to the natural logarithm used in estimating the base  $\Delta\text{FEV}_1$  (Equation 3D-15) and within the calculation of an intra-individual variance term  $\varepsilon$  (Equation 3D-16). Based on these roles, it is likely that high

<sup>86</sup> Effectively, in McDonnell et al. (2012), intra-personal variability ( $\varepsilon$ ) was solely represented by  $\nu_1$ . In McDonnell et al. (2013), the intra-personal variability ( $\varepsilon$ ) is represented by  $\nu_1 + \nu_2 \times (e^{U_i} \times M_{ijk})$  (see Equation 3D-16). According to McDonnell et al. (2013), this was done such that “individuals experiencing small effects either because exposure was low, or because of demographics (e.g. older age) or because baseline value of responsiveness ( $U_i$ ) was small would be expected to exhibit less variability in response than those with larger mean responses.”

values for  $U$  would likely yield high lung function decrements, particularly for instances of high  $O_3$  exposures that occur simultaneously with high ventilation rates over a few to several hours. Note that when comparing the variance of  $U$  in the 2012 MSS model versus the 2013 MSS model, its standard error is greater (0.917 versus 1.123) in the most recent model.

For this evaluation, we used the same APEX simulation (as described in the prior section) of 10,000 children (and 2016 air quality), which output the hourly time series of  $O_3$  exposure, EVR, and  $FEV_1$  decrements for each simulated individual. We screened the output data for simulated individuals having experienced each of the three  $FEV_1$  decrements of interest (i.e.,  $\geq 10\%$ ,  $\geq 15\%$ , and  $\geq 20\%$ ) and occurring on separate days. We recognize there are a limited number of children experiencing lung function decrements on multiple days per year (e.g., Table 3D-57), particularly when considering the highest lung function decrement, but we were interested in controlling for the influence personal variables might have on the magnitude of each of the decrements. We identified a few simulated individual children having multiple decrements at each level of interest, and first visually compared how variation in the value assigned the  $U$  variable appeared to influence the magnitude of  $FEV_1$  reduction for the subset of these simulated children that had similar time-series of  $O_3$  exposure and ventilation rate.


As an example, Figure 3D-18 illustrates the estimated hourly time-series of  $O_3$  exposure, EVR, and  $FEV_1$  decrement for two simulated children (top and bottom panels) that differ in the value they were assigned for the  $U$  variable (both runs used the 2016 year for the current standard air quality scenario for the Atlanta study area). In both cases, the  $O_3$  exposure and EVR are well correlated for each child prior to the occurrence of a lung function decrement, consistent with the controlled human exposure study data. With increasing magnitude of the  $FEV_1$  decrement (Figure 3D-18, from left to right panels) there is also progressively higher exposures and breathing rates, each occurring as peak events that continue over a few to several hours just prior to eliciting the indicated  $FEV_1$  decrement of interest. In general, for each of the three magnitudes of  $FEV_1$  decrement, the time-series of  $O_3$  exposures appears similar for the two simulated children – a consistently high exposure maintained across multiple hours for all of the instances where a lung function decrement occurred, with the highest decrement achieved when exposures were also highest. There is however a recognizable difference in the EVR time-series for the two simulated children. For the first child, with the lower value for the  $U$  variable (top panels, Figure 3D-18), the peak of the EVR time-series is broader, that is, longer in duration, than it is for the peak EVR for the second child (bottom panels, Figure 3D-18). The peak EVR for the second child (that has the higher value for the  $U$  variable) is similar in magnitude to that for the first child, but it does not persist over as long a duration. The figure illustrates this difference for three magnitudes of decrement (10%, 15% and 20%) in vertical pairs of panels from left to right, with the pairs of upper and lower panels differing only by the value of

parameter  $U$ . Specifically, the lower panel child achieves the same decrement as the upper panel child but while having a lower average EVR for the event.

The first simulated child (upper panel) has a  $U$  value of 0.963, which falls within one standard deviation of the distribution of  $U$  (i.e.,  $U$  has a standard error of 1.123, Table 3D-21). The second (lower panel) simulated child has a  $U$  value of 1.78, within the  $U$  variable parameterization (i.e., within 2 standard deviations), but is nearly twice that of the first child. Specifically, while the second child has a lower overall “normalized dose” (i.e.,  $C \times V^{\beta_6}$  in Equation 3D-12) over a similar exposure duration as the first child, the similar risk result is likely a result of the second child being assigned a higher value for  $U$ . This higher value of  $U$  yielded lung function decrements for the second child similar in magnitude to that predicted for the first simulated child even though the second child had relatively lower doses than the first child for each of the three days.

The second variable,  $\nu_l$ , a constant, is used on the calculation of the intra-individual variance term  $\varepsilon$  (Equations 3D-16). In evaluating the MSS model parameters used for this assessment, McDonnell et al. (2013) notes the estimate of  $\nu_l$  is consistent with intra-subject FEV<sub>1</sub> variability observed in the forced air trials and below threshold O<sub>3</sub> exposures. The variable  $\nu_l$  could be interpreted to represent a separate, non-ozone related contribution to response variability in the study observations. This suggests the use of non-zero values for  $\nu_l$ , as is provided by McDonnell et al. (2013) in MSS model applications (and as was done for the current risk analysis), could lead to a greater number of simulated individuals at or above the lung function decrements (in particular the lowest decrement) and a greater portion of that risk would be attributed to relatively lower exposure levels and ventilation rates, when compared to simulation results having  $\nu_l$  set as zero.

We evaluated the influence that the value of  $\nu_l$  has on risk estimates. A new APEX simulation was required for this evaluation. All model settings were the same as was done for generating the main assessment results reported in section 3D.3.3.2, except for varying the value of  $\nu_l$  (the MSS model default  $\nu_l$  value is 9.112, a new simulation had  $\nu_l$  set as zero) Again, both simulations were performed for 10,000 children in three study areas (Atlanta, Dallas, and St. Louis) for a simulated year using 2016 air quality adjusted just meet the current standard. Results for this evaluation are presented in Table 3D-70.



**Figure 3D-18. Time-series of O<sub>3</sub> exposures, EVR, and FEV<sub>1</sub> reductions of 10% (left panel), 15% (middle panel), and 20% (right panel) estimated using MSS model for two simulated children (interpersonal variability parameter  $U = 0.963$ , top panel;  $U = 1.78$ , bottom panel) in the Atlanta study area on three days in a year (2016) of the current air quality scenario.**

For each value of  $\nu_I$ , there were small differences in estimated risk across the three study areas. However, setting the  $\nu_I$  to zero (compared to the value reported by McDonnell et al., 2013) resulted in a decrease in the percent of children experiencing lung function decrements of  $\geq 10\%$ ,  $\geq 15\%$ , and  $\geq 20\%$  of about 35, 22, and 20% (regardless of study area). This reduction in risk is similar in magnitude to that resulting from excluding the contribution from low-level exposures (section 3D.3.4.2.3) and not using ventilation rates below moderate or greater exertion (section 3D.3.4.2.4) when estimating lung function decrements using the MSS model.

**Table 3D-70. Percent of children experiencing one or more FEV<sub>1</sub> decrements  $\geq 10\%$ ,  $\geq 15\%$ ,  $\geq 20\%$ , 2016 air quality adjusted to just meet the current standard, considering the setting of variability parameter,  $\nu_I$ , in the MSS model.**

| Study Area | MSS Model Parameter Setting <sup>A</sup> | Decrement (FEV <sub>1</sub> Reduction) |             |             |
|------------|--|--|-------------|-------------|
|            |  | $\geq 10\%$                            | $\geq 15\%$ | $\geq 20\%$ |
| Atlanta    | $\nu_I = 9.112$ (default)                | 15%                                    | 5.1%        | 2.1%        |
|            | $\nu_I = 0$                              | 9.7%                                   | 3.9%        | 1.7%        |
| Dallas     | $\nu_I = 9.112$ (default)                | 13%                                    | 4.1%        | 1.7%        |
|            | $\nu_I = 0$                              | 7.9%                                   | 3.2%        | 1.3%        |
| St. Louis  | $\nu_I = 9.112$ (default)                | 16%                                    | 5.8%        | 2.5%        |
|            | $\nu_I = 0$                              | 11%                                    | 4.6%        | 2.1%        |

<sup>A</sup> See Table 3D-21 and Equation 3D-16.

## 3D.4 REFERENCES

- Abt. (2013). Updated Analysis for Estimating Ozone Exposure-Response Function (Revised v.3). Technical memorandum from Jin Huang and Jacky Haskell to John Langstaff. (WA3-03, Contract No EP-D-08-100).
- Adams, WC (2000). Ozone dose-response effects of varied equivalent minute ventilation rates. *J Expo Anal Environ Epidemiol* 10(3): 217-226.
- Adams, WC (2002). Comparison of chamber and face-mask 6.6-hour exposures to ozone on pulmonary function and symptoms responses. *Inhal Toxicol* 14(7): 745-764.
- Adams, WC (2003). Comparison of chamber and face mask 6.6-hour exposure to 0.08 ppm ozone via square-wave and triangular profiles on pulmonary responses. *Inhal Toxicol* 15(3): 265-281.
- Adams, WC (2006). Comparison of chamber 6.6-h exposures to 0.04-0.08 PPM ozone via square-wave and triangular profiles on pulmonary responses. *Inhal Toxicol* 18(2): 127-136.
- Adams, WC and Ollison, WM (1997). Effects of prolonged simulated ambient ozone dosing patterns on human pulmonary function and symptomatology *Air & Waste Management Association Pittsburgh, PA.*
- Ainsworth, BE, Haskell, WL, Herrmann, SD, Meckes, N, Bassett, DR, Jr., Tudor-Locke, C, Greer, JL, Vezina, J, Whitt-Glover, MC and Leon, AS (2011). 2011 Compendium of Physical Activities: A Second Update of Codes and MET Values. *Med Sci Sports Exerc* 43(8): 1575-1581.
- Aitken ML, Franklin JL, Pierson DJ, Schoene RB. (1986) Influence of body size and gender on control of ventilation. *J Appl Physiol* 60:1894–1899.
- American Petroleum Institute (1997). Sensitivity Testing of pNEM/O<sub>3</sub> Exposure to Changes in the Model Algorithms. Health and Environmental Sciences Department. API Publication Number FR2. March 1997.
- Arjomandi, M, Balmes, JR, Frampton, MW, Bromberg, P, Rich, DQ, Stark, P, Alexis, NE, Costantini, M, Hollenbeck-Pringle, D, Dagincourt, N and Hazucha, MJ (2018). Respiratory Responses to Ozone Exposure. MOSES (The Multicenter Ozone Study in Older Subjects). *Am J Respir Crit Care Med* 197(10): 1319-1327.
- Bennett, DH, Fisk, W, Apte, MG, Wu, X, Trout, A, Faulkner, D and Sullivan, D (2012). Ventilation, temperature, and HVAC characteristics in small and medium commercial buildings in California. *Indoor Air* 22(4): 309-320.
- Box, GEP and Tiao, GC (1973). *Bayesian Inference in Statistical Analysis*. Wesley Publishing Co, Wiley Classic Library.

- 1 Brown, JS, Bateson, TF and McDonnell, WF (2008). Effects of exposure to 0.06 ppm ozone on  
2 FEV1 in humans: a secondary analysis of existing data. *Environ Health Perspect* 116(8):  
3 1023-1026.
- 4 Burmaster, DE (1998). Lognormal distributions for skin area as a function of body weight. *Risk*  
5 *Anal* 18(1): 27-32.
- 6 Che, WW, Frey, HC and Lau, AK (2014). Assessment of the effect of population and diary  
7 sampling methods on estimation of school-age children exposure to fine particles. *Risk*  
8 *Anal* 34(12): 2066-2079.
- 9 Cox, LA. (2020). Letter from Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
10 Committee, to Administrator Andrew R. Wheeler. Re: CASAC Review of the EPA's  
11 *Policy Assessment for the Review of the Ozone National Ambient Air Quality Standards*  
12 *(External Review Draft – October 2019)*. February 19, 2020. EPA-CASAC-20-003.  
13 Available at:  
14 [https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf)  
15 [D217BC07103485258515006359BA/\\$File/EPA-CASAC-20-003.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf).
- 16 Davidian, M and Giltinan, DM (2003). Nonlinear models for repeated measurement data: An  
17 overview and update. *J Agr Biol Env Stat* 8(4): 387.
- 18 Downey, N, Emery, C, Jung, J, Sakulyanontvittaya, T, Hebert, L, Blewitt, D and Yarwood, G  
19 (2015). Emission reductions and urban ozone responses under more stringent US  
20 standards. *Atmos Environ* 101: 209-216.
- 21 Dryden, DM, Spooner, CH, Stickland, MK, Vandermeer, B, Tjosvold, L, Bialy, L, Wong, K,  
22 Rowe, BH. (2010). Exercise-induced bronchoconstriction and asthma. (AHRQ  
23 Publication No. 10-E001). Rockville, MD.
- 24 Esmail, S, Bhambhani, Y and Brintnell, S (1995). Gender differences in work performance on  
25 the Baltimore Therapeutic Equipment work simulator. *Am J Occup Ther* 49(5): 405-411.
- 26 Folinsbee, LJ, Horstman, DH, Kehrl, HR, Harder, S, Abdul-Salaam, S and Ives, PJ (1994).  
27 Respiratory responses to repeated prolonged exposure to 0.12 ppm ozone. *Am J Respir*  
28 *Crit Care Med* 149(1): 98-105.
- 29 Folinsbee, LJ, McDonnell, WF and Horstman, DH (1988). Pulmonary function and symptom  
30 responses after 6.6-hour exposure to 0.12 ppm ozone with moderate exercise. *JAPCA*  
31 38(1): 28-35.
- 32 Ford, ES, Heath, GW, Mannino, DM and Redd, SC (2003). Leisure-time physical activity  
33 patterns among US adults with asthma. *Chest* 124(2): 432-437.
- 34 Frey, HC. (2014). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory  
35 Committee, to Administrator Gina McCarthy. Re: Health Risk and Exposure Assessment  
36 for Ozone (Second External Review Draft - February 2014) EPA-CASAC-14-005.  
37 Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100JR8I.txt>.



- 1 Glasgow, G and Smith, A (2017). Uncertainty in the estimated risk of lung function decrements  
2 owing to ozone exposure. *J Expo Sci Environ Epidemiol* 27(5): 535-538.
- 3 Glen, G, Smith, L, Isaacs, K, McCurdy, T and Langstaff, J (2008). A new method of longitudinal  
4 diary assembly for human exposure modeling. *J Expo Sci Environ Epidemiol* 18(3): 299-  
5 311.
- 6 Goldstein, B, Tardiff, R, Hoffnagle, G and Kester, R (1992). Valdez Air Health Study: Summary  
7 Report. Prepared for Alyeska Pipeline Service Company. Anchorage, AK.
- 8 Graham, SE and McCurdy, T (2004). Developing meaningful cohorts for human exposure  
9 models. *J Expo Anal Environ Epidemiol* 14(1): 23-43.
- 10 Graham, SE and McCurdy, T (2009). Appendix A: Revised ventilation rate (VE) equations for  
11 use in inhalation-oriented exposure models *Metabolically Derived Human Ventilation*  
12 *Rates: A Revised Approach Based Upon Oxygen Consumption Rates*. U.S. EPA, Office  
13 of Research Development, National Center for Environmental Assessment. Washington,  
14 DC EPA/600/R-06/129F.
- 15 Hartwell, TD, Clayton, CA, Michie, RM, Jr., Whitmore, RW, Zelon, HS, Whitehurst, DA and  
16 Akland, GG (1984). Study of Carbon Monoxide Exposure of Residents of Washington,  
17 D.C. and Denver, Colorado. Prepared for the U.S. Environmental Protection Agency.  
18 Research Triangle Park, NC.
- 19 Haugen, HA, Melanson, EL, Tran, ZV, Kearney, JT and Hill, JO (2003). Variability of measured  
20 resting metabolic rate. *Am J Clin Nutr* 78(6): 1141-1145.
- 21 Henderson, R. (2006). Letter from Dr. Rogene Henderson, Chair, Clean Air Scientific Advisory  
22 Committee to Honorable Stephen L. Johnson, Administrator, US EPA. Re: CASAC Peer  
23 Review of the Agency's 2nd Draft Ozone Staff Paper October 24, 2006. EPA-CASAC-  
24 07-001. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockkey=P1000WO7.txt>.
- 25 Henry, CJ (2005). Basal metabolic rate studies in humans: measurement and development of  
26 new equations. *Public Health Nutr* 8(7a): 1133-1152.
- 27 Horstman, DH, Folinsbee, LJ, Ives, PJ, Abdul-Salaam, S and McDonnell, WF (1990). Ozone  
28 concentration and pulmonary response relationships for 6.6-hour exposures with five  
29 hours of moderate exercise to 0.08, 0.10, and 0.12 ppm. *Am Rev Respir Dis* 142(5):  
30 1158-1163.
- 31 IOM (2005). *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids,*  
32 *Cholesterol, Protein, and Amino Acids*. The National Academies Press. Washington, DC.  
33 Available at: [https://www.nap.edu/catalog/10490/dietary-reference-intakes-for-energy-](https://www.nap.edu/catalog/10490/dietary-reference-intakes-for-energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino-acids)  
34 [carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino-acids](https://www.nap.edu/catalog/10490/dietary-reference-intakes-for-energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino-acids).
- 35 Isaacs, K, Glen, G, McCurdy, T and Smith, L (2007). Modeling energy expenditure and oxygen  
36 consumption in human exposure models: accounting for fatigue and EPOC. *Journal of*  
37 *Exposure Science and Environmental Epidemiology*.

- 1 Isaacs, K, McCurdy, T, Glen, G, Nysewander, M, Errickson, A, Forbes, S, Graham, S, McCurdy,  
2 L, Smith, L, Tulve, N and Vallero, D (2013). Statistical properties of longitudinal time-  
3 activity data for use in human exposure modeling. J Expo Sci Environ Epidemiol 23(3):  
4 328-336.
- 5 Isaacs, K and Smith, L (2005). New Values for Physiological Parameters for the Exposure  
6 Model Input File Physiology.txt. Memorandum submitted to the U.S. Environmental  
7 Protection Agency under EPA Contract EP-D-05-065. NERL WA 10. Alion Science and  
8 Technology. Available in the 2009 SO<sub>2</sub> REA, Appendix B at:  
9 [https://www3.epa.gov/ttn/naaqs/standards/so2/s\\_so2\\_cr\\_rea.html](https://www3.epa.gov/ttn/naaqs/standards/so2/s_so2_cr_rea.html).
- 10 Johnson, T (1984). Study of Personal Exposure to Carbon Monoxide in Denver, Colorado.  
11 Prepared for U.S. Environmental Protection Agency, Environmental Monitoring Systems  
12 Laboratory. Research Triangle Park, NC.
- 13 Johnson, T (1989). Human activity patterns in Cincinnati, Ohio [final report]. EN-6204. Electric  
14 Power Research Institute. Palo Alto, CA.
- 15 Johnson, T (2002). A guide to selected algorithms, distributions, and databases used in exposure  
16 models developed by the Office of Air Quality Planning and Standards [revised draft].  
17 U.S. Environmental Protection Agency. Research Triangle Park, NC. Available at:  
18 <http://www.epa.gov/ttn/fera/data/human/report052202.pdf>.
- 19 Johnson, T, Capel, J and Wijnberg, L (1986). Selected Data Analyses Relating to Studies of  
20 Personal Carbon Monoxide Exposure in Denver and Washington, DC. Prepared for U.S.  
21 Environmental Protection Agency. Environmental Monitoring Systems Laboratory,  
22 Research Triangle Park, NC.
- 23 Johnson, T, Pakrasi, A, Wisbeth, A, Meiners, G and Ollison, W (1995). Ozone exposures Within  
24 Motor Vehicles – Results of a Field Study in Cincinnati, Ohio Proceedings 88th annual  
25 meeting and exposition of the Air & Waste Management Association San Antonio, TX.
- 26 Kim, CS, Alexis, NE, Rappold, AG, Kehrl, H, Hazucha, MJ, Lay, JC, Schmitt, MT, Case, M,  
27 Devlin, RB, Peden, DB and Diaz-Sanchez, D (2011). Lung function and inflammatory  
28 responses in healthy young adults exposed to 0.06 ppm ozone for 6.6 hours. Am J Respir  
29 Crit Care Med 183(9): 1215-1221.
- 30 Klepeis, NE, Tsang, AM and Behar, JV (1995). Analysis of the national human activity pattern  
31 survey (NHAPS) respondents from a standpoint of exposure assessment. Final Report.  
32 EPA/600/R-96/074. Prepared for U.S. Environmental Protection Agency, National  
33 Exposure Research Laboratory. Las Vegas, NV. Available at:  
34 [http://exposurescience.org/pub/reports/NHAPS\\_Report1.pdf#....Local](http://exposurescience.org/pub/reports/NHAPS_Report1.pdf#....Local)
- 35 Knowledge Networks (2009). Field report: National-scale activity survey (NSAS). Research  
36 Triangle Institute. Research Triangle Park, NC.
- 37 Lagus Applied Technology (1995). Air change rates in non-residential buildings in California,  
38 California Energy Commission. July 1995. Contract 400-91-034. Sacramento, CA.

- 1 Langstaff, J (2007). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-OAR-2005-  
2 0172). Analysis of Uncertainty in Ozone Population Exposure Modeling. Docket ID No.  
3 EPA-HQ-OAR-2005-0172-0174.
- 4 Lee, K, Vallarino, J, Dumyahn, T, Ozkaynak, H and Spengler, JD (1999). Ozone decay rates in  
5 residences. *J Air Waste Manag Assoc* 49(10): 1238-1244.
- 6 Leonard, WR, Levy, SB, Tarskaia, LA, Klimova, TM, Fedorova, VI, Baltakhinova, ME,  
7 Krivoschapkin, VG and Snodgrass, JJ (2014). Seasonal variation in basal metabolic rates  
8 among the Yakut (Sakha) of Northeastern Siberia. *Am J Hum Biol* 26(4): 437-445.
- 9 Liu, LJ, Box, M, Kalman, D, Kaufman, J, Koenig, J, Larson, T, Lumley, T, Sheppard, L and  
10 Wallace, L (2003). Exposure assessment of particulate matter for susceptible populations  
11 in Seattle. *Environ Health Perspect* 111(7): 909-918.
- 12 Lunn, D, Jackson, C, Best, N and Thomas, A (2012). *The BUGS Book - A Practical Introduction*  
13 *to Bayesian Analysis*. CRC Press: Chapman and Hall.
- 14 Mansfield, C, Houtven, G, Johnson, FR and Yang, J-C (2009). Environmental Risks and  
15 Behavior: Do children spend less time outdoors when ozone pollution is high? . ASSA  
16 annual meeting, January 5, 2009. Update of Houtven et al. (2003) using the OAB CHAD  
17 data set and related to Mansfield et al. (2006).
- 18 McCurdy, T (2000). Conceptual basis for multi-route intake dose modeling using an energy  
19 expenditure approach. *J Expo Anal Environ Epidemiol* 10(1): 86-97.
- 20 McDonnell, WF, 3rd, Chapman, RS, Leigh, MW, Strope, GL and Collier, AM (1985).  
21 Respiratory responses of vigorously exercising children to 0.12 ppm ozone exposure. *The*  
22 *American review of respiratory disease* 132(4): 875-879.
- 23 McDonnell, WF, Abbey, DE, Nishino, N and Lebowitz, MD (1999). Long-term ambient ozone  
24 concentration and the incidence of asthma in nonsmoking adults: the AHSMOG Study.  
25 *Environ Res* 80(2 Pt 1): 110-121.
- 26 McDonnell, WF, Horstman, DH, Hazucha, MJ, Seal, E, Jr., Haak, ED, Salaam, SA and House,  
27 DE (1983). Pulmonary effects of ozone exposure during exercise: Dose-response  
28 characteristics. *J Appl Physiol* (1985) 54(5): 1345-1352.
- 29 McDonnell, WF, Kehrl, HR, Abdul-Salaam, S, Ives, PJ, Folinsbee, LJ, Devlin, RB, O'Neil, JJ  
30 and Horstman, DH (1991). Respiratory response of humans exposed to low levels of  
31 ozone for 6.6 hours. *Arch Environ Health* 46(3): 145-150.
- 32 McDonnell, WF, Stewart, PW and Smith, MV (2007). The temporal dynamics of ozone-induced  
33 FEV1 changes in humans: an exposure-response model. *Inhal Toxicol* 19(6-7): 483-494.
- 34 McDonnell, WF, Stewart, PW and Smith, MV (2010). Prediction of ozone-induced lung function  
35 responses in humans. *Inhal Toxicol* 22(2): 160-168.

1 McDonnell, WF, Stewart, PW and Smith, MV (2013). Ozone exposure-response model for lung  
2 function changes: an alternate variability structure. *Inhal Toxicol* 25(6): 348-353.

3 McDonnell, WF, Stewart, PW, Smith, MV, Kim, CS and Schelegle, ES (2012). Prediction of  
4 lung function response for populations exposed to a wide range of ozone conditions.  
5 *Inhal Toxicol* 24(10): 619-633.

6 Ogden, CL, Lamb, MM, Carroll, MD and Flegal, KM (2010). Obesity and Socioeconomic Status  
7 in Children and Adolescents: United States, 2005-2008. NCHS Data Brief. Number 51.  
8 Available at: <https://files.eric.ed.gov/fulltext/ED530165.pdf>.

9 Roth Associates (1988). LA\_part1 and LA\_part2 (A Study of Activity Patterns Among a Group  
10 of Los Angeles Asthmatics) Electric Power Research Institute.

11 Samet, JM. (2009). Letter from Jonathan Samet, Chair, Clean Air Scientific Advisory  
12 Committee's (CASAC), to Administrator Lisa P. Jackson. RE: CASAC Review of EPA's  
13 Risk and Exposure Assessment (REA) to Support the Review of the SO<sub>2</sub> Primary  
14 National Ambient Air Quality Standards: Second Draft. May 18th, 2009. EPA-CASAC-  
15 09-007. Available at:  
16 [https://yosemite.epa.gov/sab/sabproduct.nsf/D21C100175A2BE99852575BB00452632/\\$](https://yosemite.epa.gov/sab/sabproduct.nsf/D21C100175A2BE99852575BB00452632/$File/EPA-CASAC-09-007-unsigned.pdf)  
17 [File/EPA-CASAC-09-007-unsigned.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/D21C100175A2BE99852575BB00452632/$File/EPA-CASAC-09-007-unsigned.pdf).

18 Santuz, P, Baraldi, E, Filippone, M and Zacchello, F (1997). Exercise performance in children  
19 with asthma: is it different from that of healthy controls? *Eur Respir J* 10(6): 1254-1260.

20 SAS. (2017). Base SAS® 9.4 Procedures Guide, Seventh Edition. Available at:  
21 [http://documentation.sas.com/api/collections/pgmmvacdc/9.4/docsets/proc/content/proc.p](http://documentation.sas.com/api/collections/pgmmvacdc/9.4/docsets/proc/content/proc.pdf?locale=en#nameddest=bookinfo)  
22 [df?locale=en#nameddest=bookinfo](http://documentation.sas.com/api/collections/pgmmvacdc/9.4/docsets/proc/content/proc.pdf?locale=en#nameddest=bookinfo). Also used were SAS/ETS 14.2 User's Guide, edited  
23 by A. Baxter, E. Huddleston and SAS/QC 14.2 User's Guide, edited by A. Baxter, V.  
24 Clark, E. Huddleston, S. Prabhu, R. Rodriguez, D. Sawyer, J. Simmons.

25 Schelegle, ES, Morales, CA, Walby, WF, Marion, S and Allen, RP (2009). 6.6-hour inhalation of  
26 ozone concentrations from 60 to 87 parts per billion in healthy humans. *Am J Respir Crit*  
27 *Care Med* 180(3): 265-272.

28 Schofield, WN (1985). Predicting basal metabolic rate, new standards and review of previous  
29 work. *Hum Nutr Clin Nutr* 39 Suppl 1: 5-41.

30 Settergren, SK, Hartwell, TD and Clayton, CA (1984). Study of Carbon Monoxide Exposure of  
31 Residents of Washington, DC: Additional Analyses. Prepared for U.S. Environmental  
32 Protection Agency. Environmental Monitoring Systems Laboratory. Research Triangle  
33 Park, NC. Settergren S.K., Hartwell T.D. and Clayton C.A.

34 Shendell, DG, Winer, AM, Weker, R and Colome, SD (2004). Evidence of inadequate  
35 ventilation in portable classrooms: results of a pilot study in Los Angeles County. *Indoor*  
36 *Air* 14(3): 154-158.

- Simon, H, Baker, KR and Phillips, S (2012). Compilation and interpretation of photochemical model performance statistics published between 2006 and 2012. *Atmos Environ* 61: 124-139.
- Spier, CE, Little, DE, Trim, SC, Johnson, TR, Linn, WS and Hackney, JD (1992). Activity patterns in elementary and high school students exposed to oxidant pollution. *Journal of Exposure Science & Environmental Epidemiology* 2(3): 277-293.
- Tsang, AM and Klepeis, NE (1996). Descriptive Statistics Tables from a Detailed Analysis of the National Human Activity Pattern Survey (NHAPS) Data. U.S. Environmental Protection Agency. Washington, DC. Available at: <https://nepis.epa.gov>.
- Turk, BH, Grimsrud, DT, Brown, JT, Geisling-Sobotka, KL, Harrison, J and Prill, RJ (1989). Commercial building ventilation rates and particle concentrations. *American Society of Heating, Refrigerating and Air-Conditioning Engineers Journal* 1: 422-433.
- U.S. Bureau of Labor Statistics (2014). American Time Use Survey User's Guide: Understanding ATUS 2003 to 2013. US Bureau of Labor Statistics. Washington, DC; December 2014. . Available at: <http://www.bls.gov/tus/atususersguide.pdf>.
- U.S. Census Bureau (2012). Technical documentation - 2010 Census Summary File 1— Technical Documentation/prepared by the U.S. Census Bureau, Revised 2012. Available at: <http://www.census.gov/prod/cen2010/doc/sf1.pdf>. Employment Status from the 5-year American Community Survey (ACS) data, 2010 U.S. Census American FactFinder. Available at: <http://factfinder2.census.gov/>. Commuting times file from U.S. Census data portal (<http://dataferrett.census.gov/>), Table P31, variables P031001-P031015.
- U.S. Census Bureau (2019). American Housing Survey (AHS) Data. 2015, 2017 data. Available at: <https://www.census.gov/programs-surveys/ahs/data/interactive/ahstablecreator.html>. 2011 data. Available at <https://www.census.gov/programs-surveys/ahs/data/2011/ahs-2011-summary-tables/ahs-metropolitan-summary-tables.html>.
- U.S. DHHS (1999). Promoting physical activity: a guide for community action. Department of Health and Human Services, Centers for Disease Control and Prevention (see Table 2-1). Available at: [http://www.cdc.gov/nccdphp/dnpa/physical/pdf/PA\\_Intensity\\_table\\_2\\_1.pdf](http://www.cdc.gov/nccdphp/dnpa/physical/pdf/PA_Intensity_table_2_1.pdf).
- U.S. DOT (2012). Bureau of Transportation Statistics, Census Transportation Planning Package, Part 3-The Journey to Work. Available at: <http://transtats.bts.gov/>.
- U.S. EPA (1986). Air quality criteria for ozone and other photochemical oxidants. Research Triangle Park, NC. U.S. EPA. EPA-600/8-84-020aF – EPA/600/8-84-020eF. Available at: <https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchQuery=PB87142956&starDB=GRAHIST>.
- U.S. EPA (1996). Air Quality Criteria for Ozone and Related Photochemical Oxidants. Volumes 1 to 3. Research Triangle Park, NC. U.S. EPA. EPA/600/P-93/004aF, EPA/600/P-93/004bF, and EPA/600/P-93/004cF.

- 1 U.S. EPA (2006). Air Quality Criteria for Ozone and Related Photochemical Oxidants (Volumes  
2 I-III). EPA-600/R-05-004aF, EPA-600/R-05-004bF and EPA-600/R-05-004cF. U.S.  
3 Environmental Protection Agency. Washington, DC. Available at:  
4 [http://www.epa.gov/ttn/naaqs/standards/ozone/s\\_o3\\_cr\\_cd.html](http://www.epa.gov/ttn/naaqs/standards/ozone/s_o3_cr_cd.html).
- 5 U.S. EPA (2007a). Ozone Population Exposure Analysis for Selected Urban Areas. Office of Air  
6 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452-R-07-  
7 010. Available at: [http://www.epa.gov/ttn/naaqs/standards/ozone/s\\_o3\\_cr\\_td.html](http://www.epa.gov/ttn/naaqs/standards/ozone/s_o3_cr_td.html).
- 8 U.S. EPA (2007b). Ozone Population Health Risk Assessment for Selected Urban Areas.  
9 Research Triangle Park, NC. EPA Office of Air Quality Planning and Standards. EPA-  
10 452/R-07-009. Available at:  
11 [https://www3.epa.gov/ttn/naaqs/standards/ozone/s\\_o3\\_cr\\_td.html](https://www3.epa.gov/ttn/naaqs/standards/ozone/s_o3_cr_td.html).
- 12 U.S. EPA (2008). Risk and Exposure Assessment to Support the Review of the NO<sub>2</sub> Primary  
13 National Ambient Air Quality Standard. EPA-452/R-08-008a. Office of Air Quality  
14 Planning and Standards. Research Triangle Park, NC. Available at:  
15 [https://www3.epa.gov/ttn/naaqs/standards/nox/s\\_nox\\_cr\\_rea.html](https://www3.epa.gov/ttn/naaqs/standards/nox/s_nox_cr_rea.html).
- 16 U.S. EPA (2009). Risk and Exposure Assessment to Support the Review of the SO<sub>2</sub> Primary  
17 National Ambient Air Quality Standard. Office of Air Quality Planning and Standards.  
18 Research Triangle Park, NC. US EPA. EPA-452/R-09-007. Available at:  
19 <https://www3.epa.gov/ttn/naaqs/standards/so2/data/200908SO2REAFinalReport.pdf>.
- 20 U.S. EPA (2010). Quantitative Risk and Exposure Assessment for Carbon Monoxide - Amended.  
21 Office of Air Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA.  
22 EPA-452/R-10-006. Available at: [https://www.epa.gov/naaqs/carbon-monoxide-co-](https://www.epa.gov/naaqs/carbon-monoxide-co-standards-risk-and-exposure-assessments-current-review)  
23 [standards-risk-and-exposure-assessments-current-review](https://www.epa.gov/naaqs/carbon-monoxide-co-standards-risk-and-exposure-assessments-current-review).
- 24 U.S. EPA (2013). Integrated Science Assessment of Ozone and Related Photochemical Oxidants  
25 (Final Report). Office of Research and Development, National Center for Environmental  
26 Assessment. Research Triangle Park, NC. U.S. EPA. EPA-600/R-10-076F. February  
27 2013. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KETF.txt>.
- 28 U.S. EPA (2014). Health Risk and Exposure Assessment for Ozone. (Final Report). Office of Air  
29 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-14-  
30 004a. August 2014. Available at:  
31 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KBUF.txt>.
- 32 U.S. EPA (2018). Risk and Exposure Assessment for the Review of the Primary National  
33 Ambient Air Quality Standard for Sulfur Oxides. Office of Air Quality Planning and  
34 Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-18-003. Available at:  
35 [https://www.epa.gov/sites/production/files/2018-05/documents/primary\\_so2\\_naaqs\\_-](https://www.epa.gov/sites/production/files/2018-05/documents/primary_so2_naaqs_-_final_rea_-_may_2018.pdf)  
36 [\\_final\\_rea\\_-\\_may\\_2018.pdf](https://www.epa.gov/sites/production/files/2018-05/documents/primary_so2_naaqs_-_final_rea_-_may_2018.pdf).
- 37 U.S. EPA (2019a). Air Pollutants Exposure Model Documentation (APEX, Version 5) Volume I:  
38 User's Guide. Office of Air Quality Planning and Standards. Research Triangle Park, NC.  
39 EPA-452/R-19-005a. Available at: <https://www.epa.gov/fera/apex-user-guides>.

- 1 U.S. EPA (2019b). Air Pollutants Exposure Model Documentation (APEX, Version 5) Volume  
2 II: Technical Support Document. Office of Air Quality Planning and Standards. Research  
3 Triangle Park, NC. EPA-452/R-19-005b. Available at: [https://www.epa.gov/fera/apex-](https://www.epa.gov/fera/apex-user-guides)  
4 [user-guides](https://www.epa.gov/fera/apex-user-guides).
- 5 U.S. EPA (2019c). The Consolidated Human Activity Database (CHAD). Documentation and  
6 User's Guide. Research Triangle Park, NC. US EPA. EPA-452/B-19-001. Available at:  
7 [https://www.epa.gov/healthresearch/consolidated-human-activity-database-chad-use-](https://www.epa.gov/healthresearch/consolidated-human-activity-database-chad-use-human-exposure-and-health-studies-and)  
8 [human-exposure-and-health-studies-and](https://www.epa.gov/healthresearch/consolidated-human-activity-database-chad-use-human-exposure-and-health-studies-and).
- 9 U.S. EPA (2019d). Integrated Review Plan for the Ozone National Ambient Air Quality  
10 Standards. Office of Air Quality Planning and Standards. Research Triangle Park, NC.  
11 U.S. EPA. EPA-452/R-19-002.
- 12 U.S. EPA (2020a). Integrated Science Assessment for Ozone and Related Photochemical  
13 Oxidants. U.S. Environmental Protection Agency. Washington, DC. Office of Research  
14 and Development. EPA/600/R-20/012.
- 15 U.S. EPA (2020b). Policy Assessment for the Review of the Ozone National Ambient Air  
16 Quality Standards. U.S. Environmental Protection Agency, Office of Air Quality  
17 Planning and Standards, Health and Environmental Impacts Division. Research Triangle  
18 Park, NC. U.S. EPA. EPA-452/R-20-001. 2020 Available at: [https://www.epa.gov/](https://www.epa.gov/naaqs/ozone-o3-standards-policyassessments-current-review)  
19 [naaqs/ozone-o3-standards-policyassessments-current-review](https://www.epa.gov/naaqs/ozone-o3-standards-policyassessments-current-review).
- 20 University of Michigan (2016). "Panel Study of Income Dynamics." from  
21 <http://psidonline.isr.umich.edu/Studies.aspx>.
- 22 van Gent, R, van der Ent, CK, van Essen-Zandvliet, LE, Rovers, MM, Kimpen, JL, de Meer, G  
23 and Klijn, PH (2007). No differences in physical activity in (un)diagnosed asthma and  
24 healthy controls. *Pediatr Pulmonol* 42(11): 1018-1023.
- 25 van Ooijen, AM, van Marken Lichtenbelt, WD, van Steenhoven, AA and Westerterp, KR (2004).  
26 Seasonal changes in metabolic and temperature responses to cold air in humans. *Physiol*  
27 *Behav* 82(2-3): 545-553.
- 28 Whitfield, R, Biller, W, Jusko, M and Keisler, J (1996). A Probabilistic Assessment of Health  
29 Risks Associated with Short- and Long-Term Exposure to Tropospheric Ozone. Argonne,  
30 IL: Argonne National Laboratory.
- 31 WHO (2008). WHO/IPCS Harmonization Project Document No. 6. Part 1: Guidance Document  
32 on Characterizing and Communicating Uncertainty in Exposure Assessment.  
33 International Programme on Chemical Safety. World Health Organization. Geneva,  
34 Switzerland. Available at:  
35 <http://www.who.int/ipcs/methods/harmonization/areas/exposure/en/>.
- 36 Williams, R, Rea, A, Vette, A, Croghan, C, Whitaker, D, Stevens, C, McDow, S, Fortmann, R,  
37 Sheldon, L, Wilson, H, Thornburg, J, Phillips, M, Lawless, P, Rodes, C and Daughtrey, H

- (2009). The design and field implementation of the Detroit Exposure and Aerosol Research Study. *J Expo Sci Environ Epidemiol* 19(7): 643-659.
- Williams, R, Suggs, J, Creason, J, Rodes, C, Lawless, P, Kwok, R, Zweidinger, R and Sheldon, L (2000). The 1998 Baltimore particulate matter epidemiology-exposure study: Part 2- Personal exposure assessment associated with an elderly study population. *J Expo Anal Environ Epidemiol* 10(6): 533-543.
- Williams, R, Suggs, J, Rea, A, Leovic, K, Vette, A, Croghan, C, Sheldon, L, Rodes, C, Thornburg, J, Ejire, A, Herbst, M and Sanders, W, Jr. (2003a). The Research Triangle Park particulate matter panel study: PM mass concentration relationships. *Atmos Environ* 37(38): 5349-5363.
- Williams, R, Suggs, J, Rea, A, Sheldon, L, Rodes, C and Thornburg, J (2003b). The Research Triangle Park particulate matter panel study: modeling ambient source contribution to personal and residential PM mass concentrations. *Atmos Environ* 37(38): 5365-5378.
- Williams, RW, Wallace, LA, Suggs, JC, Evans, EG, Creason, JP, Highsmith, VR, Sheldon, LS, Rea, AW, Vette, AF, Zweidinger, RB, Leovic, KW, Norris, GA, Landis, MS, HowardReed, C, Stevens, C, Conner, TL, Rodes, CE, Lawless, PA, Thornburg, J, Liu, LS, Kalman, D, Kaufman, J, Koenig, JQ, Larson, TL, Lumley, T, Sheppard, L, Brown, K, Suh, H, Wheeler, A, Gold, D, Koutrakis, P and Lippmann, M (2001). Preliminary particulate matter mass concentrations associated with longitudinal panel studies: assessing human exposures of high risk subpopulations to particulate matter. EPA/600/R-01/086. National Exposure Research Laboratory, Office of Research Development, U.S. EPA. Research Triangle Park, NC.
- Xue, J, McCurdy, T, Spengler, J and Ozkaynak, H (2004). Understanding variability in time spent in selected locations for 7-12-year old children. *J Expo Anal Environ Epidemiol* 14(3): 222-233.
- Zahran, HS and Bailey, C (2013). Factors associated with asthma prevalence among racial and ethnic groups--United States, 2009-2010 behavioral risk factor surveillance system. *J Asthma* 50(6): 583-589.



## **APPENDIX 3D, ATTACHMENT 1: ESTIMATING U.S. CENSUS TRACT LEVEL ASTHMA PREVALENCE (2013-2017)**

### **OVERVIEW**

This attachment describes the development of the 2013-2017 census tract-level asthma prevalence file used by EPA's Air Pollution Exposure Model (APEX) to identify individuals with asthma during exposure model simulations. The approach used to estimate the APEX file four basic steps: 1) processing National Health Interview Survey (NHIS) regional asthma prevalence data, 2) processing U.S. Census poverty/income status data, and 3) combining the two sets considering variables known to influence asthma (e.g., age, sex, poverty status, U.S. region) to estimate asthma prevalence stratified by age and sex for all U.S. Census tracts, and 4) the NHIS regionally derived data were adjusted to account for state level asthma prevalence data obtained from the Behavioral Risk Factor Surveillance System (BRFSS). Details regarding the data sets and the processing approaches used are provided below.

### **GENERAL HISTORY**

The current NHIS data processing approach is in part based on work originally performed by Cohen and Rosenbaum (2005) and then revised and extended by U.S. EPA (2014, 2018). Briefly, Cohen and Rosenbaum (2005) calculated asthma prevalence for children aged 0 to 17 years for each age, sex, and four U.S. regions using 2003 NHIS survey data.<sup>1</sup> The regions defined by the NHIS were 'Midwest', 'Northeast', 'South', and 'West'. The asthma prevalence was defined as the probability of a 'Yes' response to the question "EVER been told that [the child] had asthma?"<sup>2</sup> among those persons that responded either 'Yes' or 'No' to this question.<sup>3</sup> The responses were weighted to take into account the complex survey design of the NHIS.<sup>4</sup> Standard errors and confidence intervals for the prevalence were calculated using a logistic model (PROC SURVEY LOGISTIC). A scatterplot technique (LOESS smoother) was applied to smooth the prevalence curves across ages and used to compute the standard errors and

---

<sup>1</sup> The National Health Interview Survey (NHIS) is the principal source of information on the health of the civilian noninstitutionalized population of the United States and is one of the major data collection programs of the National Center for Health Statistics (NCHS) which is part of the Centers for Disease Control and Prevention (CDC). See <https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm> for data and documentation.

<sup>2</sup> The response was recorded as variable "CASHMEV" in the downloaded dataset. Data and documentation are available at [http://www.cdc.gov/nchs/nhis/quest\\_data\\_related\\_1997\\_forward.htm](http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm).

<sup>3</sup> If there were another response to this variable other than "yes" or "no" (i.e., refused, not ascertained, don't know, and missing), the NHIS surveyed individual was excluded from the analysis data set.

<sup>4</sup> In the SURVEY LOGISTIC procedure, the variable "WTF\_SC" was used for weighting, "PSU" was used for clustering, and "STRATUM" was used to define the stratum.

confidence intervals for the smoothed prevalence estimates. Logistic analysis of the raw and smoothed prevalence curves showed statistically significant differences in prevalence by gender and region, supporting their use as stratification variables in the final data set (Cohen and Rosenbaum, 2005). These smoothed prevalence estimates were then used as an input to APEX to estimate air pollutant exposure in children with asthma (U.S. EPA 2007; 2008; 2009).

For the 2014 O<sub>3</sub> REA (U.S. EPA, 2014), we updated the asthma prevalence database used by APEX by combining several years of NHIS survey data (2006-2010). Asthma prevalence for children (by age year) was estimated as described above and, for this update, we also included an estimate of asthma prevalence for adults. In addition, two sets of asthma prevalence for each adults and children were estimated. The first data set, as was done previously, was based on responses to the question “EVER been told that [the child/adult] had asthma”. A second data set was developed using the probability of a ‘Yes’ response to a question that followed those that answered ‘Yes’ to the first question regarding ever having asthma, specifically, do those persons “STILL have asthma?”.<sup>5</sup> Further, in addition to the nominal variables region and sex, the asthma prevalence were stratified by a income/poverty threshold (i.e., whether the family income was below or at/above the US Census estimate of poverty level for the given year). These 2006-2010 asthma prevalence data were then linked to 2000 U.S. Census tract level income/poverty threshold probabilities, also stratified by age (section 5C-5 of Appendix 5C, US EPA, 2014). Staff considered the variability in population exposures to be better represented when accounting for and modeling these newly refined attributes of this at-risk population. This is was done because of the 1) significant observed differences in asthma prevalence by age, sex, region, and poverty status, 2) the variability in the spatial distribution of poverty status across census tracts, stratified by age, and 3) the potential for spatial variability in local scale ambient concentrations.

And finally, asthma prevalence files used by APEX for the most recent SO<sub>2</sub> REA (Appendix E of U.S. EPA, 2018) were updated in a similar manner using data that reasonably bounded the exposure assessment period of interest (2011-2015) and, as was done for the 2014 O<sub>3</sub> REA, linked the asthma prevalence to the 2010 U.S census tract income to poverty ratio probabilities. The approach to update the asthma prevalence used for the current O<sub>3</sub> REA analyses follows the same approach used previously, although now employs an adjustment to account for local more asthma prevalence information at the state level, rather than relying solely on the regional data. This is described in the four steps that follow below.

## **Step 1: NHIS Data Set Description and Processing**

---

<sup>5</sup> The response was recorded as variable “CASSTILL” for children and “AASSTILL” for adults in the respective downloaded datasets. Ultimately, the asthma prevalence used by APEX was based on this variable rather than those using the data for those individuals responding “Yes” to “Ever” having asthma.

The objective of this processing step is to estimate asthma prevalence for children and adults considering several influential variables. First, raw 2013-2017 data and associated documentation were downloaded from the Center for Disease Control (CDC) and Prevention's NHIS website.<sup>6</sup> The 'Sample Child' and 'Sample Adult' files were selected because of the availability of person-level attributes of interest within these files, i.e., age in years ('age\_p'), sex ('sex'), U.S. geographic region ('region'), coupled with the response to questions of whether or not the surveyed individual ever had and still has asthma. In total, five years of survey data were used, comprising nearly 60,000 children and 165,000 adults for years 2013-2017 (Table 1).

Information regarding personal and family income and poverty ranking are also provided by the NHIS in additional survey files. Data files ('INCIMPx.dat') are available for every survey year, each containing either the actual response for the desired financial variable (where provided by survey participant) or the imputed value.<sup>7</sup> For this current analysis, the ratio of family income-to-poverty was provided as a continuous variable ('POVRATI3') and used to develop a nominal variable for this evaluation: either the survey participant was below or above a selected family income-to-poverty ratio threshold. This was done to be consistent with data generated as part of the next data set processing step, i.e., developing a database containing the census tract level family income-to-poverty ratio probabilities, stratified by age (see Step 2 below).

When considering the number of stratification variables used in the development of the asthma prevalence file (i.e., age years and sex), the level of asthma prevalence (8%, on average), and the distribution of family income-to-poverty ratios among the surveyed population (12%, on average), sample size was an important motivation for aggregating the adult data into age groups. When considering the adult data, there were insufficient numbers of persons available to stratify the data by single age years (for some ages there were no survey persons). Therefore, the adult survey data were grouped into the following age groups: ages 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, and,  $\geq 75$ .<sup>8</sup> To increase the number of persons within the age, sex, and four region groupings of our characterization of 'below poverty', the family income-to-poverty ratio threshold was selected as  $<1.5$ , thus including persons that were within 50% above the threshold. For individuals containing the imputed family income information, typically there were 5 estimated values. If the mean of the 5 imputed values were  $<1.5$ , the person's family income was

---

<sup>6</sup> Data and documentation are available at [http://www.cdc.gov/nchs/nhis/quest\\_data\\_related\\_1997\\_forward.htm](http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm) (for 2013-2015, accessed April 11, 2017; for 2016-2017 accessed March 11, 2019).

<sup>7</sup> Financial information was not collected from all persons; therefore, the NHIS provides imputed data. Details into the available variables and imputation method are provided with each year's data set. For example, see "Multiple Imputation of Family Income and Personal Earnings in the National Health Interview Survey: Methods and Examples" at <https://www.cdc.gov/nchs/data/nhis/tecdoc15.pdf>.

<sup>8</sup> These same age groupings were used to create the companion file containing the census tract level family income-to-poverty ratio probabilities (Step 2).

categorized ‘below’ the poverty threshold; if the mean of the 5 values were  $\geq 1.5$ , the person’s family income was categorized ‘above’ the poverty threshold.

These processed person-level income files were then merged with the ‘Sample Adult’ and ‘Sample Child’ files using the ‘HHX’ (a household identifier), ‘FMX’ (a family identifier), and ‘FPX’ (an individual identifier) variables. Note, all persons within the ‘Sample Adult’ and ‘Sample Child’ files had corresponding financial survey data.

As was done for previous asthma prevalence data analysis, two asthma survey response variables were of interest in this analysis and were used to develop the two separate prevalence data sets for each children and adults. The response to the first question “Have you EVER been told by a doctor or other health professional that you [or your child] had asthma?” was recorded as variable name ‘CASHMEV’ for children and ‘AASMEV’ for adults. Only persons having responses of either ‘Yes’ or ‘No’ to this question were retained to estimate the asthma prevalence. This assumes that the exclusion of those responding otherwise, i.e., those that ‘refused’ to answer, instances where it was “not ascertained”, or the person ‘does not know’, does not affect the estimated prevalence rate if either ‘Yes’ or ‘No’ answers could actually be given by these persons. There were very few persons providing an unusable response (Table 1), thus the above assumption is reasonable. A second question was asked as a follow to persons responding “Yes” to the first question, specifically, “Do you STILL have asthma?” and noted as variables ‘CASSTILL’ and ‘AASSTILL’ for children and adults, respectively. Again, while only persons responding ‘Yes’ and ‘No’ were retained for further analysis, the representativeness of the screened data set is assumed unchanged from the raw survey data given the few persons in each survey year having unusable data.

**Table 1. Number of total surveyed persons from NHIS (2013-2017) sample adult and child files and the number of those responding to asthma survey questions.**

| Children                    | 2013   | 2014   | 2015   | 2016   | 2017   | TOTAL   |
|-----------------------------|--------|--------|--------|--------|--------|---------|
| All Children                | 12,860 | 13,380 | 12,291 | 11,107 | 8,845  | 58,483  |
| Yes/No to Ever Have Asthma  | 12,851 | 13,366 | 12,281 | 11,098 | 8,832  | 58,428  |
| Yes/No to Still Have Asthma | 12,844 | 13,359 | 12,269 | 11,087 | 8,823  | 58,382  |
| Adults                      |        |        |        |        |        |         |
| All Adults                  | 34,557 | 36,697 | 33,672 | 33,028 | 26,742 | 164,696 |
| Yes/No to Ever Have Asthma  | 34,525 | 36,667 | 33,641 | 33,007 | 26,720 | 164,560 |
| Yes/No to Still Have Asthma | 34,498 | 36,615 | 33,614 | 32,959 | 26,681 | 164,367 |

### *Logistic Models*

As described in the previous section, four person-level analytical data sets were created from the raw NHIS data files, generally containing similar variables: a ‘Yes’ or ‘No’ asthma

response variable (either ‘EVER’ or ‘STILL’), an age (or age group for adults), their sex (‘male’ or ‘female’), US geographic region (‘Midwest’, ‘Northeast’, ‘South’, and ‘West’), and poverty status (‘below’ or above’). One approach to calculate prevalence rates and their uncertainties for a given sex, region, poverty status, and age is to calculate the proportion of ‘Yes’ responses among the ‘Yes’ and ‘No’ responses for that demographic group, appropriately weighting each response by the survey weight. This simplified approach was initially used to develop ‘raw’ asthma prevalence rates however this approach may not be completely appropriate. The two main issues with such a simplified approach are that the distributions of the estimated prevalence rates would not be well approximated by normal distributions and that the estimated confidence intervals based on a normal approximation would often extend outside the [0, 1] interval. A better approach for such survey data is to use a logistic transformation and fit the model:

$$Prob (asthma) = \exp(beta) / (1 + \exp(beta)),$$

where beta may depend on the explanatory variables for age, sex, poverty status, or region. This is equivalent to the model:

$$Beta = \text{logit} \{prob (asthma)\} = \log \{prob (asthma) / [1 - prob (asthma)]\}.$$

The distribution of the estimated values of *beta* is more closely approximated by a normal distribution than the distribution of the corresponding estimates of *Prob (asthma)*. By applying a logit transformation to the confidence intervals for *beta*, the corresponding confidence intervals for *Prob (asthma)* will always fall within [0, 1]. Another advantage of the logistic modeling is that it can be used to compare alternative statistical models, e.g., as models where the prevalence probability depends upon age, region, poverty status, and sex, or on age, region, poverty status but not sex.

In earlier analyses using the NHIS asthma prevalence data, a variety of logistic models were developed and evaluated for use in estimating asthma prevalence, where the transformed probability variable beta is a given function of age, gender, poverty status, and region (Cohen and Rosenbaum, 2005; U.S. EPA, 2014). The SAS procedure SURVEYLOGISTIC was used to fit the various logistic models, taking into account the NHIS survey weights and survey design (using both stratification and clustering options), as well as considering various combinations of the selected explanatory variables.

As an example, Table 2 lists the models fit and their log-likelihood goodness-of-fit measures using the ‘Sample Child’ data set and for the “STILL” asthma response variable using the 2013-2017 NHIS data. A total of 32 logistic models were fit, depending on the inclusion of selected explanatory variables and how age was considered in the model. The ‘Strata’ column lists the eight possible stratifications: no stratification, stratified by sex, by region, by poverty status, by region and sex, by region and poverty status, by sex and poverty status, and by region,

gender and poverty status. For example, “5. region, sex” indicates that separate prevalence estimates were made for each combination of region and gender. As another example, “2. sex” means that separate prevalence estimates were made for each sex, so that for each sex, the prevalence is assumed to be the same for each region. Note the prevalence estimates are independently calculated for each stratum. The ‘Description’ column of Table 2 indicates how beta depends upon the age:

|                         |  |
|-------------------------|--|
| <i>Linear in age</i>    | <i>Beta = <math>\alpha + \beta \times \text{age}</math>, where <math>\alpha</math> and <math>\beta</math> vary with strata</i>   |
| <i>Quadratic in age</i> | <i>Beta = <math>\alpha + \beta \times \text{age} + \gamma \times \text{age}^2</math> where <math>\alpha</math>, <math>\beta</math> and <math>\gamma</math> vary with strata</i>  |
| <i>Cubic in age</i>     | <i>Beta = <math>\alpha + \beta \times \text{age} + \gamma \times \text{age}^2 + \delta \times \text{age}^3</math> where <math>\alpha</math>, <math>\beta</math>, <math>\gamma</math>, and <math>\delta</math> vary with the strata</i> |
| <i>f(age)</i>           | <i>Beta = arbitrary function of age, with different functions for different strata</i>   |

The category *f(age)* is equivalent to making age one of the stratification variables, and is also equivalent to making beta a polynomial of degree 17 in age (since the maximum age for children is 17), with coefficients that may vary with the strata. The fitted models are listed in order of complexity, where the simplest model (model 1) is a non-stratified linear model in age and the most complex model (model 32) has a prevalence that is an arbitrary function of age, sex, poverty status, and region. Model 32 is equivalent to calculating independent prevalence estimates for each of the 288 combinations of age, sex, poverty status, and region.

Table 2 also includes the -2 Log Likelihood statistic, a goodness-of-fit measure, and the associated degrees of freedom (DF), which is the total number of estimated parameters. Any two models can be compared using their -2 Log Likelihood values: models having lower values are preferred. If the first model is a special case of the second model, then the approximate statistical significance of the first model is estimated by comparing the difference in the -2 Log Likelihood values with a chi-squared random variable having *r* degrees of freedom, where *r* is the difference in the DF (hence a likelihood ratio test). For all pairs of models from Table 2, all the differences in the -2 Log Likelihood statistic are at least 50,000 and thus are significant at p-values well below 1 percent. Based on its having the lowest -2 Log Likelihood value, the last model fit (model 32: retaining all explanatory variables and using *f(age)*) was preferred and used to estimate the asthma prevalence in the prior analyses<sup>9</sup> as well as employed for this 2013-2017 NHIS data analysis.

---

<sup>9</sup> Similar results were obtained when estimating prevalence using the ‘EVER’ have asthma variable as well as when investigating model fit using the adult data sets. In the Cohen and Rosenbaum (2005) analysis, adult data were not used and the family income-to-poverty ratio was not a variable in their models. Also, because age was a

**Table 2. Logistic models and model fit statistics for estimating child asthma prevalence using the “STILL” asthma response variable from 2013-2017 NHIS data.**

| Model | Description                       | Strata                     | - 2 Log Likelihood | DF  |
|-------|-----------------------------------|----------------------------|--------------------|-----|
| 1     | 1. logit(prob) = linear in age    | 1. none                    | 209411405          | 2   |
| 2     | 1. logit(prob) = linear in age    | 2. gender                  | 208645067          | 4   |
| 3     | 1. logit(prob) = linear in age    | 3. region                  | 209056169.8        | 8   |
| 4     | 1. logit(prob) = linear in age    | 4. poverty                 | 208433518.7        | 4   |
| 5     | 1. logit(prob) = linear in age    | 5. region, gender          | 208230032          | 16  |
| 6     | 1. logit(prob) = linear in age    | 6. region, poverty         | 207999872.9        | 16  |
| 7     | 1. logit(prob) = linear in age    | 7. gender, poverty         | 207630301.3        | 8   |
| 8     | 1. logit(prob) = linear in age    | 8. region, gender, poverty | 207046731.4        | 32  |
| 9     | 2. logit(prob) = quadratic in age | 1. none                    | 207554776.3        | 3   |
| 10    | 2. logit(prob) = quadratic in age | 2. gender                  | 206754508.8        | 6   |
| 11    | 2. logit(prob) = quadratic in age | 3. region                  | 207092990.7        | 12  |
| 12    | 2. logit(prob) = quadratic in age | 4. poverty                 | 206568831.2        | 6   |
| 13    | 2. logit(prob) = quadratic in age | 5. region, gender          | 206177195.9        | 24  |
| 14    | 2. logit(prob) = quadratic in age | 6. region, poverty         | 205966568.6        | 24  |
| 15    | 2. logit(prob) = quadratic in age | 7. gender, poverty         | 205719195.5        | 12  |
| 16    | 2. logit(prob) = quadratic in age | 8. region, gender, poverty | 204888997.5        | 48  |
| 17    | 3. logit(prob) = cubic in age     | 1. none                    | 207244848.3        | 4   |
| 18    | 3. logit(prob) = cubic in age     | 2. gender                  | 206429982.6        | 8   |
| 19    | 3. logit(prob) = cubic in age     | 3. region                  | 206770493.7        | 16  |
| 20    | 3. logit(prob) = cubic in age     | 4. poverty                 | 206240699          | 8   |
| 21    | 3. logit(prob) = cubic in age     | 5. region, gender          | 205817245.3        | 32  |
| 22    | 3. logit(prob) = cubic in age     | 6. region, poverty         | 205532902.7        | 32  |
| 23    | 3. logit(prob) = cubic in age     | 7. gender, poverty         | 205380882.1        | 16  |
| 24    | 3. logit(prob) = cubic in age     | 8. region, gender, poverty | 204406907.3        | 64  |
| 25    | 4. logit(prob) = f(age)           | 1. none                    | 206929745.9        | 18  |
| 26    | 4. logit(prob) = f(age)           | 2. gender                  | 205902376.7        | 36  |
| 27    | 4. logit(prob) = f(age)           | 3. region                  | 205961955.1        | 72  |
| 28    | 4. logit(prob) = f(age)           | 4. poverty                 | 205783757.8        | 36  |
| 29    | 4. logit(prob) = f(age)           | 5. region, gender          | 204430849.5        | 144 |
| 30    | 4. logit(prob) = f(age)           | 6. region, poverty         | 204133603.6        | 144 |
| 31    | 4. logit(prob) = f(age)           | 7. gender, poverty         | 204565028.6        | 72  |
| 32    | 4. logit(prob) = f(age)           | 8. region, gender, poverty | 201725493.2        | 288 |

categorical variable in the adult data sets in U.S. EPA (2014, 2018) and analyses conducted here, it could only be evaluated using  $f(\text{age\_group})$ .

The SURVEYLOGISTIC procedure produces estimates of the beta values and their 95% confidence intervals for each combination of age, region, poverty status, and gender. By applying the inverse logit transformation,

$$Prob (asthma) = \exp( \beta ) / (1 + \exp( \beta ) ),$$

one can convert the beta values and associated 95% confidence intervals into predictions and 95% confidence intervals for the prevalence. The standard error for the prevalence was estimated as:

$$Std Error \{Prob (asthma)\} = Std Error ( \beta ) \times \exp( - \beta ) / (1 + \exp( \beta ) )^2,$$

which follows from the delta method (i.e., a first order Taylor series approximation).

Estimated asthma prevalence using this approach and termed here as ‘unsmoothed’ are provided in the supplement at the end of this document. Graphical representation is provided in a series of figures incorporating the following variables:

- Region
- Gender
- Age (in years) or Age\_group (age categories)
- Poverty Status
- Prevalence = predicted prevalence
- SE = standard error of predicted prevalence
- LowerCI = lower bound of 95% confidence interval for predicted prevalence
- UpperCI = upper bound of 95% confidence interval for predicted prevalence

A series of plots are provided per figure that vary by the four regions and two income-to-poverty ratios. Historically, we have used the prevalence results based on the ‘STILL’ have asthma variable. Supplemental Figures S-1 through S-4 show the estimated prevalence for children and adults by age (or age-group), stratified by gender. Data used for each figure/plot (as well as plots for the ‘EVER’ variable) can be provided upon request.

### *Loess Smoother*

The estimated prevalence curves show that the prevalence is not necessarily a smooth function of age. The linear, quadratic, and cubic functions of age modeled by SURVEYLOGISTIC were identified as a potential method for smoothing the curves, but they did not provide the best fit to the data. One reason for this might be due to the attempt to fit a global regression curve to all the age groups, which means that the predictions for age *A* are



affected by data for very different ages. A local regression approach that separately fits a regression curve to each age  $A$  and its neighboring ages was used, giving a regression weight of 1 to the age  $A$ , and lower weights to the neighboring ages using a tri-weight function:

$$Weight = \{1 - [ |age - A| / q ]^3\}, \text{ where } |age - A| \leq q.$$

The parameter  $q$  defines the number of points in the neighborhood of the age  $A$ . Instead of calling  $q$  the smoothing parameter, SAS defines the smoothing parameter as the proportion of points in each neighborhood. A quadratic function of age to each age neighborhood was fit separately for each gender and region combination. These local regression curves were fit to the beta values, the logits of the asthma prevalence estimates, and then converted them back to estimated prevalence rates by applying the inverse logit function  $\exp(\text{beta}) / (1 + \exp(\text{beta}))$ . In addition to the tri-weight variable, each beta value was assigned a weight of  $1 / [\text{std error}(\text{beta})]^2$ , to account for their uncertainties.

In this application of LOESS, weights of  $1 / [\text{std error}(\text{beta})]^2$  were used such that  $\sigma^2 = 1$ . The LOESS procedure estimates  $\sigma^2$  from the weighted sum of squares. Because it is assumed  $\sigma^2 = 1$ , the estimated standard errors are multiplied by  $1 / \text{estimated } \sigma$  and adjusted the widths of the confidence intervals by the same factor.

There are several potential values that can be selected for the smoothing parameter; the optimum value was determined by evaluating three regression diagnostics: the residual standard error, normal probability plots, and studentized residuals. To generate these statistics, the LOESS procedure was applied to estimated smoothed curves for beta, the logit of the prevalence, as a function of age, separately for each region, gender, and poverty classification. For the children data sets, curves were fit using the choices of 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 for the smoothing parameter. This selected range of values was bounded using the following observations. With only 18 points (i.e., the number of single year ages for children), a smoothing parameter of 0.2 cannot be used because the weight function assigns zero weights to all ages except age  $A$ , and a quadratic model cannot be uniquely fit to a single value. A smoothing parameter of 0.3 also cannot be used because that choice assigns a neighborhood of 5 points only ( $0.3 \times 18 = 5$ , rounded down), of which the two outside ages have assigned weight zero, making the local quadratic model fit exactly at every point except for the end points (ages 0, 1, 16 and 17). Usually one uses a smoothing parameter below 1 so that not all the data are used for the local regression at a given  $x$  value. Note also that a smoothing parameter of 0 can be used to generate the raw, unsmoothed, prevalence. The selection of the smoothing parameter used for the adult curves would follow a similar logic, although the lower bound could effectively be extended only to 0.9 given the number of age groups. This limits the selection of smoothing

parameter applied to the two adult data sets to a value of 0.9, though values of 0.8 – 1.0 were nevertheless compared for good measure.


The first regression diagnostic used was the residual standard error, which is the LOESS estimate of  $\sigma$ . As discussed above, the true value of  $\sigma$  equals 1, so the best choice of smoothing parameter should have residual standard errors as close to 1 as possible. For children ‘EVER’ having asthma and when considering the best models (of the 112 possible, those having  $0.95 < \text{RSE} < 1.05$ ) using this criterion, the best choice varies with gender, region, and poverty status between smoothing parameters of 0.5 and 0.6 (Table 3). For the ‘STILL’ data set, a value of 0.7 or 0.8 would be slightly preferred. Both the ‘EVER’ and ‘STILL’ adult data sets had, at best, only one model with an RSE within the set criterion, and could be smoothed using a value of 0.8.

**Table 3. Top model smoothing fits where residual standard error at or a value of 1.0.**

| Study Group | Asthma Question | Smoothing Parameter |     |     |     |     |     |     |
|-------------|-----------------|---------------------|-----|-----|-----|-----|-----|-----|
|             |                 | 0.4                 | 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1.0 |
| Children    | EVER            | 1                   | 4   | 4   | 3   | 2   | 3   | 4   |
|             | STILL           | 3                   | 3   | 3   | 4   | 4   | 3   | 2   |
| Adults      | EVER            | n/a <sup>A</sup>    | n/a | n/a | n/a | 1   | 0   | 1   |
|             | STILL           | n/a                 | n/a | n/a | n/a | 1   | 0   | 1   |


<sup>A</sup> n/a is not available.

The second regression diagnostic was developed from an approximate studentized residual. The residual errors from the LOESS model were divided by standard error (beta) to make their variances approximately constant. These approximate studentized residuals should be approximately normally distributed with a mean of zero and a variance of  $\sigma^2 = 1$ . To test this assumption, normal probability plots of the residuals were created for each smoothing parameter, combining all the studentized residuals across genders, regions, poverty status, and ages. The results for the children data indicate little distinction or affect by the selection of a particular smoothing parameter (e.g., see Figure 1), although linearity in the plotted curve is best expressed with smoothing parameters generally between 0.6 and 0.8. When considering the adult data sets, the appropriate value would generally be 0.9.



**Figure 1. Normal probability plot of studentized residuals generated using logistic model, ‘STILL’ prevalence data, with smoothing set to 0.7 and 0.9 for children (left) and adults (right), respectively.**

The third regression diagnostic are plots of the studentized residuals against the smoothed beta values. All the studentized residuals for a given smoothing parameter are plotted together within the same graph. Also plotted is a LOESS smoothed curve fit to the same set of points, with SAS’s optimal smoothing parameter choice, to indicate the typical pattern. Ideally there should be no obvious pattern and an average studentized residual close to zero with no regression slope (e.g., see Figure 2). For the children data sets, these plots generally indicate no unusual patterns, and the results for smoothing parameters 0.4 through 0.6 indicate a fit LOESS curve closest to the studentized residual equals zero line. When considering the adult data sets, 0.8 to 0.9 appears to be appropriate values.



**Figure 2. Studentized residuals versus model predicted betas generated using a logistic model and the ‘STILL’ prevalence data, smoothing set to 0.5 and 0.8 for children (left) and adults (right), respectively.**

When considering both children asthma prevalence responses evaluated, the residual standard error (estimated values for sigma) suggests the choice of smoothing parameter as varied, ranging from 0.7 to 0.8. The normal probability plots of the studentized residuals suggest preference for smoothing at or above 0.6. The plots of residuals against smoothed predictions suggest the choices of 0.4 through 0.6. We therefore chose the final value of 0.6 to use for smoothing the children's asthma prevalence. For the adults, there were small differences in the statistical metrics used to evaluate the smoothing. A value of 0.9 was selected for smoothing based on the above findings and to remain consistent with what was used in the prior analysis (U.S. EPA, 2014; 2018).

The smoothed asthma prevalence and associated graphical presentation are provided in Supplemental Figures S-5 through S-8. A similar format to that presented using the non-smoothed asthma prevalence was followed, and again, only providing the results for children and adults that reported 'STILL' having asthma.

## **Step 2: U.S. Census Tract Poverty Ratio Data Set Description and Processing**

This section briefly describes the approach used to generate census tract level poverty ratios for all U.S. census tracts, stratified by age and age groups where available. The following steps were performed using data from the 2017 U.S. Census 5-year American Community Survey (ACS)<sup>10</sup> and modified SAS data processing files.<sup>11</sup>

First, ACS internal point latitudes and longitudes were obtained from the 2017 Gazetteer files.<sup>12</sup> Next, the individual state level ACS sequence files (SF-56) were downloaded,<sup>13</sup> retaining the number of persons across the variable "B17024" for each state considering the appropriate logical record number.<sup>14</sup> The data provided by the B17024 variable is stratified by age or age groups (ages <5, 5, 6-11, 12-14, 15, 16-17, 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, and ≥75)

---

<sup>10</sup> <https://www.census.gov/newsroom/press-kits/2018/acs-5year.html>.

<sup>11</sup> ACS file processing code was adapted from ACS 2012 SAS programs and from ACS 2012 SAS Macros available at [http://www2.census.gov/acs2012\\_5yr/summaryfile/UserTools/SF20125YR\\_SAS.zip](http://www2.census.gov/acs2012_5yr/summaryfile/UserTools/SF20125YR_SAS.zip) and [http://www2.census.gov/acs2012\\_5yr/summaryfile/UserTools/SF\\_All\\_Macro.sas](http://www2.census.gov/acs2012_5yr/summaryfile/UserTools/SF_All_Macro.sas). These were the same processing files used for updating the 2011-2015 asthma prevalence data set (US EPA, 2018).

<sup>12</sup> Data available at: <https://www.census.gov/geographies/reference-files/time-series/geo/gazetteer-files>.

<sup>13</sup> We used the summary tables (B17024), giving census tract populations by poverty income ratio and age group downloaded from [https://www2.census.gov/programs-surveys/acs/summary\\_file/2017/data/5\\_year\\_by\\_state/](https://www2.census.gov/programs-surveys/acs/summary_file/2017/data/5_year_by_state/). Each state's ACS2017 5-yr table compressed file was unzipped with the sequence file 56 (SF-56; *e20175[state abbreviation]0056000.txt*) and appropriate geography file (*g20175[state abbreviation].txt*) retained.

<sup>14</sup> Variable names (2017 Code List.pdf) are available at <https://www.census.gov/programs-surveys/acs/technical-documentation/summary-file-documentation.html>, along with the file for the appropriate logical record number (*ACS\_2017\_SF\_5YR\_Appendices.xls*).

and income/poverty ratios, given in increments of 0.25. We calculated two new variables for each age using the number of persons from the B17024 stratifications; the fraction of those persons having poverty ratios  $< 1.5$  and  $\geq 1.5$  by summing the appropriate B17024 variable and dividing by the total number of persons in that age/age group. Then, the individual state level geographic data (g20175[xx].txt files) were screened for tract level information using the “sumlev” variable equal to ‘140’. Also identified was the US Region for each state, consistent with that used for the NHIS asthma prevalence data.<sup>15</sup>

Finally, the poverty ratio data were combined with the above described census tract level geographic data using the “stusab” and “logrecno” variables. Because APEX requires the input data files to be entirely complete (no missing values), additional processing of the poverty probability file was needed. For where there was missing tract level poverty information,<sup>16</sup> we substituted an age-specific value using the average for the particular county the tract was located within, or the state-wide average. The percent of tracts substituted using county averaged values varied by age group though, on average, was approximately 1.6% of the total tracts (Table 4). Few tracts in six of the age groups were substituted using state averaged values (in total only 9 tracts had a substitution using state values for one of the age groups). The final output was a single file containing relevant tract level poverty probabilities (pov\_acs2017\_5yr.sas7bdat) by age groups for all U.S. census tracts.

**Table 4. Percent of tracts substituted with county average or state average poverty status.**

| Percent Substituted         | Age Groups (years) |       |       |       |       |        |       |       |       |           |       |
|-----------------------------|--------------------|-------|-------|-------|-------|--------|-------|-------|-------|-----------|-------|
|                             | $\leq 5$           | 6-11  | 12-17 | 18-24 | 25-34 | 35- 44 | 45-54 | 55-64 | 65-74 | $\geq 75$ | all   |
| Filled using County Average | 1.9%               | 2.0%  | 1.9%  | 1.5%  | 1.4%  | 1.4%   | 1.3%  | 1.3%  | 1.6%  | 1.9%      | 1.6%  |
| Filled using State Average  | <0.1%              | <0.1% | <0.1% | none  | <0.1% | none   | none  | none  | none  | none      | <0.1% |

### Step 3: Combining Census Tract Poverty Ratios with the NHIS Regional Asthma Prevalence Data

The two data sets were merged considering the region identifier and stratified by age and sex. The Census tract-level asthma prevalence data set was calculated using the following weighting scheme:

<sup>15</sup> <https://www2.census.gov/geo/pdfs/maps-data/maps/reference/> (using file *us\_regdiv.pdf*)

<sup>16</sup> Whether there were no data collected by the Census for poverty status or there were no people in an age group is relatively inconsequential to estimating the exposed people with asthma, particularly considering latter case as no people in that age group would be modeled by APEX when using the same Census population data set.

$$\text{Asthma prevalence} = \text{round}((\text{pov\_prob} * \text{prev\_belowpov}) + ((1 - \text{pov\_prob}) * \text{prev\_abovepov}), 0.0001);$$

whereas each U.S. census tract contains a tract-specific poverty-weighted asthma prevalence, stratified by ages (children 0-17), age groups (adults), and two sexes.

To evaluate the overall accuracy of the Census tract-level estimated asthma prevalence, we first compared these values with the NHIS national summary data for asthma prevalence reported for 2013 to 2017.<sup>17</sup> According to the CDC, the NHIS are the principal source of national asthma prevalence data for the US. Note also, the NHIS 2013-2017 raw data was used to estimate the asthma prevalence for four U.S. regions in step 1 above. The NHIS national summary data are stratified by two age groups (children and adults) and for the two sexes (male and female) and were simply averaged across the five years of data available for the comparison. The Census tract-level estimated asthma prevalence were population-weighted using 2010 U.S. Census tract population data and aggregated to generate a similar national summary metric (and also considered data from 2013-2017 in their initial development). Table 5 show reasonable agreement between the two data sets: where present, the differences between the two data sets were generally small ( $\leq 0.1$  percentage points) with the greatest percentage point difference found for adult females ( $\sim 0.4$  percentage points). The adult asthma prevalence estimated for both sexes using the Census tract-level was lower than the NHIS reported value, while the children's asthma prevalence data were generally similar between the two data sets. Overall, this degree of agreement was expected given that the 2013-2017 NHIS regional asthma prevalence (stratified by age, sex, and family income) served as the source for extrapolating asthma prevalence to the census tract level.

#### **Step 4: Adjusting NHIS Regionally-derived Prevalence Data to Reflect State-level Asthma Prevalence**

We then compared the NHIS Regionally-derived census tract-level estimated asthma prevalence to the Behavioral Risk Factor Surveillance System (BRFSS),<sup>18</sup> an independent source providing state (and national) data about U.S. residents regarding their chronic health conditions such as asthma (among other health issues). For this comparison, the BRFSS asthma prevalence data were available for 2013-2016 and averaged across those four years to obtain a national summary metric. This BRFSS metric is similar to that calculated using the Census tract-level and

<sup>17</sup> Downloaded was Table 4-1, the 2013-2017 NHIS current asthma prevalence percents by age groups and sex available at [https://www.cdc.gov/asthma/nhis/default.htm#anchor\\_1524067853614](https://www.cdc.gov/asthma/nhis/default.htm#anchor_1524067853614). Accessed 5/7/19.

<sup>18</sup> Downloaded was table C2.1 (for each adults and children), the 2013-2016 BRFSS current asthma prevalence percents by state and sex available at <https://www.cdc.gov/asthma/brfss/default.htm>. Table C1 was also downloaded to obtain the asthma prevalence for the two age groups not stratified by sex. Accessed 5/3/19.

NHIS asthma prevalence data sets and is provided in Table 5. The asthma prevalence data reported from BRFSS are consistently greater than that calculated using the Census tract-level data, particularly when considering adults. Overall, the BRFSS adult asthma prevalence is 1.6 percentage points greater than that estimated using the Census tract-level estimated prevalence, with the greatest difference observed for the two data sets of 2.8 percentage points observed for adult females. Asthma prevalence for the two data sets were closer when considering children, though the Census-tract level estimated data were still consistently lower than the BRFSS reported values (~0.2 to 0.4 percentage points).

**Table 5. Asthma prevalence stratified by two age groups and sex using Census tract-level estimates, NHIS and BRFSS reported data.**

| Data Set (years of data)   | All Ages,<br>Both Sexes | Children (<18 years old) |        |       | Adults (≥ 18 years old) |        |      |
|--|-------------------------|--------------------------|--------|-------|-------------------------|--------|------|
|  |                         | all                      | female | male  | all                     | female | male |
| NHIS (2013-2017)   | 7.8%                    | 8.4%                     | 7.2%   | 9.6%  | 7.6%                    | 9.6%   | 5.5% |
| Census tract-level estimate  | 7.6%                    | 8.5%                     | 7.2%   | 9.7%  | 7.3%                    | 9.2%   | 5.3% |
| BRFSS (2013-2016) <sup>A</sup>   | n/a                     | 8.8%                     | 7.4%   | 10.1% | 8.9%                    | 11.4%  | 6.3% |
| <sup>A</sup> The BRFSS does not have any data for some states, and where represented, not all four years of data were available for those state. n/a is not available. |                         |                          |        |       |                         |        |      |

It is unlikely that additional data are available for meaningful comparison, certainly not to the extent to which the NHIS Regionally-derived Census tract-level asthma prevalence is stratified and also not without inconsistencies in methodology used in their collection and reporting, if these data do exist at a local level (e.g., county health department data across all US counties). However, we were concerned with the potential for underestimating asthma prevalence that is indicated by the comparison of the NHIS Regionally-derived census tract-level asthma prevalence with the BRFSS data. Note, we used the NHIS 2013-2017 raw data set in Step 1 to serve as the basis for the census tract-level estimated asthma prevalence given its large sample size for both children and adults and because of the stratification of important influential variables (i.e., age, sex, family income). Contrary to this, the NHIS data are aggregated to four US regions and could account for less spatial variability than that provided by the individual state-level data obtained from BRFSS. With that in mind, we chose to adjust the NHIS-Census tract-level data (upwards or downwards) based on the percent difference observed between a population weighted state level aggregate of the census tract level data and the BRFSS state-level asthma prevalence (Table 6) and was calculated as follows:

$$\text{State Adjustment Factor} = (\text{NHIS\_Census}_{\text{regional prevalence}} - \text{BRFSS}_{\text{state prevalence}}) / \text{BRFSS}_{\text{state prevalence}}$$

**Table 6. Factors used to adjust NHIS Regionally-derived census tract-level asthma prevalence and based on BRFSS state level data.**

| State                | Adjustment Factor – Children <sup>A</sup> |        | Adjustment Factor – Adults <sup>A</sup> |        |
|----------------------|---|--------|---|--------|
|                      | male                                      | female | male                                    | female |
| Alabama              | 0.510                                     | 0.413  | 0.356                                   | 0.399  |
| Alaska               | 0   | 0      | 0.076                                   | 0.296  |
| Arizona <sup>B</sup> | 0.157                                     | 0.058  | 0.199                                   | 0.237  |
| Arkansas             | 0   | 0      | 0.343                                   | 0.299  |
| California           | 0.099                                     | 0.199  | -0.023                                  | 0.108  |
| Colorado             | 0   | 0      | 0.165                                   | 0.179  |
| Connecticut          | 0.114                                     | 0.153  | 0.220                                   | 0.365  |
| Delaware             | 0   | 0      | 0.286                                   | 0.476  |
| Florida              | -0.124                                    | -0.11  | 0.155                                   | 0.136  |
| Georgia              | 0.234                                     | 0.015  | 0.183                                   | 0.320  |
| Hawaii               | 0.59                                      | 1.002  | 0.277                                   | 0.355  |
| Idaho                | 0   | 0      | 0.182                                   | 0.171  |
| Illinois             | -0.016                                    | -0.151 | 0.044                                   | 0.134  |
| Indiana              | -0.107                                    | 0.030  | 0.239                                   | 0.388  |
| Iowa                 | 0   | 0      | 0.044                                   | 0.049  |
| Kansas               | 0.140                                     | 0.035  | 0.111                                   | 0.176  |
| Kentucky             | 0.076                                     | -0.016 | 0.701                                   | 0.628  |
| Louisiana            | -0.051                                    | -0.174 | 0.250                                   | 0.130  |
| Maine                | -0.021                                    | -0.104 | 0.494                                   | 0.478  |
| Maryland             | 0.200                                     | 0.218  | 0.399                                   | 0.399  |
| Massachusetts        | 0.257                                     | 0.061  | 0.328                                   | 0.479  |
| Michigan             | 0.169                                     | 0.036  | 0.414                                   | 0.38   |
| Minnesota            | -0.228                                    | -0.059 | -0.014                                  | 0.069  |
| Mississippi          | 0.127                                     | -0.026 | 0.151                                   | 0.120  |
| Missouri             | 0.003                                     | 0.226  | 0.264                                   | 0.301  |
| Montana              | -0.137                                    | 0.107  | 0.154                                   | 0.173  |
| Nebraska             | -0.180                                    | -0.210 | 0.030                                   | 0      |
| Nevada               | -0.143                                    | 0.068  | -0.070                                  | 0.129  |
| New Hampshire        | -0.031                                    | 0.009  | 0.276                                   | 0.502  |
| New Jersey           | -0.094                                    | 0.009  | 0.052                                   | 0.078  |
| New Mexico           | 0.141                                     | 0.208  | 0.340                                   | 0.302  |
| New York             | -0.040                                    | -0.024 | 0.285                                   | 0.237  |
| North Carolina       | 0.171                                     | 0.416  | 0.154                                   | 0.225  |
| North Dakota         | 0   | 0      | 0.254                                   | 0.132  |
| Ohio                 | 0.024                                     | 0.016  | 0.233                                   | 0.332  |
| Oklahoma             | 0.298                                     | 0.065  | 0.549                                   | 0.365  |
| Oregon               | -0.047                                    | 0.237  | 0.400                                   | 0.443  |
| Pennsylvania         | 0.137                                     | 0.003  | 0.172                                   | 0.357  |



| State  | Adjustment Factor – Children <sup>A</sup> |        | Adjustment Factor – Adults <sup>A</sup> |        |
|--|---|--------|---|--------|
|  | male                                      | female | male                                    | female |
| Puerto Rico <sup>C</sup>   | 0   | 0      | 0                                       | 0      |
| Rhode Island   | 0.083                                     | 0.136  | 0.376                                   | 0.447  |
| South Carolina   | 0   | 0      | 0.240                                   | 0.252  |
| South Dakota   | 0   | 0      | 0.040                                   | -0.043 |
| Tennessee  | 0.116                                     | -0.111 | 0.256                                   | 0.368  |
| Texas  | -0.034                                    | -0.210 | 0.068                                   | 0.111  |
| Utah   | -0.079                                    | -0.032 | 0.239                                   | 0.160  |
| Vermont  | -0.114                                    | 0.131  | 0.333                                   | 0.453  |
| Virginia   | 0   | 0      | 0.218                                   | 0.333  |
| Wash DC  | 0.389                                     | 0.436  | 0.656                                   | 0.577  |
| Washington   | -0.108                                    | 0.091  | 0.246                                   | 0.294  |
| West Virginia  | 0.041                                     | -0.032 | 0.561                                   | 0.581  |
| Wisconsin  | -0.097                                    | 0.232  | 0.279                                   | 0.284  |
| Wyoming  | 0   | 0      | 0.146                                   | 0.190  |
| <sup>A</sup> Values of zero indicate there were no BRFSS data were available, therefore no adjustment was made.<br><sup>B</sup> Data reported for Arizona children in the 2013 BRFSS were atypical: prevalence for females were greater than that of male, having rates almost opposite that expected. These data were not used to calculate the adjustment factor.<br><sup>C</sup> The NHIS-Census regional data was not used for estimating asthma prevalence for Puerto Rico, therefore only BRFSS data for the two age groups and sexes were used. |   |        |   |        |

The adjustment factor was applied to the census tract estimated asthma prevalence considering the state level information as follows:

$$Prevalence_{Adjusted} = NHIS/Census_{prevalence} + (Adjustment\ Factor \times NHIS/Census_{prevalence})$$

By design, the adjustment has better aligned the estimated NHIS Regionally-derived census tract-level asthma prevalence with the BRFSS reported values at the state and national level (Table 7). These BRFSS-adjusted census tract-level asthma prevalence data are used for the APEX simulations and are found within the *asthma\_prev\_1317\_tract\_051319\_adjusted.txt* file. For brevity, data are shown only for a few states most relevant to the study areas of interest in the current O<sub>3</sub> exposure and risk analysis.

**Table 7. Population-weighted state level asthma prevalence stratified by two age groups and sex: Original census tract-level estimates based on 2013-2017 NHIS regional prevalence and US Census family income data, 2013-2016 BRFSS reported prevalence, and BRFSS-adjusted census tract-level estimates used for the APEX asthma prevalence file.**

| State                      | Related Study Area <sup>A</sup> | Sex    | Child Asthma Prevalence     |                           |                               | Adult Asthma Prevalence     |                           |                               |
|----------------------------|---------------------------------|--------|-----------------------------|---------------------------|-------------------------------|-----------------------------|---------------------------|-------------------------------|
|                            |                                 |        | Census tract-level estimate | BRFSS state reported data | Adjusted APEX prevalence file | Census tract-level estimate | BRFSS state reported data | Adjusted APEX prevalence file |
| Georgia                    | Atlanta                         | female | 7.9%                        | 8.1%                      | 8.0%                          | 8.7%                        | 11.4%                     | 11.4%                         |
|                            |                                 | male   | 10.0%                       | 12.4%                     | 12.3%                         | 4.7%                        | 5.6%                      | 5.5%                          |
| Massachusetts <sup>2</sup> | Boston                          | female | 7.7%                        | 8.2%                      | 8.1%                          | 9.5%                        | 14.0%                     | 14.0%                         |
|                            |                                 | male   | 10.9%                       | 13.7%                     | 13.6%                         | 5.8%                        | 7.7%                      | 7.6%                          |
| Texas <sup>2</sup>         | Dallas                          | female | 7.9%                        | 6.2%                      | 6.3%                          | 8.6%                        | 9.5%                      | 9.5%                          |
|                            |                                 | male   | 10.0%                       | 9.6%                      | 9.6%                          | 4.7%                        | 5.0%                      | 5.0%                          |
| Michigan                   | Detroit                         | female | 7.1%                        | 7.4%                      | 7.4%                          | 9.7%                        | 13.4%                     | 13.4%                         |
|                            |                                 | male   | 9.9%                        | 11.6%                     | 11.6%                         | 5.8%                        | 8.2%                      | 8.2%                          |
| Pennsylvania               | Philadelphia                    | female | 8.0%                        | 8.0%                      | 8.0%                          | 9.6%                        | 13.0%                     | 13.0%                         |
|                            |                                 | male   | 11.0%                       | 12.6%                     | 12.5%                         | 5.8%                        | 6.8%                      | 6.8%                          |
| Arizona <sup>B</sup>       | Phoenix                         | female | 5.9%                        | 6.2%                      | 6.2%                          | 9.5%                        | 11.7%                     | 11.7%                         |
|                            |                                 | male   | 8.6%                        | 9.9%                      | 9.9%                          | 5.6%                        | 6.8%                      | 6.7%                          |
| California                 | Sacramento                      | female | 5.9%                        | 7.1%                      | 7.0%                          | 9.4%                        | 10.4%                     | 10.4%                         |
|                            |                                 | male   | 8.6%                        | 9.4%                      | 9.4%                          | 5.6%                        | 5.5%                      | 5.5%                          |
| Missouri                   | St. Louis                       | female | 7.0%                        | 8.5%                      | 8.5%                          | 9.7%                        | 12.6%                     | 12.6%                         |
|                            |                                 | male   | 9.7%                        | 9.7%                      | 9.7%                          | 5.8%                        | 7.3%                      | 7.3%                          |
| All US States              |                                 | female | 7.2%                        | 7.4%                      | 7.4%                          | 9.2%                        | 11.4%                     | 11.4%                         |
|                            |                                 | male   | 9.7%                        | 10.1%                     | 10.1%                         | 5.3%                        | 6.3%                      | 6.3%                          |
|                            |                                 | both   | 8.5%                        | 8.8%                      | 8.8%                          | 7.3%                        | 8.9%                      | 8.9%                          |

<sup>A</sup> Each study area is defined by a Consolidated Statistical Area (CSA) may involve counties from more than one US state. This information is added for relevance to the spatial scale and not meant to be absolute in defining the prevalence for any of the study areas.

<sup>B</sup> Data for children were only available for the following years in a few states: 2016 (Arizona), 2015 and 2016 (Massachusetts), 2013-2015 (Texas). Adults based on 2013-2016.

The asthma prevalence estimates vary for the different ages and sexes of children and adults that reside in each census tract of each study area. We evaluated the spatial distribution of the asthma prevalence using the specific census tracts that comprise the consolidated statistical area (CSA) that generally define each study area. We first separated data for children from those for adults and calculated simple descriptive statistics of asthma prevalence for the tracts, stratified by sex (Table 8). Consistent with broadly defined national asthma prevalence (e.g., Table 3-1 of the draft PA), on average, children have higher estimated rates than adults, male children have higher rates than female children, and adult females have higher rates than adult males.

By using age, sex, and family income variables to develop the tract level prevalence, we also observe that there is spatial variability in the estimated prevalence both within and across the CSAs. Atlanta, Boston, Detroit, and Philadelphia have some of the highest asthma prevalence for male children considering most of the statistics with rates as high as 25.5% in one or more census tracts for males of a given year of age. The Dallas study area exhibits some of the lowest asthma prevalence when considering adults (both sexes) with rates as low as 3.8% in one or more tracts for males within a given age group. These summary statistics represent the range of age- and sex-specific values for the census blocks used in each APEX simulation to estimate the number of individuals that have asthma.

**Table 8. Descriptive statistics for non-population weighted asthma prevalence for children (ages 5-17) and adults (age >17) using all census tracts from 8 consolidated statistical areas (CSAs) in the APEX asthma prevalence file (2013-2017).**

| CSA Name - ID#<br>(# tracts)<br>and<br>Population group   |       | Sex    | Asthma Prevalence across all ages (or age groups) and census tracts <sup>A</sup> |                       |         |        |                                |                                |         |
|---|-------|--------|--|-----------------------|---------|--------|--------------------------------|--------------------------------|---------|
|   |       |        | Mean   | Standard<br>Deviation | Minimum | Median | 95 <sup>th</sup><br>percentile | 99 <sup>th</sup><br>percentile | Maximum |
| Atlanta-122<br>(1,077)  | adult | female | 11.1%  | 1.8%                  | 7.7%    | 11.1%  | 14.0%                          | 15.9%                          | 20.9%   |
|   |       | male   | 5.5%   | 0.8%                  | 4.3%    | 5.4%   | 7.1%                           | 7.5%                           | 7.9%    |
|   | child | female | 9.7%   | 1.7%                  | 6.5%    | 9.6%   | 12.9%                          | 13.9%                          | 15.0%   |
|   |       | male   | 14.1%  | 1.7%                  | 10.6%   | 14.0%  | 16.8%                          | 17.6%                          | 18.3%   |
| Boston-148<br>(1,753)   | adult | female | 13.8%  | 1.8%                  | 10.5%   | 13.5%  | 17.3%                          | 20.5%                          | 28.9%   |
|   |       | male   | 7.6%   | 0.9%                  | 5.4%    | 7.5%   | 9.1%                           | 10.0%                          | 12.9%   |
|   | child | female | 9.4%   | 2.0%                  | 5.6%    | 9.5%   | 12.4%                          | 13.5%                          | 17.1%   |
|   |       | male   | 15.4%  | 2.5%                  | 8.7%    | 15.1%  | 19.5%                          | 20.8%                          | 23.4%   |
| Dallas-206<br>(1,422)   | adult | female | 9.3%   | 1.5%                  | 6.5%    | 9.3%   | 11.8%                          | 13.5%                          | 16.5%   |
|   |       | male   | 4.9%   | 0.7%                  | 3.8%    | 4.9%   | 6.4%                           | 6.8%                           | 9.7%    |
|   | child | female | 7.6%   | 1.3%                  | 5.0%    | 7.4%   | 10.0%                          | 10.9%                          | 13.5%   |
|   |       | male   | 11.0%  | 1.4%                  | 8.3%    | 11.0%  | 13.2%                          | 13.8%                          | 18.1%   |
| Detroit-220<br>(1,583)  | adult | female | 13.3%  | 2.5%                  | 7.8%    | 13.4%  | 17.8%                          | 20.6%                          | 25.6%   |
|   |       | male   | 7.9%   | 2.2%                  | 1.0%    | 7.6%   | 12.4%                          | 14.7%                          | 19.0%   |
|   | child | female | 8.6%   | 1.5%                  | 6.4%    | 8.2%   | 11.6%                          | 12.5%                          | 13.2%   |
|   |       | male   | 13.3%  | 3.0%                  | 7.7%    | 12.7%  | 19.9%                          | 23.6%                          | 25.5%   |
| Philadelphia-428<br>(1,725)   | adult | female | 12.1%  | 2.3%                  | 8.2%    | 12.0%  | 16.4%                          | 19.8%                          | 26.5%   |
|   |       | male   | 6.5%   | 0.9%                  | 4.6%    | 6.4%   | 8.1%                           | 9.0%                           | 11.4%   |
|   | child | female | 9.1%   | 1.9%                  | 5.6%    | 9.2%   | 12.0%                          | 13.1%                          | 15.3%   |
|   |       | male   | 13.6%  | 2.4%                  | 8.2%    | 13.3%  | 17.8%                          | 19.2%                          | 21.1%   |
| Phoenix-429<br>(988)  | adult | female | 11.6%  | 1.6%                  | 8.6%    | 11.7%  | 14.4%                          | 16.0%                          | 19.7%   |
|   |       | male   | 7.0%   | 1.5%                  | 5.1%    | 7.1%   | 9.1%                           | 11.7%                          | 16.7%   |
|   | child | female | 7.6%   | 1.5%                  | 4.6%    | 8.0%   | 9.5%                           | 9.6%                           | 9.6%    |
|   |       | male   | 11.5%  | 1.8%                  | 8.5%    | 11.6%  | 14.8%                          | 15.9%                          | 17.1%   |
| Sacramento-472<br>(539)   | adult | female | 10.4%  | 1.4%                  | 7.7%    | 10.5%  | 12.7%                          | 14.0%                          | 16.5%   |
|   |       | male   | 5.7%   | 1.1%                  | 4.2%    | 5.9%   | 7.3%                           | 9.0%                           | 13.6%   |
|   | child | female | 8.5%   | 1.7%                  | 5.2%    | 9.0%   | 10.7%                          | 10.9%                          | 10.9%   |
|   |       | male   | 10.8%  | 1.7%                  | 8.1%    | 10.9%  | 13.7%                          | 14.8%                          | 16.2%   |
| St. Louis-476<br>(638)  | adult | female | 11.8%  | 2.1%                  | 6.8%    | 11.9%  | 15.0%                          | 17.4%                          | 21.5%   |
|   |       | male   | 6.5%   | 1.8%                  | 0.9%    | 6.5%   | 9.9%                           | 11.8%                          | 14.5%   |
|   | child | female | 9.2%   | 2.0%                  | 5.3%    | 9.1%   | 12.9%                          | 14.2%                          | 15.6%   |
|   |       | male   | 11.1%  | 2.4%                  | 6.5%    | 10.7%  | 15.9%                          | 19.3%                          | 21.9%   |
| A As described in the text, prevalence is based on single year ages (children) or age group (adults) and sex derived from 2013-2017 CDC NHIS asthma prevalence and considering U.S. census tract level family income/poverty ratio data. Data presented are not population-weighted and represent the distribution of applied probabilities used by APEX for tracts having a non-zero population. Note also, upper and lower percentiles could represent prevalence for a single-year age/sex group residing in a single tract within a study area. |       |        |  |                       |         |        |                                |                                |         |

## Evaluation of Additional Asthma Prevalence Questions and Responses

To estimate asthma prevalence, we used responses to the question of whether an NHIS study participant responded ‘Yes’ to the survey question of ‘STILL’ having asthma rather than using the responses to the question of ‘EVER’ having asthma (with the former being a subset of the latter group). According to the CDC, lifetime asthma is defined by responding ‘Yes’ to “Have you ever been told by a doctor {nurse or other health professional} that you have asthma?”, while current asthma is defined as responding ‘Yes’ to both the aforementioned and this subsequent question “Do you still have asthma?”.<sup>19</sup> Because the exposure and risk analyses in this review reflect a generally current actualized hypothetical single-year scenario that is not covering the lifetime of the simulated individuals, the prevalence estimate based on those participants responding as currently (‘STILL’) having asthma was deemed most appropriate. We note that the response of survey participants who stated they do not still have asthma does not reflect a doctor’s/health professional’s diagnosis, thus it is possible there may be individuals in this group that might actually still have asthma and experience asthma-related health effects, potentially leading to an underestimate in the asthma prevalence used in our exposure and risk simulations. Because we used the responses to the “STILL” having asthma question to estimate prevalence in this assessment, we evaluated additional related questions in the NHIS data to estimate the magnitude of this potential underestimate in asthma prevalence.

There are two additional questions related to asthma prevalence that are asked of NHIS survey participants who responded ‘Yes’ to the ‘EVER’ having asthma question that could provide insight into the likelihood that people could ‘STILL’ have asthma but did not respond ‘Yes’ to that latter question. The first additional asthma question is, “DURING THE PAST 12 MONTHS, have you had an episode of asthma or an asthma attack?” (i.e., variable ‘CASHYR’ or ‘AASHYR’ for children and adults, respectively); the second is, “DURING THE PAST 12 MONTHS, have you had to visit an emergency room or urgent care center because of asthma?” (i.e., variable ‘CASERYR1’ or ‘AASERYR1’). We evaluated the responses to all four of these asthma questions using children’s 2017 data set as an example, the results of which are presented in Table 9.

Most survey participants responded either yes or no to the ‘EVER’ having asthma question; those not providing a response were removed from the analysis. There were few individuals not responding to the question (13 of 8,845), thus it was assumed there would be no bias to the overall conclusions following their removal. Of the remaining children surveyed, 13.2% (i.e., 1,168 of 8,832) had a doctor/health professional diagnose them as having asthma at some time in their life, with a majority of those ‘EVER’ having asthma (63.3%) responding

---

<sup>19</sup> <https://www.cdc.gov/asthma/brfss/default.htm>.

‘Yes’ to ‘STILL’ having asthma. Based on these responses to the ‘STILL’ having asthma question, the overall asthma prevalence for children would be estimated as 8.4% (i.e., 739 of 8,832). As mentioned above, it is possible that prevalence is underestimated due to the nature of the diagnosis (i.e., self assessment) and at most, could be underestimated by a factor of 1.6 (i.e., 13.2/8.4) if assuming ‘EVER’ having asthma response was appropriate to use in this assessment. We suggest solely using this ‘EVER’ having asthma response would likely bias the prevalence high based on the below analysis of responses to the two additional asthma questions.

**Table 9. Children’s responses to four questions regarding their asthma status, 2017 NHIS.**

| Diganosed by a Doctor as EVER Having Asthma? | Participant Reported as STILL Having Asthma? | Participant Reported in Past 12 Months Did You Have: |                          | Survey Participants (n) |
|--|--|--|--------------------------|-------------------------|
|  |  | Asthma Attack?                                       | Asthma-related ER Visit? |                         |
| Did not respond                              | -  | -  | -                        | 13                      |
| No   | -  | -  | -                        | 7,664                   |
| Yes (n=1,168)                                | No (n=420)                                   | No   | No                       | 396                     |
|  |  | No   | Yes                      | 5                       |
|  |  | Yes  | No                       | 15                      |
|  |  | Yes  | Yes                      | 4                       |
|  | I don't know (n=9)                           | No   | No                       | 5                       |
|  |  | Yes  | No                       | 4                       |
|  | Yes (n=739)                                  | No   | No                       | 336                     |
|  |  | No   | Yes                      | 22                      |
|  |  | Yes  | No                       | 248                     |
|  |  | Yes  | Yes                      | 131                     |
|  |  | I don't know   | No                       | 1                       |
|  |  | I don't know   | I don't know             | 1                       |
| Sum of EVER (Y/N), all ages                  |  |  |                          | 8,832                   |

There were a few participants (6.5%, 28 of 429) who reported they did not or did not know they ‘STILL’ have asthma (note also, an unprofessional diagnosis), but also reported they had an asthma attack and/or had to be treated by a doctor because of asthma. Based on these data, asthma prevalence estimated using the response for the ‘STILL’ having asthma question alone might be underestimated by about 0.3 percentage points (i.e., 28/8832, the number reporting asthma attack or ER visit but also reporting “no” for still having asthma divided by total respondents), such that the overall asthma prevalence for children might be 8.7% rather than 8.4%. This would be with the assumption that the individual has accurately self-diagnosed an asthma attack, a perhaps reasonable assumption given they had been diagnosed with asthma at some time in their life. When considering the participants that stated they ‘STILL’ have asthma,

approximately 54% reported they had an asthma attack and/or had to be treated by a doctor because of asthma (i.e., 401 of 739). This clearly indicates that when survey participants reported they ‘STILL’ have asthma, they are more likely to have asthma attacks/ER visits than those who do not state they ‘STILL’ have asthma. An alternative hypothesis is also possible, in that they could have indicated they still have asthma as a result of the asthma attack/ER visit. Regardless, the health condition and the adverse response appear to be interrelated.


Additionally, we could assume that all participants that ‘EVER and ‘STILL’ have asthma (100% rather than the 54% estimated above) would have an asthma attack/ER visit at some time in their life (and perhaps not just within 12 months). Applying that information to survey participants who stated they did not ‘STILL’ have asthma and also report they have experienced an asthma attack/ER visit, implies that the asthma prevalence derived without these individuals (i.e., 0.3 percentage points) might be underestimated by a factor of about two. Thus, based on this analysis and including assumptions made using the responses to the additional questions, it is possible that asthma prevalence estimated using the ‘STILL’ variable alone (as was done for this assessment) could be underestimated by about 0.6 percentage points (i.e., an overall ‘current’ asthma prevalence for children would be about 9.0% rather than the 8.4% used in the simulations).

## REFERENCES

- Cohen J and Rosenbaum A. (2005). Analysis of NHIS Asthma Prevalence Data. Memorandum to John Langstaff by ICF Incorporated. For US EPA Work Assignment 3-08 under EPA contract 68D01052. Available in US EPA (2007) Appendix G.
- U.S. EPA. (2007). Ozone Population Exposure Analysis for Selected Urban Areas (July 2007). Office of Air Quality Planning and Standards, Research Triangle Park, NC. EPA-452/R-07-010. Available at [http://epa.gov/ttn/naaqs/standards/ozone/s\\_o3\\_cr\\_td.html](http://epa.gov/ttn/naaqs/standards/ozone/s_o3_cr_td.html).
- U.S. EPA. (2008). Risk and Exposure Assessment to Support the Review of the NO<sub>2</sub> Primary National Ambient Air Quality Standard. Report no. EPA-452/R-08-008a. November 2008. Available at [http://www.epa.gov/ttn/naaqs/standards/nox/data/20081121\\_NO2\\_REA\\_final.pdf](http://www.epa.gov/ttn/naaqs/standards/nox/data/20081121_NO2_REA_final.pdf).
- U.S. EPA. (2009). Risk and Exposure Assessment to Support the Review of the SO<sub>2</sub> Primary National Ambient Air Quality Standard. Report no. EPA-452/R-09-007. August 2009. Available at <http://www.epa.gov/ttn/naaqs/standards/so2/data/200908SO2REAFinalReport.pdf>.
- U.S. EPA. (2014). Health Risk and Exposure Assessment for Ozone, Final Report. Chapter 5 Appendices. Report no. EPA-452/R-14-004c. August 2014. Available at <https://nepis.epa.gov/Exe/ZyPDF.cgi/P100KCI7.PDF?Dockey=P100KCI7.PDF>.
- U.S. EPA. (2018). Risk and Exposure Assessment for the Review of the Primary National Ambient Air Quality Standard for Sulfur Oxides. Office of Air Quality Planning and Standards, Research Triangle Park, NC, EPA-452/R-18-003, May 2018. Available at [https://www.epa.gov/sites/production/files/2018-05/documents/primary\\_so2\\_naaqs\\_-\\_final\\_rea\\_-\\_may\\_2018.pdf](https://www.epa.gov/sites/production/files/2018-05/documents/primary_so2_naaqs_-_final_rea_-_may_2018.pdf).


## SUPPLEMENTAL FIGURES S-1 to S-4, ASTHMA PREVALENCE NON-SMOOTHED

**Figure S-1. Non-smoothed asthma prevalence for children that still have asthma. Above (left panels) and below poverty level (right panels) for Midwest (top panels) and Northeast (bottom panels) regions.**







**Figure S-2. Non-smoothed asthma prevalence for children that still have asthma. Above (left panels) and below poverty level (right panels) for South (top panels) and West (bottom panels) regions.**



**Figure S-3. Non-smoothed asthma prevalence for adults that still have asthma. Above (left panels) and below poverty level (right panels) for Midwest (top panels) and Northeast (bottom panels) regions.**




**Figure S-4. Non-smoothed asthma prevalence for adults that still have asthma. Above (left panels) and below poverty level (right panels) for South (top panels) and West (bottom panels) regions.**




## SUPPLEMENTAL FIGURES S-5 to S-8, ASTHMA PREVALENCE SMOOTHED


**Figure S-5. Smoothed asthma prevalence for children that still have asthma. Above (left panels) and below poverty level (right panels) for Midwest (top panels) and Northeast (bottom panels) regions.**




**Figure S-6. Smoothed asthma prevalence for children that still have asthma. Above (left panels) and below poverty level (right panels) for South (top panels) and West (bottom panels) regions.**



**Figure S-7. Smoothed asthma prevalence for adults that still have asthma. Above (left panels) and below poverty level (right panels) for Midwest (top panels) and Northeast (bottom panels) regions.**



**Figure S-8. Smoothed asthma prevalence for adults that still have asthma. Above (left panels) and below poverty level (right panels) for South (top panels) and West (bottom panels) regions.**



**APPENDIX 3D, ATTACHMENT 2:**  
**ICF TECHNICAL MEMO: IDENTIFICATION OF SIMULATED INDIVIDUALS AT**  
**MODERATE EXERTION**



# MEMORANDUM

**To:** John Langstaff and Stephen Graham, EPA  
**From:** Jeanne Luh, Graham Glen, and Chris Holder, ICF  
**Date:** March 26, 2019  
**Re:** Identification of Simulated Individuals at Moderate Exertion

---

## 1. Introduction

Under Work Assignment 4-55 of U.S. Environmental Protection Agency (EPA) Contract EP-W-12-010, the EPA Work Assignment Manager (WAM) asked ICF (hereafter “us”, “we”, etc.) to evaluate the approach used in the Air Pollutants Exposure Model (APEX; U.S. EPA, 2017a and 2017b) to identify when simulated individuals are at moderate exertion on average during any 8-hour exposure period. APEX uses the **ModEVR8** parameter, where EVR is equivalent ventilation rate, to define the threshold EVR for moderate exertion. EVR, calculated as ventilation rate divided by body surface area ( $V_e/BSA$ ), values at or above **ModEVR8** (but below **HeavyEVR8**, the threshold for heavy exertion) are classified as moderate exertion. The **ModEVR8** value typically used in regulatory runs of APEX is 13 L/min-m<sup>2</sup>, which was developed by Whitfield (1996) using clinical data from McDonnell et al. (1991). In McDonnell et al., study participants were required to maintain a  $V_e$  of 40 L/min while exposed to ozone and performing activities classified as moderate exertion over a 6.6-hour period. Using this data, Whitfield (1996) defined the EVR range to be 13–27 L/min-m<sup>2</sup> for 8-hour-average exposures at moderate exertion.

The approach used to define moderate exertion was noted in public comments in the last review of EPA’s Health Risk and Exposure Assessment for Ozone in 2014 (U.S. EPA, 2014). The bullets below summarize two critiques that some public commenters had about the **ModEVR8** value of 13 L/min-m<sup>2</sup>.

- A **ModEVR8** value of 13 L/min-m<sup>2</sup> was too low and resulted in an overstatement of the number of exposures. This, in turn, resulted in an overestimation of the lung function decrement risk when exposure-response functions were used to estimate risk.
- The strenuous nature of the exercise performed in the clinical studies to achieve an EVR of 20 L/min-m<sup>2</sup> was not comparable to the activities and range of actual 8-hour EVRs in the populations of interest. They suggested that use of the clinical studies data may not be reasonable in defining **ModEVR8**.

Due to the lack of available controlled studies for human exposure to ozone, we focused on evaluating how **ModEVR8** is defined and we performed our analyses using an expanded dataset of clinical studies provided by the EPA WAM where the target EVR under moderate exertion was 20 L/min-m<sup>2</sup>.

## 2. Data Sources

In Table 1 we list the clinical studies with data available on  $V_e$  and EVR for individuals undergoing moderate exertion during 6.6-hour exposure to filtered air and ozone. Adult study participants were required to maintain an EVR of 20 L/min-m<sup>2</sup> while undergoing intermittent moderate exercise, which consisted of six periods of 50-minute exercise on the treadmill or cycle ergometer, each followed by a 10-minute break, and with a 35-minute lunch after the third period.

**Table 1. Clinical Studies with 6.6-hour Moderate Exertion**

| Reference               | No. Subjects / Gender | Age Range (years) | O <sub>3</sub> Exposure (ppm)   |
|-------------------------|-----------------------|-------------------|---|
| Folinsbee et al. (1998) | 10 Males              | 18–33             | 0, 0.12   |
| Horstman et al. (1990)  | 22 Males              | 18–35             | FA, 0.08, 0.10, 0.12  |
| McDonnell et al. (1991) | 28 Males              | 18–30             | 0, 0.08   |
| McDonnell et al. (1991) | 10 Males              | 18–30             | 0, 0.08, 0.1  |
| Folinsbee et al. (1994) | 17 Males              | 25±4              | FA, 0.12  |
| Schelegle et al. (2009) | 15 Males, 16 Females  | 18–25             | Mean: FA, 0.06, 0.07, 0.08, 0.087<br>Max: n/a, 0.09, 0.09, 0.15, 0.12 |
| Kim et al. (2011)       | 27 Males, 32 Females  | 19–35             | FA, 0.06  |

Notes: No. = number; O<sub>3</sub> = ozone; ppm = parts per million; FA = filtered air; max = maximum; n/a = not available.

## 3. Equivalent Ventilation Rates

### 3.1. Original EVR Threshold

The **ModEVR8** of 13 L/min-m<sup>2</sup> typically used in regulatory runs of APEX was based on the range of 13–27 L/min-m<sup>2</sup> defined by Whitfield (1996) for 8-hour exposures. However, details were not available on how this range was obtained from the McDonnell et al. (1991) data. We analyzed the data to determine

- if the mean EVR was calculated based on all data points or based on the person-averaged EVR values, and
- the number of standard deviations away from the mean that would result in the range of values reported.

The EPA WAM provided a SAS data file with 4,024 individual EVR data points corresponding to 485 experiments. The McDonnell et al. (1991) data were provided as two separate datasets with Study IDs of “Ozi-2” and “Pokoz”, which were identified within the SAS dataset as OZI and POK, respectively. Using the McDonnell et al. (1991) OZI and POK datasets individually and combined, we calculated the mean, standard deviation, and upper and lower bounds (defined as mean ± 3 standard deviations) using (i) all individual EVR data points and (ii) person-averaged EVR values. The person-averaged EVRs are the average over time, resulting in one person-averaged EVR per unique subject and experiment, which is more consistent with how APEX evaluates whether a profile is at moderate exertion (by calculating the profile’s 8-hour-average EVR). In Table 2 we present the results of this analysis, which suggest that the range of 13–27 L/min-m<sup>2</sup> used by Whitfield (1996) was obtained using individual EVR data from the OZI dataset and three standard deviations away from the mean (see gray-shaded cells in the table).

**Table 2. EVR Metrics for Individual EVR Data Points and Person-averaged EVRs, during Intermittent Moderate Exercise**

|   | McDonnell et al. (1991) Datasets |       |                    |
|---|----------------------------------|-------|--------------------|
|   | OZI                              | POK   | OZI + POK Superset |
| <b>Individual EVR Data Points (L/min-m<sup>2</sup>)</b> |                                  |       |                    |
| Mean  | 20.29                            | 20.22 | 20.26              |
| Standard Deviation                                      | 2.30                             | 1.95  | 2.14               |
| Lower Bound   | <b>13.37</b>                     | 14.38 | 13.83              |
| Upper Bound   | <b>27.20</b>                     | 26.06 | 26.69              |
| <b>Person-averaged EVRs (L/min-m<sup>2</sup>)</b>       |                                  |       |                    |
| Mean  | 20.29                            | 20.22 | 20.26              |
| Standard Deviation                                      | 2.05                             | 1.61  | 1.85               |
| Lower Bound   | 14.15                            | 15.39 | 14.72              |
| Upper Bound   | 26.43                            | 25.06 | 25.80              |

Notes: EVR = equivalent ventilation rate; L/min-m<sup>2</sup> = liters per minute per square meter; lower bound = mean - 3 standard deviations; upper bound = mean + 3 standard deviations.

Cells shaded in gray indicate metrics lining up with the 13–27 L/min-m<sup>2</sup> range of moderate-exertion EVRs defined by Whitfield (1996) for 8-hour exposures based on the McDonnell et al. (1991) data.

### 3.2. EVR Threshold from All Clinical Studies

**ModEVR8** can be re-calculated for the expanded dataset following the original approach of three standard deviations away from the mean. In Table 3 we present the mean, median, standard deviation, and upper- and lower-bound EVRs using person-averaged EVR values from all datasets listed in Table 1.

The EVRs measured in the studies were collected during periods of exertion and represent exercise-only conditions. However, during the 6.6-hour experiment, only 5 hours were used for exercise (i.e., six 50-minute periods of treadmill or cycle ergometer), with the remaining 1.6 hours for rest or lunch. During resting times/lunch, EVR values are expected to drop. As discussed below, we estimated the impact on EVRs from incorporating rest time.

Of the studies in Table 1, only Schelegle et al. (2009) mentioned resting  $V_e$  (and, by default, resting EVR), which was estimated using regression equations derived from the data of Aitken et al. (1986). For college-age males, this was  $V_e = 7.61 \times \text{BSA}$ , and for college-age females, this was  $V_e = 8.05 \times \text{BSA}$ . These resting EVR values, 7.61 and 8.05 L/min-m<sup>2</sup> for college-age males and females respectively, are consistent with expected resting EVR values. For example, Adams (2006) reported group-mean-total and exercise-only  $V_e$ , which can be used with their reported BSAs to estimate a resting EVR of 6.38 L/min-m<sup>2</sup> for that study. In our analysis, we used those college-age male and female values to calculate resting EVR for each study, as the weighted average based on the number of males and females in the study. We then calculated total (exercise and rest) EVR as a weighted average based on 5 hours of exercise and 1.6 hours of rest/lunch. As expected, the values in Table 3 show that total (exercise and rest) EVRs are lower than exercise-only EVRs.

**Table 3. EVR Metrics Derived from All Clinical Studies in Table 1, during Intermittent Moderate Exercise**

|                    | Person-averaged EVRs (L/min-m <sup>2</sup> ) |                 |
|--------------------|--|-----------------|
|                    | Exercise Only                                | Exercise + Rest |
| Mean               | 20.39  | 17.32           |
| Standard Deviation | 1.65   | 1.25            |
| Lower Bound        | 15.44  | 13.57           |
| Upper Bound        | 25.34  | 21.08           |
| Median             | 20.35  | 17.31           |

Notes: EVR = equivalent ventilation rate; L/min-m<sup>2</sup> = liters per minute per square meter; lower bound = mean - 3 standard deviations; upper bound = mean + 3 standard deviations.

### 3.3. Parameters for Distribution Sampling

An alternative to setting **ModEVR8** to a single value is to allow it to be sampled from a distribution for each person. This introduces variability in **ModEVR8** and reflects the variability across individuals in  $V_e$ , and thus EVR, when performing moderate-exertion activities.

We modified the APEX code to allow for sampling **ModEVR8** from a distribution. The distribution parameters are specified in the modified physiology input file, where users can specify the distribution shape and corresponding parameters. For each profile, the APEX code samples **ModEVR8** from the distribution. EVR values at or above this sampled **ModEVR8** (but below **HeavyEVR8**) are classified as being at moderate exertion. The sampled **ModEVR8** values are then written to the *Profile Summary* output file.

## 4. Comparison of Approaches in Defining Moderate Exertion

### 4.1. APEX Runs

We conducted four APEX runs, listed in Table 4, to compare how different **ModEVR8** values (including dynamic sampling of values from a distribution) would affect the exposure outcomes. We used internal version APEX5.04, modified on December 20, 2018 to allow sampling of **ModEVR8** from a distribution. (A more updated version will be provided to the EPA WAM soon following this memorandum, containing additional model updates unrelated to EVR). The simulations were for the Los Angeles area, time period of January 1 to December 31, 2007, for 10,000 profiles, and for both children (ages 5 to 18 years) and total population (ages 5 years and up). We calculated the **ModEVR8** values listed in Table 4 from exercise-only data.

**Table 4. Model Runs**

| Run Name | ModEVR8 (L/min-m <sup>2</sup> ) | Comments  |
|----------|---------------------------------|---|
| EVR13    | 13                              | Original <b>ModEVR8</b> value, calculated as: <ul style="list-style-type: none"> <li>■ Three standard deviations below the mean (see shaded lower-bound value in Table 2)</li> <li>■ Using the OZI group of McDonnell et al. (1991) data</li> <li>■ From individual EVR data points (instead of person-averaged EVRs)</li> </ul>  |
| EVR16    | 15.4                            | Updated <b>ModEVR8</b> value, calculated as: <ul style="list-style-type: none"> <li>■ Three standard deviations below the mean (see lower-bound exercise-only value in Table 3)</li> <li>■ Using the data specified in Table 1</li> <li>■ From person-averaged EVRs (instead of individual EVR data points)</li> </ul>  |
| EVR_Med  | 20.4                            | Median value using person-averaged EVRs from the data specified in Table 1 (see median exercise-only value in Table 3)  |
| DIST20_1 | varies                          | <b>ModEVR8</b> sampled for each profile from a distribution. <ul style="list-style-type: none"> <li>■ Distribution parameters calculated using person-averaged EVRs from the data specified in Table 1</li> <li>■ Normal distribution; mean = 20.4; standard deviation = 1.7; upper truncation = 25.3; lower truncation = 15.4 (see exercise-only column in Table 3)</li> </ul> |

Notes: L/min-m<sup>2</sup> = liters per minute per square meter; EVR = equivalent ventilation rate; ModEVR8 = the model parameter for the threshold of moderate-exertion EVR for an 8-hour period.

## 4.2. Simulated Population Results

Across the test runs, for all profiles and children only, we compared the percent of the profiles reaching moderate exertion at least once and the person-day counts at moderate exertion. Results for both metrics and profile groups, presented in Table 5 to Table 8 and graphically in Figure 1 and Figure 2, show that as the **ModEVR8** value increases, the metrics decrease as expected (EVR13 > EVR15 > EVR\_Med).

**Table 5. Percent of Modeled Profiles Reaching Moderate Exertion (Ages 5 Years and Up)**

| Level (ppm) | Run Name (see Table 4) |       |         |          |
|-------------|------------------------|-------|---------|----------|
|             | EVR13                  | EVR15 | EVR_Med | DIST20_1 |
| 0           | 86.7                   | 66.3  | 18.5    | 20.8     |
| 0.01        | 84.8                   | 64.3  | 17.2    | 19.4     |
| 0.02        | 83.9                   | 63.3  | 16.3    | 18.5     |
| 0.03        | 82.2                   | 61.0  | 14.4    | 16.8     |
| 0.04        | 79.8                   | 57.3  | 12.1    | 14.3     |
| 0.05        | 76.3                   | 51.7  | 9.1     | 11.2     |
| 0.06        | 69.8                   | 43.2  | 6.0     | 7.9      |
| 0.07        | 57.3                   | 31.2  | 3.4     | 4.8      |
| 0.08        | 38.3                   | 18.4  | 1.5     | 2.1      |
| 0.09        | 18.3                   | 7.3   | 0.46    | 0.74     |
| 0.10        | 3.5                    | 1.3   | 0.04    | 0.06     |
| 0.11        | 0.36                   | 0.07  | 0       | 0        |
| 0.12        | 0                      | 0     | 0       | 0        |
| 0.13        | 0                      | 0     | 0       | 0        |
| 0.14        | 0                      | 0     | 0       | 0        |
| 0.15        | 0                      | 0     | 0       | 0        |
| 0.16        | 0                      | 0     | 0       | 0        |

Notes: ppm = parts per million.



Shading indicates relative magnitude of values (reds and oranges are higher values; yellows and greens are lower values).

**Table 6. Percent of Modeled Child Profiles (Ages 5 to 18 Years) Reaching Moderate Exertion**

| Level (ppm) | Run Name (see Table 4) |       |         |          |
|-------------|------------------------|-------|---------|----------|
|             | EVR13                  | EVR15 | EVR_Med | DIST20_1 |
| 0           | 99.4                   | 93.7  | 41.2    | 43.3     |
| 0.01        | 98.4                   | 90.7  | 37.1    | 39.2     |
| 0.02        | 98.2                   | 89.8  | 35.4    | 37.6     |
| 0.03        | 97.6                   | 88.0  | 31.2    | 33.7     |
| 0.04        | 97.1                   | 85.8  | 26.7    | 29.9     |
| 0.05        | 96.0                   | 82.1  | 20.8    | 24.7     |
| 0.06        | 93.4                   | 72.9  | 13.6    | 17.6     |
| 0.07        | 86.3                   | 59.4  | 8.3     | 11.2     |
| 0.08        | 65.7                   | 38.6  | 4.0     | 5.4      |
| 0.09        | 33.8                   | 17.2  | 1.3     | 2.1      |
| 0.10        | 5.8                    | 2.6   | 0       | 0.1      |
| 0.11        | 0.3                    | 0.1   | 0       | 0        |
| 0.12        | 0                      | 0     | 0       | 0        |
| 0.13        | 0                      | 0     | 0       | 0        |
| 0.14        | 0                      | 0     | 0       | 0        |
| 0.15        | 0                      | 0     | 0       | 0        |
| 0.16        | 0                      | 0     | 0       | 0        |

Notes: ppm = parts per million.

Shading indicates relative magnitude of values (reds and oranges are higher values; yellows and greens are lower values).



Notes: ppm = parts per million.

Legend entries are the run names specified in Table 4.

**Figure 1. Percent of Modeled Profiles Reaching Moderate Exertion for (a) All Profiles and (b) Children Only**

**Table 7. Number of Modeled Person-days Reaching Moderate Exertion (Ages 5 Years and Up)**

| Run Name (see |         |         |         |          |
|---------------|---------|---------|---------|----------|
| Table 4)      |         |         |         |          |
| Level (ppm)   | EVR13   | EVR15   | EVR_Med | DIST20_1 |
| 0             | 1.7E+06 | 7.4E+05 | 4.9E+04 | 8.1E+04  |
| 0.01          | 1.5E+06 | 6.5E+05 | 4.1E+04 | 6.9E+04  |
| 0.02          | 1.3E+06 | 5.3E+05 | 3.2E+04 | 5.4E+04  |
| 0.03          | 9.1E+05 | 3.6E+05 | 2.2E+04 | 3.6E+04  |
| 0.04          | 5.0E+05 | 1.9E+05 | 1.1E+04 | 1.8E+04  |
| 0.05          | 2.3E+05 | 8.6E+04 | 4.8E+03 | 8.0E+03  |
| 0.06          | 9.3E+04 | 3.4E+04 | 1.9E+03 | 3.2E+03  |
| 0.07          | 3.4E+04 | 1.3E+04 | 6.8E+02 | 1.1E+03  |
| 0.08          | 1.1E+04 | 3.9E+03 | 2.0E+02 | 3.2E+02  |
| 0.09          | 2.7E+03 | 9.6E+02 | 4.8E+01 | 8.7E+01  |
| 0.10          | 4.0E+02 | 1.3E+02 | 4.0E+00 | 6.0E+00  |
| 0.11          | 3.8E+01 | 8.0E+00 | 0       | 0        |
| 0.12          | 0       | 0       | 0       | 0        |
| 0.13          | 0       | 0       | 0       | 0        |
| 0.14          | 0       | 0       | 0       | 0        |
| 0.15          | 0       | 0       | 0       | 0        |
| 0.16          | 0       | 0       | 0       | 0        |

Notes: ppm = parts per million.

Shading indicates relative magnitude of values (reds and oranges are higher values; yellows and greens are lower values).


**Table 8. Number of Modeled Person-days Reaching Moderate Exertion (Ages 5 to 18 Years)**

| Run Name (see |         |         |         |          |
|---------------|---------|---------|---------|----------|
| Table 4)      |         |         |         |          |
| Level (ppm)   | EVR13   | EVR15   | EVR_Med | DIST20_1 |
| 0             | 6.4E+05 | 3.8E+05 | 3.4E+04 | 5.2E+04  |
| 0.01          | 5.8E+05 | 3.4E+05 | 2.8E+04 | 4.4E+04  |
| 0.02          | 4.9E+05 | 2.7E+05 | 2.1E+04 | 3.4E+04  |
| 0.03          | 3.7E+05 | 2.0E+05 | 1.4E+04 | 2.3E+04  |
| 0.04          | 2.1E+05 | 1.1E+05 | 7.1E+03 | 1.2E+04  |
| 0.05          | 1.0E+05 | 4.9E+04 | 3.1E+03 | 5.2E+03  |
| 0.06          | 4.3E+04 | 2.0E+04 | 1.2E+03 | 2.1E+03  |
| 0.07          | 1.6E+04 | 7.3E+03 | 4.4E+02 | 7.3E+02  |
| 0.08          | 5.0E+03 | 2.2E+03 | 1.2E+02 | 2.0E+02  |
| 0.09          | 1.2E+03 | 5.3E+02 | 2.9E+01 | 5.6E+01  |
| 0.10          | 1.4E+02 | 6.0E+01 | 0       | 2.0E+00  |
| 0.11          | 7.0E+00 | 4.0E+00 | 0       | 0        |
| 0.12          | 0       | 0       | 0       | 0        |
| 0.13          | 0       | 0       | 0       | 0        |
| 0.14          | 0       | 0       | 0       | 0        |
| 0.15          | 0       | 0       | 0       | 0        |
| 0.16          | 0       | 0       | 0       | 0        |

Notes: ppm = parts per million.

Shading indicates relative magnitude of values (reds and oranges are higher values; yellows and greens are lower values).





Notes: ppm = parts per million.

Legend entries are the run names specified in Table 4.

**Figure 2. Number of Modeled Person-days Reaching Moderate Exertion for (a) All Profiles and (b) Children Only**

The alternative method where one **ModEVR8** value per person is sampled from a distribution resulted in higher metrics as compared to setting the **ModEVR8** equal to the median of the distribution (DIST20\_1 > EVR\_Med). These results are expected because sampling from the distribution allows the selection of **ModEVR8** values lower than the median value. Lower **ModEVR8** values will result in more profiles reaching “moderate exertion” in the modeling. Specifically, for person-day counts, sampling **ModEVR8** from a distribution results in counts that are more than 50 percent greater than when **ModEVR8** is set to the median value. While the sampling also allows the selection of higher **ModEVR8** values (resulting in fewer profiles reaching “moderate exertion”), profiles reach lower EVRs much more commonly than higher EVRs, so much so that using lower **ModEVR8** values brings many more profiles into the “moderate exertion” pool than are excluded when higher **ModEVR8** values are used.

However, sampling from a distribution still gives metrics that are much lower than when setting the **ModEVR8** value to three standard deviations below the mean (DIST20\_1 < EVR15). As an example, for an exposure level of 0.05 parts per million, DIST20\_1 results in 40 percent fewer profiles overall reaching moderate exertion at least once (11.2 percent with DIST20\_1 versus 51.7 percent with EVR15), and 57 percent fewer children (82.1 percent with DIST20\_1 versus 24.7 percent with EVR15). When considering person-day counts, in general, DIST20\_1 counts were nearly an order of magnitude lower than EVR15 counts.

## 5. References

- Adams WC. (2006) Comparison of Chamber 6.6-h Exposures to 0.04–0.08 PPM Ozone via Square-wave and Triangular Profiles on Pulmonary Responses. *Inhal Toxicol* 18(2):127-136. DOI: <https://doi.org/10.1080/08958370500306107>.
- Aitken ML, Franklin JL, Pierson DJ, Schoene RB. (1986) Influence of Body Size and Gender on Control of Ventilation. *J Appl Physiol* 60(6): 1894-1899. DOI: <https://doi.org/10.1152/jappl.1986.60.6.1894>.
- Folinsbee LJ, McDonnell WF, Horstman DH. (1988) Pulmonary Function and Symptom Responses after 6.6-Hour Exposure to 0.12 ppm Ozone with Moderate Exercise. *JAPCA* 38(1):28-35. DOI: <https://doi.org/10.1080/08940630.1988.10466349>.
- Folinsbee LJ, Horstman DH, Kehrl HR, Harder S, Abdul-Salaam S, Ives PJ. (1994) Respiratory Responses to Repeated Prolonged Exposure to 0.12 ppm Ozone. *Am J Respir Crit Care Med* 149(1):98-105. DOI: <https://doi.org/10.1164/ajrccm.149.1.8111607>.
- Horstman DH, Folinsbee LJ, Ives PJ, Abdul-Salaam S, McDonnell WF. (1990) Ozone Concentration and Pulmonary Response Relationships for 6.6-Hour Exposures with Five Hours of Moderate Exercise to 0.08, 0.10, and 0.12 ppm. *Am Rev Respir Dis* 142(5):1158-1163. DOI: <https://doi.org/10.1164/ajrccm/142.5.1158>.
- Kim CS, Alexis NE, Rappold AG, Kehrl H, Hazucha MJ, Lay JC, Schmitt MT, Case M, Devlin RB, Peden DB, Diaz-Sanchez D. (2011) Lung Function and Inflammatory Responses in Healthy Young Adults Exposed to 0.06 ppm Ozone for 6.6 Hours. *Am J Respir Crit Care Med* 183(9):1215-1221. DOI: <https://doi.org/10.1164/rccm.201011-1813OC>.
- McDonnell WF, Kehrl HR, Abdul-Salaam S, Ives PJ, Folinsbee LJ, Devlin RB, O'Neil JJ, Horstman DH. (1991) Respiratory Response of Humans Exposed to Low Levels of

Ozone for 6.6 Hours. *Arch Environ Health* 46(3):145-150. DOI: <https://doi.org/10.1080/00039896.1991.9937441>.

Schelegle ES, Morales CA, Walby WF, Marion S, Allen RP. (2009) 6.6-Hour Inhalation of Ozone Concentrations from 60 to 87 Parts per Billion in Healthy Humans. *Am J Respir Crit Care Med* 180(3):265-272. DOI: <https://doi.org/10.1164/rccm.200809-1484OC>.

U.S. EPA, 2014. Health Risk and Exposure Assessment for Ozone: Final Report. Office of Air Quality Planning and Standards, U.S. Environmental Protection Agency, Research Triangle Park, NC, 27711. EPA-452/R-14-004a. August 2014. Available at: <https://www3.epa.gov/ttn/naaqs/standards/ozone/data/20140829healthrea.pdf>.

U.S. EPA, 2017a. Air Pollutants Exposure Model Documentation (APEX, Version 5) Volume I: User's Guide. Office of Air Quality Planning and Standards, U.S. Environmental Protection Agency, Research Triangle Park, NC, 27711. EPA-452/B-17-001a. January 2017. Available at: <https://www.epa.gov/fera/apex-user-guides>.

U.S. EPA, 2017b. Air Pollutants Exposure Model Documentation (APEX, Version 5) Volume II: Technical Support Document. Office of Air Quality Planning and Standards, U.S. Environmental Protection Agency, Research Triangle Park, NC, 27711. EPA-452/B-17-001b. January 2017. Available at: <https://www.epa.gov/fera/apex-user-guides>.

Whitfield RG, Biller WG, Jusko MJ, Keisler JM. (1996) A Probabilistic Assessment of Health Risks Associated with Short- and Long-Term Exposure to Tropospheric Ozone. Argonne, IL: Argonne National Laboratory.

**APPENDIX 3D, ATTACHMENT 3:**  
**ICF TECHNICAL MEMO: UPDATES TO THE METEOROLOGY DATA AND**  
**ACTIVITY LOCATIONS WITHIN CHAD**

# MEMORANDUM

**To:** John Langstaff and Stephen Graham, U.S. EPA-OAQPS

**From:** John Hader, Graham Glen, Caroline Foster, Samuel Kovach, Delaney Reilly, Chris Holder, River Williams, Anna Stamatogiannakis, and George Agyeman-Badu, ICF

**Date:** June 18, 2019

**Re:** Updates to the Meteorology Data and Activity Locations within CHAD

---

## 1. Introduction

In the November 1, 2016 version of CHAD, approximately 18 percent (32,723 out of 179,912) of diary-days are missing values for daily-maximum temperature (Tmax) and thus cannot be used by APEX. The temperature data currently in CHAD originate from a variety of sources, including from the original studies and from EPA or contractors who encoded the study data into CHAD. As discussed in Section 2, we used a methodical process to replace most of these missing values. As part of this exercise, for diary-days without county-location information, we identified county locations for over 10,000 diary-days based on respondent zip code and for over 6,000 diary-days based on the metropolitan locations of several of the studies. Some of the diary-days that received repaired county locations were not missing temperature data; nonetheless, we made the repairs as part of a “cleaning up” of the diary data. After this process, only 0.3 percent (565) of diary-days have missing values for Tmax and remain unusable by APEX.

In the same version of CHAD, six studies have at least 200 minutes per day (on average) of time spent in locations that are not sufficiently clear (they are ambiguous). Unspecified and missing location codes are ambiguous, as are those taking place at a residence or a place of employment without specifying whether they are in the three broad microenvironments (MEs) of indoors, outdoors, or in-vehicle. If studies have an apparent bias (via ambiguity) in time spent in the three broad MEs, then the APEX-modeled exposures will also be biased. As discussed in Section 3, we used paired activity-location information from the other 15 studies in CHAD to derive frequency distributions of location codes used per each activity code, with different distributions intended for reassigning unspecified/missing locations, ambiguous residential locations, and ambiguous workplace locations. For the six targeted studies, for a diary event with an ambiguous location code, we reassigned the location code based on the activity by sampling from these frequency distributions. After this process, the time spent per day in ambiguous locations dropped substantially for the six studies, though one study still had more than 200 minutes per day spent in ambiguous locations. These location-code reassignments will substantially reduce bias in APEX exposure estimates, particularly given that one of the six studies constitutes more than half of all CHAD diary-days.

These modifications do not impact the official EPA CHAD-Master database, which remains unchanged. Instead, the modifications are specific to the version of the diary data used for APEX modeling.

## 2. Temperature Data

### 2.1. Overview and Objectives

The current CHAD questionnaire file includes Tmax and daily-average temperature (Tavg; °F) as well as daily precipitation (inches) and daily number of hours with precipitation. Only Tmax is typically used by APEX modelers, and it is used to help select a set of diaries that have similar temperature values as those experienced by a simulated profile at his/her location on a given modeling day. Diary-days without values for Tmax cannot be selected for use by any simulated profile.

As shown in Table 2-1, approximately 18 percent of diary-days are currently unusable by APEX on the basis of missing Tmax. Less than 1 percent of those are missing all indicators of respondent location (state, county, and zip code) and are not from studies of a single metropolitan area; it will not be possible to identify reasonable temperature data for those diary-days. Most of the remaining diary-days have only state information (no information on county or zip code).

**Table 2-1. Information on Diary-days Missing Daily-maximum Temperature Values**

|              |  | Count  | Percent of All Diary-Days | Percent of Diary-days Missing Tmax |
|--------------|--|--------|---------------------------|------------------------------------|
| Missing Tmax |  | 32,723 | 18%                       | 100%                               |
| →            | From the 1980s   | 14     | 0.008%                    | 0.04%                              |
|              | From the 1990s   | 1,230  | 0.7%                      | 4%                                 |
|              | From the 2000s   | 25,512 | 14%                       | 78%                                |
|              | From the 2010s   | 5,967  | 3%                        | 18%                                |
|              | Missing All Location Information (state, county, zip code; is not a single-metropolitan study) | 111    | 0.06%                     | 0.3%                               |
|              | Is a Study of a Single Metropolitan Area   | 0      | 0%                        | 0%                                 |
|              | Has State Location but not County (and is not a single-metropolitan study)                     | 30,895 | 17%                       | 94%                                |
| →            | Has Zip Code   | 30     | 0.02%                     | 0.09%                              |

Notes: Studies limited to one metropolitan area were put into CHAD without county or zip-code information.

Tmax = daily-maximum temperature

The objective of this task is to use historical meteorological records to identify reasonable temperature values for diary-days currently missing those values. Identifying these values relies on knowing or estimating the geographic location of each diary-day. Since most of the target diary-days identify the respondent's state but not county or zip code, in most cases we have made assumptions about respondent locations within the state.

A structured methodology of identifying appropriate temperature data allows us to identify reasonable temperature values for nearly all diary-days, not just those currently missing temperature data. While we will generally not update temperature data in CHAD that are not already missing (unless we believe the current values are erroneous), we can compare current and "new" temperatures as part of quality control (QC). With this in mind, as detailed in Section 2.2, we developed a hierarchy to assign a county location to nearly all diary-days. Then, as detailed in Section 2.3, we matched county locations to the five closest meteorological stations from the historical records, thus enabling the assignment of temperature values.

## 2.2. Assigning County Locations to Diary-days

Matching diary-days with nearby meteorological stations requires knowing (or estimating) where the diary-days took place. County is the primary indicator of diary location, though zip codes are also available for some diaries, and assigning temperature data on a county basis is reasonable given the typical spatial resolution of counties and typical temperature gradients.

About 43 percent (77,811) of all diary-days already had county designations. For these diary-days, we “cleaned up” the county names to be more consistent with the names provided by the U.S. Census Bureau. While the county and state locations of diary-days are not used in APEX, creating consistent location designations (and use of the more reliable state-county FIPS designations) made the temperature-assignment process more reliable.

The remaining 57 percent (102,101) of all diary-days had no county locations. As indicated in Table 2-2, 111 had no location information at all and they were not from studies located in a single metropolitan area. We could not assign counties to these 111 diary-days, and thus we could not replace missing temperature data if needed.

**Table 2-2. Information on Diary-days Without County Designations**

|  |              | How County Locations Were Determined<br>(showing counts of diary-days) |                                  |                                   |          |  |
|--|--------------|--|----------------------------------|-----------------------------------|----------|--|
|  |              | Count  | Percent of<br>All Diary-<br>Days | Metropolitan<br>Study<br>Location | Zip Code | State's Population<br>Distribution   |
| Missing All Location Information<br>(state, county, zip code; is not a<br>single-metropolitan study) |              | 111  | 0.06%                            | 0                                 | 0        | 0  |
| Is a Study of a Single Metropolitan<br>Area  |              | 6,150  | 2%                               | 6,150                             | 0        | 0  |
| Has State Location but not County<br>(and is not a single-metropolitan<br>study)                     |              | 95,840   | 55%                              | 0                                 | 0        | 84,141<br>(14 from 1980s;<br>6,139 from 1990s;<br>64,046 from 2000s;<br>13,942 from 2010s) |
| →  | Has Zip Code | 11,699   | 7%                               | 0                                 | 11,635   | 64<br>(1 from 1980s;<br>62 from 1990s;<br>1 from 2000s;<br>0 from 2010s)                   |

Note: Studies limited to one metropolitan area were put into CHAD without county or zip-code information.

For the other 101,990 diary-days without county designations, a small amount (6,150) were from studies located within a single metropolitan area. Diary-days from these studies were originally put into CHAD without county or zip-code information. We made the assumption that all such respondents lived in the primary county associated with the area, as listed below.



- Hamilton County, Ohio for the Cincinnati Activity Patterns Study (CIN)
- Wayne County, Michigan for the Detroit Exposure and Aerosol Research Study (DEA)
- Denver County, Colorado for the Denver, Colorado Personal Exposure Study (DEN)
- King County, Washington for the Seattle Study (SEA)
- District of Columbia for the Washington, DC Study (WAS)

Additionally, a small amount (11,635) of diary-days without county designations had reliable zip codes that we geocoded to their most likely counties, following the process listed below. Note that we used geospatial files representing the year 2000 because most of the CHAD diary-days (129,569 diary-days, which is 72 percent of all diary-days) were from the 2000s, and county boundaries have remained unchanged through the last few decades for nearly all U.S. counties.

- Use GIS software to convert the year-2000 county polygons<sup>1</sup> to centroid points (one centroid per county).
- Use GIS software to identify the county centroid (year 2000) closest to each zip-code centroid (also year 2000; from the zip-code tabulation areas file.<sup>2</sup> These centroid-proximity matches were restricted to within the same state (e.g., a zip-code centroid located in California could only be matched to a county in California).
- A small number of zip codes (145) could not be identified in the Gazetteer files. We identified the county locations of 85 such zip codes with reasonable confidence using Internet searches, leaving 60 zip codes unmatched to counties.

For the remaining 84,205 diary-days without county designations (which includes 64 diary-days that could not be reliably matched to counties via zip code), we assigned them to counties within the state based on population distributions. We used U.S. Census data to calculate the population distributions within each state. Since such distributions change over time, we did this on a decadal basis, covering the decades represented by the CHAD diary-days (the 1980s through 2010s), as indicated below. The majority of such population-based assignments were for diary-days in the 2000s decade (as indicated in Table 2-2).

- **2000s and 2010s:** We queried decadal census data from the U.S. Census Bureau (filtering by Population Total, the 2010 or 2000 year, and All Counties within United States).<sup>3</sup> The SF1 100% datasets were employed.
- **1980s and 1990s:** We used intercensal data from the U.S. Census Bureau's State and County Intercensal Datasets websites for 1980 to 1989 and 1990 to 1999.<sup>4</sup> The county

---

<sup>1</sup> From the U.S. Census cartographic boundary files available at <https://www.census.gov/geographies/mapping-files/time-series/geo/cartographic-boundary-file.2000.html>.

<sup>2</sup> From the U.S. Census Gazetteer files available at <https://www.census.gov/geographies/reference-files/time-series/geo/gazetteer-files.2000.html>.

<sup>3</sup> The American FactFinder website, used at the time of these analyses were performed, has been decommissioned as of March 30, 2020. Similar data queries can be made at <https://data.census.gov/cedsci/>.

<sup>4</sup> Data available at <https://www.census.gov/data/tables/time-series/demo/popest/1980s-county.html> and <https://www.census.gov/data/datasets/time-series/demo/popest/intercensal-1990-2000-state-and-county-characteristics.html>.



populations were partitioned by demographics, which we aggregated to county-total population values.

## 2.3. Assigning Temperature Data to Diary-days

The National Centers for Environmental Information (NCEI) distributes several databases of land-based meteorology station data. We utilized the Global Historical Climatology Network–Daily (GHCND), as it provided QCed daily temperature data at a relatively high spatial resolution across the U.S.<sup>5</sup> We narrowed the GHCND database based on the criteria listed below.

- Stations must be located 24–50° N and 126–66° W (for contiguous U.S.), 51–72° N and 179.999–129° W (for Alaska; we did not use any stations in the far-western Aleutian Islands), and 18.5–22.5° N and 160.5–154.5° W (for Hawaii). Note that these boundaries may extend somewhat into neighboring countries.
- Stations must include Tmax and daily-minimum temperature (Tmin) as typically reported parameters (requiring Tavg was too restrictive; we elected to calculate Tavg as the average of Tmax and Tmin).
- On a decadal basis, stations must report data for the entirety of that decade (or for 2010–2014 for the 2010s).

Some of the GHCND stations were of ‘higher quality’ than others, as they are part of the U.S. Historical Climatology Network (HCN), the U.S. Climate Reference Network (CRN) and/or the Global Climate Observing System Surface Network (GSN). We preferred data from these stations in our temperature assignments.


In Table 2-3, we indicate the number of meteorological stations per decade, including the number of higher-quality stations, that meet all the selection criteria listed above. In Figure 2-1 and Figure 2-2, for the 1980s and 2010s respectively, we show examples of the geographic spread of meteorology stations (with higher-quality stations differentiated) in North and South Carolina.

**Table 2-3. Number of GHCND Meteorological Stations Meeting Selection Criteria, per Decade and U.S. Region**


| Year | Number of Meteorological Station Counts (higher-quality Stations) <sup>a</sup> |          |        |
|------|--|----------|--------|
|      | Contiguous U.S.  | Alaska   | Hawaii |
| 1980 | 6,621 (1,225)  | 230 (19) | 54 (2) |
| 1990 | 7,207 (1,233)  | 251 (19) | 56 (2) |
| 2000 | 7,813 (1,151)  | 341 (21) | 72 (2) |
| 2010 | 8,445 (1,210)  | 388 (29) | 85 (4) |

<sup>a</sup> Note that a small number of stations included here may be across the U.S. border in other countries.

<sup>5</sup> <https://www.ncdc.noaa.gov/data-access/land-based-station-data/land-based-datasets>.



**Figure 2-1. GHCND Meteorological Stations from the 1980s Meeting Selection Criteria, in the North and South Carolina Region**



**Figure 2-2. GHCND Meteorological Stations from the 2010s Meeting Selection Criteria, in the North and South Carolina Region**

By decade (with county locations fixed at the year-2000 definitions), we used ArcMap's "Generate Near Table" tool to map each U.S. county to its five closest meteorological stations from the GHCND dataset. The stations were initially sorted by closest proximity to the county centroid. Then, we resorted the matches to ensure that the closest higher-quality within 30 miles of the county centroid was the preferred station of the five stations.

The median distance from county centroid to the preferred meteorological station was 19 km—only in Alaska were some county centroids more than 100 km from the preferred station, and a few counties in Arizona, California, Nevada, and Texas were 50–70 km from the preferred station. The median distance from county centroid to the fifth selected station was 42 km.

Based on the county location and decade of the diary-day, and the five meteorological stations selected for that county and decade, we identified Tmax and Tmin from the preferred station. If the preferred station's Tmax and Tmin values were missing, then we used the values from the second station, and so on until we identified non-missing values. If none of the five stations supplied non-missing Tmax and Tmin values, then the values were left missing.

Using the method above, 178,893 diary-days (> 99 percent) were matched with new Tmax and Tavg values, leaving 1,019 diary-days (0.6 percent) without matched values. As a QC check, we compared the newly matched temperature values ("new" temperatures) to the existing temperature values where available ("old" temperatures). Using Tmax, there were 146,735 diary-days (82 percent) available for comparison. In Table 2-4, we indicate how many diary-days were negligibly different ( $\leq 5^\circ$ ),  $5\text{--}10^\circ$  different,  $10\text{--}20^\circ$  different, or  $> 20^\circ$  different.



**Table 2-4. Comparison of Old (in Current CHAD-Master) and New (Identified Here) Daily-maximum Temperatures**

| Difference between Old Tmax and New Tmax | Number of Diary-days | Percent of Diary-days Available for Comparison |
|--|----------------------|--|
| ≤ 5 °F                                   | 101,507              | 69.2%  |
| 5–10 °F                                  | 24,604               | 16.8%  |
| 10–20 °F                                 | 16,032               | 10.9%  |
| > 20 °F                                  | 4,592                | 3.1%   |

During this QC check, we further examined the 4,592 diary-days (3 percent) where the Tmax values were > 20° different. During this step, we discovered that most of these diary-days were from the American Time Use Survey by the Bureau of Labor Statistics (BLS). In 2,431 of the 4,592 diary-days with differences over 20°, they were from the BLS study *and* the old Tmax was equivalent to the old Tavg. This indicated a systematic error in the old BLS temperatures.

Using a similar approach, we compared the old and new Tavg values. The results are indicated in Table 2-5. The results comparing the old and new Tavg values were similar to those for Tmax.

**Table 2-5. Comparison of Old and New Average Temperatures**

| Difference between Old Tmax and New Tmax | Number of Diary-days | Percent of Diary-days Available for Comparison |
|--|----------------------|--|
| ≤ 5 °F                                   | 109,632              | 74.7%  |
| 5–10 °F                                  | 24,430               | 16.6%  |
| 10–20 °F                                 | 10,271               | 7.0%   |
| > 20 °F                                  | 2,363                | 1.6%   |

We further examined the 2,363 diary-days (1.3%) where differences in Tavg values were > 20°. For 1,569 of these diary-days, they were from the BLS study *and* the old Tavg was equivalent to the old Tmax, again indicating a systematic error in the old BLS temperatures.

As an additional check, we examined the mean Tmax and mean Tavg across all diary-days. The mean Tmax and mean Tavg for the old values were 68.0° and 58.4°, respectively. For the new data, the mean Tmax and mean Tavg were 68.4° and 57.8° respectively. The consistency between the two was expected and provides additional assurance.

At the direction of EPA, and given the errors found in the temperatures of the BLS study, we developed a diary dataset using a combination of the old and new temperatures. To create this dataset, we replaced all the old temperatures (maximum and average) of the BLS diary-days. Next, we replaced all previously missing values where new values were available (across all studies). Following these rules, we replaced values for 125,581 diary-days, such that the new diary dataset now has Tmax and Tavg values for 179,347 diary-days. Temperatures remain missing for 565 diary-days, while 53,766 diary-days retained their old temperatures.

In addition to the new temperature data, we updated the dataset with information that was used as intermediate to this process, with fields indicated in Table 2-6.

**Table 2-6. Updated or Added Fields in the CHAD Dataset**

| Field Name | Description  |
|------------|--|
| county     | Values updated to include newly georeferenced data       |
| state      | Values updated to include newly georeferenced data       |
| FIPS       | Field added to provide a unique ID to every state-county |

| Field Name           | Description   |
|----------------------|---|
| old_avgtemp          | Field renamed to identify the temperatures (°F) in the November 2016 CHAD   |
| old_maxtemp          | Field renamed to identify the temperatures (°F) in the November 2016 CHAD   |
| FIPSfromZip          | Field added: TRUE or FALSE—if the county originally was missing, did we identify by zip code?   |
| FIPSfromStudy        | Field added: TRUE or FALSE—if the county originally was missing, did we identify by study location?   |
| FIPSfromCountyRandom | Field added: TRUE or FALSE—if the county originally was missing, did we identify by county population distributions in the state?   |
| new_avgtemp          | Field added to provide new temperatures (°F) queried in this task   |
| new_maxtemp          | Field added to provide new temperatures (°F) queried in this task   |
| ReplacedMaxTemp      | Field added to provide the final temperatures (°F) to use in future applications (either the old or new value, depending on the study and other criteria as discussed in this memorandum) |
| ReplacedAvgTemp      | Field added to provide the final temperatures (°F) to use in future applications (either the old or new value, depending on the study and other criteria as discussed in this memorandum) |

## 3. CHAD Activity Locations

### 3.1. Introduction

Each diary-day reports a series of “events” covering 24 hours. Event durations vary, but each event has one location code and one activity code. To use diaries in APEX, the location codes are mapped to APEX MEs, each of which has a method for determining its air quality. While the number of MEs is flexible, generally all APEX runs distinguish between time spent in three basic MEs: indoor, outdoor, and in-vehicle. Yet six of the location codes are ambiguous, even at that coarse level of defining MEs (i.e., they do not distinguish between the three basic MEs). CHAD is composed of 21 originally separate studies, and some of these studies use these ambiguous codes, but others do not.

These six ambiguous location codes are shown below, and in Table 3-1 we show the average amount of time spent in ambiguous locations (by study).

- Residential:
  - ◆ 30000 (Residence, general)
  - ◆ 30010 (Your residence)
  - ◆ 30020 (Other’s residence)
- Workplace:
  - ◆ 33400 (At work: no specific location, moving among locations)

- Unknown:
  - ◆ U (Uncertain)
  - ◆ X (Missing)

**Table 3-1. Average Amount of Ambiguous Time by Study**

| Study   | Average Ambiguous Time<br>(minutes per day) |
|---|---|
| BAL: Baltimore Retirement Home Study                                    | 3   |
| <b>BLS: American Time Use Survey (ATUS), Bureau of Labor Statistics</b> | <b>498</b>                                  |
| CAA: California Adults Activity Pattern Studies                         | 67  |
| CAC: California Children Activity Pattern Studies                       | 0   |
| CAY: California Youth Activity Pattern Studies                          | 101   |
| CIN: Cincinnati Activity Patterns Study                                 | 2   |
| <b>DEA: Detroit Exposure and Aerosol Research Study</b>                 | <b>1,186</b>                                |
| DEN: Denver, Colorado Personal Exposure Study                           | 16  |
| <b>EPA: EPA Longitudinal Studies</b>                                    | <b>333</b>                                  |
| ISR: Population Study of Income Dynamics I, II, III                     | 58  |
| LAE: Los Angeles Ozone Exposure Study: Elementary School                | 34  |
| LAH: Los Angeles Ozone Exposure Study: High School                      | 2   |
| NHA: National Human Activity Pattern Study: Air                         | 18  |
| NHW: National Human Activity Pattern Study: Water                       | 18  |
| NSA: National-scale Activity Study                                      | 154   |
| OAB: RTI Ozone Averting Behavior Stud                                   | 121   |
| <b>RTP: RTP Particulate Matter Panel Study</b>                          | <b>1,081</b>                                |
| <b>SEA: Seattle Study</b>   | <b>1,205</b>                                |
| <b>SUP: Study of Use of Products and Exposure-related Behaviors</b>     | <b>804</b>                                  |
| VAL: Valdez Air Health Study  | 2   |
| WAS: Washington, DC Study   | 16  |

Note: Bolded studies have relatively large average amounts of ambiguous time.

APEX assigns MEs based only on the location code (not the activity code), and furthermore, APEX uses a deterministic mapping (that is, the same location code maps to the same ME throughout that APEX run). But this rule may lead to an unavoidable bias if applied to certain diary studies. We examined the CHAD activity code that is paired with each location code (on the event level), to determine the likely place of occurrence of each event. Since this is not always a certainty, part of this exercise is to probabilistically assign specific locations to events with ambiguous location codes, based on the paired activity.

## 3.2. Methods

The starting point is the November 2016 version of CHAD. It has 179,912 diary-days. Two of those (EPA002171 and EPA002172) have been deleted because they each contained 24 hours of missing data.

For our purposes, we divided all location codes into six general MEs and temporarily related them to the location codes shown as shown below, which are unambiguous. The codes are typical examples of the categories shown. For example, 31110 is a car; while not all vehicular travel is in a car, it is reasonable that the air quality in a car would be similar to that found in other types of vehicles.

- IH (indoors at a residence) → Code 30120 (Your residence, indoor)

- IO (indoors elsewhere) → Code 32000 (Other, indoor general)
- OH (outdoors at a residence) → Code 30200 (Residence, outdoor)
- OV (outdoors near traffic) → Code 35200 (Public garage / parking lot)
- O (outdoors elsewhere) → Code 35000 (Other outdoor, general)
- V (in an enclosed vehicle) → Code 31110 (Motorized travel by car)

The six ambiguous location codes had more than one mapping option for a location category, as shown below. They were reassigned location codes based on activity (and occupation where applicable), as discussed later.

- Codes 30000 (residence, general), 30010 (your residence), 30020 (other's residence)
  - ◆ Could be either IH or OH; occasionally V or OV
- Code 33400 (at work; no specific location, moving among locations)
  - ◆ Could be any, but depends on occupation
    - Occupation TRANS (transportation and material moving)
      - V (specifically 31120, travel by truck)
    - Occupation FARM (farming, forestry, and fishing)
      - O
    - Occupation HSHLD (private household)
      - IH
    - Activity code  $\geq 18000$  (travel)
      - V
    - Activity codes 17700–17823 (active-leisure activities; exercise activities)
      - OV
    - All others
      - IO
- Codes U (uncertain), X (missing)
  - ◆ Could be any

For analysis purposes, we divided CHAD into two parts. The “bad” part consisted of the six studies with at least 200 minutes per day on average spent in ambiguous locations (see Table 3-1; the studies were BLS, DEA, EPA [EPA Longitudinal Studies], RTP [RTP Particulate Matter Panel Study], SEA, and SUP [Study of Use of Products and Exposure-related Behaviors]). The “good” part consisted of the 15 studies with an average of fewer than 200 minutes per day of ambiguous time.

For the purposes of replacing location codes U and X in the “bad” part of CHAD, we analyzed the “good” part to determine the time fractions in each of the six location categories for each activity code (except activity codes U and X). We excluded any time in ambiguous locations. For example, the “eating” code (14400) divided as IH = 76 percent, IO = 21 percent, OH = 2 percent, O = 1 percent, and OV and V = less than 1 percent. A few activity codes did not have examples in the “good” part of CHAD, and so we mapped them to similar activities. These cases occurred extremely rarely in the “bad” part of CHAD, as well. The number of such cases increased if we stratified CHAD by age group, and for most activities the allocation to the six location categories was not very different between age groups. Therefore, we did not treat age groups separately. We linked the time-fraction distributions to the activities in the six studies in the “bad” part of CHAD. We reassigned U and X locations by activity (excluding activity codes U and X), following these distributions from the “good” part of CHAD.

For the purposes of replacing ambiguous residential location codes (30000 – Residence, general; 30010 – Your residence; and 30020 – Other’s residence), we made separate time-fraction determinations (also from the “good” part of CHAD) where we generally restricted time to three categories: IH, OH, and OV. We used the last of these (OV) for time in the garage or working on cars. We made an exception for selected travel activity codes over 18000, which indicate that the person was in a vehicle. For example, we assigned 18031 (drive a motor vehicle) and similar codes to V. We linked these refined time-fraction determinations to the activities in the six studies in the “bad” part of CHAD, for all events with location codes 30000, 30010, or 30020. We reassigned these locations by activity (for activities other than U and X), following these distributions of time spent. We made an exception for the DEA study, where it was clear that the residential codes up to 30020 were used only for indoor events. Note the before the location reassignments, the DEA study averaged 83 minutes in OH locations but only 29 minutes in IH locations.

In many cases, the same diary had the same activity code for several consecutive events with ambiguous location codes. For example, the person might be sleeping for several hours, but the location is not clear. It would not make sense for them to be relocated part way through, so for such consecutive events we determined the reassignment (from the activity’s distribution across the six location categories) only for the first of such events, and then subsequent events received the same new location reassignment.

### 3.3. Discussion

As shown in Table 3-2, five of the six studies where we reassigned location codes now have fewer than 200 minutes per day of ambiguous location time. The exception is the SUP study, in which most diaries were shorter than 24 hours and were padded with missing activities and locations to fill out the day. Many of the SUP diaries were previously rejected by APEX, and might continue to be, but most of the other diaries will now be acceptable. In particular, the BLS diaries constitute more than half of CHAD, and they have gone from 498 ambiguous minutes to just 10 such minutes per diary-day.



**Table 3-2. Minutes per Day in the Six Location Categories, Before (“Old”) and After (“New”) Location Reassignments, For the Six Studies With 200 Minutes per Day or More of Time Spent in Ambiguous Locations**

| Location Category | BLS        |           | DEA          |             | EPA        |            | RTP          |            | SEA          |           | SUP        |            |
|-------------------|------------|-----------|--------------|-------------|------------|------------|--------------|------------|--------------|-----------|------------|------------|
|                   | Old        | New       | Old          | New         | Old        | New        | Old          | New        | Old          | New       | Old        | New        |
| IH                | 754        | 1,049     | 29           | 1,157       | 677        | 903        | 90           | 973        | 0.04         | 1,121     | 327        | 787        |
| IO                | 79         | 228       | 48           | 95          | 246        | 346        | 131          | 170        | 139          | 145       | 175        | 176        |
| OH                | 22         | 47        | 83           | 83          | 50         | 55         | 36           | 77         | 16           | 73        | 22         | 47         |
| O                 | 17         | 23        | 19           | 19          | 23         | 23         | 17           | 17         | 24           | 25        | 45         | 45         |
| OV                | 0.3        | 1.7       | 3.3          | 3.4         | 24         | 24         | 5.8          | 6.8        | 1.0          | 2.1       | 5.0        | 5.1        |
| V                 | 70         | 81        | 72           | 72          | 87         | 87         | 80           | 80         | 54           | 54        | 61         | 61         |
| <b>Ambiguous</b>  | <b>498</b> | <b>10</b> | <b>1,186</b> | <b>10.3</b> | <b>333</b> | <b>2.4</b> | <b>1,081</b> | <b>116</b> | <b>1,205</b> | <b>21</b> | <b>804</b> | <b>317</b> |
| Indoor Total      | 833        | 1,277     | 78           | 1,252       | 923        | 1,249      | 220          | 1,143      | 139          | 1,265     | 503        | 963        |
| Outdoor Total     | 39         | 72        | 105          | 106         | 96         | 102        | 59           | 101        | 41           | 99        | 72         | 98         |


Several questions remained, as listed below. We discussed these questions with EPA in May 2019, with decisions noted below.

1. Should the “good” part of CHAD be defined differently?
  - a. No, keep it as-is.
2. Should other location codes be deemed ambiguous?
  - a. Not at this time.
3. Should this method be applied to the ambiguous events in “good” CHAD?
  - a. No.

The last question is perhaps the most important. The CAY, NSA, and OAB studies average over 100 minutes of ambiguous time per diary, which is significant. The same method could be applied there, and might significantly reduce the ambiguous time in those studies. One reason not to apply this method is that the time percentages would then be applied to some of the same studies used to derive the percentages, and this presents the appearance of circular reasoning. It is not exactly circular because we excluded ambiguous time when deriving the percentages, but even so, there may be a correlation between the choice of location code and choice of activity code within a single study. For example, there may be a reason particular to the given study for why some eating events were assigned specific location codes, and others were assigned location X. Hence, it is not clear whether general percentages for all eating events should apply to those (relatively few) coded with location X. This is less of a concern when most or all eating events are paired with location X.

## 4. Diagram of Processing

In Figure 4-1, we indicate the input and output files for the temperature and location-code updates discussed above, as well as the processing programs and ancillary files. We briefly discuss these files and programs below the figure.



**Figure 4-1. Files and Processing Programs Used in this Task**

Both the temperature and location-code tasks began with the November 2016 version of the CHAD-master files (*quest\_110116.sas7bdat* and *events\_110116.sas7bdat*), which we converted to text or CSV files (*Current\_CHAD.csv* for the questionnaire file; *Events\_2016.txt* for the events file) for easier processing in R programs.

We used four different R scripts to modify temperatures and county designations in the questionnaire file. *County\_pop\_met\_station\_processor.R* reformatted GIS data, outputting the

ranking of up to five meteorology stations for every county, by decade and reorganized based on distance and station quality. *CHAD\_County\_assignments.R* filled in missing location data, based on zip code, study, and random assignment based on population density.

*ChadCode\_MetAssignment\_Top5.R* combined the outputs of the previous two scripts to assign temperatures (and other intermediate details) the questionnaire file. *CHAD\_PostProcessing.R* cleaned the data of unnecessary fields and reformatted the data for processing back into a SAS dataset. The resulting updated questionnaire file was

*Final\_CHAD\_WithTemp\_Final\_Replaced.csv*.

The location-code reassignments were made by *New\_locs\_5.R* (where 5 is the version number of the script). The output events file was *chad\_new2.csv*.

The new questionnaire and events files were not directly suitable as input to APEX because they contains extra variables, including both the old and new location codes, details about county reassignments and meteorological stations, etc. The program *Chad2019a.sas* converted the files to SAS format and utilized field names conforming to those of CHAD-Master, producing *quest\_new\_060419.sas7bdat* and *events\_new\_060419.sas7bdat*.

Finally, the EPA WAM's program (*WriteApexChadFiles.sas*) processed the above-mentioned SAS datasets in various ways, most importantly producing the APEX-ready diary files (*quest\_new\_060419A.txt* and *events\_new\_060419A.txt*).

**APPENDIX 3D, ATTACHMENT 4:  
DETAILED EXPOSURE AND RISK RESULTS**

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Atlanta    | S65         | 2015 | 0               | 782548  | 702709   | 652006   | 613670   | 581448   | 553463   |
| All Children | Atlanta    | S65         | 2015 | 10              | 737635  | 650392   | 594402   | 553161   | 518598   | 488576   |
| All Children | Atlanta    | S65         | 2015 | 20              | 638508  | 531491   | 470336   | 424273   | 390699   | 360596   |
| All Children | Atlanta    | S65         | 2015 | 30              | 498684  | 383940   | 321655   | 279970   | 246820   | 222104   |
| All Children | Atlanta    | S65         | 2015 | 40              | 321736  | 210321   | 154209   | 118800   | 93619    | 74875    |
| All Children | Atlanta    | S65         | 2015 | 50              | 110083  | 37448    | 14991    | 6335     | 2805     | 1352     |
| All Children | Atlanta    | S65         | 2015 | 60              | 11501   | 585      | 101      | 20       | 0        | 0        |
| All Children | Atlanta    | S65         | 2015 | 70              | 424   | 20       | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2016 | 0               | 790356  | 714553   | 665988   | 626301   | 592142   | 564218   |
| All Children | Atlanta    | S65         | 2016 | 10              | 752243  | 669035   | 614820   | 572006   | 537181   | 508631   |
| All Children | Atlanta    | S65         | 2016 | 20              | 662941  | 562038   | 500480   | 454800   | 419047   | 390195   |
| All Children | Atlanta    | S65         | 2016 | 30              | 534497  | 422316   | 358800   | 315319   | 284086   | 259612   |
| All Children | Atlanta    | S65         | 2016 | 40              | 357993  | 246719   | 191476   | 156167   | 129352   | 107985   |
| All Children | Atlanta    | S65         | 2016 | 50              | 139824  | 55465    | 25887    | 13720    | 6981     | 3773     |
| All Children | Atlanta    | S65         | 2016 | 60              | 21165   | 1917     | 202      | 61       | 0        | 0        |
| All Children | Atlanta    | S65         | 2016 | 70              | 1473  | 20       | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2016 | 80              | 81  | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2017 | 0               | 787491  | 708984   | 655456   | 615486   | 582962   | 554835   |
| All Children | Atlanta    | S65         | 2017 | 10              | 743406  | 655093   | 596157   | 553746   | 519042   | 489362   |
| All Children | Atlanta    | S65         | 2017 | 20              | 640061  | 533004   | 470074   | 424596   | 389488   | 360696   |
| All Children | Atlanta    | S65         | 2017 | 30              | 493943  | 379743   | 317155   | 274704   | 244822   | 220005   |
| All Children | Atlanta    | S65         | 2017 | 40              | 295708  | 189377   | 137604   | 105160   | 82462    | 64767    |
| All Children | Atlanta    | S65         | 2017 | 50              | 70477   | 18744    | 6638     | 2320     | 868      | 504      |
| All Children | Atlanta    | S65         | 2017 | 60              | 3955  | 40       | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2017 | 70              | 40  | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2015 | 0               | 782548  | 702709   | 652006   | 613670   | 581448   | 553463   |
| All Children | Atlanta    | S70         | 2015 | 10              | 741489  | 655557   | 599325   | 558225   | 524187   | 494528   |
| All Children | Atlanta    | S70         | 2015 | 20              | 653358  | 549630   | 486417   | 441806   | 406941   | 376999   |
| All Children | Atlanta    | S70         | 2015 | 30              | 530462  | 416666   | 353433   | 311526   | 277266   | 250391   |
| All Children | Atlanta    | S70         | 2015 | 40              | 382185  | 267884   | 208121   | 169826   | 141680   | 119163   |
| All Children | Atlanta    | S70         | 2015 | 50              | 191173  | 94729    | 54598    | 32787    | 19470    | 11985    |
| All Children | Atlanta    | S70         | 2015 | 60              | 38981   | 6618     | 1493     | 363      | 81       | 20       |
| All Children | Atlanta    | S70         | 2015 | 70              | 4580  | 182      | 20       | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2015 | 80              | 182   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Atlanta    | S70         | 2016 | 0               | 790356  | 714553   | 665988   | 626301   | 592142   | 564218   |
| All Children | Atlanta    | S70         | 2016 | 10              | 755774  | 673776   | 620167   | 577675   | 543436   | 513857   |
| All Children | Atlanta    | S70         | 2016 | 20              | 676823  | 578381   | 517468   | 472071   | 435531   | 407264   |
| All Children | Atlanta    | S70         | 2016 | 30              | 564036  | 453105   | 391244   | 346311   | 313302   | 286891   |
| All Children | Atlanta    | S70         | 2016 | 40              | 415839  | 301135   | 242926   | 204631   | 177513   | 153927   |
| All Children | Atlanta    | S70         | 2016 | 50              | 226825  | 124368   | 77559    | 51148    | 35349    | 24131    |
| All Children | Atlanta    | S70         | 2016 | 60              | 63455   | 13801    | 3914     | 1190     | 343      | 101      |
| All Children | Atlanta    | S70         | 2016 | 70              | 9947  | 282      | 20       | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2016 | 80              | 1211  | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2016 | 90              | 121   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2017 | 0               | 787491  | 708984   | 655456   | 615486   | 582962   | 554835   |
| All Children | Atlanta    | S70         | 2017 | 10              | 747340  | 660036   | 602573   | 559436   | 524914   | 495012   |
| All Children | Atlanta    | S70         | 2017 | 20              | 654730  | 549529   | 486094   | 440414   | 406356   | 376495   |
| All Children | Atlanta    | S70         | 2017 | 30              | 528767  | 412591   | 348328   | 305534   | 273877   | 248333   |
| All Children | Atlanta    | S70         | 2017 | 40              | 359082  | 248031   | 191112   | 155198   | 130058   | 108005   |
| All Children | Atlanta    | S70         | 2017 | 50              | 147228  | 62003    | 31597    | 17029    | 9887     | 5770     |
| All Children | Atlanta    | S70         | 2017 | 60              | 17291   | 1675     | 343      | 61       | 0        | 0        |
| All Children | Atlanta    | S70         | 2017 | 70              | 1069  | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2015 | 0               | 782548  | 702709   | 652006   | 613670   | 581448   | 553463   |
| All Children | Atlanta    | S75         | 2015 | 10              | 744495  | 658725   | 602654   | 561595   | 528021   | 498018   |
| All Children | Atlanta    | S75         | 2015 | 20              | 664192  | 562724   | 500016   | 454921   | 419471   | 389953   |
| All Children | Atlanta    | S75         | 2015 | 30              | 557055  | 442896   | 379057   | 335698   | 301862   | 274260   |
| All Children | Atlanta    | S75         | 2015 | 40              | 427219  | 312717   | 251642   | 210442   | 180197   | 156651   |
| All Children | Atlanta    | S75         | 2015 | 50              | 269115  | 159395   | 108792   | 77417    | 55808    | 41201    |
| All Children | Atlanta    | S75         | 2015 | 60              | 92348   | 28126    | 10573    | 4136     | 1897     | 807      |
| All Children | Atlanta    | S75         | 2015 | 70              | 16202   | 1412     | 141      | 40       | 20       | 0        |
| All Children | Atlanta    | S75         | 2015 | 80              | 2320  | 40       | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2015 | 90              | 141   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2016 | 0               | 790356  | 714553   | 665988   | 626301   | 592142   | 564218   |
| All Children | Atlanta    | S75         | 2016 | 10              | 758457  | 677267   | 623819   | 581610   | 547632   | 517852   |
| All Children | Atlanta    | S75         | 2016 | 20              | 687718  | 591173   | 529352   | 485186   | 449635   | 419975   |
| All Children | Atlanta    | S75         | 2016 | 30              | 588470  | 478528   | 415052   | 370825   | 336464   | 309327   |
| All Children | Atlanta    | S75         | 2016 | 40              | 460429  | 344999   | 283178   | 243773   | 215123   | 191617   |
| All Children | Atlanta    | S75         | 2016 | 50              | 299642  | 189660   | 136837   | 101831   | 78265    | 60913    |
| All Children | Atlanta    | S75         | 2016 | 60              | 129312  | 48424    | 22053    | 10431    | 4984     | 2603     |
| All Children | Atlanta    | S75         | 2016 | 70              | 33957   | 4257     | 666      | 182      | 20       | 0        |
| All Children | Atlanta    | S75         | 2016 | 80              | 6658  | 121      | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2016 | 90              | 1069  | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2016 | 100             | 161   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2017 | 0               | 787491  | 708984   | 655456   | 615486   | 582962   | 554835   |
| All Children | Atlanta    | S75         | 2017 | 10              | 749862  | 663668   | 606407   | 563350   | 529070   | 498906   |
| All Children | Atlanta    | S75         | 2017 | 20              | 666311  | 563209   | 499612   | 453852   | 419027   | 388580   |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Atlanta    | S75         | 2017 | 30              | 553786  | 439062   | 374881   | 331198   | 297625   | 270003   |
| All Children | Atlanta    | S75         | 2017 | 40              | 408475  | 292762   | 233120   | 194845   | 167001   | 144848   |
| All Children | Atlanta    | S75         | 2017 | 50              | 222527  | 120656   | 76106    | 51168    | 34885    | 24373    |
| All Children | Atlanta    | S75         | 2017 | 60              | 57846   | 12832    | 3793     | 1211     | 424      | 222      |
| All Children | Atlanta    | S75         | 2017 | 70              | 5387  | 262      | 20       | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2017 | 80              | 404   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Atlanta    | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2015 | 0               | 862212  | 765847   | 702953   | 654281   | 613301   | 578919   |
| All Children | Boston     | S65         | 2015 | 10              | 828103  | 724661   | 659401   | 605997   | 564037   | 530315   |
| All Children | Boston     | S65         | 2015 | 20              | 719792  | 597213   | 524695   | 471381   | 429331   | 395632   |
| All Children | Boston     | S65         | 2015 | 30              | 564197  | 430947   | 358701   | 309347   | 271005   | 242494   |
| All Children | Boston     | S65         | 2015 | 40              | 352717  | 224814   | 164424   | 124171   | 95705    | 74976    |
| All Children | Boston     | S65         | 2015 | 50              | 124717  | 41686    | 16383    | 6667     | 2822     | 1456     |
| All Children | Boston     | S65         | 2015 | 60              | 22754   | 1456     | 114      | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2015 | 70              | 3095  | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2015 | 80              | 114   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2016 | 0               | 865716  | 770989   | 706503   | 658309   | 617829   | 583447   |
| All Children | Boston     | S65         | 2016 | 10              | 832676  | 731123   | 663975   | 612618   | 571000   | 535344   |
| All Children | Boston     | S65         | 2016 | 20              | 725617  | 603038   | 527539   | 472769   | 430036   | 396747   |
| All Children | Boston     | S65         | 2016 | 30              | 564310  | 430924   | 357654   | 309278   | 273554   | 244315   |
| All Children | Boston     | S65         | 2016 | 40              | 359884  | 232050   | 168383   | 128995   | 100393   | 79754    |
| All Children | Boston     | S65         | 2016 | 50              | 137300  | 47739    | 19887    | 8988     | 3572     | 1502     |
| All Children | Boston     | S65         | 2016 | 60              | 15314   | 1160     | 114      | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2016 | 70              | 1251  | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2017 | 0               | 862462  | 763776   | 699927   | 649867   | 610434   | 576484   |
| All Children | Boston     | S65         | 2017 | 10              | 825941  | 722226   | 656693   | 605155   | 564288   | 526902   |
| All Children | Boston     | S65         | 2017 | 20              | 718654  | 597805   | 519871   | 464532   | 421185   | 386393   |
| All Children | Boston     | S65         | 2017 | 30              | 563013  | 424871   | 353672   | 302247   | 265089   | 235008   |
| All Children | Boston     | S65         | 2017 | 40              | 377155  | 243518   | 175369   | 131475   | 100142   | 77706    |
| All Children | Boston     | S65         | 2017 | 50              | 173912  | 69924    | 29968    | 12925    | 5006     | 2162     |
| All Children | Boston     | S65         | 2017 | 60              | 33631   | 4323     | 432      | 46       | 0        | 0        |
| All Children | Boston     | S65         | 2017 | 70              | 3140  | 23       | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2015 | 0               | 862212  | 765847   | 702953   | 654281   | 613301   | 578919   |
| All Children | Boston     | S70         | 2015 | 10              | 828717  | 725776   | 660493   | 606952   | 565312   | 532022   |
| All Children | Boston     | S70         | 2015 | 20              | 727164  | 605655   | 532318   | 479391   | 437682   | 402185   |
| All Children | Boston     | S70         | 2015 | 30              | 585199  | 452449   | 378338   | 328256   | 289505   | 259810   |
| All Children | Boston     | S70         | 2015 | 40              | 396041  | 265772   | 201468   | 157802   | 127061   | 104761   |
| All Children | Boston     | S70         | 2015 | 50              | 184288  | 81643    | 41686    | 21867    | 12287    | 7031     |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Boston     | S70         | 2015 | 60              | 46465   | 6690     | 1479     | 410      | 114      | 46       |
| All Children | Boston     | S70         | 2015 | 70              | 7554  | 91       | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2015 | 80              | 592   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2016 | 0               | 865716  | 770989   | 706503   | 658309   | 617829   | 583447   |
| All Children | Boston     | S70         | 2016 | 10              | 833541  | 732397   | 665204   | 614120   | 571842   | 536391   |
| All Children | Boston     | S70         | 2016 | 20              | 735037  | 612709   | 537597   | 482440   | 438205   | 405166   |
| All Children | Boston     | S70         | 2016 | 30              | 587497  | 453519   | 380659   | 330122   | 292144   | 262336   |
| All Children | Boston     | S70         | 2016 | 40              | 409466  | 275238   | 209227   | 166836   | 134365   | 111315   |
| All Children | Boston     | S70         | 2016 | 50              | 208021  | 97139    | 52836    | 30969    | 18067    | 10672    |
| All Children | Boston     | S70         | 2016 | 60              | 50242   | 8783     | 1661     | 137      | 46       | 23       |
| All Children | Boston     | S70         | 2016 | 70              | 5438  | 273      | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2016 | 80              | 91  | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2017 | 0               | 862462  | 763776   | 699927   | 649867   | 610434   | 576484   |
| All Children | Boston     | S70         | 2017 | 10              | 826737  | 723250   | 657877   | 605951   | 564652   | 527835   |
| All Children | Boston     | S70         | 2017 | 20              | 726527  | 605655   | 528700   | 473475   | 429217   | 393493   |
| All Children | Boston     | S70         | 2017 | 30              | 585313  | 446647   | 372081   | 321020   | 282178   | 251300   |
| All Children | Boston     | S70         | 2017 | 40              | 418909  | 284977   | 213687   | 168428   | 134274   | 108038   |
| All Children | Boston     | S70         | 2017 | 50              | 238512  | 116890   | 63735    | 35497    | 20320    | 10922    |
| All Children | Boston     | S70         | 2017 | 60              | 81939   | 18477    | 4369     | 865      | 68       | 23       |
| All Children | Boston     | S70         | 2017 | 70              | 11923   | 660      | 23       | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2017 | 80              | 432   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2015 | 0               | 862212  | 765847   | 702953   | 654281   | 613301   | 578919   |
| All Children | Boston     | S75         | 2015 | 10              | 828581  | 725457   | 659970   | 606952   | 565107   | 531203   |
| All Children | Boston     | S75         | 2015 | 20              | 729826  | 609137   | 535981   | 482758   | 440799   | 404847   |
| All Children | Boston     | S75         | 2015 | 30              | 594164  | 461028   | 387895   | 336902   | 297446   | 267524   |
| All Children | Boston     | S75         | 2015 | 40              | 417408  | 285637   | 219558   | 174731   | 143012   | 120235   |
| All Children | Boston     | S75         | 2015 | 50              | 218625  | 107765   | 60845    | 34974    | 21730    | 12970    |
| All Children | Boston     | S75         | 2015 | 60              | 68559   | 14677    | 3823     | 1069     | 296      | 91       |
| All Children | Boston     | S75         | 2015 | 70              | 12788   | 341      | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2015 | 80              | 1047  | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2015 | 90              | 23  | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2016 | 0               | 865716  | 770989   | 706503   | 658309   | 617829   | 583447   |
| All Children | Boston     | S75         | 2016 | 10              | 833905  | 732921   | 665295   | 614165   | 571933   | 536027   |
| All Children | Boston     | S75         | 2016 | 20              | 737950  | 616577   | 541215   | 486103   | 441982   | 407760   |
| All Children | Boston     | S75         | 2016 | 30              | 598032  | 463827   | 389966   | 338950   | 301337   | 270255   |
| All Children | Boston     | S75         | 2016 | 40              | 434087  | 297651   | 229729   | 184379   | 152000   | 126583   |
| All Children | Boston     | S75         | 2016 | 50              | 244815  | 127971   | 76705    | 48649    | 31629    | 20684    |
| All Children | Boston     | S75         | 2016 | 60              | 82553   | 20957    | 5643     | 1479     | 387      | 137      |
| All Children | Boston     | S75         | 2016 | 70              | 12356   | 819      | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2016 | 80              | 865   | 0        | 0        | 0        | 0        | 0        |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Boston     | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2017 | 0               | 862462  | 763776   | 699927   | 649867   | 610434   | 576484   |
| All Children | Boston     | S75         | 2017 | 10              | 826806  | 723091   | 658263   | 605701   | 564447   | 527357   |
| All Children | Boston     | S75         | 2017 | 20              | 729462  | 609432   | 531726   | 475659   | 431902   | 395450   |
| All Children | Boston     | S75         | 2017 | 30              | 596212  | 457569   | 381296   | 329712   | 289983   | 258604   |
| All Children | Boston     | S75         | 2017 | 40              | 440594  | 303226   | 233188   | 184425   | 150452   | 124285   |
| All Children | Boston     | S75         | 2017 | 50              | 275738  | 145651   | 85557    | 52267    | 32425    | 20206    |
| All Children | Boston     | S75         | 2017 | 60              | 119711  | 35724    | 11400    | 2890     | 887      | 182      |
| All Children | Boston     | S75         | 2017 | 70              | 26532   | 3322     | 455      | 23       | 0        | 0        |
| All Children | Boston     | S75         | 2017 | 80              | 1957  | 23       | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Boston     | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2015 | 0               | 931702  | 848139   | 790894   | 748592   | 711327   | 679098   |
| All Children | Dallas     | S65         | 2015 | 10              | 886185  | 790965   | 727382   | 681320   | 641596   | 608800   |
| All Children | Dallas     | S65         | 2015 | 20              | 783658  | 667299   | 593194   | 540819   | 500811   | 466643   |
| All Children | Dallas     | S65         | 2015 | 30              | 636205  | 503034   | 429047   | 377902   | 341606   | 310985   |
| All Children | Dallas     | S65         | 2015 | 40              | 459431  | 325149   | 255276   | 210066   | 176632   | 151780   |
| All Children | Dallas     | S65         | 2015 | 50              | 231229  | 118748   | 69021    | 44146    | 28635    | 19366    |
| All Children | Dallas     | S65         | 2015 | 60              | 39772   | 7188     | 1537     | 213      | 24       | 24       |
| All Children | Dallas     | S65         | 2015 | 70              | 1017  | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2016 | 0               | 933499  | 848896   | 794440   | 751618   | 716860   | 687137   |
| All Children | Dallas     | S65         | 2016 | 10              | 888573  | 794582   | 736249   | 689313   | 651291   | 619157   |
| All Children | Dallas     | S65         | 2016 | 20              | 783895  | 670018   | 601091   | 547203   | 505729   | 473737   |
| All Children | Dallas     | S65         | 2016 | 30              | 627078  | 496176   | 424507   | 375443   | 338036   | 310016   |
| All Children | Dallas     | S65         | 2016 | 40              | 418005  | 287411   | 220423   | 177081   | 145372   | 120497   |
| All Children | Dallas     | S65         | 2016 | 50              | 152608  | 62873    | 29486    | 16292    | 7992     | 4635     |
| All Children | Dallas     | S65         | 2016 | 60              | 12343   | 307      | 47       | 24       | 0        | 0        |
| All Children | Dallas     | S65         | 2016 | 70              | 946   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2017 | 0               | 938796  | 854973   | 800967   | 757435   | 720619   | 688911   |
| All Children | Dallas     | S65         | 2017 | 10              | 899119  | 806003   | 744430   | 698038   | 658219   | 624146   |
| All Children | Dallas     | S65         | 2017 | 20              | 798578  | 682053   | 612749   | 560587   | 518214   | 484850   |
| All Children | Dallas     | S65         | 2017 | 30              | 647318  | 516937   | 444204   | 394312   | 357307   | 328081   |
| All Children | Dallas     | S65         | 2017 | 40              | 455577  | 319970   | 251659   | 205101   | 171737   | 144072   |
| All Children | Dallas     | S65         | 2017 | 50              | 218200  | 102243   | 54645    | 31094    | 18278    | 11208    |
| All Children | Dallas     | S65         | 2017 | 60              | 36343   | 3547     | 497      | 24       | 0        | 0        |
| All Children | Dallas     | S65         | 2017 | 70              | 922   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2015 | 0               | 931702  | 848139   | 790894   | 748592   | 711327   | 679098   |



| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Dallas     | S70         | 2015 | 10              | 887982  | 792738   | 729415   | 683567   | 643653   | 611708   |
| All Children | Dallas     | S70         | 2015 | 20              | 793802  | 677797   | 603290   | 551578   | 510955   | 477284   |
| All Children | Dallas     | S70         | 2015 | 30              | 657793  | 526466   | 449311   | 398261   | 360357   | 329169   |
| All Children | Dallas     | S70         | 2015 | 40              | 499298  | 363786   | 292211   | 244069   | 209664   | 181810   |
| All Children | Dallas     | S70         | 2015 | 50              | 304601  | 181905   | 122294   | 87063    | 63748    | 47386    |
| All Children | Dallas     | S70         | 2015 | 60              | 96261   | 29273    | 10759    | 4422     | 1773     | 780      |
| All Children | Dallas     | S70         | 2015 | 70              | 9718  | 757      | 24       | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2015 | 80              | 236   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2016 | 0               | 933499  | 848896   | 794440   | 751618   | 716860   | 687137   |
| All Children | Dallas     | S70         | 2016 | 10              | 890677  | 797491   | 738992   | 692008   | 654436   | 622774   |
| All Children | Dallas     | S70         | 2016 | 20              | 792218  | 680233   | 611377   | 557111   | 515755   | 483219   |
| All Children | Dallas     | S70         | 2016 | 30              | 648784  | 518356   | 444606   | 395872   | 358158   | 328294   |
| All Children | Dallas     | S70         | 2016 | 40              | 459006  | 327111   | 259414   | 214512   | 180108   | 154405   |
| All Children | Dallas     | S70         | 2016 | 50              | 218271  | 109455   | 63086    | 39062    | 23929    | 15157    |
| All Children | Dallas     | S70         | 2016 | 60              | 34499   | 5226     | 1301     | 260      | 71       | 47       |
| All Children | Dallas     | S70         | 2016 | 70              | 3168  | 24       | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2016 | 80              | 284   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2017 | 0               | 938796  | 854973   | 800967   | 757435   | 720619   | 688911   |
| All Children | Dallas     | S70         | 2017 | 10              | 901176  | 808509   | 747575   | 701017   | 660796   | 627007   |
| All Children | Dallas     | S70         | 2017 | 20              | 807256  | 691914   | 622893   | 571369   | 528996   | 494900   |
| All Children | Dallas     | S70         | 2017 | 30              | 668552  | 537958   | 465106   | 414576   | 377145   | 346217   |
| All Children | Dallas     | S70         | 2017 | 40              | 494308  | 359222   | 288215   | 242106   | 207323   | 177838   |
| All Children | Dallas     | S70         | 2017 | 50              | 279820  | 153388   | 95693    | 62471    | 40859    | 28185    |
| All Children | Dallas     | S70         | 2017 | 60              | 78621   | 16907    | 4469     | 1277     | 402      | 95       |
| All Children | Dallas     | S70         | 2017 | 70              | 4705  | 47       | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2015 | 0               | 931702  | 848139   | 790894   | 748592   | 711327   | 679098   |
| All Children | Dallas     | S75         | 2015 | 10              | 888668  | 794204   | 730645   | 684867   | 644859   | 612559   |
| All Children | Dallas     | S75         | 2015 | 20              | 799950  | 685009   | 610975   | 559002   | 517670   | 483904   |
| All Children | Dallas     | S75         | 2015 | 30              | 674652  | 543042   | 466099   | 412732   | 374260   | 343048   |
| All Children | Dallas     | S75         | 2015 | 40              | 528287  | 393106   | 319687   | 269700   | 233121   | 204250   |
| All Children | Dallas     | S75         | 2015 | 50              | 362036  | 231938   | 164691   | 123760   | 95859    | 75405    |
| All Children | Dallas     | S75         | 2015 | 60              | 162894  | 67602    | 32725    | 16670    | 9293     | 4942     |
| All Children | Dallas     | S75         | 2015 | 70              | 29912   | 4280     | 828      | 95       | 24       | 0        |
| All Children | Dallas     | S75         | 2015 | 80              | 2081  | 24       | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2015 | 90              | 47  | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2016 | 0               | 933499  | 848896   | 794440   | 751618   | 716860   | 687137   |
| All Children | Dallas     | S75         | 2016 | 10              | 891623  | 799217   | 740623   | 693663   | 656138   | 624311   |
| All Children | Dallas     | S75         | 2016 | 20              | 798129  | 686570   | 618211   | 563873   | 522518   | 489579   |
| All Children | Dallas     | S75         | 2016 | 30              | 664745  | 534600   | 459692   | 409871   | 370808   | 341890   |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Dallas     | S75         | 2016 | 40              | 489508  | 355391   | 285992   | 241160   | 206283   | 178736   |
| All Children | Dallas     | S75         | 2016 | 50              | 273507  | 151662   | 96852    | 65734    | 45399    | 32347    |
| All Children | Dallas     | S75         | 2016 | 60              | 66964   | 15819    | 5131     | 1726     | 520      | 189      |
| All Children | Dallas     | S75         | 2016 | 70              | 9860  | 166      | 24       | 24       | 0        | 0        |
| All Children | Dallas     | S75         | 2016 | 80              | 1419  | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2016 | 90              | 71  | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2017 | 0               | 938796  | 854973   | 800967   | 757435   | 720619   | 688911   |
| All Children | Dallas     | S75         | 2017 | 10              | 902051  | 809810   | 749372   | 702791   | 662901   | 629040   |
| All Children | Dallas     | S75         | 2017 | 20              | 813262  | 699267   | 631098   | 577730   | 535806   | 502064   |
| All Children | Dallas     | S75         | 2017 | 30              | 683118  | 554250   | 479837   | 427557   | 390008   | 359151   |
| All Children | Dallas     | S75         | 2017 | 40              | 522257  | 387313   | 316022   | 267714   | 232411   | 202500   |
| All Children | Dallas     | S75         | 2017 | 50              | 328932  | 197936   | 133644   | 94251    | 67768    | 49017    |
| All Children | Dallas     | S75         | 2017 | 60              | 125037  | 38755    | 13998    | 5344     | 2317     | 851      |
| All Children | Dallas     | S75         | 2017 | 70              | 16126   | 804      | 71       | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2017 | 80              | 71  | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Dallas     | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2015 | 0               | 658727  | 585868   | 537967   | 501043   | 471369   | 444747   |
| All Children | Detroit    | S65         | 2015 | 10              | 631377  | 552916   | 501598   | 463617   | 433093   | 405847   |
| All Children | Detroit    | S65         | 2015 | 20              | 556680  | 464033   | 407303   | 366963   | 334324   | 307407   |
| All Children | Detroit    | S65         | 2015 | 30              | 448043  | 347730   | 291521   | 253903   | 225322   | 202412   |
| All Children | Detroit    | S65         | 2015 | 40              | 314483  | 214118   | 161863   | 128912   | 106001   | 87409    |
| All Children | Detroit    | S65         | 2015 | 50              | 142110  | 62349    | 31096    | 16129    | 9261     | 5064     |
| All Children | Detroit    | S65         | 2015 | 60              | 14932   | 1179     | 121      | 17       | 0        | 0        |
| All Children | Detroit    | S65         | 2015 | 70              | 87  | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2016 | 0               | 666184  | 595199   | 547679   | 510322   | 479989   | 454772   |
| All Children | Detroit    | S65         | 2016 | 10              | 639771  | 562646   | 512264   | 474179   | 442545   | 416842   |
| All Children | Detroit    | S65         | 2016 | 20              | 566774  | 476190   | 421542   | 379832   | 347903   | 320883   |
| All Children | Detroit    | S65         | 2016 | 30              | 464831  | 363269   | 306783   | 267657   | 238139   | 215645   |
| All Children | Detroit    | S65         | 2016 | 40              | 336769  | 231982   | 177941   | 145318   | 120205   | 100521   |
| All Children | Detroit    | S65         | 2016 | 50              | 178287  | 88571    | 50625    | 28321    | 16580    | 9903     |
| All Children | Detroit    | S65         | 2016 | 60              | 38276   | 5498     | 884      | 87       | 17       | 0        |
| All Children | Detroit    | S65         | 2016 | 70              | 815   | 17       | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2017 | 0               | 661623  | 588886   | 542771   | 505899   | 475913   | 448996   |
| All Children | Detroit    | S65         | 2017 | 10              | 635990  | 558553   | 509212   | 469409   | 439267   | 411813   |
| All Children | Detroit    | S65         | 2017 | 20              | 565681  | 473381   | 417328   | 376519   | 344695   | 316963   |
| All Children | Detroit    | S65         | 2017 | 30              | 458899  | 357563   | 301129   | 261274   | 232675   | 209019   |
| All Children | Detroit    | S65         | 2017 | 40              | 326727  | 225721   | 174316   | 140133   | 116008   | 96948    |
| All Children | Detroit    | S65         | 2017 | 50              | 159730  | 72980    | 40427    | 22199    | 12695    | 7770     |
| All Children | Detroit    | S65         | 2017 | 60              | 17725   | 1353     | 139      | 35       | 0        | 0        |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Detroit    | S65         | 2017 | 70              | 330   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2015 | 0               | 658727  | 585868   | 537967   | 501043   | 471369   | 444747   |
| All Children | Detroit    | S70         | 2015 | 10              | 632365  | 553732   | 502535   | 464501   | 433630   | 406766   |
| All Children | Detroit    | S70         | 2015 | 20              | 562663  | 471733   | 415056   | 374352   | 341677   | 314708   |
| All Children | Detroit    | S70         | 2015 | 30              | 464952  | 364032   | 306557   | 269044   | 239890   | 215835   |
| All Children | Detroit    | S70         | 2015 | 40              | 348025  | 246394   | 192491   | 158048   | 132675   | 112609   |
| All Children | Detroit    | S70         | 2015 | 50              | 197330  | 106868   | 65470    | 41398    | 26882    | 17499    |
| All Children | Detroit    | S70         | 2015 | 60              | 52203   | 10805    | 2549     | 746      | 191      | 17       |
| All Children | Detroit    | S70         | 2015 | 70              | 1492  | 69       | 17       | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2016 | 0               | 666184  | 595199   | 547679   | 510322   | 479989   | 454772   |
| All Children | Detroit    | S70         | 2016 | 10              | 640326  | 564016   | 513287   | 475132   | 443204   | 417831   |
| All Children | Detroit    | S70         | 2016 | 20              | 573121  | 483076   | 429069   | 386908   | 354823   | 327855   |
| All Children | Detroit    | S70         | 2016 | 30              | 481740  | 380855   | 323623   | 283994   | 253244   | 228825   |
| All Children | Detroit    | S70         | 2016 | 40              | 369669  | 264361   | 208569   | 172027   | 146203   | 125478   |
| All Children | Detroit    | S70         | 2016 | 50              | 235329  | 136820   | 90965    | 62626    | 43653    | 30697    |
| All Children | Detroit    | S70         | 2016 | 60              | 95509   | 28894    | 9764     | 3035     | 1041     | 399      |
| All Children | Detroit    | S70         | 2016 | 70              | 9487  | 520      | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2016 | 80              | 52  | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2017 | 0               | 661623  | 588886   | 542771   | 505899   | 475913   | 448996   |
| All Children | Detroit    | S70         | 2017 | 10              | 636528  | 559455   | 510460   | 470120   | 440203   | 412610   |
| All Children | Detroit    | S70         | 2017 | 20              | 572202  | 479763   | 423866   | 383092   | 351372   | 323467   |
| All Children | Detroit    | S70         | 2017 | 30              | 475115  | 374508   | 316980   | 277005   | 246619   | 223015   |
| All Children | Detroit    | S70         | 2017 | 40              | 359315  | 255586   | 202498   | 166078   | 140705   | 120517   |
| All Children | Detroit    | S70         | 2017 | 50              | 221142  | 123379   | 79327    | 52602    | 35710    | 23934    |
| All Children | Detroit    | S70         | 2017 | 60              | 61169   | 13788    | 3885     | 1214     | 451      | 156      |
| All Children | Detroit    | S70         | 2017 | 70              | 4301  | 139      | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2017 | 80              | 35  | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S75         | 2015 | 0               | 658727  | 585868   | 537967   | 501043   | 471369   | 444747   |
| All Children | Detroit    | S75         | 2015 | 10              | 631446  | 552691   | 501182   | 463409   | 432347   | 405430   |
| All Children | Detroit    | S75         | 2015 | 20              | 564398  | 473589   | 417102   | 376173   | 343221   | 315784   |
| All Children | Detroit    | S75         | 2015 | 30              | 473277  | 372357   | 314154   | 274733   | 245596   | 222148   |
| All Children | Detroit    | S75         | 2015 | 40              | 366634  | 263165   | 208204   | 172269   | 146047   | 125998   |
| All Children | Detroit    | S75         | 2015 | 50              | 234982  | 137375   | 91242    | 63424    | 44329    | 31738    |
| All Children | Detroit    | S75         | 2015 | 60              | 89387   | 26223    | 8776     | 3018     | 1041     | 572      |
| All Children | Detroit    | S75         | 2015 | 70              | 9296  | 416      | 52       | 0        | 0        | 0        |
| All Children | Detroit    | S75         | 2015 | 80              | 69  | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group  | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Detroit      | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit      | S75         | 2016 | 0               | 666184  | 595199   | 547679   | 510322   | 479989   | 454772   |
| All Children | Detroit      | S75         | 2016 | 10              | 639615  | 563132   | 512056   | 473970   | 442059   | 416513   |
| All Children | Detroit      | S75         | 2016 | 20              | 575254  | 485244   | 430665   | 388035   | 355812   | 328756   |
| All Children | Detroit      | S75         | 2016 | 30              | 489926  | 389666   | 332034   | 291174   | 260667   | 234965   |
| All Children | Detroit      | S75         | 2016 | 40              | 387931  | 282450   | 226328   | 188052   | 160615   | 139526   |
| All Children | Detroit      | S75         | 2016 | 50              | 271472  | 167587   | 118610   | 86698    | 65436    | 49879    |
| All Children | Detroit      | S75         | 2016 | 60              | 144191  | 60701    | 28061    | 12921    | 5983     | 2792     |
| All Children | Detroit      | S75         | 2016 | 70              | 34981   | 4561     | 607      | 69       | 0        | 0        |
| All Children | Detroit      | S75         | 2016 | 80              | 1249  | 17       | 0        | 0        | 0        | 0        |
| All Children | Detroit      | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit      | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit      | S75         | 2017 | 0               | 661623  | 588886   | 542771   | 505899   | 475913   | 448996   |
| All Children | Detroit      | S75         | 2017 | 10              | 635452  | 558501   | 509160   | 468629   | 438036   | 410859   |
| All Children | Detroit      | S75         | 2017 | 20              | 573607  | 481029   | 425965   | 384601   | 352482   | 324178   |
| All Children | Detroit      | S75         | 2017 | 30              | 483544  | 381740   | 323935   | 282971   | 252655   | 229450   |
| All Children | Detroit      | S75         | 2017 | 40              | 376519  | 271472   | 216928   | 179536   | 153695   | 132606   |
| All Children | Detroit      | S75         | 2017 | 50              | 253262  | 154180   | 105880   | 74298    | 53070    | 39248    |
| All Children | Detroit      | S75         | 2017 | 60              | 109747  | 38432    | 14950    | 6157     | 2549     | 989      |
| All Children | Detroit      | S75         | 2017 | 70              | 15106   | 694      | 35       | 0        | 0        | 0        |
| All Children | Detroit      | S75         | 2017 | 80              | 746   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit      | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Detroit      | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2015 | 0               | 844309  | 758097   | 699407   | 656192   | 618084   | 586655   |
| All Children | Philadelphia | S65         | 2015 | 10              | 815062  | 724070   | 661496   | 615312   | 577248   | 545077   |
| All Children | Philadelphia | S65         | 2015 | 20              | 730465  | 621184   | 550272   | 501426   | 463187   | 430295   |
| All Children | Philadelphia | S65         | 2015 | 30              | 600755  | 476806   | 407466   | 359296   | 323393   | 294801   |
| All Children | Philadelphia | S65         | 2015 | 40              | 413773  | 289279   | 226901   | 184974   | 153894   | 130169   |
| All Children | Philadelphia | S65         | 2015 | 50              | 163999  | 72811    | 37955    | 21040    | 12419    | 7268     |
| All Children | Philadelphia | S65         | 2015 | 60              | 20975   | 2204     | 437      | 44       | 0        | 0        |
| All Children | Philadelphia | S65         | 2015 | 70              | 393   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2016 | 0               | 846469  | 759581   | 703030   | 656803   | 619197   | 588532   |
| All Children | Philadelphia | S65         | 2016 | 10              | 817310  | 724070   | 664639   | 616928   | 580064   | 548831   |
| All Children | Philadelphia | S65         | 2016 | 20              | 729047  | 618826   | 551276   | 500487   | 459957   | 429095   |
| All Children | Philadelphia | S65         | 2016 | 30              | 593814  | 471022   | 401660   | 353730   | 317609   | 287009   |
| All Children | Philadelphia | S65         | 2016 | 40              | 401660  | 274416   | 211776   | 169674   | 139489   | 116200   |
| All Children | Philadelphia | S65         | 2016 | 50              | 155531  | 63644    | 30556    | 14754    | 7508     | 3623     |
| All Children | Philadelphia | S65         | 2016 | 60              | 21171   | 1702     | 109      | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2016 | 70              | 175   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2017 | 0               | 843414  | 754867   | 696046   | 650277   | 613959   | 581897   |
| All Children | Philadelphia | S65         | 2017 | 10              | 813403  | 717894   | 655690   | 609703   | 572185   | 540101   |

| Study Group  | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Philadelphia | S65         | 2017 | 20              | 721168  | 607914   | 538857   | 488286   | 449153   | 417418   |
| All Children | Philadelphia | S65         | 2017 | 30              | 575524  | 450462   | 381231   | 332298   | 296896   | 268042   |
| All Children | Philadelphia | S65         | 2017 | 40              | 380860  | 254227   | 193049   | 151602   | 122268   | 99875    |
| All Children | Philadelphia | S65         | 2017 | 50              | 139991  | 52447    | 23550    | 10651    | 5042     | 2335     |
| All Children | Philadelphia | S65         | 2017 | 60              | 18203   | 1484     | 109      | 22       | 0        | 0        |
| All Children | Philadelphia | S65         | 2017 | 70              | 480   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2015 | 0               | 844309  | 758097   | 699407   | 656192   | 618084   | 586655   |
| All Children | Philadelphia | S70         | 2015 | 10              | 816219  | 725838   | 663744   | 617080   | 578973   | 547085   |
| All Children | Philadelphia | S70         | 2015 | 20              | 738344  | 629521   | 559853   | 509807   | 471240   | 439047   |
| All Children | Philadelphia | S70         | 2015 | 30              | 621140  | 497715   | 427087   | 378590   | 342272   | 312021   |
| All Children | Philadelphia | S70         | 2015 | 40              | 460066  | 332145   | 266624   | 223933   | 192023   | 165156   |
| All Children | Philadelphia | S70         | 2015 | 50              | 238250  | 129711   | 80493    | 52426    | 35947    | 25165    |
| All Children | Philadelphia | S70         | 2015 | 60              | 54674   | 11764    | 3405     | 1157     | 349      | 65       |
| All Children | Philadelphia | S70         | 2015 | 70              | 4627  | 131      | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2015 | 80              | 44  | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2016 | 0               | 846469  | 759581   | 703030   | 656803   | 619197   | 588532   |
| All Children | Philadelphia | S70         | 2016 | 10              | 818467  | 725860   | 666472   | 618717   | 581286   | 550795   |
| All Children | Philadelphia | S70         | 2016 | 20              | 736598  | 627993   | 560268   | 509698   | 469429   | 437323   |
| All Children | Philadelphia | S70         | 2016 | 30              | 614963  | 490753   | 422089   | 372719   | 336204   | 305888   |
| All Children | Philadelphia | S70         | 2016 | 40              | 448913  | 319726   | 253114   | 209986   | 177160   | 151296   |
| All Children | Philadelphia | S70         | 2016 | 50              | 229476  | 119234   | 69777    | 44743    | 28068    | 18115    |
| All Children | Philadelphia | S70         | 2016 | 60              | 53560   | 9210     | 1899     | 480      | 44       | 22       |
| All Children | Philadelphia | S70         | 2016 | 70              | 5151  | 65       | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2017 | 0               | 843414  | 754867   | 696046   | 650277   | 613959   | 581897   |
| All Children | Philadelphia | S70         | 2017 | 10              | 814844  | 719487   | 657436   | 611187   | 573996   | 542196   |
| All Children | Philadelphia | S70         | 2017 | 20              | 728807  | 616753   | 547303   | 497584   | 458232   | 425974   |
| All Children | Philadelphia | S70         | 2017 | 30              | 597263  | 471153   | 401594   | 352203   | 314640   | 285001   |
| All Children | Philadelphia | S70         | 2017 | 40              | 426148  | 296481   | 233143   | 188531   | 156796   | 132133   |
| All Children | Philadelphia | S70         | 2017 | 50              | 205599  | 99984    | 55787    | 31080    | 18705    | 11589    |
| All Children | Philadelphia | S70         | 2017 | 60              | 51116   | 9451     | 2073     | 349      | 87       | 0        |
| All Children | Philadelphia | S70         | 2017 | 70              | 4191  | 175      | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2017 | 80              | 87  | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2015 | 0               | 844309  | 758097   | 699407   | 656192   | 618084   | 586655   |
| All Children | Philadelphia | S75         | 2015 | 10              | 816895  | 726187   | 664508   | 617932   | 579431   | 547740   |
| All Children | Philadelphia | S75         | 2015 | 20              | 745307  | 637357   | 568758   | 518013   | 478247   | 446403   |
| All Children | Philadelphia | S75         | 2015 | 30              | 640718  | 517162   | 446206   | 396422   | 359711   | 328784   |
| All Children | Philadelphia | S75         | 2015 | 40              | 503608  | 373701   | 306281   | 261167   | 226835   | 199815   |

| Study Group  | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Philadelphia | S75         | 2015 | 50              | 316932  | 197130   | 138681   | 102494   | 78267    | 60239    |
| All Children | Philadelphia | S75         | 2015 | 60              | 113669  | 38850    | 16784    | 8185     | 3536     | 1550     |
| All Children | Philadelphia | S75         | 2015 | 70              | 20036   | 1964     | 393      | 87       | 0        | 0        |
| All Children | Philadelphia | S75         | 2015 | 80              | 1550  | 22       | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2015 | 90              | 22  | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2016 | 0               | 846469  | 759581   | 703030   | 656803   | 619197   | 588532   |
| All Children | Philadelphia | S75         | 2016 | 10              | 819165  | 726668   | 666821   | 620201   | 581963   | 551101   |
| All Children | Philadelphia | S75         | 2016 | 20              | 742906  | 637357   | 568496   | 518100   | 477985   | 445028   |
| All Children | Philadelphia | S75         | 2016 | 30              | 635960  | 512098   | 442671   | 391424   | 354189   | 323305   |
| All Children | Philadelphia | S75         | 2016 | 40              | 491582  | 362504   | 293993   | 246675   | 212605   | 186654   |
| All Children | Philadelphia | S75         | 2016 | 50              | 310210  | 189142   | 129994   | 94506    | 69100    | 52076    |
| All Children | Philadelphia | S75         | 2016 | 60              | 115153  | 36493    | 13139    | 4845     | 1986     | 829      |
| All Children | Philadelphia | S75         | 2016 | 70              | 18377   | 1113     | 87       | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2016 | 80              | 240   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2017 | 0               | 843414  | 754867   | 696046   | 650277   | 613959   | 581897   |
| All Children | Philadelphia | S75         | 2017 | 10              | 815477  | 720513   | 658811   | 612170   | 574171   | 542982   |
| All Children | Philadelphia | S75         | 2017 | 20              | 736511  | 624305   | 554484   | 505180   | 465871   | 433176   |
| All Children | Philadelphia | S75         | 2017 | 30              | 617211  | 492259   | 421696   | 371388   | 333476   | 302069   |
| All Children | Philadelphia | S75         | 2017 | 40              | 467094  | 337296   | 271076   | 225482   | 191303   | 164588   |
| All Children | Philadelphia | S75         | 2017 | 50              | 281509  | 162624   | 105091   | 70846    | 48104    | 33830    |
| All Children | Philadelphia | S75         | 2017 | 60              | 107950  | 33306    | 11677    | 4060     | 1353     | 371      |
| All Children | Philadelphia | S75         | 2017 | 70              | 16173   | 1310     | 109      | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2017 | 80              | 633   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Philadelphia | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix      | S65         | 2015 | 0               | 573408  | 527665   | 497306   | 475283   | 455327   | 438640   |
| All Children | Phoenix      | S65         | 2015 | 10              | 554797  | 505302   | 472721   | 448448   | 427020   | 409314   |
| All Children | Phoenix      | S65         | 2015 | 20              | 507326  | 445844   | 408479   | 379182   | 355687   | 336241   |
| All Children | Phoenix      | S65         | 2015 | 30              | 435880  | 362750   | 321153   | 291530   | 268772   | 249707   |
| All Children | Phoenix      | S65         | 2015 | 40              | 332632  | 254859   | 213489   | 185041   | 164306   | 147209   |
| All Children | Phoenix      | S65         | 2015 | 50              | 173265  | 100206   | 66323    | 46720    | 33572    | 25094    |
| All Children | Phoenix      | S65         | 2015 | 60              | 11323   | 2066     | 510      | 142      | 71       | 14       |
| All Children | Phoenix      | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix      | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix      | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix      | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix      | S65         | 2016 | 0               | 573705  | 529561   | 500023   | 476840   | 457549   | 440310   |
| All Children | Phoenix      | S65         | 2016 | 10              | 555165  | 506718   | 475722   | 451067   | 429483   | 411494   |
| All Children | Phoenix      | S65         | 2016 | 20              | 508459  | 447599   | 410036   | 382565   | 359905   | 340812   |
| All Children | Phoenix      | S65         | 2016 | 30              | 435611  | 365510   | 323602   | 294276   | 271418   | 253543   |
| All Children | Phoenix      | S65         | 2016 | 40              | 327140  | 251561   | 210064   | 182904   | 161574   | 145383   |
| All Children | Phoenix      | S65         | 2016 | 50              | 145100  | 77178    | 47230    | 30996    | 21683    | 15526    |
| All Children | Phoenix      | S65         | 2016 | 60              | 7982  | 722      | 142      | 42       | 42       | 28       |
| All Children | Phoenix      | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Phoenix    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S65         | 2017 | 0               | 575177  | 529830   | 499174   | 476614   | 457889   | 440961   |
| All Children | Phoenix    | S65         | 2017 | 10              | 557655  | 508204   | 475637   | 451548   | 432045   | 414169   |
| All Children | Phoenix    | S65         | 2017 | 20              | 512337  | 452510   | 414792   | 387080   | 363727   | 343572   |
| All Children | Phoenix    | S65         | 2017 | 30              | 443282  | 373436   | 332504   | 303263   | 280420   | 261327   |
| All Children | Phoenix    | S65         | 2017 | 40              | 347408  | 270767   | 230416   | 202747   | 180993   | 164080   |
| All Children | Phoenix    | S65         | 2017 | 50              | 187234  | 113524   | 80164    | 59147    | 44456    | 34378    |
| All Children | Phoenix    | S65         | 2017 | 60              | 25334   | 4388     | 1076     | 354      | 71       | 14       |
| All Children | Phoenix    | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2015 | 0               | 573408  | 527665   | 497306   | 475283   | 455327   | 438640   |
| All Children | Phoenix    | S70         | 2015 | 10              | 555674  | 506336   | 473953   | 449439   | 428379   | 410532   |
| All Children | Phoenix    | S70         | 2015 | 20              | 511742  | 452100   | 414608   | 385636   | 362071   | 342256   |
| All Children | Phoenix    | S70         | 2015 | 30              | 449213  | 376988   | 334967   | 305627   | 282005   | 262318   |
| All Children | Phoenix    | S70         | 2015 | 40              | 361405  | 283817   | 240508   | 212003   | 190192   | 173803   |
| All Children | Phoenix    | S70         | 2015 | 50              | 236842  | 159409   | 121322   | 95521    | 77334    | 63633    |
| All Children | Phoenix    | S70         | 2015 | 60              | 68177   | 24061    | 10912    | 5803     | 3284     | 1713     |
| All Children | Phoenix    | S70         | 2015 | 70              | 807   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2016 | 0               | 573705  | 529561   | 500023   | 476840   | 457549   | 440310   |
| All Children | Phoenix    | S70         | 2016 | 10              | 556084  | 507807   | 476911   | 452737   | 430714   | 412626   |
| All Children | Phoenix    | S70         | 2016 | 20              | 512988  | 453869   | 416518   | 388339   | 366189   | 347903   |
| All Children | Phoenix    | S70         | 2016 | 30              | 448279  | 379621   | 337543   | 308231   | 284595   | 265955   |
| All Children | Phoenix    | S70         | 2016 | 40              | 357598  | 281694   | 239913   | 212144   | 190277   | 173067   |
| All Children | Phoenix    | S70         | 2016 | 50              | 218768  | 142326   | 103645   | 79598    | 62388    | 49961    |
| All Children | Phoenix    | S70         | 2016 | 60              | 50754   | 14153    | 5576     | 2633     | 1189     | 594      |
| All Children | Phoenix    | S70         | 2016 | 70              | 269   | 14       | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2017 | 0               | 575177  | 529830   | 499174   | 476614   | 457889   | 440961   |
| All Children | Phoenix    | S70         | 2017 | 10              | 558575  | 509647   | 476911   | 452963   | 433616   | 415655   |
| All Children | Phoenix    | S70         | 2017 | 20              | 517517  | 458568   | 421076   | 393434   | 371256   | 350437   |
| All Children | Phoenix    | S70         | 2017 | 30              | 456587  | 386556   | 346176   | 316992   | 293823   | 274858   |
| All Children | Phoenix    | S70         | 2017 | 40              | 375955  | 298579   | 258256   | 230586   | 208026   | 190546   |
| All Children | Phoenix    | S70         | 2017 | 50              | 254335  | 175954   | 136834   | 111104   | 93058    | 78240    |
| All Children | Phoenix    | S70         | 2017 | 60              | 89775   | 36643    | 18074    | 9554     | 5392     | 3326     |
| All Children | Phoenix    | S70         | 2017 | 70              | 4784  | 269      | 42       | 14       | 0        | 0        |
| All Children | Phoenix    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Phoenix    | S75         | 2015 | 0               | 573408  | 527665   | 497306   | 475283   | 455327   | 438640   |
| All Children | Phoenix    | S75         | 2015 | 10              | 555575  | 506251   | 473372   | 449198   | 428167   | 410065   |
| All Children | Phoenix    | S75         | 2015 | 20              | 513992  | 455016   | 417170   | 388849   | 365198   | 344931   |
| All Children | Phoenix    | S75         | 2015 | 30              | 456728  | 385763   | 343332   | 313567   | 289308   | 270527   |
| All Children | Phoenix    | S75         | 2015 | 40              | 379408  | 301664   | 258553   | 229539   | 207007   | 189471   |
| All Children | Phoenix    | S75         | 2015 | 50              | 276655  | 198147   | 157470   | 130678   | 110382   | 94134    |
| All Children | Phoenix    | S75         | 2015 | 60              | 136778  | 69054    | 41186    | 25844    | 16899    | 11535    |
| All Children | Phoenix    | S75         | 2015 | 70              | 13191   | 1613     | 226      | 28       | 0        | 0        |
| All Children | Phoenix    | S75         | 2015 | 80              | 198   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2016 | 0               | 573705  | 529561   | 500023   | 476840   | 457549   | 440310   |
| All Children | Phoenix    | S75         | 2016 | 10              | 555830  | 507850   | 476882   | 452241   | 430403   | 412173   |
| All Children | Phoenix    | S75         | 2016 | 20              | 515309  | 456742   | 419590   | 391241   | 368765   | 350026   |
| All Children | Phoenix    | S75         | 2016 | 30              | 456303  | 387915   | 346219   | 316171   | 292153   | 273230   |
| All Children | Phoenix    | S75         | 2016 | 40              | 376564  | 301268   | 258058   | 229256   | 207134   | 189584   |
| All Children | Phoenix    | S75         | 2016 | 50              | 264469  | 186329   | 145666   | 117175   | 97856    | 82726    |
| All Children | Phoenix    | S75         | 2016 | 60              | 111769  | 50527    | 27599    | 16574    | 9794     | 6171     |
| All Children | Phoenix    | S75         | 2016 | 70              | 8025  | 863      | 113      | 28       | 0        | 0        |
| All Children | Phoenix    | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2017 | 0               | 575177  | 529830   | 499174   | 476614   | 457889   | 440961   |
| All Children | Phoenix    | S75         | 2017 | 10              | 558717  | 509322   | 476755   | 452836   | 433899   | 415358   |
| All Children | Phoenix    | S75         | 2017 | 20              | 519710  | 461611   | 424289   | 396152   | 374469   | 353734   |
| All Children | Phoenix    | S75         | 2017 | 30              | 464880  | 396180   | 355121   | 325612   | 302244   | 282543   |
| All Children | Phoenix    | S75         | 2017 | 40              | 393434  | 317233   | 276132   | 247315   | 224868   | 206228   |
| All Children | Phoenix    | S75         | 2017 | 50              | 294871  | 215216   | 174185   | 147237   | 127295   | 111274   |
| All Children | Phoenix    | S75         | 2017 | 60              | 151653  | 83660    | 53358    | 34902    | 24400    | 16956    |
| All Children | Phoenix    | S75         | 2017 | 70              | 29255   | 5775     | 1302     | 368      | 85       | 14       |
| All Children | Phoenix    | S75         | 2017 | 80              | 1062  | 14       | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Phoenix    | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2015 | 0               | 311348  | 285237   | 266859   | 252643   | 241284   | 230547   |
| All Children | Sacramento | S65         | 2015 | 10              | 297194  | 266813   | 246867   | 231750   | 219397   | 208582   |
| All Children | Sacramento | S65         | 2015 | 20              | 261494  | 224025   | 200368   | 183411   | 170259   | 159218   |
| All Children | Sacramento | S65         | 2015 | 30              | 207977  | 166113   | 141516   | 125033   | 113239   | 103596   |
| All Children | Sacramento | S65         | 2015 | 40              | 127797  | 85902    | 64349    | 50218    | 40886    | 33494    |
| All Children | Sacramento | S65         | 2015 | 50              | 32718   | 9930     | 3439     | 1359     | 551      | 225      |
| All Children | Sacramento | S65         | 2015 | 60              | 1599  | 78       | 8        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2016 | 0               | 311681  | 285283   | 268039   | 253940   | 242146   | 232146   |
| All Children | Sacramento | S65         | 2016 | 10              | 297411  | 267612   | 247962   | 233093   | 220857   | 210849   |
| All Children | Sacramento | S65         | 2016 | 20              | 260516  | 223901   | 201493   | 184847   | 171633   | 160949   |



| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Sacramento | S65         | 2016 | 30              | 207891  | 165950   | 141718   | 125763   | 114039   | 104101   |
| All Children | Sacramento | S65         | 2016 | 40              | 132176  | 88394    | 66608    | 52679    | 42400    | 34744    |
| All Children | Sacramento | S65         | 2016 | 50              | 41716   | 16374    | 7430     | 3867     | 1840     | 908      |
| All Children | Sacramento | S65         | 2016 | 60              | 2632  | 163      | 8        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2017 | 0               | 311363  | 284484   | 266269   | 252263   | 240694   | 230686   |
| All Children | Sacramento | S65         | 2017 | 10              | 297395  | 267574   | 247418   | 231797   | 219157   | 209382   |
| All Children | Sacramento | S65         | 2017 | 20              | 262069  | 225112   | 201657   | 185616   | 172409   | 161159   |
| All Children | Sacramento | S65         | 2017 | 30              | 210352  | 167906   | 144746   | 128286   | 115755   | 105964   |
| All Children | Sacramento | S65         | 2017 | 40              | 132277  | 88759    | 66965    | 52881    | 43230    | 35396    |
| All Children | Sacramento | S65         | 2017 | 50              | 33564   | 9643     | 3408     | 1413     | 590      | 272      |
| All Children | Sacramento | S65         | 2017 | 60              | 1266  | 8        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2015 | 0               | 311348  | 285237   | 266859   | 252643   | 241284   | 230547   |
| All Children | Sacramento | S70         | 2015 | 10              | 298141  | 268063   | 248078   | 233218   | 220803   | 209863   |
| All Children | Sacramento | S70         | 2015 | 20              | 266067  | 229289   | 206012   | 189405   | 175631   | 164645   |
| All Children | Sacramento | S70         | 2015 | 30              | 220384  | 178318   | 154109   | 137067   | 124357   | 114676   |
| All Children | Sacramento | S70         | 2015 | 40              | 156811  | 112890   | 90684    | 74869    | 63207    | 54558    |
| All Children | Sacramento | S70         | 2015 | 50              | 71810   | 36313    | 21398    | 13354    | 8735     | 5544     |
| All Children | Sacramento | S70         | 2015 | 60              | 10645   | 1281     | 186      | 8        | 0        | 0        |
| All Children | Sacramento | S70         | 2015 | 70              | 707   | 31       | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2016 | 0               | 311681  | 285283   | 268039   | 253940   | 242146   | 232146   |
| All Children | Sacramento | S70         | 2016 | 10              | 298125  | 268816   | 249002   | 234320   | 222169   | 212060   |
| All Children | Sacramento | S70         | 2016 | 20              | 265446  | 229320   | 207006   | 190546   | 177068   | 166136   |
| All Children | Sacramento | S70         | 2016 | 30              | 219522  | 178846   | 154567   | 136772   | 124311   | 114396   |
| All Children | Sacramento | S70         | 2016 | 40              | 159016  | 115079   | 91375    | 75630    | 63984    | 54892    |
| All Children | Sacramento | S70         | 2016 | 50              | 81841   | 44434    | 28331    | 18960    | 13137    | 9340     |
| All Children | Sacramento | S70         | 2016 | 60              | 18378   | 4278     | 1219     | 411      | 179      | 47       |
| All Children | Sacramento | S70         | 2016 | 70              | 1203  | 16       | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2017 | 0               | 311363  | 284484   | 266269   | 252263   | 240694   | 230686   |
| All Children | Sacramento | S70         | 2017 | 10              | 298413  | 268730   | 248971   | 233155   | 220616   | 210655   |
| All Children | Sacramento | S70         | 2017 | 20              | 266782  | 230213   | 207480   | 191090   | 177681   | 166788   |
| All Children | Sacramento | S70         | 2017 | 30              | 222519  | 180049   | 156175   | 139909   | 127587   | 117144   |
| All Children | Sacramento | S70         | 2017 | 40              | 161167  | 117308   | 93736    | 78184    | 66849    | 57881    |
| All Children | Sacramento | S70         | 2017 | 50              | 76748   | 39247    | 23634    | 15381    | 10482    | 7050     |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Sacramento | S70         | 2017 | 60              | 15761   | 2244     | 435      | 54       | 8        | 0        |
| All Children | Sacramento | S70         | 2017 | 70              | 272   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2015 | 0               | 311348  | 285237   | 266859   | 252643   | 241284   | 230547   |
| All Children | Sacramento | S75         | 2015 | 10              | 298661  | 268715   | 248854   | 233823   | 221564   | 210624   |
| All Children | Sacramento | S75         | 2015 | 20              | 268893  | 232806   | 209677   | 193077   | 179544   | 167999   |
| All Children | Sacramento | S75         | 2015 | 30              | 228280  | 186167   | 162091   | 144901   | 131679   | 121694   |
| All Children | Sacramento | S75         | 2015 | 40              | 173395  | 128783   | 105413   | 89838    | 77462    | 68425    |
| All Children | Sacramento | S75         | 2015 | 50              | 99838   | 59015    | 39775    | 28479    | 20878    | 15699    |
| All Children | Sacramento | S75         | 2015 | 60              | 29457   | 7919     | 2562     | 901      | 326      | 93       |
| All Children | Sacramento | S75         | 2015 | 70              | 3603  | 202      | 23       | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2015 | 80              | 116   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2016 | 0               | 311681  | 285283   | 268039   | 253940   | 242146   | 232146   |
| All Children | Sacramento | S75         | 2016 | 10              | 298878  | 269383   | 249646   | 234996   | 222922   | 212767   |
| All Children | Sacramento | S75         | 2016 | 20              | 268404  | 232798   | 210329   | 193955   | 180352   | 169389   |
| All Children | Sacramento | S75         | 2016 | 30              | 226626  | 186734   | 162487   | 144334   | 131298   | 120731   |
| All Children | Sacramento | S75         | 2016 | 40              | 173760  | 130157   | 106562   | 90226    | 78029    | 68565    |
| All Children | Sacramento | S75         | 2016 | 50              | 109147  | 66243    | 46724    | 35094    | 26763    | 20342    |
| All Children | Sacramento | S75         | 2016 | 60              | 41445   | 15878    | 7438     | 3766     | 1964     | 1040     |
| All Children | Sacramento | S75         | 2016 | 70              | 6499  | 761      | 116      | 8        | 0        | 0        |
| All Children | Sacramento | S75         | 2016 | 80              | 217   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2017 | 0               | 311363  | 284484   | 266269   | 252263   | 240694   | 230686   |
| All Children | Sacramento | S75         | 2017 | 10              | 298739  | 269421   | 249670   | 233885   | 221331   | 211385   |
| All Children | Sacramento | S75         | 2017 | 20              | 269841  | 233528   | 211059   | 194863   | 180996   | 170189   |
| All Children | Sacramento | S75         | 2017 | 30              | 230050  | 187821   | 164086   | 147417   | 134466   | 123930   |
| All Children | Sacramento | S75         | 2017 | 40              | 176990  | 133340   | 109505   | 93076    | 81010    | 71406    |
| All Children | Sacramento | S75         | 2017 | 50              | 106570  | 64162    | 44465    | 32632    | 24713    | 19123    |
| All Children | Sacramento | S75         | 2017 | 60              | 33851   | 9464     | 3230     | 1328     | 575      | 248      |
| All Children | Sacramento | S75         | 2017 | 70              | 4643  | 280      | 16       | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2017 | 80              | 54  | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | Sacramento | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2015 | 0               | 355693  | 320478   | 297229   | 278469   | 263525   | 250485   |
| All Children | St. Louis  | S65         | 2015 | 10              | 338755  | 300106   | 275045   | 255985   | 239703   | 226653   |
| All Children | St. Louis  | S65         | 2015 | 20              | 297047  | 249820   | 221043   | 199980   | 183269   | 170010   |
| All Children | St. Louis  | S65         | 2015 | 30              | 235887  | 183552   | 155822   | 136744   | 121463   | 109297   |
| All Children | St. Louis  | S65         | 2015 | 40              | 159583  | 108140   | 82360    | 64911    | 52636    | 43356    |
| All Children | St. Louis  | S65         | 2015 | 50              | 65585   | 26864    | 12348    | 5828     | 2978     | 1439     |
| All Children | St. Louis  | S65         | 2015 | 60              | 4034  | 200      | 9        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group  | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|--------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | St. Louis  | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2016 | 0               | 359080  | 325268   | 301645   | 283232   | 267933   | 254646   |
| All Children | St. Louis  | S65         | 2016 | 10              | 344483  | 306763   | 281083   | 260903   | 244975   | 231552   |
| All Children | St. Louis  | S65         | 2016 | 20              | 305898  | 258790   | 228693   | 206910   | 190855   | 177541   |
| All Children | St. Louis  | S65         | 2016 | 30              | 248399  | 195764   | 166413   | 146461   | 131635   | 119815   |
| All Children | St. Louis  | S65         | 2016 | 40              | 174308  | 122456   | 95655    | 77469    | 64037    | 54257    |
| All Children | St. Louis  | S65         | 2016 | 50              | 87059   | 42300    | 23049    | 13141    | 7522     | 4435     |
| All Children | St. Louis  | S65         | 2016 | 60              | 16847   | 2204     | 392      | 109      | 18       | 0        |
| All Children | St. Louis  | S65         | 2016 | 70              | 55  | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2017 | 0               | 355702  | 320669   | 297356   | 279526   | 264764   | 252179   |
| All Children | St. Louis  | S65         | 2017 | 10              | 342115  | 304487   | 279471   | 260520   | 244875   | 231352   |
| All Children | St. Louis  | S65         | 2017 | 20              | 305215  | 259682   | 231033   | 210498   | 194106   | 180801   |
| All Children | St. Louis  | S65         | 2017 | 30              | 251869  | 200053   | 171804   | 151988   | 137309   | 125425   |
| All Children | St. Louis  | S65         | 2017 | 40              | 179900  | 128548   | 101711   | 83753    | 70503    | 60222    |
| All Children | St. Louis  | S65         | 2017 | 50              | 77387   | 35270    | 19178    | 11028    | 6693     | 3943     |
| All Children | St. Louis  | S65         | 2017 | 60              | 5764  | 464      | 27       | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2017 | 70              | 146   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2015 | 0               | 355693  | 320478   | 297229   | 278469   | 263525   | 250485   |
| All Children | St. Louis  | S70         | 2015 | 10              | 339492  | 301063   | 276193   | 256868   | 240896   | 227636   |
| All Children | St. Louis  | S70         | 2015 | 20              | 301664  | 255257   | 225533   | 205134   | 188351   | 175019   |
| All Children | St. Louis  | S70         | 2015 | 30              | 246742  | 194862   | 166531   | 146433   | 131271   | 119023   |
| All Children | St. Louis  | S70         | 2015 | 40              | 181020  | 128612   | 101556   | 83106    | 69893    | 59484    |
| All Children | St. Louis  | S70         | 2015 | 50              | 102157  | 54403    | 32711    | 20781    | 13660    | 8751     |
| All Children | St. Louis  | S70         | 2015 | 60              | 22320   | 4071     | 883      | 209      | 36       | 18       |
| All Children | St. Louis  | S70         | 2015 | 70              | 446   | 9        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2016 | 0               | 359080  | 325268   | 301645   | 283232   | 267933   | 254646   |
| All Children | St. Louis  | S70         | 2016 | 10              | 345411  | 307656   | 282367   | 262223   | 246469   | 232745   |
| All Children | St. Louis  | S70         | 2016 | 20              | 310497  | 264108   | 234567   | 212611   | 196091   | 183033   |
| All Children | St. Louis  | S70         | 2016 | 30              | 259664  | 206792   | 177141   | 156888   | 141279   | 129195   |
| All Children | St. Louis  | S70         | 2016 | 40              | 195627  | 143046   | 114843   | 96156    | 82004    | 71568    |
| All Children | St. Louis  | S70         | 2016 | 50              | 120880  | 70330    | 46462    | 32274    | 22429    | 16064    |
| All Children | St. Louis  | S70         | 2016 | 60              | 47609   | 14325    | 5036     | 1803     | 519      | 182      |
| All Children | St. Louis  | S70         | 2016 | 70              | 4863  | 155      | 9        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children | St. Louis  | S70         | 2017 | 0               | 355702  | 320669   | 297356   | 279526   | 264764   | 252179   |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children    | St. Louis  | S70         | 2017 | 10              | 343053  | 305771   | 280855   | 261850   | 246314   | 232782   |
| All Children    | St. Louis  | S70         | 2017 | 20              | 309878  | 264991   | 236688   | 216326   | 199579   | 186092   |
| All Children    | St. Louis  | S70         | 2017 | 30              | 262851  | 211363   | 182614   | 162597   | 147025   | 134686   |
| All Children    | St. Louis  | S70         | 2017 | 40              | 202211  | 149748   | 122019   | 103132   | 89763    | 78763    |
| All Children    | St. Louis  | S70         | 2017 | 50              | 119123  | 69201    | 45870    | 32410    | 23859    | 17685    |
| All Children    | St. Louis  | S70         | 2017 | 60              | 28595   | 6520     | 1949     | 574      | 219      | 46       |
| All Children    | St. Louis  | S70         | 2017 | 70              | 1685  | 36       | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S70         | 2017 | 80              | 36  | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2015 | 0               | 355693  | 320478   | 297229   | 278469   | 263525   | 250485   |
| All Children    | St. Louis  | S75         | 2015 | 10              | 339574  | 301336   | 276420   | 257105   | 241196   | 227846   |
| All Children    | St. Louis  | S75         | 2015 | 20              | 303931  | 257825   | 228420   | 207748   | 190864   | 177468   |
| All Children    | St. Louis  | S75         | 2015 | 30              | 253353  | 201200   | 172569   | 152708   | 137054   | 124186   |
| All Children    | St. Louis  | S75         | 2015 | 40              | 193851  | 140742   | 113149   | 94144    | 80119    | 69246    |
| All Children    | St. Louis  | S75         | 2015 | 50              | 123958  | 73544    | 49458    | 34760    | 24742    | 18186    |
| All Children    | St. Louis  | S75         | 2015 | 60              | 46635   | 14662    | 5245     | 2031     | 729      | 291      |
| All Children    | St. Louis  | S75         | 2015 | 70              | 4162  | 255      | 27       | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2016 | 0               | 359080  | 325268   | 301645   | 283232   | 267933   | 254646   |
| All Children    | St. Louis  | S75         | 2016 | 10              | 345867  | 308029   | 282950   | 262851   | 246778   | 233301   |
| All Children    | St. Louis  | S75         | 2016 | 20              | 313065  | 266849   | 237608   | 215935   | 199151   | 185846   |
| All Children    | St. Louis  | S75         | 2016 | 30              | 266685  | 213503   | 183834   | 163372   | 147171   | 134914   |
| All Children    | St. Louis  | S75         | 2016 | 40              | 208531  | 155148   | 126526   | 107166   | 92805    | 81522    |
| All Children    | St. Louis  | S75         | 2016 | 50              | 141707  | 89590    | 63491    | 46871    | 35661    | 27447    |
| All Children    | St. Louis  | S75         | 2016 | 60              | 70922   | 29259    | 13223    | 6675     | 3215     | 1539     |
| All Children    | St. Louis  | S75         | 2016 | 70              | 17730   | 2113     | 310      | 73       | 9        | 0        |
| All Children    | St. Louis  | S75         | 2016 | 80              | 555   | 9        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2017 | 0               | 355702  | 320669   | 297356   | 279526   | 264764   | 252179   |
| All Children    | St. Louis  | S75         | 2017 | 10              | 343545  | 306290   | 281420   | 262369   | 246815   | 233392   |
| All Children    | St. Louis  | S75         | 2017 | 20              | 312455  | 267942   | 240076   | 219768   | 202757   | 189143   |
| All Children    | St. Louis  | S75         | 2017 | 30              | 268880  | 218348   | 189107   | 168644   | 152963   | 140642   |
| All Children    | St. Louis  | S75         | 2017 | 40              | 215106  | 161833   | 133420   | 114788   | 100673   | 88780    |
| All Children    | St. Louis  | S75         | 2017 | 50              | 143109  | 91931    | 66141    | 50159    | 39022    | 30835    |
| All Children    | St. Louis  | S75         | 2017 | 60              | 55623   | 19743    | 8351     | 3843     | 1730     | 829      |
| All Children    | St. Louis  | S75         | 2017 | 70              | 6484  | 565      | 64       | 9        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2017 | 80              | 492   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Children    | St. Louis  | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2015 | 0               | 96464   | 87526    | 81735    | 77135    | 73342    | 70214    |
| Asthma Children | Atlanta    | S65         | 2015 | 10              | 91420   | 81271    | 74714    | 69912    | 66119    | 62689    |
| Asthma Children | Atlanta    | S65         | 2015 | 20              | 79899   | 67854    | 60409    | 54961    | 50825    | 47072    |
| Asthma Children | Atlanta    | S65         | 2015 | 30              | 63011   | 49392    | 41705    | 36277    | 32061    | 28953    |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Atlanta    | S65         | 2015 | 40              | 41221   | 27259    | 20358    | 15617    | 12570    | 10330    |
| Asthma Children | Atlanta    | S65         | 2015 | 50              | 14164   | 5206     | 2219     | 928      | 565      | 323      |
| Asthma Children | Atlanta    | S65         | 2015 | 60              | 1654  | 101      | 20       | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2015 | 70              | 40  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2016 | 0               | 99390   | 90068    | 83935    | 78951    | 74875    | 71627    |
| Asthma Children | Atlanta    | S65         | 2016 | 10              | 94850   | 84600    | 77680    | 72595    | 68156    | 64948    |
| Asthma Children | Atlanta    | S65         | 2016 | 20              | 84278   | 71586    | 63899    | 58209    | 53549    | 50139    |
| Asthma Children | Atlanta    | S65         | 2016 | 30              | 67733   | 53549    | 45619    | 40313    | 37105    | 33755    |
| Asthma Children | Atlanta    | S65         | 2016 | 40              | 46043   | 31637    | 24333    | 20035    | 16747    | 14124    |
| Asthma Children | Atlanta    | S65         | 2016 | 50              | 18260   | 6961     | 3087     | 1735     | 908      | 484      |
| Asthma Children | Atlanta    | S65         | 2016 | 60              | 2724  | 222      | 40       | 20       | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2016 | 70              | 222   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2016 | 80              | 20  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2017 | 0               | 96827   | 88757    | 82361    | 77922    | 73786    | 70416    |
| Asthma Children | Atlanta    | S65         | 2017 | 10              | 91904   | 82502    | 75521    | 70860    | 66562    | 62810    |
| Asthma Children | Atlanta    | S65         | 2017 | 20              | 80605   | 68621    | 60792    | 54921    | 50462    | 46850    |
| Asthma Children | Atlanta    | S65         | 2017 | 30              | 63092   | 49190    | 41059    | 35914    | 32182    | 29175    |
| Asthma Children | Atlanta    | S65         | 2017 | 40              | 38073   | 25261    | 18623    | 13982    | 11178    | 9180     |
| Asthma Children | Atlanta    | S65         | 2017 | 50              | 9100  | 2219     | 807      | 282      | 101      | 61       |
| Asthma Children | Atlanta    | S65         | 2017 | 60              | 424   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2017 | 70              | 20  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2015 | 0               | 96464   | 87526    | 81735    | 77135    | 73342    | 70214    |
| Asthma Children | Atlanta    | S70         | 2015 | 10              | 91985   | 82119    | 75218    | 70376    | 66764    | 63254    |
| Asthma Children | Atlanta    | S70         | 2015 | 20              | 81574   | 69952    | 62325    | 56938    | 52963    | 49049    |
| Asthma Children | Atlanta    | S70         | 2015 | 30              | 67047   | 53085    | 45660    | 40333    | 36257    | 32747    |
| Asthma Children | Atlanta    | S70         | 2015 | 40              | 49049   | 34744    | 27480    | 22396    | 18724    | 15879    |
| Asthma Children | Atlanta    | S70         | 2015 | 50              | 24515   | 12913    | 7627     | 4620     | 2805     | 1634     |
| Asthma Children | Atlanta    | S70         | 2015 | 60              | 5044  | 1090     | 303      | 101      | 20       | 0        |
| Asthma Children | Atlanta    | S70         | 2015 | 70              | 585   | 40       | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2016 | 0               | 99390   | 90068    | 83935    | 78951    | 74875    | 71627    |
| Asthma Children | Atlanta    | S70         | 2016 | 10              | 95254   | 85004    | 78346    | 73281    | 69125    | 65675    |
| Asthma Children | Atlanta    | S70         | 2016 | 20              | 85871   | 73665    | 65977    | 60489    | 56010    | 52197    |
| Asthma Children | Atlanta    | S70         | 2016 | 30              | 71385   | 57423    | 49453    | 44187    | 40373    | 37569    |
| Asthma Children | Atlanta    | S70         | 2016 | 40              | 52802   | 38396    | 31254    | 26411    | 23021    | 19934    |
| Asthma Children | Atlanta    | S70         | 2016 | 50              | 28691   | 15919    | 10028    | 6557     | 4540     | 2926     |
| Asthma Children | Atlanta    | S70         | 2016 | 60              | 8333  | 1715     | 504      | 101      | 20       | 0        |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Atlanta    | S70         | 2016 | 70              | 1271  | 20       | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2016 | 80              | 202   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2016 | 90              | 20  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2017 | 0               | 96827   | 88757    | 82361    | 77922    | 73786    | 70416    |
| Asthma Children | Atlanta    | S70         | 2017 | 10              | 92187   | 83067    | 76207    | 71385    | 67349    | 63738    |
| Asthma Children | Atlanta    | S70         | 2017 | 20              | 82381   | 71022    | 62830    | 57100    | 52742    | 49090    |
| Asthma Children | Atlanta    | S70         | 2017 | 30              | 66966   | 53125    | 44731    | 39425    | 35813    | 32726    |
| Asthma Children | Atlanta    | S70         | 2017 | 40              | 45821   | 32424    | 24898    | 21105    | 17554    | 14608    |
| Asthma Children | Atlanta    | S70         | 2017 | 50              | 19127   | 7990     | 4156     | 1997     | 1211     | 686      |
| Asthma Children | Atlanta    | S70         | 2017 | 60              | 2078  | 202      | 81       | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2017 | 70              | 141   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2015 | 0               | 96464   | 87526    | 81735    | 77135    | 73342    | 70214    |
| Asthma Children | Atlanta    | S75         | 2015 | 10              | 92368   | 82522    | 75884    | 70719    | 67208    | 63818    |
| Asthma Children | Atlanta    | S75         | 2015 | 20              | 82704   | 71264    | 63778    | 58653    | 54335    | 50542    |
| Asthma Children | Atlanta    | S75         | 2015 | 30              | 70537   | 56575    | 48626    | 43400    | 39385    | 35874    |
| Asthma Children | Atlanta    | S75         | 2015 | 40              | 54941   | 40494    | 32747    | 27541    | 23486    | 20802    |
| Asthma Children | Atlanta    | S75         | 2015 | 50              | 34522   | 21185    | 14628    | 10270    | 7808     | 6134     |
| Asthma Children | Atlanta    | S75         | 2015 | 60              | 12025   | 3834     | 1614     | 807      | 404      | 161      |
| Asthma Children | Atlanta    | S75         | 2015 | 70              | 2119  | 202      | 20       | 20       | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2015 | 80              | 282   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2016 | 0               | 99390   | 90068    | 83935    | 78951    | 74875    | 71627    |
| Asthma Children | Atlanta    | S75         | 2016 | 10              | 95718   | 85488    | 78608    | 73523    | 69710    | 66260    |
| Asthma Children | Atlanta    | S75         | 2016 | 20              | 87344   | 75299    | 67430    | 62144    | 57584    | 54093    |
| Asthma Children | Atlanta    | S75         | 2016 | 30              | 74774   | 60610    | 52540    | 47274    | 43158    | 39829    |
| Asthma Children | Atlanta    | S75         | 2016 | 40              | 58209   | 43783    | 36298    | 31112    | 27541    | 24979    |
| Asthma Children | Atlanta    | S75         | 2016 | 50              | 37912   | 23808    | 17412    | 13135    | 10088    | 7788     |
| Asthma Children | Atlanta    | S75         | 2016 | 60              | 17009   | 5972     | 2764     | 1311     | 605      | 242      |
| Asthma Children | Atlanta    | S75         | 2016 | 70              | 4439  | 565      | 101      | 20       | 20       | 0        |
| Asthma Children | Atlanta    | S75         | 2016 | 80              | 888   | 20       | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2016 | 90              | 182   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2016 | 100             | 20  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2017 | 0               | 96827   | 88757    | 82361    | 77922    | 73786    | 70416    |
| Asthma Children | Atlanta    | S75         | 2017 | 10              | 92368   | 83672    | 76711    | 71808    | 67934    | 64141    |
| Asthma Children | Atlanta    | S75         | 2017 | 20              | 83773   | 72373    | 64726    | 58835    | 54356    | 50805    |
| Asthma Children | Atlanta    | S75         | 2017 | 30              | 70114   | 56837    | 48323    | 42794    | 38739    | 35269    |
| Asthma Children | Atlanta    | S75         | 2017 | 40              | 52277   | 38073    | 30547    | 26129    | 22376    | 19491    |
| Asthma Children | Atlanta    | S75         | 2017 | 50              | 29054   | 15899    | 9685     | 6477     | 4459     | 3067     |
| Asthma Children | Atlanta    | S75         | 2017 | 60              | 7425  | 1614     | 464      | 182      | 61       | 40       |
| Asthma Children | Atlanta    | S75         | 2017 | 70              | 545   | 61       | 20       | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2017 | 80              | 61  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Atlanta    | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Atlanta    | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2015 | 0               | 110791  | 99209    | 91427    | 85625    | 79800    | 75522    |
| Asthma Children | Boston     | S65         | 2015 | 10              | 106673  | 94181    | 86421    | 79072    | 73474    | 69310    |
| Asthma Children | Boston     | S65         | 2015 | 20              | 93157   | 78526    | 69333    | 62484    | 57000    | 52677    |
| Asthma Children | Boston     | S65         | 2015 | 30              | 73633   | 57273    | 47921    | 41595    | 36748    | 33153    |
| Asthma Children | Boston     | S65         | 2015 | 40              | 47307   | 30218    | 22572    | 16861    | 13129    | 10331    |
| Asthma Children | Boston     | S65         | 2015 | 50              | 17066   | 5689     | 2275     | 910      | 319      | 182      |
| Asthma Children | Boston     | S65         | 2015 | 60              | 3163  | 319      | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2015 | 70              | 455   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2015 | 80              | 68  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2016 | 0               | 115661  | 104420   | 96593    | 90403    | 85056    | 80756    |
| Asthma Children | Boston     | S65         | 2016 | 10              | 112270  | 99710    | 91609    | 84647    | 79049    | 74430    |
| Asthma Children | Boston     | S65         | 2016 | 20              | 99209   | 83486    | 73815    | 65988    | 59935    | 55498    |
| Asthma Children | Boston     | S65         | 2016 | 30              | 78526   | 60845    | 50924    | 43939    | 39274    | 35474    |
| Asthma Children | Boston     | S65         | 2016 | 40              | 51220   | 33859    | 24916    | 18954    | 14972    | 11946    |
| Asthma Children | Boston     | S65         | 2016 | 50              | 19705   | 7031     | 3163     | 1456     | 683      | 250      |
| Asthma Children | Boston     | S65         | 2016 | 60              | 2298  | 205      | 23       | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2016 | 70              | 91  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2017 | 0               | 112976  | 101257   | 93612    | 86990    | 82075    | 77684    |
| Asthma Children | Boston     | S65         | 2017 | 10              | 108607  | 96661    | 88469    | 81962    | 76364    | 71540    |
| Asthma Children | Boston     | S65         | 2017 | 20              | 96843   | 81529    | 71244    | 63235    | 57819    | 52927    |
| Asthma Children | Boston     | S65         | 2017 | 30              | 76341   | 57592    | 48763    | 42073    | 37340    | 33176    |
| Asthma Children | Boston     | S65         | 2017 | 40              | 50697   | 33563    | 24734    | 18067    | 13903    | 11286    |
| Asthma Children | Boston     | S65         | 2017 | 50              | 23915   | 9716     | 4460     | 1752     | 592      | 250      |
| Asthma Children | Boston     | S65         | 2017 | 60              | 5165  | 523      | 46       | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2017 | 70              | 387   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2015 | 0               | 110791  | 99209    | 91427    | 85625    | 79800    | 75522    |
| Asthma Children | Boston     | S70         | 2015 | 10              | 106764  | 94203    | 86763    | 79140    | 73770    | 69492    |
| Asthma Children | Boston     | S70         | 2015 | 20              | 94249   | 79754    | 70380    | 63235    | 57956    | 53632    |
| Asthma Children | Boston     | S70         | 2015 | 30              | 76341   | 59867    | 50378    | 43893    | 39069    | 35269    |
| Asthma Children | Boston     | S70         | 2015 | 40              | 52904   | 35429    | 27669    | 21617    | 17453    | 14495    |
| Asthma Children | Boston     | S70         | 2015 | 50              | 25804   | 11286    | 5552     | 3004     | 1547     | 865      |
| Asthma Children | Boston     | S70         | 2015 | 60              | 6166  | 1047     | 250      | 91       | 23       | 23       |
| Asthma Children | Boston     | S70         | 2015 | 70              | 1024  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2015 | 80              | 114   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2016 | 0               | 115661  | 104420   | 96593    | 90403    | 85056    | 80756    |
| Asthma Children | Boston     | S70         | 2016 | 10              | 112452  | 99892    | 91541    | 84783    | 79185    | 74612    |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Boston     | S70         | 2016 | 20              | 100370  | 84738    | 75363    | 67603    | 61346    | 56954    |
| Asthma Children | Boston     | S70         | 2016 | 30              | 81893   | 63781    | 54269    | 46851    | 41345    | 37545    |
| Asthma Children | Boston     | S70         | 2016 | 40              | 57887   | 39456    | 30559    | 24552    | 19842    | 16747    |
| Asthma Children | Boston     | S70         | 2016 | 50              | 29968   | 14176    | 8146     | 4892     | 2822     | 1889     |
| Asthma Children | Boston     | S70         | 2016 | 60              | 7782  | 1343     | 250      | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2016 | 70              | 796   | 68       | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2017 | 0               | 112976  | 101257   | 93612    | 86990    | 82075    | 77684    |
| Asthma Children | Boston     | S70         | 2017 | 10              | 108744  | 96775    | 88674    | 81939    | 76318    | 71813    |
| Asthma Children | Boston     | S70         | 2017 | 20              | 97344   | 82417    | 72200    | 64486    | 58843    | 53678    |
| Asthma Children | Boston     | S70         | 2017 | 30              | 79140   | 60504    | 51015    | 44144    | 39297    | 35019    |
| Asthma Children | Boston     | S70         | 2017 | 40              | 56386   | 39365    | 29945    | 23665    | 18590    | 15382    |
| Asthma Children | Boston     | S70         | 2017 | 50              | 32812   | 16247    | 8624     | 4778     | 2731     | 1502     |
| Asthma Children | Boston     | S70         | 2017 | 60              | 11605   | 2617     | 455      | 137      | 0        | 0        |
| Asthma Children | Boston     | S70         | 2017 | 70              | 1616  | 23       | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2017 | 80              | 68  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2015 | 0               | 110791  | 99209    | 91427    | 85625    | 79800    | 75522    |
| Asthma Children | Boston     | S75         | 2015 | 10              | 106809  | 94021    | 86603    | 79094    | 73588    | 69333    |
| Asthma Children | Boston     | S75         | 2015 | 20              | 94454   | 80232    | 70880    | 63417    | 58251    | 53928    |
| Asthma Children | Boston     | S75         | 2015 | 30              | 77274   | 61050    | 51584    | 45008    | 40071    | 36384    |
| Asthma Children | Boston     | S75         | 2015 | 40              | 55430   | 38318    | 29695    | 23938    | 20183    | 16725    |
| Asthma Children | Boston     | S75         | 2015 | 50              | 29968   | 14654    | 8374     | 5074     | 3254     | 1684     |
| Asthma Children | Boston     | S75         | 2015 | 60              | 9375  | 2184     | 614      | 182      | 68       | 23       |
| Asthma Children | Boston     | S75         | 2015 | 70              | 1752  | 68       | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2015 | 80              | 137   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2016 | 0               | 115661  | 104420   | 96593    | 90403    | 85056    | 80756    |
| Asthma Children | Boston     | S75         | 2016 | 10              | 112430  | 100006   | 91609    | 84715    | 79185    | 74430    |
| Asthma Children | Boston     | S75         | 2016 | 20              | 100666  | 85147    | 75704    | 67968    | 61915    | 57341    |
| Asthma Children | Boston     | S75         | 2016 | 30              | 82940   | 65283    | 55566    | 48239    | 42596    | 38546    |
| Asthma Children | Boston     | S75         | 2016 | 40              | 60777   | 42824    | 33130    | 27146    | 22618    | 18954    |
| Asthma Children | Boston     | S75         | 2016 | 50              | 35383   | 18795    | 11013    | 7486     | 5097     | 3459     |
| Asthma Children | Boston     | S75         | 2016 | 60              | 12674   | 3163     | 933      | 205      | 46       | 0        |
| Asthma Children | Boston     | S75         | 2016 | 70              | 1684  | 137      | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2016 | 80              | 137   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2017 | 0               | 112976  | 101257   | 93612    | 86990    | 82075    | 77684    |
| Asthma Children | Boston     | S75         | 2017 | 10              | 108789  | 96547    | 88674    | 81848    | 76364    | 71677    |
| Asthma Children | Boston     | S75         | 2017 | 20              | 97935   | 82894    | 72632    | 64691    | 59184    | 53792    |
| Asthma Children | Boston     | S75         | 2017 | 30              | 80528   | 62120    | 52335    | 45145    | 40412    | 36271    |
| Asthma Children | Boston     | S75         | 2017 | 40              | 59435   | 41572    | 32653    | 26168    | 21002    | 17703    |



| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Boston     | S75         | 2017 | 50              | 37932   | 20274    | 11696    | 7122     | 4505     | 2958     |
| Asthma Children | Boston     | S75         | 2017 | 60              | 16315   | 4915     | 1343     | 319      | 114      | 46       |
| Asthma Children | Boston     | S75         | 2017 | 70              | 3641  | 387      | 68       | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2017 | 80              | 319   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Boston     | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2015 | 0               | 90113   | 82594    | 76635    | 73254    | 69872    | 66775    |
| Asthma Children | Dallas     | S65         | 2015 | 10              | 86330   | 77250    | 71267    | 67248    | 63488    | 60249    |
| Asthma Children | Dallas     | S65         | 2015 | 20              | 77155   | 66373    | 59350    | 54408    | 50247    | 46463    |
| Asthma Children | Dallas     | S65         | 2015 | 30              | 63181   | 50649    | 43177    | 38258    | 35161    | 32229    |
| Asthma Children | Dallas     | S65         | 2015 | 40              | 46014   | 32844    | 26246    | 21967    | 18373    | 15984    |
| Asthma Children | Dallas     | S65         | 2015 | 50              | 23196   | 11846    | 6834     | 4043     | 2601     | 1702     |
| Asthma Children | Dallas     | S65         | 2015 | 60              | 3878  | 709      | 95       | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2015 | 70              | 71  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2016 | 0               | 90420   | 83208    | 78266    | 74318    | 71315    | 68501    |
| Asthma Children | Dallas     | S65         | 2016 | 10              | 86164   | 78361    | 73325    | 68879    | 65427    | 62069    |
| Asthma Children | Dallas     | S65         | 2016 | 20              | 77273   | 67106    | 60367    | 55212    | 51145    | 48142    |
| Asthma Children | Dallas     | S65         | 2016 | 30              | 62022   | 49466    | 42846    | 37880    | 33955    | 31212    |
| Asthma Children | Dallas     | S65         | 2016 | 40              | 41427   | 28895    | 22038    | 17592    | 14802    | 12059    |
| Asthma Children | Dallas     | S65         | 2016 | 50              | 14991   | 5817     | 2743     | 1584     | 662      | 355      |
| Asthma Children | Dallas     | S65         | 2016 | 60              | 1395  | 47       | 24       | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2016 | 70              | 47  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2017 | 0               | 91035   | 83563    | 78645    | 74341    | 70724    | 68028    |
| Asthma Children | Dallas     | S65         | 2017 | 10              | 87819   | 79023    | 72592    | 68241    | 64623    | 61218    |
| Asthma Children | Dallas     | S65         | 2017 | 20              | 78196   | 67153    | 60509    | 55661    | 51263    | 48119    |
| Asthma Children | Dallas     | S65         | 2017 | 30              | 63252   | 51192    | 43933    | 39133    | 35634    | 32583    |
| Asthma Children | Dallas     | S65         | 2017 | 40              | 44974   | 31638    | 25301    | 20524    | 17427    | 14282    |
| Asthma Children | Dallas     | S65         | 2017 | 50              | 21588   | 10735    | 5675     | 3003     | 1608     | 1040     |
| Asthma Children | Dallas     | S65         | 2017 | 60              | 3476  | 402      | 47       | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2017 | 70              | 118   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2015 | 0               | 90113   | 82594    | 76635    | 73254    | 69872    | 66775    |
| Asthma Children | Dallas     | S70         | 2015 | 10              | 86401   | 77368    | 71362    | 67461    | 63606    | 60532    |
| Asthma Children | Dallas     | S70         | 2015 | 20              | 77935   | 67082    | 60130    | 55401    | 51074    | 47740    |
| Asthma Children | Dallas     | S70         | 2015 | 30              | 65285   | 52706    | 44903    | 40150    | 36556    | 33931    |
| Asthma Children | Dallas     | S70         | 2015 | 40              | 50176   | 37052    | 29912    | 25395    | 21659    | 18869    |
| Asthma Children | Dallas     | S70         | 2015 | 50              | 30668   | 18467    | 12698    | 8654     | 6006     | 4564     |
| Asthma Children | Dallas     | S70         | 2015 | 60              | 9813  | 2861     | 1064     | 473      | 213      | 71       |
| Asthma Children | Dallas     | S70         | 2015 | 70              | 946   | 118      | 0        | 0        | 0        | 0        |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Dallas     | S70         | 2015 | 80              | 24  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2016 | 0               | 90420   | 83208    | 78266    | 74318    | 71315    | 68501    |
| Asthma Children | Dallas     | S70         | 2016 | 10              | 86259   | 78598    | 73727    | 69116    | 65640    | 62471    |
| Asthma Children | Dallas     | S70         | 2016 | 20              | 77817   | 67933    | 61384    | 56087    | 52375    | 49041    |
| Asthma Children | Dallas     | S70         | 2016 | 30              | 64245   | 51665    | 44761    | 40079    | 35894    | 32702    |
| Asthma Children | Dallas     | S70         | 2016 | 40              | 45707   | 32867    | 25608    | 21446    | 18373    | 15677    |
| Asthma Children | Dallas     | S70         | 2016 | 50              | 21494   | 10144    | 5746     | 3689     | 2270     | 1513     |
| Asthma Children | Dallas     | S70         | 2016 | 60              | 2908  | 378      | 118      | 24       | 24       | 0        |
| Asthma Children | Dallas     | S70         | 2016 | 70              | 426   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2017 | 0               | 91035   | 83563    | 78645    | 74341    | 70724    | 68028    |
| Asthma Children | Dallas     | S70         | 2017 | 10              | 88008   | 79236    | 72899    | 68525    | 64883    | 61502    |
| Asthma Children | Dallas     | S70         | 2017 | 20              | 79047   | 68052    | 61407    | 56773    | 52446    | 49183    |
| Asthma Children | Dallas     | S70         | 2017 | 30              | 65238   | 52942    | 46085    | 41261    | 37525    | 34570    |
| Asthma Children | Dallas     | S70         | 2017 | 40              | 49159   | 35137    | 28469    | 24378    | 20974    | 18089    |
| Asthma Children | Dallas     | S70         | 2017 | 50              | 28114   | 15913    | 9907     | 6503     | 4209     | 2767     |
| Asthma Children | Dallas     | S70         | 2017 | 60              | 8134  | 1561     | 402      | 142      | 24       | 0        |
| Asthma Children | Dallas     | S70         | 2017 | 70              | 355   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2015 | 0               | 90113   | 82594    | 76635    | 73254    | 69872    | 66775    |
| Asthma Children | Dallas     | S75         | 2015 | 10              | 86519   | 77604    | 71504    | 67650    | 63748    | 60627    |
| Asthma Children | Dallas     | S75         | 2015 | 20              | 78621   | 67815    | 60840    | 56134    | 52115    | 48568    |
| Asthma Children | Dallas     | S75         | 2015 | 30              | 66798   | 54077    | 46487    | 41782    | 37951    | 35043    |
| Asthma Children | Dallas     | S75         | 2015 | 40              | 52824   | 40055    | 32536    | 28044    | 24095    | 21210    |
| Asthma Children | Dallas     | S75         | 2015 | 50              | 36580   | 23622    | 16859    | 12958    | 10357    | 7425     |
| Asthma Children | Dallas     | S75         | 2015 | 60              | 15724   | 6313     | 2956     | 1490     | 969      | 520      |
| Asthma Children | Dallas     | S75         | 2015 | 70              | 2956  | 355      | 47       | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2015 | 80              | 166   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2016 | 0               | 90420   | 83208    | 78266    | 74318    | 71315    | 68501    |
| Asthma Children | Dallas     | S75         | 2016 | 10              | 86282   | 78739    | 73774    | 69352    | 65876    | 62708    |
| Asthma Children | Dallas     | S75         | 2016 | 20              | 78408   | 68525    | 62046    | 56655    | 53131    | 49916    |
| Asthma Children | Dallas     | S75         | 2016 | 30              | 65971   | 53250    | 46345    | 41592    | 37431    | 34286    |
| Asthma Children | Dallas     | S75         | 2016 | 40              | 48781   | 35847    | 28611    | 23764    | 20572    | 18136    |
| Asthma Children | Dallas     | S75         | 2016 | 50              | 27311   | 15015    | 9104     | 6313     | 4327     | 3121     |
| Asthma Children | Dallas     | S75         | 2016 | 60              | 6006  | 1348     | 331      | 142      | 24       | 0        |
| Asthma Children | Dallas     | S75         | 2016 | 70              | 1111  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2016 | 80              | 47  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Dallas     | S75         | 2017 | 0               | 91035   | 83563    | 78645    | 74341    | 70724    | 68028    |
| Asthma Children | Dallas     | S75         | 2017 | 10              | 88127   | 79401    | 73277    | 68595    | 65214    | 61715    |
| Asthma Children | Dallas     | S75         | 2017 | 20              | 79685   | 68737    | 61951    | 57151    | 52989    | 49679    |
| Asthma Children | Dallas     | S75         | 2017 | 30              | 66822   | 54763    | 47598    | 42373    | 38826    | 35657    |
| Asthma Children | Dallas     | S75         | 2017 | 40              | 52091   | 38164    | 31236    | 26578    | 23196    | 20666    |
| Asthma Children | Dallas     | S75         | 2017 | 50              | 32560   | 19508    | 13596    | 10144    | 7236     | 5249     |
| Asthma Children | Dallas     | S75         | 2017 | 60              | 13100   | 3831     | 1064     | 473      | 213      | 47       |
| Asthma Children | Dallas     | S75         | 2017 | 70              | 1371  | 95       | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2017 | 80              | 24  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Dallas     | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2015 | 0               | 77853   | 70222    | 64551    | 60129    | 56729    | 53504    |
| Asthma Children | Detroit    | S65         | 2015 | 10              | 74853   | 66806    | 60319    | 55550    | 51995    | 48960    |
| Asthma Children | Detroit    | S65         | 2015 | 20              | 66285   | 55741    | 49168    | 44242    | 39872    | 36542    |
| Asthma Children | Detroit    | S65         | 2015 | 30              | 53486   | 41467    | 34652    | 30246    | 26656    | 23847    |
| Asthma Children | Detroit    | S65         | 2015 | 40              | 38155   | 25911    | 19632    | 15366    | 12435    | 10024    |
| Asthma Children | Detroit    | S65         | 2015 | 50              | 16927   | 7267     | 3711     | 1890     | 1041     | 468      |
| Asthma Children | Detroit    | S65         | 2015 | 60              | 1717  | 173      | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2016 | 0               | 80871   | 72806    | 67187    | 62747    | 58741    | 55706    |
| Asthma Children | Detroit    | S65         | 2016 | 10              | 78079   | 68627    | 62956    | 58204    | 54180    | 51249    |
| Asthma Children | Detroit    | S65         | 2016 | 20              | 69008   | 58065    | 51492    | 46393    | 42508    | 38987    |
| Asthma Children | Detroit    | S65         | 2016 | 30              | 56244   | 44034    | 37496    | 32796    | 29136    | 26223    |
| Asthma Children | Detroit    | S65         | 2016 | 40              | 40323   | 28287    | 21488    | 17777    | 13996    | 11655    |
| Asthma Children | Detroit    | S65         | 2016 | 50              | 21904   | 10857    | 6053     | 3018     | 1682     | 850      |
| Asthma Children | Detroit    | S65         | 2016 | 60              | 5064  | 486      | 104      | 17       | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2016 | 70              | 52  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2017 | 0               | 79917   | 71558    | 66060    | 62140    | 58516    | 54718    |
| Asthma Children | Detroit    | S65         | 2017 | 10              | 76847   | 67968    | 62123    | 57215    | 53885    | 50451    |
| Asthma Children | Detroit    | S65         | 2017 | 20              | 68609   | 57649    | 50937    | 45959    | 41762    | 38033    |
| Asthma Children | Detroit    | S65         | 2017 | 30              | 56122   | 43236    | 36663    | 31998    | 28443    | 25442    |
| Asthma Children | Detroit    | S65         | 2017 | 40              | 39820   | 28079    | 21540    | 17222    | 14169    | 11377    |
| Asthma Children | Detroit    | S65         | 2017 | 50              | 19806   | 8914     | 5238     | 2636     | 1422     | 954      |
| Asthma Children | Detroit    | S65         | 2017 | 60              | 2012  | 173      | 35       | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2017 | 70              | 35  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2015 | 0               | 77853   | 70222    | 64551    | 60129    | 56729    | 53504    |
| Asthma Children | Detroit    | S70         | 2015 | 10              | 74905   | 66910    | 60406    | 55723    | 51977    | 49064    |
| Asthma Children | Detroit    | S70         | 2015 | 20              | 67205   | 56469    | 50139    | 45005    | 40756    | 37635    |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Detroit    | S70         | 2015 | 30              | 55793   | 43288    | 36369    | 31825    | 28200    | 25668    |
| Asthma Children | Detroit    | S70         | 2015 | 40              | 41762   | 29518    | 23396    | 18904    | 15730    | 12938    |
| Asthma Children | Detroit    | S70         | 2015 | 50              | 24107   | 12366    | 7544     | 4613     | 3035     | 1960     |
| Asthma Children | Detroit    | S70         | 2015 | 60              | 6209  | 1301     | 243      | 52       | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2015 | 70              | 121   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2016 | 0               | 80871   | 72806    | 67187    | 62747    | 58741    | 55706    |
| Asthma Children | Detroit    | S70         | 2016 | 10              | 78218   | 68852    | 63112    | 58446    | 54215    | 51336    |
| Asthma Children | Detroit    | S70         | 2016 | 20              | 69771   | 58897    | 52498    | 47555    | 43583    | 40115    |
| Asthma Children | Detroit    | S70         | 2016 | 30              | 58325   | 45994    | 39334    | 34998    | 31148    | 28096    |
| Asthma Children | Detroit    | S70         | 2016 | 40              | 44624   | 32137    | 25390    | 21020    | 17690    | 14672    |
| Asthma Children | Detroit    | S70         | 2016 | 50              | 28477   | 16372    | 10753    | 7267     | 4839     | 3313     |
| Asthma Children | Detroit    | S70         | 2016 | 60              | 11776   | 3469     | 1110     | 243      | 139      | 69       |
| Asthma Children | Detroit    | S70         | 2016 | 70              | 1110  | 17       | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2017 | 0               | 79917   | 71558    | 66060    | 62140    | 58516    | 54718    |
| Asthma Children | Detroit    | S70         | 2017 | 10              | 76986   | 68193    | 62297    | 57371    | 53954    | 50538    |
| Asthma Children | Detroit    | S70         | 2017 | 20              | 69321   | 58533    | 51544    | 46792    | 42681    | 38918    |
| Asthma Children | Detroit    | S70         | 2017 | 30              | 57770   | 45526    | 38242    | 33993    | 30229    | 27125    |
| Asthma Children | Detroit    | S70         | 2017 | 40              | 43878   | 31270    | 25113    | 20500    | 17222    | 14655    |
| Asthma Children | Detroit    | S70         | 2017 | 50              | 27055   | 15314    | 9712     | 6348     | 4492     | 2792     |
| Asthma Children | Detroit    | S70         | 2017 | 60              | 7648  | 1769     | 572      | 191      | 139      | 35       |
| Asthma Children | Detroit    | S70         | 2017 | 70              | 503   | 17       | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S75         | 2015 | 0               | 77853   | 70222    | 64551    | 60129    | 56729    | 53504    |
| Asthma Children | Detroit    | S75         | 2015 | 10              | 74732   | 66823    | 60146    | 55602    | 51821    | 48873    |
| Asthma Children | Detroit    | S75         | 2015 | 20              | 67465   | 56885    | 50399    | 45318    | 41086    | 37947    |
| Asthma Children | Detroit    | S75         | 2015 | 30              | 56573   | 44346    | 37652    | 32605    | 28980    | 26258    |
| Asthma Children | Detroit    | S75         | 2015 | 40              | 43878   | 31235    | 24957    | 20621    | 17308    | 14499    |
| Asthma Children | Detroit    | S75         | 2015 | 50              | 28911   | 16615    | 10631    | 7249     | 4891     | 3208     |
| Asthma Children | Detroit    | S75         | 2015 | 60              | 11030   | 3243     | 798      | 277      | 52       | 35       |
| Asthma Children | Detroit    | S75         | 2015 | 70              | 1214  | 35       | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit    | S75         | 2016 | 0               | 80871   | 72806    | 67187    | 62747    | 58741    | 55706    |
| Asthma Children | Detroit    | S75         | 2016 | 10              | 78061   | 68748    | 62817    | 58412    | 54163    | 51232    |
| Asthma Children | Detroit    | S75         | 2016 | 20              | 69962   | 59140    | 52671    | 47763    | 43722    | 40132    |
| Asthma Children | Detroit    | S75         | 2016 | 30              | 59504   | 47277    | 40097    | 35536    | 31825    | 28894    |
| Asthma Children | Detroit    | S75         | 2016 | 40              | 46861   | 34010    | 27680    | 23084    | 19442    | 16597    |
| Asthma Children | Detroit    | S75         | 2016 | 50              | 32744   | 20066    | 14169    | 10094    | 7353     | 5654     |

| Study Group     | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Detroit      | S75         | 2016 | 60              | 17673   | 7492     | 3261     | 1231     | 520      | 225      |
| Asthma Children | Detroit      | S75         | 2016 | 70              | 4544  | 520      | 104      | 17       | 0        | 0        |
| Asthma Children | Detroit      | S75         | 2016 | 80              | 69  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit      | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit      | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit      | S75         | 2017 | 0               | 79917   | 71558    | 66060    | 62140    | 58516    | 54718    |
| Asthma Children | Detroit      | S75         | 2017 | 10              | 76899   | 68037    | 62175    | 57284    | 53781    | 50243    |
| Asthma Children | Detroit      | S75         | 2017 | 20              | 69598   | 58689    | 51787    | 47121    | 42890    | 38883    |
| Asthma Children | Detroit      | S75         | 2017 | 30              | 58828   | 46306    | 38970    | 34548    | 30992    | 27801    |
| Asthma Children | Detroit      | S75         | 2017 | 40              | 45925   | 33229    | 26726    | 22130    | 18696    | 16233    |
| Asthma Children | Detroit      | S75         | 2017 | 50              | 30853   | 18991    | 12955    | 8828     | 6452     | 4717     |
| Asthma Children | Detroit      | S75         | 2017 | 60              | 13458   | 4683     | 1821     | 763      | 364      | 208      |
| Asthma Children | Detroit      | S75         | 2017 | 70              | 1682  | 87       | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit      | S75         | 2017 | 80              | 52  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit      | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Detroit      | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2015 | 0               | 100049  | 90817    | 84248    | 78616    | 73924    | 70432    |
| Asthma Children | Philadelphia | S65         | 2015 | 10              | 97016   | 87172    | 79315    | 73575    | 69493    | 66198    |
| Asthma Children | Philadelphia | S65         | 2015 | 20              | 87631   | 75146    | 66612    | 60872    | 56703    | 52709    |
| Asthma Children | Philadelphia | S65         | 2015 | 30              | 73073   | 58428    | 50243    | 43848    | 39505    | 35620    |
| Asthma Children | Philadelphia | S65         | 2015 | 40              | 50352   | 35314    | 27675    | 22284    | 18552    | 15605    |
| Asthma Children | Philadelphia | S65         | 2015 | 50              | 20102   | 9058     | 4954     | 2794     | 1441     | 808      |
| Asthma Children | Philadelphia | S65         | 2015 | 60              | 2248  | 218      | 44       | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2015 | 70              | 44  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2016 | 0               | 98522   | 89180    | 82632    | 77241    | 72745    | 69144    |
| Asthma Children | Philadelphia | S65         | 2016 | 10              | 95400   | 85666    | 78442    | 72331    | 67856    | 64233    |
| Asthma Children | Philadelphia | S65         | 2016 | 20              | 85775   | 72854    | 64975    | 58973    | 54237    | 50767    |
| Asthma Children | Philadelphia | S65         | 2016 | 30              | 69581   | 55590    | 47711    | 42036    | 38348    | 35030    |
| Asthma Children | Philadelphia | S65         | 2016 | 40              | 47515   | 33110    | 25711    | 21040    | 16937    | 14230    |
| Asthma Children | Philadelphia | S65         | 2016 | 50              | 18421   | 7923     | 3667     | 1724     | 851      | 327      |
| Asthma Children | Philadelphia | S65         | 2016 | 60              | 2750  | 262      | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2016 | 70              | 22  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2017 | 0               | 98958   | 89180    | 82501    | 76958    | 73051    | 69515    |
| Asthma Children | Philadelphia | S65         | 2017 | 10              | 95728   | 85426    | 77743    | 72505    | 68140    | 64561    |
| Asthma Children | Philadelphia | S65         | 2017 | 20              | 85688   | 72593    | 64408    | 58820    | 54477    | 50614    |
| Asthma Children | Philadelphia | S65         | 2017 | 30              | 68620   | 53910    | 45812    | 40094    | 35947    | 32761    |
| Asthma Children | Philadelphia | S65         | 2017 | 40              | 46052   | 30185    | 23528    | 18465    | 15191    | 12506    |
| Asthma Children | Philadelphia | S65         | 2017 | 50              | 16937   | 6308     | 3012     | 1179     | 655      | 306      |
| Asthma Children | Philadelphia | S65         | 2017 | 60              | 1964  | 218      | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2017 | 70              | 65  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group     | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Philadelphia | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2015 | 0               | 100049  | 90817    | 84248    | 78616    | 73924    | 70432    |
| Asthma Children | Philadelphia | S70         | 2015 | 10              | 97125   | 87325    | 79533    | 73858    | 69668    | 66394    |
| Asthma Children | Philadelphia | S70         | 2015 | 20              | 88635   | 75910    | 67791    | 61767    | 57402    | 53691    |
| Asthma Children | Philadelphia | S70         | 2015 | 30              | 75212   | 60741    | 52491    | 46423    | 41578    | 37562    |
| Asthma Children | Philadelphia | S70         | 2015 | 40              | 56114   | 40574    | 33001    | 27282    | 23397    | 19840    |
| Asthma Children | Philadelphia | S70         | 2015 | 50              | 28897   | 15562    | 9953     | 6766     | 4845     | 3274     |
| Asthma Children | Philadelphia | S70         | 2015 | 60              | 6264  | 1375     | 437      | 109      | 22       | 22       |
| Asthma Children | Philadelphia | S70         | 2015 | 70              | 611   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2016 | 0               | 98522   | 89180    | 82632    | 77241    | 72745    | 69144    |
| Asthma Children | Philadelphia | S70         | 2016 | 10              | 95510   | 85841    | 78682    | 72593    | 68009    | 64473    |
| Asthma Children | Philadelphia | S70         | 2016 | 20              | 86561   | 73880    | 66285    | 60021    | 55437    | 51487    |
| Asthma Children | Philadelphia | S70         | 2016 | 30              | 72374   | 57860    | 49806    | 44241    | 40290    | 37017    |
| Asthma Children | Philadelphia | S70         | 2016 | 40              | 53189   | 38413    | 30578    | 25776    | 21717    | 18399    |
| Asthma Children | Philadelphia | S70         | 2016 | 50              | 27326   | 14885    | 8425     | 5020     | 3318     | 2030     |
| Asthma Children | Philadelphia | S70         | 2016 | 60              | 6504  | 1113     | 175      | 44       | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2016 | 70              | 655   | 44       | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2017 | 0               | 98958   | 89180    | 82501    | 76958    | 73051    | 69515    |
| Asthma Children | Philadelphia | S70         | 2017 | 10              | 95946   | 85557    | 77896    | 72636    | 68424    | 64779    |
| Asthma Children | Philadelphia | S70         | 2017 | 20              | 86517   | 73553    | 65368    | 59672    | 55481    | 51858    |
| Asthma Children | Philadelphia | S70         | 2017 | 30              | 71567   | 56420    | 48584    | 42429    | 37890    | 34485    |
| Asthma Children | Philadelphia | S70         | 2017 | 40              | 51400   | 35532    | 28177    | 22786    | 19490    | 16326    |
| Asthma Children | Philadelphia | S70         | 2017 | 50              | 24248   | 12463    | 7224     | 3907     | 2401     | 1288     |
| Asthma Children | Philadelphia | S70         | 2017 | 60              | 6024  | 1375     | 284      | 22       | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2017 | 70              | 524   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2015 | 0               | 100049  | 90817    | 84248    | 78616    | 73924    | 70432    |
| Asthma Children | Philadelphia | S75         | 2015 | 10              | 97147   | 87434    | 79642    | 73989    | 69733    | 66547    |
| Asthma Children | Philadelphia | S75         | 2015 | 20              | 89638   | 76783    | 68642    | 62575    | 58078    | 54477    |
| Asthma Children | Philadelphia | S75         | 2015 | 30              | 77569   | 62946    | 54739    | 48519    | 44154    | 39963    |
| Asthma Children | Philadelphia | S75         | 2015 | 40              | 61461   | 46074    | 37824    | 31778    | 27588    | 24248    |
| Asthma Children | Philadelphia | S75         | 2015 | 50              | 38261   | 23768    | 16850    | 12572    | 9800     | 7552     |
| Asthma Children | Philadelphia | S75         | 2015 | 60              | 13859   | 4474     | 2095     | 939      | 393      | 196      |
| Asthma Children | Philadelphia | S75         | 2015 | 70              | 2183  | 175      | 44       | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2015 | 80              | 218   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2016 | 0               | 98522   | 89180    | 82632    | 77241    | 72745    | 69144    |

| Study Group     | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Philadelphia | S75         | 2016 | 10              | 95619   | 85884    | 78529    | 72702    | 68184    | 64473    |
| Asthma Children | Philadelphia | S75         | 2016 | 20              | 87085   | 75059    | 67027    | 61265    | 56441    | 52731    |
| Asthma Children | Philadelphia | S75         | 2016 | 30              | 74950   | 60392    | 52120    | 46598    | 42386    | 38981    |
| Asthma Children | Philadelphia | S75         | 2016 | 40              | 58275   | 43564    | 35380    | 30098    | 26082    | 23157    |
| Asthma Children | Philadelphia | S75         | 2016 | 50              | 36798   | 23354    | 15976    | 11524    | 8272     | 6068     |
| Asthma Children | Philadelphia | S75         | 2016 | 60              | 14078   | 4562     | 1375     | 480      | 196      | 87       |
| Asthma Children | Philadelphia | S75         | 2016 | 70              | 2270  | 196      | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2016 | 80              | 65  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2017 | 0               | 98958   | 89180    | 82501    | 76958    | 73051    | 69515    |
| Asthma Children | Philadelphia | S75         | 2017 | 10              | 95946   | 85710    | 78049    | 72767    | 68577    | 64779    |
| Asthma Children | Philadelphia | S75         | 2017 | 20              | 87434   | 74208    | 65914    | 60501    | 56398    | 52578    |
| Asthma Children | Philadelphia | S75         | 2017 | 30              | 74077   | 58886    | 50876    | 44852    | 40050    | 36624    |
| Asthma Children | Philadelphia | S75         | 2017 | 40              | 55961   | 40552    | 32957    | 27304    | 23463    | 20342    |
| Asthma Children | Philadelphia | S75         | 2017 | 50              | 33088   | 19512    | 13205    | 9080     | 6155     | 4212     |
| Asthma Children | Philadelphia | S75         | 2017 | 60              | 13292   | 4103     | 1724     | 567      | 262      | 44       |
| Asthma Children | Philadelphia | S75         | 2017 | 70              | 1942  | 131      | 22       | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2017 | 80              | 87  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Philadelphia | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2015 | 0               | 58411   | 53655    | 50924    | 48659    | 46819    | 44993    |
| Asthma Children | Phoenix      | S65         | 2015 | 10              | 56727   | 51745    | 48532    | 46196    | 44158    | 42488    |
| Asthma Children | Phoenix      | S65         | 2015 | 20              | 51886   | 46253    | 42502    | 39658    | 36742    | 34548    |
| Asthma Children | Phoenix      | S65         | 2015 | 30              | 44923   | 37520    | 33260    | 30274    | 27641    | 25844    |
| Asthma Children | Phoenix      | S65         | 2015 | 40              | 34619   | 26778    | 22306    | 19107    | 17126    | 15243    |
| Asthma Children | Phoenix      | S65         | 2015 | 50              | 18541   | 10643    | 7034     | 4897     | 3468     | 2633     |
| Asthma Children | Phoenix      | S65         | 2015 | 60              | 1500  | 226      | 14       | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2016 | 0               | 56995   | 52580    | 49848    | 47584    | 45701    | 44130    |
| Asthma Children | Phoenix      | S65         | 2016 | 10              | 55127   | 50329    | 47456    | 45163    | 43026    | 41512    |
| Asthma Children | Phoenix      | S65         | 2016 | 20              | 50442   | 44654    | 41186    | 38384    | 36360    | 34548    |
| Asthma Children | Phoenix      | S65         | 2016 | 30              | 43380   | 37266    | 33133    | 30161    | 27910    | 26014    |
| Asthma Children | Phoenix      | S65         | 2016 | 40              | 33289   | 25518    | 21414    | 18725    | 16630    | 15073    |
| Asthma Children | Phoenix      | S65         | 2016 | 50              | 15059   | 7982     | 5081     | 3354     | 2364     | 1571     |
| Asthma Children | Phoenix      | S65         | 2016 | 60              | 778   | 71       | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix      | S65         | 2017 | 0               | 58340   | 53684    | 50457    | 48121    | 46437    | 44894    |
| Asthma Children | Phoenix      | S65         | 2017 | 10              | 56925   | 51518    | 48150    | 45645    | 44031    | 42375    |
| Asthma Children | Phoenix      | S65         | 2017 | 20              | 52325   | 46338    | 42460    | 39488    | 37252    | 35341    |
| Asthma Children | Phoenix      | S65         | 2017 | 30              | 45772   | 38058    | 33855    | 30939    | 28901    | 27160    |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Phoenix    | S65         | 2017 | 40              | 35907   | 27953    | 24146    | 21103    | 18697    | 16956    |
| Asthma Children | Phoenix    | S65         | 2017 | 50              | 19348   | 12002    | 8464     | 6199     | 4671     | 3637     |
| Asthma Children | Phoenix    | S65         | 2017 | 60              | 2788  | 481      | 127      | 42       | 0        | 0        |
| Asthma Children | Phoenix    | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2015 | 0               | 58411   | 53655    | 50924    | 48659    | 46819    | 44993    |
| Asthma Children | Phoenix    | S70         | 2015 | 10              | 56826   | 51801    | 48659    | 46281    | 44257    | 42573    |
| Asthma Children | Phoenix    | S70         | 2015 | 20              | 52339   | 46819    | 42984    | 40210    | 37520    | 35256    |
| Asthma Children | Phoenix    | S70         | 2015 | 30              | 46310   | 39148    | 34789    | 31788    | 29085    | 27203    |
| Asthma Children | Phoenix    | S70         | 2015 | 40              | 37351   | 29566    | 24896    | 22192    | 19716    | 17946    |
| Asthma Children | Phoenix    | S70         | 2015 | 50              | 24995   | 16588    | 12738    | 10063    | 8209     | 6610     |
| Asthma Children | Phoenix    | S70         | 2015 | 60              | 7034  | 2406     | 1203     | 665      | 354      | 170      |
| Asthma Children | Phoenix    | S70         | 2015 | 70              | 127   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2016 | 0               | 56995   | 52580    | 49848    | 47584    | 45701    | 44130    |
| Asthma Children | Phoenix    | S70         | 2016 | 10              | 55269   | 50414    | 47612    | 45347    | 43224    | 41639    |
| Asthma Children | Phoenix    | S70         | 2016 | 20              | 50782   | 45305    | 41823    | 38922    | 36983    | 35100    |
| Asthma Children | Phoenix    | S70         | 2016 | 30              | 44427   | 38440    | 34435    | 31519    | 29283    | 27089    |
| Asthma Children | Phoenix    | S70         | 2016 | 40              | 35978   | 28717    | 24542    | 21584    | 19475    | 17777    |
| Asthma Children | Phoenix    | S70         | 2016 | 50              | 22192   | 14734    | 10714    | 8591     | 6680     | 5308     |
| Asthma Children | Phoenix    | S70         | 2016 | 60              | 5336  | 1444     | 623      | 212      | 127      | 85       |
| Asthma Children | Phoenix    | S70         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2017 | 0               | 58340   | 53684    | 50457    | 48121    | 46437    | 44894    |
| Asthma Children | Phoenix    | S70         | 2017 | 10              | 57010   | 51674    | 48362    | 45871    | 44173    | 42559    |
| Asthma Children | Phoenix    | S70         | 2017 | 20              | 52806   | 46947    | 43040    | 40210    | 38030    | 35949    |
| Asthma Children | Phoenix    | S70         | 2017 | 30              | 46961   | 39445    | 35270    | 32425    | 30331    | 28505    |
| Asthma Children | Phoenix    | S70         | 2017 | 40              | 38624   | 30868    | 26877    | 23877    | 21640    | 19857    |
| Asthma Children | Phoenix    | S70         | 2017 | 50              | 26453   | 18343    | 14351    | 11507    | 9822     | 8308     |
| Asthma Children | Phoenix    | S70         | 2017 | 60              | 9143  | 3977     | 2109     | 1033     | 609      | 382      |
| Asthma Children | Phoenix    | S70         | 2017 | 70              | 552   | 71       | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2015 | 0               | 58411   | 53655    | 50924    | 48659    | 46819    | 44993    |
| Asthma Children | Phoenix    | S75         | 2015 | 10              | 56769   | 51730    | 48518    | 46267    | 44243    | 42602    |
| Asthma Children | Phoenix    | S75         | 2015 | 20              | 52495   | 47046    | 43295    | 40549    | 37818    | 35511    |
| Asthma Children | Phoenix    | S75         | 2015 | 30              | 47145   | 40139    | 35681    | 32737    | 29977    | 27995    |
| Asthma Children | Phoenix    | S75         | 2015 | 40              | 39191   | 31307    | 26637    | 23877    | 21626    | 19659    |
| Asthma Children | Phoenix    | S75         | 2015 | 50              | 28844   | 20480    | 16404    | 13814    | 11450    | 9780     |
| Asthma Children | Phoenix    | S75         | 2015 | 60              | 14451   | 7402     | 4161     | 2774     | 1840     | 1161     |



| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Phoenix    | S75         | 2015 | 70              | 1302  | 170      | 28       | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2015 | 80              | 14  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2016 | 0               | 56995   | 52580    | 49848    | 47584    | 45701    | 44130    |
| Asthma Children | Phoenix    | S75         | 2016 | 10              | 55269   | 50428    | 47555    | 45234    | 43054    | 41526    |
| Asthma Children | Phoenix    | S75         | 2016 | 20              | 51108   | 45489    | 42078    | 39191    | 37195    | 35270    |
| Asthma Children | Phoenix    | S75         | 2016 | 30              | 45078   | 39077    | 35185    | 32524    | 30090    | 27981    |
| Asthma Children | Phoenix    | S75         | 2016 | 40              | 37605   | 30628    | 26495    | 23466    | 21202    | 19447    |
| Asthma Children | Phoenix    | S75         | 2016 | 50              | 26835   | 19135    | 14847    | 12172    | 10091    | 8733     |
| Asthma Children | Phoenix    | S75         | 2016 | 60              | 11634   | 5364     | 2802     | 1755     | 1019     | 580      |
| Asthma Children | Phoenix    | S75         | 2016 | 70              | 807   | 142      | 14       | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2017 | 0               | 58340   | 53684    | 50457    | 48121    | 46437    | 44894    |
| Asthma Children | Phoenix    | S75         | 2017 | 10              | 56953   | 51773    | 48291    | 45942    | 44215    | 42403    |
| Asthma Children | Phoenix    | S75         | 2017 | 20              | 53033   | 47272    | 43338    | 40323    | 38172    | 36204    |
| Asthma Children | Phoenix    | S75         | 2017 | 30              | 47470   | 40479    | 36233    | 33331    | 30996    | 29184    |
| Asthma Children | Phoenix    | S75         | 2017 | 40              | 40507   | 32425    | 28618    | 25787    | 23636    | 21810    |
| Asthma Children | Phoenix    | S75         | 2017 | 50              | 30670   | 22504    | 18145    | 15187    | 13064    | 11620    |
| Asthma Children | Phoenix    | S75         | 2017 | 60              | 15668   | 8931     | 5789     | 3595     | 2562     | 1897     |
| Asthma Children | Phoenix    | S75         | 2017 | 70              | 3128  | 637      | 113      | 99       | 14       | 0        |
| Asthma Children | Phoenix    | S75         | 2017 | 80              | 156   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Phoenix    | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2015 | 0               | 30691   | 27958    | 26095    | 24744    | 23595    | 22454    |
| Asthma Children | Sacramento | S65         | 2015 | 10              | 29286   | 26297    | 24239    | 22733    | 21382    | 20334    |
| Asthma Children | Sacramento | S65         | 2015 | 20              | 25536   | 21941    | 19620    | 17935    | 16600    | 15637    |
| Asthma Children | Sacramento | S65         | 2015 | 30              | 20691   | 16569    | 14006    | 12384    | 11258    | 10202    |
| Asthma Children | Sacramento | S65         | 2015 | 40              | 12904   | 8735     | 6491     | 5124     | 4185     | 3540     |
| Asthma Children | Sacramento | S65         | 2015 | 50              | 3362  | 1017     | 435      | 163      | 70       | 31       |
| Asthma Children | Sacramento | S65         | 2015 | 60              | 217   | 16       | 8        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2016 | 0               | 31786   | 28968    | 27198    | 25738    | 24597    | 23463    |
| Asthma Children | Sacramento | S65         | 2016 | 10              | 30280   | 27190    | 25101    | 23587    | 22267    | 21351    |
| Asthma Children | Sacramento | S65         | 2016 | 20              | 26281   | 22461    | 20233    | 18548    | 17166    | 16126    |
| Asthma Children | Sacramento | S65         | 2016 | 30              | 20668   | 16763    | 14185    | 12741    | 11421    | 10489    |
| Asthma Children | Sacramento | S65         | 2016 | 40              | 13137   | 8851     | 6755     | 5443     | 4270     | 3463     |
| Asthma Children | Sacramento | S65         | 2016 | 50              | 4262  | 1770     | 784      | 342      | 155      | 78       |
| Asthma Children | Sacramento | S65         | 2016 | 60              | 295   | 23       | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Sacramento | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2017 | 0               | 30598   | 27990    | 26118    | 24698    | 23448    | 22500    |
| Asthma Children | Sacramento | S65         | 2017 | 10              | 29340   | 26281    | 24302    | 22632    | 21320    | 20412    |
| Asthma Children | Sacramento | S65         | 2017 | 20              | 25893   | 22190    | 19721    | 18215    | 16918    | 15885    |
| Asthma Children | Sacramento | S65         | 2017 | 30              | 20497   | 16219    | 13773    | 12423    | 11328    | 10350    |
| Asthma Children | Sacramento | S65         | 2017 | 40              | 12702   | 8595     | 6530     | 5132     | 4177     | 3432     |
| Asthma Children | Sacramento | S65         | 2017 | 50              | 3253  | 1002     | 318      | 148      | 85       | 47       |
| Asthma Children | Sacramento | S65         | 2017 | 60              | 124   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2015 | 0               | 30691   | 27958    | 26095    | 24744    | 23595    | 22454    |
| Asthma Children | Sacramento | S70         | 2015 | 10              | 29379   | 26390    | 24356    | 22920    | 21561    | 20458    |
| Asthma Children | Sacramento | S70         | 2015 | 20              | 26080   | 22454    | 20125    | 18463    | 17112    | 16126    |
| Asthma Children | Sacramento | S70         | 2015 | 30              | 21910   | 17834    | 15249    | 13502    | 12399    | 11452    |
| Asthma Children | Sacramento | S70         | 2015 | 40              | 15753   | 11320    | 9092     | 7648     | 6475     | 5582     |
| Asthma Children | Sacramento | S70         | 2015 | 50              | 7221  | 3781     | 2337     | 1374     | 893      | 598      |
| Asthma Children | Sacramento | S70         | 2015 | 60              | 1157  | 179      | 39       | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2015 | 70              | 70  | 8        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2016 | 0               | 31786   | 28968    | 27198    | 25738    | 24597    | 23463    |
| Asthma Children | Sacramento | S70         | 2016 | 10              | 30389   | 27291    | 25194    | 23727    | 22430    | 21491    |
| Asthma Children | Sacramento | S70         | 2016 | 20              | 26786   | 22989    | 20839    | 19146    | 17741    | 16693    |
| Asthma Children | Sacramento | S70         | 2016 | 30              | 21864   | 17966    | 15668    | 13874    | 12539    | 11553    |
| Asthma Children | Sacramento | S70         | 2016 | 40              | 15994   | 11592    | 9200     | 7710     | 6467     | 5427     |
| Asthma Children | Sacramento | S70         | 2016 | 50              | 8269  | 4705     | 2958     | 1918     | 1343     | 924      |
| Asthma Children | Sacramento | S70         | 2016 | 60              | 1871  | 396      | 132      | 70       | 23       | 0        |
| Asthma Children | Sacramento | S70         | 2016 | 70              | 155   | 8        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2017 | 0               | 30598   | 27990    | 26118    | 24698    | 23448    | 22500    |
| Asthma Children | Sacramento | S70         | 2017 | 10              | 29449   | 26367    | 24434    | 22811    | 21483    | 20513    |
| Asthma Children | Sacramento | S70         | 2017 | 20              | 26421   | 22609    | 20280    | 18688    | 17547    | 16491    |
| Asthma Children | Sacramento | S70         | 2017 | 30              | 21763   | 17539    | 14860    | 13533    | 12492    | 11514    |
| Asthma Children | Sacramento | S70         | 2017 | 40              | 15621   | 11196    | 8975     | 7469     | 6328     | 5551     |
| Asthma Children | Sacramento | S70         | 2017 | 50              | 7283  | 3750     | 2182     | 1312     | 939      | 668      |
| Asthma Children | Sacramento | S70         | 2017 | 60              | 1522  | 272      | 31       | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2017 | 70              | 54  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2015 | 0               | 30691   | 27958    | 26095    | 24744    | 23595    | 22454    |
| Asthma Children | Sacramento | S75         | 2015 | 10              | 29426   | 26468    | 24418    | 22958    | 21654    | 20536    |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Sacramento | S75         | 2015 | 20              | 26359   | 22811    | 20497    | 18805    | 17485    | 16336    |
| Asthma Children | Sacramento | S75         | 2015 | 30              | 22578   | 18587    | 16041    | 14286    | 13121    | 12190    |
| Asthma Children | Sacramento | S75         | 2015 | 40              | 17306   | 13044    | 10575    | 9006     | 7811     | 7050     |
| Asthma Children | Sacramento | S75         | 2015 | 50              | 10000   | 5940     | 4162     | 2943     | 2174     | 1685     |
| Asthma Children | Sacramento | S75         | 2015 | 60              | 3059  | 846      | 318      | 93       | 39       | 16       |
| Asthma Children | Sacramento | S75         | 2015 | 70              | 427   | 23       | 8        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2015 | 80              | 23  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2016 | 0               | 31786   | 28968    | 27198    | 25738    | 24597    | 23463    |
| Asthma Children | Sacramento | S75         | 2016 | 10              | 30435   | 27337    | 25280    | 23836    | 22531    | 21553    |
| Asthma Children | Sacramento | S75         | 2016 | 20              | 27066   | 23370    | 21103    | 19534    | 18044    | 16965    |
| Asthma Children | Sacramento | S75         | 2016 | 30              | 22586   | 18696    | 16413    | 14527    | 13207    | 12151    |
| Asthma Children | Sacramento | S75         | 2016 | 40              | 17345   | 13207    | 10808    | 9270     | 7950     | 6863     |
| Asthma Children | Sacramento | S75         | 2016 | 50              | 10947   | 6778     | 4860     | 3540     | 2717     | 2065     |
| Asthma Children | Sacramento | S75         | 2016 | 60              | 4301  | 1739     | 769      | 349      | 163      | 78       |
| Asthma Children | Sacramento | S75         | 2016 | 70              | 675   | 78       | 23       | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2016 | 80              | 23  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2017 | 0               | 30598   | 27990    | 26118    | 24698    | 23448    | 22500    |
| Asthma Children | Sacramento | S75         | 2017 | 10              | 29496   | 26452    | 24503    | 22873    | 21522    | 20606    |
| Asthma Children | Sacramento | S75         | 2017 | 20              | 26646   | 22920    | 20629    | 19030    | 17850    | 16801    |
| Asthma Children | Sacramento | S75         | 2017 | 30              | 22586   | 18455    | 15668    | 14247    | 13082    | 12065    |
| Asthma Children | Sacramento | S75         | 2017 | 40              | 17260   | 12772    | 10536    | 9061     | 7756     | 6724     |
| Asthma Children | Sacramento | S75         | 2017 | 50              | 10388   | 6242     | 4363     | 3106     | 2236     | 1724     |
| Asthma Children | Sacramento | S75         | 2017 | 60              | 3253  | 978      | 357      | 171      | 70       | 16       |
| Asthma Children | Sacramento | S75         | 2017 | 70              | 404   | 8        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2017 | 80              | 23  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | Sacramento | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2015 | 0               | 37965   | 34049    | 31527    | 29587    | 27775    | 26391    |
| Asthma Children | St. Louis  | S65         | 2015 | 10              | 36016   | 31764    | 29150    | 27101    | 25161    | 23586    |
| Asthma Children | St. Louis  | S65         | 2015 | 20              | 31490   | 26200    | 23049    | 20690    | 18942    | 17557    |
| Asthma Children | St. Louis  | S65         | 2015 | 30              | 24642   | 19333    | 16292    | 14288    | 12594    | 11247    |
| Asthma Children | St. Louis  | S65         | 2015 | 40              | 16647   | 11256    | 8360     | 6584     | 5400     | 4471     |
| Asthma Children | St. Louis  | S65         | 2015 | 50              | 6793  | 2477     | 1093     | 474      | 228      | 91       |
| Asthma Children | St. Louis  | S65         | 2015 | 60              | 328   | 9        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2016 | 0               | 36882   | 32765    | 30461    | 28595    | 27037    | 25826    |
| Asthma Children | St. Louis  | S65         | 2016 | 10              | 35133   | 30880    | 28367    | 26327    | 24697    | 23440    |
| Asthma Children | St. Louis  | S65         | 2016 | 20              | 30871   | 26027    | 23194    | 21045    | 19361    | 17913    |
| Asthma Children | St. Louis  | S65         | 2016 | 30              | 25025   | 19743    | 16665    | 14525    | 13050    | 11702    |
| Asthma Children | St. Louis  | S65         | 2016 | 40              | 17785   | 12230    | 9243     | 7549     | 6211     | 5409     |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | St. Louis  | S65         | 2016 | 50              | 8779  | 4216     | 2176     | 1166     | 729      | 483      |
| Asthma Children | St. Louis  | S65         | 2016 | 60              | 1657  | 173      | 36       | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2016 | 70              | 27  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2017 | 0               | 37656   | 33967    | 31427    | 29505    | 27966    | 26864    |
| Asthma Children | St. Louis  | S65         | 2017 | 10              | 36344   | 32419    | 29596    | 27647    | 25926    | 24533    |
| Asthma Children | St. Louis  | S65         | 2017 | 20              | 32501   | 27529    | 24497    | 22329    | 20490    | 19087    |
| Asthma Children | St. Louis  | S65         | 2017 | 30              | 26737   | 21073    | 18013    | 16292    | 14552    | 13259    |
| Asthma Children | St. Louis  | S65         | 2017 | 40              | 19370   | 13897    | 10682    | 8597     | 7249     | 6101     |
| Asthma Children | St. Louis  | S65         | 2017 | 50              | 8251  | 3643     | 1849     | 965      | 483      | 310      |
| Asthma Children | St. Louis  | S65         | 2017 | 60              | 510   | 36       | 9        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2017 | 70              | 9   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S65         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2015 | 0               | 37965   | 34049    | 31527    | 29587    | 27775    | 26391    |
| Asthma Children | St. Louis  | S70         | 2015 | 10              | 36135   | 31873    | 29305    | 27165    | 25316    | 23723    |
| Asthma Children | St. Louis  | S70         | 2015 | 20              | 32000   | 26855    | 23577    | 21291    | 19442    | 17913    |
| Asthma Children | St. Louis  | S70         | 2015 | 30              | 25808   | 20399    | 17230    | 15317    | 13696    | 12230    |
| Asthma Children | St. Louis  | S70         | 2015 | 40              | 18741   | 13268    | 10409    | 8469     | 7121     | 6065     |
| Asthma Children | St. Louis  | S70         | 2015 | 50              | 10582   | 5309     | 3114     | 2013     | 1229     | 738      |
| Asthma Children | St. Louis  | S70         | 2015 | 60              | 2195  | 337      | 82       | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2015 | 70              | 18  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2016 | 0               | 36882   | 32765    | 30461    | 28595    | 27037    | 25826    |
| Asthma Children | St. Louis  | S70         | 2016 | 10              | 35242   | 30962    | 28504    | 26445    | 24879    | 23531    |
| Asthma Children | St. Louis  | S70         | 2016 | 20              | 31390   | 26582    | 23795    | 21519    | 19861    | 18368    |
| Asthma Children | St. Louis  | S70         | 2016 | 30              | 26136   | 20936    | 17785    | 15691    | 13951    | 12676    |
| Asthma Children | St. Louis  | S70         | 2016 | 40              | 19697   | 14234    | 11128    | 9407     | 8014     | 6939     |
| Asthma Children | St. Louis  | S70         | 2016 | 50              | 12121   | 6967     | 4562     | 3096     | 2067     | 1457     |
| Asthma Children | St. Louis  | S70         | 2016 | 60              | 4927  | 1211     | 455      | 155      | 64       | 9        |
| Asthma Children | St. Louis  | S70         | 2016 | 70              | 437   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2017 | 0               | 37656   | 33967    | 31427    | 29505    | 27966    | 26864    |
| Asthma Children | St. Louis  | S70         | 2017 | 10              | 36454   | 32556    | 29769    | 27748    | 26063    | 24688    |
| Asthma Children | St. Louis  | S70         | 2017 | 20              | 32993   | 28230    | 25180    | 22912    | 21073    | 19643    |
| Asthma Children | St. Louis  | S70         | 2017 | 30              | 27839   | 22184    | 19087    | 17129    | 15572    | 14243    |
| Asthma Children | St. Louis  | S70         | 2017 | 40              | 21482   | 16000    | 12959    | 10855    | 9307     | 8050     |
| Asthma Children | St. Louis  | S70         | 2017 | 50              | 12631   | 7130     | 4617     | 3269     | 2340     | 1748     |
| Asthma Children | St. Louis  | S70         | 2017 | 60              | 2969  | 592      | 173      | 64       | 36       | 9        |
| Asthma Children | St. Louis  | S70         | 2017 | 70              | 118   | 9        | 0        | 0        | 0        | 0        |

| Study Group     | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-----------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | St. Louis  | S70         | 2017 | 80              | 9   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S70         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2015 | 0               | 37965   | 34049    | 31527    | 29587    | 27775    | 26391    |
| Asthma Children | St. Louis  | S75         | 2015 | 10              | 36153   | 31946    | 29350    | 27147    | 25371    | 23750    |
| Asthma Children | St. Louis  | S75         | 2015 | 20              | 32201   | 27165    | 23914    | 21619    | 19634    | 18213    |
| Asthma Children | St. Louis  | S75         | 2015 | 30              | 26436   | 20927    | 17822    | 15909    | 14370    | 12767    |
| Asthma Children | St. Louis  | S75         | 2015 | 40              | 19980   | 14716    | 11629    | 9535     | 8241     | 7012     |
| Asthma Children | St. Louis  | S75         | 2015 | 50              | 12968   | 7495     | 4954     | 3506     | 2359     | 1712     |
| Asthma Children | St. Louis  | S75         | 2015 | 60              | 4808  | 1402     | 492      | 155      | 46       | 9        |
| Asthma Children | St. Louis  | S75         | 2015 | 70              | 364   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2015 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2016 | 0               | 36882   | 32765    | 30461    | 28595    | 27037    | 25826    |
| Asthma Children | St. Louis  | S75         | 2016 | 10              | 35315   | 30980    | 28522    | 26500    | 24888    | 23622    |
| Asthma Children | St. Louis  | S75         | 2016 | 20              | 31645   | 26919    | 24069    | 21892    | 20135    | 18723    |
| Asthma Children | St. Louis  | S75         | 2016 | 30              | 26855   | 21637    | 18477    | 16355    | 14416    | 13177    |
| Asthma Children | St. Louis  | S75         | 2016 | 40              | 21027   | 15426    | 12303    | 10345    | 9125     | 8050     |
| Asthma Children | St. Louis  | S75         | 2016 | 50              | 14142   | 8788     | 6138     | 4526     | 3379     | 2586     |
| Asthma Children | St. Louis  | S75         | 2016 | 60              | 7212  | 2705     | 1102     | 619      | 346      | 137      |
| Asthma Children | St. Louis  | S75         | 2016 | 70              | 1767  | 191      | 27       | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2016 | 80              | 82  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2016 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2017 | 0               | 37656   | 33967    | 31427    | 29505    | 27966    | 26864    |
| Asthma Children | St. Louis  | S75         | 2017 | 10              | 36454   | 32592    | 29806    | 27729    | 26145    | 24715    |
| Asthma Children | St. Louis  | S75         | 2017 | 20              | 33266   | 28494    | 25517    | 23203    | 21400    | 19898    |
| Asthma Children | St. Louis  | S75         | 2017 | 30              | 28540   | 22967    | 19616    | 17621    | 16182    | 14853    |
| Asthma Children | St. Louis  | S75         | 2017 | 40              | 22812   | 17239    | 14088    | 12157    | 10491    | 9234     |
| Asthma Children | St. Louis  | S75         | 2017 | 50              | 15181   | 9607     | 6812     | 5081     | 3943     | 2969     |
| Asthma Children | St. Louis  | S75         | 2017 | 60              | 5719  | 1931     | 856      | 301      | 155      | 100      |
| Asthma Children | St. Louis  | S75         | 2017 | 70              | 610   | 55       | 18       | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2017 | 80              | 18  | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Children | St. Louis  | S75         | 2017 | 100             | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults      | Atlanta    | S65         | 2015 | 0               | 1444098   | 1258787  | 1143840  | 1058756  | 992690   | 936765   |
| All Adults      | Atlanta    | S65         | 2015 | 10              | 1250476   | 1029174  | 893026   | 791391   | 713280   | 645875   |
| All Adults      | Atlanta    | S65         | 2015 | 20              | 845906  | 585443   | 443590   | 360197   | 299694   | 252363   |
| All Adults      | Atlanta    | S65         | 2015 | 30              | 523391  | 319838   | 230388   | 178478   | 139388   | 111848   |
| All Adults      | Atlanta    | S65         | 2015 | 40              | 282368  | 140022   | 81703    | 49867    | 31836    | 20074    |
| All Adults      | Atlanta    | S65         | 2015 | 50              | 72265   | 15073    | 3663     | 986      | 141      | 0        |
| All Adults      | Atlanta    | S65         | 2015 | 60              | 5564  | 0        | 0        | 0        | 0        | 0        |
| All Adults      | Atlanta    | S65         | 2015 | 70              | 211   | 0        | 0        | 0        | 0        | 0        |
| All Adults      | Atlanta    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults      | Atlanta    | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults      | Atlanta    | S65         | 2016 | 0               | 1444309   | 1253434  | 1141445  | 1056925  | 990647   | 933878   |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Atlanta    | S65         | 2016 | 10              | 1277311   | 1066293  | 940498   | 843089   | 769556   | 704335   |
| All Adults  | Atlanta    | S65         | 2016 | 20              | 912325  | 650946   | 510502   | 413304   | 346181   | 293637   |
| All Adults  | Atlanta    | S65         | 2016 | 30              | 591148  | 379707   | 281170   | 222218   | 182282   | 151291   |
| All Adults  | Atlanta    | S65         | 2016 | 40              | 336390  | 181437   | 113398   | 76843    | 54234    | 37682    |
| All Adults  | Atlanta    | S65         | 2016 | 50              | 93254   | 20919    | 5916     | 1197     | 493      | 141      |
| All Adults  | Atlanta    | S65         | 2016 | 60              | 10706   | 352      | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S65         | 2016 | 70              | 704   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S65         | 2017 | 0               | 1447972   | 1257872  | 1140248  | 1056854  | 990154   | 935568   |
| All Adults  | Atlanta    | S65         | 2017 | 10              | 1256111   | 1034034  | 900210   | 806111   | 722577   | 650665   |
| All Adults  | Atlanta    | S65         | 2017 | 20              | 844568  | 581569   | 446055   | 357379   | 296877   | 251729   |
| All Adults  | Atlanta    | S65         | 2017 | 30              | 521560  | 320120   | 236868   | 184254   | 147910   | 121216   |
| All Adults  | Atlanta    | S65         | 2017 | 40              | 269972  | 128189   | 76491    | 46345    | 29934    | 19017    |
| All Adults  | Atlanta    | S65         | 2017 | 50              | 45218   | 7536     | 1761     | 352      | 70       | 0        |
| All Adults  | Atlanta    | S65         | 2017 | 60              | 1057  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2015 | 0               | 1444098   | 1258787  | 1143840  | 1058756  | 992690   | 936765   |
| All Adults  | Atlanta    | S70         | 2015 | 10              | 1262379   | 1040162  | 907888   | 807590   | 731240   | 663554   |
| All Adults  | Atlanta    | S70         | 2015 | 20              | 894224  | 627281   | 478596   | 389356   | 325051   | 274831   |
| All Adults  | Atlanta    | S70         | 2015 | 30              | 567835  | 353224   | 254194   | 200665   | 160166   | 128893   |
| All Adults  | Atlanta    | S70         | 2015 | 40              | 348998  | 185944   | 119737   | 81421    | 56347    | 39795    |
| All Adults  | Atlanta    | S70         | 2015 | 50              | 140022  | 43950    | 17397    | 5705     | 2043     | 493      |
| All Adults  | Atlanta    | S70         | 2015 | 60              | 20003   | 1972     | 211      | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2015 | 70              | 2254  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2016 | 0               | 1444309   | 1253434  | 1141445  | 1056925  | 990647   | 933878   |
| All Adults  | Atlanta    | S70         | 2016 | 10              | 1290834   | 1078759  | 955078   | 861120   | 785615   | 722718   |
| All Adults  | Atlanta    | S70         | 2016 | 20              | 956275  | 697925   | 549804   | 451760   | 379143   | 323783   |
| All Adults  | Atlanta    | S70         | 2016 | 30              | 638761  | 415205   | 308851   | 245320   | 201792   | 168406   |
| All Adults  | Atlanta    | S70         | 2016 | 40              | 405767  | 231656   | 155869   | 111708   | 85084    | 64940    |
| All Adults  | Atlanta    | S70         | 2016 | 50              | 168547  | 60784    | 25779    | 10917    | 3663     | 1479     |
| All Adults  | Atlanta    | S70         | 2016 | 60              | 34160   | 3592     | 282      | 141      | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2016 | 70              | 5001  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2016 | 80              | 352   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2017 | 0               | 1447972   | 1257872  | 1140248  | 1056854  | 990154   | 935568   |
| All Adults  | Atlanta    | S70         | 2017 | 10              | 1267098   | 1048332  | 915494   | 824847   | 741242   | 672499   |
| All Adults  | Atlanta    | S70         | 2017 | 20              | 885560  | 621998   | 481061   | 386821   | 322163   | 272507   |
| All Adults  | Atlanta    | S70         | 2017 | 30              | 565299  | 351956   | 261308   | 204187   | 164533   | 138261   |
| All Adults  | Atlanta    | S70         | 2017 | 40              | 331178  | 174464   | 112694   | 76209    | 53389    | 37752    |
| All Adults  | Atlanta    | S70         | 2017 | 50              | 106566  | 26624    | 9649     | 3522     | 1127     | 423      |
| All Adults  | Atlanta    | S70         | 2017 | 60              | 9790  | 211      | 70       | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2017 | 70              | 282   | 0        | 0        | 0        | 0        | 0        |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Atlanta    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2015 | 0               | 1444098   | 1258787  | 1143840  | 1058756  | 992690   | 936765   |
| All Adults  | Atlanta    | S75         | 2015 | 10              | 1269634   | 1047980  | 918030   | 816395   | 740608   | 674189   |
| All Adults  | Atlanta    | S75         | 2015 | 20              | 929088  | 662286   | 510079   | 414853   | 345124   | 292088   |
| All Adults  | Atlanta    | S75         | 2015 | 30              | 610517  | 383651   | 277156   | 217217   | 173971   | 143332   |
| All Adults  | Atlanta    | S75         | 2015 | 40              | 397386  | 221654   | 148544   | 104312   | 77688    | 57333    |
| All Adults  | Atlanta    | S75         | 2015 | 50              | 207286  | 85577    | 40147    | 20285    | 9931     | 4649     |
| All Adults  | Atlanta    | S75         | 2015 | 60              | 55220   | 9368     | 1479     | 352      | 141      | 0        |
| All Adults  | Atlanta    | S75         | 2015 | 70              | 7396  | 282      | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2015 | 80              | 1057  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2016 | 0               | 1444309   | 1253434  | 1141445  | 1056925  | 990647   | 933878   |
| All Adults  | Atlanta    | S75         | 2016 | 10              | 1297737   | 1086648  | 961699   | 870487   | 796039   | 733987   |
| All Adults  | Atlanta    | S75         | 2016 | 20              | 989943  | 732720   | 588049   | 485287   | 408796   | 348716   |
| All Adults  | Atlanta    | S75         | 2016 | 30              | 680951  | 443661   | 334629   | 263633   | 217499   | 183197   |
| All Adults  | Atlanta    | S75         | 2016 | 40              | 455775  | 271521   | 189677   | 140867   | 109947   | 84731    |
| All Adults  | Atlanta    | S75         | 2016 | 50              | 240530  | 107341   | 55502    | 29652    | 15777    | 8029     |
| All Adults  | Atlanta    | S75         | 2016 | 60              | 75153   | 15214    | 3522     | 563      | 141      | 70       |
| All Adults  | Atlanta    | S75         | 2016 | 70              | 15495   | 916      | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2016 | 80              | 2817  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2016 | 90              | 211   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2017 | 0               | 1447972   | 1257872  | 1140248  | 1056854  | 990154   | 935568   |
| All Adults  | Atlanta    | S75         | 2017 | 10              | 1274353   | 1055516  | 925073   | 834566   | 750046   | 684332   |
| All Adults  | Atlanta    | S75         | 2017 | 20              | 917607  | 655524   | 510150   | 414219   | 343011   | 291735   |
| All Adults  | Atlanta    | S75         | 2017 | 30              | 604812  | 380059   | 280818   | 219119   | 179183   | 149601   |
| All Adults  | Atlanta    | S75         | 2017 | 40              | 382595  | 212920   | 145868   | 100931   | 75434    | 55995    |
| All Adults  | Atlanta    | S75         | 2017 | 50              | 167984  | 60291    | 25004    | 12608    | 7184     | 3240     |
| All Adults  | Atlanta    | S75         | 2017 | 60              | 33456   | 2888     | 211      | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2017 | 70              | 3099  | 70       | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Atlanta    | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2015 | 0               | 1850655   | 1592858  | 1438181  | 1324300  | 1230183  | 1160719  |
| All Adults  | Boston     | S65         | 2015 | 10              | 1661832   | 1370968  | 1193299  | 1069439  | 961624   | 873475   |
| All Adults  | Boston     | S65         | 2015 | 20              | 1148099   | 795108   | 600318   | 478709   | 398190   | 333325   |
| All Adults  | Boston     | S65         | 2015 | 30              | 699132  | 430672   | 313269   | 244295   | 194399   | 159765   |
| All Adults  | Boston     | S65         | 2015 | 40              | 359447  | 173462   | 97151    | 56745    | 36199    | 23481    |
| All Adults  | Boston     | S65         | 2015 | 50              | 76214   | 14675    | 2152     | 1076     | 391      | 98       |
| All Adults  | Boston     | S65         | 2015 | 60              | 8707  | 98       | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2015 | 70              | 1174  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2015 | 80              | 196   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2016 | 0               | 1865134   | 1607632  | 1447964  | 1340345  | 1253076  | 1178330  |
| All Adults  | Boston     | S65         | 2016 | 10              | 1689128   | 1394253  | 1216877  | 1087441  | 986279   | 895977   |
| All Adults  | Boston     | S65         | 2016 | 20              | 1166883   | 813501   | 616461   | 491036   | 404647   | 341446   |
| All Adults  | Boston     | S65         | 2016 | 30              | 701969  | 434389   | 315226   | 246447   | 203302   | 169060   |
| All Adults  | Boston     | S65         | 2016 | 40              | 378819  | 186670   | 113098   | 72007    | 44711    | 30231    |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Boston     | S65         | 2016 | 50              | 101553  | 19469    | 4500     | 1174     | 294      | 0        |
| All Adults  | Boston     | S65         | 2016 | 60              | 7533  | 98       | 98       | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2016 | 70              | 685   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2017 | 0               | 1856329   | 1605871  | 1448453  | 1339367  | 1248478  | 1172460  |
| All Adults  | Boston     | S65         | 2017 | 10              | 1682867   | 1396698  | 1219323  | 1092430  | 987062   | 896075   |
| All Adults  | Boston     | S65         | 2017 | 20              | 1182635   | 811251   | 617341   | 494460   | 407582   | 335086   |
| All Adults  | Boston     | S65         | 2017 | 30              | 715373  | 438694   | 318846   | 247915   | 195573   | 155754   |
| All Adults  | Boston     | S65         | 2017 | 40              | 392614  | 189312   | 110848   | 67213    | 42852    | 27981    |
| All Adults  | Boston     | S65         | 2017 | 50              | 135502  | 26024    | 6457     | 1663     | 587      | 98       |
| All Adults  | Boston     | S65         | 2017 | 60              | 15360   | 978      | 98       | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2017 | 70              | 1468  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2015 | 0               | 1850655   | 1592858  | 1438181  | 1324300  | 1230183  | 1160719  |
| All Adults  | Boston     | S70         | 2015 | 10              | 1662713   | 1371555  | 1191929  | 1069830  | 964559   | 875725   |
| All Adults  | Boston     | S70         | 2015 | 20              | 1173144   | 816143   | 621744   | 497493   | 411300   | 345848   |
| All Adults  | Boston     | S70         | 2015 | 30              | 730244  | 448967   | 324129   | 249969   | 200367   | 164559   |
| All Adults  | Boston     | S70         | 2015 | 40              | 408463  | 206726   | 124251   | 79149    | 51755    | 35612    |
| All Adults  | Boston     | S70         | 2015 | 50              | 122490  | 31601    | 7925     | 2152     | 881      | 196      |
| All Adults  | Boston     | S70         | 2015 | 60              | 19274   | 1076     | 196      | 98       | 0        | 0        |
| All Adults  | Boston     | S70         | 2015 | 70              | 2152  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2015 | 80              | 294   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2016 | 0               | 1865134   | 1607632  | 1447964  | 1340345  | 1253076  | 1178330  |
| All Adults  | Boston     | S70         | 2016 | 10              | 1689911   | 1397188  | 1219714  | 1091061  | 985594   | 896662   |
| All Adults  | Boston     | S70         | 2016 | 20              | 1196429   | 838352   | 642290   | 512071   | 423236   | 355045   |
| All Adults  | Boston     | S70         | 2016 | 30              | 738364  | 450826   | 327846   | 257307   | 209074   | 174930   |
| All Adults  | Boston     | S70         | 2016 | 40              | 425388  | 219738   | 140100   | 92552    | 63202    | 45004    |
| All Adults  | Boston     | S70         | 2016 | 50              | 159570  | 44026    | 15654    | 6261     | 2837     | 1370     |
| All Adults  | Boston     | S70         | 2016 | 60              | 23383   | 1468     | 98       | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2016 | 70              | 2739  | 98       | 98       | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2016 | 80              | 98  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2017 | 0               | 1856329   | 1605871  | 1448453  | 1339367  | 1248478  | 1172460  |
| All Adults  | Boston     | S70         | 2017 | 10              | 1684237   | 1396601  | 1221182  | 1093702  | 987649   | 896662   |
| All Adults  | Boston     | S70         | 2017 | 20              | 1209833   | 837080   | 639550   | 511484   | 421768   | 347805   |
| All Adults  | Boston     | S70         | 2017 | 30              | 748441  | 455913   | 332347   | 254568   | 202813   | 161135   |
| All Adults  | Boston     | S70         | 2017 | 40              | 440846  | 226782   | 137557   | 89226    | 60267    | 40308    |
| All Adults  | Boston     | S70         | 2017 | 50              | 188235  | 48331    | 14675    | 4794     | 1859     | 391      |
| All Adults  | Boston     | S70         | 2017 | 60              | 48429   | 4794     | 98       | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2017 | 70              | 5283  | 196      | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2017 | 80              | 489   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2015 | 0               | 1850655   | 1592858  | 1438181  | 1324300  | 1230183  | 1160719  |
| All Adults  | Boston     | S75         | 2015 | 10              | 1659582   | 1368130  | 1187820  | 1064351  | 961429   | 871029   |



| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Boston     | S75         | 2015 | 20              | 1183319   | 827101   | 630451   | 503755   | 415996   | 350642   |
| All Adults  | Boston     | S75         | 2015 | 30              | 742082  | 455815   | 328140   | 251339   | 201443   | 164364   |
| All Adults  | Boston     | S75         | 2015 | 40              | 426954  | 220619   | 135209   | 88150    | 59288    | 40993    |
| All Adults  | Boston     | S75         | 2015 | 50              | 152819  | 44124    | 14480    | 4598     | 2152     | 587      |
| All Adults  | Boston     | S75         | 2015 | 60              | 31014   | 3131     | 489      | 391      | 0        | 0        |
| All Adults  | Boston     | S75         | 2015 | 70              | 4305  | 98       | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2015 | 80              | 489   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2016 | 0               | 1865134   | 1607632  | 1447964  | 1340345  | 1253076  | 1178330  |
| All Adults  | Boston     | S75         | 2016 | 10              | 1686878   | 1394253  | 1216290  | 1088223  | 982659   | 893433   |
| All Adults  | Boston     | S75         | 2016 | 20              | 1209148   | 849994   | 649334   | 521463   | 430476   | 362480   |
| All Adults  | Boston     | S75         | 2016 | 30              | 756072  | 459044   | 332347   | 257992   | 210542   | 175615   |
| All Adults  | Boston     | S75         | 2016 | 40              | 444271  | 234414   | 149982   | 102825   | 70931    | 49896    |
| All Adults  | Boston     | S75         | 2016 | 50              | 188627  | 58897    | 23089    | 10958    | 5087     | 2348     |
| All Adults  | Boston     | S75         | 2016 | 60              | 44124   | 4403     | 489      | 98       | 98       | 0        |
| All Adults  | Boston     | S75         | 2016 | 70              | 5283  | 196      | 98       | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2016 | 80              | 391   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2017 | 0               | 1856329   | 1605871  | 1448453  | 1339367  | 1248478  | 1172460  |
| All Adults  | Boston     | S75         | 2017 | 10              | 1682182   | 1393470  | 1218638  | 1091256  | 984909   | 892357   |
| All Adults  | Boston     | S75         | 2017 | 20              | 1218834   | 847646   | 647279   | 517843   | 424801   | 352403   |
| All Adults  | Boston     | S75         | 2017 | 30              | 765758  | 465697   | 336652   | 256231   | 204085   | 161918   |
| All Adults  | Boston     | S75         | 2017 | 40              | 462468  | 240773   | 148318   | 98031    | 68289    | 47255    |
| All Adults  | Boston     | S75         | 2017 | 50              | 213379  | 63495    | 21817    | 7925     | 3620     | 1565     |
| All Adults  | Boston     | S75         | 2017 | 60              | 78366   | 10762    | 1272     | 196      | 0        | 0        |
| All Adults  | Boston     | S75         | 2017 | 70              | 10664   | 783      | 98       | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2017 | 80              | 685   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Boston     | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2015 | 0               | 1659225   | 1460056  | 1340038  | 1250572  | 1177202  | 1118443  |
| All Adults  | Dallas     | S65         | 2015 | 10              | 1471229   | 1236976  | 1093362  | 983580   | 895364   | 818634   |
| All Adults  | Dallas     | S65         | 2015 | 20              | 1054684   | 754797   | 588992   | 480070   | 401621   | 341925   |
| All Adults  | Dallas     | S65         | 2015 | 30              | 663456  | 419670   | 307232   | 241598   | 194638   | 158304   |
| All Adults  | Dallas     | S65         | 2015 | 40              | 400527  | 210734   | 133613   | 87903    | 59462    | 42506    |
| All Adults  | Dallas     | S65         | 2015 | 50              | 162836  | 50867    | 18206    | 7345     | 3047     | 1250     |
| All Adults  | Dallas     | S65         | 2015 | 60              | 20472   | 1016     | 234      | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2015 | 70              | 547   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2016 | 0               | 1670711   | 1470213  | 1353634  | 1261824  | 1191110  | 1126335  |
| All Adults  | Dallas     | S65         | 2016 | 10              | 1483731   | 1252057  | 1103051  | 994754   | 906147   | 830667   |
| All Adults  | Dallas     | S65         | 2016 | 20              | 1043745   | 748390   | 588210   | 481789   | 400918   | 344581   |
| All Adults  | Dallas     | S65         | 2016 | 30              | 658142  | 424437   | 315827   | 246676   | 200654   | 166899   |
| All Adults  | Dallas     | S65         | 2016 | 40              | 367866  | 191590   | 120096   | 76574    | 50085    | 34927    |
| All Adults  | Dallas     | S65         | 2016 | 50              | 97749   | 21253    | 4766     | 938      | 313      | 156      |
| All Adults  | Dallas     | S65         | 2016 | 60              | 4923  | 78       | 78       | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2016 | 70              | 234   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Dallas     | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2017 | 0               | 1672743   | 1467478  | 1349961  | 1259792  | 1182828  | 1124460  |
| All Adults  | Dallas     | S65         | 2017 | 10              | 1490841   | 1258698  | 1109380  | 1003349  | 920446   | 848014   |
| All Adults  | Dallas     | S65         | 2017 | 20              | 1069061   | 774097   | 611886   | 502182   | 418420   | 359662   |
| All Adults  | Dallas     | S65         | 2017 | 30              | 683693  | 438345   | 329735   | 264101   | 214875   | 179323   |
| All Adults  | Dallas     | S65         | 2017 | 40              | 396464  | 214328   | 135254   | 92748    | 62509    | 45553    |
| All Adults  | Dallas     | S65         | 2017 | 50              | 141974  | 37662    | 11720    | 3438     | 1172     | 469      |
| All Adults  | Dallas     | S65         | 2017 | 60              | 17659   | 547      | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2017 | 70              | 156   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2015 | 0               | 1659225   | 1460056  | 1340038  | 1250572  | 1177202  | 1118443  |
| All Adults  | Dallas     | S70         | 2015 | 10              | 1476308   | 1241664  | 1099691  | 990769   | 902162   | 825432   |
| All Adults  | Dallas     | S70         | 2015 | 20              | 1082423   | 783317   | 617668   | 505151   | 420686   | 357474   |
| All Adults  | Dallas     | S70         | 2015 | 30              | 703071  | 445221   | 324188   | 255115   | 207452   | 170025   |
| All Adults  | Dallas     | S70         | 2015 | 40              | 440533  | 241598   | 159007   | 110563   | 77433    | 54539    |
| All Adults  | Dallas     | S70         | 2015 | 50              | 226674  | 87044    | 39928    | 18753    | 9064     | 4610     |
| All Adults  | Dallas     | S70         | 2015 | 60              | 54461   | 6798     | 1328     | 234      | 78       | 0        |
| All Adults  | Dallas     | S70         | 2015 | 70              | 4141  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2016 | 0               | 1670711   | 1470213  | 1353634  | 1261824  | 1191110  | 1126335  |
| All Adults  | Dallas     | S70         | 2016 | 10              | 1485997   | 1258698  | 1110317  | 1001317  | 912867   | 839028   |
| All Adults  | Dallas     | S70         | 2016 | 20              | 1070468   | 772846   | 610088   | 501635   | 418108   | 357864   |
| All Adults  | Dallas     | S70         | 2016 | 30              | 687756  | 445143   | 331611   | 261757   | 212453   | 177838   |
| All Adults  | Dallas     | S70         | 2016 | 40              | 410606  | 221438   | 144865   | 99546    | 69229    | 47819    |
| All Adults  | Dallas     | S70         | 2016 | 50              | 148459  | 43131    | 14924    | 5470     | 1953     | 625      |
| All Adults  | Dallas     | S70         | 2016 | 60              | 14611   | 1250     | 313      | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2016 | 70              | 1328  | 78       | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2016 | 80              | 78  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2017 | 0               | 1672743   | 1467478  | 1349961  | 1259792  | 1182828  | 1124460  |
| All Adults  | Dallas     | S70         | 2017 | 10              | 1496155   | 1263386  | 1120084  | 1012491  | 929197   | 856530   |
| All Adults  | Dallas     | S70         | 2017 | 20              | 1095940   | 801601   | 638061   | 525467   | 440923   | 377867   |
| All Adults  | Dallas     | S70         | 2017 | 30              | 715026  | 461551   | 345441   | 276915   | 227377   | 191200   |
| All Adults  | Dallas     | S70         | 2017 | 40              | 439595  | 247380   | 161430   | 114470   | 83684    | 61571    |
| All Adults  | Dallas     | S70         | 2017 | 50              | 195810  | 65088    | 27348    | 10314    | 4297     | 1406     |
| All Adults  | Dallas     | S70         | 2017 | 60              | 40865   | 3125     | 313      | 78       | 78       | 0        |
| All Adults  | Dallas     | S70         | 2017 | 70              | 1485  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2015 | 0               | 1659225   | 1460056  | 1340038  | 1250572  | 1177202  | 1118443  |
| All Adults  | Dallas     | S75         | 2015 | 10              | 1476152   | 1240414  | 1099534  | 991238   | 902084   | 827307   |
| All Adults  | Dallas     | S75         | 2015 | 20              | 1104535   | 803085   | 635561   | 520388   | 434204   | 368647   |
| All Adults  | Dallas     | S75         | 2015 | 30              | 733153  | 466396   | 339346   | 265117   | 214484   | 176588   |
| All Adults  | Dallas     | S75         | 2015 | 40              | 471787  | 265429   | 174010   | 124315   | 90169    | 63916    |
| All Adults  | Dallas     | S75         | 2015 | 50              | 276290  | 115720   | 58055    | 32505    | 16721    | 10001    |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Dallas     | S75         | 2015 | 60              | 98139   | 21097    | 5157     | 1406     | 313      | 156      |
| All Adults  | Dallas     | S75         | 2015 | 70              | 12971   | 625      | 234      | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2015 | 80              | 781   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2016 | 0               | 1670711   | 1470213  | 1353634  | 1261824  | 1191110  | 1126335  |
| All Adults  | Dallas     | S75         | 2016 | 10              | 1487481   | 1258464  | 1111177  | 1002567  | 913648   | 840903   |
| All Adults  | Dallas     | S75         | 2016 | 20              | 1087970   | 792381   | 626653   | 515856   | 432172   | 367397   |
| All Adults  | Dallas     | S75         | 2016 | 30              | 709243  | 463427   | 341768   | 268398   | 220579   | 183855   |
| All Adults  | Dallas     | S75         | 2016 | 40              | 440455  | 241676   | 161742   | 115095   | 82278    | 59618    |
| All Adults  | Dallas     | S75         | 2016 | 50              | 192059  | 67588    | 27895    | 11252    | 4923     | 2969     |
| All Adults  | Dallas     | S75         | 2016 | 60              | 31489   | 3125     | 625      | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2016 | 70              | 3751  | 78       | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2016 | 80              | 313   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2016 | 90              | 78  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2017 | 0               | 1672743   | 1467478  | 1349961  | 1259792  | 1182828  | 1124460  |
| All Adults  | Dallas     | S75         | 2017 | 10              | 1498186   | 1264793  | 1122819  | 1014053  | 932635   | 861062   |
| All Adults  | Dallas     | S75         | 2017 | 20              | 1111724   | 821525   | 655720   | 540469   | 454519   | 391150   |
| All Adults  | Dallas     | S75         | 2017 | 30              | 737294  | 478429   | 357474   | 285276   | 234018   | 196904   |
| All Adults  | Dallas     | S75         | 2017 | 40              | 470224  | 270821   | 181667   | 129863   | 97670    | 74620    |
| All Adults  | Dallas     | S75         | 2017 | 50              | 237847  | 92045    | 43600    | 20472    | 10158    | 5391     |
| All Adults  | Dallas     | S75         | 2017 | 60              | 66416   | 8282     | 1485     | 234      | 78       | 78       |
| All Adults  | Dallas     | S75         | 2017 | 70              | 6329  | 156      | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Dallas     | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2015 | 0               | 1188134   | 1019169  | 920988   | 847385   | 790298   | 745861   |
| All Adults  | Detroit    | S65         | 2015 | 10              | 1064065   | 871635   | 763557   | 679533   | 612353   | 558740   |
| All Adults  | Detroit    | S65         | 2015 | 20              | 746779  | 519153   | 395805   | 320497   | 267343   | 226708   |
| All Adults  | Detroit    | S65         | 2015 | 30              | 467441  | 292380   | 217008   | 170604   | 138358   | 114697   |
| All Adults  | Detroit    | S65         | 2015 | 40              | 278682  | 147009   | 93396    | 62789    | 43519    | 31198    |
| All Adults  | Detroit    | S65         | 2015 | 50              | 98771   | 27790    | 10159    | 3474     | 1311     | 655      |
| All Adults  | Detroit    | S65         | 2015 | 60              | 9700  | 393      | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2016 | 0               | 1181777   | 1016416  | 916465   | 845615   | 790167   | 742060   |
| All Adults  | Detroit    | S65         | 2016 | 10              | 1065703   | 876551   | 765851   | 685891   | 623364   | 564311   |
| All Adults  | Detroit    | S65         | 2016 | 20              | 773126  | 542814   | 420383   | 344027   | 285367   | 241782   |
| All Adults  | Detroit    | S65         | 2016 | 30              | 494838  | 303588   | 224414   | 180763   | 148189   | 121841   |
| All Adults  | Detroit    | S65         | 2016 | 40              | 295526  | 155005   | 99951    | 67835    | 47780    | 32836    |
| All Adults  | Detroit    | S65         | 2016 | 50              | 128068  | 39128    | 14026    | 5374     | 1901     | 655      |
| All Adults  | Detroit    | S65         | 2016 | 60              | 24578   | 2228     | 131      | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2016 | 70              | 786   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2017 | 0               | 1196917   | 1026247  | 926100   | 854791   | 800588   | 755102   |
| All Adults  | Detroit    | S65         | 2017 | 10              | 1074813   | 885268   | 774830   | 694477   | 630377   | 572832   |
| All Adults  | Detroit    | S65         | 2017 | 20              | 764016  | 539471   | 418089   | 337079   | 279075   | 236342   |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Detroit    | S65         | 2017 | 30              | 489267  | 307913   | 228805   | 179846   | 145109   | 121514   |
| All Adults  | Detroit    | S65         | 2017 | 40              | 293888  | 156185   | 102638   | 70654    | 49287    | 36048    |
| All Adults  | Detroit    | S65         | 2017 | 50              | 108864  | 28707    | 10356    | 3670     | 1114     | 721      |
| All Adults  | Detroit    | S65         | 2017 | 60              | 8520  | 328      | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2017 | 70              | 262   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2015 | 0               | 1188134   | 1019169  | 920988   | 847385   | 790298   | 745861   |
| All Adults  | Detroit    | S70         | 2015 | 10              | 1064917   | 873274   | 763688   | 680910   | 614516   | 561559   |
| All Adults  | Detroit    | S70         | 2015 | 20              | 764737  | 538750   | 413566   | 334458   | 279469   | 237456   |
| All Adults  | Detroit    | S70         | 2015 | 30              | 487497  | 307586   | 225725   | 176437   | 142880   | 119679   |
| All Adults  | Detroit    | S70         | 2015 | 40              | 311912  | 170998   | 114173   | 78781    | 58332    | 42471    |
| All Adults  | Detroit    | S70         | 2015 | 50              | 147337  | 52630    | 23923    | 11076    | 5374     | 2884     |
| All Adults  | Detroit    | S70         | 2015 | 60              | 30215   | 3212     | 590      | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2015 | 70              | 1049  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2016 | 0               | 1181777   | 1016416  | 916465   | 845615   | 790167   | 742060   |
| All Adults  | Detroit    | S70         | 2016 | 10              | 1065769   | 876944   | 765524   | 687791   | 626183   | 566736   |
| All Adults  | Detroit    | S70         | 2016 | 20              | 791806  | 564246   | 439455   | 359495   | 300573   | 254104   |
| All Adults  | Detroit    | S70         | 2016 | 30              | 521906  | 323054   | 236736   | 189087   | 154219   | 127740   |
| All Adults  | Detroit    | S70         | 2016 | 40              | 326789  | 179387   | 119154   | 86121    | 61806    | 45355    |
| All Adults  | Detroit    | S70         | 2016 | 50              | 176175  | 67377    | 31919    | 15861    | 7341     | 3867     |
| All Adults  | Detroit    | S70         | 2016 | 60              | 62264   | 9438     | 1966     | 262      | 66       | 66       |
| All Adults  | Detroit    | S70         | 2016 | 70              | 7668  | 131      | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2017 | 0               | 1196917   | 1026247  | 926100   | 854791   | 800588   | 755102   |
| All Adults  | Detroit    | S70         | 2017 | 10              | 1075469   | 885923   | 775420   | 694083   | 629787   | 574143   |
| All Adults  | Detroit    | S70         | 2017 | 20              | 781843  | 559068   | 435260   | 350843   | 290545   | 246042   |
| All Adults  | Detroit    | S70         | 2017 | 30              | 514500  | 322136   | 239488   | 188038   | 151597   | 126560   |
| All Adults  | Detroit    | S70         | 2017 | 40              | 325216  | 179059   | 121055   | 84483    | 62854    | 46534    |
| All Adults  | Detroit    | S70         | 2017 | 50              | 160576  | 57283    | 25299    | 11732    | 5964     | 2425     |
| All Adults  | Detroit    | S70         | 2017 | 60              | 30280   | 2884     | 262      | 66       | 0        | 0        |
| All Adults  | Detroit    | S70         | 2017 | 70              | 2359  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S75         | 2015 | 0               | 1188134   | 1019169  | 920988   | 847385   | 790298   | 745861   |
| All Adults  | Detroit    | S75         | 2015 | 10              | 1059804   | 866064   | 754840   | 673110   | 606127   | 552842   |
| All Adults  | Detroit    | S75         | 2015 | 20              | 769259  | 539865   | 416122   | 335703   | 279600   | 235621   |
| All Adults  | Detroit    | S75         | 2015 | 30              | 496607  | 310994   | 226577   | 176503   | 141832   | 117778   |
| All Adults  | Detroit    | S75         | 2015 | 40              | 326462  | 181091   | 121710   | 86318    | 63379    | 47845    |
| All Adults  | Detroit    | S75         | 2015 | 50              | 174733  | 70785    | 35065    | 18155    | 9307     | 5768     |
| All Adults  | Detroit    | S75         | 2015 | 60              | 51450   | 9372     | 1966     | 524      | 0        | 0        |
| All Adults  | Detroit    | S75         | 2015 | 70              | 5964  | 197      | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Detroit      | S75         | 2016 | 0               | 1181777   | 1016416  | 916465   | 845615   | 790167   | 742060   |
| All Adults  | Detroit      | S75         | 2016 | 10              | 1060591   | 870783   | 760739   | 679992   | 618580   | 560510   |
| All Adults  | Detroit      | S75         | 2016 | 20              | 798950  | 570931   | 446665   | 364541   | 303326   | 256529   |
| All Adults  | Detroit      | S75         | 2016 | 30              | 536129  | 331574   | 239685   | 189546   | 154022   | 127806   |
| All Adults  | Detroit      | S75         | 2016 | 40              | 344879  | 189939   | 126495   | 92544    | 67573    | 51581    |
| All Adults  | Detroit      | S75         | 2016 | 50              | 203309  | 86711    | 44109    | 24119    | 13764    | 7275     |
| All Adults  | Detroit      | S75         | 2016 | 60              | 91627   | 20252    | 5702     | 1573     | 131      | 131      |
| All Adults  | Detroit      | S75         | 2016 | 70              | 21170   | 1180     | 0        | 0        | 0        | 0        |
| All Adults  | Detroit      | S75         | 2016 | 80              | 1049  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit      | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit      | S75         | 2017 | 0               | 1196917   | 1026247  | 926100   | 854791   | 800588   | 755102   |
| All Adults  | Detroit      | S75         | 2017 | 10              | 1069242   | 878517   | 765655   | 685432   | 621398   | 565688   |
| All Adults  | Detroit      | S75         | 2017 | 20              | 785776  | 561690   | 438144   | 353006   | 290545   | 243290   |
| All Adults  | Detroit      | S75         | 2017 | 30              | 526560  | 327445   | 241192   | 188235   | 151597   | 124922   |
| All Adults  | Detroit      | S75         | 2017 | 40              | 338194  | 187186   | 126560   | 89398    | 67377    | 49746    |
| All Adults  | Detroit      | S75         | 2017 | 50              | 189087  | 73931    | 37948    | 19597    | 10290    | 5505     |
| All Adults  | Detroit      | S75         | 2017 | 60              | 62526   | 10093    | 1966     | 328      | 197      | 0        |
| All Adults  | Detroit      | S75         | 2017 | 70              | 6161  | 131      | 0        | 0        | 0        | 0        |
| All Adults  | Detroit      | S75         | 2017 | 80              | 328   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Detroit      | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2015 | 0               | 1659016   | 1438982  | 1297637  | 1196813  | 1118472  | 1057385  |
| All Adults  | Philadelphia | S65         | 2015 | 10              | 1497106   | 1244393  | 1091719  | 979829   | 887632   | 810337   |
| All Adults  | Philadelphia | S65         | 2015 | 20              | 1079694   | 764064   | 597709   | 487039   | 408175   | 348918   |
| All Adults  | Philadelphia | S65         | 2015 | 30              | 694176  | 443903   | 330444   | 262821   | 212627   | 181779   |
| All Adults  | Philadelphia | S65         | 2015 | 40              | 406170  | 219512   | 142303   | 96641    | 67622    | 48800    |
| All Adults  | Philadelphia | S65         | 2015 | 50              | 121128  | 29280    | 9150     | 3137     | 523      | 174      |
| All Adults  | Philadelphia | S65         | 2015 | 60              | 8714  | 261      | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2015 | 70              | 174   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2016 | 0               | 1662589   | 1436019  | 1305567  | 1206137  | 1125879  | 1063572  |
| All Adults  | Philadelphia | S65         | 2016 | 10              | 1504338   | 1256506  | 1104791  | 992726   | 899222   | 826981   |
| All Adults  | Philadelphia | S65         | 2016 | 20              | 1083702   | 774870   | 603025   | 492964   | 413490   | 351794   |
| All Adults  | Philadelphia | S65         | 2016 | 30              | 688512  | 441115   | 329311   | 263431   | 218814   | 182563   |
| All Adults  | Philadelphia | S65         | 2016 | 40              | 388568  | 206440   | 126356   | 85138    | 59693    | 41480    |
| All Adults  | Philadelphia | S65         | 2016 | 50              | 104571  | 23267    | 6884     | 1656     | 784      | 174      |
| All Adults  | Philadelphia | S65         | 2016 | 60              | 8714  | 174      | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2016 | 70              | 87  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2017 | 0               | 1653788   | 1437500  | 1306351  | 1209797  | 1131369  | 1064182  |
| All Adults  | Philadelphia | S65         | 2017 | 10              | 1503554   | 1249883  | 1099649  | 985493   | 896259   | 815042   |
| All Adults  | Philadelphia | S65         | 2017 | 20              | 1059477   | 755437   | 585248   | 474490   | 396933   | 338722   |
| All Adults  | Philadelphia | S65         | 2017 | 30              | 675353  | 425952   | 311708   | 245654   | 199382   | 168272   |
| All Adults  | Philadelphia | S65         | 2017 | 40              | 371575  | 191713   | 116771   | 74681    | 51065    | 33898    |
| All Adults  | Philadelphia | S65         | 2017 | 50              | 88624   | 16121    | 3747     | 523      | 174      | 87       |
| All Adults  | Philadelphia | S65         | 2017 | 60              | 8976  | 349      | 0        | 0        | 0        | 0        |

| Study Group | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Philadelphia | S65         | 2017 | 70              | 174   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2015 | 0               | 1659016   | 1438982  | 1297637  | 1196813  | 1118472  | 1057385  |
| All Adults  | Philadelphia | S70         | 2015 | 10              | 1501463   | 1249447  | 1097906  | 984621   | 896172   | 818528   |
| All Adults  | Philadelphia | S70         | 2015 | 20              | 1111849   | 794390   | 626466   | 511351   | 430135   | 367828   |
| All Adults  | Philadelphia | S70         | 2015 | 30              | 728074  | 468303   | 349092   | 274586   | 222736   | 189535   |
| All Adults  | Philadelphia | S70         | 2015 | 40              | 455667  | 260120   | 175592   | 123916   | 90802    | 68232    |
| All Adults  | Philadelphia | S70         | 2015 | 50              | 190842  | 64224    | 24836    | 10719    | 5316     | 2440     |
| All Adults  | Philadelphia | S70         | 2015 | 60              | 27973   | 2266     | 349      | 87       | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2015 | 70              | 1481  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2015 | 80              | 87  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2016 | 0               | 1662589   | 1436019  | 1305567  | 1206137  | 1125879  | 1063572  |
| All Adults  | Philadelphia | S70         | 2016 | 10              | 1509393   | 1263564  | 1111675  | 1000830  | 907588   | 835957   |
| All Adults  | Philadelphia | S70         | 2016 | 20              | 1115074   | 809465   | 632218   | 516144   | 433620   | 369309   |
| All Adults  | Philadelphia | S70         | 2016 | 30              | 724763  | 464730   | 344648   | 275806   | 230056   | 193717   |
| All Adults  | Philadelphia | S70         | 2016 | 40              | 442160  | 246961   | 162608   | 113808   | 81740    | 60128    |
| All Adults  | Philadelphia | S70         | 2016 | 50              | 176550  | 54638    | 21350    | 8191     | 4183     | 1743     |
| All Adults  | Philadelphia | S70         | 2016 | 60              | 25968   | 1830     | 87       | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2016 | 70              | 1481  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2017 | 0               | 1653788   | 1437500  | 1306351  | 1209797  | 1131369  | 1064182  |
| All Adults  | Philadelphia | S70         | 2017 | 10              | 1509218   | 1258423  | 1106098  | 991854   | 905845   | 823931   |
| All Adults  | Philadelphia | S70         | 2017 | 20              | 1093114   | 783584   | 613569   | 497321   | 418283   | 355367   |
| All Adults  | Philadelphia | S70         | 2017 | 30              | 708119  | 447040   | 326610   | 258028   | 209926   | 176812   |
| All Adults  | Philadelphia | S70         | 2017 | 40              | 424035  | 234413   | 146661   | 102654   | 71544    | 50455    |
| All Adults  | Philadelphia | S70         | 2017 | 50              | 145005  | 40434    | 12548    | 4444     | 2091     | 959      |
| All Adults  | Philadelphia | S70         | 2017 | 60              | 25184   | 1656     | 261      | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2017 | 70              | 1830  | 87       | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2015 | 0               | 1659016   | 1438982  | 1297637  | 1196813  | 1118472  | 1057385  |
| All Adults  | Philadelphia | S75         | 2015 | 10              | 1500853   | 1248053  | 1099475  | 984447   | 898612   | 821665   |
| All Adults  | Philadelphia | S75         | 2015 | 20              | 1137295   | 822362   | 651999   | 533660   | 450177   | 384733   |
| All Adults  | Philadelphia | S75         | 2015 | 30              | 763628  | 493487   | 365649   | 287047   | 232932   | 197639   |
| All Adults  | Philadelphia | S75         | 2015 | 40              | 501417  | 291578   | 203565   | 148142   | 112588   | 84615    |
| All Adults  | Philadelphia | S75         | 2015 | 50              | 268573  | 113546   | 58734    | 31458    | 17254    | 9934     |
| All Adults  | Philadelphia | S75         | 2015 | 60              | 71195   | 12461    | 3224     | 523      | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2015 | 70              | 8017  | 349      | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2015 | 80              | 523   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2015 | 90              | 87  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2016 | 0               | 1662589   | 1436019  | 1305567  | 1206137  | 1125879  | 1063572  |
| All Adults  | Philadelphia | S75         | 2016 | 10              | 1509654   | 1262344  | 1111762  | 1003008  | 909679   | 838048   |
| All Adults  | Philadelphia | S75         | 2016 | 20              | 1142349   | 839878   | 659232   | 540893   | 453750   | 386215   |
| All Adults  | Philadelphia | S75         | 2016 | 30              | 763106  | 488259   | 362512   | 287395   | 239293   | 199643   |

| Study Group | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Philadelphia | S75         | 2016 | 40              | 492877  | 281906   | 190232   | 136378   | 102392   | 77731    |
| All Adults  | Philadelphia | S75         | 2016 | 50              | 259946  | 103699   | 50891    | 25968    | 13768    | 7756     |
| All Adults  | Philadelphia | S75         | 2016 | 60              | 62742   | 8889     | 1830     | 436      | 261      | 0        |
| All Adults  | Philadelphia | S75         | 2016 | 70              | 6884  | 87       | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2016 | 80              | 87  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2017 | 0               | 1653788   | 1437500  | 1306351  | 1209797  | 1131369  | 1064182  |
| All Adults  | Philadelphia | S75         | 2017 | 10              | 1509480   | 1260253  | 1106621  | 995078   | 904712   | 825848   |
| All Adults  | Philadelphia | S75         | 2017 | 20              | 1119343   | 810947   | 639538   | 519107   | 436932   | 370529   |
| All Adults  | Philadelphia | S75         | 2017 | 30              | 742191  | 470394   | 339245   | 269008   | 218727   | 183086   |
| All Adults  | Philadelphia | S75         | 2017 | 40              | 469174  | 266481   | 173239   | 125485   | 91848    | 68407    |
| All Adults  | Philadelphia | S75         | 2017 | 50              | 215329  | 78341    | 32766    | 14814    | 7407     | 4270     |
| All Adults  | Philadelphia | S75         | 2017 | 60              | 57340   | 7494     | 871      | 87       | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2017 | 70              | 8627  | 261      | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2017 | 80              | 261   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Philadelphia | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2015 | 0               | 1055538   | 935690   | 867248   | 816686   | 771836   | 738559   |
| All Adults  | Phoenix      | S65         | 2015 | 10              | 968570  | 838738   | 758227   | 701705   | 654670   | 614787   |
| All Adults  | Phoenix      | S65         | 2015 | 20              | 749734  | 578529   | 479840   | 411100   | 357756   | 315539   |
| All Adults  | Phoenix      | S65         | 2015 | 30              | 520915  | 360886   | 287079   | 241633   | 206816   | 181635   |
| All Adults  | Phoenix      | S65         | 2015 | 40              | 347724  | 219531   | 162215   | 123623   | 98988    | 80611    |
| All Adults  | Phoenix      | S65         | 2015 | 50              | 144881  | 57168    | 27516    | 14106    | 7251     | 3725     |
| All Adults  | Phoenix      | S65         | 2015 | 60              | 7947  | 546      | 50       | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2016 | 0               | 1041681   | 923074   | 850410   | 799650   | 758078   | 722913   |
| All Adults  | Phoenix      | S65         | 2016 | 10              | 962858  | 825875   | 749386   | 691921   | 644041   | 606989   |
| All Adults  | Phoenix      | S65         | 2016 | 20              | 741439  | 571079   | 474873   | 405735   | 356217   | 315638   |
| All Adults  | Phoenix      | S65         | 2016 | 30              | 515302  | 360339   | 288321   | 239498   | 206369   | 180194   |
| All Adults  | Phoenix      | S65         | 2016 | 40              | 345141  | 218985   | 161668   | 124616   | 100974   | 82051    |
| All Adults  | Phoenix      | S65         | 2016 | 50              | 115179  | 41522    | 17930    | 8096     | 3775     | 1738     |
| All Adults  | Phoenix      | S65         | 2016 | 60              | 4818  | 199      | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2017 | 0               | 1040042   | 922379   | 855427   | 801637   | 762201   | 726489   |
| All Adults  | Phoenix      | S65         | 2017 | 10              | 957742  | 828358   | 756290   | 699172   | 655067   | 616724   |
| All Adults  | Phoenix      | S65         | 2017 | 20              | 755098  | 587271   | 492555   | 421728   | 371713   | 326366   |
| All Adults  | Phoenix      | S65         | 2017 | 30              | 528911  | 371862   | 296119   | 245358   | 210939   | 185906   |
| All Adults  | Phoenix      | S65         | 2017 | 40              | 361978  | 234630   | 176668   | 138821   | 114136   | 94418    |
| All Adults  | Phoenix      | S65         | 2017 | 50              | 148457  | 63277    | 31887    | 17483    | 10579    | 6457     |
| All Adults  | Phoenix      | S65         | 2017 | 60              | 12814   | 745      | 99       | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix      | S70         | 2015 | 0               | 1055538   | 935690   | 867248   | 816686   | 771836   | 738559   |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Phoenix    | S70         | 2015 | 10              | 970308  | 839533   | 760810   | 701954   | 656359   | 616773   |
| All Adults  | Phoenix    | S70         | 2015 | 20              | 767267  | 601079   | 501197   | 431116   | 378220   | 334115   |
| All Adults  | Phoenix    | S70         | 2015 | 30              | 547338  | 382243   | 301086   | 250872   | 214862   | 186850   |
| All Adults  | Phoenix    | S70         | 2015 | 40              | 383137  | 247196   | 185757   | 146222   | 118060   | 97994    |
| All Adults  | Phoenix    | S70         | 2015 | 50              | 216402  | 106637   | 64717    | 40827    | 25678    | 17036    |
| All Adults  | Phoenix    | S70         | 2015 | 60              | 45893   | 9040     | 2285     | 894      | 497      | 199      |
| All Adults  | Phoenix    | S70         | 2015 | 70              | 298   | 50       | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2016 | 0               | 1041681   | 923074   | 850410   | 799650   | 758078   | 722913   |
| All Adults  | Phoenix    | S70         | 2016 | 10              | 963603  | 827961   | 750876   | 693361   | 645730   | 608926   |
| All Adults  | Phoenix    | S70         | 2016 | 20              | 761456  | 592983   | 498167   | 428036   | 375786   | 333121   |
| All Adults  | Phoenix    | S70         | 2016 | 30              | 542669  | 378170   | 300639   | 249233   | 215856   | 188340   |
| All Adults  | Phoenix    | S70         | 2016 | 40              | 380107  | 248835   | 186502   | 149649   | 121736   | 101272   |
| All Adults  | Phoenix    | S70         | 2016 | 50              | 189482  | 91736    | 53244    | 31042    | 19619    | 12020    |
| All Adults  | Phoenix    | S70         | 2016 | 60              | 33178   | 4718     | 1043     | 199      | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2016 | 70              | 149   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2017 | 0               | 1040042   | 922379   | 855427   | 801637   | 762201   | 726489   |
| All Adults  | Phoenix    | S70         | 2017 | 10              | 959928  | 829848   | 757333   | 702152   | 657054   | 619207   |
| All Adults  | Phoenix    | S70         | 2017 | 20              | 775710  | 611856   | 515501   | 446314   | 393070   | 347227   |
| All Adults  | Phoenix    | S70         | 2017 | 30              | 560301  | 393865   | 313503   | 258024   | 221319   | 194846   |
| All Adults  | Phoenix    | S70         | 2017 | 40              | 397640  | 264630   | 201552   | 161370   | 135642   | 113441   |
| All Adults  | Phoenix    | S70         | 2017 | 50              | 221071  | 118159   | 75942    | 50711    | 33923    | 23691    |
| All Adults  | Phoenix    | S70         | 2017 | 60              | 54585   | 11324    | 2881     | 844      | 348      | 199      |
| All Adults  | Phoenix    | S70         | 2017 | 70              | 1788  | 50       | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2015 | 0               | 1055538   | 935690   | 867248   | 816686   | 771836   | 738559   |
| All Adults  | Phoenix    | S75         | 2015 | 10              | 965242  | 833772   | 753906   | 695993   | 648859   | 610168   |
| All Adults  | Phoenix    | S75         | 2015 | 20              | 771439  | 609274   | 508597   | 439609   | 385272   | 340472   |
| All Adults  | Phoenix    | S75         | 2015 | 30              | 561891  | 391729   | 309181   | 256534   | 217495   | 188886   |
| All Adults  | Phoenix    | S75         | 2015 | 40              | 401315  | 261500   | 198472   | 154417   | 126404   | 105296   |
| All Adults  | Phoenix    | S75         | 2015 | 50              | 257726  | 139815   | 91786    | 60843    | 43310    | 30595    |
| All Adults  | Phoenix    | S75         | 2015 | 60              | 101769  | 30148    | 11175    | 4619     | 2334     | 993      |
| All Adults  | Phoenix    | S75         | 2015 | 70              | 6854  | 397      | 50       | 0        | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2015 | 80              | 50  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2016 | 0               | 1041681   | 923074   | 850410   | 799650   | 758078   | 722913   |
| All Adults  | Phoenix    | S75         | 2016 | 10              | 959977  | 823391   | 745810   | 687053   | 640117   | 602171   |
| All Adults  | Phoenix    | S75         | 2016 | 20              | 769353  | 602022   | 505319   | 436132   | 381299   | 338734   |
| All Adults  | Phoenix    | S75         | 2016 | 30              | 557967  | 387656   | 308287   | 255044   | 218637   | 189780   |
| All Adults  | Phoenix    | S75         | 2016 | 40              | 398335  | 261252   | 197926   | 158937   | 131123   | 110014   |
| All Adults  | Phoenix    | S75         | 2016 | 50              | 237064  | 127050   | 81852    | 55081    | 38244    | 26175    |
| All Adults  | Phoenix    | S75         | 2016 | 60              | 78276   | 19470    | 6308     | 2086     | 894      | 199      |
| All Adults  | Phoenix    | S75         | 2016 | 70              | 4718  | 99       | 50       | 0        | 0        | 0        |



| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Phoenix    | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2017 | 0               | 1040042   | 922379   | 855427   | 801637   | 762201   | 726489   |
| All Adults  | Phoenix    | S75         | 2017 | 10              | 956451  | 826818   | 752615   | 698080   | 652137   | 614141   |
| All Adults  | Phoenix    | S75         | 2017 | 20              | 783309  | 621244   | 524590   | 455651   | 400073   | 356713   |
| All Adults  | Phoenix    | S75         | 2017 | 30              | 576294  | 406331   | 322890   | 264431   | 225640   | 197975   |
| All Adults  | Phoenix    | S75         | 2017 | 40              | 418649  | 278139   | 212280   | 171503   | 143490   | 121438   |
| All Adults  | Phoenix    | S75         | 2017 | 50              | 268007  | 153970   | 103358   | 74502    | 55777    | 40728    |
| All Adults  | Phoenix    | S75         | 2017 | 60              | 105991  | 35711    | 13708    | 6010     | 3179     | 1192     |
| All Adults  | Phoenix    | S75         | 2017 | 70              | 12318   | 993      | 99       | 50       | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2017 | 80              | 397   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Phoenix    | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2015 | 0               | 580206  | 508974   | 467127   | 437713   | 414074   | 393207   |
| All Adults  | Sacramento | S65         | 2015 | 10              | 515920  | 432254   | 384489   | 350559   | 324776   | 301709   |
| All Adults  | Sacramento | S65         | 2015 | 20              | 358935  | 262777   | 211525   | 178367   | 153584   | 134604   |
| All Adults  | Sacramento | S65         | 2015 | 30              | 232591  | 155328   | 120626   | 96844    | 81094    | 68917    |
| All Adults  | Sacramento | S65         | 2015 | 40              | 115252  | 58341    | 34759    | 22239    | 14607    | 10205    |
| All Adults  | Sacramento | S65         | 2015 | 50              | 19323   | 2658     | 657      | 57       | 29       | 0        |
| All Adults  | Sacramento | S65         | 2015 | 60              | 715   | 29       | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2016 | 0               | 579921  | 510346   | 467641   | 437456   | 414474   | 392607   |
| All Adults  | Sacramento | S65         | 2016 | 10              | 512176  | 432311   | 385690   | 351274   | 324490   | 300336   |
| All Adults  | Sacramento | S65         | 2016 | 20              | 360993  | 263348   | 210753   | 176452   | 152241   | 132975   |
| All Adults  | Sacramento | S65         | 2016 | 30              | 232992  | 155528   | 118797   | 95415    | 78750    | 66516    |
| All Adults  | Sacramento | S65         | 2016 | 40              | 112337  | 55111    | 31614    | 20266    | 12949    | 8918     |
| All Adults  | Sacramento | S65         | 2016 | 50              | 24668   | 5031     | 1286     | 457      | 114      | 57       |
| All Adults  | Sacramento | S65         | 2016 | 60              | 1172  | 86       | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2017 | 0               | 578434  | 512118   | 468527   | 437942   | 412988   | 393893   |
| All Adults  | Sacramento | S65         | 2017 | 10              | 513891  | 434740   | 389434   | 355247   | 328549   | 305825   |
| All Adults  | Sacramento | S65         | 2017 | 20              | 359678  | 263720   | 211039   | 176537   | 151040   | 131860   |
| All Adults  | Sacramento | S65         | 2017 | 30              | 232791  | 157100   | 120941   | 98673    | 83381    | 71976    |
| All Adults  | Sacramento | S65         | 2017 | 40              | 114824  | 57426    | 35216    | 21981    | 14549    | 9747     |
| All Adults  | Sacramento | S65         | 2017 | 50              | 19094   | 2801     | 515      | 114      | 29       | 0        |
| All Adults  | Sacramento | S65         | 2017 | 60              | 1315  | 29       | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2015 | 0               | 580206  | 508974   | 467127   | 437713   | 414074   | 393207   |
| All Adults  | Sacramento | S70         | 2015 | 10              | 518121  | 435255   | 388176   | 354504   | 328406   | 305567   |
| All Adults  | Sacramento | S70         | 2015 | 20              | 375142  | 279470   | 226074   | 191287   | 163760   | 144094   |
| All Adults  | Sacramento | S70         | 2015 | 30              | 249713  | 167419   | 130173   | 105505   | 89241    | 75692    |
| All Adults  | Sacramento | S70         | 2015 | 40              | 147410  | 83810    | 56368    | 39132    | 28785    | 21181    |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Sacramento | S70         | 2015 | 50              | 49280   | 14292    | 5202     | 2115     | 715      | 343      |
| All Adults  | Sacramento | S70         | 2015 | 60              | 4688  | 257      | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2015 | 70              | 372   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2016 | 0               | 579921  | 510346   | 467641   | 437456   | 414474   | 392607   |
| All Adults  | Sacramento | S70         | 2016 | 10              | 514834  | 435369   | 388920   | 354304   | 328206   | 303538   |
| All Adults  | Sacramento | S70         | 2016 | 20              | 376342  | 277155   | 225017   | 187885   | 162645   | 141836   |
| All Adults  | Sacramento | S70         | 2016 | 30              | 250628  | 168248   | 128115   | 104390   | 86011    | 72662    |
| All Adults  | Sacramento | S70         | 2016 | 40              | 143837  | 78493    | 49851    | 34530    | 24926    | 18237    |
| All Adults  | Sacramento | S70         | 2016 | 50              | 56654   | 18551    | 8147     | 3544     | 1744     | 772      |
| All Adults  | Sacramento | S70         | 2016 | 60              | 9176  | 972      | 143      | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2016 | 70              | 600   | 29       | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2017 | 0               | 578434  | 512118   | 468527   | 437942   | 412988   | 393893   |
| All Adults  | Sacramento | S70         | 2017 | 10              | 516921  | 437570   | 392864   | 359449   | 332151   | 310198   |
| All Adults  | Sacramento | S70         | 2017 | 20              | 375885  | 279556   | 227303   | 188771   | 160644   | 140864   |
| All Adults  | Sacramento | S70         | 2017 | 30              | 249085  | 168105   | 130745   | 106105   | 89755    | 77550    |
| All Adults  | Sacramento | S70         | 2017 | 40              | 146438  | 83609    | 56140    | 40161    | 28785    | 21781    |
| All Adults  | Sacramento | S70         | 2017 | 50              | 54253   | 16150    | 6374     | 3087     | 1601     | 772      |
| All Adults  | Sacramento | S70         | 2017 | 60              | 8089  | 486      | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2017 | 70              | 229   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2015 | 0               | 580206  | 508974   | 467127   | 437713   | 414074   | 393207   |
| All Adults  | Sacramento | S75         | 2015 | 10              | 519550  | 436884   | 389891   | 356533   | 330064   | 307368   |
| All Adults  | Sacramento | S75         | 2015 | 20              | 385747  | 289703   | 236507   | 200491   | 172364   | 151555   |
| All Adults  | Sacramento | S75         | 2015 | 30              | 264034  | 177166   | 136891   | 110622   | 94128    | 80036    |
| All Adults  | Sacramento | S75         | 2015 | 40              | 167848  | 98588    | 68946    | 50566    | 38818    | 30299    |
| All Adults  | Sacramento | S75         | 2015 | 50              | 75006   | 28384    | 12806    | 6632     | 3487     | 1601     |
| All Adults  | Sacramento | S75         | 2015 | 60              | 15779   | 1887     | 314      | 57       | 0        | 0        |
| All Adults  | Sacramento | S75         | 2015 | 70              | 1515  | 57       | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2015 | 80              | 114   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2016 | 0               | 579921  | 510346   | 467641   | 437456   | 414474   | 392607   |
| All Adults  | Sacramento | S75         | 2016 | 10              | 516206  | 436941   | 390206   | 355504   | 329578   | 305453   |
| All Adults  | Sacramento | S75         | 2016 | 20              | 386347  | 288731   | 233849   | 196203   | 169477   | 148325   |
| All Adults  | Sacramento | S75         | 2016 | 30              | 264663  | 176480   | 134947   | 109821   | 90270    | 77264    |
| All Adults  | Sacramento | S75         | 2016 | 40              | 165447  | 93385    | 62714    | 44677    | 33444    | 25554    |
| All Adults  | Sacramento | S75         | 2016 | 50              | 81351   | 32872    | 16865    | 9804     | 5202     | 2830     |
| All Adults  | Sacramento | S75         | 2016 | 60              | 22382   | 4259     | 943      | 372      | 86       | 57       |
| All Adults  | Sacramento | S75         | 2016 | 70              | 2687  | 114      | 29       | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2016 | 80              | 200   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2017 | 0               | 578434  | 512118   | 468527   | 437942   | 412988   | 393893   |
| All Adults  | Sacramento | S75         | 2017 | 10              | 517978  | 439200   | 394779   | 361679   | 334238   | 312056   |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Sacramento | S75         | 2017 | 20              | 387948  | 290532   | 236850   | 198519   | 169220   | 147467   |
| All Adults  | Sacramento | S75         | 2017 | 30              | 262005  | 177138   | 136891   | 111622   | 94128    | 81294    |
| All Adults  | Sacramento | S75         | 2017 | 40              | 165447  | 99245    | 69403    | 51795    | 39446    | 30585    |
| All Adults  | Sacramento | S75         | 2017 | 50              | 80837   | 32186    | 15579    | 8918     | 5174     | 3402     |
| All Adults  | Sacramento | S75         | 2017 | 60              | 18008   | 2172     | 457      | 57       | 0        | 0        |
| All Adults  | Sacramento | S75         | 2017 | 70              | 2944  | 114      | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | Sacramento | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2015 | 0               | 677754  | 588086   | 534292   | 493660   | 463115   | 438972   |
| All Adults  | St. Louis  | S65         | 2015 | 10              | 598923  | 495985   | 435109   | 388898   | 350841   | 319652   |
| All Adults  | St. Louis  | S65         | 2015 | 20              | 414328  | 288034   | 224154   | 179588   | 148935   | 125865   |
| All Adults  | St. Louis  | S65         | 2015 | 30              | 257882  | 161167   | 117531   | 90849    | 73538    | 60983    |
| All Adults  | St. Louis  | S65         | 2015 | 40              | 143999  | 72608    | 44244    | 27577    | 18778    | 13305    |
| All Adults  | St. Louis  | S65         | 2015 | 50              | 42849   | 9121     | 2361     | 715      | 179      | 0        |
| All Adults  | St. Louis  | S65         | 2015 | 60              | 1931  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2016 | 0               | 676395  | 585725   | 533433   | 493839   | 461291   | 436754   |
| All Adults  | St. Louis  | S65         | 2016 | 10              | 603394  | 501100   | 442298   | 398018   | 361643   | 330025   |
| All Adults  | St. Louis  | S65         | 2016 | 20              | 433285  | 304523   | 237852   | 194216   | 161847   | 138992   |
| All Adults  | St. Louis  | S65         | 2016 | 30              | 280737  | 177871   | 130622   | 104011   | 85913    | 70748    |
| All Adults  | St. Louis  | S65         | 2016 | 40              | 168965  | 89061    | 56298    | 38629    | 27434    | 19600    |
| All Adults  | St. Louis  | S65         | 2016 | 50              | 65740   | 20352    | 6367     | 2146     | 1001     | 465      |
| All Adults  | St. Louis  | S65         | 2016 | 60              | 9049  | 429      | 72       | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2016 | 70              | 107   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2017 | 0               | 675465  | 586905   | 532217   | 492587   | 461505   | 436397   |
| All Adults  | St. Louis  | S65         | 2017 | 10              | 608080  | 508754   | 448021   | 403062   | 368117   | 337643   |
| All Adults  | St. Louis  | S65         | 2017 | 20              | 442334  | 318293   | 249978   | 202979   | 169895   | 145823   |
| All Adults  | St. Louis  | S65         | 2017 | 30              | 288499  | 185096   | 138527   | 110378   | 90777    | 76399    |
| All Adults  | St. Louis  | S65         | 2017 | 40              | 180196  | 101400   | 67743    | 45997    | 32942    | 23893    |
| All Adults  | St. Louis  | S65         | 2017 | 50              | 60554   | 18134    | 6688     | 2253     | 1288     | 501      |
| All Adults  | St. Louis  | S65         | 2017 | 60              | 2897  | 179      | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2017 | 70              | 36  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S65         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2015 | 0               | 677754  | 588086   | 534292   | 493660   | 463115   | 438972   |
| All Adults  | St. Louis  | S70         | 2015 | 10              | 600676  | 498131   | 438686   | 391652   | 355062   | 322943   |
| All Adults  | St. Louis  | S70         | 2015 | 20              | 429887  | 303736   | 235921   | 191248   | 158556   | 133662   |
| All Adults  | St. Louis  | S70         | 2015 | 30              | 273799  | 170431   | 124470   | 96607    | 78616    | 64488    |
| All Adults  | St. Louis  | S70         | 2015 | 40              | 168249  | 89847    | 59016    | 39308    | 27076    | 19922    |
| All Adults  | St. Louis  | S70         | 2015 | 50              | 72965   | 23106    | 8906     | 4149     | 1896     | 465      |
| All Adults  | St. Louis  | S70         | 2015 | 60              | 11016   | 858      | 179      | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2015 | 70              | 72  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|-------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | St. Louis  | S70         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2016 | 0               | 676395  | 585725   | 533433   | 493839   | 461291   | 436754   |
| All Adults  | St. Louis  | S70         | 2016 | 10              | 605755  | 504140   | 444909   | 402167   | 365184   | 333530   |
| All Adults  | St. Louis  | S70         | 2016 | 20              | 448164  | 321262   | 251086   | 208094   | 173757   | 148649   |
| All Adults  | St. Louis  | S70         | 2016 | 30              | 298478  | 189638   | 139099   | 110664   | 92029    | 75684    |
| All Adults  | St. Louis  | S70         | 2016 | 40              | 192857  | 106944   | 71785    | 51898    | 38164    | 28471    |
| All Adults  | St. Louis  | S70         | 2016 | 50              | 96715   | 37591    | 17490    | 8119     | 4006     | 2289     |
| All Adults  | St. Louis  | S70         | 2016 | 60              | 28185   | 4435     | 572      | 143      | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2016 | 70              | 2075  | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2017 | 0               | 675465  | 586905   | 532217   | 492587   | 461505   | 436397   |
| All Adults  | St. Louis  | S70         | 2017 | 10              | 610583  | 511901   | 452420   | 406996   | 372302   | 342901   |
| All Adults  | St. Louis  | S70         | 2017 | 20              | 457177  | 335819   | 266037   | 216356   | 182055   | 155910   |
| All Adults  | St. Louis  | S70         | 2017 | 30              | 307134  | 197900   | 147504   | 117281   | 96464    | 80655    |
| All Adults  | St. Louis  | S70         | 2017 | 40              | 203945  | 120107   | 82658    | 60018    | 44781    | 33872    |
| All Adults  | St. Louis  | S70         | 2017 | 50              | 100220  | 39952    | 19279    | 9764     | 4936     | 2611     |
| All Adults  | St. Louis  | S70         | 2017 | 60              | 17741   | 2468     | 393      | 36       | 36       | 0        |
| All Adults  | St. Louis  | S70         | 2017 | 70              | 680   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S70         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2015 | 0               | 677754  | 588086   | 534292   | 493660   | 463115   | 438972   |
| All Adults  | St. Louis  | S75         | 2015 | 10              | 600712  | 498989   | 439294   | 391866   | 355026   | 323944   |
| All Adults  | St. Louis  | S75         | 2015 | 20              | 438292  | 312928   | 243683   | 196291   | 164208   | 137668   |
| All Adults  | St. Louis  | S75         | 2015 | 30              | 285852  | 177120   | 129370   | 100041   | 81514    | 66956    |
| All Adults  | St. Louis  | S75         | 2015 | 40              | 181912  | 100184   | 66313    | 45889    | 32942    | 24429    |
| All Adults  | St. Louis  | S75         | 2015 | 50              | 93102   | 35445    | 17347    | 8548     | 4650     | 2253     |
| All Adults  | St. Louis  | S75         | 2015 | 60              | 25967   | 3577     | 644      | 107      | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2015 | 70              | 1753  | 36       | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2015 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2016 | 0               | 676395  | 585725   | 533433   | 493839   | 461291   | 436754   |
| All Adults  | St. Louis  | S75         | 2016 | 10              | 606434  | 504891   | 446304   | 401774   | 366257   | 334424   |
| All Adults  | St. Louis  | S75         | 2016 | 20              | 457893  | 329739   | 260314   | 215641   | 180625   | 153871   |
| All Adults  | St. Louis  | S75         | 2016 | 30              | 311605  | 197292   | 144321   | 115528   | 95177    | 78795    |
| All Adults  | St. Louis  | S75         | 2016 | 40              | 206556  | 116530   | 80119    | 58623    | 44351    | 33836    |
| All Adults  | St. Louis  | S75         | 2016 | 50              | 117424  | 50968    | 27398    | 14879    | 8370     | 4900     |
| All Adults  | St. Louis  | S75         | 2016 | 60              | 45961   | 10802    | 2361     | 644      | 143      | 0        |
| All Adults  | St. Louis  | S75         | 2016 | 70              | 8226  | 179      | 36       | 0        | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2016 | 80              | 250   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2016 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| All Adults  | St. Louis  | S75         | 2017 | 0               | 675465  | 586905   | 532217   | 492587   | 461505   | 436397   |
| All Adults  | St. Louis  | S75         | 2017 | 10              | 611585  | 513117   | 453386   | 408892   | 373053   | 345154   |
| All Adults  | St. Louis  | S75         | 2017 | 20              | 467443  | 346549   | 276481   | 226800   | 190461   | 163170   |
| All Adults  | St. Louis  | S75         | 2017 | 30              | 320403  | 207915   | 153084   | 121716   | 100220   | 83552    |
| All Adults  | St. Louis  | S75         | 2017 | 40              | 217930  | 129585   | 91528    | 67529    | 51111    | 40024    |
| All Adults  | St. Louis  | S75         | 2017 | 50              | 124148  | 56584    | 30116    | 17276    | 10194    | 6295     |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults    | St. Louis  | S75         | 2017 | 60              | 37270   | 7583     | 1538     | 429      | 250      | 107      |
| All Adults    | St. Louis  | S75         | 2017 | 70              | 3291  | 215      | 0        | 0        | 0        | 0        |
| All Adults    | St. Louis  | S75         | 2017 | 80              | 179   | 0        | 0        | 0        | 0        | 0        |
| All Adults    | St. Louis  | S75         | 2017 | 90              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2015 | 0               | 99029   | 84802    | 77054    | 70433    | 65362    | 60221    |
| Asthma Adults | Atlanta    | S65         | 2015 | 10              | 84309   | 67898    | 58037    | 49867    | 44091    | 39936    |
| Asthma Adults | Atlanta    | S65         | 2015 | 20              | 55149   | 38738    | 29371    | 23525    | 20144    | 16974    |
| Asthma Adults | Atlanta    | S65         | 2015 | 30              | 35146   | 22257    | 15284    | 11692    | 9297     | 7325     |
| Asthma Adults | Atlanta    | S65         | 2015 | 40              | 18665   | 9579     | 5353     | 3592     | 2254     | 1761     |
| Asthma Adults | Atlanta    | S65         | 2015 | 50              | 5423  | 1197     | 282      | 70       | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2015 | 60              | 423   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2016 | 0               | 99029   | 86211    | 75998    | 69236    | 64306    | 60643    |
| Asthma Adults | Atlanta    | S65         | 2016 | 10              | 86985   | 72476    | 62474    | 55079    | 49867    | 45570    |
| Asthma Adults | Atlanta    | S65         | 2016 | 20              | 61700   | 41767    | 33033    | 25567    | 20637    | 17538    |
| Asthma Adults | Atlanta    | S65         | 2016 | 30              | 37964   | 23595    | 17397    | 13101    | 10635    | 8241     |
| Asthma Adults | Atlanta    | S65         | 2016 | 40              | 21905   | 11762    | 6269     | 4226     | 2747     | 1902     |
| Asthma Adults | Atlanta    | S65         | 2016 | 50              | 4860  | 845      | 70       | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2016 | 60              | 211   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2017 | 0               | 103255  | 88535    | 79519    | 72194    | 67194    | 62615    |
| Asthma Adults | Atlanta    | S65         | 2017 | 10              | 86704   | 69940    | 59939    | 52543    | 47050    | 43035    |
| Asthma Adults | Atlanta    | S65         | 2017 | 20              | 57262   | 37752    | 28807    | 22680    | 19087    | 16622    |
| Asthma Adults | Atlanta    | S65         | 2017 | 30              | 34372   | 20496    | 15707    | 11833    | 9297     | 7889     |
| Asthma Adults | Atlanta    | S65         | 2017 | 40              | 16411   | 8100     | 5212     | 3240     | 1690     | 1338     |
| Asthma Adults | Atlanta    | S65         | 2017 | 50              | 2676  | 352      | 70       | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2017 | 60              | 70  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2015 | 0               | 99029   | 84802    | 77054    | 70433    | 65362    | 60221    |
| Asthma Adults | Atlanta    | S70         | 2015 | 10              | 85365   | 69166    | 58953    | 50994    | 44796    | 40851    |
| Asthma Adults | Atlanta    | S70         | 2015 | 20              | 57967   | 41344    | 31061    | 25286    | 21553    | 18031    |
| Asthma Adults | Atlanta    | S70         | 2015 | 30              | 38245   | 24159    | 16693    | 13030    | 10706    | 8170     |
| Asthma Adults | Atlanta    | S70         | 2015 | 40              | 22891   | 12326    | 7748     | 4930     | 3451     | 2606     |
| Asthma Adults | Atlanta    | S70         | 2015 | 50              | 8804  | 3310     | 1479     | 634      | 282      | 70       |
| Asthma Adults | Atlanta    | S70         | 2015 | 60              | 1268  | 70       | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2015 | 70              | 70  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2016 | 0               | 99029   | 86211    | 75998    | 69236    | 64306    | 60643    |
| Asthma Adults | Atlanta    | S70         | 2016 | 10              | 88394   | 73040    | 63601    | 56347    | 50853    | 46627    |
| Asthma Adults | Atlanta    | S70         | 2016 | 20              | 64588   | 45782    | 35710    | 28526    | 23313    | 19651    |
| Asthma Adults | Atlanta    | S70         | 2016 | 30              | 40922   | 25567    | 18947    | 14861    | 11762    | 9720     |
| Asthma Adults | Atlanta    | S70         | 2016 | 40              | 25708   | 14580    | 8804     | 6550     | 4719     | 3310     |
| Asthma Adults | Atlanta    | S70         | 2016 | 50              | 10072   | 3029     | 845      | 211      | 70       | 0        |
| Asthma Adults | Atlanta    | S70         | 2016 | 60              | 2113  | 211      | 0        | 0        | 0        | 0        |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Atlanta    | S70         | 2016 | 70              | 141   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2017 | 0               | 103255  | 88535    | 79519    | 72194    | 67194    | 62615    |
| Asthma Adults | Atlanta    | S70         | 2017 | 10              | 88042   | 71208    | 60855    | 54304    | 48599    | 44303    |
| Asthma Adults | Atlanta    | S70         | 2017 | 20              | 59516   | 40570    | 30779    | 25004    | 20637    | 17890    |
| Asthma Adults | Atlanta    | S70         | 2017 | 30              | 37259   | 22609    | 16622    | 13594    | 11058    | 8875     |
| Asthma Adults | Atlanta    | S70         | 2017 | 40              | 21130   | 11340    | 7466     | 5212     | 3944     | 2747     |
| Asthma Adults | Atlanta    | S70         | 2017 | 50              | 6480  | 1338     | 563      | 70       | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2017 | 60              | 775   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2015 | 0               | 99029   | 84802    | 77054    | 70433    | 65362    | 60221    |
| Asthma Adults | Atlanta    | S75         | 2015 | 10              | 86281   | 69729    | 59657    | 51909    | 46204    | 41344    |
| Asthma Adults | Atlanta    | S75         | 2015 | 20              | 59868   | 42964    | 33526    | 26624    | 22539    | 19228    |
| Asthma Adults | Atlanta    | S75         | 2015 | 30              | 41415   | 26060    | 18594    | 14157    | 11692    | 9368     |
| Asthma Adults | Atlanta    | S75         | 2015 | 40              | 26835   | 15284    | 9931     | 6902     | 4789     | 3451     |
| Asthma Adults | Atlanta    | S75         | 2015 | 50              | 12889   | 5564     | 2888     | 1690     | 916      | 352      |
| Asthma Adults | Atlanta    | S75         | 2015 | 60              | 3310  | 775      | 70       | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2015 | 70              | 423   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2016 | 0               | 99029   | 86211    | 75998    | 69236    | 64306    | 60643    |
| Asthma Adults | Atlanta    | S75         | 2016 | 10              | 89028   | 73744    | 63954    | 56629    | 51487    | 47754    |
| Asthma Adults | Atlanta    | S75         | 2016 | 20              | 66630   | 48529    | 38457    | 30498    | 25074    | 21553    |
| Asthma Adults | Atlanta    | S75         | 2016 | 30              | 44655   | 27187    | 20567    | 15848    | 12889    | 11128    |
| Asthma Adults | Atlanta    | S75         | 2016 | 40              | 29159   | 16904    | 10635    | 7959     | 6339     | 4930     |
| Asthma Adults | Atlanta    | S75         | 2016 | 50              | 15566   | 5987     | 2817     | 986      | 282      | 141      |
| Asthma Adults | Atlanta    | S75         | 2016 | 60              | 4156  | 704      | 70       | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2016 | 70              | 1057  | 70       | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2016 | 80              | 70  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2017 | 0               | 103255  | 88535    | 79519    | 72194    | 67194    | 62615    |
| Asthma Adults | Atlanta    | S75         | 2017 | 10              | 88605   | 71842    | 61348    | 54727    | 49163    | 45077    |
| Asthma Adults | Atlanta    | S75         | 2017 | 20              | 61911   | 42894    | 32681    | 26624    | 22327    | 19017    |
| Asthma Adults | Atlanta    | S75         | 2017 | 30              | 40147   | 24088    | 17890    | 14791    | 12115    | 9931     |
| Asthma Adults | Atlanta    | S75         | 2017 | 40              | 24863   | 13735    | 9861     | 6550     | 5423     | 3874     |
| Asthma Adults | Atlanta    | S75         | 2017 | 50              | 10072   | 3310     | 1479     | 704      | 563      | 141      |
| Asthma Adults | Atlanta    | S75         | 2017 | 60              | 2254  | 70       | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2017 | 70              | 211   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2015 | 0               | 171995  | 144601   | 128654   | 117011   | 105564   | 99107    |
| Asthma Adults | Boston     | S65         | 2015 | 10              | 152525  | 122783   | 105564   | 90498    | 80225    | 72692    |
| Asthma Adults | Boston     | S65         | 2015 | 20              | 100673  | 67506    | 50679    | 38449    | 32384    | 25535    |
| Asthma Adults | Boston     | S65         | 2015 | 30              | 58310   | 33949    | 24459    | 19078    | 13990    | 11251    |
| Asthma Adults | Boston     | S65         | 2015 | 40              | 27296   | 11642    | 6164     | 3424     | 2152     | 1468     |
| Asthma Adults | Boston     | S65         | 2015 | 50              | 4990  | 1076     | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2015 | 60              | 489   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2015 | 70              | 196   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Boston     | S65         | 2016 | 0               | 177180  | 150275   | 133448   | 122588   | 112902   | 105369   |
| Asthma Adults | Boston     | S65         | 2016 | 10              | 157711  | 127382   | 109674   | 97444    | 86878    | 79247    |
| Asthma Adults | Boston     | S65         | 2016 | 20              | 104097  | 69952    | 52048    | 42265    | 35123    | 29546    |
| Asthma Adults | Boston     | S65         | 2016 | 30              | 62125   | 39428    | 28764    | 21915    | 17610    | 14675    |
| Asthma Adults | Boston     | S65         | 2016 | 40              | 34145   | 16632    | 9588     | 6457     | 4011     | 2739     |
| Asthma Adults | Boston     | S65         | 2016 | 50              | 8414  | 1565     | 294      | 196      | 98       | 0        |
| Asthma Adults | Boston     | S65         | 2016 | 60              | 196   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2017 | 0               | 174636  | 148416   | 131589   | 120925   | 110750   | 103216   |
| Asthma Adults | Boston     | S65         | 2017 | 10              | 156145  | 127284   | 109086   | 97151    | 87171    | 77486    |
| Asthma Adults | Boston     | S65         | 2017 | 20              | 105369  | 71029    | 54103    | 44613    | 36199    | 29448    |
| Asthma Adults | Boston     | S65         | 2017 | 30              | 62713   | 39526    | 28372    | 21719    | 15947    | 12621    |
| Asthma Adults | Boston     | S65         | 2017 | 40              | 33949   | 17415    | 9392     | 5479     | 3913     | 2250     |
| Asthma Adults | Boston     | S65         | 2017 | 50              | 11251   | 2348     | 489      | 294      | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2017 | 60              | 1565  | 98       | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2017 | 70              | 98  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2015 | 0               | 171995  | 144601   | 128654   | 117011   | 105564   | 99107    |
| Asthma Adults | Boston     | S70         | 2015 | 10              | 152428  | 122979   | 105662   | 90987    | 80421    | 72594    |
| Asthma Adults | Boston     | S70         | 2015 | 20              | 103314  | 69757    | 51951    | 39526    | 33362    | 26318    |
| Asthma Adults | Boston     | S70         | 2015 | 30              | 61343   | 35319    | 25731    | 19763    | 14675    | 11447    |
| Asthma Adults | Boston     | S70         | 2015 | 40              | 31014   | 14871    | 8120     | 5185     | 3131     | 1859     |
| Asthma Adults | Boston     | S70         | 2015 | 50              | 8512  | 1957     | 685      | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2015 | 60              | 1370  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2015 | 70              | 196   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2015 | 80              | 98  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2016 | 0               | 177180  | 150275   | 133448   | 122588   | 112902   | 105369   |
| Asthma Adults | Boston     | S70         | 2016 | 10              | 158200  | 128751   | 110163   | 97346    | 86780    | 79345    |
| Asthma Adults | Boston     | S70         | 2016 | 20              | 107228  | 71713    | 53516    | 43830    | 36395    | 30622    |
| Asthma Adults | Boston     | S70         | 2016 | 30              | 65550   | 40895    | 29448    | 23187    | 18491    | 14969    |
| Asthma Adults | Boston     | S70         | 2016 | 40              | 39036   | 20154    | 11740    | 8218     | 5283     | 3718     |
| Asthma Adults | Boston     | S70         | 2016 | 50              | 12621   | 3816     | 1663     | 587      | 196      | 98       |
| Asthma Adults | Boston     | S70         | 2016 | 60              | 2055  | 489      | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2017 | 0               | 174636  | 148416   | 131589   | 120925   | 110750   | 103216   |
| Asthma Adults | Boston     | S70         | 2017 | 10              | 155950  | 126990   | 109282   | 97444    | 87269    | 77583    |
| Asthma Adults | Boston     | S70         | 2017 | 20              | 108010  | 73474    | 56255    | 45493    | 36982    | 30916    |
| Asthma Adults | Boston     | S70         | 2017 | 30              | 65843   | 40700    | 29351    | 22698    | 16730    | 13697    |
| Asthma Adults | Boston     | S70         | 2017 | 40              | 38743   | 20643    | 11447    | 7631     | 5381     | 3522     |
| Asthma Adults | Boston     | S70         | 2017 | 50              | 16241   | 4403     | 783      | 294      | 98       | 0        |
| Asthma Adults | Boston     | S70         | 2017 | 60              | 4207  | 294      | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2017 | 70              | 685   | 98       | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2017 | 80              | 98  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2015 | 0               | 171995  | 144601   | 128654   | 117011   | 105564   | 99107    |
| Asthma Adults | Boston     | S75         | 2015 | 10              | 152428  | 122392   | 105662   | 90400    | 79834    | 71909    |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Boston     | S75         | 2015 | 20              | 104488  | 70833    | 52538    | 41091    | 33851    | 26611    |
| Asthma Adults | Boston     | S75         | 2015 | 30              | 62419   | 35514    | 26024    | 19665    | 15164    | 11447    |
| Asthma Adults | Boston     | S75         | 2015 | 40              | 32775   | 16241    | 9392     | 6261     | 3620     | 2446     |
| Asthma Adults | Boston     | S75         | 2015 | 50              | 10664   | 3033     | 1076     | 98       | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2015 | 60              | 2250  | 196      | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2015 | 70              | 391   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2015 | 80              | 196   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2016 | 0               | 177180  | 150275   | 133448   | 122588   | 112902   | 105369   |
| Asthma Adults | Boston     | S75         | 2016 | 10              | 158004  | 128458   | 109674   | 96661    | 86584    | 79149    |
| Asthma Adults | Boston     | S75         | 2016 | 20              | 108402  | 72203    | 54005    | 44319    | 37373    | 31307    |
| Asthma Adults | Boston     | S75         | 2016 | 30              | 66724   | 41287    | 29448    | 23285    | 18687    | 15262    |
| Asthma Adults | Boston     | S75         | 2016 | 40              | 40895   | 20937    | 12719    | 8903     | 6164     | 4109     |
| Asthma Adults | Boston     | S75         | 2016 | 50              | 16045   | 5283     | 2837     | 1468     | 391      | 196      |
| Asthma Adults | Boston     | S75         | 2016 | 60              | 3033  | 587      | 98       | 98       | 98       | 0        |
| Asthma Adults | Boston     | S75         | 2016 | 70              | 294   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2017 | 0               | 174636  | 148416   | 131589   | 120925   | 110750   | 103216   |
| Asthma Adults | Boston     | S75         | 2017 | 10              | 155558  | 126599   | 109282   | 97542    | 86878    | 77290    |
| Asthma Adults | Boston     | S75         | 2017 | 20              | 108499  | 73768    | 56745    | 45591    | 37569    | 31992    |
| Asthma Adults | Boston     | S75         | 2017 | 30              | 67702   | 41776    | 29644    | 22600    | 17317    | 13599    |
| Asthma Adults | Boston     | S75         | 2017 | 40              | 41580   | 21817    | 12621    | 8414     | 5674     | 3913     |
| Asthma Adults | Boston     | S75         | 2017 | 50              | 18784   | 6066     | 1174     | 391      | 196      | 98       |
| Asthma Adults | Boston     | S75         | 2017 | 60              | 6164  | 881      | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2017 | 70              | 783   | 98       | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2017 | 80              | 98  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2015 | 0               | 102827  | 89701    | 81887    | 75558    | 70401    | 66650    |
| Asthma Adults | Dallas     | S65         | 2015 | 10              | 90091   | 74933    | 64853    | 57430    | 51492    | 46726    |
| Asthma Adults | Dallas     | S65         | 2015 | 20              | 63759   | 44538    | 34536    | 27660    | 22972    | 18440    |
| Asthma Adults | Dallas     | S65         | 2015 | 30              | 39693   | 24457    | 17034    | 12814    | 10001    | 7814     |
| Asthma Adults | Dallas     | S65         | 2015 | 40              | 23675   | 11564    | 7110     | 4610     | 3360     | 2422     |
| Asthma Adults | Dallas     | S65         | 2015 | 50              | 9064  | 1875     | 703      | 234      | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2015 | 60              | 938   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2016 | 0               | 106500  | 93217    | 84700    | 77668    | 72432    | 67510    |
| Asthma Adults | Dallas     | S65         | 2016 | 10              | 94154   | 78605    | 66807    | 59696    | 54539    | 50007    |
| Asthma Adults | Dallas     | S65         | 2016 | 20              | 64853   | 46726    | 36255    | 28754    | 23753    | 20784    |
| Asthma Adults | Dallas     | S65         | 2016 | 30              | 42115   | 26098    | 19143    | 14143    | 11486    | 9454     |
| Asthma Adults | Dallas     | S65         | 2016 | 40              | 21956   | 10158    | 6720     | 4376     | 2422     | 1641     |
| Asthma Adults | Dallas     | S65         | 2016 | 50              | 5079  | 1328     | 313      | 78       | 78       | 78       |
| Asthma Adults | Dallas     | S65         | 2016 | 60              | 156   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2016 | 70              | 78  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2017 | 0               | 102046  | 89701    | 82668    | 75870    | 70870    | 66103    |
| Asthma Adults | Dallas     | S65         | 2017 | 10              | 91732   | 77042    | 65400    | 59618    | 54227    | 50007    |
| Asthma Adults | Dallas     | S65         | 2017 | 20              | 61884   | 45241    | 35161    | 29614    | 25160    | 21800    |
| Asthma Adults | Dallas     | S65         | 2017 | 30              | 39381   | 25551    | 19534    | 16096    | 13049    | 10548    |



| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Dallas     | S65         | 2017 | 40              | 23285   | 12814    | 7970     | 5626     | 3829     | 2813     |
| Asthma Adults | Dallas     | S65         | 2017 | 50              | 8908  | 2578     | 469      | 78       | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2017 | 60              | 859   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2015 | 0               | 102827  | 89701    | 81887    | 75558    | 70401    | 66650    |
| Asthma Adults | Dallas     | S70         | 2015 | 10              | 90638   | 75402    | 65400    | 57899    | 52351    | 47429    |
| Asthma Adults | Dallas     | S70         | 2015 | 20              | 65400   | 45944    | 35943    | 29301    | 23753    | 19065    |
| Asthma Adults | Dallas     | S70         | 2015 | 30              | 41959   | 25941    | 18362    | 13830    | 11252    | 8361     |
| Asthma Adults | Dallas     | S70         | 2015 | 40              | 26254   | 13596    | 8204     | 5782     | 3751     | 2969     |
| Asthma Adults | Dallas     | S70         | 2015 | 50              | 13439   | 3907     | 1953     | 703      | 313      | 234      |
| Asthma Adults | Dallas     | S70         | 2015 | 60              | 3047  | 156      | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2015 | 70              | 234   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2016 | 0               | 106500  | 93217    | 84700    | 77668    | 72432    | 67510    |
| Asthma Adults | Dallas     | S70         | 2016 | 10              | 94389   | 79074    | 67432    | 59931    | 54930    | 50398    |
| Asthma Adults | Dallas     | S70         | 2016 | 20              | 66963   | 47585    | 37974    | 30161    | 25082    | 21566    |
| Asthma Adults | Dallas     | S70         | 2016 | 30              | 44147   | 27738    | 20315    | 15002    | 11642    | 9923     |
| Asthma Adults | Dallas     | S70         | 2016 | 40              | 25472   | 12189    | 7970     | 5782     | 3516     | 2266     |
| Asthma Adults | Dallas     | S70         | 2016 | 50              | 8048  | 2344     | 859      | 313      | 156      | 78       |
| Asthma Adults | Dallas     | S70         | 2016 | 60              | 781   | 78       | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2016 | 70              | 78  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2017 | 0               | 102046  | 89701    | 82668    | 75870    | 70870    | 66103    |
| Asthma Adults | Dallas     | S70         | 2017 | 10              | 92123   | 77199    | 66494    | 59852    | 55242    | 50242    |
| Asthma Adults | Dallas     | S70         | 2017 | 20              | 64462   | 47194    | 36412    | 30708    | 26332    | 22972    |
| Asthma Adults | Dallas     | S70         | 2017 | 30              | 41334   | 26723    | 20315    | 16956    | 13908    | 11330    |
| Asthma Adults | Dallas     | S70         | 2017 | 40              | 25082   | 15237    | 9689     | 7267     | 5235     | 3751     |
| Asthma Adults | Dallas     | S70         | 2017 | 50              | 11720   | 4610     | 1563     | 469      | 156      | 0        |
| Asthma Adults | Dallas     | S70         | 2017 | 60              | 2500  | 78       | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2015 | 0               | 102827  | 89701    | 81887    | 75558    | 70401    | 66650    |
| Asthma Adults | Dallas     | S75         | 2015 | 10              | 90404   | 75402    | 65322    | 57899    | 52508    | 47507    |
| Asthma Adults | Dallas     | S75         | 2015 | 20              | 66728   | 47819    | 36802    | 29848    | 24613    | 19534    |
| Asthma Adults | Dallas     | S75         | 2015 | 30              | 44381   | 27191    | 19456    | 14768    | 11564    | 8986     |
| Asthma Adults | Dallas     | S75         | 2015 | 40              | 27504   | 15002    | 9064     | 6642     | 4610     | 3204     |
| Asthma Adults | Dallas     | S75         | 2015 | 50              | 16565   | 6251     | 2813     | 1485     | 703      | 313      |
| Asthma Adults | Dallas     | S75         | 2015 | 60              | 5313  | 859      | 156      | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2015 | 70              | 469   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2016 | 0               | 106500  | 93217    | 84700    | 77668    | 72432    | 67510    |
| Asthma Adults | Dallas     | S75         | 2016 | 10              | 94389   | 78996    | 67432    | 60399    | 55086    | 50554    |
| Asthma Adults | Dallas     | S75         | 2016 | 20              | 68057   | 48679    | 38756    | 30864    | 25629    | 21566    |
| Asthma Adults | Dallas     | S75         | 2016 | 30              | 45163   | 29223    | 21019    | 15315    | 12033    | 10158    |
| Asthma Adults | Dallas     | S75         | 2016 | 40              | 27348   | 13518    | 8517     | 6798     | 4376     | 2969     |
| Asthma Adults | Dallas     | S75         | 2016 | 50              | 11095   | 3907     | 1406     | 547      | 234      | 156      |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Dallas     | S75         | 2016 | 60              | 1719  | 78       | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2016 | 70              | 234   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2016 | 80              | 78  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2017 | 0               | 102046  | 89701    | 82668    | 75870    | 70870    | 66103    |
| Asthma Adults | Dallas     | S75         | 2017 | 10              | 92123   | 77433    | 66416    | 60087    | 55242    | 50476    |
| Asthma Adults | Dallas     | S75         | 2017 | 20              | 65400   | 48288    | 37427    | 32114    | 27035    | 23128    |
| Asthma Adults | Dallas     | S75         | 2017 | 30              | 42741   | 27817    | 21175    | 17659    | 14299    | 11799    |
| Asthma Adults | Dallas     | S75         | 2017 | 40              | 26566   | 16799    | 10705    | 7814     | 5938     | 4219     |
| Asthma Adults | Dallas     | S75         | 2017 | 50              | 14221   | 6485     | 3047     | 1328     | 547      | 234      |
| Asthma Adults | Dallas     | S75         | 2017 | 60              | 4454  | 469      | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2017 | 70              | 156   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2015 | 0               | 117319  | 100672   | 87825    | 81337    | 75569    | 71178    |
| Asthma Adults | Detroit    | S65         | 2015 | 10              | 104145  | 83762    | 72751    | 64034    | 56497    | 50729    |
| Asthma Adults | Detroit    | S65         | 2015 | 20              | 70850   | 47452    | 35458    | 27921    | 23202    | 19859    |
| Asthma Adults | Detroit    | S65         | 2015 | 30              | 42799   | 25823    | 19138    | 14812    | 12125    | 9831     |
| Asthma Adults | Detroit    | S65         | 2015 | 40              | 24709   | 12781    | 7931     | 4916     | 3408     | 2294     |
| Asthma Adults | Detroit    | S65         | 2015 | 50              | 9045  | 2884     | 1049     | 197      | 131      | 66       |
| Asthma Adults | Detroit    | S65         | 2015 | 60              | 655   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2016 | 0               | 116467  | 99557    | 89923    | 82189    | 74717    | 69867    |
| Asthma Adults | Detroit    | S65         | 2016 | 10              | 103883  | 84745    | 73210    | 64296    | 57611    | 51450    |
| Asthma Adults | Detroit    | S65         | 2016 | 20              | 73406   | 49877    | 38735    | 31001    | 26020    | 21563    |
| Asthma Adults | Detroit    | S65         | 2016 | 30              | 46141   | 27658    | 20383    | 15861    | 13108    | 10093    |
| Asthma Adults | Detroit    | S65         | 2016 | 40              | 26741   | 13567    | 7996     | 5374     | 4195     | 3015     |
| Asthma Adults | Detroit    | S65         | 2016 | 50              | 10552   | 3408     | 1311     | 459      | 131      | 66       |
| Asthma Adults | Detroit    | S65         | 2016 | 60              | 2032  | 262      | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2016 | 70              | 66  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2017 | 0               | 116205  | 99885    | 89464    | 81534    | 75504    | 70195    |
| Asthma Adults | Detroit    | S65         | 2017 | 10              | 104670  | 85269    | 73406    | 64689    | 57087    | 52302    |
| Asthma Adults | Detroit    | S65         | 2017 | 20              | 72882   | 51188    | 39325    | 32115    | 25889    | 21498    |
| Asthma Adults | Detroit    | S65         | 2017 | 30              | 46403   | 29100    | 22153    | 17762    | 14091    | 12256    |
| Asthma Adults | Detroit    | S65         | 2017 | 40              | 28117   | 15861    | 10093    | 7078     | 4785     | 3343     |
| Asthma Adults | Detroit    | S65         | 2017 | 50              | 10749   | 2949     | 1442     | 328      | 197      | 131      |
| Asthma Adults | Detroit    | S65         | 2017 | 60              | 721   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2017 | 70              | 66  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S70         | 2015 | 0               | 117319  | 100672   | 87825    | 81337    | 75569    | 71178    |
| Asthma Adults | Detroit    | S70         | 2015 | 10              | 104407  | 84286    | 73079    | 64099    | 56431    | 50991    |
| Asthma Adults | Detroit    | S70         | 2015 | 20              | 72161   | 49484    | 36900    | 29231    | 24119    | 20842    |
| Asthma Adults | Detroit    | S70         | 2015 | 30              | 44634   | 27527    | 19990    | 15402    | 12846    | 10356    |
| Asthma Adults | Detroit    | S70         | 2015 | 40              | 28248   | 15009    | 9569     | 6685     | 4588     | 3539     |
| Asthma Adults | Detroit    | S70         | 2015 | 50              | 13108   | 4653     | 2294     | 655      | 393      | 131      |
| Asthma Adults | Detroit    | S70         | 2015 | 60              | 2425  | 197      | 66       | 0        | 0        | 0        |
| Asthma Adults | Detroit    | S70         | 2015 | 70              | 66  | 0        | 0        | 0        | 0        | 0        |

| Study Group   | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Detroit      | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S70         | 2016 | 0               | 116467  | 99557    | 89923    | 82189    | 74717    | 69867    |
| Asthma Adults | Detroit      | S70         | 2016 | 10              | 103818  | 85204    | 72948    | 64427    | 58004    | 52040    |
| Asthma Adults | Detroit      | S70         | 2016 | 20              | 74914   | 52105    | 40374    | 32574    | 26741    | 22612    |
| Asthma Adults | Detroit      | S70         | 2016 | 30              | 48763   | 29494    | 21301    | 16582    | 13698    | 11208    |
| Asthma Adults | Detroit      | S70         | 2016 | 40              | 29756   | 15664    | 9897     | 7013     | 5112     | 3998     |
| Asthma Adults | Detroit      | S70         | 2016 | 50              | 15206   | 5637     | 2622     | 1507     | 524      | 197      |
| Asthma Adults | Detroit      | S70         | 2016 | 60              | 5047  | 590      | 66       | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S70         | 2016 | 70              | 655   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S70         | 2017 | 0               | 116205  | 99885    | 89464    | 81534    | 75504    | 70195    |
| Asthma Adults | Detroit      | S70         | 2017 | 10              | 104473  | 85204    | 73144    | 64362    | 57349    | 52433    |
| Asthma Adults | Detroit      | S70         | 2017 | 20              | 74324   | 53089    | 40898    | 33098    | 27134    | 22743    |
| Asthma Adults | Detroit      | S70         | 2017 | 30              | 48566   | 31067    | 23005    | 18221    | 14747    | 12453    |
| Asthma Adults | Detroit      | S70         | 2017 | 40              | 31919   | 18286    | 12387    | 8586     | 6226     | 4457     |
| Asthma Adults | Detroit      | S70         | 2017 | 50              | 14878   | 5571     | 2818     | 1114     | 590      | 262      |
| Asthma Adults | Detroit      | S70         | 2017 | 60              | 2425  | 197      | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S70         | 2017 | 70              | 197   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2015 | 0               | 117319  | 100672   | 87825    | 81337    | 75569    | 71178    |
| Asthma Adults | Detroit      | S75         | 2015 | 10              | 104670  | 83696    | 71244    | 62854    | 55579    | 50008    |
| Asthma Adults | Detroit      | S75         | 2015 | 20              | 73013   | 49353    | 37096    | 30018    | 23923    | 20646    |
| Asthma Adults | Detroit      | S75         | 2015 | 30              | 45617   | 28052    | 20646    | 15468    | 12912    | 9831     |
| Asthma Adults | Detroit      | S75         | 2015 | 40              | 29559   | 15795    | 10356    | 7210     | 4981     | 3801     |
| Asthma Adults | Detroit      | S75         | 2015 | 50              | 15730   | 6030     | 3080     | 1245     | 524      | 459      |
| Asthma Adults | Detroit      | S75         | 2015 | 60              | 4719  | 721      | 197      | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2015 | 70              | 524   | 66       | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2016 | 0               | 116467  | 99557    | 89923    | 82189    | 74717    | 69867    |
| Asthma Adults | Detroit      | S75         | 2016 | 10              | 103031  | 84286    | 72489    | 63510    | 57349    | 51253    |
| Asthma Adults | Detroit      | S75         | 2016 | 20              | 75438   | 53351    | 41029    | 32902    | 26938    | 22808    |
| Asthma Adults | Detroit      | S75         | 2016 | 30              | 50467   | 30018    | 21629    | 16844    | 13764    | 11273    |
| Asthma Adults | Detroit      | S75         | 2016 | 40              | 31329   | 16975    | 10945    | 7799     | 5899     | 4653     |
| Asthma Adults | Detroit      | S75         | 2016 | 50              | 17631   | 7144     | 3867     | 2228     | 1245     | 590      |
| Asthma Adults | Detroit      | S75         | 2016 | 60              | 7472  | 1966     | 393      | 131      | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2016 | 70              | 1835  | 66       | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2017 | 0               | 116205  | 99885    | 89464    | 81534    | 75504    | 70195    |
| Asthma Adults | Detroit      | S75         | 2017 | 10              | 104211  | 84155    | 72161    | 63706    | 56693    | 52105    |
| Asthma Adults | Detroit      | S75         | 2017 | 20              | 74848   | 53351    | 41291    | 33033    | 26872    | 21956    |
| Asthma Adults | Detroit      | S75         | 2017 | 30              | 49943   | 31788    | 23333    | 18548    | 14550    | 12584    |
| Asthma Adults | Detroit      | S75         | 2017 | 40              | 33295   | 18614    | 12256    | 9241     | 7013     | 4850     |
| Asthma Adults | Detroit      | S75         | 2017 | 50              | 17893   | 7013     | 3998     | 2228     | 1180     | 655      |
| Asthma Adults | Detroit      | S75         | 2017 | 60              | 6620  | 786      | 262      | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2017 | 70              | 459   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Detroit      | S75         | 2017 | 80              | 131   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2015 | 0               | 137336  | 115725   | 101608   | 91238    | 85487    | 80868    |

| Study Group   | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Philadelphia | S65         | 2015 | 10              | 120866  | 97077    | 84005    | 75117    | 67187    | 60738    |
| Asthma Adults | Philadelphia | S65         | 2015 | 20              | 84964   | 58995    | 46708    | 37297    | 30761    | 25533    |
| Asthma Adults | Philadelphia | S65         | 2015 | 30              | 55945   | 36426    | 25794    | 20217    | 16557    | 14378    |
| Asthma Adults | Philadelphia | S65         | 2015 | 40              | 33114   | 17603    | 12113    | 7843     | 5403     | 3747     |
| Asthma Adults | Philadelphia | S65         | 2015 | 50              | 10370   | 2876     | 610      | 87       | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2015 | 60              | 871   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2016 | 0               | 131672  | 112152   | 101434   | 93242    | 85748    | 79474    |
| Asthma Adults | Philadelphia | S65         | 2016 | 10              | 119298  | 97077    | 84790    | 75291    | 67448    | 61958    |
| Asthma Adults | Philadelphia | S65         | 2016 | 20              | 85487   | 61087    | 45053    | 36600    | 31110    | 26927    |
| Asthma Adults | Philadelphia | S65         | 2016 | 30              | 55161   | 33898    | 24661    | 19258    | 16034    | 13246    |
| Asthma Adults | Philadelphia | S65         | 2016 | 40              | 30587   | 14814    | 8279     | 4531     | 2701     | 1830     |
| Asthma Adults | Philadelphia | S65         | 2016 | 50              | 6536  | 1394     | 436      | 87       | 87       | 0        |
| Asthma Adults | Philadelphia | S65         | 2016 | 60              | 436   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2017 | 0               | 136726  | 115725   | 102654   | 95247    | 88972    | 82088    |
| Asthma Adults | Philadelphia | S65         | 2017 | 10              | 121999  | 98122    | 85835    | 77121    | 69627    | 63004    |
| Asthma Adults | Philadelphia | S65         | 2017 | 20              | 81740   | 58908    | 45837    | 37645    | 32504    | 28234    |
| Asthma Adults | Philadelphia | S65         | 2017 | 30              | 54900   | 33986    | 24923    | 20043    | 15773    | 12636    |
| Asthma Adults | Philadelphia | S65         | 2017 | 40              | 29367   | 14988    | 7930     | 4009     | 2701     | 2091     |
| Asthma Adults | Philadelphia | S65         | 2017 | 50              | 7581  | 697      | 87       | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2017 | 60              | 871   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2015 | 0               | 137336  | 115725   | 101608   | 91238    | 85487    | 80868    |
| Asthma Adults | Philadelphia | S70         | 2015 | 10              | 121041  | 97599    | 84702    | 75378    | 68058    | 61610    |
| Asthma Adults | Philadelphia | S70         | 2015 | 20              | 87752   | 61348    | 48625    | 38778    | 32766    | 27276    |
| Asthma Adults | Philadelphia | S70         | 2015 | 30              | 58473   | 37907    | 27101    | 21698    | 17603    | 14814    |
| Asthma Adults | Philadelphia | S70         | 2015 | 40              | 36251   | 20827    | 14466    | 10283    | 7146     | 5664     |
| Asthma Adults | Philadelphia | S70         | 2015 | 50              | 16470   | 5141     | 1830     | 174      | 87       | 87       |
| Asthma Adults | Philadelphia | S70         | 2015 | 60              | 2614  | 174      | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2016 | 0               | 131672  | 112152   | 101434   | 93242    | 85748    | 79474    |
| Asthma Adults | Philadelphia | S70         | 2016 | 10              | 119995  | 98209    | 85487    | 75727    | 67971    | 63091    |
| Asthma Adults | Philadelphia | S70         | 2016 | 20              | 88101   | 63265    | 47493    | 38517    | 32853    | 28757    |
| Asthma Adults | Philadelphia | S70         | 2016 | 30              | 57688   | 35467    | 25620    | 20653    | 17167    | 14117    |
| Asthma Adults | Philadelphia | S70         | 2016 | 40              | 35293   | 17777    | 12026    | 6971     | 4793     | 3224     |
| Asthma Adults | Philadelphia | S70         | 2016 | 50              | 12113   | 3573     | 1220     | 523      | 261      | 174      |
| Asthma Adults | Philadelphia | S70         | 2016 | 60              | 1569  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2017 | 0               | 136726  | 115725   | 102654   | 95247    | 88972    | 82088    |
| Asthma Adults | Philadelphia | S70         | 2017 | 10              | 122958  | 98994    | 86097    | 77731    | 70585    | 63527    |
| Asthma Adults | Philadelphia | S70         | 2017 | 20              | 84702   | 61435    | 48190    | 39563    | 33986    | 29193    |

| Study Group   | Study Area   | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|--------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |              |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Philadelphia | S70         | 2017 | 30              | 56817   | 35380    | 26753    | 20914    | 16383    | 14030    |
| Asthma Adults | Philadelphia | S70         | 2017 | 40              | 33811   | 18387    | 11503    | 6884     | 4357     | 2963     |
| Asthma Adults | Philadelphia | S70         | 2017 | 50              | 12461   | 3137     | 523      | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2017 | 60              | 2353  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2017 | 70              | 261   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2015 | 0               | 137336  | 115725   | 101608   | 91238    | 85487    | 80868    |
| Asthma Adults | Philadelphia | S75         | 2015 | 10              | 121041  | 98558    | 84964    | 75030    | 68145    | 62307    |
| Asthma Adults | Philadelphia | S75         | 2015 | 20              | 89757   | 63091    | 49235    | 40783    | 33898    | 29106    |
| Asthma Adults | Philadelphia | S75         | 2015 | 30              | 59954   | 40347    | 28408    | 22134    | 18300    | 15511    |
| Asthma Adults | Philadelphia | S75         | 2015 | 40              | 39563   | 23877    | 16034    | 12200    | 8627     | 6449     |
| Asthma Adults | Philadelphia | S75         | 2015 | 50              | 22657   | 9150     | 4270     | 1656     | 610      | 349      |
| Asthma Adults | Philadelphia | S75         | 2015 | 60              | 5926  | 784      | 87       | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2015 | 70              | 697   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2016 | 0               | 131672  | 112152   | 101434   | 93242    | 85748    | 79474    |
| Asthma Adults | Philadelphia | S75         | 2016 | 10              | 120431  | 98122    | 85574    | 76075    | 67797    | 63265    |
| Asthma Adults | Philadelphia | S75         | 2016 | 20              | 90367   | 65270    | 49933    | 40085    | 33550    | 29803    |
| Asthma Adults | Philadelphia | S75         | 2016 | 30              | 60477   | 37297    | 27276    | 21350    | 17603    | 14378    |
| Asthma Adults | Philadelphia | S75         | 2016 | 40              | 40173   | 20740    | 13943    | 8540     | 6361     | 4793     |
| Asthma Adults | Philadelphia | S75         | 2016 | 50              | 19346   | 6884     | 3050     | 1481     | 871      | 349      |
| Asthma Adults | Philadelphia | S75         | 2016 | 60              | 3573  | 436      | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2016 | 70              | 523   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2017 | 0               | 136726  | 115725   | 102654   | 95247    | 88972    | 82088    |
| Asthma Adults | Philadelphia | S75         | 2017 | 10              | 123481  | 99517    | 86009    | 77818    | 70062    | 63614    |
| Asthma Adults | Philadelphia | S75         | 2017 | 20              | 87578   | 63004    | 49845    | 40783    | 35206    | 30238    |
| Asthma Adults | Philadelphia | S75         | 2017 | 30              | 58821   | 37123    | 27711    | 21960    | 17254    | 14291    |
| Asthma Adults | Philadelphia | S75         | 2017 | 40              | 38081   | 21176    | 13681    | 9324     | 6361     | 3921     |
| Asthma Adults | Philadelphia | S75         | 2017 | 50              | 17603   | 5839     | 2091     | 436      | 174      | 174      |
| Asthma Adults | Philadelphia | S75         | 2017 | 60              | 5141  | 174      | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2017 | 70              | 610   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix      | S65         | 2015 | 0               | 81554   | 71968    | 65512    | 60297    | 56472    | 53790    |
| Asthma Adults | Phoenix      | S65         | 2015 | 10              | 74055   | 63475    | 55826    | 49817    | 46588    | 42565    |
| Asthma Adults | Phoenix      | S65         | 2015 | 20              | 55578   | 42615    | 34420    | 28907    | 25132    | 22152    |
| Asthma Adults | Phoenix      | S65         | 2015 | 30              | 39386   | 26076    | 20066    | 17036    | 14205    | 12367    |
| Asthma Adults | Phoenix      | S65         | 2015 | 40              | 25231   | 14950    | 10877    | 8245     | 6357     | 5215     |
| Asthma Adults | Phoenix      | S65         | 2015 | 50              | 10579   | 3775     | 1490     | 944      | 447      | 447      |
| Asthma Adults | Phoenix      | S65         | 2015 | 60              | 596   | 50       | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix      | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix      | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix      | S65         | 2016 | 0               | 78177   | 68243    | 61687    | 58012    | 54734    | 51853    |
| Asthma Adults | Phoenix      | S65         | 2016 | 10              | 71621   | 60247    | 53095    | 48327    | 44751    | 42118    |
| Asthma Adults | Phoenix      | S65         | 2016 | 20              | 52697   | 39237    | 31837    | 26970    | 23493    | 21109    |
| Asthma Adults | Phoenix      | S65         | 2016 | 30              | 35413   | 23840    | 19519    | 16589    | 14155    | 12516    |
| Asthma Adults | Phoenix      | S65         | 2016 | 40              | 23940   | 15347    | 10977    | 8146     | 6755     | 5612     |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Phoenix    | S65         | 2016 | 50              | 8593  | 2930     | 1341     | 447      | 199      | 149      |
| Asthma Adults | Phoenix    | S65         | 2016 | 60              | 248   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S65         | 2017 | 0               | 77233   | 66604    | 60942    | 56323    | 52797    | 50214    |
| Asthma Adults | Phoenix    | S65         | 2017 | 10              | 69882   | 58757    | 52598    | 48277    | 45098    | 43012    |
| Asthma Adults | Phoenix    | S65         | 2017 | 20              | 53293   | 39833    | 33377    | 28807    | 23989    | 21506    |
| Asthma Adults | Phoenix    | S65         | 2017 | 30              | 35661   | 24983    | 20562    | 16539    | 14702    | 13410    |
| Asthma Adults | Phoenix    | S65         | 2017 | 40              | 24884   | 16539    | 12715    | 10281    | 8195     | 6804     |
| Asthma Adults | Phoenix    | S65         | 2017 | 50              | 10430   | 4818     | 2384     | 1242     | 497      | 248      |
| Asthma Adults | Phoenix    | S65         | 2017 | 60              | 944   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2015 | 0               | 81554   | 71968    | 65512    | 60297    | 56472    | 53790    |
| Asthma Adults | Phoenix    | S70         | 2015 | 10              | 74104   | 63277    | 55926    | 49717    | 46787    | 43360    |
| Asthma Adults | Phoenix    | S70         | 2015 | 20              | 56969   | 44204    | 36108    | 30049    | 26324    | 23443    |
| Asthma Adults | Phoenix    | S70         | 2015 | 30              | 40728   | 28162    | 21158    | 17533    | 14553    | 12914    |
| Asthma Adults | Phoenix    | S70         | 2015 | 40              | 27814   | 17036    | 12665    | 10033    | 7996     | 6606     |
| Asthma Adults | Phoenix    | S70         | 2015 | 50              | 15397   | 7301     | 4073     | 2334     | 1440     | 993      |
| Asthma Adults | Phoenix    | S70         | 2015 | 60              | 3328  | 695      | 199      | 149      | 50       | 50       |
| Asthma Adults | Phoenix    | S70         | 2015 | 70              | 50  | 50       | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2016 | 0               | 78177   | 68243    | 61687    | 58012    | 54734    | 51853    |
| Asthma Adults | Phoenix    | S70         | 2016 | 10              | 71819   | 60396    | 53095    | 48674    | 45098    | 42218    |
| Asthma Adults | Phoenix    | S70         | 2016 | 20              | 54535   | 41026    | 33675    | 28559    | 24784    | 22400    |
| Asthma Adults | Phoenix    | S70         | 2016 | 30              | 36853   | 25082    | 20016    | 17284    | 15049    | 13063    |
| Asthma Adults | Phoenix    | S70         | 2016 | 40              | 26771   | 17135    | 13212    | 10480    | 8146     | 6804     |
| Asthma Adults | Phoenix    | S70         | 2016 | 50              | 14006   | 6258     | 3824     | 2334     | 1341     | 695      |
| Asthma Adults | Phoenix    | S70         | 2016 | 60              | 2831  | 397      | 99       | 50       | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2017 | 0               | 77233   | 66604    | 60942    | 56323    | 52797    | 50214    |
| Asthma Adults | Phoenix    | S70         | 2017 | 10              | 70329   | 58906    | 52598    | 48625    | 45049    | 42963    |
| Asthma Adults | Phoenix    | S70         | 2017 | 20              | 55081   | 41522    | 34817    | 30347    | 26125    | 22897    |
| Asthma Adults | Phoenix    | S70         | 2017 | 30              | 37499   | 26175    | 21655    | 17682    | 15149    | 13559    |
| Asthma Adults | Phoenix    | S70         | 2017 | 40              | 27218   | 18526    | 14056    | 11920    | 10083    | 8344     |
| Asthma Adults | Phoenix    | S70         | 2017 | 50              | 15198   | 8593     | 5712     | 3924     | 2583     | 1788     |
| Asthma Adults | Phoenix    | S70         | 2017 | 60              | 3973  | 1142     | 99       | 50       | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2017 | 70              | 99  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S75         | 2015 | 0               | 81554   | 71968    | 65512    | 60297    | 56472    | 53790    |
| Asthma Adults | Phoenix    | S75         | 2015 | 10              | 73856   | 62879    | 55032    | 49419    | 46290    | 42814    |
| Asthma Adults | Phoenix    | S75         | 2015 | 20              | 57168   | 44651    | 36456    | 30943    | 26970    | 23940    |
| Asthma Adults | Phoenix    | S75         | 2015 | 30              | 41622   | 28311    | 21953    | 18029    | 14801    | 13112    |
| Asthma Adults | Phoenix    | S75         | 2015 | 40              | 29403   | 18029    | 13659    | 10381    | 8394     | 6953     |
| Asthma Adults | Phoenix    | S75         | 2015 | 50              | 18725   | 9338     | 6159     | 3973     | 2682     | 1689     |
| Asthma Adults | Phoenix    | S75         | 2015 | 60              | 7599  | 1887     | 646      | 298      | 248      | 50       |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Phoenix    | S75         | 2015 | 70              | 298   | 50       | 50       | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S75         | 2016 | 0               | 78177   | 68243    | 61687    | 58012    | 54734    | 51853    |
| Asthma Adults | Phoenix    | S75         | 2016 | 10              | 71770   | 59850    | 52946    | 48128    | 44999    | 41622    |
| Asthma Adults | Phoenix    | S75         | 2016 | 20              | 55131   | 41622    | 33824    | 29304    | 25678    | 22648    |
| Asthma Adults | Phoenix    | S75         | 2016 | 30              | 37896   | 25579    | 20761    | 17433    | 15347    | 13112    |
| Asthma Adults | Phoenix    | S75         | 2016 | 40              | 27913   | 18129    | 14106    | 11424    | 8791     | 7450     |
| Asthma Adults | Phoenix    | S75         | 2016 | 50              | 17135   | 8791     | 5861     | 3675     | 2483     | 1738     |
| Asthma Adults | Phoenix    | S75         | 2016 | 60              | 6159  | 1589     | 447      | 149      | 99       | 0        |
| Asthma Adults | Phoenix    | S75         | 2016 | 70              | 447   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S75         | 2017 | 0               | 77233   | 66604    | 60942    | 56323    | 52797    | 50214    |
| Asthma Adults | Phoenix    | S75         | 2017 | 10              | 69982   | 58509    | 52201    | 48128    | 45049    | 42764    |
| Asthma Adults | Phoenix    | S75         | 2017 | 20              | 55677   | 42317    | 35810    | 30744    | 26870    | 23890    |
| Asthma Adults | Phoenix    | S75         | 2017 | 30              | 38592   | 27168    | 21854    | 17880    | 15546    | 13808    |
| Asthma Adults | Phoenix    | S75         | 2017 | 40              | 28509   | 19768    | 14751    | 12566    | 10877    | 9238     |
| Asthma Adults | Phoenix    | S75         | 2017 | 50              | 18178   | 11175    | 7251     | 5364     | 4222     | 3129     |
| Asthma Adults | Phoenix    | S75         | 2017 | 60              | 7947  | 2930     | 993      | 397      | 99       | 50       |
| Asthma Adults | Phoenix    | S75         | 2017 | 70              | 1043  | 50       | 0        | 0        | 0        | 0        |
| Asthma Adults | Phoenix    | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2015 | 0               | 36274   | 31357    | 28213    | 26012    | 24583    | 23096    |
| Asthma Adults | Sacramento | S65         | 2015 | 10              | 31643   | 25726    | 22439    | 20324    | 18694    | 16979    |
| Asthma Adults | Sacramento | S65         | 2015 | 20              | 21467   | 14978    | 12063    | 10233    | 8833     | 7546     |
| Asthma Adults | Sacramento | S65         | 2015 | 30              | 13921   | 9004     | 7003     | 5431     | 4745     | 4059     |
| Asthma Adults | Sacramento | S65         | 2015 | 40              | 7289  | 3373     | 2344     | 1486     | 800      | 572      |
| Asthma Adults | Sacramento | S65         | 2015 | 50              | 1343  | 200      | 29       | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2015 | 60              | 57  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2016 | 0               | 36960   | 31586    | 28127    | 26040    | 24383    | 22896    |
| Asthma Adults | Sacramento | S65         | 2016 | 10              | 31443   | 25526    | 22667    | 20409    | 18894    | 17236    |
| Asthma Adults | Sacramento | S65         | 2016 | 20              | 21181   | 15350    | 12406    | 10319    | 9033     | 7775     |
| Asthma Adults | Sacramento | S65         | 2016 | 30              | 13806   | 8947     | 6717     | 5460     | 4602     | 4030     |
| Asthma Adults | Sacramento | S65         | 2016 | 40              | 6660  | 3373     | 1972     | 1229     | 772      | 543      |
| Asthma Adults | Sacramento | S65         | 2016 | 50              | 1658  | 286      | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2016 | 60              | 57  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2016 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2017 | 0               | 36588   | 31614    | 28413    | 25983    | 23725    | 22267    |
| Asthma Adults | Sacramento | S65         | 2017 | 10              | 31814   | 25926    | 22582    | 19723    | 17665    | 16265    |
| Asthma Adults | Sacramento | S65         | 2017 | 20              | 21067   | 14578    | 11177    | 9290     | 7804     | 6689     |
| Asthma Adults | Sacramento | S65         | 2017 | 30              | 12663   | 8204     | 6632     | 5374     | 4316     | 3802     |
| Asthma Adults | Sacramento | S65         | 2017 | 40              | 6117  | 3144     | 1801     | 1201     | 829      | 629      |
| Asthma Adults | Sacramento | S65         | 2017 | 50              | 943   | 143      | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2017 | 60              | 86  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Sacramento | S70         | 2015 | 0               | 36274   | 31357    | 28213    | 26012    | 24583    | 23096    |
| Asthma Adults | Sacramento | S70         | 2015 | 10              | 31700   | 25955    | 22696    | 20524    | 18780    | 17494    |
| Asthma Adults | Sacramento | S70         | 2015 | 20              | 22296   | 16207    | 13006    | 11005    | 9376     | 8032     |
| Asthma Adults | Sacramento | S70         | 2015 | 30              | 14864   | 9747     | 7746     | 6060     | 5059     | 4402     |
| Asthma Adults | Sacramento | S70         | 2015 | 40              | 9347  | 5117     | 3201     | 2458     | 1829     | 1401     |
| Asthma Adults | Sacramento | S70         | 2015 | 50              | 3259  | 972      | 429      | 57       | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2015 | 60              | 257   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2015 | 70              | 57  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2016 | 0               | 36960   | 31586    | 28127    | 26040    | 24383    | 22896    |
| Asthma Adults | Sacramento | S70         | 2016 | 10              | 31529   | 25755    | 22839    | 20724    | 19123    | 17465    |
| Asthma Adults | Sacramento | S70         | 2016 | 20              | 21953   | 16122    | 13235    | 11119    | 9433     | 8261     |
| Asthma Adults | Sacramento | S70         | 2016 | 30              | 14892   | 9776     | 7318     | 5860     | 5088     | 4230     |
| Asthma Adults | Sacramento | S70         | 2016 | 40              | 8347  | 4688     | 3030     | 2230     | 1629     | 1172     |
| Asthma Adults | Sacramento | S70         | 2016 | 50              | 3716  | 1201     | 343      | 143      | 57       | 29       |
| Asthma Adults | Sacramento | S70         | 2016 | 60              | 286   | 86       | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2016 | 70              | 29  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2017 | 0               | 36588   | 31614    | 28413    | 25983    | 23725    | 22267    |
| Asthma Adults | Sacramento | S70         | 2017 | 10              | 31929   | 26298    | 22868    | 20266    | 18094    | 16608    |
| Asthma Adults | Sacramento | S70         | 2017 | 20              | 22124   | 15436    | 11948    | 9804     | 8318     | 7175     |
| Asthma Adults | Sacramento | S70         | 2017 | 30              | 14035   | 9090     | 7175     | 5688     | 4716     | 4059     |
| Asthma Adults | Sacramento | S70         | 2017 | 40              | 7918  | 4602     | 3287     | 2144     | 1629     | 1372     |
| Asthma Adults | Sacramento | S70         | 2017 | 50              | 3030  | 772      | 143      | 57       | 29       | 0        |
| Asthma Adults | Sacramento | S70         | 2017 | 60              | 343   | 29       | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2017 | 70              | 29  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2015 | 0               | 36274   | 31357    | 28213    | 26012    | 24583    | 23096    |
| Asthma Adults | Sacramento | S75         | 2015 | 10              | 31729   | 26098    | 22982    | 20781    | 18894    | 17637    |
| Asthma Adults | Sacramento | S75         | 2015 | 20              | 23039   | 16893    | 13578    | 11405    | 9719     | 8432     |
| Asthma Adults | Sacramento | S75         | 2015 | 30              | 15836   | 10262    | 8089     | 6317     | 5260     | 4574     |
| Asthma Adults | Sacramento | S75         | 2015 | 40              | 10490   | 6088     | 4202     | 3116     | 2315     | 1915     |
| Asthma Adults | Sacramento | S75         | 2015 | 50              | 4888  | 1829     | 915      | 400      | 257      | 114      |
| Asthma Adults | Sacramento | S75         | 2015 | 60              | 972   | 143      | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2015 | 70              | 86  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2015 | 80              | 29  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2016 | 0               | 36960   | 31586    | 28127    | 26040    | 24383    | 22896    |
| Asthma Adults | Sacramento | S75         | 2016 | 10              | 31643   | 25869    | 22896    | 20867    | 19180    | 17551    |
| Asthma Adults | Sacramento | S75         | 2016 | 20              | 22953   | 16722    | 13663    | 11777    | 9976     | 8575     |
| Asthma Adults | Sacramento | S75         | 2016 | 30              | 15693   | 10147    | 7661     | 6146     | 5260     | 4431     |
| Asthma Adults | Sacramento | S75         | 2016 | 40              | 9576  | 5517     | 3830     | 2858     | 2230     | 1658     |
| Asthma Adults | Sacramento | S75         | 2016 | 50              | 5145  | 2001     | 972      | 515      | 286      | 114      |
| Asthma Adults | Sacramento | S75         | 2016 | 60              | 1629  | 286      | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2016 | 70              | 114   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2017 | 0               | 36588   | 31614    | 28413    | 25983    | 23725    | 22267    |
| Asthma Adults | Sacramento | S75         | 2017 | 10              | 31986   | 26526    | 23153    | 20495    | 18208    | 16665    |



| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Sacramento | S75         | 2017 | 20              | 23296   | 16236    | 12491    | 10090    | 8718     | 7603     |
| Asthma Adults | Sacramento | S75         | 2017 | 30              | 14950   | 9519     | 7575     | 5888     | 4888     | 4202     |
| Asthma Adults | Sacramento | S75         | 2017 | 40              | 9004  | 5460     | 3887     | 2773     | 2144     | 1744     |
| Asthma Adults | Sacramento | S75         | 2017 | 50              | 4345  | 1744     | 829      | 429      | 200      | 114      |
| Asthma Adults | Sacramento | S75         | 2017 | 60              | 972   | 143      | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2017 | 70              | 114   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2015 | 0               | 59231   | 50503    | 45496    | 41812    | 38843    | 36447    |
| Asthma Adults | St. Louis  | S65         | 2015 | 10              | 51719   | 41562    | 35767    | 31439    | 28256    | 25431    |
| Asthma Adults | St. Louis  | S65         | 2015 | 20              | 34873   | 23463    | 18062    | 14378    | 11696    | 9693     |
| Asthma Adults | St. Louis  | S65         | 2015 | 30              | 20602   | 12805    | 9013     | 6975     | 5544     | 4793     |
| Asthma Adults | St. Louis  | S65         | 2015 | 40              | 11231   | 5687     | 3434     | 2075     | 1538     | 1037     |
| Asthma Adults | St. Louis  | S65         | 2015 | 50              | 3505  | 715      | 215      | 72       | 36       | 0        |
| Asthma Adults | St. Louis  | S65         | 2015 | 60              | 143   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2016 | 0               | 56262   | 47570    | 43028    | 39094    | 36053    | 33764    |
| Asthma Adults | St. Louis  | S65         | 2016 | 10              | 49824   | 40524    | 34945    | 30402    | 27398    | 25180    |
| Asthma Adults | St. Louis  | S65         | 2016 | 20              | 34337   | 23249    | 17669    | 14307    | 11624    | 9657     |
| Asthma Adults | St. Louis  | S65         | 2016 | 30              | 21496   | 12876    | 9693     | 7762     | 6259     | 5437     |
| Asthma Adults | St. Louis  | S65         | 2016 | 40              | 13019   | 6903     | 4149     | 3076     | 1967     | 1431     |
| Asthma Adults | St. Louis  | S65         | 2016 | 50              | 5294  | 1645     | 572      | 72       | 36       | 0        |
| Asthma Adults | St. Louis  | S65         | 2016 | 60              | 930   | 72       | 36       | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2016 | 70              | 36  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2017 | 0               | 58694   | 50897    | 45746    | 42062    | 39094    | 36769    |
| Asthma Adults | St. Louis  | S65         | 2017 | 10              | 52435   | 43243    | 37556    | 34158    | 30760    | 27577    |
| Asthma Adults | St. Louis  | S65         | 2017 | 20              | 37198   | 26217    | 20495    | 16524    | 13556    | 11338    |
| Asthma Adults | St. Louis  | S65         | 2017 | 30              | 23249   | 15165    | 10694    | 8405     | 6832     | 5437     |
| Asthma Adults | St. Louis  | S65         | 2017 | 40              | 14271   | 7368     | 4686     | 3112     | 2253     | 1717     |
| Asthma Adults | St. Louis  | S65         | 2017 | 50              | 4328  | 1180     | 644      | 286      | 179      | 107      |
| Asthma Adults | St. Louis  | S65         | 2017 | 60              | 72  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2017 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2015 | 0               | 59231   | 50503    | 45496    | 41812    | 38843    | 36447    |
| Asthma Adults | St. Louis  | S70         | 2015 | 10              | 52006   | 42134    | 36125    | 31547    | 28578    | 25896    |
| Asthma Adults | St. Louis  | S70         | 2015 | 20              | 36232   | 24679    | 18849    | 15487    | 12411    | 10337    |
| Asthma Adults | St. Louis  | S70         | 2015 | 30              | 22211   | 13949    | 9621     | 7475     | 5830     | 5007     |
| Asthma Adults | St. Louis  | S70         | 2015 | 40              | 13341   | 7153     | 4542     | 3040     | 2003     | 1610     |
| Asthma Adults | St. Louis  | S70         | 2015 | 50              | 5794  | 1717     | 644      | 215      | 107      | 0        |
| Asthma Adults | St. Louis  | S70         | 2015 | 60              | 787   | 72       | 72       | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2015 | 70              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2016 | 0               | 56262   | 47570    | 43028    | 39094    | 36053    | 33764    |
| Asthma Adults | St. Louis  | S70         | 2016 | 10              | 50432   | 40632    | 35195    | 30796    | 27791    | 25287    |
| Asthma Adults | St. Louis  | S70         | 2016 | 20              | 35588   | 24358    | 18635    | 15559    | 12197    | 10194    |
| Asthma Adults | St. Louis  | S70         | 2016 | 30              | 22784   | 13913    | 9979     | 8012     | 6545     | 5615     |

| Study Group   | Study Area | AQ Scenario | Year | Benchmark (ppb) | Number of People with 7-hr Exposure at or above Benchmark |          |          |          |          |          |
|---------------|------------|-------------|------|-----------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                 | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | St. Louis  | S70         | 2016 | 40              | 14665   | 8262     | 5580     | 3899     | 2683     | 1860     |
| Asthma Adults | St. Louis  | S70         | 2016 | 50              | 7618  | 2826     | 1431     | 501      | 286      | 143      |
| Asthma Adults | St. Louis  | S70         | 2016 | 60              | 2325  | 358      | 36       | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2016 | 70              | 179   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2016 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2017 | 0               | 58694   | 50897    | 45746    | 42062    | 39094    | 36769    |
| Asthma Adults | St. Louis  | S70         | 2017 | 10              | 52685   | 43672    | 37985    | 34372    | 31082    | 28256    |
| Asthma Adults | St. Louis  | S70         | 2017 | 20              | 38307   | 27684    | 21997    | 17383    | 14378    | 12447    |
| Asthma Adults | St. Louis  | S70         | 2017 | 30              | 24894   | 16203    | 11660    | 8835     | 7511     | 5973     |
| Asthma Adults | St. Louis  | S70         | 2017 | 40              | 16453   | 9478     | 6009     | 4221     | 2790     | 2325     |
| Asthma Adults | St. Louis  | S70         | 2017 | 50              | 7332  | 2754     | 1431     | 823      | 501      | 358      |
| Asthma Adults | St. Louis  | S70         | 2017 | 60              | 1073  | 143      | 36       | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2017 | 70              | 36  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2017 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2015 | 0               | 59231   | 50503    | 45496    | 41812    | 38843    | 36447    |
| Asthma Adults | St. Louis  | S75         | 2015 | 10              | 52041   | 42420    | 36518    | 31726    | 28757    | 25896    |
| Asthma Adults | St. Louis  | S75         | 2015 | 20              | 36876   | 25538    | 19600    | 15809    | 12912    | 10802    |
| Asthma Adults | St. Louis  | S75         | 2015 | 30              | 23499   | 14522    | 10015    | 7762     | 6009     | 5115     |
| Asthma Adults | St. Louis  | S75         | 2015 | 40              | 14593   | 8048     | 5222     | 3434     | 2718     | 1896     |
| Asthma Adults | St. Louis  | S75         | 2015 | 50              | 7618  | 2861     | 1180     | 537      | 215      | 72       |
| Asthma Adults | St. Louis  | S75         | 2015 | 60              | 2039  | 250      | 72       | 36       | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2015 | 70              | 36  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2015 | 80              | 0   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2016 | 0               | 56262   | 47570    | 43028    | 39094    | 36053    | 33764    |
| Asthma Adults | St. Louis  | S75         | 2016 | 10              | 50360   | 40846    | 35481    | 30831    | 27720    | 25395    |
| Asthma Adults | St. Louis  | S75         | 2016 | 20              | 36626   | 24787    | 19493    | 15809    | 12805    | 10444    |
| Asthma Adults | St. Louis  | S75         | 2016 | 30              | 24071   | 14450    | 10373    | 8298     | 6653     | 5723     |
| Asthma Adults | St. Louis  | S75         | 2016 | 40              | 15416   | 8870     | 6080     | 4614     | 3291     | 2432     |
| Asthma Adults | St. Louis  | S75         | 2016 | 50              | 9264  | 3863     | 2218     | 1109     | 537      | 322      |
| Asthma Adults | St. Louis  | S75         | 2016 | 60              | 3577  | 787      | 143      | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2016 | 70              | 858   | 72       | 36       | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2016 | 80              | 36  | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2017 | 0               | 58694   | 50897    | 45746    | 42062    | 39094    | 36769    |
| Asthma Adults | St. Louis  | S75         | 2017 | 10              | 52685   | 43815    | 38343    | 34623    | 31082    | 28328    |
| Asthma Adults | St. Louis  | S75         | 2017 | 20              | 39237   | 28542    | 22855    | 18456    | 14986    | 13019    |
| Asthma Adults | St. Louis  | S75         | 2017 | 30              | 26003   | 16846    | 12089    | 9156     | 7690     | 6224     |
| Asthma Adults | St. Louis  | S75         | 2017 | 40              | 17204   | 10122    | 6617     | 4757     | 3398     | 2861     |
| Asthma Adults | St. Louis  | S75         | 2017 | 50              | 9550  | 4256     | 2182     | 1252     | 930      | 680      |
| Asthma Adults | St. Louis  | S75         | 2017 | 60              | 2539  | 644      | 107      | 107      | 107      | 36       |
| Asthma Adults | St. Louis  | S75         | 2017 | 70              | 107   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S75         | 2017 | 80              | 36  | 0        | 0        | 0        | 0        | 0        |

| Study Group  | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|--------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Atlanta    | S65         | 2015 | 10                         | 119728  | 64262    | 44045    | 33433    | 25947    | 20943    |
| All Children | Atlanta    | S65         | 2015 | 15                         | 31879   | 15718    | 9806     | 6739     | 4802     | 3612     |
| All Children | Atlanta    | S65         | 2015 | 20                         | 12812   | 4903     | 2663     | 1897     | 1291     | 1069     |
| All Children | Atlanta    | S65         | 2016 | 10                         | 141680  | 82320    | 57846    | 44510    | 36156    | 29619    |
| All Children | Atlanta    | S65         | 2016 | 15                         | 40636   | 19955    | 12994    | 9261     | 7122     | 5649     |
| All Children | Atlanta    | S65         | 2016 | 20                         | 15213   | 6457     | 3914     | 2583     | 1957     | 1392     |
| All Children | Atlanta    | S65         | 2017 | 10                         | 111112  | 60772    | 41019    | 31072    | 24373    | 19713    |
| All Children | Atlanta    | S65         | 2017 | 15                         | 28368   | 13357    | 8535     | 6134     | 4600     | 3470     |
| All Children | Atlanta    | S65         | 2017 | 20                         | 9443  | 3975     | 2119     | 1372     | 989      | 646      |
| All Children | Atlanta    | S70         | 2015 | 10                         | 154048  | 87284    | 61922    | 47536    | 38457    | 31536    |
| All Children | Atlanta    | S70         | 2015 | 15                         | 48303   | 24232    | 16444    | 11561    | 8777     | 6941     |
| All Children | Atlanta    | S70         | 2015 | 20                         | 20217   | 8979     | 4903     | 3369     | 2441     | 1856     |
| All Children | Atlanta    | S70         | 2016 | 10                         | 182558  | 110689   | 80424    | 63455    | 51955    | 43561    |
| All Children | Atlanta    | S70         | 2016 | 15                         | 60328   | 32040    | 21125    | 15536    | 12187    | 9765     |
| All Children | Atlanta    | S70         | 2016 | 20                         | 25685   | 11904    | 7607     | 5206     | 3914     | 3087     |
| All Children | Atlanta    | S70         | 2017 | 10                         | 141680  | 80585    | 57443    | 44106    | 35228    | 28711    |
| All Children | Atlanta    | S70         | 2017 | 15                         | 40676   | 20338    | 13720    | 9967     | 7647     | 5972     |
| All Children | Atlanta    | S70         | 2017 | 20                         | 15233   | 7042     | 4358     | 2764     | 1957     | 1372     |
| All Children | Atlanta    | S75         | 2015 | 10                         | 192081  | 114563   | 83491    | 65170    | 53266    | 44631    |
| All Children | Atlanta    | S75         | 2015 | 15                         | 68560   | 36136    | 24736    | 18482    | 14668    | 11682    |
| All Children | Atlanta    | S75         | 2015 | 20                         | 29680   | 14890    | 9624     | 6335     | 4822     | 3632     |
| All Children | Atlanta    | S75         | 2016 | 10                         | 226744  | 142527   | 107238   | 85791    | 70739    | 60489    |
| All Children | Atlanta    | S75         | 2016 | 15                         | 85367   | 47516    | 32484    | 25039    | 19309    | 15798    |
| All Children | Atlanta    | S75         | 2016 | 20                         | 39385   | 19370    | 12590    | 9019     | 6840     | 5306     |
| All Children | Atlanta    | S75         | 2017 | 10                         | 175435  | 105584   | 75824    | 59057    | 47839    | 40252    |
| All Children | Atlanta    | S75         | 2017 | 15                         | 56918   | 30103    | 20580    | 15294    | 11803    | 9221     |
| All Children | Atlanta    | S75         | 2017 | 20                         | 23728   | 11561    | 7445     | 5145     | 3632     | 2744     |
| All Children | Boston     | S65         | 2015 | 10                         | 142102  | 77729    | 54110    | 40116    | 31196    | 25713    |
| All Children | Boston     | S65         | 2015 | 15                         | 41823   | 18909    | 11855    | 7850     | 5529     | 4210     |
| All Children | Boston     | S65         | 2015 | 20                         | 15746   | 5825     | 3368     | 2207     | 1365     | 956      |
| All Children | Boston     | S65         | 2016 | 10                         | 144536  | 79345    | 54884    | 40594    | 32061    | 25804    |
| All Children | Boston     | S65         | 2016 | 15                         | 41686   | 20138    | 12606    | 8851     | 6508     | 4960     |
| All Children | Boston     | S65         | 2016 | 20                         | 16474   | 6713     | 3868     | 2435     | 1752     | 1206     |
| All Children | Boston     | S65         | 2017 | 10                         | 155777  | 83827    | 56295    | 41117    | 32152    | 26259    |
| All Children | Boston     | S65         | 2017 | 15                         | 51380   | 23141    | 13994    | 9352     | 6508     | 4505     |
| All Children | Boston     | S65         | 2017 | 20                         | 21435   | 7668     | 3868     | 2480     | 1661     | 1115     |
| All Children | Boston     | S70         | 2015 | 10                         | 168747  | 94590    | 66762    | 51152    | 40685    | 33267    |
| All Children | Boston     | S70         | 2015 | 15                         | 55225   | 25849    | 16998    | 11832    | 8738     | 6553     |
| All Children | Boston     | S70         | 2015 | 20                         | 22368   | 9079     | 5234     | 3390     | 2480     | 1616     |
| All Children | Boston     | S70         | 2016 | 10                         | 177849  | 99960    | 70061    | 52972    | 41709    | 34086    |
| All Children | Boston     | S70         | 2016 | 15                         | 56932   | 28853    | 18454    | 13425    | 9830     | 7691     |
| All Children | Boston     | S70         | 2016 | 20                         | 24461   | 10672    | 6030     | 4050     | 2890     | 2230     |
| All Children | Boston     | S70         | 2017 | 10                         | 192821  | 107742   | 73019    | 54929    | 42187    | 34223    |
| All Children | Boston     | S70         | 2017 | 15                         | 68218   | 32471    | 20502    | 14358    | 10331    | 7850     |
| All Children | Boston     | S70         | 2017 | 20                         | 31924   | 12697    | 6485     | 4323     | 2981     | 2048     |

| Study Group  | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|--------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Boston     | S75         | 2015 | 10                         | 186109  | 106309   | 75021    | 57409    | 45736    | 38023    |
| All Children | Boston     | S75         | 2015 | 15                         | 64054   | 30969    | 20502    | 14654    | 10786    | 8328     |
| All Children | Boston     | S75         | 2015 | 20                         | 26827   | 11491    | 7031     | 4278     | 3095     | 2321     |
| All Children | Boston     | S75         | 2016 | 10                         | 199238  | 114159   | 80437    | 62506    | 48990    | 39661    |
| All Children | Boston     | S75         | 2016 | 15                         | 68673   | 35156    | 23050    | 16656    | 12265    | 9602     |
| All Children | Boston     | S75         | 2016 | 20                         | 30514   | 13857    | 8214     | 5484     | 3891     | 2822     |
| All Children | Boston     | S75         | 2017 | 10                         | 217328  | 123124   | 84783    | 63849    | 49354    | 39547    |
| All Children | Boston     | S75         | 2017 | 15                         | 80960   | 39820    | 25417    | 17384    | 13107    | 9989     |
| All Children | Boston     | S75         | 2017 | 20                         | 39684   | 16702    | 9375     | 5893     | 3937     | 2662     |
| All Children | Dallas     | S65         | 2015 | 10                         | 184931  | 109857   | 77865    | 59799    | 48355    | 40103    |
| All Children | Dallas     | S65         | 2015 | 15                         | 58735   | 30621    | 20146    | 14258    | 10853    | 8489     |
| All Children | Dallas     | S65         | 2015 | 20                         | 23362   | 10451    | 6242     | 4091     | 2885     | 2270     |
| All Children | Dallas     | S65         | 2016 | 10                         | 158708  | 92406    | 66018    | 50956    | 41261    | 33600    |
| All Children | Dallas     | S65         | 2016 | 15                         | 43957   | 20832    | 14400    | 10428    | 8087     | 6573     |
| All Children | Dallas     | S65         | 2016 | 20                         | 16717   | 7236     | 3902     | 2790     | 1844     | 1395     |
| All Children | Dallas     | S65         | 2017 | 10                         | 183891  | 109739   | 78621    | 61100    | 50128    | 41238    |
| All Children | Dallas     | S65         | 2017 | 15                         | 57482   | 29084    | 19247    | 13738    | 10617    | 8796     |
| All Children | Dallas     | S65         | 2017 | 20                         | 23196   | 10499    | 6857     | 4469     | 3074     | 2365     |
| All Children | Dallas     | S70         | 2015 | 10                         | 222622  | 134637   | 98578    | 77108    | 62660    | 52209    |
| All Children | Dallas     | S70         | 2015 | 15                         | 76942   | 42869    | 28587    | 21352    | 16812    | 13123    |
| All Children | Dallas     | S70         | 2015 | 20                         | 34853   | 16410    | 10215    | 7094     | 5013     | 4067     |
| All Children | Dallas     | S70         | 2016 | 10                         | 185830  | 109975   | 80300    | 62140    | 50625    | 42207    |
| All Children | Dallas     | S70         | 2016 | 15                         | 57317   | 28658    | 19484    | 14282    | 11232    | 9174     |
| All Children | Dallas     | S70         | 2016 | 20                         | 22747   | 10475    | 6597     | 4540     | 3310     | 2246     |
| All Children | Dallas     | S70         | 2017 | 10                         | 213211  | 130192   | 95173    | 75878    | 61833    | 51760    |
| All Children | Dallas     | S70         | 2017 | 15                         | 72473   | 38968    | 25986    | 19271    | 14707    | 11752    |
| All Children | Dallas     | S70         | 2017 | 20                         | 31165   | 14329    | 9198     | 6668     | 4753     | 3760     |
| All Children | Dallas     | S75         | 2015 | 10                         | 257783  | 161049   | 118582   | 94062    | 77628    | 65380    |
| All Children | Dallas     | S75         | 2015 | 15                         | 96899   | 56182    | 38637    | 28753    | 22794    | 18183    |
| All Children | Dallas     | S75         | 2015 | 20                         | 45612   | 23527    | 15393    | 10428    | 7921     | 6195     |
| All Children | Dallas     | S75         | 2016 | 10                         | 211343  | 127142   | 93305    | 72828    | 60367    | 50861    |
| All Children | Dallas     | S75         | 2016 | 15                         | 70274   | 37005    | 25230    | 18562    | 14873    | 11941    |
| All Children | Dallas     | S75         | 2016 | 20                         | 29770   | 13785    | 8796     | 6171     | 4635     | 3570     |
| All Children | Dallas     | S75         | 2017 | 10                         | 240285  | 148494   | 111110   | 88718    | 73230    | 61927    |
| All Children | Dallas     | S75         | 2017 | 15                         | 86992   | 48000    | 32252    | 24449    | 19035    | 15393    |
| All Children | Dallas     | S75         | 2017 | 20                         | 39819   | 19295    | 12154    | 8938     | 7023     | 5391     |
| All Children | Detroit    | S65         | 2015 | 10                         | 124524  | 70240    | 49393    | 37392    | 29483    | 24523    |
| All Children | Detroit    | S65         | 2015 | 15                         | 37045   | 18592    | 11707    | 7943     | 6018     | 4527     |
| All Children | Detroit    | S65         | 2015 | 20                         | 14117   | 6174     | 3399     | 2012     | 1474     | 1075     |
| All Children | Detroit    | S65         | 2016 | 10                         | 144399  | 83143    | 58585    | 44364    | 35710    | 29778    |
| All Children | Detroit    | S65         | 2016 | 15                         | 46514   | 23205    | 14828    | 10510    | 7995     | 6174     |
| All Children | Detroit    | S65         | 2016 | 20                         | 18696   | 8186     | 4891     | 3278     | 2255     | 1544     |
| All Children | Detroit    | S65         | 2017 | 10                         | 133039  | 77108    | 54561    | 42525    | 34322    | 28079    |
| All Children | Detroit    | S65         | 2017 | 15                         | 40548   | 20829    | 13649    | 9920     | 7718     | 5931     |
| All Children | Detroit    | S65         | 2017 | 20                         | 16979   | 7683     | 4475     | 2896     | 2168     | 1665     |

| Study Group  | Study Area   | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|--------------|--------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|              |              |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Detroit      | S70         | 2015 | 10                         | 149480  | 87982    | 63337    | 48613    | 38883    | 32067    |
| All Children | Detroit      | S70         | 2015 | 15                         | 50434   | 26015    | 17326    | 12574    | 9348     | 7458     |
| All Children | Detroit      | S70         | 2015 | 20                         | 21037   | 9729     | 5689     | 3885     | 2706     | 1908     |
| All Children | Detroit      | S70         | 2016 | 10                         | 176362  | 107267   | 76709    | 59001    | 47659    | 40028    |
| All Children | Detroit      | S70         | 2016 | 15                         | 63632   | 33819    | 22928    | 16025    | 12504    | 9816     |
| All Children | Detroit      | S70         | 2016 | 20                         | 28547   | 13302    | 8394     | 5584     | 4041     | 3052     |
| All Children | Detroit      | S70         | 2017 | 10                         | 162228  | 97798    | 69650    | 54561    | 44121    | 36715    |
| All Children | Detroit      | S70         | 2017 | 15                         | 56018   | 30004    | 19910    | 14759    | 11533    | 9053     |
| All Children | Detroit      | S70         | 2017 | 20                         | 24541   | 11897    | 7458     | 5047     | 3659     | 2567     |
| All Children | Detroit      | S75         | 2015 | 10                         | 168471  | 100070   | 73101    | 56157    | 45734    | 37531    |
| All Children | Detroit      | S75         | 2015 | 15                         | 61048   | 31929    | 21922    | 16129    | 12123    | 9747     |
| All Children | Detroit      | S75         | 2015 | 20                         | 26587   | 12574    | 7562     | 5134     | 3746     | 2740     |
| All Children | Detroit      | S75         | 2016 | 10                         | 202568  | 126674   | 91797    | 71749    | 58082    | 48387    |
| All Children | Detroit      | S75         | 2016 | 15                         | 80143   | 44017    | 29986    | 22130    | 17100    | 13649    |
| All Children | Detroit      | S75         | 2016 | 20                         | 38415   | 18991    | 12106    | 8221     | 6001     | 4665     |
| All Children | Detroit      | S75         | 2017 | 10                         | 185519  | 113355   | 82189    | 64621    | 52342    | 43601    |
| All Children | Detroit      | S75         | 2017 | 15                         | 68679   | 38727    | 25703    | 18522    | 14516    | 11811    |
| All Children | Detroit      | S75         | 2017 | 20                         | 32119   | 16112    | 10389    | 7197     | 5238     | 3885     |
| All Children | Philadelphia | S65         | 2015 | 10                         | 164741  | 96099    | 67878    | 51749    | 41556    | 34419    |
| All Children | Philadelphia | S65         | 2015 | 15                         | 46620   | 23834    | 15693    | 11197    | 8447     | 6526     |
| All Children | Philadelphia | S65         | 2015 | 20                         | 17351   | 7595     | 4496     | 2968     | 2030     | 1484     |
| All Children | Philadelphia | S65         | 2016 | 10                         | 162035  | 94266    | 65084    | 49872    | 40749    | 33612    |
| All Children | Philadelphia | S65         | 2016 | 15                         | 45921   | 23244    | 15060    | 10760    | 8294     | 6810     |
| All Children | Philadelphia | S65         | 2016 | 20                         | 17526   | 7923     | 4365     | 2837     | 1899     | 1462     |
| All Children | Philadelphia | S65         | 2017 | 10                         | 150445  | 85099    | 60021    | 45267    | 36493    | 29356    |
| All Children | Philadelphia | S65         | 2017 | 15                         | 42648   | 20691    | 12877    | 9123     | 6701     | 5347     |
| All Children | Philadelphia | S65         | 2017 | 20                         | 16348   | 6831     | 3841     | 2532     | 1724     | 1331     |
| All Children | Philadelphia | S70         | 2015 | 10                         | 196192  | 118929   | 85841    | 66547    | 53888    | 44568    |
| All Children | Philadelphia | S70         | 2015 | 15                         | 62400   | 32913    | 22437    | 16544    | 12550    | 10258    |
| All Children | Philadelphia | S70         | 2015 | 20                         | 25449   | 11677    | 7159     | 5282     | 3754     | 2619     |
| All Children | Philadelphia | S70         | 2016 | 10                         | 193355  | 116397   | 82458    | 63404    | 52076    | 43586    |
| All Children | Philadelphia | S70         | 2016 | 15                         | 61221   | 32302    | 21935    | 15955    | 12681    | 9800     |
| All Children | Philadelphia | S70         | 2016 | 20                         | 25012   | 11677    | 7312     | 5020     | 3579     | 2488     |
| All Children | Philadelphia | S70         | 2017 | 10                         | 178688  | 104546   | 74775    | 56943    | 46358    | 37955    |
| All Children | Philadelphia | S70         | 2017 | 15                         | 56856   | 29508    | 19119    | 13576    | 10280    | 7857     |
| All Children | Philadelphia | S70         | 2017 | 20                         | 23615   | 10324    | 5653     | 4038     | 2903     | 2248     |
| All Children | Philadelphia | S75         | 2015 | 10                         | 237072  | 147695   | 109936   | 87085    | 71720    | 59824    |
| All Children | Philadelphia | S75         | 2015 | 15                         | 84204   | 46162    | 32499    | 24423    | 18923    | 15584    |
| All Children | Philadelphia | S75         | 2015 | 20                         | 37278   | 18814    | 11873    | 8599     | 6482     | 5085     |
| All Children | Philadelphia | S75         | 2016 | 10                         | 232750  | 145032   | 106575   | 83855    | 67987    | 57904    |
| All Children | Philadelphia | S75         | 2016 | 15                         | 83440   | 46074    | 32084    | 24161    | 18552    | 15016    |
| All Children | Philadelphia | S75         | 2016 | 20                         | 37628   | 18574    | 11742    | 8425     | 6242     | 4889     |
| All Children | Philadelphia | S75         | 2017 | 10                         | 216861  | 129929   | 94615    | 73793    | 59759    | 49828    |
| All Children | Philadelphia | S75         | 2017 | 15                         | 77525   | 42058    | 27042    | 19927    | 15453    | 12070    |
| All Children | Philadelphia | S75         | 2017 | 20                         | 35358   | 16326    | 9647     | 6548     | 4933     | 3776     |

| Study Group  | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|--------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|              |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children | Phoenix    | S65         | 2015 | 10                         | 141180  | 90695    | 69549    | 55764    | 47541    | 40592    |
| All Children | Phoenix    | S65         | 2015 | 15                         | 43974   | 25150    | 18145    | 14196    | 11436    | 9398     |
| All Children | Phoenix    | S65         | 2015 | 20                         | 17423   | 9115     | 6015     | 4529     | 3482     | 2760     |
| All Children | Phoenix    | S65         | 2016 | 10                         | 135773  | 87001    | 66676    | 54349    | 45390    | 39106    |
| All Children | Phoenix    | S65         | 2016 | 15                         | 39856   | 23424    | 16970    | 13035    | 10601    | 9143     |
| All Children | Phoenix    | S65         | 2016 | 20                         | 15484   | 8166     | 5463     | 4161     | 3298     | 2831     |
| All Children | Phoenix    | S65         | 2017 | 10                         | 153889  | 101649   | 78027    | 63633    | 54306    | 47187    |
| All Children | Phoenix    | S65         | 2017 | 15                         | 48588   | 29524    | 21230    | 16927    | 13899    | 11860    |
| All Children | Phoenix    | S65         | 2017 | 20                         | 20041   | 11054    | 7459     | 5308     | 4232     | 3453     |
| All Children | Phoenix    | S70         | 2015 | 10                         | 170378  | 112646   | 87680    | 72125    | 61256    | 52933    |
| All Children | Phoenix    | S70         | 2015 | 15                         | 59798   | 36034    | 26070    | 20409    | 16956    | 14535    |
| All Children | Phoenix    | S70         | 2015 | 20                         | 25844   | 14493    | 9851     | 7501     | 5959     | 4869     |
| All Children | Phoenix    | S70         | 2016 | 10                         | 164589  | 108372   | 83873    | 69479    | 58906    | 50980    |
| All Children | Phoenix    | S70         | 2016 | 15                         | 54688   | 32468    | 23990    | 18895    | 15781    | 13417    |
| All Children | Phoenix    | S70         | 2016 | 20                         | 22773   | 12596    | 8860     | 6893     | 5746     | 4572     |
| All Children | Phoenix    | S70         | 2017 | 10                         | 185182  | 125399   | 98889    | 81962    | 70399    | 61921    |
| All Children | Phoenix    | S70         | 2017 | 15                         | 65827   | 41342    | 31251    | 24698    | 21060    | 17932    |
| All Children | Phoenix    | S70         | 2017 | 20                         | 30302   | 17210    | 12384    | 9469     | 7530     | 6128     |
| All Children | Phoenix    | S75         | 2015 | 10                         | 197312  | 132787   | 104721   | 87482    | 74135    | 65219    |
| All Children | Phoenix    | S75         | 2015 | 15                         | 76117   | 47484    | 34930    | 27712    | 22872    | 19645    |
| All Children | Phoenix    | S75         | 2015 | 20                         | 36105   | 20607    | 14351    | 11153    | 8747     | 7218     |
| All Children | Phoenix    | S75         | 2016 | 10                         | 190306  | 128668   | 99908    | 83137    | 71389    | 62869    |
| All Children | Phoenix    | S75         | 2016 | 15                         | 69167   | 42771    | 31619    | 25901    | 21456    | 18399    |
| All Children | Phoenix    | S75         | 2016 | 20                         | 31576   | 18130    | 12894    | 10006    | 8152     | 6949     |
| All Children | Phoenix    | S75         | 2017 | 10                         | 213036  | 148242   | 118449   | 99271    | 85684    | 75848    |
| All Children | Phoenix    | S75         | 2017 | 15                         | 84439   | 53528    | 40889    | 33374    | 28080    | 24188    |
| All Children | Phoenix    | S75         | 2017 | 20                         | 40549   | 24499    | 17762    | 14012    | 11337    | 9568     |
| All Children | Sacramento | S65         | 2015 | 10                         | 48758   | 27826    | 19938    | 15808    | 12896    | 10645    |
| All Children | Sacramento | S65         | 2015 | 15                         | 12919   | 6250     | 3804     | 2873     | 2205     | 1755     |
| All Children | Sacramento | S65         | 2015 | 20                         | 4193  | 1716     | 1040     | 714      | 528      | 373      |
| All Children | Sacramento | S65         | 2016 | 10                         | 51701   | 30303    | 21444    | 16406    | 13269    | 10986    |
| All Children | Sacramento | S65         | 2016 | 15                         | 13828   | 6972     | 4441     | 3253     | 2601     | 2112     |
| All Children | Sacramento | S65         | 2016 | 20                         | 4985  | 2244     | 1328     | 916      | 637      | 458      |
| All Children | Sacramento | S65         | 2017 | 10                         | 50614   | 29030    | 20132    | 15559    | 12640    | 10536    |
| All Children | Sacramento | S65         | 2017 | 15                         | 12896   | 6367     | 3898     | 2896     | 2073     | 1623     |
| All Children | Sacramento | S65         | 2017 | 20                         | 4255  | 1677     | 1017     | 637      | 435      | 334      |
| All Children | Sacramento | S70         | 2015 | 10                         | 64364   | 38712    | 28059    | 22182    | 18649    | 15862    |
| All Children | Sacramento | S70         | 2015 | 15                         | 20024   | 10559    | 7267     | 5311     | 4169     | 3269     |
| All Children | Sacramento | S70         | 2015 | 20                         | 7904  | 3540     | 2213     | 1599     | 1188     | 916      |
| All Children | Sacramento | S70         | 2016 | 10                         | 68293   | 41406    | 30466    | 24045    | 19767    | 16638    |
| All Children | Sacramento | S70         | 2016 | 15                         | 21871   | 11848    | 7896     | 5955     | 4705     | 3797     |
| All Children | Sacramento | S70         | 2016 | 20                         | 9286  | 4371     | 2756     | 1988     | 1467     | 1157     |
| All Children | Sacramento | S70         | 2017 | 10                         | 67066   | 40909    | 29030    | 23036    | 18975    | 15901    |
| All Children | Sacramento | S70         | 2017 | 15                         | 20101   | 10567    | 7275     | 5326     | 4169     | 3292     |
| All Children | Sacramento | S70         | 2017 | 20                         | 8230  | 3556     | 2135     | 1522     | 1149     | 815      |

| Study Group     | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-----------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Children    | Sacramento | S75         | 2015 | 10                         | 77253   | 48300    | 35521    | 28432    | 23649    | 20520    |
| All Children    | Sacramento | S75         | 2015 | 15                         | 26693   | 14992    | 10497    | 7958     | 6165     | 5008     |
| All Children    | Sacramento | S75         | 2015 | 20                         | 11755   | 5769     | 3758     | 2694     | 2073     | 1568     |
| All Children    | Sacramento | S75         | 2016 | 10                         | 82439   | 51996    | 38867    | 31118    | 25746    | 21623    |
| All Children    | Sacramento | S75         | 2016 | 15                         | 29504   | 16685    | 11871    | 8929     | 6995     | 5629     |
| All Children    | Sacramento | S75         | 2016 | 20                         | 13354   | 6980     | 4410     | 3284     | 2547     | 2065     |
| All Children    | Sacramento | S75         | 2017 | 10                         | 81057   | 50839    | 37586    | 29667    | 24511    | 20947    |
| All Children    | Sacramento | S75         | 2017 | 15                         | 27539   | 15311    | 10567    | 8036     | 6250     | 5194     |
| All Children    | Sacramento | S75         | 2017 | 20                         | 11957   | 5893     | 3711     | 2702     | 2026     | 1514     |
| All Children    | St. Louis  | S65         | 2015 | 10                         | 61187   | 34086    | 23668    | 18195    | 14543    | 11702    |
| All Children    | St. Louis  | S65         | 2015 | 15                         | 17066   | 8542     | 5555     | 4062     | 2951     | 2249     |
| All Children    | St. Louis  | S65         | 2015 | 20                         | 6338  | 2832     | 1776     | 1157     | 892      | 583      |
| All Children    | St. Louis  | S65         | 2016 | 10                         | 71851   | 42218    | 30070    | 23149    | 18696    | 15508    |
| All Children    | St. Louis  | S65         | 2016 | 15                         | 22839   | 11584    | 7750     | 5418     | 3980     | 2941     |
| All Children    | St. Louis  | S65         | 2016 | 20                         | 9243  | 3779     | 2195     | 1357     | 1020     | 719      |
| All Children    | St. Louis  | S65         | 2017 | 10                         | 69365   | 40633    | 28822    | 21901    | 17621    | 14680    |
| All Children    | St. Louis  | S65         | 2017 | 15                         | 19716   | 10081    | 6548     | 4908     | 3816     | 3023     |
| All Children    | St. Louis  | S65         | 2017 | 20                         | 7668  | 3542     | 2268     | 1421     | 1047     | 838      |
| All Children    | St. Louis  | S70         | 2015 | 10                         | 76632   | 44731    | 31691    | 24579    | 19861    | 16574    |
| All Children    | St. Louis  | S70         | 2015 | 15                         | 24351   | 12704    | 8587     | 6356     | 4963     | 3843     |
| All Children    | St. Louis  | S70         | 2015 | 20                         | 10309   | 4826     | 3078     | 2158     | 1557     | 1175     |
| All Children    | St. Louis  | S70         | 2016 | 10                         | 89017   | 54612    | 40087    | 31582    | 25517    | 21382    |
| All Children    | St. Louis  | S70         | 2016 | 15                         | 32356   | 17175    | 11729    | 8587     | 6739     | 5282     |
| All Children    | St. Louis  | S70         | 2016 | 20                         | 14507   | 6775     | 4180     | 2732     | 2013     | 1475     |
| All Children    | St. Louis  | S70         | 2017 | 10                         | 87368   | 53055    | 38393    | 30352    | 24742    | 20390    |
| All Children    | St. Louis  | S70         | 2017 | 15                         | 28303   | 15508    | 10409    | 7932     | 6047     | 4918     |
| All Children    | St. Louis  | S70         | 2017 | 20                         | 11738   | 5783     | 3907     | 2623     | 1994     | 1548     |
| All Children    | St. Louis  | S75         | 2015 | 10                         | 88406   | 53228    | 38621    | 30452    | 24697    | 20526    |
| All Children    | St. Louis  | S75         | 2015 | 15                         | 31172   | 16610    | 11319    | 8515     | 6739     | 5282     |
| All Children    | St. Louis  | S75         | 2015 | 20                         | 13724   | 6848     | 4462     | 3087     | 2176     | 1694     |
| All Children    | St. Louis  | S75         | 2016 | 10                         | 102931  | 65203    | 48420    | 38430    | 31627    | 26600    |
| All Children    | St. Louis  | S75         | 2016 | 15                         | 40724   | 22557    | 15417    | 11638    | 9143     | 7422     |
| All Children    | St. Louis  | S75         | 2016 | 20                         | 19433   | 9744     | 6338     | 4380     | 3151     | 2486     |
| All Children    | St. Louis  | S75         | 2017 | 10                         | 101192  | 63691    | 46890    | 37055    | 30625    | 25726    |
| All Children    | St. Louis  | S75         | 2017 | 15                         | 36080   | 20289    | 13833    | 10536    | 8405     | 6739     |
| All Children    | St. Louis  | S75         | 2017 | 20                         | 15845   | 8269     | 5409     | 3779     | 2941     | 2359     |
| Asthma Children | Atlanta    | S65         | 2015 | 10                         | 15415   | 8030     | 5306     | 3975     | 2905     | 2058     |
| Asthma Children | Atlanta    | S65         | 2015 | 15                         | 3712  | 1574     | 1009     | 625      | 424      | 282      |
| Asthma Children | Atlanta    | S65         | 2015 | 20                         | 1271  | 363      | 222      | 182      | 161      | 101      |
| Asthma Children | Atlanta    | S65         | 2016 | 10                         | 18966   | 10835    | 7869     | 6154     | 5044     | 4298     |
| Asthma Children | Atlanta    | S65         | 2016 | 15                         | 5811  | 2825     | 1937     | 1513     | 1130     | 948      |
| Asthma Children | Atlanta    | S65         | 2016 | 20                         | 2300  | 1009     | 545      | 343      | 282      | 202      |
| Asthma Children | Atlanta    | S65         | 2017 | 10                         | 13619   | 7465     | 5165     | 3773     | 3127     | 2522     |
| Asthma Children | Atlanta    | S65         | 2017 | 15                         | 3612  | 1796     | 1150     | 807      | 605      | 343      |
| Asthma Children | Atlanta    | S65         | 2017 | 20                         | 1190  | 464      | 262      | 202      | 202      | 101      |

| Study Group     | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-----------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Atlanta    | S70         | 2015 | 10                         | 19834   | 11218    | 7607     | 5750     | 4661     | 3652     |
| Asthma Children | Atlanta    | S70         | 2015 | 15                         | 5831  | 2583     | 1776     | 1291     | 948      | 706      |
| Asthma Children | Atlanta    | S70         | 2015 | 20                         | 2199  | 807      | 484      | 242      | 161      | 141      |
| Asthma Children | Atlanta    | S70         | 2016 | 10                         | 23929   | 14608    | 10673    | 8636     | 7203     | 5972     |
| Asthma Children | Atlanta    | S70         | 2016 | 15                         | 8434  | 4681     | 3127     | 2421     | 1876     | 1614     |
| Asthma Children | Atlanta    | S70         | 2016 | 20                         | 3733  | 1715     | 1130     | 847      | 625      | 484      |
| Asthma Children | Atlanta    | S70         | 2017 | 10                         | 17776   | 9725     | 7183     | 5710     | 4580     | 3672     |
| Asthma Children | Atlanta    | S70         | 2017 | 15                         | 4802  | 2361     | 1836     | 1352     | 1049     | 747      |
| Asthma Children | Atlanta    | S70         | 2017 | 20                         | 2078  | 847      | 484      | 262      | 242      | 222      |
| Asthma Children | Atlanta    | S75         | 2015 | 10                         | 24393   | 14446    | 10593    | 8272     | 6658     | 5468     |
| Asthma Children | Atlanta    | S75         | 2015 | 15                         | 8615  | 4298     | 2845     | 2058     | 1634     | 1291     |
| Asthma Children | Atlanta    | S75         | 2015 | 20                         | 3390  | 1453     | 928      | 686      | 444      | 262      |
| Asthma Children | Atlanta    | S75         | 2016 | 10                         | 28994   | 18764    | 14083    | 11501    | 9584     | 8071     |
| Asthma Children | Atlanta    | S75         | 2016 | 15                         | 11723   | 6638     | 4661     | 3672     | 2986     | 2583     |
| Asthma Children | Atlanta    | S75         | 2016 | 20                         | 5448  | 2724     | 1876     | 1392     | 1090     | 888      |
| Asthma Children | Atlanta    | S75         | 2017 | 10                         | 21730   | 12994    | 9241     | 7445     | 6134     | 5044     |
| Asthma Children | Atlanta    | S75         | 2017 | 15                         | 6820  | 3672     | 2562     | 1997     | 1574     | 1251     |
| Asthma Children | Atlanta    | S75         | 2017 | 20                         | 3087  | 1554     | 928      | 565      | 424      | 282      |
| Asthma Children | Boston     | S65         | 2015 | 10                         | 18499   | 10353    | 7418     | 5438     | 4323     | 3663     |
| Asthma Children | Boston     | S65         | 2015 | 15                         | 5416  | 2366     | 1707     | 1069     | 728      | 592      |
| Asthma Children | Boston     | S65         | 2015 | 20                         | 2184  | 910      | 432      | 341      | 250      | 159      |
| Asthma Children | Boston     | S65         | 2016 | 10                         | 19751   | 10217    | 7463     | 5939     | 4665     | 3823     |
| Asthma Children | Boston     | S65         | 2016 | 15                         | 5643  | 3095     | 2162     | 1502     | 1001     | 683      |
| Asthma Children | Boston     | S65         | 2016 | 20                         | 2298  | 956      | 523      | 319      | 182      | 137      |
| Asthma Children | Boston     | S65         | 2017 | 10                         | 20047   | 11286    | 7463     | 5552     | 4278     | 3322     |
| Asthma Children | Boston     | S65         | 2017 | 15                         | 6963  | 2822     | 1707     | 1320     | 887      | 592      |
| Asthma Children | Boston     | S65         | 2017 | 20                         | 2457  | 1024     | 569      | 319      | 296      | 228      |
| Asthma Children | Boston     | S70         | 2015 | 10                         | 21366   | 12788    | 9125     | 6849     | 5598     | 4665     |
| Asthma Children | Boston     | S70         | 2015 | 15                         | 7259  | 3390     | 2298     | 1525     | 1251     | 933      |
| Asthma Children | Boston     | S70         | 2015 | 20                         | 2844  | 1434     | 796      | 432      | 341      | 228      |
| Asthma Children | Boston     | S70         | 2016 | 10                         | 24165   | 13243    | 9375     | 7350     | 6075     | 4847     |
| Asthma Children | Boston     | S70         | 2016 | 15                         | 7691  | 4210     | 2913     | 2230     | 1684     | 1229     |
| Asthma Children | Boston     | S70         | 2016 | 20                         | 3368  | 1570     | 887      | 501      | 364      | 228      |
| Asthma Children | Boston     | S70         | 2017 | 10                         | 24529   | 14267    | 9898     | 7372     | 5734     | 4619     |
| Asthma Children | Boston     | S70         | 2017 | 15                         | 9056  | 3937     | 2366     | 1707     | 1365     | 1092     |
| Asthma Children | Boston     | S70         | 2017 | 20                         | 3959  | 1547     | 887      | 592      | 410      | 296      |
| Asthma Children | Boston     | S75         | 2015 | 10                         | 23483   | 13835    | 10331    | 7759     | 6235     | 5347     |
| Asthma Children | Boston     | S75         | 2015 | 15                         | 8146  | 4119     | 2640     | 1934     | 1525     | 1092     |
| Asthma Children | Boston     | S75         | 2015 | 20                         | 3413  | 1661     | 1001     | 546      | 455      | 319      |
| Asthma Children | Boston     | S75         | 2016 | 10                         | 26827   | 14972    | 10626    | 8920     | 6986     | 5552     |
| Asthma Children | Boston     | S75         | 2016 | 15                         | 9284  | 5006     | 3527     | 2708     | 2116     | 1570     |
| Asthma Children | Boston     | S75         | 2016 | 20                         | 4187  | 2002     | 1229     | 751      | 523      | 364      |
| Asthma Children | Boston     | S75         | 2017 | 10                         | 27965   | 16429    | 11332    | 8669     | 6599     | 5438     |
| Asthma Children | Boston     | S75         | 2017 | 15                         | 10626   | 5165     | 3004     | 2071     | 1616     | 1388     |
| Asthma Children | Boston     | S75         | 2017 | 20                         | 5256  | 2048     | 1229     | 774      | 478      | 341      |



| Study Group     | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-----------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Dallas     | S65         | 2015 | 10                         | 18869   | 11042    | 8441     | 6361     | 5155     | 4398     |
| Asthma Children | Dallas     | S65         | 2015 | 15                         | 6030  | 3050     | 2010     | 1348     | 1111     | 969      |
| Asthma Children | Dallas     | S65         | 2015 | 20                         | 2530  | 1111     | 686      | 426      | 378      | 307      |
| Asthma Children | Dallas     | S65         | 2016 | 10                         | 15393   | 8985     | 6881     | 5249     | 4280     | 3452     |
| Asthma Children | Dallas     | S65         | 2016 | 15                         | 4753  | 2435     | 1537     | 1040     | 828      | 567      |
| Asthma Children | Dallas     | S65         | 2016 | 20                         | 1750  | 615      | 284      | 236      | 142      | 95       |
| Asthma Children | Dallas     | S65         | 2017 | 10                         | 18443   | 11539    | 8087     | 6361     | 5533     | 4540     |
| Asthma Children | Dallas     | S65         | 2017 | 15                         | 5911  | 3405     | 2270     | 1726     | 1419     | 1159     |
| Asthma Children | Dallas     | S65         | 2017 | 20                         | 2719  | 1301     | 828      | 520      | 355      | 307      |
| Asthma Children | Dallas     | S70         | 2015 | 10                         | 22298   | 13785    | 10309    | 8158     | 6715     | 5509     |
| Asthma Children | Dallas     | S70         | 2015 | 15                         | 7779  | 4587     | 2979     | 1986     | 1655     | 1301     |
| Asthma Children | Dallas     | S70         | 2015 | 20                         | 3689  | 1679     | 1040     | 851      | 567      | 473      |
| Asthma Children | Dallas     | S70         | 2016 | 10                         | 17781   | 10570    | 7921     | 6432     | 5438     | 4374     |
| Asthma Children | Dallas     | S70         | 2016 | 15                         | 5911  | 3121     | 2104     | 1442     | 1111     | 875      |
| Asthma Children | Dallas     | S70         | 2016 | 20                         | 2388  | 1017     | 615      | 426      | 260      | 142      |
| Asthma Children | Dallas     | S70         | 2017 | 10                         | 21376   | 13241    | 9647     | 7779     | 6597     | 5557     |
| Asthma Children | Dallas     | S70         | 2017 | 15                         | 7590  | 4445     | 2932     | 2128     | 1797     | 1513     |
| Asthma Children | Dallas     | S70         | 2017 | 20                         | 3547  | 1773     | 1230     | 828      | 567      | 473      |
| Asthma Children | Dallas     | S75         | 2015 | 10                         | 25915   | 16221    | 12438    | 9624     | 8110     | 6857     |
| Asthma Children | Dallas     | S75         | 2015 | 15                         | 9931  | 5651     | 4138     | 3192     | 2365     | 1821     |
| Asthma Children | Dallas     | S75         | 2015 | 20                         | 4682  | 2317     | 1466     | 993      | 851      | 733      |
| Asthma Children | Dallas     | S75         | 2016 | 10                         | 20406   | 12319    | 9080     | 7212     | 6242     | 5202     |
| Asthma Children | Dallas     | S75         | 2016 | 15                         | 7354  | 3902     | 2696     | 2104     | 1537     | 1230     |
| Asthma Children | Dallas     | S75         | 2016 | 20                         | 3168  | 1395     | 875      | 615      | 402      | 260      |
| Asthma Children | Dallas     | S75         | 2017 | 10                         | 23835   | 15015    | 11184    | 9056     | 7567     | 6479     |
| Asthma Children | Dallas     | S75         | 2017 | 15                         | 8914  | 5084     | 3783     | 2956     | 2246     | 1892     |
| Asthma Children | Dallas     | S75         | 2017 | 20                         | 4398  | 2341     | 1537     | 1111     | 899      | 686      |
| Asthma Children | Detroit    | S65         | 2015 | 10                         | 14811   | 8741     | 6417     | 4856     | 3642     | 3087     |
| Asthma Children | Detroit    | S65         | 2015 | 15                         | 4908  | 2237     | 1492     | 1075     | 798      | 590      |
| Asthma Children | Detroit    | S65         | 2015 | 20                         | 1700  | 780      | 451      | 260      | 173      | 87       |
| Asthma Children | Detroit    | S65         | 2016 | 10                         | 17985   | 10649    | 7475     | 5567     | 4422     | 3850     |
| Asthma Children | Detroit    | S65         | 2016 | 15                         | 6122  | 3295     | 2046     | 1353     | 1058     | 798      |
| Asthma Children | Detroit    | S65         | 2016 | 20                         | 2567  | 1197     | 746      | 382      | 243      | 191      |
| Asthma Children | Detroit    | S65         | 2017 | 10                         | 16441   | 9782     | 6868     | 5376     | 4301     | 3469     |
| Asthma Children | Detroit    | S65         | 2017 | 15                         | 5238  | 2549     | 1734     | 1283     | 1041     | 746      |
| Asthma Children | Detroit    | S65         | 2017 | 20                         | 2133  | 1058     | 624      | 382      | 277      | 225      |
| Asthma Children | Detroit    | S70         | 2015 | 10                         | 17603   | 10649    | 8134     | 6226     | 4839     | 3989     |
| Asthma Children | Detroit    | S70         | 2015 | 15                         | 6521  | 3295     | 2046     | 1596     | 1127     | 902      |
| Asthma Children | Detroit    | S70         | 2015 | 20                         | 2653  | 1214     | 798      | 468      | 382      | 156      |
| Asthma Children | Detroit    | S70         | 2016 | 10                         | 21662   | 13510    | 9938     | 7423     | 5827     | 5047     |
| Asthma Children | Detroit    | S70         | 2016 | 15                         | 8151  | 4544     | 3052     | 2151     | 1682     | 1335     |
| Asthma Children | Detroit    | S70         | 2016 | 20                         | 3902  | 1821     | 1145     | 780      | 468      | 382      |
| Asthma Children | Detroit    | S70         | 2017 | 10                         | 19841   | 11949    | 8672     | 6781     | 5723     | 4683     |
| Asthma Children | Detroit    | S70         | 2017 | 15                         | 7007  | 3711     | 2497     | 1960     | 1613     | 1179     |
| Asthma Children | Detroit    | S70         | 2017 | 20                         | 3035  | 1509     | 1006     | 590      | 468      | 347      |

| Study Group     | Study Area   | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-----------------|--------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|                 |              |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Detroit      | S75         | 2015 | 10                         | 20083   | 12088    | 9157     | 7128     | 5706     | 4613     |
| Asthma Children | Detroit      | S75         | 2015 | 15                         | 7666  | 4006     | 2688     | 1942     | 1509     | 1162     |
| Asthma Children | Detroit      | S75         | 2015 | 20                         | 3295  | 1509     | 989      | 607      | 503      | 347      |
| Asthma Children | Detroit      | S75         | 2016 | 10                         | 24575   | 15539    | 11672    | 9070     | 7249     | 5845     |
| Asthma Children | Detroit      | S75         | 2016 | 15                         | 10319   | 5584     | 4024     | 3000     | 2203     | 1925     |
| Asthma Children | Detroit      | S75         | 2016 | 20                         | 5064  | 2740     | 1630     | 1075     | 798      | 572      |
| Asthma Children | Detroit      | S75         | 2017 | 10                         | 22355   | 13857    | 9972     | 7995     | 6799     | 5567     |
| Asthma Children | Detroit      | S75         | 2017 | 15                         | 8654  | 4856     | 3330     | 2428     | 1942     | 1578     |
| Asthma Children | Detroit      | S75         | 2017 | 20                         | 3972  | 1942     | 1422     | 989      | 624      | 486      |
| Asthma Children | Philadelphia | S65         | 2015 | 10                         | 19294   | 12135    | 8294     | 6111     | 4780     | 4038     |
| Asthma Children | Philadelphia | S65         | 2015 | 15                         | 5478  | 2706     | 2008     | 1528     | 1135     | 960      |
| Asthma Children | Philadelphia | S65         | 2015 | 20                         | 2139  | 1069     | 611      | 415      | 284      | 175      |
| Asthma Children | Philadelphia | S65         | 2016 | 10                         | 18683   | 10804    | 7181     | 5195     | 4169     | 3558     |
| Asthma Children | Philadelphia | S65         | 2016 | 15                         | 4758  | 2488     | 1659     | 1179     | 851      | 611      |
| Asthma Children | Philadelphia | S65         | 2016 | 20                         | 1877  | 808      | 437      | 262      | 196      | 175      |
| Asthma Children | Philadelphia | S65         | 2017 | 10                         | 18355   | 10411    | 7377     | 5937     | 4693     | 3710     |
| Asthma Children | Philadelphia | S65         | 2017 | 15                         | 5195  | 2706     | 1659     | 1244     | 982      | 786      |
| Asthma Children | Philadelphia | S65         | 2017 | 20                         | 2357  | 917      | 567      | 371      | 153      | 109      |
| Asthma Children | Philadelphia | S70         | 2015 | 10                         | 23135   | 14449    | 10651    | 8272     | 6439     | 5173     |
| Asthma Children | Philadelphia | S70         | 2015 | 15                         | 7923  | 3841     | 2859     | 2183     | 1812     | 1375     |
| Asthma Children | Philadelphia | S70         | 2015 | 20                         | 2903  | 1375     | 960      | 786      | 589      | 349      |
| Asthma Children | Philadelphia | S70         | 2016 | 10                         | 22175   | 13816    | 9669     | 7093     | 5435     | 4649     |
| Asthma Children | Philadelphia | S70         | 2016 | 15                         | 6722  | 3318     | 2292     | 1790     | 1310     | 1048     |
| Asthma Children | Philadelphia | S70         | 2016 | 20                         | 2575  | 1091     | 698      | 458      | 306      | 240      |
| Asthma Children | Philadelphia | S70         | 2017 | 10                         | 21869   | 12572    | 9320     | 7181     | 6002     | 4867     |
| Asthma Children | Philadelphia | S70         | 2017 | 15                         | 6701  | 3820     | 2488     | 1746     | 1484     | 1157     |
| Asthma Children | Philadelphia | S70         | 2017 | 20                         | 3099  | 1484     | 720      | 546      | 393      | 327      |
| Asthma Children | Philadelphia | S75         | 2015 | 10                         | 27850   | 17766    | 13510    | 10826    | 8796     | 7159     |
| Asthma Children | Philadelphia | S75         | 2015 | 15                         | 10280   | 5347     | 3841     | 2925     | 2401     | 2117     |
| Asthma Children | Philadelphia | S75         | 2015 | 20                         | 4343  | 2226     | 1484     | 1069     | 917      | 742      |
| Asthma Children | Philadelphia | S75         | 2016 | 10                         | 26911   | 17199    | 12593    | 9669     | 7639     | 6395     |
| Asthma Children | Philadelphia | S75         | 2016 | 15                         | 9712  | 4823     | 3427     | 2575     | 2052     | 1637     |
| Asthma Children | Philadelphia | S75         | 2016 | 20                         | 4147  | 1855     | 1310     | 873      | 502      | 458      |
| Asthma Children | Philadelphia | S75         | 2017 | 10                         | 26191   | 15889    | 11677    | 9276     | 7508     | 6199     |
| Asthma Children | Philadelphia | S75         | 2017 | 15                         | 9516  | 5282     | 3470     | 2510     | 2183     | 1746     |
| Asthma Children | Philadelphia | S75         | 2017 | 20                         | 4452  | 2204     | 1353     | 939      | 720      | 524      |
| Asthma Children | Phoenix      | S65         | 2015 | 10                         | 15215   | 9992     | 7685     | 6086     | 5223     | 4444     |
| Asthma Children | Phoenix      | S65         | 2015 | 15                         | 4982  | 2972     | 2066     | 1656     | 1373     | 1118     |
| Asthma Children | Phoenix      | S65         | 2015 | 20                         | 1882  | 1090     | 722      | 538      | 467      | 368      |
| Asthma Children | Phoenix      | S65         | 2016 | 10                         | 13785   | 9058     | 7119     | 5817     | 4982     | 4119     |
| Asthma Children | Phoenix      | S65         | 2016 | 15                         | 4331  | 2717     | 1840     | 1514     | 1189     | 1005     |
| Asthma Children | Phoenix      | S65         | 2016 | 20                         | 1727  | 920      | 580      | 396      | 340      | 269      |
| Asthma Children | Phoenix      | S65         | 2017 | 10                         | 16064   | 10502    | 8166     | 6666     | 5732     | 4925     |
| Asthma Children | Phoenix      | S65         | 2017 | 15                         | 5223  | 3255     | 2392     | 1882     | 1557     | 1373     |
| Asthma Children | Phoenix      | S65         | 2017 | 20                         | 2335  | 1231     | 977      | 736      | 637      | 538      |

| Study Group     | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-----------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | Phoenix    | S70         | 2015 | 10                         | 18201   | 12200    | 9539     | 7940     | 6695     | 5746     |
| Asthma Children | Phoenix    | S70         | 2015 | 15                         | 6836  | 4161     | 2930     | 2293     | 1911     | 1571     |
| Asthma Children | Phoenix    | S70         | 2015 | 20                         | 2930  | 1684     | 1104     | 878      | 708      | 566      |
| Asthma Children | Phoenix    | S70         | 2016 | 10                         | 16460   | 11025    | 8846     | 7445     | 6298     | 5506     |
| Asthma Children | Phoenix    | S70         | 2016 | 15                         | 6114  | 3552     | 2689     | 2081     | 1783     | 1543     |
| Asthma Children | Phoenix    | S70         | 2016 | 20                         | 2434  | 1429     | 991      | 750      | 651      | 538      |
| Asthma Children | Phoenix    | S70         | 2017 | 10                         | 18994   | 13049    | 10346    | 8534     | 7331     | 6341     |
| Asthma Children | Phoenix    | S70         | 2017 | 15                         | 7119  | 4331     | 3354     | 2703     | 2307     | 2024     |
| Asthma Children | Phoenix    | S70         | 2017 | 20                         | 3199  | 1996     | 1429     | 1033     | 934      | 807      |
| Asthma Children | Phoenix    | S75         | 2015 | 10                         | 20735   | 14139    | 11294    | 9539     | 8294     | 7289     |
| Asthma Children | Phoenix    | S75         | 2015 | 15                         | 8492  | 5378     | 3935     | 3114     | 2548     | 2137     |
| Asthma Children | Phoenix    | S75         | 2015 | 20                         | 4331  | 2307     | 1613     | 1203     | 934      | 793      |
| Asthma Children | Phoenix    | S75         | 2016 | 10                         | 18937   | 12964    | 10473    | 8648     | 7530     | 6610     |
| Asthma Children | Phoenix    | S75         | 2016 | 15                         | 7473  | 4727     | 3482     | 2873     | 2349     | 2052     |
| Asthma Children | Phoenix    | S75         | 2016 | 20                         | 3383  | 1953     | 1401     | 1146     | 948      | 764      |
| Asthma Children | Phoenix    | S75         | 2017 | 10                         | 21513   | 15328    | 12214    | 10219    | 8874     | 7813     |
| Asthma Children | Phoenix    | S75         | 2017 | 15                         | 8931  | 5506     | 4444     | 3666     | 3057     | 2604     |
| Asthma Children | Phoenix    | S75         | 2017 | 20                         | 4303  | 2802     | 2052     | 1656     | 1288     | 1132     |
| Asthma Children | Sacramento | S65         | 2015 | 10                         | 4891  | 2725     | 1988     | 1630     | 1328     | 1126     |
| Asthma Children | Sacramento | S65         | 2015 | 15                         | 1250  | 567      | 303      | 248      | 194      | 124      |
| Asthma Children | Sacramento | S65         | 2015 | 20                         | 334   | 124      | 70       | 31       | 23       | 16       |
| Asthma Children | Sacramento | S65         | 2016 | 10                         | 5256  | 3075     | 2189     | 1731     | 1429     | 1211     |
| Asthma Children | Sacramento | S65         | 2016 | 15                         | 1413  | 745      | 528      | 427      | 365      | 280      |
| Asthma Children | Sacramento | S65         | 2016 | 20                         | 590   | 272      | 163      | 124      | 78       | 47       |
| Asthma Children | Sacramento | S65         | 2017 | 10                         | 5039  | 2896     | 1933     | 1460     | 1219     | 986      |
| Asthma Children | Sacramento | S65         | 2017 | 15                         | 1242  | 551      | 349      | 287      | 248      | 194      |
| Asthma Children | Sacramento | S65         | 2017 | 20                         | 419   | 194      | 140      | 70       | 54       | 31       |
| Asthma Children | Sacramento | S70         | 2015 | 10                         | 6328  | 3773     | 2686     | 2174     | 1871     | 1638     |
| Asthma Children | Sacramento | S70         | 2015 | 15                         | 1988  | 1048     | 714      | 520      | 435      | 280      |
| Asthma Children | Sacramento | S70         | 2015 | 20                         | 699   | 233      | 155      | 140      | 101      | 70       |
| Asthma Children | Sacramento | S70         | 2016 | 10                         | 6972  | 4294     | 3113     | 2453     | 2096     | 1731     |
| Asthma Children | Sacramento | S70         | 2016 | 15                         | 2244  | 1320     | 831      | 683      | 551      | 466      |
| Asthma Children | Sacramento | S70         | 2016 | 20                         | 978   | 536      | 373      | 303      | 225      | 163      |
| Asthma Children | Sacramento | S70         | 2017 | 10                         | 6576  | 4053     | 2873     | 2244     | 1794     | 1506     |
| Asthma Children | Sacramento | S70         | 2017 | 15                         | 1941  | 994      | 629      | 481      | 388      | 311      |
| Asthma Children | Sacramento | S70         | 2017 | 20                         | 745   | 334      | 225      | 179      | 163      | 132      |
| Asthma Children | Sacramento | S75         | 2015 | 10                         | 7477  | 4635     | 3432     | 2795     | 2376     | 2057     |
| Asthma Children | Sacramento | S75         | 2015 | 15                         | 2733  | 1530     | 1040     | 792      | 582      | 474      |
| Asthma Children | Sacramento | S75         | 2015 | 20                         | 1064  | 551      | 311      | 210      | 155      | 101      |
| Asthma Children | Sacramento | S75         | 2016 | 10                         | 8440  | 5427     | 4006     | 3238     | 2725     | 2244     |
| Asthma Children | Sacramento | S75         | 2016 | 15                         | 2950  | 1747     | 1250     | 955      | 784      | 637      |
| Asthma Children | Sacramento | S75         | 2016 | 20                         | 1312  | 745      | 520      | 396      | 334      | 303      |
| Asthma Children | Sacramento | S75         | 2017 | 10                         | 7772  | 5047     | 3758     | 2927     | 2368     | 1980     |
| Asthma Children | Sacramento | S75         | 2017 | 15                         | 2686  | 1522     | 978      | 691      | 543      | 466      |
| Asthma Children | Sacramento | S75         | 2017 | 20                         | 1149  | 505      | 349      | 264      | 225      | 194      |

| Study Group     | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-----------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|                 |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Children | St. Louis  | S65         | 2015 | 10                         | 6730  | 3843     | 2659     | 2158     | 1794     | 1412     |
| Asthma Children | St. Louis  | S65         | 2015 | 15                         | 1821  | 993      | 665      | 464      | 346      | 282      |
| Asthma Children | St. Louis  | S65         | 2015 | 20                         | 729   | 337      | 219      | 146      | 109      | 73       |
| Asthma Children | St. Louis  | S65         | 2016 | 10                         | 7149  | 4171     | 3133     | 2431     | 2022     | 1758     |
| Asthma Children | St. Louis  | S65         | 2016 | 15                         | 2340  | 1202     | 920      | 610      | 474      | 301      |
| Asthma Children | St. Louis  | S65         | 2016 | 20                         | 1002  | 410      | 237      | 137      | 100      | 91       |
| Asthma Children | St. Louis  | S65         | 2017 | 10                         | 7422  | 4235     | 2987     | 2441     | 2031     | 1685     |
| Asthma Children | St. Louis  | S65         | 2017 | 15                         | 2204  | 1120     | 738      | 528      | 410      | 319      |
| Asthma Children | St. Louis  | S65         | 2017 | 20                         | 838   | 355      | 246      | 164      | 127      | 82       |
| Asthma Children | St. Louis  | S70         | 2015 | 10                         | 8278  | 4863     | 3624     | 2741     | 2249     | 1958     |
| Asthma Children | St. Louis  | S70         | 2015 | 15                         | 2650  | 1421     | 956      | 747      | 583      | 455      |
| Asthma Children | St. Louis  | S70         | 2015 | 20                         | 1157  | 501      | 346      | 228      | 191      | 164      |
| Asthma Children | St. Louis  | S70         | 2016 | 10                         | 9043  | 5437     | 4034     | 3151     | 2705     | 2277     |
| Asthma Children | St. Louis  | S70         | 2016 | 15                         | 3206  | 1721     | 1275     | 965      | 829      | 647      |
| Asthma Children | St. Louis  | S70         | 2016 | 20                         | 1512  | 747      | 474      | 319      | 200      | 182      |
| Asthma Children | St. Louis  | S70         | 2017 | 10                         | 9234  | 5509     | 3961     | 3096     | 2614     | 2222     |
| Asthma Children | St. Louis  | S70         | 2017 | 15                         | 3169  | 1739     | 1166     | 865      | 610      | 519      |
| Asthma Children | St. Louis  | S70         | 2017 | 20                         | 1311  | 610      | 446      | 319      | 219      | 173      |
| Asthma Children | St. Louis  | S75         | 2015 | 10                         | 9371  | 5628     | 4289     | 3315     | 2705     | 2349     |
| Asthma Children | St. Louis  | S75         | 2015 | 15                         | 3442  | 1921     | 1320     | 1029     | 783      | 592      |
| Asthma Children | St. Louis  | S75         | 2015 | 20                         | 1503  | 783      | 455      | 337      | 246      | 209      |
| Asthma Children | St. Louis  | S75         | 2016 | 10                         | 10400   | 6511     | 4763     | 3743     | 3160     | 2668     |
| Asthma Children | St. Louis  | S75         | 2016 | 15                         | 4025  | 2277     | 1603     | 1311     | 1065     | 865      |
| Asthma Children | St. Louis  | S75         | 2016 | 20                         | 1994  | 1084     | 738      | 501      | 346      | 264      |
| Asthma Children | St. Louis  | S75         | 2017 | 10                         | 10591   | 6602     | 4836     | 3770     | 3151     | 2759     |
| Asthma Children | St. Louis  | S75         | 2017 | 15                         | 3934  | 2186     | 1585     | 1211     | 938      | 701      |
| Asthma Children | St. Louis  | S75         | 2017 | 20                         | 1785  | 956      | 628      | 419      | 328      | 246      |
| All Adults      | Atlanta    | S65         | 2015 | 10                         | 75293   | 32047    | 19440    | 12960    | 8663     | 5846     |
| All Adults      | Atlanta    | S65         | 2015 | 15                         | 19228   | 6480     | 2676     | 1831     | 1268     | 1057     |
| All Adults      | Atlanta    | S65         | 2015 | 20                         | 7325  | 2324     | 1127     | 704      | 423      | 211      |
| All Adults      | Atlanta    | S65         | 2016 | 10                         | 89662   | 43387    | 26835    | 18665    | 14016    | 11340    |
| All Adults      | Atlanta    | S65         | 2016 | 15                         | 24088   | 10565    | 6550     | 4015     | 3099     | 2465     |
| All Adults      | Atlanta    | S65         | 2016 | 20                         | 9649  | 3522     | 2043     | 1409     | 1127     | 916      |
| All Adults      | Atlanta    | S65         | 2017 | 10                         | 74941   | 32118    | 20355    | 13101    | 8522     | 6691     |
| All Adults      | Atlanta    | S65         | 2017 | 15                         | 17608   | 6198     | 3029     | 1902     | 1127     | 845      |
| All Adults      | Atlanta    | S65         | 2017 | 20                         | 5564  | 1550     | 634      | 211      | 141      | 141      |
| All Adults      | Atlanta    | S70         | 2015 | 10                         | 101142  | 43528    | 27046    | 18947    | 13594    | 9861     |
| All Adults      | Atlanta    | S70         | 2015 | 15                         | 27187   | 10354    | 5494     | 3029     | 1831     | 1268     |
| All Adults      | Atlanta    | S70         | 2015 | 20                         | 10988   | 3451     | 1620     | 1268     | 986      | 704      |
| All Adults      | Atlanta    | S70         | 2016 | 10                         | 117483  | 58037    | 37752    | 26553    | 20426    | 16693    |
| All Adults      | Atlanta    | S70         | 2016 | 15                         | 35639   | 15495    | 9790     | 7325     | 5212     | 4015     |
| All Adults      | Atlanta    | S70         | 2016 | 20                         | 15284   | 6198     | 3592     | 2395     | 1550     | 1338     |
| All Adults      | Atlanta    | S70         | 2017 | 10                         | 97903   | 44444    | 27539    | 20496    | 13735    | 10283    |
| All Adults      | Atlanta    | S70         | 2017 | 15                         | 25779   | 10424    | 5423     | 3522     | 1902     | 1268     |
| All Adults      | Atlanta    | S70         | 2017 | 20                         | 8804  | 3029     | 1338     | 634      | 141      | 141      |

| Study Group | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Atlanta    | S75         | 2015 | 10                         | 129598  | 60361    | 37048    | 25849    | 19228    | 14791    |
| All Adults  | Atlanta    | S75         | 2015 | 15                         | 39513   | 16200    | 9156     | 5635     | 3522     | 2113     |
| All Adults  | Atlanta    | S75         | 2015 | 20                         | 16974   | 5283     | 2536     | 1690     | 1338     | 986      |
| All Adults  | Atlanta    | S75         | 2016 | 10                         | 153404  | 76491    | 49726    | 36414    | 27610    | 22116    |
| All Adults  | Atlanta    | S75         | 2016 | 15                         | 49796   | 22116    | 14298    | 9790     | 7536     | 5635     |
| All Adults  | Atlanta    | S75         | 2016 | 20                         | 22046   | 9790     | 6128     | 3733     | 2606     | 1761     |
| All Adults  | Atlanta    | S75         | 2017 | 10                         | 121286  | 57333    | 35498    | 26342    | 19017    | 14791    |
| All Adults  | Atlanta    | S75         | 2017 | 15                         | 35146   | 14650    | 8522     | 5705     | 3592     | 2465     |
| All Adults  | Atlanta    | S75         | 2017 | 20                         | 13805   | 5212     | 2606     | 1550     | 634      | 493      |
| All Adults  | Boston     | S65         | 2015 | 10                         | 104195  | 46374    | 26611    | 17904    | 13599    | 10958    |
| All Adults  | Boston     | S65         | 2015 | 15                         | 25535   | 9881     | 5577     | 2642     | 1761     | 1272     |
| All Adults  | Boston     | S65         | 2015 | 20                         | 9294  | 2935     | 1370     | 587      | 391      | 294      |
| All Adults  | Boston     | S65         | 2016 | 10                         | 114272  | 50287    | 32286    | 21426    | 16828    | 12523    |
| All Adults  | Boston     | S65         | 2016 | 15                         | 31209   | 14186    | 7729     | 4598     | 2935     | 2055     |
| All Adults  | Boston     | S65         | 2016 | 20                         | 13893   | 4892     | 1957     | 978      | 783      | 489      |
| All Adults  | Boston     | S65         | 2017 | 10                         | 123175  | 51951    | 30818    | 21426    | 15849    | 12229    |
| All Adults  | Boston     | S65         | 2017 | 15                         | 30427   | 11740    | 7142     | 4990     | 3326     | 2348     |
| All Adults  | Boston     | S65         | 2017 | 20                         | 12816   | 4500     | 2739     | 1663     | 881      | 587      |
| All Adults  | Boston     | S70         | 2015 | 10                         | 121022  | 55473    | 34047    | 22111    | 16339    | 12816    |
| All Adults  | Boston     | S70         | 2015 | 15                         | 32286   | 12621    | 6946     | 4403     | 2544     | 1957     |
| All Adults  | Boston     | S70         | 2015 | 20                         | 12229   | 4305     | 2152     | 1174     | 881      | 587      |
| All Adults  | Boston     | S70         | 2016 | 10                         | 136285  | 60756    | 39917    | 28079    | 21622    | 16436    |
| All Adults  | Boston     | S70         | 2016 | 15                         | 39036   | 17513    | 10958    | 6457     | 4109     | 2642     |
| All Adults  | Boston     | S70         | 2016 | 20                         | 18295   | 6164     | 3131     | 1859     | 881      | 685      |
| All Adults  | Boston     | S70         | 2017 | 10                         | 149395  | 63495    | 37275    | 25731    | 19763    | 15752    |
| All Adults  | Boston     | S70         | 2017 | 15                         | 41874   | 16143    | 9784     | 5968     | 4696     | 3424     |
| All Adults  | Boston     | S70         | 2017 | 20                         | 17806   | 5968     | 3620     | 2544     | 1468     | 881      |
| All Adults  | Boston     | S75         | 2015 | 10                         | 133448  | 60169    | 36884    | 23774    | 18882    | 15262    |
| All Adults  | Boston     | S75         | 2015 | 15                         | 37667   | 14969    | 8120     | 5087     | 3033     | 2152     |
| All Adults  | Boston     | S75         | 2015 | 20                         | 14773   | 5381     | 2544     | 1370     | 881      | 587      |
| All Adults  | Boston     | S75         | 2016 | 10                         | 152036  | 66430    | 43830    | 31405    | 23676    | 18882    |
| All Adults  | Boston     | S75         | 2016 | 15                         | 44319   | 19763    | 12229    | 7631     | 5577     | 3424     |
| All Adults  | Boston     | S75         | 2016 | 20                         | 21132   | 7925     | 4109     | 2446     | 1468     | 587      |
| All Adults  | Boston     | S75         | 2017 | 10                         | 169060  | 72203    | 41776    | 29448    | 22502    | 17708    |
| All Adults  | Boston     | S75         | 2017 | 15                         | 49603   | 18491    | 11447    | 7142     | 5185     | 4109     |
| All Adults  | Boston     | S75         | 2017 | 20                         | 20741   | 7435     | 4305     | 3326     | 2055     | 1272     |
| All Adults  | Dallas     | S65         | 2015 | 10                         | 118845  | 55008    | 36177    | 23832    | 17346    | 12033    |
| All Adults  | Dallas     | S65         | 2015 | 15                         | 33677   | 13752    | 7110     | 4766     | 3360     | 2266     |
| All Adults  | Dallas     | S65         | 2015 | 20                         | 12346   | 3751     | 2032     | 1094     | 703      | 469      |
| All Adults  | Dallas     | S65         | 2016 | 10                         | 101734  | 46804    | 29067    | 18675    | 14611    | 10861    |
| All Adults  | Dallas     | S65         | 2016 | 15                         | 26488   | 10548    | 6095     | 4141     | 3125     | 2188     |
| All Adults  | Dallas     | S65         | 2016 | 20                         | 10001   | 3907     | 2110     | 938      | 625      | 391      |
| All Adults  | Dallas     | S65         | 2017 | 10                         | 118142  | 52898    | 33286    | 22972    | 16721    | 12814    |
| All Adults  | Dallas     | S65         | 2017 | 15                         | 31020   | 11173    | 6329     | 4454     | 2735     | 1797     |
| All Adults  | Dallas     | S65         | 2017 | 20                         | 11408   | 3751     | 1875     | 1328     | 781      | 469      |

| Study Group | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Dallas     | S70         | 2015 | 10                         | 144083  | 68916    | 45397    | 31801    | 23363    | 17424    |
| All Adults  | Dallas     | S70         | 2015 | 15                         | 44694   | 18675    | 10627    | 6563     | 5235     | 3672     |
| All Adults  | Dallas     | S70         | 2015 | 20                         | 19222   | 6720     | 3360     | 2422     | 1406     | 781      |
| All Adults  | Dallas     | S70         | 2016 | 10                         | 119705  | 57118    | 34380    | 23519    | 17815    | 13986    |
| All Adults  | Dallas     | S70         | 2016 | 15                         | 33442   | 13908    | 7579     | 4923     | 3907     | 2735     |
| All Adults  | Dallas     | S70         | 2016 | 20                         | 13127   | 5391     | 2891     | 1485     | 1172     | 781      |
| All Adults  | Dallas     | S70         | 2017 | 10                         | 138145  | 64853    | 41569    | 29223    | 20862    | 16174    |
| All Adults  | Dallas     | S70         | 2017 | 15                         | 40553   | 15705    | 8048     | 5704     | 3594     | 2500     |
| All Adults  | Dallas     | S70         | 2017 | 20                         | 14690   | 5626     | 3516     | 1563     | 1094     | 781      |
| All Adults  | Dallas     | S75         | 2015 | 10                         | 170650  | 81652    | 54617    | 38912    | 29457    | 22347    |
| All Adults  | Dallas     | S75         | 2015 | 15                         | 56024   | 24457    | 13752    | 9064     | 6642     | 5079     |
| All Adults  | Dallas     | S75         | 2015 | 20                         | 25394   | 9142     | 4844     | 3047     | 2188     | 1250     |
| All Adults  | Dallas     | S75         | 2016 | 10                         | 137364  | 65635    | 40631    | 28520    | 21956    | 16956    |
| All Adults  | Dallas     | S75         | 2016 | 15                         | 40475   | 16721    | 9376     | 6095     | 5001     | 3125     |
| All Adults  | Dallas     | S75         | 2016 | 20                         | 17190   | 6954     | 3594     | 2032     | 1485     | 1094     |
| All Adults  | Dallas     | S75         | 2017 | 10                         | 156663  | 77511    | 49617    | 35474    | 26410    | 19768    |
| All Adults  | Dallas     | S75         | 2017 | 15                         | 49226   | 19768    | 10939    | 7657     | 5001     | 3438     |
| All Adults  | Dallas     | S75         | 2017 | 20                         | 19065   | 7110     | 3907     | 2266     | 1719     | 1250     |
| All Adults  | Detroit    | S65         | 2015 | 10                         | 77732   | 34344    | 20580    | 14222    | 10487    | 8717     |
| All Adults  | Detroit    | S65         | 2015 | 15                         | 19662   | 8127     | 3998     | 2491     | 1639     | 1376     |
| All Adults  | Detroit    | S65         | 2015 | 20                         | 6751  | 2491     | 1311     | 918      | 655      | 459      |
| All Adults  | Detroit    | S65         | 2016 | 10                         | 88481   | 40767    | 24644    | 16582    | 12387    | 9372     |
| All Adults  | Detroit    | S65         | 2016 | 15                         | 24119   | 10159    | 5505     | 3736     | 2097     | 1639     |
| All Adults  | Detroit    | S65         | 2016 | 20                         | 9569  | 3343     | 1966     | 1049     | 852      | 524      |
| All Adults  | Detroit    | S65         | 2017 | 10                         | 85663   | 38407    | 24185    | 16451    | 11863    | 9176     |
| All Adults  | Detroit    | S65         | 2017 | 15                         | 22284   | 9438     | 5243     | 3212     | 2556     | 1639     |
| All Adults  | Detroit    | S65         | 2017 | 20                         | 8651  | 3605     | 1573     | 786      | 393      | 197      |
| All Adults  | Detroit    | S70         | 2015 | 10                         | 97067   | 44634    | 26020    | 17893    | 13829    | 11339    |
| All Adults  | Detroit    | S70         | 2015 | 15                         | 26872   | 11142    | 5833     | 3801     | 2491     | 1835     |
| All Adults  | Detroit    | S70         | 2015 | 20                         | 10159   | 3867     | 1966     | 1114     | 852      | 590      |
| All Adults  | Detroit    | S70         | 2016 | 10                         | 110175  | 52368    | 33098    | 22743    | 17106    | 13829    |
| All Adults  | Detroit    | S70         | 2016 | 15                         | 33426   | 14681    | 7996     | 5571     | 3932     | 2818     |
| All Adults  | Detroit    | S70         | 2016 | 20                         | 13764   | 5571     | 2622     | 1704     | 1311     | 786      |
| All Adults  | Detroit    | S70         | 2017 | 10                         | 105128  | 48566    | 30739    | 21432    | 16320    | 12518    |
| All Adults  | Detroit    | S70         | 2017 | 15                         | 30936   | 13567    | 7472     | 5112     | 3605     | 2687     |
| All Adults  | Detroit    | S70         | 2017 | 20                         | 12060   | 4260     | 2359     | 1639     | 852      | 590      |
| All Adults  | Detroit    | S75         | 2015 | 10                         | 109454  | 50860    | 30477    | 20252    | 15664    | 12191    |
| All Adults  | Detroit    | S75         | 2015 | 15                         | 31722   | 13370    | 7210     | 4391     | 3212     | 2228     |
| All Adults  | Detroit    | S75         | 2015 | 20                         | 12846   | 4785     | 2622     | 1704     | 918      | 786      |
| All Adults  | Detroit    | S75         | 2016 | 10                         | 131476  | 61806    | 39915    | 27986    | 20383    | 15599    |
| All Adults  | Detroit    | S75         | 2016 | 15                         | 43192   | 18286    | 10290    | 6816     | 4916     | 3932     |
| All Adults  | Detroit    | S75         | 2016 | 20                         | 18745   | 7603     | 3605     | 2097     | 1639     | 1114     |
| All Adults  | Detroit    | S75         | 2017 | 10                         | 122300  | 56431    | 35917    | 25168    | 18745    | 14878    |
| All Adults  | Detroit    | S75         | 2017 | 15                         | 37162   | 16451    | 9045     | 6358     | 4260     | 3212     |
| All Adults  | Detroit    | S75         | 2017 | 20                         | 16582   | 5505     | 3080     | 2163     | 1180     | 852      |

| Study Group | Study Area   | AQ Scenario | Year | FEV <sub>1</sub><br>(percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-------------|--------------|-------------|------|-------------------------------|---|----------|----------|----------|----------|----------|
|             |              |             |      |                               | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Philadelphia | S65         | 2015 | 10                            | 109538  | 48364    | 29628    | 20914    | 15947    | 12374    |
| All Adults  | Philadelphia | S65         | 2015 | 15                            | 27711   | 10719    | 6884     | 4009     | 3050     | 1917     |
| All Adults  | Philadelphia | S65         | 2015 | 20                            | 9760  | 3573     | 1917     | 1220     | 523      | 349      |
| All Adults  | Philadelphia | S65         | 2016 | 10                            | 109712  | 49671    | 30326    | 22221    | 15773    | 12461    |
| All Adults  | Philadelphia | S65         | 2016 | 15                            | 26317   | 10544    | 6100     | 4270     | 2527     | 1743     |
| All Adults  | Philadelphia | S65         | 2016 | 20                            | 8889  | 3834     | 1743     | 1046     | 959      | 610      |
| All Adults  | Philadelphia | S65         | 2017 | 10                            | 103874  | 49235    | 30761    | 21263    | 15250    | 11241    |
| All Adults  | Philadelphia | S65         | 2017 | 15                            | 25620   | 10370    | 6361     | 3573     | 2266     | 1656     |
| All Adults  | Philadelphia | S65         | 2017 | 20                            | 9499  | 2963     | 1656     | 871      | 436      | 261      |
| All Adults  | Philadelphia | S70         | 2015 | 10                            | 135506  | 61261    | 37994    | 26840    | 20217    | 16208    |
| All Adults  | Philadelphia | S70         | 2015 | 15                            | 37123   | 14640    | 9586     | 6100     | 4531     | 2963     |
| All Adults  | Philadelphia | S70         | 2015 | 20                            | 14030   | 5054     | 2963     | 1917     | 1046     | 436      |
| All Adults  | Philadelphia | S70         | 2016 | 10                            | 135506  | 62830    | 38691    | 27363    | 21524    | 16557    |
| All Adults  | Philadelphia | S70         | 2016 | 15                            | 35903   | 13943    | 7669     | 5926     | 3921     | 2876     |
| All Adults  | Philadelphia | S70         | 2016 | 20                            | 14030   | 5316     | 2701     | 1917     | 1394     | 1133     |
| All Adults  | Philadelphia | S70         | 2017 | 10                            | 124004  | 60128    | 37820    | 27450    | 20653    | 15250    |
| All Adults  | Philadelphia | S70         | 2017 | 15                            | 35118   | 13856    | 8714     | 5403     | 3311     | 2527     |
| All Adults  | Philadelphia | S70         | 2017 | 20                            | 14466   | 4706     | 2440     | 1394     | 784      | 436      |
| All Adults  | Philadelphia | S75         | 2015 | 10                            | 172542  | 78951    | 49410    | 35990    | 26578    | 20478    |
| All Adults  | Philadelphia | S75         | 2015 | 15                            | 50194   | 20740    | 12723    | 8801     | 6013     | 4531     |
| All Adults  | Philadelphia | S75         | 2015 | 20                            | 20827   | 8017     | 4967     | 2614     | 1917     | 1220     |
| All Adults  | Philadelphia | S75         | 2016 | 10                            | 165658  | 80084    | 50107    | 35380    | 27450    | 22134    |
| All Adults  | Philadelphia | S75         | 2016 | 15                            | 50804   | 21263    | 11677    | 7843     | 5926     | 4444     |
| All Adults  | Philadelphia | S75         | 2016 | 20                            | 20043   | 7930     | 4531     | 3311     | 2179     | 1656     |
| All Adults  | Philadelphia | S75         | 2017 | 10                            | 151541  | 74594    | 48103    | 34944    | 26666    | 20827    |
| All Adults  | Philadelphia | S75         | 2017 | 15                            | 46883   | 19694    | 11241    | 7669     | 4706     | 3311     |
| All Adults  | Philadelphia | S75         | 2017 | 20                            | 20304   | 7320     | 3660     | 1830     | 1220     | 959      |
| All Adults  | Phoenix      | S65         | 2015 | 10                            | 104253  | 55181    | 37151    | 28857    | 23046    | 18228    |
| All Adults  | Phoenix      | S65         | 2015 | 15                            | 28758   | 14255    | 9089     | 6407     | 4867     | 3377     |
| All Adults  | Phoenix      | S65         | 2015 | 20                            | 11225   | 4619     | 2881     | 1689     | 993      | 646      |
| All Adults  | Phoenix      | S65         | 2016 | 10                            | 99584   | 55429    | 37549    | 28708    | 22897    | 18774    |
| All Adults  | Phoenix      | S65         | 2016 | 15                            | 29254   | 13261    | 8543     | 6258     | 4520     | 3775     |
| All Adults  | Phoenix      | S65         | 2016 | 20                            | 10480   | 4420     | 2781     | 1788     | 1540     | 894      |
| All Adults  | Phoenix      | S65         | 2017 | 10                            | 114931  | 61240    | 42665    | 30595    | 23989    | 19470    |
| All Adults  | Phoenix      | S65         | 2017 | 15                            | 31042   | 15645    | 10530    | 7500     | 5811     | 4271     |
| All Adults  | Phoenix      | S65         | 2017 | 20                            | 12566   | 5960     | 3129     | 2235     | 1341     | 1093     |
| All Adults  | Phoenix      | S70         | 2015 | 10                            | 129484  | 70776    | 48029    | 36555    | 29354    | 24983    |
| All Adults  | Phoenix      | S70         | 2015 | 15                            | 40529   | 20960    | 13212    | 8791     | 6506     | 5066     |
| All Adults  | Phoenix      | S70         | 2015 | 20                            | 16887   | 7152     | 4222     | 2732     | 1838     | 1242     |
| All Adults  | Phoenix      | S70         | 2016 | 10                            | 121636  | 68690    | 48227    | 36903    | 29552    | 24437    |
| All Adults  | Phoenix      | S70         | 2016 | 15                            | 40132   | 20513    | 12814    | 9040     | 6655     | 5414     |
| All Adults  | Phoenix      | S70         | 2016 | 20                            | 16887   | 7202     | 4172     | 3030     | 2285     | 1838     |
| All Adults  | Phoenix      | S70         | 2017 | 10                            | 143440  | 78624    | 55230    | 41423    | 32234    | 26423    |
| All Adults  | Phoenix      | S70         | 2017 | 15                            | 43658   | 21655    | 14205    | 10828    | 8046     | 6308     |
| All Adults  | Phoenix      | S70         | 2017 | 20                            | 18327   | 8642     | 5761     | 4172     | 2583     | 1987     |

| Study Group | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|-------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|             |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults  | Phoenix    | S75         | 2015 | 10                         | 152530  | 82945    | 57267    | 44552    | 35016    | 29453    |
| All Adults  | Phoenix    | S75         | 2015 | 15                         | 50115   | 26274    | 17533    | 12119    | 9238     | 7251     |
| All Adults  | Phoenix    | S75         | 2015 | 20                         | 22052   | 10579    | 6457     | 4172     | 3129     | 2235     |
| All Adults  | Phoenix    | S75         | 2016 | 10                         | 142298  | 80462    | 57118    | 44204    | 35214    | 28311    |
| All Adults  | Phoenix    | S75         | 2016 | 15                         | 49270   | 25728    | 16738    | 11771    | 8990     | 7301     |
| All Adults  | Phoenix    | S75         | 2016 | 20                         | 22152   | 9785     | 6059     | 4073     | 3278     | 2334     |
| All Adults  | Phoenix    | S75         | 2017 | 10                         | 169218  | 93574    | 65611    | 50462    | 40579    | 32979    |
| All Adults  | Phoenix    | S75         | 2017 | 15                         | 56075   | 28807    | 18675    | 13311    | 10728    | 8543     |
| All Adults  | Phoenix    | S75         | 2017 | 20                         | 24735   | 11771    | 7947     | 5712     | 4222     | 2881     |
| All Adults  | Sacramento | S65         | 2015 | 10                         | 32672   | 14692    | 8775     | 6803     | 5231     | 4116     |
| All Adults  | Sacramento | S65         | 2015 | 15                         | 7661  | 3316     | 1887     | 1315     | 1000     | 800      |
| All Adults  | Sacramento | S65         | 2015 | 20                         | 2916  | 1086     | 715      | 457      | 172      | 114      |
| All Adults  | Sacramento | S65         | 2016 | 10                         | 32329   | 14864    | 9118     | 6031     | 4516     | 3516     |
| All Adults  | Sacramento | S65         | 2016 | 15                         | 7804  | 2973     | 1801     | 1258     | 743      | 515      |
| All Adults  | Sacramento | S65         | 2016 | 20                         | 2773  | 858      | 372      | 257      | 143      | 114      |
| All Adults  | Sacramento | S65         | 2017 | 10                         | 31843   | 15235    | 9747     | 6660     | 5174     | 4002     |
| All Adults  | Sacramento | S65         | 2017 | 15                         | 7546  | 3287     | 2144     | 1229     | 829      | 600      |
| All Adults  | Sacramento | S65         | 2017 | 20                         | 3001  | 1058     | 343      | 257      | 200      | 57       |
| All Adults  | Sacramento | S70         | 2015 | 10                         | 43734   | 21152    | 13263    | 9547     | 7375     | 6117     |
| All Adults  | Sacramento | S70         | 2015 | 15                         | 11691   | 5260     | 3287     | 2287     | 1658     | 1229     |
| All Adults  | Sacramento | S70         | 2015 | 20                         | 4802  | 1887     | 1172     | 715      | 515      | 343      |
| All Adults  | Sacramento | S70         | 2016 | 10                         | 44306   | 21038    | 13863    | 9919     | 7232     | 5260     |
| All Adults  | Sacramento | S70         | 2016 | 15                         | 12291   | 5088     | 3087     | 1972     | 1401     | 1058     |
| All Adults  | Sacramento | S70         | 2016 | 20                         | 4831  | 1887     | 1000     | 486      | 314      | 200      |
| All Adults  | Sacramento | S70         | 2017 | 10                         | 43820   | 21067    | 13578    | 10119    | 7175     | 6003     |
| All Adults  | Sacramento | S70         | 2017 | 15                         | 10948   | 5260     | 3201     | 2344     | 1801     | 1229     |
| All Adults  | Sacramento | S70         | 2017 | 20                         | 4888  | 1944     | 1029     | 629      | 457      | 200      |
| All Adults  | Sacramento | S75         | 2015 | 10                         | 53196   | 26641    | 17008    | 12034    | 9204     | 7718     |
| All Adults  | Sacramento | S75         | 2015 | 15                         | 15350   | 7060     | 4316     | 2887     | 2258     | 1829     |
| All Adults  | Sacramento | S75         | 2015 | 20                         | 6460  | 2744     | 1572     | 1172     | 743      | 572      |
| All Adults  | Sacramento | S75         | 2016 | 10                         | 54939   | 26984    | 17608    | 12834    | 9662     | 7546     |
| All Adults  | Sacramento | S75         | 2016 | 15                         | 17008   | 6717     | 4145     | 2944     | 2287     | 1744     |
| All Adults  | Sacramento | S75         | 2016 | 20                         | 6975  | 3001     | 1486     | 943      | 657      | 486      |
| All Adults  | Sacramento | S75         | 2017 | 10                         | 54739   | 26669    | 17465    | 12720    | 9833     | 7746     |
| All Adults  | Sacramento | S75         | 2017 | 15                         | 15407   | 7318     | 4545     | 3116     | 2258     | 1801     |
| All Adults  | Sacramento | S75         | 2017 | 20                         | 6460  | 2830     | 1601     | 943      | 657      | 457      |
| All Adults  | St. Louis  | S65         | 2015 | 10                         | 38915   | 16453    | 9836     | 6653     | 4864     | 4006     |
| All Adults  | St. Louis  | S65         | 2015 | 15                         | 9192  | 3612     | 2325     | 1466     | 1001     | 715      |
| All Adults  | St. Louis  | S65         | 2015 | 20                         | 3326  | 1180     | 537      | 322      | 215      | 72       |
| All Adults  | St. Louis  | S65         | 2016 | 10                         | 48465   | 23034    | 13162    | 8906     | 6402     | 5007     |
| All Adults  | St. Louis  | S65         | 2016 | 15                         | 13127   | 5079     | 3004     | 1860     | 1431     | 1037     |
| All Adults  | St. Louis  | S65         | 2016 | 20                         | 5329  | 1717     | 930      | 680      | 393      | 179      |
| All Adults  | St. Louis  | S65         | 2017 | 10                         | 47535   | 22283    | 14200    | 9514     | 7118     | 5472     |
| All Adults  | St. Louis  | S65         | 2017 | 15                         | 12697   | 4972     | 2861     | 1967     | 1395     | 1073     |
| All Adults  | St. Louis  | S65         | 2017 | 20                         | 4578  | 1824     | 930      | 644      | 501      | 286      |



| Study Group   | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|---------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| All Adults    | St. Louis  | S70         | 2015 | 10                         | 48965   | 21174    | 12948    | 9156     | 6903     | 5759     |
| All Adults    | St. Louis  | S70         | 2015 | 15                         | 13985   | 5437     | 3076     | 2182     | 1466     | 1037     |
| All Adults    | St. Louis  | S70         | 2015 | 20                         | 5508  | 1896     | 1073     | 680      | 358      | 179      |
| All Adults    | St. Louis  | S70         | 2016 | 10                         | 62593   | 30545    | 19100    | 12447    | 9121     | 6975     |
| All Adults    | St. Louis  | S70         | 2016 | 15                         | 19207   | 7762     | 4435     | 2683     | 1896     | 1466     |
| All Adults    | St. Louis  | S70         | 2016 | 20                         | 8226  | 3040     | 1574     | 1073     | 823      | 644      |
| All Adults    | St. Louis  | S70         | 2017 | 10                         | 60304   | 29830    | 19207    | 13520    | 9943     | 8262     |
| All Adults    | St. Louis  | S70         | 2017 | 15                         | 18313   | 7583     | 4471     | 3076     | 2075     | 1610     |
| All Adults    | St. Louis  | S70         | 2017 | 20                         | 7189  | 2647     | 1502     | 1109     | 715      | 537      |
| All Adults    | St. Louis  | S75         | 2015 | 10                         | 57442   | 26074    | 15273    | 10766    | 8620     | 6832     |
| All Adults    | St. Louis  | S75         | 2015 | 15                         | 17776   | 7082     | 3934     | 2826     | 1931     | 1431     |
| All Adults    | St. Louis  | S75         | 2015 | 20                         | 7225  | 2504     | 1538     | 1037     | 572      | 286      |
| All Adults    | St. Louis  | S75         | 2016 | 10                         | 72965   | 36840    | 23070    | 15702    | 11839    | 9192     |
| All Adults    | St. Louis  | S75         | 2016 | 15                         | 24536   | 10301    | 5866     | 3756     | 2504     | 1753     |
| All Adults    | St. Louis  | S75         | 2016 | 20                         | 10659   | 4149     | 2361     | 1574     | 966      | 751      |
| All Adults    | St. Louis  | S75         | 2017 | 10                         | 70927   | 35624    | 23392    | 16381    | 12519    | 10194    |
| All Adults    | St. Louis  | S75         | 2017 | 15                         | 23893   | 10229    | 6188     | 3612     | 2826     | 2039     |
| All Adults    | St. Louis  | S75         | 2017 | 20                         | 9586  | 3827     | 2182     | 1538     | 1180     | 894      |
| Asthma Adults | Atlanta    | S65         | 2015 | 10                         | 5494  | 2324     | 1479     | 845      | 493      | 282      |
| Asthma Adults | Atlanta    | S65         | 2015 | 15                         | 1409  | 493      | 70       | 70       | 70       | 0        |
| Asthma Adults | Atlanta    | S65         | 2015 | 20                         | 282   | 70       | 70       | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S65         | 2016 | 10                         | 6691  | 3381     | 2254     | 1550     | 1197     | 986      |
| Asthma Adults | Atlanta    | S65         | 2016 | 15                         | 1690  | 916      | 775      | 563      | 423      | 282      |
| Asthma Adults | Atlanta    | S65         | 2016 | 20                         | 775   | 493      | 282      | 211      | 211      | 211      |
| Asthma Adults | Atlanta    | S65         | 2017 | 10                         | 5635  | 2254     | 1620     | 845      | 563      | 423      |
| Asthma Adults | Atlanta    | S65         | 2017 | 15                         | 1831  | 352      | 211      | 70       | 70       | 70       |
| Asthma Adults | Atlanta    | S65         | 2017 | 20                         | 282   | 141      | 70       | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S70         | 2015 | 10                         | 7677  | 3381     | 2113     | 1620     | 986      | 634      |
| Asthma Adults | Atlanta    | S70         | 2015 | 15                         | 2043  | 986      | 282      | 141      | 141      | 0        |
| Asthma Adults | Atlanta    | S70         | 2015 | 20                         | 634   | 141      | 70       | 70       | 70       | 0        |
| Asthma Adults | Atlanta    | S70         | 2016 | 10                         | 8875  | 4367     | 3240     | 2113     | 1690     | 1550     |
| Asthma Adults | Atlanta    | S70         | 2016 | 15                         | 2395  | 916      | 775      | 704      | 563      | 493      |
| Asthma Adults | Atlanta    | S70         | 2016 | 20                         | 1127  | 563      | 493      | 423      | 211      | 211      |
| Asthma Adults | Atlanta    | S70         | 2017 | 10                         | 7818  | 3663     | 2324     | 1409     | 986      | 634      |
| Asthma Adults | Atlanta    | S70         | 2017 | 15                         | 2395  | 634      | 282      | 282      | 141      | 70       |
| Asthma Adults | Atlanta    | S70         | 2017 | 20                         | 493   | 211      | 141      | 0        | 0        | 0        |
| Asthma Adults | Atlanta    | S75         | 2015 | 10                         | 10142   | 4296     | 2747     | 2113     | 1479     | 1057     |
| Asthma Adults | Atlanta    | S75         | 2015 | 15                         | 2817  | 1409     | 493      | 211      | 211      | 70       |
| Asthma Adults | Atlanta    | S75         | 2015 | 20                         | 1338  | 423      | 70       | 70       | 70       | 0        |
| Asthma Adults | Atlanta    | S75         | 2016 | 10                         | 11903   | 5494     | 3733     | 2958     | 2113     | 1902     |
| Asthma Adults | Atlanta    | S75         | 2016 | 15                         | 3803  | 1479     | 986      | 916      | 704      | 563      |
| Asthma Adults | Atlanta    | S75         | 2016 | 20                         | 1479  | 775      | 704      | 423      | 352      | 211      |
| Asthma Adults | Atlanta    | S75         | 2017 | 10                         | 9649  | 4226     | 3099     | 2183     | 1620     | 1197     |
| Asthma Adults | Atlanta    | S75         | 2017 | 15                         | 2747  | 916      | 634      | 423      | 282      | 211      |
| Asthma Adults | Atlanta    | S75         | 2017 | 20                         | 1057  | 352      | 141      | 141      | 70       | 0        |

| Study Group   | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|---------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Boston     | S65         | 2015 | 10                         | 9490  | 3816     | 1957     | 1468     | 1076     | 978      |
| Asthma Adults | Boston     | S65         | 2015 | 15                         | 1859  | 881      | 587      | 294      | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2015 | 20                         | 685   | 98       | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S65         | 2016 | 10                         | 9784  | 4403     | 3229     | 1957     | 1370     | 1174     |
| Asthma Adults | Boston     | S65         | 2016 | 15                         | 2642  | 1370     | 881      | 196      | 196      | 196      |
| Asthma Adults | Boston     | S65         | 2016 | 20                         | 978   | 489      | 294      | 98       | 98       | 0        |
| Asthma Adults | Boston     | S65         | 2017 | 10                         | 11838   | 4892     | 2837     | 1761     | 1468     | 1076     |
| Asthma Adults | Boston     | S65         | 2017 | 15                         | 3131  | 881      | 391      | 294      | 294      | 196      |
| Asthma Adults | Boston     | S65         | 2017 | 20                         | 1272  | 391      | 196      | 196      | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2015 | 10                         | 11447   | 4598     | 2250     | 1468     | 1174     | 978      |
| Asthma Adults | Boston     | S70         | 2015 | 15                         | 2348  | 978      | 587      | 294      | 196      | 98       |
| Asthma Adults | Boston     | S70         | 2015 | 20                         | 881   | 196      | 0        | 0        | 0        | 0        |
| Asthma Adults | Boston     | S70         | 2016 | 10                         | 12425   | 5479     | 3522     | 2739     | 1761     | 1370     |
| Asthma Adults | Boston     | S70         | 2016 | 15                         | 3522  | 1859     | 881      | 489      | 294      | 196      |
| Asthma Adults | Boston     | S70         | 2016 | 20                         | 1468  | 587      | 294      | 196      | 98       | 98       |
| Asthma Adults | Boston     | S70         | 2017 | 10                         | 15067   | 5870     | 3326     | 2446     | 1957     | 1370     |
| Asthma Adults | Boston     | S70         | 2017 | 15                         | 3816  | 1272     | 489      | 391      | 391      | 294      |
| Asthma Adults | Boston     | S70         | 2017 | 20                         | 1663  | 489      | 196      | 196      | 98       | 98       |
| Asthma Adults | Boston     | S75         | 2015 | 10                         | 12425   | 5381     | 2348     | 1565     | 1370     | 1272     |
| Asthma Adults | Boston     | S75         | 2015 | 15                         | 2642  | 978      | 685      | 489      | 196      | 98       |
| Asthma Adults | Boston     | S75         | 2015 | 20                         | 783   | 294      | 98       | 0        | 0        | 0        |
| Asthma Adults | Boston     | S75         | 2016 | 10                         | 14186   | 5870     | 3620     | 2935     | 2152     | 1468     |
| Asthma Adults | Boston     | S75         | 2016 | 15                         | 3718  | 2152     | 1468     | 881      | 587      | 294      |
| Asthma Adults | Boston     | S75         | 2016 | 20                         | 1859  | 783      | 489      | 196      | 98       | 98       |
| Asthma Adults | Boston     | S75         | 2017 | 10                         | 16143   | 6653     | 3522     | 2739     | 2250     | 1370     |
| Asthma Adults | Boston     | S75         | 2017 | 15                         | 4403  | 1565     | 783      | 587      | 391      | 391      |
| Asthma Adults | Boston     | S75         | 2017 | 20                         | 2055  | 489      | 294      | 196      | 98       | 98       |
| Asthma Adults | Dallas     | S65         | 2015 | 10                         | 6407  | 2422     | 1797     | 1328     | 1172     | 547      |
| Asthma Adults | Dallas     | S65         | 2015 | 15                         | 1797  | 859      | 313      | 156      | 78       | 78       |
| Asthma Adults | Dallas     | S65         | 2015 | 20                         | 547   | 0        | 0        | 0        | 0        | 0        |
| Asthma Adults | Dallas     | S65         | 2016 | 10                         | 5782  | 2266     | 1016     | 625      | 391      | 391      |
| Asthma Adults | Dallas     | S65         | 2016 | 15                         | 1172  | 313      | 313      | 313      | 156      | 156      |
| Asthma Adults | Dallas     | S65         | 2016 | 20                         | 391   | 234      | 234      | 156      | 78       | 78       |
| Asthma Adults | Dallas     | S65         | 2017 | 10                         | 8439  | 3516     | 2657     | 2110     | 1719     | 1485     |
| Asthma Adults | Dallas     | S65         | 2017 | 15                         | 2813  | 1250     | 1016     | 859      | 469      | 313      |
| Asthma Adults | Dallas     | S65         | 2017 | 20                         | 1641  | 391      | 156      | 156      | 78       | 0        |
| Asthma Adults | Dallas     | S70         | 2015 | 10                         | 8751  | 3438     | 2188     | 1485     | 1172     | 1016     |
| Asthma Adults | Dallas     | S70         | 2015 | 15                         | 2110  | 859      | 547      | 313      | 234      | 156      |
| Asthma Adults | Dallas     | S70         | 2015 | 20                         | 703   | 156      | 78       | 78       | 78       | 0        |
| Asthma Adults | Dallas     | S70         | 2016 | 10                         | 6876  | 2891     | 1250     | 938      | 469      | 391      |
| Asthma Adults | Dallas     | S70         | 2016 | 15                         | 1563  | 469      | 313      | 313      | 234      | 156      |
| Asthma Adults | Dallas     | S70         | 2016 | 20                         | 391   | 234      | 234      | 156      | 156      | 156      |
| Asthma Adults | Dallas     | S70         | 2017 | 10                         | 9611  | 4532     | 3282     | 2657     | 2110     | 1953     |
| Asthma Adults | Dallas     | S70         | 2017 | 15                         | 3360  | 1485     | 1094     | 938      | 625      | 469      |
| Asthma Adults | Dallas     | S70         | 2017 | 20                         | 1641  | 859      | 625      | 234      | 78       | 78       |

| Study Group   | Study Area   | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|---------------|--------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|               |              |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Dallas       | S75         | 2015 | 10                         | 10861   | 3985     | 2735     | 1641     | 1406     | 1250     |
| Asthma Adults | Dallas       | S75         | 2015 | 15                         | 2735  | 938      | 625      | 547      | 313      | 156      |
| Asthma Adults | Dallas       | S75         | 2015 | 20                         | 1250  | 313      | 156      | 78       | 78       | 0        |
| Asthma Adults | Dallas       | S75         | 2016 | 10                         | 8361  | 3672     | 1641     | 1094     | 781      | 469      |
| Asthma Adults | Dallas       | S75         | 2016 | 15                         | 2266  | 547      | 313      | 313      | 313      | 156      |
| Asthma Adults | Dallas       | S75         | 2016 | 20                         | 547   | 234      | 234      | 234      | 156      | 156      |
| Asthma Adults | Dallas       | S75         | 2017 | 10                         | 10705   | 5313     | 3829     | 3125     | 2344     | 2110     |
| Asthma Adults | Dallas       | S75         | 2017 | 15                         | 4141  | 1797     | 1328     | 1250     | 859      | 547      |
| Asthma Adults | Dallas       | S75         | 2017 | 20                         | 1875  | 1016     | 703      | 391      | 313      | 234      |
| Asthma Adults | Detroit      | S65         | 2015 | 10                         | 7603  | 3146     | 1507     | 1114     | 655      | 590      |
| Asthma Adults | Detroit      | S65         | 2015 | 15                         | 1770  | 721      | 262      | 131      | 131      | 131      |
| Asthma Adults | Detroit      | S65         | 2015 | 20                         | 655   | 262      | 131      | 131      | 0        | 0        |
| Asthma Adults | Detroit      | S65         | 2016 | 10                         | 8979  | 3932     | 2163     | 1770     | 1507     | 1376     |
| Asthma Adults | Detroit      | S65         | 2016 | 15                         | 2425  | 1376     | 852      | 721      | 393      | 262      |
| Asthma Adults | Detroit      | S65         | 2016 | 20                         | 1376  | 655      | 328      | 66       | 66       | 0        |
| Asthma Adults | Detroit      | S65         | 2017 | 10                         | 8914  | 4260     | 2753     | 2097     | 1507     | 1114     |
| Asthma Adults | Detroit      | S65         | 2017 | 15                         | 2687  | 1311     | 590      | 393      | 393      | 328      |
| Asthma Adults | Detroit      | S65         | 2017 | 20                         | 1442  | 393      | 328      | 262      | 66       | 0        |
| Asthma Adults | Detroit      | S70         | 2015 | 10                         | 9241  | 4064     | 1901     | 1376     | 983      | 852      |
| Asthma Adults | Detroit      | S70         | 2015 | 15                         | 2359  | 983      | 524      | 197      | 197      | 131      |
| Asthma Adults | Detroit      | S70         | 2015 | 20                         | 852   | 328      | 131      | 131      | 131      | 66       |
| Asthma Adults | Detroit      | S70         | 2016 | 10                         | 11011   | 5047     | 2949     | 2359     | 1901     | 1770     |
| Asthma Adults | Detroit      | S70         | 2016 | 15                         | 3343  | 1704     | 1180     | 852      | 786      | 721      |
| Asthma Adults | Detroit      | S70         | 2016 | 20                         | 1770  | 852      | 459      | 262      | 262      | 131      |
| Asthma Adults | Detroit      | S70         | 2017 | 10                         | 11273   | 5047     | 3212     | 2687     | 1901     | 1573     |
| Asthma Adults | Detroit      | S70         | 2017 | 15                         | 3474  | 1639     | 918      | 590      | 459      | 393      |
| Asthma Adults | Detroit      | S70         | 2017 | 20                         | 1966  | 459      | 459      | 328      | 262      | 197      |
| Asthma Adults | Detroit      | S75         | 2015 | 10                         | 10356   | 4653     | 2622     | 1507     | 1114     | 918      |
| Asthma Adults | Detroit      | S75         | 2015 | 15                         | 2753  | 1114     | 590      | 262      | 262      | 131      |
| Asthma Adults | Detroit      | S75         | 2015 | 20                         | 1180  | 393      | 262      | 197      | 131      | 131      |
| Asthma Adults | Detroit      | S75         | 2016 | 10                         | 12977   | 6095     | 3736     | 2556     | 2097     | 1770     |
| Asthma Adults | Detroit      | S75         | 2016 | 15                         | 4326  | 1901     | 1311     | 918      | 786      | 721      |
| Asthma Adults | Detroit      | S75         | 2016 | 20                         | 1966  | 1114     | 655      | 393      | 393      | 328      |
| Asthma Adults | Detroit      | S75         | 2017 | 10                         | 13239   | 6161     | 3998     | 2949     | 2163     | 1901     |
| Asthma Adults | Detroit      | S75         | 2017 | 15                         | 4195  | 2097     | 1180     | 786      | 524      | 459      |
| Asthma Adults | Detroit      | S75         | 2017 | 20                         | 2359  | 655      | 459      | 393      | 328      | 262      |
| Asthma Adults | Philadelphia | S65         | 2015 | 10                         | 10370   | 4619     | 2701     | 1917     | 1220     | 959      |
| Asthma Adults | Philadelphia | S65         | 2015 | 15                         | 2614  | 1046     | 784      | 349      | 349      | 261      |
| Asthma Adults | Philadelphia | S65         | 2015 | 20                         | 1133  | 349      | 174      | 174      | 87       | 87       |
| Asthma Adults | Philadelphia | S65         | 2016 | 10                         | 8453  | 3137     | 1917     | 1394     | 1133     | 697      |
| Asthma Adults | Philadelphia | S65         | 2016 | 15                         | 1394  | 349      | 174      | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2016 | 20                         | 349   | 174      | 0        | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S65         | 2017 | 10                         | 9760  | 4357     | 3224     | 2179     | 1569     | 1133     |
| Asthma Adults | Philadelphia | S65         | 2017 | 15                         | 2440  | 1307     | 436      | 261      | 174      | 87       |
| Asthma Adults | Philadelphia | S65         | 2017 | 20                         | 1133  | 174      | 0        | 0        | 0        | 0        |

| Study Group   | Study Area   | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|---------------|--------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|               |              |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Philadelphia | S70         | 2015 | 10                         | 12026   | 5141     | 3050     | 2701     | 1830     | 1220     |
| Asthma Adults | Philadelphia | S70         | 2015 | 15                         | 3399  | 1481     | 959      | 610      | 436      | 349      |
| Asthma Adults | Philadelphia | S70         | 2015 | 20                         | 1569  | 436      | 349      | 349      | 87       | 87       |
| Asthma Adults | Philadelphia | S70         | 2016 | 10                         | 10631   | 4357     | 2701     | 1656     | 1394     | 959      |
| Asthma Adults | Philadelphia | S70         | 2016 | 15                         | 1917  | 610      | 261      | 174      | 174      | 0        |
| Asthma Adults | Philadelphia | S70         | 2016 | 20                         | 436   | 261      | 87       | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S70         | 2017 | 10                         | 11067   | 6013     | 3660     | 2789     | 2091     | 1656     |
| Asthma Adults | Philadelphia | S70         | 2017 | 15                         | 3399  | 1569     | 959      | 523      | 261      | 174      |
| Asthma Adults | Philadelphia | S70         | 2017 | 20                         | 1656  | 436      | 174      | 0        | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2015 | 10                         | 15773   | 7233     | 4183     | 3311     | 2353     | 1743     |
| Asthma Adults | Philadelphia | S75         | 2015 | 15                         | 4531  | 1917     | 1220     | 784      | 523      | 436      |
| Asthma Adults | Philadelphia | S75         | 2015 | 20                         | 1917  | 784      | 349      | 349      | 174      | 87       |
| Asthma Adults | Philadelphia | S75         | 2016 | 10                         | 13594   | 5403     | 3660     | 2440     | 2004     | 1394     |
| Asthma Adults | Philadelphia | S75         | 2016 | 15                         | 3921  | 1569     | 784      | 349      | 174      | 87       |
| Asthma Adults | Philadelphia | S75         | 2016 | 20                         | 697   | 261      | 87       | 87       | 0        | 0        |
| Asthma Adults | Philadelphia | S75         | 2017 | 10                         | 13507   | 6710     | 4706     | 3573     | 2527     | 2266     |
| Asthma Adults | Philadelphia | S75         | 2017 | 15                         | 4444  | 1743     | 1133     | 959      | 436      | 261      |
| Asthma Adults | Philadelphia | S75         | 2017 | 20                         | 1917  | 610      | 349      | 87       | 0        | 0        |
| Asthma Adults | Phoenix      | S65         | 2015 | 10                         | 8444  | 4321     | 2583     | 2036     | 1639     | 1291     |
| Asthma Adults | Phoenix      | S65         | 2015 | 15                         | 2334  | 1440     | 844      | 497      | 397      | 248      |
| Asthma Adults | Phoenix      | S65         | 2015 | 20                         | 844   | 397      | 298      | 199      | 99       | 0        |
| Asthma Adults | Phoenix      | S65         | 2016 | 10                         | 6953  | 3973     | 2483     | 1589     | 1291     | 1192     |
| Asthma Adults | Phoenix      | S65         | 2016 | 15                         | 2086  | 795      | 447      | 298      | 199      | 99       |
| Asthma Adults | Phoenix      | S65         | 2016 | 20                         | 596   | 149      | 50       | 0        | 0        | 0        |
| Asthma Adults | Phoenix      | S65         | 2017 | 10                         | 8046  | 4172     | 2732     | 2086     | 1738     | 1391     |
| Asthma Adults | Phoenix      | S65         | 2017 | 15                         | 2235  | 1341     | 993      | 695      | 497      | 497      |
| Asthma Adults | Phoenix      | S65         | 2017 | 20                         | 894   | 546      | 298      | 248      | 149      | 99       |
| Asthma Adults | Phoenix      | S70         | 2015 | 10                         | 10232   | 5612     | 3626     | 2781     | 1987     | 1738     |
| Asthma Adults | Phoenix      | S70         | 2015 | 15                         | 3328  | 1788     | 1142     | 695      | 546      | 447      |
| Asthma Adults | Phoenix      | S70         | 2015 | 20                         | 1738  | 646      | 397      | 248      | 149      | 50       |
| Asthma Adults | Phoenix      | S70         | 2016 | 10                         | 8543  | 4818     | 3526     | 2285     | 1788     | 1440     |
| Asthma Adults | Phoenix      | S70         | 2016 | 15                         | 2632  | 1341     | 795      | 497      | 248      | 248      |
| Asthma Adults | Phoenix      | S70         | 2016 | 20                         | 1093  | 497      | 149      | 50       | 50       | 50       |
| Asthma Adults | Phoenix      | S70         | 2017 | 10                         | 9785  | 5414     | 3924     | 2732     | 2036     | 1788     |
| Asthma Adults | Phoenix      | S70         | 2017 | 15                         | 2980  | 1788     | 1142     | 844      | 646      | 596      |
| Asthma Adults | Phoenix      | S70         | 2017 | 20                         | 1242  | 646      | 447      | 397      | 248      | 199      |
| Asthma Adults | Phoenix      | S75         | 2015 | 10                         | 11871   | 6705     | 4420     | 3328     | 2483     | 2086     |
| Asthma Adults | Phoenix      | S75         | 2015 | 15                         | 4023  | 2185     | 1540     | 1093     | 745      | 596      |
| Asthma Adults | Phoenix      | S75         | 2015 | 20                         | 1937  | 1043     | 546      | 298      | 149      | 149      |
| Asthma Adults | Phoenix      | S75         | 2016 | 10                         | 10182   | 5612     | 4222     | 2881     | 2285     | 1838     |
| Asthma Adults | Phoenix      | S75         | 2016 | 15                         | 3526  | 1689     | 1093     | 745      | 546      | 397      |
| Asthma Adults | Phoenix      | S75         | 2016 | 20                         | 1589  | 646      | 348      | 99       | 50       | 50       |
| Asthma Adults | Phoenix      | S75         | 2017 | 10                         | 11473   | 6308     | 4470     | 3328     | 2682     | 2185     |
| Asthma Adults | Phoenix      | S75         | 2017 | 15                         | 4073  | 2136     | 1391     | 1142     | 944      | 695      |
| Asthma Adults | Phoenix      | S75         | 2017 | 20                         | 1738  | 894      | 646      | 546      | 397      | 298      |

| Study Group   | Study Area | AQ Scenario | Year | FEV <sub>1</sub> (percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|---------------|------------|-------------|------|----------------------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                            | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | Sacramento | S65         | 2015 | 10                         | 2287  | 858      | 515      | 457      | 343      | 343      |
| Asthma Adults | Sacramento | S65         | 2015 | 15                         | 543   | 172      | 86       | 86       | 86       | 29       |
| Asthma Adults | Sacramento | S65         | 2015 | 20                         | 257   | 29       | 29       | 29       | 0        | 0        |
| Asthma Adults | Sacramento | S65         | 2016 | 10                         | 2172  | 1143     | 715      | 543      | 400      | 343      |
| Asthma Adults | Sacramento | S65         | 2016 | 15                         | 515   | 200      | 143      | 86       | 86       | 57       |
| Asthma Adults | Sacramento | S65         | 2016 | 20                         | 172   | 57       | 57       | 57       | 57       | 29       |
| Asthma Adults | Sacramento | S65         | 2017 | 10                         | 2115  | 915      | 486      | 400      | 314      | 314      |
| Asthma Adults | Sacramento | S65         | 2017 | 15                         | 457   | 257      | 172      | 57       | 57       | 29       |
| Asthma Adults | Sacramento | S65         | 2017 | 20                         | 172   | 86       | 0        | 0        | 0        | 0        |
| Asthma Adults | Sacramento | S70         | 2015 | 10                         | 2887  | 1286     | 858      | 657      | 543      | 400      |
| Asthma Adults | Sacramento | S70         | 2015 | 15                         | 715   | 314      | 286      | 114      | 114      | 29       |
| Asthma Adults | Sacramento | S70         | 2015 | 20                         | 343   | 143      | 86       | 29       | 29       | 29       |
| Asthma Adults | Sacramento | S70         | 2016 | 10                         | 2830  | 1429     | 1029     | 772      | 543      | 400      |
| Asthma Adults | Sacramento | S70         | 2016 | 15                         | 772   | 400      | 343      | 200      | 114      | 86       |
| Asthma Adults | Sacramento | S70         | 2016 | 20                         | 343   | 172      | 114      | 86       | 57       | 29       |
| Asthma Adults | Sacramento | S70         | 2017 | 10                         | 2716  | 1258     | 743      | 515      | 400      | 314      |
| Asthma Adults | Sacramento | S70         | 2017 | 15                         | 800   | 257      | 200      | 143      | 86       | 57       |
| Asthma Adults | Sacramento | S70         | 2017 | 20                         | 229   | 143      | 86       | 29       | 0        | 0        |
| Asthma Adults | Sacramento | S75         | 2015 | 10                         | 3544  | 1744     | 1172     | 800      | 657      | 572      |
| Asthma Adults | Sacramento | S75         | 2015 | 15                         | 1058  | 429      | 343      | 200      | 143      | 86       |
| Asthma Adults | Sacramento | S75         | 2015 | 20                         | 400   | 143      | 86       | 86       | 57       | 29       |
| Asthma Adults | Sacramento | S75         | 2016 | 10                         | 3602  | 1744     | 1258     | 943      | 657      | 457      |
| Asthma Adults | Sacramento | S75         | 2016 | 15                         | 1229  | 600      | 372      | 372      | 257      | 114      |
| Asthma Adults | Sacramento | S75         | 2016 | 20                         | 457   | 229      | 143      | 114      | 86       | 57       |
| Asthma Adults | Sacramento | S75         | 2017 | 10                         | 3430  | 1544     | 972      | 657      | 486      | 400      |
| Asthma Adults | Sacramento | S75         | 2017 | 15                         | 943   | 400      | 314      | 200      | 114      | 86       |
| Asthma Adults | Sacramento | S75         | 2017 | 20                         | 314   | 200      | 86       | 86       | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2015 | 10                         | 3684  | 1466     | 894      | 537      | 322      | 322      |
| Asthma Adults | St. Louis  | S65         | 2015 | 15                         | 894   | 250      | 107      | 72       | 36       | 0        |
| Asthma Adults | St. Louis  | S65         | 2015 | 20                         | 179   | 36       | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S65         | 2016 | 10                         | 4185  | 1931     | 1073     | 715      | 572      | 429      |
| Asthma Adults | St. Louis  | S65         | 2016 | 15                         | 1145  | 501      | 358      | 215      | 143      | 143      |
| Asthma Adults | St. Louis  | S65         | 2016 | 20                         | 537   | 179      | 107      | 72       | 36       | 0        |
| Asthma Adults | St. Louis  | S65         | 2017 | 10                         | 4435  | 1896     | 1252     | 751      | 537      | 322      |
| Asthma Adults | St. Louis  | S65         | 2017 | 15                         | 1001  | 429      | 286      | 143      | 36       | 36       |
| Asthma Adults | St. Louis  | S65         | 2017 | 20                         | 358   | 72       | 0        | 0        | 0        | 0        |
| Asthma Adults | St. Louis  | S70         | 2015 | 10                         | 4435  | 1860     | 1145     | 751      | 537      | 465      |
| Asthma Adults | St. Louis  | S70         | 2015 | 15                         | 1288  | 501      | 215      | 107      | 72       | 36       |
| Asthma Adults | St. Louis  | S70         | 2015 | 20                         | 322   | 72       | 36       | 36       | 36       | 0        |
| Asthma Adults | St. Louis  | S70         | 2016 | 10                         | 5687  | 2611     | 1574     | 1073     | 787      | 608      |
| Asthma Adults | St. Louis  | S70         | 2016 | 15                         | 1610  | 787      | 429      | 250      | 143      | 143      |
| Asthma Adults | St. Louis  | S70         | 2016 | 20                         | 715   | 286      | 215      | 143      | 107      | 36       |
| Asthma Adults | St. Louis  | S70         | 2017 | 10                         | 5651  | 2468     | 1610     | 1109     | 787      | 608      |
| Asthma Adults | St. Louis  | S70         | 2017 | 15                         | 1610  | 608      | 358      | 215      | 107      | 72       |
| Asthma Adults | St. Louis  | S70         | 2017 | 20                         | 608   | 179      | 107      | 36       | 0        | 0        |

| Study Group   | Study Area | AQ Scenario | Year | FEV <sub>1</sub><br>(percent) | Number of People at or above FEV <sub>1</sub> Decrement |          |          |          |          |          |
|---------------|------------|-------------|------|-------------------------------|---|----------|----------|----------|----------|----------|
|               |            |             |      |                               | ≥ 1 Day   | ≥ 2 Days | ≥ 3 Days | ≥ 4 Days | ≥ 5 Days | ≥ 6 Days |
| Asthma Adults | St. Louis  | S75         | 2015 | 10                            | 5079  | 2253     | 1431     | 858      | 680      | 537      |
| Asthma Adults | St. Louis  | S75         | 2015 | 15                            | 1717  | 608      | 322      | 179      | 107      | 72       |
| Asthma Adults | St. Louis  | S75         | 2015 | 20                            | 465   | 143      | 36       | 36       | 36       | 0        |
| Asthma Adults | St. Louis  | S75         | 2016 | 10                            | 6545  | 3219     | 2039     | 1395     | 1073     | 787      |
| Asthma Adults | St. Louis  | S75         | 2016 | 15                            | 1967  | 1001     | 465      | 286      | 215      | 143      |
| Asthma Adults | St. Louis  | S75         | 2016 | 20                            | 1001  | 358      | 250      | 215      | 143      | 72       |
| Asthma Adults | St. Louis  | S75         | 2017 | 10                            | 6724  | 2933     | 1931     | 1109     | 1073     | 823      |
| Asthma Adults | St. Louis  | S75         | 2017 | 15                            | 2146  | 823      | 465      | 215      | 179      | 107      |
| Asthma Adults | St. Louis  | S75         | 2017 | 20                            | 823   | 250      | 179      | 72       | 36       | 36       |

## APPENDIX 4A

### EXPOSURE-RESPONSE FUNCTIONS FOR 11 TREE SPECIES AND TEN CROPS

#### TABLE OF CONTENTS

|            |  |    |
|------------|--|----|
| 4A.1       | Background .....   | 2  |
| 4A.1.1     | Tree Species Seedling E-R Functions .....  | 3  |
| 4A.1.2     | Crop Species E-R Functions .....   | 10 |
| 4A.1.3     | Summary Tables for Tree Species and Crops .....  | 11 |
| 4A.2       | Tree Seedling RBL Studies.....   | 16 |
| 4A.3       | Analysis of RBL across Multiple Years .....  | 22 |
| 4A.3.1     | Comparison of Predicted and Observed O <sub>3</sub> Growth Impacts in the 2013 and 2020<br>ISAs .....        | 22 |
| 4A.3.2     | Example Calculations Comparing Estimated Impacts of Constant and Annually<br>Varying Seasonal Exposure ..... | 23 |
| References | .....  | 30 |

#### Attachment

Derivation of Composite Median Equations (parameterized models) in Lee and Hogsett (1996)

## 4A.1 BACKGROUND

Air quality criteria documents (AQCDs) for prior ozone (O<sub>3</sub>) reviews have presented exposure-response functions derived in the 1980s through mid-1990s from the results of a series of studies on the growth effects of a range of seasonal O<sub>3</sub> exposure levels. These studies included research conducted by the National Crop Loss Assessment Network (NCLAN) on commercial crop species and by the EPA's National Health and Environmental Effects Laboratory Western Ecology Division (NHEERL/WED) on seedlings of 11 tree species<sup>1</sup>. These studies also included documentation of hourly concentrations across the full exposures, and multiple exposure scenarios per experiment, which has resulted in their being the focus of work to characterize exposure-response (E-R) relationships for growth impacts on crops and tree species.

The experimental study results were analyzed to define a quantitative model that would well describe the E-R relationships of seasonal O<sub>3</sub> exposure and first impaired tree seedling growth and crop yield.<sup>2</sup> Those studies, which used several different metrics to quantify exposure (e.g., SUM06, W126), concluded that for the use of a single metric, such as W126 index, a three-parameter Weibull model form provides the most appropriate model for the response of absolute yield and growth to O<sub>3</sub> exposure because of the interpretability of its parameters, its flexibility (given the small number of parameters), and its tractability for estimation (2013 ISA, section 9.6.2). This three-parameter Weibull model is presented in equation 4A-1.

$$Y = \alpha e^{-\left(\frac{W126}{\eta}\right)^{\beta}}$$

Equation 4A-1

where:

Y = total yield or biomass;

W126 = O<sub>3</sub> exposure (e.g., 3-month sum of daily cumulative W126 from 8am to 8pm);

and,

η and β are species-specific variables

With removal of the intercept term, α, the model estimates relative yield or biomass without any further reparameterization. In order to compare E-R functions and associated estimates across species, genotypes, or experiments (of same species/genotype) for which

---

<sup>1</sup> These programs and the research conducted under them is described in detail in the 1996 AQCD (sections 5.5 and 5.6), summarized in the 2006 AQCD (section 9.5), 2013 ISA (section 9.6), and the 2020 ISA (Appendix 8, section 8.13).

<sup>2</sup> Examples of these analyses include Lee et al. (1994), Gumpertz and Rawlings (1992), Heck et al. (1984), Hogsett et al. (1997), Lee and Hogsett (1999), Lee et al. (1987), Lee et al. (1988), Lee et al. (1989), Lesser et al. (1990), Rawlings and Cure (1985).



absolute values of the response may vary greatly, the model is reformulated in terms of relative annual yield (or biomass) or relative yield (or biomass) loss (yield loss= [1-relative yield]). The resultant 2-parameter model of relative yield was presented in the 1996 and 2006 AQCDs and 2013 and 2020 ISA as basis for deriving common models for multiple species, multiple genotypes within species and multiple experimental locations (2013 ISA, section 9.6.2; 2020 ISA, Appendix 8, section 8.13.2). The models presented in the AQCDs were in terms of SUM06 over a 3-month season; those models were updated for 12-hour W126 over a 3-month season in the 2013 ISA (2013 ISA, section 9.6.2). The 2-parameter model structure, for relative biomass loss (RBL) or relative yield loss (RYL) as a function of W126 is described in equation 4A-2.

$$RBL = 1 - \exp[-(W126/\eta)\beta] \quad \text{Equation 4A-2}$$

Based on this model structure, functions for estimating RBL from seasonal W126 index, parameterized for each of eleven tree species, are presented and discussed in section 4A.1.1 below, and RYL functions for the 10 crop species are presented in section 4A.1.2.

#### 4A.1.1 Tree Species Seedling E-R Functions


The RBL functions for each of 11 common tree species were derived as median composite functions from response estimates based on functions derived for each study or experiment for which data were collected for that species (Lee and Hogsett, 1996, Tables 12 and 13). The eleven species-specific (composite median) functions, based on Lee and Hogsett (1996),<sup>3</sup> are presented in Table 4A-1.

**Table 4A-1. RBL functions for tree species.**

| Species   | RBL Function                   | $\eta$ (ppm) | $\beta$ |
|---|--------------------------------|--------------|---------|
| Red Maple ( <i>Acer rubrum</i> )  | $1 - \exp[-(W126/\eta)^\beta]$ | 318.12       | 1.3756  |
| Sugar Maple ( <i>Acer saccharum</i> )   |                                | 36.35        | 5.7785  |
| Red Alder ( <i>Alnus rubra</i> )  |                                | 179.06       | 1.2377  |
| Tulip Poplar ( <i>Liriodendron tulipifera</i> )   |                                | 51.38        | 2.0889  |
| Ponderosa Pine ( <i>Pinus ponderosa</i> )   |                                | 159.63       | 1.1900  |
| Eastern White Pine ( <i>Pinus strobus</i> )   |                                | 63.23        | 1.6582  |
| Loblolly Pine ( <i>Pinus taeda</i> )  |                                | 1,021.63     | 0.9954  |
| Virginia Pine ( <i>Pinus virginiana</i> )   |                                | 1,714.64     | 1.0000  |
| Quaking Aspen ( <i>Populus tremuloides</i> ), wild  |                                | 109.81       | 1.2198  |
| Black Cherry ( <i>Prunus serotina</i> )   |                                | 38.92        | 0.9921  |
| Douglas Fir ( <i>Pseudotsuga menziesii</i> )  |                                | 106.83       | 5.9631  |
| Source: These functions are those presented in Lee and Hogsett (1996), Table 13 or, for loblolly pine, as presented in Table 8-24 of Appendix 8 of the ISA. |                                |              |         |

<sup>3</sup> The functions presented in Table 4A-1 reflect the median composite response functions presented in Table 13 of Lee and Hogsett (1996), with the addition of the response curve for loblolly pine from Table 8-24 of Appendix 8 of the 2020 ISA. The process for deriving the composite functions is described in Lee and Hogsett (1996).


Figure 4A-1 presents species-specific E-R functions for the tree seedlings. The figures illustrate how the values of the two parameters affect the shape of the resulting curves. The value of  $\eta$  in the RBL function affects the point of the curve where the slope appreciably changes, and  $\beta$  affects the steepness of the curve. The response functions with smaller values of  $\beta$  (e.g., Virginia Pine) or with  $\eta$  values that are above the range shown for of W126 index values (e.g., functions for ponderosa pine and red alder) exhibit smaller slopes that have less change across this W126 range. These functions describe a more constant rate of change in RBL over the range of  $O_3$  exposure shown (e.g., up to 30 ppm-hrs). In contrast, the response functions with larger  $\beta$  values (e.g., the function for Sugar Maple) exhibit a threshold-like behavior, with large changes in RBL over a small range of W126 index values and relatively small changes at other index values. In these cases, the “threshold” is determined by the  $\eta$  parameter of the model.



**Figure 4A-1. RBL functions for seedlings of 11 tree species.**


1 The shape of curves presented in Figure 4A-1 also illustrate how sensitive the RBL value  
2 is to changes in O<sub>3</sub>. Two species, Loblolly Pine (dark grey line) and Virginia Pine (yellow line)  
3 have E-R functions that approach linearity within the W126 range represented on the x-axis,  
4 meaning that any 1 percent change in W126 produces the same change in RBL. Black Cherry  
5 (blue line) has an E-R function that exhibits a declining slope with increasing W126 (each  
6 successive equal change in W126 produces a smaller change in RBL), with the appearance of  
7 leveling off (Figure 4A-1). The functions for the remaining species appear to be somewhat  
8 linear, e.g., each 1% change in W126 across the W126 range produces an identical (or somewhat  
9 similar) percent change in RBL.

10 As mentioned above, the species-specific functions were derived from median estimates  
11 based on the functions from the individual experiments for each species. Figure 4A-2 through  
12 Figure 4A-12 present the species-specific functions along with the functions derived from the  
13 experiments available for that species.<sup>4</sup> These figures provide a sense of the across-experiment  
14 variability for each species, where such information is available.




16  
17 **Figure 4A-2. RBL functions for Red Maple (*Acer rubrum*).**


18  
<sup>4</sup> For aspen, the dark (red) line shown in Figure 4A-1 is the median composite for wild (vs clonal genotype) studies.




1  
2 **Figure 4A-3. RBL functions for Sugar Maple (*Acer saccharum*).**




3  
4 **Figure 4A-4. RBL functions for Red Alder (*Alnus rubra*).**




5  
6 **Figure 4A-5. RBL functions for Tulip Poplar (*Liriodendron tulipifera*).**




**Figure 4A-6. RBL functions for Ponderosa Pine (*Pinus ponderosa*).**




**Figure 4A-7. RBL functions for White Pine (*Pinus strobus*).**




**Figure 4A-8. RBL functions for Loblolly Pine (*Pinus taeda*).**




**Figure 4A-9. RBL functions for Virginia Pine (*Pinus virginiana*).**



**Figure 4A-10. RBL functions for Aspen (*Populus tremuloides*). Red lines = wild, black=clone.**



**Figure 4A-11. RBL functions for Black Cherry (*Prunus serotina*).**




**Figure 4A-12. RBL functions for Douglas Fir (*Pseudotsuga menziesii*).**

In the 2015 review, consideration of the E-R functions for the seedlings of 11 tree species focused on the median estimate across the 11 species-specific functions. Recognizing the extent to which experimental variation contributes to uncertainty in the species-specific E-R functions, a stochastic analysis was performed in the quantitative exposure/risk assessment for the 2015 review as an approach to investigating the impact of uncertainty and variability in the E-R function dataset; an update of this analysis is presented in Figure 4A-13. This figure illustrates different approaches to estimating a median E-R function from the functions from the individual experiments. In this figure, each grey curve is the median across 11 species-specific functions where the species-specific functions are represented by a random draw from the experiment-specific functions available for each species.<sup>5</sup> The red points are the median across the random draws at that W126 value and the whiskers extend to the 75<sup>th</sup> and 25<sup>th</sup> percentiles of those draws. For reference, the green line is the median across the 11 species-specific functions, and the red line is the median across the 51 experiments (regardless of species).<sup>6</sup>

<sup>5</sup> For example, there are seven separate experiment-specific E-R functions for ponderosa pine (Lee and Hogsett, 1996). In each iteration, one of the seven is drawn. This is performed for all eleven species. Each iteration of these random draws is represented by a single grey line that plots the median of the 11 RBLs derived from the 11 functions for each W126 index level across the range of W126 presented in the figure. At different parts of the W126 range, different species' E-R functions will produce the median estimate. As a result, the grey line for each iteration of the random draws has an area of rapid change over a particular range of W126 levels (when the E-R function producing the median estimate switches to a different species) and then a smoothing (as the median estimates are being produced by the same E-R function). That is, since there are 11 species (i.e., an odd number), each point on each grey line in the figure comes from the curve for the species' function that predicts the 6th highest (or lowest) RBL for that W126 index value.

<sup>6</sup> Both the green and red lines include two step-like changes along the W126 index range from 8 to 26 ppm-hrs. These steps reflect the influence on the median of the functions of species with inflection points that differ from the others (that can be seen in Figure 4A-1). For example, on the green curve (for the median across the species-specific functions), from a W126 index of approximately 8 ppm-hrs to 23 ppm-hrs, the curve largely follows the response function for red alder (which is somewhat centrally located among the functions over that W126 range).



**Figure 4A-13. Stochastic analyses of median E-R function across 11 species.**

#### 4A.1.2 Crop Species E-R Functions

The RYL functions for the 10 crop species are presented in Table 4A-2, and Figure 4A-14 presents the functions graphically.


**Table 4A-2. RYL functions for crop species**

| Species   | RYL Function                   | $\eta$ (ppm) | $\beta$ |
|---|--------------------------------|--------------|---------|
| Barley  | $1 - \exp[-(W126/\eta)^\beta]$ | 6,998.5      | 1.388   |
| Field Corn  |                                | 97.9         | 2.968   |
| Cotton  |                                | 96.1         | 1.482   |
| Kidney Bean   |                                | 43.1         | 2.219   |
| Lettuce   |                                | 54.6         | 4.917   |
| Peanut  |                                | 96.8         | 1.890   |
| Potato  |                                | 99.5         | 1.242   |
| Grain Sorghum   |                                | 205.3        | 1.957   |
| Soybean   |                                | 110.2        | 1.359   |
| Winter Wheat  |                                | 53.4         | 2.367   |
| Source: These functions are derived from those presented in Lee and Hogsett (1996). |                                |              |         |

in Figure 4A-1). The step between 23 and 24 ppm-hrs is driven by the rapid changes of the response-function for sugar maple and above that level of W126, the response-function for ponderosa pine is central and represented by the median.



1



2

3 **Figure 4A-14. RYL functions for crop species.**

4

5 **4A.1.3 Summary Tables for Tree Species and Crops**

6 Table 4A-3 and Table 4A-4 below provide estimates of the relative loss for tree biomass  
7 and crop yield, respectively, at various W126 index values using the composite E-R functions for  
8 each species for each integer W126 index value between 7 ppm-hrs and 30 ppm-hrs. The cross-  
9 species median of the species-specific composite functions is calculated for all 11 tree species.  
10 These tables also provide estimates of the number of species for trees and crops respectively that  
11 would be below various reference values (e.g., 2% RBL for trees) at various W126 index values.  
12 Table 4A-5 summarizes the median values for each integer W126 index value between 7 ppm-  
13 hrs and 23 ppm-hrs.

14

1 **Table 4A-3. Relative biomass loss for eleven individual tree seedlings and median at various W126 index values.**

| W126 | Douglas Fir | Loblolly | Virginia Pine | Red maple | Sugar maple | Red Alder | Ponderosa Pine | Aspen | Tulip Poplar | Eastern White Pine | Black Cherry | Median (11 species) | Number of Species ≤ 2% | Number of Species ≤ 5% | Number of Species ≤ 10% | Number of Species ≤ 15% |
|------|-------------|----------|---------------|-----------|-------------|-----------|----------------|-------|--------------|--------------------|--------------|---------------------|------------------------|------------------------|-------------------------|-------------------------|
| 30   | 0.1%        | 0.8%     | 1.7%          | 3.8%      | 28.1%       | 10.4%     | 12.8%          | 18.6% | 27.7%        | 25.2%              | 53.8%        | 12.8%               | 3                      | 4                      | 4                       | 6                       |
| 29   | 0.0%        | 0.7%     | 1.7%          | 3.6%      | 23.7%       | 10.0%     | 12.3%          | 17.9% | 26.1%        | 24.0%              | 52.6%        | 12.3%               | 3                      | 4                      | 5                       | 6                       |
| 28   | 0.0%        | 0.7%     | 1.6%          | 3.5%      | 19.9%       | 9.6%      | 11.8%          | 17.2% | 24.5%        | 22.8%              | 51.4%        | 11.8%               | 3                      | 4                      | 5                       | 6                       |
| 27   | 0.0%        | 0.7%     | 1.6%          | 3.3%      | 16.4%       | 9.2%      | 11.4%          | 16.5% | 23.0%        | 21.6%              | 50.1%        | 11.4%               | 3                      | 4                      | 5                       | 6                       |
| 26   | 0.0%        | 0.7%     | 1.5%          | 3.1%      | 13.4%       | 8.8%      | 10.9%          | 15.8% | 21.4%        | 20.5%              | 48.8%        | 10.9%               | 3                      | 4                      | 5                       | 7                       |
| 25   | 0.0%        | 0.6%     | 1.4%          | 3.0%      | 10.9%       | 8.4%      | 10.4%          | 15.2% | 19.9%        | 19.3%              | 47.5%        | 10.4%               | 3                      | 4                      | 5                       | 7                       |
| 24   | 0.0%        | 0.6%     | 1.4%          | 2.8%      | 8.7%        | 8.0%      | 10.0%          | 14.5% | 18.4%        | 18.2%              | 46.2%        | 8.7%                | 3                      | 4                      | 7                       | 8                       |
| 23   | 0.0%        | 0.6%     | 1.3%          | 2.7%      | 6.9%        | 7.6%      | 9.5%           | 13.8% | 17.0%        | 17.1%              | 44.8%        | 7.6%                | 3                      | 4                      | 7                       | 8                       |
| 22   | 0.0%        | 0.6%     | 1.3%          | 2.5%      | 5.3%        | 7.2%      | 9.0%           | 13.1% | 15.6%        | 15.9%              | 43.3%        | 7.2%                | 3                      | 4                      | 7                       | 8                       |
| 21   | 0.0%        | 0.5%     | 1.2%          | 2.4%      | 4.1%        | 6.8%      | 8.6%           | 12.4% | 14.3%        | 14.9%              | 41.9%        | 6.8%                | 3                      | 5                      | 7                       | 10                      |
| 20   | 0.0%        | 0.5%     | 1.2%          | 2.2%      | 3.1%        | 6.4%      | 8.1%           | 11.8% | 13.0%        | 13.8%              | 40.3%        | 6.4%                | 3                      | 5                      | 7                       | 10                      |
| 19   | 0.0%        | 0.5%     | 1.1%          | 2.1%      | 2.3%        | 6.0%      | 7.6%           | 11.1% | 11.8%        | 12.7%              | 38.8%        | 6.0%                | 3                      | 5                      | 7                       | 10                      |
| 18   | 0.0%        | 0.5%     | 1.0%          | 1.9%      | 1.7%        | 5.7%      | 7.2%           | 10.4% | 10.6%        | 11.7%              | 37.2%        | 5.7%                | 5                      | 5                      | 7                       | 10                      |
| 17   | 0.0%        | 0.4%     | 1.0%          | 1.8%      | 1.2%        | 5.3%      | 6.7%           | 9.8%  | 9.4%         | 10.7%              | 35.6%        | 5.3%                | 5                      | 5                      | 9                       | 10                      |
| 16   | 0.0%        | 0.4%     | 0.9%          | 1.6%      | 0.9%        | 4.9%      | 6.3%           | 9.1%  | 8.4%         | 9.7%               | 33.9%        | 4.9%                | 5                      | 6                      | 10                      | 10                      |
| 15   | 0.0%        | 0.4%     | 0.9%          | 1.5%      | 0.6%        | 4.5%      | 5.8%           | 8.4%  | 7.4%         | 8.8%               | 32.2%        | 4.5%                | 5                      | 6                      | 10                      | 10                      |
| 14   | 0.0%        | 0.4%     | 0.8%          | 1.4%      | 0.4%        | 4.2%      | 5.4%           | 7.8%  | 6.4%         | 7.9%               | 30.4%        | 4.2%                | 5                      | 6                      | 10                      | 10                      |
| 13   | 0.0%        | 0.3%     | 0.8%          | 1.2%      | 0.3%        | 3.8%      | 4.9%           | 7.1%  | 5.5%         | 7.0%               | 28.6%        | 3.8%                | 5                      | 7                      | 10                      | 10                      |
| 12   | 0.0%        | 0.3%     | 0.7%          | 1.1%      | 0.2%        | 3.5%      | 4.5%           | 6.5%  | 4.7%         | 6.2%               | 26.7%        | 3.5%                | 5                      | 8                      | 10                      | 10                      |
| 11   | 0.0%        | 0.3%     | 0.6%          | 1.0%      | 0.1%        | 3.1%      | 4.1%           | 5.9%  | 3.9%         | 5.4%               | 24.8%        | 3.1%                | 5                      | 8                      | 10                      | 10                      |
| 10   | 0.0%        | 0.3%     | 0.6%          | 0.9%      | 0.1%        | 2.8%      | 3.6%           | 5.2%  | 3.2%         | 4.6%               | 22.9%        | 2.8%                | 5                      | 9                      | 10                      | 10                      |
| 9    | 0.0%        | 0.2%     | 0.5%          | 0.7%      | 0.0%        | 2.4%      | 3.2%           | 4.6%  | 2.6%         | 3.9%               | 20.9%        | 2.4%                | 5                      | 10                     | 10                      | 10                      |
| 8    | 0.0%        | 0.2%     | 0.5%          | 0.6%      | 0.0%        | 2.1%      | 2.8%           | 4.0%  | 2.0%         | 3.2%               | 18.8%        | 2.0%                | 5                      | 10                     | 10                      | 10                      |
| 7    | 0.0%        | 0.2%     | 0.4%          | 0.5%      | 0.0%        | 1.8%      | 2.4%           | 3.4%  | 1.5%         | 2.6%               | 16.7%        | 1.5%                | 7                      | 10                     | 10                      | 10                      |

2  
3

1 **Table 4A-4. Relative yield loss for ten individual crop species and median at various W126 index values.**

| W126 | Barley | Lettuce | Field<br>Corn | Grain<br>Sorghum | Peanut | Cotton | Soybean | Winter<br>Wheat | Potato | Kidney<br>Bean | Median<br>(10<br>species) | Number<br>of<br>Species<br>≤ 5% | Number<br>of<br>Species<br>≤ 10% | Number<br>of<br>Species<br>≤ 20% | Number<br>of Species<br>> 5% and<br>≤ 10% | Number<br>of Species<br>> 10%<br>and ≤<br>20% |
|------|--------|---------|---------------|------------------|--------|--------|---------|-----------------|--------|----------------|---------------------------|---------------------------------|----------------------------------|----------------------------------|---|---|
| 30   | 0.1%   | 5.1%    | 2.9%          | 2.3%             | 10.4%  | 16.3%  | 15.7%   | 22.5%           | 20.2%  | 36.1%          | 13.0%                     | 3                               | 4                                | 7                                | 1   | 3   |
| 29   | 0.0%   | 4.4%    | 2.7%          | 2.1%             | 9.7%   | 15.6%  | 15.0%   | 21.0%           | 19.4%  | 34.0%          | 12.4%                     | 4                               | 5                                | 8                                | 1   | 3   |
| 28   | 0.0%   | 3.7%    | 2.4%          | 2.0%             | 9.1%   | 14.9%  | 14.4%   | 19.5%           | 18.7%  | 31.9%          | 11.8%                     | 4                               | 5                                | 9                                | 1   | 4   |
| 27   | 0.0%   | 3.1%    | 2.2%          | 1.9%             | 8.6%   | 14.1%  | 13.7%   | 18.0%           | 18.0%  | 29.8%          | 11.2%                     | 4                               | 5                                | 9                                | 1   | 4   |
| 26   | 0.0%   | 2.6%    | 1.9%          | 1.7%             | 8.0%   | 13.4%  | 13.1%   | 16.6%           | 17.2%  | 27.8%          | 10.6%                     | 4                               | 5                                | 9                                | 1   | 4   |
| 25   | 0.0%   | 2.1%    | 1.7%          | 1.6%             | 7.4%   | 12.7%  | 12.5%   | 15.3%           | 16.5%  | 25.8%          | 10.0%                     | 4                               | 5                                | 9                                | 1   | 4   |
| 24   | 0.0%   | 1.7%    | 1.5%          | 1.5%             | 6.9%   | 12.0%  | 11.8%   | 14.0%           | 15.7%  | 23.9%          | 9.4%                      | 4                               | 5                                | 9                                | 1   | 4   |
| 23   | 0.0%   | 1.4%    | 1.3%          | 1.4%             | 6.4%   | 11.3%  | 11.2%   | 12.7%           | 15.0%  | 22.0%          | 8.8%                      | 4                               | 5                                | 9                                | 1   | 4   |
| 22   | 0.0%   | 1.1%    | 1.2%          | 1.3%             | 5.9%   | 10.6%  | 10.6%   | 11.5%           | 14.2%  | 20.1%          | 8.2%                      | 4                               | 5                                | 9                                | 1   | 4   |
| 21   | 0.0%   | 0.9%    | 1.0%          | 1.1%             | 5.4%   | 10.0%  | 10.0%   | 10.4%           | 13.5%  | 18.4%          | 7.7%                      | 4                               | 7                                | 10                               | 3   | 3   |
| 20   | 0.0%   | 0.7%    | 0.9%          | 1.0%             | 5.0%   | 9.3%   | 9.4%    | 9.3%            | 12.7%  | 16.6%          | 7.1%                      | 5                               | 8                                | 10                               | 3   | 2   |
| 19   | 0.0%   | 0.6%    | 0.8%          | 0.9%             | 4.5%   | 8.7%   | 8.8%    | 8.3%            | 12.0%  | 15.0%          | 6.4%                      | 5                               | 8                                | 10                               | 3   | 2   |
| 18   | 0.0%   | 0.4%    | 0.7%          | 0.8%             | 4.1%   | 8.0%   | 8.2%    | 7.3%            | 11.3%  | 13.4%          | 5.7%                      | 5                               | 8                                | 10                               | 3   | 2   |
| 17   | 0.0%   | 0.3%    | 0.6%          | 0.8%             | 3.7%   | 7.4%   | 7.6%    | 6.4%            | 10.5%  | 11.9%          | 5.1%                      | 5                               | 8                                | 10                               | 3   | 2   |
| 16   | 0.0%   | 0.2%    | 0.5%          | 0.7%             | 3.3%   | 6.8%   | 7.0%    | 5.6%            | 9.8%   | 10.5%          | 4.4%                      | 5                               | 9                                | 10                               | 4   | 1   |
| 15   | 0.0%   | 0.2%    | 0.4%          | 0.6%             | 2.9%   | 6.2%   | 6.4%    | 4.8%            | 9.1%   | 9.2%           | 3.9%                      | 6                               | 10                               | 10                               | 4   | 0   |
| 14   | 0.0%   | 0.1%    | 0.3%          | 0.5%             | 2.6%   | 5.6%   | 5.9%    | 4.1%            | 8.4%   | 7.9%           | 3.3%                      | 6                               | 10                               | 10                               | 4   | 0   |
| 13   | 0.0%   | 0.1%    | 0.2%          | 0.5%             | 2.2%   | 5.0%   | 5.3%    | 3.5%            | 7.7%   | 6.8%           | 2.8%                      | 6                               | 10                               | 10                               | 4   | 0   |
| 12   | 0.0%   | 0.1%    | 0.2%          | 0.4%             | 1.9%   | 4.5%   | 4.8%    | 2.9%            | 7.0%   | 5.7%           | 2.4%                      | 8                               | 10                               | 10                               | 2   | 0   |
| 11   | 0.0%   | 0.0%    | 0.2%          | 0.3%             | 1.6%   | 3.9%   | 4.3%    | 2.3%            | 6.3%   | 4.7%           | 2.0%                      | 9                               | 10                               | 10                               | 1   | 0   |
| 10   | 0.0%   | 0.0%    | 0.1%          | 0.3%             | 1.4%   | 3.4%   | 3.8%    | 1.9%            | 5.6%   | 3.8%           | 1.6%                      | 9                               | 10                               | 10                               | 1   | 0   |
| 9    | 0.0%   | 0.0%    | 0.1%          | 0.2%             | 1.1%   | 2.9%   | 3.3%    | 1.5%            | 4.9%   | 3.0%           | 1.3%                      | 10                              | 10                               | 10                               | 0   | 0   |
| 8    | 0.0%   | 0.0%    | 0.1%          | 0.2%             | 0.9%   | 2.5%   | 2.8%    | 1.1%            | 4.3%   | 2.4%           | 1.0%                      | 10                              | 10                               | 10                               | 0   | 0   |
| 7    | 0.0%   | 0.0%    | 0.0%          | 0.1%             | 0.7%   | 2.0%   | 2.3%    | 0.8%            | 3.6%   | 1.8%           | 0.8%                      | 10                              | 10                               | 10                               | 0   | 0   |

2  
3

1 **Table 4A-5. Tree seedling RBL and CYL estimated for seasonal W126 O<sub>3</sub> exposure.**

| W126 index value for exposure period | Tree seedling biomass loss <sup>A</sup>  |  | Crop yield loss <sup>C</sup>                  |  |
|--------------------------------------|--|--|---|--|
|                                      | Median Value <sup>B</sup>                | Individual Species   | Median Value <sup>D</sup>                     | Individual Species   |
| 23 ppm-hrs                           | Median species w. 7.6% loss <sup>B</sup> | $\leq$ 2% loss: 3/11 species<br>$\leq$ 5% loss: 4/11 species<br>$\leq$ 10% loss: 8/11 species<br>$\leq$ 15% loss: 10/11 species<br>>40% loss: 1/11 species | Median species w. 8.8 % loss <sup>D</sup>     | $\leq$ 5% loss: 4/10 species<br>>5,<10% loss: 1/10 species<br>>10,<20% loss: 4/10 species<br>>20: 1/10 species |
| 22 ppm-hrs                           | Median species w. 7.2% loss <sup>B</sup> | $\leq$ 2% loss: 3/11 species<br>$\leq$ 5% loss: 4/11 species<br>$\leq$ 10% loss: 7/11 species<br>$\leq$ 15% loss: 10/11 species<br>>40% loss: 1/11 species | Median species w. 8.2 % loss <sup>D</sup>     | $\leq$ 5% loss: 4/10 species<br>>5,<10% loss: 1/10 species<br>>10,<20% loss: 4/10 species<br>>20: 1/10 species |
| 21 ppm-hrs                           | Median species w. 6.8% loss <sup>B</sup> | $\leq$ 2% loss: 3/11 species<br>$\leq$ 5% loss: 4/11 species<br>$\leq$ 10% loss: 7/11 species<br>$\leq$ 15% loss: 10/11 species<br>>40% loss: 1/11 species | Median species w. 7.7 % loss <sup>D</sup>     | $\leq$ 5% loss: 4/10 species<br>>5,<10% loss: 3/10 species<br>>10,<20% loss: 3/10 species                      |
| 20 ppm-hrs                           | Median species w. 6.4% loss <sup>B</sup> | $\leq$ 2% loss: 3/11 species<br>$\leq$ 5% loss: 5/11 species<br>$\leq$ 10% loss: 7/11 species<br>$\leq$ 15% loss: 10/11 species<br>>40% loss: 1/11 species | Median species w. 7.1 % loss <sup>D</sup>     | $\leq$ 5% loss: 5/10 species<br>>5,<10% loss: 3/10 species<br>>10,<20% loss: 2/10 species                      |
| 19 ppm-hrs                           | Median species w. 6.0% loss <sup>B</sup> | $\leq$ 2% loss: 3/11 species<br>$\leq$ 5% loss: 5/11 species<br>$\leq$ 10% loss: 7/11 species<br>$\leq$ 15% loss: 10/11 species<br>>30% loss: 1/11 species | Median species w. 6.4 % loss <sup>D</sup>     | $\leq$ 5% loss: 5/10 species<br>>5, <10% loss: 3/10 species<br>>10,<20% loss: 2/10 species                     |
| 18 ppm-hrs                           | Median species w. 5.7% loss <sup>B</sup> | $\leq$ 2% loss: 5/11 species<br>$\leq$ 5% loss: 5/11 species<br>$\leq$ 10% loss: 7/11 species<br>$\leq$ 15% loss: 10/11 species<br>>30% loss: 1/11 species | Median species w. 5.7 % loss <sup>D</sup>     | $\leq$ 5% loss: 5/10 species<br>>5,<10% loss: 3/10 species<br>>10,<20% loss: 2/10 species                      |
| 17 ppm-hrs                           | Median species w. 5.3% loss <sup>B</sup> | $\leq$ 2% loss: 5/11 species<br>$\leq$ 5% loss: 5/11 species<br>$\leq$ 10% loss: 9/11 species<br>$\leq$ 15% loss: 10/11 species<br>>30% loss: 1/11 species | Median species w. 5.1 % loss <sup>D</sup>     | $\leq$ 5% loss: 5/10 species<br>>5, <10% loss: 3/10 species<br>>10,<20% loss: 2/10 species                     |
| 16 ppm-hrs                           | Median species w. 4.9% loss <sup>B</sup> | $\leq$ 2% loss: 5/11 species<br>$\leq$ 5% loss: 6/11 species<br>$\leq$ 10% loss: 10/11 species<br>>30% loss: 1/11 species                                  | Median species w. $\leq$ 5% loss <sup>D</sup> | $\leq$ 5% loss: 5/10 species<br>>5,<10% loss: 4/10 species<br>>10,<20% loss: 1/10 species                      |

| W126 index value for exposure period  | Tree seedling biomass loss <sup>A</sup>  |  | Crop yield loss <sup>C</sup>             |  |
|---|--|--|--|--|
|   | Median Value <sup>B</sup>                | Individual Species   | Median Value <sup>D</sup>                | Individual Species                                     |
| 15 ppm-hrs  | Median species w. 4.5% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br>≤ 5% loss: 6/11 species<br>≤ 10% loss: 10/11 species<br>>30% loss: 1/11 species | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: 6/10 species<br>>5, <10% loss: 4/10 species |
| 14 ppm-hrs  | Median species w. 4.2% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br>≤ 5% loss: 6/11 species<br>≤ 10% loss: 10/11 species<br>>30% loss: 1/11 species | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: 6/10 species<br>>5, <10% loss: 4/10 species |
| 13 ppm-hrs  | Median species w. 3.8% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br><5% loss: 7/11 species<br><10% loss: 10/11 species<br>>20% loss: 1/11 species   | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: 6/10 species<br>>5, <10% loss: 4/10 species |
| 12 ppm-hrs  | Median species w. 3.5% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br>≤ 5% loss: 8/11 species<br>≤ 10% loss: 10/11 species<br>>20% loss: 1/11 species | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: 8/10 species<br>>5, <10% loss: 2/10 species |
| 11 ppm-hrs  | Median species w. 3.1% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br>≤ 5% loss: 8/11 species<br>≤ 10% loss: 10/11 species<br>>20% loss: 1/11 species | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: 9/10 species<br>>5, <10% loss: 1/10 species |
| 10 ppm-hrs  | Median species w. 2.8% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br>≤ 5% loss: 9/11 species<br><10% loss: 10/11 species<br>>20% loss: 1/11 species  | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: 9/10 species<br>>5, <10% loss: 1/10 species |
| 9 ppm-hrs   | Median species w. 2.4% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br>≤ 5% loss: 10/11 species<br>>20% loss: 1/11 species                             | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: all species                                 |
| 8 ppm-hrs   | Median species w. 2.0% loss <sup>B</sup> | ≤ 2% loss: 5/11 species<br>≤ 5% loss: 10/11 species<br>>15% loss: 1/11 species                             | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: all species                                 |
| 7 ppm-hrs   | Median species w. ≤ 2% loss <sup>B</sup> | ≤ 2% loss: 7/11 species<br>≤ 5% loss: 10/11 species<br>>15% loss: 1/11 species                             | Median species w. ≤ 5% loss <sup>D</sup> | ≤ 5% loss: all species                                 |
| <p>A Estimates here are based on the 11 E-R functions for tree seedlings described in section 4A.1.</p> <p>B This median value is the median of the composite E-R functions for 11 tree species in Table 4A-3.</p> <p>C Estimates here are based on the 10 E-R functions for crops described in section 4A.1.</p> <p>D This median value is the median of the composite E-R functions for 10 crops in Table 4A-4.</p> |  |  |  |  |

## 4A.2 TREE SEEDLING RBL STUDIES

The experimental cases on which the 11 species-specific E-R functions are based are listed in Table 4A-6 below. As summarized in section 4A.1.1 (and described more fully in Attachment 1 below), 51 E-R functions were derived, one for each of row in Table 4A-6 (e.g., Lee and Hogsett, 1996, Table 12 and 1996 AQCD, Table 5-28). As indicated by the rows in Table 4A-6, the cases are defined by the species, the exposure (e.g., year), and harvest time (e.g., immediately after exposure or the subsequent spring) of the dataset used to derive each of the 51 functions. Thus, the eleven species-specific functions for the eleven tree species are represented by the 51 cases. As described in section 4A.1 above, species-specific (composite) functions were derived for each species, and Table 4A-5 above presents median RBL estimates from the 11 species-specific functions.

The O<sub>3</sub> exposure studies represented by the 51 cases were conducted from 1988 to 1992 at the U.S. Environmental Protection Agency research laboratory in Corvallis, Oregon, Michigan Technological University's Ford Forestry Center in Alberta, Michigan and by researchers from Appalachian State University at Great Smoky Mountains National Park near Gatlinburg, Tennessee (Hogsett et al 1995; Hogsett et al., 1997; Neufeld et al 2000; Neufeld et al., 1995; Lefohn et al., 1991; Karnosky et al., 1996; Anderson et al., 1997). Similar experimental protocols were used to expose seedlings to O<sub>3</sub> in 3-meter diameter, 2.4-meter tall modified open-top chambers (Heagle et al., 1973). Experiments used a common standard operating procedure developed by the US EPA to ensure federal guidelines for data quality were met (Hogsett et al., 1985). For all studies at all sites, the experimental design was a single-factor nested experiment with a range of O<sub>3</sub> treatment levels including charcoal-filtered air (control), a baseline O<sub>3</sub> profile (1.0x ambient) and several modified O<sub>3</sub> profiles (e.g., 0.5x, 1.5x, 2.0x ambient air O<sub>3</sub>), with multiple replicate chambers for each treatment. For experiments described in Karnosky et al (1996), the "baseline ambient" is a modified profile intended to reflect 6-year averages of Pinkerton and Lefohn (1987).

Based on archived datasets at U.S. EPA U.S. EPA, Center for Public Health and Environmental Assessment, Pacific Ecological Systems Division, Corvallis, WA, for some of the exposures, O<sub>3</sub> treatments across the exposure periods of various dates and durations are given in Table 4A-6 in terms of W126, SUM06 and N100. Additionally, SUM06 exposures previously reported in Hogsett et al. (1995) are also presented as available.

1 **Table 4A-6. Individual tree seedling experimental cases for which E-R functions were derived in Lee and Hogsett (1996).**

2

| Study ID <sup>A</sup>  | Species      | Site | Year exp'd | Exposure Period (days) <sup>B</sup> | Exposure (derived from hourly O <sub>3</sub> concentrations over the identified exposure periods). Values are averages of replicates; N100 values are rounded to whole numbers. W126 and SUM06 are for 12-hr periods 8am-8pm. <sup>C</sup> |       |     |       |      |      |       |       | Harvest <sup>D</sup> | Study/Source and notes, with SUM06 (ppm-hr) <sup>E</sup> reported for full exposure period, e.g., per Hogsett et al 1997, Table 2 (which does not specify whether 12 or 24 hrs SUM06).  |   |
|--|--------------|------|------------|-------------------------------------|--|-------|-----|-------|------|------|-------|-------|----------------------|---|---|
| Rows specify individual experimental datasets (uniquely defined by 1 <sup>st</sup> four columns and harvest) for E-R functions in Lee & Hogsett, 1996 (e.g., Table 12), as described in Attachment 1 to this Appendix (and also presented in 1996 AQCD, Table 5-28). |              |      |            |                                     |  |       |     |       |      |      |       |       |                      |   |   |
| 1  | Aspen - wild | OR   | 1989       | 6/6-9/18 (105) <sup>F</sup>         | SUM06  | 0     |     | 0.7   | 76.6 | 62.9 | 103.9 | 104.4 | 1                    |   |   |
| 1  | Aspen - wild | OR   |            |                                     | :  | 0     |     | 6.8   | 48.5 | 56.0 | 92.3  | 97.9  | 2                    |   |   |
|  |              |      |            |                                     | W126:  | 0     |     | 0     | 5    | 228  | 82    | 472   |                      |   |   |
|  |              |      |            |                                     | N100:  |       |     |       |      |      |       |       |                      |   |   |
| 2  | Aspen - wild | OR   | 1991       | 6/5-9/11 (99) <sup>F</sup>          | SUM06  | 0     |     |       | 13.6 | 25.8 | 77.7  |       | 1                    |   |   |
| 2  | Aspen - wild | OR   |            |                                     | :  | 0     |     |       | 11   | 23.4 | 70.1  |       | 2                    |   |   |
|  |              |      |            |                                     | W126:  | 0     |     |       | 18   | 71   | 296   |       |                      |   |   |
|  |              |      |            |                                     | N100:  |       |     |       |      |      |       |       |                      |   |   |
| 3  | Aspen - wild | OR   | 1990       | 6/5-9/19 (107) <sup>F</sup>         | SUM06  | 0     |     |       | 15.1 | 62   | 86    |       | 1                    | Hogsett (unpublished) cited in Hogsett et al., 1997<br>Hogsett et al., 1995 , SUM06: 0.2, 16.1, 72.1, 102.8   |   |
| 3  | Aspen - wild | OR   |            |                                     | W126:  | 0     |     |       | 12.1 | 54.7 | 76.6  |       | 2                    |   |   |
|  |              |      |            |                                     | N100:  | 0     |     |       | 25   | 228  | 328   |       |                      |   |   |
| 4  | Aspen - 216  | MI   | 1990       | 6/20–9/10 (82)                      | SUM06  | 0     |     |       |      |      |       |       | 1                    | May be reported in Karnosky et al., 1996, where detailed description has similarities (all 4 genotypes, 5 exposures in 1990), but with dates as June 20 to Sept 16 in 1990 (which tally to ~88 days), vs recovered ORD dataset dates that match 82 days in Lee & Hogsett 1996 & 1996 AQCD. This experiment is not listed in the Hogsett 1995 & 1997 papers. Karnosky et al 1996 presents N100 of 0, 0, 4, 42, 79 (for 1990) and 0, 24, 38, 45, 84 (for 1991).   |   |
| 4  | Aspen 253    | MI   |            |                                     |  |       |     |       |      |      |       |       |                      |   | 1 |
| 4  | Aspen 259    | MI   |            |                                     |  |       |     |       |      |      |       |       |                      |   | 1 |
| 4  | Aspen - 271  | MI   |            |                                     |  |       |     | W126: | 0    | 6.8  | 7.3   | 8     | 26.1                 |   |   |
|  |              |      |            |                                     | W126:  | 0     | 5.7 | 6.5   | 7    | 22.5 |       |       |                      |   |   |
|  |              |      |            |                                     | N100:  | 0     | 1   | 7     | 6    | 60   |       |       |                      |   |   |
| 5  | Aspen – 216  | MI   | 1991       | 6/9-9/14 (98)                       | SUM06  | 0     |     |       |      |      |       |       | 1                    | Karnosky et al (1995, in press) cited in Hogsett et al., 1995 Hogsett et al., 1997 for 259, 271, WT, which reported SUM06: 0.0, 11.5, 24.5, 32.4, 40.3, 60.5. Published as Karnosky et al., 1996, who report exposure of clones 216, 259 and 271 (and also WT seedlings) June 9-Sept 14, 1991, via 5 exposures (0, 0.5x, 1x, 1.5x and 2x). The N100 reported for these exposures are: 0, 24, 38, 45, and 84. Across clone average had statistically significant total biomass loss at highest exposures (as did 216). |   |
| 5  | Aspen – 259  | MI   |            |                                     |  | W126: | 0   |       | 19.2 |      | 36.3  |       | 1                    |   |   |
| 5  | Aspen – 271  | MI   |            |                                     |  | N100: | 0   |       | 16.6 |      | 31.5  |       |                      |   |   |
|  |              |      |            |                                     |  |       | 43  |       | 86   |      |       |       |                      |   |   |

| Study ID <sup>A</sup>  | Species        | Site | Year exp'd | Exposure Period (days) <sup>B</sup>    | Exposure (derived from hourly O <sub>3</sub> concentrations over the identified exposure periods). Values are averages of replicates; N100 values are rounded to whole numbers. W126 and SUM06 are for 12-hr periods 8am-8pm. <sup>C</sup> |                   |                    |                    |                    |                    |                     |                     | Harvest <sup>D</sup> | Study/Source and notes, with SUM06 (ppm-hr) <sup>E</sup> reported for full exposure period, e.g., per Hogsett et al 1997, Table 2 (which does not specify whether 12 or 24 hrs SUM06).   |
|--|----------------|------|------------|--|--|-------------------|--------------------|--------------------|--------------------|--------------------|---------------------|---------------------|----------------------|--|
| Rows specify individual experimental datasets (uniquely defined by 1 <sup>st</sup> four columns and harvest) for E-R functions in Lee & Hogsett, 1996 (e.g., Table 12), as described in Attachment 1 to this Appendix (and also presented in 1996 AQCD, Table 5-28). |                |      |            |  |  |                   |                    |                    |                    |                    |                     |                     |                      |  |
| 6  | Aspen-wild     | MI   | 1991       | 6/9-9/14 (98)                          | SUM06<br>W126:<br>N100:  | 0<br>0<br>0       | 14.2<br>12.7<br>29 | 19.2<br>16.6<br>43 | 32.0<br>27.0<br>56 | 36.3<br>31.5<br>86 |                     |                     | 1                    | Karnosky et al (1995, in press) cited in Hogsett et al., 1995 Hogsett et al., 1997 for 259, 271, WT, which reported SUM06: 0.0, 11.5, 24.5, 32.4, 40.3, 60.5 Published as Karnosky et al., 1996, who report exposure of WT seedlings June 9-Sept 14, 1991, via 5 exposures (0, 0.5x, 1x, 1.5x and 2x). The N100 reported for these exposures are: 0, 24, 38, 45, and 84. |
| 7  | Douglas Fir    | OR   | 1989       | 6/7-9/27 (113)                         | SUM06  | 0.1               |                    |                    | 16.4               | 66.4               | 91.6                | 110.4               | 1                    |  |
| 7  | Douglas Fir    | OR   |            |  | W126:<br>N100:   | 0<br>0            |                    |                    | 13.3<br>25         | 59.2<br>241        | 82.8<br>351         | 103.4<br>491        | 2                    |  |
| 7  | Douglas Fir    | OR   | Plus 1990  | 6/5-10/3 (121)<br>2-yr total =234 days | SUM06  | 0.1               |                    |                    | 16.6               | 69.0               | 95.1                | 117.1               | 3                    | Hogsett (unpublished) cited in Hogsett et al., 1995 Hogsett et al., 1997, SUM06: 0.1, 33.4, 147.2, 207.2, 261.5 (for full 234 days)  |
| 7  | Douglas Fir    | OR   |            |  | W126:<br>N100:   | 0<br>0            |                    |                    | 13.5<br>25         | 61.5<br>253        | 85.8<br>355         | 109.5<br>515        | 4                    |  |
| 8  | Douglas Fir    | OR   | 1991       | 6/5-9/30 (118)                         | SUM06  | 0                 |                    |                    | 16.1               | 30.6               | 66.8                | 91.7                | 1                    |  |
| 8  | Douglas Fir    | OR   |            |  | W126:<br>N100:   | 0<br>0            |                    |                    | 13<br>24           | 27.7<br>84         | 59.8<br>244         | 82.6<br>384         | 2                    |  |
| 8  | Douglas Fir    | OR   | Plus 1992  | 6/2-9/21 (112)<br>2-yr total =230 days | SUM06<br>W126:<br>N100:  | 0.1<br>0.1<br>0.5 |                    |                    | 14.7<br>11.8<br>19 | 28.1<br>25.6<br>78 | 63.9<br>56.9<br>234 | 88.2<br>79.4<br>340 | 3                    | Hogsett (unpublished) cited in Hogsett et al., 1995 Hogsett et al., 1997, SUM06: 0.1, 30.4, 60.6, 143.0, 202.9 (for full 230 days)   |
| 9  | Ponderosa Pine | OR   | 1989       | 6/7-9/27 (111)                         | SUM06  | 0                 |                    |                    | 0.7                |                    | 83.2                | 113.0               | 1                    |  |
| 9  | Ponderosa Pine | OR   |            |  | W126:<br>N100:   | 0<br>0            |                    |                    | 7.3<br>0           |                    | 53.8<br>5           | 100.4<br>84         | 2                    |  |
| 10   | Ponderosa Pine | OR   | 1989       | 6/7-9/27 (113)                         | SUM06  | 0.1               |                    |                    | 16.4               | 66.4               | 91.6                | 110.4               | 1                    | May be described in Andersen et al., 1997 (although only 2 treatments plus control are reported): Seedlings exposed to O <sub>3</sub> for two growing seasons were statistically significant smaller than CF-exposed seedlings (SUM00 greater than 253). Total biomass reduced 58% at highest exposure.  |
| 10   | Ponderosa Pine | OR   |            |  | W126:<br>N100:   | 0<br>0            |                    |                    | 13.3<br>25         | 59.2<br>241        | 82.8<br>351         | 103.4<br>491        | 2                    |  |
| 10   | Ponderosa Pine | OR   | Plus 1990  | 6/5-10/3 (121)<br>2-yr total =234 days | SUM06  | 0.1               |                    |                    | 16.6               | 69.0               | 95.1                | 117.1               | 3                    |  |
| 10   | Ponderosa Pine | OR   |            |  | W126:<br>N100:   | 0<br>0            |                    |                    | 13.5<br>25         | 61.5<br>253        | 85.8<br>355         | 109.5<br>515        | 4                    |  |
| 11   | Ponderosa Pine | OR   | 1991       |  | SUM06  | 0                 |                    |                    | 16.1               | 30.6               | 66.8                | 91.7                | 1                    |  |



| Study ID <sup>A</sup>  | Species        | Site               | Year exp'd | Exposure Period (days) <sup>B</sup>    | Exposure (derived from hourly O <sub>3</sub> concentrations over the identified exposure periods). Values are averages of replicates; N100 values are rounded to whole numbers. W126 and SUM06 are for 12-hr periods 8am-8pm. <sup>C</sup> |           |           |           |              |               |               | Harvest <sup>D</sup> | Study/Source and notes, with SUM06 (ppm-hr) <sup>E</sup> reported for full exposure period, e.g., per Hogsett et al 1997, Table 2 (which does not specify whether 12 or 24 hrs SUM06). |  |   |
|--|----------------|--------------------|------------|--|--|-----------|-----------|-----------|--------------|---------------|---------------|----------------------|--|--|---|
| Rows specify individual experimental datasets (uniquely defined by 1 <sup>st</sup> four columns and harvest) for E-R functions in Lee & Hogsett, 1996 (e.g., Table 12), as described in Attachment 1 to this Appendix (and also presented in 1996 AQCD, Table 5-28). |                |                    |            |  |  |           |           |           |              |               |               |                      |  |  |   |
| 11   | Ponderosa Pine | OR                 |            | 6/5–9/30 (118)                         | W126: N100:  | 0 0       |           |           | 13.0 24      | 27.7 84       | 59.8 244      | 82.6 384             | 2  | Lee and Hogsett, 1999, who statistically significant biomass loss at the 2 highest exposures (12-hr W126 greater than 59)  |   |
| 11   | Ponderosa Pine | OR                 | Plus 1992  | 6/2–9/21 (112)<br>2-yr total =230 days | SUM06 W126: N100:  | 0.1 0.1 1 |           |           | 14.7 11.8 19 | 28.1 25.6 78  | 63.9 56.9 234 | 88.2 79.4 340        | 3  |  | Hogsett (unpublished) cited in Hogsett et al., 1995 Hogsett et al., 1997, 0.1, 30.4, 60.6, 143.0, 202.9 (for full 230 days) |
| 12   | Ponderosa Pine | OR                 | 1992       | 140                                    |  |           |           |           |              |               |               |                      | 1  |  |   |
| 13   | Ponderosa Pine | OR                 | 1991       | 84                                     |  |           |           |           |              |               |               |                      | 1  |  |   |
| 14   | Red Alder      | OR                 | 1990       | 6/5–10/3 (121)                         | SUM06 W126: N100:  | 0.1 0 0   |           |           | 16.5 13.5 25 | 69.0 61.5 253 | 95.1 85.8 355 | 117.1 109.5 515      | 1  |  |   |
| 15   | Red Alder      | OR                 | 1989       | 6/7–9/27 (113)                         | SUM06 W126: N100:  | 0.1 0 0   |           |           | 16.4 13.3 25 | 66.4 59.2 241 | 91.6 82.8 351 | 110.4 103.4 491      | 1 2  |  |   |
| 15   | Red Alder      | OR                 |            |  |  |           |           |           |              |               |               |                      |  |  |   |
| 16   | Red Alder      | OR                 | 1991       | 6/5–9/30 (118)                         | SUM06 W126: N100:  | 0 0 0     |           |           | 16.1 13 24   | 30.6 27.7 84  | 66.8 59.8 244 | 91.7 82.6 384        | 1 2  | Hogsett (unpublished) cited in Hogsett et al., 1995 Hogsett et al., 1997, SUM06: 0.0, 16.0, 31.8, 73.4, 103.6  |   |
| 16   | Red Alder      | OR                 |            |  |  |           |           |           |              |               |               |                      |  |  |   |
| 17   | Red Alder      | OR                 | 1992       | 6/2–9/21 (112)                         | SUM06 W126: N100:  | 0.1 0.1 1 |           |           | 14.7 11.8 19 | 28.1 25.6 78  | 63.9 56.9 234 | 88.2 79.4 340        | 1  | Hogsett (unpublished) per Hogsett et al., 1995 Hogsett et al., 1997, SUM06: 0.1, 14.5, 29.1, 70.1, 99.9.   |   |
| 18   | Black Cherry   | SM NP <sup>G</sup> | 1989       | 6/14–8/28 (76)                         | SUM06 W126: N100:  | 0 0 0     | 1.9 1.9 0 |           | 13.5 11.1 10 |               | 25.8 23 77    |                      | 1  | Neufeld et al., 1995 cited in Hogsett et al., 1995 Hogsett et al., 1997, SUM06: 0.0, 1.9, 17.1, 40.6. Also Neufeld and Renfro, 1993. [Statistically significant reduction in highest treatment group]                    |   |
| 19   | Black Cherry   | SM NP              | 1992       | 5/20–10/6 (140)                        | SUM06 W126: N100:  | 0 0 0     | 0.9 0 0   | 1.6 1.4 0 | 18.6 15.1 5  |               | 45.6 39.5 103 |                      | 1  | Neufeld, pers comm in Hogsett et al., 1995 Hogsett et al., 1997, SUM06: 0.0, 00, 0.8, 18.1, 50.2. Described in Neufeld et al., 1995, Neufeld and Renfro, 1993 [Statistically significant reduction in highest treatment] |   |
| 20   | Red Maple      | SM NP              | 1988       | 7/1-8/24 (55)                          | SUM06 W126: N100:  | 0 0 0     |           | 2.8 2.4 0 | 15.7 12.0 3  |               | 64.4 59.8 300 |                      | 1  | Neufeld (pers comm) cited in Hogsett et al., 1995 Hogsett et al., 1997. SUM06: 9.2, 12, 47, 125.4  |   |

| Study ID <sup>A</sup>  | Species             | Site  | Year exp'd | Exposure Period (days) <sup>B</sup>    | Exposure (derived from hourly O <sub>3</sub> concentrations over the identified exposure periods). Values are averages of replicates; N100 values are rounded to whole numbers. W126 and SUM06 are for 12-hr periods 8am-8pm. <sup>C</sup> |                 |                 |                 |                    |                     |                    |  | Harvest <sup>D</sup> | Study/Source and notes, with SUM06 (ppm-hr) <sup>E</sup> reported for full exposure period, e.g., per Hogsett et al 1997, Table 2 (which does not specify whether 12 or 24 hrs SUM06).  |  |
|--|---------------------|-------|------------|--|--|-----------------|-----------------|-----------------|--------------------|---------------------|--------------------|--|----------------------|---|--|
| Rows specify individual experimental datasets (uniquely defined by 1 <sup>st</sup> four columns and harvest) for E-R functions in Lee & Hogsett, 1996 (e.g., Table 12), as described in Attachment 1 to this Appendix (and also presented in 1996 AQCD, Table 5-28). |                     |       |            |  |  |                 |                 |                 |                    |                     |                    |  |                      |   |  |
| 21   | Tulip Poplar        | SM NP | 1990       | 6/30–9/12 (75)                         | SUM06<br>W126:<br>N100:  | 0.1<br>0.1<br>0 | 0.1<br>0.1<br>0 | 0.9<br>1.5<br>0 | 13.3<br>11.2<br>12 | 30.1<br>39.7<br>51  |                    |  | 1                    |   |  |
| 21   | Tulip Poplar        | SM NP | plus-1991  | 5/3–8/19 (109)<br>2-yr total =184 days | SUM06<br>W126:<br>N100:  | 0<br>0<br>0     | 0.3<br>0.4<br>1 | 0.7<br>1.5<br>0 | 22.7<br>18.7<br>8  | 54.2<br>45.3<br>102 |                    |  | 3                    | Neufeld (pers comm) cited in Hogsett et al., 1995<br>Hogsett et al., 1997, SUM06: 0.1, 0.5, 1.4, 34.5, 88.7 ( <u>for full 184 days</u> )  |  |
| 22   | Tulip Poplar        | SM NP | 1992       | 5/20–10/8 (142)                        | SUM06<br>W126:<br>N100:  | 0<br>0<br>0     | 0<br>0<br>0     | 0.9<br>1.4<br>0 | 18.7<br>15.2<br>5  | 45.9<br>39.7<br>103 |                    |  | 1                    |   |  |
| 23   | Loblolly GAKR 15-23 | AL    | 1988-89    | 5/23/88-11/28/89 (555)                 | W126: (24hr)   | 6.7             |                 |                 | 50.8               | 267.8               | 486                |  | 3                    | Qiu et al., 1992 and Lefohn et al., 1992 (cited by Hogsett et al., 1995 Hogsett et al., 1997; SUM06: 4.9, 58.5, 301.5, 507)<br>Statistically significant reductions at highest treatment for GARK15-91 only (90 <sup>th</sup> percentile for 2 <sup>nd</sup> highest treatment ranges 142-156 ppb across replicates; maximum ranges 210-260 ppb)  |  |
| 23   | Loblolly GAKR 15-91 | AL    |            |  |  |                 |                 |                 |                    |                     |                    |  | 3                    |   |  |
| 24   | Sugar Maple         | MI    | 1990       | (83)                                   | SUM06<br>W126:<br>N100:  | 0<br>0<br>0     | 0.60.<br>8<br>0 | 6.8<br>5.7<br>1 | 7.3<br>6.5<br>7    | 8<br>7<br>6         | 26.1<br>22.5<br>60 |  | 1                    |   |  |
| 24   | Sugar Maple         | MI    | Plus 1991  | (97)<br>2-yr total =180 days           |  |                 |                 |                 |                    |                     |                    |  | 3                    | Karnosky (pers. comm.) cited by Hogsett et al., 1995<br>Hogsett et al., 1997 (SUM06: 0.0, 25.2, 27.8, 49.8, 67.6, 94.4, <u>for full 180 days</u> ).<br>May be described in Rebbeck and Loats, 1997, who reported no statistically significant treatment effects in any of the seedlings exposed to O <sub>3</sub> between two individual seasons or after exposure to 304 ppm (SUM00 index) over two growing seasons (total of 225 days). |  |
| 25   | E. White Pine       | MI    | 1990       | 6/20–9/10 (83)                         | SUM06<br>W126:<br>N100:  | 0<br>0<br>0     | 0.60.<br>8<br>0 | 6.8<br>5.7<br>1 | 7.3<br>6.5<br>7    | 8<br>7<br>6         | 26.1<br>22.5<br>60 |  | 1                    | Karnosky (pers. comm.) cited by Hogsett et al., 1995<br>Hogsett et al., 1997 (SUM06: 0.0, 25.2, 27.7, 49.8, 64.2, 94.4, <u>for full 180 days</u> )  |  |
| 25   | E. White Pine       | MI    | Plus 1990  | (97)                                   |  |                 |                 |                 |                    |                     |                    |  | 3                    | May be described in Isebrands et al., 2000 pg 170 which reported no statistically significant difference in height,   |  |

| Study ID <sup>A</sup>  | Species       | Site  | Year exp'd | Exposure Period (days) <sup>B</sup> | Exposure (derived from hourly O <sub>3</sub> concentrations over the identified exposure periods). Values are averages of replicates; N100 values are rounded to whole numbers. W126 and SUM06 are for 12-hr periods 8am-8pm. <sup>C</sup> |   |     |            |  |             |      |  | Harvest <sup>D</sup> | Study/Source and notes, with SUM06 (ppm-hr) <sup>E</sup> reported for full exposure period, e.g., per Hogsett et al 1997, Table 2 (which does not specify whether 12 or 24 hrs SUM06).  |
|--|---------------|-------|------------|-------------------------------------|--|---|-----|------------|--|-------------|------|--|----------------------|---|
| Rows specify individual experimental datasets (uniquely defined by 1 <sup>st</sup> four columns and harvest) for E-R functions in Lee & Hogsett, 1996 (e.g., Table 12), as described in Attachment 1 to this Appendix (and also presented in 1996 AQCD, Table 5-28). |               |       |            |                                     |  |   |     |            |  |             |      |  |                      |   |
|  |               |       |            | 2-yr total =180 days                |  |   |     |            |  |             |      |  |                      | stem, root or current year needle biomass in response to O <sub>3</sub>   |
| 26   | Virginia Pine | SM NP | 1992       | 5/4–10/9 (159)                      | SUM06  | 0 | 2   | <u>2.9</u> |  | <u>24.6</u> | 56.1 |  | 1                    | Neufeld (pers. comm.) cited in Hogsett et al., 1995<br>Hogsett et al., 1997 (SUM06: 0.0, 0.0, 1.9, 21.7, 51.6)<br>May be described in Neufeld et al. (2000), who reported no statistically significant treatment effects on biomass from 152-day duration (SUM06 up to 56.2). |
|  |               |       |            |                                     | W126:  | 0 | 0.1 | 2.5        |  | 20.0        | 49.1 |  |                      |   |
|  |               |       |            |                                     | N100:  | 0 | 1   | 0          |  | 18          | 134  |  |                      |   |

A Study ID as in Lee and Hogsett (1996), Table 12 (and 1996 AQCD).

B Duration corresponds to length in days of the first year of exposure for Harvests 1 and 2 and to the total length of the first and second years' exposure periods for Harvest 3.

C Exposure metric values derived from recently recovered datasets associated with Lee and Hogsett research at U.S. EPA, Center for Public Health and Environmental Assessment, Pacific Ecological Systems Division, Corvallis, WA.

D Harvest 1 occurs immediately following end of first year of exposure. Harvest 2 occurs in spring following first year of exposures. Harvest 3 occurs immediately following end of second year of exposures. Harvest 4 occurs in spring following second year of exposures.

E First SUM06 treatment value corresponds to charcoal-filtered exposure (Hogsett et al., 1997 Table 2).

F For the three Oregon exposures of aspen in 1989, 1990 and 1991, the durations of exposure reported in Lee and Hogsett, 1996, Hogsett et al 1995 and Hogsett et al 1997 (84, 118 and 112 days, respectively) differ from the number of days of exposure data for each in the recovered dataset for the research described in footnote C above (105, 99 and 107 days, respectively). Based on review of the information by staff from USEPA, CPHEA, PSAD (including coauthor on Lee and Hogsett, 1996), the values for numbers of days duration in the 1995-1997 publications are presumed to reflect typographic errors. Accordingly, the exposure metric values reported in this table are concluded to reflect the study exposures and the dataset from which the E-R functions were derived in Lee and Hogsett, 1996.

G SMNP = Smoky Mountains National Park.

H The duration of exposure reported in Lee and Hogsett, 1996, Hogsett et al 1995 and Hogsett et al 1997 for the 1992 tulip poplar and Virginia pine exposures (81 and 98 days, respectively) differs from the number of days of exposure data in the recovered dataset for the research (142 and 159 or 152 days). The lead investigator on these studies has affirmed that the values for number of days duration in the 1995-1997 publications are erroneous. Accordingly, the exposure metric values reported in this table are concluded to reflect the study exposures and the dataset from which the E-R functions were derived in Lee and Hogsett, 1996.

1

2

## 4A.3 ANALYSIS OF RBL ACROSS MULTIPLE YEARS

There are few studies of multiple year O<sub>3</sub> exposures that provide detailed O<sub>3</sub> concentrations during the exposures and quantify growth for each year that might be analyzed with regard to the influence of each season's O<sub>3</sub> exposures across a multiple-year period. In section 4A.3.1, one such study that has been analyzed in the 2013 and 2020 ISAs is described. Section 4A.3.2 includes a somewhat basic set of example calculations as a theoretical illustration that considers potential impacts of different patterns of annual cumulative O<sub>3</sub> exposures across multiple years.

### 4A.3.1 Comparison of Predicted and Observed O<sub>3</sub> Growth Impacts in the 2013 and 2020 ISAs

The 2013 and 2020 ISAs present comparisons of aspen stand growth observations from an Aspen FACE multiyear O<sub>3</sub> exposure study with predictions derived through the application of a median composite E-R function for wild aspen and aspen clones<sup>7</sup> to seasonal W126 index values (2013 ISA, section 9.6.3.2; 2020 ISA, Appendix 8, Figure 8-17). The Aspen FACE study monitored growth of aspen stands annually from 1997 through 2003 (King et al., 2005).<sup>8</sup> Growth was monitored for stands grown in ambient air and under elevated O<sub>3</sub> conditions. The elevated O<sub>3</sub> treatment involved increasing hourly concentrations by approximately 1.5 times over the O<sub>3</sub> concentrations occurring in ambient air at the site (King et al., 2005).

For the ISA comparisons of growth impacts predicted using the aspen E-R function (described in section 4A.1.1 above) to those observed in the study, hourly O<sub>3</sub> measurements were obtained from the authors (for both the “ambient” and “elevated” treatments) and used to calculate seasonal W126 index. For the 2013 ISA, a cumulative (multiyear) seasonal average W126 index was related to growth response and for the 2020 ISA the single-year seasonal W126 index was used. The values for “observed” above ground total biomass for the aspen stands were derived from measurements obtained from the authors and allometric equations (2013 ISA, section 9.6.3.2; King et al., 2005 and associated Corrigendum).<sup>9</sup>

---

<sup>7</sup> The median composite function used in the ISAs “was developed from NHEERL/WED data for 11 studies of wild-type seedlings of aspen as well as four clonally propagated genotypes” (2013 ISA, p. 9-133).

<sup>8</sup> Other studies have involved observations involving the same aspen stand extended out to 2008 (e.g., Talhelm et al., 2014; Zak et al., 2011). Complications associated with performing similar types of comparisons over this longer time period relate to variation in both the tree measurements taken over the extended period (e.g., diameter measurements at varying tree heights), and the O<sub>3</sub> treatments (e.g., the difference in single-year W126 index ranged from approximately 20 to 30 ppm-hrs through 2003 and then dropped to 10 ppm-hrs for four of the last five years), as well as changing growth patterns associated with aging trees.

<sup>9</sup> The publication by King et al., (2005) reports on measurements for the years 1997 through 2003.

Both the 2013 ISA comparison of observed biomass to predicted biomass based on application of the E-R function to W126 in terms of cumulative (multiyear) seasonal average<sup>10</sup> and the 2020 ISA comparison using W126 in terms of single year seasonal index indicate the E-R function to describe generally similar O<sub>3</sub> impacts on Aspen biomass. Based on the 2013 analysis (presented in the Tables 9-14 and 9-15, and Figure 9-20 of the 2013 ISA), the 2013 ISA concludes “the agreement between predictions ... and observations was very close” and “the function based on one year of growth was shown to be applicable to subsequent years.” (p 9-135).<sup>11</sup> The 2020 ISA also notes a closeness of predictions to observations (2020 ISA, Appendix 8, p. 8-192 and Figure 8-17). The variation in the comparisons of predictions to observations in the two presentations illustrate the variability inherent in the magnitude of growth impacts of O<sub>3</sub> and also the quantitative relationship of O<sub>3</sub> exposure and RBL, while also supporting ISA conclusions of a general agreement of model predictions using either multiyear or single year W126 estimates with experimental observations (2013 ISA, Figure 9-20; 2020 ISA, Appendix 8, Figure 8-17).

#### **4A.3.2 Example Calculations Comparing Estimated Impacts of Constant and Annually Varying Seasonal Exposure**

This section explores estimates of aspen growth affected by multiple years of O<sub>3</sub> exposure based on application of the E-R function for aspen described in section 4A.1.1 above. Estimates of aspen absolute biomass are calculated in response to O<sub>3</sub>-related RBL for several scenarios with different ways of expressing single-year O<sub>3</sub> exposure conditions that all have the same 3-year average W126 index. In this way, absolute biomass of aspen is estimated across multiple years in response to O<sub>3</sub> exposures expressed as a constant annual W126 index value and compared to estimated absolute biomass in response to O<sub>3</sub> exposures expressed as the same W126 index value in terms of a 3-year average but with varying annual values. Several different scenarios with varying annual W126 are included, with all meeting the 3-year average limit of the constant W126 index scenario (Figure 4A-15), with the extent of the variation reflecting what is shown to be common at U.S. monitoring locations, although with the highest single-year value somewhat higher than that occurring in U.S. monitoring locations that meet the existing NAAQS (e.g., Appendix 4D, section 4D.3.1.2).

---

<sup>10</sup> The cumulative seasonal average for each year is calculated as the average of the seasonal W126 index values for that year and all of the preceding years.

<sup>11</sup> Using the values reported in Table 9-15 of the 2013 ISA (which are plotted in Figure 9-20), to derive correlation coefficients related to that analysis, the  $r^2$  for predicted O<sub>3</sub> impact versus observed impact is 0.99 and for the percent difference versus year is approximately 0.85. This indicates a strong correlation for the 2013 ISA analysis of the experimental observations with predictions based on a cumulative multiyear W126 index, and a good fit for the exposure metric reflecting cumulative multiyear exposure.

This analysis is not intensive or elaborate; rather, it is a mathematical exercise intended to provide an illustration of concepts associated with application of the E-R functions described in section 4A.1 using data from a study with aspen of the effects of a six-year exposure on accumulating biomass (King et al., 2005), which is also utilized in a different type of analysis in the 2013 ISA, that is summarized in the ISA and also in section 4A.3.1 above (2020 ISA, Appendix 8, Figure 8-17; 2013 ISA, section 9.6.3.2).

**Description of Analysis:** The analysis presented here is intended to simply illustrate the application of the tree seedling E-R function for aspen over a multi-year period using two types of air quality scenarios: (1) one in which the O<sub>3</sub> concentrations are limited such that each year's W126 is no higher than 17 ppm-hrs, and (2) a second in which the O<sub>3</sub> concentrations are allowed to vary each year as long as the 3-year average is no higher than 17 ppm-hrs. More specifically, the two scenarios are (1) repeated years of W126=17 ppm-hrs and (2) repeated 3-year cycles of the same varying W126 (e.g., 10, 17 and 24 ppm-hrs).

|          | O <sub>3</sub> exposure in terms of single year W126 index (ppm-hrs) |        |        |        |        |        |
|----------|--|--------|--------|--------|--------|--------|
| Scenario | Year 1   | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 |
| Constant | 17   | 17     | 17     | 17     | 17     | 17     |
| Varying  | 10   | 24     | 17     | 10     | 24     | 17     |
| Varying  | 24   | 17     | 10     | 24     | 17     | 10     |
| Varying  | 24   | 10     | 17     | 24     | 10     | 17     |
| Varying  | 10   | 17     | 24     | 10     | 17     | 24     |
|          |  |        |        |        |        |        |

This analysis is intended to inform consideration of potential magnitude of an over or under estimation of growth reduction when the target W126 value was calculated from a 3-year average or for each individual year. In this analysis, above-ground tree biomass is estimated for each year through a six-year period.<sup>12</sup> The example for this analysis uses aspen, beginning with a seedling, and utilizes data on growth rates (annual biomass increases) for the control treatment in a study by King et al., 2005. Based on the annual measurements,<sup>13</sup> we derived the following linear model ( $r^2 = 0.4137$ ):

$$\text{W126 scenario annual growth} = 0.2395 * \text{Previous Year Biomass} + 215.05$$

<sup>12</sup> In order to avoid extrapolation baseline growth beyond that presented in King et al. (2005), the analysis is limited to the six-year time period. While other Aspen FACE studies have followed the same stand for additional years, there are aspects of the longer dataset (e.g., different height of tree measurements) that would contribute uncertainties that lead to the decision to limit the analysis to this duration.

<sup>13</sup> Individual tree growth measurements from Aspen FACE (1997-2008) research, including annual biomass increases in King et al. (2005), received from researchers (Ozone NAAQS Docket, EPA-HQ-OAR-2018-0279).

1 This function was then used to estimate each year's annual growth prior to application of the O<sub>3</sub>  
2 growth effect which was estimated by applying the established E-R function for aspen. In our  
3 analysis, above ground biomass loss<sup>14</sup> was calculated using the estimated growth rate (yearly  
4 biomass production) and the relative biomass loss (RBL) for the pertinent W126 value based on  
5 the aspen E-R function. This biomass loss was calculated for the 3-year average W126 of 17  
6 ppm and for each of the three individual year values of 10, 17 and 24 ppm (Table 4A-7).

7 The above ground biomass of the aspen stand across the six years of growth was  
8 compared across the two exposure scenarios (Figure 4A-15; Table 4A-7). The difference  
9 between the two scenarios in total above ground biomass for the stand varied from year to year.  
10 After the first year, this difference in the year's total above ground biomass (not to be confused  
11 with annual growth in biomass, to which RBL is applied) was always less than 3%. In summary,  
12 the estimated impact of O<sub>3</sub> on absolute biomass of aspen following multiple years of exposure  
13 does not differ appreciably whether the E-R function is applied to annual growth with a single-  
14 year W126 index varying across a 3-year period or with a W126 index for each year set equal to  
15 the average across the three years. In summary, and consistent with the analysis described above,  
16 the estimated impact of O<sub>3</sub> using different annual measurements does not differ appreciably  
17 across the six years of growth.

18 **Summary of Analysis Limitations, Assumptions and Uncertainties:** Given the limited  
19 availability of multiple year O<sub>3</sub> exposure studies providing detailed O<sub>3</sub> concentrations during the  
20 exposures and quantified annual growth, as well as the simply conceptual or illustrative nature of  
21 the analysis, there are multiple inherent assumptions, limitations and uncertainties.

- 22 • Consistent with the general concept that a tree's annual growth is related to the size of the  
23 tree going into the growing season, the analysis derives estimates of annual growth as a  
24 function of prior year biomass (with the function derived from the annual biomass  
25 measurements from the Aspen FACE research).<sup>15</sup> There is uncertainty in the resulting  
26 estimates from a number of sources including that the function used did not account for  
27 influences other than tree size on annual growth. The impact of these uncertainties  
28 (including direction and magnitude) on this analysis are unknown.
- 29 • Variables other than O<sub>3</sub> that can affect growth in a given year (e.g., precipitation,  
30 temperature, community competition) are represented in the current analysis only through  
31 their effects on the annual measurements provided by the "control" from the aspen study  
32 by King et al. (2005) on which the annual growth function is based.

---

<sup>14</sup> Above-ground growth (foliage and wood) is used consistent with 2013 and 2020 ISA analyses described in section 4A.3.1 above).

<sup>15</sup> This differs from the approach of the analysis in the 2020 PA.

- 1 • Additionally, this analysis is based on aspen, and the specific pattern of differences  
2 between the two scenarios might be expected to vary for species with different biomass  
3 growth rates (and E-R functions). However, while many multi-year tree growth studies  
4 may exist, datasets of tree growth that investigate the impact of O<sub>3</sub> across multiple-year  
5 periods (providing annual growth measurements and also detailed records of hourly  
6 concentrations that support derivation of W126 index metrics) such as that available for  
7 aspen in the study by King et al. (2005) are not prevalent.
- 8 • This example analysis includes a W126 index value of 24 ppm-hrs every third year. Yet,  
9 the frequency of such a value is quite rare, as can be seen from the air quality analyses in  
10 Appendix 4D, which show that across the period from 2000 through 2020 for even just  
11 the subset of sites meeting the current standard but with design value closest to 70 ppb  
12 (66-70 ppb), the 99<sup>th</sup> percentile is below 20 ppm-hrs (PA, Appendix 4D, Figure 4D-8).  
13 Focusing just on Class I areas for the full period from 2000 to 2020, there are no more  
14 than 15 occurrences of a single-year W126 index value above 19 ppm-hrs, all of which  
15 date prior to 2013 (85 FR 49904, August 14, 2020). Thus, this example includes as one of  
16 the three years, a magnitude of W126 index that has been quite rarely observed in areas  
17 that meet the current standard since 2000. W126 index values below 17 ppm-hrs are more  
18 common.
- 19 • The shape of the E-R curve for aspen species is generally linear, as are eight of the other  
20 species with E-R curves (see section 4A.1.1 above), but we recognize that varying shapes  
21 of curves may have the potential to influence the differences in the comparison analyzed.  
22 Although EPA does not have growth information to complete an analysis such as this one  
23 for another of the 11 species, uncertainties related to the shape of the two species with  
24 less linear E-R curves were considered. Black cherry has an E-R function with a  
25 declining slope with increasing W126, with the appearance of leveling off, which  
26 produces a smaller change in RBL relative to the change in W126. This slope presents the  
27 opposite pattern to that of sugar maple. Sugar maple has a small slope at or below 19  
28 ppm-hrs (RBL estimates associated with its E-R function in this range are appreciably  
29 lower than those for the aspen<sup>16</sup>) and does not have a large change in slope until at or  
30 above 26 ppm-hrs (the highest W126 values observed at U.S. ambient air monitoring  
31 sites). Furthermore, the geographic range of sugar maple is generally limited to the  
32 northeast and upper midwest of the U.S., areas with among the relatively lower W126  
33 index levels across the U.S. (see Appendix 4D, Figure 4D-2).<sup>17</sup>
- 34 • Additionally, while the availability of multi-year experimental data that can be examined  
35 with regard to this issue for the range of exposures investigated here is limited, a multi-  
36 year study available in the 2015 review (King et al., 2005) is discussed in section 4A.3.1  
37 above (2013 ISA section 9.6.3.2). As summarized in section 4A.3.1, the multi-year

---

<sup>16</sup> At sites and time periods during 2000 through 2018 in which the current standard was met, and focusing on the higher values of W126 index observed at sites with design values closest to the current standard (e.g., 66 -70 ppb), the sugar maple RBL estimated for the 75<sup>th</sup> percentile is less than 1% (PA, Appendix 4A, Table 4A-4 and Appendix 4D, Figure 4D-8).

<sup>17</sup> A noteworthy uncertainty regarding the shape of this E-R function is that a W126 index of 22.5 ppm-hrs may be the highest experimental exposure level in the first season of the two season's exposure on which the sugar maple E-R function is based (see Table 4A-6 above).




1 experimental dataset from King et al. (2005) was assessed in the 2013 ISA and is also  
2 discussed in the 2020 ISA with regard to growth effects and correspondence of E-R  
3 function predictions with study observations (2020 ISA, Appendix 8, section 8.13.2 and  
4 Figure 8-17; 2013 ISA, section 9.6.3.2, Table 9-15, Figure 9-20). The analysis in the  
5 2013 ISA, which focused on the six years for which the aspen study reported data,  
6 compared observed reductions in growth for each year of a 6-year period to those  
7 predicted by applying the established E-R function for Aspen to cumulative multi-year  
8 average W126 index values (2013 ISA, section 9.6.3.2).<sup>18</sup> One finding of this evaluation  
9 was that “the function based on one year of growth was shown to be applicable to  
10 subsequent years” (2013 ISA, p. 9-135), indicating that the approach employed in the  
11 illustrative analysis presented here -for the initial six years- may be reasonable for the  
12 circumstances examined here.<sup>19</sup>

---

<sup>18</sup> For example, the growth impact estimate for year 1 used the W126 index for year 1; the estimate for year 2 used the average of W126 index in year 1 and W126 index in year 2; the estimate for year 3 used the average of W126 index in years 1, 2 and 3; and so on.

<sup>19</sup> In the 2020 ISA, an evaluation slightly different from that in the 2013 ISA was performed, applying the E-R functions to the W126 index for each year rather than the cumulative multi-year W126 (2020 ISA, Appendix 8, Figure 8-17). This approach, while indicating a just slightly less tight fit to the observations (than the 2013 ISA approach) in the later years, was similarly concluded to be “exceptionally close” to the experimental observations (2020 ISA, Appendix 8, p. 8-192), indicating the aspen E-R functions to predict the yearly findings generally reliably from the six years of exposures of the Aspen FACE experiment.

1



2

3

4 **Figure 4A-15. Estimated aboveground biomass of aspen with different patterns of annual**  
 5 **seasonal W126 index using annual growth as a function of prior year**  
 6 **absolute biomass for trees in the same scenario.**

**Table 4A-7. Comparison of total aspen above ground biomass estimated for different patterns of varying annual exposures and constant exposures equal to 3-year average (17 ppm-hrs) using annual growth as a function of prior year absolute biomass for trees in the same scenario.**

| Year  | Predicted Biomass* | Growth - % increase | W126=17, biomass (g/m2) | W126=10, 24, 17, etc - biomass (g/m2) | W126= 24, 17, 10, etc - biomass (g/m2) | W126= 24, 10, 17, etc - biomass (g/m2) | W126= 10, 17, 24 etc - biomass (g/m2) | % difference in total tree biomass of W126 10-17-24 vs 17 | % difference in total tree biomass of W126 10-24-17 vs 17 | % difference in total tree biomass of W126 24-17-10 vs 17 | % difference in total tree biomass of W126 24-10-17 vs 17 |
|---|--------------------|---------------------|-------------------------|---------------------------------------|--|--|---------------------------------------|---|---|---|---|
| y0 - 1997   | 9.1                |                     | 9.1                     | 9.1                                   | 9.1                                    | 9.1                                    | 9.1                                   |   |   |   |   |
| y1  | 226.3              | 2387.14%            | 205.0                   | 215.0                                 | 194.8                                  | 194.8                                  | 215.0                                 | 4.9%  | 4.9%  | -5.0%   | -5.0%   |
| y2  | 495.6              | 118.97%             | 443.3                   | 442.9                                 | 430.9                                  | 442.9                                  | 455.5                                 | 2.7%  | -0.1%   | -2.8%   | -0.1%   |
| y3  | 829.3              | 67.34%              | 733.1                   | 732.6                                 | 732.6                                  | 732.6                                  | 732.6                                 | -0.1%   | -0.1%   | -0.1%   | -0.1%   |
| y4  | 1243.0             | 49.88%              | 1085.4                  | 1102.8                                | 1066.5                                 | 1066.5                                 | 1102.8                                | 1.6%  | 1.6%  | -1.7%   | -1.7%   |
| y5  | 1755.8             | 41.25%              | 1513.8                  | 1512.5                                | 1490.8                                 | 1512.5                                 | 1535.0                                | 1.4%  | -0.1%   | -1.5%   | -0.1%   |
| y6-2003   | 2391.3             | 36.20%              | 2034.8                  | 2033.2                                | 2033.2                                 | 2033.2                                 | 2033.2                                | -0.1%   | -0.1%   | -0.1%   | -0.1%   |
| * The value in the first row of this and other columns is the total absolute biomass measurement from King et al. 2005, Table 3 (foliage plus wood). The subsequent rows of the first column utilize the function (above) to derive current year biomass as function of prior year biomass. In the other columns, the annual increment derived with the function is reduced by predicted RBL for the applicable W126 index value. The W126-RBL E-R function used is $1 - \exp[-W126/109.81]^{1.2198}$ . |                    |                     |                         |                                       |  |  |                                       |   |   |   |   |

## 1 REFERENCES

- 2 Andersen, CP and Scagel, CF (1997). Nutrient availability alters belowground respiration of  
3 ozone-exposed ponderosa pine. *Tree Physiology* 17(6): 377-387.
- 4 Andersen, CP, Wilson, R, Plocher, M and Hogsett, WE (1997). Carry-over effects of ozone on  
5 root growth and carbohydrate concentrations of ponderosa pine seedlings. *Tree*  
6 *Physiology* 17(12): 805-811.
- 7 Gumpertz, ML and Rawlings, JO (1992). Nonlinear regression with variance components:  
8 Modeling effects of ozone on crop yield. *Crop Science* 32(1): 219-224.
- 9 Heck, WW, Cure, WW, Rawlings, JO, Zaragoza, LJ, Heagle, AS, Heggstad, HE, Kohut, RJ,  
10 Kress, LW and Temple, PJ (1984). Assessing impacts of ozone on agricultural crops: II.  
11 Crop yield functions and alternative exposure statistics. *Journal of the Air Pollution*  
12 *Control Association* 34(8): 810-817.
- 13 Hogsett, WE, Herstrom, AA, Laurence, JA, Lee, EH, Weber, JE and Tingey, DT, Eds. (1995).  
14 Risk characterization of tropospheric ozone to forests. *Air & Waste Management*  
15 *Association* Pittsburgh, PA.
- 16 Hogsett, WE, Weber, JE, Tingey, D, Herstrom, A, Lee, EH and Laurence, JA (1997).  
17 Environmental auditing: An approach for characterizing tropospheric ozone risk to  
18 forests. *Journal of Environmental Management* 21(1): 105-120.
- 19 Isebrands, JG, Dickson, RE, Rebbeck, J and Karnosky, DF, Eds. (2000). Interacting effects of  
20 multiple stresses on growth and physiological processes in northern forest trees. Springer-  
21 Verlag New York, NY.
- 22 Karnosky, DF, Gagnon, ZE, Dickson, RE, Coleman, MD, Lee, EH and Isebrands, JG (1996).  
23 Changes in growth, leaf abscission, biomass associated with seasonal tropospheric ozone  
24 exposures of *Populus tremuloides* clones and seedlings. *Can J For Res* 26(1): 23-37.
- 25 King, JS, Kubiske, ME, Pregitzer, KS, Hendrey, GR, McDonald, EP, Giardina, CP, Quinn, VS  
26 and Karnosky, DF (2005). Tropospheric O<sub>3</sub> compromises net primary production in  
27 young stands of trembling aspen, paper birch and sugar maple in response to elevated  
28 atmospheric CO<sub>2</sub>. *New Phytol* 168(3): 623-635.
- 29 Lee, EH and Hogsett, WE (1996). methodology for calculating inputs for ozone secondary  
30 standard benefits analysis part II. Office of Air Quality Planning and Standards. Research  
31 Triangle Park, NC.
- 32 Lee, EH and Hogsett, WE (1999). Role of concentrations and time of day in developing ozone  
33 exposure indices for a secondary standard. *J Air Waste Manage Assoc* 49(6): 669-681.
- 34 Lee, EH, Hogsett, WE and Tingey, DT (1994). Attainment and effects issues regarding  
35 alternative secondary ozone air quality standards. *Journal of Environmental Quality*  
36 23(6): 1129-1140.

- 1 Lee, EH, Tingey, DT and Hogsett, WE (1987). Selection of the best exposure-response model  
2 using various 7-hour ozone exposure statistics. U.S. Environmental Protection Agency.  
3 Research Triangle Park, NC.
- 4 Lee, EH, Tingey, DT and Hogsett, WE (1988). Evaluation of ozone exposure indices in  
5 exposure-response modeling. *Environmental Pollution* 53(1-4): 43-62.
- 6 Lee, EH, Tingey, DT and Hogsett, WE (1989). Interrelation of experimental exposure and  
7 ambient air quality data for comparison of ozone exposure indices and estimating  
8 agricultural losses. EPA/600/3-89/047. U.S. Environmental Protection Agency. Corvallis,  
9 OR.
- 10 Lefohn, A, Shadwick, D, Somerville, M, Chappelka, A, Lockaby, B and Meldahl, R (1992). The  
11 characterization and comparison of ozone exposure indices used in assessing the response  
12 of loblolly pine to ozone. *Atmospheric Environment, Part A: General Topics* 26(2): 287-  
13 298.
- 14 Lesser, VM, Rawlings, JO, Spruill, SE and Somerville, MC (1990). Ozone effects on agricultural  
15 crops: Statistical methodologies and estimated dose-response relationships. *Crop Science*  
16 30(1): 148-155.
- 17 Neufeld, HS, Lee, EH, Renfro, JR, Hacker, WD and Yu, BH (1995). Sensitivity of seedlings of  
18 black cherry (*Prunus serotina* Ehrh) to ozone in Great Smoky Mountains National Park I  
19 Exposure-response curves for biomass. *New Phytol* 130(3): 447-459.
- 20 Neufeld, HS and Renfro, JR (1993). Sensitivity of black cherry seedlings (*Prunus serotina* Ehrh.)  
21 to ozone in Great Smoky Mountains National Park: The 1989 seedling set. NPS/NRTR-  
22 93/112. U.S. Department of the Interior; National Park Service. Washington, DC.
- 23 Qiu, Z, Chappelka, AH, Somers, GL, Lockaby, BG and Meldahl, RS (1992). Effects of ozone  
24 and simulated acidic precipitation on above- and below-ground growth of loblolly pine  
25 (*Pinus taeda*). *Can J For Res* 22(4): 582-587.
- 26 Rawlings, JO and Cure, WW (1985). The Weibull function as a dose-response model to describe  
27 ozone effects on crop yields. *Crop Science* 25(5): 807-814.
- 28 Rebbeck, J and Loats, K (1997). Ozone effects on seedling sugar maple (*Acer saccharum*) and  
29 yellow-poplar (*Liriodendron tulipifera*): gas exchange. *Can J For Res* 27(10): 1595-1605.
- 30 Talhelm, AF, Pregitzer, KS, Kubiske, ME, Zak, DR, Company, CE, Burton, AJ, Dickson, RE,  
31 Hendrey, GR, Isebrands, JG, Lewin, KF, Nagy, J and Karnosky, DF (2014). Elevated  
32 carbon dioxide and ozone alter productivity and ecosystem carbon content in northern  
33 temperate forests. *Global Change Biol* 20(8): 2492-2504.
- 34 U.S. EPA (2006). Air Quality Criteria for Ozone and Related Photochemical Oxidants (Volume I  
35 - III). Office of Research and Development U.S. EPA. EPA-600/R-05-004aF, EPA-  
36 600/R-05-004bF, EPA-600/R-05-004cF February 2006. Available at:  
37 <https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=149923>.

- 1 U.S. EPA (2007). Review of the National Ambient Air Quality Standards for Ozone: Policy  
2 Assessment of Scientific and Technical Information: OAQPS Staff Paper. Office of Air  
3 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-07-  
4 003. January 2007. Available at:  
5 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P10083VX.txt>. Cox, LA. (2018). Letter  
6 from Dr. Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory Committee, to  
7 Acting Administrator Andrew R. Wheeler, Re: Consultation on the EPA's *Integrated*  
8 *Review Plan for the Review of the Ozone*. December 10, 2018. EPA-CASAC-19-001.  
9 Office of the Administrator, Science Advisory Board U.S. EPA HQ, Washington DC.  
10 Available at:  
11 [https://yosemite.epa.gov/sab/sabproduct.nsf/LookupWebReportsLastMonthCASAC/A286](https://yosemite.epa.gov/sab/sabproduct.nsf/LookupWebReportsLastMonthCASAC/A286A0F0151DC8238525835F007D348A/$File/EPA-CASAC-19-001.pdf)  
12 [A0F0151DC8238525835F007D348A/\\$File/EPA-CASAC-19-001.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/LookupWebReportsLastMonthCASAC/A286A0F0151DC8238525835F007D348A/$File/EPA-CASAC-19-001.pdf).
- 13 Cox, LA. (2020a). Letter from Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
14 Committee, to Administrator Andrew R. Wheeler. Re: CASAC Review of the EPA's  
15 *Integrated Science Assessment for Ozone and Related Photochemical Oxidants (External*  
16 *Review Draft – September 2019)*. February 19, 2020. EPA-CASAC-20-002. Office of the  
17 Administrator, Science Advisory Board Washington, DC Available at:  
18 [https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/F22](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/F228E5D4D848BBED85258515006354D0/$File/EPA-CASAC-20-002.pdf)  
19 [8E5D4D848BBED85258515006354D0/\\$File/EPA-CASAC-20-002.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/F228E5D4D848BBED85258515006354D0/$File/EPA-CASAC-20-002.pdf).
- 20 Cox, LA. (2020b). Letter from Louis Anthony Cox, Jr., Chair, Clean Air Scientific Advisory  
21 Committee, to Administrator Andrew R. Wheeler. Re: CASAC Review of the EPA's  
22 *Policy Assessment for the Review of the Ozone National Ambient Air Quality Standards*  
23 *(External Review Draft – October 2019)*. February 19, 2020. EPA-CASAC-20-003.  
24 Office of the Administrator, Science Advisory Board Washington, DC Available at:  
25 [https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf)  
26 [D217BC07103485258515006359BA/\\$File/EPA-CASAC-20-003.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/264cb1227d55e02c85257402007446a4/4713D217BC07103485258515006359BA/$File/EPA-CASAC-20-003.pdf).
- 27 Duffney, PF, Brown, JS, and Stone, SL (2022). Memorandum to the Review of the Ozone  
28 National Ambient Air Quality Standards (NAAQS) Docket (EPA-HQ-ORD-2018-  
29 0279). Re: Provisional Evaluation of Newly Identified Controlled Human Exposure  
30 Studies in the context of the 2020 Integrated Science Assessment for Ozone and Related  
31 Photochemical Oxidants. April 15, 2020. Docket ID No. EPA-HQ- OAR-2018-0279.  
32 Office of Air Quality Planning and Standards Research Triangle Park, NC.
- 33 Frey, HC. (2014a). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory  
34 Committee, to Administrator Gina McCarthy. Re: CASAC Review of the EPA's Welfare  
35 Risk and Exposure Assessment for Ozone (Second External Review Draft). June 18,  
36 2014. EPA-CASAC-14-003. Office of the Administrator, Science Advisory Board  
37 Washington, DC. Available at:  
38 <http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P100JMSY.PDF>.
- 39 Frey, HC. (2014b). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory  
40 Committee to Honorable Gina McCarthy, Administrator, US EPA. Re: CASAC Review  
41 of the EPA's Second Draft Policy Assessment for the Review of the Ozone National  
42 Ambient Air Quality Standards. June 26, 2014. EPA-CASAC-14-004. Office of the

- Administrator, Science Advisory Board Washington, DC. Available at:  
<https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100JR6F.txt>.
- Frey, HC. (2014c). Letter from Dr. H. Christopher Frey, Chair, Clean Air Scientific Advisory Committee, to Administrator Gina McCarthy. Re: Health Risk and Exposure Assessment for Ozone (Second External Review Draft - February 2014) EPA-CASAC-14-005. Office of the Administrator, Science Advisory Board Washington, DC. Available at:  
<https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100JR8I.txt>.
- Luben, T, Lassiter, M and Herrick, J (2020). Memorandum to Ozone NAAQS Review Docket (EPA–HQ–ORD–2018–0279). RE: List of Studies Identified by Public Commenters That Have Been Provisionally Considered in the Context of the Conclusions of the 2020 Integrated Science Assessment for Ozone and Related Photochemical Oxidants. December 2020. Docket ID No. EPA–HQ– OAR–2018–0279. Office of Air Quality Planning and Standards Research Triangle Park, NC.
- Pruitt, E. (2018). Memorandum from E. Scott Pruitt, Administrator, U.S. EPA to Assistant Administrators. Back-to-Basics Process for Reviewing National Ambient Air Quality Standards. May 9, 2018. Office of the Administrator U.S. EPA HQ, Washington DC. Available at: <https://www.epa.gov/criteria-air-pollutants/back-basics-process-reviewing-national-ambient-air-quality-standards>.
- Samet, JM. (2010). Letter from Jonathan Samet, Chair, Clean Air Scientific Advisory Committee, to Administrator Lisa Jackson. Re: CASAC Review of EPA’s Proposed Ozone National Ambient Air Quality Standard (Federal Register, Vol. 75, Nov. 11, January 19, 2010). . February 19, 2010. EPA-CASAC-10-007. Office of the Administrator, Science Advisory Board U.S. EPA HQ, Washington DC. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P10072T1.txt>.
- Samet, JM. (2011). Letter from Jonathan Samet, Chair, Clean Air Scientific Advisory Committee, to Administrator Lisa Jackson. Re: CASAC Response to Charge Questions on the Reconsideration of the 2008 Ozone National Ambient Air Quality Standards. . March 30, 2011. EPA-CASAC-11-004. Office of the Administrator, Science Advisory Board U.S. EPA HQ, Washington DC. Available at:  
[https://yosemite.epa.gov/sab/sabproduct.nsf/368203f97a15308a852574ba005bbd01/F08BEB48C1139E2A8525785E006909AC/\\$File/EPA-CASAC-11-004-unsigned+.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/368203f97a15308a852574ba005bbd01/F08BEB48C1139E2A8525785E006909AC/$File/EPA-CASAC-11-004-unsigned+.pdf).
- U.S. DHEW (1970). Air Quality Criteria for Photochemical Oxidants. National Air Pollution Control Administration Washington, DC. U.S. DHEW. publication no. AP-63. NTIS, Springfield, VA; PB-190262/BA.
- U.S. EPA (1978). Air Quality Criteria for Ozone and Other Photochemical Oxidants Environmental Criteria and Assessment Office. Research Triangle Park, NC. EPA-600/8-78-004. April 1978. Available at:  
<https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=200089CW.txt>.
- U.S. EPA (1986). Air Quality Criteria for Ozone and Other Photochemical Oxidants (Volume I - V). Environmental Criteria and Assessment Office. Research Triangle Park, NC. U.S.

- 1 EPA. EPA-600/8-84-020aF, EPA-600/8-84-020bF, EPA-600/8-84-020cF, EPA-600/8-  
2 84-020dF, EPA-600/8-84-020eF. August 1986. Available at:  
3 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001D3J.txt>  
4 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001DAV.txt>  
5 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001DNN.txt>  
6 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001E0F.txt>  
7 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=30001E9R.txt>.
- 8 U.S. EPA (1989). Review of the National Ambient Air Quality Standards for Ozone: Policy  
9 Assessment of Scientific and Technical Information. OAQPS Staff Paper. Office of Air  
10 Quality Planning and Standards. Research Triangle Park, NC U.S. EPA.
- 11 U.S. EPA (1992). Summary of Selected New Information on Effects of Ozone on Health and  
12 Vegetation: Supplement to 1986 Air Quality Criteria for Ozone and Other Photochemical  
13 Oxidants. Office of Research and Development. Washington, DC. U.S. EPA. EPA/600/8-  
14 88/105F.
- 15 U.S. EPA (1996). Air Quality Criteria for Ozone and Related Photochemical Oxidants. Volume I  
16 - III. Office of Research and Development Research Triangle Park, NC. U.S. EPA. EPA-  
17 600/P-93-004aF, EPA-600/P-93-004bF, EPA-600/P-93-004cF. July 1996. Available at:  
18 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=300026GN.txt>  
19 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=300026SH.txt>  
20 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=10004RHL.txt>.
- 21 U.S. EPA (2006). Air Quality Criteria for Ozone and Related Photochemical Oxidants (Volume I  
22 - III). Office of Research and Development U.S. EPA. EPA-600/R-05-004aF, EPA-  
23 600/R-05-004bF, EPA-600/R-05-004cF February 2006. Available at:  
24 <https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=149923>.
- 25 U.S. EPA (2013). Integrated Science Assessment of Ozone and Related Photochemical Oxidants  
26 (Final Report). Office of Research and Development, National Center for Environmental  
27 Assessment. Research Triangle Park, NC. U.S. EPA. EPA-600/R-10-076F. February  
28 2013. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KETF.txt>.
- 29 U.S. EPA (2014a). Policy Assessment for the Review of National Ambient Air Quality  
30 Standards for Ozone (Final Report). Office of Air Quality Planning and Standards, Health  
31 and Environmental Impacts Division. Research Triangle Park, NC. U.S. EPA. EPA-  
32 452/R-14-006 August 2014. Available at:  
33 <https://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P100KCZ5.txt>.
- 34 U.S. EPA (2014b). Welfare Risk and Exposure Assessment for Ozone (Final). . Office of Air  
35 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/P-14-  
36 005a August 2014. Available at:  
37 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KB9D.txt>.
- 38 U.S. EPA (2014c). Health Risk and Exposure Assessment for Ozone. (Final Report). Office of  
39 Air Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-



1 14-004a. August 2014. Available at:  
2 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KBUF.txt>.

3 U.S. EPA (2019). Integrated Review Plan for the Ozone National Ambient Air Quality  
4 Standards. Office of Air Quality Planning and Standards. Research Triangle Park, NC.  
5 U.S. EPA. EPA-452/R-19-002. Available at:  
6 [https://www.epa.gov/sites/production/files/2019-08/documents/o3-irp-aug27-](https://www.epa.gov/sites/production/files/2019-08/documents/o3-irp-aug27-2019_final.pdf)  
7 [2019\\_final.pdf](https://www.epa.gov/sites/production/files/2019-08/documents/o3-irp-aug27-2019_final.pdf).

8 U.S. EPA (2020). Integrated Science Assessment for Ozone and Related Photochemical  
9 Oxidants. U.S. Environmental Protection Agency. Washington, DC. Office of Research  
10 and Development. EPA/600/R-20/012. Available at: [https://www.epa.gov/isa/integrated-](https://www.epa.gov/isa/integrated-science-assessment-isa-ozone-and-related-photochemical-oxidants)  
11 [science-assessment-isa-ozone-and-related-photochemical-oxidants](https://www.epa.gov/isa/integrated-science-assessment-isa-ozone-and-related-photochemical-oxidants).

12 Zak, DR, Pregitzer, KS, Kubiske, ME and Burton, AJ (2011). Forest productivity under elevated  
13 CO<sub>2</sub> and O<sub>3</sub>: positive feedbacks to soil N cycling sustain decade-long net primary  
14 productivity enhancement by CO<sub>2</sub>. *Ecol Lett* 14(12): 1220-1226.

1

2

## **Attachment to Appendix 4A**

3

**Derivation of Composite Median Equations (parameterized models)  
in Lee and Hogsett (1996)**

*The following describes the methodology used to produce the sets of parameters in Tables 2, 12, and 13 of Lee and Hogsett (1996), which have been used in some form in AQCDs and ISAs since 1996. “Regression”, “parameter estimation”, “model estimation” and “model fitting” all refer to the same statistical procedure of using nonlinear ordinary least square regression to obtain values for model parameters from a dataset.*

- 1) Tables 12, 13, and 2 in Lee and Hogsett (1996) primarily summarize parameter values estimated through regression from 51 controlled exposure studies of tree seedlings conducted by NHEERL/WED. In those studies, 11 species of trees were exposed to a set of ozone concentrations for durations varying from 55 to 234 days or up to 555 days (in the case of one species).
- 2) The model fitted to the data from each of the 51 individual studies (in Table 12) is a three-parameter Weibull model with the following parameterization:  $Predicted\ Biomass = A \exp(-[exposure/B]^c)$ . When removing the intercept  $A$ , this model gives biomass relative to no exposure, and the resulting two-parameter equations all have the same 0-1 range of relative biomass response and can thus be compared or aggregated across studies with different ranges of absolute biomass.  $Predicted\ Relative\ Biomass = \exp(-[exposure/B]^c)$  and  $Predicted\ Relative\ Biomass\ Loss = 1 - \exp(-[exposure/B]^c)$ . When estimating each set of three parameters for each separate study, the ozone exposure was quantified using the 12-hour daytime W126 index, summed over the duration of each study.
  - a. Table 12 gives parameter values for 51 models, one per study, that reflect W126 over each study duration. This table also presents the W126 index estimated for a 92-day duration for RBLs of 10% and 20%.
  - b. Table 13 presents parameter values for the 51 models given in Table 12, as well as parameter values for composite models for the 11 tree species included in those 51 studies, two sets of values per species (one for the median and the second for the 75<sup>th</sup> percentile). This table also presents W126 index estimates for RBLs of 10%, 20% and 30%. These three estimates for the composite models are estimates for a 92-day duration.
  - c. Table 2 presents values for composite models for all experiments for all species aggregated.
- 3) The median composite models, one per species (table 13) are derived as follows. For each of the studies for a given species, the predicted relative biomass loss is first generated at six values of exposure: 10, 20, 30, 40, 50, and 60 ppm-hr, using the study-specific two-parameter equation. This is done in a way to obtain six values of exposure for 12-hour daytime exposures summed over 92 days.<sup>20</sup> All but the median of the relative biomass loss estimates at

<sup>20</sup> Since the W126 index is cumulative, and the duration of exposure varied between studies, the calculated values of exposure at which some given percent loss is expected were prorated to 92 days using simple linear scaling. For example, the duration of the first ponderosa pine study in Table 12 is 111 days. To derive the 92day RBL for 10 ppm-hrs, a factor of 92/111 is applied to 10 ppm-hrs before it is input to the experiment-specific equation to derive an RBL estimate for 10 ppm-hrs over a 92-day exposure.

each value of exposure are then discarded, and the two-parameter model for relative biomass loss is fitted to the remaining six median points. For example, Ponderosa Pine was the subject of 11 studies; 11 sets of parameters were estimated through regression (see item 2 above); 66 values of predicted relative biomass loss were then computed, 11 at each of the six exposure values. All but the median of those 11 relative biomass loss estimates were discarded at each of the six levels of exposure, and the two-parameter model fitted to the six remaining points, giving the Ponderosa Pine median composite equation for a 92-day exposure.

4) The all-species, median composite models (table 2) were estimated using the same aggregation method but applied to all 51 studies at once. The 51 equations in Table 12 were used to compute 306 values of relative biomass loss, six values each for the 51 sets of  $B$  and  $C$  parameters, with those six values of exposure generated in a way to obtain 12-hour daytime exposures summed over 92 days. The two-parameter model was then fitted to the 75<sup>th</sup> percentile and the median as in item 3 above. Table 2 also includes the results of the same method using other exposure indices besides the 12-hour W126 index.

5) For every equation in the tables, values of exposure at which some given percent loss is expected relative to no exposure, or any other exposure, can be back-calculated using:  $Exposure = B * (-\ln(1 - predicted\ relative\ biomass\ loss))^{1/C}$ . Some of those expected values of exposure are presented for various loss percentages in tables 2, 12, and 13 for the all-species median composite model, the 51 studies, and the 11 species-level median composite, respectively. In the case of single-study calculations in Table 12, the value of exposure for a given loss percentage was first calculated based on the respective duration of each study, then simply prorated. For example, the duration of Study 1 Harvest 1 in table 12 was 84 days and the exposure at which 10% loss is expected over that duration is 13.71 ppm-hr. The prorated exposure value for a 10% loss over 92 days is calculated as  $13.71 * 92 / 84 = 15.01$  ppm-hr. Median models for species in Table 13 or for all species in Table 2 were parameterized with 92-day durations and the exposure values for the various loss percentages did not therefore require prorating.

1  
2  
3  
4  
5

## **APPENDIX 4B**

### **U.S. DISTRIBUTION OF 11 TREE SPECIES**

## 4B.1. DESCRIPTION

This appendix presents maps of the distribution across the U.S. of 11 tree species for which there are established exposure-response (E-R) functions, as described in Appendix 4A. Historical ranges were based on Little (1971, 1976, 1977, and 1978) and basal area of each species was taken from Wilson et. al (2013) raster data to show present range and estimated density. Basal area is computed at the stand level as the sum of the basal area values for each individual tree (in sq. ft.), which is summed across all of the basal area per tree in the hectare. The map construction consists of tree species abundance, distribution, and basal area at a 250-meter (m) pixel size for the contiguous United States (Wilson 2013).






Table 4B-1. Distribution of quaking aspen (*Populus tremuloides*) in the continental U.S.




**Table 4B-2. Distribution of red maple (*Acer rubrum*) in the continental U.S.**





**Table 4B-3. Distribution of sugar maple (*Acer saccharum*) in the continental U.S.**

1



2

3

**Table 4B-4. Distribution of red alder (*Alnus rubra*) in the continental U.S.**





Table 4B-5. Distribution of tulip poplar (*Liriodendron tulipifera*) in the continental U.S.



**Table 4B-6. Distribution of ponderosa pine (*Pinus ponderosa*) in the continental U.S.**








Table 4B-7. Distribution of eastern white pine (*Pinus strobus*) in the continental U.S.




**Table 4B-8. Distribution of loblolly pine (*Pinus taeda*) in the continental U.S.**



**Table 4B-9. Distribution of Virginia pine (*Pinus virginiana*) in the continental U.S.**





**Table 4B-10. Distribution of black cherry (*Prunus serotina*) in the continental U.S.**






Table 4B-11. Distribution of Douglas fir (*Pseudotsuga menziesii*) in the continental U.S.

## REFERENCES

- Little, E.L., Jr., 1971, Atlas of United States trees, volume 1, conifers and important hardwoods: U.S. Department of Agriculture Miscellaneous Publication 1146, 9 p., 200 maps.
- Little, E.L., Jr., 1976, Atlas of United States trees, volume 3, minor Western hardwoods: U.S. Department of Agriculture Miscellaneous Publication 1314, 13 p., 290 maps.
- Little, E.L., Jr., 1977, Atlas of United States trees, volume 4, minor Eastern hardwoods: U.S. Department of Agriculture Miscellaneous Publication 1342, 17 p., 230 maps.
- Little, E.L., Jr. 1978, Atlas of United States trees, volume 5, Florida: U.S. Department of Agriculture Miscellaneous Publication 1361, 262 maps.
- Wilson, Barry Tyler; Lister, Andrew J.; Riemann, Rachel I.; Griffith, Douglas M. 2013. Live tree species basal area of the contiguous United States (2000-2009). Newtown Square, PA: USDA Forest Service, Rocky Mountain Research Station. <https://doi.org/10.2737/RDS-2013-0013>

1 **APPENDIX 4C**

2 **VISIBLE FOLIAR INJURY SCORES AT U.S. FOREST SERVICE**  
3 **BIOSITES (2006-2010)**

4 **TABLE OF CONTENTS**

|    |      |   |    |
|----|------|---|----|
| 5  | 4C.1 | Introduction.....   | 2  |
| 6  | 4C.2 | Dataset Preparation .....   | 2  |
| 7  | 4C.3 | Dataset Characteristics.....  | 5  |
| 8  | 4C.4 | Relationships of Biosite Index Scores with W126 Estimates and Soil Moisture               |    |
| 9  |      | Categories .....  | 6  |
| 10 |      | 4C.4.1 Relationships Examined in Full Dataset.....  | 6  |
| 11 |      | 4C.4.2 Examination of Relationships in Dataset Stratified by Soil Moisture Category ..... | 9  |
| 12 | 4C.5 | Limitations and Uncertainties .....   | 19 |
| 13 | 4C.6 | Summary and Key Observations .....  | 20 |
| 14 |      | References.....   | 23 |

## 4C.1 INTRODUCTION

It has long been recognized that elevated ozone (O<sub>3</sub>) can cause visible foliar injury in some plants (ISA, Appendix 8, section 8.2). As discussed in the current and past ISAs as well as past Air Quality Criteria Documents, the severity and extent of visible foliar injury can vary with a variety of environmental variables (e.g., climatic variables as well as pollutant exposure) as well as variation in genetic factors within the same plant population (ISA, Appendix 8, section 8.2). Visible foliar injury “occurs only when sensitive plants are exposed to elevated O<sub>3</sub> concentrations in a predisposing environment,” and “a major modifying factor is the amount of soil moisture available to a plant during the year when assessed” (U.S. EPA, 2013 [2013 ISA], p. 9-39).

In recognition of the long-standing evidence regarding O<sub>3</sub> and visible foliar injury in susceptible species, the U.S. Forest Service (USFS) and U.S. Park Service have used plant species with this susceptibility in their biomonitoring programs. A number of publications have focused on findings from biomonitoring surveys in the USFS-Forest Health Monitoring (FHM) and Forest Inventory and Analyses (FIA) programs. From the mid 1990s through 2010, this survey work included collecting information on the presence of visible foliar injury at the biomonitoring sites (biosites). Data on visible foliar injury incidence and severity data were collected each year at biosites in forested areas at states across the U.S. and summarized in terms of a biosite index (BI). The BI is a measure of the severity of O<sub>3</sub>-induced visible foliar injury observed at each biosite.

Data from the multi-year USFS survey were used in analyses developed in the 2015 O<sub>3</sub> NAAQS review (80 FR 65292, October 26, 2015). These analyses utilized a dataset that had been developed by merging biosite data collected as part of the USFS FHM/FIA Network during the years 2006 through 2010, with NOAA soil moisture index values (as a surrogate for soil moisture measurements) and W126 estimates of seasonal O<sub>3</sub> exposure for those sites based on ambient air monitoring data for those 5 years (Smith and Murphy, 2015; U.S. EPA, 2014 [2014 WREA]). The resultant combined dataset included a BI score, soil moisture index value and a W126 index estimate each for 5,284 records at locations in 37 states for 1 or more of the years in the 5-year period from 2006-2010. This appendix brings forward key presentations developed from the combined dataset for the 2015 O<sub>3</sub> review and also includes additional presentations of key aspects of the dataset and the variables represented within it.

## 4C.2 DATASET PREPARATION

The combined dataset was developed from three datasets: (1) the national-scale FIA/FHM dataset of BI scores, (2) the NOAA’s National Climatic Data Center national dataset of monthly drought indices and (3) national surfaces of estimated seasonal W126 index

1 developed by the EPA for the WREA in the last O<sub>3</sub> NAAQS review and further analyzed in a  
2 subsequent technical memo (Smith and Murphy, 2015). These individual datasets and how they  
3 were used to create the combined dataset, are described below.

4 Biosite Index: The USFS O<sub>3</sub> biomonitoring program has developed a national-scale data  
5 set focused on visible foliar injury and that includes BI scores at biosites in U.S. forests (Smith,  
6 2012). The field methods, sampling procedures, and analytical techniques are consistent across  
7 biosites and years. The BI is calculated from species-specific scores based on a combination of  
8 the proportion of leaves affected on individual bioindicator plants and the severity of symptoms  
9 on injured foliage using an established scale (Horsfall and Cowling, 1978; Smith, 2012). Each  
10 site is sampled until 30 plants of at least two species have been evaluated (Smith et al., 2007).  
11 The site BI is the average score for each species averaged across all species on the biosite  
12 multiplied by 1,000 (Smith, 2012). The BI score ranges from zero to greater than 25, with a score  
13 of zero indicating no presence of foliar injury symptoms and scores increasingly greater than  
14 zero indicating increasingly greater severity of symptoms (Smith, 2012). Categories that have  
15 been used in publications include little or very light injury (BI greater than 0 up to 5), light injury  
16 (BI greater than 5 up to 15), moderate (BI greater than 15 up to 25) and heavy/severe (BI above  
17 25) (Smith, 2012; Coulston et al., 2003).

18 The biosite data (BI scores) were obtained from the USFS for the years 2006 to 2010.  
19 While including most states in the contiguous U.S., the data obtained did not include records for  
20 most of the western states (Montana, Idaho, Wyoming, Nevada, Utah, Colorado, Arizona, New  
21 Mexico, Oklahoma, and portions of Texas) because biosite data were not available for those  
22 states during the 2006-2010 period (Smith et al., 2012).

23 Soil Moisture Index: The NOAA Palmer Z drought index is a monthly moisture anomaly  
24 index that is derived from measurements such as precipitation and temperature. This index  
25 represents the difference between monthly soil moisture and long-term average soil moisture  
26 (Palmer, 1965). The Palmer Z index is derived each month for each of 344 climate region  
27 divisions within the contiguous U.S. by the National Climatic Data Center (NCDC).<sup>1</sup> The index  
28 values typically range from -4 to +4, with positive values representing more wetness than normal  
29 and negative values representing more dryness than normal. For the combined dataset, index  
30 values for April through August in the years 2006-2010 were obtained from the NCDC website  
31 (NOAA, 2012). These monthly values were then averaged to create a single growing season  
32 index for each year in each division. Moisture categories were then assigned consistent with

---

<sup>1</sup> There are 344 climate divisions in the continental U.S. For each climate division, monthly station temperature and precipitation values are computed from the daily observations as described on the website for the National Climatic Data Center of the U.S. National Atmospheric and Oceanic Administration:  
<https://www.ncdc.noaa.gov/monitoring-references/maps/us-climate-divisions.php>

NOAA's Palmer Z drought index, with index values less than -1.25 identified as "dry", values greater than or equal to 1 identified as "wet", and index values between -1.25 and 1 identified as "normal." Values beyond the range from -2.75 to +3.5 could be interpreted as extreme drought and extremely moist, respectively (NCDC, 2012c). The NCDC climate divisions with Palmer Z data are shown in Figure 4C-1.



**Figure 4C-1. Climate divisions for which there are Palmer Z soil moisture index values.**

W126 Index Estimates: Estimates of seasonal W126 exposure index for the years 2006 through 2010 were developed for 12 kilometer (km) by 12 km grid cells in a national-scale spatial surface. The estimates at this scale were derived from applying a spatial interpolation technique to annual W126 values derived from O<sub>3</sub> measurements at ambient air monitoring locations. Specifically, the Voronoi Neighbor Averaging (VNA) spatial interpolation technique was applied to the monitor-location W126 index values to derive an W126 index estimates for each grid cell (U.S. EPA, 2014, Appendix 4A).<sup>2</sup>

Combined Dataset: To create the dataset that relates the grid cells with W126 index estimates to grid cells with BI scores, the EPA provided a file with the national-scale surface of grid cells (a "shape" file) to USFS staff, who assigned the BI scores (with sampling year specified) to grid cells for all but three states. Having this step performed by the USFS ensured

<sup>2</sup>The VNA application step used to estimate W126 indices at the centroid of every 12 km x 12 km grid cell, rather than only at each monitor location (described in Appendix 4A of the WREA), can result in a lowering of the highest values in each region (80 FR 65374-65375; October 26, 2015).

1 that the precise and accurate geographic coordinates for each biosite were used in this step,  
2 which allowed the most accurate matching of Palmer Z and W126 index values as possible with  
3 these datasets.<sup>3</sup> For three states (California, Oregon, and Washington) the EPA downloaded  
4 biosite indices from the public website and assigned them to the grid cells in which the biosite  
5 was located based on the publicly available geographic coordinates.<sup>4</sup> The EPA overlaid the  
6 Palmer Z dataset for each year on the national surface of W126 index estimates for that year to  
7 assign a Palmer Z index to each grid cell in each year's national surface. The completed dataset  
8 (Smith and Murphy, 2015, Appendix) includes the following variables: identifier, year, W126  
9 index, BI score, Palmer Z index, state and soil moisture category (dry, wet, normal)<sup>5</sup>.

#### 10 **4C.3 DATASET CHARACTERISTICS**

11 The dataset for the analyses included 5,284 biosite records distributed across the 37  
12 different states and the five years from 2006 – 2010 (Smith and Murphy, 2015, Appendix).  
13 Figure 4C-2, reprinted from 2014 WREA, indicates the distribution of sites across the  
14 continental U.S. Table 4C-2 summarizes the biosite index values for each year. The “Damage”  
15 categories used follow the USFS risk categories with the exception of including a separate  
16 category for a biosite index of zero (Smith, 2008, 2012). The zero category was defined and used  
17 as a measure of the presence or absence of any level of visible foliar injury. Across all of the  
18 sites, over 81 percent of the observations recorded no foliar injury. This percentage was similar  
19 across all of the years, with a low value of 78 percent and a high value of 85 percent. Across the  
20 5,284 records in the dataset, only 998 had BI scores greater than zero.


---

<sup>3</sup> This step was taken because the publicly available USFS BI dataset includes location coordinates that have been slightly altered to avoid specifying the true biosite location for privacy considerations of some property owners.

<sup>4</sup> As a result, there is a potential for the biosites for these states to be matched with the W126 index estimate for an adjacent grid cell rather than the one in which the biosite is truly located.

<sup>5</sup> As described earlier in the section on “Soil Moisture Index,” all index values less than -1.25 were categorized as “dry” and all index values greater than or equal to 1 were categorized as “wet.”





**Figure 4C-2. USFS biomonitoring sites for visible foliar injury (“Biosites”).**

**Table 4C-1. Summary of biosite index scores for 2006 to 2010 USFS biomonitoring sites.**

| Biosite Index | Damage     | 2006 | 2007 | 2008 | 2009  | 2010  | Total |
|---------------|------------|------|------|------|-------|-------|-------|
| 0             | None       | 744  | 769  | 796  | 902   | 1,075 | 4,286 |
| < 5           | Very Light | 139  | 131  | 98   | 135   | 183   | 686   |
| 5 to 15       | Light      | 41   | 29   | 29   | 61    | 65    | 225   |
| 15 to 25      | Moderate   | 15   | 6    | 8    | 6     | 12    | 47    |
| > 25          | Heavy      | 12   | 4    | 4    | 8     | 12    | 40    |
| Total         |            | 951  | 939  | 935  | 1,112 | 1,347 | 5,284 |


## 4C.4 RELATIONSHIPS OF BIOSITE INDEX SCORES WITH W126 ESTIMATES AND SOIL MOISTURE CATEGORIES

### 4C.4.1 Relationships Examined in Full Dataset


Scatterplots of the full dataset show no clear relationship between  $O_3$  and biosite index (Figure 4C-3), as well as no clear relationship between  $O_3$  and the Palmer Z drought index, measured as an average value of the months from April to August (Figure 4C-4). The lack of a clear relationship is partly due to the high number of observations with no foliar injury (see Table 4C-1 above and also the distribution of records by soil moisture category and W126 summarized in section 4C.4.2 below) and may also reflect, in part, differing spatial resolutions of



the O<sub>3</sub> exposure surface, NCDC climate divisions, and the biosites. To investigate the strength of any relationship in light of the high percentage of zero values, a censored regression was conducted using a threshold of zero (i.e., including only the non-zero observations). The results of the regression (Table 4C-2) are consistent with the evaluation of the evidence in the ISA (and prior ISA and AQCDs), indicating a significant relationship between foliar injury and both O<sub>3</sub> and moisture (as measured by Palmer Z), and also a significant interaction between O<sub>3</sub> and moisture. The censored regression does not provide a “goodness of fit” statistic as easily interpreted as the r-squared value associated with a standard regression, so the results are more difficult to interpret. Thus, while higher O<sub>3</sub> corresponds to higher BI score, the parameters describing such a relationship in predictive quantitative terms are unresolved.



**Figure 4C-3. Scatter plot of biosite index score *versus* W126 index (ppm-hrs).**



**Figure 4C-4. Scatter plot of biosite index score *versus* Palmer Z (April to August).**

**Table 4C-2. Statistics from censored regression.**

| Coefficient        | Intercept Estimate | Standard Error | t-value | p        |
|--------------------|--------------------|----------------|---------|----------|
| Intercept          | -22.5967           | 0.8934         | -25.293 | < 0.0001 |
| W126               | 0.7307             | 0.0613         | 11.919  | <0.0001  |
| Palmer Z (Apr-Aug) | 1.8357             | 0.4850         | 3.785   | 0.0002   |
| W126: Palmer Z     | 0.1357             | 0.0437         | 3.104   | 0.0019   |
|                    | Marginal Effect    |                |         |          |
| W126               | 0.1178             | 0.0099         | 11.918  | <0.0001  |
| Palmer Z (Apr-Aug) | 0.2960             | 0.0777         | 3.812   | 0.0001   |
| W126: Palmer Z     | 0.0219             | 0.0070         | 3.093   | 0.0020   |

An exploration (in the 2014 WREA) of the use of regression coefficients to calculate estimated biosite index values did not accurately predict the observed values, likely due in part to the large number of non-injury observations. It is also of note that the W126 index bin with the largest percentage of records of each category of BI score (e.g., all, zero, above zero, above 5, above 15) is that for the lowest W126 index values (0).

**Table 4C-3. Cumulative percentage of records with specified BI score.**

| < 7<br>ppm-hrs  | >7 -9<br>ppm-hrs | >9 – 11<br>ppm-hrs | >11 -13<br>ppm-hrs | >13 -15<br>ppm-hrs | >15 -17<br>ppm-hrs | >17 - 19<br>ppm-hrs | >19 - 25<br>ppm-hrs | >25<br>ppm-hrs |
|---|------------------|--------------------|--------------------|--------------------|--------------------|---------------------|---------------------|----------------|
| <i>Cumulative Percentage of Records (percent of records in bin plus all bins to its left)</i> |                  |                    |                    |                    |                    |                     |                     |                |
| <b>Of All Records</b>   |                  |                    |                    |                    |                    |                     |                     |                |
| 42%   | 59%              | 73%                | 82%                | 88%                | 92%                | 96%                 | 98%                 | 100%           |
| <b>Of Records with BI=0 (total in dataset =4286)</b>  |                  |                    |                    |                    |                    |                     |                     |                |
| 43%   | 60%              | 73%                | 83%                | 88%                | 93%                | 97%                 | 99%                 | 100%           |
| <b>Of Records with BI&gt;0 (total in dataset =998)</b>  |                  |                    |                    |                    |                    |                     |                     |                |
| 37%   | 53%              | 69%                | 78%                | 84%                | 87%                | 93%                 | 96%                 | 100%           |
| <b>Of Records with BI&gt;5 (total in dataset =310)</b>  |                  |                    |                    |                    |                    |                     |                     |                |
| 36%   | 49%              | 64%                | 73%                | 78%                | 82%                | 88%                 | 91%                 | 100%           |
| <b>Of Records with BI &gt; 15 (total in dataset =85)</b>                                      |                  |                    |                    |                    |                    |                     |                     |                |
| 33%   | 45%              | 49%                | 59%                | 64%                | 69%                | 78%                 | 86%                 | 100%           |

#### 4C.4.2 Examination of Relationships in Dataset Stratified by Soil Moisture Category

The following tables and figures describe the data in this dataset with a focus on consideration of potential trends with W126 index for the different soil moisture categories. The W126 index estimates were rounded to integer values for consistency with Appendix 4D analyses and associated clarity in binning of the values.<sup>6</sup> Additionally, consistent with USFS publications (e.g., Campbell et al., 2007), the BI scores<sup>7</sup> are rounded to one decimal place. Table 4C-4 presents the counts of records in total and stratified by soil moisture category and W126 index bin. Table 4C-5 presents average BI scores by soil moisture category and W126 bin, and Table 4C-6 presents the fraction of records with BI scores of differing severity levels (corresponding to the USFS severity scheme), in the full dataset and also in the subsets by soil moisture category.

The distribution of records across W126 bins are presented in Table 4C-4 and Figure 4C-5, and the distribution of scores per bin is presented in Figure 4C-6 through Figure 4C-11. These figures show that even the lowest W126 index bin (for estimates below 7 ppm-hrs) includes scores well above 5, and several above 15. Further, zero scores comprise more than half the dry and normal soil category record scores in every bin, including the highest bin (>25 ppm hrs), as

<sup>6</sup> The presentations here are not precise statistical analyses. Rather, they are intended to generally inform conclusions regarding ability of available datasets to discern air quality conditions contributing to visible foliar injury occurrences of potential concern. In this light, binning was used to explore the potential for clear differences in BI scores among sites with differing W126 estimates across the range of interest while also maintaining reasonable sample sizes.

<sup>7</sup> Two records with estimated W126 index below 7 ppm-hrs and BI scores just over 150 are omitted from presentations in this section as the next highest BI score in this dataset for any W126 index was below 100.

1 seen by the median lines merged with the zero line in Figure 4C-6 and Figure 4C-8. This is also  
2 the case for all but the two highest bins for the wet soil moisture category records, which,  
3 however, contain just a total of 9 records, limiting the extent to which they provide a basis for  
4 interpretation of patterns across W126 bins. The wet soil moisture records have quite limited  
5 sample sizes for the higher W126 index bins, e.g., the number of samples in bins for W126 index  
6 estimates above 13 ppm-hrs represent no more than 1 percent of the total number of wet soil  
7 moisture records (Figure 4C-10).

8 Focusing on the distribution of scores for records in the normal soil moisture category, it  
9 can be seen that scores are noticeably increased in the highest W126 bin, index estimates greater  
10 than 25 ppm-hrs, over those for the lower bins (Figure 4C-6 and Figure 4C-7). This is also for  
11 the average BI scores per bin, where the highest W126 bin (>25 ppm-hrs) has an average BI  
12 appreciably higher than the others (Table 4C-5). The average BI in this highest bin is 7.9 *versus*  
13 averages of 1.6 (for W126 >19 to 25 ppm-hrs) and 2.3 (for W126 >17 to 19 ppm-hrs) in the next  
14 lower bins and varying from 0.8 to 1.2 in all the others. Among the records with nonzero scores,  
15 the highest average BI is also in the highest W126 index bin (>25 ppm-hrs); in this case the BI is  
16 approximately 15, more than double the next highest average BI scores for any of the other  
17 W126 index bins (for which no other trend is exhibited). The incidence of records with BI scores  
18 categorized by the USFS as “moderate” or “severe” injury (BI score above 15) is also greatest in  
19 the bin for the highest W126 index estimates (> 25 ppm-hrs), with 20% of those records in this  
20 bin having such a BI score compared to only 2 to 4% of the records in each of the lower bins. A  
21 similar pattern holds for the records with BI scores above 5, while there is much more variability  
22 across the bins for records with any nonzero score (Table 4C-6).

23 With regard to the dry soil moisture category, there is a suggestion of an increased  
24 incidence of the highest severity scores in the highest two W126 bins. For example, the  
25 proportion of dry soil moisture category records with BI scores categorized by the USFS as  
26 “moderate” or “severe” injury (BI score above 15), is 7 and 8% in the bin for the two highest  
27 W126 index estimates (>19 to 25 and > 25 ppm-hrs, respectively), compared to 0 to 3% in each  
28 of the lower bins. It is noteworthy, however, that the percentages of 7 and 8% reflect no more  
29 than 4 or 5 individual records with this severity score.


30 As noted above, sample size for the wet soil moisture category is particularly limited for  
31 the W126 index bins above 13 ppm-hrs. In the lower W126 bins, the proportion of such records  
32 with BI scores above 15 varies from 1 to 2%. For BI scores above 5 or above 0, there is a  
33 suggestion of an increased incidence in the relatively higher *versus* lower W126 index bins,  
34 although it is not known if the significant reduction in sample size that also occurs in comparing  
35 across these bins (see Table 4C-4) and associated variability is playing a role (Table 4C-6).

1 **Table 4C-4. Number of biosite records in different W126 index bins.**


|   | < 7<br>ppm-hrs | >7 -9<br>ppm-hrs | >9 – 11<br>ppm-hrs | >11 -13<br>ppm-hrs | >13 -15<br>ppm-hrs | >15 -17<br>ppm-hrs | >17 - 19<br>ppm-hrs | >19 - 25<br>ppm-hrs | >25<br>ppm-hrs |
|---|----------------|------------------|--------------------|--------------------|--------------------|--------------------|---------------------|---------------------|----------------|
| <b>All Records (n=5282 <sup>A</sup>)</b>  |                |                  |                    |                    |                    |                    |                     |                     |                |
| Dry (n=866)   | 155            | 117              | 116                | 76                 | 83                 | 97                 | 99                  | 73                  | 50             |
| Normal (n=3227)   | 1181           | 613              | 522                | 360                | 222                | 147                | 92                  | 49                  | 41             |
| Wet (n=1189)  | 868            | 179              | 81                 | 43                 | 9 <sup>B</sup>     | 7 <sup>B</sup>     | 2 <sup>B</sup>      | 0 <sup>B</sup>      | 0 <sup>B</sup> |
| All   | 2204           | 909              | 719                | 479                | 314                | 251                | 193                 | 122                 | 91             |
| <b>Records with BI &gt; 15 (total in dataset =85)</b>   |                |                  |                    |                    |                    |                    |                     |                     |                |
| Dry   | 3              | 0                | 0                  | 0                  | 0                  | 0                  | 3                   | 5                   | 4              |
| Normal  | 20             | 7                | 3                  | 7                  | 4                  | 3                  | 3                   | 2                   | 8              |
| Wet   | 5              | 3                | 1                  | 1                  | 0 <sup>B</sup>     | 2 <sup>B</sup>     | 1 <sup>B</sup>      | 0 <sup>B</sup>      | 0 <sup>B</sup> |
| All   | 28             | 10               | 4                  | 8                  | 4                  | 5                  | 7                   | 7                   | 12             |
| <b>Records with BI&gt;5 (total in dataset =310)</b>   |                |                  |                    |                    |                    |                    |                     |                     |                |
| Dry   | 6              | 3                | 5                  | 3                  | 4                  | 1                  | 5                   | 8                   | 10             |
| Normal  | 56             | 30               | 28                 | 18                 | 11                 | 8                  | 12                  | 3                   | 17             |
| Wet   | 49             | 9                | 13                 | 6                  | 1 <sup>B</sup>     | 2 <sup>B</sup>     | 2 <sup>B</sup>      | 0 <sup>B</sup>      | 0 <sup>B</sup> |
| All   | 111            | 42               | 46                 | 27                 | 16                 | 11                 | 19                  | 11                  | 27             |
| <b>Records with BI&gt;0 (total in dataset =998)</b>   |                |                  |                    |                    |                    |                    |                     |                     |                |
| Dry   | 10             | 13               | 9                  | 6                  | 6                  | 9                  | 15                  | 15                  | 23             |
| Normal  | 158            | 117              | 109                | 68                 | 52                 | 20                 | 35                  | 15                  | 21             |
| Wet   | 197            | 36               | 34                 | 17                 | 5 <sup>B</sup>     | 4 <sup>B</sup>     | 2 <sup>B</sup>      | 0 <sup>B</sup>      | 0 <sup>B</sup> |
| All   | 365            | 166              | 152                | 91                 | 63                 | 33                 | 52                  | 30                  | 44             |
| <b>Records with BI=0 (total in dataset =4286)</b>   |                |                  |                    |                    |                    |                    |                     |                     |                |
| Dry   | 145            | 104              | 107                | 70                 | 77                 | 88                 | 84                  | 58                  | 27             |
| Normal  | 1023           | 496              | 413                | 292                | 170                | 127                | 57                  | 34                  | 20             |
| Wet   | 671            | 143              | 47                 | 26                 | 4 <sup>B</sup>     | 3 <sup>B</sup>     | 0 <sup>B</sup>      | 0 <sup>B</sup>      | 0 <sup>B</sup> |
| All   | 1839           | 743              | 567                | 388                | 251                | 218                | 141                 | 92                  | 47             |
| <sup>A</sup> As noted in the beginning of section 4C.1.2, this count reflects the omission of two outlier values. |                |                  |                    |                    |                    |                    |                     |                     |                |
| <sup>B</sup> Sample size for this W126 bin is below 1% of all samples assigned this soil moisture category.       |                |                  |                    |                    |                    |                    |                     |                     |                |

2

1




2



3


**Figure 4C-5. Distribution of biosite records by W126 bin and soil moisture type.**

1




Key: The boxes denote the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles, the x's the mean and the whiskers denote the value equal to the 75<sup>th</sup> percentile plus 1.5 times the interquartile range (75<sup>th</sup> minus 25<sup>th</sup> percentile). Circles show scores higher than that.

**Figure 4C-6. Distribution of BI scores (including zeros) at USFS biosites (normal soil moisture) grouped by W126 index values.**




Key: The boxes denote the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles, the x's the mean and the whiskers denote the value equal to the 75<sup>th</sup> percentile plus 1.5 times the interquartile range (75<sup>th</sup> minus 25<sup>th</sup> percentile). Circles show scores higher than that.

**Figure 4C-7. Distribution of nonzero BI scores at USFS biosites (normal soil moisture) grouped by W126 index values.**



Key: The boxes denote the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles, the x's the mean and the whiskers denote the value equal to the 75<sup>th</sup> percentile plus 1.5 times the interquartile range (75<sup>th</sup> minus 25<sup>th</sup> percentile). Circles show scores higher than that.


**Figure 4C-8. Distribution of BI scores (including zeros) at USFS biosites (dry soil moisture) grouped by W126 index values.**



Key: The boxes denote the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles, the x's the mean and the whiskers denote the value equal to the 75<sup>th</sup> percentile plus (or 25<sup>th</sup> percentile minus) 1.5 times the interquartile range (75<sup>th</sup> minus 25<sup>th</sup> percentile). Circles show still higher scores


**Figure 4C-9. Distribution of nonzero BI scores at USFS biosites (dry soil moisture) grouped by W126 index values.**





Key: The boxes denote the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles, the x's the mean and the whiskers denote the value equal to the 75<sup>th</sup> percentile plus 1.5 times the interquartile range (75<sup>th</sup> minus 25<sup>th</sup> percentile). Circles show scores higher than that.

**Figure 4C-10. Distribution of BI scores (including zeros) at USFS biosites (wet soil moisture) grouped by W126 index values.**



Key: The boxes denote the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles, the x's the mean and the whiskers denote the value equal to the 75<sup>th</sup> percentile plus (and the 25<sup>th</sup> minus) 1.5 times the interquartile range (75<sup>th</sup> minus 25<sup>th</sup> percentile). Circles show scores above that.

**Figure 4C-11. Distribution of nonzero BI scores at USFS biosites (wet soil moisture) grouped by W126 index values.**

1 **Table 4C-5. Average BI scores of the records in each W126 index bin.**

| Soil Moisture  | ≤ 7 ppm-hrs | >7 -9 ppm-hrs | >9 - 11 ppm-hrs | >11 -13 ppm-hrs | >13 -15 ppm-hrs | >15 -17 ppm-hrs | > 17 - 19 ppm-hrs | > 19 - 25 ppm-hrs | > 25 ppm-hrs |
|--|-------------|---------------|-----------------|-----------------|-----------------|-----------------|-------------------|-------------------|--------------|
| <b>Average BI (all records)</b>  |             |               |                 |                 |                 |                 |                   |                   |              |
| Dry  | 0.9         | 0.3           | 0.4             | 0.4             | 0.4             | 0.2             | 2.3               | 2.1               | 3.5          |
| Normal   | 0.9         | 0.9           | 0.8             | 1.2             | 1.2             | 0.9             | 2.3               | 1.6               | 7.9          |
| Wet <sup>c</sup>   | 0.9         | 0.9           | 1.9             | 1.9             | [2.2]           | [6.7]           | [13.9]            | -                 | -            |
| All  | 0.9         | 0.8           | 0.8             | 1.1             | 1.0             | 0.8             | 2.4               | 1.9               | 5.5          |
| <b>Average BI (records with BI &gt; 0)</b>   |             |               |                 |                 |                 |                 |                   |                   |              |
| Dry  | 14.2        | 3.0           | 5.1             | 4.2             | 5.1             | 2.6             | 15.0              | 10.40             | 7.60         |
| Normal   | 6.8         | 4.7           | 3.7             | 6.3             | 5.2             | 6.9             | 6.0               | 5.19              | 15.42        |
| Wet <sup>c</sup>   | 3.8         | 4.3           | 4.6             | 4.9             | [4.0]           | [11.8]          | [13.9]            | -                 | -            |
| All  | 5.4         | 4.4           | 4.0             | 6.0             | 5.1             | 6.3             | 9.0               | 7.8               | 11.3         |
| <b>Average BI (records with BI &gt;5)</b>  |             |               |                 |                 |                 |                 |                   |                   |              |
| Dry  | 23.6        | 6.9           | 8.1             | 6.6             | 7.1             | 6.3             | 41.1              | 18.4              | 14.2         |
| Normal   | 17.0        | 14.3          | 10.5            | 19.0            | 19.7            | 15.1            | 13.8              | 18.3              | 18.5         |
| Wet <sup>c</sup>   | 11.4        | 14.2          | 9.7             | 10.4            | [12.5]          | [20.2]          | [13.9]            | -                 | -            |
| All  | 14.9        | 13.7          | 10.0            | 15.7            | 16.1            | 15.2            | 21.0              | 18.4              | 16.9         |
| <b>Average BI (records with BI &gt;15)</b>   |             |               |                 |                 |                 |                 |                   |                   |              |
| Dry  | 39          | -             | -               | -               | -               | -               | 60.3              | 24.1              | 22.9         |
| Normal   | 32.0        | 31.2          | 22.2            | 36.0            | 38.0            | 27.5            | 30.5              | 24.4              | 27.9         |
| Wet <sup>c</sup>   | 34.4        | 25.8          | 15.2            | 16.7            | -               | [20.2]          | [17.4]            | -                 | -            |
| All  | 33.2        | 29.6          | 20.4            | 33.6            | 38.0            | 24.6            | 41.4              | 24.2              | 26.3         |
| <sup>a</sup> Brackets indicate bins in which total sample size for that bin is below 1% of all for that soil moisture category (i.e., 0 to 9 samples). |             |               |                 |                 |                 |                 |                   |                   |              |

2

3

1 **Table 4C-6. Proportion of records in each W126 index bin with specified BI score.**

| Soil Moisture   | ≤ 7 ppm-hrs | >7 -9 ppm-hrs | >9 - 11 ppm-hrs | >11 -13 ppm-hrs | >13 -15 ppm-hrs | >15 -17 ppm-hrs | > 17 - 19 ppm-hrs | > 19 – 25 ppm-hrs | >25 ppm-hrs |
|---|-------------|---------------|-----------------|-----------------|-----------------|-----------------|-------------------|-------------------|-------------|
| <b>Proportion of Records with BI &gt;15</b> ( <i>USFS categories of “moderate” and “severe”</i> )   |             |               |                 |                 |                 |                 |                   |                   |             |
| Dry   | 0.02        | 0.00          | 0.00            | 0.00            | 0.00            | 0.00            | 0.03              | 0.07              | 0.08        |
| Normal  | 0.02        | 0.01          | 0.01            | 0.02            | 0.02            | 0.02            | 0.03              | 0.04              | 0.20        |
| Wet <sup>A</sup>  | 0.01        | 0.02          | 0.01            | 0.02            | [0.00]          | [0.29 (2)]      | [0.50 (1)]        | [0.00]            | [0.00]      |
| All   | 0.01        | 0.01          | 0.01            | 0.02            | 0.01            | 0.02            | 0.04              | 0.06              | 0.13        |
| <b>Proportion of Records with BI &gt;5</b> ( <i>USFS categories of “low,” “moderate” and “severe”</i> )   |             |               |                 |                 |                 |                 |                   |                   |             |
| Dry   | 0.04        | 0.03          | 0.04            | 0.04            | 0.05            | 0.01            | 0.05              | 0.11              | 0.20        |
| Normal  | 0.05        | 0.05          | 0.05            | 0.05            | 0.05            | 0.05            | 0.13              | 0.06              | 0.41        |
| Wet <sup>A</sup>  | 0.06        | 0.05          | 0.16            | 0.14            | [0.11 (1)]      | [0.29 (2)]      | [1.00 (2)]        | [0.00]            | [0.00]      |
| All   | 0.05        | 0.05          | 0.06            | 0.06            | 0.05            | 0.04            | 0.10              | 0.09              | 0.30        |
| <b>Proportion of Records with BI &gt;5 &amp; ≤15</b> ( <i>USFS category of “low”</i> )  |             |               |                 |                 |                 |                 |                   |                   |             |
| Dry   | 0.02        | 0.03          | 0.04            | 0.04            | 0.05            | 0.01            | 0.02              | 0.04              | 0.12        |
| Normal  | 0.03        | 0.04          | 0.05            | 0.03            | 0.03            | 0.03            | 0.10              | 0.02              | 0.22        |
| Wet <sup>A</sup>  | 0.05        | 0.03          | 0.15            | 0.12            | [0.11 (1)]      | [0.00]          | [0.50 (1)]        | [0.00]            | [0.00]      |
| All   | 0.04        | 0.04          | 0.06            | 0.04            | 0.04            | 0.02            | 0.06              | 0.03              | 0.16        |
| <b>Proportion of Records with BI &gt;0 &amp; ≤5</b> ( <i>USFS category of “little”</i> )  |             |               |                 |                 |                 |                 |                   |                   |             |
| Dry   | 0.03        | 0.09          | 0.03            | 0.04            | 0.02            | 0.08            | 0.10              | 0.10              | 0.26        |
| Normal  | 0.09        | 0.14          | 0.16            | 0.14            | 0.18            | 0.08            | 0.25              | 0.24              | 0.10        |
| Wet <sup>A</sup>  | 0.17        | 0.15          | 0.26            | 0.26            | [0.44 (4)]      | [0.29 (2)]      | 0.00              | [0.00]            | 0.00        |
| All   | 0.12        | 0.14          | 0.15            | 0.13            | 0.15            | 0.09            | 0.17              | 0.16              | 0.19        |
| <b>Proportion of Records with BI &gt;0</b> ( <i>USFS categories of “little,” “low,” “moderate” and “severe”</i> )   |             |               |                 |                 |                 |                 |                   |                   |             |
| Dry   | 0.          | 0.11          | 0.08            | 0.08            | 0.07            | 0.09            | 0.15              | 0.21              | 0.46        |
| Normal  | 0.13        | 0.19          | 0.21            | 0.19            | 0.23            | 0.14            | 0.38              | 0.31              | 0.51        |
| Wet <sup>A</sup>  | 0.23        | 0.20          | 0.42            | 0.40            | [0.56 (5)]      | [0.57 (4)]      | [1.00 (2)]        | [0.00]            | [0.00]      |
| All   | 0.17        | 0.18          | 0.21            | 0.19            | 0.20            | 0.13            | 0.27              | 0.25              | 0.48        |
| <b>Proportion of Records with BI =0</b> ( <i>USFS category of no injury</i> )   |             |               |                 |                 |                 |                 |                   |                   |             |
| Dry   | 0.94        | 0.89          | 0.92            | 0.92            | 0.93            | 0.91            | 0.85              | 0.79              | 0.54        |
| Normal  | 0.87        | 0.81          | 0.79            | 0.81            | 0.77            | 0.86            | 0.62              | 0.69              | 0.49        |
| Wet <sup>A</sup>  | 0.77        | 0.80          | 0.58            | 0.60            | [0.44 (4)]      | [0.43 (3)]      | [0.00]            | [0.00]            | [0.00]      |
| All   | 0.83        | 0.82          | 0.79            | 0.81            | 0.80            | 0.87            | 0.73              | 0.75              | 0.52        |
| <sup>A</sup> Brackets indicate bins in which total sample size for that bin is below 1% of all for that soil moisture category (i.e., 0 to 9 samples). Additionally, for these entries the value in parenthesis is the number of records in specified BI bin. |             |               |                 |                 |                 |                 |                   |                   |             |

2

3

1 The observations of visible foliar injury for the highest W126 bin compared to the others  
2 is generally consistent with the evidence regarding visible foliar injury as an indicator of O<sub>3</sub>  
3 exposure (e.g., ISA, Appendix 8, section 8.2; 2013 ISA, section 9.4.2; U.S. EPA, 2006 [2006  
4 AQCD], p. AX9-22). The evidence indicates a generally greater extent and severity of visible  
5 foliar injury with higher O<sub>3</sub> exposure levels and an influence for soil moisture conditions (ISA,  
6 Appendix 8, Section 8.2). Further, consistent with this evidence, the censored regression of the  
7 USFS dataset described in section 4C.1.1 above found a significant relationship between visible  
8 foliar injury and both O<sub>3</sub> and moisture, as measured by Palmer Z.

9 A study cited in the current and 2013 ISAs, which analyzed trends in the incidence and  
10 severity of foliar injury, observed a declining trend in the incidence of foliar injury as peak O<sub>3</sub>  
11 concentrations declined (2013 ISA, p. 9-40; Smith, 2012). Another study, also available in the  
12 last review, that focused on O<sub>3</sub>-induced visible foliar injury in west coast forests observed that  
13 both percentage of biosites with injury and average BI were higher for sites with average  
14 cumulative O<sub>3</sub> concentrations above 25 ppm-hrs in terms of SUM06<sup>8</sup> as compared to groups of  
15 biosites with lower average cumulative exposure concentrations, with much less clear differences  
16 between the two lower exposure groups (Campbell et al., 2007, Figures 27 and 28 and p. 30). A  
17 similar finding was reported in the 2007 Staff Paper which reported on an analysis that showed a  
18 smaller percentage of biosites with injury among the group of biosites with O<sub>3</sub> exposures at or  
19 below a SUM06 metric of 15 ppm-hrs or a 4<sup>th</sup> high metric of 74 ppb as compared to larger  
20 groups that also included biosites with SUM06 values up to 25 ppm-hrs or 4<sup>th</sup> high metric up to  
21 84 ppb, respectively (U.S. EPA, 2007 [2007 Staff Paper], pp. 7-63 to 7-64).

22 The observations described here have a general consistency with the extensive evidence  
23 base on foliar injury, which indicates that visible foliar injury prevalence and severity are  
24 generally higher at higher (compared to lower) O<sub>3</sub> concentrations. As the FIA/FHM biosites vary  
25 in the type of vegetation and species that are present and the vegetation types and species vary in  
26 sensitivity, BI scores would be expected to differ even between two biosites identical in all  
27 environmental characteristics when there are different species present. Therefore, limitations in  
28 the biosite dataset can affect patterns and relationships observed in the BI scores. Additionally,  
29 various environmental and genetic factors influence the exposure-response relationship, with the  
30 most well understood being soil moisture conditions (ISA, Appendix 8, Section 8.2). Our  
31 understanding of specific aspects of these influences on the relationship between O<sub>3</sub> exposures,  
32 the most appropriate exposure metrics, and the occurrence or severity of visible foliar injury is,  
33 however, still incomplete.

---

<sup>8</sup> Based on an approach used in the 2007 Staff Paper (and the associated temporal patterns of O<sub>3</sub> concentrations in data available at that time), a SUM06 index value of 25 ppm-hrs would be estimated to correspond to a W126 index of approximately 21 ppm-hrs (2007 Staff Paper, Appendix 7B, p. 7B-2).

## 4C.5 LIMITATIONS AND UNCERTAINTIES

The purpose of the analyses and presentations summarized above was to investigate the potential relationship between BI scores at USFS biosites and O<sub>3</sub> in terms of the seasonal W126 index. The lack of a clear relationship (across W126 bins below 25 ppm-hrs) in the presentations above may relate to inherent limitations and uncertainties in the different aspects of the dataset. The limitations and uncertainties associated with aspects of the dataset developed for the 2014 WREA, and further investigated above, are presented here. In summarizing these below, they are grouped into four areas: 1) biosite scores, 2) soil moisture categorization, 3) W126 index estimates, and 4) combining of datasets.

**Biosite data:** Site selection, availability, and species presence also contribute to uncertainty within the dataset and analysis. Data are lacking from many western states including Montana, Idaho, Wyoming, Nevada, Utah, Colorado, Arizona, New Mexico, Oklahoma, and portions of Texas. Furthermore, in certain states (California, Washington, and Oregon) exact locations of sampled sites were not available, and these sites were assigned to the grid based on publicly available geographic coordinates, increasing the level of uncertainty. Because the grid sizes are relatively small, limiting the geographic skew of estimated location (7 km in any direction), it is likely that these locations were at least assigned to adjacent grid cells. While the extent of such differences and magnitude of any effect on the resultant dataset are unknown, it may have relatively small difference and low magnitude of influence on the dataset (2014 WREA, p. 7-60).

**Soil moisture categories:** The use of the Palmer Z soil moisture index contributes uncertainty of unknown directionality and magnitude. Short-term estimates of soil moisture can be highly variable from month to month within a single year. Using averages contributes to a potential temporal mismatch between soil moisture and injury. Soil moisture is also substantially spatially variable, and the soil moisture data can be hundreds of miles wide in climate regions. There is much diversity within regions, and some vegetation, such as that along riverbanks, may experience sufficient soil moisture during periods of drought to exhibit foliar injury. All of these factors contribute uncertainty to this categorization (2014 WREA, p. 7-61).

**W126 index estimates:** Ambient air quality measurements have some inherent uncertainties (considered low [2014 WREA, p. 4-39]) associated with them. These uncertainties relate to monitoring network design, O<sub>3</sub> monitoring seasons, monitor malfunctions, wildlife and wildfire/smoke impacts, and interpolations of missing data. There is likely somewhat greater uncertainty associated with the assignment of W126 index estimates to all biosites due to the need for interpolating between monitor sites to estimate concentrations in unmonitored areas

(2014 WREA, sections 4A.2.1).<sup>9</sup> Accordingly, there is relatively greater uncertainty associated with sites at some distance from monitoring sites and lesser uncertainty in densely monitored areas (2014 WREA, p. 4-40). Unfortunately, which sites are which is unknown.

**Combining datasets:** Uncertainty is associated with the combination of data types of different spatial resolution. For example, the biosite scores are available at a much finer spatial resolution than the W126 index estimates, which represent a much small spatial area than that represented by the soil moisture categorization. Yet, as recognized above, soil moisture may vary on much finer scales. To avoid losing resolution of the finest-scale dataset (the biosite scores), the finest spatial resolution available was used (e.g., rather than averaging the BI scores across the grids for which W126 index was estimated or across the climate regions for which the soil moisture scores area available), although this approach contributes its own uncertainty.

There is also uncertainty in the combination step associated with the differing temporal scales or time-of-year represented by the three types of data.

Overall, we recognize a number of limitations and uncertainties that may be affecting our ability to identify a relationship between O<sub>3</sub>, as quantified by seasonal W126 index, and visible foliar injury at USFS locations (based on BI scores), particularly at sites with W126 index estimates at or below 25 ppm-hrs.

## 4C.6 SUMMARY AND KEY OBSERVATIONS

The following are key observations concerning the dataset presented in this appendix, which includes the subset of USFS biosite data for the years 2006 through 2010, and for which limitations and uncertainties are recognized in section 4C.5 above.

### **Full Dataset:**

- The combined dataset includes more than 5,000 records, each of which documents a biotic index scores, soil moisture index value and W126 index estimate, for USFS biosites in 37 states in one or more years from 2006 to 2010.
- The majority of the records are for W126 index estimates at or below 9 ppm-hrs, with fewer than 10% of records assigned W126 index estimates above 15 ppm-hrs.
- The BI scores (in all soil moisture categories) are quite variable, with at least half the scores in nearly all bins being zero, and even the bin for the lowest W126 index estimates (below 7 ppm-hrs) having at least one scores above 5 and 15.
- With regard to soil moisture conditions most of the dataset (61% of all records ) are for soil moisture conditions categorized as normal. The remainder include somewhat more

---

<sup>9</sup> Evaluations of the VNA interpolation technique describe correlations with monitoring data and indicate more accurate prediction of monitoring data by the VNA method than use of an air quality model (2014 WREA, section 4.A.3.1).

records for wet soil moisture conditions than dry, with 23% of all records categorized as wet soil moisture conditions and 16% as dry soil moisture.

### **Records in Wet Soil Moisture Category:**

- The wet soil moisture records are concentrated in the two lower W126 index bins which contain nearly 90% of all records for this soil moisture category.
  - Accordingly, interpretations of patterns across W126 bins for this soil moisture category are limited by small sample size across the bins. For example, the number of records in each of the W126 bins above 13 ppm-hrs (ranging from zero to 9) comprise less than 1% of the records in this soil moisture category.

### **Records in Normal Soil Moisture Category:**

- Among records in the normal soil moisture category, BI scores are noticeably increased in the highest W126 index bin (index estimates above 25 ppm-hrs), averaging 7.9.
  - The percentages of records in this W126 bin with scores above 15 or above 5 are more than three times greater than percentages for these score magnitudes in any of the lower W126 index bins.
  - The average BI score for records in the highest W126 bin is also appreciably greater than scores for records in the other bins. The average scores in the next two highest W126 bins are 1.6 and 2.3, respectively, which are only slightly higher than average scores for the rest of the bins, which vary from 0.8 to 1.2 without a clear relationship to estimated W126 index.
  - Among the records in this category with nonzero scores, the highest average BI is also in the highest W126 index bin (>25 ppm-hrs); in this case the BI is approximately 15, more than double the next highest average scores across the other W126 index bins (for which no other trend is exhibited). The proportion of records with any injury is also highest in the highest W126 index bin; it is also slightly increased in the next lower W126 bins compared to the rest (the bins at or below 17 ppm-hrs) across which there is little evident pattern.

### **Records in Dry Soil Moisture Category:**

- Dry soil moisture category records in the two highest W126 bins (>19 and > 25 ppm-hrs) exhibit the greatest percentages of records with BI above 15 and above 5. For scores above 15, the percentages are 7 and 8% compared to 0 to 3 % in the other bins, and for scores above 5, the scores are 11 and 20% compared to 1 to 5% in the other bins.

In summary, the observations described here are generally consistent with the extensive evidence base on foliar injury and O<sub>3</sub>, which indicates that foliar injury prevalence and severity are generally higher at higher (compared to lower) O<sub>3</sub> concentrations. The presentations here of USFS data do not indicate clear trends in BI across the full range of W126 index estimates. Rather, they indicate increased BI for the highest estimates, with the increase in both incidence of higher scores and in average score being most clear for W126 index estimates above 25 ppm-hrs, with a suggestion of slight increase for some records with W126 index estimates above 17 or

1 19 ppm-hrs (dry soil moisture category). Variability as well as sample size limitations contribute  
2 to the lack of more precise conclusions. Additionally, as indicated in the evidence summarized in  
3 the ISA and prior scientific assessments, various environmental and genetic factors influence the  
4 exposure-response relationship. Our understanding of specific aspects of these influences on the  
5 relationship between O<sub>3</sub> exposures, the most appropriate exposure metrics, and the occurrence or  
6 severity of visible foliar injury is, however, still incomplete.

7

8



## 1 REFERENCES

- 2 Campbell, SJ, Wanek, R and Coulston, JW (2007). Ozone injury in west coast forests: 6 years of  
3 monitoring - Introduction. U.S. Department of Agriculture. Portland, OR.
- 4 Coulston, JW, Smith, GC and Smith, WD (2003). Regional assessment of ozone sensitive tree  
5 species using bioindicator plants. *Environmental Monitoring and Assessment* 83(2): 113-  
6 127.
- 7 Horsfall, J and Cowling, E (1978). *Plant disease, an advanced treatise*. Academic Press. New  
8 York, NY.
- 9 Palmer, WC (1965). Meteorological drought. U.S. Department of Commerce. Washington, DC.  
10 <https://www.ncdc.noaa.gov/temp-and-precip/drought/docs/palmer.pdf>.
- 11 Smith, G (2012). Ambient ozone injury to forest plants in Northeast and North Central USA: 16  
12 years of biomonitoring. *Environmental Monitoring and Assessment* 184(7): 4049-4065.
- 13 Smith, GC, Morin, RS and McCaskill, GL (2012). Ozone injury to forests across the Northeast  
14 and North Central United States, 1994-2010. General Technical Report NRS-103. United  
15 States Department of Agriculture, US Forest Service, Northern Research Station.
- 16 Smith J. T.; Murphy, D. (2015). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-  
17 OAR-2008-0699). Additional Observations from WREA Datasets for Visible Foliar  
18 Injury. September 24, 2015. . Docket ID No. EPA-HQ-OAR-2008-0699. Office of Air  
19 Quality Planning and Standards Research Triangle Park, NC. Available at:  
20 [https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-](https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-4250&contentType=pdf)  
21 [4250&contentType=pdf](https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-4250&contentType=pdf).
- 22 U.S. EPA (2006). Air Quality Criteria for Ozone and Related Photochemical Oxidants (Volume I  
23 - III). Office of Research and Development U.S. EPA. EPA-600/R-05-004aF, EPA-  
24 600/R-05-004bF, EPA-600/R-05-004cF February 2006. Available at:  
25 <https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=149923>.
- 26 U.S. EPA (2007). Review of the National Ambient Air Quality Standards for Ozone: Policy  
27 Assessment of Scientific and Technical Information: OAQPS Staff Paper. Office of Air  
28 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/R-07-  
29 003. January 2007. Available at:  
30 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P10083VX.txt>.
- 31 U.S. EPA (2013). Integrated Science Assessment of Ozone and Related Photochemical Oxidants  
32 (Final Report). Office of Research and Development, National Center for Environmental  
33 Assessment. Research Triangle Park, NC. U.S. EPA. EPA-600/R-10-076F. February  
34 2013. Available at: <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KETF.txt>.
- 35 U.S. EPA (2014). Welfare Risk and Exposure Assessment for Ozone (Final). . Office of Air  
36 Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/P-14-

1 005a August 2014. Available at:  
2 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KB9D.txt>.

3

# APPENDIX 4D

## ANALYSIS OF THE W126 O<sub>3</sub> EXPOSURE INDEX AT U.S. AMBIENT AIR MONITORING SITES

### Table of Contents

|   |       |
|---|-------|
| 4D.1 Overview .....   | 4D-2  |
| 4D.2 Data Handling .....  | 4D-2  |
| 4D.2.1 Data Retrieval and Preparation .....   | 4D-2  |
| 4D.2.2 Derivation of the 4 <sup>th</sup> Max and W126 Metrics .....                     | 4D-2  |
| 4D.2.3 Derivation of Temporal Trends .....  | 4D-4  |
| 4D.2.4 Identification of O <sub>3</sub> Monitoring Sites in Federal Class I Areas ..... | 4D-5  |
| 4D.2.5 Assignment of Monitoring Sites to NOAA Climate Regions .....                     | 4D-6  |
| 4D.3 Results .....  | 4D-6  |
| 4D.3.1 National Analysis Using Recent Air Quality Data .....                            | 4D-6  |
| 4D.3.1.1 Comparison of the 4 <sup>th</sup> Max and W126 Metrics .....                   | 4D-8  |
| 4D.3.1.2 Relationships Between Metrics and the Annual W126 Index .....                  | 4D-10 |
| 4D.3.2 National Analysis Using Historical Air Quality Data .....                        | 4D-15 |
| 4D.3.2.1 Comparison of the 4 <sup>th</sup> Max and W126 Metrics .....                   | 4D-16 |
| 4D.3.2.2 Trends in W126 Metric .....  | 4D-18 |
| 4D.3.2.3 Comparison of Trends in the 4 <sup>th</sup> Max and W126 Metrics .....         | 4D-20 |
| 4D.3.2.4 W126 Metric Values in Federal Class I Areas .....                              | 4D-25 |
| 4D.4 Key Limitations and Uncertainties .....  | 4D-33 |
| 4D.5 Summary .....  | 4D-34 |
| 4D.6 References .....   | 4D-36 |

## 4D.1 OVERVIEW

This appendix presents various analyses of ambient air monitoring data for ozone (O<sub>3</sub>) concentrations in the U.S. relating to the W126-based cumulative exposure index. These analyses focus on the annual maximum 3-month sum of daytime hourly weighted O<sub>3</sub> concentrations, averaged over 3 consecutive years, hereafter referred to as the “W126 metric,” calculated as described in section 2 below. These analyses examine spatial and temporal patterns in the W126 metric using monitoring data from 2000 to 2020 and make various comparisons between the W126 metric and design values for the current O<sub>3</sub> standard (the annual 4<sup>th</sup> highest daily maximum 8-hour O<sub>3</sub> concentration, averaged over 3 consecutive years; hereafter referred to as the “4<sup>th</sup> max metric”). Additional analyses assess the relative variability between the W126 metric and its constituent annual index values and the magnitude of W126 index values at monitoring sites in or near federally protected ecosystems known as Class I areas. These analyses are largely parallel to analyses that were completed for the last review of the O<sub>3</sub> NAAQS (79 FR 75331, December 17, 2014; 80 FR 65385, October 26, 2015; U.S. EPA, 2014a, Wells, 2014, Wells, 2015).

## 4D.2 DATA HANDLING

### 4D.2.1 Data Retrieval and Preparation

Hourly O<sub>3</sub> concentration data were retrieved from the EPA’s Air Quality System (AQS, <https://www.epa.gov/aqs>) database for 2,021 ambient air monitoring sites which operated between 2000 and 2020. These data were used to calculate W126 and 4<sup>th</sup> max metric values for each 3-year period from 2000-2002 to 2018-2020. Before calculating these metrics, some initial processing was done on the hourly data. First, data collected using monitoring methods other than federal reference or equivalent methods, and data collected at monitoring sites not meeting EPA’s quality assurance or other criteria in 40 CFR part 58 were removed from the analysis. Second, data collected by multiple monitoring instruments operating at the same location were combined according to Appendix U to 40 CFR Part 50. Finally, data were combined across 108 pairs of monitoring sites approved for such combination by the EPA Regional Offices. The final hourly O<sub>3</sub> concentration dataset contained 1,808 monitoring sites.

### 4D.2.2 Derivation of the 4<sup>th</sup> Max and W126 Metrics

The 4<sup>th</sup> max metric values were calculated according to the data handling procedures in Appendix U to 40 CFR part 50. First, moving 8-hour averages were calculated from the hourly O<sub>3</sub> concentration data for each site. For each 8-hour period, an 8-hour average value was calculated if there were at least 6 hourly O<sub>3</sub> concentrations available. Each 8-hour average was stored in the first hour of the period (e.g., the 8-hour average from 12:00 PM to 8:00 PM is

1 stored in the 12:00 PM hour). Daily maximum 8-hour average values were found using the 8-  
2 hour periods beginning from 7:00 AM to 11:00 PM each day. These daily maximum values were  
3 used if at least 13 of the 17 possible 8-hour averages were available, or if the daily maximum  
4 value was greater than 70 parts per billion (ppb). Finally, the annual 4th highest daily maximum  
5 value was found for each year, then averaged across each consecutive 3-year period to obtain the  
6 final set of 4th max metric values in units of ppb. Any decimal digits in these values were  
7 truncated for applications requiring direct comparison to a 4th max level (e.g., Table 4D-2),  
8 otherwise, all decimal digits were retained. The 4th max metric values were considered valid if  
9 daily maximum values were available for at least 90% of the days in the O<sub>3</sub> monitoring season  
10 (defined in Appendix D to 40 CFR part 58) on average across the three years, with a minimum of  
11 75% of the days in the O<sub>3</sub> monitoring season in any calendar year. In addition, 4th max metric  
12 values were considered valid if they were greater than the 4th max levels to which they were  
13 being compared.

14 The W126 metric values were calculated using the hourly O<sub>3</sub> concentration data in parts  
15 per million (80 FR 65374, October 26, 2015). For daytime hours (defined as the 12-hour period  
16 from 8:00 AM to 8:00 PM Local Standard Time each day), the hourly concentration values at  
17 each O<sub>3</sub> monitoring site were weighted using the following equation:

$$\text{Weighted O}_3 = \text{O}_3 / (1 + 4403 * \exp (-126 * \text{O}_3)).$$

19 These weighted values were summed over each calendar month, then adjusted for  
20 missing data (e.g., if 80% of the daytime hourly concentrations were available, the sum would be  
21 multiplied by  $1/0.8 = 1.25$ ) to obtain the monthly W126 index values. Monthly W126 index  
22 values were not calculated for months where fewer than 75% of the possible daytime hourly  
23 concentrations were available. Next, moving 3-month sums were calculated from the monthly  
24 index values, and the highest of these 3-month sums was determined to be the annual W126  
25 index. Three-month periods spanning multiple years (e.g., November to January, December to  
26 February) were not considered in these calculations. The annual W126 index values were  
27 averaged across each consecutive 3-year period to obtain the final W126 metric values, with  
28 units in parts per million-hours (ppm-hrs). The W126 metric values were rounded to the nearest  
29 unit ppm-hr for applications requiring direct comparison to a W126 level (e.g., Table 4D-3),  
30 otherwise, all decimal digits were retained. For consistency with the 4<sup>th</sup> max metric calculations,  
31 the W126 metric values were considered valid if hourly O<sub>3</sub> concentration values were available  
32 for at least 90% of the daytime hours during the O<sub>3</sub> monitoring season on average across the  
33 three years, with a minimum of 75% of the daytime hours during the O<sub>3</sub> monitoring season in  
34 any calendar year. Also, for consistency with the 4<sup>th</sup> max metric calculations, the W126 metric

values were considered valid if they were greater than the W126 levels to which they were being compared.

In summary, the “4<sup>th</sup> max metric” refers to the average of the 4<sup>th</sup> highest daily maximum 8-hour averages in three consecutive years and the “W126 metric” refers to the average of annual W126 index values (“annual” or “single-year” W126 index) over three years. In the final dataset, 1,578 of the 1,808 O<sub>3</sub> monitoring sites had sufficient data to calculate valid 4<sup>th</sup> max and W126 metric values for at least one 3-year period between 2000-2002 and 2018-2020. The number of sites with valid 4<sup>th</sup> max and W126 metric values ranged from a low of 992 in 2000-2002 to a high of 1,118 in 2015-2017, and 510 sites had valid 4<sup>th</sup> max and W126 metric values for all nineteen 3-year periods.

#### **4D.2.3 Derivation of Temporal Trends**

Site-level trends for the W126 metric and annual W126 index values were computed in a similar manner to the site-level trends for the 4<sup>th</sup> max metric presented in Chapter 2. Specifically, for the annual W126 index, a site must have at least 75% annual data completeness for at least 16 of the 21 years, with no more than two consecutive years having less than 75% data completeness in order to be included in the analysis. For the W126 metric, a site must have a valid W126 metric value (according to the data completeness criteria presented in the previous section) in at least 15 of the 19 3-year periods, and no more than two consecutive 3-year periods that do not have valid W126 metric values. There were 822 sites meeting these criteria for the annual W126 index and 666 sites meeting these criteria for the W126 metric. The national median, 10<sup>th</sup> percentile, and 90<sup>th</sup> percentile values of these site-level trends are presented in Figure 4D-9.

Other analyses presented in Section 4D.3.2.2 use trends in the 4<sup>th</sup> max and W126 metrics as well as the annual W126 index calculated with non-parametric regression methods. These trends were computed using the Theil-Sen estimator (Sen, 1968; Theil, 1950), a type of regression method that chooses the median slope among all lines crossing through each possible pair of sample points<sup>1</sup>. These trends are reported in units of ppb/yr for the 4<sup>th</sup> max metric or ppm-hr/yr for the W126 metric and annual W126 index. The data completeness criteria described in the previous paragraph were also applied to site for which these trends were calculated.<sup>2</sup>

---

<sup>1</sup> For example, if applying this method to a dataset with W126 metric values for four consecutive years (e.g., W126<sub>1</sub>, W126<sub>2</sub>, W126<sub>3</sub>, and W126<sub>4</sub>), the trend would be the median of the per-year changes observed in the six possible pairs of values (e.g., the median of [W126<sub>4</sub>-W126<sub>3</sub>]/1, [W126<sub>3</sub>-W126<sub>2</sub>]/1, [W126<sub>2</sub>-W126<sub>1</sub>]/1, [W126<sub>4</sub>-W126<sub>2</sub>]/2, [W126<sub>3</sub>-W126<sub>1</sub>]/2, and [W126<sub>4</sub>-W126<sub>1</sub>]/3).

<sup>2</sup> For the 4<sup>th</sup> max metric, the data completeness criteria used were valid 4<sup>th</sup> max metric values (as defined in section 4D.2.2) in 15 of the 19 3-year periods, and no more than two consecutive periods that do not have valid 4<sup>th</sup> max

1 Statistical tests for significance of the Theil-Sen estimator were computed using the non-  
2 parametric Mann-Kendall test (Kendall, 1948; Mann; 1945).

#### 3 **4D.2.4 Identification of O<sub>3</sub> Monitoring Sites in Federal Class I Areas**

4 The Clean Air Act (section 162) designated certain federally areas as Class I areas. These  
5 areas are federally mandated to preserve certain air quality values. Class I designation allows the  
6 least amount of deterioration of existing air quality. Areas designated as Class I include all  
7 international parks, national wilderness areas which exceed 5,000 acres in size, national  
8 memorial parks which exceed 5,000 acres in size, and national parks which exceed 6,000 acres in  
9 size, provided the park or wilderness area was in existence on August 7, 1977. There are 158  
10 such areas (e.g., 44 FR 69122, November 30, 1979). Other areas may, and have been,  
11 subsequently designated as Class I consistent with the CAA (section 162). As of January 2022,  
12 six Class II areas on Tribal lands have been re-designated as Class I.<sup>3</sup>

13 To identify which O<sub>3</sub> monitoring sites represented air quality in federal Class I areas,  
14 shapefiles (i.e., files that specify area boundaries) for all 158 mandated federal Class I areas<sup>4</sup>  
15 were downloaded from EPA’s Environmental Dataset Gateway (EDG; <https://edg.epa.gov/>) and  
16 augmented with the six tribal areas redesignated as Class I. These boundaries were matched to  
17 the 1,808 O<sub>3</sub> monitoring sites in the hourly O<sub>3</sub> concentration dataset described in section 4D.2.1.  
18 Since Class I areas include federally designated wilderness areas in which permanent structures  
19 such as air monitoring trailers are prohibited, if there was no monitor located within the area  
20 boundary, the matching was expanded to include the nearest monitoring site within 15 km of the  
21 boundary. For each Class I area and 3-year period, if a 4<sup>th</sup> max or W126 metric value was not  
22 available for the nearest monitor, the values from the next nearest monitor within 15 km were  
23 used, where applicable. In addition, if a Class I area had multiple monitors inside the boundary,  
24 we used the monitor with the highest 4<sup>th</sup> max metric value in each 3-year period. These monitors  
25 were extracted from the 4<sup>th</sup> max and W126 dataset described in section 4D.2.2, yielding a final  
26 Class I areas dataset with a total of 980 records that had valid 4<sup>th</sup> max and W126 metric values at  
27 78 O<sub>3</sub> monitoring sites representing 65 Class I areas (out of 164 total Class I areas).

---

metric values. There were 658 sites meeting these criteria, and all these sites also met the data completeness criteria for the W126 metric and the annual W126 index.

<sup>3</sup> The Class I areas on Tribal lands as of December 2020 are listed at:  
<https://www.nps.gov/subjects/air/tribalclass1.htm>. Since then, one additional area has been designated Class I on Tribal lands (84 FR 34306, July 18, 2019).

<sup>4</sup> The set of Class I areas identified in 1977 are referred to here as “mandated.”

#### 4D.2.5 Assignment of Monitoring Sites to NOAA Climate Regions

In order to examine regional differences, many of the further analyses were stratified into the nine NOAA climate regions (Karl and Koss, 1984), which are shown in Figure 4D-1. Since the NOAA climate regions only cover the contiguous U.S., Alaska was added to the Northwest region, Hawaii was added to the West region, and Puerto Rico was added to the Southeast region.




Figure 4D-1. Map of the nine NOAA climate regions.


### 4D.3 RESULTS

#### 4D.3.1 National Analysis Using Recent Air Quality Data

This section presents various results based on the 4<sup>th</sup> max and W126 metrics for the 2018-2020 period. Figure 4D-2 shows a map of the observed W126 metric values based on 2018-2020 data. From this figure, it is apparent that W126 metric values are generally at or below 13 ppm-hrs in the eastern and northwestern U.S. In the U.S. as a whole, about 66% of all monitoring sites recorded W126 metric values at or below 7 ppm-hrs, and about 93% of all monitoring sites recorded W126 metric values at or below 17 ppm-hrs. The highest W126 metric values occur in the southwestern U.S. where there are numerous monitoring sites with W126 metric values above 17 ppm-hrs, however, none of these sites meet the current standard. Table 4D-1 shows the



number of sites in each NOAA climate region that have a valid 2018-2020 design value meeting the current standard and the number of sites in each region that have a 2018-2020 design value not meeting the current standard.



**Figure 4D-2. Map of W126 metric values at U.S. O<sub>3</sub> monitoring sites based on 2018-2020 data.** Circles indicate monitoring sites with 4<sup>th</sup> max metric values less than or equal to 70 ppb, while triangles indicate monitoring sites with 4<sup>th</sup> max metric values greater than 70 ppb.

**Table 4D-1. Number of O<sub>3</sub> monitoring sites with valid 2018-2020 design values in each NOAA climate region**

| NOAA Climate Region | Total # of Sites | # of Sites with Design Value ≤ 70 ppb | # of Sites with Design Value > 70 ppb |
|---------------------|------------------|---------------------------------------|---------------------------------------|
| Central             | 203              | 179                                   | 24                                    |
| EastNorthCentral    | 78               | 62                                    | 16                                    |
| NorthEast           | 179              | 160                                   | 19                                    |
| NorthWest           | 23               | 23                                    | 0                                     |
| South               | 130              | 105                                   | 25                                    |
| SouthEast           | 157              | 157                                   | 0                                     |
| SouthWest           | 106              | 59                                    | 47                                    |
| West                | 170              | 88                                    | 82                                    |
| WestNorthCentral    | 44               | 44                                    | 0                                     |
| National            | 1,090            | 877                                   | 213                                   |

#### 4D.3.1.1 Comparison of the 4<sup>th</sup> Max and W126 Metrics

The following analyses make several comparisons between the 4<sup>th</sup> max and W126 metric values (both of which are 3-year average metrics) based on 2018-2020 data. Table 4D-2 shows the number of sites with 4<sup>th</sup> max metric values greater than each 4<sup>th</sup> max level, and the number of sites with 4<sup>th</sup> max metric values less than or equal to each 4<sup>th</sup> max level. Table 4D-3 shows the number of sites with W126 metric values greater than each W126 level, and the number of sites with W126 metric values less than or equal to each W126 level.

The 4<sup>th</sup> max and W126 metric values were also compared to each combination of 4<sup>th</sup> max and W126 levels based on 2018-2020 data. Table 4D-4 shows the number of sites with 4<sup>th</sup> max metric values greater than each 4<sup>th</sup> max level, and W126 metric values less than or equal to each W126 level (e.g., 127 sites had 4<sup>th</sup> max metric values greater than 70 ppb and W126 metric values less than or equal to 13 ppm-hrs). Table 4D-5 shows the number of sites with 4<sup>th</sup> max metric values less than or equal to each 4<sup>th</sup> max level, and W126 metric values greater than each W126 level (e.g., 13 sites with a 4<sup>th</sup> max metric value at or below 70 ppb had a W126 metric value greater than 13 ppm-hrs). Finally, Table 4D-6 shows the number of sites with 4<sup>th</sup> max metric values greater than each 4<sup>th</sup> max level, and W126 metric values greater than each W126 level.

**Table 4D-2. Number of sites with 4<sup>th</sup> max metric values greater than various 4<sup>th</sup> max levels based on 2018-2020 data.**

| 4 <sup>th</sup> Max Level (ppb)  | 75    | 70    | 65    |
|--|-------|-------|-------|
| # of Sites > Level   | 93    | 213   | 468   |
| # of Sites ≤ Level   | 989   | 877   | 629   |
| Total # of Sites <sup>A</sup>  | 1,082 | 1,090 | 1,097 |
| <sup>A</sup> For each 4 <sup>th</sup> max level, a site with a 4 <sup>th</sup> max metric value less than or equal to the level is counted only if it meets the data completeness criteria described in section 4D.2.2, whereas a site with a 4 <sup>th</sup> max metric value greater than the level is counted regardless of data completeness. Therefore, the total number of sites may differ among the columns. |       |       |       |

**Table 4D-3. Number of sites with W126 metric values greater than various W126 levels based on 2018-2020 data.**

| W126 Level (ppm-hrs)  | 19    | 17    | 15    | 13    | 11    | 9     | 7     |
|---|-------|-------|-------|-------|-------|-------|-------|
| # of Sites > Level  | 58    | 77    | 98    | 127   | 170   | 245   | 379   |
| # of Sites ≤ Level  | 1,027 | 1,009 | 991   | 963   | 921   | 850   | 722   |
| Total # of Sites <sup>A</sup>   | 1,085 | 1,086 | 1,089 | 1,090 | 1,091 | 1,095 | 1,101 |
| <sup>A</sup> For each W126 level, a site with a W126 metric value less than or equal to the level is counted only if it meets the data completeness criteria described in section 4D.2.2, whereas a site with a W126 metric value greater than the level is counted regardless of data completeness. Therefore, the total number of sites may differ among the columns. |       |       |       |       |       |       |       |

**Table 4D-4. Number of sites with 4<sup>th</sup> max metric values greater than various 4<sup>th</sup> max levels and W126 metric values less than or equal to various W126 levels based on 2018-2020 data.**

| # Sites > 4 <sup>th</sup> Max Level<br>AND ≤ W126 Level |    | W126 Level (ppm-hrs) |     |     |     |     |     |     |
|---|----|----------------------|-----|-----|-----|-----|-----|-----|
|   |    | 19                   | 17  | 15  | 13  | 11  | 9   | 7   |
| 4 <sup>th</sup> Max<br>Level (ppb)                      | 75 | 37                   | 25  | 19  | 14  | 11  | 4   | 1   |
|   | 70 | 146                  | 128 | 112 | 95  | 81  | 52  | 13  |
|   | 65 | 393                  | 375 | 357 | 329 | 287 | 225 | 114 |

**Table 4D-5. Number of sites with 4<sup>th</sup> max metric values less than or equal to various 4<sup>th</sup> max levels and W126 metric values greater than various W126 levels based on 2018-2020 data.**

| # Sites ≤ 4 <sup>th</sup> Max Level<br>AND > W126 Level |    | W126 Level (ppm-hrs) |    |    |    |    |     |     |
|---|----|----------------------|----|----|----|----|-----|-----|
|   |    | 19                   | 17 | 15 | 13 | 11 | 9   | 7   |
| 4 <sup>th</sup> Max<br>Level (ppb)                      | 75 | 3                    | 9  | 21 | 44 | 83 | 147 | 272 |
|   | 70 | 0                    | 0  | 2  | 13 | 41 | 83  | 172 |
|   | 65 | 0                    | 0  | 0  | 0  | 0  | 9   | 25  |

**Table 4D-6. Number of sites with 4<sup>th</sup> max metric values greater than various 4<sup>th</sup> max levels and W126 metric values greater than various W126 levels based on 2018-2020 data.**

| # Sites > 4 <sup>th</sup> Max Level<br>AND > W126 Level |    | W126 Level (ppm-hrs) |    |    |     |     |     |     |
|---|----|----------------------|----|----|-----|-----|-----|-----|
|   |    | 19                   | 17 | 15 | 13  | 11  | 9   | 7   |
| 4 <sup>th</sup> Max<br>Level (ppb)                      | 75 | 55                   | 68 | 74 | 79  | 82  | 89  | 92  |
|   | 70 | 58                   | 77 | 96 | 114 | 129 | 159 | 199 |
|   | 65 | 58                   | 77 | 98 | 127 | 170 | 234 | 349 |

According to Table 4D-2, 9% of U.S. O<sub>3</sub> monitoring sites had 2018-2020 4<sup>th</sup> max metric values greater than 75 ppb, 19% of sites had 4<sup>th</sup> max metric values greater than 70 ppb, and 43% of sites had 4<sup>th</sup> max metric values greater than 65 ppb. According to Table 4D-3, 7% of U.S. O<sub>3</sub> monitoring sites had 2018-2020 W126 metric values greater than 17 ppm-hrs, 12% of sites had W126 metric values greater than 13 ppm-hrs, and 34% of sites had W126 metric values greater than 7 ppm-hrs. According to Table 4D-5, there were no monitoring sites with a 4<sup>th</sup> max metric value less than or equal to 70 ppb and a W126 metric value greater than 17 ppm-hrs, only two monitoring sites with a 4<sup>th</sup> max less than or equal to 70 ppb and a W126 greater than 15 ppm-hrs in the 2018-2020 period.


#### 4D.3.1.2 Relationships Between Metrics and the Annual W126 Index

Figure 4D-3 shows a scatter plot comparing the 4<sup>th</sup> max (x-axis) and W126 (y-axis) metric values (both 3-year averages) based on 2018-2020 data, with points colored by NOAA climate region. This figure indicates that there is a strong, positive, non-linear relationship between the 4<sup>th</sup> max and W126 metrics. The amount of variability in the relationship between the 4<sup>th</sup> max and W126 metrics appears to increase as the metric values themselves increase. The relationship between the 4<sup>th</sup> max and W126 metrics also appears to vary across regions. In particular, the Southwest and West regions (i.e., the southwestern U.S.) appear to have higher W126 metric values relative to their respective 4<sup>th</sup> max metric values than the rest of the U.S.


Figure 4D-4 shows the same information as Figure 4D-3, but only for monitoring sites meeting the current standard. This figure shows that all monitoring sites meeting the current standard have W126 metric values of 16 ppm-hrs or less, and all sites outside the Southwest and West climate regions have W126 metric values of 13 ppm-hrs or less.

Finally, Figure 4D-5 shows a scatter plot comparing the 4<sup>th</sup> max metric values (x-axis) to the annual W126 index values (y-axis) based on 2018-2020 data, with points colored by NOAA climate region. This figure shows that the annual W126 index values have a similar positive, non-linear relationship with the 4<sup>th</sup> max metric values as the W126 metric values. As might be expected, there is generally more variability in the relationship between the annual W126 index values and the 4<sup>th</sup> max metric values than between the W126 metric values and the 4<sup>th</sup> max metric values.

Figure 4D-6 shows a scatter plot of the deviations in the 2018, 2019, and 2020 annual W126 index values (y-axis) from the 2018-2020 average W126 metric values (x-axis). This figure shows that the magnitude of the annual W126 index deviations from the 3-year average tend to increase as the W126 metric value increases. About 40% of the annual W126 index values are within +/- 1 ppm-hr of the 3-year average value, about 73% are within +/- 2 ppm-hrs of the 3-year average value, and about 96% are within +/- 5 ppm-hrs of the 3-year average value. Figure 4D-7 also presents the deviations in the 2018, 2019, and 2020 annual W126 index values from their respective 2018-2020 averages for the sites meeting the current standard. For these sites, 42% of annual W126 index values are within 1 ppm-hr of the 3-yr average, 78% are within 2 ppm-hrs, and 99% are within 5 ppm-hrs (Figure 4D-7). From these two figures it can be seen that lower 4<sup>th</sup> max metric values generally correspond to smaller inter-annual variation within W126 metric values, especially for sites meeting the current standard.




**Figure 4D-3. Scatter plot of W126 metric values versus 4<sup>th</sup> max metric values (design values) based on 2018-2020 monitoring data.**




**Figure 4D-4. Scatter plot of W126 metric values versus 4<sup>th</sup> max metric values (design values) at monitoring sites meeting the current standard based on 2018-2020 monitoring data.**






**Figure 4D-5. Scatter plot of annual W126 index values versus 4th max metric values (design values) based on 2018-2020 monitoring data.**



**Figure 4D-6. Deviation in annual W126 index values from their respective 3-year averages for all U.S. monitoring sites in 2018-2020.**





**Figure 4D-7. Deviation in annual W126 index values from their respective 3-year averages for all U.S. monitoring sites with 4<sup>th</sup> max metric values at or below 70 ppb in 2018-2020.**

#### 4D.3.2 National Analysis Using Historical Air Quality Data

This section presents various results based on the 4<sup>th</sup> max and W126 metrics for the full 19-year period spanning years 2000 to 2020. Comparisons similar to those shown in section 4D.3.1 are shown in section 4D.3.2.1, trends in W126 are shown in section 4D.3.2.2, and several comparisons of the trends in the 4<sup>th</sup> max and W126 metrics are shown in section 4D.3.2.3.

#### 4D.3.2.1 Comparison of the 4<sup>th</sup> Max and W126 Metrics

Table 4D-7 to Table 4D-11 present similar information to Table 4D-2 to Table 4D-6, respectively, except that the values shown in each cell contain the number of occurrences summed over all 19 consecutive 3-year periods (2000-2002 to 2018-2020) instead of just the 2018-2020 period. For example, Table 4D-10 shows that over all 19 consecutive 3-year periods, there were 276 occurrences where sites had 4<sup>th</sup> max metric values less than or equal to 70 ppb and W126 metric values greater than 13 ppm-hrs. In general, the relative magnitudes of the numbers shown in Table 4D-7 to Table 4D-11 compare well to their respective counterparts in Table 4D-2 to Table 4D-6. According to Table 4D-10, there have been no occurrences over the entire 21-year period where a site has had a 4<sup>th</sup> max metric value less than or equal to 70 ppb and a W126 metric value greater than 19 ppm-hrs.<sup>5</sup>

Figure 4D-8 shows the distribution of annual W126 index values observed at sites during 3-year periods with different 4<sup>th</sup> max metric values (which are the design values for the current standard). These distributions are illustrated by box-and-whisker plots with boxes showing the 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentile of the annual W126 index values occurring with 4<sup>th</sup> max metric values within each bin, whiskers extending to the 1<sup>st</sup> and 99<sup>th</sup> percentiles of the annual W126 index values, and points occurring outside the 1<sup>st</sup> and 99<sup>th</sup> percentiles represented by dots. This figure shows that for the bin with the highest 4<sup>th</sup> max metric values meeting the current standard, 66-70 ppb, the 99<sup>th</sup> percentile of the annual W126 index values was about 19 ppm-hours, or in other words, for sites meeting the current standard, annual W126 index values were less than or equal to 19 ppm-hrs about 99% of the time.

---

<sup>5</sup> There was a single occurrence of a site with a 4<sup>th</sup> max of 70 ppb and a W126 that when rounded, just equaled 19 ppm-hrs.

**Table 4D-7. Total number of 4<sup>th</sup> max metric values greater than various 4<sup>th</sup> max levels based on all 17 consecutive 3-year periods (2000-2002 to 2018-2020).**

| 4 <sup>th</sup> Max Level (ppb)   | 75           | 70           | 65           |
|---|--------------|--------------|--------------|
| Values > Level  | 6,848 (33%)  | 11,142 (53%) | 15,947 (74%) |
| Values ≤ Level  | 14,059 (67%) | 10,039 (47%) | 5,622 (26%)  |
| Total # of Values <sup>A</sup>  | 20,907       | 21,181       | 21,569       |
| <sup>A</sup> For each 4 <sup>th</sup> max level, a site with a 4 <sup>th</sup> max metric value less than or equal to the level is counted only if it meets the data completeness criteria described in section 4D.2.2, whereas a site with a 4 <sup>th</sup> max metric value greater than the level is counted regardless of data completeness. Therefore, the total number of values may differ among the columns. |              |              |              |

**Table 4D-8. Total number of W126 metric values greater than various W126 levels based on all 17 consecutive 3-year periods (2000-2002 to 2018-2020).**

| W126 Level (ppm-hrs)   | 19     | 17     | 15     | 13     | 11     | 9      | 7      |
|--|--------|--------|--------|--------|--------|--------|--------|
| Values > Level   | 2,424  | 3,329  | 4,579  | 6,262  | 8,315  | 10,860 | 13,748 |
| Values ≤ Level   | 18,303 | 17,438 | 16,233 | 14,628 | 12,693 | 10,282 | 7,587  |
| Total # of Values <sup>A</sup>   | 20,727 | 20,767 | 20,812 | 20,890 | 21,008 | 21,142 | 21,335 |
| <sup>A</sup> For each W126 level, a site with a W126 metric value less than or equal to the level is counted only if it meets the data completeness criteria described in section 4D.2.2, whereas a site with a W126 metric value greater than the level is counted regardless of data completeness. Therefore, the total number of values may differ among the columns. |        |        |        |        |        |        |        |

**Table 4D-9. Total number of 4<sup>th</sup> max metric values greater than various 4<sup>th</sup> max levels and W126 metric values less than or equal to various W126 levels based on all 17 consecutive 3-year periods (2000-2002 to 2018-2020).**


| Values > 4 <sup>th</sup> Max Level<br>AND ≤ W126 Level |    | W126 Level (ppm-hrs) |        |        |       |       |       |       |
|--|----|----------------------|--------|--------|-------|-------|-------|-------|
|  |    | 19                   | 17     | 15     | 13    | 11    | 9     | 7     |
| 4 <sup>th</sup> Max<br>Level (ppb)                     | 75 | 4,290                | 3,603  | 2,719  | 1,716 | 856   | 280   | 41    |
|  | 70 | 8,228                | 7,372  | 6,228  | 4,837 | 3,254 | 1,529 | 408   |
|  | 65 | 12,650               | 11,785 | 10,580 | 8,975 | 7,056 | 4,781 | 2,340 |

**Table 4D-10. Total number of 4<sup>th</sup> max metric values less than or equal to various 4<sup>th</sup> max levels and W126 metric values greater than various W126 levels based on all 17 consecutive 3-year periods (2000-2002 to 2018-2020).**

| Values ≤ 4 <sup>th</sup> Max Level<br>AND > W126 Level |    | W126 Level (ppm-hrs) |     |     |       |       |       |       |
|--|----|----------------------|-----|-----|-------|-------|-------|-------|
|  |    | 19                   | 17  | 15  | 13    | 11    | 9     | 7     |
| 4 <sup>th</sup> Max<br>Level (ppb)                     | 75 | 95                   | 267 | 585 | 1,181 | 2,251 | 4,069 | 6,518 |
|  | 70 | 0                    | 8   | 68  | 276   | 625   | 1,304 | 2,879 |
|  | 65 | 0                    | 0   | 0   | 0     | 16    | 150   | 400   |

**Table 4D-11. Total number of 4<sup>th</sup> max metric values greater than various 4<sup>th</sup> max levels and W126 metric values greater than various W126 levels based on all 17 consecutive 3-year periods (2000-2002 to 2018-2020).**

| Values > 4 <sup>th</sup> Max Level<br>AND > W126 Level |    | W126 Level (ppm-hrs) |       |       |       |       |        |        |
|--|----|----------------------|-------|-------|-------|-------|--------|--------|
|  |    | 19                   | 17    | 15    | 13    | 11    | 9      | 7      |
| 4 <sup>th</sup> Max<br>Level (ppb)                     | 75 | 2,318                | 3,032 | 3,940 | 4,982 | 5,895 | 6,506  | 6,761  |
|  | 70 | 2,424                | 3,317 | 4,500 | 5,946 | 7,615 | 9,420  | 10,611 |
|  | 65 | 2,424                | 3,329 | 4,579 | 6,262 | 8,295 | 10,685 | 13,286 |




**Figure 4D-8. Annual W126 index values in ppm-hrs binned by 4<sup>th</sup> max metric values based on monitoring data for years 2000-2020.** Boxes show 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentiles, whiskers extend to the 1<sup>st</sup> and 99<sup>th</sup> percentiles, and points below the 1<sup>st</sup> percentile or above the 99<sup>th</sup> percentile are represented by dots.

#### 4D.3.2.2 Trends in W126 Metric

Figure 4D-9 below shows national trends in both the annual W126 index and the 3-year W126 metric based on the monitoring sites reporting data for the full period. Most notably, the


figure shows decreasing trends in W126 metric values, with the median value decreasing by about 65% from 2002 to 2020. The annual W126 index shows considerable year-to-year variability, with the median value sometimes increasing or decreasing by up to a factor of two from one year to the next, while the 3-year average is less impacted by this inter-annual variability, resulting in a smoother trend line.



**Figure 4D-9. National trends in annual W126 index values (2000-2020) and W126 metric values (2002-2020).**

Figure 4D-10 shows a map of the site-level trends in the W126 metric values from 2000-2002 to 2018-2020. According to Figure 4D-10, nearly 88% of U.S. monitoring sites experienced significant decreases in W126 over this period, especially in the eastern U.S. and California where many O<sub>3</sub> monitoring sites saw decreases of 0.5 ppm-hr/yr or more. Many locations in the western U.S. experienced little or no change over this period. Only six monitors in disparate locations showed significant increasing trends in the W126 metric during the 2002-2020 period.





**Figure 4D-10. Map of trends in W126 metric values at U.S. O<sub>3</sub> monitoring sites from 2000-2002 to 2018-2020.**

#### 4D.3.2.3 Comparison of Trends in the 4<sup>th</sup> Max and W126 Metrics

Figure 4D-11 shows a scatter plot comparing the trends in the 4<sup>th</sup> max metric values (x-axis, ppb/yr) to the trends in the W126 metric values (y-axis, ppm-hr/yr). These trends are calculated using the Thiel-Sen estimator as in Figure 4D-10. The relationship between the trends in the two metrics was linear and positive (Pearson correlation coefficient  $R = 0.81$ ), meaning a decrease in the 4<sup>th</sup> max metric is usually accompanied by a decrease in the W126 metric. The slope of the regression line shown in Table 4D-12 indicates that, on average, there was a change of approximately 0.59 ppm-hr in the W126 metric values per unit ppb change in the 4<sup>th</sup> max metric values.

Figure 4D-12 shows scatter plots comparing the trends in the 4<sup>th</sup> max metric values (x-axis, ppb/yr) to the trends in the W126 metric values (y-axis, ppm-hr/yr) in each NOAA climate region and the associated regression lines fit using the sites within each region. Table 4D-12 provides some summary statistics based on the regional trends comparisons. Figure 4D-12 and Table 4D-12 show that the positive, linear relationship between the trends in the 4<sup>th</sup> max metric values and the trends in the W126 metric values persists within each region, with Pearson correlation coefficients ranging from 0.65 to 0.94. The regression lines shown in Figure 4D-12

with slopes listed in Table 4D-12 indicate that the Southwest region, which had the greatest potential for sites having higher W126 metric values relative to their 4<sup>th</sup> max metric values, also exhibited the greatest response in the W126 metric values per unit change in the 4<sup>th</sup> max metric values. In Figure 4D-11 and Figure 4D-13 (as well as the West region panels in Figure 4D-12 and Figure 4D-14), there appear to be three sites in the West region with an increasing trend in the W126 metric (slope > 0.3) and a decreasing trend in the 4<sup>th</sup> max metric (slope < -0.4). These three sites are all located downwind of Los Angeles, CA and generally have 4<sup>th</sup> max metric values of 100 ppb or greater, along with W126 metric values in the 30-50 ppm-hr range.

Figure 4D-13, Figure 4D-14 and Table 4D-13 present information similar to that shown in Figure 4D-11, Figure 4D-12 and Table 4D-12, respectively, except that trends in annual W126 index values are presented instead of W126 metric values. The figures show that the same general pattern occurs when comparing annual W126 index values to the 4<sup>th</sup> max metric values as was seen for the W126 metric values. There is slightly more variability in the relationship, as can be seen from the slight increase in scatter in the figures and the slightly lower correlation values shown in Table 4D-12 as compared to Table 4D-11.




Figure 4D-11. Scatter plot comparing trends in 4<sup>th</sup> max metric values (x-axis) to trends in W126 metric values (y-axis).





Figure 4D-12. Scatter plots comparing the trends in 4<sup>th</sup> max metric values (x-axis, ppb) and W126 metric values (y-axis, ppm-hrs) based on O<sub>3</sub> monitoring sites within each of the nine NOAA climate regions.




**Table 4D-12. Summary statistics based on regional comparisons of trends in 4<sup>th</sup> max metric values to trends in W126 metric values.**

| NOAA Climate Region | Number of O <sub>3</sub> Sites | Mean Trend in 4 <sup>th</sup> Max Metric Value (ppb/yr) | Mean Trend in W126 Metric Value (ppm-hr/yr) | Regression Slope | Pearson Correlation Coefficient |
|---------------------|--------------------------------|---|---|------------------|---------------------------------|
| Central             | 149                            | -1.06   | -0.63                                       | 0.64             | 0.90                            |
| East North Central  | 45                             | -0.92   | -0.38                                       | 0.39             | 0.75                            |
| Northeast           | 104                            | -1.33   | -0.67                                       | 0.84             | 0.81                            |
| Northwest           | 12                             | -0.25   | -0.06                                       | 0.23             | 0.79                            |
| South               | 83                             | -1.09   | -0.55                                       | 0.40             | 0.65                            |
| Southeast           | 115                            | -1.22   | -0.64                                       | 0.75             | 0.94                            |
| Southwest           | 39                             | -0.35   | -0.24                                       | 0.93             | 0.83                            |
| West                | 102                            | -0.70   | -0.49                                       | 0.83             | 0.76                            |
| West North Central  | 9                              | -0.16   | -0.16                                       | 0.58             | 0.85                            |
| National            | 658                            | -1.00   | -0.55                                       | 0.59             | 0.81                            |



**Figure 4D-13. Scatter plot comparing trends in 4<sup>th</sup> max metric values (x-axis) and trends in annual W126 index values (y-axis).**

1



2

3 **Figure 4D-14. Scatter plots comparing trends in 4<sup>th</sup> max metric values (x-axis, ppb) to**  
 4 **trends in annual W126 index values (y-axis, ppm-hrs) based on O<sub>3</sub> monitoring**  
 5 **sites within each of the nine NOAA climate regions.**

6

**Table 4D-13. Summary statistics based on regional comparisons of trends in 4<sup>th</sup> max metric values and trends in annual W126 index values.**

| NOAA Climate Region | Number of O <sub>3</sub> Sites | Mean Trend in 4 <sup>th</sup> Max Metric Value (ppb/yr) | Mean Trend in Annual W126 Index Value (ppm-hr/yr) | Regression Slope | Pearson Correlation Coefficient |
|---------------------|--------------------------------|---|---|------------------|---------------------------------|
| Central             | 149                            | -1.06   | -0.56   | 0.64             | 0.88                            |
| East North Central  | 45                             | -0.92   | -0.29   | 0.30             | 0.70                            |
| Northeast           | 104                            | -1.33   | -0.61   | 0.75             | 0.79                            |
| Northwest           | 12                             | -0.25   | -0.09   | 0.20             | 0.69                            |
| South               | 83                             | -1.09   | -0.54   | 0.35             | 0.55                            |
| Southeast           | 115                            | -1.22   | -0.61   | 0.67             | 0.91                            |
| Southwest           | 39                             | -0.35   | -0.23   | 0.84             | 0.74                            |
| West                | 102                            | -0.70   | -0.45   | 0.77             | 0.72                            |
| West North Central  | 9                              | -0.16   | -0.15   | 0.50             | 0.80                            |
| National            | 658                            | -1.00   | -0.50   | 0.55             | 0.78                            |

#### 4D.3.2.4 W126 Metric Values in Federal Class I Areas

Table 4D-14 below lists the 65 federal Class I areas for which we have monitoring data available for at least one 3-year period within the 2000-2020 period from a monitor located either within the area boundaries or within 15 km of the boundary. This summary table indicates the number of three-year periods for which the two metrics are available, the number of periods where 4<sup>th</sup> max metric values were at or below 70 ppb (i.e., when the current standard was met) and the range of the W126 metric values (which are also 3-year averages) during those periods. In total, the table is summarizing the 980 combinations of Class I areas and 3-year periods of which 589 have a 4<sup>th</sup> max metric value at or below 70 ppb and 391 have a 4<sup>th</sup> max metric value above 70 ppb. In the most recent period (2018-2020), of the 56 areas for which we have monitors, 47 sites have 4<sup>th</sup> max metric values at or below 70 ppb.

Table 4D-15 lists the Class I areas with the highest W126 metric values when the 4<sup>th</sup> max metric value is at or below 70 ppb. Among areas with a 4<sup>th</sup> max metric value at or below 70 ppb during any of the 3-year periods from 2000 to 2020, five areas (all located in the Southwest region) had one or more W126 metric values above 17 ppm-hrs, with the highest W126 metric values equal to 19 ppm-hrs and the highest annual W126 index values equal to 23 ppm-hrs, when rounded. All seven instances where a Class I area observed a 4<sup>th</sup> max metric value at or below 70 ppb and a W126 metric value above 17 ppm-hrs occurred prior to 2011. This contrasts with the much higher values observed in Class I areas when the current standard is not met (Table 4D-17). In the 2018-2020 period, the W126 metric values range up to 41 ppm-hrs at sites in Class I areas when the standard is not met, with higher values in the historical Class I dataset.

Figure 4D-15 shows the distribution of annual W126 index values in Class I areas during 3-year periods with different 4<sup>th</sup> max metric values. The full distribution of annual W126 index

1 values, including the minimum and maximums, increase with increasing 4<sup>th</sup> max metric values.  
2 For example, the 99<sup>th</sup> percentile increases from about 20 ppm-hrs or lower to higher than 25  
3 ppm-hrs for 4<sup>th</sup> max metric values at and below 70 ppb compared to 4<sup>th</sup> max metric values above  
4 70 ppb. As indicated by Table 4D-15, the 3-year periods with the highest W126 metric values  
5 occurring for 4<sup>th</sup> max metric values at or below 70 ppb occurred in the earlier years of the dataset  
6 (2000-2010).

7 Table 4D-16 summarizes the occurrence of relatively higher annual W126 index values  
8 in Class I areas during 3-year periods when the 4<sup>th</sup> max metric value is at or below 70 ppb. This  
9 figure summarizes the W126 metric (i.e., 3-year average of annual W126 index values), as well  
10 as maximum annual W126 index values in each 3-year period meeting the current standard. For  
11 all instances of an area and 3-year period with a maximum annual W126 index value above 19  
12 ppm-hrs, Figure 4D-16 illustrates the variation among the annual W126 index values and the  
13 extent to which they differ from the 3-year average.

14 Finally, Table 4D-17 further documents the ranges of W126 metric values occurring  
15 during periods when the 4<sup>th</sup> max metric value was above 70 ppb, indicating the extent to which  
16 the current standard appears to be controlling the W126 metric.  
17

1 **Table 4D-14. W126 metric values in Class I areas with 4<sup>th</sup> max metric values at or below 70**  
2 **ppb (2000-2020).**

| NOAA Region<br>(number of Class I areas <sup>1</sup> ,<br>number of states <sup>1</sup> with an<br>area in region) | State          | Area Name <sup>2</sup>  | Number<br>of 3-<br>year<br>periods<br>with<br>data                        | Number<br>of 3-<br>year<br>periods<br>with 4 <sup>th</sup><br>max ≤<br>70 ppb | Range of<br>W126<br>Metric<br>Values<br>when 4 <sup>th</sup><br>max ≤ 70<br>ppb |
|--|----------------|---|---|---|---|
| Central<br>(7, 4)  | Kentucky       | Mammoth Cave National Park <sup>RM, VP</sup>                                | 19  | 9   | 5-11  |
|  | Tennessee      | Great Smoky Mountains National Park <sup>3 SM, YP, LP, VP, RM, BC, WP</sup> | 19  | 8   | 6-10  |
|  | West Virginia  | Otter Creek Wilderness <sup>VP, YP, RM, SM, BC, LP, WP</sup>                | 18  | 11  | 4-8   |
| EastNorthCentral<br>(6, 3)   | Michigan       | Seney Wilderness Area <sup>* QA, RM, SM, BC, WP</sup>                       | 17  | 9   | 4-6   |
|  | Minnesota      | Boundary Waters Canoe Area Wilderness Area <sup>* SM, QA, WP</sup>          | 6   | 6   | 2-4   |
|  |                | Voyageurs National Park <sup>QA, RM, WP</sup>                               | 15  | 15  | 2-6   |
| NorthEast<br>(6, 4)  | Maine          | Acadia National Park <sup>RM, QA, SM, WP</sup>                              | 19  | 8   | 4-5   |
|  | New Hampshire  | Great Gulf Wilderness Area <sup>* WP</sup>                                  | 16  | 16  | 3-8   |
|  | New Jersey     | Brigantine Wilderness Area <sup>* BC</sup>                                  | 18  | 7   | 4-8   |
| NorthWest<br>(29, 4)   | Idaho          | Craters of the Moon Wilderness Area <sup>* DF, QA</sup>                     | 13  | 13  | 6-13  |
|  | Washington     | Alpine Lakes Wilderness <sup>* DF, PP</sup>                                 | 19  | 17  | 2-6   |
|  |                | Mount Rainer National Park, <sup>DF</sup>                                   | 17  | 16  | 2-6   |
|  |                | North Cascades National Park <sup>* PP, DF, RA</sup>                        | 3   | 3   | 1-2   |
|  |                | Olympic National Park <sup>DF, RA</sup>                                     | 8   | 8   | 1-6   |
|  | Alaska         | Denali National Park <sup>QA</sup> (Formerly Mt. McKinley Nat Pk)           | 19  | 19  | 2-4   |
| South<br>(6, 4)  | Arkansas       | Caney Creek Wilderness Area <sup>*</sup>                                    | 14  | 8   | 4-7   |
|  |                | Upper Buffalo Wilderness Area <sup>* SM</sup>                               | 19  | 13  | 3-8   |
|  | Texas          | Big Bend National Park <sup>QA, DF, PP</sup>                                | 18  | 15  | 6-13  |
| SouthEast<br>(16, 6)   | Alabama        | Sipsey Wilderness <sup>* WP, RM, SM, YP, LP, VP</sup>                       | 6   | 1   | 11  |
|  | Florida        | St. Marks Wilderness Area <sup>*</sup>                                      | 17  | 12  | 4-11  |
|  | Georgia        | Cohutta Wilderness Area <sup>* WP, VP, YP</sup>                             | 19  | 8   | 4-6   |
|  | North Carolina | Great Smoky Mountains National Park <sup>* SM, YP, LP, VP, RM, BC, WP</sup> | See Tennessee for monitor with highest design value (4 <sup>th</sup> max) |   |   |
|  |                | Linville Gorge Wilderness Area <sup>* VP, WP, RM, YP</sup>                  | 19  | 15  | 5-11  |
|  |                | Shining Rock Wilderness Area <sup>*</sup>                                   | 19  | 12  | 5-10  |
|  | South Carolina | Cape Romain Wilderness <sup>*</sup>   | 17  | 10  | 3-8   |
|  | Virginia       | James River Face Wilderness <sup>* WP</sup>                                 | 19  | 13  | 3-10  |
|  |                | Shenandoah National Park <sup>WP, VP, QA, BC, RM, SM, YP</sup>              | 19  | 8   | 5-11  |
| SouthWest<br>(38, 4)   | Arizona        | Chiricahua National Monument <sup>DF, PP</sup>                              | 19  | 11  | 11-17   |
|  |                | Grand Canyon National Park <sup>DF, PP, QA</sup>                            | 19  | 11  | 10-19   |
|  |                | Mazatzal Wilderness Area <sup>DF, PP</sup>                                  | 19  | 2   | 15  |

| NOAA Region<br>(number of Class I areas <sup>1</sup> ,<br>number of states <sup>1</sup> with an<br>area in region) | State        | Area Name <sup>2</sup>                           | Number<br>of 3-<br>year<br>periods<br>with<br>data | Number<br>of 3-<br>year<br>periods<br>with 4 <sup>th</sup><br>max ≤<br>70 ppb | Range of<br>W126<br>Metric<br>Values<br>when 4 <sup>th</sup><br>max ≤ 70<br>ppb |
|--|--------------|--|--|---|---|
|  |              | Petrified Forest National Park                   | 11   | 11  | 11-17   |
|  |              | Saguaro Wilderness Area* 2 DF, PP                | 19   | 7   | 12-15   |
|  |              | Superstition Wilderness Area* PP                 | 19   | 1   | 13  |
|  |              | Yavapai Reservation* QA, PP, DF                  | 4  | 4   | 10-15   |
|  | Colorado     | Maroon Bells-Snowmass Wilderness. Area* QA, DF   | 14   | 14  | 11-19   |
|  |              | Mesa Verde National Park* PP, DF                 | 19   | 17  | 11-18   |
|  |              | Rocky Mountain National Park* DF, PP, QA         | 19   | 5   | 13-15   |
|  |              | Weminuche Wilderness Area* DF, PP                | 8  | 3   | 13-18   |
|  | New Mexico   | San Pedro Parks Wilderness* PP, DF               | 5  | 5   | 11-14   |
|  | Utah         | Canyonlands National Park PP, DF                 | 18   | 12  | 10-15   |
|  |              | Zion National Park* DF, PP, QA                   | 13   | 8   | 11-18   |
| West<br>(32, 3)  | California   | Agua Tibia Wilderness* DF                        | 6  | 0   | -   |
|  |              | Cucamonga Wilderness Area* DF, PP                | 19   | 0   | -   |
|  |              | Desolation Wilderness Area* PP                   | 8  | 4   | 8-13  |
|  |              | Joshua Tree Wilderness Area*                     | 19   | 0   | -   |
|  |              | Kaiser Wilderness Area*                          | 1  | 0   | -   |
|  |              | Lassen Volcanic National Park DF, PP             | 19   | 13  | 7-14  |
|  |              | Pinnacles Wilderness Area*                       | 19   | 10  | 7-10  |
|  |              | San Gabriel Wilderness Area* DF, PP              | 19   | 0   | -   |
|  |              | San Geronio Wilderness Area* PP, QA              | 15   | 0   | -   |
|  |              | San Jacinto Wilderness Area* PP                  | 19   | 0   | -   |
|  |              | San Rafael Wilderness Area*                      | 19   | 11  | 5-9   |
|  |              | Sequoia National Park PP, QA, DF                 | 19   | 0   | -   |
|  |              | Ventana Wilderness Area*                         | 19   | 19  | 2-4   |
|  |              | Yosemite National Park DF, PP, QA                | 19   | 0   | -   |
|  | Hawaii       | Hawaii Volcanoes National Park                   | 2  | 2   | 0   |
| WestNorthCentral<br>(26, 4)  | Montana      | Gates of the Mountain Wilderness Area*           | 8  | 8   | 3-6   |
|  |              | Glacier National Park QA, PP, DF                 | 19   | 19  | 2-3   |
|  |              | Northern Cheyenne Reservation*                   | 9  | 9   | 3-5   |
|  | North Dakota | Lostwood Wilderness*                             | 15   | 15  | 4-5   |
|  |              | Theodore Roosevelt National Park <sup>2</sup> PP | 18   | 18  | 4-7   |
|  | South Dakota | Badlands Wilderness*                             | 13   | 13  | 3-12  |
|  |              | Wind Cave National Park PP                       | 12   | 12  | 5-15  |

| NOAA Region<br>(number of Class I areas <sup>1</sup> ,<br>number of states <sup>1</sup> with an<br>area in region) | State   | Area Name <sup>2</sup>                      | Number<br>of 3-<br>year<br>periods<br>with<br>data | Number<br>of 3-<br>year<br>periods<br>with 4 <sup>th</sup><br>max ≤<br>70 ppb | Range of<br>W126<br>Metric<br>Values<br>when 4 <sup>th</sup><br>max ≤ 70<br>ppb |
|--|---------|---|--|---|---|
|  | Wyoming | Bridger Wilderness*                         | 15   | 14  | 9-16  |
|  |         | Grand Teton National Park <sup>DF, OA</sup> | 7  | 7   | 5-8   |
|  |         | Yellowstone National Park <sup>DF, OA</sup> | 19   | 19  | 6-11  |

\*The monitoring site is outside of the area but within 15 km of the area boundary.


<sup>1</sup> Areas are counted in all regions and states with a Class I area.

<sup>2</sup> The 2-letter superscripts associated with some area names are abbreviations for species documented to be present in the area for which there is an established exposure-response function described in Appendix 4A: OA=Quaking Aspen, BC=Black Cherry, C=Cottonwood, DF=Douglas Fir, LP=Loblolly Pine, PP=Ponderosa Pine, RM=Red Maple, SM=Sugar Maple, VP=Virginia Pine, YP=Yellow (Tulip) Poplar. Sources include [www.NPS.gov](http://www.NPS.gov), [www.inaturalist.org/guides](http://www.inaturalist.org/guides), [www.fs.usda.gov](http://www.fs.usda.gov), [www.msjnha.org/trees](http://www.msjnha.org/trees), [www.wilderness.net](http://www.wilderness.net)

<sup>3</sup> This area has two monitors; it is represented by the one with consistently higher values.

**Table 4D-15. Highest W126 metric values occurring in Class I areas when the 4<sup>th</sup> max metric value is at or below 70 ppb (2000-2020).**

| Class I Area   | State/County  | 4 <sup>th</sup> max<br>Range<br>(ppb) | 3-year Periods  | W126 Metric<br>Range<br>(ppm-hrs) |
|--|---------------|---------------------------------------|---|-----------------------------------|
| <b>Areas with W126 metric values above 17</b>                    |               |                                       |   |                                   |
| Grand Canyon National Park                                       | AZ/Coconino   | 70                                    | 2006-2008   | 19                                |
| Maroon Bells-Snowmass Wilderness                                 | CO/Gunnison   | 70                                    | 2000-2002, 2001-2003,<br>2002-2004                        | 18-19                             |
| Mesa Verde National Park   | CO/Montezuma  | 70                                    | 2006-2008   | 18                                |
| Weminuche Wilderness <sup>A</sup>                                | CO/LaPlata    | 70                                    | 2006-2008   | 18                                |
| Zion National Park <sup>B</sup>                                  | UT/Washington | 70                                    | 2008-2010   | 18                                |
| <b>Areas with W126 metric values at or below 17 and above 15</b> |               |                                       |   |                                   |
| Bridger Wilderness   | WY/Sublette   | 70                                    | 2001-2003   | 16                                |
| Canyonlands National Park  | UT/San Juan   | 70                                    | 2006-2008   | 17                                |
| Chiricahua National Monument                                     | AZ/Cochise    | 69                                    | 2006-2008   | 17                                |
| Maroon Bells-Snowmass Wilderness                                 | CO/Gunnison   | 68                                    | 2003-2005, 2004-2006,<br>2005-2007                        | 16                                |
| Mesa Verde National Park   | CO/Montezuma  | 67-70                                 | 2000-2002, 2001-2003<br>2002-2004, 2003-2005<br>2011-2013 | 16-17                             |
| Petrified Forest National Park                                   | AZ/Navajo     | 70                                    | 2011-2013, 2012-2014                                      | 16-17                             |
| Zion National Park   | UT/Washington | 70                                    | 2007-2009, 2009-2011<br>2012-2014                         | 16-17                             |
| <sup>A</sup> Monitoring site is 15.0 km from area.               |               |                                       |   |                                   |
| <sup>B</sup> Monitoring site is 3.4 km from area.                |               |                                       |   |                                   |



**Figure 4D-15. Range of annual W126 index values in ppm-hrs observed at monitoring sites in Class I areas based on 2000-2020 monitoring data. Values are binned according to 4<sup>th</sup> max metric values in ppb. Boxes show 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentiles, whiskers extend to 1<sup>st</sup> and 99<sup>th</sup> percentiles, and points below the 1<sup>st</sup> percentile or above the 99<sup>th</sup> percentile are represented by dots.**

**Table 4D-16. Summary of Class I area W126 index values when 4<sup>th</sup> max is at/below 70 ppb.**


| Time period | Total number of Area-DVs in time period<br>(Number of areas) | Among areas with design values (DVs) ≤ 70 ppb               |                    |          |   |                      |          |
|-------------|--|---|--------------------|----------|---|----------------------|----------|
|             |  | Number of area-DVs with W126 metric...<br>(Number of areas) |                    |          | Number of Area-DVs with maximum annual W126 index...<br>(Number of areas) |                      |          |
|             |  | >19   | >17                | ≤ 17     | >19   | >17                  | ≤ 17     |
| 2018-2020   | 57 (56)  | 0   | 0                  | 47 (46)  | 0   | 2 (2) <sup>A</sup>   | 45 (44)  |
| 2000-2020   | 980 (65)   | 0   | 7 (5) <sup>A</sup> | 589 (56) | 15 (10) <sup>B</sup>  | 39 (18) <sup>C</sup> | 531 (55) |

<sup>A</sup> These areas are all in the Southwest Region.

<sup>B</sup> All but two of these areas are in Southwest Region; the other two are in West and West North Central Regions. The highest maximum annual W126 index value in dataset is 23 ppm-hrs of which there are four occurrences, all from prior to 2012 in SW. The most recent maximum annual W126 index value above 19 ppm-hrs is during 2012-2014 period (in 2012) when there are three (20, 20 and 21 ppm-hrs).

<sup>C</sup> All but eight of these areas are in Southwest Region; the others are in West, South, Central and West North Central Regions.





**Figure 4D-16. Range of annual W126 index values observed in each 3-year period where a site in a Class I area had a design value meeting the current standard and had at least one annual W126 index value greater than 19 ppm-hrs.** Each vertical column is one such 3-year period. Dots show annual W126 index values and squares show the W126 metric value.

1 **Table 4D-17. W126 values in Class I areas with 4<sup>th</sup> max metric values above 70 ppb (2000-2020).**

| NOAA Region      | W126 metric >19 |                             |                                   | W126 metric >17 |                             |                                   | W126 metric >15 |                             |                                   | W126 metric ≤15 |                             |                                   |
|------------------|-----------------|-----------------------------|-----------------------------------|-----------------|-----------------------------|-----------------------------------|-----------------|-----------------------------|-----------------------------------|-----------------|-----------------------------|-----------------------------------|
|                  | Number of areas | W126 metric range (ppm-hrs) | Annual W126 index range (ppm-hrs) | Number of areas | W126 metric range (ppm-hrs) | Annual W126 index range (ppm-hrs) | Number of areas | W126 metric range (ppm-hrs) | Annual W126 index range (ppm-hrs) | Number of areas | W126 metric range (ppm-hrs) | Annual W126 index range (ppm-hrs) |
|                  | 2018-2020       |                             |                                   |                 |                             |                                   |                 |                             |                                   |                 |                             |                                   |
| Central          | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 |
| EastNorthCentral | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 |
| NorthEast        | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 |
| NorthWest        | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 |
| South            | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 |
| SouthEast        | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 |
| SouthWest        | 0               | -                           | -                                 | 0               | -                           | -                                 | 2               | 17                          | 11-21                             | 0               | -                           | -                                 |
| West             | 7               | 20-41                       | 14-47                             | 8               | 19-41                       | 12-47                             | 8               | 19-41                       | 12-47                             | 0               | -                           | -                                 |
| WestNorthCentral | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 |
|                  | 2000-2020       |                             |                                   |                 |                             |                                   |                 |                             |                                   |                 |                             |                                   |
| Central          | 1               | 20-31                       | 9-37                              | 2               | 19-31                       | 9-37                              | 2               | 16-31                       | 9-37                              | 3               | 9-15                        | 6-22                              |
| EastNorthCentral | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 1               | 6-8                         | 4-11                              |
| NorthEast        | 1               | 20                          | 17-24                             | 1               | 20                          | 17-24                             | 1               | 17-20                       | 9-24                              | 2               | 5-14                        | 4-18                              |
| NorthWest        | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 2               | 6-7                         | 3-10                              |
| South            | 0               | -                           | -                                 | 0               | -                           | -                                 | 0               | -                           | -                                 | 3               | 7-14                        | 5-18                              |
| SouthEast        | 1               | 22                          | 18-25                             | 1               | 22                          | 18-25                             | 3               | 16-22                       | 10-25                             | 8               | 7-15                        | 5-22                              |
| SouthWest        | 8               | 20-33                       | 9-39                              | 10              | 18-33                       | 9-39                              | 10              | 16-33                       | 9-39                              | 5               | 11-15                       | 7-24                              |
| West             | 12              | 20-61                       | 14-74                             | 13              | 18-61                       | 12-74                             | 13              | 16-61                       | 12-74                             | 4               | 10-15                       | 8-20                              |
| WestNorthCentral | 0               | -                           | -                                 | 0               | -                           | -                                 | 1               | 17                          | 14-19                             | 0               | -                           | -                                 |

## 4D.4 KEY LIMITATIONS AND UNCERTAINTIES

This section summarizes key limitations and uncertainties associated with aspects of the datasets analyzed in the preceding sections. The first section summarizes key limitations and uncertainties associated with complete dataset monitoring sites in all U.S. locations (urban and rural), which focus on patterns and relationships across all monitoring sites. The second section concentrates on the Class I area sites. Overall, we recognize that while the datasets analyzed are quite extensive (e.g., more than 1,100 sites covering all 50 states in the most recent 3-year period), there are limitations and uncertainties associated with the spatial representation of O<sub>3</sub> monitoring sites in rural areas and Class I areas, specifically.

**Analyses of data for all U.S. monitoring sites:** Given that there has been a longstanding emphasis on urban areas in the EPA's monitoring regulations, urban areas are generally well represented in the U.S. dataset, with the effect being that the current dataset is more representative of locations where people live than of complete spatial coverage for all areas in the U.S., (i.e., the current dataset is more population weighted than geographically weighted). Thus, the spatial coverage of the current O<sub>3</sub> monitoring network may be less representative of natural areas which tend to be more sparsely populated. As O<sub>3</sub> precursor sources are also generally more associated with urban areas, one impact of this may be a greater representation of relatively higher concentration sites. One method that has been suggested to create a more geographically representative dataset is the use of photochemical air quality modeling to estimate concentrations. However, this approach has been found to present its own uncertainties with regard to estimating annual W126 index values (U.S. EPA, 2014b, Appendix 4A), making it less useful for the current analyses.

**Dataset for Class I monitoring sites:** A limitation of this dataset is that it includes sites in only 65 of the 164 Class I areas in the U.S. The representation of states containing Class I areas is somewhat greater, with monitoring sites in Class I areas in 29 of the 36 states that have such an area. All nine NOAA climate regions are represented. As can be seen from Figure 4D-2, sites outside of Class I areas in the states not represented (LA, MO, NV, OK, OR, VT, WI) have W126 metric values at or below 13 ppm-hrs during the recent 3-year period (2018-2020). Across the states represented in the dataset, the fraction of a given state's Class I areas included in the dataset generally ranges from about a third to 100%. An exception to that is New Mexico, for which a monitoring site is in or near only one of the nine Class I areas in the state. This contrasts with neighboring Arizona, also in the Southwest region and for which more than half the Class I areas are represented in the dataset.

## 4D.5 SUMMARY

The preceding sections present analyses based on 21 years of O<sub>3</sub> concentration data reported at monitoring sites across the U.S. These analyses, intended to inform the review of the current O<sub>3</sub> secondary standard, investigate spatial and temporal patterns in the W126 metric using monitoring data from 2000 to 2020 and the extent of relationships between the W126 metric, annual W126 index values and design values for the current secondary O<sub>3</sub> standard (i.e., the 4<sup>th</sup> max metric). Further analyses of O<sub>3</sub> concentrations in or near federally protected ecosystems known as Class I areas focus on examining the levels and distributions of levels of the W126 metric and the annual W126 index occurring in such areas when the current secondary standard is met and also when the current secondary standard is not met.

The analyses based on recent (2018-2020) data showed that about one in five U.S. sites had 4<sup>th</sup> max metric values greater than the current standard level of 70 ppb. By contrast, only about 1 in 14 U.S. sites had W126 metric values greater than 17 ppm-hrs, and about 1 in 9 U.S. sites had W126 metric values greater than 13 ppm-hrs. There were O<sub>3</sub> monitors exceeding the current standard level of 70 ppb in 6 of 9 climate regions, while only two regions, the West and Southwest, had O<sub>3</sub> monitors with W126 metric values exceeding 13 ppm-hrs.

When examining the 4<sup>th</sup> max and W126 metrics in combination, the 2018-2020 data showed that there were many U.S. O<sub>3</sub> sites with 4<sup>th</sup> max metric values exceeding the current standard that had W126 metric values less than or equal to 17 ppm-hrs (128) and 13 ppm-hrs (95). By contrast, there were relatively few sites meeting the current standard that had W126 metric values greater than 13 ppm-hrs (13); and there were no sites that had a W126 metric value above 17 ppm-hrs. The 13 sites that met the current standard and had W126 metric values greater than 13 ppm-hrs were located exclusively in the Southwest and West climate regions, whereas the 95 sites that exceeded the current standard and had W126 metric values less than or equal to 13 ppm-hrs had a much broader geographic distribution.

Among O<sub>3</sub> monitoring sites in Federal Class I areas, few areas since 2000 have had 4<sup>th</sup> max metric values meeting the current standard and W126 metric values above 17 ppm-hrs, the most recent of which occurred during the 2012-2014 period. These instances are all in or near Class I areas in the Southwest region, with the highest (19 ppm-hrs) occurring during the 2006-2008 period.

The analysis of inter-annual variability shows that the distribution of annual W126 index deviations from their respective 3-year averages generally increase with increasing W126 metric values. For sites with W126 metric values below 20 ppm-hrs (e.g., focusing on W126 metric values that have occurred with 4<sup>th</sup> max metric values at or below 70 ppb), the annual deviation was generally within 5 ppm-hrs. Additionally, well over 99% of 4<sup>th</sup> max metric values meeting

1 the current standard were associated with annual W126 index values of less than or equal to 19  
2 ppm-hrs.

3 The trends analysis showed that both W126 metric values and annual W126 index values  
4 have generally decreased since 2000, with U.S. median W126 metric values decreasing by over  
5 65%, from 17 ppm-hrs in 2002 to less than 6 ppm-hrs in 2020. A substantial number of U.S. sites  
6 have experienced decreases of over 10 ppm-hrs in the past decade, particularly in the eastern  
7 U.S.

8 The analysis comparing trends in the 4th max metric values and to trends in the W126  
9 metric values based on data from 2000-2020 showed that there was a positive, linear relationship  
10 between the per-year changes in the 4th max and W126 metrics. Nationally, the W126 metric  
11 values decreased by approximately 0.6 ppm-hr per unit ppb decrease in the 4th max metric  
12 values. This relationship varied across the NOAA climate regions. The Southwest and West  
13 regions which showed the greatest potential for exceeding only the W126 levels of interest also  
14 showed the greatest improvement in the W126 metric values per unit decrease in 4th max metric  
15 values. This analysis indicates that W126 metric values in those areas not meeting the current  
16 standard would be expected to decline as the 4th max metric values are reduced to meet the  
17 current standard, consistent with the relationship shown in Figure 4D-11.

## 4D.6 REFERENCES

- Karl, T and Koss, WJ (1984). Regional and national monthly, seasonal, and annual temperature weighted by area, 1895-1983. 4-3. National Environmental Satellite and Data Information Service (NESDIS). Asheville, NC.
- U.S. EPA (2014a). Policy Assessment for the Review of National Ambient Air Quality Standards for Ozone (Final Report). Office of Air Quality Planning and Standards, Health and Environmental Impacts Division. Research Triangle Park, NC. U.S. EPA. EPA-452/R-14-006 August 2014. Available at:  
<https://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=P100KCZ5.txt>.
- U.S. EPA (2014b). Welfare Risk and Exposure Assessment for Ozone (Final) with Executive Summary and Appendices. Office of Air Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/P-14-005a, EPA-452/R-14-005b and EPA-452/R-14-005c February 2014. Available at:  
<https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KQLJ.txt>.
- Wells, B. (2014). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-OAR-2008-0699). Comparison of Ozone Metrics Considered in Current NAAQS Review. November 20, 2014. . Docket ID No. EPA-HQ-OAR-2008-0699. Available at:  
<https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-0155&contentType=pdf>.
- Wells, B. (2015). Memorandum to Ozone NAAQS Review Docket (EPA-HQ-OAR-2008-0699). Expanded Comparison of Ozone Metrics Considered in the Current NAAQS Review. September 28, 2015. Docket ID No. EPA-HQ-OAR-2008-0699. Available at:  
<https://www.regulations.gov/contentStreamer?documentId=EPA-HQ-OAR-2008-0699-4325&contentType=pdf>.

1

## **APPENDIX 4E**

2

### **OZONE WELFARE EFFECTS AND RELATED ECOSYSTEM SERVICES AND PUBLIC WELFARE ASPECTS**

3

**Table 4E-1. Ecosystem services and aspects of public welfare potentially affected by the different types of O<sub>3</sub> welfare effects.**

| O <sub>3</sub> Effect <sup>A</sup>  | Aspect of Public Welfare Potentially Affected (Examples) <sup>B</sup>  | Ecosystem Services <sup>C</sup>             |
|---|--|---|
| Visible foliar injury   | <ul style="list-style-type: none"> <li>Appearance and scenic beauty of forests wilderness areas, including federal, tribal, state, municipally protected areas</li> <li>Quality of specific agricultural crops, plant leaf products</li> <li>Appearance of plants in residential/commercial areas (ornamentals)</li> </ul> | Cultural Recreation Provisioning            |
| Reduced vegetation growth   | <ul style="list-style-type: none"> <li>Food, raw material, and unique biological material and product production</li> <li>Shade provision</li> <li>Quality of plants of cultural importance to Native American Tribes</li> <li>Changes to national yield and prices</li> </ul>   | Cultural Provisioning                       |
| Reduced plant reproduction  |  |   |
| Reduced yield and quality of agricultural crops   |  |   |
| Reduced productivity in terrestrial ecosystems  |  |   |
| <i>Reduced carbon sequestration in terrestrial systems</i>  | <ul style="list-style-type: none"> <li>Regulation/control of climatological features and meteorological phenomena</li> <li>Changes in pollution removal in urban areas</li> </ul>  | Regulating Supporting                       |
| <i>Increased tree mortality</i>   | <ul style="list-style-type: none"> <li>Regulation/control of wildfires</li> <li>Regulation of erosion and soil stability</li> <li>Decline of ecosystem services provided by trees (see Table 4E-2)</li> </ul>  | Regulating Cultural Supporting Provisioning |
| <i>Alteration of terrestrial community composition</i>  | <ul style="list-style-type: none"> <li>Intrinsic value of areas specially protected from anthropogenic degradation</li> <li>Production of preferred species of timber</li> <li>Preservation of unique or endangered ecosystems or species</li> <li>Species diversity in protected areas</li> </ul>                         | Cultural Provisioning Supporting            |
| Alteration of belowground biogeochemical cycles   | <ul style="list-style-type: none"> <li>Soil quality</li> <li>Soil nutrient cycling, decomposition, and availability</li> <li>Carbon storage</li> <li>Regulation of soil fauna and microbial communities</li> <li>Water quality and resource management</li> <li>Regulation of hydraulic flow</li> </ul>                    | Supporting Regulating                       |
| <i>Alteration of ecosystem water cycling</i>  | <ul style="list-style-type: none"> <li>Water quality and resource management</li> <li>Regulation of hydraulic flow</li> </ul>  | Provisioning Regulating Supporting          |
| <i>Altered of herbivore growth and reproduction</i>   | <ul style="list-style-type: none"> <li>Food sources, habitat, and protection for native fauna</li> </ul>   | Supporting Regulating                       |
| <i>Alteration of plant insect signaling</i>   | <ul style="list-style-type: none"> <li>Plant-pollinator interactions</li> <li>Timber and agricultural plant resistance to insect pest damage</li> </ul>  | Supporting Provisioning                     |
| Radiative forcing and related climate effects   | <ul style="list-style-type: none"> <li>Regulation/control of meteorological phenomena</li> </ul>   | Regulating                                  |
| <p><b>NOTE:</b> Sources include ISA (Appendix 8, Figure 8-1 and Table 8-1) and 2014 WREA (Section 5).<br/> <sup>A</sup> Effects identified as causally or <i>likely causally</i> related to O<sub>3</sub> (draft ISA, Appendices 8 and 9).<br/> <sup>B</sup> Examples provided in Costanza et al., 2017) and 2014 WREA, Section 5 (U.S. EPA, 2014)<br/> <sup>C</sup> Description of Ecosystem Services in 2013 ISA, Section 9.4.1.2 and in the 2014 WREA, Section 5.1:</p> <ul style="list-style-type: none"> <li><i>Regulating:</i> Services of importance for human society such as carbon sequestration, climate and water regulation, protection from natural hazards such as floods, avalanches, or rock-fall, water and air purification, and disease and pest regulation.</li> <li><i>Supporting:</i> The services needed by all the other ecosystem services, either indirectly or directly, such biomass production, production of atmospheric O<sub>2</sub>, soil formation and retention, nutrient cycling, water cycling, biodiversity, and provisioning of habitat.</li> <li><i>Provisioning:</i> Services that include market goods, such as food, water, fiber, and medicinal and cosmetic products</li> <li><i>Cultural:</i> services that satisfy human spiritual and aesthetic appreciation of ecosystems and their components including recreational and other nonmaterial benefits</li> </ul> |  |   |



**Table 4E-2. Ecosystem services and specific uses of the 11 tree species with robust E-R functions for reduced growth.**

| Tree Species  | O <sub>3</sub> Effect                  | Role in Ecosystems and Public Uses   |
|---|--|--|
| <b>Black Cherry</b><br><i>Prunus serotina</i>   | Biomass loss,<br>Visible foliar injury | Cabinets, furniture, paneling, veneers, crafts, toys; Cough remedy, tonic, sedative; Flavor for rum and brandy; Wine making and jellies; Food and habitat for songbirds, game birds, and mammals   |
| <b>Eastern White Pine</b><br><i>Pinus strobus</i>   | Biomass loss                           | Commercial timber, furniture, woodworking, and Christmas trees; Medicinal uses as expectorant and antiseptic; Food and habitat for songbirds and mammals; Used to stabilize strip mine soils   |
| <b>Quaking Aspen</b><br><i>Populus tremuloides</i>  | Biomass loss,<br>Visible foliar injury | Commercial logging for pulp, flake-board, pallets, boxes, and plywood; Products including matchsticks, tongue depressors, and ice cream sticks; Valued for its white bark and brilliant fall color; Important as a fire break Habitat for variety of wildlife; Traditional native American use as a food source  |
| <b>Yellow (Tulip) Poplar</b><br><i>Liriodendron tulipifera</i>  | Biomass loss,<br>Visible foliar injury | Furniture stock, veneer, and pulpwood; Street, shade, or ornamental tree – unusual flowers; Food and habitat for wildlife; Rapid growth for reforestation projects   |
| <b>Ponderosa Pine</b><br><i>Pinus ponderosa</i>   | Biomass loss,<br>Visible foliar injury | Lumber for cabinets and construction; Ornamental and erosion control use; Recreation areas; Food and habitat for many bird species, including the red-winged blackbird, chickadee, finches, and nuthatches   |
| <b>Red Alder</b><br><i>Alnus rubra</i>  | Biomass loss,<br>Visible foliar injury | Commercial use in products such as furniture, cabinets, and millwork; Preferred for smoked salmon; Dyes for baskets, hides, moccasins; Medicinal use for rheumatic pain, diarrhea, stomach cramps – the bark contains salicin, a chemical similar to aspirin; Roots used for baskets; Food and habitat for mammals and birds – dam and lodge construction for beavers; Conservation and erosion control  |
| <b>Red Maple<sup>^</sup></b><br><i>Acer rubrum</i>  | Biomass loss                           | One of the most abundant and widespread trees in eastern U.S. Used for revegetation, especially in riparian buffers and landscaping, where it is valued for its brilliant fall foliage, some lumber and syrup production; Important wildlife browse food, especially for elk and white-tailed deer in winter, also leaves are important food source for some species of butterflies and moths.   |
| <b>Virginia Pine</b><br><i>Pinus virginiana</i>   | Biomass loss,<br>Visible foliar injury | Pulpwood, stabilization of strip mine spoil banks and severely eroded soils; Nesting for woodpeckers, food and habitat for songbirds and small mammals   |
| <b>Sugar Maple</b><br><i>Acer saccharum</i>   | Biomass loss                           | Commercial syrup production; Native Americans used sap as a candy, beverage – fresh or fermented into beer, soured into vinegar and used to cook meat; Valued for its fall foliage and as an ornamental; Commercial logging for furniture, flooring, paneling, and veneer; Woodenware, musical instruments; Food and habitat for many birds and mammals  |
| <b>Loblolly Pine<sup>*</sup></b>  | Biomass loss,<br>visible foliar injury | Most important and widely cultivated timber species in the southern U.S.; Furniture, pulpwood, plywood, composite boards, posts, poles, pilings, crates, boxes, pallets. Also planted to stabilize eroded or damaged soils. It can be used for shade or ornamental trees, as well as bark mulch; Provides habitat, food and cover for white-tailed deer, gray squirrel, fox squirrel, bobwhite quail and wild turkey, red-cockaded woodpeckers, and a variety of other birds and small mammals. Standing dead trees are frequently used for cavity nests by woodpeckers. |
| <b>Douglas Fir</b><br><i>Pseudotsuga menziesii</i>  | Biomass loss                           | Commercial timber and used for Christmas trees; Medicinal uses, spiritual and cultural uses for several Native American tribes; Spotted owl habitat; Food and habitat for mammals including antelope and mountain sheep  |
| Sources: 2014 WREA, USDA-NRCS (2013); Burns and Honkala, 1990).<br><sup>^</sup> Red maple information from <a href="https://www.srs.fs.usda.gov/pubs/misc/ag_654/volume_2/silvics_v2.pdf">https://www.srs.fs.usda.gov/pubs/misc/ag_654/volume_2/silvics_v2.pdf</a><br><sup>*</sup> Loblolly pine use information from <a href="https://projects.ncsu.edu/project/dendrology/index/plantae/vascular/seedplants/gymnosperms/conifers/pine/pinus/australes/loblolly/loblollypine.html">https://projects.ncsu.edu/project/dendrology/index/plantae/vascular/seedplants/gymnosperms/conifers/pine/pinus/australes/loblolly/loblollypine.html</a> . |  |  |

## 1   **REFERENCES**

2   Burns, RM and Honkala, BH, Eds. (1990). Volume 1: Conifers: *Abies balsamea* (L.) mill.  
3       Balsam fir. Agriculture Handbook 654. U.S. Department of Agriculture, U.S. Forest  
4       Service Washington, DC.

5   Costanza, R, De Groot, R, Braat, L, Kubiszewski, I, Fioramonti, L, Sutton, P, Farber, S and  
6       Grasso, M (2017). Twenty years of ecosystem services: How far have we come and how  
7       far do we still need to go? *Ecosystem Services* 28: 1-16.

8   U.S. EPA (2014). Welfare Risk and Exposure Assessment for Ozone (Final). . Office of Air  
9       Quality Planning and Standards. Research Triangle Park, NC. U.S. EPA. EPA-452/P-14-  
10      005a August 2014. Available at:  
11      <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100KB9D.txt>.

# APPENDIX 4F

## ANALYSIS OF THE N100 AND D100 OZONE CONCENTRATION METRICS AT U.S. AMBIENT AIR MONITORING SITES

### TABLE OF CONTENTS

|   |       |
|---|-------|
| 4F.1. Overview .....  | 4F-2  |
| 4F.2. Data Handling.....  | 4F-2  |
| 4F.2.1 Data Retrieval and Preparation.....                          | 4F-2  |
| 4F.2.2 Derivation of the Metrics.....                               | 4F-2  |
| 4F.2.3 Assignment of Monitoring Sites to NOAA Climate Regions ..... | 4F-4  |
| 4F.3. Results .....   | 4F-5  |
| 4F.3.1 National Analysis Using Recent Air Quality Data.....         | 4F-5  |
| 4F.3.2 National Analysis Using Historical Air Quality Data .....    | 4F-18 |
| 4F.4. Summary .....   | 4F-21 |
| 4F.5. References .....  | 4F-22 |

## 4F.1 OVERVIEW

This technical memorandum presents various analyses of ambient air monitoring data for ozone (O<sub>3</sub>) concentrations in the U.S. relating to the form and averaging time of the current secondary standard and some metrics reported in environmental assessments. These metrics include the W126-based cumulative exposure index, the N100 (number of hours at or above 100 ppb), and D100 (number of days with one or more hours at or above 100 ppb). The calculation of these metrics is described in Section 4F.2 below. These analyses describe relationships between the three environmental metrics and the design values for the current standard (the annual 4<sup>th</sup> highest daily maximum 8-hour O<sub>3</sub> concentration, averaged over 3 consecutive years; hereafter referred to as the “4<sup>th</sup> max metric”). The analyses presented here are an extension of analyses that are presented Section 2.4.5, Appendix 2A, and Appendix 4D of the Policy Assessment for the review (U.S. EPA, 2022).

## 4F.2 DATA HANDLING

### 4F.2.1 Data Retrieval and Preparation

Hourly O<sub>3</sub> concentration data were retrieved from the EPA’s Air Quality System (AQS, <https://www.epa.gov/aqs>) database for 2,021 ambient air monitoring sites which operated between 2000 and 2020. These data were used to calculate W126 and 4<sup>th</sup> max metric values for each 3-year period from 2000-2002 to 2018-2020. Before calculating these metrics, some initial processing was done on the hourly data. First, data collected using monitoring methods other than federal reference or equivalent methods and data collected at monitoring sites not meeting EPA’s quality assurance or other criteria in 40 CFR part 58 were removed from the analysis. Second, data collected by multiple monitoring instruments operating at the same location were combined according to Appendix U to 40 CFR Part 50. Finally, data were combined across pairs of monitoring sites approved for such combination by the EPA Regional Offices. The final hourly O<sub>3</sub> concentration dataset contained 1,808 monitoring sites.

### 4F.2.2 Derivation of the Metrics

The 4<sup>th</sup> max metric values were calculated according to the data handling procedures in Appendix U to 40 CFR part 50. First, moving 8-hour averages were calculated from the hourly O<sub>3</sub> concentration data for each site. For each 8-hour period, an 8-hour average value was calculated if there were at least 6 hourly O<sub>3</sub> concentrations available. Each 8-hour average was stored in the first hour of the period (e.g., the 8-hour average from 12:00 PM to 8:00 PM is stored in the 12:00 PM hour). Daily maximum 8-hour average values were found using the 8-hour periods beginning from 7:00 AM to 11:00 PM each day. These daily maximum values were used if at least 13 of the 17 possible 8-hour averages were available, or if the daily maximum

value was greater than 70 parts per billion (ppb). Finally, the annual 4th highest daily maximum value was found for each year, then averaged across each consecutive 3-year period to obtain the final set of 4th max metric values in units of ppb. Any decimal digits in these values were truncated for applications requiring direct comparison to a 4th max level (e.g., Table 1), otherwise, all decimal digits were retained. The 4th max metric values were considered valid if daily maximum values were available for at least 90% of the days in the O<sub>3</sub> monitoring season (defined in Appendix D to 40 CFR part 58) on average across the three years, with a minimum of 75% of the days in the O<sub>3</sub> monitoring season in any calendar year. In addition, 4th max metric values were considered valid if they were greater than the 4th max levels to which they were being compared.

The W126 metric values were calculated using the hourly O<sub>3</sub> concentration data in parts per million (80 FR 65374, October 26, 2015). For daytime hours (defined as the 12-hour period from 8:00 AM to 8:00 PM Local Standard Time each day), the hourly concentration values at each O<sub>3</sub> monitoring site were weighted using the following equation:

$$\text{Weighted O}_3 = \text{O}_3 / (1 + 4403 * \exp(-126 * \text{O}_3)).$$

These weighted values were summed over each calendar month, then adjusted for missing data (e.g.; if 80% of the daytime hourly concentrations were available, the sum would be multiplied by  $1/0.8 = 1.25$ ) to obtain the monthly W126 index values. Monthly W126 index values were not calculated for months where fewer than 75% of the possible daytime hourly concentrations were available. Next, moving 3-month sums were calculated from the monthly index values, and the highest of these 3-month sums was determined to be the annual W126 index. Three-month periods spanning multiple years (e.g., November to January, December to February) were not considered in these calculations. The annual W126 index values were averaged across each consecutive 3-year period to obtain the final W126 metric values, with units in parts per million-hours (ppm-hrs). The W126 metric values were rounded to the nearest unit ppm-hr for applications requiring direct comparison to a W126 level (e.g., Table 1), otherwise, all decimal digits were retained. For consistency with the 4<sup>th</sup> max metric calculations, the W126 metric values were considered valid if hourly O<sub>3</sub> concentration values were available for at least 90% of the daytime hours during the O<sub>3</sub> monitoring season on average across the three years, with a minimum of 75% of the daytime hours during the O<sub>3</sub> monitoring season in any calendar year. For consistency with the 4<sup>th</sup> max metric calculations, the W126 metric values were considered valid if they were greater than the W126 levels to which they were being compared.


The N100 metric was calculated as the maximum number of hours with an hourly O<sub>3</sub> concentration of 100 ppb or greater in the three consecutive calendar months yielding the highest

1 number in a given year. Similarly, the D100 metric was calculated as the maximum number of  
2 days with at least one hourly O<sub>3</sub> concentration of 100 ppb or greater in the three consecutive  
3 calendar months yielding the highest number in a given year. These metrics were considered  
4 valid if the annual data completeness rate for the O<sub>3</sub> monitoring season was at least 75 percent.

5 In summary, the “4<sup>th</sup> max metric” refers to the average of the 4<sup>th</sup> highest daily maximum  
6 8-hour averages in three consecutive years and the “W126 metric” refers to the average of annual  
7 W126 index values (“annual” or “single-year” W126 index) over three years. Where a single-  
8 year value is intended, it is referred to as annual or single-year. In the final dataset, 1,757 of the  
9 1,808 O<sub>3</sub> monitoring sites had sufficient data to calculate valid annual 4<sup>th</sup> max, W126, N100 and  
10 D100 values for at least one year between 2000 and 2020. The number of sites with valid annual  
11 metric values ranged from 1,102 in 2000 to 1,225 in 2014, and 586 sites had valid annual metric  
12 values in all 21 years. Additionally, 1,578 of the 1,808 O<sub>3</sub> monitoring sites had sufficient data to  
13 calculate valid 4<sup>th</sup> max and W126 metric values for at least one 3-year period between 2000-  
14 2002 and 2018-2020. The number of sites with valid 4<sup>th</sup> max and W126 metric values ranged  
15 from a low of 992 in 2000-2002 to a high of 1,118 in 2015-2017, and 510 sites had valid 4<sup>th</sup> max  
16 and W126 metric values for all nineteen 3-year periods.

#### 17 **4F.2.3 Assignment of Monitoring Sites to NOAA Climate Regions**

18 In order to examine regional differences, many of the further analyses were stratified into  
19 the nine NOAA climate regions (Karl and Koss, 1984), which are shown in Figure 4F-1. Since  
20 the NOAA climate regions only cover the contiguous U.S., Alaska was added to the Northwest  
21 region, Hawaii was added to the West region, and Puerto Rico was added to the Southeast  
22 region.



**Figure 4F-1. Map of the nine NOAA climate regions.**

### 4F.3 RESULTS

#### 4F.3.1 National Analysis Using Recent Air Quality Data

This section presents various results based on the annual 4<sup>th</sup> max, W126, N100, and D100 metrics as well as the 3-year average 4<sup>th</sup> max and W126 metrics<sup>1</sup> for the 2018-2020 period. Figure 4F-2 and Figure 4F-3 show maps of the average annual N100 and D100 values, respectively, at sites with valid 4<sup>th</sup> max metric values (design values) for 2018-2020. About 74% of the O<sub>3</sub> monitoring sites did not have any hourly concentrations at or above 100 ppb in 2018-2020, and an additional 18% of the sites had an average of one day or less per year where hourly O<sub>3</sub> concentrations reached 100 ppb or more. Sites with more than one day per year where hourly O<sub>3</sub> concentrations reached 100 ppb or more were generally located near large urban areas, with the most extreme values located downwind of Los Angeles, CA.


Figure 4F-4 and Figure 4F-5 show scatter plots comparing the 4<sup>th</sup> max metric values (x-axis) at each O<sub>3</sub> monitoring site for the 2018-2020 period to their respective N100 and D100 values (y-axis) for 2018, 2019, and 2020. Similarly, Figure 4F-6 and Figure 4F-7 show scatter plots comparing W126 metric values (x-axis) at each O<sub>3</sub> monitoring site for the 2018-2020 period to their respective N100 and D100 values (y-axis) for 2018, 2019, and 2020. For sites meeting the current standard (i.e., 4<sup>th</sup> max metric value  $\leq$  70 ppb), the hourly O<sub>3</sub> concentrations

<sup>1</sup> As defined in section 4F.2.2 above, the term “W126 metric” refers to the 3-year average W126 index. The term “annual W126” is used in reference to single-year W126 index values.

1 reached 100 ppb or more for at most ten hours across four distinct days. By contrast, it was only  
2 at sites with W126 metric values of 7 ppm-hrs or lower where at most ten total hourly  
3 concentrations reached 100 ppb or higher, occurring on no more than four distinct days. Sites  
4 with W126 metric values of 10 ppm-hrs or lower had as many as ten days with at least one hour  
5 at or above 100 ppb. Focusing on sites with W126 metric values below 20 ppm-hrs, several sites  
6 had N100 values of ten or greater and D100 values of five or greater, with individual sites having  
7 as many as 29 hours on up to 12 distinct days with concentrations of 100 ppb or greater.


8 Figure 4F-8 and Figure 4F-9 show scatter plots (similar to Figure 4F-4 and Figure 4F-5)  
9 that compare sites having different 2018, 2019, and 2020 annual 4<sup>th</sup> max values (x-axis) with  
10 regard to the 2018, 2019, and 2020 N100 and D100 values (y-axis), respectively. As can be seen  
11 from these figures, sites where the annual 4<sup>th</sup> max value was at or below 70 ppb generally had at  
12 most five hours on two distinct days where the O<sub>3</sub> concentrations reached 100 ppb or more.

13 Figure 4F-10 and Figure 4F-11 show similar scatter plots comparing sites having different 2018,  
14 2019, and 2020 annual W126 values (x-axis) with regard to the 2018, 2019, and 2020 N100 and  
15 D100 values (y-axis), respectively. There were sites that had five or more hours at or above 100  
16 ppb on up to three distinct days at annual W126 levels as low as 5 ppm-hrs. Focusing on sites  
17 where the annual W126 values were below 20 ppm-hrs, several sites had ten or more hours on  
18 five or more distinct days where O<sub>3</sub> concentrations reached 100 ppb or more.






1




2


3 **Figure 4F-3. Map of 2018-2020 Average D100 Values at sites with valid design values.**



**Figure 4F-4. Scatter plot of annual N100 values (y-axis) versus 4<sup>th</sup> max metric values (design values, x-axis) based on 2018-2020 monitoring data.**




**Figure 4F-5. Scatter plot of annual D100 values (y-axis) versus 4<sup>th</sup> max metric values (design values, x-axis) based on 2018-2020 monitoring data.**




**Figure 4F-6. Scatter plot of annual N100 values (y-axis) versus W126 metric values (x-axis) based on 2018-2020 monitoring data.**







**Figure 4F-7. Scatter plot of annual D100 values (y-axis) versus W126 metric values (x-axis) based on 2018-2020 monitoring data.**



**Figure 4F-8. Scatter plot of annual N100 values (Y-axis) versus annual 4<sup>th</sup> max values (x-axis), based on 2018-2020 monitoring data.**




**Figure 4F-9. Scatter plot of annual D100 values (Y-axis) versus annual 4<sup>th</sup> max values (x-axis), based on 2018-2020 monitoring data.**




**Figure 4F-10. Scatter plot of annual N100 values (Y-axis) versus annual W126 values (x-axis), based on 2018-2020 monitoring data.**





**Figure 4F-11. Scatter plot of annual D100 values (Y-axis) versus annual W126 values (X-axis), based on 2018-2020 monitoring data.**



**Figure 4F-12. Boxplots showing distribution of N100 values (top panels) and D100 values (bottom panels) based on 2016-2020 data binned according to design values (left panels) and W126 values (right panels, annual W126 in red, 3-year W126 in blue).** The boxes represent the 25<sup>th</sup>, 50<sup>th</sup> and 75<sup>th</sup> percentiles and the whiskers extend to the 1<sup>st</sup> and 99<sup>th</sup> percentiles. Outlier values are represented by circles.

Table 4F-1 below shows the number of sites where the 2018-2020 4<sup>th</sup> max metric values meet the current standard or the number of instances (i.e., site-years) where the 2018, 2019, and 2020 annual 4<sup>th</sup> max values are at or below the level of the current standard and the 2018, 2019,

1 and 2020 N100 or D100 values are above various thresholds. The table also shows number of  
2 sites where the 2018-2020 W126 metric values are at or below specific W126 levels or the  
3 number of instances where the 2018, 2019, and 2020 annual W126 values are at or below  
4 specific W126 levels and the 2018, 2019, and 2020 N100 or D100 values are above various  
5 thresholds. The number of sites or instances where the N100 and D100 values were nonzero are  
6 always equal, because having at least one hour where the concentration is at or above 100 ppb  
7 guarantees having at least one day where the maximum hourly concentration is at least 100 ppb.  
8 The number of sites or instances where the D100 values exceeded 2 and 5 were generally similar  
9 to the number of sites or instances where the N100 values exceeded 5 and 10, respectively.

10 With regard to sites at or below specific annual 4<sup>th</sup> max and W126 values in any of the  
11 three years, according to Table 4F-1, there were no instances out of over 2,700 site-years where  
12 the N100 value exceeded 5 for sites during a year where the annual 4<sup>th</sup> max value was at or  
13 below the level of the current standard. Additionally, there were only ten sites out 877 (about  
14 1%) that met the current standard based on 2018-2020 data and also had N100 values exceeding  
15 5 in one or more years. By contrast, there were 47 instances out of over 3,300 (1.4%) where the  
16 N100 value exceeded 5 for sites that had an annual W126 value at or below 19 ppm-hrs; and  
17 additionally, 37 sites out of over 1,000 (more than 3%) that had a 2018-2020 W126 metric value  
18 was at or below 17 ppm-hrs and a N100 value exceeding 5 in one or more years. Even when  
19 looking at sites at or below a W126 level of 7 ppm-hrs, there were nearly as many sites (9) with  
20 N100 values exceeding 5 than for sites meeting the current standard (10).

21 Table 4F-2 shows the same statistics as in Table 4F-1 for the annual 4<sup>th</sup> max and annual  
22 W126 values broken out into individual years, with the maximum annual value across the three  
23 years for each combination of 4<sup>th</sup> max/W126 and N100/D100 thresholds highlighted in light  
24 blue. This table shows that while there is considerable inter-annual variation in the 4<sup>th</sup> max and  
25 W126 values across years, the annual W126 values always have a higher proportion of sites  
26 below the threshold and above the N100 or D100 thresholds compared to those of the annual 4<sup>th</sup>  
27 max values. Further, during the highest year for the different N100 and D100 thresholds, the  
28 proportion of sites exceeding those thresholds is greater for the sites at/below the different annual  
29 W126 levels than it is for sites with design values at/below 70 ppb. This is also evident in  
30 comparing Figure 4F-5 to Figure 4F-11 and Figure 4F-4 to Figure 4F-10.

**Table 4F-1. Number of instances where 4<sup>th</sup> max or W126 values are at or below various thresholds and N100 or D100 values are above various thresholds based on O<sub>3</sub> monitoring data from recent years (2018-2020).**

|  | Total* | Number of instances where:                               |               |                | Number of instances where: |               |               |
|--|--------|--|---------------|----------------|----------------------------|---------------|---------------|
|  |        | N100 > 0   | N100 > 5      | N100 > 10      | D100 > 0                   | D100 > 2      | D100 > 5      |
|  |        | Number of sites exceeding threshold in one or more years |               |                |                            |               |               |
| 3-year Total**   | 1,073  | 278<br>(26%)   | 80<br>(7%)    | 39<br>(4%)     | 278<br>(26%)               | 83<br>(8%)    | 34<br>(3%)    |
| 3-year 4 <sup>th</sup> Max ≤ 70                            | 877    | 125<br>(14%)   | 10<br>(1%)    | 1<br>(0.1%)    | 125<br>(14%)               | 9<br>(1%)     | 0<br>(0%)     |
| 3-year W126 ≤ 19   | 1,027  | 233<br>(23%)   | 43<br>(4%)    | 12<br>(1%)     | 233<br>(23%)               | 41<br>(4%)    | 9<br>(0.9%)   |
| 3-year W126 ≤ 17   | 1,009  | 218<br>(22%)   | 37<br>(4%)    | 10<br>(1%)     | 218<br>(22%)               | 34<br>(3%)    | 7<br>(0.7%)   |
| 3-year W126 ≤ 15   | 991    | 207<br>(21%)   | 37<br>(4%)    | 10<br>(1%)     | 207<br>(21%)               | 34<br>(3%)    | 7<br>(0.7%)   |
| 3-year W126 ≤ 7  | 722    | 100<br>(14%)   | 11<br>(2%)    | 0<br>(0%)      | 100<br>(14%)               | 9<br>(1%)     | 0<br>(0%)     |
| Average number of sites exceeding threshold per year       |        |  |               |                |                            |               |               |
| 3-year Total**   | 1,073  | 145.3<br>(14%)   | 44.7<br>(4%)  | 24.7<br>(2%)   | 145.3<br>(14%)             | 46.7<br>(4%)  | 22.7<br>(2%)  |
| 3-year 4 <sup>th</sup> Max ≤ 70                            | 877    | 49<br>(6%)   | 3.3<br>(0.4%) | 0.3<br>(<0.1%) | 49<br>(6%)                 | 3<br>(0.3%)   | 0<br>(0%)     |
| 3-year W126 ≤ 19   | 1,027  | 107.7<br>(10%)   | 17.7<br>(2%)  | 4.7<br>(0.5%)  | 107.7<br>(10%)             | 16.3<br>(2%)  | 3.3<br>(0.3%) |
| 3-year W126 ≤ 17   | 1,009  | 100<br>(10%)   | 15<br>(1%)    | 3.7<br>(0.4%)  | 100<br>(10%)               | 13.7<br>(1%)  | 2.7<br>(0.3%) |
| 3-year W126 ≤ 15   | 991    | 94.7<br>(10%)  | 15<br>(2%)    | 3.7<br>(0.4%)  | 94.7<br>(10%)              | 13.7<br>(1%)  | 2.7<br>(0.3%) |
| 3-year W126 ≤ 7  | 722    | 43<br>(6%)   | 4<br>(0.6%)   | 0<br>(0%)      | 43<br>(6%)                 | 3.3<br>(0.5%) | 0<br>(0%)     |
| Total number of instances (site/years) exceeding threshold |        |  |               |                |                            |               |               |
| Annual Total***  | 3,522  | 473<br>(13%)   | 143<br>(4%)   | 77<br>(2%)     | 473<br>(13%)               | 149<br>(4%)   | 70<br>(2%)    |
| Annual 4 <sup>th</sup> Max ≤ 70                            | 2,743  | 96<br>(3%)   | 0<br>(0%)     | 0<br>(0%)      | 96<br>(3%)                 | 0<br>(0%)     | 0<br>(0%)     |
| Annual W126 ≤ 25   | 3,421  | 375<br>(11%)   | 64<br>(2%)    | 19<br>(0.6%)   | 375<br>(11%)               | 66<br>(2%)    | 12<br>(0.4%)  |
| Annual W126 ≤ 19   | 3,336  | 333<br>(10%)   | 47<br>(1%)    | 10<br>(0.3%)   | 333<br>(10%)               | 47<br>(1%)    | 6<br>(0.2%)   |
| Annual W126 ≤ 17   | 3,285  | 309<br>(9%)  | 41<br>(1%)    | 7<br>(0.2%)    | 309<br>(9%)                | 38<br>(1%)    | 5<br>(0.2%)   |
| Annual W126 ≤ 15   | 3,196  | 281<br>(9%)  | 37<br>(1%)    | 6<br>(0.2%)    | 281<br>(9%)                | 35<br>(1%)    | 4<br>(0.1%)   |
| Annual W126 ≤ 7  | 2,319  | 115<br>(5%)  | 9<br>(0.4%)   | 0<br>(0%)      | 115<br>(5%)                | 8<br>(0.3%)   | 0<br>(0%)     |

|   | Total* | Number of instances where:                               |          |           | Number of instances where: |          |          |
|---|--------|--|----------|-----------|----------------------------|----------|----------|
|   |        | N100 > 0   | N100 > 5 | N100 > 10 | D100 > 0                   | D100 > 2 | D100 > 5 |
|   |        | Number of sites exceeding threshold in one or more years |          |           |                            |          |          |
| * Total number of sites where the 3-year 4 <sup>th</sup> max or W126 value is at or below the threshold, or the total number of instances (i.e., site/years) where the annual 4 <sup>th</sup> max or W126 value is at or below the threshold.             |        |  |          |           |                            |          |          |
| ** First column shows the number of sites with sufficient data to calculate valid 3-year 4 <sup>th</sup> max and W126 values. Subsequent columns tally the subset of those sites where the N100 or D100 value exceeds the threshold in one or more years. |        |  |          |           |                            |          |          |
| *** First column shows the number of instances where a site had sufficient data to calculate valid annual 4 <sup>th</sup> max and W126 values. Subsequent columns tally the subset of those instances where the N100 or D100 value exceeds the threshold. |        |  |          |           |                            |          |          |

**Table 4F-2. Number of instances where annual 4<sup>th</sup> max or W126 values are at or below various thresholds and N100 or D100 values are above various thresholds based on O<sub>3</sub> monitoring data from 2018-2020**

|  | Total<br>Number<br>of Sites* | Number of sites where:   |           |           | Number of sites where: |          |          |
|--|------------------------------|--|-----------|-----------|------------------------|----------|----------|
|  |                              | N100 > 0   | N100 > 5  | N100 > 10 | D100 > 0               | D100 > 2 | D100 > 5 |
|  |                              | Number of sites exceeding threshold in the maximum year of the three |           |           |                        |          |          |
| 3-year 4 <sup>th</sup> Max ≤ 70  | 877                          | 75 (9%)  | 5 (0.6%)  | 1 (0.1%)  | 75 (9%)                | 4 (0.5%) | 0 (0%)   |
| Annual 4 <sup>th</sup> Max ≤ 70  | See<br>Below                 | 39 (4%)  | 0 (0%)    | 0 (0%)    | 39 (4%)                | 0 (0%)   | 0 (0%)   |
| Annual W126 ≤ 25   |                              | 166 (15%)  | 26 (2%)   | 7 (0.6%)  | 166 (15%)              | 26 (2%)  | 5 (0.4%) |
| Annual W126 ≤ 19   |                              | 146 (13%)  | 21 (2%)   | 4 (0.4%)  | 146 (13%)              | 20 (28%) | 3 (0.3%) |
| Annual W126 ≤ 17   |                              | 139 (13%)  | 20 (2%)   | 3 (0.3%)  | 139 (13%)              | 18 (2%)  | 3 (0.3%) |
| Annual W126 ≤ 15   |                              | 131 (13%)  | 20 (2%)   | 3 (0.3%)  | 131 (13%)              | 18 (2%)  | 3 (0.3%) |
| Annual W126 ≤ 7  |                              | 47 (8%)  | 8 (1%)    | 0 (0%)    | 47 (8%)                | 6 (1%)   | 0 (0%)   |
|  |                              | Number of sites exceeding threshold in individual years              |           |           |                        |          |          |
| 2020 Total**   | 1,172                        | 165 (14%)  | 56 (5%)   | 32 (3%)   | 165 (14%)              | 56 (5%)  | 27 (2%)  |
| 2019 Total**   | 1,163                        | 101 (9%)   | 27 (2%)   | 19 (2%)   | 101 (9%)               | 31 (3%)  | 19 (2%)  |
| 2018 Total**   | 1,187                        | 207 (17%)  | 60 (5%)   | 26 (2%)   | 207 (17%)              | 62 (5%)  | 24 (2%)  |
| 2020 4 <sup>th</sup> Max ≤ 70  | 941                          | 39 (4%)  | 0 (0%)    | 0 (0%)    | 39 (4%)                | 0 (0%)   | 0 (0%)   |
| 2019 4 <sup>th</sup> Max ≤ 70  | 1,000                        | 25 (3%)  | 0 (0%)    | 0 (0%)    | 25 (3%)                | 0 (0%)   | 0 (0%)   |
| 2018 4 <sup>th</sup> Max ≤ 70  | 802                          | 32 (4%)  | 0 (0%)    | 0 (0%)    | 32 (4%)                | 0 (0%)   | 0 (0%)   |
| 2020 W126 ≤ 25   | 1,134                        | 131 (12%)  | 26 (2%)   | 7 (0.6%)  | 131 (12%)              | 26 (2%)  | 5 (0.4%) |
| 2019 W126 ≤ 25   | 1,144                        | 78 (7%)  | 13 (1%)   | 6 (0.5%)  | 78 (7%)                | 15 (1%)  | 5 (0.4%) |
| 2018 W126 ≤ 25   | 1,143                        | 166 (15%)  | 25 (2%)   | 6 (0.5%)  | 166 (15%)              | 25 (2%)  | 2 (0.2%) |
| 2020 W126 ≤ 19   | 1,116                        | 114 (10%)  | 15 (1%)   | 2 (0.2%)  | 114 (10%)              | 14 (1%)  | 2 (0.2%) |
| 2019 W126 ≤ 19   | 1,129                        | 73 (6%)  | 11 (1%)   | 4 (0.4%)  | 73 (6%)                | 13 (1%)  | 3 (0.3%) |
| 2018 W126 ≤ 19   | 1,091                        | 146 (13%)  | 21 (2%)   | 4 (0.4%)  | 146 (13%)              | 20 (2%)  | 1 (0.1%) |
| 2020 W126 ≤ 17   | 1,101                        | 103 (9%)   | 11 (1%)   | 1 (0.1%)  | 103 (9%)               | 9 (0.9%) | 1 (0.1%) |
| 2019 W126 ≤ 17   | 1,117                        | 67 (6%)  | 10 (0.9%) | 3 (0.3%)  | 67 (6%)                | 11 (1%)  | 3 (0.3%) |
| 2018 W126 ≤ 17   | 1,067                        | 139 (13%)  | 20 (27%)  | 3 (0.3%)  | 139 (13%)              | 18 (2%)  | 1 (0.1%) |
| 2020 W126 ≤ 15   | 1,074                        | 85 (8%)  | 8 (0.7%)  | 0 (0%)    | 85 (8%)                | 6 (0.6%) | 0 (0%)   |
| 2019 W126 ≤ 15   | 1,091                        | 65 (6%)  | 9 (0.8%)  | 3 (0.3%)  | 65 (6%)                | 11 (1%)  | 3 (0.3%) |
| 2018 W126 ≤ 15   | 1,031                        | 131 (13%)  | 20 (2%)   | 3 (0.3%)  | 131 (13%)              | 18 (2%)  | 1 (0.1%) |
| 2020 W126 ≤ 7  | 833                          | 34 (4%)  | 0 (0%)    | 0 (0%)    | 34 (4%)                | 0 (0%)   | 0 (0%)   |
| 2019 W126 ≤ 7  | 860                          | 34 (4%)  | 1 (0.1%)  | 0 (0%)    | 34 (4%)                | 2 (0.2%) | 0 (0%)   |
| 2018 W126 ≤ 7  | 626                          | 47 (8%)  | 8 (1%)    | 0 (0%)    | 47 (8%)                | 6 (1%)   | 0 (0%)   |
| * Total number of sites where the annual 4 <sup>th</sup> max or W126 value is at or below the threshold.   |                              |  |           |           |                        |          |          |
| ** First column represents the number of sites with sufficient data to calculate a valid annual 4 <sup>th</sup> max value. Subsequent columns tally the subset of those sites where the N100 or D100 value exceeds the threshold in one or more years. |                              |  |           |           |                        |          |          |

**Table 4F-3. Average % of monitoring sites per year during 2016-2020 with 4<sup>th</sup> max or W126 metrics at or below various thresholds that have N100 or D100 values above various thresholds.**

|                                 | Percent of sites where:   |          |           | Percent of sites where: |          |          |
|---------------------------------|---|----------|-----------|-------------------------|----------|----------|
|                                 | N100 > 0  | N100 > 5 | N100 > 10 | D100 > 0                | D100 > 2 | D100 > 5 |
|                                 | <i>Average percent of sites exceeding N100 or D100 threshold per year (2016 – 2020)</i> |          |           |                         |          |          |
| 3-year 4 <sup>th</sup> Max ≤ 70 | 5.1   | 0.3      | 0.01      | 5.1                     | 0.2      | 0        |
| 3-year W126 ≤ 19                | 10.1  | 1.4      | 0.4       | 10.1                    | 1.4      | 0.2      |
| 3-year W126 ≤ 17                | 9.7   | 1.4      | 0.3       | 9.7                     | 1.3      | 0.2      |
| 3-year W126 ≤ 15                | 9.4   | 1.3      | 0.3       | 9.4                     | 1.2      | 0.2      |
| 3-year W126 ≤ 7                 | 6.1   | 0.5      | 0.04      | 6.1                     | 0.3      | 0.01     |
| Annual W126 ≤ 25                | 11.0  | 1.7      | 0.5       | 11.0                    | 1.8      | 0.4      |
| Annual W126 ≤ 19                | 10.0  | 1.4      | 0.3       | 10.0                    | 1.4      | 0.2      |
| Annual W126 ≤ 17                | 9.5   | 1.2      | 0.2       | 9.5                     | 1.2      | 0.1      |
| Annual W126 ≤ 15                | 9.1   | 1.2      | 0.2       | 9.1                     | 1.1      | 0.1      |
| Annual W126 ≤ 7                 | 5.1   | 0.4      | 0         | 5.1                     | 0.3      | 0        |
| Annual 4 <sup>th</sup> Max ≤ 70 | 3.3   | 0.02     | 0         | 3.3                     | 0.02     | 0        |

#### 4F.3.2 National Analysis Using Historical Air Quality Data

Figure 4F-13 and Figure 4F-14 show the trend in national 10<sup>th</sup> percentile, median, 90<sup>th</sup> percentile and mean N100 and D100 values, respectively, based on 822 U.S. O<sub>3</sub> monitoring sites with complete data for 2000 to 2020. A site must have 75% annual data completeness in terms of the 4<sup>th</sup> max metric (see section 4F.2.2) for at least 16 of the 21 years, with no more than two consecutive years missing to be included in the trend. As can be seen from the figures, the median N100 and D100 values in the U.S. have been zero since 2006, meaning over half of the monitoring sites have N100 and D100 values of zero. The mean N100 value has decreased from more than ten in 2000-2002 to less than two in recent years, a decline of more than 80%. Similarly, the mean D100 value has decreased from four or more in 2000-2002 to less than one in recent years, also a decline of more than 80%. The 90<sup>th</sup> percentile values of both metrics have decreased at an even faster rate.







Figure 4F-13. Trend in N100 values from 2000 to 2020 based on data from 808 U.S. O<sub>3</sub> monitoring sites





**Figure 4F-14. Trend in D100 values from 2000 to 2020 based on data from 808 U.S. O<sub>3</sub> monitoring sites**

Table 4F-4 below shows the number of instances (site-years) where a site had an annual 4<sup>th</sup> max value or 4<sup>th</sup> max metric value at or below the level of the current standard and an annual N100 or D100 value above various thresholds based on the full dataset spanning years 2000 to 2020. The table also shows number of instances (site-years) where a site had an annual W126 value or W126 metric value at or below specific W126 levels and N100 or D100 values above various thresholds based on the full 2000-2020 dataset. The numbers in Table 4F-4 are generally proportionally similar to those shown previously in Table 4F-1.

According to Table 4F-4, there were only 8 instances where the N100 value exceeded 5 at a site with an annual 4<sup>th</sup> max value at or below the level of the current standard, and only 107 instances out of over 10,000 (about 1%) that met the current standard and also had N100 values exceeding 5 in one or more of the three years of the design value period. By contrast, there were over 1,500 instances where the annual W126 value was less than or equal to 19 ppm-hrs and the N100 value in that year exceeded 5, and over 2,600 instances (more than 15%) where the W126

metric value was at or below 17 ppm-hrs and the N100 value exceeded 5 in one or more years of the 3-year period. Even when looking at sites at or below a W126 level of 7 ppm-hrs, there were more instances with N100 values exceeding 5 (170) than for sites meeting the current standard (107).

**Table 4F-4. Number of instances where 4<sup>th</sup> max or W126 values are at or below various thresholds and N100 or D100 values are above various thresholds based on data from all years (2000-2020)**

|                                 | Total* | Number of instances where:  |                |                | Number of instances where: |                |                |
|---------------------------------|--------|---|----------------|----------------|----------------------------|----------------|----------------|
|                                 |        | N100 > 0  | N100 > 5       | N100 > 10      | D100 > 0                   | D100 > 2       | D100 > 5       |
|                                 |        | Number of instances where site exceeds threshold in one or more years |                |                |                            |                |                |
| 3-year Total**                  | 20,483 | 10,103<br>(49%)   | 4,942<br>(24%) | 3,213<br>(16%) | 10,103<br>(49%)            | 4,920<br>(24%) | 2,486<br>(12%) |
| 3-year 4 <sup>th</sup> Max ≤ 70 | 10,026 | 1,638<br>(16%)  | 107<br>(1%)    | 16<br>(0.2%)   | 1,638<br>(16%)             | 89<br>(0.9%)   | 7<br>(0.1%)    |
| 3-year W126 ≤ 19                | 18,292 | 7,994<br>(44%)  | 3,178<br>(17%) | 1,695<br>(9%)  | 7,994<br>(44%)             | 3,095<br>(17%) | 1,054<br>(6%)  |
| 3-year W126 ≤ 17                | 17,427 | 7,255<br>(42%)  | 2,664<br>(15%) | 1,328<br>(8%)  | 7,255<br>(42%)             | 2,576<br>(15%) | 768<br>(4%)    |
| 3-year W126 ≤ 15                | 16,222 | 6,307<br>(39%)  | 2,076<br>(13%) | 951<br>(6%)    | 6,307<br>(39%)             | 1,997<br>(12%) | 522<br>(3%)    |
| 3-year W126 ≤ 7                 | 7,576  | 1,427<br>(19%)  | 170<br>(2%)    | 40<br>(0.5%)   | 1,427<br>(19%)             | 152<br>(2%)    | 23<br>(0.3%)   |
|                                 |        | Total number of instances (site/years) exceeding threshold            |                |                |                            |                |                |
| Annual Total***                 | 24,987 | 7,908<br>(32%)  | 3,652<br>(15%) | 2,327<br>(9%)  | 7,908<br>(32%)             | 3,609<br>(14%) | 1,715<br>(7%)  |
| Annual 4 <sup>th</sup> Max ≤ 70 | 12,402 | 563<br>(5%)   | 8<br>(0.1%)    | 0<br>(0%)      | 563<br>(5%)                | 3<br>(<0.1%)   | 0<br>(0%)      |
| Annual W126 ≤ 25                | 23,482 | 6,504<br>(28%)  | 2,444<br>(10%) | 1,274<br>(5%)  | 6,504<br>(28%)             | 2,370<br>(10%) | 709<br>(3%)    |
| Annual W126 ≤ 19                | 21,660 | 5,121<br>(24%)  | 1,587<br>(7%)  | 736<br>(3%)    | 5,121<br>(24%)             | 1,503<br>(7%)  | 344<br>(2%)    |
| Annual W126 ≤ 17                | 20,600 | 4,427<br>(21%)  | 1,226<br>(6%)  | 530<br>(3%)    | 4,427<br>(21%)             | 1,162<br>(6%)  | 234<br>(1%)    |
| Annual W126 ≤ 15                | 19,225 | 3,663<br>(19%)  | 885<br>(5%)    | 324<br>(2%)    | 3,663<br>(19%)             | 839<br>(4%)    | 144<br>(0.8%)  |
| Annual W126 ≤ 7                 | 10,427 | 770<br>(7%)   | 62<br>(0.6%)   | 4<br>(<0.1%)   | 770<br>(7%)                | 50<br>(0.5%)   | 2<br>(<0.1%)   |

\* Total number of sites where the 3-year 4<sup>th</sup> max or W126 value is at or below the threshold, or the total number of instances (i.e., site/years) where the annual 4<sup>th</sup> max or W126 value is at or below the threshold.

\*\* First column shows the number of sites with sufficient data to calculate valid 3-year 4<sup>th</sup> max and W126 values. Subsequent columns tally the subset of those sites where the N100 or D100 value exceeds the threshold in one or more years.

\*\*\* First column shows the number of instances where a site had sufficient data to calculate valid annual 4<sup>th</sup> max and W126 values. Subsequent columns tally the subset of those instances where the N100 or D100 value exceeds the threshold.

#### 4F.4 SUMMARY

The presentation here shows various analyses of ambient air monitoring data for O<sub>3</sub> concentrations in the U.S. relating to the form and averaging time of the current secondary standard, the W126-based cumulative exposure index, the N100 metric (number of hours at or above 100 ppb) and D100 metric (number of days with one or more hours at or above 100 ppb).

- About 74% of the O<sub>3</sub> monitoring sites with valid design values in 2018-2020 did not have any hourly concentrations at or above 100 ppb, and another 18% had only a single day where hourly O<sub>3</sub> concentrations reached 100 ppb or more (Figure 4F-2 and Figure 4F-3).
- Based on data from 2018-2020, sites where the current standard was met (4<sup>th</sup> max metric value was at or below 70 ppb) had a maximum annual N100 count of 10 and D100 count of 4 (Figure 4F-4 and Figure 4F-5). Sites with W126 metric values as low as 7 ppm-hrs also had a maximum annual N100 count of 10 and D100 count of 4. At sites with W126 metric values below 20 ppm-hrs, several sites had N100 values of ten or greater and D100 values of five or greater, with individual sites having as many as 29 hours on up to 12 distinct days with concentrations of 100 ppb or greater (Figure 4F-6 and Figure 4F-7).
- In 2018-2020, sites where the annual 4<sup>th</sup> max value was at or below 70 ppb had a maximum annual N100 count of 5 and D100 count of 2 (Figure 4F-8 and Figure 4F-9). Sites with annual W126 values as low as 5 ppm-hrs had a maximum N100 count of 8 and D100 count of 3. At sites with annual W126 values below 20 ppm-hrs, several sites had ten or more hours on five or more distinct days where O<sub>3</sub> concentrations reached 100 ppb or more (Figure 4F-10 and Figure 4F-11).
- Based on data from 2018-2020, about 1% of sites that met the current standard had an N100 value exceeding 5 in one or more years. By comparison, more than 3% of sites where the W126 metric value was at or below 17 ppm-hrs had an N100 value exceeding 5 (Table 4F-1). There were no sites with N100 values exceeding 5 among sites with annual 4<sup>th</sup> max values at or below the level of the current standard compared with between 11 and 21 sites per year with N100 values exceeding 5 among sites with annual W126 values at or below 19 ppm-hrs (Table 4F-2).
- Based on data from 2000-2020, about 1% of design values that met the current standard had N100 values exceeding 5 in one or more years of the 3-year period. By comparison, about 15% of W126 metric values at or below 17 ppm-hrs had N100 values exceeding 5 in one or more years of the 3-year period (Table 4F-4).
- Since 2000-2002, the national mean N100 and D100 values have decreased by more than 80% (Figure 4F-13 and Figure 4F-14).

## 4F.5 REFERENCES

- Karl, T and Koss, WJ (1984). Regional and national monthly, seasonal, and annual temperature weighted by area, 1895-1983. 4-3. National Environmental Satellite and Data Information Service (NESDIS). Asheville, NC.
- U.S. EPA (2020). Policy Assessment for the Review of National Ambient Air Quality Standards for Ozone. Office of Air Quality Planning and Standards, Health and Environmental Impacts Division. Research Triangle Park, NC. U.S. EPA. EPA-452/R-20-001. May 2020.

---

United States  
Environmental Protection  
Agency

Office of Air Quality Planning and Standards  
Health and Environmental Impacts Division  
Research Triangle Park, NC

Publication No. EPA-452/D-22-002  
April 2022

---